<SEC-DOCUMENT>0001378325-26-000010.txt : 20260326
<SEC-HEADER>0001378325-26-000010.hdr.sgml : 20260326
<ACCEPTANCE-DATETIME>20260326164407
ACCESSION NUMBER:		0001378325-26-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260326
DATE AS OF CHANGE:		20260326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CapsoVision, Inc
		CENTRAL INDEX KEY:			0001378325
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				203369494
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42705
		FILM NUMBER:		26798965

	BUSINESS ADDRESS:	
		STREET 1:		18805 COX AVENUE SUITE 250
		CITY:			SARATOGA
		STATE:			CA
		ZIP:			95070
		BUSINESS PHONE:		(408) 370-4790

	MAIL ADDRESS:	
		STREET 1:		18805 COX AVENUE SUITE 250
		CITY:			SARATOGA
		STATE:			CA
		ZIP:			95070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Capso Vision Inc
		DATE OF NAME CHANGE:	20061016
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cv-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:f6bf459f-a2e0-444d-b980-8a4fe7868fb4,g:35023aa4-34fd-4178-a912-d615028dd0bb,d:e17ceeaa833a498eadbb73e6ee8311e7-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:cv="http://capsovision.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cv-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0001378325</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-36">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" id="f-344">http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember</ix:nonNumeric><ix:nonNumeric contextRef="c-74" name="us-gaap:GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-484">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cv-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>cv:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="member"><xbrli:measure>cv:member</xbrli:measure></xbrli:unit><xbrli:unit id="monthly_installment"><xbrli:measure>cv:monthly_installment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-18</xbrli:startDate><xbrli:endDate>2025-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-18</xbrli:startDate><xbrli:endDate>2025-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cv:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cv:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cv:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cv:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cv:HealthcareClinicalTrialActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cv:HealthcareClinicalTrialActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-27</xbrli:startDate><xbrli:endDate>2025-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-07</xbrli:startDate><xbrli:endDate>2025-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-07</xbrli:startDate><xbrli:endDate>2025-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-15</xbrli:startDate><xbrli:endDate>2025-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-31</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesC1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesD1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesD2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesF1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesF2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesG1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-02</xbrli:startDate><xbrli:endDate>2025-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-02</xbrli:startDate><xbrli:endDate>2025-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-03</xbrli:startDate><xbrli:endDate>2025-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearAfter2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearAfter2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearBefore2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearBefore2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearIndefiniteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearIndefiniteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-12</xbrli:startDate><xbrli:endDate>2026-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-12</xbrli:startDate><xbrli:endDate>2026-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-16</xbrli:startDate><xbrli:endDate>2026-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001378325</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-16</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_145"></div><div style="min-height:45.36pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ___________ to ____________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number  <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-42705</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">CAPSOVISION, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.779%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">20-3369494</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">18805 Cox Avenue, Suite 250</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">95070</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Saratoga</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">408</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">624 1488</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">common stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">CV</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to section 12(g) of the Act: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</span></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"/><td style="width:26.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-26">o</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant did not have an aggregate market value for the common equity held by non-affiliates of the Registrant on the last business day of its most recently completed second fiscal quarter because there was <ix:nonFraction unitRef="usd" contextRef="c-2" decimals="INF" name="dei:EntityPublicFloat" format="ixt:fixed-zero" scale="0" id="f-30">no</ix:nonFraction> public market for the Registrant&#8217;s common equity as of such date.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;25, 2026, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">49,838,211</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the Registrant's definitive Proxy Statement relating to the Registrant's 2025 Annual Stockholders' Meeting, to be filed within 120 days of the Registrant's fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span><br/></span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_157">PART I</a></span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_160">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_160">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_160">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_549755815509">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_549755815509">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_549755815509">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_166">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_166">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_166">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_1738">Item 1</a><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_1738">C</a><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_1738">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_1738">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_1738">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_169">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_169">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_169">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_549755815490">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_549755815490">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_549755815490">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_175">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_175">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_175">96</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_178">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_181">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_181">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_181">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_184">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_184">[ Reserved ]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_184">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_187">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_187">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_187">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_190">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_190">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_190">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_193">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_193">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_193">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_211">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_211">Changes in and Disagreements with Accountants On Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_211">149</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_549755815472">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_549755815472">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_549755815472">149</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_217">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_217">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_217">150</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_220">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_220">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_220">151</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_223">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_226">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_226">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_226">152</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_229">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_229">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_229">152</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_232">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_232">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_232">152</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_235">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_235">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_235">152</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_238">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_238">Principal Account</a><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_238">ant</a><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_238"> Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_238">153</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_241">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_244">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_244">Exhibits</a><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_244"> and</a><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_244"> Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_244">154</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_247">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_247">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_247">155</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_250">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie17ceeaa833a498eadbb73e6ee8311e7_250">156</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K (the "Annual Report") contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management, and expected market growth, are forward-looking statements. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;shall,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221; &#8220;seeks,&#8221; &#8220;continues,&#8221; &#8220;target,&#8221; &#8220;contemplates,&#8221; &#8220;estimates,&#8221; &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; or &#8220;hopes&#8221; or the negative of these or similar terms or expressions that concern our expectations, strategy, plans, or intentions. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the acceptance of our products by patients and doctors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the potential market size for our current CapsoCam Plus capsule and CapsoCam Colon (once FDA cleared) and those markets that we may pursue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to increase small bowel capsule sales following recent 510(k) clearance for pediatric use and telehealth supervision and related products currently under development;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expected receipt of and related timing for FDA 510(k) clearance of our CapsoCam Colon and related sales;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and efforts to expand into new indications in terms of new GI pathologies and expanded patient populations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and efforts to introduce enhancements and improvements to our products and technologies, including the AI capabilities incorporated into our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization capabilities and strategies, including our plans to increase revenues and sales capabilities in and outside the United States (the &#8220;U.S.&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our strategic plan for our business and products and technology;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our relationships with, and capabilities of, our assembly manufacturers and component suppliers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the protection of our intellectual property (including our AI capabilities) including through patents and trade secret protections;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected performance of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage our growth;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated use of proceeds from this offering;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) or smaller reporting company under U.S. securities laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing, and our ability to obtain additional capital;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue as a going concern; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our future financial performance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We caution you that the foregoing list does not contain all of the forward-looking statements made in this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Annual Report primarily on our current expectations, estimates, forecasts, and projections about future events and trends that we believe may affect our business, financial condition, results of operations, and prospects. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, and other factors described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">looking statements contained in this Annual Report. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements made in this Annual Report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Annual Report to reflect events or circumstances after the date of this Annual Report or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report and the documents that we reference in this Annual Report and have filed as exhibits to the registration statement, of which this Annual Report is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this Annual Report by these cautionary statements. </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the principal risks and uncertainties that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks that we face, follows this summary, and should be carefully considered, together with other information in this Annual Report and our other filings with the SEC before making investment decisions regarding our securities. This summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks and uncertainties described in more detail in this Annual Report: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses, and we expect to incur additional losses in the foreseeable future.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our audited financial statements for the years ended December 31, 2025 and December 31, 2024 include a footnote raising substantial doubt about our ability to continue as a &#8220;going concern&#8221; and we will likely need to raise additional financing to fund our business and revenue growth plans.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All of our revenues to date have been, and in the near-term will continue to be, generated from CapsoCam Plus related sales for the small bowel; and our ability to grow our small-bowel-related revenue is subject to our ability to successfully and timely execute related elements of our revenue growth strategy.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CapsoCam Colon is our initial strategic effort to expand revenues for our GI-tract capsule endoscopy solution beyond small-bowel-related sales; we do not currently expect to generate CapsoCam Colon-related revenues until the middle of 2027 based on the anticipated timing of FDA clearance for the second generation of our CapsoCam Colon solution.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Broad adoption of our CapsoCam Colon solution (once cleared) and growing related revenues depend on, among other things, expanding beyond CapsoCam Colon&#8217;s initial indicated patient population, increasing the accuracy of our initial CapsoCam Colon solution, and achieving and maintaining a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">satisfactory successful completion rate for capsule endoscopies using our CapsoCam Colon solution; and we may fail to successfully and timely execute related elements of our CapsoCam Colon adoption and revenue growth strategy.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our longer term efforts to expand our GI-tract capsule endoscopy solutions beyond small bowel and colon pathologies and medical conditions may not succeed.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any failure or defect in our GI-tract capsule endoscopy solution could harm our reputation, expose us to liability, and reduce our sales.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial geopolitical and trade risks (including a possible trade war and imposition of tariffs and supply chain interruptions) and natural disaster risks associated with our business operations in Asia (particularly Taiwan and Japan).</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may face expansion risks when expanding in existing and entering into new foreign markets.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The clinical results of our various clinical studies (including those for our CapsoCam Colon capsule) may not be released in any peer-reviewed publications.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not obtain or may experience delays in obtaining 510(k) clearance for our planned second generation of our CapsoCam Colon solution (with improved optics and other components), which would adversely impact our ability to commercialize this product and generate related revenue.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to obtain or delays in obtaining 510(k) clearance for our CapsoCam Colon capsule endoscopy solution could result in additional costs or liabilities and adversely impact our reputation, ability to sell our CapsoCam Plus capsule endoscopy solution, and our ability to compete effectively in this or other markets. Any of these outcomes could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may face regulatory challenges and delays in obtaining 510(k) clearance for marketing of those CapsoCam capsules incorporating our self-developed AI technology, including our CapsoCam Colon capsule endoscopy solution and CapsoCam Plus capsule endoscopy solution (small bowel).</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If Medicare and other third-party payors, including managed care organizations, do not approve reimbursement for our products at adequate reimbursement rates, we may be unable to successfully commercialize our products which would likely have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on various suppliers to assist us in the assembly and manufacture of our GI-tract capsule endoscopy solution and sourcing of critical and other components and many of these suppliers are single source suppliers located in Asia (particularly Taiwan and Japan); any disruption in our supply chain could adversely affect our ability to meet the demand for our products and fulfil our orders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_160"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our GI-tract capsule endoscopy solution comprises our single-use CapsoCam capsule and the associated software, CapsoCloud and CapsoView. The CapsoCam capsule, with its panoramic view, acquires and stores video images in onboard memory while moving through the GI tract and the software component allows healthcare providers to view the video retrieved from the capsule by either streaming it from the cloud, where it is securely stored, anywhere at their convenience using our CapsoCloud software or downloading data from the capsule themselves and reviewing it in our CapsoView software. Our first U.S. Food and Drug Administration (&#8220;FDA&#8221;) cleared capsule endoscopy is our small bowel capsule (the current generation of which we refer to as CapsoCam Plus), for which we received a CE Mark in 2011 and began commercial sales in Europe in 2012, subsequent to which we received 510(k) clearance in 2016 and began commercial sales in the U.S. in 2017. CapsoCam Plus is classified as a Class II device and is used to visualize the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged 2 years and above. As of December 31, 2025, our CapsoCam Plus has been used in more than 161,000 patients. For the years ended December 31, 2025 and 2024, we generated approximately $13.6 million and $11.8 million, respectively, in revenue from sales of CapsoCam Plus, an increase of approximately 15% over the prior year. Our revenue has increased in each year since we began U.S. direct sales in 2020, primarily driven by an increase in the number of CapsoCam Plus capsules sold. We are in the process of updating CapsoCam Plus to add our self-developed AI assisted pathology detection technology. We made the related FDA 510(k) submission in December 2025 and are targeting related EU submission in the second quarter of 2026. We anticipate to obtain FDA clearance of the updated capsule by the middle of 2026 and EU clearance in the third quarter of 2026, with commercialization in U.S. and EU shortly thereafter. Our AI assisted pathology detection tools detect and highlight suspected abnormalities for a clinician, reducing their time to review a capsule video and making capsule endoscopy more financially attractive to their practice.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building upon the commercial success and the existing design of our CapsoCam Plus capsule, we developed our next pipeline capsule endoscope, CapsoCam Colon. Our CapsoCam Colon capsule (i) leverages CapsoCam Plus&#8217;s existing capsule design with its panoramic view and (ii) incorporates both our self-developed AI to automatically detect polyps in the video and our polyp-size measurement tool enabled by a 3D sensor in the capsule (polyp size being highly correlated with a polyp&#8217;s risk of becoming cancer). We submitted the 510(k) application for our first generation CapsoCam Colon capsule to the FDA in June 2025 and received responses from the FDA in September 2025. During our meeting with the FDA in December 2025, the FDA raised inquiries on topics including panoramic image processing methodology, and the proposed study design, sample size and primary endpoint for an extended study. Based on our communications with the FDA, we have decided not to further pursue the first generation CapsoCam Colon capsule submission and approval, and to prioritize our resources for the development of our second generation CapsoCam Colon capsule, featuring improved imaging quality and increased field of review with use of AI and better lens. We also expanded a second arm pivotal study to enroll approximately 800 patients at up to 20 sites in the U.S. in preparation for submitting a new 510(k) application for the second generation CapsoCam Colon capsule. As of the date of this Annual Report, over 500 patients have been enrolled for the second arm pivotal study. We currently expect to submit the 510(k) application for the second generation CapsoCam Colon capsule to the FDA in the third quarter of 2026. The CapsoCam Colon would be classified as a Class II device. Additionally, we intend to seek EU approval and commercialization for the second generation CapsoCam Colon capsule shortly after the FDA clearance. There is no guarantee that the clinical results of any of our clinical trials will demonstrate the requisite performance needed to meet applicable regulatory requirements in order to obtain FDA clearance. Further, FDA review of our 510(k) submissions may be delayed and we may not receive 510(k) clearances from the FDA on a timely basis or at all.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently sell CapsoCam Plus capsules in the U.S. to our customers, which primarily include gastroenterologists practicing in clinics and/or hospitals, primarily through our in-house sales team. Outside the U.S., we sell CapsoCam Plus through a combination of our in-house sales team and qualified distributors. In 2025 and 2024, international sales accounted for 21% and 23% of total revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our GI-tract capsule endoscopy solution is positioned to benefit from (i) our existing sales and marketing structure (with our in-house sales team and marketing team targeting sales of our various approved GI tract diagnostic products to the same target customer base), (ii) technological advancements (including improvements to our proprietary AI and other technologies and third-party supplier improvements in optics and storage capacity) and (iii) increased telemedicine adoption (following FDA clearance in December 2024 of remote ingestion of our CapsoCam Plus). We also believe our solution can be adapted to address new GI indications. Potential new medical indications include esophageal medical conditions (such as esophageal varices and Barrett&#8217;s esophagus) and pancreatic cancer. We plan to (i) commence feasibility studies of CapsoCam&#8217;s accuracy in detecting abnormalities indicative of cancerous and precancerous pancreatic neoplasia (abnormal cell growth) in the second quarter of 2026 and (ii) commence clinical studies of CapsoCam's accuracy in screening esophageal varices (i.e. enlarged blood veins in the esophagus) in cirrhotic patients with portal hypertension in the first half of 2027, in each case, subject to timely availability of sufficient funding and liquidity and/or potential adjustment of our clinical development priorities. In connection with our efforts to address pancreatic cancer, we submitted an FDA &#8220;Breakthrough Device Designation&#8221; for our capsule endoscopy solution on November 6, 2025. A response from FDA in January 2026 determined that the CapsoCam UGI, our capsule endoscopy system for use in early-stage pancreatic cancer detection, does allow for visualization of the papilla and its abnormalities, for both pre-cancerous and cancerous lesions. Due to the fact that the device does not specifically define diagnostic criteria, the application was not approved. The Company expects to resubmit the Breakthrough Device Designation application following the study, when additional data is available. The breakthrough designation is a part of the on-going project, potentially supplementing the regulatory pathway and approval for early pancreas cancer detection. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoCam Plus</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diseases of the small bowel include obscure GI bleeding, chronic iron-deficiency anemia, Crohn&#8217;s disease, tumors, and polyposis. Capsule endoscopy is the first-line modality for imaging the mucosa of the small bowel including the pathologies characterizing these diseases. Various methods of enteroscopy for reaching the entirety of the small bowel, which is approximately 20 feet long, are invasive, time consuming, and require a high level of skill from the operator of the endoscope. Enteroscopy is still required for biopsy or to provide certain therapies, but for diagnostic visualization, capsule endoscopy is preferred for its simplicity, non-invasiveness, and relatively low cost. Competitor capsule endoscopy systems that are currently available in the market consist of capsules with end-view systems, which provide only limited &#8220;tunnel&#8221; or partial &#8220;wall&#8221; views of the small bowel, and wired data recorders worn on the body, which incur an upfront capital expense and clinical workflow complications for providers and discomfort and multiple clinical visits for patients.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our CapsoCam Plus is a superior capsule endoscopy system, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables. Our CapsoCam captures a full 360&#176; panoramic video, providing a complete view of the GI mucosa&#8212;unobstructed by folds and with complete coverage of the bending intestine&#8217;s inner curvature, ultimately resulting in superior diagnostic yield. This was demonstrated by a large, single center retrospective study comparing the clinical performance of the CapsoCam system to competitor systems between 2012 and 2018. The same study also noted CapsoCam&#8217;s operational benefits, which included, greater lesion detection, 60% better visualization of the papilla, higher exam completion rates of 97% and less lost data.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In particular, our CapsoCam is a zero-capex &#8220;wire-free&#8221; data collection solution for providers as it stores the entire video in onboard memory. Following retrieval, our cloud-based platform, CapsoCloud, gives providers in the U.S. the ability to remotely access data from the cloud and stream in vivo </span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Thomas Pachofszky. World&#8217;s largest series with CapsoCam. Feasibility, completion and detection rate of the new generation of capsule endoscope with a 360&#176; lateral panoramic view&#8212;as single center retrospective study. Abstract UEG Week 2019.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">videos anywhere at their convenience. Outside of the U.S., providers review procedure videos using CapsoView software (primarily due to foreign data privacy and access regulations).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the use of AI in our CapsoCam Plus capsule, we made 510(k) submission in December 2025 and are targeting making EU submission in the second quarter of 2026. We anticipate to obtain FDA clearance by the middle of 2026 and EU clearance in the third quarter of 2026. Also, we are currently developing a capsule delivery device with full commercialization expected in the fourth quarter of 2026, and a patency capsule (for verifying a capsule endoscope can pass through the bowel without retention prior to an exam) with tentative FDA 510(k) submission planned by the end of the second quarter of 2026. Our 510(k) submissions and FDA review thereof may be delayed and we may not receive 510(k) clearances from the FDA on a timely basis or at all. The recent indication for children aged 2 years and above and the delivery device should enable faster penetration of the pediatric market. Of the patients who are unable to swallow a capsule, many are children. Patency capsules are used primarily with Crohn&#8217;s disease patients to verify that a capsule endoscope can pass through the GI tract without retention at a stricture, a narrowing of the small bowel which can result from inflammation and scarring associated with Crohn&#8217;s disease. The patency capsule is the same diameter as a capsule endoscope such that if it passes without delay, the CapsoCam is also likely to pass without retention (but will dissolve if retained). The global capsule endoscopy market for the small bowel is forecasted to reach approximately $335 million in 2030. The U.S. capsule endoscopy market for the small bowel is forecasted to reach approximately $126 million in 2030.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoCam Colon</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A colon polyp is a clump of cells that forms on the lining of the colon. Most colon polyps are harmless, but, over time, some colon polyps develop into CRC. The size of a polyp is highly correlated with its risk of becoming cancerous. Currently, optical colonoscopy, accompanied by polypectomy and biopsy, is considered the gold-standard for the detection of colorectal polyps and cancers. Colon capsule endoscopy provides non-invasive visualization of the entire colon from the cecum to the rectum, and it has demonstrated good sensitivity and specificity for the detection of colon polyps. It is intended to be used for (a) patients after an incomplete optical colonoscopy with adequate preparation and a complete evaluation of the colon was not technically possible and (b) patients with evidence of GI bleeding of lower GI origin with major risks for colonoscopy or moderate sedation, but who can tolerate colonoscopy and moderate sedation in the event a clinically significant colon abnormality is identified on capsule endoscopy. Currently, only two competitive products are available in the market for these indications&#8211;only one of which, Medtronic&#8217;s PillCam COLON 2, is available in the U.S. These competitor capsules have end-view systems, which provide only limited &#8220;tunnel&#8221; views of the colon, and wired data recorders worn on the body, which incur an upfront capital expense and clinical workflow complications for providers and discomfort and multiple clinical visits for patients.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our CapsoCam Colon, once FDA cleared, will be a superior capsule endoscopy system, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables. Our CapsoCam Colon utilizes our self-developed AI for automated polyp detection. AI improves diagnostic yield and provides more consistent accuracy with reduced dependency on the experience level of the physician video reader and their level of fatigue and distraction. Our CapsoCam Colon also incorporates our proprietary 3D-sensing technology to more accurately measure the size of polyps in the GI tract, enabling physicians to more confidently decide that patients with small (e.g., less than 6mm) polyps may forgo a follow-on colonoscopy, increasing the utility of the procedure for healthcare providers and patients alike. Similar to our CapsoCam Plus, our CapsoCam Colon also captures a full 360&#176; panoramic video, is a zero-capex &#8220;wire-free&#8221; data collection solution for providers and utilizes our cloud-based platform, CapsoCloud, for providers in the U.S. and CapsoView software for providers outside of the U.S. Further, CapsoCam Colon is a panenteric capsule which, when programmed with slightly different operating parameters, can be used to visualize both the small bowel and the colon in one procedure for the evaluation of Crohn&#8217;s disease, ulcerative colitis, irritable bowel syndrome and obscure GI bleeding.</span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Grand View Research, Inc., &#8220;Capsule Endoscopy Market Estimates &amp; Trend Analysis From 2018 to 2030,&#8221; an independent report commissioned by CapsoVision, Inc.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current indications for colon capsule endoscopy are limited to patients with evidence of lower-GI bleeding (such as a positive stool test) for whom the risk of colonoscopy or moderate sedation is significant and for patients who have had an incomplete colonoscopy, with adequate preparation. The global colon capsule endoscopy market is forecasted to reach approximately $311 million in 2030.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This estimate only considers current products on the market and does not take into account advanced products currently in development and/or awaiting approval for introduction into the market. We believe that our CapsoCam Colon, once FDA cleared and commercialized, will be a superior capsule endoscopy system that will expand the market for colon capsule endoscopy.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a competitive advantage through multiple strategic initiatives, including investing substantial resources to create our intellectual property portfolio. As of December 31, 2025, we had over 140 issued patents covering multiple aspects of our capsules and technology.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in research and development initiatives that are focused on introducing enhancements and improvements aimed at increasing the value provided by our GI-tract capsule endoscopy solution. Our research and development team includes hardware and software engineers with deep expertise in medical technology, optics, data science, AI, and cloud-based data and security architecture and individuals with extensive clinical development expertise.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Program</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed our first commercial product, the CapsoCam capsule endoscopy solution (the current generation of which we refer to as CapsoCam Plus), for visualization of the small bowel mucosa. The following table summarizes key information about our clinical program for the small bowel capsule:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:34.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Clinical Trials</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Timeline</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visualize small bowel and detect pathologies</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Received FDA 510(k) clearance in 2016*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Collection (AI) Study</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA 510(k) submitted at the end of 2025</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Received FDA 510(k) clearance in December 2024 for pediatric (children aged 2 years and above) use and telemedicine supervision (i.e., remote ingestion) indications.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed our next pipeline product, the CapsoCam Colon capsule endoscopy system, for visualization of the colon and detection and measurement of polyps. The following table summarizes key information about our clinical program for CapsoCam Colon:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:34.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Clinical Trials</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated Timeline</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visualize colon and detect/measure polyps</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Feasibility Study</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed in 2018**</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pilot Study</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed in 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pivotal Study (first arm)&#8212;1st generation capsule</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed in 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pivotal Study (second arm)&#8212;improved 2nd generation capsule</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA 510(k) submission expected in the third quarter of 2026</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Operationally, the study used to enroll feasibility study subjects remains active to facilitate continued research and development of the CapsoCam Colon, which from time to time requires a limited investigation in healthy volunteers.</span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Grand View Research, Inc., &#8220;Capsule Endoscopy Market Estimates &amp; Trend Analysis From 2018 to 2030,&#8221; an independent report commissioned by CapsoVision, Inc.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Strengths</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the continued growth of our Company will be driven by the following factors:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Sole capsule endoscope with a 360&#176; panoramic view available in the market</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe only our CapsoCam Plus boasts a 360&#176; panoramic lateral view. It houses four high-resolution cameras around its circumference, and the images from each are stitched into a single panoramic image. Compared to competitive end-view systems, a 360&#176; panoramic lateral view provides a complete view of the GI mucosa&#8212;unobstructed by folds and with complete coverage of the bending intestine&#8217;s inner curvature, resulting in demonstrated superior diagnostic yield.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Telemedicine-enabled and zero-capex &#8220;wire-free&#8221; data collection and remote data analysis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our CapsoCam is a zero-capex &#8220;wire-free&#8221; data collection solution for providers, as it stores the entire video in onboard memory. In December 2024, we received FDA 510(k) clearance for telemedicine supervision (i.e., remote ingestion) of our CapsoCam Plus, allowing patients to ingest our capsule in the comfort of their own homes, under the remote supervision of providers. The CapsoCam solution frees up exam-room schedules for providers and provides flexibility to administer capsules any day at any time. A provider&#8217;s practice can easily scale to multiple capsules per day with no added cost, and there is no equipment to recover from patients. Our CapsoCam Plus solution includes our cloud-based platform, CapsoCloud, which provides a flexible, trackable, streamlined, and capital-equipment-free workflow for providers in the U.S. It also allows clinicians to track procedures and stream in vivo videos anywhere at their convenience, generate reports, store and manage patient data, and transfer data to third-party reading services. We believe at-home procedures and remote analysis via CapsoCloud will be attractive to providers and patients alike, particularly for future screening indications.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Automated pathology detection due to usage of AI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. CapsoCam Colon (subject to FDA clearance) incorporates deep learning AI for automated pathology detection of polyps, a capability that competitive systems lack. For the use of AI in our CapsoCam Plus capsule, we made 510(k) submission in December 2025 and are targeting making EU submission by the second quarter of 2026. We anticipate to obtain FDA clearance by the middle of 2026 and EU clearance in the third quarter of 2026. Our AI assisted pathology detection tools detect and highlight suspected abnormalities for a clinician, reducing their time to review the video and making capsule endoscopy more financially attractive to their practice. CapsoCloud continuously acquires consenting patients&#8217; clinical data, enabling our in-house AI experts to develop ever-improving automated lesion detection and classification. Our 510(k) submission and FDA review thereof may be delayed and we may not receive 510(k) clearance from the FDA on a timely basis or at all.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">3D-sensing technology informs follow-on care decisions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our CapsoCam Colon (subject to FDA clearance) incorporates our proprietary 3D-sensing technology to more accurately measure polyp sizes. Polyp size is highly correlated with its risk of becoming cancer. No other capsule endoscope currently in the market has 3D-enabled measurement capability. With automated pathology detection and the ability to manually review video frames adjacent to an identified polyp, physicians can more confidently decide that patients with small (e.g., less than 6mm) polyps may forgo a follow-on colonoscopy, increasing the utility of the procedure for healthcare providers and patients alike.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Experienced leadership team</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our senior management team consists of industry professionals with deep industry expertise across various disciplines, including medical technology, engineering, optics, sales and marketing, finance, operations, data science, AI, and clinical operations and research.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Growth Strategies</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term, lifesaving vision is an ingestible capsule that, in a single convenient non-invasive procedure, screens for multiple cancers&#8212;esophageal, gastric, pancreatic, small-bowel, and colorectal&#8212;at early and precancerous stages, utilizing AI to analyze thousands of images captured in the GI tract. We are building towards </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this goal with a planned succession of FDA-cleared indications, targeting existing and nascent markets. Until then, key elements of our nearer-term growth strategy include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Obtain 510(k) clearance of CapsoCam Colon</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have developed our next pipeline product, CapsoCam Colon, for visualization of the colon and detection and measurement of polyps. In addition to having a 360&#176; panoramic lateral view, it incorporates deep learning AI for automated pathology detection of polyps and 3D-sensing technology to more accurately measure polyp sizes. We submitted the 510(k) application for our first generation CapsoCam Colon capsule to the FDA in June 2025 and received responses from the FDA in September 2025. During our meeting with the FDA in December 2025, the FDA raised inquiries on topics including panoramic image processing methodology, and the proposed study design, sample size and primary endpoint for an extended study. Based on our communications with the FDA, we have decided not to further pursue the first generation CapsoCam Colon capsule submission and approval, and to prioritize our resources for the development of our second generation CapsoCam Colon capsule, featuring improved imaging quality and increased field of review with use of AI and better lens. We also expanded a second arm pivotal study to enroll approximately 800 patients at up to 20 sites in the U.S. in preparation for submitting a new 510(k) application for the second generation CapsoCam Colon capsule. As of the date of this Annual Report, over 500 patients have been enrolled for the second arm pivotal study. We currently expects to submit the 510(k) application for the second generation CapsoCam Colon capsule to the FDA in the third quarter of 2026. There is no guarantee that the clinical results of any of our clinical trials will demonstrate the requisite performance needed to meet applicable regulatory requirements in order to obtain FDA clearance. Current indications for colon capsule endoscopy are limited to patients with evidence of lower-GI bleeding (such as a positive stool test) for whom the risk of colonoscopy or moderate sedation is significant and for patients who have had an incomplete colonoscopy, with adequate preparation. As a part of this 510(k) application, to increase the population of indicated patients, we intend to seek FDA clearance of expanded indications that remove the requirement for evidence of GI bleeding of lower GI origin for patients with major risks for colonoscopy or moderate sedation. Our 510(k) submission for the second generation of CapsoCam Colon and FDA review of our 510(k) applications may be delayed and we may not receive 510(k) clearances from the FDA on a timely basis or at all. Additionally, we intend to seek EU approval and commercialization for the second generation CapsoCam Colon capsule shortly after the FDA clearance. The global colon capsule endoscopy market is forecasted to reach approximately $311 million in 2030.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This estimate only considers current products on the market and does not consider advanced products currently in development and/or awaiting approval for introduction into the market. We believe that our CapsoCam Colon, once FDA cleared and commercialized, will be a superior capsule endoscopy system that will expand the market for colon capsule endoscopy.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expand clinical use cases and accessories for CapsoCam Plus.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2024, we received 510(k) clearance of our CapsoCam Plus for pediatric use in children aged 2 years and above and telemedicine supervision (i.e., remote ingestion). Also, we are currently developing a capsule delivery device with full commercialization expected in the fourth quarter of 2026 for patients who are unable to swallow the capsule, many of whom are children. The capsule delivery device should enable faster penetration of the newly indicated pediatric market. We are also currently developing a patency capsule with tentative FDA 510(k) submission planned by  the end of the second quarter of 2026, which is used primarily with Crohn&#8217;s disease patients to verify that a capsule endoscope can pass through the GI tract without retention at a stricture, a narrowing of the small bowel which can result from inflammation and scarring associated with Crohn&#8217;s disease.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Continue to improve and innovate our GI-tract capsule endoscopy solution.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our research and development initiatives are focused on introducing enhancements and improvements aimed at increasing the value provided by our GI-tract capsule endoscopy solution. In particular, we are working on improvements to our CapsoCam, including a new lens and illumination optics with an increased field of </span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Grand View Research, Inc., &#8220;Capsule Endoscopy Market Estimates &amp; Trend Analysis From 2018 to 2030,&#8221; an independent report commissioned by CapsoVision, Inc.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">view, improved image quality and higher peak frame rate. For our AI assisted pathology detection technology, we plan to continue investing to (i) improve the pathology-detection and classification accuracy and the scope of our AI algorithms and (ii) apply AI, including large language models, to streamline the diagnostic and medical-report-generation processes, which in turn improves the efficiency and effectiveness of our healthcare provider customers. We also plan to continue making improvements to our CapsoCloud and CapsoView software.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:13.8pt">Expand into new indications and clinical use cases beyond small bowel and colon</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In the first half of 2027, we plan to commence clinical studies of our CapsoCam&#8217;s accuracy in screening esophageal varices in cirrhotic patients with portal hypertension, subject to timely availability of sufficient funding and liquidity and/or potential adjustment of our clinical development priorities. Patients with cirrhosis who develop portal hypertension are at risk for complications, including bleeding from esophageal varices. Portal hypertension is the result of resistance to portal blood flow, which most often occurs in the liver and with increases in portal blood flow. When esophageal varices rupture, bleeding may be severe and life- threatening. There are approximately 5.5 million people in the U.S. with Cirrhosis.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Up to 85% of cirrhotic patients at some point develop esophageal varices15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, a significant clinical stage.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Esophageal varices is one of the most common causes of acute upper gastrointestinal bleeding. Acute variceal bleeding is a potentially fatal complication of liver cirrhosis and represents an important economic and population health issue.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We believe that our CapsoCam&#8217;s panoramic imaging is particularly well suited to visualizing the esophagus and measuring the size of varices, which may translate to significant improvement in sensitivity and staging accuracy. In the second quarter of 2026, we plan to commence feasibility studies of our CapsoCam&#8217;s accuracy in detecting abnormalities indicative of cancerous and precancerous pancreatic neoplasia (abnormal cell growth) by visualizing abnormalities of the duodenal papilla, subject to timely availability of sufficient funding and liquidity and/or potential adjustment of our clinical development priorities. A dilated, or unnaturally opened, duodenal papilla is correlated with GI tract content reflux into the pancreas duct and pancreatic neoplasia and may indicate the presence of, or elevated risk of developing, serious abnormalities like pancreatitis or a tumor of the pancreas. The CapsoCam has detected the duodenal papilla (Ampulla of Vater) at a higher rate than non-panoramic systems in prior studies. For example, a 2024 retrospective study was conducted at a single Japanese center with 33 patients ingesting the CapsoCam Plus and another random sample of propensity-score-matched patients ingesting the Medtronic PillCam SB3. Physician video readers observed the duodenal papilla at a significantly higher rate using the CapsoCam Plus (82% vs. 15%, p &lt; 0.001).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> There is currently no effective screening for pancreatic cancer. In connection with our efforts to address pancreatic cancer, we submitted an FDA &#8220;Breakthrough Device Designation&#8221; for our capsule endoscopy solution on November 6, 2025. A response from FDA in January 2026 determined that the CapsoCam UGI does allow for visualization of the papilla and its abnormalities, for both pre-cancerous and cancerous lesions. Due to the fact that the device does not specifically define diagnostic criteria, the application was not approved. The Company expects to resubmit the Breakthrough Device Designation application following the study, when additional data is available. The breakthrough designation is a part of the on-going </span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> https://gi.org/topics/liver-cirrhosis/</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Socrate Pallio, et al. Diagnosis and Management of Esophagogastric Varices. Diagnostics 2023, 13, 1031.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> D&#8217;Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014; 39:1180&#8211;1193.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Socrate Pallio, et al. Diagnosis and Management of Esophagogastric Varices. Diagnostics 2023, 13, 1031.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hirata, Issei; Tsuboi, Akiyoshi; Matsubara, Yuka; Sumioka, Akihiko; Takasago, Takeshi; Tanaka, Hidenori; Yamashita, Ken; Takigawa, Hidehiko; Urabe, Yuji; Oka, Shiro. Clinical usefulness and acceptability of small-bowel capsule endoscopy with panoramic imaging compared with axial imaging in Japanese patients. DEN Open. 2024 Jun 6</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">project, potentially supplementing the regulatory pathway and approval for early pancreas cancer detection. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Market Overview</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview and Challenges of Visualizing Small Bowel and Detecting Small Bowel Pathologies</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diseases of the small bowel include obscure GI bleeding, chronic iron-deficiency anemia, Crohn&#8217;s disease, tumors, and polyposis.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obscure GI bleeding is recurrent or persistent GI bleeding of uncertain origin. 5% of all GI bleeding is obscure GI bleeding. In approximately 80% of obscure GI bleeding cases, the origin is localized to the small bowel.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Chronic iron-deficiency anemia is a condition in which blood lacks adequate healthy red blood cells. Red blood cells carry oxygen to the body&#8217;s tissues. Chronic iron-deficiency is the most common nutrient deficiency in the world and a significant common cause of anemia worldwide. Crohn&#8217;s disease is a type of inflammatory bowel disease that causes swelling and irritation of the tissues, called inflammation, in the digestive tract. This can lead to belly pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn&#8217;s disease can affect different areas of the digestive tract in different people. Crohn&#8217;s disease most commonly affects the end of the small intestine and the beginning of the large intestine. The inflammation often spreads into the deeper layers of the bowel. Crohn&#8217;s disease often begins in a person&#8217;s teens or twenties, though some patients experience symptoms even earlier.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capsule endoscopy is the first-line modality for imaging the mucosa of the small bowel including the pathologies characterizing these diseases. Various methods of enteroscopy for reaching the entirety of the small bowel, which is approximately 20 feet long, are invasive, time consuming, and require a high level of skill from the operator of the endoscope. Enteroscopy is still required for biopsy or to provide certain therapies. For diagnostic visualization, however, capsule endoscopy is preferred given its simplicity, non-invasiveness, and relatively low cost.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After obtaining negative esophagogastroduodenoscopy and colonoscopy procedure results, capsule endoscopy of the small bowel is the first-line investigational procedure for obscure GI bleeding. The reported diagnostic yield of capsule endoscopy ranges from 30% to 70%, exceeding that of alternative diagnostic methods, such as push enteroscopy (which has a reported diagnostic yield estimated at approximately 31%), double-balloon enteroscopy (which has a reported diagnostic yield estimated at approximately 23%), and small-bowel series (which has a reported diagnostic yield estimated at approximately 5%). Capsule endoscopy has the additional advantage of non-invasiveness. Due to the often-intermittent nature of GI bleeding, performing capsule endoscopy within 14 days of a bleeding episode maximizes the diagnostic yield.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">11</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sources of bleeding found by capsule endoscopy include ulcers, vascular anomalies, tumors, polyps, and non-specific enteritis. Sometimes blood is detected without identifying a source lesion. Over one half of patients regularly taking non-steroidal anti-inflammatory drugs have small-bowel lesions with the potential to bleed. Capsule endoscopy identifies the type, location, and extent of lesions, and helps determine therapeutic interventions and monitor their effectiveness. The localization of lesions determines the route (upper or lower) of follow-on device-assisted enteroscopy.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capsule endoscopy is indicated for patients with chronic iron-deficiency anemia when obscure GI bleeding is merely suspected, after obtaining negative esophagogastroduodenoscopy and colonoscopy procedure results. In particular, capsule endoscopy can be considered for patients with severe anemia&#8212;requiring blood transfusions, hemoglobin level &lt;100 g/L, or persistent or recurrent iron-deficiency anemia despite iron replacement therapy.</span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lee, Bo-In (2022). Indications and Contraindications of Small-bowel Capsule Endoscopy. In: Chun, H.J., Seol, SY., Choi, MG., Cho, J.Y. (eds) Small Intestine Disease. Springer, Singapore.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lee, Bo-In (2022). Indications and Contraindications of Small-bowel Capsule Endoscopy. In: Chun, H.J., Seol, SY., Choi, MG., Cho, J.Y. (eds) Small Intestine Disease. Springer, Singapore.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capsule endoscopy is also indicated for patients presenting with clinical features consistent with Crohn&#8217;s disease, after negative ileocolonoscopy and imaging studies. Capsule endoscopy has shown good sensitivity (91%-100%) and specificity (91%-92%) when using ileocolonoscopy as the reference test. A prospective study reported that capsule endoscopy aided Crohn&#8217;s disease diagnosis in 83% of cases, influenced decision making in 72%, and changed management in 78%.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Capsule endoscopy can be used to provide additional information influencing disease management in patients with known Crohn&#8217;s disease, when ileocolonoscopy or imaging results do not fully explain the clinical presentation. It further can be used to assess mucosal healing or when Crohn&#8217;s disease is recurrent after colectomy.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capsule endoscopy is recommended for ongoing surveillance of polyps in patients with intestinal polyposis syndromes, especially Peutz-Jeghers Syndrome. Hereditary polyposis syndromes (including Peutz-Jeghers Syndrome) present a significant risk of complications including bleeding and intussusception. Capsule endoscopy has better diagnostic yield than endoscopy for polyps beyond the duodenum. Capsule endoscopy also has demonstrated detection of more polyps and smaller polyps compared to other non-invasive imaging modalities, such as radiography or magnetic resonance enterography, and similar detection compared to device-assisted enteroscopy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">13</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Addressable Market Opportunity in Visualizing Small Bowel and Detecting Small Bowel Pathologies</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global capsule endoscopy market for the small bowel is forecasted to reach approximately $335 million in 2030. The U.S. capsule endoscopy market for the small bowel is forecasted to reach approximately $126 million in 2030.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">14</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview and Challenges of Detecting Colon Polyps</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A colon polyp is a clump of cells that forms on the lining of the colon. Most colon polyps are harmless, but, over time, some colon polyps develop into CRC. The size of a polyp is highly correlated with its risk of becoming cancerous.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, optical colonoscopy, accompanied by polypectomy and biopsy, is considered the gold-standard for the detection of colorectal polyps and cancers. Each year in the U.S., there are approximately 153,000 new cases of CRC and approximately 53,000 deaths.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is widely accepted that CRC is among the most preventable, yet least-prevented cancers. CRC can take up to 10-15 years to progress from a pre-cancerous lesion to metastatic cancer and death. Patients who are diagnosed early in the progression of the disease&#8212;with pre-cancerous lesions or early-stage cancer&#8212;are more likely to have a complete recovery and to be treated less expensively.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Colon capsule endoscopy provides non-invasive visualization of the entire colon from the cecum to the rectum, and it has demonstrated good sensitivity and specificity for the detection of colon polyps. It is intended to be used for (a) patients after an incomplete optical colonoscopy with adequate preparation and a complete evaluation of the colon was not technically possible and (b) patients with evidence of GI bleeding of lower GI origin with major risks for colonoscopy or moderate sedation, but who can tolerate colonoscopy and moderate sedation in the event a clinically significant colon abnormality is identified on capsule endoscopy. As a part of our 510(k) application for our second generation CapsoCam Colon and to increase the population of indicated patients, we intend to seek </span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Enns, Robert A.; Hookey, Lawrence; Armstrong, David; Bernstein Charles N.; Heitman, Steven J; Teshima, Christopher; Leontiadis, Grigorios I.; Tse, Frances; Sadowski, Daniel. Clinical Practice Guidelines for the Use of Video Capsule Endoscopy. Gastroenterology. 2017 Feb;152(3):497-514.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Enns, Robert A.; Hookey, Lawrence; Armstrong, David; Bernstein Charles N.; Heitman, Steven J; Teshima, Christopher; Leontiadis, Grigorios I.; Tse, Frances; Sadowski, Daniel. Clinical Practice Guidelines for the Use of Video Capsule Endoscopy. Gastroenterology. 2017 Feb;152(3):497-514.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Grand View Research, Inc., &#8220;Capsule Endoscopy Market Estimates &amp; Trend Analysis From 2018 to 2030,&#8221; an independent report commissioned by CapsoVision, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA clearance of expanded indications that remove the requirement for evidence of GI bleeding of lower GI origin for patients with major risks for colonoscopy or moderate sedation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incomplete colonoscopies are reported at rates from 4% to 25%. Of these, approximately half result from inadequate bowel preparation and otherwise due to the tortuosity of the colon, adhesions from previous surgeries, angulation, fixation of bowel loops, diverticulosis, or ineffective sedation. A large multicenter study found that 50% of screening patients had a significant dysplastic lesion in the proximal colon. The risk of proximal cancer is 2 times greater when colonoscopy is incomplete.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A complete colonoscopy can often be achieved in a second attempt, especially by highly skilled endoscopists employing specialized equipment and techniques, taking extra time, and choosing an appropriate sedation. However, often a non-invasive procedure to visualize the proximal colon is preferred. Computed tomography colonography (&#8220;CTC&#8221;) and colon capsule endoscopy are both non-invasive options. CTC, also referred to as virtual colonoscopy, is an imaging examination of the entire colon and rectum. CTC uses computed tomography to acquire images and advanced two-dimensional and three-dimensional image display techniques for interpretation. Following incomplete colonoscopy, compared to CTC, colon capsule endoscopy has demonstrated a 61.5% higher diagnostic yield for polyps greater than 5mm and 3 times greater for all polyps.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In a multicenter prospective study, among 286 analyzable subjects of average risk in a screening population, the sensitivity for polyps greater than or equal to 6mm for colon capsule endoscopy was 78.2% compared to only 26.8% for CTC.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">18</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many patients have an elevated risk for colonoscopy or the moderate sedation that typically accompanies it. For them, the risk of a screening or surveillance colonoscopy may not be justified without prior evidence that a significant lesion requiring polypectomy is present. Colon capsule endoscopy is a non-invasive low-risk procedure that does not require sedation. It may be used as a preliminary test to determine if a significant polyp is present. However, colon capsule endoscopy is not yet widely used for these patients. A major reason may be that the labeled indications stipulate that these patients have evidence of bleeding from a lower GI origin, such as a positive stool test, prior to colon capsule endoscopy. In most cases, after a positive stool test, providers in the U.S. are likely to refer patients to colonoscopy directly, with colon capsule endoscopy reserved for those cases where the patient refuses colonoscopy or the risk associated with colonoscopy or sedation is especially high.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Addressable Market Opportunity in Colon Capsule Endoscopy</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global colon capsule endoscopy market is forecasted to reach approximately $311 million in 2030.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This estimate only considers current products on the market and does not consider advanced products currently in development and/or awaiting approval for introduction into the market. We believe that our CapsoCam Colon, once FDA cleared and commercialized, will be a superior capsule endoscopy system that will expand the market for colon capsule endoscopy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Potential Opportunities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first half of 2027, we plan to commence clinical studies of our CapsoCam&#8217;s accuracy in screening esophageal varices in cirrhotic patients with portal hypertension, subject to timely availability of sufficient funding </span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Franco, Diana L.; Leighton, Jonathan A.; Gurudu, Suryakanth R. Approach to Incomplete Colonoscopy: New Techniques and Technologies. Gastroenterol Hepatol (N Y). 2017 Aug;13(8):476-483.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Deding, Ulrik; Kaalby; Lasse; B&#248;ggild, Henrik; Plantener, Eva; Wollesen, Mie K; Kobaek-Larsen, Morten; Hansen, Siri J.; Baatrup, Gunnar. Colon Capsule Endoscopy vs. CT Colonography Following Incomplete Colonoscopy: A Systematic Review with Meta-Analysis. Cancers (Basel). 2020 Nov 13;12(11):3367.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash, Brooks D; Fleisher, Mark R.; Fern, Steven; Rajan, Elizabeth; Haithcock, Robyn; Kastenberg, David M; Pound, David; Papageorgiou Neofytos P; Fern&#225;ndez-Uri&#233;n Ignacio; Schmelkin Ira J; Rex Douglas K. Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study). Gut. 2021 Nov;70(11):2115-2122. DOI:10.1136/gutjnl-2020-322578</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Grand View Research, Inc., &#8220;Capsule Endoscopy Market Estimates &amp; Trend Analysis From 2018 to 2030,&#8221; an independent report commissioned by CapsoVision, Inc.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and liquidity and/or potential adjustment of our clinical development priorities. Patients with cirrhosis who develop portal hypertension are at risk for complications, including bleeding from esophageal varices. Portal hypertension is the result of resistance to portal blood flow, which most often occurs in the liver and with increases in portal blood flow. When esophageal varices rupture, bleeding may be severe and life threatening. There are approximately 5.5 million people in the U.S. with Cirrhosis.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Up to 85% of cirrhotic patients at some point develop esophageal varices</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a significant clinical stage.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Esophageal varices is one of the most common causes of acute upper gastrointestinal bleeding. Acute variceal bleeding is a potentially fatal complication of liver cirrhosis and represents an important economic and population health issue.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Esophageal varices screening or surveillance is typically conducted for decompensated cirrhosis or compensated but liver stiffness &gt; 20 KPa or platelet count &lt; 150,000/mL (CSPH).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Traditional endoscopy poses a risk for rupture of the varices and an increased risk of sedation-related complications typical of those with liver cirrhosis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with potential medicolegal implications. Medicare reimbursement is indicated as an alternative to endoscopy for suitable patients with CSPH, for example those anticipated to tolerate adequate doses of beta-blockers to alleviate CSPH if varices are detected or those who cannot tolerate traditional endoscopy or when endoscopic procedures may be inappropriate or contraindicated. Despite the potential benefits of capsule endoscopy to screen for varices, the Medtronic PillCam is not widely used for this purpose, mostly because the sensitivity is insufficient. In a prospective study with 330 cirrhotic patients with no known esophageal varices, only 64% of those with varices detected by endoscopy were correctly diagnosed and correctly staged by the PillCam.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that our CapsoCam&#8217;s panoramic imaging is particularly well suited to visualizing the esophagus and measuring the size of varices, which may translate to significant improvement in sensitivity and staging accuracy.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in the second quarter of 2026, we plan to commence feasibility studies of our CapsoCam&#8217;s accuracy in detecting abnormalities indicative of cancerous and precancerous pancreatic neoplasia (abnormal cell growth) by visualizing abnormalities of the duodenal papilla, subject to timely availability of sufficient funding and liquidity and/or potential adjustment of our clinical development priorities. A dilated, or unnaturally opened, duodenal papilla is correlated with GI tract content reflux into the pancreas duct and pancreatic neoplasia and may indicate the presence of, or elevated risk of developing, serious abnormalities like pancreatitis or a tumor of the pancreas. The CapsoCam has detected the duodenal papilla (Ampulla of Vater) at a higher rate than non-panoramic systems in prior studies. For example, a 2024 retrospective study was conducted at a single Japanese center with 33 patients ingesting the CapsoCam Plus and another random sample of propensity-score-matched patients ingesting the Medtronic PillCam SB3. Physician video readers observed the duodenal papilla at a significantly higher rate using the CapsoCam Plus (82% vs. 15%, p &lt; 0.001).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Another retrospective single-center study in Austria compared the detection of the duodenal papilla in 516 CapsoCam Plus, 803 Medtronic PillCam, and 315 IntroMedic MiroCam procedures from 2012-2018 and observed an 82% detection rate for CapsoCam Plus and an average of 10% detection rate for PillCam and MiroCam. According to the ACS, pancreatic cancer is estimated to be diagnosed in 67,530 patients in the U.S. in 2026, and approximately 52,740 patients are estimated to die from it. Due to the asymptomatic early stages, in most cases this disease is detected too late, making pancreatic cancer one of the most lethal malignant neoplasms. The overall 5-year survival rate is approximately 13%, which is the lowest survival rate of all cancer types. On the other hand, the 5-year survival rate is around 44% if the pancreatic cancer is still in the early stages at the time of diagnosis. A definitive diagnosis is currently made </span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> https://gi.org/topics/liver-cirrhosis/</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Socrate Pallio, et al. Diagnosis and Management of Esophagogastric Varices. Diagnostics 2023, 13, 1031.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> D&#8217;Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014; 39:1180&#8211;1193.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Socrate Pallio, et al. Diagnosis and Management of Esophagogastric Varices. Diagnostics 2023, 13, 1031.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Socrate Pallio, et al. Diagnosis and Management of Esophagogastric Varices. Diagnostics 2023, 13, 1031.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Socrate Pallio, et al. Diagnosis and Management of Esophagogastric Varices. Diagnostics 2023, 13, 1031.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sacher-Huvelin S, Cales P, Bureau C, et al. Screening of esophageal varices by esophageal capsule endoscopy: results of a French multicenter prospective study. Endoscopy. 2015; 47:486&#8211;92.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hirata, Issei; Tsuboi, Akiyoshi; Matsubara, Yuka; Sumioka, Akihiko; Takasago, Takeshi; Tanaka, Hidenori; Yamashita, Ken; Takigawa, Hidehiko; Urabe, Yuji; Oka, Shiro. Clinical usefulness and acceptability of small-bowel capsule endoscopy with panoramic imaging compared with axial imaging in Japanese patients. DEN Open. 2024 Jun 6</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through a series of investigations, including imaging scans, blood tests and biopsy, which are usually only performed in symptomatic patients. There is currently no effective screening for pancreatic cancer. In connection with our efforts to address pancreatic cancer, we submitted an FDA &#8220;Breakthrough Device Designation&#8221; for our capsule endoscopy solution on November 6, 2025. A response from FDA in January 2026 determined that the CapsoCam UGI does allow for visualization of the papilla and its abnormalities, for both pre-cancerous and cancerous lesions. Due to the fact that the device does not specifically define diagnostic criteria, the application was not approved. The Company expects to resubmit the Breakthrough Device Designation application following the study, when additional data is available. The breakthrough designation is a part of the on-going project, potentially supplementing the regulatory pathway and approval for early pancreas cancer detection.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite its advantages, colon capsule endoscopy has not yet been granted approval for a CRC screening indication in the U.S., and is not widely used for screening in other markets. Although many studies suggest that colon capsule endoscopy has polyp-detection accuracy similar to that of a colonoscopy, the quantity of high-quality evidence establishing its effectiveness in a screening population is currently considered insufficient.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Colon capsule endoscopy adoption is also hindered by a relatively high percentage of procedures that do not afford complete visualization of the colon, due to inadequate bowel preparation or a battery life shorter than the GI transit time. In many cases, significant polyps detected by colon capsule endoscopy are not detected during subsequent colonoscopy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In part, this reflects the imperfect sensitivity of colonoscopy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">30</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Colon capsule endoscopy has advantages relative to other non-invasive tests that are used for CRC screening. Compared to CTC, colon capsule endoscopy has demonstrated superior polyp detection accuracy and diagnostic yield. Stool tests and blood tests have demonstrated good sensitivity for cancer, but sensitivity for advanced precancerous lesions is under 50%. Relatively high false-positive rates for multi-targeted stool DNA tests, such as Cologuard, lead to unnecessary colonoscopies. In a study with over 10,000 average-risk screening patients, advanced neoplasia was not detected by colonoscopy in 75% of Cologuard-positive cases.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">31</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the large, underserved population of unscreened and inadequately screened patients represents a significant opportunity for our CapsoCam Colon capsule endoscopy solution. CRC is the second leading cause of cancer deaths in the U.S. and the leading cause of cancer deaths in the U.S. among non-smokers. Each year in </span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See (1)Vuik, Fanny ER; Nieuwenburg, Stella AV; Moen, Sarah; Spada, Cristiano; Senore, Carlo; Hassan, Cesare; Pennazio, Marco; Rondonotti, Emanuele; Pecere, Silvia; Kuipers, Ernest J; Spaander, Manon CW. Colon capsule endoscopy in colorectal cancer screening: a systematic review. Endoscopy. 2021 Aug;53(8):815-824. DOI: 10.1055/a-1308-1297; (2) Deding, Ulrik; Kaalby; Lasse; B&#248;ggild, Henrik; Plantener, Eva; Wollesen, Mie K; Kobaek-Larsen, Morten; Hansen, Siri J.; Baatrup, Gunnar. Colon Capsule Endoscopy vs. CT Colonography Following Incomplete Colonoscopy: A Systematic Review with Meta-Analysis. Cancers (Basel). 2020 Nov 13;12(11):3367.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rex, Douglas K; Adler, Samuel N; Aisenberg, James; Burch, Wilmot C Jr; Carretero, Cristina; Chowers, Yehuda; Fein, Steven A; Fern, Steven E; Fernandez-Urien Sainz, Ignaico; Fich, Alexander; Gal, Eyal; Horlander Joh C Sr; Isaacs, Kim L; Kariv, Revital; Lahat, Adi; Leung, Wai-Keung; Malik, Pramond; Morgan, Doug; Papageorgiou, Neofytos; Romeo, David P; Shah Smita S; Waterman Matti. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population. Gastroenterology. 2015 May;148(5):948-957.e2. doi: 10.1053/j.gastro.2015.01.025</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Zhao, Shengbing; Wang, Shuling; Pan, Peng; Xia, Tian; Chang, Xin; Yang, Xia; Guo, Liliangzi; Meng, Qianqian; Yang, Fan; Qian, Wei; Xu, Zhichao; Wang, Yuanqiong; Wang, Zhijie; Gu, Lun; Wang, Rundong; Jia, Fangzhou; Yao, Jun; Li, Zhaoshen; Bai, Yu. Magnitude, Risk Factors, and Factors Associated With Adenoma Miss Rate of Tandem Colonoscopy: A Systematic Review and Meta-analysis. Gastroenterology. 2019 May;156(6):1661-1674.e11. doi: 10.1053/j.gastro.2019.01.260</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For FIT test, see Imperiale, Thomas F.; Ransohoff, David F.; Itzkowitz, Steven H.; Levin, Theodore R; Lanvin, Philip;Lidgard, Graham P. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. N Engl J Med. 2014 April 13. DOI: 10.1056/NEJMoa1311194 For blood test, see Chung, Daniel C; Gray, Darrell M.; Singh, Harminder; Issaka, Rachel B.; Raymond, Victoria M.; Eagle, Craig; Hu Sylvia; Chudova, Darya I.; Talasaz AmirAli; Greenson, Joel K.; Sinicrope Frank A.; Gupta, S,amir;Grady, William M. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):973-983. DOI: 10.1056/NEJMoa2304714.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the U.S., there are approximately 153,000 new cases of CRC and approximately 53,000 deaths.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is widely accepted that CRC is among the most preventable, yet least-prevented cancers. CRC can take up to 10-15 years to progress from a pre-cancerous lesion to metastatic cancer and death. Patients who are diagnosed early in the progression of the disease&#8212;with pre-cancerous lesions or early-stage cancer&#8212;are more likely to have a complete recovery and to be treated less expensively. The ACS recommends that men and women over the age of 45 receive an optical colonoscopy every 10 years or other structural test, such as sigmoidoscopy or CTC, every 5 years or alternatively, a multi-targeted stool DNA test, such as Cologuard, should be performed every 3 years, or other stool-based test, such as FIT or FOBT, should be performed every year. The U.S. colon screening, diagnostic, and surveillance market is forecasted to reach approximately $21.8 billion in 2030.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">33</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we intend to conduct clinical studies to support FDA approval of a premarket approval application (&#8220;PMA&#8221;) for use of CapsoCam Colon as a method for non-invasive detection of cancer and pre-cancerous lesions in the colon. In other words, we would like to seek FDA approval of CapsoCam Colon as a screening test for both the potential prevention of and the detection of cancer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solutions</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoCam Plus</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa, to detect abnormalities of the small bowel in adults and children aged 2 years and above. Capsule endoscopy is the first-line modality for imaging the mucosa of the small bowel. After first launching our small bowel capsule in Europe in 2012, we launched in the U.S. in 2017, and as of December 31, 2025, our CapsoCam Plus has been used in more than 161,000 patients.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Benefits of CapsoCam Plus</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our CapsoCam Plus is a superior capsule endoscopy system compared to competitor systems, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables. The benefits delivered by the CapsoCam Plus include the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Sole capsule endoscope with a 360&#176; panoramic view available in the market.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe our CapsoCam is the only capsule endoscope currently available in the market that captures a full 360&#176; panoramic video, providing a complete view of the GI mucosa&#8212;unobstructed by folds and with complete coverage of the bending intestine&#8217;s inner curvature. Our CapsoCam houses four high-resolution cameras around the capsule circumference, and the images from each are stitched into a single panoramic image. Our competitors&#8217; end-view systems have a camera at one end of the capsule, which affords a limited &#8220;tunnel view&#8221; when the capsule is in a straight section of the small bowel or a partial &#8220;wall view&#8221; of the outer curvature when it is in a curved section of the small bowel.</span></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g1.jpg" alt="BUSINESS.jpg" style="height:113px;margin-bottom:5pt;vertical-align:text-bottom;width:336px" id="i-1"/></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">33</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Grand View Research, Inc., &#8220;Colon Screening Market Estimates &amp; Trend Analysis From 2018 to 2030,&#8221; an independent report commissioned by CapsoVision, Inc.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.148%"><tr><td style="width:1.0%"/><td style="width:38.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Competitor&#8217;s &#8220;tunnel<br/>view&#8221; can miss inner<br/>curvature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CapsoCam&#8217;s direct<br/>mucosal view sees<br/>inner curvature</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g2.jpg" alt="BUSINESS 2.jpg" style="height:343px;margin-bottom:5pt;vertical-align:text-bottom;width:336px" id="i-2"/></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g3.jpg" alt="BUSINESS 3.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:336px" id="i-3"/></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoCam captures a complete 360&#176; view of the GI mucosa:</span></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g4.jpg" alt="BUSINESS 4.jpg" style="height:253px;margin-bottom:5pt;vertical-align:text-bottom;width:672px" id="i-4"/></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitive capsules have a &#8220;tunnel view&#8221; in straight sections of the small bowel:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g5.jpg" alt="BUSINESS 5.jpg" style="height:228px;margin-bottom:5pt;vertical-align:text-bottom;width:672px" id="i-5"/></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitive capsules have a partial wall view in curved sections of the small bowel:</span></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g6.jpg" alt="BUSINESS 6.jpg" style="height:286px;margin-bottom:5pt;vertical-align:text-bottom;width:288px" id="i-6"/></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Telemedicine-enabled and zero-capex &#8220;wire-free&#8221; data collection.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our CapsoCam is a zero-capex solution for providers as it stores the entire video in onboard memory. In addition, patients are able to ingest our capsule in the comfort of their own homes, under the remote supervision of providers. The CapsoCam solution frees up exam-room schedules for providers and provides flexibility to administer capsules any day at any time. A provider&#8217;s practice can easily scale to multiple capsules per day with no added cost. In contrast, our competitors&#8217; data recorder comprises a belt that must be worn close to the skin around the patient&#8217;s abdomen, which is connected by wires to a recorder module. We believe this system is an uncomfortable and inconvenient encumbrance for patients. In addition, this system is a burden for providers as it is a piece of capital equipment with upfront cost. The equipment must be recovered from the patient, cleaned and batteries recharged, before it is ready to be fitted for the next patient. The data must also be downloaded from the recorder to a computer, which takes additional time.</span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g7.jpg" alt="BUSINESS 7.jpg" style="height:365px;margin-bottom:5pt;vertical-align:text-bottom;width:336px" id="i-7"/></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Zero-capex remote data analysis via cloud-based platform.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our cloud-based platform, CapsoCloud, provides a flexible, trackable, streamlined, and capital-equipment-free workflow for providers in the U.S. By giving providers the ability following capsule retrieval to remotely access data obtained from the capsule endoscopy, CapsoCloud allows clinicians to track procedures and stream in vivo videos anywhere at their convenience, generate reports, store and manage patient data, and transfer data to third-party reading services. In contrast, our competitors&#8217; data recorder equipment must be returned to the provider after the procedure.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Components of CapsoCam Plus</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal component of the CapsoCam Plus capsule endoscopy system is a single-use ingestible capsule that acquires and stores video images in onboard memory while moving through the GI tract, propelled by natural peristalsis. The patient or an authorized caregiver retrieves the capsule after it is egested using the retrieval kit and may return it directly to the clinic, or, in the U.S., mail it in a pre-paid envelop to a CapsoVision-affiliated download center. Thereupon, the capsule is cleaned and disinfected and the procedure data is downloaded using the CapsoAccess system.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g8.jpg" alt="BUSINESS 8.jpg" style="height:304px;margin-bottom:5pt;vertical-align:text-bottom;width:336px" id="i-8"/></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of a CapsoCam Plus capsule include the capsule housing, a lens module, the image sensor, the multichip package, an illumination system, a battery pack, a switch, the optical transceiver, and a printed circuit board assembly.</span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g9.jpg" alt="BUSINESS 9.jpg" style="height:312px;margin-bottom:5pt;vertical-align:text-bottom;width:336px" id="i-9"/></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, our CapsoCam Plus capsule consists of a diagnostic imaging system in a capsule housing. The four cameras within the image sensor share a single custom CMOS image sensor, and, as the capsule passes through the GI tract, they together capture a full 360&#176; panorama of the GI tract and the high-resolution color images and other data are stored in the onboard flash memory. The multichip package contains 1.5 GB memory to store the procedure data and an application-specific integrated circuit for controlling the capsule and performing image processing functions, including image compression.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Specifications:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Length</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 mm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diameter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 mm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mass</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 grams</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camera combined field of view</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#176; x 360&#176;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depth of field</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 to 18 mm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Video Format</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JPEG color images</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Video resolution</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1152 x 212 pixels</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frame rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 20 fps, 3-5 fps per camera</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating time (typical)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-20 hours</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CapsoCam Plus procedure comprises the following steps:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt;text-decoration:underline">Preparation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To ensure that the upper GI tract is free of food, the patient abstains from eating the morning of the procedure and may begin fasting at some point the prior day, depending on the physician&#8217;s instructions. A light dose of osmotic laxative is recommended to further clean the small bowel.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt;text-decoration:underline">Ingestion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The patient ingests the capsule with a glass of water under the clinician&#8217;s supervision. Unlike competing capsule endoscopy systems, the patient need not be fitted with a data recorder and the in-office procedure consists only of the capsule ingestion and instructing the patient on the retrieval process. In the U.S., the patient may swallow the capsule at home or another remote location with telemedicine supervision by the clinician. Removing the capsule from its package activates it. Once the patient has successfully swallowed the capsule, they are free to go about their day, and after an additional four hours of fasting, they may eat a light meal.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt;text-decoration:underline">Capsule Recovery</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Patients place a rubber pan on the toilet to collect the capsule after excretion. When the patient next has a bowel movement, typically the next morning, they use the retrieval kit, CapsoRetrieve, to recover the capsule using a magnetic wand and package it for return to the clinic or to a data download center. The capsule is typically excreted within 3 to 30 hours after swallowing.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt;text-decoration:underline">Data Access</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Capsule Data Access system, CapsoAccess, is used to recover the procedure video from the capsule after it has been cleaned and disinfected, which may be done at the clinic if the patient returns the capsule there. Alternatively, the patient may use a pre-paid envelope to mail the capsule to an authorized download center where the data is accessed and transmitted via the Internet to the clinician.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt;text-decoration:underline">Video Review</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The physician reviews the procedure video and generates a report, using either CapsoView software or by streaming the video from CapsoCloud. CapsoCloud, a cloud-based software application, provides the physician the flexibility to review the procedure on any computer or Apple iPad connected to the Internet, at their convenience. CapsoCloud also stores the videos and reports, allows management and tracking of the procedure, and facilitates video review by third-party services or multiple physician colleagues.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoRetrieve major elements&#8212;retrieval pan, magnetic wand, and capsule container:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g10.jpg" alt="BUSINESS 10.jpg" style="height:321px;margin-bottom:5pt;vertical-align:text-bottom;width:336px" id="i-10"/></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoAccess accesses procedure data from the CapsoCam Plus capsule after its retrieval:</span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g11.jpg" alt="BUSINESS 11.jpg" style="height:256px;margin-bottom:5pt;vertical-align:text-bottom;width:326px" id="i-11"/></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoCam Colon</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed our next pipeline product, CapsoCam Colon, for visualization of the colon and detection and measurement of polyps. We submitted the 510(k) application for our first generation CapsoCam Colon capsule to the FDA in June 2025 and received responses from the FDA in September 2025. During our meeting with the FDA in December 2025, the FDA raised inquiries on topics including panoramic image processing methodology, and the proposed study design, sample size and primary endpoint for an extended study. Based on our communications with the FDA, we have decided not to further pursue the first generation CapsoCam Colon capsule submission and approval, and to prioritize our resources for the development of our second generation CapsoCam Colon capsule, featuring improved imaging quality and increased field of review with use of AI and better lens. We also expanded a second arm pivotal study to enroll approximately 800 patients at up to 20 sites in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the U.S. in preparation for submitting a new 510(k) application for the second generation CapsoCam Colon capsule. As of the date of this Annual Report, over 500 patients have been enrolled for the second arm pivotal study. We currently expects to submit the 510(k) application for the second generation CapsoCam Colon capsule to the FDA in the third quarter of 2026. As a part of this second 510(k) application and to increase the population of indicated patients, we intend to seek FDA clearance of expanded indications that remove the requirement for evidence of GI bleeding of lower GI origin for patients with major risks for colonoscopy or moderate sedation. There is no guarantee that the clinical results of any of our clinical trials will demonstrate the requisite performance needed to meet applicable regulatory requirements in order to obtain FDA clearance. Further, our 510(k) submission for the second generation of CapsoCam Colon and FDA review of our 510(k) applications may be delayed and we may not receive 510(k) clearances from the FDA on a timely basis or at all.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Benefits of CapsoCam Colon</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our CapsoCam Colon, once FDA cleared, will be a superior capsule endoscopy system compared to competitor systems, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables. The benefits delivered by the CapsoCam Colon include the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Sole capsule endoscope with a 360&#176; panoramic view</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe our CapsoCam is the only colon capsule endoscope that captures a full 360&#176; panoramic video, providing a complete view of the colon mucosa&#8212;unobstructed by folds and with complete coverage of the bending intestine&#8217;s inner curvature. Our CapsoCam houses four high-resolution cameras around the capsule circumference, and the images from each are stitched into a single panoramic image. Our competitors&#8217; end-view systems have a camera at each end of the capsule, which affords a limited &#8220;tunnel view&#8221; and polyps may be hidden by pockets (haustra) between folds. Our CapsoCam, by contrast, has a panoramic view of the colon and can visualize polyps on folds or within the pockets (haustra) between folds. In addition, the inflatable balloon which extends the CapsoCam Colon capsule helps to stabilize its movement through the intestines, resulting in a smoother video.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoCam captures a complete 360&#176; view of the colon mucosa:</span></div><div style="text-align:center"><img src="cv-20251231_g12.jpg" alt="BUSINESS  12.jpg" style="height:86px;margin-bottom:5pt;vertical-align:text-bottom;width:672px" id="i-12"/></div><div style="margin-bottom:12pt;text-align:center"><img src="cv-20251231_g13.jpg" alt="BUSINESS 13.jpg" style="height:89px;margin-bottom:5pt;vertical-align:text-bottom;width:672px" id="i-13"/><img src="cv-20251231_g14.jpg" alt="BUSINESS 14.jpg" style="height:89px;margin-bottom:5pt;vertical-align:text-bottom;width:672px" id="i-14"/></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitive capsules have a &#8220;tunnel view&#8221; of the colon:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><img src="cv-20251231_g15.jpg" alt="BUSINESS 16.jpg" style="height:212px;margin-bottom:5pt;vertical-align:text-bottom;width:672px" id="i-15"/></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Automated pathology detection due to usage of AI.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe our CapsoCam Colon is the only colon capsule endoscopy system (subject to FDA clearance) that utilizes AI for automated polyp detection. Instead of reviewing the entire procedure video, clinicians can focus on those frames with suspected lesions, highlighted with a bonding box, reducing the time taken to review the video and making colon capsule endoscopy financially attractive to their practice. AI improves diagnostic yield and provides more consistent accuracy with reduced dependency on the experience level of the physician video reader and their level of fatigue and distraction. Without AI, physicians can overlook polyps captured in the video. In addition, CapsoCloud automatically accumulates patient data critical to develop and train improved AI-based lesion-detection and classification capabilities. We have an in-house AI development team of experts who will leverage archived patient data on CapsoCloud as it grows during commercial use of CapsoCam Colon to make ongoing improvements to the AI algorithm. In contrast, with competitor capsule endoscopy systems, the clinic downloads patient data from the data recorder and the manufacturer does not have ready access to that data.</span></div><div style="margin-bottom:12pt;text-align:justify"><img src="cv-20251231_g16.jpg" alt="BUSINESS 18.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:672px" id="i-16"/></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">3D-sensing technology informs follow-on care decisions.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our CapsoCam Colon (subject to FDA clearance) also incorporates our proprietary 3D-sensing technology to more accurately measure polyp sizes. Polyp size is highly correlated with its risk of becoming cancer. No other capsule endoscope currently in the market has 3D-enabled measurement capability. With automated pathology detection and the ability to manually review video frames adjacent to an identified polyp, physicians can more confidently decide that patients with small (e.g., less than 6mm) polyps may forgo a follow-on colonoscopy, increasing the utility of the procedure for healthcare providers and patients alike.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Telemedicine-enabled and zero-capex &#8220;wire-free&#8221; data collection</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our CapsoCam is a zero-capex solution for providers as it stores the entire video in onboard memory. In contrast, our competitors&#8217; data recorder comprises a belt that must be worn close to the skin around the patient&#8217;s abdomen, which is connected by wires to a recorder module. We believe this system is an uncomfortable and inconvenient encumbrance for patients. In addition, this system is a burden for providers as it is a piece of capital equipment with upfront cost. The equipment must be recovered from the patient, cleaned and batteries recharged, before it is ready to be fitted for the next patient. The data must also be downloaded from the recorder to a computer, which takes additional time. With no data recorder, our CapsoCam frees up exam-room schedules for providers and provides flexibility to administer capsules any day at any time. A provider&#8217;s practice can easily scale to multiple capsules per day with no added cost.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Zero-capex remote data analysis via cloud-based platform</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our cloud-based platform, CapsoCloud, provides a flexible, trackable, streamlined, and capital-equipment-free workflow for providers in the U.S. In contrast, our competitors&#8217; data recorder equipment must be returned to the provider after the procedure. Following the commercial launch of our CapsoCam Colon solution, providers will initially utilize CapsoCloud to download in vivo videos for remote review. Within one year of commercial launch, we plan to introduce user-friendly streaming functions to facilitate via CapsoCloud remote in vivo video review, procedure report generation and image annotation.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Panenteric capsule</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. CapsoCam Colon is a panenteric capsule which, when programmed with slightly different operating parameters, can be used to visualize both the small bowel and the colon in one procedure for the evaluation of Crohn&#8217;s disease, ulcerative colitis, irritable bowel syndrome and obscure GI bleeding.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Components of CapsoCam Colon</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal component of the CapsoCam Colon capsule endoscopy system is a single-use ingestible capsule that acquires and stores video images in onboard memory while moving through the GI tract, propelled by natural peristalsis. The patient or an authorized caregiver retrieves the capsule after it is egested using the retrieval kit and may return it directly to the clinic, or, in the U.S., mail it in a pre-paid envelop to a CapsoVision-affiliated download center. Thereupon, the capsule is cleaned and disinfected and the procedure data is downloaded using the CapsoAccess system.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of a CapsoCam Colon capsule include the capsule housing, a balloon, a shell, a lens module, the image sensor, the multichip package, an illumination system, a structured-light projector, a battery pack, a switch, the optical transceiver and a printed circuit board assembly.</span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><img src="cv-20251231_g17.jpg" alt="BUSINESS 19.jpg" style="height:307px;margin-bottom:5pt;vertical-align:text-bottom;width:305px" id="i-17"/><img src="cv-20251231_g18.jpg" alt="BUSINESS 20.jpg" style="height:315px;margin-bottom:5pt;vertical-align:text-bottom;width:288px" id="i-18"/></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, our CapsoCam Colon capsule consists of a diagnostic imaging system in a capsule housing with an attached inflatable balloon, where the inflatable balloon is protected by an outer dissolvable shell covering only the balloon end of the camera capsule. Once inside a liquid environment, the shell softens and dissolves. When the balloon is fully inflated, typically after about 2-3 hours, the capsule is slightly buoyant, enabling it to move through the intestines more readily with flowing liquid, increasing the likelihood of a complete colon visualization.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Specifications:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Length (at ingestion / at max inflation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6 mm / 38 mm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diameter (at ingestion / at max inflation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 mm / 12.4 mm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mass</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 grams</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camera combined field of view</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#176; x 360&#176;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depth of field</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 to 18 mm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Video Format</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JPEG color images</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Video resolution</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1152 x 144 pixels</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frame rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 48 fps, 12 fps per camera</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating time (typical)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 hours</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CapsoCam Colon procedure comprises the following steps:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt;text-decoration:underline">Preparation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The colon is cleansed with a preparation similar to that needed for a colonoscopy. The exact protocol is determined by the patient&#8217;s physician, but the recommended process comprises a low-residue diet for several days, clear liquids the day before and on the day of ingestion, and 4 liters of PEG osmotic laxative solution split between the night before and the morning of ingestion. Shortly before ingesting the capsule, the patient may be administered a prokinetic to speed the capsule&#8217;s transit through the stomach and small bowel.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt;text-decoration:underline">Ingestion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The patient ingests the capsule with a glass of water under the clinician&#8217;s supervision. Unlike competing capsule endoscopy systems, the patient need not be fitted with a data recorder and the in-office procedure consists only of the capsule ingestion and instructing the patient on the retrieval process. Where authorized, the patient may swallow the capsule at home or another remote location with telemedicine supervision by the clinician. Removing the capsule from its package activates it. The patient continues a clear-liquid diet until the capsule is egested or the following morning, whichever comes first. The patient drinks low-volume osmotic laxative boosters every few hours for a total of 2-4 doses, stopping if the capsule is egested. If the capsule has not yet been egested, a bisacodyl suppository in the evening and upon arising the next day is recommended.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt;text-decoration:underline">Capsule Recovery</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Patients place a rubber pan on the toilet to collect the capsule after excretion. When the patient next has a bowel movement, they use the retrieval kit, CapsoRetrieve, to recover the capsule using a magnetic wand and package it for return to the clinic or to a data download center. The capsule is typically excreted within 1 to 24 hours after swallowing.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt;text-decoration:underline">Data Access</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Capsule Data Access system, CapsoAccess, is used to recover the procedure video from the capsule after it has been cleaned and disinfected, which may be done at the clinic if the patient returns the capsule there. Alternatively, the patient may use a pre-paid envelope to mail the capsule to an authorized download center where the data is accessed and transmitted via the Internet to the clinician.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt;text-decoration:underline">Video Review</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The physician reviews the procedure video and generates a report, using either CapsoView software or, when and where available, by streaming the video from CapsoCloud. Following the commercial launch of our CapsoCam Colon solution, providers will initially utilize CapsoCloud to download in vivo videos for remote review. Within one year of commercial launch, we plan to introduce user-friendly streaming functions to facilitate via CapsoCloud remote in vivo video review, procedure report generation and image annotation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Development</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoCam Colon</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of our Pilot Study described below, in 2021, we commenced our pivotal study for CapsoCam Colon (described below). We submitted the 510(k) application for our first generation CapsoCam Colon capsule to the FDA in June 2025 and received responses from the FDA in September 2025. During our meeting with the FDA in December 2025, the FDA raised inquiries on topics including panoramic image processing methodology, and the proposed study design, sample size and primary endpoint for an extended study. Based on our communications with the FDA, we have decided not to further pursue the first generation CapsoCam Colon capsule submission and approval, and to prioritize our resources for the development of our second generation CapsoCam Colon capsule, featuring improved imaging quality and increased field of review with use of AI and better lens. We also expanded a second arm pivotal study to enroll approximately 800 patients at up to 20 sites in the U.S. in preparation for submitting a new 510(k) application for the second generation CapsoCam Colon capsule. As of the date of this Annual Report, over 500 patients have been enrolled for the second arm pivotal study. We currently expects to submit the 510(k) application for the second generation CapsoCam Colon capsule to the FDA in the third quarter of 2026.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, the FDA has only authorized one colon capsule imaging system, the Medtronic PillCam COLON 2, introduced in 2014, which does not include any AI-driven analytics; and one AI-driven capsule endoscopy analysis software, the AnX Robotics NaviCam ProScan, introduced in 2023, which exclusively supports AnX Robotics&#8217; small bowel capsule system. These devices will respectively serve as predicate devices for our second generation CapsoCam Colon 510(k) submission. In particular, to receive FDA clearance for our second generation CapsoCam Colon, the clinical results must demonstrate that:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CapsoCam Colon, considered without the integration of AI, demonstrates a polyp-detection accuracy that is, at a minimum, comparable to the performance of the predicate device (i.e., Medtronic PillCam COLON 2); and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our AI technology can (i) reliably and accurately identify and analyze images and video of the colon to detect abnormalities as quantified by diagnostic accuracy measures such as sensitivity and specificity, and, in doing so, (ii) aid qualified physicians in achieving improved diagnostic performance relative to not using AI.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pivotal Study</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Arm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On June 10, 2025, we completed analyzing the data collected from the first arm of our pivotal study and have made our 510(k) submission seeking FDA clearance of our initial, first generation CapsoCam Colon capsule endoscope.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This study was a prospective, open label, pivotal study of the accuracy of CapsoCam Colon in detecting colonic polyps, using colonoscopy as the reference. Enrollment began in 2021 and was completed in October 2024. A total of 1,327 patients were enrolled at 20 sites throughout the U.S. The patient population were males and females between 45-75 years of age referred for colonoscopy. The study was designed to enroll sufficient subjects with clinically-significant colon polyps (&#8805;6mm), accounting for sufficient polyp prevalence in the study population, which is necessary to evaluate the device performance in accordance with study endpoints, as discussed below.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of this pivotal study was to evaluate the safety and effectiveness of our CapsoCam Colon capsule endoscope system in the visualization of the colon and in the detection and size measurement of colonic polyps and to show that AI-based computer assisted detection improves the polyp-detection accuracy and efficiency of capsule video readers. In the study, each enrolled patient (i.e., patients who were otherwise scheduled to receive a colonoscopy under applicable standard of care) agreed for comparative purposes to (i) first, undergo a capsule endoscopy using the CaspsoCam Colon capsule and (ii) second, within a specified time period (typically, 3-6 weeks) undergo an optical colonoscopy, conducted per standard of care with administration by a GI at a medical facility and sedation as appropriate. The capsule video resulting from the capsule endoscopy was then interpreted </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by a video reader twice with a month&#8217;s separation: once relying solely on the video and once with the aid of AI recommendations. Following this, the results of the capsule endoscopy readings were compared to the findings of optical colonoscopy to evaluate diagnostic performance. If these comparative findings suggest that a clinically-significant polyp was missed in the colonoscopy (as determined by an independent Clinical Events Committee), a second colonoscopy may be recommended for the patient. Additional notable study activities and analyses following these initial activities are required, including the measurement and characterization of polyps detected within the study (e.g., to facilitate appropriate subject stratification for endpoint analysis and facilitate evaluation of size measurement accuracy) and the use of a subset of the study data to conduct a standalone performance assessment of the AI algorithm.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pivotal study&#8217;s coprimary endpoints were (a) sensitivity of the CapsoCam Colon for detecting the presence in a patient of the largest polyp detected by optical colonoscopy if that polyp is &#8805; 6mm, where a match is considered to have occurred if a polyp detected by the CapsoCam Colon is assessed as having a size within plus or minus 50% of the size of the polyp detected by optical colonoscopy and as having a location within the same or an adjacent colon segment and (b) specificity of the CapsoCam Colon for not detecting any polyp &#8805; 6mm in a patient for whom optical colonoscopy did not detect any polyp &#8805; 6mm.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secondary endpoints included, among others, the sensitivity and specificity of non-AI assisted detection reading versus AI-assisted detection reading for polyps &#8805; 6mm and for advanced neoplasia.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2025, we completed analyzing the data collected and made our filing with the FDA of our 510(k) Premarket Notification to seek marketing clearance for the first-generation CapsoCam Colon. We received responses from the FDA in September 2025. During our meeting with the FDA in December 2025, the FDA raised inquiries on topics including panoramic image processing methodology, and the proposed study design, sample size and primary endpoint for an extended study. Based on our communications with the FDA, we have decided not to further pursue the first generation CapsoCam Colon capsule submission and approval, and to prioritize its resources for the development of its second generation CapsoCam Colon capsule, featuring improved imaging quality and increased field of review with use of AI and better lens.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Arm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The second arm of the pivotal study (modeled after the first arm of the pivotal study) will evaluate the safety and effectiveness of our second-generation CapsoCam Colon capsule in a similar patient population expected to involve approximately 800 patients enrolled at up to 20 sites in the U.S. In the third quarter of 2025, we commenced enrollment of patients within the second arm. As of the date of this Annual Report, over 500 patients have been enrolled for the second arm pivotal study. We currently expects to submit the 510(k) application for the second generation CapsoCam Colon capsule to the FDA in the third quarter of 2026.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pilot Study</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the initiation of the pivotal study, we completed our pilot study for our CapsoCam Colon in 2021. That study was a prospective, open label, pilot study of the CapsoCam Colon capsule endoscope compared to optical colonoscopy. Enrollment began in January 2020 and was completed in February 2021. A total of 112 patients ingested the capsule at 5 sites in the U.S. and results from 105 patients were included in the analysis. The patient population were males and females between 50-75 years of age who had been referred for colonoscopy and had an increased risk for having colon polyps.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This was a non-significant risk pilot study designed to evaluate the safety and performance of the CapsoCam Colon capsule endoscope in patients who met the eligibility criteria and were scheduled for colonoscopy. This study was not statistically powered.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Primary Efficacy Assessments: Sensitivity/Specificity</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coprimary endpoints were (a) sensitivity of the CapsoCam Colon for detecting the presence in a patient of the largest polyp detected by optical colonoscopy if that polyp was &#8805; 6mm, where a match was considered to have occurred if a polyp detected by the CapsoCam Colon was assessed as having a size within plus or minus 50% of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the size of the polyp detected by optical colonoscopy and as having a location within the same or an adjacent colon segment and (b) specificity of the CapsoCam Colon for not detecting any polyp &#8805; 6mm in a patient for whom optical colonoscopy did not detect any polyp &#8805; 6mm.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, across 105 patients and for polyps &#8805; 6mm in size, with a prevalence of 21.9%, sensitivity was 84.8% (95% confidence interval (&#8220;C.I.&#8221;): 71.1-95.5%) and specificity was 92.7% (95% C.I.: 87.5-97.9%). Overall, for polyps &#8805; 10mm in size, with a prevalence of 7.6%, sensitivity was 87.5% (95% C.I.: 57.9 &#8211; 100%) and specificity was 99.0% (95% C.I.: 78.5 &#8211; 100%).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Safety Analysis</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no reports of device-related adverse events, serious adverse events or unanticipated adverse device effects across 112 patients. All events and observations reported in the pilot study were not related to the study or related to medications for bowel preparation or to the prokinetic boosters. There were no serious adverse events reported for bowel preparation or booster consumption. These results are supportive of the safety of the CapsoCam Colon.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoCam Plus</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made 510(k) submission on December 26, 2025 for the use of AI in our small bowel capsule, CapsoCam Plus, targeting obtaining FDA clearance by the middle of 2026. We are targeting making EU submission in the second quarter of 2026 and obtaining EU clearance in the third quarter of 2026 for the use of AI in our small bowel capsule, CapsoCam Plus. The incorporation of AI technology into our GI-tract capsule endoscopy solution (including the associated software, CapsoCloud and CapsoView) requires appropriate FDA regulatory authorization, supported by requisite clinical and other studies, prior to its commercialization in the U.S. Under the FDA&#8217;s current regulatory framework, our capsule endoscopy solution and the AI technology are assessed separately, with each component falling under a different regulatory classification and subject to distinct regulatory requirements. This bifurcated approach, set by precedent, ensures that each component meets the necessary safety, effectiveness, and performance expectations. Our 510(k) submission and FDA review thereof may be delayed and we may not receive 510(k) clearance from the FDA on a timely basis or at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking 510(k) clearance for our AI technology as incorporated into CapsoCam Plus we are (i) utilizing the NaviCam ProScan as the predicate device (confirmed with the FDA) and (ii) currently conducting a retrospective clinical study of the CapsoCam Plus solution with the AI technology incorporated to analyze in vivo videos from completed, real-world clinical cases, to assess the performance of the AI technology for small bowel. Similar to the first arm of our CapsoCam Colon pivotal study, the study seeks to demonstrate that the AI technology can (i) reliably and accurately identify and analyze images and video of the small bowel to detect abnormalities as quantified by diagnostic accuracy measures such as sensitivity and specificity, and, in doing so, (ii) aid qualified physicians in achieving improved diagnostic performance relative to not using AI.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales, Marketing and Distribution</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily generate revenues from the sales of our CapsoCam Plus capsule to our customers, including gastroenterologists practicing in clinics and/or hospitals, which typically place their orders on a monthly or bimonthly basis, as well as our distributors. We engage our customers by using data mining platforms to identify potential customers, initiating their comprehensive evaluation of our CapsoCam capsule and solutions, followed by our strategic sales efforts that ensure a high retention rate. Our customer retention rate stands at approximately 90% for 2025, showcasing our commitment to customer satisfaction and loyalty.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate with two sales groups and conduct our marketing strategies differently: one for the U.S. market and one for the international market, each tailored to effectively serve different geographical markets. Our U.S. market sales group, primarily using a direct sales model, focuses on the U.S. domestic market. Our international market sales group is comprised primarily of qualified distributors responsible for selling to customers outside the U.S. Using distributors internationally allows us to extend our global reach and effectively penetrate diverse markets. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are confident that our skilled sales force can be effectively leveraged to promote and distribute our CapsoCam Plus capsules and future CapsoCam capsules (including, once FDA cleared, our CapsoCam Colon capsules).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues for the years ended December 31, 2025 and 2024 totaled approximately $13.6 million and $11.8 million, respectively, representing a year-over-year growth of approximately 15%. In 2025 and 2024, international sales accounted for 21% and 23% of total revenue. Our average accounts receivable balance for 2025 was $2.0 million with 11% of our accounts receivable aged more than 60 days. As of December 31, 2025, we only had one customer representing more than 10% of our outstanding accounts receivable (with an accounts receivable balance of approximately $0.6 million).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Market</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market our CapsoCam Plus capsule endoscopy solution in the U.S. through a combination of our in-house sales team, integrated GPOs, and to a limited extent, select independent sales representatives. We intend to expand our direct sales force by increasing the number of sales employees and independent sales representatives and contractors. This strategic growth should enhance our market reach and drive higher sales performance. As of December 31, 2025, we had 28 full-time sales employees, including 4 sales directors and 23 territory managers covering all of the states in the U.S. We offer comprehensive training programs to our sales employees, sales representatives and contractors, aimed at enhancing sales performance and ensuring strict compliance with FDA regulations and any other applicable regulations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the launch of our CapsoCam Plus capsule in 2017, we have endeavored to market our CapsoCam Plus capsule endoscopy solution effectively by leveraging the network outreach of independent sales representatives, who managed to bring our products to the attention of GI physicians across the U.S. Meanwhile, we also invested in building our in-house sales team by establishing the role of territory managers for overseeing and coordinating our sales effort in a specific state or states. We believe our hybrid marketing and sales team will enable our CapsoCam capsules to further penetrate into the healthcare market.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-house Sales Team</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built a dedicated team of sales directors and territory managers to promote our CapsoCam capsules. Based on our current sales output and strategic planning, we have put in place four regional sales directors, each overseeing a distinct region within the U.S. Our regional sales directors are responsible for supervising the work of territory managers within their region, providing them with technical support and training, as well as setting overall sales strategies for the region. Our regional sales directors are industry veterans who possess rich experience in medical device sales and distribution matters.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our territory managers are our front-line sales persons who interact with physicians, clinics, hospitals and other healthcare providers on a daily basis. Utilizing the data-mining platforms we have procured, each of our territory managers generates a list of potential customers, and reaches out to introduce them to our CapsoCam capsule. After this introduction, subject to their protocols and practices, the potential customers will generally make an initial purchase of 5 to 10 capsules for evaluation, before placing subsequent orders. We provide constant assistance and monitoring throughout the customer evaluation process to answer questions, identify potential issues and obtain relevant feedback to a potential customer&#8217;s purchase decision. Following the evaluation process, we seek to onboard the customer, with customers typically ordering capsules, subject to their needs, on a monthly or bi-monthly basis and we strive to meet their expected timeline of delivery.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our territory managers provide continued service and support to our customers, including periodic education of physicians, nurses and other healthcare providers about our capsule, feedback collection to understand and attend to any issues encountered in the course of using our capsule and CapsoCloud, and tracking any adverse events. As a result, we were able to secure a high customer retention rate of approximately 90% for 2025.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Independent Sales Representatives</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage independent sales representatives to complement our in-house sales team. We pay our independent sales representatives commissions and bonuses, if eligible, based on their sales results. We discourage our independent sales representatives from concurrently representing our competitors in promoting similar products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing Methods</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use various sales and marketing methods to generate awareness and demand for our CapsoCam Plus capsule, such as traditional marketing through direct sales, channel partners and trade shows as well as digital marketing through websites, social media, videos and organic and paid searches.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Arrangement with GPOs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with several GPOs, which are organizations that leverage the collective purchasing power of their members, such as hospitals, clinics, and other healthcare providers, to negotiate favorable pricing and terms for medical products and services. Our arrangement with GPOs can significantly enhance our ability to meet the stringent requirements set by hospitals, clinics, and other healthcare providers. By leveraging the collective purchasing power and compliance expertise of GPOs, we can ensure adherence to industry standards and regulations more effectively. Under these agreements, the GPOs&#8217; members may elect to purchase our CapsoCam capsules from us on a direct sale basis. During the term of these agreements, which typically ranges from two to three years and are subject to renewal, we are generally prohibited from entering into new contracts outside of these agreements with the GPOs&#8217; members for our CapsoCam capsules. The agreements also contain firm pricing provisions, which may limit our ability to adjust our prices in response to market conditions or competitive pressures. However, we may offer bulk purchase options or special promotions to the GPOs&#8217; members, subject to certain conditions and approvals. We also agree to provide the GPOs&#8217; members with pricing, terms, and conditions that are equal or better than those offered to our other customers. In addition, we agree to negotiate in good faith to equitably adjust the pricing for any current products under the agreements if it is affected by any new technology. We pay administrative fees to the GPOs based on a percentage of sales for products their members purchase from us.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Market</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initially began commercial sales in Europe in 2012 for our GI-tract capsule endoscopy solution (i.e., our small bowel capsule). Since then, we have expanded into other non-U.S. countries or regions, and our largest international shipping destinations now include France, Germany, and Canada. Our distributors typically have exclusivity in their respective country or territory. As of December 31, 2025, we had entered into distribution agreements with approximately 55 exclusive distributors in connection with multiple non-U.S. regions, including the European Union (&#8220;EU&#8221;), South and Central America, Asia, Australia, the Middle East and Africa, which respectively accounted for approximately 43%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 9%, 4%, 3%, 6% and 5% of our total non-U.S. sales revenue in 2025. As of December 31, 2025, the total revenue generated from our top ten distributors, most of which are in the EU, accounted for approximately 72% of our total non-U.S. sales revenue. We also have one exclusive distributor for sales of our CapsoCam capsule for the veterinary market worldwide. Although we have historically utilized exclusive distributors to access various countries or regions, we may choose to implement a direct sales model. For example, (i) in 2023, we established a direct sales team in Germany to better serve our customers and strengthen our market presence in this key market and (ii) we are transitioning to a direct sales model in some pivotal countries, including the G7 countries, to enhance market penetration and drive growth.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both our direct sales and distributor sales, we are responsible for obtaining and maintaining the regulatory permits for our current CapsoCam Plus capsule, future CapsoCam capsules and associated software, CapsoCloud and CapsoView, in the relevant countries and regions.</span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Including shipments to Aureliance, our authorized agent and importer in the EU and EEA.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Distribution Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically enter into exclusive distribution agreements with our international distributors, which typically specify the purchase price, payment terms, minimum purchase obligations, territory, term, renewal, termination, and other rights and obligations of the parties. The purchase price is usually agreed in the distribution agreement and may be revised through mutual agreement, taking into account the prevailing market prices. Such revision usually occurs no more than once per year. The payment terms vary depending on the distributor&#8217;s creditworthiness and performance, but generally range from 30 to 60 days from the date of invoice. The minimum purchase obligations are based on the projected sales volume and growth potential of the territory. The territory is defined as the country or region where the distributor has the exclusive right to sell and market our CapsoCam capsule endoscopy solution. The term of the distribution agreement is initially one to five years, and may be renewed for additional one to three years upon agreement or automatically, unless terminated earlier by either party for cause or convenience. Our exclusive distributors usually have the right of first offer for any new products that we develop.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the manufacturing, supply, packaging, and labeling of our CapsoCam capsules and for obtaining and maintaining the regulatory permit to manufacture and market our capsule endoscopy solution in the U.S. and other countries or regions where we export our products. We are also required to report any death, serious injury, or malfunction incidents involving our CapsoCam product to the relevant authorities and to conduct any necessary product recalls or corrective actions. Our distributors agree to supply us with any information and assistance related to such incidents and to comply with our instructions and policies regarding product safety and quality. Our distributors also agree to forward any customer and/or regulatory complaints or correspondence regarding our CapsoCam capsule endoscopy solution to us promptly and to cooperate with us in resolving any such issues.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are prohibited from selling our CapsoCam capsules or engaging another distributor to sell our CapsoCam capsules in the territory of our exclusive distributors, unless we terminate the distribution agreement with the existing distributor. Our distributors are prohibited from advertising, marketing, or selling our CapsoCam capsules outside their territory or soliciting orders from persons or entities located outside their territory.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate our distribution agreements with our exclusive distributors for cause, such as breach of contract, failure to meet minimum purchase obligations, insolvency, or misconduct, or for convenience, subject to a prior notice period and a break-up fee based on the anticipated margin, if applicable. We also agree to honor our obligations to the distributor&#8217;s key customers (including governmental bodies) for a period of at least one year following the termination of the distribution agreement, unless we assign such obligations to a successor distributor.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coverage and Reimbursement for CapsoCam</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we derive substantially all of our revenue from gastroenterologists practicing in clinics and/or hospitals that use our CapsoCam Plus capsule endoscopy solution. These providers, in turn, bill third-party payers, including private insurers, Medicare, and Medicaid, for the services and items they provide to patients. The CapsoCam Plus enables our customers to operate under the existing reimbursement structure for optical capsule endoscopy of the small bowel, which has well-established reimbursement levels via CPT codes that varies by state. Subject to patient and provider compliance with guidelines around recommended procedures, government and commercial payers generally provide coverage for optical capsule endoscopy of the small bowel under this framework.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, our CapsoCam Colon, once FDA cleared, is expected to be covered under the existing reimbursement structure for colon capsule endoscopy for our initially indicated patient group, which has reimbursement levels via CPT codes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in research and development initiatives that are focused on introducing enhancements and improvements aimed at increasing the value provided by our GI-tract capsule endoscopy solution. Our solution is currently comprised of our CapsoCam Plus capsule for the small bowel, our planned CapsoCam Colon (subject to FDA clearance), CapsoCloud, our cloud-based platform, and our CapsoView software. In doing so, we hope to realize our vision of creating an ingestible capsule that, in a single convenient non-invasive procedure, cost-effectively screens and/or identifies multiple pathologies in a broad patient population. In particular, for CRC, we hope to screen for both cancerous and precancerous polyps and lesions, recognizing that early detection can assist in the prevention and treatment of CRC. Our research and development team includes hardware and software engineers with deep expertise in medical technology, optics, data science, AI, and cloud-based data and security architecture and individuals with extensive clinical development expertise.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial and recent research and development efforts focused on developing our first capsule endoscopy, the small bowel capsule (510(k) clearance received in 2016) and improved versions thereof (the current generation of which we refer to as CapsoCam Plus), development of our AI assisted pathology detection  technology and improving on CapsoCam Plus to develop CapsoCam Colon (with 510(k) submission for the second generation of CapsoCam Colon targeted for the third quarter of 2026). CapsoCam Colon incorporates our self-developed AI technology and other multiple self-developed proprietary technologies designed to assist in effectively visualizing the colon and detecting and measuring polyps. In addition to having AI for automated pathology detection of polyps, it incorporates a 360&#176; panoramic lateral view and 3D-sensing technology to more accurately measure polyp sizes. We are researching and developing improvements to our CapsoCam Plus capsule to incorporate our AI assisted pathology detection technology. We are working on improvements to our CapsoCam, including a new lens and illumination optics with an increased field of view, improved image quality and higher peak frame rate. For our AI assisted pathology detection technology, we plan to incorporate improvements designed to deliver increased sensitivity for identifying polyps and pre-cancerous lesions, reduced viewing times, enhanced usability of the polyp size measurement tool, improved camera dynamic range for a clearer view of dark areas and improvements to increase completion rates. We also plan to continue making improvements to our CapsoCloud and CapsoView software.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our research and development efforts may also include conducting and overseeing clinical studies and obtaining FDA clearance, which may or may not be granted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $18.3 million and $15.1 million in research and development expenses for the years ended December 31, 2025 and 2024, respectively. For additional information, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Components of our Results of Operations &#8212; Operating Expenses.&#8221;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage all aspects of manufacturing, supply chain and distribution of our GI-tract capsule endoscopy products from our headquarters in Saratoga, California. We manufacture our products using component suppliers and assembly manufacturers based in Asia. The critical components of our products, such as lens modules, CMOS image sensors, and ASICs are provided by single-source suppliers. In particular, our lens modules are sourced from Largan, a single supplier based in Taiwan who we have an over 17-year relationship with, our CMOS image sensors are sourced from Toshiba, a single supplier based in Japan who we have an over 11-year relationship with, and our ASICs are sourced from Moai/Speedbridge, suppliers based in Taiwan who we have, respectively, an over 11-year and 6-year relationship with. As a result of our long-standing relationships with these suppliers, we are able to source those component parts on favorable terms and within reasonable lead-times.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, we have entered into a memorandum of understanding with Largan Precision Company, Ltd. (&#8220;Largan&#8221;), which is based in Taiwan, in May 2008, for the supply of lens modules for our first-generation capsules, pursuant to which we make purchases on a purchase order basis. The terms of the memorandum of understanding were subsequently amended in January 2010 (as amended, the &#8220;First Largan MOU&#8221;). In addition, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we entered into another memorandum of understanding with Largan in October 2022, for the supply of lens modules for our second-generation capsules (together with the First Largan MOU, collectively, the &#8220;Largan MOUs&#8221;). Each Largan MOU was effective upon signing and will continue until terminated in accordance thereunder. Either party may terminate either Largan MOU for certain breaches of the agreement by the other party and that party fails to cure the breach within 45 days after notice of such breach from the terminating party.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into a development agreement with Toshiba, which is based in Japan, in August 2013 (the &#8220;Toshiba Agreement&#8221;), for the development and supply of our CMOS image sensors, pursuant to which we make purchases on a purchase order basis. The Toshiba Agreement contains a provision, pursuant to which Toshiba may discontinue the supply of CMOS image sensors to us if we do not place purchase orders totaling more than a specified number of units in any consecutive 12 months. The Toshiba Agreement was effective upon signing and will continue until terminated in accordance thereunder. If Toshiba intends to discontinue supply of the CMOS image sensors to us, Toshiba must provide us with 12 months&#8217; prior notice and obtain our approval. Either party may also immediately terminate the Toshiba Agreement upon written notice if any of the Force Majeure events (as defined therein) extends for a period in excess of 30 days.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into a development and manufacturing agreement with Moai, which is based in Taiwan, in June 2014, for the supply of our ASICs, pursuant to which we make purchases on a purchase order basis. The terms of the development and manufacturing agreement were subsequently amended in March 2015 (as amended, the &#8220;Moai Agreement&#8221;) and supplemented in February 2020, pursuant to which Moai, the owner of the ASIC design, outsourced the maintenance and technical support functions to Speedbridge (the &#8220;Speedbridge Supplement&#8221;, and together with the Moai Agreement, the &#8220;Moai/Speedbridge Agreement&#8221;). The Moai/Speedbridge Agreement was effective upon signing and will continue until terminated in accordance thereunder. We may terminate the Moai/Speedbridge Agreement if Moai and/or Speedbridge (i) breach(es) certain quality requirements, (ii) fail(s) to manufacture products and/or provide services specified therein, or (iii) breach(es) or is/are unable to perform any of the agreements or obligations thereunder, and, in the case of (i) and (ii) above, the breach is not cured within 30 days after notice thereof. The Moai/Speedbridge Agreement prohibits Moai and/or Speedbridge (including any subsidiary or affiliate) from entering into or continuing any discussions to develop, make or otherwise commercialize any competing products during the term thereof and for a period ending on the first anniversary of the termination thereof.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, assembled CapsoCam capsules are shipped from Taiwan to our U.S. facility where we complete the manufacturing process before distributing the capsules to our distribution network. Once the assembled products in test form are delivered to us, we are responsible for the testing, cleaning, packaging and labeling of our products at our headquarters in Saratoga, California.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also in the process of planning or implementing various mitigation measures to address supply chain risks (including qualifying a backup supplier for certain critical components and looking to build reserve supplies of capsules and critical components to address unanticipated delays).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive industry. The medical device market, particularly in the area of diagnostic imaging and endoscopic procedures, is characterized by rapid technological advancements and the continuous introduction of new products. The competition that we face for our current and future GI-tract capsule endoscopy solutions will vary based on numerous factors including: the nature of the pathology(ies) or medical condition(s); the ease of use of our products; the relevant patient population and related indicated patients; available indicated means to diagnose or treat the pathology/condition and related accuracy, reliability and safety; patient considerations (such as adherence, comfort, safety, and convenience); provider considerations (such as clinical workflow and convenience); and economic and time considerations (such as cost, availability of third-party reimbursement and provider time required).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoCam Plus (small bowel).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The competition that we face for our small bowel CapsoCam Plus is primarily from traditional enteroscopy procedures performed by trained physicians in hospital or clinical settings and other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capsule-based imaging solutions manufactured by companies such as Medtronic, IntroMedic, JinShan and Ankon. Those competitors include well-established companies with significant resources and brand recognition such as Medtronic, that are constantly developing and marketing innovative products that may offer superior features or lower costs. With respect to Medtronic, it also enjoys other competitive advantages including (i) a &#8220;first mover advantage&#8221; as the first manufacturer of a small bowel capsule endoscopy and a colon capsule endoscopy (described below); (ii) exclusive supply arrangements (sometimes up to three years) with some of the larger GI practices and hospitals (particularly in the Northeast region of the U.S.) which our sales team also targets; and (iii) greater brand recognition and financial resources.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competitor capsule endoscopy systems currently available in the market (i) consist of capsules with end-view systems, providing only limited &#8220;tunnel&#8221; or partial &#8220;wall&#8221; views of the small bowel and (ii) utilize wired data recorders worn on the patients. As a result, providers are forced to incur upfront capital expenses and clinical workflow complications and patients experience discomfort and multiple clinical visits. We believe our CapsoCam Plus is a superior capsule endoscopy system, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables. Our CapsoCam captures a full 360&#176; panoramic video, providing a complete view of the GI mucosa&#8212;unobstructed by folds and with complete coverage of the bending intestine&#8217;s inner curvature, ultimately resulting in superior diagnostic yield. Also, our CapsoCam is a zero-capex &#8220;wire-free&#8221; data collection solution for providers as it stores the entire video in onboard memory. Following retrieval, our cloud-based platform, CapsoCloud, gives providers in the U.S. the ability to remotely access data from the cloud and stream in vivo videos anywhere at their convenience. Outside of the U.S., providers review procedure videos using CapsoView software (primarily due to foreign data privacy and access regulations).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoCam Colon. The competition that we face for CapsoCam Colon is primarily from (i) procedure-based detection technologies such as optical colonoscopy, flexible sigmoidoscopy and CTC (or &#8220;virtual&#8221; colonoscopy); (ii) stool-based DNA tests such as Cologuard (initial FDA clearance in 2014); and (iii) other capsule-based imaging solutions like PillCam COLON 2 (initial FDA clearance in 2014). Other sources of competition include (a) other common CRC screening tests, such as the FOBT and the FIT, and (b) other screening technologies including liquid biopsy tests, such as Epi proColon (510(k) clearance received in 2016) and C-Scan (CE Mark obtained in 2019). Those competitors include well-established companies with significant resources such as Medtronic, and are constantly developing and marketing innovative products that may offer superior features or lower costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our CapsoCam Colon, once FDA cleared, will compare favorably to other available products and services. All other colorectal cancer detection methods in use today are constrained by some combination of poor sensitivity, poor adherence, or high cost. For example, colonoscopy requires advanced dietary restrictions and bowel cleansing, potential time away from work, someone to drive the patient home from the procedure and can also be uncomfortable, time-consuming, hazardous, and expensive. Fecal blood testing, including FIT testing, suffers from poor sensitivity, with only a 74% detection rate for cancer and 24% detection rate for advanced precancerous lesions. Stool tests and blood tests have demonstrated good sensitivity for cancer, but sensitivity for advanced precancerous lesions is under 50%. Relatively high false-positive rates for multi-targeted stool DNA tests, such as Cologuard, lead to unnecessary colonoscopies. In a study with over 10,000 average-risk screening patients, advanced neoplasia was not detected by colonoscopy in 75% of Cologuard-positive cases.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">35</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Colon capsule endoscopy provides non-invasive visualization of the entire colon from the cecum to the rectum, and it has demonstrated good sensitivity and specificity for the detection of colon polyps. Currently, the only two competitor products that are available in the market for a limited subset of indicated patients have end-view systems and require wired data recorders to be worn on the body. We believe our CapsoCam Colon, once FDA cleared, will be a superior capsule endoscopy system, both in how it captures and presents images of the GI tract </span></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For FIT test, see Imperiale, Thomas F.; Ransohoff, David F.; Itzkowitz, Steven H.; Levin, Theodore R; Lanvin, Philip;Lidgard, Graham P. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. N Engl J Med. 2014 April 13. DOI: 10.1056/NEJMoa1311194 For blood test, see Chung, Daniel C; Gray, Darrell M.; Singh, Harminder; Issaka, Rachel B.; Raymond, Victoria M.; Eagle, Craig; Hu Sylvia; Chudova, Darya I.; Talasaz AmirAli; Greenson, Joel K.; Sinicrope Frank A.; Gupta, S,amir;Grady, William M. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):973-983. DOI: 10.1056/NEJMoa2304714.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the clinical workflow and patient experience that it enables. In addition to the competitive advantages described above for our CapsoCam Plus, which also apply to our CapsoCam Colon, CapsoCam Colon utilizes our self-developed AI for automated polyp detection and incorporates our proprietary 3D-sensing technology to more accurately measure the size of polyps in the GI tract.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoCloud</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our cloud-based platform, CapsoCloud, provides a flexible, trackable, streamlined, and capital-equipment-free workflow for providers in the U.S. By giving providers the ability following capsule retrieval to remotely access data obtained from the capsule endoscopy, CapsoCloud (in connection with the CapsoCam Plus) allows clinicians to track procedures and stream in vivo videos anywhere at their convenience, generate reports, store and manage patient data, and transfer data to third-party reading services. Following the commercial launch of our CapsoCam Colon solution, providers will initially utilize CapsoCloud to download in vivo videos for remote review. Within one year of commercial launch, we plan to introduce user-friendly streaming functions to facilitate via CapsoCloud remote in vivo video review, procedure report generation and image annotation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoView</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Outside of the U.S., providers review procedure videos using CapsoView software (primarily due to foreign data privacy and access regulations).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We might not be able to compete successfully in our market, particularly as we seek to obtain the required FDA clearance and seek to commercialize CapsoCam Colon. If our competitors introduce new diagnostic tests that compete with or surpass the accuracy, price or ease of use of our products, we may be unable to satisfy existing customers or attract new customers at the prices and levels that would allow us to generate attractive rates of return on our investment. Increased competition could result in price reductions and revenue shortfalls, loss of customers and loss of market share, which could harm our business, prospects, financial condition and operating results.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and operations are subject to extensive regulation by the FDA and other federal and state authorities in the United States, as well as comparable authorities in foreign jurisdictions. Our product candidates are subject to regulation as medical devices in the United States under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), as implemented and enforced by the FDA.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United States Regulation of Medical Devices</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising, promotion, marketing and distribution, and import and export of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">FDA premarket clearance and approval requirements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an exemption applies, each medical device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, or approval of a premarket approval (&#8220;PMA&#8221;) application. Under the FDCA, medical devices are classified into one of three classes&#8212;Class I, Class II, or Class III&#8212;depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class I includes devices with the lowest risk to the patient for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance with the applicable portions of the Quality Management System Regulation (the &#8220;QMSR&#8221;), facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class II devices are subject to the FDA&#8217;s General Controls, as well as any special controls deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance standards, post-market surveillance, patient registries and FDA guidance documents. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting and some implantable devices, devices that have a new intended use, or devices that use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class III, requiring approval of a PMA.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While most Class I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA, requesting permission to commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. Some pre-amendment devices are unclassified, but are subject to FDA&#8217;s premarket notification and clearance process in order to be commercially distributed. The products we currently market are classified as Class II devices and have received FDA marketing authorization through the 510(k) clearance process.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">510(k) Clearance marketing pathway</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain 510(k) clearance, a manufacturer must submit to the FDA a premarket notification demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was found substantially equivalent through the 510(k) process. The FDA&#8217;s 510(k) clearance process usually takes from three to twelve months, but may take longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. FDA collects user fees for certain medical device submissions and annual fees and for medical device establishments. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously-cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements. The PMA process requires that the manufacturer demonstrate that the device is safe and effective for its intended uses, which generally requires the submission of extensive data, including results from pre-clinical studies and human clinical trials. A PMA must also contain a full description of the device and its components, the methods, facilities, and controls used for manufacturing, and proposed labeling. The PMA process is burdensome, and in practice, the FDA&#8217;s review of a PMA application may take up to several years following initial submission. Alternatively, a manufacturer can request a risk-based classification determination for a novel device in accordance with the &#8220;de novo&#8221; process, described below. We currently do not market any medical devices pursuant to a PMA. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device receives 510(k) clearance or de novo classification, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or de novo classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), de novo request or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing clearance or PMA approval is obtained or a de novo request is granted. In these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">De novo classification process</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical device types that the FDA has not previously classified as Class I, II, or III are automatically classified into Class III regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a route to market for low-to-moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification procedure. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Manufacturers may request de novo classification directly without first submitting a 510(k) pre-market notification to the FDA and receiving a not-substantially-equivalent determination. De novo classification requests are subject to the payment of user fees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By statute, FDA is required to classify the device within 120 days following receipt of the de novo request, although the process may take significantly longer. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. If FDA grants the de novo request, the device may be legally marketed in the United States. However, the FDA may reject the request if the FDA identifies a legally marketed predicate device that would be appropriate for a 510(k) notification, determines that the device is not low-to-moderate risk, or determines that General Controls would be inadequate to control the risks and/or special controls cannot be developed. After a device receives de novo classification, any modification that could significantly affect its safety or efficacy, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, another de novo request or even PMA approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Medical device clinical trials</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are sometimes required to support 510(k) or de novo submissions. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;), regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. If the device under evaluation does not present a significant risk to human health, then the device sponsor is not required to submit an IDE application to the FDA before initiating human clinical trials, but must still comply with abbreviated IDE requirements when conducting such trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or presents a potential for serious risk to a patient in some other way. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the degree of risk presented by the medical device, clinical studies must be approved by, and conducted under the oversight of, an Institutional Review Board (the &#8220;IRB&#8221;), for each clinical site. The IRB is responsible for the initial and continuing review of the clinical study, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA&#8217;s regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, such as strategic business decisions or a belief that the risks to study subjects may outweigh the anticipated benefits.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Expedited development and review programs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following passage of the 21st Century Cures Act, the FDA implemented the Breakthrough Devices Program, which is a voluntary program offered to manufacturers of certain medical devices and device-led combination products that may provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the program is to provide patients and health care providers with more timely access to qualifying devices by expediting their development, assessment and review, while preserving the statutory standards for PMA approval, 510(k) clearance and de novo classification. The program is available for medical devices that meet certain eligibility criteria, including that the device provides more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, and that: (i) the device represents a breakthrough technology, (ii) no approved or cleared alternatives exist, (iii) the device offers significant advantages over existing approved or cleared alternatives, or (iv) the availability of the device is in the best interest of patients. Breakthrough Device Designation provides certain benefits to device developers, including more interactive and timely communications with FDA staff; use of post-market data collection, when scientifically appropriate, to facilitate expedited and efficient development and review of the device; opportunities for more efficient and flexible clinical study design; and prioritized review of premarket submissions. When reviewing Breakthrough Device Designation requests, the FDA may require a combination of literature or preliminary bench, animal or clinical data to demonstrate a reasonable likelihood of clinical and technological success. Receiving a Breakthrough Device Designation from the FDA does not guarantee that the FDA will grant marketing authorization for the device.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Post-market regulation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment registration and device listing with the FDA;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">QMSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling regulations and FDA prohibitions against the promotion of investigational products, or the promotion of &#8220;off-label&#8221; uses of cleared or approved products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements related to promotional activities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clearance or approval of product modifications to cleared devices or devices authorized through the de novo classification process that could significantly affect safety or effectiveness, or that would constitute a major change in intended use of such devices, or approval of certain modifications to PMA-approved devices;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing processes for medical devices are required to comply with the applicable portions of the QMSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QMSR also requires, among other things, maintenance of a medical device file and complaint files. As a manufacturer, we are subject to periodic scheduled or unscheduled inspections by the FDA. Failure to maintain compliance with the QMSR requirements could result in the shutdown of, or restrictions on, manufacturing operations and the recall or seizure of marketed products. The discovery of previously unknown problems with marketed medical devices, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions, among others:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters, untitled letters, it has come to our attention letters, fines, injunctions, consent decrees, and civil penalties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recalls, withdrawals, or administrative detention or product seizures;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions or partial suspension or total shutdown of production;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawing 510(k) clearances or PMA approvals that have already been granted;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to grant export approvals for devices being shipped to foreign markets; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to regulation by the California Department of Public Health Food and Drug Branch (&#8220;FDB&#8221;) through the Medical Device Safety Program. We must maintain a California Medical Device Manufacturing license. Our facilities may be subjected to scheduled or unscheduled inspections by the FDB.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Fraud and Abuse Laws</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we are subject to a number of federal and state healthcare regulatory laws that restrict business practices in the healthcare industry. These laws include, but are not limited to, federal and state anti-kickback, false claims, and other healthcare fraud and abuse laws.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item, or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal false claims laws, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the government. Actions under the civil False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the civil monetary penalties statute, subject to certain exceptions, prohibits, among other things, the offer or transfer of remuneration, including waivers of copayments and deductible amounts (or any part thereof), to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information on certain covered healthcare providers, health plans, and healthcare clearinghouses, as well as business associates, independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physician Payments Sunshine Act ("Sunshine Act") was signed into law in 2010 as part of the Affordable Care Act and amended in 2018 with the SUPPORT Act. The Sunshine Act applies to (a) group purchasing organizations and (b) requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program ("Applicable Manufacturers"), with specific exceptions. Applicable Manufacturers must report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other healthcare professionals such as physician assistants and nurse practitioners, and teaching hospitals, including ownership and investment interests held by physicians and their immediate family members. CMS has issued implementing regulations and the reported data is publicly available on the CMS Open Payments website.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several states in which we operate have also adopted fraud and abuse laws similar to those described above. The scope of these laws and the interpretations of them vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. Some state fraud and abuse laws apply to items or services </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursed by any payer, including patients and commercial insurers, not just those reimbursed by a federally funded healthcare program.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of fraud and abuse laws, including federal and state anti-kickback and false claims laws, may be punishable by criminal and civil sanctions, including fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid), disgorgement, and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such companies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement Regulation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our commercial success depends in part on the extent to which governmental authorities, private health insurers and other third-party payers provide coverage for and establish adequate reimbursement levels for our products and related services. Use of the CapsoCam Plus is reimbursed under existing physician and hospital codes. We do not bill any third-party payers for the CapsoCam Plus. Instead, we invoice healthcare providers, and the cost is bundled into the reimbursement received by healthcare providers when the CapsoCam Plus is used. Failure by physicians, hospitals, and other users of our products to obtain adequate reimbursement from third-party payers for services performed with our products, or adverse changes in government and private third-party payers&#8217; coverage and reimbursement policies, could adversely impact demand for our products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement for use of the CapsoCam Plus can differ significantly from payer to payer. Third-party payers are increasingly auditing and challenging the prices charged for medical products and services, with concern for upcoding, miscoding, using inappropriate modifiers, or billing for inappropriate care settings. Some third-party payers must approve coverage for new or innovative devices before they will reimburse healthcare providers who use the products or therapies. Even though a new product may have been cleared for commercial distribution by the FDA, we may find limited demand for the product unless and until reimbursement approval has been obtained from governmental and private third-party payers.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to uncertainties surrounding coverage policies, there are periodic changes to reimbursement levels. Third-party payers regularly update reimbursement amounts and, from time to time, revise the methodologies used to determine reimbursement amounts. These changes include routine updates to payments to hospitals under the IPPS. These updates could directly impact the demand for our products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the overall escalating cost of medical products and services being paid for by the government and private health insurance has led to, and will continue to lead to, increased pressures on the healthcare and medical device industries to reduce the costs of products and services. Third-party payers are developing increasingly sophisticated methods of controlling healthcare costs through prospective reimbursement and capitation programs, group purchasing, redesign of benefits, and exploration of more cost-effective methods of delivering healthcare. In the United States, some insured individuals enroll in managed care programs, which monitor and often require pre-approval of the services that a member will receive. Some managed care programs pay their providers on a per capita (patient) basis, which puts the providers at financial risk for the services provided to their patients by paying these providers a predetermined payment per member per month and, consequently, may limit the willingness of these providers to use our products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we also sell into international markets, we note that reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific product lines and procedures. In particular, in Europe, reimbursement is entirely regulated at member state level, varies significantly between countries, and member states are facing increased pressure to limit public healthcare spending. There can be no assurance that our products will be considered cost-effective by third party payers, that an adequate level of reimbursement will be available or that the third-party payers&#8217; reimbursement policies will not adversely affect our ability to sell our products profitably. More and more, local, product-specific reimbursement law is applied as an overlay to medical device regulation, which has provided an additional layer of clearance requirements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payers and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of the Affordable Care Act (the &#8220;ACA&#8221;) in the United States, for example, substantially changed healthcare financing and delivery by both governmental and private insurers, and significantly affected medical device manufacturers. The ACA, among other things, provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research, and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians, and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally, the ACA expanded eligibility criteria for Medicaid programs and created a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. Since its enactment, there have been judicial, executive and political challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a judicial challenge to the ACA brought by several states without specifically ruling on its constitutionality.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, reduced Medicare payments to providers, effective on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In 2025, as part of the budget reconciliation process, the One Big Beautiful Bill Act included significant reforms to Medicaid, including an estimated $1 trillion in reduced federal Medicaid spending from 2025 through 2034, the imposition of work requirements for certain adult enrollees, more frequent eligibility redeterminations and increased cost-sharing for beneficiaries. These changes are expected to reduce overall Medicaid enrollment and access to care. Although the effect on our business is currently unknown, any decrease in the number of insured patients or reimbursement levels for our products could adversely affect our revenue and commercial prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Medical Devices Outside the United States </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., the regulation of medical devices is also complex. In Europe, for instance, products are subject to extensive regulatory requirements. In 2021, a new regulatory scheme for medical devices, the Medical Devices Regulation (&#8220;MDR&#8221;), became effective in EU member states. The MDR sets out the basic regulatory framework for medical devices in the EU and the European Economic Area (&#8220;EEA&#8221;) Countries. The MDR requires that medical devices may only be placed on the market if they are safe and effective and do not compromise safety and health when properly installed, maintained, and used in accordance with their intended purpose. The MDR has significant requirements for many medical devices, including requirements for clinical evidence and documentation, device identification and traceability, registration of economic operators throughout the distribution chain and post-market surveillance. The system of regulating medical devices operates by way of a certification for each medical device. Each certified device is marked with an EC certificate of conformity (&#8220;CE Mark&#8221;) which shows that the device has a Certificat de Conformit&#233;. There are national bodies known as Competent Authorities </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in each member state which oversee the implementation of the MDR within their jurisdiction. The means for achieving the requirements for the CE Mark vary according to the nature of the device. Devices are classified in accordance with their perceived risks, similarly to the U.S. system. The class of a product determines the conformity assessment required before the CE Mark can be placed on a product. Conformity assessments for our products are carried out as required by the MDR. Each member state can appoint Notified Bodies within its jurisdiction. If a Notified Body of one member state has issued a Certificat de Conformit&#233;, the device can be sold throughout the EU and the EEA without further conformance tests being required in other member states. The CE Mark is contingent upon continued compliance with the applicable regulations and the quality system requirements of the ISO 13485:2016 standard. Our current CE Mark is issued by T&#220;V Rheinland. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some regions, the level of government regulation of medical devices is increasing, which can lengthen time to market and increase registration and approval costs. In many countries, the national health or social security organizations require products to be qualified before they can be marketed and considered eligible for reimbursement. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many instances, global regulatory agencies have come together in an attempt to harmonize medical device regulatory requirements. In 2011, the regulatory agencies of the U.S., Canada, Brazil, Australia and Japan came together and established the International Medical Device Regulators Forum (the &#8220;IMDRF&#8221;). The IMDRF continues to grow and now has a management committee of regulatory agency representatives from 11 countries and affiliate members representing 7 countries. One example of the IMDRF harmonizing medical device regulatory requirements is the Medical Device Single Audit Program (the &#8220;MDSAP&#8221;), whereby a medical device manufacturer can have a single Quality Management System audit of their facility which covers the regulatory requirements of Australia, Brazil, Canada, Japan and the U.S. Instead of having periodic quality inspections from regulators of each of these countries, a single comprehensive inspection is performed. We are audited in compliance with the MDSAP. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other regional groups working to harmonize regulatory requirements are the Asia-Pacific Economic Cooperation group, Global Harmonization Working Party and African Medical Devices Forum. While regulatory requirements are constantly evolving, regulatory agencies recognize the impact and are attempting to harmonize their efforts. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the list of regulated countries continues to grow, many of the regulated countries leverage device approvals from the U.S. or Europe, meaning that the testing and clinical studies required to satisfy device safety and efficacy requirements of the U.S. and Europe, often carry over to other geographies. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security Laws</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal, and foreign laws, regulations, and standards govern the collection, use, disclosure, access to, confidentiality, and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our collaborators, third-party providers, and others upon whom we commercially rely upon. In the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, and consumer protection laws and regulations govern the collection, use, disclosure and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property rights are important to us. We seek to protect our intellectual property and proprietary technologies through combined means, including by pursuing patent applications that cover our technologies and product candidates, as well as any other relevant inventions and improvements that are considered commercially important to the development of our business. We have developed, and are continuing to develop, a comprehensive intellectual property portfolio related to our capsule camera products and their portable usage, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including structural and compartmental design, imaging mechanics and algorithms for optimizing the screening and detection performance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to: (a) obtain, maintain, protect and enforce intellectual property and other proprietary rights for our current and future technology, inventions, improvements, and know-how we consider important to our business, (b) preserve the confidentiality of our trade secrets, (c) defend and enforce our intellectual property rights, (d) prevent others from infringing, misappropriating, or violating our intellectual property and other proprietary rights, and (e) operate without infringing, misappropriating, or violating the intellectual property and other proprietary rights of others. Our objective is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the U.S. and in jurisdictions outside of the U.S. related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. Our patent portfolio is intended to cover components of our products, as well as any other inventions that are important to our business. We also rely on trademarks, trade secrets, and know-how to develop and maintain our proprietary position.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As set forth in the tables below, our patent portfolio, as of December 31, 2025, contains over 140 issued patents worldwide with anticipated expiration dates and types as indicated. With respect to non-U.S. patents, the corresponding estimated expiration dates provided are anticipatory in nature. The actual expiration date of a non-U.S. patent can be subject to variations due to the complexities and nuances of individual country patent laws, regulations, and administrative practices, such as any applicable country specific term adjustment laws or regulations.</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Patent No.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of Expiration</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo autonomous camera with&#160;on-board&#160;data storage or digital wireless transmission in regulatory approved band</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8073223</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/19/2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capture control for in vivo camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7940973</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/19/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Image capture control for in vivo autonomous camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7792344</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/19/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onboard data storage and method</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7495993</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/25/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System and method for capsule camera with&#160;on-board&#160;storage</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8472795</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/22/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods to compensate Manufacturing Variations and Design Imperfections in a Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9307233</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods to compensate manufacturing variations and design imperfections in a display device</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11019318</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods to compensate manufacturing variations and design imperfections in a display device</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10499029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/20/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems and methods for capsule camera control</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8213698</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/23/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoramic imaging system</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7817354</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lighting control for in vivo capsule camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7796870</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/5/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detection of when a capsule camera enters into or goes out of a human body and associated operations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9025017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/2/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo camera with multiple sources to illuminate tissue at different distances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8956281</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/29/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Patent No.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of Expiration</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrieval pan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D737,959</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/1/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Design</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo autonomous camera with&#160;on-board&#160;data storage or digital wireless transmission in regulatory approved band</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7983458</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/24/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detection of when a capsule camera enters into or goes out of a human body and associated operations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8187174</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/10/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capture control for in vivo camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7974454</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/10/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiple capsule camera apparatus and methods for using the same</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9041785</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods to compensate manufacturing variations and design imperfections in a capsule camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8405711</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/14/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System and method for multiple viewing-window display of capsule images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8150124</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/20/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System and method for image enhancement of dark areas of capsule images</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8150123</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule imaging system having a folded optical axis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9001187</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/25/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System and method for display of panoramic capsule images</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8724868</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/3/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods to compensate manufacturing variations and design imperfections in a capsule camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9007478</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/29/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data communication between capsulated camera and its external environments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9285670</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/7/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-stream image decoding apparatus and method</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8803961</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/12/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo image capturing system including capsule enclosing a camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8773500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/18/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System and method for capsule camera with capture control and motion-compensated video compression</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8165374</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/9/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imaging system having a folded optical axis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8717413</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/10/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo camera with multiple sources to illuminate tissue at different distances</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8636653</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/3/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiple capsule camera apparatus and methods for using the same</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8300091</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/31/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camera system with multiple pixel arrays on a chip</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9118850</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/3/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo camera with multiple sources to illuminate tissue at different distances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10244929</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/5/2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camera System with&#160;multiple&#160;Pixel Arrays On A Chip</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9621825</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/12/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo camera with multiple sources to illuminate tissue at different distances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11103129</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/2/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System and Method for Displaying Annotated Capsule Images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9626477</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/16/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule orientation detection for capsule docking system with inductive power drive circuit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10159400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Patent No.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of Expiration</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Optical docking system with inductive powering for capsule camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10602913</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Docking system with inductive powering for capsule camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10869594</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Docking system with inductive powering for capsule camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10881282</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System and method for displaying bookmarked capsule images</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10154226</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System and Method for Displaying Annotated Capsule Images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9304669</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of overlap-dependent image stitching for images captured using a capsule camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9324172</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/19/2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power source control for medical capsules</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11129516</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/10/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Image sensor with integrated power conservation control</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9357150</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo capsule device with electrodes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10531786</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/20/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconstruction of images from an in vivo multi-camera capsule</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10068334</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/28/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power source control for medical capsules</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10206557</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/13/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for endoscope with distance measuring for object scaling</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10402992</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single image sensor for capturing mixed structured-light images and regular images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10447950</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscope employing structured light providing physiological feature size measurement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10531074</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscope with images optimized based on depth map derived from structured light images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10624533</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single image sensor for capturing mixed structured-light images and regular images</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10742909</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single image sensor for capturing mixed structured-light images and regular images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10785428</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus of sharpening of gastrointestinal images based on depth information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10943333</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single image sensor for capturing mixed structured-light images and regular images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11102428</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscope employing structured light providing physiological feature size measurement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11019327</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconstruction with Object Detection for Images Captured from a Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9672620</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule orientation detection for capsule docking system with inductive power drive circuit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10010241</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/28/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single image sensor control for capturing mixed mode images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10201266</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/28/2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconstruction of images from an in vivo multi-camera capsule with&#160;two-stage&#160;confidence matching</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11116390</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/12/2037</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Patent No.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of Expiration</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single Image Sensor for Capturing Mixed Structured-light Images and Regular Images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9936151</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/9/2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconstruction of images from an in vivo multi-camera capsule with&#160;two-stage&#160;confidence matching</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11120547</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/28/2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus of sharpening of gastrointestinal images based on depth information</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11354783</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/15/2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single image sensor for capturing mixed structured-light images and regular images</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10484629</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for image stitching of images captured using a capsule camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10943342</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/4/2037</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule device having variable specific gravity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10098526</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/10/2037</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule device having variable specific gravity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RE48181</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/10/2037</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">De-ghosting&#160;of images captured using a capsule camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10015372</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/18/2037</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of image processing and display for images captured by a capsule camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11074672</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/19/2037</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus of lens alignment for capsule</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10638920</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2037</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for estimating area or volume of object of interest from gastrointestinal images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10580157</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/4/2037</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for estimating area or volume of object of interest from gastrointestinal images</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10736559</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/4/2037</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for area or volume of object of interest from gastrointestinal images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10346978</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/18/2037</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule enteric coating for controlling balloon expansion start time</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10674899</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/9/2038</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for capturing images and associated 3D model based on a single image sensor and structured-light patterns in the visible spectrum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10593055</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/12/2038</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for travelled distance measuring by a capsule camera in the gastrointestinal tract</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10506921</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/11/2038</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for travelled distance measuring by a capsule camera in the gastrointestinal tract</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10835113</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/11/2038</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for detecting missed areas during endoscopy</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11219358</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2040</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for leveraging residue energy of capsule endoscope</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11612303</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2041</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and apparatus for objective assessment of gastrointestinal conditions based on images captured in the GI tract</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11948303</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/7/2042</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and Apparatus for Objective Assessment of Gastrointestinal Conditions based on Images Captured in the GI Tract</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12490889</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2045</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Patent No.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of Expiration</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Vivo Sensor with Panoramic Camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP5,695,142B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/19/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Vivo Sensor with Panoramic Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP5,523,713B</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/19/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-Stream Image Decoding Apparatus And Method</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP5,368,469B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method to Compensate Manufactoring Variation and Design Imperfections In A Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP5,926,345B</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/12/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-Stream Image Decoding Apparatus And Method</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP5,592,358</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Optical Wireless Docking System for Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP6,177,315</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power Source Control For Medical Capsulese</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP6,280,876</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/24/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconstruction of Images from an in Vivo Multi-Cameras Capsule</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP6,501,800</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/27/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System and Method for Capsule Device with Multiple Phases of Density</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP6,510,591</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/22/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods to Compensate Manufacturing Variations and Design Imperfections In A Display Device</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP6,737,937</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/25/2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods to Compensate Manufacturing Variations and Design Imperfections In A Display Device</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP6,563,870</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/25/2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single Image Sensor for Capturing Mixed Structured-light Images and Regular Images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP6,803,908</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/22/2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single Image Sensor for Capturing Mixed Structured-light Images and Regular Images</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP7,114,666</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/22/2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single Image Sensor for Capturing Mixed Structured-light Images and Regular Images</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP7,114,667</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/22/2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camera System With Multiple Pixel Arrays On A Chip</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP5,368,469</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscope Employing Structured Light Providing Physiological Feature Size Measurement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JP6,891,345</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/12/2038</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data communication between capsulated camera and its external environments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP2198342</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/12/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo sensor with panoramic camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP1974240</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/19/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camera system with multiple pixel arrays on a chip</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP2225877</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power source control for medical capsules</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP 2816946</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/24/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule endoscopic docking system</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP 2858549</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/23/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-stream image decoding apparatus and method</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP2291119</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Optical wireless docking system for capsule camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP 2849627</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power source control for medical capsules</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP 3272270</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/24/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In vivo camera with multiple sources to illuminate tissue at different distances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP 2299895</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Patent No.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of Expiration</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule device having variable specific gravity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP 3270761</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconstruction of images from an in vivo multi-camera capsule with confidence matching</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP 3148399</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/27/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule coating for image capture control</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP 3226745</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/4/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single image sensor for capturing structured-light images and regular images and its method of operation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP3362989</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/22/2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconstruction of images from an in vivo multi-camera capsule</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TWI532460</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/26/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and Apparatus for Endoscope with Distance Measuring for Object Scaling</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TW-I596931</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/5/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule Orientation Detection for Capsule Docking System with Inductive Power Drive Circuit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TW-I592129</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/25/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Image Capture Control For In Vivo Camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201180011653.4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/21/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-Stream Image Decoding Apparatus And Method</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL200980129312.X</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Vivo Camera with Multiple Sources to Illuminate Tissue At different Distances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL200980120587.7</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Communication Between Capsulated Camera and Its External Environments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL200880106599.X</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/12/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Vivo Autonomous Camera with&#160;On-Board&#160;Data Storage or Digital Wireless Transmission in Regulatory Approved Band</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL200680040026.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/26/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camera System With Multiple Pixel Arrays On A Chip</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL200880125638.0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/26/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method to Compensate Manufactoring Variation and Design Imperfections In A Capsule Camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL200780052067.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/12/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method to Compensate Manufactoring Variation and Design Imperfections In A Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201210082410.6</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/12/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power Source Control for Medical Capsules</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201380004147.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/24/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Optical Wireless Docking System for Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201380026186.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Vivo Camera With Multiple Sources To Illuminate Tissue At Different Distance</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201410534382.6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Vivo Capsule Device with Electrodes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201310346793.8</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/9/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule Camera Device With Multi-Spectral Light Sources</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201380081896.4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/27/2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Vivo Sensor with Panoramic Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL200680050987.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/19/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconstruction of Images From An In Vivo Multi-Camera Capsule</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201480030874.X</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/19/2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Vivo Camera With Multiple Sources To Illuminate Tissue At Different Distances</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201410532920.8</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Patent No.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of Expiration</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Vivo Camera With Multiple Sources To Illuminate Tissue At Different Distances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201811307576.7</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of Overlap-Dependent Image Stitching for Images Captured Using a Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201680020175.6</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capsule Device Having Variable Specific Gravity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201680016549.7</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconstruction With Object Detection For Images Captured From A Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201680047653.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/25/2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single Image Sensor for Capturing Mixed Structured-light Images and Regular Images</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201680059418.7</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/22/2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and Apparatus for Gastric Examination Using a Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201780097479.7</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2037</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Image Sensor with Integrated Power Conservation Control</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201580079351.9</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/28/2035</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and Apparatus of Lens Alignment for Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201780036954.X</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2037</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and Apparatus for Area or Volume of Object of Interest From Gastrointestinal Images</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201710768987.5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/31/2037</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">De-ghosting&#160;of Images Captured Using a Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201711016971.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/26/2037</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and Apparatus for Image Stitching of Images Captured Using a Capsule Camera</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201680091275.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/30/2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and Apparatus for Travelled Distance Measuring by a Capsule Camera in the Gastrointestinal Tract</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201910119473.6</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2039</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscope Employing Structured Light Providing Physiological Feature Size Measurement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201880045690.9</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/12/2038</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of Image Processing and Display for Images Captured by a Capsule Camera</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201780089753.6</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/19/2037</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and Apparatus for Capturing Images and Associated 3D Model Based on a Single Image Sensor and Structured-Light Patterns in the Visible Spectrum</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL201910228496.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2039</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method and Apparatus for Travelled Distance Measuring by a Capsule Camera in the Gastrointestinal Tract</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZL202210637502.X</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2039</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apparatus and&#160;Method</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we also rely upon trademarks, trade secrets, know-how, and continuing technological innovation to develop and maintain our competitive position. We maintain and are seeking registered trademarks. We have certain know-how and trade secrets relating to our capsule camera and other technologies. We rely on trade secrets to protect certain aspects of our technology. See the section titled &#8220;Risk factors&#8212;Risks Relating to Our Intellectual Property&#8221; for a more comprehensive description of risks related to our intellectual property.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Resources</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we had approximately 99 full time employees. None of our employees are represented by a labor union or party to a collective bargaining agreement. We consider our relationship with our employees to be good.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and additional employees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located at 18805 Cox Avenue, Suite 250, Saratoga, California 95070. Our telephone number is (408) 624-1488. We use our website at www.capsovision.com to communicate important information about our company, including news releases and financial information. We also make available on our investor relations webpage, free of charge, copies of our Securities and Exchange Commission (&#8220;SEC&#8221;) filings and submissions, which can be found at the SEC&#8217;s website, www.sec.gov, as soon as reasonably practicable after electronically filing or furnishing such documents with the SEC. Website references are provided throughout this document for convenience only. The contents of these websites do not constitute a part of this Annual Report and shall not be deemed incorporated by reference into this Annual Report unless expressly noted.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Report, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) or 15(d) of the Exchange Act are available on our website, free of charge, as soon as reasonably practicable after the reports are electronically filed or furnished to the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information that we file with the SEC electronically. We intend to announce material information to the public through filings with the SEC, the investor relations page on our website, which is located at www.capsovision.com, press releases, public conference calls, and public webcasts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information disclosed through the foregoing channels could be deemed to be material information. As such, we encourage investors, the media, and others to follow the channels listed above and to review the information disclosed through such channels. The information we post through these channels is not a part of this Annual Report. Any updates to the list of disclosure channels through which we will announce information will be posted on the investor relations page on our website.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815509"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks and uncertainties described below, as well as the other information in this Annual Report and in our other public filings, including in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and in our financial statements and the related notes appearing elsewhere in this Annual Report and in our other public filings, which could materially affect our business, financial condition or future results. The risks described below are not the only risks that we face. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, results of operations and prospects. We may disclose changes to risk factors or additional risk factors from time to time in our future filings with the SEC. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business and Industry Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses, and we expect to incur additional losses in the foreseeable future.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since inception, and we expect to incur additional losses in the foreseeable future. For the years ended December&#160;31, 2025 and December&#160;31, 2024, we incurred net losses of $25.3 million and $19.9 million, respectively. As of December&#160;31, 2025 we had an accumulated deficit of $155.7 million. Our accumulated deficit reflects significant front-end spending and investment related to both completed and ongoing key operational milestones, including: (i) the initial and continued development of CapsoCam Plus and CapsoCloud, our cloud-based platform; (ii) development of our next pipeline capsule endoscope, CapsoCam Colon; (iii) initial development and ongoing improvements to our AI assisted pathology detection tools and technologies; and (iv) funding of completed and ongoing related clinical and other studies. As we execute on our business strategy to grow our business and revenues (including seeking FDA 510(k) clearance for CapsoCam Colon), we will continue to incur development costs and clinical study expenses and will make additional investments. Additionally, as a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. Accordingly, we expect to continue to incur losses for at least the near-term and we may never achieve profitability or, if we do achieve profitability, sustain profitability. Our failure to achieve and sustain profitability in the future would make it more difficult to finance our business and accomplish our strategic objectives, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our audited financial statements for the years ended December&#160;31, 2025 and December 31, 2024 include a footnote raising substantial doubt about our ability to continue as a &#8220;going concern&#8221; and we will likely need to raise additional financing to fund our business and revenue growth plans.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2025 and 2024 audited financial statements include a footnote raising substantial doubt about our ability to continue as a going concern. We have funded our historical net losses and negative cash flows through the issuance of convertible preferred stock and IPO common stock. As of December 31, 2024, we had cash of approximately $9.3 million, including $20.4 million raised in 2023 and $15.0 million raised in 2024 through the issuance of preferred stock to our investors. As of December&#160;31, 2025, we had cash of approximately $10.1 million, including $23.4 million raised through the IPO.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue as a going concern depends on a number of factors including whether we can successfully implement our business and revenue growth plans to generate sufficient cash flow from operating activities, and our ability to raise as needed other equity financing or loan facilities. We closed a private placement on March 16, 2026, and raised $14.0 million from certain accredited investors. We will likely need to undertake additional capital-raising activities before the year-end of 2026 to fund our operations and planned clinical studies as contemplated by our growth strategy, such as the second arm pivotal study for the second generation CapsoCam Colon capsule and the planned study for early pancreatic cancer detection using the CapsoCam UGI system. There is no certainty regarding the occurrence, magnitude, or timing of these capital-raising activities. If we raise additional funds through the sale of equity, convertible debt, or other equity-linked securities, our stockholders&#8217; ownership will be diluted. The inability to secure adequate financing on favorable terms, or at all, could have a material adverse effect on our financial position, results of operations, cash flows, and ability to achieve our intended business objectives. See the risk factor titled &#8220;We may require additional capital to support business growth, and this capital might not be available on terms favorable to us, or at all, and may dilute existing stockholders&#8217; ownership of our common stock&#8221; below.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the substantial doubt about our ability to continue as a going concern, potential investors must exercise caution when evaluating our financial condition, results of operations, and business prospects. Our inability to raise sufficient financing or meet our strategic plans could result in a material adverse effect on our financial position, results of operations, cash flows, and ability to achieve our intended business objectives.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All of our revenues to date have been, and in the near-term will continue to be, generated from CapsoCam Plus related sales for the small bowel; and our ability to grow our small-bowel-related revenue is subject to our ability to successfully and timely execute related elements of our revenue growth strategy.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Near term actions to grow our CapsoCam Plus small-bowel-related revenues include those set forth below. We may be unable to timely and effectively execute these or other activities designed to increase our small-bowel-related revenues.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging the patient and provider benefits of CapsoCam Plus capsule endoscopy solution (which includes the associated software products, CapsoCloud and CapsoView) to effectively compete against competitors, such as (i) Medtronic, with its comparatively greater overall brand recognition, financial resources and other competitive advantages; and (ii) the U.S. subsidiary of a non-U.S. (Chinese) competitor who was the first to use AI-driven lesion detection software to support its small bowel capsule endoscopy system.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Further penetrating the small bowel market in the U.S. and internationally, including by (i) increasing the size and effectiveness of our U.S. and international sales teams; (ii) pursuing the pediatric market (with children comprising a significant portion of the Crohn&#8217;s disease patient population) following FDA clearance in December 2024 for this newly indicated patient population; (iii) introducing complementary products such as our (a) capsule delivery device with full commercialization expected in the fourth quarter of 2026 and (b) patency capsule (for verifying a capsule endoscope can pass through the bowel without retention prior to an exam) with tentative FDA 510(k) submission planned by the end of the second quarter of 2026; and (iv) facilitating increased telemedicine adoption following FDA clearance in December 2024 of remote ingestion of our CapsoCam Plus, allowing patients to ingest our capsules in the comfort of their own homes with remote provider supervision.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Incorporating our AI assisted pathology detection technology into our CapsoCam Plus capsule. We conducted related clinical studies to demonstrate the benefits of our AI technology as incorporated into CapsoCam Plus and submitted the related 510(k) application to the FDA in December 2025. We are targeting the related EU submission in the second quarter of 2026. We anticipate to obtain FDA clearance by the middle of 2026 and EU clearance in the third quarter of 2026 with commercialization planned to begin in US and EU shortly thereafter.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these activities is subject to numerous risks. For example, (i) we may be unable to compete effectively against our competitors; (ii) the introduction of our capsule delivery device and patency capsule may be delayed or these products may not be sufficiently adopted by providers and patients initially or in the longer term; and (iii) we may fail to obtain all required FDA and EU approvals for incorporating our AI assisted pathology detection technology into our CapsoCam Plus solution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see the other risks set forth under this &#8220;Risk Factors&#8221; section including &#8220;We operate in a highly competitive industry, and competitive pressures could have a material adverse effect on our business, financial condition, results of operations, and prospects,&#8221; &#8220;Our longer term efforts to expand our GI-tract capsule endoscopy solution beyond small bowel and colon pathologies and medical conditions may not succeed,&#8221; and &#8220;We may face regulatory challenges and delays in obtaining 510(k) clearance for marketing of those CapsoCam capsules incorporating our self-developed AI technology, including our CapsoCam Colon capsule endoscopy solution and CapsoCam Plus capsule endoscopy solution (small bowel).&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CapsoCam Colon is our initial strategic effort to expand revenues for our GI-tract capsule endoscopy solution beyond small-bowel-related sales; we do not currently expect to generate CapsoCam Colon-related revenues until FDA clearance for the second generation of our CapsoCam Colon solution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CapsoCam Colon capsule endoscopy solution (which includes associated software products, CapsoCloud and CapsoView) is our initial strategic effort to grow our revenues beyond small-bowel-related sales. We do not expect to generate CapsoCam Colon related sales in the U.S. or internationally until after (i) obtaining initial FDA 510(k) or EU clearance, as applicable, for our second generation of our CapsoCam Colon capsule for use by the indicated patients (who are a subset of the colorectal cancer screening and surveillance population) and (ii) satisfying the related conditions for obtaining these clearances.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second generation of our CapsoCam Colon solution incorporates our AI assisted pathology detection technology. The second-generation product will incorporate improvements&#8212;such as a new lens and illumination optics with an increased field of view and improved image quality&#8212;designed to increase the accuracy (measured in terms of polyp-detection sensitivity and specificity) and benefits of using our CapsoCam Colon solution to visualize the colon and detect and measure polyps. We plan to focus our regulatory efforts on first obtaining U.S. FDA clearance followed by obtaining EU clearance. We plan to use the clinical results of the second arm of our pivotal study to support submission to the FDA of a 510(k) application in the third quarter of 2026. FDA review of our 510(k) submissions may be delayed and we may not receive 510(k) clearances from the FDA on a timely basis or at all. Staff reductions in the FDA office charged with regulating devices may cause delay. Related risks with respect to, among other things, receiving requisite regulatory clearances and the timing thereof and commercializing our CapsoCam Colon capsule endoscopy solution are described further below in these &#8220;Risk Factors.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Broad adoption of our CapsoCam Colon solution (once cleared) and growing related revenues depend on, among other things, expanding beyond CapsoCam Colon&#8217;s initial indicated patient population, increasing the accuracy of our initial CapsoCam Colon solution, and achieving and maintaining a satisfactory successful completion rate for capsule endoscopies using our CapsoCam Colon solution; and we may fail to successfully and timely execute related elements of our CapsoCam Colon adoption and revenue growth strategy.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broader adoption of our CapsoCam Colon capsule endoscopy solution by providers and patients (once cleared) and growing related revenues would involve, among other things:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing the indicated patient population for our CapsoCam Colon solution. The initial indicated patient population is a subset of the colorectal cancer screening and surveillance populations. More specifically, GI patients with (i) major risks for colonoscopy or moderate sedation coupled with evidence of GI bleeding of lower GI origin and (ii) an incomplete colonoscopy with adequate bowel preparation. As part of seeking FDA clearance for the planned second generation of our CapsoCam Colon solution, we plan to seek FDA clearance to remove the GI bleeding requirement. Successful removal of the GI bleeding requirement would significantly increase CapsoCam Colon&#8217;s addressable market. There is no assurance that the FDA will permit this request or any future request to expand the indicated patient population for our CapsoCam Colon solution on a timely basis or at all. Any such request would involve significant effort and require, among other things, related regulatory submissions and our conducting non-clinical and clinical studies to generate data and evidence to support the request; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued enhancements and improvements to our CapsoCam Colon solution to increase its accuracy (measured in terms of polyp-detection sensitivity and specificity) and benefits of using CapsoCam Colon to visualize the colon and detect and measure polyps. Our success in implementing these enhancements and improvements (including obtaining related FDA 510(k) and EU clearances) is critical to (i) our initial and ongoing commercialization efforts (including efforts to increase provider and patient acceptance of our solution); (ii) our ability to increase CapsoCam Colon&#8217;s indicated patient populations; and (iii) consequently, increasing that portion of the colorectal cancer screening, surveillance, and diagnostic patient populations for which our CapsoCam Colon may be used. We may be unable to successfully make continued enhancements and improvements to sufficiently increase the accuracy and benefits of using our CapsoCam Colon system on a timely basis or at all; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieving and maintaining a satisfactory and successful examination completion rate for capsule endoscopy using CapsoCam Colon. A successful completion rate for CapsoCam Colon endoscopies much lower than that for traditional colonoscopies may (i) limit the patient population for whom CapsoCam Colon is deemed appropriate; (ii) limit its acceptance by providers and patients; and (iii) result in an unacceptable number of patients requiring a follow-on colonoscopy or other diagnostic test to confirm that they lack significant colon polyps or do not have cancer. A successful colon capsule endoscopy involves successful imaging of either (i) a patient&#8217;s entire colon without detecting significant polyps or (ii) a sufficient portion of the patient&#8217;s colon to identify the presence of one or more significant </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">polyps (i.e., indicating preventative or treatment driven colonoscopy is recommended). Capsule colonoscopy procedures are unsuccessful most often due to inadequate bowel preparation and/or slow capsule transit through the colon. CapsoCam Colon&#8217;s successful completion rate (as demonstrated in our pivotal study) is supported by a physical design that encourages timely transit the GI-tract and a battery lifetime that is currently twice the competition&#8217;s. However, the bowel preparation, which is similar to that used for colonoscopy, produces a level of cleansing that is patient specific, and capsule endoscopy does not afford an opportunity, as colonoscopy does, for targeted additional cleansing by the physician during the exam. Although we are positioned to benefit from improvements in bowel preparation medications on the market, these developments are outside our business and difficult to predict.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to timely and effectively drive broad provider and patient adoption of our CapsoCam Colon solution (once cleared) and grow related revenue. Each of the above activities is subject to numerous risks described above or elsewhere in these &#8220;Risk Factors.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our longer term efforts to expand our GI-tract capsule endoscopy solutions beyond small bowel and colon pathologies and medical conditions may not succeed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our CapsoCam Plus (small bowel) and CapsoCam Colon solutions, incorporating our panoramic imaging solution, can be adapted to address new GI medical indications. In connection with our efforts to address pancreatic cancer, we submitted an FDA &#8220;Breakthrough Device Designation&#8221; for our capsule endoscopy solution on November 6, 2025. A response from FDA in January 2026 determined that the CapsoCam UGI does allow for visualization of the papilla and its abnormalities, for both pre-cancerous and cancerous lesions. Due to the fact that the device does not specifically define diagnostic criteria, the application was not approved. The Company expects to resubmit the Breakthrough Device Designation application following the study, when additional data is available. The breakthrough designation is a part of the on-going project, potentially supplementing the regulatory pathway and approval for early pancreas cancer detection. However, additional research and studies to collect data may delay our anticipated timeline for obtaining the regulatory clearance (including obtaining the Breakthrough Device Designation) and may  result in an increase in our research and development expenditures that exceed our current expectations. Starting with a planned study, we will build on established scientific literature and work with leading opinion leaders (including leadership on leading Societies in pancreatobiliary field) to define malignancy diagnosis with the device. We expect that the study will start in the second quarter of 2026, and enroll approximately 90 patients using the CapsoCam UGI system to define diagnosis criteria. However, there can be no assurance that our reshaped strategy will be successful. A Breakthrough Device Designation prioritizes a device in the FDA&#8217;s review queue for all future regulatory submissions and accelerates communications (i.e., negotiations and feedback) with the FDA, thereby expediting the marketing application process. However, our proposed capsule endoscopy solution may not meet the eligibility requirements for this designation and, even if a Breakthrough Device Designation is received, it may not receive the FDA authorization required to market the proposed capsule endoscopy solution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in the capsule endoscopy market for our current and planned medical conditions. Our success in expanding our capsule endoscopy solution is contingent upon our ability to execute on our related strategies, differentiate our technology with initial or improved product accuracy (such as sensitivity and specificity) and features, and secure acceptance in the GI medical community. Any failure in these areas could significantly impede our growth prospects and adversely affect our financial performance. There is no assurance that our efforts will yield successful outcomes in addressing pancreatic cancer, esophageal medical conditions or other targeted medical conditions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure or defect in our GI-tract capsule endoscopy solution could harm our reputation, expose us to liability, and reduce our sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GI-tract capsule endoscopy solution comprises our CapsoCam capsules and the associated software (CapsoCloud and CapsoView), including their related components. We may encounter technical, operational, or regulatory challenges or limitations in developing, testing, validating, or implementing improvements to our GI-tract capsule endoscopy solution, which could delay or prevent us from achieving our desired outcomes. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, related components (including the lens module, image sensor, processor and storage module) and incorporated AI technology may fail or malfunction due to defects, errors, bugs, viruses, cyberattacks, or other causes, which could compromise the quality, accuracy, or reliability of our products and the images and analyses they produce. Any failure or defect in our GI-tract capsule endoscopy solution (including capsule components and the associated software, CapsoCloud and CapsoView) could harm our reputation, expose us to liability, and reduce our sales. Any of these outcomes could have a material adverse effect on our business, financial condition, and results of operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial geopolitical and trade risks (including a possible trade war and imposition of tariffs and supply chain interruptions) and natural disaster risks associated with our business operations in Asia (particularly Taiwan and Japan).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face substantial geopolitical risks due to our business operations in Asia (particularly Taiwan and Japan). Our major assembly manufacturers are located in Taiwan. Most of our single-source suppliers of critical components of our products are located primarily in Taiwan and Japan. Political events, trade and other international disputes, geopolitical tensions, conflict, terrorism, public health issues, industrial accidents and other business interruptions in these areas can have a material adverse effect on our business operations. Restrictions on international trade, such as tariffs and other controls on imports or exports of goods, technology or data, can materially adversely affect our business and supply chain. Restrictive measures can increase the cost of our products, and can require us to take various actions, including changing suppliers and restructuring our supply chain, business relationships and operations. Changing our business and supply chain in accordance with new or changed restrictions on international trade can be expensive, time-consuming and disruptive to our operations. Such restrictions can be announced with little or no advance notice, which can create uncertainty, and we may not be able to effectively mitigate all adverse impacts from such measures. For example, an increase in the recent tensions between mainland China and Taiwan and the possibility of instability and uncertainty caused by prolonged or regular military drills in the Taiwan Strait may result in disruptions in the overall trading environment, and in turn result in higher transportation cost and interruption in delivery of our products or its critical components from our single-source suppliers in Taiwan, adversely affecting our business and financial condition. For additional information, see the risk factor titled &#8220;Changes to U.S. tariff measures and other political changes in international trade relations implemented by the U.S. could have a material adverse effect on our business, financial condition, cash flows and results of operations&#8221; below.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to political risks, Taiwan and Japan are susceptible to natural disasters, such as earthquakes and typhoons, that could disrupt the normal operations of our business and adversely affect earnings. There can be no assurance that future natural disasters will not occur and result in major damages to our component suppliers and assembly manufacturers (many of whom are single-source and located in Taiwan and Japan), which could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face expansion risks when expanding in existing and entering into new foreign markets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth strategy includes increasing our international revenues and potential entry into new international markets (including through qualified exclusive distributors in targeted regions). In the years ended December&#160;31, 2025 and 2024, international sales accounted for approximately 21% and 23% of our revenue, respectively. Our largest international shipping destinations in 2025 include France, Germany and Colombia. Some of our existing and new international markets may be highly regulated and competitive. However, we may face significant challenges and risks in expanding in existing and entering into new international markets (including risks related to expanding our market share and customer base), such as the following: </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The need to grow our sales and marketing team (including potentially through qualified distributors) in these markets.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The need to comply with complex and evolving regulatory requirements, quality standards, and post-market surveillance obligations, which may entail significant time, cost, and resources, and may subject us to regulatory actions, penalties, or product recalls if we fail to meet them.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The need to compete with established and emerging players in the capsule endoscopy market, which may have greater financial capabilities, brand recognition, market access, distribution networks, or technological capabilities, and which may offer lower prices, superior features, or better customer service.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The need to secure adequate reimbursement and coverage policies from public and private payers, which may affect the affordability, accessibility, and adoption of our CapsoCam capsule endoscopy solution, and which may be subject to changes, limitations, or uncertainties due to budget constraints, policy reforms, or competitive pressures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to successfully execute on our growth strategy, overcome these challenges and risks, or achieve our expected returns on our investments in these foreign markets. In addition, we may encounter unforeseen difficulties or liabilities related to our operations, supply chain, intellectual property, or litigation in these foreign markets. Any of these factors could negatively impact our sales, margins, reputation, or market position in new foreign markets, and as a result, our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The clinical results of our various clinical studies (including those for our CapsoCam Colon capsule) may not be released in any peer-reviewed publications.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2025, we submitted the results of the first arm of our pivotal study for CapsoCam Colon to the FDA as part of an initial 510(k) clearance submission for our &#8220;first generation&#8221; product. We received responses from the FDA in September 2025. During our meeting with the FDA in December 2025, the FDA raised inquiries on topics including panoramic image processing methodology, and the proposed study design, sample size and primary endpoint for an extended study. Based on our communications with the FDA, we have decided not to further pursue the first generation CapsoCam Colon capsule submission and approval, and to prioritize our resources for the development of our second generation CapsoCam Colon capsule, featuring improved imaging quality and increased field of review with use of AI and better lens.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, top-line or preliminary data from our pivotal studies, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the pivotal study or additional data collected at a later time. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. The data from a study may not be released in any peer-reviewed publication, either initially or in the future. As a result, the interim, top-line, or preliminary results that we report may differ from future results of the same trial, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. The FDA may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of our study (including our CapsoCam Colon pivotal study), or potential for the regulatory approval or for commercialization.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not plan to release the clinical results from our various clinical studies (including the second arm of our CapsoCam Colon clinical study and our planned CapsoCam Plus clinical study (AI)) before submitting, as applicable, the related 510(k) clearance submission to the FDA. Typically, the submission of study results for publication in a peer-reviewed journal occurs after its use for an FDA submission. The initial or future absence of peer-reviewed research could hinder the acceptance of our GI-tract capsule endoscopy solution products within the medical community, potentially affecting its credibility and market adoption.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the results of the utilization of our GI-tract capsule endoscopy solution (including CapsoCam Colon) may not be accepted or replicated by the scientific or medical community, or may be challenged or disputed by our competitors or other third parties. Physicians and third-party payors may be skeptical of new technologies and may require substantial evidence of clinical efficacy and cost-effectiveness before adopting new products. If the results of our research and clinical studies and our sales and marketing activities relating to communication of these results do not convince thought-leading gastroenterologists, guidelines organizations, primary care physicians, third-party payors, and patients that our GI-tract capsule endoscopy solution (including CapsoCam Colon) is reliable, effective, and superior to existing screening methods, we may not achieve the necessary </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market acceptance. The publication of negative or inconclusive results, or the emergence of new or conflicting data, could undermine the validity or reliability of our study and our GI-tract capsule endoscopy solution, and could reduce the demand for or acceptance of our CapsoCam capsules by physicians, patients, payors, or other stakeholders. Any of these outcomes could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive industry, and competitive pressures could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive industry, and competitive pressures could have a material adverse effect on our business, financial condition, results of operations, and prospects. The medical device market, particularly in the area of diagnostic imaging and endoscopic procedures, is characterized by rapid technological advancements and the continuous introduction of new products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition that we face for our small bowel CapsoCam Plus is primarily from traditional enteroscopy procedures performed by trained physicians in hospital or clinical settings and other capsule-based imaging solutions manufactured by companies such as Medtronic, IntroMedic, JinShan and Ankon. Those competitors include well-established companies with significant resources and brand recognition such as Medtronic, that are constantly developing and marketing innovative products that may offer superior features or lower costs. With respect to Medtronic, it also enjoys other competitive advantages including (i) a &#8220;first mover advantage&#8221; as the first manufacturer of a small bowel capsule endoscopy and a colon capsule endoscopy (as described below); (ii) exclusive supply arrangements (sometimes up to three years) with some of the larger GI practices and hospitals (particularly in the Northeast region of the U.S.) which our sales team also targets; and (iii) greater brand recognition and financial resources.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notably, one competitor, Ankon (through its affiliate AnX Robotics), has already established a market presence with their FDA-cleared AI product for the small bowel in the U.S. and various other markets outside the U.S. This puts us at a market disadvantage until we can launch our own AI product for the small bowel, subject to FDA clearance which is anticipated to occur by the middle of 2026. The delay in our product launch could result in a loss of market share and reduced revenue opportunities, as potential customers may opt for the already available and proven solutions from our competitors. Additionally, the competitive landscape is further impacted by the pricing strategies of Asia-based capsule endoscopy companies, such as Ankon (China), Jinshan (China) and IntroMedic (South Korea), who are offering their products at lower than average prices. This aggressive pricing approach could pressure us to lower our prices to remain competitive, potentially impacting our profit margins.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition that we face for CapsoCam Colon is primarily from (i) procedure-based detection technologies such as optical colonoscopy, flexible sigmoidoscopy and CTC (or &#8220;virtual&#8221; colonoscopy); (ii) stool- based DNA tests such as Cologuard (initial FDA clearance in 2014); and (iii) other capsule-based imaging solutions like PillCam COLON 2 (initial FDA clearance in 2014). Other sources of competition include (a) common CRC screening tests, such as the fecal occult blood test (&#8220;FOBT&#8221;) and the fecal immunochemical test (&#8220;FIT&#8221;), and (b) screening technologies including liquid biopsy tests, such as Epi proColon (FDA approval in 2016) and C-Scan (CE Mark obtained in 2019). Those competitors include well-established companies with significant resources and brand recognition such as Medtronic, that are constantly developing and marketing innovative products that may offer superior features or lower costs. For instance, the Medtronic PillCam COLON 2 is the only U.S. FDA approved colon capsule endoscopy and is prominent in the market outside the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combination of these factors could significantly affect our ability to attract and retain customers, thereby adversely impacting our overall business performance and future growth prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost-containment efforts of our customers and purchasing groups could have a material adverse effect on our sales and results of operations. Consolidation in the healthcare industry or group purchasing organizations could lead to demands for price concessions, which may affect our ability to sell our products at prices necessary to support our current business strategies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost-containment efforts of our customers and integrated group purchasing organizations (&#8220;GPOs&#8221;) have a material adverse effect on our sales and results of operations. In the United States, many clinics and hospitals, including some of our customers, are members of the GPOs, which are organizations that leverage the collective purchasing power of their members, such as hospitals, clinics, and other healthcare providers, to negotiate favorable pricing and terms for medical products and services. These entities negotiate pricing arrangements with medical device companies and distributors, offering these negotiated prices to affiliated hospitals and other members. GPOs typically award contracts on a category-by-category basis through a competitive bidding process, soliciting bids from multiple providers to drive down pricing or reduce the number of vendors. Due to the highly competitive nature of these contracting processes, we may face challenges in obtaining new or maintaining existing contract positions with major GPOs. The increasing leverage of the GPOs may reduce market prices for our products, thereby impacting our revenue and margins.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While securing a contract with a GPO can facilitate sales to their members and enhance our ability to meet the stringent requirements set by their members, it does not guarantee any level of sales, as purchases are typically made through individual purchase orders. Even as a sole contracted supplier for a certain product category, members of the GPO are generally free to purchase from other suppliers. Consequently, members of the GPOs may opt for alternative products based on price or quality offered by other companies, potentially leading to a decline in our sales volumes and revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rising healthcare costs over the past decade have led to numerous cost reform initiatives by legislators, regulators, and third-party payors, triggering a consolidation trend in the healthcare industry to aggregate purchasing power. This trend may result in more requests for pricing concessions in the future. We anticipate that market demand, government regulation, third-party coverage and reimbursement policies, and societal pressures will continue to evolve the healthcare industry, leading to further business consolidations and alliances among our customers. These changes may exert additional downward pressure on the prices of our products, affecting our results of operations and our ability to support our current business strategies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The effectiveness of our CapsoCam capsules heavily relies on patients adhering to our use protocols. Other companies or institutions may develop and market novel or improved methods that may make our technologies less competitive or obsolete.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our CapsoCam capsule endoscopy relies on patients adhering to proper dietary restriction and bowel cleansing protocols prior to the screening procedure. Inadequate preparation can result in suboptimal imaging, which may lead to missed screenings and diagnoses or the need for repeat procedures or alternative procedure such as colonoscopy. This dependence on patient compliance introduces a variable that is beyond our direct control, potentially impacting the reliability and accuracy of our diagnostic results. If patients do not follow the prescribed fasting and cleansing regimen, the performance of our CapsoCam capsules may be compromised, leading to decreased diagnostic accuracy and patient dissatisfaction.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our CapsoCam capsule also requires manual retrieval of the capsule by the patient, who must send it back to our download center for data collection and analysis. This manual retrieval process, while designed to be as convenient as possible, may not meet the expectations of all patients and could lead to potential errors as patients are required to diligently monitor their bowel movements to ensure the capsule is retrieved, which may be inconvenient and burdensome for them. The capsules are transported by shipping companies. There have been instances where the shipping company has either lost or damaged the capsules, leading to the loss of critical patient data. This compromises the integrity of the patient data and disrupts the entire procedure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If other companies or institutions develop or market methods that do not require fasting or bowel cleansing or require less stringent preparation, our products may become less attractive to patients. For example, non-invasive stool-based DNA tests generally requires no specific dietary restrictions or bowel preparation and enables patients to collect a stool sample at home using the provided kit and send it to the lab for analysis. Such test may be more attractive to low-risk or average-risk patients who require more convenient options for GI-tract screening. Also, recent advancements in medical research have opened up new possibilities for early detection and screening of colorectal cancer by leveraging key metabolites and early diagnostic biomarkers. Advances in technology or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alternative screening methods that eliminate or reduce the need for fasting or bowel cleansing could provide a more convenient and patient-friendly option, potentially making our CapsoCam capsules less competitive. Should such alternatives gain acceptance in the market, we may experience a decline in demand for our products, which could materially and adversely affect our business, financial condition, and results of operations. Additionally, our ability to compete effectively may be further challenged if these new methods are protected by patents or other intellectual property rights that we cannot circumvent.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are risks associated with use of our CapsoCam capsules, including capsule retention, component failures and aspiration.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CapsoCam capsule endoscopy is generally a safe procedure providing non-invasive visualization of the entire small bowel and colon (once cleared). However, there are risks associated with this procedure, including capsule retention, component failures and, in rare cases, aspiration.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2025, we recorded a provider complaint rate of approximately 2.5% (based on number of capsules sold in 2025). The bulk of recorded complaints related to patient failure to (i) timely retrieve the capsule following completion of the procedure and (ii) enter the correct serial number or use the correct shipping label when returning the capsule for download. Although small, these failures indicate potential issues with the usability or clarity of instructions provided to patients by providers or us and shipment and inventory management issues. These issues, in turn, can significantly impact customer and patient satisfaction and our reputation and potential sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capsule retention by a patient refers to the capsule getting stuck in the GI tract, which can occur due to various reasons such as strictures, tumors, or inflammatory bowel diseases. We believe the industry retention rate may be as high as 2%. Based on (i) incidences reported to us for all CapsoCam capsule patients in the year ended December 31, 2025, and (ii) total CapsoCam capsules sold by us in 2025 and 2024 retention rate was less than 1/10 of 1%. However, we believe our retention rate is understated due to (i) underreporting by providers and patients and, relatedly, (ii) the fact that most retained capsules are eventually excreted without the need for invasive intervention and medication may be used to encourage this process. In some instances, endoscopic retrieval or surgical intervention may be necessary to remove the retained capsule. Aspiration is rare but potentially fatal where the capsule is accidentally inhaled into the respiratory tract instead of being swallowed into the esophagus. As of the date of this Annual Report, there has been one complaint regarding an aspiration incident involving a CapsoCam capsule, where the capsule went into the patient&#8217;s lungs and was later endoscopically removed and placed in the patient&#8217;s GI track. The capsule was retrieved, data downloaded and read by the customer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we strive to ensure the highest safety standards and patient experience for our CapsoCam capsule, we cannot guarantee that it is entirely free of safety issues, component failures or errors. Despite rigorous testing and quality control measures, unforeseen complications may arise during the use of our GI-tract capsule endoscopy solution. These could include, but are not limited to, adverse reactions, product malfunction, or unforeseen interactions with the patient&#8217;s medical condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional capital to execute our business plan, and we may be unable to raise additional capital on acceptable terms.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executing our business plan will require additional capital. We may need to raise funds to support research and development, and expand our sales and marketing efforts. If we are unable to raise additional capital on acceptable terms, we may not be able to implement our business plan effectively, which could adversely affect our growth prospects and financial condition. Furthermore, market conditions and other factors outside our control could make it difficult to raise capital when needed. If we are unable to secure additional financing, we may have to delay, reduce, or eliminate certain aspects of our business plan, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing sales and marketing team may face challenges in selling additional products and features added to our GI-tract capsule endoscopy solution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face unique challenges in leveraging our existing sales channels to sell and market product and service additions to our GI-tract capsule endoscopy solution (including CapsoCam Colon once cleared). For example, the primary difference between small-bowel and colon diagnostic visualization lies in their distinct medical purposes, preparation requirements, and market dynamics. A small bowel capsule endoscopy is typically conducted to diagnose conditions such as OGIB, Crohn&#8217;s disease, or small bowel tumors and a different cleansing preparation compared to a colon capsule endoscopy which requires more rigorous bowel preparation. Additionally, the market for colorectal cancer screening is highly competitive, with established products such as traditional colonoscopies, other imaging technologies (mainly CT colonography and to a decreasing extent sigmoidoscopy) and stool-based screening products already in widespread use. These and other procedure and market differences and dynamics will require additional sales force training and may necessitate tailored marketing strategies and sales approaches, which could complicate our efforts to utilize our current sales teams for products beyond small bowel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The success of our business is substantially dependent upon the efforts of our senior management team and certain other key personnel and our ability to retain these individuals and to attract additional key personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to attract and retain managerial and key personnel, including our senior executive officers and various highly skilled employees. If we were to lose any of our senior management team or these key personnel, we may experience difficulties in competing effectively, developing our technologies, and implementing our business strategies. Competition for desirable personnel is intense, and there can be no assurance that we will be able to attract and retain the necessary staff. The failure to maintain management or to attract sales and key personnel as we move towards the commercialization of our CapsoCam capsules could materially adversely affect our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Macroeconomic conditions could materially adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macroeconomic conditions, such as high inflationary pressure, potential military conflicts, possible trade wars, introduction of or changes in tariffs or trade barriers, changes to monetary policy, high interest rates, volatile currency exchange rates, credit and debt concerns, decreasing consumer confidence and spending, including capital spending, concerns about the stability and liquidity of certain financial institutions, and global recessions can adversely impact demand for our products, which could negatively impact our business, financial condition, results of operations, and prospects. Recent macroeconomic conditions have been adversely impacted by geopolitical instability and military hostilities in multiple geographies and monetary and financial uncertainties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impacts of these macroeconomic conditions, and the actions taken by governments, central banks, companies, and consumers in response, have resulted in, and may continue to result in, higher inflation in the United States and globally, which is likely, in turn, to lead to an increase in costs and may cause changes in fiscal and monetary policy, including additional increases in interest rates. Other adverse impacts of recent macroeconomic conditions have been, and may continue to be, supply chain constraints, logistics challenges, liquidity concerns in the broader financial services industry, and fluctuations in labor availability. In a higher inflationary environment, we may be unable to raise the prices of our products sufficiently to keep up with the rate of inflation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry could adversely affect our current and projected business operations, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to bank failures and market-wide liquidity problems. We are exposed to concentrations of credit risk through our financial instruments, which primarily include demand deposits held at reputable financial institutions and accounts receivable. These financial instruments are subject </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to potential credit risk, as we rely on the financial stability and creditworthiness of these institutions and its customers. While we take measures to mitigate these risks, such as conducting thorough credit evaluations and maintaining relationships with well-established financial institutions, there remains an inherent risk of financial loss if these counterparties fail to meet their obligations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our cash deposits may occasionally exceed the limits insured by the U.S. Federal Deposit Insurance Corporation. This situation can arise during periods of high cash flow or when large payments are received. When cash deposits exceed FDIC insurance limits, we are exposed to the risk of loss in the event of a bank failure. Although we strive to manage this risk by spreading out our cash deposits in accounts with multiple reputable and financially stable banks, the potential for uninsured losses remains a significant risk factor that could adversely impact our financial position and operational stability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shutdowns of the U.S. federal government could materially adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has shut down multiple times in the past, and certain regulatory agencies, including the FDA, the CMS , the U.S. International Trade Commission, the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) , the U.S. Department of Defense, and the U.S. Department of Veterans Affairs, have had to furlough employees and suspend some of their activities. A prolonged shutdown could delay regulatory reviews and approvals, litigation proceedings, or government program implementations and could ultimately disrupt or delay our research and development, manufacturing, commercialization, or intellectual property enforcement activities. Any such delays or disruptions could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Related to Regulatory Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not obtain or may experience delays in obtaining 510(k) clearance for our planned second generation of our CapsoCam Colon solution (with improved optics and other components), which would adversely impact our ability to commercialize this product and generate related revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 510(k) application process can be lengthy. There is no guarantee that the FDA will grant 510(k) clearance for our planned second generation CapsoCam Colon capsule endoscopy solution, and their timeline for doing so may not align with our planned commercialization schedule. Staff reductions in the FDA office charged with regulating devices may also cause delay. Similar consequences may result in the case of events which affect FDA operations, such as a federal government shutdown.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our CapsoCam Plus solution, which visualizes the small bowel, has been cleared by the FDA, the CapsoCam Colon capsule endoscopy solution will require a distinct, unrelated regulatory submission, as it is subject to different statutory requirements. This is due to its use in the colon (part of the lower GI-tract) and incorporation of new capabilities (including AI assisted pathology detection technology) to facilitate visualization of the colon and to identify and measure polyps, each of which introduces different safety and effectiveness considerations. As a part of the marketing submission review, the FDA may require additional analysis, data, studies, or modifications to our products or labeling, which could increase our costs, delay our launch, or limit our market opportunity. The FDA may also require other conditions on our products to achieve initial clearance, such as additional studies or clinical trials, labeling restrictions, or post-market surveillance commitments, which could increase our regulatory burden and liability. Risks related to the separate FDA clearance of the AI assisted pathology detection technology incorporated in our CapsoCam Colon capsule endoscopy solution and CapsoCam Plus capsule endoscopy solution are discussed in the risk factor titled &#8220;We may face regulatory challenges and delays in obtaining 510(k) clearance for marketing of those CapsoCam capsules incorporating our self-developed AI technology, including our CapsoCam Colon capsule endoscopy solution and CapsoCam Plus capsule endoscopy solution (small bowel)&#8221; below.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is required by statute to review 510(k) applications within defined timelines. For most 510(k) submissions, a 90-day maximum review period is mandated. While this requirement provides predictability for the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review process, it also places constraints on available opportunities to address any questions posed by FDA. Factors critical to a timely review and clearance of our 510(k) applications include (i) the quality of our regulatory submission (including both in terms of clarity in presentation and the supportiveness of data) and (ii) the availability of qualified FDA review resources (i.e., individuals possessing relevant technical understanding and requiring a minimal &#8220;learning curve&#8221;). Although we have (x) engaged with the FDA in early communications (including several pre-submission meetings) regarding our CapsoCam Colon solution and (y) considered FDA feedback during product development, there is no guarantee that the FDA staff members involved in those discussions and/or who are familiar with the CapsoCam technology will be available to participate in the post-submission review of our 510(k) application. The involvement of less experienced FDA staff members may result in a &#8220;learning curve&#8221; potentially reducing the effective time available to the FDA to critically review our submissions. Likewise, changes in review staff levels or workload&#8212;possibly due to changes in FDA funding or operations, including as a result of a government shutdown, or the emergence of competing public health priorities (e.g., addressing a device shortage) may lead to review delay and an inability to complete the FDA review process within the statutorily mandated period, potentially leading to a longer review process for our applications.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain or delays in obtaining 510(k) clearance for our CapsoCam Colon capsule endoscopy solution could result in additional costs or liabilities and adversely impact our reputation, ability to sell our CapsoCam Plus capsule endoscopy solution, and our ability to compete effectively in this or other markets. Any of these outcomes could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to capture the market opportunity for our GI-tract capsule endoscopy solution depends on several factors, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance in the GI medical community;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients screened or tested for specific pathology or medical indication and the number of patients who use our CapsoCam capsules for that purpose;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to introduce enhancements and improvements aimed at increasing the value provided by our GI-tract capsule endoscopy solution;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and commercialize our CapsoCam capsule endoscopy solution for new indications, patient populations and clinical use cases;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully complete any required clinical or other studies and obtain and maintain any required regulatory approval or clearances;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">insurer and third-party reimbursement of the costs associated with our GI-tract capsule endoscopy solution (which may be adversely impacted by U.S. governmental budgetary and cost-cutting activity);</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful management of our global supply chain including our component suppliers and assembly manufacturers for our CapsoCam solution, many of which are located in Asia (particularly Taiwan and Japan) and some of which are currently single-source suppliers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful growth and leveraging of our global sales team (including, where appropriate, distributors) and marketing team to sell and market our GI-tract capsule endoscopy solution; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and nature of competition from other GI-tract diagnostic products or procedures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to effectively manage our business through the various challenges we face, may result in an inability to execute on our business plan and revenue growth strategies, respond to competitive pressures, take advantage </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of market opportunities, satisfy customer requirements, or maintain high-quality products, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face regulatory challenges and delays in obtaining 510(k) clearance for marketing of those CapsoCam capsules incorporating our self-developed AI technology, including our CapsoCam Colon capsule endoscopy solution and CapsoCam Plus capsule endoscopy solution (small bowel).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2025, we submitted to the FDA the clinical results of the first arm of our CapsoCam Colon pivotal study in a related 510(k) submission and it has been accepted for review. This submission seeks FDA clearance of our initial CapsoCam Colon capsule endoscopy solution which incorporates our self-developed AI technology. Following our decision not to further pursue the first generation CapsoCam Colon capsule submission and approval, and to prioritize its resources for the development of its second generation CapsoCam Colon capsule, the second generation also features improved imaging quality and increased field of review with use of AI and better lens. Our 510(k) submissions and FDA review thereof may be delayed and we may not receive 510(k) clearances from the FDA on a timely basis or at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incorporation of AI technology into our GI-tract capsule endoscopy solution (including the associated software products, CapsoCloud and CapsoView) requires appropriate FDA regulatory authorization, supported by requisite clinical and other studies, prior to its commercialization in the U.S. Under the FDA&#8217;s current regulatory framework, our capsule endoscopy solution and the AI technology are assessed separately, with each component falling under a different regulatory classification and subject to distinct regulatory requirements. This bifurcated approach, set by precedent, ensures that each component meets the necessary safety, effectiveness, and performance expectations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of CapsoCam Colon, as of the date of this Annual Report, the FDA has only authorized one colon capsule imaging system, the Medtronic PillCam COLON 2, introduced in 2014, which does not include any AI-driven analytics; and one AI-driven capsule endoscopy analysis software, the AnX Robotics NaviCam ProScan, introduced in 2023, which exclusively supports AnX Robotics&#8217; small bowel capsule system. These devices respectively serve as predicate devices for our planned second generation CapsoCam Colon 510(k) submission. In particular, to receive FDA clearance for our second generation CapsoCam Colon, the clinical results must demonstrate that:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CapsoCam Colon, considered without the integration of AI, demonstrates a polyp-detection accuracy that is, at a minimum, comparable to the performance of the predicate device (i.e., Medtronic PillCam COLON 2); and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our AI technology can (i) reliably and accurately identify and analyze images and video of the colon to detect abnormalities as quantified by diagnostic accuracy measures such as sensitivity and specificity, and, in doing so, (ii) aid qualified physicians in achieving improved diagnostic performance relative to not using AI.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clearance of the incorporated AI technology is unlikely to occur if the CapsoCam Colon solution, absent AI, fails to meet the applicable regulatory requirements. In connection with FDA clearance of our planned second generation of CapsoCam Colon, which will incorporate various hardware and image processing improvements, we will need to demonstrate that the incorporated AI technology is not compromised by these modifications.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not agree that our AI technology meets these evidentiary requirements, or it may require us to submit additional data or information over the course of regulatory review to support the safety and effectiveness of CapsoCam Colon (including the incorporated AI technology). Also, the FDA may determine that CapsoCam Colon (including the incorporated AI technology) is not eligible for the 510(k) pathway and that we must utilize a different, more rigorous and costly regulatory pathway, such as a PMA or a De Novo request, which could significantly delay our ability to market CapsoCam Colon (including the incorporated AI technology), increase our development costs and reduce our competitive advantage. The FDA recognizes that there are challenges within the current regulatory framework for medical devices incorporating artificial intelligence and is actively pursuing </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory reforms to better foster innovation while maintaining patient safety. We proactively monitor new FDA policies and programs and will update our regulatory strategy to reduce regulatory uncertainty and burden where applicable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking 510(k) clearance for our AI technology as incorporated into CapsoCam Plus we are (i) utilizing the NaviCam ProScan as the predicate device (confirmed with the FDA) and (ii) currently conducting a retrospective clinical study of the CapsoCam Plus solution with the AI technology incorporated to analyze in vivo videos from completed, real-world clinical cases, to assess the performance of the AI technology for small bowel. Similar to the first arm of our CapsoCam Colon pivotal study, the study seeks to demonstrate that the AI technology can (i) reliably and accurately identify and analyze images and video of the small bowel to detect abnormalities as quantified by diagnostic accuracy measures such as sensitivity and specificity, and, in doing so, (ii) aid qualified physicians in achieving improved diagnostic performance relative to not using AI.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory considerations may apply to updates or improvements to previously cleared AI technology, such as major changes in algorithm design, significant changes in clinical performance, or the addition of new functions (e.g., detection of new types of abnormalities). In these scenarios, we will be expected to demonstrate the safety and performance of the updated technology through the appropriate studies and pursue regulatory clearance through additional FDA filings prior to commercial distribution. Also, changes to the device hardware or imaging processing methods contained in CapsoCam capsules incorporating our AI technology may affect the performance of the incorporated AI technology, even if the related algorithm is not directly changed. As a result, we may be required to demonstrate that performance of the incorporated AI technology is not degraded by those critical capsule component changes and obtain regulatory clearance prior to distribution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If Medicare and other third-party payors, including managed care organizations, do not approve reimbursement for our products at adequate reimbursement rates, we may be unable to successfully commercialize our products which would likely have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase sales of our products depends, in significant part, on the availability of adequate coverage and reimbursement from third-party payers, including governmental payers, managed care organizations, and private health insurers. If Medicare and other third-party payors do not approve reimbursement for our CapsoCam capsules at adequate reimbursement rates, we may be unable to successfully commercialize our products which would have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, we believe that obtaining a positive national coverage decision and favorable reimbursement rate from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) for our CapsoCam capsules will be a necessary element in achieving material commercial success. These third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for new healthcare products approved for marketing by the FDA. As a result, there is significant uncertainty surrounding whether the use of capsules will be eligible for coverage by third-party payors or, if eligible for coverage, what the reimbursement rates will be for those products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS currently reimburses properly submitted reimbursement claims for most capsule endoscopies utilizing our small bowel CapsoCam Plus capsule. For CapsoCam Colon, we expect to qualify for CMS reimbursement for our initial indicated patient population. CMS currently provides reimbursement for capsule endoscopy procedures for patients with major risks for colonoscopy or moderate sedation with evidence of GI bleeding of lower GI origin and patients who have had an incomplete colonoscopy with adequate preparation. As a part of our 510(k) FDA application for our second generation CapsoCam Colon capsule and to increase the population of indicated patients, we intend to seek FDA clearance of expanded indications that remove the requirement for evidence of GI bleeding of lower GI origin for patients with major risks for colonoscopy or moderate sedation. Successfully growing our CapsoCam Colon revenues will depend on our success in timely securing CMS reimbursement for this and any newly indicated patient population.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement of capsule endoscopy by a third-party payor may depend on a number of factors, including a payor&#8217;s determination that products using our technologies are: effective for detecting or diagnosing </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gastrointestinal disorders; not experimental or investigational; approved by the major guidelines organizations; reliable, safe and minimally invasive; medically necessary; appropriate for the specific patient; and cost-effective.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain positive policy decisions from third-party payors, including Medicare and managed care organizations, approving reimbursement for our CapsoCam capsules, including our CapsoCam Colon, at adequate levels, the commercial success of these products would be compromised and our revenues would be significantly limited. Moreover, coverage policies and reimbursement rates are subject to change and we cannot guarantee that even if we initially achieve adequate coverage and reimbursement rates that they will be applicable to our products in the future. Any failure to obtain or maintain favorable reimbursement could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our distributors fail to comply with regulatory requirements, we may be subject to stringent penalties and our business may be materially adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing and sale of our CapsoCam capsules are subject to various state, federal, and foreign regulations. Compliance with these regulatory requirements is essential to avoid significant penalties and ensure the continued commercialization of our products. However, the regulatory landscape is complex and constantly evolving, making it challenging to stay compliant. Any failure by us or our distributors to adhere to applicable regulations could result in substantial fines, sanctions, or other enforcement actions and damage to our reputation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare policy changes and increased scrutiny of marketing practices in the medical device industry add another layer of risk. New regulations or changes to existing laws could impose additional burdens on our business, affecting our ability to operate effectively. Ensuring ongoing compliance with regulatory requirements is critical to maintaining our market position and avoiding adverse impacts on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare policy and funding/budgetary changes could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, the healthcare industry in the United States has experienced significant legislative and regulatory changes aimed at reducing costs, increasing access to health insurance, and improving the overall efficiency of healthcare delivery. The Affordable Care Act (the &#8220;ACA&#8221;) has been a cornerstone of these efforts, expanding health insurance coverage through public program expansion and private sector reforms. Additionally, the American Rescue Plan Act and the Inflation Reduction Act have introduced enhanced subsidies to make health insurance more affordable. More recently, the One Big Beautiful Bill Act (the &#8220;OBBBA&#8221;) was signed into law, which included significant reforms to Medicaid, including an estimated $1 trillion in reduced federal Medicaid spending from 2025 through 2034, the imposition of work requirements for certain adult enrollees, more frequent eligibility redeterminations and increased cost-sharing for beneficiaries. However, these changes bring uncertainty regarding the number of individuals who will obtain public or private health insurance and the scope of such coverage. This uncertainty can impact our business by potentially reducing the number of insured individuals or altering the scope of insurance coverage, which may affect our revenue streams and financial stability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA has been subject to continuous legislative, regulatory, and judicial challenges, creating an unpredictable environment for healthcare providers. Changes in the interpretation or implementation of the ACA could eliminate or modify provisions that are beneficial to our business while maintaining or introducing provisions that reduce our reimbursement rates or otherwise negatively impact our operations. For instance, if certain beneficial provisions are repealed or altered, we may face increased financial pressure due to reduced reimbursement rates or additional regulatory compliance costs. This uncertainty makes it challenging to plan for the future and could lead to financial instability if adverse changes are implemented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, other health reform initiatives at both federal and state levels add another layer of complexity. These initiatives could result in funding and coverage reductions or decreased enrollment in Medicaid, further impacting our revenue. Additionally, recent reforms focused on price transparency and out-of-network charges, such as the No Surprises Act, may limit our ability to set and negotiate prices, affecting our relationships with insurers and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients. Further, the Trump administration has enacted several executive actions and the U.S. Congress is considering budget cuts that would adversely impact the U.S. federal government&#8217;s budget and potential changes in budgetary priorities and spending levels (including those related to Medicare and Medicaid). Such pressures and uncertainty could (i) result in a reduction in the market opportunity and demand for our current or future pipeline products and (ii) adversely affect staffing levels and the funding for the FDA and as a result, prevent or delay marketing approval of our current or future pipeline products, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval, each of which may negatively impact our business. These factors collectively create a challenging environment that could adversely affect our financial condition, results of operations, and cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to U.S. tariff measures and other potential changes in international trade relations implemented by the U.S. could have a material adverse effect on our business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our supply chain is heavily reliant on products and components manufactured and assembled in various Asian countries (particularly Taiwan and Japan). These import operations are subject to tariff and other international trade regulations. When imported into the U.S., such products and components are subject to applicable rates of duty. The U.S. government has recently made statements and taken certain actions that have created significant uncertainty about the future relationship between the U.S. and various other countries, including Taiwan and Japan, with respect to trade policies, treaties, government regulations and tariffs, including implementing tariffs on certain countries and implementing and subsequently pausing such implementation of tariffs on certain other countries. As a result of these statements and actions, we are exposed to the risk of product supply disruption and increased costs and expenses. There continues to exist significant uncertainty about the future relationship between the U.S. and other countries with respect to such trade policies, treaties and tariffs. We cannot predict with certainty the future trade policy of the U.S. or other countries. We experienced an increase of customs and tariffs expenses as a result of the imposition of tariffs and keep evaluating measures that we might implement to address or mitigate the impact on our business. We cannot predict the likelihood, nature or extent of the potential impact or our ability to avoid the related adverse effects. Relevant factors include whether such tariffs are ultimately implemented, the timing and duration of implementation and the amount, scope and nature of such tariffs and potential exclusions from the application of those tariffs. These tariffs and other unfavorable government policies on international trade (such as export controls) may increase the cost of manufacturing our commercialized products or developing our pipeline products, affect the demand for our products (if and once approved), or restrict our access to raw materials and components used in the manufacture of our current products and the development of our future products, each of which could negatively impact our financial condition and results of operations. Further, such developments, or the perception that any such developments could occur, may have a material adverse effect on global economic conditions and the stability of global financial markets, and may have and could continue to significantly reduce global trade and, in particular, trade between the impacted nations and the U.S. Any of these factors could depress economic activity and adversely impact the price and demand for our products, increase our costs, and affect our customers and suppliers and have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or tax rulings could adversely affect our effective tax rates, results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax regimes we are subject to or operate under are unsettled and may be subject to significant change. This challenge will continue to increase as we expand our operations globally. Changes in tax laws, issuance of new tax rulings or changes in interpretations of existing laws could cause us to be subject to additional income-based taxes and non-income-based taxes, including payroll, sales, use, value-added, digital, net worth, property and goods and services taxes, which in turn could adversely affect our results of operations and financial condition. In particular, the U.S. government may enact significant changes to the taxation of business entities including, among others, an increase in the corporate income tax rate, the imposition of minimum taxes or surtaxes on certain types of income, significant changes to the taxation of income derived from international operations, and it may enact further limitations on the deductibility of business interest. For example, on August 16, 2022, the Inflation Reduction Act (the &#8220;IRA&#8221;) was signed into law in the U.S. Among other changes, the IRA, along with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent regulations, imposes a minimum tax on certain corporations with book income of at least $1 billion, subject to certain adjustments, and a 1% excise tax on certain stock buybacks and similar corporate actions. Furthermore, on July 4, 2025, the OBBB Act was enacted, introducing amendments to U.S. tax laws with various effective dates from 2025 to 2027, including changes to the treatment of research and development expenses under Section 174 of the Internal Revenue Code of 1986, as amended, modifications to the global intangible low-taxed income regime, new minimum or book-based taxes, and limitations on interest deductibility.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many countries in the European Union, as well as a number of other countries and organizations, have recently proposed or recommended changes to existing tax laws or have enacted new laws that could impact our tax obligations in the future. We are unable to predict what changes to the tax laws of the U.S. and other jurisdictions may be proposed or enacted in the future or what effect such changes would have on our business. Any of these or similar developments or changes to tax laws or rulings (which changes may have retroactive application) could adversely affect our effective tax rate and our results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with board-certified physicians are subject to various state laws and there is no assurance that our current practices will remain compliant.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide remote capsule endoscopy reading services through board-certified physicians to our customers with $295 and $232 thousand in revenue for the years ended December&#160;31, 2025 and 2024, respectively. Our relationships with board-certified physicians are subject to various state laws including those with respect to physician licensing requirements. The interpretation and enforcement of these laws vary significantly across states, and there is no assurance that our current practices will remain compliant. If regulatory authorities determine that our arrangements with physicians violate these laws, we may be forced to restructure or terminate these relationships, leading to potential disciplinary actions, penalties, and a loss of revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products must be manufactured in accordance with applicable laws and regulations, and we could be forced to recall our products or terminate production if we fail to comply with these regulations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CapsoCam capsules are regulated as medical devices in the United States and must be manufactured in compliance with the FDA&#8217;s current good manufacturing practices (cGMPs) for medical devices, known as the QMSR. The FDA enforces the QMSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the facilities of subcontractors. Failure to comply with applicable FDA requirements or later discovery of previously unknown problems with our products or manufacturing processes could result in, among other things, warning letters, fines, injunctions, civil penalties, suspension or withdrawal of marketing authorizations, product recalls, and total or partial suspension of production or distribution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our products are subject to similar state regulations governing manufacturing. Our third-party manufacturers may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our medical devices. If we or our third-party manufacturers fail to comply with applicable laws and regulations, we could be forced to recall our products or terminate production, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our activities may subject us to risks under federal and state laws prohibiting &#8220;kickbacks&#8221; and false or fraudulent claims.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business practices and relationships with healthcare providers are subject to scrutiny under various federal and state laws designed to prevent fraud and abuse, including the federal Physician Payments Sunshine Act, Anti-Kickback Statute and the False Claims Act. The Physician Payments Sunshine Act increases the transparency of financial relationships between medical device manufacturers and healthcare providers in order to uncover potential conflicts of interest that could compromise treatment decisions and medical research, or that could increase the cost of healthcare services billed to federal health programs. The Anti-Kickback Statute prohibits the exchange of remuneration to induce or reward the referral of business reimbursable under federal healthcare programs. The False Claims Act imposes liability on individuals and companies who submit false claims under </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal health care programs. Violations of these laws can result in severe penalties, including criminal and civil fines, exclusion from participation in federal healthcare programs, and significant reputational harm.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, state laws often mirror or expand upon federal prohibitions, applying to all payers, not just federal programs. Compliance with these laws requires substantial resources and ongoing monitoring of our business practices. Any failure to comply with these laws, whether intentional or inadvertent, could lead to investigations, legal actions, and significant financial penalties, which could materially and adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent sales representatives earn commissions for capsule sales in their territories, with potential additional commissions for reorders from new accounts and quarterly bonuses. Despite our efforts to provide compliance training and integrate some of them into our direct sales team to improve regulatory oversight, there remains a risk that they might inadvertently breach laws or ethical guidelines in their pursuit of higher earnings, which is not entirely within our control. Independent sales representatives, motivated by commissions and bonuses, might engage in practices that could be construed as kickbacks. If our independent sales representatives engage in unethical or illegal practices to boost sales, it could lead to the submission of false or fraudulent claims for payment submitted to the government. Their malfeasance may expose us to legal and financial liabilities under the federal and state laws.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with the Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), economic and trade sanctions regulations, and similar laws could subject us to penalties and other adverse consequences.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the FCPA and other laws that prohibit improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining or retaining business. Our operations in countries with a high risk of corruption expose us to the risk that our employees, contractors, or agents may engage in activities that violate the FCPA or similar laws, despite our policies and procedures designed to prevent such conduct. Violations of these laws can result in severe penalties, including substantial fines, criminal sanctions, and reputational damage.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are subject to economic and trade sanctions regulations administered by the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control (OFAC), which restrict our ability to engage in transactions with certain countries, entities, and individuals. Non-compliance with these regulations can lead to significant financial penalties, restrictions on our business operations, and adverse effects on our reputation. Ensuring compliance with these complex and evolving regulations requires significant resources and ongoing vigilance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our GI-tract capsule endoscopy products in the international market through a combination of our direct sales team and third-party distributors. Additionally, the bulk of our component suppliers and assembly manufacturers are currently located outside the U.S., and we anticipate increasing our international activities in the future. Despite our implementation of policies, internal controls, and other measures designed to ensure compliance with applicable anti-corruption and anti-bribery laws and regulations, as well as U.S. trade sanctions laws, there remains a risk that our employees or agents may engage in improper conduct for which we could be held accountable. Any violations, or even allegations of violations, of these laws can result in investigations and enforcement actions that may disrupt our operations, divert significant management attention, and incur substantial costs and expenses, including legal fees. If we, our sales representatives or distributors are found to have violated these laws, we could face severe penalties, including fines, profit disgorgement, injunctions, securities litigation, bans on government business transactions, delisting from securities exchanges, and other consequences that could materially and adversely affect our business, financial condition, and results of operations. Furthermore, our reputation, net sales, or stock price could suffer if we become the subject of negative publicity related to actual or potential violations of anti-corruption, anti-bribery, or trade sanctions laws and regulations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on various suppliers to assist us in the assembly and manufacture of our GI-tract capsule endoscopy solution and sourcing of critical and other components and many of these suppliers are single source suppliers located in Asia (particularly Taiwan and Japan); any disruption in our supply chain could adversely affect our ability to meet the demand for our products and fulfil our orders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To assist us in manufacturing our GI-tract capsule endoscopy products we rely on component suppliers and assembly manufacturers based in Asia (particularly Taiwan and Japan). Critical components found in our CapsoCam capsules include lens modules from Largan, complementary metal oxide semiconductor (&#8220;CMOS&#8221;) image sensors from Toshiba Corporation (&#8220;Toshiba&#8221;), and application-specific integrated circuits (&#8220;ASICs&#8221;) from Moai Electronics Corporation (&#8220;Moai&#8221;) / Speedbridge Technology Co. (&#8220;Speedbridge&#8221;). Many of our suppliers/manufacturers are single source and located in Asia. For example, the single source suppliers of our lens modules and ASICs are located in Taiwan and the single source supplier of our CMOS image sensors is located in Japan. Currently, assembled CapsoCam capsules are shipped by Largan from Taiwan to our U.S. facility where we complete the manufacturing process before distributing the capsules to our distribution network. Any disruption to our supply chain could significantly harm our ability to effectively manufacture and deliver our CapsoCam capsules and, in turn materially harm, our financial results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The numerous supply chain related risks we face that could adversely impact our ability to manufacture and sell our CapsoCam capsules include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our supplier may be unable to meet our demand requirements, including demands for desired improvements or upgrades, or may prioritize the orders of its other customers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our supplier may be unable to meet our quality standards, specifications, or requirements for critical components, or may experience defects, errors, or failures in these components, which could compromise the quality, performance, or safety of our CapsoCam capsules and the images and analyses they produce;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our supplier may increase or seek to increase prices, or impose unfavorable purchase terms or conditions, which could increase our costs and reduce our margins;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our supplier may discontinue the production of critical components, or cease to do business with us, for any reason;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it may be difficult for us to find an alternative or second supply source, which may not be available, affordable, or compatible with our CapsoCam capsules and, for commercial reasons, we may prefer or be required to work on an exclusive basis with our supplier; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supplier concentration in Asia (particularly Taiwan and Japan) subjects us to heightened risks related to geopolitical tensions (particularly between China and Taiwan), potential trade disputes, the imposition of new or increased tariffs or threats of tariffs, transportation interruptions, natural disasters, and manufacturing constraints, any of which can affect the manufacture and delivery of our CapsoCam capsules and lead to delays, increased costs, and potential shortages of our CapsoCam capsules and critical components. For additional information, see the risk factor titled &#8220;We face substantial geopolitical and trade risks (including a possible trade war and imposition of tariffs and supply chain interruptions) and natural disaster risks associated with our business operations in Asia (particularly Taiwan and Japan)&#8221; and &#8220;Changes to U.S. tariff measures and other political changes in international trade relations implemented by the U.S. could have a material adverse effect on our business, financial condition, cash flows and results of operations&#8221; below.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are in the process of planning or implementing various mitigation measures to address supply chain risks (including qualifying a backup supplier for certain critical components and looking to build reserve supplies of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capsules and critical components to address unanticipated delays), these efforts may not be successful. For example, implementation of mitigation measures to address the supply chain disruption of CMOS image sensors would be complicated, and resolving an industry-wide issue relating to CMOS image sensors would require a significant amount of time and coordinated efforts across multiple industry participants.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our operations depend heavily on expedited and reliable shipping services to ensure the secure and timely delivery of our products to customers. Any delivery performance issues, such as loss, damage, or destruction of our CapsoCam capsules or the components thereof, would incur substantial costs for timely replacement and could tarnish our reputation, leading to decreased demand for our products and increased operational expenses. Additionally, significant increases in shipping rates could negatively affect our operating margins and overall financial performance. Service interruptions caused by strikes, severe weather, natural disasters, or other disruptions could further impede our ability to process orders promptly. These factors collectively pose a risk to our business, financial condition, and operational results, and can potentially damage our reputation. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our authorized agent and importer for a significant portion of our revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on Aureliance, our authorized agent and importer in the EU and EEA for a significant portion of our revenue. It has historically contributed a significant percentage of our revenue generated from EU countries, such that if it were to materially reduce or terminate its business with us, our revenue generated from such countries would suffer. For the years ended and as of December&#160;31, 2025 and December&#160;31, 2024, Aureliance represented approximately 9% and 10% of our revenue, respectively, and 22% and 21% of our accounts receivable balance, respectively. The loss of it or a significant reduction in its business with us could have a material adverse effect on our financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct and support our clinical trials. These third parties may not properly and successfully carry out their contractual duties or meet expected deadlines, which could harm our ability to obtain marketing authorization of or commercialize future products we develop.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize and depend upon independent investigators and collaborators, such as third-party clinical institutions and hospitals to conduct and support portions of our clinical trials under agreements with us, and may in the future rely on CROs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied on these third parties for our clinical trials and expect to continue to do so, and we control only certain aspects of their activities. As a result, we have less direct control over the conduct, timing, and completion of these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements, and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for medical devices in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or other bodies may require us to perform additional clinical trials. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our investigational devices must be produced in accordance with cGMP requirements known as the QMSR. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the marketing authorization process. Moreover, our business may be implicated if any of these third parties violates federal, state or foreign fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties conducting or supporting portions of our clinical trials are not our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our investigational products. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other product development activities, which could affect their performance on our behalf. These third parties may not successfully carry out their contractual duties or obligations or meet expected deadlines. They may need to be replaced or the quality or accuracy of the clinical data they obtain may be compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons. Accordingly, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain marketing authorizations for or successfully commercialize our future devices. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switching or adding third parties to conduct or support portions of our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays may occur, which could have an adverse impact on our product development, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on relationships with contracted physicians to provide reading services to certain customers.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract directly or indirectly with physicians to provide remote reading services to certain customers. If these physicians terminate their contracts, we or our partners may not be able to contract with alternative physicians to provide such services in a timely manner, or at all, which would impact our ability to provide services to certain customers and could adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Data Privacy Risk Factors </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face risks associated with our use and development of artificial intelligence, including our AI technology.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinicians are subject to fatigue and distraction and have varying degrees of expertise in identifying GI-tract abnormalities. Our AI assisted pathology detection tool is designed to (i) reduce viewing times for clinicians by highlighting the areas of interest (via a bonding box placed around suspected abnormalities) and (ii) improve diagnostic yield and provide more consistent accuracy by providing suggestions or recommendations. However, risks related to the use of our AI technology include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our AI assisted pathology detection technology may fail to accurately identify all or a sufficient portion of the patient&#8217;s GI-tract abnormalities (measured in terms of sensitivity and specificity);</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a clinician may (i) place undue reliance on our AI assisted pathology detection technology to identify GI-tract abnormalities (e.g., polyps in colon) or (ii) fail to fully utilize product features designed to supplement a clinician&#8217;s review (such as the ability to review frames adjacent to an AI bonded frame identifying a suspected GI-tract abnormality or view the video in non-AI mode);</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our AI technology may not prevent or reduce the occurrence or impact of clinician alertness fatigue; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product enhancements and improvements (including improvements to our AI algorithms) may fail to deliver improved viewing, accuracy improvements (including as measured in terms of sensitivity and specificity) and other expected benefits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to further invest in AI to improve our products. However, we may not achieve the expected benefits from our AI investments, or we may face technical, regulatory, ethical or legal challenges that could limit or delay the development, deployment or adoption of our AI technology. Additionally, we may encounter difficulties in integrating our AI technology with our existing or future products, software or platforms, or in ensuring the compatibility, interoperability or reliability of our AI technology.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AI technology may introduce errors or biases that could compromise the quality or validity of the clinician&#8217;s viewing. In particular, for data collected by CapsoCloud to serve as the clinically derived reference standard (&#8220;ground truth&#8221;) for enhancing AI capabilities, it is imperative that the collected data be meticulously labeled. This labeling process is resource-intensive and necessitates the involvement of qualified gastroenterologists who meticulously review and annotate the images. The accuracy of these labels is crucial, as it directly impacts the AI&#8217;s ability to make precise and reliable predictions based on the data. If the models underlying our AI technologies are incorrectly designed or implemented; trained or reliant on incomplete, inadequate, inaccurate, biased, or otherwise poor quality data (including as a result of the labeling process described above), or on data to which we do not have sufficient rights or in relation to which we and/or the providers of such data have not implemented sufficient legal compliance measures; used without sufficient oversight and governance to ensure their responsible use; misused or used outside of scope of applicable regulatory authorizations; and/or adversely impacted by unforeseen defects, technical challenges, cybersecurity threats, or material performance issues, the performance of our products, as well as our reputation, could suffer or we could incur liability resulting from the violation of laws or contracts to which we are a party, regulatory enforcement actions, or civil claims.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of any algorithm incorporated in our AI technology will generally be assessed by comparing the output of the algorithm against a ground truth for a specified dataset. This applies to internal evaluation of an algorithm&#8217;s performance, supporting external presentations and publications, and testing to support regulatory submissions. Our algorithm output will not always agree with the opinion of a qualified gastroenterologist, and in some cases multiple qualified gastroenterologists may not agree with each other. While we constantly work to improve our GI-tract capsule endoscopy solution, our AI technology is novel and complex, and our AI technology may not perform as intended under all circumstances.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoCloud is designed to automatically accumulate patient data critical to develop and train AI-based GI-tract abnormality detection and classification capabilities. If we are unable to obtain sufficient rights to use such data under applicable regulatory frameworks or our patients were to withdraw or withhold their consent, our ability to continue to develop new or improved CapsoCam capsule endoscopy products, and our revenue prospects, could be materially adversely impacted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory landscape for AI technologies is rapidly changing as various federal, state, and international government bodies introduce or consider new laws and regulations. The FDA has issued guidance on incorporating AI into medical devices, and existing laws may be interpreted in ways that impact AI operations or could be rescinded or amended as new administrations take differing approaches to evolving AI technologies. This creates uncertainty around implementation standards and enforcement practices, making it difficult to predict the future impact on businesses. In the U.S., the Trump administration rescinded an executive order relating to AI technologies that was previously implemented by the Biden administration. The Trump administration may continue to rescind other existing federal orders and/or administrative policies relating to AI technologies, or may implement new executive orders and/or other rule-making relating to AI technologies in the future. Any such changes at the federal level could require us to expend significant resources to modify our products, services, or operations to ensure compliance or remain competitive. U.S. legislation related to AI technologies has also been introduced at the federal level and is advancing at the state level. Such additional regulations may impact our ability to develop, use, and commercialize AI technologies in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that further new laws and regulations will be adopted in the U.S. and other jurisdictions, potentially limiting the use of AI technologies or requiring changes that could negatively affect business performance. Compliance with these laws may necessitate significant resource expenditure, especially if regulations vary across jurisdictions. The cost of compliance could increase operating expenses due to additional reporting obligations. Any failure, actual or perceived, to comply with these laws and regulations could materially and adversely impact our business operations, financial condition, and future prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or perceived failures to comply with applicable data privacy and security laws, regulations, standards and other requirements could adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect, store, process and analyze large amounts of data for GI tract from our products, customers, patients, hospitals and other sources, to support our AI technology. With CapsoCloud, we have access to a rich and growing source of clinical data from patients, which enables us to develop ever-improving automated detection and classification of GI-tract abnormalities. However, the collection and use of such data involves significant risks and challenges, such as data breaches, cyberattacks, unauthorized access, theft, loss, corruption, misuse, manipulation, infringement, disclosure or destruction. Any of these events could compromise the security, privacy, integrity, availability or accuracy of our data, and expose us to legal, regulatory, reputational or financial liabilities, as well as potential claims, fines, penalties, sanctions, litigation or investigations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with various U.S. laws and regulations that protect personal information, especially health-related information, such as the Health Insurance Portability and Accountability Act (HIPAA), which imposes privacy, security, and breach notification obligations and penalties on entities that handle such information. Some states, such as California, have also enacted their own privacy and security laws, which may differ from or conflict with federal laws and require additional disclosures, responses, and contracts. These laws and regulations are subject to interpretation and change, and may increase our compliance costs and risks.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also face data protection laws and regulations in foreign jurisdictions, such as the General Data Protection Regulation, which applies to personal data of individuals in the European Economic Area and imposes stringent requirements and fines on data processors and controllers, including for transfers of such data to third countries like the U.S. These laws and regulations may affect how we conduct business, transfer data, and provide services, and may expose us to additional costs, complaints, investigations, or fines. The Federal Trade Commission may also take action against us for misleading, deceptive, or unfair practices related to privacy and data security.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations, research protocols, and other obligations, any actual or perceived failure by us or our employees, representatives, contractors, consultants, or other third parties to comply with such requirements or adequately address data privacy and security concerns, even if unfounded, could result in, among other adverse impacts, damage to our reputation, loss of customer confidence in our security measures, withdrawal or withholding of customer consent for using patient data, government investigations, and enforcement actions and litigation and claims by third parties, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We leverage cloud-based CapsoCloud for easy access to patients&#8217; in vivo videos, however use of CapsoCloud faces complicated compliance requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilizing our cloud-based platform, CapsoCloud, physicians can remotely access and analyze their patients&#8217; in vivo videos and other exam data. However, the regulatory environment for cloud-based platforms is complex and varies across different jurisdictions, and as described below, some states or countries may impose restrictions or prohibitions on the use of cloud-based platforms or the transmission of patient data across borders. Initially, following the commercial launch of our CapsoCam Colon solution, providers will utilize CapsoCloud to download in vivo videos for remote review. Within one year of commercial launch, we plan to introduce user-friendly streaming functions to facilitate via CapsoCloud remote in vivo video review, procedure report generation and image annotation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., CapsoCloud also faces significant operational and compliance issues due to stringent data privacy and security regulations in various countries. This necessitates the development of country-specific cloud infrastructures for CapsoCloud, which can lead to increased costs, complexity, and potential delays in service delivery. Additionally, for certain U.S. government-related customers, such as the U.S. Department of Defense and Veterans Administration associated hospitals, CapsoCloud must implement additional layers of IT security to meet their stringent security requirements before these customers can utilize CapsoCloud. This could further complicate our cloud infrastructure, increase the risk of security breaches if not properly managed, and require substantial investment in specialized security measures and compliance protocols.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to comply with these regulations or obtain the necessary approvals or licenses, we may face legal actions, fines, penalties, or loss of business, which could adversely affect our reputation, operations, and financial results. Additionally, we may incur significant costs and resources to adapt CapsoCloud to meet the changing regulatory requirements or customer preferences in different markets and countries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations may suffer in the event of information technology system failures, cyberattacks, or deficiencies in our cybersecurity.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily on information technology systems and infrastructure to operate our business, including the collection, storage, and transmission of sensitive patient exam data. Our systems, including CapsoCloud, and those of our third-party service providers, are vulnerable to cyberattacks, data breaches, and other security incidents that could compromise the confidentiality, integrity, and availability of our data. Such incidents could result in significant disruptions to our operations, financial losses, and damage to our reputation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect against cybersecurity threats. Among other measures, our CapsoCloud systems are HIPAA-compliant and operate in an ISO 27001 certified cloud-computing environment, we have adopted various cybersecurity controls and procedures and we conduct cybersecurity related trainings. However, there is no guarantee that our systems will be immune to cyber threats. For example, in October 2019, we observed and investigated a cyberattack that breached our Amazon Web Services (AWS) account hosting the CapsoCloud service. In connection with this investigation, we determined no data was compromised during this incident and, in addition to related employee trainings, we adopted additional procedures and controls designed to protect against these types of incidents. Any failure to adequately protect our IT systems and sensitive patient exam data collected, stored and transmitted on or through our systems could lead to regulatory investigations, legal actions, and substantial costs associated with remediation and notification efforts, which could materially and adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success will depend on our ability to obtain, maintain, enforce, and protect our intellectual property rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success and ability to compete depends in part on our ability to obtain, maintain, enforce, and protect issued patents, trademarks, trade secret, and other intellectual property rights and proprietary technology in the U.S. and elsewhere. If we cannot adequately obtain, maintain, and enforce our intellectual property rights and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have and our ability to compete, which could harm our business and ability to achieve profitability and/or cause us to incur significant expenses. We generally seek to protect our proprietary position by filing patent applications that are important to our business. We also seek to protect our proprietary position by acquiring or in-licensing relevant issued patents or pending patent applications or other intellectual property or proprietary rights from third parties. If we are unable to obtain or maintain patent protection with respect to any proprietary technology, our business, financial condition, results of operations, and prospects could be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of contractual provisions, confidentiality procedures, and patent, trademark, copyright, trade secret and other intellectual property laws to protect the proprietary aspects of our brands, technologies, trade secrets, know-how, and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property rights and proprietary information. In addition, patents have a limited lifespan. In the U.S., for example, the natural expiration of a utility patent is generally 20 years from the earliest effective non-provisional filing date. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how, and obtaining, maintaining, and enforcing other intellectual property rights. We may not be able to obtain, maintain, and/or enforce our intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process and enforcement of any resulting patents are expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, defend, or license all necessary or desirable patents or patent applications at a reasonable cost or in a timely manner, or in all jurisdictions. Moreover, pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover relevant product, service, or the technology. There can be no assurance that our current or future patent applications will result in patents being issued or that our issued patents will afford sufficient protection against competitors or other third parties with similar products, services or technologies competitive with ours, nor can there be any assurance that the patents issued will not be infringed, designed around, or invalidated by third parties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even our issued patents may later be found invalid or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. In addition, our issued patents may later be found to be unenforceable for a number of possible reasons, such as for a failure to properly identify material prior art or other references to the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;). The degree of future protection for our intellectual property or other proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect or be able to enforce the intellectual property or other proprietary rights relating to our products, services and technologies could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that the claims in our U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign territories will be considered patentable by the USPTO, courts in the U.S., or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our future issued patents will not be found invalid or unenforceable if challenged. Our ability to obtain and maintain valid and enforceable patents depends in part on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Additionally, regardless of when filed, we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is invalid or not infringed by our products, services, technologies, or activities. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain, maintain, and/or enforce intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the U.S. and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology, and other intellectual property rights by others, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated, or otherwise violated by others.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain. Therefore, we cannot ensure that others will not develop, manufacture and/or commercialize similar or alternative products, services, or technologies that do not infringe, misappropriate, or violate any patents or other intellectual property rights that we own or have rights to. We cannot ensure that any patents issued to us will provide a basis for an exclusive market for our products, services, or technologies, will provide us with any competitive advantages or will not be challenged, invalidated, modified, revoked, or circumvented by third parties. We cannot ensure that any of our challenged patents will be found to ultimately be valid and enforceable. We cannot ensure that any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our products, services, or technologies. We cannot ensure that any of our pending patent applications will issue as patents, or even if issued, will include claims with a scope sufficient to protect our products, services, or technologies. We cannot ensure that we will be able to successfully develop, manufacture, and commercialize our products, services, or technologies on a substantial scale before relevant patents we may have expire. We cannot ensure that we were the first to make the inventions covered by each of our patents and pending patent applications or we were the first to file patent applications for such inventions. We cannot ensure that we will </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop additional proprietary inventions, products, services, or technologies that are separately patentable. In addition, we cannot ensure that our commercial activities, products, services, or technologies will not infringe upon the patents of others. Defending against any such infringement claims is also expensive, time-consuming, complex, and can distract us from pursuing commercial activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to identify our patentable inventions or adequately protect our patent rights, the commercial value of our products, services or technologies may be adversely affected and our competitive position may be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely in part on our portfolio of issued patents and pending patent applications in the U.S. and other countries to protect our intellectual property and competitive position. However, it is also possible that we may fail to identify patentable aspects of inventions made in the course of the development, manufacture, and commercial activities conducted by or on behalf of us before it is too late to obtain patent protection on such inventions. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, suppliers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection, and any of these parties may decide to independently file for intellectual property without naming us as owners, inventors, or co-owners for the intellectual property. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, should we become a licensee or co-owner of a third party&#8217;s patents or patent applications, depending on the terms of any future in-licenses or co-ownership agreement to which we may become a party, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain or enforce the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted, maintained, and/or enforced in a manner consistent with the best interests of our business. While we may apply for patents in some countries outside of the U.S., we may not accurately predict all of the countries where patent protection will ultimately be desirable. Furthermore, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from importing, using, manufacturing, and/or commercializing our own products or services, or otherwise practicing our own technology. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, invalid, or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include claims with a scope sufficient to protect our products, services, or technology. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our issued patents will be sufficient to stop a competitor from developing, manufacturing, and commercializing one or more products, services, or technologies in a non-infringing manner that would be competitive with one or more of our products, services, or technologies, or otherwise provide us with any competitive advantage. Furthermore, any successful challenge to these patents or any other patents owned by us after patent issuance could deprive us of rights necessary for our commercial success. Further, there can be no assurance that we will have adequate resources to enforce our patents.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products or services. Patents, if issued, may be challenged, deemed unenforceable, invalidated, narrowed, or circumvented. Proceedings challenging our patents or patent applications could result in either loss of the patent, or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. Any successful challenge to our patents and patent applications could deprive us of exclusive rights necessary for our commercial success. In addition, defending such challenges in such proceedings may be costly. Thus, any patents that we own may not provide the anticipated level of, or any, protection against competitors. Furthermore, an adverse decision may result in a third party receiving a patent right sought by us, which in turn could affect our ability to develop, manufacture, commercialize, import, or otherwise use our products, services, or technologies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patents and patent applications are or may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third- party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services, or technologies. In addition, we may need the cooperation of any such co-owners of our patents to enforce such patents against third parties, and such cooperation may not be provided to us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees, and various other government fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent and/or applications and any patent rights we may obtain in the future. While an unintentional lapse of a patent or patent application can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. If we fail to maintain our patents and patent applications, we may not be able to stop a competitor from marketing products, services, or technologies that are the same as or similar to our products, services, or technologies, which would have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our patents will eventually expire, and our patent protection will be reduced or eliminated by expiration of patents in our patent portfolio.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prosecuted and obtained a variety of patents to protect the intellectual property rights to our products and services. These patents protect our inventions relating to camera, image sensor, display and imaging system, capsule detection, power source control, and other key and ancillary components of our products. We rely on these patents to prevent others from using, developing, manufacturing and selling competing products or solutions or infringing on our proprietary rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, patents have a limited lifespan, with the term of individual patents depends upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in jurisdictions in which they are obtained. In most countries, including the U.S., issued patents are granted a term of 20 years from the earliest effective non-provisional filing date. We have patents that are anticipated to expire. After patents in our portfolio begin to expire, we cannot guarantee that our remaining patents will be sufficient to maintain our competitive advantage or prevent competitors from developing similar or superior products. Once our patents expire, we may lose the exclusive right to prevent others from using, developing, manufacturing or selling products that </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporate our patented technology that are claimed in the expired patents. If third parties use our technology within the scope of such expired patents, we may not be able to sue them for infringement or recover any damages. This could result in increased competition, reduced market share, lower revenues and margins, and harm to our reputation and brand.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances, a patent term of a U.S. patent may be adjusted to recapture a portion of delay by the USPTO in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. While the adjustment of the patent term based upon delay by the USPTO is automatically calculated by the USPTO, it is possible that this patent term adjustment is improperly calculated by the USPTO and thus does not accurately reflect the true amount of adjustment that is entitled to a patent holder. Indeed, the USPTO has publicly acknowledged in 2024 that numerous errors have possibly occurred for patent term adjustments that have been calculated by the USPTO for previously issued patents. Moreover, it is possible that actions we have taken to prosecute a patent application will be considered applicant delay and will reduce the amount of patent term adjustment that is granted to a patent. For a patent term extension based upon the FDA regulatory review period, the period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of approval. Only one patent among those eligible for an extension may be extended. However, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions may be less than the maximum extension available. In addition, this type of patent term extension will only be granted if requested within a designated timeframe after FDA approval. If the applicable authorities do not approve the extension or if we do not make a timely application for extension, then it is possible that a term extension will not be granted for a given patent in our patent portfolio, thereby reducing the amount of enforceable term for the patent.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. or foreign patent laws or their interpretations could diminish the value of our patents in general, thereby impairing our ability to protect our current and future products, services, or technologies, and could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our current or future patents.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to obtain patents and the breadth of any patents obtained is uncertain in part because, to date, some legal principles remain unresolved, and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the U.S. and other countries. Changes in either patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property rights or narrow the scope of our patent protection, which in turn could diminish the commercial value of our products, services, and technologies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement, and defense of our patents and applications. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the U.S. are interpreted. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we own or that we might obtain or license in the future. An inability to obtain, enforce, and defend patents covering our proprietary technologies would materially and adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. Changes in patent laws and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them, or changes in how the relevant governmental authority </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or may obtain in the future. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. In addition, any protection afforded by foreign patents may be more limited than that provided under U.S. patent and intellectual property laws. We may encounter significant problems in enforcing and defending our intellectual property both in the U.S. and abroad. For example, if the issuance in a given country of a patent covering an invention is not followed by the issuance in other countries of patents covering the same invention, or if any judicial interpretation of the validity, enforceability or scope of the claims or the written description or enablement in a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in other countries, our ability to protect our intellectual property rights in those countries may be limited. We cannot predict future changes in the interpretation of patent laws in the U.S. and other countries or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the European Unitary Patent system and the European Unified Patent Court (&#8220;UPC&#8221;) were launched. European patent applications now have the option, upon grant of a patent, of becoming a Unitary Patent which is subject to the jurisdiction of the UPC. In addition, conventional European patents, both already granted at the time the new system began and granted thereafter, are subject to the jurisdiction of the UPC, unless actively opted out. This was a significant change in European patent practice, and deciding whether to opt-in or opt-out of Unitary Patent practice entail strategic and cost considerations. The UPC provides third parties with a new forum to centrally revoke our European patents and makes it possible for a third party to obtain pan-European injunctions against us. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. While we have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, doing so may preclude us from realizing the benefits of the UPC. Moreover, the decision whether to opt-in or opt-out of Unitary Patent status will require coordinating with co-applicants, if any, adding complexity to any such decision.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal systems in certain countries may also favor state-sponsored or companies headquartered in particular jurisdictions over our first-in-time patents and other intellectual property protection. We are aware of incidents where such entities have stolen the intellectual property of other companies in order to create competing products. For example, through its &#8220;Annual Special 301 Report on Intellectual Property,&#8221; the Office of the United States Trade Representative has been reporting on the adequacy and effectiveness of intellectual property protection in a number of foreign countries that are U.S. trading partners and their protection and enforcement of intellectual property rights. Placement of a country on the Priority Watch List indicates that particular problems exist in that country with respect to intellectual property protection, enforcement, or market access for persons relying on intellectual property rights. Countries placed on the Priority Watch List are the focus of increased bilateral attention concerning the specific problem areas. It is possible that we will not be able to enforce our intellectual property rights against third parties that misappropriate our proprietary technology in those countries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents on our products, services, and technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. The requirements for patentability may differ in certain countries, particularly in developing countries. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third-parties from practicing our inventions in all countries outside the U.S. or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, services, or technologies and, further, may export otherwise infringing products, services, or technologies to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products, services, or technologies may compete with our products, services, or technologies, and our patents or other intellectual property rights may not be effective or sufficient to prevent such competition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries may not favor the enforcement of patents and other intellectual property protection, particularly those relating to medical devices and related services and technologies, which could make it difficult for us to stop the infringement of our patents or marketing of competing products, services, and technologies in violation of our intellectual property and proprietary rights. In addition, some jurisdictions, such as Europe, Japan, and China, may have a higher standard for patentability than in the U.S., including, for example, imposing a high standard for making claim amendments and for the submission of supplemental experimental data during patent examination. Under those heightened patentability requirements, we may not be able to obtain sufficient patent protection in certain jurisdictions even though the same or similar patent protection can be secured in the U.S. and other jurisdictions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patent rights at risk of being invalidated or interpreted narrowly, could put our owned patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop, own or license. Various countries outside the U.S., including certain countries in Europe, India, and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. In addition, many countries limit the enforceability of patents against government agencies or government contractors. As a result, a patent owner in such countries may have limited remedies in certain circumstances, which could materially diminish the value of such patent. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from our intellectual property.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied predictably. As such, we do not know the degree of world-wide uniform protection that we will have on our technologies and products in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot successfully enforce our intellectual property rights, the commercial value of our products, services, or technologies may be adversely affected and our competitive position may be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties, including our competitors, may currently, or in the future, infringe, misappropriate, or otherwise violate our issued patents or other intellectual property rights, and we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time-consuming, and unsuccessful. We regularly monitor for unauthorized use of our intellectual property rights and, from time to time, analyze whether to seek to enforce our rights against potential infringement, misappropriation, or violation of our intellectual property rights. However, the steps we have taken, and are taking, to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation, or violation of our intellectual property rights. In certain circumstances it may not be practicable or cost-effective for us to enforce our intellectual property rights fully, particularly in certain developing countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual property rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products, services, or technologies. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product, services, or technologies. Thus, we may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our products, services, and technologies. We may in the future become involved in lawsuits to protect or enforce our intellectual property rights. An adverse result in any litigation proceeding could harm our business. In any lawsuit </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we bring to enforce our intellectual property rights, a court may refuse to stop the other party from manufacturing, commercializing, using or importing the product, service, offering or technology at issue on grounds that our intellectual property rights do not cover, and the other party is not infringing, violating or otherwise misappropriating our intellectual property, through the manufacture, commercialization, use or importation of the product, service, offering or technology in question. Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate, or otherwise violate their intellectual property rights. If we initiate legal proceedings against a third party to enforce a patent covering a product, service, offering or technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are common, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from USPTO, or made a misleading statement, during prosecution. Mechanisms for such challenges include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). In a patent or other intellectual property proceeding, a court may decide that a patent or other intellectual property right of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims or other intellectual property narrowly or refuse to stop the other party from manufacturing, commercializing, using or importing the product, service, offering, or technology at issue on the grounds that our patents or other intellectual property do not cover the manufacture, commercialization, use, or importation of the product, service, offering, or technology in question. Furthermore, even if our patents or other intellectual property rights are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market. An adverse result in any litigation or administrative proceeding could put one or more of our patents or other intellectual property rights at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business, financial condition, results of operations and prospects. Moreover, even if we are successful in any litigation, we may incur significant expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage as a result of the infringement and the proceedings.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a party to intellectual property litigation or administrative proceedings that could be expensive, time-consuming, and unsuccessful, and could interfere with our ability to develop, manufacture, commercialize, import, or otherwise use our products, services, or technologies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on our ability to develop, manufacture, commercialize, import, or use our products, services, and technologies without infringing, misappropriating, or otherwise violating the intellectual property rights of third parties. Our industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. While we do not intend to infringe upon, misappropriate, or otherwise violate the intellectual property rights of others, there may be pertinent rights of which we are presently unaware.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights. The outcomes of such proceedings are uncertain and could have a negative impact on the success of our business. It is possible that U.S. and foreign patents and pending patent applications controlled by third parties may be alleged to cover our products, services, and technologies, or that we may be accused of misappropriating third parties&#8217; trade secrets or infringing third parties&#8217; trademarks. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our products, services, or technologies, including interference proceedings, post grant review, and inter partes review before the USPTO or equivalent foreign regulatory authority. Furthermore, we may also become involved in other proceedings, such as reexamination, derivation, or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Third parties may assert infringement claims against us based on existing patents or patents that may </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be granted in the future, regardless of their merit. Because patent applications can take many years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware and which may result in issued patents, which our current or future products, services, or technologies infringe. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid and enforceable, and infringed by the use of our products, services, or technologies, which could have a negative impact on the commercial success of our current and any future products, services, or technologies. If we were to challenge the validity of any such third-party U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We will have similar burdens to overcome in foreign courts in order to successfully challenge a third-party claim of patent infringement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense of any litigation or interference proceedings may fail and, even if successful, defending such claims brought against us would cause us to incur substantial expenses and distract our management and other employees. If such claims are successfully asserted against us, we could be forced to pay substantial damages. Further, if a patent infringement or other intellectual property rights-related lawsuit were brought against us, we could be forced, including by court order, to cease developing, manufacturing, commercializing, importing, or using the infringing product, service, or technology. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Although patent, trademark, trade secret, and other intellectual property disputes have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may not be able to obtain licenses on commercially reasonable terms or at all, in which event our business would be materially and adversely affected. Even if we were able to obtain a license, the rights may be non-exclusive, which could result in our competitors and other third parties gaining access to the same intellectual property. Ultimately, if we are unable to obtain such licenses or make any necessary changes to our products, services, or technologies, we could be forced to cease some aspect of our business operations, which could harm our business significantly.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A finding of infringement or an unfavorable interference or derivation proceedings outcome could prevent us from developing, manufacturing, commercializing, importing, or using our products, services, or technologies, or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations, and prospects. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources and more mature and developed intellectual property portfolios. We could encounter delays in product introductions while we attempt to develop alternative products or technologies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third parties assert infringement, misappropriation, or other claims against our customers, these claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, regardless of the merits of these claims. If any of these claims succeed or settle, we may be forced to pay damages or settlement payments on behalf of our customers or may be required to obtain licenses for the products, services, or technologies they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products, services, or technologies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, and may have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit, or otherwise interfere with our ability to make, use, sell, import, and/or export our products, services, or technologies. As the number of competitors in our market grows and the number of patents issued in this area increases, the possibility of patent infringement </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims against us may increase. Moreover, individuals and groups that are non-practicing entities, commonly referred to as &#8220;patent trolls,&#8221; purchase patents, and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products, services, or technologies and business operations infringe, misappropriate, or otherwise violate the intellectual property rights of others. These matters can be time-consuming, costly to defend in litigation, divert management&#8217;s attention and resources, damage our reputation and brand, and cause us to incur significant expenses or make substantial payments. In addition, we purchase product components, including hardware and software, from suppliers, and the design of these components may be outside of our direct control. These suppliers may not indemnify us in the event that a third party alleges the use of such components infringes its intellectual property rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any lawsuits relating to intellectual property rights could subject us to significant liability for damages and invalidate our intellectual property. Any potential intellectual property litigation also could force us to do one or more of the following: (a) stop developing, making, selling, importing, or using products, services, or technologies that allegedly infringe, misappropriate, or otherwise violate the asserted intellectual property right; (b) pay substantial damages or royalties to the party whose intellectual property rights we may be found to be infringing, misappropriating, or otherwise violating; (c) redesign those products, services, or technologies that contain the allegedly infringing intellectual property, which could be costly, disruptive, and infeasible; and attempt to obtain a license to the relevant intellectual property rights from third parties, which may not be available on commercially reasonable terms or at all, or from third parties who may attempt to license rights that they do not have; (d) lose the opportunity to license our intellectual property rights to others or to collect royalty payments based upon successful protection and assertion of our intellectual property rights against others; (e) incur significant legal expenses; or (f) pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing, misappropriating, or otherwise violating.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, inter partes review, and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products, services, or technologies. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products, services, or technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearing, motions, or other interim developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Even if we ultimately prevail, a court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, even if resolved in our favor, the monetary cost of such litigation and the diversion of the attention of our management could outweigh any benefit we receive as a result of the proceedings. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business. Any of the foregoing may cause us to incur substantial costs and could place a significant strain on our financial resources, divert the attention of management from our core business, and harm our reputation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that our current or former employees, contractors, partners, vendors or other third parties have an ownership interest in our current or future patents, patent applications, or other intellectual property rights, including as an inventor, co-inventor, or co-owner. We may be subject to ownership or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventorship disputes in the future arising, for example, from conflicting obligations of employees, consultants, partners, vendors, or others who were or are involved in developing our products, services, or technologies. Although it is our policy to require those who may be involved in the conception or development of inventions to execute agreements assigning such inventions and intellectual property rights therein to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops inventions that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of inventions may not be self-executing, or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership of inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or the right to use, valuable intellectual property rights, and other owners may be able to license their interest in such intellectual property rights to other third parties, including our competitors. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to claims from third parties challenging inventorship or ownership of intellectual property rights we regard as our own, based on claims that our agreements with employees, consultants, partners, vendors, or others who were or are involved in developing our products, services, or technologies obligating them to assign their inventions and intellectual property rights therein to us are ineffective or in conflict with prior or competing contractual obligations to assign inventions and intellectual property rights therein to another employer, to a former employer, or to another person or entity. Many of our current and former employees and consultants were previously employed at or engaged by other medical device companies, including our competitors or potential competitors. Some of these employees and consultants have executed with such previous employment or engagements confidential information non-disclosure and non-use agreements and inventions assignment agreements, which may have included non-competition provisions. Although we try to ensure that such employees and consultants do not use or otherwise disclose confidential information or intellectual property rights of others in their work for us without such other person&#8217;s consent, we may be subject to claims that we or our current or former employees or consultants have, inadvertently or otherwise, infringed, violated, or otherwise misappropriated the confidential information or the intellectual property rights of these former employers, clients, or other third parties. To the extent that our current or former employees or consultants disclose or use confidential information or intellectual property rights owned by others in their work for us, disputes may arise as to the rights in any related or resulting inventions and litigation may be necessary to defend against these claims. It may also be necessary or we may desire to obtain a license to such third party&#8217;s intellectual property rights to settle any such claim; however, there can be no assurance that we would be able to obtain such license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages or a settlement payment, a court could prohibit us from manufacturing, commercializing, using or importing the product, service, or technology features or practicing other intellectual property rights that are essential to our business, which could have a material adverse effect on our competitive position as well as our business, financial condition, results of operations, and prospects. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management and our employees. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with collaborators, partners, services provides, or contractors. A loss of key personnel or their work product could hamper or prevent our ability to develop, manufacture, commercialize, import, or use our products, services, or technologies, which could materially and adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the disclosure and use of our confidential information and trade secrets, the value of our products, services, and technologies and our business and competitive position could be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other intellectual property rights, including trade secrets, know-how, and/or other proprietary information that is not patentable or that we elect not to patent. However, trade secrets can be difficult to protect, and some courts are less willing or unwilling to protect trade secrets. To protect </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and maintain the confidentiality of our trade secrets and other proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators, and other third parties. We generally enter into confidentiality and inventions assignment agreements with our employees, consultants, and applicable third parties upon their commencement of a relationship with us. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes, and we may not enter into such agreements with all employees, consultants, and third parties who have been involved in the development of our inventions. Although we generally require all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, despite the protections we place on our intellectual property and our other proprietary rights, monitoring unauthorized use and disclosure by employees, consultants, and other third parties who have access to such intellectual property or other proprietary rights is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such employees, consultants, advisors, or third parties, despite the existence of our protections, including non-disclosure and use restrictions. These agreements may not provide meaningful protection against the unauthorized disclosure or use or of our trade secrets, know-how, or other proprietary information in the event the unwanted use is outside the scope of the provisions of the contracts or in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how or other proprietary information that we fail to detect. There can be no assurances that such employees, consultants, advisors, or third parties will not intentionally or unintentionally breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by third parties, including our competitors. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that information to compete with us. In addition to contractual measures, we try to protect the confidential nature of our proprietary information by maintaining physical security of our premises and electronic security of our information technology systems. Such security measures may not, for example, in the case of misappropriation of a trade secret by an employee, consultant or other third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee, consultant, or other third party from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material adverse effect on our business, financial condition, results of operations, and prospects. In particular, a failure to protect our proprietary rights may allow competitors to copy our products, services, or technologies, which could adversely affect our pricing and market share. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products, services, or technologies that we consider proprietary. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality, non-disclosure, and non-use provisions, and outcomes of such litigation are unpredictable. Enforcing a claim that a party illegally disclosed, used or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. While we use commonly accepted security measures, trade secret violations are often a combination of federal and state law in the U.S., and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases. Finally, even if we were to be successful on the enforcement of our claims, we may not be able to obtain adequate remedies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that others may independently develop information or technologies that are the same as or similar to our trade secrets or other proprietary technologies and develop products, services, or technologies without obtaining access to our trade secrets or other proprietary information in which case we could not assert any intellectual property rights, including trade secret rights, against such parties in a manner that could prevent legal recourse by us. If we fail to obtain or maintain trade secret protection, or if any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or used by others without our consent or otherwise misappropriated, or if any such information was independently developed by a competitor, or if our competitors obtain our trade secrets or independently develop products, services, or technologies that are the same as or similar to ours, our competitive market position could be materially and adversely harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build brand name recognition in our markets of interest and our competitive position may be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks could be challenged, opposed, invalidated, infringed, and circumvented by third parties, and our trademarks could also be diluted, declared generic or descriptive, or found to be infringing on other marks. If any of the foregoing occurs, we could be forced to re-brand our Company, products, services, or technologies, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. Further, there can be no assurance that competitors will not infringe our trademarks or that we will have adequate resources to enforce our trademarks. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our trademarks, trade names, and brand names to distinguish our products, services, and technologies from the products, services, and technologies of our competitors, and have registered or applied to register many of these trademarks in the U.S. and certain countries outside the U.S.; however, we have not yet registered all of our trademarks in all of our current and potential markets. There can be no assurance that all of our trademark applications will be approved for registration. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties have opposed and may oppose in the future further our trademark applications and may seek to cancel trademark registrations or otherwise challenge our use of the trademarks. Opposition or cancellation proceedings may be filed against our trademark filings in these agencies, and such filings may not survive such proceedings. While we may be able to continue the use of our trademarks in the event registration is not available, particularly in the U.S., where trademark rights are acquired based on use and not registration, third parties may be able to enjoin the continued use of our trademarks if such parties are able to successfully claim infringement in court. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. Our trademarks or trade names may be infringed, circumvented, declared generic, or determined to be violating or infringing on other marks.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products contain third-party open source software components and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell our products, affect our ability to protect our proprietary information, and subject us to possible litigation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products contain software tools licensed by third parties under open source software licenses. Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source software licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code. Some open source software licenses contain requirements that the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensee make its source code publicly available if the licensee creates modifications or derivative works using such open source software, depending on the type of open source software the licensee uses and how the licensee uses it. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source software licenses, be required to make available the source code of certain of our proprietary software to the public for free. This could allow our competitors to create similar products with less development effort and time and ultimately could result in a loss of product sales and revenue. In addition, some companies that use third-party open source software have faced claims challenging their use of such open source software and their compliance with the terms of the applicable open source license. We may be subject to suits by third parties claiming ownership of what we believe to be open source software or claiming non-compliance with the applicable open source licensing terms. Use of open source software may also present additional security risks because the public availability of such software may make it easier for hackers and other third parties to compromise or attempt to compromise our technology platform and systems.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we typically review our use of open source software to avoid subjecting our products, services or technology to conditions we do not intend, the terms of many open source software licenses have not been interpreted by U.S. courts, and there is a risk that these licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to commercialize our products, services or technology. Moreover, our processes for monitoring and controlling our use of open source software in our products, services or technology may not be effective. If we are held to have breached the terms of an open source software license, we could be required to seek licenses from third parties to continue offering our solutions on terms that are not economically feasible, to re-engineer our products, services, or technology, to discontinue the sale of our products, services, or technology if re-engineering could not be accomplished on a timely basis, to pay statutory or other damages to the license holder, or to make generally available, in source code form, our proprietary code, any of which could materially adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Financial and Accounting Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and research and development tax credits may be limited.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced net operating losses (&#8220;NOLs&#8221;) for tax purposes since our inception. As of December 31, 2025, we have total available gross (pre-tax) Federal and U.S. state NOL carryforwards of $126 million and $93 million, respectively. Under the Federal Tax Cuts and Jobs Act of 2017, NOLs incurred in tax years beginning on or after January 1, 2018, are carried forward indefinitely and are subject to a usage limitation of 80% of taxable income. NOLs incurred in tax years prior to January 1, 2018, are subject to a twenty-year carryforward period before expiring but are not subject to a usage limitation based on taxable income.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of NOL carryforwards and research and development tax credit carryforwards may be subject to substantial annual limitations under Section 382 of the Internal Revenue Code of 1986, as amended (&#8220;Section 382&#8221;), or, for states, under state laws, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. We have not conducted a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since inception. If we have experienced an ownership change, as defined by Section 382, at any time since inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382. Any limitation may result in the expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inability to fully utilize the NOL carryforwards and research and development tax credits could adversely affect our financial position and results of operations. If we are unable to generate sufficient taxable income in future periods to utilize the NOL carryforwards and research and development tax credit carryforwards before they </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expire, we may incur higher tax liabilities, which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified two material weaknesses in our internal control over financial reporting. These material weaknesses could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our management is likewise required, on a quarterly basis, to evaluate the effectiveness of our internal controls and to disclose any changes and material weaknesses identified through such evaluation in those internal controls. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified two material weaknesses in our internal control over financial reporting.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first material weakness relates to our failure to design or maintain sufficient controls over implementation of information technology general controls or complementary user entity controls for applications (such as our enterprise resource planning (&#8220;ERP&#8221;), payroll and stock option management IT systems) used in the preparation of our financial statements. More specifically, we did not design or maintain sufficient controls related to user access provisioning and monitoring, change management, program development and data management.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second material weakness relates to a lack of segregation of duties in the financial reporting function due to a limited number of staff performing the financial reporting function. More specifically, there is a limited level of multiple reviews among those tasked with preparing our financial records and with respect to our existing ERP system proper segregation of duties was not enforced (i.e., for journal entries we did not always different individuals responsible for the entry process and another approving the journal entry).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to remediate these material weaknesses could adversely impact our ability to report our financial position and results from operations on a timely and accurate basis. If our financial statements are not accurate, investors may not have a complete understanding of our operations. Likewise, if our financial statements are not filed on a timely basis, we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities. Either of the foregoing could have a material adverse effect on our business. Ineffective internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can give no assurance that the measures we have taken and plan to take in the future will remediate the material weaknesses identified or that any additional material weaknesses or restatements of financial results will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting or circumvention of these controls. In addition, even if we are successful in strengthening our controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation of our financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face litigation and other risks as a result of the material weaknesses in our internal control over financial reporting.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of such material weaknesses and other matters raised or that may in the future be raised by the SEC, we face potential for litigation or other disputes which may include, among others, claims invoking the federal and state securities laws, contractual claims or other claims arising from the restatement and material weaknesses in our internal control over financial reporting and the preparation of our financial statements. Any such litigation or dispute, whether successful or not, could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. We will remain an &#8220;emerging growth company&#8221; until the earliest to occur of:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the last day of the fiscal year during which our total annual revenue equals or exceeds $1.235 billion (subject to adjustment for inflation);</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the last day of the fiscal year following the fifth anniversary of our IPO;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the Exchange Act.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our &#8220;emerging growth company&#8221; status, we may take advantage of exemptions from various reporting requirements that would otherwise be applicable to public companies including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates plus the aggregate amount of gross proceeds to us as a result our IPO is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our annual report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. Investors may find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the market price of our common stock may be adversely affected and more volatile.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will incur increased costs and are subject to additional regulations and requirements as a result of operating as a public company, which could lower our profits or make it more difficult to run our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we will incur significant legal, accounting, and other expenses that we have not incurred as a private company, including costs associated with public company reporting requirements. We will also incur costs associated with the Sarbanes-Oxley Act and related rules implemented by the SEC and The Nasdaq Stock Market, LLC. The expenses generally incurred by public companies for reporting and corporate governance purposes have been increasing. We expect these rules and regulations to increase our legal and financial compliance costs and to make some activities more time-consuming and costly, although we are currently unable to estimate these costs with any degree of certainty. These laws and regulations also could make it more difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on our board committees or as our executive officers. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions, other regulatory action, and potentially civil litigation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to design, implement, and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. In addition, beginning with our second annual report on Form 10-K, we will be required to furnish a report by management on the effectiveness of our internal control over financial reporting, pursuant to the rules and regulations of the SEC regarding compliance with Section 404 of the Sarbanes-Oxley Act. The process of designing, implementing and testing the internal control over financial reporting required to comply with this obligation is time consuming, costly and complicated. See the risk factor titled &#8220;We have identified two material weaknesses in our internal control over financial reporting. These material weaknesses could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner.&#8221; Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we or, if required, our auditors, are unable to assert that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline, and we could also become subject to investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities, which could require additional financial and management resources. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we continue to scale and improve our operations, including our internal systems and processes, we are currently evaluating the implementation of a variety of critical systems, such as supply chain management, customer relationship management, billing, human resource information systems and accounting systems. We cannot assure you that new systems, including any increases in scale or related improvements, will be successfully implemented or that appropriate personnel will be available to facilitate and manage these processes. Failure to implement necessary systems and procedures, transition to new systems and processes or hire the necessary personnel could result in higher costs, compromised internal reporting and processes and system errors or failures. For example, we are evaluating an upgrade to or replacement of our existing ERP system that facilitates orderly maintenance of books and records and the preparation of financial statements. ERP system implementations are complex projects that require significant investment of capital and human resources, the reengineering of many business processes and the attention of many employees who would otherwise be focused on other aspects of our business. The implementation and transition to any new critical system, including a new ERP system, may be disruptive to our business if they do not work as planned or if we experience issues related to such implementation or transition, which could have a material adverse effect on our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends in the foreseeable future. As a result, your ability to achieve a return on your investment will depend on appreciation in the market price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination related to dividend policy will be made at the discretion of our board of directors, subject to applicable laws, and will depend </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon, among other factors, our results of operations, prospects, financial condition, contractual restrictions and capital requirements. In addition, our ability to pay cash dividends on our capital stock may be limited by the terms of any future debt or preferred securities we issue or any future credit facilities we enter into.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, investors must for the foreseeable future rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may require additional capital to support business growth, and this capital might not be available on terms favorable to us, or at all, and may dilute existing stockholders&#8217; ownership of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to make investments to support our business growth and may require additional funds to respond to business challenges and opportunities, including the need to advance clinical studies and pursue regulatory clearances for new or next-generation product pipeline. The scope, cost, timeline of these clinical development efforts are inherently uncertain, there can be no assurance that such efforts will yield successful outcomes or that the capital resources required to fund them will not exceed our current expectations. Accordingly, we may need to engage in equity or debt financings to secure additional funds. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. In addition, the incurrence of indebtedness would increase our fixed obligations and include covenants or other restrictions that would impede our ability to manage our operations. Further, if additional financing is needed, we may not be able to obtain additional financing on terms favorable to us or at all. Our inability to obtain adequate financing or financing on terms satisfactory to us, when we require it, could significantly limit our ability to continue supporting our business growth and advancing our new or next-generation product pipeline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. Lock-up agreements covering approximately 41.1 million pre-IPO shares of our outstanding common stock entered into in connection with our initial public offering expired in early January 2026 and these shares may now be sold, subject to any applicable volume limitations under federal securities laws, at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly and impair our ability to raise adequate capital through the sale of additional equity or equity-linked securities at a time and price that we deem appropriate. If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market , the trading price of our common stock could decline. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">No cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death, or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The required approval of at least 66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8260;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or to repeal certain provisions of our amended and restated certificate of incorporation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The requirement that a special meeting of stockholders may be called only by our board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the anti-takeover provisions contained in Section 203 of the General Corporation Law of the State of Delaware (the &#8220;Delaware General Corporation Law&#8221;). Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors, officers, and other employees or agents may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors, officers and certain other employees provide that:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees, and agents and to obtain insurance to indemnify such persons.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not retroactively amend our amended and restated bylaws provisions to reduce our indemnification obligations to directors, officers, employees, and agents.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, or stockholders to us or to our stockholders, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws (as either may be amended from time to time), or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation also provides that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees, or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation or amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any action the subject matter of which is within the scope described above is filed in a court other than a court located within the State of Delaware (a &#8220;Foreign Action&#8221;), in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and having service of process made upon such stockholder in any such action by service upon such stockholder&#8217;s counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of incorporation contains the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums, and protection against the burdens of multi-forum litigation. However, this choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees, or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. In addition, this choice of forum provision may result in increased costs for stockholders to bring a claim. Furthermore, the enforceability of similar choice of forum provisions in other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile, which could cause the value of your investment to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be highly volatile and could be subject to wide fluctuations. Securities markets worldwide experience significant price and volume fluctuations. This market volatility, as well as general economic, market, or political conditions, could reduce the market price of our common stock regardless of our operating performance. In addition, our results of operations could be below the expectations of public market analysts and investors due to a number of potential factors, including variations in our quarterly results of operations, additions or departures of key management personnel, failure to meet analysts&#8217; earnings estimates, publication of research reports about our industry, litigation and government investigations, data privacy and security-related events, changes or proposed changes in laws or regulations or differing interpretations or enforcement thereof affecting our business, adverse market reaction to any indebtedness we may incur or securities we may issue in the future, changes in market valuations of similar companies or speculation in the press or investment community, announcements by our competitors, adverse publicity about the medical device industry, or individual scandals, and, in response, the market price of our common stock could decrease significantly.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock markets experience extreme price and volume fluctuations. In the past, following periods of volatility in the overall market and the market price of a company&#8217;s securities, securities class action litigation has often been instituted against these companies. Such litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the market price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our results of operations fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product and professional liability suits against us could result in expensive and time-consuming litigation, payment of substantial damages and increases in our insurance rates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CapsoCam capsules are cleared or authorized by the FDA for specific intended uses. However, if physicians elect to use our products in manners outside of these intended uses, such use may result in adverse outcomes and may pose significant risks, especially for individuals with known or suspected gastrointestinal obstructions, strictures, or fistulas, as the capsule may become lodged, potentially leading to an obstruction that requires urgent medical or surgical intervention. We cannot prevent physicians from using our products off-label or from using non-our products in conjunction with our products. The risk of injury to patients may increase if physicians attempt off-label use. Additionally, we cannot guarantee that physicians are adequately trained by us or their peers before using our products. Complications from off-label use or use by untrained physicians may not effectively treat conditions and may expose us to product liability claims or litigation, harming our reputation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale and use of our CapsoCam capsules could lead to product or professional liability claims based on allegations that one of our CapsoCam capsules contained a design or manufacturing defect, which resulted in the failure to detect the disease for which it was designed. A product or professional liability claim could result in substantial damages and be costly and time-consuming to defend, either of which could materially harm our business or financial condition. We cannot assure you that our liability insurance would protect our assets from the financial impact of defending a liability claim.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any claim brought against us, with or without merit, could increase our liability insurance rates or prevent us from securing insurance coverage in the future. Furthermore, product liability claims could result in negative publicity, injury to our reputation, and loss of revenue. Even successful defense would require significant financial and management resources, which could adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders and reduce our financial resources.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may enter into transactions to acquire other businesses, products, or technologies. Because we have not made any acquisitions to date, our ability to do so successfully is unproven. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may decide to incur debt in connection with an acquisition or issue our common stock or other securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies, and operations into our existing business in an effective, timely, and non-disruptive manner.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties we depend on may be adversely affected by natural disasters and other catastrophic events, and our business continuity and disaster recovery plans may not adequately protect us from a serious natural disaster or other catastrophic event. Any interruption in our operations or the operations of third parties who supply components or other materials for our products may have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severe weather, natural disasters and other catastrophic events, including pandemics or other public health crises (such as the COVID-19 pandemic), earthquakes, tsunamis, hurricanes, floods, fires, explosions, accidents, power outages, cyber attacks, telecommunications failures, mechanical failures, unscheduled downtimes, civil unrest, strikes, transportation interruptions, unpermitted discharges or releases of toxic or hazardous substances, other environmental risks, wars or other conflicts (including wars in Ukraine and the Middle East), sabotage, terrorist attacks, or other intentional acts of vandalism or misconduct could severely disrupt our operations, or the operations of third parties who manufacture or supply components or other materials for our products, and have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a natural disaster or other catastrophic event occurs that prevents us or third-party suppliers or manufacturers from using all or a significant portion of our or their headquarters or other facilities, that damages critical infrastructure or that otherwise disrupts operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar catastrophic event. The potential impact of any disruption would depend on the nature and extent of the damage caused by a disaster. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our corporate headquarters and manufacturing facilities are located in Saratoga, California, near major earthquake faults and fire zones. We do not carry earthquake insurance. Furthermore, integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen, and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_166"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1738"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1744"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-37">developed and implemented</ix:nonNumeric> a cybersecurity risk management program designed to protect the confidentiality, integrity, and availability of our critical systems and information. Our strategy utilizes on a &#8220;Defense in Depth&#8221; architecture that is aligned with the international standard ISO/IEC 27001:2022, and adheres to the regulatory requirements under HIPAA, FDA cybersecurity guidance, GDPR and Sarbanes-Oxley IT General Controls (SOX ITGC). We employ a multi-layered approach to assess, identify and manage material cybersecurity risks relevant to our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key elements of the cybersecurity risk management program include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continuous Risk Assessment: Periodic risk assessment and treatment across critical systems and information, including corporate networks and <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-38">third-party managed services</ix:nonNumeric>.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Threat Management: Utilization of advanced security software for real-time threat detection and response, patch management and behavior data analysis and monitoring.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vulnerability Validation: Internal and external testing to identify vulnerabilities, including vulnerability scan and penetration testing, to proactively identify security gaps.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance Auditing: Regular internal and external audits to ensure the implementation of our cybersecurity program is compliant with the international standards and regulatory frameworks.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Incident Response: A formalized process that includes procedures for identifying, containment, eradication and recovery from cybersecurity incidents.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data Protection: Encryption of critical data at rest and in transit to ensure personal health information and financial data are protected. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Resiliency and Recovery: Disaster recovery and business continuity plans designed to maintain critical operations and minimize the downtime.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Security Culture: Mandatory cybersecurity awareness training for our employees, incident response personnel, and senior management.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain Security: Vendor risk assessment for key service providers and partners.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-39" continuedAt="f-39-1">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. See the risk </ix:nonNumeric></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-39-1">factor titled, &#8220;Our business and operations may suffer in the event of information technology system failures, cyber attacks, or deficiencies in our cybersecurity.&#8221; for additional information.</ix:continuation></span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1750"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Governance</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-40" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee oversight of cybersecurity risks, including responsibility for our controls and procedures for mitigating cybersecurity and other information technology risks, and our plans to respond to data breaches.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Audit Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The internal security team, led by the <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-41">Senior Director of Information Technology</ix:nonNumeric>, exercises oversight through a multi-faceted monitoring approach, which integrates threat intelligence from security communities, guidance from external advisors and governmental agencies, and aggregated analytics produced by security technologies deployed in our IT environment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Director of Information Technology oversees the daily assessment and management of material risks arising from cybersecurity threats, and reports on the company&#8217;s cybersecurity posture during semi-annual management review meetings. The reviews evaluate the achievement of security objectives, risk management and mitigation, personnel and access control change, resource allocation, key performance metrics, and opportunities for continuous improvement.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_169"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal office is located at 18805 Cox Avenue, Suite 250, Saratoga, California 95070, where we lease 14,058 square feet of space to house our principal office, manufacturing and warehouse facilities to support our business operations and clinical trial supply. This lease will expire in 2027, subject to our option to an additional three-year term. We lease two office facilities in Taiwan, where a small group of our employees are stationed, pursuant to two lease agreements: (i) a lease agreement for 12 months that commenced on February 15, 2025 and was renewed on the original expiration date of February 14, 2026 for another year until February 14, 2027, and (ii) a lease agreement for 12 months which commenced on May 16, 2025 and will expire on May 15, 2026.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing facilities will continue to support our research and development, finance, marketing, and administrative teams. We believe that our facilities are adequate to support our expansion through the end of the facilities&#8217; lease periods. We believe that suitable additional or alternative space would be available in the future as required on commercially reasonable terms.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815490"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in various legal proceedings arising from the normal course of business activities. We are not presently a party to any litigation the outcome of which, we believe, if determined adversely to us, would individually or taken together, materially and adversely affect our business, financial condition, or results of operations. Future litigation may be necessary to defend ourselves, our partners, and our customers by determining the scope, enforceability, and validity of third-party proprietary rights, to establish our proprietary rights or for other matters. Involvement in such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of legal expenses and settlement costs, diversion of management attention, and resources and other factors.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_175"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_178"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_181"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1758"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been listed on the Nasdaq Global Select Market under the symbol &#8220;CV&#8221; since July 2, 2025. Prior to this date, there was no public market for our common stock.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1764"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Records</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;25, 2026, there were approximately 340 registered holders of record of our common stock. The actual number of holders is greater than this number and includes stockholders who are beneficial owners but whose shares are held in &#8220;street name&#8221; by banks, brokers, and other financial institutions. This number of record holders also does not include stockholders whose shares may be held in trust by other entities.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1771"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We do not expect to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our earnings, if any, will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our Board of Directors and would depend upon various factors, including our results of operations, financial condition and capital requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our Board of Directors.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1783"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 12 of Part III of this Annual Report for information about our equity compensation plans which is incorporated by reference herein.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1788"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2025 we granted stock options under the 2005 Plan to purchase an aggregate of 171,171 shares of our common stock at a weighted average price of $2.63 per share to a total of 5 employees and contractors. During the six months ended June 30, 2025 we issued shares in connection with the exercise previously granted stock options under the 2005 Plan and sold an aggregate of 353,223 shares of our common stock at a weighted average price of $0.37 per share to a total of 70 employees and contractors. During the six months ended June 30, 2025 we issued shares in connection with the exercise previously granted warrant and sold an aggregate of 15,015 shares of our common stock at a weighted average price of $4.83 per share to one contractor. During the six months ended June 30, 2025, stock options under the 2005 Plan for an aggregate of 72,999 shares of our common stock at a weighted average price of $0.32 per share were forfeited, cancelled or expired. The issuances and sales of the foregoing securities were deemed to be exempt from registration under the Securities Act in reliance on Rule 701 promulgated under Section 3(b) of the Securities Act, as transactions pursuant to compensatory benefit plans and contracts relating to compensation as provided under Rule 701.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, immediately prior to the completion of our initial public offering (the IPO), 38,665,477 outstanding shares of convertible preferred stock converted into 38,665,477 shares of common stock. Immediately prior to the completion of the IPO, we filed an Amended and Restated Certificate of Incorporation, which authorized a total of 300,000,000 shares of common stock and 10,000,000 shares of preferred stock. Upon the filing of the Amended and Restated Certificate of Incorporation, 38,665,477 shares of our convertible preferred stock then outstanding were automatically converted into 38,665,477 shares of our common stock. Due to such conversion, the issuance of such shares of our common stock was exempt from registration under Section 3(a)(9) or Section 4(a)(2) of the Securities Act. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2025, in connection with the repayment of a promissory note in a principal amount of $1 million provided to us by an investor prior to our IPO, we issued to the investor 7,508 shares of common stock pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 as a transaction not involving a public offering. This loan was repaid in full with interest on July 11, 2025.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1777"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from our Initial Public Offering</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, we completed our IPO, in which we issued and sold 5,629,978 shares of our common stock (including 129,978 shares of common stock issued in connection with the partial exercise by the underwriters of their option to purchase up to an additional 825,000 shares) each at a price to the public of $5.00 per share. The net proceeds to the Company from the IPO were approximately $23.4 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities. There has been no material change in the planned use of proceeds from the IPO from that described in our Final Prospectus dated and filed with the SEC pursuant to Rule 424(b)(4) on July 3, 2025.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_1793"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Repurchases of Equity Securities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_184"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [ Reserved ]</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_187"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs that involve significant risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to those differences include those discussed below and elsewhere in this Annual Report, particularly in &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221;.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815402"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global medical technology company that develops advanced imaging and AI technologies, deployed in our capsule endoscopy solutions to identify abnormalities of the GI tract for diagnostic and screening purposes. Our capsule endoscope system, currently comprising the CapsoCam Plus single-use capsule and the CapsoCloud and CapsoView software, including 360 degree panoramic visualization of the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn&#8217;s disease, while our AI assisted pathology detection tools detect and highlight suspected abnormalities for a clinician, reducing their time to review the video and making capsule endoscopy more financially attractive to their practice. Our cloud-based solution enables medical professionals to access their patients&#8217; videos and review those videos anytime, anywhere, 24/7, without a need to have an on-site server and maintain it, while accumulating an immense data trove on the cloud storage for AI training.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were founded in 2005 and are headquartered in Saratoga, California. We sell our small bowel capsule system to our provider customers (i.e., primarily gastroenterologists practicing in clinics and/or hospitals) both internationally and in the U.S. through our global sales and marketing team. In the U.S., we sell to customers directly. Internationally, we sell both directly and through qualified exclusive distributors in specified regions. Our largest international shipping destinations in 2025 include France, Germany, and Columbia. We currently manufacture and intend to continue manufacturing our CapsoCam capsules included in our GI-tract capsule endoscopy solution (including CapsoCam Colon capsules). To assist us in manufacturing our GI-tract capsule endoscopy products, we rely on component suppliers and assembly manufacturers based in Asia (particularly Taiwan and Japan).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our effort to expand and grow our revenues beyond small-bowel-related, we are developing our next pipeline capsule endoscope product, CapsoCam Colon. Our CapsoCam Colon capsule (i) leverages CapsoCam Plus&#8217;s existing capsule design with its panoramic view and (ii) incorporates both our self-developed AI to automatically detect polyps and polyp-size measurement tool enabled by a 3D sensor in the capsule (polyp size being highly correlated with a polyp&#8217;s risk of becoming cancer). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025 we filed our 510(k) submission to the FDA for our initial CapsoCam Colon capsule endoscopy solution (the "First-Generation Product&#8221;). We received responses from the FDA in September 2025. During our meeting with the FDA in December 2025, the FDA raised inquiries on topics including panoramic image processing methodology, and the proposed study design, sample size and primary endpoint for an extended study. Based on our communications with the FDA, we have decided not to further pursue the submission and approval for the First-Generation Product, and to prioritize our resources for the development of our second-generation of CapsoCam Colon capsule (the "Second-Generation Product"),which features improved imaging quality and increased field of review with use of AI and better lens. We also expanded a second arm pivotal study to enroll approximately 800 patients at up to 20 sites in the U.S. in preparation for submitting a new 510(k) application for the Second-Generation Product. As of the date of this Annual Report, over 500 patients have been enrolled for the second arm pivotal study. We currently expects to submit the 510(k) application for the Second-Generation Product in the third quarter of 2026.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we continue to invest in AI to improve our existing products, we completed a clinical study to demonstrate the benefits of our incorporation of AI technology into CapsoCam Plus, our existing product for the small bowel. We  submitted the related 510(k) application to the FDA in December 2025. We expect that it will take approximately six months for the FDA to review our application, and issue their pending clearance. The commercialization is planned to begin shortly thereafter.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Longer term, we believe our CapsoCam family of products, incorporating our panoramic imaging solution, can be adapted to address new GI medical indications. Potential new medical indications include esophageal medical conditions (such as esophageal varices) and pancreatic cancer. In connection with our efforts to address pancreatic cancer, we submitted an FDA &#8220;Breakthrough Device Designation&#8221; application for our capsule endoscopy solution on November 6, 2025. A response from FDA in January 2026 determined that the CapsoCam UGI does allow for visualization of the papilla and its abnormalities, for both pre-cancerous and cancerous lesions. Due to the fact that the device does not specifically define diagnostic criteria, the application was not approved. The Company expects to resubmit the Breakthrough Device Designation application following the study, when additional data is available. The breakthrough designation is a part of the on-going project, potentially supplementing the regulatory pathway and approval for early pancreas cancer detection. However, additional research and studies to collect data may delay our anticipated timeline for obtaining the regulatory clearance (including obtaining the Breakthrough Device Designation) and may increase our research and development costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2025, the Company entered into a development agreement with Canon Inc, for the development of complementary metal-oxide-semiconductor (&#8220;CMOS&#8221;) image sensor samples with higher resolution and higher dynamic range to allow the Company to evaluate functionality and performance, conduct clinical evaluation of capsule endoscopies that incorporate Canon image sensors and obtain FDA 510(k) clearance thereof. The image sensors developed under this Agreement will be incorporated in future versions of the Company&#8217;s capsule endoscopies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred a net loss of $25.3 million and $19.9 million during the years ended December&#160;31, 2025 and 2024, respectively. As of December&#160;31, 2025, we had an accumulated deficit of $155.7 million, cash and cash equivalents of $10.1 million. To date, we have funded our operations primarily through proceeds from the sale of shares of our convertible preferred stock, IPO proceeds and cash generated from the sale of CapsoCam capsules and the use of CapsoCloud or CapsoView, CapsoCloud data access, and capsule video reading service. We expect to continue to incur significant losses for the foreseeable future as we continue to build our operations and transition to operating as a public company, as well as advance our current and future products through clinical development.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. When used in this Annual Report on Form 10-K, the terms "we," "us," "our" and "the Company" mean CapsoVision.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815408"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Model</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Factors Affecting Our Results of Operations and Performance</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations for the foreseeable future. These factors include:</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Success in further penetrating the small bowel capsule endoscopy market. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until commercialization of our CapsoCam Colon capsule (targeted for middle of 2027), to grow our revenues (and, in turn, reduce our expected losses and negative cash flows), we intend to grow our small-bowel-related revenues by, among other things: (i) retaining and growing our customer base; (ii) cost-effectively increasing the size and effectiveness of our U.S. and international sales teams and our customer-support function; (iii) pursuing the pediatric market (with children comprising a significant portion of the Crohn&#8217;s disease patient population); (iv) introducing complementary products such as our (a) capsule delivery device with full commercialization expected the fourth quarter of 2026, and (b) patency capsule (for verifying a capsule endoscope can pass through the bowel without retention prior to an exam) with tentative FDA 510(k) submission planned by the end of the second quarter of 2026; (v) facilitating increased telemedicine adoption following recent FDA clearance of remote ingestion of our CapsoCam Plus, allowing patients to ingest our capsules in the comfort of their own homes with remote provider supervision; and (vi) following related FDA 510(k) clearance (expected by the middle of 2026), commercializing our updated CapsoCam Plus which incorporates our AI assisted pathology detection technology.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Success in our clinical development efforts and managing related costs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior FDA, EU and other regulatory clearances are required (as applicable) to, among other things, (i) commercialize our GI-tract capsule endoscopy solution (including newly developed capsules or major hardware or software enhancements and improvements to a previously approved capsule or related product), (ii) target a new or expanded indicated patient population for our solution or (iii) target new medical conditions. These clearances must be supported by satisfactory clinical study data, among other things. By their nature, clinical development and related expenses often require significant upfront investment in terms of time and cost before revenue generation is ensured. Consequently, to generate or achieve and maintain revenue, we must effectively manage our planned clinical development efforts in terms of successful results and time and costs expended. In particular, our clinical study expenses may fluctuate significantly due to numerous factors, including the nature of a clinical study and relatedly, the study&#8217;s protocols, size in terms of patients and clinical sites and duration and the ability to timely enroll sufficient qualified patients (which may be impacted by competing clinical trials). We may also be required to conduct additional clinical trials or other testing of any of our products beyond those that are contemplated or if we experience significant delays in enrollment in any clinical trials, we could incur significant additional costs and the clinical development timeline for our products may be delayed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Success in our research and development efforts. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue investing in research and development to build upon and expand our GI-tract capsule endoscopy solution. Our research and development initiatives are focused on introducing new capsule products and enhancements and improvements to existing products, aimed at increasing the value provided by our GI-tract capsule endoscopy solution to patients and providers. We plan to appropriately modify our combined CapsoCam capsule and CapsoCloud and/or CapsoView solution to address new GI indications, for which we have begun and/or expect to soon begin the technical validation process for several additional indications and clinical-use cases beyond the small bowel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Success in further developing our AI product features.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We plan to continue investing to (i) improve the pathology-detection and classification accuracy and the scope of our AI algorithms and (ii) apply AI, including large language models, to streamline the diagnostic and medical-report-generation processes, which in turn improves the efficiency and effectiveness of our healthcare provider customers. Our CapsoCloud platform in the ordinary course collects patient videos and physician diagnostic reports that, with patient consent, we can utilize </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a dataset for training and validating our AI algorithms. This ever-expanding patient pathology dataset is unique among capsule endoscopy companies, and together with our in-house team of AI experts, provides a competitive advantage. Ongoing investment is required to apply expert labels to the accumulated image data and to modify, train, and test the algorithms on this labeled data to expand applications beyond the current horizon.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815414"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate (i) product revenue from the sale of CapsoCam capsules, (ii) service revenue from the provision of reading services for videos, and (iii) product or service revenue depending on which video delivery option is utilized by the customer to download and view capsule videos (CapsoCloud or CapsoView). The customer&#8217;s delivery options include (1) CapsoCam capsules shipped to the customer which works together with downloadable software (CapsoView) installed locally on a customer&#8217;s computer (classified as product revenue), or (2) a software-as-a-service offering which involves the customer mailing capsule devices to an off-site Company-operated facility which processes uploads of video content to a cloud platform (CapsoCloud) the customer can access via a web browser or a smart device application in order to view videos and generate reports (classified as service revenue). We recognize revenue for our product and reading service performance obligations at a point in time, that being when the performance obligations are satisfied and control is transferred to the customer (generally upon shipment for products, or conveyance of final deliverable for services). For the software-as-a-service video delivery offering performance obligation, the associated revenue is recognized over time, typically less than one fiscal quarter, representing the estimate of the typical period of time in which customers derive utility from the cloud-based service.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fees paid to group purchasing organizations (GPOs) that act as procurement agents for their underlying medical practice, clinic, or hospital members are deducted from revenue in the period the related revenue is recognized.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue fluctuates primarily based on the number of CapsoCam capsules sold. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture and intend to continue manufacturing our CapsoCam capsules included in our GI-tract capsule endoscopy solution. To assist us in doing so, we rely on component suppliers and assembly manufacturers based in Asia (particularly Taiwan and Japan).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue include materials, direct labor, and manufacturing overhead costs related to sold products, as well as certain period costs such as non-allocated overhead, scrap, and outbound freight costs, fees paid to physicians for providing reading services, and the costs of operating CapsoCloud as a software-as-a-service offering for video delivery of capsule videos such as shipping costs, processing costs, and data storage costs. All shipping and handling costs directly related to bringing products to their final point of sale are included in costs of revenue. As we expand our product offerings, acquire new customers and existing customers increase their use of our CapsoCam solutions, we expect that our costs of revenue will continue to increase in absolute terms in line with increased revenues.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government recently announced changes to its trade policies, including increasing tariffs on imports. Such changes could pose a risk to our business that could adversely affect our revenue, cost of revenue, gross profit, and gross margin. We will continue to evaluate the potential impact of tariffs on our business and results of operations and mitigating actions we might consider implementing.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit and Gross Margin</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate gross profit as revenue less costs of revenue. Gross margin represents gross profit as a percentage of revenue. We expect gross profit and gross margin to change and be affected by various factors going forward, including selling prices, product costs, customer mix and production volumes as well as product mix once sale of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoCam Colon capsules begin with CapsoCam Colon capsules expected to have a higher sales price and related costs of revenue as compared to CapsoCam Plus, given the additional optics and other features incorporated into the capsule.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the potential increase in cost of revenue, expected as a result of U.S. trade policies changes, including increasing tariffs on imports, our gross profit/gross margin may be adversely impacted.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and Marketing</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses include costs directly attributable to actively marketing our products and services using both direct employees and outside contractors or vendors. These costs include salaries, bonuses, benefits, and stock-based compensation, sales commissions, travel costs and expense reimbursements, and the costs to increase market awareness of our technology and our product advantages, including expenses related to sponsoring programs, events, conferences and consulting services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our selling and marketing expenses to increase in the foreseeable future as we continue to increase the size of our in-house sales organization and market penetration in the U.S. and internationally, and expand indications. However, we expect selling and marketing expenses to decrease as a percentage of revenue primarily as our revenue grows.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730. See Note 3 to our financial statements included elsewhere in this Annual Report for further details. Our research and development team includes hardware and software engineers with deep expertise in medical technology, optics, data science, AI, and cloud-based data and security architecture and individuals with extensive clinical development expertise.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GI-tract capsule endoscopy solution research and development activities include both (i) activities focused on increasing the value of our solution (such as developing new capsule products, including the associated software component, and new enhancements and features) and (ii) related clinical trial development efforts. Related research and development expenses include salaries, bonuses, benefits, and stock-based compensation for our employees focused on research and development, including engineering for our AI technology and hardware development, clinical trials, or regulatory clearance, costs of independent contractors and outside vendors, costs of supplies consumed in or product inventory utilized in clinical trials, and the costs of the clinical trials themselves as charged within the negotiated budgets by trial sites or vendors responsible for multiple trial sites. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near term, we expect our clinical development expenses to vary as, among others, we (i) finalized the first arm of our CapsoCam Colon large-scale pivotal study and began the second arm of our CapsoCam Colon pivotal study involving the second generation of that capsule (incorporating further advanced features designed to improve the accuracy of CapsoCam Colon) with the second arm expected to involve approximately 800 patients enrolled at up to 20 sites in the U.S. and plan to refine the study based on the FDA comments to the first arm pivotal study, (ii) continued clinical development of our updated small bowel CapsoCam Plus capsule incorporating our AI assisted pathology detection technology and (iii) conducted additional research and studies to collect data for the development of CapsoCam UGI.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to clinical trials costs, our research and development costs also includes engineering for our AI technology, hardware development, and regulatory personnel.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, including salaries, bonuses, benefits, and stock-based compensation expense for personnel in executive, administrative, finance, human </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources, and other supporting functions. General and administrative expenses also include professional fees for legal services, consulting services, tax matters and audits, as well as information technology expenses, office expenses, rent, insurance, and foreign exchange gains (losses).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the foreseeable future as we increase our headcount to support the continued growth of our business. We also anticipate incurring additional expenses associated with operating as a public company, including increased expenses related to audit, legal, regulatory, compliance, director and officer insurance, investor and public relations, and tax-related services associated with maintaining compliance with the rules and regulations of the SEC and standards applicable to companies listed on a national securities exchange. However, we expect general and administrative expenses to decrease as a percentage of revenue primarily as, and to the extent, our revenue grows.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815419"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Years ended December 31, 2025 and 2024</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our results of operations for the periods presented. The period-to-period comparison of financial results is not necessarily indicative of financial results to be achieved in future periods.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 20.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="21" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except for percentages and per share amount)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,756</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,798</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,379</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,002</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,377</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">796</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPERATING EXPENSES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">32,689</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">26,294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,395</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(25,516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total non-operating income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">225</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">650</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(25,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss and comprehensive loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(25,315)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,898)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,417)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share &#8211; basic and diluted </span></td><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.03)</span></td><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9.85)</span></td><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(90)</span></td><td style="background-color:#ffffff;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue has increased in each year since we began U.S. direct sales in 2020. Our revenues for the years ended December&#160;31, 2025 and 2024 were $13.6 million and $11.8 million, respectively, representing a period-over-period growth $1.8 million or approximately 15% (17% in the U.S. and 8% internationally). The primary driver for our revenue growth was an increase in the number of CapsoCam Plus capsules sold: a period-over-period increase of 15% for the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025 and 2024, international sales accounted for 21% and 23% of total revenue.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continued to scale our business, costs of revenue increased $1.0 million, or 19%, for the year ended December&#160;31, 2025, compared to the year ended December 31, 2024 from $5.4 million to $6.4 million. The increased costs of revenue was attributable to increased unit sales of CapsoCam Plus for the small-bowel and the related services and to increased customs and tariffs due to the change in U.S. trade policy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit and Gross Margin</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit increased $0.8 million, or 12%, for the year ended December&#160;31, 2025, compared to the year ended December 31, 2024, from $6.4 million to $7.2 million. For the years ended December&#160;31, 2025 and 2024, the gross margin was 53% and 54%, respectively. The increase in gross profit was a result of increased CapsoCam Plus unit sales and the related software component, while the decline of the gross margin is due to changes the U.S. government made to the trade policies and tariffs at the beginning of the year resulting in increase of expenses for customs and tariffs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a summary for our key operating expenses for the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 20.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="21" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except percentages)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">32,689</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">26,294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,395</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and Marketing Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses increased $0.6 million, or 8%, for the year ended December&#160;31, 2025, compared to the year ended December 31, 2024, from $7.0 million to $7.5 million. The increase was due to the addition to the sales force headcount and an increase in commission payouts in response to revenue growth.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $3.2 million, or 21%, for the year ended December&#160;31, 2025, compared to the year ended December 31, 2024, from $15.1 million to $18.3 million. The increase was primarily due to the design development of the new CMOS under the development agreement with Canon Inc. as described in Note 9. COMMITMENTS AND CONTINGENCIES and the design development of the new ASIC under the development agreement with an R&amp;D and manufacturing services vendor as described in Note 16. RELATED PARTIES.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $2.6 million, or 63%, for the year ended December&#160;31, 2025, compared to the year ended December 31, 2024, from $4.2 million to $6.8 million. Of the total increase, approximately $0.9 million was attributable to higher professional service expenses, including audit, legal and consulting fees, $0.5 million was attributable to stock-based compensation expenses primarily due to new stock options granted at the end of 2024 and April 2025, as well as acceleration of stock option awards associated with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the executive officer departure, $1.1 million was associated with higher payroll and benefits expenses due to hiring employees at the executive level, $0.3 million was attributable to higher corporate insurance expenses due to operating as a public company from July 2025, $0.2 million associated with a higher software expenses, and $0.1 million was associated with non-employee Board of Director's compensation for the second part of 2025, offset by $0.2 million due to receipt of refundable payroll tax credits from the U.S. Federal government and by $0.3 million due to foreign exchange gains of $0.2 million for the year ended December 31, 2025 compared to foreign exchange loss of $0.1 million for the year ended December 31, 2024.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reported net loss attributable to CapsoVision common stockholders for the years ended December&#160;31, 2025 and 2024 was $25.3 million and $19.9 million, respectively, representing a period-over-period increase of $5.4 million or 27%.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through the net proceeds we have received from the sales of our convertible preferred stock and IPO common stock as well as cash generated from sales of our CapsoCam Plus capsule endoscopy solution. We have generated losses from our operations as reflected in our accumulated deficit of $155.7 million as of December&#160;31, 2025. Net cash used in operating activities was $22.9 million and $20.1 million for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our losses primarily resulted from the costs incurred in the development and sales and marketing of our products and providing general and administrative support for our operations. We expect to continue to incur losses in the foreseeable future and to expend significant amounts of cash as we continue to scale our business, invest in research and development activities, increase sales and marketing expenses to support commercial expansion, and increase general and administrative expenses to support being a publicly-traded company. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual financial statements for the year ended December&#160;31, 2025 included in this Annual Report note that there is substantial doubt about our ability to continue as a going concern within one year after the date of issuance of the financial statements (see Note 2. GOING CONCERN). This means that we have expressed substantial doubt about our ability to continue our operations without an additional infusion of capital from external sources. Our annual financial statements have been prepared on a going concern basis and do not include any adjustments to reflect the future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may be necessary should we be unable to continue as a going concern. If we are unable to finance our operations, our business would be in jeopardy and we might not be able to continue operations and might have to liquidate our assets. In that case, investors might receive less than the value at which those assets are carried on our annual financial statements for the year ended December&#160;31, 2025, and it is likely that investors would lose all or a part of their investment. See &#8220;Risk Factors&#8212;Risks Relating to Our Business and Industry&#8212;Our annual financial statements for the year ended December&#160;31, 2025 include a footnote raising substantial doubt about our ability to continue as a 'going concern' and we will likely need to raise additional financing to fund our business and revenue growth plans."</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease obligations and other contractual obligations and commitments as part of our ordinary course of business. See Note 8. LEASES to our financial statements included elsewhere in this Annual Report for information about our lease obligations. In addition, see Note 9. COMMITMENTS AND CONTINGENCIES to our financial statements included elsewhere in this Annual Report for information about our other commitments and contingencies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Source of Liquidity</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had approximately $10.1 million in cash and cash equivalents. From our inception through December&#160;31, 2025, we have received aggregate gross proceeds of $143.6 million from sales of our convertible preferred stock, which were automatically converted into shares of our common stock in connection with the completion of our IPO. On July 3, 2025 we completed our IPO from which we received the net proceeds in the amount of $23.4 million. To provide for additional liquidity prior to the completion of our IPO, on May 28, 2025 we received $1 million as a note payable from an existing investor. The note payable, together with interest thereon (at 1% per month) was repaid shortly after completion of our IPO. In consideration for providing the note, we issued the investor 7,508 shares of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had an accumulated deficit of $155.7 million and cash and cash equivalents of $10.1 million. On July 3, 2025, we completed our IPO with the net proceeds to us of approximately $23.4 million after deducting underwriting discounts and commissions, and offering expenses payable by us. On March 16, 2026, we completed the private placement further discussed in 17. SUBSEQUENT EVENTS. Based on our current operating plan, even after this private placement of equity, we believe that our existing cash balances will not be sufficient to fund our operations for at least the next 12 months after the date of issuance of these financial statements. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. We may experience lower than expected cash generated from operating activities or greater than expected costs of revenue or operating expenses, and may need to raise additional capital to fund operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital needs will depend upon our ability to execute our revenue growth plans and many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and pace of developing new products, enhancements to existing products and our research and development activities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market acceptance of our products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and commercialize our CapsoCam capsule endoscopy solution for new indications, patient populations and clinical use cases;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully complete any required clinical or other studies and timely obtain and maintain any required regulatory approval or clearances;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">insurer and third-party reimbursement of the costs associated with our GI-tract capsule endoscopy solution;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful management of our global supply chain including our component suppliers and assembly manufacturers for our CapsoCam solution, many of which are located in Asia (particularly Taiwan and Japan) and some of which are currently single-source suppliers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful growth and leveraging of our global sales team (including, where appropriate, distributors) and marketing team to sell and market our GI-tract capsule endoscopy solution;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of attaining, defending, and enforcing our intellectual property rights;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we acquire third-party products or technologies;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and nature of competition from other GI-tract diagnostic products or procedures;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional funds to finance our operations; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the sources of cash together with expected cash generated from operating activities are insufficient to satisfy our liquidity requirements, we may need to engage in equity or debt financings to secure additional funds. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. In addition, the undertaking of indebtedness would increase our fixed obligations and include covenants or other restrictions that could impede our ability to manage our operations. Our ability to raise additional funds may be adversely impacted by deteriorating global economic conditions and the disruptions to and volatility in the credit and financial markets in the U.S. and fluctuations in interest rates, resulting from factors that include but are not limited to, inflation, the conflict between Russia and Ukraine, political tensions between China and Taiwan and other factors, diminished liquidity and credit availability, tariffs, declines in consumer confidence, declines in economic growth, increases in unemployment rates and interest rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Further, if additional financing is needed, we may not be able to obtain additional financing on terms favorable to us or at all. Our inability to obtain adequate financing or financing on terms satisfactory to us, when we require it, could significantly limit our ability to continue supporting our business growth and responding to business challenges and opportunities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain additional funding on a timely basis, we will be required to scale back our plans and place certain activities on hold. We currently do not have any commitments to obtain additional funds. Our management continues to evaluate different strategies to obtain the required funding for future operations. These strategies may include public and private placements of equity and/or debt securities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for each of the periods presented:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, net cash used in operating activities totaled $22.9 million, primarily driven by the net loss of $25.3 million for the period. Additional contributing factors included a $0.4 million increase in inventory to support increasing demand, offset by a $2.1 million increase in accrued expenses and other current liabilities, mainly due to research and development expenses, as well as $0.8 million increase in stock-based compensation expenses due to new grants and stock option accelerations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, net cash used in operating activities was $20.1 million, primarily attributable to the net loss of $19.9 million. Cash outflows were further impacted by a $0.4 million increase in inventory to meet increased demand, as well as 0.2 million increase in stock-based compensation expenses due to new grants.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities during the years ended December&#160;31, 2025 and 2024 was $0.1 million and $0.2 million, respectively, and consisted of purchases of property and equipment.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities during the year ended December&#160;31, 2025 consisted primarily of $23.4 million in net proceeds from the IPO, and $0.2 million in proceeds from the exercise of options on common stock and warrants. For the year ended December 31, 2024, net cash provided by financing activities was $15.1 million, which consisted of $15.0 million proceeds from the sales of our preferred stocks, and $0.1 million in proceeds from the exercise of options on common stock.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815426"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations at December 31, 2025 include operating lease payments of $1.0 million due within 24 months and $2.7 million in outstanding purchase commitment for the development agreement with Canon Inc. due in 15 months, which takes into account an increase of $1.0 million due to the increased features in the specification pursuant to an amendment to the original development agreement with Canon, Inc. executed in March 2026. We expect to fund these obligations through our existing cash balances and cash flows from operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no off-balance-sheet arrangements that have or are reasonably likely to have a material effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815453"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. GAAP. Preparation thereof requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and certain items included in the footnotes to our financial statements. See Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES to our financial statements included elsewhere in this Annual Report for information about our significant accounting policies. While we believe the processes used in developing our estimates to be reasonable, actual amounts may differ from estimates. The following reflects the critical accounting estimates used in the preparation of our financial statements. The term &#8220;critical accounting estimates&#8221; refers to those estimates that involve a significant level of estimation uncertainty that have had, or are reasonably likely to have, a material impact on our financial condition or results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (including Clinical Trial Expenses)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses, generally expensed as incurred, include salaries, bonuses, benefits, and stock-based compensation for employees focused on research and development or clinical trials, costs of independent contractors and outside vendors, costs of supplies consumed in or product inventory utilized in clinical trials, costs of the clinical trials themselves as charged within the negotiated budgets by trial sites or vendors responsible for multiple trial sites, and purchased or in-licensed intellectual property used in new product development where there is no alternative future use. We capitalize prepayments for goods or services, including trial device inventory or pre-paid clinical trial amounts, that will be used, consumed, or rendered for future research and development activities and recognize expense as the related goods are delivered or services are performed. We also record expenses and accruals for estimated costs of research and development activities that have not yet been billed to us, including services for clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses possess significant estimation uncertainty that have been, or are reasonably likely to be, material and include costs incurred with clinical trial sites and related vendors.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such estimation uncertainty arises because: (i) the total time periods over which costs are expected to be incurred, and attributed to, may contract or expand based upon difficult-to-predict outcomes such as better than expected progress in, or delays in, clinical trials (including due to study protocol amendments); (ii) the costs&#8217; behavior may be variable, or fixed, requiring judgments regarding proper attribution methodologies; and (iii) visibility of the precision of the exact progress of a particular study subject through the phases of the trial may be very limited, directly implicating necessary assumptions regarding informed consent, enrollment, or completion and speed of progress.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue using a five-step model prescribed by U.S. GAAP resulting in revenue being recognized as performance obligations within a contract are satisfied. Judgment is required to apply the principles-based, five-step model for revenue recognition. Management is required to make certain estimates and assumptions about our contracts with our customers. To date, with limited exception for capsule video reading service revenues, all our revenue is generated from the sale of our CapsoCam Plus capsules to our customers (classified as product revenue) and the use of CapsoCloud or CapsoAccess (together with CapsoView) as the customer selected capsule video delivery option for (i) streaming the capsule videos (via CapsoCloud) for clinician review (classified as service revenue) or (ii) downloading the capsule videos (via CapsoAccess and CapsoView) for clinician review (classified as product revenue). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those aspects of the five-step revenue recognition model prescribed by U.S. GAAP that give rise to significant levels of estimation uncertainty and have been, or are reasonably likely to be, material to our financial condition or results of operations include (i) the estimation of stand-alone selling prices for performance obligations that are not, or are rarely, sold separately or possess a wide range of observed historical selling prices and (ii) the measurement of applicable time periods to be used for recognition of revenue which is initially deferred at the time of sale and subsequently recognized over time or at a point in time. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimation of stand-alone selling prices, where we rely upon a cost-plus-expected margin approach, variability in our expected profit margin assumptions can, in turn, cause variation in estimated stand-alone selling prices and therefore the amounts of revenue allocated to different performance obligations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the estimation of applicable time periods impacting recognition of revenue deferrals, estimates are determined using historical customer behavior and deliverable timing data. Usage of historical data requires consideration of trends, patterns, and changes in the underlying data, judgments regarding sampling, and judgments as to whether historical data needs to be adjusted for future expectations. Changes in these underlying inputs have not significantly impacted service revenues or deferrals in the most recent period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, please, refer to Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES and Note 6. REVENUE AND DEFERRED REVENUE. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain equity incentive plans to provide long-term incentives for employees, consultants and members of our board of directors. These plans allow for the issuance of non-statutory and incentive stock options to employees, non-statutory stock options to consultants and restricted stock units to non-employee directors. We are required to determine the fair value of equity incentive awards and recognize compensation expense for all equity incentive awards granted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation awards, including stock options to employees and non-employees, based on their estimated grant date fair value. We recognize the fair value of stock options, which vest based on continued service, on a straight-line basis over the requisite service period, which is generally four years. As described in detail in Note 12. STOCK-BASED COMPENSATION to our financial statements included elsewhere in this Annual Report, determining the fair value of stock-based compensation to be recorded typically involves the use of an option-pricing model (which, for our Company, is the Black-Scholes option-pricing model).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant level of estimation uncertainty arises from certain inputs to the Black-Scholes model. Those inputs include (i) the fair value of the underlying common stock and (ii) the volatility of that fair value.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Valuation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to estimate the fair value of the common stock underlying our stock-based awards when performing fair value calculations using the Black-Scholes option pricing model. Prior to the IPO, the fair value of the common stock underlying our stock-based awards was determined on each grant date by our board of directors or our compensation committee, with input from management, considering our most recently available third-party valuation of common shares. All options to purchase shares of our common stock were intended to be granted with an exercise price per share no less than the fair value per share of our common stock underlying those options on the date of grant, based on the information known to us on the date of grant.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the value of our common stock was performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants (AICPA), Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation (the AICPA Practice Aid). In addition, our board of directors considered various objective and subjective factors to determine the fair value of our common stock, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">valuations of our common stock performed by independent third-party valuation specialists;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated capital structure that will directly impact the value of the currently outstanding securities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our results of operations and financial position;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the status of our research and development efforts;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the composition of, and changes to, our management team and board of directors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of liquidity of our common stock as a private company;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our stage of development and business strategy and the material risks related to our business and industry;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external market conditions affecting the life sciences and biotechnology industry sectors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and global economic conditions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an IPO or a sale of our company, given prevailing market conditions; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market value and volatility of comparable companies</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AICPA Practice Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. The cost approach establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective of our future operations, discounting to the present value with an appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors determined the income approach and market approach</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> including the back-solve method, were the most appropriate methods for estimating our enterprise value. Under the income approach, we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated the value based upon our projected financial performance. Under the back-solve method in the market approach, we estimated the value based upon our prior sales of redeemable convertible preferred stock to unrelated third parties, as well as secondary transactions undertaken in our preferred securities, using the option pricing method (the &#8220;OPM&#8221;). The back-solve analysis considered the post-transaction liquidation preferences, participation caps, dividends, conversion features, and our capital structure immediately following the closing of each financing round. Other market approaches included analyses based on the valuation of comparable publicly traded companies and mergers and acquisitions observed in related industries. We then applied these derived multiples or values to our financial metrics to estimate our market value.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For valuations performed prior to December&#160;31, 2024, the allocation of these enterprise values to each part of our capital structure, including our common stock and redeemable convertible preferred stock, was done utilizing the OPM. The OPM treats the rights of the holders of redeemable convertible preferred and common stock as equivalent to call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of redeemable convertible preferred stock, as well as their rights to participation and conversion. Thus, the estimated value of the common stock can be determined by estimating the value of its portion of each of these call option rights. The OPM back-solve derives the implied equity value of a company from a recent transaction involving our own securities issued on an arms-length basis.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our valuations performed on or after December&#160;31, 2024, the allocation of these enterprise values to each our share classes was done utilizing the hybrid method. The hybrid method is a hybrid between the probability-weighted expected returns method (the &#8220;PWERM&#8221;) and the OPM. The PWERM considers the enterprise value under various exit scenarios including an initial public offering (the &#8220;IPO Scenario&#8221;) and staying private, our estimate of the timing of each scenario and weightings based on our estimate of the probability of each event occurring. Our equity value under the IPO Scenario was estimated based on benchmarking analyses performed by the company and its bankers using market data observed for companies with recent IPOs. The equity value under the IPO Scenario was allocated to our capital stock using an IPO scenario analysis that contemplates the timing, size, valuation, and probability of an IPO event in the future. The stay private scenario estimated our equity value using an income approach based on our financial projections and market approaches based on the valuation of comparable publicly traded companies and mergers and acquisitions observed in related industries. Further, we used the OPM back-solve method and market indexing valuation method under the market approach with respect to the secondary transactions in our redeemable convertible preferred stock. The equity value was then allocated to our capital stock based on the OPM.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the equity value is determined and allocated to the various share classes, a discount for lack of marketability (&#8220;DLOM&#8221;) is applied to arrive at the fair value of the common stock. A DLOM is meant to account for the lack of marketability of a stock that is not traded on public exchanges. For financial reporting purposes, we considered the amount of time between the valuation date and the grant date of our stock options to determine whether to use the latest common stock valuation or a straight-line interpolation between the two valuation dates. This determination included an evaluation of whether the subsequent valuation indicated that any significant change in valuation had occurred between the previous valuation and the grant date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For valuations after the completion of our IPO, the fair value of each share of underlying common stock is based on the closing price of our common stock as reported on the date of grant on the Nasdaq stock exchange.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company under the Jumpstart Our Business Startups Act (JOBS Act). Under the JOBS Act, we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. However, we may elect to early adopt any new or revised accounting standards whenever such early adoption is permitted for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-public companies. We may take advantage of these exemptions up until the time that we are no longer an emerging growth company. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of our IPO, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a smaller reporting company as defined by Rule 12b-2 of the Exchange Act because both the market value of our stock held by non-affiliates is less than $700 million and our annual revenue is less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815431"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES to our financial statements included elsewhere in this Annual Report for a description of recent accounting pronouncements applicable to our financial statements.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_190"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934, as amended and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_193"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audited Financial Statements</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_196">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-42">23</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_196">114</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_19">Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_19">115</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_22">Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_22">117</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_25">Statements of Convertible Preferred Stock and Stockholders' </a><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_25">Equity (</a><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_25">Deficit</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_25">118</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_28">Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_28">120</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_205">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie17ceeaa833a498eadbb73e6ee8311e7_205">121</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_196"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To the Shareholders and the Board of Directors of CapsoVision, Inc.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:AuditorOpinionTextBlock" id="f-43" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of CapsoVision, Inc. (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern Uncertainty</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses and negative cash outflows from operations. These matters raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-44">Baker Tilly US, LLP</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-45">Santa Clara, California</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 26, 2026</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2024.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_19"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAPSOVISION, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BALANCE SHEETS </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except par value and share amounts)</span></div></div><div style="margin-bottom:12pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-46">10,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-47">9,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">2,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">2,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-50">2,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-51">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-53">898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">16,669</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">14,847</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-56">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-57">720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-58">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-59">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-60">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-61">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-62">18,164</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-63">16,803</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">1,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-65">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-67">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-68">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-69">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities &#8211; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-70">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-71">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">4,427</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">1,801</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities &#8211; long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-74">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-75">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-76">4,904</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-77">2,688</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies - Note 9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-78"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-79"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Preferred Stock (each Series: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-80"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-81">0.001</ix:nonFraction></ix:nonFraction> par value)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A, B, C, C-1, D, D-1, D-2, E, F-1, F-2, G, G-1, H: <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-82">none</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83">153,682,280</ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="0" id="f-85">none</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-87">38,665,583</ix:nonFraction></ix:nonFraction> issued and outstanding, and liquidation preference of <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:fixed-zero" scale="3" id="f-88">none</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-89">152,378</ix:nonFraction> as of December&#160;31, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-90">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-91">143,625</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAPSOVISION, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BALANCE SHEETS (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except par value and share amounts)</span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Preferred Stock (each Series: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-92"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-93">0.001</ix:nonFraction></ix:nonFraction> par value) (continued)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-94">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-95">143,625</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.76pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-96"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-97">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-98">300,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-99">190,000,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-101">46,865,051</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-103">2,090,945</ix:nonFraction></ix:nonFraction> issued and outstanding as of December&#160;31, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-104">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-105">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.76pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-106">168,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" scale="3" id="f-107">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.76pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-108">155,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-109">130,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-110">13,260</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">129,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">18,164</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span id="i40231207cdf14150a6d127e7c9149d45_9-3-1-1-64085"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">16,803</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAPSOVISION, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share and per-share amounts)</span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-114">13,554</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-115">11,756</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-116">6,381</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-117">5,379</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-118">7,173</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-119">6,377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPERATING EXPENSES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">7,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">6,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">18,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-123">15,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">6,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-125">4,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-126">32,689</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-127">26,294</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-128">25,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">19,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NON-OPERATING INCOME</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-130">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-131">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-operating income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-132">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-133">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total non-operating income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-134">225</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-135">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-136">25,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-137">19,887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-138">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-139">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss and comprehensive loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">25,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">19,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share &#8211; basic and diluted </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-142"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-143">1.03</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-144"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-145">9.85</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average common shares outstanding &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-146"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-147">24,555,381</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-148"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-149">2,020,077</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAPSOVISION, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.959%"><tr><td style="width:1.0%"/><td style="width:17.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></td><td colspan="9" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Paid-in-Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-150">35,559,025</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-151">128,625</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152">1,837,036</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-153">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-154">607</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">110,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-156">109,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Series H convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="cv:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-157">3,106,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-158">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:19.44pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock upon exercises of stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-159">253,909</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-160">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-161">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-left:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-162">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-163">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:19.44pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">19,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">19,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-166">38,665,583</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-167">143,625</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-168">2,090,945</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-170">838</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">130,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">129,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of all convertible preferred stock to common stock - initial public offering</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-173">38,665,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-174">143,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-175">38,665,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-176">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-177">143,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-178">143,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock in initial public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-179">5,629,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-180">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-181">22,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-182">22,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Underwriters Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-183">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-184">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock upon promissory note repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-185">7,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" scale="3" id="f-186">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" scale="3" id="f-187">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reverse stock split rounddown and cash in lieu payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" sign="-" name="cv:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" scale="0" id="f-188">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="f-189">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="f-190">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock upon exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-191">438,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-192">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-193">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.859%"><tr><td style="width:1.0%"/><td style="width:3.513%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.515%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAPSOVISION, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.959%"><tr><td style="width:1.0%"/><td style="width:17.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock upon exercises of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-194">15,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-195">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-196">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-197">17,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-198">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-199">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:19.44pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-200">25,315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-201">25,315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-202">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-204">46,865,051</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-205">47</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">168,878</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">155,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">13,260</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.859%"><tr><td style="width:1.0%"/><td style="width:3.513%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.515%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></td></tr></table></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAPSOVISION, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">25,315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-210">19,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-211">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-212">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-213">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="f-214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-215">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-216">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized foreign exchange (gains) losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-217">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-218">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock in lieu of debt repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="f-219">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="f-220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-221">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-222">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bad debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-223">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-224">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-225">478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-226">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-227">358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-228">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-229">174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-230">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="f-231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-232">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-233">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-234">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-235">2,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-236">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-237">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-238">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-239">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-240">276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-241">22,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-242">20,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-243">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-244">153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash used in investing activities </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-245">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-246">153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of Series H convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="f-247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="f-248">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from IPO, net of commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-249">26,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="f-250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of IPO offering costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-251">3,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from promissory note issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-253">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="f-254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repayment of promissory note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-255">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:fixed-zero" scale="3" id="f-256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from exercises of options on common stock and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromOtherEquity" scale="3" id="f-257">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromOtherEquity" scale="3" id="f-258">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-259">23,604</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-260">15,074</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="f-261">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-262">5,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-263">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-264">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-265">9,319</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-266">14,559</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-267">10,112</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-268">9,319</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUPPLEMENTAL CASH FLOW DISCLOSURES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-269">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-270">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-271">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NON-CASH FINANCING AND INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAPSOVISION, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Underwriters warrants issued in connection with the IPO</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" scale="3" id="f-273">519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" format="ixt:fixed-zero" scale="3" id="f-274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of convertible preferred stock into common stock upon initial public offering</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-275">143,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_205"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAPSOVISION, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share and per-share amounts)</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_34"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-277" continuedAt="f-277-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1. DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoVision, Inc. (&#8220;CapsoVision&#8221; or the &#8220;Company&#8221;), a commercial stage medical technology enterprise, that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (&#8220;GI&#8221;) system.  Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company is based in Saratoga, California.  Its customers include, in the U.S., gastrointestinal medical practices, clinics, and hospitals; outside of the U.S., the Company sells to distributor customers who resell products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s core technology platform is an orally ingestable capsule including multiple cameras facilitating 360 degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. This platform obviates the need for external data transmission or for a patient to remain in a medical facility throughout the digestive cycle. The Company&#8217;s products consist of (i) the on-market CapsoCam Plus&#174;, directed at the small intestines, and (ii) the in-development CapsoColon 3D&#174; directed at the large intestines (colon). Stored video imagery is downloaded from capsules with a data access device, CapsoAccess&#174; and enabling software, CapsoView&#174;. This video access solution permits on-site, on-demand video download and viewing by customers. The Company operates the CapsoCloud&#174; cloud-based software-as-a-service ecosystem as an off-premise video access and download solution. Using CapsoCloud&#174;, retrieved capsules are sent by customers to a centralized processing center for video downloading; patient video content is then made available via web portal or dedicated app access for customers to view, download, and generate patient reports. The Company&#8217;s services also include video reading; pursuant to this offering, physician customers may purchase a video reading and generation of patient report carried out by a second physician.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its 2005 formation, the Company&#8217;s organizational structure has comprised a single Delaware corporation with a branch office in Taiwan, Republic of China, the location of certain suppliers and Company personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoCam Plus&#174; was cleared by the U.S. Food and Drug Administration ("FDA") in 2016 and has since been approved in various other countries.  CapsoColon 3D&#174; is completing the second arm of our pivotal clinical study with planned submission for regulatory clearance, starting with the FDA, and we anticipate filing with the FDA in the third quarter of 2026. The Company is subject to risks and uncertainties common to life sciences companies including, but not limited to, risks associated with the success of research and development, risks associated with contract manufacturing, competition from other companies, protection of intellectual property and the risk of litigation related thereto, compliance with government regulations, and the ability to secure additional capital to fund operations and research &amp; development. Current and future programs, including for products focused on other areas of the GI system, will require significant research and development efforts, extensive clinical testing, and submissions for regulatory approval prior to commercialization.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-24" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en" id="f-278">July&#160;3, 2025</ix:nonNumeric>, the Company completed its initial public offering ("IPO") of <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" id="f-279">5,500,000</ix:nonFraction> shares of its common stock, that was followed by the issuance of <ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-280">129,978</ix:nonFraction> shares of common stock on <ix:nonNumeric contextRef="c-26" name="cv:SaleOfStockEffectivenessDate" format="ixt:date-monthname-day-year-en" id="f-281">July 18, 2025</ix:nonNumeric> in connection with the partial exercise by the underwriters of their option to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-282">825,000</ix:nonFraction> shares (the &#8220;Over-allotment Exercise&#8221;) as further described in Note 11. COMMON STOCK), each at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-283">5.00</ix:nonFraction> per share. The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-4" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-284">23.37</ix:nonFraction> million after deducting underwriting </span></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-277-1" continuedAt="f-277-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-4" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-285">1.59</ix:nonFraction> million and offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-4" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-286">3.18</ix:nonFraction> million which were recognized in additional paid-in capital as a reduction of the proceeds generated from the offering.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross proceeds to the Company from the IPO was approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-4" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="f-287">28.14</ix:nonFraction> million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection to the IPO, the Company amended and restated its certificate of incorporation (the &#8220;Restated Certificate&#8221;), under which authorized capital stock consists of <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-288">300,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-289">190,000,000</ix:nonFraction> shares of common stock as of December 31, 2025 and December 31, 2024, respectively. Authorized common stock is reserved for future issuance, including pursuant to outstanding equity awards and future equity awards under the 2005 Plan and the 2025 Plan as further described in Note 11. COMMON STOCK.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-277-2">On <ix:nonNumeric contextRef="c-30" name="us-gaap:PreferredStockConvertibleConversionDate" format="ixt:date-monthname-day-year-en" id="f-290">July 2, 2025</ix:nonNumeric>, immediately prior to the completion of the Company&#8217;s IPO and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock, all shares of the Company&#8217;s convertible preferred stock converted into shares of the Company&#8217;s common stock</ix:continuation>.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_37"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="f-291" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2. GOING CONCERN</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations since its inception. Since the launch of CapsoCam Plus&#174; in 2016, the Company has been able to fund increasing portions of its operating expenses from sales. However, the Company has continued to incur operating losses, net losses, and negative operating cash flows. The Company expects to continue to experience similar circumstances until existing and future products&#8217; sales yield further growth in revenues, achievement of break-even, and realization of future operating income, net income, and positive operating cash flows. As of December&#160;31, 2025, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-292">10,112</ix:nonFraction>. For the year then ended December 31, 2025, the Company had an operating loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-293">25,516</ix:nonFraction>, a net loss and comprehensive loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-294">25,315</ix:nonFraction>, and net cash used in operating activities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-295">22,864</ix:nonFraction>. The Company, having evaluated the extant facts and circumstances, concluded that the facts and circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date of issuance of these financial statements. While the Company completed the IPO in July 2025 and raised approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-296">23.4</ix:nonFraction>&#160;million in net proceeds, as well as subsequent private placement further discussed in 17. SUBSEQUENT EVENTS, it is not probable that these funds are sufficient to fund expenditures necessary to achieve sales growth and innovation objectives. The Company intends to consummate additional capital raising activities, but there is no certainty as to such capital raising activities occurring at all, or occurring with sufficient timing or magnitude, sufficient to alleviate such substantial doubt.</span></div></ix:nonNumeric><div id="ie17ceeaa833a498eadbb73e6ee8311e7_40"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-297" continuedAt="f-297-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-298" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). Any reference in these notes as it concerns U.S. GAAP is meant to refer to authoritative pronouncements as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reporting Entity</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s organizational structure reflects a single incorporated entity, CapsoVision, Inc..  This single entity has a foreign branch and physical presence in Taiwan, Republic of China, which is an extension of the U.S. corporation.</span></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-297-1" continuedAt="f-297-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-299" continuedAt="f-299-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-299-1">On <ix:nonNumeric contextRef="c-31" name="us-gaap:PreferredStockConvertibleConversionDate" format="ixt:date-monthname-day-year-en" id="f-300">July&#160;2, 2025</ix:nonNumeric>, the Company amended and restated its amended and restated certificate of incorporation to effect a <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityReverseStockSplit" id="f-301">1-for-3.33</ix:nonNumeric> reverse stock split of the Company's common stock, which automatically resulted in reciprocal adjustments (reductions) to the conversion ratios of each of the Company's series of convertible preferred stock (the "Reverse Stock Split"). The par values per share of the common and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All amounts for issued and outstanding common stock, convertible preferred stock, options to purchase common stock, warrants on common stock, and reserves related to common stock, as well as related per-share amounts, contained in the financial statements have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented. No fractional shares were issued as a result of the reverse stock split. In lieu of fractional shares, the Company rounded down to the next whole share and made a cash-in-lieu payment of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="f-302">1</ix:nonFraction> for <ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" sign="-" name="cv:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" scale="0" id="f-303">108</ix:nonFraction> shares</ix:continuation>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-304" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reporting currency for the financial statements of the Company is the United States Dollar. The functional currency of the U.S. corporation, and its foreign branch which is an extension of the U.S. corporation, is the U.S. Dollar. The assets, liabilities, and expenses of the Company&#8217;s foreign branch recorded in local currency are remeasured into the U.S. Dollar each period, with associated gains and losses included in operating expenses (as a component of general and administrative expenses). Monetary assets and liabilities denominated in currencies other than the functional currency are translated at exchange rates in effect at the balance sheet date with associated gains and losses included in operating expenses (as a component of general and administrative expenses). For the years ended December&#160;31, 2025 and 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-305">193</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-306">93</ix:nonFraction>), respectively, of net foreign exchange gains (losses) as components of general and administrative expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-307" continuedAt="f-307-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates&#160;</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-307-1">The preparation of financial statements in conformity with U.S. GAAP requires the making and usage of  estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities, if any. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. The Company seeks to moderate the influence of subjectivity and estimation uncertainty through reliance on useful information from market participants and peers wherever possible. Estimates and assumptions affect various financial statement amounts and their related disclosures, including, but not limited to, the recognition of revenue, underwriters' warrants valuation, stock based compensation, research and development expenses, income tax-related amounts, lease-related amounts, and allowances for credit losses. Actual results could materially differ from estimates.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-308" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Segments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized as, and managed as, <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-309"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="f-310">one</ix:nonFraction></ix:nonFraction> operating (and reportable) segment. Its chief operating decision maker is its Chief Executive Officer.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-311" continuedAt="f-311-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value Measurements&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where required, certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-297-2" continuedAt="f-297-3"><ix:continuation id="f-311-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the three levels of the hierarchy:</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - defined as inputs other than quoted prices included in Level&#160;1 that are either directly or indirectly observable</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - defined as significant unobservable inputs for which little or no market data exists, therefore necessitating entity-specific assumptions&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. An asset or liability&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s financial assets (which include cash and accounts receivable) and liabilities (which include accounts payable) approximate fair value due to their insensitivity to interest rates and/or close proximity to maturity and qualify as Level&#160;1 measurements.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-312" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentration Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of demand deposits at well-known financial institutions and accounts receivable.&#160; At times, the Company&#8217;s cash deposits may exceed U.S. Federal deposit insurance limits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sales to customers are typically originated with trade credit terms and receivables are uncollateralized, with limited exceptions for prepayments required for certain customers or credit card sales.  The Company historically has experienced insignificant levels of bad debt; allowances for credit losses on accounts receivable were insignificant for all periods presented.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s concentration risk related to revenues relates primarily to its product revenues being derived from a single product. With respect to customers, for the year ended December&#160;31, 2025, the same customer represented <ix:nonFraction unitRef="number" contextRef="c-34" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-313">9</ix:nonFraction>% of our revenue and <ix:nonFraction unitRef="number" contextRef="c-35" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-314">22</ix:nonFraction>% of our accounts receivable as of December&#160;31, 2025. For the year ended December&#160;31, 2024, that same customer represented <ix:nonFraction unitRef="number" contextRef="c-36" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-315">10</ix:nonFraction>% of our revenue and <ix:nonFraction unitRef="number" contextRef="c-37" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-316">21</ix:nonFraction>% of our accounts receivable as of December 31, 2024.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s supply concentration risk relates primarily to its materials procurement and contract manufacturing being substantially concentrated with vendors located in Asia.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-317" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) comprises net income (loss) and other comprehensive income (loss), which is defined as all changes in stockholders&#8217; equity (deficit) other than net income (loss) and those resulting from investments by and distributions to stockholders. Historically, and for all periods presented, there are no differences between net loss and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-318" continuedAt="f-318-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The core principle is that an entity should recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue using a five-step model resulting in revenue being recognized as performance obligations within a contract are satisfied. The steps within that model include: (i) identifying the existence of a contract with a customer; (ii) identifying the performance obligations within the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-318-1"><ix:continuation id="f-297-3" continuedAt="f-297-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract; (iii) determining the contract&#8217;s transaction price; (iv) allocating the transaction price to the contract&#8217;s performance obligations; and (v) recognizing revenue as the contract&#8217;s performance obligations are satisfied.  Judgment is required to apply the model and make certain estimates and assumptions about the Company&#8217;s contracts with its customers, including, among others, the nature and extent of its performance obligations, its transaction price amounts and any allocations thereof (including estimates of standalone selling prices), the events which constitute satisfaction of its performance obligations, and when control of any promised goods or services is transferred to customers. The guidance also requires certain incremental costs incurred to obtain or fulfill a contract to be deferred and amortized on a systematic basis consistent with the transfer of goods or services to a customer.&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates (i) product revenue from the sale of capsule medical devices, (ii) service revenue from the provision of reading services for videos, and (iii) product or service revenue depending on which video delivery option is utilized by the customer to download and view capsule videos.  The customer&#8217;s delivery options include (1) a capsule data reading device shipped to the customer which works together with downloadable software installed locally on a customer&#8217;s computer (classified as product revenue), or (2) a software-as-a-service offering which involves the customer mailing capsule devices to an off-site Company-operated facility which processes uploads of video content to a cloud platform the customer can access via a web browser or a smart device application in order to view videos and generate reports (classified as service revenue).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts with customers contain fixed consideration reflecting prices negotiated with customers and immaterial variable consideration.  For contracts with variable consideration, the Company uses the most likely amount method to estimate the transaction price. Variable consideration is constrained to the extent that it is deemed probable that a significant reversal of the amount of revenue recognized will not occur. Where products or services are not sold separately or experience a range of selling prices, the Company estimates standalone selling prices using a cost-plus-expected margin approach and utilizes the resultant standalone selling prices to allocate transaction prices at transaction inception on a relative standalone selling price basis. The Company recognizes revenue for its product and reading service performance obligations at a point in time, that being when the performance obligations are satisfied and control is transferred to the customer (generally upon shipment for products, or conveyance of final deliverable for services).  For the software-as-a-service video delivery offering performance obligation, the associated revenue is recognized over time, typically less than one fiscal quarter, representing the estimate of the typical period of time in which customers derive utility from the cloud-based service.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any significant financing components as payment is received at or shortly after sale. Standard trade credit terms are typically 30 to 60 days from invoice date. Costs incurred to obtain or fulfill a contract are expensed as incurred when the amortization period is less than one year, which is the case for the Company. The Company considers all shipping and handling to be fulfillment activities and not a separate performance obligation. Shipping and handling costs are recorded as costs of revenue. The Company has elected an accounting policy to exclude sales taxes and other similar taxes from the measurement of the transaction price.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain U.S. customers characterized as group purchasing organizations that function as procurement agents for their underlying medical practice, clinic, or hospital members; these group purchasing organizations typically charge the Company percentage-based fees in exchange for the right to do business with the group purchasing organization.  Such fees, which do not provide a distinct separate benefit to the Company, are recorded as reductions to revenue in the same period as the recognition of the related revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s products are sold with the same limited quality assurance warranties offered to all customers; the Company typically does not allow returns of products, except for cases of damage or defect, whereby products would be replaced.  Actual product returns have historically been immaterial given the one-time-use nature of capsule devices; estimated product returns (periodically adjusted to reflect actual experience), if warranted, are accounted for as reductions to revenue with offsets to a product return liability included within accrued expenses and other current liabilities in the balance sheet.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-297-4" continuedAt="f-297-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-319" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities; Accounts Receivable and Related Allowance</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records contract assets when it has completed performance obligations prior to receiving consideration from the customer and where such amounts are unbilled; where billed, amounts are reflected as trade accounts receivable. The Company promptly invoices its accounts receivable; therefore, the Company&#8217;s contract assets were <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="f-320"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="f-321">zero</ix:nonFraction></ix:nonFraction> for all periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities, portrayed as deferred revenue, reflect (i) obligations to provide goods for which the Company has already received consideration (generally arising from up-front payments received) and (ii) performance obligations to provide services which are not yet satisfied in the context of a particular contract (principally consisting of video delivery obligations related to the Company&#8217;s off-premise cloud-based video delivery offering).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The Company grants trade credit to most of its customers in the normal course of business and generally does not require collateral. An allowance for credit losses arises subsequent to the origination of a sale for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts.  A provision (or a reversal of the allowance) is recorded as a component of general and administrative expenses.  In determining the amount of the allowance, the Company considers aging of accounts, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance when all attempts to collect have been exhausted. Allowances for credit losses were insignificant for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-322" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue include materials, direct labor, and manufacturing overhead costs related to sold products, as well as certain period costs such as non-allocated overhead, scrap, and outbound freight costs, fees paid to physicians for providing reading services, and the costs of operating the Company&#8217;s cloud-based software-as-a-service offering for video delivery such as shipping costs, processing costs, and data storage costs. Shipping and handling costs directly related to bringing products to their final point of sale are included in costs of revenue and were $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-323">117</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-324">51</ix:nonFraction> for the years ended December&#160;31, 2025 and 2024, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-325" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses include costs directly attributable to actively marketing the Company&#8217;s products and services using both direct employees and outside contractors or vendors. These costs include, but are not limited to, salaries, bonuses, benefits, stock-based compensation, sales commissions, travel costs and expense reimbursements, and the costs of sponsoring programs, events, and conferences. Advertising costs were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:AdvertisingExpense" format="ixt:fixed-zero" scale="0" id="f-326"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="INF" name="us-gaap:AdvertisingExpense" format="ixt:fixed-zero" scale="0" id="f-327"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="INF" name="us-gaap:AdvertisingExpense" format="ixt:fixed-zero" scale="0" id="f-328"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:AdvertisingExpense" format="ixt:fixed-zero" scale="0" id="f-329">nil</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> for all periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, bonuses, benefits, and stock-based compensation related to the Company&#8217;s executive, administrative, finance, human resources, and other supporting functions. Also included are professional fees for legal services, consulting services, tax matters and audits, information technology, office expenses, rent, insurance, and foreign exchange gains (losses).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-330" continuedAt="f-330-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expenses (including Clinical Trial Expenses)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development expenses include costs directly attributable to the conduct of research and development programs, including salaries, bonuses, benefits, and stock-based compensation for employees focused on research and development or clinical trials, costs of independent contractors and outside vendors, costs of supplies consumed in or product inventory utilized in clinical trials, and the costs of clinical trial activities as charged within the negotiated budgets by trial sites or vendors responsible for multiple trial sites.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-297-5" continuedAt="f-297-6"><ix:continuation id="f-330-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes prepayments for goods or services, including trial device inventory, that will be used, consumed, or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed.  The Company also records expenses and accruals for estimated costs of research and development activities, including third party services for clinical trials.  The Company bases its estimates on information available at the time.  Costs for certain clinical trial activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the balance sheet as prepaid expenses or as accrued expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025 and 2024, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-331">6,391</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-332">7,647</ix:nonFraction>, respectively, of expenses related to ongoing clinical trial activities which are included within research and development expenses.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-333" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if options or warrants on common stock were exercised or convertible preferred stock shares were converted into common stock. Diluted net loss per share is the same as basic net loss per common share since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of incremental common shares issuable upon exercise of vested stock options, common stock warrants, and the Company&#8217;s various series of convertible preferred stock. Upon completion of the IPO in July 2025, all outstanding shares of preferred stock were converted into shares of Company's common stock (after giving effect to the <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityReverseStockSplit" id="f-334">1-for-3.33</ix:nonNumeric> reverse stock split). Subsequent to the conversion, only common stock remains outstanding. Accordingly, the two-class method is no longer applicable for periods after the IPO.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-335" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents comprises demand deposits in the form of checking accounts and money market accounts (which may be deposited into and withdrawn at will with no restrictions as to investment or redemption) and includes cash balances denominated in the Euro and New Taiwan Dollar, for which fluctuations in exchange rates result in gains or losses reported within operating expenses as a component of general and administrative expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-336" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisting of materials, direct labor and manufacturing overhead, are subdivided into raw materials, work in process, and finished goods and are stated at the lower of cost (average cost) or net realizable value.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates inventories as to (i) net realizable value and (ii) circumstances or indicators of loss, damage, insufficient time to expiry (determined by battery life), excess quantities, or obsolescence and provisions accordingly via direct charges against the carrying value of inventory.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-337" continuedAt="f-337-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at historical cost, less accumulated depreciation. The Company capitalizes major improvements and expenses repairs and maintenance as incurred. Depreciation is recorded using the straight-line method based on the estimated useful lives of the depreciable property or, for leasehold improvements, the remaining term of the lease, whichever is shorter.  <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-338" continuedAt="f-338-1" escape="true">Useful lives are as follows.</ix:nonNumeric></span></div><ix:continuation id="f-338-1" continuedAt="f-338-2"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery &amp; equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-44" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-339">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-45" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-340">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-46" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-341">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:continuation></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-297-6" continuedAt="f-297-7"><ix:continuation id="f-337-1" continuedAt="f-337-2"><ix:continuation id="f-338-2" continuedAt="f-338-3"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-47" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-342">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-343">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-344">Shorter of remaining lease term or useful life</span></span></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal (retirement or sale) of property and equipment, as applicable, the cost and related accumulated depreciation are removed and any resulting gain or loss is reflected within operating expenses. Such amounts were insignificant for all periods presented.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-337-2">Long-lived assets are evaluated for impairment as warranted by triggering events related to changes in facts and circumstances. There have historically been no impairments and there were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-345"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-346"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-347"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-348">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> for all periods presented</ix:continuation>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-349" continuedAt="f-349-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and storage space in California and office space in Taiwan, Republic of China. The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (&#8220;ROU&#8221;) assets and the corresponding lease liabilities are depicted in operating lease liabilities, current and operating lease liabilities, non-current in the balance sheet. ROU assets represent the right to use an underlying asset, and lease liabilities represent the obligation for lease payments in exchange for the ability to use the asset for the duration of the lease term. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets and lease liabilities are recognized at commencement date and determined using the present value of the future minimum lease payments over the lease term. The Company utilizes an incremental borrowing rate when assessing lease classification and measuring lease liabilities. The estimated incremental borrowing rate considers credit rating practices applied by well known statistical rating organizations to borrowers, Company-specific factors, and the actual lease term at commencement date. The lease term may include options to extend when it is reasonably certain that the Company will exercise that option. The Company recognizes operating lease expense on a straight-line basis over a lease's term.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-349-1">The Company has lease agreements which contain both lease and non-lease components, which it has elected to account for as a single lease component. Variable lease payments that are not dependent on an index or rate are not included in lease measurements and are accounted for as incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="f-350" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary means of financing from start-up through development and into the commercial stage has historically been the issuance of convertible preferred stock in various series; these series share similar rights and obligations and contain similar qualifications as to the requirements an equity initial public offering would have to meet in order for the stock to convert to common stock. Convertible preferred stock is recorded at fair value on the date of issuance (historically, the same as the issue price), net of issuance costs. Application of the guidance contained in&#160;ASC&#160;480-10-S99-3A,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SEC Staff Announcement: Classification and Measurement of Redeemable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has led the Company to present each of the series of convertible preferred stock as mezzanine equity due to the similar features of the series concerning liquidation preferences and other rights and privileges inuring to the respective series&#8217; holders, one or more of which may result in a settlement in cash not entirely within the Company&#8217;s control.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-30" name="us-gaap:PreferredStockConvertibleConversionDate" format="ixt:date-monthname-day-year-en" id="f-351">July&#160;2, 2025</ix:nonNumeric>, immediately prior to the completion of the Company&#8217;s IPO and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock, all shares of the Company&#8217;s convertible preferred stock converted into shares of the Company&#8217;s common stock.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-352" continuedAt="f-352-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for employee and nonemployee equity compensation awards in accordance with ASC 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 718&#8221;).&#160; In accordance therewith,&#160;the Company accounts for </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-297-7" continuedAt="f-297-8"><ix:continuation id="f-352-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock-based compensation for awards granted to nonemployees in a similar fashion to stock-based compensation awards to employees.&#160; ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation awards issued under the Company&#8217;s 2005 Stock Plan (the &#8220;2005 Plan&#8221;) and the Company&#8217;s 2025 Equity Incentive Plan (the &#8220;2025 Plan&#8221;) take the form of stock options (non-qualified or incentive stock options), restricted stock or restricted stock units (the "RSUs"). The 2025 Plan also provides for the grant of stock appreciation rights, stock bonuses, stock units and other forms of awards including cash awards to the Company&#8217;s officers, directors, employees, consultants and advisors. The Black-Scholes option-pricing model is used to determine the fair value of options; application of the model requires judgment to develop assumptions input into the model, some of which are more subjective, including: (i) the fair value of the underlying common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility of the underlying common stock; (iv) the risk-free interest rate; and (v) expected dividends. Income and market approaches to valuation are judgmentally weighted and combined to determine a composite value representing the fair value of the underlying common stock. In estimating the fair value of the underlying common stock prior to IPO, the Company utilized a third party professional valuation firm whose analyses supported management's concluded estimate. Post IPO the fair value of the underlying common stock is based on the Company&#8217;s closing stock price on the date of grant. An expected volatility assumption is based on stock price volatility of a peer group of comparable public companies over a similar expected term. The risk-free rate is based on U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term; no dividends are assumed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s employee and nonemployee stock-based compensation awards granted on or before December 31, 2025 contain only service conditions for vesting. The Company recognizes stock-based compensation cost as a component of the related functional expense (costs of revenue or category of operating expenses) on a straight-line basis over the requisite service period, which is explicitly stated in the case of awards issued to employees and implicitly understood to be the period over which services are provided for nonemployees. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with pre-vesting forfeitures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation awards in the form of the restricted stock units (the "RSUs") are issued to the Directors of CapsoVision, Inc, who are not employed by the Company ("Non-Employee Directors"). These RSUs are issued in lieu of annual cash compensation (annual base retainer). Each RSU granted to the Non-Employee Directors represents a right to receive one share of the Company common stock when the RSU vests. The Company estimates compensation cost based on the grant date fair value and recognizes the expense on a graded vesting basis over the vesting period of the award. Please, see Note 12. STOCK-BASED COMPENSATION for details.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-353" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, offering costs related to legal, accounting, and underwriting costs were net with the proceeds and recorded as a reduction in additional paid in capital, in the stockholders&#8217; equity section of the balance sheet. The Company also issued Underwriters Warrants (as defined in Note 11. COMMON STOCK) for services provided during the IPO to purchase <ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-354">168,898</ix:nonFraction> shares of common stock. The Underwriters Warrants are accounted for as equity instruments and are included in the Stockholders&#8217; Equity section of the balance sheet. The fair value of the Underwriters Warrants has been estimated using the Black-Scholes option pricing model.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-355" continuedAt="f-355-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC 740,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 740&#8221;), which requires that the asset and liability method be used. Deferred tax assets and liabilities are determined based on the differences between financial reporting (book basis) and the tax reporting (tax basis) amounts of assets and liabilities; these pre-tax differences are measured and reflected after-tax using the enacted tax rates and law that will be in effect when the differences are expected to reverse. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-297-8" continuedAt="f-297-9"><ix:continuation id="f-355-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets at least annually and more frequently as warranted by changes in facts and circumstances and adjusts the amount of the valuation allowance accordingly. Factors considered include the presence of reversing taxable temporary differences as a source of taxable income, forecasts of future taxable income, and available tax planning strategies that could be implemented and are both prudent and feasible. The Company has recorded a full valuation allowance with respect to all of its deferred tax assets based upon the significant negative evidence presented by its accumulated deficit position, its operating losses and negative operating cash flows, and the uncertainty associated with the timing and amount of future profits and therefore taxable income that enable realization. In future periods, if the Company generates book income and taxable income, changes in judgment may reduce or eliminate the valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with a two-step model. Firstly, a recognition threshold must be met; a tax benefit from an uncertain tax position may only be recognized if the tax position would, more likely than not, be sustained by the taxing authority assuming an examination and the application of typical practices and precedents.  Secondly, a measurement rule is applied; the amount of tax benefit that can be recognized is the portion that is greater than 50% likely of being realized upon a settlement.  The determination as to whether a tax benefit will, more likely than not, be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances, without consideration of detection risk. As of December&#160;31, 2025 and 2024 the Company&#8217;s uncertain tax positions were principally related to the non-recognition of a portion of Federal and U.S. state research and development tax credits. The Company recognizes any interest and penalties associated with its income tax positions in the provision for income taxes.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-356" continuedAt="f-356-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Standards Issued and Recently Adopted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280):&#160;Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;("ASU 2023-07"). This guidance requires disclosure on an annual and interim basis of the following: (i) significant segment expenses regularly provided to the chief operating decision maker ("CODM") and a measure of segment profit or loss; (ii) an amount for other segment items by reportable segment and a description of its composition; (iii) all annual disclosures about a reportable segment's profit and loss and assets as currently required by ASC Topic 280; (iv) clarifying if the CODM uses more than one measure of a segment's profit or loss in assessing segment performance and deciding how to allocate resources; and (v) disclosing the title and position of the CODM and how the CODM uses the reported measures. Public entities with a single reportable segment are required to provide all the disclosures required by this amendment.  ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and for quarters in the years beginning after December 15, 2024; early adoption is permitted. The Company, a single reportable segment entity, early adopted ASU 2023-07 with effect from January 1, 2023; the related disclosures are included in Note 13. SEGMENTS.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the FASB issued ASU 2023-09,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) &#8212; Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;("ASU 2023-09"). The new guidance provides for disclosure on an annual basis of the following: (i) specific categories in the rate reconciliation, and (ii) additional information for reconciling items that meet a quantitative threshold of greater than 5% of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024; early adoption is permitted. The Company adopted this standard for the fiscal year 2025 annual financial statements and has applied this standard prospectively which had a disclosure only impact on its financial statements. See Note 14. INCOME TAXES.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2024-03").  The new guidance requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the statement of operations. ASU is effective for public business entities for annual periods beginning after December 15, 2026, and for quarters in the years beginning after </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-356-1"><ix:continuation id="f-297-9"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 15, 2027; early adoption is permitted. The new guidance may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends certain aspects of the accounting for and disclosure of internal-use software costs. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted and the amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date, retrospectively to any or all prior periods presented in the financial statements, or through a modified prospective transition approach which is based on the status of the project and whether software costs were capitalized before the date of adoption. The Company is currently evaluating the impact ASU 2025-06 will have on its disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU 2025-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Reporting (Topic 270): Narrow-Scope Improvements, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides clarity about current interim disclosure requirements and adds a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, for public business entities and for interim reporting periods within annual reporting periods beginning after December 15, 2028, for entities other than public business entities. Early adoption is permitted for all entities. The amendments in this Update can be applied either (1) prospectively or (2) retrospectively to any or all prior periods presented in the financial statements. At the same time, the FASB issued  ASU 2025-12 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. If an entity adopts the amendments in this Update in an interim period, it must adopt them as of the beginning of the annual reporting period that includes that interim reporting period. An entity may elect to early adopt the amendments on an issue-by-issue basis. The Company is currently evaluating the impact ASU 2025-11 and ASU 2025-12 will have on its disclosures.</span></div></ix:continuation></ix:continuation><div id="ie17ceeaa833a498eadbb73e6ee8311e7_43"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-357" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4. FAIR VALUE MEASUREMENTS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s demand deposit accounts include money market demand deposits which constitute cash, given the lack of investment restrictions or redemption conditions and the ability to immediately withdraw funds. The carrying amounts of the Company&#8217;s financial assets (which include cash and accounts receivable) and liabilities (which include accounts payable) approximate fair value due to their insensitivity to interest rates and/or close proximity to their maturities and qualify as Level&#160;1 measurements. There were no transfers between Level 1, 2 or 3 during any periods presented.</span></div></ix:nonNumeric><div id="ie17ceeaa833a498eadbb73e6ee8311e7_46"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-358" continuedAt="f-358-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5. BALANCE SHEET COMPONENTS</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-359" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="f-360">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="f-361">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="f-362">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="f-363">897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-364">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-365">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-366">2,987</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-367">2,629</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-358-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025 and December&#160;31, 2024, there were no provisions to write down inventories. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-368" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment for insurance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-369">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-370">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for inventory purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Supplies" scale="3" id="f-371">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Supplies" scale="3" id="f-372">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred initial public offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:fixed-zero" scale="3" id="f-373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="f-374">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-375">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-376">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-377">1,072</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-378">898</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred initial public offering costs are specific incremental costs directly attributable to an initial public offering of equity securities that were reclassified from current assets to stockholders' equity and recorded as reductions to the gross proceeds from the offering.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:continuation id="f-338-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MachineryAndEquipmentGross" scale="3" id="f-379">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MachineryAndEquipmentGross" scale="3" id="f-380">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment, office equipment, and purchased software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareGross" scale="3" id="f-381">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareGross" scale="3" id="f-382">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" scale="3" id="f-383">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" scale="3" id="f-384">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-385">575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-386">359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-387">611</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-388">720</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-389">216</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-390">206</ix:nonFraction> for the years ended December&#160;31, 2025 and 2024, respectively, were recorded within costs of revenue and components of operating expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-391" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities comprised the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-392">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-393">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cv:AccruedClinicalTrialExpenseCurrent" scale="3" id="f-394">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="cv:AccruedClinicalTrialExpenseCurrent" scale="3" id="f-395">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cv:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-396">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="cv:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:fixed-zero" scale="3" id="f-397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued sales taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="f-398">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="f-399">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-400">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-401">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-402">2,697</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-403">569</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></td></tr></table></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-404" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6. REVENUE AND DEFERRED REVENUE</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-405" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue disaggregated by geographic source, type of customer, and products or services was as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States (medical practice, clinic, and hospital customers):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products (capsules and capsule reading devices)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-406">9,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-407">8,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services (cloud-based video delivery and reading services)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-408">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-409">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside United States (distributor customers):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products (capsules and capsule reading devices)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-410">2,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-411">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-412">13,554</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-413">11,756</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025 and 2024, U.S. service revenues included (i) $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-414">621</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-415">548</ix:nonFraction>, respectively, from the Company&#8217;s cloud-based software-as-a-service video delivery offering (recognized over time commencing with the shipment of capsules) and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-416">295</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-417">232</ix:nonFraction>, respectively, of revenue from the provision of video reading to customers (recognized at a point in time upon provision of deliverables).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues outside the United States are attributable to individual foreign countries based upon shipment destination. The Company&#8217;s distributor customers outside the United States typically serve the countries in which they are domiciled (and may distribute to adjacent countries or territories). Outside the United States, for the year ended December&#160;31, 2025, product revenues included $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-418">1,248</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-419">598</ix:nonFraction> attributable to France and Germany, respectively, with the balance attributable to other countries; for the year ended December&#160;31, 2024 product revenues included $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-420">1,160</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-421">565</ix:nonFraction> attributable to France and Germany, respectively, with the balance attributable to other countries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue (contract liabilities, all of which are current in nature) consists of upfront purchases by customers related to the cloud-based software-as-a-service video delivery offering and prepaid video reading services. Deferred revenue represents the excess of amounts invoiced over amounts recognized as revenues. For each component of deferred revenue, the recognition of deferrals as revenue occurred within three months.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred revenue balance was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-422">177</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-423">132</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-424">96</ix:nonFraction> as of December&#160;31, 2025, December&#160;31, 2024 and December 31, 2023, respectively. During the year ended December&#160;31, 2025, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="f-425">132</ix:nonFraction> of revenue that was included in deferred revenue as of December&#160;31, 2024. During the year ended December&#160;31, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-426">96</ix:nonFraction> of revenue that was included in deferred revenue as of December 31, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fees paid to group purchasing organizations and recorded as reductions to revenue were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cv:GroupPurchasingOrganizationFeesContraRevenue" scale="3" id="f-427">110</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="cv:GroupPurchasingOrganizationFeesContraRevenue" scale="3" id="f-428">103</ix:nonFraction> for the years ended December&#160;31, 2025 and 2024, respectively.</span></div></ix:nonNumeric><div id="ie17ceeaa833a498eadbb73e6ee8311e7_52"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-429" continuedAt="f-429-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7. NOTE PAYABLE</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-63" name="cv:ShortTermDebtOriginationDate" format="ixt:date-monthname-day-year-en" id="f-430">May 27, 2025</ix:nonNumeric>, the Company entered into a promissory note with Ching-Hang Shen, one of the beneficial owners of more than 5% of the Company's outstanding common stock, pursuant to which Mr. Shen provided to the Company a promissory note in a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="INF" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="f-431">1,000</ix:nonFraction> (such note, the &#8220;Investor Loan&#8221;) on May 28, 2025. The Investor Loan (i) had an interest rate equal to one percent (<ix:nonFraction unitRef="number" contextRef="c-63" decimals="INF" name="cv:RelatedPartyTransactionRatePerMonth" scale="-2" id="f-432">1</ix:nonFraction>%) per month, assuming a month of thirty (30) days and (ii) had maturity not later than ten (10) business days following the IPO, which was completed on <ix:nonNumeric contextRef="c-24" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en" id="f-433">July&#160;3, 2025</ix:nonNumeric>. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-64" name="us-gaap:RelatedPartyTransactionDate" format="ixt:date-monthname-day-year-en" id="f-434">July 7, 2025</ix:nonNumeric>, in connection with the repayment of the promissory note, the Company issued to Mr. Shen <ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-435">7,508</ix:nonFraction> shares of common stock at a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="f-436">31</ix:nonFraction> on the date of issuance pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 as a transaction not involving a public offering. The promissory note principal amount of </span></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-429-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:ShortTermNonBankLoansAndNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-437">1,000</ix:nonFraction> and accrued interest were repaid in cash on <ix:nonNumeric contextRef="c-64" name="cv:ShortTermNonBankLoansAndNotesPaymentDate" format="ixt:date-monthname-day-year-en" id="f-438">July 11, 2025</ix:nonNumeric>. After repayment, there were no outstanding liabilities or obligations in connection with the promissory note.</span></div></ix:continuation><div id="ie17ceeaa833a498eadbb73e6ee8311e7_55"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-439" continuedAt="f-439-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8. LEASES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and manufacturing space in California and office space in Taiwan, Republic of China, with remaining lease terms ranging from under <ix:nonNumeric contextRef="c-67" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-440">one year</ix:nonNumeric> to approximately <ix:nonNumeric contextRef="c-68" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-441">two years</ix:nonNumeric> as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not accounted for in the balance sheet; these are limited to minor leases in Taiwan, which are excluded from amounts presented in the following tables. The operating leases include certain variable payments related to operating expenses, which are billed by the landlord, as is customary with these types of charges for office space.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s existing leases contain escalation clauses and renewal options. The Company has evaluated several factors in assessing whether it is reasonably certain that the Company will exercise a contractual renewal option.  For leases with renewal options that are reasonably certain to be exercised, the Company includes the renewal term in the total lease term used in deriving the right-of-use asset and lease liability. The Company&#8217;s main office lease includes a renewal option of <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-442">three years</ix:nonNumeric>, which was excluded after evaluation of those factors.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-443" continuedAt="f-443-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts comprising total lease expense, reflected in general and administrative expenses and costs of revenue (including amounts capitalized as overhead to inventory), were as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-444">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-445">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-446">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-447">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-448">511</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-449">510</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cv:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" id="f-450" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease-related amounts reflected in the balance sheet and data related thereto were as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-451">843</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-452">1,195</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities - current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-453">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-454">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities &#8211; long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-455">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-456">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-457">887</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-458">1,238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-459">2.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-460">3.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-461">11.8</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-462">11.8</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><ix:continuation id="f-443-1"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease payments related to operating leases</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeasePayment" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:VariableLeasePayment" scale="3" id="f-464">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments related to operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-465">474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-466">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-467" escape="true"><ix:continuation id="f-439-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases are as follows as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-468">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-469">503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" scale="3" id="f-470">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="f-471">887</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ie17ceeaa833a498eadbb73e6ee8311e7_58"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-472" continuedAt="f-472-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9. COMMITMENTS AND CONTINGENCIES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, post-acquisition of raw materials, relies significantly upon third-party contract manufacturers located in Taiwan. Management believes that supply risks related to dependence on fewer key suppliers or contract manufacturers, and political risk, can potentially be hedged with the use of more than one supplier and a readiness to quickly adjust the supply chain (and geographic sourcing within Asia).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-69" name="cv:ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate" format="ixt:date-monthname-day-year-en" id="f-473">July&#160;15, 2025</ix:nonNumeric>, the Company entered into a development agreement with Canon Inc., a Japanese corporation, for the development of complementary metal-oxide-semiconductor (&#8220;CMOS&#8221;) image sensor samples to allow the Company to evaluate functionality and performance, conduct clinical evaluation of capsule endoscopies that incorporate Canon image sensors and obtain FDA 510(k) clearance thereof. Under the Agreement, the Company agreed to pay Canon a fee of approximately $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="6" id="f-474">4.1</ix:nonFraction> million for Canon&#8217;s development efforts, which is comprised of (a) an initial fee of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="cv:ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee" scale="6" id="f-475">1.0</ix:nonFraction> million that was paid in cash on <ix:nonNumeric contextRef="c-70" name="cv:ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate" format="ixt:date-monthname-day-year-en" id="f-476">July&#160;31, 2025</ix:nonNumeric> upon the Agreement&#8217;s effectiveness, and (b) following delivery of a specified number of CMOS image sensors meeting agreed specifications within the required timeframe, a remaining development fee of approximately $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="cv:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet" scale="6" id="f-477">3.1</ix:nonFraction> million. Additionally, due to the changes in the development scope by the end of fiscal year 2025, Canon and the Company agreed to increase the development fee by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cv:ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease" scale="6" id="f-478">1.0</ix:nonFraction> million and executed an amendment to the original development agreement in March 2026. For the year ended December 31, 2025 we recognized $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-479"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-480">2.4</ix:nonFraction></ix:nonFraction> million in R&amp;D expenses. The outstanding balance due to Canon was $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-481">1.4</ix:nonFraction> million and included in Accrued Expenses and Other Current Liabilities in the balance sheet as of December 31, 2025. The outstanding purchase commitment for this agreement as of December 31, 2025 is $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="cv:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding" scale="6" id="f-482">2.7</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Receipt of Federal Government Assistance</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, the Company received cash related to refundable payroll tax credits from the U.S. Federal government in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:GovernmentAssistanceOperatingExpense" scale="3" id="f-483">208</ix:nonFraction> reflecting receipt of credit claims related to calendar 2020 and 2021 remitted to the U.S. Internal Revenue Service under the Employee Retention Credit program, a source of COVID-19 pandemic era Federal relief. This amount, due to the uncertainty of eventual receipt following claims made, was not recognized until receipt in the year ended December 31, 2025 and was reflected within <span style="-sec-ix-hidden:f-484">general and administrative expenses</span> given its relationship to payroll taxes reflected as operating expenses. There can be no assurance that the Company&#8217;s program benefit received may not be examined, and if examined, possibly challenged as to a portion or all of the benefit received which, if required to be returned, would have an adverse impact on the Company&#8217;s liquidity.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Litigation and Legal Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may be the subject of adverse litigation as a defendant, arbitration, claims, or proceedings related to things such as intellectual property infringement or disputes, commercial contract breaches or disputes, employment matters, or other matters in the ordinary course of business. Such matters are subject to many uncertainties and outcomes may be unpredictable. Such matters may be fully or partially mitigated by the effect of insurance coverage in place or counter-party indemnitors. The Company provides for liabilities via a charge to operating expenses when it is both probable that a liability has been incurred and the amount of the loss can be </span></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-472-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably estimated. The Company is not a party to any material litigation, arbitration, claims or proceedings and therefore did not have any contingency-related liabilities as of December&#160;31, 2025 and December&#160;31, 2024.</span></div></ix:continuation><div id="ie17ceeaa833a498eadbb73e6ee8311e7_61"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PreferredStockTextBlock" id="f-485" continuedAt="f-485-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10. PREFERRED STOCK</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock &#8211; Financing History</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company has issued several Series of convertible preferred stock to investors (A, B, C, C-1, D, D-1, D-2, E, F-1, F-2, G, G-1, and H) as its primary financing vehicle to fund research and development and commercial stage maturity. For descriptions and discussion of Series preceding Series H, refer to the Capital Stock footnote in the Company's annual financial statements for the year ended December&#160;31, 2024 contained in the prospectus filed on July 3, 2025 with the Securities and Exchange Commission, as part of the Company's Registration Statement (File No. 333-287148).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-486">14,461,804</ix:nonFraction> shares of Series H Preferred Stock (&#8220;Series H&#8221;), par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-487">0.001</ix:nonFraction> per share, for an original issue price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="2" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="f-488">4.83</ix:nonFraction> per share. These shares were issued to various investors in the period of November 2019 to December 31, 2024 pursuant to the original financing round and subsequent extensions thereof, resulting in proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-489">69,829</ix:nonFraction> (net of issuance costs of <ix:nonFraction unitRef="usd" contextRef="c-76" decimals="INF" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt-sec:numwordsen" id="f-490">zero</ix:nonFraction>) as of December 31, 2024. There were <ix:nonFraction unitRef="shares" contextRef="c-77" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="0" id="f-491">no</ix:nonFraction> issuances of Series H in the year ended December&#160;31, 2025.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Company&#8217;s IPO on <ix:nonNumeric contextRef="c-24" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en" id="f-492">July&#160;3, 2025</ix:nonNumeric> and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock on <ix:nonNumeric contextRef="c-31" name="us-gaap:PreferredStockConvertibleConversionDate" format="ixt:date-monthname-day-year-en" id="f-493">July&#160;2, 2025</ix:nonNumeric>, all shares of the Company&#8217;s then-outstanding convertible preferred stock converted into shares of the Company&#8217;s common stock. Under the Company&#8217;s Amended and Restated Certificate of Incorporation, the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-494">none</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-495">153,682,280</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-496"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-497">0.001</ix:nonFraction></ix:nonFraction> par value convertible preferred stock as of December 31, 2025, and December 31, 2024, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:TemporaryEquityTableTextBlock" id="f-498" continuedAt="f-498-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock outstanding as of December 31, 2024 consisted of the following (in thousands, except share amounts.) </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:15.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Series </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-499">17,962,675</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-500">5,394,197</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-501">4,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-502">4,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-503">6,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-504">1,801,802</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-505">4,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-506">4,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-507">5,747,127</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-508">880,187</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-509">2,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-510">2,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-511">3,876,405</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-512">848,599</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-513">2,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-514">2,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-515">2,222,222</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-516">520,519</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-517">1,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-518">1,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-519">6,766,666</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-520">166,833</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="f-521">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="f-522">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D-2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-523">11,083,333</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-524">2,920,649</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-525">17,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-526">8,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-527">14,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-528">4,151,977</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-529">15,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-530">15,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series F-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-531">13,043,479</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-532">1,201,203</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-533">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-534">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series F-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-535">12,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-536">2,498,498</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-537">10,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-538">10,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series G</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-539">5,926,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-540">1,779,559</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-541">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-542">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series G-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-543">6,896,552</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-544">2,039,756</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-545">9,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-546">9,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series H</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-547">48,157,821</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-548">14,461,804</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-549">69,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-550">69,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-551">153,682,280</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-552">38,665,583</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" format="ixt:num-dot-decimal" scale="3" id="f-553">152,378</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-554">143,625</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-498-1">* Liquidation preference includes two times the original issue price per share.</ix:continuation> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Series of preferred stock are collectively referred to as the &#8220;Preferred Stock&#8221;.</span></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-485-1" continuedAt="f-485-2"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock - Conversion Rights</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock shares might be converted into shares of common stock at a ratio determined by dividing the original issuance price by the conversion price (the &#8220;Conversion Rate&#8221;). The conversion price was initially set at the original issuance price and might be adjusted downward, or upward, thereby reciprocally adjusting the Conversion Rate, for capital stock events such as stock splits, stock dividends, reorganizations, or other events where the consideration received relative to the number of shares issued would imperil or dilute holders of Preferred Stock.  Thus, the Conversion Rate was <ix:nonFraction unitRef="number" contextRef="c-90" decimals="INF" name="cv:TemporaryEquityLegacyConversionRatio" scale="0" id="f-555">1</ix:nonFraction>:1 at original issuance. As further described in Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, under the caption "Reverse Stock Split", the Company effectuated a reverse split of its issued and outstanding common stock which resulted in an automatic adjustment (reduction) to the Conversion Rates on all Series of Preferred Stock; there were no adjustments to Conversion Rates on any Series of Preferred Stock since original issuance and prior to the Reverse Stock Split.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock shares converted to shares of common stock (i) electively, upon the receipt by the Company of a written request consented to by holders of at least a majority of the Preferred Stock then outstanding at the effective date specified in the request (provided further that such conversion should not occur for either of Series G-1 and Series H unless a majority of holders within each of those series so consents), or (ii) automatically, upon the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, provided that the offering price per share of common stock is not less than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="cv:TemporaryEquityLegacyConversionPricePerShareMinimum" scale="0" id="f-556">9.66</ix:nonFraction> or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="cv:TemporaryEquityLegacyConversionPricePerShareMaximum" scale="0" id="f-557">9.99</ix:nonFraction>, depending on the Series (as adjusted for recapitalizations) and the aggregate gross proceeds to the Company are $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="INF" name="cv:ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum" scale="6" id="f-558">25</ix:nonFraction>&#160;million or greater. In connection with and prior to the amendment and restatement of the Company's amended and restated certificate of incorporation described in Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, under the caption "Reverse Stock Split", the holders of all Series of the Company's Preferred Stock elected, via written action, to convert all issued and outstanding Preferred Stock to common stock contingent upon the Company completing a planned initial public offering of its common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock - Liquidation Preferences</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidation, for purposes of liquidation preferences that favor holders of Preferred Stock, meant a liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary, an acquisition of the Company by another entity (other than a transaction which does not result in a change in the holders of at least 50% of voting stock outstanding before and after the transaction), or the sale, lease, exclusive license, or conveyance of all or substantially all of the Company&#8217;s assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liquidation preference for each series of Preferred Stock was the sum of (i) the original issuance price per share (as adjusted for recapitalizations) &#8211; that is, one times the original issue price, and (ii) all declared but unpaid dividends, with the exception of Series D-2, where the liquidation preference includes two times the original issue price per share.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidation preferences were rank-ordered by priority group - first: Series E, F-1, F-2, G, G-1 and H; second: Series D-2; third: Series D and D-1; fourth and last: Series A, B, C, and C-1.  Should distributable assets upon liquidation be insufficient to satisfy respective liquidation preferences within a priority group, the distributable assets were to be distributed to the stockholders within the priority group pro rata and in relationship to the proportion of available distributable assets to the full liquidation preferences that would otherwise be due. When distributable assets were sufficient for a priority group, the remaining distributable assets cascaded to the next priority group, and so on and so forth in descending order of priority group. Should remaining distributable assets exist, after satisfying the liquidation preferences of all Preferred Stock, such remainder were distributable to the holders of the Preferred Stock and common stock in proportion to the number of shares of common stock held by them on a combined basis, with the shares of Preferred Stock being treated as if converted.&#160;</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-485-2"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock &#8211; Dividends</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding shares of Preferred Stock were entitled to receive dividends, when, as and if declared by the Board of Directors at a dividend rate of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="cv:TemporaryEquityDividendRatePercentage" scale="-2" id="f-559">8.00</ix:nonFraction>% payable in preference and priority to any declaration or payment of any distribution related to common stock.  The dividends were not cumulative and Preferred Stockholders did not acquire rights to dividends because they were not declared or paid in any given year. The Company has never declared or paid any dividends.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock - Voting Rights</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Preferred Stock had the same voting rights as the holders of common stock, on an&#160;as-converted&#160;basis at the then-prevailing Conversion Rate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Board of Directors of the Company comprised <ix:nonFraction unitRef="member" contextRef="c-5" decimals="INF" name="cv:NumberOfBoardMembers" format="ixt-sec:numwordsen" scale="0" id="f-560">eight</ix:nonFraction> members. Each holder of convertible preferred stock was entitled to the number of votes equal to the number of common stock shares into which the referred shares held by such holder converted. The holders of a majority of the voting shares were able to elect all of the directors.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock - Protective Provisions</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As long as any Preferred Stock was issued and outstanding, the Company should not, without first obtaining the approval (by vote or written consent) of the holders of a majority of outstanding shares of Preferred Stock, voting together as a single class:</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amend, alter or repeal any provision of the certificate of incorporation or bylaws (including pursuant to a merger) if such action would adversely affect the Preferred Stock;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increase or decrease the authorized number of shares of Preferred Stock (including any series thereof) or common stock;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Authorize or create any new class or series of shares having rights, preferences or privileges senior to or on parity with any series of Preferred Stock;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Voluntarily liquidate or dissolve, or enter into any transaction or series of related transactions deemed to be a liquidation, dissolution or any disposition of the Company&#8217;s property;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Effect a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enter into any transaction (other than customary service or employment agreements) with any officer or director of the Company, or any party related thereto or affiliated therewith, unless approved by a majority of the Board of Directors;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issue any indebtedness that is convertible into any equity security, or incur any other indebtedness other than loans, leases and similar transactions in the ordinary course of business; and</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Redeem, repurchase or otherwise acquire any shares of Preferred Stock or common stock, except for the repurchase of shares of common stock from employees, officers, directors, consultants or other persons performing services pursuant to agreements granting the Company option or repurchase rights upon the occurrence of certain events.</span></div></ix:continuation><div id="ie17ceeaa833a498eadbb73e6ee8311e7_64"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11. COMMON STOCK</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically and prior to the IPO, the Company had several Series of Preferred stock (A, B, C, C-1, D, D-1, D-2, E, F-1, F-2, G, G-1, and H) issued to investors as its primary financing vehicle to fund research and development and commercial stage maturity. For detailed information of the Company&#8217;s Preferred stock, please see Note 10. PREFERRED STOCK. Immediately prior to the closing of the Company&#8217;s IPO on <ix:nonNumeric contextRef="c-24" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en" id="f-561">July&#160;3, 2025</ix:nonNumeric> and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock on <ix:nonNumeric contextRef="c-31" name="us-gaap:PreferredStockConvertibleConversionDate" format="ixt:date-monthname-day-year-en" id="f-562">July&#160;2, 2025</ix:nonNumeric>, all shares of the Company&#8217;s then-outstanding convertible preferred stock converted into shares of the Company&#8217;s common stock. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-24" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en" id="f-563">July&#160;3, 2025</ix:nonNumeric>, the Company completed its IPO of <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-564">5,500,000</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-565">5.00</ix:nonFraction> per share. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted to the IPO underwriters an overallotment option (the &#8220;Over-Allotment Option&#8221;) to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-566">825,000</ix:nonFraction> shares of Common Stock, which is equal to 15% of the number of shares of Common Stock sold in the Public Offering. Under the Over-Allotment Option the underwriters had the right to exercise this option, in whole or in part, for our common stock, any time during the 30-day period from the date of the closing of the IPO. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-26" name="cv:SaleOfStockEffectivenessDate" format="ixt:date-monthname-day-year-en" id="f-567">July 18, 2025</ix:nonNumeric>, a total of <ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-568">129,978</ix:nonFraction> shares of common stock were issued in connection with the partial exercise by the IPO underwriters of their Over-Allotment Option at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-569">5.00</ix:nonFraction> per share.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO share issuances, the Company issued to the IPO underwriters warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-570">168,898</ix:nonFraction> shares of Common Stock (including <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-571">3,898</ix:nonFraction> shares of Common Stock issued in connection with the Over-allotment Exercise (the "Over-allotment Exercise Underwriters' Warrants"), collectively referred to as the &#8220;Underwriters' Warrants&#8221;. The Underwriters' Warrants are exercisable at a per share exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-95" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-572">6.25</ix:nonFraction> and are exercisable at any time and from time to time, in whole or in part, for a term of <ix:nonNumeric contextRef="c-95" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-573">five years</ix:nonNumeric> commencing <ix:nonNumeric contextRef="c-29" name="cv:ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights" id="f-574">from the first day of the seventh month after <ix:nonNumeric contextRef="c-24" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en" id="f-575">July 3, 2025</ix:nonNumeric> (the &#8220;Original Closing Date&#8221;)</ix:nonNumeric>, and terminating on <ix:nonNumeric contextRef="c-95" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en" id="f-576">July 1, 2030</ix:nonNumeric>. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Underwriters&#8217; Warrants were outstanding as of December 31, 2025. The warrants were classified as equity and the fair value of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-577">519</ix:nonFraction> is reflected as additional paid-in capital. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-578" continuedAt="f-578-1" escape="true">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-578-1" continuedAt="f-578-2"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Placement Underwriters' Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over-allotment exercise Underwriters' Warrants</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-579">3.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-580">3.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-96" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-581">5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-97" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-582">4.96</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-583">78.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-584">78.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the underlying common stock for the valuation of the Initial Placement Underwriters' Warrants was equal to the IPO price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-587">5.00</ix:nonFraction> per share as of <ix:nonNumeric contextRef="c-98" name="cv:SaleOfStockEffectivenessDate" format="ixt:date-monthname-day-year-en" id="f-588">July 1, 2025</ix:nonNumeric>, when the Company&#8217;s registration statement related to the IPO was declared effective. The fair value of the underlying common stock for the valuation of the Over-allotment exercise Underwriters' Warrants is based on the Company&#8217;s closing stock price on July 18, 2025.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company&#8217;s certificate of incorporation, as amended and restated, for its $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-589"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-590">0.001</ix:nonFraction></ix:nonFraction> par value common stock, the Company had <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-591">300,000,000</ix:nonFraction> authorized shares at December&#160;31, 2025 and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-592">190,000,000</ix:nonFraction> authorized shares at December&#160;31, 2024, and had <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-593"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-594">46,865,051</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-595"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-596">2,090,945</ix:nonFraction></ix:nonFraction> issued and outstanding shares, as of December&#160;31, 2025 and December&#160;31, 2024, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authorized common stock was reserved for future issuance as follows, including pursuant to outstanding equity awards and future equity awards under the 2005 Plan and the 2025 Plan.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-597" escape="true"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="f-598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-599">38,665,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercises of stock options under 2005 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-600">1,627,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-601">2,298,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercises of stock options under 2025 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-602">348,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:fixed-zero" scale="3" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-604">168,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-605">15,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserved for future grants under 2005 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="f-606">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-607">880,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserved for future grants under 2025 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-608">3,838,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total reserved shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-610">5,982,877</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-611">41,859,552</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div id="ie17ceeaa833a498eadbb73e6ee8311e7_67"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-612" continuedAt="f-612-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12. STOCK-BASED COMPENSATION</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Stock Plan</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Plan, which was adopted by the Company's Board of Directors in May 2025 and approved by the Company's stockholders in June 2025, became effective upon the consummation of the IPO. Upon the effectiveness of the 2025 Plan, the 2005 Plan was terminated and no further grants may be made under the 2005 Plan. The Company's 2025 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors of the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-613">4,204,204</ix:nonFraction> shares of the Company&#8217;s common stock were initially authorized for issuance with respect to awards granted under the 2025 Plan. Shares subject to outstanding awards granted under the 2005 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated will be available for award grants under the 2025 Plan. In addition, the share limit will automatically increase on the first trading day in January of each year (commencing with 2026) by an amount equal to (1) 4% of the total number of shares of our common stock that are issued and outstanding on the last trading day in December in the prior year, or (2) lesser number as determined by the Company&#8217;s Board of Directors. Any shares subject to awards granted under the 2025 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, fail to vest, as well as shares used to pay the purchase or exercise price of awards or related tax withholding obligations, will become available for new award grants under the 2025 Plan. As of December 31, 2025, a total of <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-614">3,838,331</ix:nonFraction> shares is available for award purposes under the 2025 Plan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amended and Restated 2005 Stock Plan</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2005 Plan, the Company granted equity-based incentive awards prior to the IPO to the Company&#8217;s employees, directors, and consultants.&#160; The 2005 Plan permitted the grant of stock options (either Incentive Stock Options (&#8220;ISO&#8221; &#8211; employees only) or&#160;Non-Qualified&#160;Stock Options (&#8220;NQSO&#8221;)) and restricted stock awards (&#8220;RSA&#8221;); only ISOs and NQSOs were outstanding during the periods presented. Under the 2005 Plan, <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-615">880,007</ix:nonFraction> shares of common stock were reserved for issuance at December&#160;31, 2024. Upon the effectiveness of the 2025 Plan, the 2005 Plan was terminated and no new awards were granted under the 2005 Plan after the IPO, and there were <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="f-616">no</ix:nonFraction> shares of common stock available for new award grants as of December&#160;31, 2025 under the 2005 Plan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and&#160;non-employees contain only service vesting conditions, with typical grants vesting over a <ix:nonNumeric contextRef="c-112" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-617">four-years</ix:nonNumeric> period <ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="f-618" continuedAt="f-618-1">(vesting 25% on the first anniversary of the award and 1/48</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="f-618-1" continuedAt="f-618-2">th</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-618-2"> each month thereafter) but may be granted with different vesting profiles, including options that are vested-at-grant (immediate vesting) and that are subject to different vesting schedules.</ix:continuation> Options granted to employees and&#160;non-employees&#160;expire no more than <ix:nonNumeric contextRef="c-112" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-619">10</ix:nonNumeric> years from the date of grant.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, outside of the 2005 Plan, previously issued an insignificant number of warrants to purchase its common stock; of these, all have expired or been exercised with <ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-620">no</ix:nonFraction> shares remaining outstanding at December&#160;31, 2025 and <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-621">15,015</ix:nonFraction> warranted common shares remaining outstanding at December&#160;31, 2024. Being </span></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-612-1" continuedAt="f-612-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside of the 2005 Plan, they are excluded from the stock option award activity and stock-based compensation presentations which follow. The Company previously recognized immaterial warrant-related expense.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Option Modification</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective August 27, 2025, the Company's Chief Financial Officer (the "Former Executive") stepped down from his position with the Company. As part of the termination of employment of the Former Executive, there were certain supplementary modifications to the Former Executive's non-vested stock option awards including acceleration of some non-vested shares and extension of their post-termination exercise period, and voluntary forfeiture of the remaining non-vested stock option awards. During the year ended December&#160;31, 2025, the Company recorded a one-time, noncash incremental stock-based compensation expense net of required reversal of previously recognized compensation in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="3" id="f-622">159</ix:nonFraction> related to these stock option award modifications which was included in General and administrative expenses in the condensed statement of operations. The Company accounted for the resulting net incremental stock option award modification compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Options&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-623" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the year ended December&#160;31, 2025 was as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options on Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding (vested and expected to vest) as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-624">2,298,905</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-625">0.47</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-626">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-627">4,961</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-628">534,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-629">5.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-630">438,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-631">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-632">4,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited, canceled, or expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-633">419,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-634">0.66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding (vested and expected to vest) as of December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-635">1,975,648</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-636">1.74</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-637">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-638">17,869</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-639">880,289</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-640">0.46</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-641">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-642">9,005</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values are calculated as the differences between the exercise prices of the underlying options and the fair value of the Company&#8217;s common stock for options that were in the money. The Company had <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-643">1,095,359</ix:nonFraction> unvested stock options outstanding as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, unrecognized compensation cost of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-644">2,734</ix:nonFraction> related to outstanding unvested stock options is expected to be recognized as expense over a weighted average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-645">1.8</ix:nonNumeric> years.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the years ended December&#160;31, 2025 and 2024, was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-646">3.70</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-647">1.83</ix:nonFraction> per share, respectively. The total fair value of options vested were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="f-648">798</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="f-649">72</ix:nonFraction> during the years ended December&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2025 and 2024, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-650">438,808</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-651">253,909</ix:nonFraction> stock options were exercised and satisfied with newly-issued shares, resulting in cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-652">158</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-653">75</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-612-2"><ix:continuation id="f-578-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Black-Scholes option pricing model weighted-average assumptions.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-654">3.81</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-655">4.30</ix:nonFraction> %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-656">6.05</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-657">6.05</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-658">79.6</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-659">73.4</ix:nonFraction> %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-660">&#8212;</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-661">&#8212;</ix:nonFraction> %</span></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating the fair value of the underlying common stock prior to IPO, the Company utilized a third party valuation firm whose analyses supported management's concluded estimate. Post IPO the fair value of the underlying common stock is based on the Company&#8217;s closing stock price on the date of grant.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2025 the Company granted a total of <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-662">17,322</ix:nonFraction> restricted stock units (RSUs) to its six non-employee directors utilizing a fair market value (FMV) of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-663">4.33</ix:nonFraction> per share of the Company's common stock on the grant date. These RSUs vested on December&#160;31, 2025. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="f-664" escape="true"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.139%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value per Share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-666">17,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-667">4.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-668">17,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-670">75</ix:nonFraction> in stock-based compensation related to RSUs. The total fair value of RSUs vested during the year ended December&#160;31, 2025 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="f-671">185</ix:nonFraction>.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation, measured at the grant date, is recognized ratably over the requisite service period, using the straight-line method of expense attribution. Forfeitures are accounted for as a reduction in expense in the period in which they occur; no compensation cost is recorded for awards that do not vest. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-672" continuedAt="f-672-1" escape="true">The Company recognized total stock-based compensation expense for employees and non-employees as components of the statement of operations and comprehensive loss as follows.</ix:nonNumeric></span></div><ix:continuation id="f-672-1"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-673">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-674">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-675">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-676">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-677">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-678">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-679">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-680">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-681">826</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-682">156</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></td></tr></table></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-683" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13. SEGMENTS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-684"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="f-685">one</ix:nonFraction></ix:nonFraction> operating (and reportable) segment known as the Capsule Endoscopy Segment; its chief operating decision maker is its Chief Executive Officer.  The composition of this segment reflects the Company&#8217;s focus on capsule endoscope medical devices addressing different areas within the GI tract. Refer to Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES and Note 6. REVENUE AND DEFERRED REVENUE for descriptions of products and services.  Segment accounting policies are the same as those described therein.  The chief operating decision maker assesses performance for the Capsule Endoscopy Segment and decides how to allocate resources based upon net income (loss) as reported in the statement of operations and comprehensive loss; also considered is operating income (loss), measured on the same basis as in the statement of operations and comprehensive loss. Net income (loss) and operating income (loss) are used in the process of evaluating expenses and determining where to prioritize resources.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment assets are identical to those reported in the balance sheet as total assets.  Segment revenue is identical to that reported in the statement of operations and comprehensive loss; significant segment expenses are identical to those identified in the statement of operations and comprehensive loss under the line items for selling and marketing expenses, research and development expenses, and general and administrative expenses.  Other segment items are represented by non-operating income (expense), net (which includes insignificant interest income) and the provision for income taxes as reported in the statement of operations and comprehensive loss.  Segment depreciation expense and capital expenditures are identical to amounts in the statement of cash flows.</span></div></ix:nonNumeric><div id="ie17ceeaa833a498eadbb73e6ee8311e7_208"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-686" continuedAt="f-686-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14. INCOME TAXES</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-687" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of loss before income taxes are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-688">24,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-689">19,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-690">867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-691">667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-692">25,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-693">19,887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-694" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax provision are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-697">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-698">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-699">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-700">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current provision</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-701">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-702">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-709">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-710">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total income tax provision</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-711">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-712">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-686-1" continuedAt="f-686-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-713" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2025 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:58.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.752%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-714">5,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-715">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax, net of federal taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-716">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-717">0.04</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Taiwan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Local income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-718">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-719">0.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of changes in tax laws or rates enacted in the current period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="3" id="f-720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="3" id="f-722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="-2" id="f-723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-724">5,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-725">20.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nontaxable or nondeductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="f-726">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-727">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Adjustments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-728">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total effective tax rate</span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-730">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-731">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2024 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-732">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent book-tax differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-733">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-734">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and State research and development tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-735">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-736">23.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-737">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total effective tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-738">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="f-739" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of cash paid for income taxes by the Company are as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-740">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-2" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-741">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-2" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-742">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-2" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-743">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash paid for income taxes (net of refunds)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-744">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill was enacted (&#8220;OBBBA&#8221;), introducing significant and wide-ranging changes to the U.S. federal tax system. Significant components include restoration of 100% accelerated tax depreciation on qualifying property including expansion to cover qualified production property.&#160;&#160; Another major aspect includes the return to immediate expensing of domestic research and experimental expenditures (&#8220;R&amp;E&#8221;) which in some cases may include retroactive application back to 2021 for businesses with gross receipts of less than $31 million or accelerated tax deductions of R&amp;E that was previously capitalized for larger businesses.&#160; The </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-686-2" continuedAt="f-686-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legislation also reinstates EBITDA-based interest deductions for tax purposes and makes several business tax incentives permanent.&#160; Less favorable business provisions include limitations on tax deductions for charitable contributions. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are accounted for using the asset and liability method, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-745" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main components of deferred tax assets (liabilities) are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-746">32,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-747">26,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cv:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-748">5,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="cv:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-749">5,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-750">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-751">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="f-752">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="f-753">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cv:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="f-754">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="cv:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="f-755">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-756">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-757">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-758">39,670</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-759">33,830</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-760">39,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-761">33,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-762">375</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-763">446</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-764">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-765">151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="f-766">202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="f-767">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains/losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" scale="3" id="f-768">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" format="ixt:fixed-zero" scale="3" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="f-770">375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="f-771">446</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-772">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-773">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Valuation Allowance Considerations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance against a deferred tax asset must be established when it is &#8220;more likely than not&#8221; that all, or a portion of, deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. After consideration of all the information available, in particular the Company&#8217;s accumulated deficit and history of operating losses, it was concluded that uncertainty exists with respect to future realization of deferred tax assets. The valuation allowance increased during the years ended December 31, 2025 and December 31, 2024 in the amounts of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-774">5,912</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-775">4,700</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Operating Losses and Tax Credit Carryforwards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has experienced and generated net operating losses (&#8220;NOLs&#8221;) for tax purposes since inception. As of December 31, 2025 (December 31, 2024), total available gross (pre-tax) Federal and U.S. state NOL carryforward amounts were $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-776">126,094</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-777">93,244</ix:nonFraction> ($<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-778">100,304</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-779">79,481</ix:nonFraction>), respectively. Under the Federal Tax Cuts and Jobs Act of 2017, NOLs incurred in tax years beginning on or after January 1, 2018, are carried forward&#160;indefinitely and subject to a usage limitation of 80% of taxable income; NOLs incurred in tax years prior to January 1, 2018, are subject to a twenty-year carryforward before expiring and not subject to a usage limitation of taxable income. As of December 31, 2025 (December 31, 2024), total Federal and U.S. state research and development tax credit carryforward amounts, net of unrecognized tax benefits, were <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-780">1,318</ix:nonFraction> (<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-781">1,318</ix:nonFraction>), respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-686-3" continuedAt="f-686-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock" id="f-783" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="f-782" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs and tax credit carryforward values are as follows as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Operating Losses (gross; pre-tax)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; Federal (arising after December 31, 2017)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-784">77,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-135" name="cv:OperatingLossCarryforwardsExpirationTerm" id="f-785">No expiry</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; Federal (arising before January 1, 2018)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-786">48,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-137" name="cv:OperatingLossCarryforwardsExpirationTerm" id="f-787">2027</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; State - indefinite</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-788">3,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-139" name="cv:OperatingLossCarryforwardsExpirationTerm" id="f-789">No expiry</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; State &#8211; definite lived</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-790">89,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-141" name="cv:OperatingLossCarryforwardsExpirationTerm" id="f-791">2028</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Tax Credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credits &#8211; Federal and State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-792">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="cv:TaxCreditCarryforwardExpirationTerm" id="f-793">2033</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 as amended (&#8220;Section 382&#8221;), or, for states, state laws, due to ownership changes that have occurred previously or that could occur in the future.  These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.  The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception.  If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382. Any limitation may result in expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 174 Capitalization</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBBBA made changes to Section 174 of the Internal Revenue Code of 1986 as amended for taxable years beginning December 31, 2024 with the Company being able to deduct domestic research and experimental (R&amp;E) expenditures in the year they are incurred when before these costs were capitalized and amortized over 5 years. The Company is still required to capitalize foreign R&amp;E costs and amortize them over 15 years. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the tax year ended December 31, 2025 the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-794">3,545</ix:nonFraction> of foreign R&amp;D expenses which were capitalized and are being amortized over the respective period noted above. For the tax year ended December 31, 2024 the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-795">13,910</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-796">1,116</ix:nonFraction> of domestic and foreign R&amp;D expenses, respectively, which were capitalized and are being amortized over the respective periods noted above. These amounts are reflected in gross deferred tax assets (together with previous periods&#8217; amounts, net of amounts amortized for tax purposes).</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-686-4"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-797" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balance of total unrecognized tax benefits on a tax-effected basis for follows; these relate principally to research and development credit carryforwards.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized tax benefits, December 31, 2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-798">1,634</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for current tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-799">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes for previous tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-800">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized tax benefits, December 31, 2024</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-801">1,472</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for current tax positions</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-802">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes for previous tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-803">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized tax benefits, December 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-804">1,484</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet conducted a study of its research and development credit carryforwards. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, the tax assets associated with the research and development credit carryforwards have been fully offset with a reserve.  A full valuation allowance has been provided against the Company&#8217;s net deferred tax assets, and if an adjustment to the net unrecognized tax benefits were to occur, this adjustment would be offset by an equal adjustment to the valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recognized no interest and penalties associated with substantially all of its unrecognized tax benefits. There are no tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. Federal and State income tax returns in jurisdictions with varying statutes of limitations.  In the normal course of business, the Company is subject to examination by taxing authorities throughout the U.S.  These examinations could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with laws.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s remaining open tax years subject to examination by federal and state tax authorities include the years ended December&#160;31, 2019, through 2025 in the U.S and December 31, 2020 through 2025 in the Company&#8217;s foreign operations. However, for tax years from inception through the present, federal and state taxing authorities may examine and adjust loss carryforwards in the years in which those loss carryforwards are ultimately utilized.  There are currently no pending income tax examinations.</span></div></ix:continuation><div id="ie17ceeaa833a498eadbb73e6ee8311e7_76"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-805" continuedAt="f-805-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15. NET LOSS PER SHARE</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-806" escape="true"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss &#8211; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-807"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-808">25,315</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-809"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-810">19,898</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares of common stock outstanding &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-811"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-812">24,555,381</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-813"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-814">2,020,077</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share &#8211; basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-815"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-816">1.03</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-817"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-818">9.85</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is the same as diluted net loss per share as the inclusion of potential common shares outstanding would have been anti-dilutive. The Company's convertible preferred stock Series constitute </span></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-805-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participating securities; however, as a result of the net loss position, they are excluded from the calculation of basic net loss per share.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-819" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the preceding calculations because they would be anti-dilutive were as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 10pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock (all series)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-145" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-820">19,279,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-146" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-821">38,665,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants on common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-147" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-822">90,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-823">15,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options on common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-824">2,027,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-825">2,298,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-151" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-826">5,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-152" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-828">21,403,135</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-829">40,979,545</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie17ceeaa833a498eadbb73e6ee8311e7_79"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-830" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16. RELATED PARTIES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, the Company's material transactions with related parties were limited to a promissory note described in Note 7. NOTE PAYABLE and certain R&amp;D expenses ($<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-831">1,207</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="3" id="f-832">320</ix:nonFraction> for the years ended December&#160;31, 2025 and December&#160;31, 2024, respectively) for non-recurring engineering services with an R&amp;D and manufacturing services vendor that holds an insignificant percentage of the Company's capital stock. There were no other material transactions with related parties during the years ended December&#160;31, 2025 and December&#160;31, 2024 and no amounts due from or to related parties at December&#160;31, 2025 or December&#160;31, 2024.</span></div></ix:nonNumeric><div id="ie17ceeaa833a498eadbb73e6ee8311e7_82"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-833" continuedAt="f-833-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">17. SUBSEQUENT EVENTS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-153" name="us-gaap:SubsequentEventsDate" format="ixt:date-monthname-day-year-en" id="f-834">February 12, 2026</ix:nonNumeric> the Company signed a consulting agreement with Wen-Hung Tsai, one of the Company's shareholders and a former member of the Company's Board of Directors (till February 26, 2024). <ix:nonNumeric contextRef="c-154" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="f-835">Per the consulting agreement Mr.Wen-Hung Tsai will provide strategic advice, help with industrial affiliation and partnerships, as well as work on the supply chain establishment for new products. As compensation for his services, the Company granted to Mr.Wen-Hung Tsai on February 12, 2026 an option to purchase <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-836">250,000</ix:nonFraction> shares of the Company's Common Stock under the Company&#8217;s 2025 Equity Incentive Plan. Eighty percent (<ix:nonFraction unitRef="number" contextRef="c-154" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-837">80</ix:nonFraction>%) of the option grant is scheduled to vest and become exercisable on February 12, 2027. The remaining portion of the option grant is scheduled to vest and become exercisable in three (<ix:nonFraction unitRef="monthly_installment" contextRef="c-154" decimals="INF" name="cv:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments" scale="0" id="f-838">3</ix:nonFraction>) equal monthly installments on the same day of each successful calendar month following February 12, 2027.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-156" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en" id="f-839">March 16, 2026</ix:nonNumeric>, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with selected accredited investors (the &#8220;Investors&#8221;), for the purposes of raising approximately $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-840">14</ix:nonFraction> million in aggregate gross proceeds for the Company (the &#8220;Private Placement&#8221;). Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to the Investors in the Private Placement an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" id="f-841">2,867,089</ix:nonFraction> shares (the &#8220;Shares&#8221;) of common stock of the Company, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-842">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="3" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" id="f-843">4.883</ix:nonFraction> per Share. The closing of the Private Placement occurred on <ix:nonNumeric contextRef="c-156" name="cv:SaleOfStockEffectivenessDate" format="ixt:date-monthname-day-year-en" id="f-844">March 16, 2026</ix:nonNumeric>. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Private Placement, the Company entered into a registration rights agreement, dated <ix:nonNumeric contextRef="c-156" name="cv:SaleOfStockRegistrationRightsAgreementDate" format="ixt:date-monthname-day-year-en" id="f-845">March 16, 2026</ix:nonNumeric> (the &#8220;Registration Rights Agreement&#8221;), with the Investors, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the &#8220;SEC&#8221;) a registration statement to register for resale the Shares within 90 days after the closing of the Private Placement, and (ii) use commercially reasonable efforts to have such registration statement declared effective as soon as reasonably </span></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="f-833-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">practicable following the filing thereof with the SEC. The Registration Rights Agreement contains customary terms and conditions for a transaction of this type.</span></div></ix:continuation><div id="ie17ceeaa833a498eadbb73e6ee8311e7_211"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_549755815472"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for maintaining disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our management&#8217;s evaluation (with the participation of our Chief Executive Officer and our principal financial officer) of our disclosure controls and procedures as required by Rule 13a-15 under the Exchange Act and the material weaknesses previously identified and further discussed below, our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures were not effective at the reasonable level of assurance as of December&#160;31, 2025, the end of the period covered by this Annual Report. Please see below for the disclosure of the Company's material weaknesses in internal control and the remediation plan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Weaknesses in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our IPO, we have been a private company with limited accounting and financial reporting personnel and other resources to address our internal controls and procedures. We identified two material weaknesses in our financial reporting process as of December 31, 2024, which have not been fully remediated during the fiscal year ended December 31, 2025. The first material weakness relates to our failure to design or maintain sufficient controls over implementation of information technology general controls or complementary user entity controls for applications (such as our enterprise resource planning system ("ERP"), payroll, and stock option management IT systems) used in the preparation of our financial statements. More specifically, we did not design or maintain sufficient controls related to user access provisioning and monitoring, change management, program development and data management. The second material weakness relates to a lack of segregation of duties in the financial reporting function due to a limited number of staff performing the financial reporting function. More specifically, there is a limited level of multiple reviews among those tasked with preparing our financial records and with respect to our existing ERP system proper segregation of duties was not enforced (i.e., for journal entries, we did not always divide responsibilities with one person responsible for making the journal entry and a different person responsible for approving the journal entry).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remediation Plan for the Material Weaknesses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To remediate the material weaknesses described above and prevent similar deficiencies in the future, we have devoted, and plan to continue to devote, significant effort and resources to the remediation and improvement of our internal control over financial reporting. For example, in addition to hiring a Corporate Controller in the three months ended March 31, 2025, we are also evaluating the current and future accounting and financial reporting personnel to ensure proper segregation of duties. We decided to replace  our existing ERP system which would help address many of the control issues contributing to these material weaknesses. We formalized IT controls, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:5.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entity level controls and business process controls and established an Internal Controls over Financial Reporting ("ICFR") program, covering planning, risk assessment, scoping and testing that we implemented during the quarter ended September 30, 2025 with regular status updates to the Audit Committee. In the quarter ended December&#160;31, 2025, we started the implementation of a new ERP system.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have begun the implementation of these remediation efforts, the material weaknesses will not be considered fully remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. Any actions we have taken or may take to remediate these deficiencies are subject to continued management review supported by testing, as well as oversight by the Audit Committee of our board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these measures will assist us with meeting the Sarbanes-Oxley Act compliance requirements and improving our overall internal controls. However, we cannot assure you that these measures may fully address the material weaknesses in our internal control over financial reporting or that we may conclude that they have been fully remediated.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that the measures we have taken to date, and are continuing to implement, will be sufficient to remediate the material weaknesses we have identified or avoid potential future material weaknesses. If the steps we take do not correct the material weaknesses in a timely manner, we will be unable to conclude that we maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our consolidated financial statements would not be prevented or detected on a timely basis. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the remediation measures in connection with the material weaknesses described above, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act during the quarter ended December&#160;31, 2025 covered by this Annual Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include a report of management's assessment regarding internal control over financial reporting or an attestation report of the company's registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_217"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trading arrangements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended December 31, 2025, no director or officer <ix:nonNumeric contextRef="c-41" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-846"><ix:nonNumeric contextRef="c-41" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-847">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-41" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-848"><ix:nonNumeric contextRef="c-41" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-849">terminated</ix:nonNumeric></ix:nonNumeric> any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_220"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_223"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_226"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late August 2025, Kevin Lundquist stepped down as Chief Financial Officer of the Company. The responsibilities of principal financial officer and principal accounting officer were assumed by David Garcia, Senior VP of Finance who joined the Company on November 3, 2025. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2025, Rebecca Petersen, the Company&#8217;s Senior Director of Clinical Affairs, notified the Company of her planned retirement effective on October 15, 2025. Concurrently, the Company promoted Keri Jorgenson to Director of Clinical Operations and, Ms. Jorgenson, together with the other members of the clinical operations team, assumed responsibility for the Company&#8217;s clinical development operations and activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-850">adopted</ix:nonNumeric> a Code of Ethics and Business Conduct that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. A current copy of the code is posted on the Investor Relations - Governance - Documents &amp; Charters section of our website, which is located at www.capsovision.com. If the Company ever were to amend or waive any provision of its code of business conduct and ethics that applies to the Company&#8217;s principal executive officer, principal financial officer, principal accounting officer or any person performing similar functions, the Company intends to satisfy its disclosure obligations, if any, with respect to any such waiver or amendment by posting such information on its website set forth above rather than by filing a Current Report on Form 8-K. In the case of a waiver for an executive officer or a director, the disclosure required under applicable Nasdaq listing standards also will be made available on our website.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted insider trading policies and procedures governing the purchase, sale, and other dispositions of our securities by directors, officers, and employees that are designed to promote compliance with insider trading laws, rules, and regulations, and applicable Nasdaq listing standards, as well as procedures designed to further the foregoing purposes. A copy of our insider trading policy is filed with this Annual Report as Exhibit 19.1.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining information required by this Item will be set forth in the sections headed &#8220;Nominees for Election to the Board of Directors&#8221; and &#8220;The Board of Directors and Certain Governance Matters&#8221; in the Proxy Statement to be filed with the SEC within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_229"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be set forth in the section headed &#8220;Executive Compensation&#8221; in the Proxy Statement to be filed with the SEC within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_232"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owner and Management and Related Stockholder Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be set forth in the section headed &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in the Proxy Statement to be filed with the SEC within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_235"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be set forth in the section headed &#8220;Certain Relationships and Related Person Transactions&#8221; in the Proxy Statement to be filed with the SEC within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_238"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be set forth in the section headed &#8220;Principal Accountant Fees and Services&#8221; in the Proxy Statement to be filed with the SEC within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_241"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_244"></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this Annual Report:</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Financial Statements. See Index to Financial Statements included in the financial statements in this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Financial Statement Schedules. All financial statement schedules are omitted because they are not applicable or required, or the information required to be set forth therein is included in the financial statements or notes thereto included in the Index to Financial Statements of this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Exhibits. The exhibits required to be filed as part of this Annual Report are listed in the Exhibit List attached hereto and are incorporated herein by reference.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit <br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000119312525155527/d55184dex31.htm">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on July 3, 2025 (File No. 001-42705)).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000119312525155527/d55184dex32.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K filed on July 3, 2025 (File No. 001-42705)).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000119312525140836/d916440dex41.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 2 to the Registrant&#8217;s Registration Statement (File No. 333-287148), filed on June 13, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000119312525116894/d916440dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, dated November  21, 2019 (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed on July 3, 2025 (File No. 001-42705)).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000119312525149285/d916440dex43.htm">Form of Representative&#8217;s Warrant (incorporated by reference to Exhibit 4.3 to Amendment No. 3 to the Registrant&#8217;s Registration Statement (File No. 333-287148), filed on June 27, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.01#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000119312525116894/d916440dex1007.htm">2005 Stock Incentive Plan (incorporated by reference to Exhibit 10.07 to the Registrant&#8217;s Registration Statement (File No. 333-287148), filed on May 9, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.02#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000119312525116894/d916440dex1008.htm">Form Agreements under 2005 Stock Incentive Plan (incorporated by reference to Exhibit 10.08 to the Registrant&#8217;s Registration Statement (File No. 333-287148), filed on May 9, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.03#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000119312525149285/d916440dex1009.htm">2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.09 to Amendment No. 3 to the Registrant&#8217;s Registration Statement (File No. 333-287148), filed on June 27, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.04#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">Form of Stock Option Grant Agreement pursuant to 2025 Equity Incentive Plan</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">incorporated by reference to Exhibit 10.0</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">8</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm"> to</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm"> the Registrant&#8217;s </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">Quarterly Report on Form 10-Q</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm"> (File No. </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">001-</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">42705</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">)</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm"> filed on </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">November</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm"> </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">13</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1008.htm">, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.05#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoVision, Inc Director Compensation Policy (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1006.htm">incorporated by reference to Exhibit 10.0</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1006.htm">6</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1006.htm"> to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-42705) filed on November 13, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.06#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form of Director Restricted Stock Unit Award Agreement (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1007.htm">incorporated by reference to Exhibit 10.0</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1007.htm">7</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832525000040/cv-20251113xex1007.htm"> to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-42705) filed on November 13, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.07#&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex107.htm">F</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex107.htm">orm of Indemnification Agreement for Directors and Officers (amended on December 22, 2025)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.08*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832526000002/cv-20260313xex101.htm">Amendment to Sample Purchase Agreement, dated March 9, 2026, by and between the Company and Canon, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42705) filed on March 13, 2026)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.09&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/cv-20260320xex101.htm">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42705) filed on March </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/cv-20260320xex101.htm">20</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/cv-20260320xex101.htm">, 2026).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/cv-20260320xex102.htm">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42705) filed on March </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/cv-20260320xex102.htm">20</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/cv-20260320xex102.htm">, 2026).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex141.htm">CapsoVision, Inc Code of Conduct and Ethics.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex191.htm">CapsoVision, Inc Insider Trading Policy.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex231.htm">Consent of Baker Tilly</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex231.htm"> US, LLP</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex231.htm">, Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Power of Attorney. Reference is made to the signature page hereto.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cv-20260326xex971.htm">CapsoVision, Inc Recoupment of Certain Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________________</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;    Filed herewith</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#8224;  Furnished herewith</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#    Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Certain confidential information contained in this document has been omitted pursuant to Item 601 (b)(10)(iv) of Regulation S-K promulgated under the Exchange Act. The Registrant agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.</span></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_247"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155</span></div></div></div><div id="ie17ceeaa833a498eadbb73e6ee8311e7_250"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAPSOVISION, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;26, 2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Kang-Huai (Johnny) Wang</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kang-Huai (Johnny) Wang</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kang-Huai (Johnny) Wang and David Garcia and each of them, as his or her true and lawful attorneys-in-fact and agents, and each of them, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.753%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signature </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Kang-Huai (Johnny) Wang</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, President and Chief Executive Officer <br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;26, 2026</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kang-Huai (Johnny) Wang</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Garcia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior VP of Finance<br/>(Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;26, 2026</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Garcia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Chen Lung Tsai</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;26, 2026</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chen Lung Tsai</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Hui Ying (Patty) Kuo</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;26, 2026</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hui Ying (Patty) Kuo</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Julia Gouw</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;26, 2026</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Julia Gouw</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Michele Harari</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;26, 2026</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michele Harari</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Joanne Imperial, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;26, 2026</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joanne Imperial, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Wen-Herng (Henry) King</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;26, 2026</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wen-Herng (Henry) King</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>cv-20260326xex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i47bc083f93204a8aa93017732e03b1ae_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.7</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">CAPSOVISION, INC.  </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">INDEMNIFICATION AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> This Indemnification Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) is effective as of &#91;&#8226;&#93; and is between CapsoVision, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), and &#91;&#8226;&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;). </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">RECITALS  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;A.        Indemnitee&#8217;s service to the Company substantially benefits the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">B.      Individuals are reluctant to serve as directors or officers of corporations or in certain other capacities unless they are provided with adequate protection through insurance or indemnification against the risks of claims and actions against them arising out of such service.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">C.        Indemnitee does not regard the protection currently provided by applicable law, the Company&#8217;s governing documents and any insurance as adequate under the present circumstances, and Indemnitee may not be willing to serve as a director or officer without additional protection.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">D.        In order to induce Indemnitee to continue to provide services to the Company, it is reasonable, prudent and necessary for the Company to contractually obligate itself to indemnify, and to advance expenses on behalf of, Indemnitee as permitted by applicable law.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">E.         This Agreement is a supplement to and in furtherance of the indemnification provided in the Company&#8217;s certificate of incorporation and bylaws, and any resolutions adopted pursuant thereto, and this Agreement shall not be deemed a substitute therefor, nor shall this Agreement be deemed to limit, diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The parties therefore agree as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Definitions.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">(a) A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;padding-left:11.67pt">Acquisition of Stock by Third Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company&#8217;s then outstanding securities&#59;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> that, notwithstanding the foregoing, a Change in Control shall not be deemed to occur if any such change in Beneficial Ownership of the Company&#8217;s securities by any Person results solely from (A) a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, or (B) a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities that is approved by at least a majority of the independent members of the Company&#8217;s board of directors&#59;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;padding-left:8.34pt">Change in Board Composition</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  During any period of two consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Company&#8217;s board of directors, and any new directors (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 1(a)(i), 1(a)(iii) or 1(a)(iv)) whose election by the board of directors or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Company&#8217;s board of directors&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">iii.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;padding-left:5.01pt">Corporate Transactions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">iv.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;padding-left:5.67pt">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">v.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;padding-left:9pt">Other Events</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">.  Any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended, whether or not the Company is then subject to such reporting requirement.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">For purposes of this Section 1(a), the following terms shall have the following meanings&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Person</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall have the meaning as set forth in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, that &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Person</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Beneficial Owner</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall have the meaning given to such term in Rule 13d-3 under the Securities Exchange Act of 1934, as amended&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, that &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Beneficial Owner</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall exclude any Person otherwise becoming a Beneficial Owner by reason of (i) the stockholders of the Company approving a merger of the Company with another entity or (ii) the Company&#8217;s board of directors approving a sale of securities by the Company to such Person.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Corporate Status</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; describes the status of a person who is or was a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">DGCL</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the General Corporation Law of the State of Delaware.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Disinterested Director</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Enterprise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the Company and any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees and costs of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a deponent or witness in, or otherwise participating in, a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding.  Expenses also include (i) Expenses incurred in connection with any appeal resulting from any Proceeding and any federal, state, local or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond or other appeal bond or its equivalent, and (ii) for purposes of Section 12(d), Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, by litigation or otherwise.  The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are confirmed in writing by Indemnitee&#8217;s counsel as being reasonable in the good faith judgment of such counsel shall be presumed conclusively to be reasonable.  Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Independent Counsel</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means a law firm, or a partner or member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent (i) the Company or Indemnitee in any matter material to either such party (other than as Independent Counsel with respect to matters concerning Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.  Notwithstanding the foregoing, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Independent Counsel</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means any threatened, pending or completed formal or informal action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, regulatory or investigative nature, including any appeal therefrom and including without limitation any such Proceeding pending as of the date of this Agreement, in </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">which Indemnitee was, is or will be involved as a party, a potential party, a non-party witness or otherwise by reason of (i) Indemnitee&#8217;s Corporate Status, or (ii) any action taken by Indemnitee or any action or inaction on Indemnitee&#8217;s part while acting pursuant to Indemnitee&#8217;s Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification or advancement of expenses can be provided under this Agreement.  If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">h.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">Reference to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">other enterprises</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall include employee benefit plans&#59; references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">fines</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall include any excise taxes assessed on a person with respect to any employee benefit plan&#59; references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">serving at the request of the Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries&#59; and a person who acted in good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">not opposed to the best interests of the Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; as referred to in this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Indemnity in Third-Party Proceedings</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The Company shall hold harmless and indemnify Indemnitee to the fullest extent permitted by applicable law in accordance with the provisions of this Section 2 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor by reason of Indemnitee&#8217;s Corporate Status.  Pursuant to this Section 2, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, with respect to any criminal Proceeding, had no reasonable cause to believe that his or her conduct was unlawful.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Indemnity in Proceedings by or in the Right of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The Company shall hold harmless and indemnify Indemnitee to the fullest extent permitted by applicable law in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor by reason of Indemnitee&#8217;s Corporate Status.  Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company.  If applicable law so provides, no indemnification for Expenses shall be made under this Section 3 in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been finally adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as such court shall deem proper.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Indemnification for Expenses of a Party Who is Wholly or Partly Successful.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is a party to or a participant in and is successful (on the merits or otherwise) in defense of any Proceeding or any claim, issue or matter therein, the Company shall hold harmless and indemnify Indemnitee to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection therewith.  To the fullest extent permitted by applicable law, if Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, in defense of one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with (a) each successfully resolved claim, issue or matter and (b) any claim, issue or matter related to any such successfully resolved claim, issue or matter.  For purposes of this section, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Indemnification for Expenses of a Witness.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness, or is or was made (or asked) to respond to discovery requests or otherwise participate, in any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection therewith.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Additional Indemnification.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount therefor, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.  If the Company disputes a portion of the amounts for which indemnification is requested, the undisputed portion shall be paid and only the disputed portion withheld pending resolution of any such dispute.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">Notwithstanding any limitation in Sections 2, 3, 4 or 5, the Company shall hold harmless and indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) by reason of Indemnitee&#8217;s Corporate Status, including, without limitation, all liability arising out of the negligence or active or passive wrongdoing of Indemnitee, against all Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with the Proceeding or any claim, issue or matter therein.  The only limitation that shall exist upon the Company&#8217;s obligations pursuant to this Agreement shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in this Agreement) to be unlawful.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">For purposes of this Agreement, the meaning of the phrase &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">to the fullest extent permitted by applicable law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall include, but not be limited to&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.67pt">the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.34pt">the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">If (i) Indemnitee is or was affiliated with one or more venture capital funds and&#47;or one or more other entities that has invested in the Company (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Appointing Stockholder</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), and (ii) Appointing Stockholder is, or is threatened to be made, a party to or a participant in any Proceeding relating to or arising by reason of Appointing Stockholder&#8217;s position as a stockholder of, or lender to, the Company, or Appointing Stockholder&#8217;s appointment of or affiliation with Indemnitee or any other director, including, without limitation, any alleged misappropriation of a Company asset or corporate opportunity, any claim of misappropriation or infringement of intellectual property relating to the Company, any alleged false or misleading statement or omission made by the Company (or on its behalf) or its employees or agents, or any allegation of inappropriate control or influence over the Company or the members of its board of directors, officers, equity holders or debt holders, then Appointing Stockholder will be entitled to indemnification hereunder for Expenses to the same extent as Indemnitee, and the terms of this Agreement as they relate to procedures for indemnification of Indemnitee and advancement of Expenses shall apply to any such indemnification of Appointing Stockholder.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Exclusions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">for which payment has actually been made to or on behalf of Indemnitee under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid or with respect to any amounts paid under any insurance policy or other indemnity provision, provided, that the foregoing shall not affect the rights of Indemnitee&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">for an accounting or disgorgement of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of federal, state or local statutory law or common law&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Securities Exchange Act of 1934, as amended (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Sarbanes-Oxley Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act), or any reimbursement of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Company&#8217;s board of directors or the compensation committee of the Company&#8217;s board of directors, including but not limited to any such </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">policy adopted to comply with stock exchange listing requirements implementing Section 10D of the Exchange Act&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees, agents or other indemnitees, unless (i) the Company&#8217;s board of directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii) such indemnity arises in connection with any mandatory counterclaim or cross claim brought or raised by Indemnitee in any Proceeding (or the relevant part of the Proceeding), (iii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iv) otherwise authorized in Section 12(d) or (v) otherwise required by applicable law&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">if prohibited by applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Advances of Expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding any other provision of this Agreement, the Company shall advance the Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding, and such advancement shall be made as soon as reasonably practicable, but in any event no later than 30 days, after the receipt by the Company of a written statement or statements requesting such advances from time to time, whether prior to or after final disposition of such Proceeding (which shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditure made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice).  Advances shall be unsecured and interest free and made without regard to Indemnitee&#8217;s ability to repay such advances.  Indemnitee hereby undertakes to repay any advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company.  This Section 8 shall not apply to any Proceeding for which indemnity is excluded pursuant to Sections 7(b) or 7(c).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Procedures for Notification and Defense of Claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses as soon as reasonably practicable following the receipt by Indemnitee of notice thereof.  The written notification to the Company shall include, in reasonable detail, a description of the nature of the Proceeding and the facts underlying the Proceeding.  The failure by Indemnitee to notify the Company will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights, except to the extent that such failure or delay actually and materially prejudices the interests of the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">If, at the time of the receipt of a notice of a Proceeding pursuant to the terms hereof, the Company has directors&#8217; and officers&#8217; liability insurance in effect, the Company shall give prompt notice of the commencement of the Proceeding to the insurers in accordance with the procedures set forth in the applicable policies.  The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">In the event the Company may be obligated to make any indemnity in connection with a Proceeding, the Company shall be entitled to assume the defense of such Proceeding with counsel approved by Indemnitee, which approval shall not be unreasonably withheld, upon the delivery to Indemnitee of written notice of its election to do so.  After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee for any fees or expenses of counsel subsequently incurred by Indemnitee with respect to the same Proceeding.  Notwithstanding the Company&#8217;s assumption of the defense of any such Proceeding, the Company shall be obligated to pay the fees and expenses of Indemnitee&#8217;s counsel to the extent (i) the employment of counsel by Indemnitee is authorized by the Company, (ii) counsel for the Company or Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of any such defense such that Indemnitee needs to be separately represented, (iii) the fees and expenses are non-duplicative and reasonably incurred in connection with Indemnitee&#8217;s role in the Proceeding despite the Company&#8217;s assumption of the defense, (iv) the Company is not financially or legally able to perform its indemnification obligations or (v) the Company shall not have retained, or shall not continue to retain, such counsel to defend such Proceeding.  The Company shall have the right to conduct such defense as it sees fit in its sole discretion.  Regardless of any provision in this Agreement, Indemnitee shall have the right to employ counsel in any Proceeding at Indemnitee&#8217;s personal expense.  The Company shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">Indemnitee shall give the Company such information and cooperation in connection with the Proceeding as may be reasonably appropriate.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">The Company shall not be liable to indemnify Indemnitee for any settlement of any Proceeding (or any part thereof) without the Company&#8217;s prior written consent, which shall not be unreasonably withheld.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.01pt">The Company shall not settle any Proceeding (or any part thereof) without Indemnitee&#8217;s prior written consent, which shall not be unreasonably withheld, unless such settlement includes a complete and unconditional release of Indemnitee from all liability on all claims that are the subject matter of such Proceeding.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">10.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Procedures upon Application for Indemnification.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">It is the intent of this Agreement to secure for Indemnitee rights of indemnity that are as favorable as may be permitted under the DGCL and public policy of the State of Delaware.  Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to indemnification under this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">To obtain indemnification, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and as is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of the Proceeding.  The Company shall, as soon as reasonably practicable after receipt of such a request for indemnification, advise the board of directors that Indemnitee has requested indemnification.  Any delay in providing the request will not relieve the Company from its obligations under this Agreement, except to the extent such failure actually and materially prejudices the interests of the Company.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">Upon written request by Indemnitee for indemnification pursuant to Section 10(a), a determination with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Company&#8217;s board of directors, a copy of which shall be delivered to Indemnitee or (ii) if a Change in Control shall not have occurred, if required by applicable law (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#8217;s board of directors, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#8217;s board of directors, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Company&#8217;s board of directors, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Company&#8217;s board of directors, by the stockholders of the Company.  If it is determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten days after such determination.  Indemnitee shall cooperate with the person, persons or entity making the determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is reasonably available to Indemnitee and reasonably necessary to such determination.  Any Independent Counsel, member of the board of directors or stockholder of the Company shall act reasonably and in good faith in making a determination regarding the Indemnitee&#8217;s entitlement to indemnification under this Agreement.  Any costs or expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification), to the extent permitted by applicable law, and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.  The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 10(b), the Independent Counsel shall be selected as provided in this Section 10(c).  If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Company&#8217;s board of directors, and the Company shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected.  If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Company&#8217;s board of directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected.  In either event, Indemnitee or the Company, as the case may be, may, within ten days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section 1 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">has determined that such objection is without merit.  If, within 20 days after the later of (i) submission by Indemnitee of a written request for indemnification pursuant to Section 10(a) hereof and (ii) the final disposition of the Proceeding, the parties have not agreed upon an Independent Counsel, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other&#8217;s selection of Independent Counsel and for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 10(b) hereof.  Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 12(a) of this Agreement, the Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">The Company agrees to pay the reasonable fees and expenses of any Independent Counsel and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.  The Company agrees to pay any and all reasonable fees and expenses incident to the procedures of Section 10(c), regardless of the manner in which such Independent Counsel was selected or appointed.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">If the person, persons or entity empowered or selected under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Sections 10 or 11</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, that such sixty (60) day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and&#47;or information relating thereto&#59; and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, that the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 10(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 10(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination, the Company&#8217;s board of directors or the Disinterested Directors, if appropriate, resolve to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">11.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Presumptions and Effect of Certain Proceedings.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 10(a) of this Agreement, and the Company shall, to the fullest extent not </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">prohibited by law, have the burden of proof to overcome that presumption in connection with the making by such person, persons or entity of any determination contrary to that presumption.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith to the extent Indemnitee relied in good faith on (i) the records or books of account of the Enterprise, including financial statements, (ii) information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, (iii) the advice of legal counsel for the Enterprise or its board of directors or counsel selected by any committee of the board of directors or (iv) information or records given or reports made to the Enterprise by an independent certified public accountant, an appraiser, investment banker or other expert selected with reasonable care by the Enterprise or its board of directors or any committee of the board of directors.  The provisions of this Section 11(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement, and it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company.  Anyone seeking to overcome this presumption shall have the burden of proof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">Neither the knowledge, actions nor failure to act of any other director, officer, trustee, partner, managing member, fiduciary, agent or employee of the Enterprise shall be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty.  In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such action, suit or proceeding.  Anyone seeking to overcome this presumption shall have the burden of proof.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">12.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Remedies of Indemnitee.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">Subject to Section 12(d), in the event that (i) a determination is made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8 or 12(d) of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 10 of this Agreement within 60 days after the receipt by the Company of the request for indemnification, (iv) payment of </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">indemnification pursuant to this Agreement is not made (A) within ten days after a determination has been made that Indemnitee is entitled to indemnification or (B) with respect to indemnification pursuant to Sections 4, 5, 6(a) and 12(d) of this Agreement, within 30 days after receipt by the Company of a written request therefor, or (v) the Company or any other person or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or proceeding designed to deny, or to recover from, Indemnitee the benefits provided or intended to be provided to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification or advancement of Expenses.  Alternatively, Indemnitee, at his or her option, may seek an award in arbitration with respect to his or her entitlement to such indemnification or advancement of Expenses, to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.  Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 12(a)&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section 4 of this Agreement.  The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration in accordance with this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">Neither (i) the failure of the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders that Indemnitee has not met the applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has or has not met the applicable standard of conduct.  In the event that a determination shall have been made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 12 shall be conducted in all respects as a </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">de novo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> trial, or arbitration, on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination.  In any judicial proceeding or arbitration commenced pursuant to this Section 12, the Company shall, to the fullest extent not prohibited by law, have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">If a determination shall have been made pursuant to Section 10 of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any proceeding or arbitration commenced pursuant to this Section 12, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">To the extent not prohibited by law, the Company shall indemnify Indemnitee against all Expenses that are incurred by Indemnitee in connection with any action for indemnification or advancement of Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, and, if requested by Indemnitee, shall (as soon as reasonably practicable, but </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">in any event no later than 10 days, after receipt by the Company of a written request therefor) advance such Expenses to Indemnitee, subject to the provisions of Section 8.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification shall be required to be made prior to the final disposition of the Proceeding.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.01pt">The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">13.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Contribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">To the fullest extent permitted by applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount actually and reasonably incurred by Indemnitee, whether for Expenses, judgments, penalties, fines or amounts paid or to be paid in settlement, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the events and transactions giving cause to such Proceeding and (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such events and transactions.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">The Company hereby agrees to indemnify and hold harmless Indemnitee from any claims for contribution which may be brought by directors, officers or employees of the Company (other than Indemnitee) who may be jointly liable with Indemnitee.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">Whether or not the indemnification provided for in this Agreement is available, in respect of any Proceeding in which the Company is jointly liable with Indemnitee, the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such Proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee.  The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee unless such settlement provides for a full and final release of all claims asserted against Indemnitee.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee, the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee, on the one hand, and Indemnitee, on the other hand, from the transaction or events from which such action, suit or proceeding arose&#59; provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee, on the one hand, and Indemnitee, on the other hand, in connection with the transaction or events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which applicable law may require to be considered.  The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee, on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">Notwithstanding anything to the contrary, no person or entity found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act of 1933, as amended) shall be entitled to contribution from any person or entity who was not found guilty of such fraudulent misrepresentation.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">14.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Non-exclusivity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company&#8217;s certificate of incorporation or bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise.  To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company&#8217;s certificate of incorporation and bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change, subject to the restrictions expressly set forth herein or therein.  Except as expressly set forth herein, no right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  Except as expressly set forth herein, the assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">15.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">No Duplication of Payments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received payment for such amounts under any insurance policy, contract, agreement or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">16.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Insurance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, trustees, general partners, managing members, officers, agents or fiduciaries of the Company or any other Enterprise, Indemnitee shall be covered by such policy or policies to the same extent as the coverage available for any such director, trustee, general partner, managing member, officer, agent or fiduciary under such policy or policies.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">17.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Subrogation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">18.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Services to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Indemnitee agrees to serve as a director or officer of the Company or, at the request of the Company, as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of another Enterprise, for so long as Indemnitee is duly elected or appointed or until Indemnitee tenders his or her resignation, dies or is removed from such position.  Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position.  This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.  Indemnitee specifically acknowledges that any employment with the Company (or any of its subsidiaries or any Enterprise) is at will, and Indemnitee may be discharged at any time for any reason, with or without cause, with or without notice, except as may be otherwise expressly provided in any executed, written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), any existing formal severance policies adopted by the Company&#8217;s board of directors or, with respect to service as a director or officer of the Company, the Company&#8217;s certificate of incorporation or bylaws or the DGCL.  No such document shall be subject to any oral modification thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">19.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Duration of Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement shall continue for the duration of Indemnitee&#8217;s service as a director of the Company or as a director, trustee, partner, management member, officer, employee, agent, fiduciary, stockholder or controlling person of the Company or any other Enterprise and thereafter for so long as Indemnitee may be subject to any pending or possible claim due to Indemnitee&#8217;s Corporate Status (or any claim arising from a Proceeding commenced under Section 12 hereof), whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">20.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Successors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and, as the case may be, Indemnitee&#8217;s spouse, heirs, executors, administrators, successors and assigns.  The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.  Additionally, (if requested by any Indemnitee in the event of any change in control as defined in the Company&#8217;s then current directors&#8217; and officers&#8217; liability insurance and fiduciary liability insurance policies ), the Company shall pay up to an amount equal to 250% of the premium of such directors&#8217; and officers&#8217; liability insurance and fiduciary liability insurance policies to purchase or cause to be purchased a six-year extended reporting period (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Tail Coverage</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) under those policies or comparable (in quality of coverage and quality of insurer) replacement policies.  In the event the Company cannot purchase Tail Coverage with respect to the entirety of the then current directors&#8217; and officers&#8217; liability and fiduciary liability insurance policies for such premium amount, the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Company shall purchase the amount of Tail Coverage as the Company is able to purchase for such premium amount.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">21.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Severability.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law.  The Company&#8217;s inability, pursuant to court order or other applicable law, to perform its obligations under this Agreement shall not constitute a breach of this Agreement.  If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever&#58;  (i) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by applicable law&#59; (ii) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto&#59; and (iii) to the fullest extent permitted by applicable law, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.  Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee and Appointing Stockholder indemnification rights to the fullest extent permitted by applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">22.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Enforcement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.  The Company shall not seek from a court, or agree to, a &#8220;bar order&#8221; which would have the effect of prohibiting or limiting the Indemnitee&#8217;s rights to receive advancement of expenses under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">23.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Entire Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, that this Agreement is a supplement to and in furtherance of the Company&#8217;s certificate of incorporation and bylaws and applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">24.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Modification and Waiver.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">No supplement, modification, termination or amendment to this Agreement shall be binding unless executed in writing by the parties hereto.  No amendment, alteration or repeal of this Agreement shall adversely affect any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal.  No waiver of any of the provisions of this Agreement shall constitute or be deemed a waiver of any other provision of this Agreement nor shall any waiver constitute a continuing waiver.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">25.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Notices.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.68pt">if to Indemnitee, to Indemnitee&#8217;s address, facsimile number or electronic mail address as shown on the signature page of this Agreement or in the Company&#8217;s records, as may be updated in accordance with the provisions hereof, with a copy (which shall not constitute notice) to __________________________________________________________________&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">if to the Company, to the attention of the President and Chief Executive Officer or Chief Financial Officer (or, if the position of Chief Financial Officer is vacant, the Senior Vice President of Finance) of the Company at such address as the Company shall have furnished to Indemnitee, with a copy (which shall not constitute notice) to Portia Ku, O&#8217;Melveny &#38; Myers LLP., JC Plaza, 12</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> Floor, 1224 Nanjing Road West, Shanghai 200040.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">via</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), (ii) if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient&#8217;s next business day.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">26.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Applicable Law and Consent to Jurisdiction.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules.  Except with respect to any arbitration commenced by Indemnitee pursuant to Section 12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, The Corporation Trust Company, Wilmington, Delaware as its agent in the State of Delaware as such party&#8217;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">27.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Counterparts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.  This Agreement may also be executed and delivered by facsimile signature and in counterparts, each of </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.  Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">28.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Captions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">(signature page follows)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The parties are signing this Indemnification Agreement as of the date stated in the introductory sentence.</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">CAPSOVISION, INC.</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">By&#58;                                   </font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">Name</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#58; Kang-Huai (Johnny) Wang</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">Title</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#58; President and Chief Executive Officer</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">By&#58;                                   </font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">Name</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#58; David Garcia</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">Title</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#58; Senior Vice President of Finance</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">&#91;&#8226;&#93;</font></div><div><font><br></font></div><div style="text-align:center;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">(Signature)</font></div><div><font><br></font></div><div style="text-align:center;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">(Print name)</font></div><div><font><br></font></div><div style="text-align:center;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">(Street address)</font></div><div><font><br></font></div><div style="text-align:center;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">(City, State and ZIP)</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>3
<FILENAME>cv-20260326xex141.htm
<DESCRIPTION>EX-14.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ica716c7ce6ec49688e5db77bf0daed1b_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 14.1</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:107%">CapsoVision Code of Ethics and Business Conduct</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Company Vision </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CITE - Continual Improvement Towards Excellence</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Our mission of continuous improvement doesn&#8217;t end at innovation. CapsoVision is dedicated to providing medical devices that meet the highest standards for safety, reliability, and patient care.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In addition to maintaining compliance with all applicable national and international regulatory requirements, we take special care to maintain the effectiveness of our quality system by continuously evaluating and improving it.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Mission </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Our product development philosophy is driven by our mission to continuously empower clinicians and patients. Through our innovations in the field of diagnostic imaging, we aim to provide products that streamline clinical operations while allowing for better diagnostic outcomes and improved patient quality of life.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Build Trust and Credibility </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The success of our business is dependent on the trust and confidence we earn from our employees, customers and shareholders. We gain credibility by adhering to our commitments, displaying honesty and integrity, and reaching company goals solely through honorable conduct. It is easy to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">say</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"> what we must do, but the proof is in our </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">actions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">. Ultimately, we will be judged on what we do. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">When considering any action, it is wise to ask&#58; will this build trust and credibility for CapsoVision&#63; Will it help create a working environment in which CapsoVision can succeed over the long term&#63; Is the commitment I am making one that I can follow through with&#63; The only way we will maximize trust and credibility is by answering &#8220;yes&#8221; to those questions and by working every day to build our trust and credibility.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Respect for the Individual </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">We all deserve to work in an environment where we are treated with dignity and respect. CapsoVision is committed to creating such an environment because it brings out the full potential in each of us, which, in turn, contributes directly to our business success. We cannot afford to let anyone&#8217;s talents go to waste. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision is an equal employment&#47;affirmative action employer and is committed to providing a workplace that is free of discrimination of all types from abusive, offensive, or harassing behavior. Any employee who feels harassed or discriminated against should report the incident to his or her manager or to human resources. You may utilize the Whistleblower phone line or website to file your report.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">All CapsoVision employees are also expected to support an inclusive workplace by adhering to the following conduct standards&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Treat others with dignity and respect always.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Address and report inappropriate behavior and comments that are discriminatory, harassing, abusive, offensive, or unwelcome.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Foster teamwork and employee participation, encouraging the representation of different employee perspectives.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Seek out insights from employees with different experiences, perspectives, and backgrounds.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Avoid slang or idioms that might not translate across cultures.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Support flexible work arrangements for co-workers with unique needs, abilities, and&#47;or obligations.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Confront the decisions or behaviors of others that are based on conscious or unconscious biases.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Be open-minded and listen when given constructive feedback regarding others&#8217; perception of your conduct.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision will not tolerate discrimination, harassment or any behavior or language that is abusive, offensive, or unwelcome. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Create a Culture of Open and Honest Communication </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">At CapsoVision everyone should feel comfortable speaking his or her mind, particularly with respect to ethics concerns. Managers have a responsibility to create an open and supportive environment where employees feel comfortable raising </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">such questions. We all benefit tremendously when employees exercise their power to prevent mistakes or wrongdoing by asking the right questions at the right times. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision will investigate all reported instances of questionable or unethical behavior. In every instance where improper behavior is found to have occurred, CapsoVision will take appropriate action. We will not tolerate retaliation against employees who raise genuine ethics concerns in good faith.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">For your information, CapsoVision&#8217;s whistleblower policy can be found under California Policies&#47;General Policies section of the Employee Handbook.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">You may use the CapsoVision Hotline by calling (833) 204-2604 or accessing the website at https&#58;&#47;&#47;www.whistleblowerservices.com&#47;CapsoVision. Alternatively, you may contact the California State Attorney General's Whistleblower Hotline at (800) 952-5225. The Attorney General will refer your call to the appropriate government authority for review and possible investigation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Employees are encouraged, in the first instance, to address such issues with their managers or the HR manager, as most problems can be resolved swiftly. If for any reason that is not possible or if an employee is not comfortable raising the issue with his or her manager or HR, CapsoVision&#8217;s Chief Executive Officer does operate with an open-door policy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Set Tone at the Top </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Management has the added responsibility for demonstrating, through their actions, the importance of this Code. In any business, ethical behavior does not simply happen&#59; it is the product of clear and direct communication of behavioral expectations, modeled from the top and demonstrated by example. Again, ultimately, our actions are what matters. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">To make our Code work, managers must be responsible for promptly addressing ethical questions or concerns raised by employees and for taking the appropriate steps to deal with such issues. Managers should not consider employees&#8217; ethics concerns as threats or challenges to their authority, but rather as another encouraged form of business communication. At CapsoVision, we want the ethics dialogue to become a natural part of daily work.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Uphold the Law </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision&#8217;s commitment to integrity begins with complying with laws, rules, and regulations where we do business. Further, each of us must have an understanding of CapsoVision policies, laws, rules, and regulations that apply to our specific roles. If we are unsure whether a contemplated action is permitted by law or CapsoVision policy, we should seek the advice from the resource expert. We are responsible for preventing violations of law and for speaking up if we see possible violations. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Competition </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">We are dedicated to ethical, fair, and vigorous competition. We will sell CapsoVision products and services based on their merit, superior quality, functionality, and competitive pricing. We will make independent pricing and marketing decisions and will not improperly cooperate or coordinate our activities with our competitors. We will not offer or solicit improper payments or gratuities in connection with the purchase of goods or services for CapsoVision or the sales of its products or services, nor will we engage or assist in unlawful boycotts of customers. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Proprietary Information </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">It is important that we respect the property rights of others. We will not acquire or seek to acquire improper means of a competitor&#8217;s trade secrets or other proprietary or confidential information. We will not engage in unauthorized use, copying, distribution or alteration of software or other intellectual property.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Selective Disclosure </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">We will not selectively disclose (whether in one-on-one or small discussions, meetings, presentations, proposals or otherwise) any material nonpublic information with respect to CapsoVision, its securities, business operations, plans, financial condition, results of operations or any development plan. We should be particularly vigilant when making presentations or proposals to customers to ensure that our presentations do not contain material nonpublic information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Health and Safety</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision is dedicated to maintaining a healthy environment. An Illness and Injury Prevention Program has been designed to educate you on safety in the workplace. If you do not have a copy of this program, please see the HR department.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Environmental Responsibility</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision is committed to reducing our impact on the environment, whether in the office, in the field, or working remotely. All employees are expected to support this commitment by using resources wisely, minimizing waste, and following environmental guidelines wherever they work. This includes turning off devices when not in use, avoiding unnecessary printing or travel, and properly disposing of materials. Any environmental concerns should be reported to a manager or Human Resources.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Global Conduct and Cultural Awareness</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision values cultural diversity and complies with applicable laws in every country where we operate. Employees must remain sensitive to cultural differences in communication, conduct, and business practices</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Anti-Corruption, Bribery, and Fraud</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision does not allow any form of bribery, kickbacks, or corrupt payments&#8212;whether to government officials or private individuals. We expect everyone who works with us to act honestly and follow the law. Fraud is also not allowed. This includes lying, cheating, or breaking trust to gain an unfair advantage. We expect our suppliers and partners to follow the same high standards.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Ethical Use of Technology and Data Privacy</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">All employees must follow rules for using email, devices, and software, ensuring that they never share login details and report lost devices or suspicious activity to IT immediately. When communicating outside the company, avoid sharing confidential or business-related information on personal social media. Always maintain professionalism and respect online, as your words reflect on CapsoVision.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Our company is committed to the ethical development and deployment of technology, including AI-based solutions, ensuring they are transparent, safe, and respect patient rights. Employees must adhere to HIPAA compliance, safeguarding patient data at all times. This includes handling, storing, and transmitting patient information securely and only sharing it with authorized personnel. All employees are responsible for protecting sensitive data to maintain the trust and safety of both our company and our patients.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Avoid Conflicts of Interest </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Conflicts of Interest </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">We must avoid any relationship or activity that might impair, or even appear to impair, our ability to make objective and fair decisions when performing our jobs. At times, we may be faced with situations where the business actions we take on behalf of CapsoVision may conflict with our own personal or family interests. We owe a duty to CapsoVision to advance its legitimate interests when the opportunity to do so arises. We must never use CapsoVision property or information for personal gain or personally take for ourselves any opportunity that is discovered through our position with CapsoVision.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Here are some other ways in which conflicts of interest could arise&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">1. Being employed (you or a close family member) by, or acting as a consultant to, a competitor or potential competitor, supplier, or contractor, regardless of the nature of the employment, while you are employed with CapsoVision.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">2. Supervising family members or closely related people.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">3. Serving as a board member for an outside commercial company or organization without permission from the CapsoVision CEO.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">4. Owning or having a substantial interest in a competitor, supplier, or contractor.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">5. Having a personal interest, financial interest, or potential gain in any CapsoVision transaction.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">6. Placing company business with a firm owned or controlled by a CapsoVision employee or his or her family.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">7. Accepting gifts, discounts, favors, or services from a customer&#47;potential customer, competitor, or supplier, unless equally available to all CapsoVision employees. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Determining whether a conflict of interest exists is not always easy to do. Employees with a conflict-of-interest question should seek advice from management. Before engaging in any activity, transaction or relationship that might give rise to a conflict of interest, employees must seek review from their managers or the HR department.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gifts, Gratuities and Business Courtesies - Please note there is a separate Code of Conduct that covers this topic and applies to our Sales Employees in compliance with the Sunshine Act, formally known as the Physician Payments Sunshine Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision is committed to competing solely on the merit of our products and services. We should avoid any actions that create a perception that favorable treatment of outside entities by CapsoVision was sought, received, or given in exchange for personal business courtesies. Business courtesies include gifts, gratuities, meals, refreshments, entertainment or other </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">benefits from persons or companies with whom CapsoVision does or may do business. We will neither give nor accept business courtesies that constitute, or could reasonably be perceived as constituting, unfair business inducements that would violate the law, regulation or polices of CapsoVision or customers, or would cause embarrassment or reflect negatively on CapsoVision&#8217;s reputation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Accepting Business Courtesies </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Most business courtesies offered to us in the course of our employment are offered because of our positions at CapsoVision. We should not feel any entitlement to accept and keep a business courtesy. Although we may not use our position at CapsoVision to obtain business courtesies, and we must never ask for them, we may accept unsolicited business courtesies that promote successful working relationships and goodwill with the firms that CapsoVision maintains or may establish a business relationship with.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Employees who award contracts or who can influence the allocation of business, who create specifications that result in the placement of business or who participate in negotiation of contracts must be particularly careful to avoid actions that create the appearance of favoritism or that may adversely affect  CapsoVision&#8217;s reputation for impartiality and fair dealing. The prudent course is to refuse a courtesy from a supplier when CapsoVision is involved in choosing or reconfirming a supplier or under circumstances that would create an impression that offering courtesies is the way to obtain CapsoVision business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Meals, Refreshments and Entertainment </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">We may accept occasional meals, refreshments, entertainment, and similar business courtesies that are shared with the person who has offered to pay for the meal or entertainment, provided that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; They are not inappropriately lavish or excessive.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; The courtesies are not frequent and do not reflect a pattern of frequent acceptance of courtesies from the same person or entity.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; The courtesy does not create the appearance of an attempt to influence business decisions, such as accepting courtesies or entertainment from a supplier whose contract is expiring in the near future.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; The employee accepting the business courtesy would not feel uncomfortable discussing the courtesy with his or her manager or co-worker or having the courtesies known by the public. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gifts </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Employees may accept unsolicited gifts, other than money, which conform to the reasonable ethical practices of the marketplace, including&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; Flowers, fruit baskets and other modest presents that commemorate a special occasion.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; Gifts of nominal value, such as calendars, pens, mugs, caps, and t-shirts (or other novelty, advertising, or promotional items).</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Generally, employees may not accept compensation, honoraria or money of any amount from entities with whom CapsoVision does or may do business. Tangible gifts (including tickets to a sporting or entertainment event) that have a market value greater than $100 may not be accepted unless approval is obtained from management. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Employees with questions about accepting business courtesies should talk to their managers or the HR department.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Offering Business Courtesies </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Any employee who offers a business courtesy must ensure that it cannot reasonably be interpreted as an attempt to gain an unfair business advantage or otherwise reflect negatively upon CapsoVision. An employee may never use personal funds or resources to do something that cannot be done with CapsoVision resources. Accounting for business courtesies must be done in accordance with approved company procedures. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Other than to our government customers, for whom special rules apply, we may provide nonmonetary gifts (i.e., company logo apparel or similar promotional items) to our customers. Further, management may approve other courtesies, including meals, refreshments, or entertainment of reasonable value, provided that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; The practice does not violate any law or regulation or the standards of conduct of the recipient&#8217;s organization.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; The business courtesy is consistent with industry practice, is infrequent in nature and is not lavish.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; The business courtesy is properly reflected on the books and records of CapsoVision.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Set Metrics and Report Results Accurately </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Accurate Public Disclosures </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">We will make certain that all disclosures made in financial reports and public documents are full, fair, accurate, timely and understandable. This obligation applies to all employees, including all financial executives, with any responsibility for the preparation for such reports, including drafting, reviewing, and signing or certifying the information contained therein. No business goal of any kind is ever an excuse for misrepresenting facts or falsifying records.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Employees should inform Executive Management and the HR department if they learn that information in any filing or public communication was untrue or misleading at the time it was made or if subsequent information would affect a similar future filing or public communication.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Corporate Recordkeeping </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">We create, retain, and dispose of our company records as part of our normal course of business in compliance with all CapsoVision policies and guidelines, as well as all regulatory and legal requirements.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">All corporate records must be true, accurate and complete, and company data must be promptly and accurately entered in our books in accordance with CapsoVision&#8217;s and other applicable accounting principles.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">We must not improperly influence, manipulate, or mislead any unauthorized audit, nor interfere with any auditor engaged to perform an internal independent audit of CapsoVision books, records, processes, or internal controls. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Promote Substance Over Form </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">At times, we are all faced with decisions we would rather not have to make and issues we would prefer to avoid. Sometimes, we hope that if we avoid confronting a problem, it will simply go away. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">At CapsoVision, we must have the courage to tackle the tough decisions and make difficult choices, secure in the knowledge that CapsoVision is committed to doing the right thing. At times this will mean doing more than simply what the law requires. Merely because we can pursue a course of action does not mean we </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">should</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"> do so. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Although CapsoVision&#8217;s guiding principles cannot address every issue or provide answers to every dilemma, they can define the spirit in which we intend to do business and should guide us in our daily conduct. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Accountability </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Each of us is responsible for knowing and adhering to the values and standards set forth in this Code and for raising questions if we are uncertain about company policy. If we are concerned whether the standards are being met or are aware of violations of the Code, we must contact the HR department.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision takes seriously the standards set forth in the Code, and violations are cause for disciplinary action up to and including termination of employment. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Be Loyal </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Confidential and Proprietary Information </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Integral to CapsoVision&#8217;s business success is our protection of confidential company information, as well as nonpublic information entrusted to us by employees, customers and other business partners. Confidential and proprietary information includes such things as pricing and financial data, customer names&#47;addresses or nonpublic information about other companies, including current or potential supplier and vendors. We will not disclose confidential and nonpublic information without a valid business purpose and proper authorization.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Use of Company Resources </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Company resources, including time, material, equipment, and information, are provided for company business use. Nonetheless, occasional personal use is permissible as long as it does not affect job performance or cause a disruption to the workplace.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Employees and those who represent CapsoVision are trusted to behave responsibly and use good judgment to conserve company resources. Managers are responsible for the resources assigned to their departments and are empowered to resolve issues concerning their proper use. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Generally, we will not use company equipment such as computers, copiers, and fax machines in the conduct of an outside business or in support of any religious, political, or other outside daily activity, except for company-requested support to nonprofit organizations. We will not solicit contributions nor distribute non-work-related materials during work hours. </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In order to protect the interests of the CapsoVision network and our fellow employees, CapsoVision reserves the right to monitor or review all data and information contained on an employee&#8217;s company-issued computer or electronic device, the use of the Internet or CapsoVision&#8217;s intranet. We will not tolerate the use of company resources to create, access, store, print, solicit or send any materials that are harassing, threatening, abusive, sexually explicit or otherwise offensive or inappropriate. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Questions about the proper use of company resources should be directed to your manager. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Media Inquiries </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">CapsoVision is a high-profile company in our community, and from time to time, reporters and other members of the media may approach employees. In order to ensure that we speak with one voice and provide accurate information about CapsoVision, we should direct all media inquiries to the Chief Executive Officer. No one may issue a press release without first consulting with the Chief Executive Officer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Do the Right Thing </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Several key questions can help identify situations that may be unethical, inappropriate, or illegal. Ask yourself&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; Does what I am doing comply with the CapsoVision guiding principles, the Code of Conduct and company policies&#63;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; Have I been asked to misrepresent information or deviate from normal procedure&#63;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; Would I feel comfortable describing my decision at a staff meeting&#63;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; How would it look if it made the headlines&#63;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; Am I being loyal to my family, my company and myself&#63;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; What would I tell my child to do&#63;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226; Is this the right thing to do&#63;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Information and Resources </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Chief Executive Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Johnny Wang              johnny.wang&#64;capsovision.com  (408) 370-4791 Ext. 109</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Senior Vice President of Finance</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">David Garcia              david.garcia&#64;capsovision.com (408) 624-1488 Ext 151</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Manager of Human Resources </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Helen Chau                 helen.chau&#64;capsovision.com  (408) 370-4790 Ext. 110</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>cv-20260326xex191.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i0b07ecfa4a144b71b5f82d99551118bb_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">CAPSOVISION INSIDER TRADING POLICY</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.9pt">INTRODUCTION</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This Insider Trading Policy (the &#8220;Policy&#8221;) provides guidelines to all officers, employees and consultants of CapsoVision, Inc, and its subsidiaries (the &#8220;Company&#8221;) as well as members of the Company&#8217;s Board of Directors (the &#8220;Directors&#8221;) with respect to transactions in the Company&#8217;s securities, and codifies the Company&#8217;s standards on trading and enabling the trading of securities of the Company or other publicly-traded companies while in possession of material non-public information (&#8220;inside information&#8221;). The Directors, officers, employees and consultants, as well as their immediate family members may be sued civilly either by the Securities and Exchange Commission (&#34;SEC&#34;) or by private litigants if they trade in securities while in possession of inside information concerning the issuer of the securities. They may also be charged with a criminal violation. In recent years, the SEC and United States Attorneys have aggressively investigated and prosecuted persons who engaged in insider trading or tipped others.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company&#8217;s Directors, officers, employees and certain consultants and their immediate family members who possess inside information because of their relationship with the Company are considered &#8220;Insiders.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This policy defines immediate family members of each Director, officer, employee and consultant of the Company as parents, siblings, spouses, children or any persons that live in their household, and any family members who do not live in their household, but whose transactions in Company securities are directed by such Director, officer, employee or consultant or are subject to his or her influence or control (such as parents or children who consult with them before trading in Company securities), and any entity controlled, or whose securities transactions are directed, influenced or controlled, by such Director, officer, employee or consultant of the Company</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2.  MATERIAL NONPUBLIC INFORMATION OR INSIDE INFORMATION</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Information is considered &#8220;material&#8221; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell, or hold a security, or if the information is likely to have a significant effect on the market price of the security. Material information can be positive or negative and can relate to virtually any aspect of a company&#8217;s business or to any type of security, debt, or equity. Also, information that something is likely to happen in the future&#8212;or even just that it may happen&#8212;could be deemed material. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Examples of material information may include (but are not limited to) information about&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Significant changes in the company&#8217;s prospects.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.53pt">Corporate earnings or earnings forecasts.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.53pt">Significant write-downs in assets.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.53pt">Major new product candidates or product developments.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Scientific, medical or financial data relating to the Company&#8217;s products or products under development.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Important business developments, such as clinical trial results, developments regarding strategic collaborations or the status of regulatory submissions.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:12.53pt">Management or control changes.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Significant financing developments including pending public sales or offerings of debt or equity securities.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:132%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:132%;padding-left:12.53pt">Extraordinary borrowings or defaults on borrowings.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.53pt">Impending bankruptcy or liquidity problems.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.53pt">Changes in earnings estimates or unusual gains or losses in major operations.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.53pt">Major changes in management.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.53pt">A determination to declare a dividend.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.53pt">Entry into or modification or termination of a significant contract.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Proposals, plans or agreements, even if preliminary in nature, involving mergers, acquisitions or tender offer, divestitures, recapitalizations, strategic alliances, licensing arrangements, or purchases or sales of substantial assets.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:132%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:132%;padding-left:12.53pt">Cybersecurity or data security incidents.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Developments regarding significant litigation or government agency investigations, or actions of regulatory and health agencies, particularly the U.S. Food and Drug Administration.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Material information is not limited to historical facts but may also include projections and forecasts. With respect to a future event, such as a merger or acquisition or development of a new product, the point at which negotiations or new product development plans are determined to be material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have on a company&#8217;s operations or stock price should it occur. Thus, information concerning an event that would have a large effect on the stock price, such as a merger, may be material even if the possibility that the event will occur is relatively small. When in doubt about whether non-public information is material, presume it is material.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Keep in mind that materiality is judged in hindsight, and while a development may not seem material at the time, if following its announcement to the public, the Company&#8217;s stock price increases or decreases, a plaintiff&#8217;s lawyer or the SEC will use this fact to demonstrate materiality. If you are unsure whether the information is material, you should consult with the Compliance Officer (as defined below) before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Information is &#8220;nonpublic&#8221; if it is not available to the general public. In order for information to be considered &#8220;public,&#8221; it must be widely disseminated in a manner that makes it generally available to investors in a Regulation FD-compliant method, such as through a press release, a filing with the SEC or a Regulation FD- compliant conference call. The Compliance Officer (as defined below) shall have sole discretion to decide whether information is public for purposes of this Policy.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.   COMPLIANCE OFFICER</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company has appointed its Senior Vice President of Finance, David Garcia &#64; david.garcia&#64;capsovision.com as the Compliance Officer for this Policy. The duties of the Compliance Officer include, but are not limited to, the following&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Assisting with implementation of this Policy.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Circulating this Policy to all Directors, officers and employees of the Company and ensuring that this Policy is amended as necessary to remain up to date with insider trading laws.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Notifying Covered Insiders (as defined in Section 8 below) and, if appropriate, other employees of the Company of the Company&#8217;s imposition of a trading &#8220;blackout&#8221; period as described in Sections 12 and 13 below.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Reviewing and approving 10b5-1 Trading Plans (as defined below in Section 6) or revisions or amendments to such plans and referring such plans or revisions to such plans to the Board or a duly appointed committee thereof for approval if required or otherwise appropriate (as described in Section 6).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Pre-clearing all trading in securities of the Company by all Covered Insiders in accordance with the procedures set forth in Section 9 below.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In the event that the Compliance Officer is not available or desires to effect, a transaction in Company securities for which pre-clearance or approval is required under this Policy, the Corporate Controller of the Company, Anna Krylova &#64; anna.krylova&#64;capsovision.com shall serve as the Compliance Officer. In the event that the Compliance Officer is unavailable and such information is cleared by the Controller, the Compliance Officer must be informed of such clearance as soon as possible.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The circulation of rumors, even if accurate and reported in the media, does not constitute public dissemination. For information to be considered publicly disseminated, it must be widely disclosed through a press release, a filing with the SEC, a previously-announced and publicly available Company earnings call, or other media for broad public access, and a sufficient amount of time must have passed to allow the information to be fully disclosed, which such amount of time may vary depending on the nature and significance of the information. Generally speaking, information will be considered publicly disseminated after two full trading days have elapsed since the date of public disclosure of the information. You must wait until the close of business on the second trading day after the information was publicly disclosed before you can treat the information as public. For example, if an announcement of inside information of which you were aware was made prior to trading on Wednesday, then you may execute a transaction in the Company&#8217;s securities on Friday. When in doubt about whether information has been publicly disseminated, contact either David Garcia &#8211; Senior Vice President of Finance &#64; david.garcia&#64;capsovision.com or Anna Krylova, Corporate Controller &#64; anna.krylova&#64;capsovision.com</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4. STOCK TRADING</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Because officers and Directors of the Company are likely, in the view of the public, to possess inside information about the Company, we require them to do more than refrain from insider trading. We require that Covered Insiders (as defined below in Section 8), which includes officers and Directors, and certain employees and consultants, limit their transactions in the Company&#8217;s stock to defined time periods following public dissemination of quarterly and annual financial results or pursuant to a 10b5-1 trading plan as discussed below. Though these &#8220;blackouts&#8221; generally will arise because the Company is involved in a highly sensitive transaction, they may be declared for any reason. Further, we also require that Covered Insiders notify and receive pre-clearance (see below in Section 9) from the Company&#8217;s Compliance Officer by submitting an email to david.garcia&#64;capsovision.com or another method of requesting pre- clearance communicated to the Covered Insiders, at least one business day, but not more than five business days, prior to engaging in transactions in the Company&#8217;s stock and observe other restrictions designed to minimize the risk of apparent or actual insider trading.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5. WINDOW PERIOD</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Generally, except as set forth in this Sections 5, 6, 7 and 12 of this Policy and subject to the blackout periods set forth in Section 13, Covered Insiders may buy or sell securities of the Company only during a &#8220;window period&#8221; that opens after two full trading days have elapsed after the public dissemination of the Company&#8217;s annual or quarterly financial results and closes at the close of trading on March 15, June 15, September 15 and December 15, for each respective quarter. This window period may be closed early or may not open if, in the judgment of the Chief Executive Officer or principal financial officer, there exists undisclosed information that would make trades by Covered Insiders inappropriate. It is important to note that the fact that the window period has closed early or has not opened should be considered inside information. A Covered Insider who believes that special circumstances require him or her to trade outside the window period should consult with a Compliance Officer. Permission to trade outside the window period will be granted only where the circumstances are extenuating and there appears to be no significant risk that the trade may subsequently be questioned.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6. EXCEPTIONS TO WINDOW PERIOD</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">Tax Withholding. This policy permits the withholding, by the Company, of stock subject to an option or restricted stock award to satisfy any exercise price and&#47;or to cover any tax withholding liability. The Company may, in its sole discretion and in accordance with the terms of the Company&#8217;s stock option plans, withhold stock for such purposes but the Company is not obligated to do so. This policy does not apply to the sale of stock mandated by the Company in order to satisfy tax withholding obligations upon the vesting of any restricted stock.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">10b5-1 Automatic Trading Programs. A 10b5-1 trading plan is a binding, written contract between you and your broker that specifies the price, amount, and date of trades to be executed in your account in the future or provides a formula or mechanism that your broker will follow (a &#8220;Trading Plan&#8221;). A Trading Plan can only be established when you do not possess material, nonpublic information. Therefore, Covered Insiders cannot enter into these plans at any time when in possession of material, nonpublic information and cannot enter into these plans outside window periods. A Trading Plan must not permit you to exercise any subsequent influence over how, when or whether the trades are made and must comply with all other applicable requirements of Rule 105b-1 under the Securities and Exchange Act of 1934, as amended (the (&#8220;Exchange Act&#8221;), including, without limitation, requirements related to&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.4pt">Minimum cooling off periods (between when the plan is entered into and when trading can commence under the plan).</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.25pt">Representations of Directors and officers.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.25pt">Good-faith requirements.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">Prohibitions on multiple overlapping plans and single-trade plans, all in accordance with the Company&#8217;s 10b5-1 Trading Plan Policy (the &#8220;10b5-1 Policy&#8221;).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">You may have an affirmative defense against any claim by the SEC against you for insider trading if your trade was made under a Trading Plan that complied with all applicable requirements of Rule </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10b5-1 under the Exchange Act, which are very complex. You should consult with your legal and tax advisors before proceeding. Each Covered Insider must submit a request in writing for pre-clearance (see Section 9) of such person&#8217;s proposed Trading Plan in accordance with the terms of the Company&#8217;s 10b5-1 Policy. The Company reserves the right to withhold pre- clearance of any Trading Plan that the Company determines is not consistent with the rules regarding such plans.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7. PROHIBITION OF SPECULATIVE OR SHORT-TERM TRADING</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">No Director, officer, employee or consultant or their immediate family members may engage in short sales, transactions in put or call options, hedging transactions, margin accounts, pledges, or other inherently speculative transactions with respect to the Company&#8217;s stock at any time.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8. COVERED INSIDERS</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Covered insiders are the individuals described below (collectively, &#8220;Covered Insiders&#8221;)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Current Directors of the Company and their respective affiliates.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">&#8220;Executive officers&#8221; of the Company as described in Rule 3b-7 under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), and all individuals designated as &#8220;officers&#8221; of the Company for purposes of &#8220;Section 16&#8221; under the Exchange Act (&#8220;Section 16 Officers&#8221;) and their respective affiliates.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">All employees and consultants of the Company and their respective affiliates.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">Immediate family members (parents, siblings, spouses, children) and household members of each of the foregoing groups.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Covered Insiders are subject to Sections 5, 9 and 13 because of their access to sensitive Company information. Company employees and consultants who are not Covered Insiders must adhere to each of the other terms of this policy (i.e., those terms that are not solely applicable to Covered Insiders). Sections 10, 11 and 12 set forth additional restrictions on Directors and officers of the Company. These sections, as applicable, also apply to immediate family members (as defined in Section 1) of any such Covered Insider.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9. PRE-CLEARANCE</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In addition to the requirements of Sections 5 and 13, Covered Insiders may not engage in any transaction in the Company&#8217;s securities, including any purchase or sale in the open market, loan, pledge, hedge or other transfer of beneficial ownership without first obtaining pre- clearance of the transaction from the Compliance Officer. A request for pre-clearance should be submitted to the Compliance Officer by submitting an email to david.garcia&#64;capsovision.com requesting pre-clearance communicated by the Covered Insiders, at least one business day in advance of the proposed transaction. The Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance and may determine not to permit the transaction. If a person seeks pre-clearance and permission to engage in the transaction is denied, then he or she should refrain from initiating any transaction in Company securities and should not inform any other person of the restriction. When a request for pre-clearance is made, the requestor should carefully consider whether he or she may be aware of any material nonpublic information about the Company and should describe fully those circumstances to the Compliance Officer. The requestor should also indicate whether he or she has affected any non- exempt &#8220;opposite-way&#8221; transactions within the past six months. Directors and officers will also be required to comply with the requirements of Section 16 of the Exchange Act of 1934 (&#8220;Section 16&#8221;). The Compliance Officer will then determine whether the transaction may proceed and, if so, will assist the individual in complying with the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">reporting requirements under &#8220;Section 16&#8221; (a), if any. Unless revoked, a grant of permission will normally remain valid until the close of trading five days following the day on which it was granted. If the transaction does not occur during the five-day period, pre-clearance of the transaction shall require new pre- clearance under the provisions of this Section 9. The Company may, at its discretion, shorten such period of time.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10. NOTICE UPON COMPLETION OF TRANSACTIONS</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Upon completion of any transaction, officers and Directors subject to the reporting obligations under &#8220;Section 16&#8221; of the Exchange Act must immediately notify a Compliance Officer so that the Company may assist in any &#8220;Section 16&#8221; reporting obligations.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11. SHORT-SWING TRADING&#47;CONTROL STOCK&#47;&#8221; SECTION 16&#8221; REPORTS</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Officers and Directors subject to the reporting obligations under &#8220;Section 16&#8221; are responsible for adhering to the prohibition on short-swing trading &#8220;Section 16&#8221;(b) and the restrictions on sales by control persons (Rule 144 under the Securities Act of 1933, as amended), and should file all appropriate &#8220;Section 16&#8221;(a) reports (Forms 3, 4 and 5), which are enumerated and described in &#8220;Section 16&#8221;, and any notices of sale required by Rule 144. This means that &#8220;Section 16&#8221; officers and Directors who purchase Company securities may not sell any Company securities of the same class for at least six months after the purchase. This prohibition does not apply to stock option exercises (whether regular or cashless) and Employee Stock Purchase Plan purchases.</font></div><div style="text-align:justify;text-indent:-0.05pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Note that in addition to this Policy, under &#8220;Section 16&#8221;(b) of the Exchange Act, any &#8220;short-swing profits&#8221; realized by a &#8220;Section 16&#8221; officer or director of the Company from a &#8220;matching&#8221; purchase and sale or &#8220;matching&#8221; sale and purchase of Company stock occurring within a six- month period would be subject to disgorgement to the Company. Note that under &#8220;Section 16&#8221;(b), the highest sale price is matched with the lowest purchase price in determining profit, and purchases and sales that result in a loss are ignored&#8212; meaning that under these rules, you could be deemed to have a profit to be disgorged even though you actually lose money on your trades in the aggregate. There is an active group of lawyers that track purchases and sales by &#8220;Section 16&#8221; officers and Directors for violation of these rules. There is no defense against a violation of these rules.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">12. PROHIBITION OF TRADING DURING BLACKOUTS</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In accordance with Regulation BTR (Blackout Trading Restriction) under the Exchange Act, no Covered Insider shall, directly or indirectly, purchase, sell or otherwise acquire or transfer any equity security of the Company (other than an exempt security) during any &#8220;blackout period&#8217;&#8217; (as defined in Regulation BTR) with respect to such equity security, if the Covered Insider acquires or previously acquired such equity security in connection with his or her service or employment. This prohibition shall not apply to any transactions that are specifically exempted from Section 306(a)(1) of the Sarbanes-Oxley Act of 2002 (as set forth in Regulation BTR), including but not limited to, purchases or sales of the Company&#8217;s securities made pursuant to, and in compliance with, a Trading Plan&#59; compensatory grants or awards of equity securities pursuant to a plan that, by its terms, permits Covered Insiders to receive automatic grants or awards and specifies the terms of the grants and awards&#59; or acquisitions or dispositions of equity securities involving a bona fide gift or by will or the laws of descent or pursuant to a domestic relations order. The Company shall timely notify Covered Insiders of any blackout periods in accordance with the provisions of Regulation BTR.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">13. QUARTERLY BLACKOUT PERIODS</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Announcement of quarterly financial results almost always has the potential to have a material effect on the market for its securities. Therefore, to avoid even the appearance of trading on the basis of material, non-public information, and to assist compliance with insider trading laws, the Company has created the following blackout periods during which Covered Insiders may not trade in the securities of the Company&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">From March 16 until the end of the second trading day following public announcement of first quarter financial results&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">From June 16 until the end of the second trading day following public announcement of second quarter financial results&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">From September 16 until the end of the second trading day following public announcement of third quarter financial results&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.53pt">From December 16 until the end of the second trading day following public announcement of fourth quarter and year-end financial results.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Other Blackout Periods. From time to time, other types of material non-public information regarding the Company (such as negotiation of mergers, acquisitions or dispositions, new product developments, clinical trials, or other material events) may be pending and not be publicly disclosed. While such material non-public information is pending, the Company may impose special blackout periods during which Covered Insiders are prohibited from trading in the Company&#8217;s securities.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">14. STOCK OPTION EXERCISES&#59; SALE OF OPTION SHARES</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Covered Insiders may exercise vested Company stock options at any time. However, Insiders may only sell the shares obtained from such exercises if they do not possess material nonpublic corporate information when they sell these shares by complying with the pre-clearance procedure as described in Section 9 during the Window Period (as defined in Section 5).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">15. RESTRICTIONS ON TIPPING</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The term &#8220;insider trading&#8221; refers to the use of inside information (as defined in Section 2) both in trading securities or in passing on or &#8220;tipping&#8221; such information to others. As a result, in addition to refraining from trading for their own account Insiders are prohibited from engaging in any other action to take advantage of, or to communicate to others (&#8220;tip&#8221;), such information. An Insider who tips information to a person who then trades is subject to the same penalties as the tippee, even if the Insider did not trade and did not profit from the tippee&#8217;s trading.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">16. DURATION OF POLICY&#8217;S APPLICABILITY</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This policy continues to apply to your transactions in the Company&#8217;s stock or the stock of other companies engaged in business transactions with the Company even after your employment, directorship or consultancy with the Company has terminated. If you are in possession of inside information when your relationship with the Company concludes, you may not trade in the Company&#8217;s stock or the stock of such other company until the information has been publicly disseminated or is no longer material.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">17. PENALTIES</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Insider trading results in any one or more of the following legal problems&#58;</font></div><div style="text-indent:-0.05pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt">A private lawsuit may be brought against the Insider by a stockholder of the Company. This private action may be brought either by a person who has purchased from, or sold to, an insider or by a stockholder suing in the name of the Company.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:132%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:132%;padding-left:12.53pt">A civil enforcement action could be brought against the Insider by the SEC seeking&#58;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.4pt">A monetary penalty (in an amount up to three times the profit gained, or the loss</font></div><div style="padding-left:36pt;text-indent:53.94pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.96pt">avoided)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.25pt">A cease-and-desist order</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.25pt">An order barring the insider from serving as an officer and director of any public company</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Especially serious cases could result in a criminal felony prosecution.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">You should be aware that the Company cannot defend you against an insider trading violation. You would have to bear the costs of defending yourself, and those costs can be staggering. In addition, the damage to your reputation -- and that of the Company -- as a result of an insider</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">trading violation could be irreparable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Anyone who effects transactions in the Company&#8217;s stock or the stock of other companies engaged in business transactions with the Company (or provides information to enable others to do so) on the basis of inside information is subject to both civil liability and criminal penalties, as well as disciplinary action by the Company, whether or not such person&#8217;s failure to comply results in a violation of law. Each person is responsible for making sure that any applicable immediate family member, household member or entity whose transactions are subject to this Policy also complies with this Policy, and failure to do so will constitute a failure to comply with this Policy. A Director, officer, employee or consultant who has questions about this policy should contact his or her own attorney or a Compliance Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Any purchases or sales by an insider resulting in &#8220;Section 16&#8221;(b) liability will be the subject of disciplinary action including immediate termination of employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In addition to the forfeiture of short swing profits to the company, the individual will be responsible for all costs associated with such liability, including but not limited to, legal fees.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>cv-20260326xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i35c55b2b91bd4cab936b0919d6c40ab7_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:107%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%"> &#160;&#160;&#160;&#160;We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-288615) of CapsoVision, Inc. (the &#8220;Company&#8221;) of our report dated March 26, 2026, relating to the financial statements of the Company (which report expresses an unqualified opinion and includes an explanatory paragraph relating to a going concern uncertainty), appearing in the Annual Report on Form 10-K of the Company for the year ended December 31, 2025, filed with the Securities and Exchange Commission.              </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:107%">&#47;s&#47; BAKER TILLY US, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%">Santa Clara, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%">March 26, 2026</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>cv-20260326xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i3474d6161a284899bdd0c931447c0e76_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Kang-Huai (Johnny) Wang, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of CapsoVision, Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 26, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Kang-Huai (Johnny) Wang</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Kang-Huai (Johnny) Wang</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Director, President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>cv-20260326xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i6abf49566f714a63b2c11ebbbc143f25_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, David Garcia, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of CapsoVision, Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 26, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; David Garcia</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">David Garcia</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Senior VP of Finance<br>(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>cv-20260326xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i0d31a3fca8844aa6b2bdd8d3c0e5a743_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of CapsoVision, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Annual Report&#8221;), I certify pursuant to 18 U.S.C. &#167;1350, as adopted by pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Annual Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 26, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Kang-Huai (Johnny) Wang</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Kang-Huai (Johnny) Wang</font></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Director, President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>cv-20260326xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i4f9908c273ca4e12948d1ede9e77f49c_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT PURSUANT TO</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of CapsoVision, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Annual Report&#8221;), I certify pursuant to 18 U.S.C. &#167;1350, as adopted by pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Annual Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 26, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; David Garcia</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">David Garcia</font></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Senior VP of Finance<br>(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>10
<FILENAME>cv-20260326xex971.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ia88d164bb07e4620af5e7abe1797510e_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 97.1</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">Policy Regarding the Recoupment of Certain Compensation Payments</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Adopted by the Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">on May 27, 2025</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">In the event CapsoVision, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws (including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period), the Company shall recover reasonably promptly the amount of any erroneously awarded Incentive-Based Compensation from each Covered Individual unless an exception (set forth below) applies.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Incentive-Based Compensation shall be considered &#8220;erroneously awarded&#8221; under this policy to the extent such Incentive-Based Compensation (1) is received by the Covered Individual while the Company has a class of securities listed on a national securities exchange or a national securities association, (2) is received by the Covered Individual during the three completed fiscal years immediately preceding the date that the Company is required to prepare the accounting restatement (and any transition period applicable to a change in the Company&#8217;s fiscal year as required by The Nasdaq Stock Market LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Nasdaq</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) listing rules), and (3) the amount of such received Incentive-Based Compensation exceeds the amount of the Incentive-Based Compensation that would have been received by the Covered Individual had it been determined based on the restated financial results (with such Incentive-Based Compensation computed in each case without regard to any taxes paid).  For purposes of this policy, the date that the Company is required to prepare the accounting restatement is the earlier to occur of (A) the date the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), or a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare such accounting restatement, or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare such accounting restatement. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">For purposes of this policy, Incentive-Based Compensation is considered &#8220;received&#8221; by a Covered Individual in the Company&#8217;s fiscal period during which the Financial Reporting Measure applicable to the Incentive-Based Compensation is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that fiscal period.  For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the amount of erroneously awarded compensation will be determined by the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) based on a reasonable estimate of the effect of the accounting restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received.  The Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq as required by Nasdaq listing rules.  If the erroneously awarded Incentive-Based Compensation consists of shares (including share-denominated equity awards) or options that are still held by the Covered Individual at the time of recovery, the recoverable amount is the number of shares or options received in excess of the number of shares or options that would have been received based on the accounting restatement (or the value of that excess number).  If the options have been exercised but the underlying shares have not been sold, the recoverable amount is the number of shares underlying the excess options based on the restatement (or the value thereof).  If the shares have been sold, the recoverable amount is the proceeds </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">that were received in connection with the sale of the excess number of shares.  Amounts credited under plans (other than tax-qualified plans for which the exception set forth below applies) based on erroneously awarded Incentive-Based Compensation and any accrued earnings thereon are also recoverable under this policy.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The Company shall not be required under this policy to recover erroneously awarded Incentive-Based Compensation if the Committee has made a determination that recovery would be impracticable and either of the following conditions are met&#58; (1) after making a reasonable attempt to recover such erroneously awarded Incentive-Based Compensation, the Committee determines that the direct expense paid to a third party to assist in enforcing this policy would exceed the amount to be recovered (documentation evidencing the reasonable attempt to recover the erroneously awarded Incentive-Based Compensation must be maintained and provided to Nasdaq as required by listing rules), or (2) the recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Internal Revenue Code Section 401(a)(13) or Internal Revenue Code Section 411(a) and the regulations thereunder.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">For purposes of this policy, the following definitions will apply&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Covered Individual</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means any current or former officer of the Company who is or was subject to Section 16 of the Securities Exchange Act of 1934, as amended, at any time during the applicable performance period for the relevant Incentive-Based Compensation, regardless of whether such individual continues to hold such position or continues to be employed by the Company or any of its subsidiaries.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures (including, for purposes of this policy, stock price and total shareholder return).  A Financial Reporting Measure need not be presented within the Company&#8217;s financial statements or included in a filing with the Securities and Exchange Commission.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">This policy is intended to comply with the requirements of Rule 10D-1 promulgated by the Securities and Exchange Commission and the related listing rules of Nasdaq, and the terms hereof shall be construed consistent with that intent.  This policy does not limit any other remedies the Company may have available to it in the circumstances, which may include, without limitation, dismissing an employee or initiating other disciplinary procedures.  The provisions of this policy are in addition to (and not in lieu of) any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 (applicable to the Chief Executive Officer and Chief Financial Officer only) and other applicable laws.  The Company shall not indemnify any Covered Individual against the loss of erroneously-awarded Incentive-Based Compensation that is recovered by the Company pursuant to this policy.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">            The Committee shall have the sole authority to construe and interpret this policy and to make all determinations required to be made pursuant to this policy.  Any such construction, interpretation or determination by the Committee shall be final and binding.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The Committee may revise this policy from time to time.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>cv-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:f6bf459f-a2e0-444d-b980-8a4fe7868fb4,g:35023aa4-34fd-4178-a912-d615028dd0bb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cv="http://capsovision.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://capsovision.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cv-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cv-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cv-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cv-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVERPAGE" roleURI="http://capsovision.com/role/COVERPAGE">
        <link:definition>0000001 - Document - COVER PAGE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AUDITINFORMATION" roleURI="http://capsovision.com/role/AUDITINFORMATION">
        <link:definition>0000002 - Document - AUDIT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSUNAUDITED" roleURI="http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED">
        <link:definition>9952151 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSUNAUDITEDParenthetical" roleURI="http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical">
        <link:definition>9952152 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" roleURI="http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED">
        <link:definition>9952153 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED" roleURI="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED">
        <link:definition>9952154 - Statement - CONDENSED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" roleURI="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED">
        <link:definition>9952155 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTURE" roleURI="http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTURE">
        <link:definition>9952156 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOINGCONCERN" roleURI="http://capsovision.com/role/GOINGCONCERN">
        <link:definition>9952157 - Disclosure - GOING CONCERN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://capsovision.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>9952159 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTS" roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTS">
        <link:definition>9952160 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEANDDEFERREDREVENUE" roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUE">
        <link:definition>9952161 - Disclosure - REVENUE AND DEFERRED REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOTEPAYABLE" roleURI="http://capsovision.com/role/NOTEPAYABLE">
        <link:definition>9952162 - Disclosure - NOTE PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://capsovision.com/role/LEASES">
        <link:definition>9952163 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://capsovision.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREFERREDSTOCK" roleURI="http://capsovision.com/role/PREFERREDSTOCK">
        <link:definition>9952165 - Disclosure - PREFERRED STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMONSTOCK" roleURI="http://capsovision.com/role/COMMONSTOCK">
        <link:definition>9952166 - Disclosure - COMMON STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>9952167 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTS" roleURI="http://capsovision.com/role/SEGMENTS">
        <link:definition>9952168 - Disclosure - SEGMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://capsovision.com/role/INCOMETAXES">
        <link:definition>9952169 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://capsovision.com/role/NETLOSSPERSHARE">
        <link:definition>9952170 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTIES" roleURI="http://capsovision.com/role/RELATEDPARTIES">
        <link:definition>9952171 - Disclosure - RELATED PARTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://capsovision.com/role/SUBSEQUENTEVENTS">
        <link:definition>9952172 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSTables" roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSTables">
        <link:definition>9955513 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEANDDEFERREDREVENUETables" roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUETables">
        <link:definition>9955514 - Disclosure - REVENUE AND DEFERRED REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://capsovision.com/role/LEASESTables">
        <link:definition>9955515 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREFERREDSTOCKTables" roleURI="http://capsovision.com/role/PREFERREDSTOCKTables">
        <link:definition>9955516 - Disclosure - PREFERRED STOCK (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMONSTOCKTables" roleURI="http://capsovision.com/role/COMMONSTOCKTables">
        <link:definition>9955517 - Disclosure - COMMON STOCK (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9955518 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://capsovision.com/role/INCOMETAXESTables">
        <link:definition>9955519 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://capsovision.com/role/NETLOSSPERSHARETables">
        <link:definition>9955520 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails" roleURI="http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails">
        <link:definition>9955521 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOINGCONCERNDetails" roleURI="http://capsovision.com/role/GOINGCONCERNDetails">
        <link:definition>9955522 - Disclosure - GOING CONCERN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails" roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails">
        <link:definition>9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSInventoryDetails" roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails">
        <link:definition>9955525 - Disclosure - BALANCE SHEET COMPONENTS - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9955526 - Disclosure - BALANCE SHEET COMPONENTS - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails" roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails">
        <link:definition>9955527 - Disclosure - BALANCE SHEET COMPONENTS - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSAdditionalInformationDetails" roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSAdditionalInformationDetails">
        <link:definition>9955528 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9955529 - Disclosure - BALANCE SHEET COMPONENTS - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails" roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails">
        <link:definition>9955530 - Disclosure - REVENUE AND DEFERRED REVENUE - Revenue Disaggregation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEANDDEFERREDREVENUEAdditionalInformationDetails" roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails">
        <link:definition>9955531 - Disclosure - REVENUE AND DEFERRED REVENUE - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOTEPAYABLEDetails" roleURI="http://capsovision.com/role/NOTEPAYABLEDetails">
        <link:definition>9955532 - Disclosure - NOTE PAYABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESAdditionalInformationDetails" roleURI="http://capsovision.com/role/LEASESAdditionalInformationDetails">
        <link:definition>9955533 - Disclosure - LEASES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTotalLeaseExpenseDetails" roleURI="http://capsovision.com/role/LEASESTotalLeaseExpenseDetails">
        <link:definition>9955534 - Disclosure - LEASES - Total Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails" roleURI="http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails">
        <link:definition>9955535 - Disclosure - LEASES - Lease-Related Amounts Reflected in the Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSupplementalCashFlowsDetails" roleURI="http://capsovision.com/role/LEASESSupplementalCashFlowsDetails">
        <link:definition>9955536 - Disclosure - LEASES - Supplemental Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESFutureMinimumLeasePaymentsDetails" roleURI="http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails">
        <link:definition>9955537 - Disclosure - LEASES - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9955538 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREFERREDSTOCKAdditionalInformationDetails" roleURI="http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails">
        <link:definition>9955539 - Disclosure - PREFERRED STOCK - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREFERREDSTOCKPreferredStockDetails" roleURI="http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails">
        <link:definition>9955540 - Disclosure - PREFERRED STOCK - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMONSTOCKAdditionalInformationDetails" roleURI="http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails">
        <link:definition>9955541 - Disclosure - COMMON STOCK - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMONSTOCKBlackScholesOptionPricingModelDetails" roleURI="http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails">
        <link:definition>9955542 - Disclosure - COMMON STOCK - Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMONSTOCKCommonStockReservedforFutureIssuanceDetails" roleURI="http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails">
        <link:definition>9955543 - Disclosure - COMMON STOCK - Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONAdditionalInformationDetails" roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails">
        <link:definition>9955544 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockOptionActivityDetails" roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails">
        <link:definition>9955545 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails" roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails">
        <link:definition>9955546 - Disclosure - STOCK-BASED COMPENSATION - Black-Scholes Option Pricing Model Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails">
        <link:definition>9955547 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails">
        <link:definition>9955548 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTSDetails" roleURI="http://capsovision.com/role/SEGMENTSDetails">
        <link:definition>9955549 - Disclosure - SEGMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" roleURI="http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails">
        <link:definition>9955550 - Disclosure - INCOME TAXES - Domestic and Foreign Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofIncomeTaxProvisionDetails" roleURI="http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails">
        <link:definition>9955551 - Disclosure - INCOME TAXES - Components of Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails" roleURI="http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails">
        <link:definition>9955552 - Disclosure - INCOME TAXES - Reconciliation of Federal Statutory Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESCashPaidforIncomeTaxesDetails" roleURI="http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails">
        <link:definition>9955553 - Disclosure - INCOME TAXES - Cash Paid for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" roleURI="http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>9955554 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESAdditionalInformationDetails" roleURI="http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails">
        <link:definition>9955555 - Disclosure - INCOME TAXES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails" roleURI="http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails">
        <link:definition>9955556 - Disclosure - INCOME TAXES - NOLs and Tax Credit Carryforward Values (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESUnrecognizedTaxPositionsDetails" roleURI="http://capsovision.com/role/INCOMETAXESUnrecognizedTaxPositionsDetails">
        <link:definition>9955557 - Disclosure - INCOME TAXES - Unrecognized Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREDetails" roleURI="http://capsovision.com/role/NETLOSSPERSHAREDetails">
        <link:definition>9955558 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREAntidilutiveSecuritiesDetails" roleURI="http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails">
        <link:definition>9955559 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTIESDetails" roleURI="http://capsovision.com/role/RELATEDPARTIESDetails">
        <link:definition>9955560 - Disclosure - RELATED PARTIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://capsovision.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9955561 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cv_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" abstract="false" name="PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cv_UnderwriterMember" abstract="true" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_SaleOfStockEffectivenessDate" abstract="false" name="SaleOfStockEffectivenessDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="cv_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_HealthcareClinicalTrialActivitiesMember" abstract="true" name="HealthcareClinicalTrialActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_GroupPurchasingOrganizationFeesContraRevenue" abstract="false" name="GroupPurchasingOrganizationFeesContraRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_ShortTermDebtOriginationDate" abstract="false" name="ShortTermDebtOriginationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="cv_RelatedPartyTransactionRatePerMonth" abstract="false" name="RelatedPartyTransactionRatePerMonth" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cv_ShortTermNonBankLoansAndNotesPaymentDate" abstract="false" name="ShortTermNonBankLoansAndNotesPaymentDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_TemporaryEquityLegacyConversionRatio" abstract="false" name="TemporaryEquityLegacyConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cv_TemporaryEquityLegacyConversionPricePerShareMinimum" abstract="false" name="TemporaryEquityLegacyConversionPricePerShareMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cv_TemporaryEquityLegacyConversionPricePerShareMaximum" abstract="false" name="TemporaryEquityLegacyConversionPricePerShareMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum" abstract="false" name="ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_TemporaryEquityDividendRatePercentage" abstract="false" name="TemporaryEquityDividendRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cv_NumberOfBoardMembers" abstract="false" name="NumberOfBoardMembers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cv_SeriesC1PreferredStockMember" abstract="true" name="SeriesC1PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_SeriesD1PreferredStockMember" abstract="true" name="SeriesD1PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_SeriesD2PreferredStockMember" abstract="true" name="SeriesD2PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_SeriesF1PreferredStockMember" abstract="true" name="SeriesF1PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_SeriesF2PreferredStockMember" abstract="true" name="SeriesF2PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_SeriesG1PreferredStockMember" abstract="true" name="SeriesG1PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cv_TwoThousandAndFivePlanMember" abstract="true" name="TwoThousandAndFivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_TwoThousandAndTwentyFivePlanMember" abstract="true" name="TwoThousandAndTwentyFivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_FutureGrantsMember" abstract="true" name="FutureGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cv_TaxYearAfter2017Member" abstract="true" name="TaxYearAfter2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_TaxYearBefore2018Member" abstract="true" name="TaxYearBefore2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_TaxYearIndefiniteMember" abstract="true" name="TaxYearIndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_TaxYearDefiniteLivedMember" abstract="true" name="TaxYearDefiniteLivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cv_OperatingLossCarryforwardsExpirationTerm" abstract="false" name="OperatingLossCarryforwardsExpirationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cv_TaxCreditCarryforwardExpirationTerm" abstract="false" name="TaxCreditCarryforwardExpirationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cv_SaleOfStockRegistrationRightsAgreementDate" abstract="false" name="SaleOfStockRegistrationRightsAgreementDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>cv-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:f6bf459f-a2e0-444d-b980-8a4fe7868fb4,g:35023aa4-34fd-4178-a912-d615028dd0bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="cv-20251231.xsd#CONDENSEDBALANCESHEETSUNAUDITED"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a3e68a16-3325-4174-bbc5-fe4e560d2871" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9a02e012-3b4b-42ba-b029-157eb343a725" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a3e68a16-3325-4174-bbc5-fe4e560d2871" xlink:to="loc_us-gaap_LiabilitiesCurrent_9a02e012-3b4b-42ba-b029-157eb343a725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9573f71a-b530-4705-a605-8997865ba02e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a3e68a16-3325-4174-bbc5-fe4e560d2871" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9573f71a-b530-4705-a605-8997865ba02e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_24b6b9fb-7b50-4ab8-b9b7-bbf57516f308" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_32efb173-88d5-47bc-83e4-be45aee1ae8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_24b6b9fb-7b50-4ab8-b9b7-bbf57516f308" xlink:to="loc_us-gaap_AssetsCurrent_32efb173-88d5-47bc-83e4-be45aee1ae8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_38261cc0-994f-47fc-bfff-0ebdc75a805d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_24b6b9fb-7b50-4ab8-b9b7-bbf57516f308" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_38261cc0-994f-47fc-bfff-0ebdc75a805d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5159c46-9565-44ea-9fd0-3b2d0b5a8209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_24b6b9fb-7b50-4ab8-b9b7-bbf57516f308" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5159c46-9565-44ea-9fd0-3b2d0b5a8209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6a5242f9-dc65-4740-8541-b185c5a5faf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_24b6b9fb-7b50-4ab8-b9b7-bbf57516f308" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6a5242f9-dc65-4740-8541-b185c5a5faf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bd344c1b-e224-4b92-ac48-c5cb6914cd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_72b81a08-6c2a-49f2-96f1-877ba4062fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bd344c1b-e224-4b92-ac48-c5cb6914cd9e" xlink:to="loc_us-gaap_AccountsPayableCurrent_72b81a08-6c2a-49f2-96f1-877ba4062fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9f93256c-e110-4aab-a9a5-09c5f78eedb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bd344c1b-e224-4b92-ac48-c5cb6914cd9e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9f93256c-e110-4aab-a9a5-09c5f78eedb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_421973a9-29af-46cc-bae7-1434bd6fcf09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bd344c1b-e224-4b92-ac48-c5cb6914cd9e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_421973a9-29af-46cc-bae7-1434bd6fcf09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_234d5d9d-1d45-40a6-b9bf-971c7d9e443c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bd344c1b-e224-4b92-ac48-c5cb6914cd9e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_234d5d9d-1d45-40a6-b9bf-971c7d9e443c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_84d7b806-f596-44d5-89a6-fb79f5724149" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_22004a99-f141-473d-a240-b1e0355f4319" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84d7b806-f596-44d5-89a6-fb79f5724149" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_22004a99-f141-473d-a240-b1e0355f4319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9ef44bfe-bbf1-4f28-917b-4930bd94a3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84d7b806-f596-44d5-89a6-fb79f5724149" xlink:to="loc_us-gaap_StockholdersEquity_9ef44bfe-bbf1-4f28-917b-4930bd94a3e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e1e2de58-7fb2-4a03-b6cc-36427250ff79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84d7b806-f596-44d5-89a6-fb79f5724149" xlink:to="loc_us-gaap_Liabilities_e1e2de58-7fb2-4a03-b6cc-36427250ff79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c2115521-ca47-4c47-a394-133c256d6b11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_fcbbf380-6844-4154-980b-22599e87586a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2115521-ca47-4c47-a394-133c256d6b11" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_fcbbf380-6844-4154-980b-22599e87586a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f125fa20-47c7-4d16-93f1-13074206a445" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2115521-ca47-4c47-a394-133c256d6b11" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f125fa20-47c7-4d16-93f1-13074206a445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5fcdeaef-b020-408a-95cb-5f22d0d441b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2115521-ca47-4c47-a394-133c256d6b11" xlink:to="loc_us-gaap_InventoryNet_5fcdeaef-b020-408a-95cb-5f22d0d441b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e967685a-c5ad-489d-a9dd-3319b659bd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2115521-ca47-4c47-a394-133c256d6b11" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e967685a-c5ad-489d-a9dd-3319b659bd1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d46d49dc-be3d-4d4b-867c-52eb5becab02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_472d9e97-5ebf-44b6-a02c-ded1d3854b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d46d49dc-be3d-4d4b-867c-52eb5becab02" xlink:to="loc_us-gaap_CommonStockValue_472d9e97-5ebf-44b6-a02c-ded1d3854b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_60adcf10-b564-483c-8acd-5ee6c8342ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d46d49dc-be3d-4d4b-867c-52eb5becab02" xlink:to="loc_us-gaap_AdditionalPaidInCapital_60adcf10-b564-483c-8acd-5ee6c8342ed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14386393-52e4-45bc-91a2-1965ace361dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d46d49dc-be3d-4d4b-867c-52eb5becab02" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14386393-52e4-45bc-91a2-1965ace361dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" xlink:type="simple" xlink:href="cv-20251231.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d86f0351-90f3-425f-9e10-49b5a33abccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_af91ef08-f40f-4bb5-9dec-04d30a5575cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d86f0351-90f3-425f-9e10-49b5a33abccc" xlink:to="loc_us-gaap_InvestmentIncomeNet_af91ef08-f40f-4bb5-9dec-04d30a5575cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b6aaa0ab-f6ee-4b3a-8d91-5a5aee106e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d86f0351-90f3-425f-9e10-49b5a33abccc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b6aaa0ab-f6ee-4b3a-8d91-5a5aee106e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c8a08eca-aa64-4b70-805f-4b7ad5d758a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_018004c5-56df-4e20-bb4c-d5402b284b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c8a08eca-aa64-4b70-805f-4b7ad5d758a0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_018004c5-56df-4e20-bb4c-d5402b284b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e16fa0be-ce72-48ef-8599-64a19bffde85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c8a08eca-aa64-4b70-805f-4b7ad5d758a0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e16fa0be-ce72-48ef-8599-64a19bffde85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3dbbeafc-8cb2-4e56-9c4e-cdb5d598b21a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7878ebee-b757-4af4-ac0e-2f176ff72032" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3dbbeafc-8cb2-4e56-9c4e-cdb5d598b21a" xlink:to="loc_us-gaap_GrossProfit_7878ebee-b757-4af4-ac0e-2f176ff72032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a254cfec-2f1f-4c1a-a1c4-2865856fa15b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3dbbeafc-8cb2-4e56-9c4e-cdb5d598b21a" xlink:to="loc_us-gaap_OperatingExpenses_a254cfec-2f1f-4c1a-a1c4-2865856fa15b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dd85970a-166b-42b0-943f-79afb088c92b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0065508d-d7ef-4efb-8834-f456660ddf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dd85970a-166b-42b0-943f-79afb088c92b" xlink:to="loc_us-gaap_OperatingIncomeLoss_0065508d-d7ef-4efb-8834-f456660ddf6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e4ef263b-590d-47c9-93ef-84f2e05e0701" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dd85970a-166b-42b0-943f-79afb088c92b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e4ef263b-590d-47c9-93ef-84f2e05e0701" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_90aa9939-cee1-4aeb-82da-8e3aa4599821" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_ce884ab9-2a13-48f1-ac4e-6688afaf1210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_90aa9939-cee1-4aeb-82da-8e3aa4599821" xlink:to="loc_us-gaap_SellingAndMarketingExpense_ce884ab9-2a13-48f1-ac4e-6688afaf1210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61d55ce4-9b2e-42c4-adea-e82b55847b10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_90aa9939-cee1-4aeb-82da-8e3aa4599821" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61d55ce4-9b2e-42c4-adea-e82b55847b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0771ddf9-fb3b-4ca6-a2e1-3ba540d372e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_90aa9939-cee1-4aeb-82da-8e3aa4599821" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0771ddf9-fb3b-4ca6-a2e1-3ba540d372e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b8509117-88d0-4ea2-a626-b37692988ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b84e509-a692-4941-b2f6-d6ab536d53dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b8509117-88d0-4ea2-a626-b37692988ec3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b84e509-a692-4941-b2f6-d6ab536d53dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_afb9a314-2f6e-4d20-8109-d8e1ef801909" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b8509117-88d0-4ea2-a626-b37692988ec3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_afb9a314-2f6e-4d20-8109-d8e1ef801909" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="cv-20251231.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_990c21ba-2449-4953-8553-c121cde41570" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_NetIncomeLoss_990c21ba-2449-4953-8553-c121cde41570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2c3a1252-9db3-4383-bfdd-bd46cb97e386" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2c3a1252-9db3-4383-bfdd-bd46cb97e386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_296e1c55-c0af-4fff-b856-f1bd869fbf69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_296e1c55-c0af-4fff-b856-f1bd869fbf69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2dfd2953-5cea-430c-b072-9e05043cf572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2dfd2953-5cea-430c-b072-9e05043cf572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_93693dda-96b3-483f-b887-1e1980ac72a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_93693dda-96b3-483f-b887-1e1980ac72a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d10a766b-a66d-4232-a779-8e09ff0b629e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_ShareBasedCompensation_d10a766b-a66d-4232-a779-8e09ff0b629e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fedd907c-4b1b-46fb-a7e6-b11432e821c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fedd907c-4b1b-46fb-a7e6-b11432e821c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b5ea3ec1-946c-4163-ba8d-7e146090d82c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b5ea3ec1-946c-4163-ba8d-7e146090d82c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_7169efca-3a07-4e5e-9ce8-5c02c7c6b312" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_7169efca-3a07-4e5e-9ce8-5c02c7c6b312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7cd991b1-1f67-40e2-bcf9-d33cf32e9960" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7cd991b1-1f67-40e2-bcf9-d33cf32e9960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e648936a-3a73-4812-8e3c-185536f0ad1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e648936a-3a73-4812-8e3c-185536f0ad1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6540e50c-f756-4cee-bd46-86f0fadbd957" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6540e50c-f756-4cee-bd46-86f0fadbd957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_93aabfce-13e0-4c26-8581-4fc1d1c7e6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_93aabfce-13e0-4c26-8581-4fc1d1c7e6b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2851820a-4ed0-48e1-969c-aafa4a3b21e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2851820a-4ed0-48e1-969c-aafa4a3b21e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6b95454f-1d77-4b95-80b8-9ab2a50aa510" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6b95454f-1d77-4b95-80b8-9ab2a50aa510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_153048b7-3be0-4dc6-a331-8f94ad009023" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c266a-c64c-4505-91fe-c1a8275d4b42" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_153048b7-3be0-4dc6-a331-8f94ad009023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_729d4f6c-33da-4171-8a99-476c0b5a0526" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d832ad58-6fac-44d1-b0ae-68bbf0b6a73d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_729d4f6c-33da-4171-8a99-476c0b5a0526" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d832ad58-6fac-44d1-b0ae-68bbf0b6a73d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_355611bb-4813-4530-89f9-9e8d6237b1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_b1f7354a-b20f-4f32-971d-cce4c447d393" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_355611bb-4813-4530-89f9-9e8d6237b1f1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_b1f7354a-b20f-4f32-971d-cce4c447d393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_eb360788-7667-436c-805a-f24297509c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_355611bb-4813-4530-89f9-9e8d6237b1f1" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_eb360788-7667-436c-805a-f24297509c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_8c621554-e282-442b-9f3d-27175b77c488" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_355611bb-4813-4530-89f9-9e8d6237b1f1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_8c621554-e282-442b-9f3d-27175b77c488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_54a03bbf-16d7-411d-be4c-23393af04e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_355611bb-4813-4530-89f9-9e8d6237b1f1" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_54a03bbf-16d7-411d-be4c-23393af04e6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_71cc6051-2e4b-4035-bff4-b0dc6f77bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_355611bb-4813-4530-89f9-9e8d6237b1f1" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_71cc6051-2e4b-4035-bff4-b0dc6f77bb9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_5a2781be-db11-4c14-be66-a4f97b312b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_355611bb-4813-4530-89f9-9e8d6237b1f1" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_5a2781be-db11-4c14-be66-a4f97b312b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ec9f2c1a-07f1-4b78-94a3-5889e310e322" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_943e05e9-b044-458d-a699-8c57fecf7961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ec9f2c1a-07f1-4b78-94a3-5889e310e322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_943e05e9-b044-458d-a699-8c57fecf7961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b17160f7-89c6-42a2-800e-b8748724c571" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ec9f2c1a-07f1-4b78-94a3-5889e310e322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b17160f7-89c6-42a2-800e-b8748724c571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9fd3471-75a7-4421-8e96-00e860ba49da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ec9f2c1a-07f1-4b78-94a3-5889e310e322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9fd3471-75a7-4421-8e96-00e860ba49da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSInventoryDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cc684514-eff9-4f78-8c55-a0a36a61269c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4f89dfba-1359-41f2-8f8e-30e10d014c47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc684514-eff9-4f78-8c55-a0a36a61269c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4f89dfba-1359-41f2-8f8e-30e10d014c47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ede974a8-c70d-4a7b-992e-e65b502df3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc684514-eff9-4f78-8c55-a0a36a61269c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ede974a8-c70d-4a7b-992e-e65b502df3a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3f39da78-2361-40f1-887c-4132b7578323" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc684514-eff9-4f78-8c55-a0a36a61269c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3f39da78-2361-40f1-887c-4132b7578323" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_423fcf51-6a2c-476c-9d76-3cad241fff69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_a17a316d-3eef-4086-a62a-77f80903657c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_423fcf51-6a2c-476c-9d76-3cad241fff69" xlink:to="loc_us-gaap_PrepaidInsurance_a17a316d-3eef-4086-a62a-77f80903657c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_4aac69a4-5849-4b02-b436-0009d2012858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Supplies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_423fcf51-6a2c-476c-9d76-3cad241fff69" xlink:to="loc_us-gaap_Supplies_4aac69a4-5849-4b02-b436-0009d2012858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_7c99bd2d-f55b-4187-bdcf-efa89ebd3e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_423fcf51-6a2c-476c-9d76-3cad241fff69" xlink:to="loc_us-gaap_DeferredOfferingCosts_7c99bd2d-f55b-4187-bdcf-efa89ebd3e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8ccb7308-04d0-4945-9b5f-ab1f29bfc2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_423fcf51-6a2c-476c-9d76-3cad241fff69" xlink:to="loc_us-gaap_OtherAssetsCurrent_8ccb7308-04d0-4945-9b5f-ab1f29bfc2f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_08ac6372-fa60-40a9-b0fa-0ec6113f5559" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_ac3327e5-68ed-4f59-9021-3624f538f632" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_08ac6372-fa60-40a9-b0fa-0ec6113f5559" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_ac3327e5-68ed-4f59-9021-3624f538f632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_43791c7b-c9f0-4268-b981-ec613b8d9976" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_08ac6372-fa60-40a9-b0fa-0ec6113f5559" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_43791c7b-c9f0-4268-b981-ec613b8d9976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_76e18d04-dad9-493d-886c-d22e8fb2c955" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_08ac6372-fa60-40a9-b0fa-0ec6113f5559" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_76e18d04-dad9-493d-886c-d22e8fb2c955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f847f584-2161-4243-9be1-9aeb45db00b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_08ac6372-fa60-40a9-b0fa-0ec6113f5559" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f847f584-2161-4243-9be1-9aeb45db00b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4af3b4e0-87ac-4c35-b5e5-e1f7aac48660" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3d525d5-d4d1-4049-8b1c-c5f44245aedc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4af3b4e0-87ac-4c35-b5e5-e1f7aac48660" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3d525d5-d4d1-4049-8b1c-c5f44245aedc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_AccruedClinicalTrialExpenseCurrent_489f3aec-6bad-4b70-bd5b-28b74f8f943d" xlink:href="cv-20251231.xsd#cv_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4af3b4e0-87ac-4c35-b5e5-e1f7aac48660" xlink:to="loc_cv_AccruedClinicalTrialExpenseCurrent_489f3aec-6bad-4b70-bd5b-28b74f8f943d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_AccruedResearchAndDevelopmentExpenseCurrent_3a101e04-f452-40e4-b387-7b0ac48b3d3c" xlink:href="cv-20251231.xsd#cv_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4af3b4e0-87ac-4c35-b5e5-e1f7aac48660" xlink:to="loc_cv_AccruedResearchAndDevelopmentExpenseCurrent_3a101e04-f452-40e4-b387-7b0ac48b3d3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_4cb070cb-6f4b-4a76-bc83-2cb956bf362e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4af3b4e0-87ac-4c35-b5e5-e1f7aac48660" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_4cb070cb-6f4b-4a76-bc83-2cb956bf362e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_56526469-1774-47c6-9cae-a1bf24ae0603" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4af3b4e0-87ac-4c35-b5e5-e1f7aac48660" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_56526469-1774-47c6-9cae-a1bf24ae0603" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESTotalLeaseExpenseDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESTotalLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/LEASESTotalLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_398e0b88-9596-4b93-adaf-316acbf88c38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_04598a83-c63e-4c4e-9e93-62c13a7936c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_398e0b88-9596-4b93-adaf-316acbf88c38" xlink:to="loc_us-gaap_OperatingLeaseCost_04598a83-c63e-4c4e-9e93-62c13a7936c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_cccf6ad8-53c3-4249-8e92-66e6ec51f6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_398e0b88-9596-4b93-adaf-316acbf88c38" xlink:to="loc_us-gaap_ShortTermLeaseCost_cccf6ad8-53c3-4249-8e92-66e6ec51f6b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_98367457-d09d-4537-93ff-6bae101d13f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_14722279-16e6-47a8-82cf-1b54ccbda74e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_98367457-d09d-4537-93ff-6bae101d13f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_14722279-16e6-47a8-82cf-1b54ccbda74e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3404542b-ef93-4138-b618-aa6308cffe49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_98367457-d09d-4537-93ff-6bae101d13f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3404542b-ef93-4138-b618-aa6308cffe49" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019c4388-76c8-75d7-8f7c-60f6646d50f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019c4388-76c8-7880-acd3-3d71a9f32732" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019c4388-76c8-75d7-8f7c-60f6646d50f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019c4388-76c8-7880-acd3-3d71a9f32732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019c4388-76c8-7d5c-ad53-e8b9854d876a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019c4388-76c8-75d7-8f7c-60f6646d50f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019c4388-76c8-7d5c-ad53-e8b9854d876a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_019c4388-76c8-7799-8c6e-2fe51c6e97d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019c4388-76c8-75d7-8f7c-60f6646d50f0" xlink:to="loc_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_019c4388-76c8-7799-8c6e-2fe51c6e97d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b8f8e-200e-7460-8f93-bf4ce4bb0850" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b8f8e-200e-7d39-8adc-82988e99299b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b8f8e-200e-7460-8f93-bf4ce4bb0850" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b8f8e-200e-7d39-8adc-82988e99299b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b8f8e-200e-7b68-bdf8-c8ffac0b5486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b8f8e-200e-7460-8f93-bf4ce4bb0850" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b8f8e-200e-7b68-bdf8-c8ffac0b5486" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESComponentsofIncomeTaxProvisionDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_019b8f63-5e08-7d76-a04d-139821a66d49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_019b8f63-5e08-79ec-a791-cb78d7ecc2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_019b8f63-5e08-7d76-a04d-139821a66d49" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_019b8f63-5e08-79ec-a791-cb78d7ecc2fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_019b8f63-5e08-7950-9ea3-0368a8715d48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_019b8f63-5e08-7d76-a04d-139821a66d49" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_019b8f63-5e08-7950-9ea3-0368a8715d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b8f63-5e08-7c56-a447-246814ce7580" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_019b8f63-5e08-7d76-a04d-139821a66d49" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b8f63-5e08-7c56-a447-246814ce7580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b8f63-78ab-79ed-9250-35b46b859377" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_019b8f63-78ab-728d-802b-ce522c2bb9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b8f63-78ab-79ed-9250-35b46b859377" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_019b8f63-78ab-728d-802b-ce522c2bb9e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_019b8f63-78ab-7f3c-b7bf-7264f289f633" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b8f63-78ab-79ed-9250-35b46b859377" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_019b8f63-78ab-7f3c-b7bf-7264f289f633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b8f63-78ab-7bd6-a6a1-7f98639ddfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b8f63-78ab-79ed-9250-35b46b859377" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b8f63-78ab-7bd6-a6a1-7f98639ddfd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019b8f63-990d-7dc6-9bda-3f78d2716caa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_019b8f63-990d-74bb-9886-2c22cd7f487d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b8f63-990d-7dc6-9bda-3f78d2716caa" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_019b8f63-990d-74bb-9886-2c22cd7f487d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b8f63-990d-7c1d-93e9-23f7c0812569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b8f63-990d-7dc6-9bda-3f78d2716caa" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b8f63-990d-7c1d-93e9-23f7c0812569" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fe-38e1-7b0b-85fc-2b6b04cb0de0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c95fe-38e1-7a34-b631-f57d0306b462" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fe-38e1-7b0b-85fc-2b6b04cb0de0" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c95fe-38e1-7a34-b631-f57d0306b462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c95fe-38e1-73bf-919b-c25e66bdd706" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fe-38e1-7b0b-85fc-2b6b04cb0de0" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c95fe-38e1-73bf-919b-c25e66bdd706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c95fe-38e1-7082-bb0d-86da8af1a171" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fe-38e1-7b0b-85fc-2b6b04cb0de0" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c95fe-38e1-7082-bb0d-86da8af1a171" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c95fe-38e1-7976-8c5d-505f5fbb3e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fe-38e1-7b0b-85fc-2b6b04cb0de0" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c95fe-38e1-7976-8c5d-505f5fbb3e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c95fe-38e1-7f17-b01c-5bb0ad56fe39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fe-38e1-7b0b-85fc-2b6b04cb0de0" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c95fe-38e1-7f17-b01c-5bb0ad56fe39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c95fe-38e1-70a4-a54e-fea91e50fce4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fe-38e1-7b0b-85fc-2b6b04cb0de0" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c95fe-38e1-70a4-a54e-fea91e50fce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c95fe-38e1-763d-afbb-65685aa1c717" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fe-38e1-7b0b-85fc-2b6b04cb0de0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c95fe-38e1-763d-afbb-65685aa1c717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c95fe-38e1-7f51-a972-0c88f2c15534" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fe-38e1-7b0b-85fc-2b6b04cb0de0" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c95fe-38e1-7f51-a972-0c88f2c15534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7f44-8d7e-51e156356823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b8f5c-95c0-726b-b832-7ec2ad0e0509" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7f44-8d7e-51e156356823" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b8f5c-95c0-726b-b832-7ec2ad0e0509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b8f5c-95c0-756c-8fc2-f8fe2dbc41d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7f44-8d7e-51e156356823" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b8f5c-95c0-756c-8fc2-f8fe2dbc41d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019cbee1-536e-77b7-b8a6-ef7ecb5e1c20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7f44-8d7e-51e156356823" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019cbee1-536e-77b7-b8a6-ef7ecb5e1c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019cbc02-0fcd-7ec2-8f16-263816b9e0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7f44-8d7e-51e156356823" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019cbc02-0fcd-7ec2-8f16-263816b9e0b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019b8f5c-95c0-7e11-b9c9-fe2c4d73a692" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7f44-8d7e-51e156356823" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019b8f5c-95c0-7e11-b9c9-fe2c4d73a692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019b8f5c-95c0-7f54-9d48-1a7ff64a475b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7f44-8d7e-51e156356823" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019b8f5c-95c0-7f54-9d48-1a7ff64a475b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019b8f5c-95c0-722a-943f-e6bf3b9aca5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7f44-8d7e-51e156356823" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019b8f5c-95c0-722a-943f-e6bf3b9aca5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019cbc16-e811-7b67-85fc-65f3a063ec86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7f44-8d7e-51e156356823" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019cbc16-e811-7b67-85fc-65f3a063ec86" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_019b8f71-a346-75f4-bbb1-10e620520860" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_019b8f71-a346-723a-8d66-ebe25d620101" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_019b8f71-a346-75f4-bbb1-10e620520860" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_019b8f71-a346-723a-8d66-ebe25d620101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b8f71-a346-7c7e-88fe-41e999e9eba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_019b8f71-a346-75f4-bbb1-10e620520860" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b8f71-a346-7c7e-88fe-41e999e9eba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_019b8f71-78ed-79aa-a154-9156ceac1000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b8f71-78ed-7ca7-b27b-2d3a086c5f87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b8f71-78ed-79aa-a154-9156ceac1000" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b8f71-78ed-7ca7-b27b-2d3a086c5f87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_019b8f71-78ed-7bc1-bf97-e46037806b4c" xlink:href="cv-20251231.xsd#cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b8f71-78ed-79aa-a154-9156ceac1000" xlink:to="loc_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_019b8f71-78ed-7bc1-bf97-e46037806b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b8f71-78ed-751b-8e68-e8533dd6a42e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b8f71-78ed-79aa-a154-9156ceac1000" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b8f71-78ed-751b-8e68-e8533dd6a42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_019b8f71-78ed-70f7-a7f6-29c3d8f35691" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b8f71-78ed-79aa-a154-9156ceac1000" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_019b8f71-78ed-70f7-a7f6-29c3d8f35691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_DeferredTaxAssetsOperatingLeaseLiabilities_019b8f71-78ed-7dac-8ce1-718143d5d7b7" xlink:href="cv-20251231.xsd#cv_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b8f71-78ed-79aa-a154-9156ceac1000" xlink:to="loc_cv_DeferredTaxAssetsOperatingLeaseLiabilities_019b8f71-78ed-7dac-8ce1-718143d5d7b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_019b8f71-78ed-744b-804d-112c6794339c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b8f71-78ed-79aa-a154-9156ceac1000" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_019b8f71-78ed-744b-804d-112c6794339c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_019b8f71-dadb-78ba-b74f-9a15585aa808" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b8f71-dadb-748f-937d-15148c9cc053" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_019b8f71-dadb-78ba-b74f-9a15585aa808" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b8f71-dadb-748f-937d-15148c9cc053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b8f71-dadb-76ee-9cf2-0e85d773d062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_019b8f71-dadb-78ba-b74f-9a15585aa808" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b8f71-dadb-76ee-9cf2-0e85d773d062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_019c8d60-8ca5-765a-9367-e189e58e439d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_019b8f71-dadb-78ba-b74f-9a15585aa808" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_019c8d60-8ca5-765a-9367-e189e58e439d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_019b8f72-0a15-7b79-9869-708013d45c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_019b8f72-0a15-74f3-91aa-87084709569a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_019b8f72-0a15-7b79-9869-708013d45c9a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_019b8f72-0a15-74f3-91aa-87084709569a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_019b8f72-0a15-7a3b-bf77-8a0425234aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_019b8f72-0a15-7b79-9869-708013d45c9a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_019b8f72-0a15-7a3b-bf77-8a0425234aa4" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>cv-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:f6bf459f-a2e0-444d-b980-8a4fe7868fb4,g:35023aa4-34fd-4178-a912-d615028dd0bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED" xlink:type="simple" xlink:href="cv-20251231.xsd#CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_87cb4e74-aa36-4116-aa4a-e0f0a5447166" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2cd45fcb-6ad1-4958-8a0a-b97bcb575359" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_87cb4e74-aa36-4116-aa4a-e0f0a5447166" xlink:to="loc_us-gaap_StatementTable_2cd45fcb-6ad1-4958-8a0a-b97bcb575359" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1222d2bf-64d5-41a2-9edb-c4b7b79ae879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2cd45fcb-6ad1-4958-8a0a-b97bcb575359" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1222d2bf-64d5-41a2-9edb-c4b7b79ae879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1222d2bf-64d5-41a2-9edb-c4b7b79ae879_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1222d2bf-64d5-41a2-9edb-c4b7b79ae879" xlink:to="loc_us-gaap_EquityComponentDomain_1222d2bf-64d5-41a2-9edb-c4b7b79ae879_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1222d2bf-64d5-41a2-9edb-c4b7b79ae879" xlink:to="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d1473c8a-41e3-40a4-bbf0-c7f40d589868" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:to="loc_us-gaap_PreferredStockMember_d1473c8a-41e3-40a4-bbf0-c7f40d589868" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f7f3dcc0-7b49-4849-9c11-9d71b731bfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:to="loc_us-gaap_CommonStockMember_f7f3dcc0-7b49-4849-9c11-9d71b731bfa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_69d0fadb-8037-4bda-96b5-23c7389121f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_69d0fadb-8037-4bda-96b5-23c7389121f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c373b5e2-72ba-4a78-9d50-6ec30053aed0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:to="loc_us-gaap_RetainedEarningsMember_c373b5e2-72ba-4a78-9d50-6ec30053aed0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87cb4e74-aa36-4116-aa4a-e0f0a5447166" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3053f03e-220d-4e53-8705-ab730ca5cb35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3053f03e-220d-4e53-8705-ab730ca5cb35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_57dd155b-27be-4e6c-92ef-f75c6a108fad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_57dd155b-27be-4e6c-92ef-f75c6a108fad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_9ea46aa3-824c-4714-b93e-f8cee77845b1" xlink:href="cv-20251231.xsd#cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_9ea46aa3-824c-4714-b93e-f8cee77845b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_29755a7f-9637-49a7-b938-76820e4b0cee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_29755a7f-9637-49a7-b938-76820e4b0cee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1d18fedf-c17d-4238-ac83-7aaa45d98b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1d18fedf-c17d-4238-ac83-7aaa45d98b1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_92d1ff46-f330-4414-975f-b90e5e1e921e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_92d1ff46-f330-4414-975f-b90e5e1e921e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_e5b11c25-0d08-4ef2-b7ee-7aa04d86c2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a5019a67-8fa1-499c-b90f-191f72b654de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87cb4e74-aa36-4116-aa4a-e0f0a5447166" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bb196abd-7e2e-4782-9d48-258c0db2be3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bb196abd-7e2e-4782-9d48-258c0db2be3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_83627c5e-6aae-42b6-8ea9-66007b135a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockholdersEquity_83627c5e-6aae-42b6-8ea9-66007b135a2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_393eb6c8-c485-409b-b767-5adfa1fd58bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_b8e7e633-8c18-4776-9687-5e50e8d752e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_203c72ce-6026-41c8-a82b-2dcbbb438a47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_203c72ce-6026-41c8-a82b-2dcbbb438a47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e74be102-1658-4d90-913a-16edab498e44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e74be102-1658-4d90-913a-16edab498e44" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fb0c0d19-0a26-4295-867e-784c4fd8e01a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fb0c0d19-0a26-4295-867e-784c4fd8e01a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cab448c8-7a82-43cc-a0c1-5046e8eee4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cab448c8-7a82-43cc-a0c1-5046e8eee4a4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_13d756a5-3c9a-4b0c-b3dd-a8a334dd87a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_13d756a5-3c9a-4b0c-b3dd-a8a334dd87a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_c5fb8a87-3240-4835-a73a-3f7ef14e11f9" xlink:href="cv-20251231.xsd#cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_c5fb8a87-3240-4835-a73a-3f7ef14e11f9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_0dd83503-8d35-48a3-93f0-045c2a0a0bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_0dd83503-8d35-48a3-93f0-045c2a0a0bb1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6094bc66-09f4-4bf6-927b-1cd0b0f7d373" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6094bc66-09f4-4bf6-927b-1cd0b0f7d373" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_6fc8beef-7d3b-429c-b205-ef7c54f77b34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_6fc8beef-7d3b-429c-b205-ef7c54f77b34" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a2fe3d64-3b57-4b58-a569-63ce2dff2335" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a2fe3d64-3b57-4b58-a569-63ce2dff2335" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e079d350-edca-4c1e-865b-228cd271318f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e079d350-edca-4c1e-865b-228cd271318f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019bfcd2-1dfb-7118-a422-0610ee149f95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019bfcd2-1dfb-7118-a422-0610ee149f95" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3d0945a8-93d2-4e7f-9836-e37a0121049a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3d0945a8-93d2-4e7f-9836-e37a0121049a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5183a246-baea-44c1-a03f-9b8275db68fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_NetIncomeLoss_5183a246-baea-44c1-a03f-9b8275db68fa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9b76840f-8b9b-4453-905d-30d3305a3fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bc5fd773-4849-4661-9ee7-2b1970d6bbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1b8d84cd-e36f-4263-8fd9-19a064c48e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1b8d84cd-e36f-4263-8fd9-19a064c48e8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9a856304-b450-49d7-927f-62daf3cc3140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1b8d84cd-e36f-4263-8fd9-19a064c48e8c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9a856304-b450-49d7-927f-62daf3cc3140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9a856304-b450-49d7-927f-62daf3cc3140_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9a856304-b450-49d7-927f-62daf3cc3140" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9a856304-b450-49d7-927f-62daf3cc3140_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cacce2a-4ba3-4f7f-a372-8267d63bf0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9a856304-b450-49d7-927f-62daf3cc3140" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cacce2a-4ba3-4f7f-a372-8267d63bf0fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_8dce81e7-9739-4b44-b6fe-6d509e983c25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cacce2a-4ba3-4f7f-a372-8267d63bf0fa" xlink:to="loc_us-gaap_IPOMember_8dce81e7-9739-4b44-b6fe-6d509e983c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_9673da90-aef1-4a1b-818a-1ddc46289f76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cacce2a-4ba3-4f7f-a372-8267d63bf0fa" xlink:to="loc_us-gaap_OverAllotmentOptionMember_9673da90-aef1-4a1b-818a-1ddc46289f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d864cc29-02f9-4dea-af41-3a9774af6572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1b8d84cd-e36f-4263-8fd9-19a064c48e8c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d864cc29-02f9-4dea-af41-3a9774af6572" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d864cc29-02f9-4dea-af41-3a9774af6572_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d864cc29-02f9-4dea-af41-3a9774af6572" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d864cc29-02f9-4dea-af41-3a9774af6572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_dcf859a3-cf9d-4be7-b69a-4f7803c2a49b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d864cc29-02f9-4dea-af41-3a9774af6572" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_dcf859a3-cf9d-4be7-b69a-4f7803c2a49b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_4f115ef7-037c-4d81-b82f-5b1f68a390f4" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dcf859a3-cf9d-4be7-b69a-4f7803c2a49b" xlink:to="loc_cv_UnderwriterMember_4f115ef7-037c-4d81-b82f-5b1f68a390f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_ab600f2f-82b5-40a5-a829-81c434cfa675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_ab600f2f-82b5-40a5-a829-81c434cfa675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9cd81cac-f817-4b96-b5d0-42e08c6b45c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9cd81cac-f817-4b96-b5d0-42e08c6b45c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_882b7ce0-b213-4c90-bca2-bcdd718a6b66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_882b7ce0-b213-4c90-bca2-bcdd718a6b66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bae7d715-525b-4930-97ac-35e0b68963b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bae7d715-525b-4930-97ac-35e0b68963b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a758c78f-d819-4cdf-b48d-402fc0199c93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a758c78f-d819-4cdf-b48d-402fc0199c93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_32ac01ea-7770-4b19-ad05-05ff28525cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_32ac01ea-7770-4b19-ad05-05ff28525cfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a8d94601-9bda-48d9-a163-4a18af55d0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a8d94601-9bda-48d9-a163-4a18af55d0cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionDate_9bda14b6-34e6-4f9b-970d-f1874e6508d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionDate_9bda14b6-34e6-4f9b-970d-f1874e6508d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockEffectivenessDate_83be258a-d8e0-49f1-ac3a-4d8a7774b9ec" xlink:href="cv-20251231.xsd#cv_SaleOfStockEffectivenessDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_cv_SaleOfStockEffectivenessDate_83be258a-d8e0-49f1-ac3a-4d8a7774b9ec" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/GOINGCONCERNDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#GOINGCONCERNDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/GOINGCONCERNDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d845ce20-467e-4de5-b0c9-83797c451a45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d845ce20-467e-4de5-b0c9-83797c451a45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2db27a08-be0a-4b16-bc12-b02f236da98f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d845ce20-467e-4de5-b0c9-83797c451a45" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2db27a08-be0a-4b16-bc12-b02f236da98f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2db27a08-be0a-4b16-bc12-b02f236da98f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2db27a08-be0a-4b16-bc12-b02f236da98f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2db27a08-be0a-4b16-bc12-b02f236da98f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06a531ce-6dbf-4bd1-bd44-aff30a0b2728" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2db27a08-be0a-4b16-bc12-b02f236da98f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06a531ce-6dbf-4bd1-bd44-aff30a0b2728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_cb7103d3-1655-4cec-9004-c7caf547e260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06a531ce-6dbf-4bd1-bd44-aff30a0b2728" xlink:to="loc_us-gaap_IPOMember_cb7103d3-1655-4cec-9004-c7caf547e260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_d843ad61-ae74-45ce-87de-ab5f51b82c74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_d843ad61-ae74-45ce-87de-ab5f51b82c74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_835c24a4-3df3-4548-b8b7-2c5a34cd67bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_OperatingIncomeLoss_835c24a4-3df3-4548-b8b7-2c5a34cd67bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e0abc12-2a4d-491c-ad54-36a6a573254a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_NetIncomeLoss_9e0abc12-2a4d-491c-ad54-36a6a573254a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14fda9e8-d051-4c37-82fd-e5847fe8466d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14fda9e8-d051-4c37-82fd-e5847fe8466d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f076afb-a550-4c49-b97e-d2b517b7561e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f076afb-a550-4c49-b97e-d2b517b7561e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a08878a9-9176-4ec8-b819-fbd34e94ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a08878a9-9176-4ec8-b819-fbd34e94ca9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a08878a9-9176-4ec8-b819-fbd34e94ca9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a08878a9-9176-4ec8-b819-fbd34e94ca9c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a08878a9-9176-4ec8-b819-fbd34e94ca9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a7c1f12-af8d-42b6-889a-5fd11e50ea10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a08878a9-9176-4ec8-b819-fbd34e94ca9c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a7c1f12-af8d-42b6-889a-5fd11e50ea10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f032ee5a-3e2b-4d14-a642-51c34fbf8bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a7c1f12-af8d-42b6-889a-5fd11e50ea10" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f032ee5a-3e2b-4d14-a642-51c34fbf8bd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_cc9c269a-7936-40f3-a4ad-00be6b42b669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a7c1f12-af8d-42b6-889a-5fd11e50ea10" xlink:to="loc_us-gaap_AccountsReceivableMember_cc9c269a-7936-40f3-a4ad-00be6b42b669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_947751bc-13e7-4f29-90f8-60842e4a5657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_947751bc-13e7-4f29-90f8-60842e4a5657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_947751bc-13e7-4f29-90f8-60842e4a5657_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_947751bc-13e7-4f29-90f8-60842e4a5657" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_947751bc-13e7-4f29-90f8-60842e4a5657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3fda6b68-93eb-4d12-93f0-ea54fbc9e1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_947751bc-13e7-4f29-90f8-60842e4a5657" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3fda6b68-93eb-4d12-93f0-ea54fbc9e1d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ba75a99a-bbb8-4e6f-8579-c9aa114fd75a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3fda6b68-93eb-4d12-93f0-ea54fbc9e1d8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ba75a99a-bbb8-4e6f-8579-c9aa114fd75a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_be0b686b-978b-4043-9fb7-bacc07e6ae59" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_srt_MajorCustomersAxis_be0b686b-978b-4043-9fb7-bacc07e6ae59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_be0b686b-978b-4043-9fb7-bacc07e6ae59_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_be0b686b-978b-4043-9fb7-bacc07e6ae59" xlink:to="loc_srt_NameOfMajorCustomerDomain_be0b686b-978b-4043-9fb7-bacc07e6ae59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d382680e-1474-476c-87d6-80b606c36022" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_be0b686b-978b-4043-9fb7-bacc07e6ae59" xlink:to="loc_srt_NameOfMajorCustomerDomain_d382680e-1474-476c-87d6-80b606c36022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_CustomerOneMember_f5607bf7-fc07-49b5-9a5b-9dfd98d33fd0" xlink:href="cv-20251231.xsd#cv_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d382680e-1474-476c-87d6-80b606c36022" xlink:to="loc_cv_CustomerOneMember_f5607bf7-fc07-49b5-9a5b-9dfd98d33fd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a0edb9db-e203-489a-add7-bd4d567c3117" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_srt_ProductOrServiceAxis_a0edb9db-e203-489a-add7-bd4d567c3117" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0edb9db-e203-489a-add7-bd4d567c3117_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a0edb9db-e203-489a-add7-bd4d567c3117" xlink:to="loc_srt_ProductsAndServicesDomain_a0edb9db-e203-489a-add7-bd4d567c3117_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e821c148-923d-470a-bf0a-f12fc11633d0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a0edb9db-e203-489a-add7-bd4d567c3117" xlink:to="loc_srt_ProductsAndServicesDomain_e821c148-923d-470a-bf0a-f12fc11633d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_1f9e05d5-73bb-4f0e-ac60-a1fb77199db7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e821c148-923d-470a-bf0a-f12fc11633d0" xlink:to="loc_us-gaap_ShippingAndHandlingMember_1f9e05d5-73bb-4f0e-ac60-a1fb77199db7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_HealthcareClinicalTrialActivitiesMember_2887bd0f-026c-4659-9cf0-b9ab2550c229" xlink:href="cv-20251231.xsd#cv_HealthcareClinicalTrialActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e821c148-923d-470a-bf0a-f12fc11633d0" xlink:to="loc_cv_HealthcareClinicalTrialActivitiesMember_2887bd0f-026c-4659-9cf0-b9ab2550c229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1b96c617-8444-4c51-8891-febf51c635f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1b96c617-8444-4c51-8891-febf51c635f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b96c617-8444-4c51-8891-febf51c635f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1b96c617-8444-4c51-8891-febf51c635f3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b96c617-8444-4c51-8891-febf51c635f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a83a6a-0d39-4b2d-a96d-a4cb7605d7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1b96c617-8444-4c51-8891-febf51c635f3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a83a6a-0d39-4b2d-a96d-a4cb7605d7a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6db974ef-c577-49d2-b373-38ad04c82d13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a83a6a-0d39-4b2d-a96d-a4cb7605d7a0" xlink:to="loc_us-gaap_IPOMember_6db974ef-c577-49d2-b373-38ad04c82d13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61717929-6237-4cb9-a39b-fefdacfdf4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61717929-6237-4cb9-a39b-fefdacfdf4fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_61717929-6237-4cb9-a39b-fefdacfdf4fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61717929-6237-4cb9-a39b-fefdacfdf4fd" xlink:to="loc_us-gaap_EquityComponentDomain_61717929-6237-4cb9-a39b-fefdacfdf4fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b6c2dcb5-b2a0-4faa-8e51-b348b6edac35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61717929-6237-4cb9-a39b-fefdacfdf4fd" xlink:to="loc_us-gaap_EquityComponentDomain_b6c2dcb5-b2a0-4faa-8e51-b348b6edac35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a1352f20-d2a4-4f9b-bf79-ccc03788fb27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b6c2dcb5-b2a0-4faa-8e51-b348b6edac35" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a1352f20-d2a4-4f9b-bf79-ccc03788fb27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_107caac5-7902-4f5b-8457-c7aa738845e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b6c2dcb5-b2a0-4faa-8e51-b348b6edac35" xlink:to="loc_us-gaap_CommonStockMember_107caac5-7902-4f5b-8457-c7aa738845e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_59031d32-454d-4fc5-827f-98aec8b10931" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_59031d32-454d-4fc5-827f-98aec8b10931" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_59031d32-454d-4fc5-827f-98aec8b10931_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_59031d32-454d-4fc5-827f-98aec8b10931" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_59031d32-454d-4fc5-827f-98aec8b10931_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_17dc5a10-e087-4aab-921d-81b9dcbf1d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_59031d32-454d-4fc5-827f-98aec8b10931" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_17dc5a10-e087-4aab-921d-81b9dcbf1d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_779dd589-dff2-4ae5-a488-5634f0b3d0e9" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_17dc5a10-e087-4aab-921d-81b9dcbf1d6e" xlink:to="loc_cv_UnderwriterMember_779dd589-dff2-4ae5-a488-5634f0b3d0e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionDate_e83e6d01-f36a-4ada-846d-48fe316f7ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionDate_e83e6d01-f36a-4ada-846d-48fe316f7ec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_e3ca90a1-f5d6-4c0a-a45f-505acda8a5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_e3ca90a1-f5d6-4c0a-a45f-505acda8a5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_1cb81b78-eb6e-42b9-8846-8ab164785953" xlink:href="cv-20251231.xsd#cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_1cb81b78-eb6e-42b9-8846-8ab164785953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_0a287f15-eb35-4911-888d-c4bb97aef50f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_0a287f15-eb35-4911-888d-c4bb97aef50f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1a5fb1de-02d6-4377-96c2-b9fb65b3c718" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1a5fb1de-02d6-4377-96c2-b9fb65b3c718" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0ce54d7f-be0e-4aea-b857-5df1cd111dca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0ce54d7f-be0e-4aea-b857-5df1cd111dca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_21c3bebc-cd19-48e9-8734-6e9b3a521775" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_NumberOfReportableSegments_21c3bebc-cd19-48e9-8734-6e9b3a521775" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_331146d3-a12c-4ae8-92c6-9549b782102a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_331146d3-a12c-4ae8-92c6-9549b782102a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_aee79bb2-53fc-49b0-b881-5f5cf8bb00bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_aee79bb2-53fc-49b0-b881-5f5cf8bb00bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_856154df-fc71-426b-b28b-1415d34f17bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_856154df-fc71-426b-b28b-1415d34f17bd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_81293aaa-4191-4aa0-b10f-3a7b797337e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_AdvertisingExpense_81293aaa-4191-4aa0-b10f-3a7b797337e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_609be6c5-c53a-43aa-b698-237bb08676d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_609be6c5-c53a-43aa-b698-237bb08676d1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d0bcc340-d99a-4855-911b-456cd69855d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d0bcc340-d99a-4855-911b-456cd69855d0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ae795d94-4220-4853-8c2e-f78cbdc97bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ae795d94-4220-4853-8c2e-f78cbdc97bb5" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a7eb38e-971e-426f-9c62-779320de90f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e19a21dc-a22a-467c-8fc0-b305e7041da6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a7eb38e-971e-426f-9c62-779320de90f4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e19a21dc-a22a-467c-8fc0-b305e7041da6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aa828b0b-16e3-401a-8557-b4554b5cb0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e19a21dc-a22a-467c-8fc0-b305e7041da6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aa828b0b-16e3-401a-8557-b4554b5cb0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa828b0b-16e3-401a-8557-b4554b5cb0e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aa828b0b-16e3-401a-8557-b4554b5cb0e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa828b0b-16e3-401a-8557-b4554b5cb0e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aa828b0b-16e3-401a-8557-b4554b5cb0e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_160a433e-26f3-43b2-9515-982bf24d471b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_160a433e-26f3-43b2-9515-982bf24d471b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_7e8b56c6-af01-40c1-9b7f-e3cd06340d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:to="loc_us-gaap_OfficeEquipmentMember_7e8b56c6-af01-40c1-9b7f-e3cd06340d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3957ce0e-5414-40d8-aecb-c11f0e9671a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3957ce0e-5414-40d8-aecb-c11f0e9671a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_250117d3-a8c8-4883-a201-0435713c6330" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e19a21dc-a22a-467c-8fc0-b305e7041da6" xlink:to="loc_srt_RangeAxis_250117d3-a8c8-4883-a201-0435713c6330" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_250117d3-a8c8-4883-a201-0435713c6330_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_250117d3-a8c8-4883-a201-0435713c6330" xlink:to="loc_srt_RangeMember_250117d3-a8c8-4883-a201-0435713c6330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7ee4fdc-9a29-4d4a-9b9e-27e14bb5ca87" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_250117d3-a8c8-4883-a201-0435713c6330" xlink:to="loc_srt_RangeMember_c7ee4fdc-9a29-4d4a-9b9e-27e14bb5ca87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_68d7195f-68a7-4b0e-892a-2472307383bd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7ee4fdc-9a29-4d4a-9b9e-27e14bb5ca87" xlink:to="loc_srt_MinimumMember_68d7195f-68a7-4b0e-892a-2472307383bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6af0d5b8-c039-4e13-8796-2ebb794d99f1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7ee4fdc-9a29-4d4a-9b9e-27e14bb5ca87" xlink:to="loc_srt_MaximumMember_6af0d5b8-c039-4e13-8796-2ebb794d99f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85ffe294-aca6-45fa-b7e8-fbdebd4151ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a7eb38e-971e-426f-9c62-779320de90f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85ffe294-aca6-45fa-b7e8-fbdebd4151ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_56719e70-2873-4b3a-a307-623f3f238052" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a7eb38e-971e-426f-9c62-779320de90f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_56719e70-2873-4b3a-a307-623f3f238052" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bee08f87-774b-48e4-9191-867306d50949" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4b8352a0-0406-4ff5-992a-68fd16c95808" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bee08f87-774b-48e4-9191-867306d50949" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4b8352a0-0406-4ff5-992a-68fd16c95808" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2540f084-7b93-4f5f-b444-eda653a5a1ac" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b8352a0-0406-4ff5-992a-68fd16c95808" xlink:to="loc_srt_ProductOrServiceAxis_2540f084-7b93-4f5f-b444-eda653a5a1ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2540f084-7b93-4f5f-b444-eda653a5a1ac_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2540f084-7b93-4f5f-b444-eda653a5a1ac" xlink:to="loc_srt_ProductsAndServicesDomain_2540f084-7b93-4f5f-b444-eda653a5a1ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6edab9ee-5377-4214-bbe7-abd81780ef1c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2540f084-7b93-4f5f-b444-eda653a5a1ac" xlink:to="loc_srt_ProductsAndServicesDomain_6edab9ee-5377-4214-bbe7-abd81780ef1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_37bb8d29-d209-45bb-8875-85d8f0a30630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6edab9ee-5377-4214-bbe7-abd81780ef1c" xlink:to="loc_us-gaap_ProductMember_37bb8d29-d209-45bb-8875-85d8f0a30630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_b2e01a78-f2b3-42cf-9f08-d49f2e281355" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6edab9ee-5377-4214-bbe7-abd81780ef1c" xlink:to="loc_us-gaap_ServiceMember_b2e01a78-f2b3-42cf-9f08-d49f2e281355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_46d32425-72c3-49db-836f-50ea5f33a416" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b8352a0-0406-4ff5-992a-68fd16c95808" xlink:to="loc_srt_StatementGeographicalAxis_46d32425-72c3-49db-836f-50ea5f33a416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46d32425-72c3-49db-836f-50ea5f33a416_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_46d32425-72c3-49db-836f-50ea5f33a416" xlink:to="loc_srt_SegmentGeographicalDomain_46d32425-72c3-49db-836f-50ea5f33a416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6ac1996d-407a-4779-b41f-518eea549057" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_46d32425-72c3-49db-836f-50ea5f33a416" xlink:to="loc_srt_SegmentGeographicalDomain_6ac1996d-407a-4779-b41f-518eea549057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1db4c4a1-6960-4971-9237-750186348d59" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6ac1996d-407a-4779-b41f-518eea549057" xlink:to="loc_country_US_1db4c4a1-6960-4971-9237-750186348d59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_c8b5c4be-fca9-4914-ac87-ce8b19eae91c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6ac1996d-407a-4779-b41f-518eea549057" xlink:to="loc_us-gaap_NonUsMember_c8b5c4be-fca9-4914-ac87-ce8b19eae91c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52796414-41bf-493f-860b-907bdb6d2c31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bee08f87-774b-48e4-9191-867306d50949" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52796414-41bf-493f-860b-907bdb6d2c31" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60c6c3cb-5dd1-497d-99fe-c1fea03dbda9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:to="loc_srt_ProductOrServiceAxis_60c6c3cb-5dd1-497d-99fe-c1fea03dbda9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_60c6c3cb-5dd1-497d-99fe-c1fea03dbda9_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_60c6c3cb-5dd1-497d-99fe-c1fea03dbda9" xlink:to="loc_srt_ProductsAndServicesDomain_60c6c3cb-5dd1-497d-99fe-c1fea03dbda9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_598e1158-3010-4e8e-b854-1be63950ebab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_60c6c3cb-5dd1-497d-99fe-c1fea03dbda9" xlink:to="loc_srt_ProductsAndServicesDomain_598e1158-3010-4e8e-b854-1be63950ebab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_6e2e9ff4-db0e-4790-a097-2128cdbbe9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_598e1158-3010-4e8e-b854-1be63950ebab" xlink:to="loc_us-gaap_ServiceMember_6e2e9ff4-db0e-4790-a097-2128cdbbe9cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019cd849-44c9-7968-8e04-3bf7bb60cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_598e1158-3010-4e8e-b854-1be63950ebab" xlink:to="loc_us-gaap_ProductMember_019cd849-44c9-7968-8e04-3bf7bb60cc49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b599ddc0-a482-482f-a4f6-047c65d6cb3a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:to="loc_srt_StatementGeographicalAxis_b599ddc0-a482-482f-a4f6-047c65d6cb3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b599ddc0-a482-482f-a4f6-047c65d6cb3a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b599ddc0-a482-482f-a4f6-047c65d6cb3a" xlink:to="loc_srt_SegmentGeographicalDomain_b599ddc0-a482-482f-a4f6-047c65d6cb3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b599ddc0-a482-482f-a4f6-047c65d6cb3a" xlink:to="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b9eb13d3-21e4-4ae6-9065-c68a3c6474fc" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:to="loc_country_US_b9eb13d3-21e4-4ae6-9065-c68a3c6474fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_019cd82b-c609-7fdb-baa4-e25d6733d4d7" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:to="loc_country_FR_019cd82b-c609-7fdb-baa4-e25d6733d4d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_019cd82c-13d2-75f1-b71e-e968e2e7e97f" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:to="loc_country_DE_019cd82c-13d2-75f1-b71e-e968e2e7e97f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_fff0a216-acf1-4260-83e4-94790bba31a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_fff0a216-acf1-4260-83e4-94790bba31a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_fff0a216-acf1-4260-83e4-94790bba31a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_fff0a216-acf1-4260-83e4-94790bba31a2" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_fff0a216-acf1-4260-83e4-94790bba31a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_56fee1dc-c758-49d6-adc9-ac10cb6ea12e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_fff0a216-acf1-4260-83e4-94790bba31a2" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_56fee1dc-c758-49d6-adc9-ac10cb6ea12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_731df24e-8d07-4232-85f7-e744a2c5740d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_56fee1dc-c758-49d6-adc9-ac10cb6ea12e" xlink:to="loc_us-gaap_TransferredOverTimeMember_731df24e-8d07-4232-85f7-e744a2c5740d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_d3b1434b-cd46-4590-8a90-1fd96a0df047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_56fee1dc-c758-49d6-adc9-ac10cb6ea12e" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_d3b1434b-cd46-4590-8a90-1fd96a0df047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fab4249b-e2ad-42a4-9d80-9de387db9e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fab4249b-e2ad-42a4-9d80-9de387db9e8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f45f55f3-a504-4bc7-8cd9-bf90ddbdf5af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f45f55f3-a504-4bc7-8cd9-bf90ddbdf5af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cdf24-098f-7461-b010-a3c351ffb2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cdf24-098f-7461-b010-a3c351ffb2c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_GroupPurchasingOrganizationFeesContraRevenue_ab430aa1-e946-4f00-b99f-5d3342efa20c" xlink:href="cv-20251231.xsd#cv_GroupPurchasingOrganizationFeesContraRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:to="loc_cv_GroupPurchasingOrganizationFeesContraRevenue_ab430aa1-e946-4f00-b99f-5d3342efa20c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/NOTEPAYABLEDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#NOTEPAYABLEDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/NOTEPAYABLEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbd39281-fc9a-4371-9d62-f89282d48de4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbd39281-fc9a-4371-9d62-f89282d48de4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5f64301-25d4-4f21-9683-027688fc4284" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbd39281-fc9a-4371-9d62-f89282d48de4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5f64301-25d4-4f21-9683-027688fc4284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d5f64301-25d4-4f21-9683-027688fc4284_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5f64301-25d4-4f21-9683-027688fc4284" xlink:to="loc_us-gaap_RelatedPartyDomain_d5f64301-25d4-4f21-9683-027688fc4284_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2d90fd27-a4e9-41a5-bf46-4cd08ffffcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5f64301-25d4-4f21-9683-027688fc4284" xlink:to="loc_us-gaap_RelatedPartyDomain_2d90fd27-a4e9-41a5-bf46-4cd08ffffcd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_b0da6c98-6328-4214-9cfc-e5ffa6244cff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2d90fd27-a4e9-41a5-bf46-4cd08ffffcd1" xlink:to="loc_us-gaap_InvestorMember_b0da6c98-6328-4214-9cfc-e5ffa6244cff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_73065c69-e6f1-4e02-8504-24bd8f7499f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbd39281-fc9a-4371-9d62-f89282d48de4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_73065c69-e6f1-4e02-8504-24bd8f7499f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73065c69-e6f1-4e02-8504-24bd8f7499f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_73065c69-e6f1-4e02-8504-24bd8f7499f6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73065c69-e6f1-4e02-8504-24bd8f7499f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_55fe6367-1e53-4f8d-9400-fee3e12fb4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_73065c69-e6f1-4e02-8504-24bd8f7499f6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_55fe6367-1e53-4f8d-9400-fee3e12fb4e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_c52ef778-356a-4cf5-af33-a6e56a426804" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_55fe6367-1e53-4f8d-9400-fee3e12fb4e4" xlink:to="loc_us-gaap_IPOMember_c52ef778-356a-4cf5-af33-a6e56a426804" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ShortTermDebtOriginationDate_bb9c74d0-7be1-40ba-ba17-54d9bc843d46" xlink:href="cv-20251231.xsd#cv_ShortTermDebtOriginationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_cv_ShortTermDebtOriginationDate_bb9c74d0-7be1-40ba-ba17-54d9bc843d46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_a80cecc4-f702-4848-8373-0691c9d211f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_a80cecc4-f702-4848-8373-0691c9d211f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_RelatedPartyTransactionRatePerMonth_49638ac1-4c92-40c4-9a40-f22e44dcfb5d" xlink:href="cv-20251231.xsd#cv_RelatedPartyTransactionRatePerMonth"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_cv_RelatedPartyTransactionRatePerMonth_49638ac1-4c92-40c4-9a40-f22e44dcfb5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_d3d046e3-236d-47a6-afd6-7bb064697dec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_d3d046e3-236d-47a6-afd6-7bb064697dec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDate_f2072aea-c2c2-43ef-8e20-6430a648773e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_RelatedPartyTransactionDate_f2072aea-c2c2-43ef-8e20-6430a648773e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_abe2a876-9668-4e90-86cc-8b9939e5e1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_abe2a876-9668-4e90-86cc-8b9939e5e1d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_eb74c61d-1242-4023-9b9b-dd83eaf9633a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_eb74c61d-1242-4023-9b9b-dd83eaf9633a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ShortTermNonBankLoansAndNotesPaymentDate_69e65679-ca74-4742-97c2-80372ddd4ad4" xlink:href="cv-20251231.xsd#cv_ShortTermNonBankLoansAndNotesPaymentDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_cv_ShortTermNonBankLoansAndNotesPaymentDate_69e65679-ca74-4742-97c2-80372ddd4ad4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2981fd64-496f-493d-a2be-84fa68547a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2981fd64-496f-493d-a2be-84fa68547a0a" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/LEASESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd4fc071-ce4c-4507-a7e9-0270a92b1541" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f682c367-6d11-402d-a6a7-879e68b3cdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd4fc071-ce4c-4507-a7e9-0270a92b1541" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f682c367-6d11-402d-a6a7-879e68b3cdc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbf78abb-4cc0-4a1a-a4a2-7b9e55318b60" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f682c367-6d11-402d-a6a7-879e68b3cdc7" xlink:to="loc_srt_RangeAxis_cbf78abb-4cc0-4a1a-a4a2-7b9e55318b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbf78abb-4cc0-4a1a-a4a2-7b9e55318b60_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cbf78abb-4cc0-4a1a-a4a2-7b9e55318b60" xlink:to="loc_srt_RangeMember_cbf78abb-4cc0-4a1a-a4a2-7b9e55318b60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbd119e6-76a7-404b-9983-15cca78081b3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cbf78abb-4cc0-4a1a-a4a2-7b9e55318b60" xlink:to="loc_srt_RangeMember_cbd119e6-76a7-404b-9983-15cca78081b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d33ff6aa-c418-4f41-8b3f-661b66cc0238" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cbd119e6-76a7-404b-9983-15cca78081b3" xlink:to="loc_srt_MinimumMember_d33ff6aa-c418-4f41-8b3f-661b66cc0238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0954926b-66c2-4593-bc8d-e097a2d36543" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cbd119e6-76a7-404b-9983-15cca78081b3" xlink:to="loc_srt_MaximumMember_0954926b-66c2-4593-bc8d-e097a2d36543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_06c71e9d-4553-470c-bcde-7da5a98558f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd4fc071-ce4c-4507-a7e9-0270a92b1541" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_06c71e9d-4553-470c-bcde-7da5a98558f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5a5139ed-546b-4c08-8154-5e6a7a78d369" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd4fc071-ce4c-4507-a7e9-0270a92b1541" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5a5139ed-546b-4c08-8154-5e6a7a78d369" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_20d809b8-7d9c-432b-a81d-e136458a5195" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_20d809b8-7d9c-432b-a81d-e136458a5195" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_8a206935-ef7c-4e68-be0c-bea22e61d936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_20d809b8-7d9c-432b-a81d-e136458a5195" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_8a206935-ef7c-4e68-be0c-bea22e61d936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8a206935-ef7c-4e68-be0c-bea22e61d936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_8a206935-ef7c-4e68-be0c-bea22e61d936" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8a206935-ef7c-4e68-be0c-bea22e61d936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3eca5133-edc2-4516-bd12-05adbd2283e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_8a206935-ef7c-4e68-be0c-bea22e61d936" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3eca5133-edc2-4516-bd12-05adbd2283e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseProvisionTermsMember_285ad862-59ba-40df-af13-7540c7c0aea6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseProvisionTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3eca5133-edc2-4516-bd12-05adbd2283e7" xlink:to="loc_us-gaap_PurchaseProvisionTermsMember_285ad862-59ba-40df-af13-7540c7c0aea6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate_586fe228-9d7b-453b-8629-098fff6b1931" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate_586fe228-9d7b-453b-8629-098fff6b1931" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_0dc57da3-bdd5-48d1-9e7e-0c69baffedd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_0dc57da3-bdd5-48d1-9e7e-0c69baffedd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee_b7f378b3-72c5-4440-9669-6d57be23a22a" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee_b7f378b3-72c5-4440-9669-6d57be23a22a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate_bfa5ffd5-d565-42ee-9b87-1c7bd5623336" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate_bfa5ffd5-d565-42ee-9b87-1c7bd5623336" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet_4fefb520-5ce6-4f46-a1f5-3b0db321c6b5" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet_4fefb520-5ce6-4f46-a1f5-3b0db321c6b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease_019c980f-afca-7d45-b339-d15ba0a484de" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease_019c980f-afca-7d45-b339-d15ba0a484de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9bccb7eb-2f94-48bd-ad61-0834855d7577" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9bccb7eb-2f94-48bd-ad61-0834855d7577" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d3edce16-7fae-4160-887f-9734d884f8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d3edce16-7fae-4160-887f-9734d884f8fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding_45377553-d62d-430a-9f19-5c477b6f6c9e" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding_45377553-d62d-430a-9f19-5c477b6f6c9e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceOperatingExpense_019cd444-3129-7d42-8cc6-791023fbbe98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_GovernmentAssistanceOperatingExpense_019cd444-3129-7d42-8cc6-791023fbbe98" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019cd518-c57d-7f29-b234-2a215b4d0051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019cd518-c57d-7f29-b234-2a215b4d0051" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#PREFERREDSTOCKAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f9a76184-0321-4108-9d20-5dce85eb5e59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f9a76184-0321-4108-9d20-5dce85eb5e59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f9a76184-0321-4108-9d20-5dce85eb5e59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f9a76184-0321-4108-9d20-5dce85eb5e59" xlink:to="loc_us-gaap_ClassOfStockDomain_f9a76184-0321-4108-9d20-5dce85eb5e59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ba93a7b-bbc3-41ac-aae4-283b934713c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f9a76184-0321-4108-9d20-5dce85eb5e59" xlink:to="loc_us-gaap_ClassOfStockDomain_9ba93a7b-bbc3-41ac-aae4-283b934713c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_d8d9c7f2-1710-4fb0-b97f-5c68bd134f08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9ba93a7b-bbc3-41ac-aae4-283b934713c3" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_d8d9c7f2-1710-4fb0-b97f-5c68bd134f08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c93f7e71-8bdd-491c-8b68-73976883941d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c93f7e71-8bdd-491c-8b68-73976883941d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c93f7e71-8bdd-491c-8b68-73976883941d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c93f7e71-8bdd-491c-8b68-73976883941d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c93f7e71-8bdd-491c-8b68-73976883941d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c47a1246-1a24-4926-bc56-36f9da4df1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c93f7e71-8bdd-491c-8b68-73976883941d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c47a1246-1a24-4926-bc56-36f9da4df1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_e4418a9d-ea6f-4e0f-991d-5f098af36ec4" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c47a1246-1a24-4926-bc56-36f9da4df1b0" xlink:to="loc_cv_UnderwriterMember_e4418a9d-ea6f-4e0f-991d-5f098af36ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cc63bc9a-d655-4c85-b1bf-aeea295353d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cc63bc9a-d655-4c85-b1bf-aeea295353d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc63bc9a-d655-4c85-b1bf-aeea295353d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cc63bc9a-d655-4c85-b1bf-aeea295353d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc63bc9a-d655-4c85-b1bf-aeea295353d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21f033c1-d0ba-4091-922d-e5cda6521588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cc63bc9a-d655-4c85-b1bf-aeea295353d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21f033c1-d0ba-4091-922d-e5cda6521588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_a231922c-a07d-4438-89cb-f0890439b24e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21f033c1-d0ba-4091-922d-e5cda6521588" xlink:to="loc_us-gaap_IPOMember_a231922c-a07d-4438-89cb-f0890439b24e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_85eda10d-b570-4844-9f9b-7ee9b442610d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_85eda10d-b570-4844-9f9b-7ee9b442610d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_ecb60e60-b05d-46f0-9b9b-d68c403bcb99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_ecb60e60-b05d-46f0-9b9b-d68c403bcb99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_63bbb9b5-3e30-481a-a55d-04bd0e8d7c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_63bbb9b5-3e30-481a-a55d-04bd0e8d7c8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_bbd4223a-99dc-4d95-938c-d860ef008aac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_bbd4223a-99dc-4d95-938c-d860ef008aac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ebd14175-e372-46e9-a069-26289c5a71c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ebd14175-e372-46e9-a069-26289c5a71c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_db10d6ed-7b51-4653-99d7-4c3de1c38a53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_db10d6ed-7b51-4653-99d7-4c3de1c38a53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionDate_e235a0a9-24c5-40ef-af3b-c1fb7151b4be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionDate_e235a0a9-24c5-40ef-af3b-c1fb7151b4be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_6b6afa5b-1e04-47eb-a5c1-1529cef32e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_6b6afa5b-1e04-47eb-a5c1-1529cef32e40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityLegacyConversionRatio_de610a83-fa06-4781-be41-ab26e9ef1fd4" xlink:href="cv-20251231.xsd#cv_TemporaryEquityLegacyConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_TemporaryEquityLegacyConversionRatio_de610a83-fa06-4781-be41-ab26e9ef1fd4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityLegacyConversionPricePerShareMinimum_b2dc815a-5a50-4735-a754-cf1fceb48f70" xlink:href="cv-20251231.xsd#cv_TemporaryEquityLegacyConversionPricePerShareMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_TemporaryEquityLegacyConversionPricePerShareMinimum_b2dc815a-5a50-4735-a754-cf1fceb48f70" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityLegacyConversionPricePerShareMaximum_090d1fb4-186f-446d-b9ed-189cbce9961e" xlink:href="cv-20251231.xsd#cv_TemporaryEquityLegacyConversionPricePerShareMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_TemporaryEquityLegacyConversionPricePerShareMaximum_090d1fb4-186f-446d-b9ed-189cbce9961e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum_44b3b82a-a51c-4a39-980d-54e50ff1820b" xlink:href="cv-20251231.xsd#cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum_44b3b82a-a51c-4a39-980d-54e50ff1820b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityDividendRatePercentage_7414d27b-0540-4247-b770-5f97166a6f2c" xlink:href="cv-20251231.xsd#cv_TemporaryEquityDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_TemporaryEquityDividendRatePercentage_7414d27b-0540-4247-b770-5f97166a6f2c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_NumberOfBoardMembers_a3e63e54-a1a4-4aab-911e-d1778af35a34" xlink:href="cv-20251231.xsd#cv_NumberOfBoardMembers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_NumberOfBoardMembers_a3e63e54-a1a4-4aab-911e-d1778af35a34" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#PREFERREDSTOCKPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_c0a2b389-fb80-4d9b-9878-3b3edd040f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_c0a2b389-fb80-4d9b-9878-3b3edd040f17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_de07df3a-1243-4949-a450-b845fae4385e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_c0a2b389-fb80-4d9b-9878-3b3edd040f17" xlink:to="loc_us-gaap_StatementClassOfStockAxis_de07df3a-1243-4949-a450-b845fae4385e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_de07df3a-1243-4949-a450-b845fae4385e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_de07df3a-1243-4949-a450-b845fae4385e" xlink:to="loc_us-gaap_ClassOfStockDomain_de07df3a-1243-4949-a450-b845fae4385e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_de07df3a-1243-4949-a450-b845fae4385e" xlink:to="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f3b3b3bb-0740-40bc-8b8e-64cf32e00b36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f3b3b3bb-0740-40bc-8b8e-64cf32e00b36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBMember_71fd40df-9c48-4b0a-b8d6-35d7f5e17f69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesBMember_71fd40df-9c48-4b0a-b8d6-35d7f5e17f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_71806dce-95a3-486e-b3fe-6e85685de970" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_71806dce-95a3-486e-b3fe-6e85685de970" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesC1PreferredStockMember_dfe64b0d-14aa-4484-9127-3c5a22069cd8" xlink:href="cv-20251231.xsd#cv_SeriesC1PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesC1PreferredStockMember_dfe64b0d-14aa-4484-9127-3c5a22069cd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_323af2fb-c381-48ca-b8cd-31607fb8cfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_323af2fb-c381-48ca-b8cd-31607fb8cfc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesD1PreferredStockMember_13098f14-123e-4551-9747-05539dae1e1e" xlink:href="cv-20251231.xsd#cv_SeriesD1PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesD1PreferredStockMember_13098f14-123e-4551-9747-05539dae1e1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesD2PreferredStockMember_823d2a11-f3b0-4995-bc58-366544755d41" xlink:href="cv-20251231.xsd#cv_SeriesD2PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesD2PreferredStockMember_823d2a11-f3b0-4995-bc58-366544755d41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_d74a5f96-0de0-4765-9cde-0f2ada27e645" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_d74a5f96-0de0-4765-9cde-0f2ada27e645" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesF1PreferredStockMember_e56ab11a-f704-4427-b627-ed6359220ec8" xlink:href="cv-20251231.xsd#cv_SeriesF1PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesF1PreferredStockMember_e56ab11a-f704-4427-b627-ed6359220ec8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesF2PreferredStockMember_e5b41fdb-7fd2-485e-9dfe-0660bff73c15" xlink:href="cv-20251231.xsd#cv_SeriesF2PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesF2PreferredStockMember_e5b41fdb-7fd2-485e-9dfe-0660bff73c15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_16acbce5-ca75-4959-afc1-f4478d24245e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_16acbce5-ca75-4959-afc1-f4478d24245e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesG1PreferredStockMember_33c3888d-205d-47df-9129-2cbe023ddd48" xlink:href="cv-20251231.xsd#cv_SeriesG1PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesG1PreferredStockMember_33c3888d-205d-47df-9129-2cbe023ddd48" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_f39afea5-2796-4c40-a1b4-6290df520b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_f39afea5-2796-4c40-a1b4-6290df520b7a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_5c98fde2-71d4-4902-88b6-b894802ba4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_5c98fde2-71d4-4902-88b6-b894802ba4b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_62b0ae32-bb87-44bd-9632-37d13cba6b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_62b0ae32-bb87-44bd-9632-37d13cba6b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_f929d9ec-e4fb-4ecd-be44-0dfcb6bb8628" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_f929d9ec-e4fb-4ecd-be44-0dfcb6bb8628" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_447a9f12-61bd-476a-8bfb-c3c7ebb7a680" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_447a9f12-61bd-476a-8bfb-c3c7ebb7a680" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMONSTOCKAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06bf25c3-783d-4a42-bbe2-64448049cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06bf25c3-783d-4a42-bbe2-64448049cd20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06bf25c3-783d-4a42-bbe2-64448049cd20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06bf25c3-783d-4a42-bbe2-64448049cd20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06bf25c3-783d-4a42-bbe2-64448049cd20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c40c9f85-ac86-433d-ac6a-9d54717ab314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06bf25c3-783d-4a42-bbe2-64448049cd20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c40c9f85-ac86-433d-ac6a-9d54717ab314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b112b3f0-e806-48b2-b1e7-09adb9acaa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c40c9f85-ac86-433d-ac6a-9d54717ab314" xlink:to="loc_us-gaap_IPOMember_b112b3f0-e806-48b2-b1e7-09adb9acaa6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7202edd9-4c4f-4b0b-8d98-6fdb8784b840" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c40c9f85-ac86-433d-ac6a-9d54717ab314" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7202edd9-4c4f-4b0b-8d98-6fdb8784b840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c58d3186-8cb0-492a-863b-e52fe273be49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c58d3186-8cb0-492a-863b-e52fe273be49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c58d3186-8cb0-492a-863b-e52fe273be49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c58d3186-8cb0-492a-863b-e52fe273be49" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c58d3186-8cb0-492a-863b-e52fe273be49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5e39a25b-f0f7-47ad-a618-f104c6bfb903" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c58d3186-8cb0-492a-863b-e52fe273be49" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5e39a25b-f0f7-47ad-a618-f104c6bfb903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_d2ce998f-2e26-4420-936b-b0b31222e0c0" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e39a25b-f0f7-47ad-a618-f104c6bfb903" xlink:to="loc_cv_UnderwriterMember_d2ce998f-2e26-4420-936b-b0b31222e0c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c0c67637-3599-414f-8e0e-776de7cec235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c0c67637-3599-414f-8e0e-776de7cec235" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c0c67637-3599-414f-8e0e-776de7cec235_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c0c67637-3599-414f-8e0e-776de7cec235" xlink:to="loc_us-gaap_EquityComponentDomain_c0c67637-3599-414f-8e0e-776de7cec235_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ee710bbb-b054-4efa-9ab1-ac761674394b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c0c67637-3599-414f-8e0e-776de7cec235" xlink:to="loc_us-gaap_EquityComponentDomain_ee710bbb-b054-4efa-9ab1-ac761674394b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d00648f2-8173-4efe-8944-c1394ee42320" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ee710bbb-b054-4efa-9ab1-ac761674394b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d00648f2-8173-4efe-8944-c1394ee42320" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_772fe619-e96d-4bf7-b380-6f70097df446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_772fe619-e96d-4bf7-b380-6f70097df446" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionDate_23dba560-e6fb-4582-817e-75a918ff115c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionDate_23dba560-e6fb-4582-817e-75a918ff115c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5491013b-703b-485a-91fa-68873aef8dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5491013b-703b-485a-91fa-68873aef8dfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockEffectivenessDate_e1d98b37-740b-4783-894e-77695d3e19bc" xlink:href="cv-20251231.xsd#cv_SaleOfStockEffectivenessDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_cv_SaleOfStockEffectivenessDate_e1d98b37-740b-4783-894e-77695d3e19bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a96c4f0c-07ee-41a1-908c-e22ceda8a689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a96c4f0c-07ee-41a1-908c-e22ceda8a689" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_138ef337-7275-4eb5-b991-6c1283c65337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_138ef337-7275-4eb5-b991-6c1283c65337" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f31e06ba-f304-4ce5-a58e-58af445fe804" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f31e06ba-f304-4ce5-a58e-58af445fe804" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_06ed92b3-89e1-42ea-8ced-01367dd2ae77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_06ed92b3-89e1-42ea-8ced-01367dd2ae77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights_b0bfad6d-e3b4-4c37-b04c-cc25104598e8" xlink:href="cv-20251231.xsd#cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights_b0bfad6d-e3b4-4c37-b04c-cc25104598e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_ca25abaa-ceb5-4006-8e6f-e1861addcd38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_ca25abaa-ceb5-4006-8e6f-e1861addcd38" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_348252c1-3c0a-4910-8a57-b5bc0d35eec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_348252c1-3c0a-4910-8a57-b5bc0d35eec1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b0f1e815-190c-4df6-8ba4-6ffeb94709e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b0f1e815-190c-4df6-8ba4-6ffeb94709e7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_02357c40-7f91-4a9f-b52a-e2a2ce854386" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_02357c40-7f91-4a9f-b52a-e2a2ce854386" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_325bb7e4-c562-4328-90c1-a46f7f7a16b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_325bb7e4-c562-4328-90c1-a46f7f7a16b3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_dbd67f6a-193c-481a-a547-d1aff7f282e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_CommonStockSharesIssued_dbd67f6a-193c-481a-a547-d1aff7f282e6" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMONSTOCKBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c30b642c-fa44-4a4f-ad0c-9e84cdd21c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c30b642c-fa44-4a4f-ad0c-9e84cdd21c5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0421083f-8e22-4000-aab9-0dc76c9ea664" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c30b642c-fa44-4a4f-ad0c-9e84cdd21c5d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0421083f-8e22-4000-aab9-0dc76c9ea664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0421083f-8e22-4000-aab9-0dc76c9ea664_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0421083f-8e22-4000-aab9-0dc76c9ea664" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0421083f-8e22-4000-aab9-0dc76c9ea664_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_145f1d8f-2a80-4061-85e5-c17d77e99b12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0421083f-8e22-4000-aab9-0dc76c9ea664" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_145f1d8f-2a80-4061-85e5-c17d77e99b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_b380ff80-2ff4-47cb-8e43-cc56e84a9045" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_145f1d8f-2a80-4061-85e5-c17d77e99b12" xlink:to="loc_cv_UnderwriterMember_b380ff80-2ff4-47cb-8e43-cc56e84a9045" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2d23fd97-6566-4f30-8769-45debff2316b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c30b642c-fa44-4a4f-ad0c-9e84cdd21c5d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2d23fd97-6566-4f30-8769-45debff2316b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d23fd97-6566-4f30-8769-45debff2316b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d23fd97-6566-4f30-8769-45debff2316b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d23fd97-6566-4f30-8769-45debff2316b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85efdbc8-31bf-4d79-ad44-40058bed1836" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d23fd97-6566-4f30-8769-45debff2316b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85efdbc8-31bf-4d79-ad44-40058bed1836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9a17d1fe-7712-48d5-896c-60a1e2549a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85efdbc8-31bf-4d79-ad44-40058bed1836" xlink:to="loc_us-gaap_IPOMember_9a17d1fe-7712-48d5-896c-60a1e2549a4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_4ca6ed77-2501-46bd-893f-8b15db1d190d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85efdbc8-31bf-4d79-ad44-40058bed1836" xlink:to="loc_us-gaap_OverAllotmentOptionMember_4ca6ed77-2501-46bd-893f-8b15db1d190d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b022a1ca-8ca1-4760-a8a9-f361dd56a743" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b022a1ca-8ca1-4760-a8a9-f361dd56a743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c0f15ff-89ba-4028-b8e2-5cac19d34567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c0f15ff-89ba-4028-b8e2-5cac19d34567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3535a0bb-c173-46aa-82fd-9dd6b4f603ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3535a0bb-c173-46aa-82fd-9dd6b4f603ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c8bbe947-875a-4f43-a614-f19866d83568" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c8bbe947-875a-4f43-a614-f19866d83568" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMONSTOCKCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0f3e111-38e5-495c-9ae6-5fe593965b13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0f3e111-38e5-495c-9ae6-5fe593965b13" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8a7fc280-fa1f-4038-a016-7f291c4c201d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:to="loc_us-gaap_PlanNameAxis_8a7fc280-fa1f-4038-a016-7f291c4c201d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8a7fc280-fa1f-4038-a016-7f291c4c201d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8a7fc280-fa1f-4038-a016-7f291c4c201d" xlink:to="loc_us-gaap_PlanNameDomain_8a7fc280-fa1f-4038-a016-7f291c4c201d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b685a016-de23-424d-9213-9ee8a3a7c967" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8a7fc280-fa1f-4038-a016-7f291c4c201d" xlink:to="loc_us-gaap_PlanNameDomain_b685a016-de23-424d-9213-9ee8a3a7c967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndFivePlanMember_67a62088-0489-4d5d-9b0b-72369f75b393" xlink:href="cv-20251231.xsd#cv_TwoThousandAndFivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b685a016-de23-424d-9213-9ee8a3a7c967" xlink:to="loc_cv_TwoThousandAndFivePlanMember_67a62088-0489-4d5d-9b0b-72369f75b393" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndTwentyFivePlanMember_d9eda006-9d01-47ef-a972-56accd38f2dc" xlink:href="cv-20251231.xsd#cv_TwoThousandAndTwentyFivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b685a016-de23-424d-9213-9ee8a3a7c967" xlink:to="loc_cv_TwoThousandAndTwentyFivePlanMember_d9eda006-9d01-47ef-a972-56accd38f2dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43af3204-3e7f-408c-974c-f9b72b9059b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43af3204-3e7f-408c-974c-f9b72b9059b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_43af3204-3e7f-408c-974c-f9b72b9059b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43af3204-3e7f-408c-974c-f9b72b9059b7" xlink:to="loc_us-gaap_ClassOfStockDomain_43af3204-3e7f-408c-974c-f9b72b9059b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bfa3c8fc-4b0e-47a5-85be-cf0f9ea03f77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43af3204-3e7f-408c-974c-f9b72b9059b7" xlink:to="loc_us-gaap_ClassOfStockDomain_bfa3c8fc-4b0e-47a5-85be-cf0f9ea03f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_88bf57a9-1c29-43dc-982d-58e30bfb987b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bfa3c8fc-4b0e-47a5-85be-cf0f9ea03f77" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_88bf57a9-1c29-43dc-982d-58e30bfb987b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3109f6ec-1a55-4d2c-9000-c24d451bb1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:to="loc_us-gaap_AwardTypeAxis_3109f6ec-1a55-4d2c-9000-c24d451bb1a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3109f6ec-1a55-4d2c-9000-c24d451bb1a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3109f6ec-1a55-4d2c-9000-c24d451bb1a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3109f6ec-1a55-4d2c-9000-c24d451bb1a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3109f6ec-1a55-4d2c-9000-c24d451bb1a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25c6f468-e40e-498b-a750-ee08b6575b00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25c6f468-e40e-498b-a750-ee08b6575b00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4588f663-1b3c-4698-99c4-df1e65059157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4588f663-1b3c-4698-99c4-df1e65059157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_51c0f24b-1db4-4852-8e9f-a896fe2e82d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:to="loc_us-gaap_WarrantMember_51c0f24b-1db4-4852-8e9f-a896fe2e82d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_FutureGrantsMember_7f2975bc-f1ec-4f20-b428-624f993566ed" xlink:href="cv-20251231.xsd#cv_FutureGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:to="loc_cv_FutureGrantsMember_7f2975bc-f1ec-4f20-b428-624f993566ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_412c15fe-2480-44f5-9f8d-82bb73a66e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0f3e111-38e5-495c-9ae6-5fe593965b13" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_412c15fe-2480-44f5-9f8d-82bb73a66e02" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATIONAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dac5e75a-4c96-4011-b30a-301ca8088b72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:to="loc_us-gaap_AwardTypeAxis_dac5e75a-4c96-4011-b30a-301ca8088b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dac5e75a-4c96-4011-b30a-301ca8088b72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dac5e75a-4c96-4011-b30a-301ca8088b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dac5e75a-4c96-4011-b30a-301ca8088b72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dac5e75a-4c96-4011-b30a-301ca8088b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_FutureGrantsMember_2b9da768-d835-44e0-a8c6-40f567ca4e2d" xlink:href="cv-20251231.xsd#cv_FutureGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:to="loc_cv_FutureGrantsMember_2b9da768-d835-44e0-a8c6-40f567ca4e2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1afb0b3d-ee9f-47ff-8d47-91ba06a11a80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1afb0b3d-ee9f-47ff-8d47-91ba06a11a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_89e92621-bb8c-4921-ad57-d12bf4589335" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_89e92621-bb8c-4921-ad57-d12bf4589335" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_287d7af4-fd7e-4c2d-8482-12f5fa9f628c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:to="loc_us-gaap_PlanNameAxis_287d7af4-fd7e-4c2d-8482-12f5fa9f628c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_287d7af4-fd7e-4c2d-8482-12f5fa9f628c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_287d7af4-fd7e-4c2d-8482-12f5fa9f628c" xlink:to="loc_us-gaap_PlanNameDomain_287d7af4-fd7e-4c2d-8482-12f5fa9f628c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0cdabcc7-8b6c-4b93-a586-e0c85bfba2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_287d7af4-fd7e-4c2d-8482-12f5fa9f628c" xlink:to="loc_us-gaap_PlanNameDomain_0cdabcc7-8b6c-4b93-a586-e0c85bfba2b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndTwentyFivePlanMember_2cb91c3f-709c-4288-b2b3-cb2cca6dfad7" xlink:href="cv-20251231.xsd#cv_TwoThousandAndTwentyFivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0cdabcc7-8b6c-4b93-a586-e0c85bfba2b5" xlink:to="loc_cv_TwoThousandAndTwentyFivePlanMember_2cb91c3f-709c-4288-b2b3-cb2cca6dfad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndFivePlanMember_7ff6cf21-69d7-46e4-888b-ea49e39964ab" xlink:href="cv-20251231.xsd#cv_TwoThousandAndFivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0cdabcc7-8b6c-4b93-a586-e0c85bfba2b5" xlink:to="loc_cv_TwoThousandAndFivePlanMember_7ff6cf21-69d7-46e4-888b-ea49e39964ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_72ac904d-1ec0-47df-8485-f7d8c683203c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_72ac904d-1ec0-47df-8485-f7d8c683203c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_72ac904d-1ec0-47df-8485-f7d8c683203c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_72ac904d-1ec0-47df-8485-f7d8c683203c" xlink:to="loc_us-gaap_EquityComponentDomain_72ac904d-1ec0-47df-8485-f7d8c683203c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe40e9ac-7921-49f7-9317-49191c228ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_72ac904d-1ec0-47df-8485-f7d8c683203c" xlink:to="loc_us-gaap_EquityComponentDomain_fe40e9ac-7921-49f7-9317-49191c228ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5575319e-ad9e-4ad5-aea6-192d4c42d345" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe40e9ac-7921-49f7-9317-49191c228ad6" xlink:to="loc_us-gaap_CommonStockMember_5575319e-ad9e-4ad5-aea6-192d4c42d345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_019bfcf4-e89e-7a8c-a52d-0fce123d95de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe40e9ac-7921-49f7-9317-49191c228ad6" xlink:to="loc_us-gaap_WarrantMember_019bfcf4-e89e-7a8c-a52d-0fce123d95de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_e5257182-7175-440b-b7a0-65cb3e832f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_e5257182-7175-440b-b7a0-65cb3e832f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9f96abfd-3740-4bc9-8f6c-65a92a8b12a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9f96abfd-3740-4bc9-8f6c-65a92a8b12a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_98d8c35f-5d61-4083-a4eb-11e800e8a919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_98d8c35f-5d61-4083-a4eb-11e800e8a919" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b19ff116-1d42-4b7c-9091-09052ad87c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b19ff116-1d42-4b7c-9091-09052ad87c91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_9e1715c1-b54a-4458-a6d7-6e5ae2ae37b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_9e1715c1-b54a-4458-a6d7-6e5ae2ae37b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_08e3d448-a03a-4dfc-8064-b0d095e303b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_08e3d448-a03a-4dfc-8064-b0d095e303b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cdf27-db53-7da1-bbd7-003cdc93b13b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cdf27-db53-7da1-bbd7-003cdc93b13b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cdf28-b1c0-7f90-8a73-c8be458eebdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cdf28-b1c0-7f90-8a73-c8be458eebdc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019ce262-b00c-7f2f-ac72-56b90964d14d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019ce262-b00c-7f2f-ac72-56b90964d14d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019ce264-8d4a-7f6e-8d94-63a310cdcbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019ce264-8d4a-7f6e-8d94-63a310cdcbb6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_914dae40-9788-4b3c-9086-8e66e30da9df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_914dae40-9788-4b3c-9086-8e66e30da9df" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_cf166243-a708-41f7-ae64-8b93d6bda72d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_cf166243-a708-41f7-ae64-8b93d6bda72d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f0251142-1cf6-491e-9827-ef67c8fee4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f0251142-1cf6-491e-9827-ef67c8fee4d2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60c77a07-3cbb-43d8-b6ab-6118f73c678f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60c77a07-3cbb-43d8-b6ab-6118f73c678f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019bfcad-9084-7be5-bbac-ed05b703a902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019bfcad-9084-7be5-bbac-ed05b703a902" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019bfcb1-2e15-74ea-b205-d4b6b575a478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019bfcb1-2e15-74ea-b205-d4b6b575a478" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_10b8d3b2-0112-4cfb-b03a-ced5e4e591a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_10b8d3b2-0112-4cfb-b03a-ced5e4e591a9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019bfcf4-688f-7c7c-9863-2dff07d2d212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019bfcf4-688f-7c7c-9863-2dff07d2d212" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb31385-c012-47b8-8791-b57af643953e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a8330f7-47e2-44ef-b474-29afbfae8838" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb31385-c012-47b8-8791-b57af643953e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a8330f7-47e2-44ef-b474-29afbfae8838" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76cb6401-3bbe-4d8a-a992-aceb3b6e21c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a8330f7-47e2-44ef-b474-29afbfae8838" xlink:to="loc_us-gaap_AwardTypeAxis_76cb6401-3bbe-4d8a-a992-aceb3b6e21c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cb6401-3bbe-4d8a-a992-aceb3b6e21c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_76cb6401-3bbe-4d8a-a992-aceb3b6e21c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cb6401-3bbe-4d8a-a992-aceb3b6e21c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c251e2d-f832-467e-a4fe-e36d84f1ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_76cb6401-3bbe-4d8a-a992-aceb3b6e21c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c251e2d-f832-467e-a4fe-e36d84f1ce7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7ea0a3e9-b429-4e7b-b848-6b625c1f2bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c251e2d-f832-467e-a4fe-e36d84f1ce7c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7ea0a3e9-b429-4e7b-b848-6b625c1f2bc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb31385-c012-47b8-8791-b57af643953e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_814fa1ca-5dc4-49fd-8276-37e16eabc19e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_814fa1ca-5dc4-49fd-8276-37e16eabc19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e727565-644d-4d77-8830-80744fdd62f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e727565-644d-4d77-8830-80744fdd62f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019bfcfc-a136-7de2-bf00-2925b509523f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019bfcfc-a136-7de2-bf00-2925b509523f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21a1d4af-a890-4c42-b23f-ce6bde2a263e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_cb6f9fee-f08e-447c-a450-207469b14988" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb31385-c012-47b8-8791-b57af643953e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_cb6f9fee-f08e-447c-a450-207469b14988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1136a36-33c2-4276-ae3a-9f56e6c92ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_cb6f9fee-f08e-447c-a450-207469b14988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1136a36-33c2-4276-ae3a-9f56e6c92ed8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5645a3d6-80f2-475b-9803-8c20c2da413a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0bd94ee-8293-4f7f-a728-56f74667c1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5645a3d6-80f2-475b-9803-8c20c2da413a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0bd94ee-8293-4f7f-a728-56f74667c1e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c6c32171-e2b6-4202-899f-d158d56d0468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0bd94ee-8293-4f7f-a728-56f74667c1e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c6c32171-e2b6-4202-899f-d158d56d0468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c6c32171-e2b6-4202-899f-d158d56d0468_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c6c32171-e2b6-4202-899f-d158d56d0468" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c6c32171-e2b6-4202-899f-d158d56d0468_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c6c32171-e2b6-4202-899f-d158d56d0468" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f941ced6-9e5d-4f90-91dd-7d672a22fe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:to="loc_us-gaap_CostOfSalesMember_f941ced6-9e5d-4f90-91dd-7d672a22fe5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_80d24038-0869-4032-95bd-268ae88951ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_80d24038-0869-4032-95bd-268ae88951ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b9c02d7c-b7a1-423e-b6a9-80278f1a7775" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b9c02d7c-b7a1-423e-b6a9-80278f1a7775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a7164a91-0bcb-4f64-b0a0-fde5783fa635" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a7164a91-0bcb-4f64-b0a0-fde5783fa635" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_35c2f6e8-6d6f-448c-9b4a-6a042f9f8e79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5645a3d6-80f2-475b-9803-8c20c2da413a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_35c2f6e8-6d6f-448c-9b4a-6a042f9f8e79" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESCashPaidforIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c9607-a8ac-7477-9e91-eccc0610a4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c9607-a8ac-73fc-9fad-0265e4ed406e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c9607-a8ac-7477-9e91-eccc0610a4f0" xlink:to="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c9607-a8ac-73fc-9fad-0265e4ed406e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c9608-a486-7d26-a389-2a1277b1e18a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c9607-a8ac-73fc-9fad-0265e4ed406e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c9608-a486-7d26-a389-2a1277b1e18a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c9608-a486-7d26-a389-2a1277b1e18a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c9608-a486-7d26-a389-2a1277b1e18a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c9608-a486-7d26-a389-2a1277b1e18a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c9608-a486-7b70-bafa-9c1b93ea20b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c9608-a486-7d26-a389-2a1277b1e18a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c9608-a486-7b70-bafa-9c1b93ea20b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9608-a486-7b70-bafa-9c1b93ea20b3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_019c9608-cdf1-7eed-a514-358f0065f2e1" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:to="loc_stpr_CA_019c9608-cdf1-7eed-a514-358f0065f2e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_019c9609-0916-7992-b70f-aa9a18ce5ca2" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:to="loc_stpr_MA_019c9609-0916-7992-b70f-aa9a18ce5ca2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_019c9609-2902-72a8-bdc0-21e3091f4dfb" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:to="loc_stpr_NC_019c9609-2902-72a8-bdc0-21e3091f4dfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_019c9609-4e3e-74d4-88b7-818c7f6e1de5" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:to="loc_stpr_NY_019c9609-4e3e-74d4-88b7-818c7f6e1de5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c9607-a8ac-7f32-b052-5b5dd0b15281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c9607-a8ac-7477-9e91-eccc0610a4f0" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c9607-a8ac-7f32-b052-5b5dd0b15281" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_019ba458-32ec-7e5c-8580-5d92f1b62635" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_ValuationAllowanceTable_019ba458-32ec-7e5c-8580-5d92f1b62635" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019ba458-32ec-7d49-b612-1882f254b669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_019ba458-32ec-7e5c-8580-5d92f1b62635" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019ba458-32ec-7d49-b612-1882f254b669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7d49-b612-1882f254b669_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019ba458-32ec-7d49-b612-1882f254b669" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7d49-b612-1882f254b669_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019ba458-32ec-7d49-b612-1882f254b669" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019ba45a-412e-79cf-b771-646e527d4834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:to="loc_us-gaap_DomesticCountryMember_019ba45a-412e-79cf-b771-646e527d4834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019ba460-e3d3-7c42-b3bb-09dc0383d322" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019ba460-e3d3-7c42-b3bb-09dc0383d322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019ba458-32ec-754f-8c3f-8e761a09182d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:to="loc_us-gaap_ForeignCountryMember_019ba458-32ec-754f-8c3f-8e761a09182d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019b9f2a-2b3e-749a-8e39-554c40f85b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019b9f2a-2b3e-749a-8e39-554c40f85b53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019ba45b-c3f1-7d44-8594-c459098692a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019ba45b-c3f1-7d44-8594-c459098692a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019ba460-02b1-7f1b-b23a-c5712e2d84af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019ba460-02b1-7f1b-b23a-c5712e2d84af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019ba458-32ec-7446-a305-980de0909f43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019ba458-32ec-7446-a305-980de0909f43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_019c9852-bfa4-7b74-a9f4-53e09f3f4fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_019c9852-bfa4-7b74-a9f4-53e09f3f4fbb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-72a6-8625-fd2adfed1fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-72a6-8625-fd2adfed1fb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019b8f77-dad2-7977-a8a4-41bb066b814f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-72a6-8625-fd2adfed1fb9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019b8f77-dad2-7977-a8a4-41bb066b814f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7977-a8a4-41bb066b814f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019b8f77-dad2-7977-a8a4-41bb066b814f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7977-a8a4-41bb066b814f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7e18-9983-09a0349967da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019b8f77-dad2-7977-a8a4-41bb066b814f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7e18-9983-09a0349967da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019b8f78-4157-7006-9e83-8b4424080eca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7e18-9983-09a0349967da" xlink:to="loc_us-gaap_DomesticCountryMember_019b8f78-4157-7006-9e83-8b4424080eca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019b8f79-7491-7cd8-a88a-0d1dda030a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7e18-9983-09a0349967da" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019b8f79-7491-7cd8-a88a-0d1dda030a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_019b8f7a-3ad1-799f-85b6-a27cbae47f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-72a6-8625-fd2adfed1fb9" xlink:to="loc_us-gaap_TaxPeriodAxis_019b8f7a-3ad1-799f-85b6-a27cbae47f2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-799f-85b6-a27cbae47f2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_019b8f7a-3ad1-799f-85b6-a27cbae47f2c" xlink:to="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-799f-85b6-a27cbae47f2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_019b8f7a-3ad1-799f-85b6-a27cbae47f2c" xlink:to="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearAfter2017Member_019b8f7a-a2f3-7a52-80d3-66e3998f5399" xlink:href="cv-20251231.xsd#cv_TaxYearAfter2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:to="loc_cv_TaxYearAfter2017Member_019b8f7a-a2f3-7a52-80d3-66e3998f5399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearBefore2018Member_019b8f7b-3fb8-700b-988f-702193b82212" xlink:href="cv-20251231.xsd#cv_TaxYearBefore2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:to="loc_cv_TaxYearBefore2018Member_019b8f7b-3fb8-700b-988f-702193b82212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearIndefiniteMember_019b8f7b-b5b5-7b5b-a545-252bc0817e4c" xlink:href="cv-20251231.xsd#cv_TaxYearIndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:to="loc_cv_TaxYearIndefiniteMember_019b8f7b-b5b5-7b5b-a545-252bc0817e4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearDefiniteLivedMember_019b8f7c-5c9d-7b82-a460-820303ceae2f" xlink:href="cv-20251231.xsd#cv_TaxYearDefiniteLivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:to="loc_cv_TaxYearDefiniteLivedMember_019b8f7c-5c9d-7b82-a460-820303ceae2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019b8f77-dad2-7617-9345-c0fdac9e0c89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019b8f77-dad2-7617-9345-c0fdac9e0c89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_OperatingLossCarryforwardsExpirationTerm_019b8f82-503c-751f-bb20-033601858dee" xlink:href="cv-20251231.xsd#cv_OperatingLossCarryforwardsExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:to="loc_cv_OperatingLossCarryforwardsExpirationTerm_019b8f82-503c-751f-bb20-033601858dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_019b8f80-96cd-7b94-8549-bd3ad7544366" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_019b8f80-96cd-7b94-8549-bd3ad7544366" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxCreditCarryforwardExpirationTerm_019c437f-a973-7f83-9db5-fbd12ef97d9d" xlink:href="cv-20251231.xsd#cv_TaxCreditCarryforwardExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:to="loc_cv_TaxCreditCarryforwardExpirationTerm_019c437f-a973-7f83-9db5-fbd12ef97d9d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#NETLOSSPERSHAREAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_58b878ba-f6be-4f30-8879-2df1a7fedfed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_12242091-c88d-474f-ac44-5d9248cda661" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_58b878ba-f6be-4f30-8879-2df1a7fedfed" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_12242091-c88d-474f-ac44-5d9248cda661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6506ad83-f216-4270-a600-526a052aef71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_12242091-c88d-474f-ac44-5d9248cda661" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6506ad83-f216-4270-a600-526a052aef71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6506ad83-f216-4270-a600-526a052aef71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6506ad83-f216-4270-a600-526a052aef71" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6506ad83-f216-4270-a600-526a052aef71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6506ad83-f216-4270-a600-526a052aef71" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_93891124-8575-4d1b-8b2a-686e3dc007bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_93891124-8575-4d1b-8b2a-686e3dc007bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_290979fb-2fa5-43f5-92b9-8173188164eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:to="loc_us-gaap_WarrantMember_290979fb-2fa5-43f5-92b9-8173188164eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5023aef-2faa-4e3c-a4a8-ec7618ba073b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5023aef-2faa-4e3c-a4a8-ec7618ba073b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8d4276bf-ef99-4909-837c-4bef9611be1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8d4276bf-ef99-4909-837c-4bef9611be1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f15e1cc7-b5c4-4700-b7b0-8f2a3cf86b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_58b878ba-f6be-4f30-8879-2df1a7fedfed" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f15e1cc7-b5c4-4700-b7b0-8f2a3cf86b0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://capsovision.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_629e914d-623d-4153-9d5e-21f3e542c1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_629e914d-623d-4153-9d5e-21f3e542c1e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_629e914d-623d-4153-9d5e-21f3e542c1e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_629e914d-623d-4153-9d5e-21f3e542c1e5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_629e914d-623d-4153-9d5e-21f3e542c1e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ab01fb3b-d990-4981-ae7b-20ac1e6322a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_629e914d-623d-4153-9d5e-21f3e542c1e5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ab01fb3b-d990-4981-ae7b-20ac1e6322a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7148d1f6-0274-427b-947c-220e708f76fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ab01fb3b-d990-4981-ae7b-20ac1e6322a4" xlink:to="loc_us-gaap_SubsequentEventMember_7148d1f6-0274-427b-947c-220e708f76fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019ca0c8-00dd-7532-a353-be4f2c5d0b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:to="loc_us-gaap_AwardTypeAxis_019ca0c8-00dd-7532-a353-be4f2c5d0b0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019ca0c8-00dd-7532-a353-be4f2c5d0b0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019ca0c8-00dd-7532-a353-be4f2c5d0b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019ca0c8-00dd-7532-a353-be4f2c5d0b0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019ca0c8-00dd-7195-a48f-36a25577c7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019ca0c8-00dd-7532-a353-be4f2c5d0b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019ca0c8-00dd-7195-a48f-36a25577c7f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019ca0c8-2d3f-7a04-b716-90ac41894e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019ca0c8-00dd-7195-a48f-36a25577c7f5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019ca0c8-2d3f-7a04-b716-90ac41894e1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019cdf2f-e938-7143-96c2-0e0caa1dc4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019cdf2f-e938-7143-96c2-0e0caa1dc4b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cdf2f-e938-7143-96c2-0e0caa1dc4b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019cdf2f-e938-7143-96c2-0e0caa1dc4b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cdf2f-e938-7143-96c2-0e0caa1dc4b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cdf2f-e938-71e2-a361-80bd75ef2937" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019cdf2f-e938-7143-96c2-0e0caa1dc4b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cdf2f-e938-71e2-a361-80bd75ef2937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019cdf31-62bc-7d60-a897-84e8bab0ffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cdf2f-e938-71e2-a361-80bd75ef2937" xlink:to="loc_us-gaap_PrivatePlacementMember_019cdf31-62bc-7d60-a897-84e8bab0ffbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsDate_53cde999-31d9-408f-81c9-9fdccd582827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SubsequentEventsDate_53cde999-31d9-408f-81c9-9fdccd582827" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_019ca0ca-4800-7f5c-a5e9-61cb0fb90352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_019ca0ca-4800-7f5c-a5e9-61cb0fb90352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019ca0c9-aaf1-7db0-b2a7-7338ade15eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019ca0c9-aaf1-7db0-b2a7-7338ade15eb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019ca0db-e7d4-737b-8db7-b1135f20da01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019ca0db-e7d4-737b-8db7-b1135f20da01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments_019ca0df-2759-7960-aabd-7ed7a514d240" xlink:href="cv-20251231.xsd#cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments_019ca0df-2759-7960-aabd-7ed7a514d240" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_019cdf2f-cf16-7fd6-98ca-b2c2b304a75a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_019cdf2f-cf16-7fd6-98ca-b2c2b304a75a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cdf3a-8f1b-702b-8e0d-73d78d05303b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cdf3a-8f1b-702b-8e0d-73d78d05303b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cdf39-246d-7897-9ead-e0d1a5494609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cdf39-246d-7897-9ead-e0d1a5494609" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cdf35-4c8b-79cc-8018-8e6202df1c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cdf35-4c8b-79cc-8018-8e6202df1c1b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019cdf38-501d-75da-bdd7-2968a795bc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019cdf38-501d-75da-bdd7-2968a795bc3e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockEffectivenessDate_019cdf32-8ff3-7863-b4de-2f1f624af4a6" xlink:href="cv-20251231.xsd#cv_SaleOfStockEffectivenessDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_cv_SaleOfStockEffectivenessDate_019cdf32-8ff3-7863-b4de-2f1f624af4a6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockRegistrationRightsAgreementDate_019cdf37-4674-7344-af05-929a8d0167d0" xlink:href="cv-20251231.xsd#cv_SaleOfStockRegistrationRightsAgreementDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_cv_SaleOfStockRegistrationRightsAgreementDate_019cdf37-4674-7344-af05-929a8d0167d0" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="loc_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="21"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>cv-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:f6bf459f-a2e0-444d-b980-8a4fe7868fb4,g:35023aa4-34fd-4178-a912-d615028dd0bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_41cb02dd-5c1d-43eb-9c4d-923c93fa6977_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriters warrants issued in connection with the IPO</link:label>
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_label_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Significant Noncash Transaction, Value of Consideration Given</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:to="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_019b8f6d-a112-76ff-8135-0e86c26d1ff9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_661002f6-393d-4329-8e4a-28aa65ad1591_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_0602d345-0f78-468c-9d04-ed65e6a0307d_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock (each Series: $0.001 par value)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019cd518-c57d-75b0-aa9e-b9e00a09b2f5_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Operating Expense, Decrease (Increase), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Operating Expense, Decrease (Increase), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_84f7a671-142c-4592-819f-d6318c0abb2c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split rounddown and cash in lieu payment</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Down Round Feature, Increase (Decrease) in Equity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="lab_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e09d81e7-5aaf-4066-bd1e-c72ee2dacfba_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_630f6e79-5d8f-482b-a012-266da6a5081f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in-Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_0bda5854-271c-43cd-b276-9ae098b58cc6_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ShortTermNonBankLoansAndNotesPaymentDate_cd7477d5-28b1-4136-8d0b-ddb218bc9867_terseLabel_en-US" xlink:label="lab_cv_ShortTermNonBankLoansAndNotesPaymentDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment date</link:label>
    <link:label id="lab_cv_ShortTermNonBankLoansAndNotesPaymentDate_label_en-US" xlink:label="lab_cv_ShortTermNonBankLoansAndNotesPaymentDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term NonBank Loans And Notes Payment Date</link:label>
    <link:label id="lab_cv_ShortTermNonBankLoansAndNotesPaymentDate_documentation_en-US" xlink:label="lab_cv_ShortTermNonBankLoansAndNotesPaymentDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term NonBank Loans And Notes Payment Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ShortTermNonBankLoansAndNotesPaymentDate" xlink:href="cv-20251231.xsd#cv_ShortTermNonBankLoansAndNotesPaymentDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ShortTermNonBankLoansAndNotesPaymentDate" xlink:to="lab_cv_ShortTermNonBankLoansAndNotesPaymentDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0dc8a48e-28c0-412c-9b48-9ff3675d0d90_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Issued and Recently Adopted / Accounting Pronouncements Issued and Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_9b836fd4-ebef-45f4-9f2d-5c14474c5883_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_7b420ce0-890f-4340-8449-3d11cf0ea938_terseLabel_en-US" xlink:label="lab_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series H convertible preferred stock (in shares)</link:label>
    <link:label id="lab_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="cv-20251231.xsd#cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_a40ab4fd-d646-4d72-9adc-4c0539d81044_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c9600-7429-7935-a289-bbe9481f41bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c38fbe8c-c637-45c6-b43f-b6f653e06bd1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_460ae5a5-a844-4cb1-80cb-44cb173f9777_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTIES</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_6a2a9351-a128-4413-95d1-b67f08ba143e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE AND DEFERRED REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_a1d74f51-115b-47cb-add0-3b72e99414b4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon promissory note repayment</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d9875b07-8d3a-4d48-a349-390c3ed5a504_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_019b8f71-78ed-78ed-8e21-a89231c4b4b7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_019b8f63-5e08-7899-9ec6-cae1e4459c33_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDate_c00674ed-58ee-40dd-90b1-14fd94e21e47_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction, date</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDate_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDate" xlink:to="lab_us-gaap_RelatedPartyTransactionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_93db0e2d-7f23-4576-9f3d-03b19fe9c074_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3487088d-4d5f-4b92-8c6e-ebcd7a886112_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_HealthcareClinicalTrialActivitiesMember_3271fe32-903d-4582-8fb9-90cb540871b8_terseLabel_en-US" xlink:label="lab_cv_HealthcareClinicalTrialActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare clinical trial activities</link:label>
    <link:label id="lab_cv_HealthcareClinicalTrialActivitiesMember_label_en-US" xlink:label="lab_cv_HealthcareClinicalTrialActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Healthcare Clinical Trial Activities [Member]</link:label>
    <link:label id="lab_cv_HealthcareClinicalTrialActivitiesMember_documentation_en-US" xlink:label="lab_cv_HealthcareClinicalTrialActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Healthcare Clinical Trial Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_HealthcareClinicalTrialActivitiesMember" xlink:href="cv-20251231.xsd#cv_HealthcareClinicalTrialActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_HealthcareClinicalTrialActivitiesMember" xlink:to="lab_cv_HealthcareClinicalTrialActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cfe4b69d-63a2-4b29-b985-321419de66b8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercises of stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_57295ff8-0e8d-40c8-a769-5264a3e9287e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options on common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_32110c09-54fb-45d7-9743-1496eaf5011a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_da3a5ed6-277c-4470-99d6-c5963372d2b6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses (including Clinical Trial Expenses)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1bddeb0a-5bf0-4624-b98a-00c621e8ef03_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_d02af840-da49-4a86-8c12-e2c689eed99d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019b8f5b-9c31-76c9-9d9d-bbade8fabb4e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_881943cb-06f7-4d96-b512-8ccbeaf8f235_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c670f086-69dc-442b-80b5-c1ae386a8625_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_334103ec-b72e-43de-a256-b38955411455_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a345875e-e13a-4d19-a980-3d7d3cb38c53_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_019c9609-4e3e-75dc-8e1f-40dc49bd0089_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York State</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_339f0eef-b0b7-4dad-8cca-a9decfef57cc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_5c20c8f7-a631-4615-9ea7-619659b9f319_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_48342f10-b8b3-43a2-8f60-892d7a517a03_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_56c7e134-3eda-44af-b984-b7b2eac1e5d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-7a5b-a450-adae426b01d8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5478ef6e-57e9-45ff-8551-25cf7c87faec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in initial public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_199857d1-a7f1-4b1d-81cc-94d83cfdd546_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_db5f045b-9f8f-4863-b13d-22864730688d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f13d1b36-d0e7-4755-a2e4-291a812a1a66_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34f45d9b-e086-430d-9a4e-b8e9f7fbbe73_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9e51752b-9c3e-43ff-b8e9-e4fe14ea5ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options on Common Stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_449d50e1-3a46-44d8-83a7-8be3245d3050_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_974c87d7-4252-4b40-86dd-db315fe70cb7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum_edec81fc-da9c-478b-b356-c57177b5660b_terseLabel_en-US" xlink:label="lab_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum prospective proceeds from initial public offering</link:label>
    <link:label id="lab_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum_label_en-US" xlink:label="lab_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prospective Proceeds From Issuance Initial Public Offering Minimum</link:label>
    <link:label id="lab_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum_documentation_en-US" xlink:label="lab_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prospective Proceeds From Issuance Initial Public Offering Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum" xlink:href="cv-20251231.xsd#cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum" xlink:to="lab_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_14a2ad32-76fc-43a6-843d-bc7e22b2de46_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_83edb84e-797b-41a0-8699-cba2601d75c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834d85be-ab6f-4b64-8307-759897132d81_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_019b8f79-7491-771c-a05f-75e9c88ad252_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_019b8f6e-47d5-743c-bef9-ebc8c37f2afc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d2f1293d-eed2-432e-a203-a686b27b0d91_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_31bb69a7-5d4a-41e4-a74a-8ce43716e9ef_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b3ef7cd1-dfbc-4f6b-9ea1-8723f3a80135_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_65c91804-86bd-4f6f-adb5-df83126b3413_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Minimum Lease Payments under Non-Cancellable Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_d02a886f-82ea-4e3b-a18b-9918d0aef8c7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eca4469-8f28-465e-b8d2-8ddb429c469c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_b146965e-304d-41de-9566-77d9b21b2637_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019bfcb1-2e15-73cf-bc59-1a97e52323b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7cc2baaf-fc01-4bf4-8931-d81cac3a4df7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8b7fe04d-9729-40f3-ae25-443542a24e0f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_74345e7d-005e-4cd0-bb7d-015e23ca861d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercises of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_dee7f761-19c6-4786-af86-75fecf946f8f_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b9f0587-1f3a-4e1c-8cf0-7acaeaba1877_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_bbde568e-fbdf-43b5-ae06-722d1d00a207_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_b407a654-75ba-4b46-9a03-b273dea4fc3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terms of award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseProvisionTermsMember_e2ec60ef-062a-4607-94df-70712e3b8f28_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseProvisionTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Provision Terms</link:label>
    <link:label id="lab_us-gaap_PurchaseProvisionTermsMember_label_en-US" xlink:label="lab_us-gaap_PurchaseProvisionTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Provision Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseProvisionTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseProvisionTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseProvisionTermsMember" xlink:to="lab_us-gaap_PurchaseProvisionTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019c9606-156e-7067-b0f1-07c2c4f731b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amounts of Cash Paid for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_496da98b-5f00-4796-a62d-0ce973aeedab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019b8f57-5709-70f6-9ff4-63925edc5f12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Domestic and Foreign Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b8f53-3c12-7009-938d-5bd64fceab16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d944ca1b-6b0e-4f12-b953-6031ce1c7c7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Expense for Employees and Non-employees</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_11738e4e-4034-4b65-b3a1-2c64ddfbc7f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet_0971b151-d838-4ba3-ae16-a6b980f3430c_terseLabel_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development agreement, development fee</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet_label_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Costs Incurred, Net</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet_documentation_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Costs Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet" xlink:to="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1c0ceed5-838a-494d-b347-6861512f9a3c_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ab4cc69e-04f0-4520-9374-0920e7b0c452_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee_20a8aeae-ab02-4bf1-baed-924f4c944817_terseLabel_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development agreement, initial fee</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee_label_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Initial Fee</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee_documentation_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Initial Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee" xlink:to="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_79e0ae6d-9fb0-40e2-89a3-9ce2652ad8f1_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cd27ced9-e98f-436e-ab30-d517529bda07_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_68da2e5a-baf3-4384-ba3e-76bfb14fe41c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1582413c-83fe-4e7e-bea4-16396159cd56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fafc06c9-962b-4a41-9787-d114deb72011_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_114b65f1-20e9-4793-8642-4ad1d26dd739_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-7997-abb3-e7e3e83bf9e0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019b8f5b-19ef-75ba-ae51-a13647d33acd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_AuditInformationAbstract_label_en-US" xlink:label="lab_cv_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_cv_AuditInformationAbstract_documentation_en-US" xlink:label="lab_cv_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_AuditInformationAbstract" xlink:href="cv-20251231.xsd#cv_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_AuditInformationAbstract" xlink:to="lab_cv_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_a408f438-90a9-422a-86a3-815ca40b5a85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f9754497-68b8-4486-8ce8-10578db86b5c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2ff7b2a3-d1af-4b2d-8367-248981252019_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c3472-9299-7fc2-9316-7388f0c4c022_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_019b8f71-a346-7890-9900-260423c8e1d8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d78fb41c-fc08-444d-a143-739fe9f5a3e5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d6f5257a-21c2-48c5-85c6-1868b54fa04e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_bc8c15d0-b8e8-4e2c-80ad-04a8ed1a2f19_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_93840989-a5bd-4ca1-b99c-949d77d9de0f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_76dc0d71-49f9-46b0-976b-3a53557a96da_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants on common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_84d3705a-5d7c-4e02-87d2-59dc1b94d52d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c6e7d1ad-2dcd-44e0-bd03-a9056a80d2e9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TaxCreditCarryforwardExpirationTerm_019c437f-a973-7eb3-b152-22043a708601_terseLabel_en-US" xlink:label="lab_cv_TaxCreditCarryforwardExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Term</link:label>
    <link:label id="lab_cv_TaxCreditCarryforwardExpirationTerm_label_en-US" xlink:label="lab_cv_TaxCreditCarryforwardExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiration Term</link:label>
    <link:label id="lab_cv_TaxCreditCarryforwardExpirationTerm_documentation_en-US" xlink:label="lab_cv_TaxCreditCarryforwardExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiration Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxCreditCarryforwardExpirationTerm" xlink:href="cv-20251231.xsd#cv_TaxCreditCarryforwardExpirationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TaxCreditCarryforwardExpirationTerm" xlink:to="lab_cv_TaxCreditCarryforwardExpirationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bb97c63b-0b42-4bf2-9553-f6ee1b612d36_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_907a2b77-240a-447b-b199-1ea95ec684fd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_f79d3fb7-59c0-4a09-8edc-3cfce2932daa_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c95fc-5ac8-7bfe-a461-bc418049a0a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_d5041e3d-4a07-47ce-b428-1920891e364b_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6ba54cf9-ede0-4715-b816-ee14239a2522_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8596c11a-92e5-41cf-8931-0e28a30497b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c10d294c-85c5-41bf-ac8a-fa01581b155c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_66c64c44-3f58-425c-9d57-995b2b6cbeaf_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_019b8f65-fcd0-74a6-a4dc-e6686b676724_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_285e9fe6-983c-4c85-b30f-31935756880f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cb295023-75e9-45c9-af44-15e401cd7efe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_bb76a71c-6418-4e4f-9140-daeeae8242d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f07e970e-cf27-4351-9d42-b007698eebe8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NON-CASH FINANCING AND INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_AccruedResearchAndDevelopmentExpenseCurrent_09cf8862-cbc1-4a41-bb36-09bfe3591f28_terseLabel_en-US" xlink:label="lab_cv_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued R&amp;D expenses</link:label>
    <link:label id="lab_cv_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_cv_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_cv_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_cv_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="cv-20251231.xsd#cv_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_cv_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_4c932cb7-5604-46a6-9603-c4e1747f5424_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange (gains) losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f64-bf83-7e93-ae15-755e6532c9b1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c9607-a8ac-76b0-aee5-c74a0df97f1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Paid, by Individual Jurisdiction [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, by Individual Jurisdiction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019b9f2a-2b3e-793d-abdc-5dc9a134ca7b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_cce14d62-1159-4cce-8d82-592ac9871cce_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_SaleOfStockEffectivenessDate_581e3598-22a9-4d84-a54f-e278427f0093_terseLabel_en-US" xlink:label="lab_cv_SaleOfStockEffectivenessDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, effectiveness date</link:label>
    <link:label id="lab_cv_SaleOfStockEffectivenessDate_label_en-US" xlink:label="lab_cv_SaleOfStockEffectivenessDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Effectiveness Date</link:label>
    <link:label id="lab_cv_SaleOfStockEffectivenessDate_documentation_en-US" xlink:label="lab_cv_SaleOfStockEffectivenessDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Effectiveness Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockEffectivenessDate" xlink:href="cv-20251231.xsd#cv_SaleOfStockEffectivenessDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_SaleOfStockEffectivenessDate" xlink:to="lab_cv_SaleOfStockEffectivenessDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0666b54d-4dfc-42dd-b64b-de24e2a593b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_38608b0c-3056-4d75-b1f7-eb7fc00baf62_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercises of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c95fd-2306-77e4-bdb7-593f39905408_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b8f72-7989-766c-aa3a-d8710d92f8a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2431f79d-259c-4b0f-8d2a-780bd7eadefc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_45ee66c1-4049-46b8-acb4-56ace28368f3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_13217a76-08a5-4c44-b205-e7fef3a56e65_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_51fba5c9-5967-490a-9076-0540fc384118_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_019b8f77-dad2-7309-ad7a-1043dfb91b6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e1b34ece-5d70-48f2-aad1-b9cf9381d6de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d7d4b32e-122f-4d93-8f26-3706c112c94b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expense and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_99064c6e-4db0-4a05-a86e-7a1e0b9b4be1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TemporaryEquityLegacyConversionPricePerShareMinimum_12673ff2-6554-40dd-a44b-b3edb98901dc_terseLabel_en-US" xlink:label="lab_cv_TemporaryEquityLegacyConversionPricePerShareMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum legacy conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_cv_TemporaryEquityLegacyConversionPricePerShareMinimum_label_en-US" xlink:label="lab_cv_TemporaryEquityLegacyConversionPricePerShareMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Legacy Conversion Price Per Share, Minimum</link:label>
    <link:label id="lab_cv_TemporaryEquityLegacyConversionPricePerShareMinimum_documentation_en-US" xlink:label="lab_cv_TemporaryEquityLegacyConversionPricePerShareMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Legacy Conversion Price Per Share, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityLegacyConversionPricePerShareMinimum" xlink:href="cv-20251231.xsd#cv_TemporaryEquityLegacyConversionPricePerShareMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TemporaryEquityLegacyConversionPricePerShareMinimum" xlink:to="lab_cv_TemporaryEquityLegacyConversionPricePerShareMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_098dda29-513d-4c4e-8205-faf8af5e6b3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019b8f63-990d-7787-941a-b67007e3d640_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_92d97e91-3821-4da7-8594-0d148f46c8fe_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_01c7d366-67bf-41b4-949f-cde3f657e311_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series H convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_10b17fb4-33e9-470e-b382-0afe72a54833_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_4246e80b-ddad-4090-97cb-2515eca1377c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_f62c6fe1-ed35-42d5-9408-fb0db2cb87b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_aa244cf7-f904-4154-a53e-1980ccb18af7_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series H</link:label>
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series H Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesHPreferredStockMember" xlink:to="lab_us-gaap_SeriesHPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_1aa38425-f02c-4a37-8e6e-f3100dacda0a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse Stock Split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c9607-a8ac-7d21-be19-c4824ad026d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Paid, by Individual Jurisdiction [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, by Individual Jurisdiction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3998ef04-070e-4fbd-b474-9bc0663c9413_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_dd181e8b-3178-41fa-b909-14ce623fdf00_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercises of options on common stock and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_NumberOfBoardMembers_be82d2b5-9dc3-4ada-a1f9-3825d85834d4_terseLabel_en-US" xlink:label="lab_cv_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of board members</link:label>
    <link:label id="lab_cv_NumberOfBoardMembers_label_en-US" xlink:label="lab_cv_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Board Members</link:label>
    <link:label id="lab_cv_NumberOfBoardMembers_documentation_en-US" xlink:label="lab_cv_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Board Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_NumberOfBoardMembers" xlink:href="cv-20251231.xsd#cv_NumberOfBoardMembers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_NumberOfBoardMembers" xlink:to="lab_cv_NumberOfBoardMembers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_120b1a71-59a0-4fd4-9d87-68a00a7d0795_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3872750a-ff46-44fd-a869-edc086d5091f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_72d4e970-f351-41a6-a93e-935e0482dc7a_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c95fd-6a57-73e6-b3a9-e988f83496ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Adjustments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_53a9143a-c317-4b7d-8e6d-a689f4779567_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ac09fbc3-68bf-43ca-8153-a872ee4f03cf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c5d752c5-2304-4c61-aa42-c11c41199968_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8d934726-74aa-4133-896f-13b052fb54d2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cdf27-db53-7b01-86f7-d9c728e3ead5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to outstanding unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TwoThousandAndTwentyFivePlanMember_fe9f6d33-c9e3-494d-9eab-b0357fa74d51_terseLabel_en-US" xlink:label="lab_cv_TwoThousandAndTwentyFivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Plan</link:label>
    <link:label id="lab_cv_TwoThousandAndTwentyFivePlanMember_label_en-US" xlink:label="lab_cv_TwoThousandAndTwentyFivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Twenty Five Plan [Member]</link:label>
    <link:label id="lab_cv_TwoThousandAndTwentyFivePlanMember_documentation_en-US" xlink:label="lab_cv_TwoThousandAndTwentyFivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Twenty Five Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndTwentyFivePlanMember" xlink:href="cv-20251231.xsd#cv_TwoThousandAndTwentyFivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TwoThousandAndTwentyFivePlanMember" xlink:to="lab_cv_TwoThousandAndTwentyFivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_87899848-2823-447d-a1cd-b1a4f2833031_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3ec62916-4e50-40ee-a743-93616ad21c80_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_d361a971-84d2-4b4f-81f8-68398661b0b7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TaxYearBefore2018Member_019b8f7b-3fb8-7d50-a8b6-d0d9849ab0d6_terseLabel_en-US" xlink:label="lab_cv_TaxYearBefore2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arising before January 1, 2018</link:label>
    <link:label id="lab_cv_TaxYearBefore2018Member_label_en-US" xlink:label="lab_cv_TaxYearBefore2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year Before 2018 [Member]</link:label>
    <link:label id="lab_cv_TaxYearBefore2018Member_documentation_en-US" xlink:label="lab_cv_TaxYearBefore2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year Before 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearBefore2018Member" xlink:href="cv-20251231.xsd#cv_TaxYearBefore2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TaxYearBefore2018Member" xlink:to="lab_cv_TaxYearBefore2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_905a203d-06c5-4d85-a274-a4111d3c0d43_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fa3e5e36-ad56-4d17-81e5-3344b11ddc52_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ded3f0cb-87cb-4334-bdb0-9d5366f8331f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Black-Scholes Option Pricing Model Weighted-Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_f36dc125-37b4-4fc2-89ed-77314b1e2db3_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_398ecb4d-f141-4ac1-8378-873ed291f137_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_0fbf3c50-8727-48b1-b040-df22ef43ebdf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Lease Expense and Supplemental Cash Flows</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_019b8f61-8554-732a-9795-08f9f08205cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_49acbb79-fdcb-4dd6-bd9b-a6428fb40982_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_baaa6d3f-0f37-44ed-a2ee-e4afd8381f5e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_e1138141-e119-4cfd-8b37-a9df8566a6be_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_94e6ae1c-c90d-4ad5-8010-f52484fcbc36_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_94606dfa-f15c-4f53-a307-e39126a66c65_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_019b8f8c-6542-71fe-925e-95113890afb8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_37f91d5a-db48-47be-b5bd-9cd259df17f6_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_89b9c3be-e0ff-4781-9ec2-e77a84b0f932_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercises of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_90decc14-4bee-4162-9830-7e9d3dacf72e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_1b240435-1086-4f34-88aa-d4e2115aa0c4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_51615ec3-6e2d-481c-b27f-99e1e4e6c32e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-71cf-b2b5-2f0d44932ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_41cb460e-e527-4708-9ffa-08c058c503e3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_GroupPurchasingOrganizationFeesContraRevenue_c11f3241-ecf1-4e11-af6c-7d5536149d79_terseLabel_en-US" xlink:label="lab_cv_GroupPurchasingOrganizationFeesContraRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees paid to group purchasing organizations</link:label>
    <link:label id="lab_cv_GroupPurchasingOrganizationFeesContraRevenue_label_en-US" xlink:label="lab_cv_GroupPurchasingOrganizationFeesContraRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Group Purchasing Organization Fees Contra Revenue</link:label>
    <link:label id="lab_cv_GroupPurchasingOrganizationFeesContraRevenue_documentation_en-US" xlink:label="lab_cv_GroupPurchasingOrganizationFeesContraRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Group Purchasing Organization Fees Contra Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_GroupPurchasingOrganizationFeesContraRevenue" xlink:href="cv-20251231.xsd#cv_GroupPurchasingOrganizationFeesContraRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_GroupPurchasingOrganizationFeesContraRevenue" xlink:to="lab_cv_GroupPurchasingOrganizationFeesContraRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_019b8f85-8f14-7c92-882f-f8a71e3ba01a_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Operating Loss Carryforwards and Tax Credit Carryforward Values</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e47a9f7d-cdc7-43e2-b393-d08db4f41ec8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DISCLOSURES</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c386ae90-6664-404e-b586-1762a62e1339_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate_3ba27306-cd8a-4cc0-b9f8-b8becd226262_terseLabel_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development agreement, initial fee payment date</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate_label_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Initial Fee Date</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate_documentation_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Initial Fee Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate" xlink:to="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a37e6d1a-9059-4860-9bee-43e2842ef579_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dd072b5a-b881-424e-a73f-95499528b5c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e8ff75c1-76ac-4728-bc1d-00f53b180335_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_83365ff5-e2d2-4cc7-8ff4-65c59acc01ee_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_857f9b18-d3a0-4414-9a73-8e0129f484bd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7d78-980e-c38c00c68e06_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_182be87d-8a95-4430-a072-a3ce59f2dd41_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_67486514-9f7c-436a-9d56-a38d75ed4478_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-708d-ada2-ea01406443d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_019c92f0-ff8c-7995-8aba-90ec42cdc6d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Unamortized Loan Cost (Fee) and Purchase Premium (Discount)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" xlink:to="lab_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_a820c558-cb8d-40d9-9bd7-8509f3f16d14_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_32aaaf05-6b59-44c2-b3a3-c514a18a3fb6_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_691c7a0a-5ff1-42d3-9352-2f5e333c4398_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd6bfaff-4409-43b8-b365-e3c498c0e5db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments_019ca0df-2759-7c8d-b9b5-9e2351ba40fd_terseLabel_en-US" xlink:label="lab_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of monthly installments</link:label>
    <link:label id="lab_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Number Of Monthly Installments</link:label>
    <link:label id="lab_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments" xlink:href="cv-20251231.xsd#cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments" xlink:to="lab_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e6a3632f-7c4b-4479-a04f-1cc4793d0ee8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable_eff566b0-709b-490a-afc8-f659f0bde622_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding balance of promissory note</link:label>
    <link:label id="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable_label_en-US" xlink:label="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Nonbank Loan and Note Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:to="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0b26f3b0-68e7-4f74-8b30-15706ab3a7df_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d578c453-234f-407b-91b4-e02eefa37c69_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_488c7aa4-7451-496c-b5d6-2a18e9d37896_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_fd02c259-70bb-4481-b221-6b13517748f6_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GOING CONCERN</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_29cb6d65-5f8e-433a-b027-577d510f9b4c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_OperatingLossCarryforwardsExpirationTerm_019b8f82-503c-7670-88cf-b87ca8f4b06e_terseLabel_en-US" xlink:label="lab_cv_OperatingLossCarryforwardsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Term</link:label>
    <link:label id="lab_cv_OperatingLossCarryforwardsExpirationTerm_label_en-US" xlink:label="lab_cv_OperatingLossCarryforwardsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration Term</link:label>
    <link:label id="lab_cv_OperatingLossCarryforwardsExpirationTerm_documentation_en-US" xlink:label="lab_cv_OperatingLossCarryforwardsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_OperatingLossCarryforwardsExpirationTerm" xlink:href="cv-20251231.xsd#cv_OperatingLossCarryforwardsExpirationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_OperatingLossCarryforwardsExpirationTerm" xlink:to="lab_cv_OperatingLossCarryforwardsExpirationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5c-95c0-7de5-a93f-8603c6284dd7_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f6c157ee-ec24-4250-a78c-c24a4b9ef9c6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_019b8f8b-37f5-7b3d-850e-eaac024d99a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes for previous tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_0b44872a-7f57-40e1-a478-a9d7a1695ced_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_71a9e6e2-d774-4f8c-9752-d9cb71c0eb90_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_5d10afac-b680-4ff4-a71c-650b819ccd0a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TemporaryEquityLegacyConversionRatio_be272bbc-1f06-4d7d-a618-357c7a4779b2_terseLabel_en-US" xlink:label="lab_cv_TemporaryEquityLegacyConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_cv_TemporaryEquityLegacyConversionRatio_label_en-US" xlink:label="lab_cv_TemporaryEquityLegacyConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Legacy Conversion Ratio</link:label>
    <link:label id="lab_cv_TemporaryEquityLegacyConversionRatio_documentation_en-US" xlink:label="lab_cv_TemporaryEquityLegacyConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Legacy Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityLegacyConversionRatio" xlink:href="cv-20251231.xsd#cv_TemporaryEquityLegacyConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TemporaryEquityLegacyConversionRatio" xlink:to="lab_cv_TemporaryEquityLegacyConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cdf28-b1c0-7ae0-8946-aba1a6845935_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TemporaryEquityLegacyConversionPricePerShareMaximum_1672ae67-a41d-4c8e-a725-1e4d5210223d_terseLabel_en-US" xlink:label="lab_cv_TemporaryEquityLegacyConversionPricePerShareMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum legacy conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_cv_TemporaryEquityLegacyConversionPricePerShareMaximum_label_en-US" xlink:label="lab_cv_TemporaryEquityLegacyConversionPricePerShareMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Legacy Conversion Price Per Share, Maximum</link:label>
    <link:label id="lab_cv_TemporaryEquityLegacyConversionPricePerShareMaximum_documentation_en-US" xlink:label="lab_cv_TemporaryEquityLegacyConversionPricePerShareMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Legacy Conversion Price Per Share, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityLegacyConversionPricePerShareMaximum" xlink:href="cv-20251231.xsd#cv_TemporaryEquityLegacyConversionPricePerShareMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TemporaryEquityLegacyConversionPricePerShareMaximum" xlink:to="lab_cv_TemporaryEquityLegacyConversionPricePerShareMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TwoThousandAndFivePlanMember_d3d1b810-2bdf-4b2c-8d65-da5fad9bfab9_terseLabel_en-US" xlink:label="lab_cv_TwoThousandAndFivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2005 Plan</link:label>
    <link:label id="lab_cv_TwoThousandAndFivePlanMember_label_en-US" xlink:label="lab_cv_TwoThousandAndFivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Five Plan [Member]</link:label>
    <link:label id="lab_cv_TwoThousandAndFivePlanMember_documentation_en-US" xlink:label="lab_cv_TwoThousandAndFivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Five Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndFivePlanMember" xlink:href="cv-20251231.xsd#cv_TwoThousandAndFivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TwoThousandAndFivePlanMember" xlink:to="lab_cv_TwoThousandAndFivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4c9cafca-2dc4-499c-a821-7e7de8e860ab_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercises of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9f1021e0-02b7-4eef-9fc5-8a84e788b396_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8c53da89-fc68-4b8f-b769-2762cb95fe36_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_019b8f71-858b-751f-aad5-03d111bd34d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5eac32aa-1aa5-4aba-8529-b04cec8406cb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_704c49cf-6c47-46e2-b9dc-a48eebcc0f01_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_bd6120f5-51e0-4ab9-a0ab-deda8d4509ed_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_0b80c1d8-7b61-47ce-a466-9d29a0d9b232_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_8ca9e287-544a-41d5-9332-b0468d7e7100_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEGMENTS</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_cae4351a-1f1f-435f-93ab-361097112856_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b8f69-8240-7da6-bae8-f13a9dcc4c1f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_019b8f60-d78f-744e-a967-e893a832e7b6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_023d8fc7-2775-4481-a57e-f51211a7fa85_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d26fa42c-c962-4441-ab19-e13609b12c4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBMember_62b9d84f-4bea-4ade-9bff-3a22f8e28231_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B</link:label>
    <link:label id="lab_us-gaap_SeriesBMember_label_en-US" xlink:label="lab_us-gaap_SeriesBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBMember" xlink:to="lab_us-gaap_SeriesBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_1ae8ba0b-183d-428a-96c1-1fc5f5bc3db4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_994d583e-cc68-47f2-bc43-8a1acd0c26fc_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D</link:label>
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_us-gaap_SeriesDPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_cd0d03fe-df74-47a3-b2e5-2da693071ef4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7738f9ef-dbc3-4b89-ba2a-d26318a653f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_bac10d71-fb0e-42a1-8d68-44360ff6f344_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9a2c4725-13f5-44dc-87d8-7df5dce90dfa_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ff4f584b-6d6b-47e8-b48a-53f46534d2ae_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_976621dc-d0ca-4ce6-a9a4-895725524723_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets and Contract Liabilities; Accounts Receivable and Related Allowance</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c95fc-9d94-79e7-8627-1ad397ccf926_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_dd68799a-0ec3-429c-ae32-4518664c2b35_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b72da2f4-b472-4fd4-ad8d-e7229c422e57_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0c845735-9c04-4c59-9326-9239548e777c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_dae05580-e0a3-4edf-a4c6-20484d97169f_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_39d1fbbe-5ed1-4a1d-bc71-e4e09460fead_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_18a248b4-aeda-4540-93ee-93976cde82e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_8648bffb-f38e-4eb6-a43f-53b5fc37ca96_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3d1c0a3d-5e05-4904-888f-9b0f6b5085a3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1ff9e838-7229-413f-90b6-c39a4de51945_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1cf008c8-7196-4fe1-8a06-af6a7d0abaeb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b8f5a-7bfe-7c15-98c0-d0f247c6ee22_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_fee1e15f-8f06-47de-b110-42763e86962f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c1714f0f-cb10-4360-b44b-8d03d886733c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_8e020a52-6ef1-4edd-88fc-c413b96eb1c8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, transaction date</link:label>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_label_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Transaction Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockTransactionDate" xlink:to="lab_us-gaap_SaleOfStockTransactionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a94d9f86-e827-4aa6-8f3e-3cc455d3c26e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_645b3dea-eccf-4fad-a98c-f9115f9b13cb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ebbe31e1-c36c-402a-b0ad-98483af22961_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019ca0db-e7d4-773d-b64c-06446b03ab23_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage to occur on February 12, 2027</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fcc60f3b-5838-499d-aca5-f0f0ec715c4f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights_722ef4c1-6122-4f36-ba77-8ffd78f1a598_terseLabel_en-US" xlink:label="lab_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise date of warrants</link:label>
    <link:label id="lab_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights_label_en-US" xlink:label="lab_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Date Of Warrants Or Rights</link:label>
    <link:label id="lab_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights_documentation_en-US" xlink:label="lab_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Date Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights" xlink:href="cv-20251231.xsd#cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights" xlink:to="lab_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_e912896c-f18c-4a4c-9e6c-bce91d967970_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7b43205e-1ff2-4cb2-ac20-00fedb4b144b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities &#8211; long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_87b5e83b-c3d7-4d7e-926c-dc521a6fc434_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_34cae5c1-bc0c-42ff-9861-49225752b3fb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of all convertible preferred stock to common stock - initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_88eaf14e-a254-4be6-afc2-ebe7e249ec62_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PREFERRED STOCK</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock" xlink:to="lab_us-gaap_PreferredStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ce859ec9-0a51-4d44-b904-5bdfe53f145c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a9e2fdb9-025d-4c1c-8d8d-fa4bf0c9bc41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_30de48da-d2fe-4ee5-b9d5-c667d401840a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_45662467-b214-4fb2-831c-ca50142964cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_453c45a2-d6fd-4816-920e-fb60efc8905b_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_019ba460-844d-749a-a68b-a5e130f0cff3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating operating losses</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_019b8f76-8602-7693-b25b-427c2b40d70a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Operating Losses (gross; pre-tax)</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_0228b21c-0468-4939-a5e5-84306ef4c407_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f709982c-d8d7-4134-ac44-e7254a9f9443_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_75f82730-e83f-4aad-a89d-e1e41af25970_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_962bf583-5407-4c67-89a1-d8724c7b57f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9d87cd7e-4757-485c-b3b1-cea5fecd66d5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ShortTermDebtOriginationDate_d96e27b8-8fa2-49f7-8ef6-aec3483e4e14_terseLabel_en-US" xlink:label="lab_cv_ShortTermDebtOriginationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short term debt origination date</link:label>
    <link:label id="lab_cv_ShortTermDebtOriginationDate_label_en-US" xlink:label="lab_cv_ShortTermDebtOriginationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Debt, Origination Date</link:label>
    <link:label id="lab_cv_ShortTermDebtOriginationDate_documentation_en-US" xlink:label="lab_cv_ShortTermDebtOriginationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Debt, Origination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ShortTermDebtOriginationDate" xlink:href="cv-20251231.xsd#cv_ShortTermDebtOriginationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ShortTermDebtOriginationDate" xlink:to="lab_cv_ShortTermDebtOriginationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70fa0d1d-9259-4186-8347-8a993cca6ae5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_019cd82c-13d2-72d2-aa32-445b6f7a56c2_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_522f3ee6-2eb0-41f9-b6b7-08e75eb6177f_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa842d04-31a4-4b1d-8e6e-b80d0a07c38f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d79a20aa-407a-44bc-89fd-469ba483a43c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_39d50b34-37e7-43d8-9127-555a1f25d464_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b8f61-db4b-78f2-a6e9-9c40bdcecaf2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_541ea5b5-8a27-434e-a300-70187227c251_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7c61610e-2352-462d-ab2a-b9417b9f7425_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_cf985582-d696-4fd8-a1cd-fc3be792cfc1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_bd5d785a-0d00-4fad-96fd-ccc722e8a6a6_terseLabel_en-US" xlink:label="lab_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split rounddown and cash in lieu payment (in shares)</link:label>
    <link:label id="lab_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_label_en-US" xlink:label="lab_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Down Round Feature, Increase (Decrease) in Equity, Shares</link:label>
    <link:label id="lab_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_documentation_en-US" xlink:label="lab_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in equity shares for down round feature triggered for convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" xlink:href="cv-20251231.xsd#cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" xlink:to="lab_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_a6d209d8-289b-4697-a130-b580b708674f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_AccruedClinicalTrialExpenseCurrent_ede77432-4a1e-438d-a679-90fe8c9d13bd_terseLabel_en-US" xlink:label="lab_cv_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_cv_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_cv_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_cv_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_cv_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_AccruedClinicalTrialExpenseCurrent" xlink:href="cv-20251231.xsd#cv_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_cv_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_UnderwriterMember_c90a1d74-c250-404b-a350-2ecfbbe47ca3_terseLabel_en-US" xlink:label="lab_cv_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriter</link:label>
    <link:label id="lab_cv_UnderwriterMember_label_en-US" xlink:label="lab_cv_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriter [Member]</link:label>
    <link:label id="lab_cv_UnderwriterMember_documentation_en-US" xlink:label="lab_cv_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwriter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_UnderwriterMember" xlink:to="lab_cv_UnderwriterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b8f72-7989-7a00-9fa8-0c3d8d6ca998_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_295e9fea-9028-4cc4-9fed-913edbd24d56_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_019b8f6d-2271-7b59-86f7-06b4a29f1256_terseLabel_en-US" xlink:label="lab_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized R&amp;D expenses</link:label>
    <link:label id="lab_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development Expenses</link:label>
    <link:label id="lab_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:href="cv-20251231.xsd#cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="lab_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c95fc-cba7-7852-82a1-f7cf5e2fefd7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of changes in tax laws or rates enacted in the current period</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_6642be81-e229-4288-b717-a555419650d8_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, original issue price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad84cc0c-4405-4378-aa03-38960e130f90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_78c708f5-23e3-4ba5-9763-bc627ffad898_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_517142ad-c522-45cc-81e3-a88c7728caf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of IPO offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_26b08d51-6245-4264-8464-c0ca204cffd9_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_c2bcfef0-f7c3-4bd2-97fe-a851aff2bd2e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f65-4061-733a-86f2-280862a38c12_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_71724967-4acf-4bcc-ac00-9dbbde2cde4a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7cc18062-d416-4ab8-8352-a1ea508c594b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cdf24-098f-74d9-b653-eba1a6edf074_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_019ba458-32ec-7bbe-a766-4ab3accfbaac_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_0630b9e9-d01d-49ab-bac6-71b5e9d5b149_terseLabel_en-US" xlink:label="lab_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease-Related Amounts Reflected in the Balance Sheet</link:label>
    <link:label id="lab_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information Related To Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:href="cv-20251231.xsd#cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="lab_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_a362333f-303b-4b68-8c72-5fdebf857a6e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c95ff-2931-73e5-80ff-23d90755fb62_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorOpinionTextBlock_019cb66b-ffc7-7862-9b8e-81b9478614f9_terseLabel_en-US" xlink:label="lab_dei_AuditorOpinionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Opinion</link:label>
    <link:label id="lab_dei_AuditorOpinionTextBlock_label_en-US" xlink:label="lab_dei_AuditorOpinionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorOpinionTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorOpinionTextBlock" xlink:to="lab_dei_AuditorOpinionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_bb44e2c5-3959-4f73-bba5-941b8b8c1a75_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development arrangement, fee</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_20478a96-dcc5-49ab-8300-256b51774df6_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_afdb328d-dec0-480b-844b-fad508c406db_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_fda4acb1-52e0-4dad-829b-30c825827685_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of all convertible preferred stock to common stock - initial public offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_afb6dbda-cef1-4183-bb80-f32ffe33de08_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_78c23759-d8ba-42e5-9ffc-056cfd68d780_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_dcffe4b3-905d-442a-9213-7663ed5968dd_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionDate_91a3b4cf-47c9-4858-b32d-708c122a4531_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, conversion date</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionDate_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Conversion Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionDate" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_019ba458-32ec-7c03-bd67-9d71cc18284a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_019b8f72-7989-7896-bf69-c38df514c0d9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_aec202f0-3065-4b8a-a912-b5b30c0aea6d_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_370e011c-1e4a-429c-8372-354e2dc9c32b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b8f53-725f-7540-ace5-a1508a86b85f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeasePayment_ab600edf-eb00-4b91-a841-9da375772921_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease payments related to operating leases</link:label>
    <link:label id="lab_us-gaap_VariableLeasePayment_label_en-US" xlink:label="lab_us-gaap_VariableLeasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeasePayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeasePayment" xlink:to="lab_us-gaap_VariableLeasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f02f34c4-6610-4037-ba26-35204481eb8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4a71a032-bbd8-4a02-8171-055d52078102_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_4b571ba5-80c8-4ad1-a66b-5d2042c715a6_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_6ad3e7c5-05ac-4fde-8227-af2bee7715b0_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Outstanding</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_06fd6bbd-e60d-4cfb-b422-c355e6794cea_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_294fa51e-7f4c-440c-8b91-21b0bc3e07bd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_647c85cb-6b88-485d-8e5f-d41334ea6a2d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued sales taxes</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8dcd17b-3840-4eb0-844e-0d8685c18a6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_14ea29f8-c350-4cec-953c-85855b9aba02_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_961fb9e7-3092-4577-9997-2e0bfd528880_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of promissory note</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TaxYearAfter2017Member_019b8f7a-a2f3-78ae-8978-64ebada68a7d_terseLabel_en-US" xlink:label="lab_cv_TaxYearAfter2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arising after December 31, 2017</link:label>
    <link:label id="lab_cv_TaxYearAfter2017Member_label_en-US" xlink:label="lab_cv_TaxYearAfter2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year After 2017 [Member]</link:label>
    <link:label id="lab_cv_TaxYearAfter2017Member_documentation_en-US" xlink:label="lab_cv_TaxYearAfter2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year After 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearAfter2017Member" xlink:href="cv-20251231.xsd#cv_TaxYearAfter2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TaxYearAfter2017Member" xlink:to="lab_cv_TaxYearAfter2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_7154745b-c6f7-49e1-9464-4a9865329a89_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5fa2cd5a-4c91-4cde-a9ea-59e0860ef279_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOTE PAYABLE</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsDate_2adfb296-d067-4ea5-bfdf-10eff17db43c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event date</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsDate_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event, Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsDate" xlink:to="lab_us-gaap_SubsequentEventsDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_96106905-de17-4e35-a7b0-2d242cca2925_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_5465979f-ee7a-4050-a06e-5d4fbc3b379a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments related to operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d1cd1953-eb67-4897-bb43-232de7712a61_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_019b8f74-a978-7067-b8ac-70d435d0d2c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_abd771d7-cef4-4e65-9039-5e7efc3dd45a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8de85bd0-47db-476d-8b8e-89671f83047c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: 300,000,000 and 190,000,000 shares authorized; 46,865,051 and 2,090,945 issued and outstanding as of December&#160;31, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_019b8f7a-3ad1-7b81-a16e-017781e757cf_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_019b8f61-2bfd-7d7a-adb6-c760ab2cc6a7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8f328116-38dc-4c9d-9ce8-6b9a60bc9748_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34276e80-89f7-410e-9062-faddd579c4a8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54192891-4996-4635-a36b-31ec37fb2759_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares of common stock outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_SeriesD1PreferredStockMember_9c0562d7-8e1a-48b8-92be-02906a9f3d03_terseLabel_en-US" xlink:label="lab_cv_SeriesD1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D-1</link:label>
    <link:label id="lab_cv_SeriesD1PreferredStockMember_label_en-US" xlink:label="lab_cv_SeriesD1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D-1 Preferred Stock [Member]</link:label>
    <link:label id="lab_cv_SeriesD1PreferredStockMember_documentation_en-US" xlink:label="lab_cv_SeriesD1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D-1 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesD1PreferredStockMember" xlink:href="cv-20251231.xsd#cv_SeriesD1PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_SeriesD1PreferredStockMember" xlink:to="lab_cv_SeriesD1PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_b5990344-b8b3-48fa-80e2-7f7e2b6951d2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_49a05f4e-9ab3-49a8-bc99-546db45e5922_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies - Note 9</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019ce264-8d4a-77b3-962b-aefa1595105b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_SaleOfStockRegistrationRightsAgreementDate_019cdf37-4674-755b-8751-cad864a44b2e_terseLabel_en-US" xlink:label="lab_cv_SaleOfStockRegistrationRightsAgreementDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, registration rights agreement date</link:label>
    <link:label id="lab_cv_SaleOfStockRegistrationRightsAgreementDate_label_en-US" xlink:label="lab_cv_SaleOfStockRegistrationRightsAgreementDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Registration Rights Agreement Date</link:label>
    <link:label id="lab_cv_SaleOfStockRegistrationRightsAgreementDate_documentation_en-US" xlink:label="lab_cv_SaleOfStockRegistrationRightsAgreementDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Registration Rights Agreement Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockRegistrationRightsAgreementDate" xlink:href="cv-20251231.xsd#cv_SaleOfStockRegistrationRightsAgreementDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_SaleOfStockRegistrationRightsAgreementDate" xlink:to="lab_cv_SaleOfStockRegistrationRightsAgreementDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1ec68f9b-8251-4f17-a19b-4a3091d1843a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_e61186e1-bd58-4b8b-bfc6-f15b09c86700_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_eab801a1-8611-4f28-beac-62ebd5722c7a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment, office equipment, and purchased software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Computer Software, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_0657a65c-c6e0-444b-80be-5e3b02ccdce7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_019b8f61-07f0-7cef-b1e9-ec8fe5718b90_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1426afb3-a134-4d42-8d43-b94e491b10ba_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-7568-b62c-33b0b89336d8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_10f635c2-0adf-48b0-bb7c-0f05ac397118_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_019b8f72-0a15-7045-9c42-f7ac0652b75c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_019b8f86-41ad-7085-95ae-c578bfc8397e_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Operating Loss Carryforwards and Tax Credit Carryforward Values</link:label>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Tax Credit Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_10bbac0a-7703-4e1f-9f57-c81e30b5e205_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_002a3b1f-4032-4f9d-8a4f-a298ebedeb0f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ad931ce9-6f3b-4dd7-85a1-63e442bc03fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, canceled, or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4ade04d4-8c75-42e7-a0c2-60f1a6b9e1aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_cdf331dd-d445-4a14-9adc-c5ec134265ed_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BALANCE SHEET COMPONENTS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b420109d-e8c0-4ae6-ae24-f1a823b51d85_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_SeriesD2PreferredStockMember_7066225c-757c-476f-8373-791ab1049813_terseLabel_en-US" xlink:label="lab_cv_SeriesD2PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D-2</link:label>
    <link:label id="lab_cv_SeriesD2PreferredStockMember_label_en-US" xlink:label="lab_cv_SeriesD2PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D-2 Preferred Stock [Member]</link:label>
    <link:label id="lab_cv_SeriesD2PreferredStockMember_documentation_en-US" xlink:label="lab_cv_SeriesD2PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D-2 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesD2PreferredStockMember" xlink:href="cv-20251231.xsd#cv_SeriesD2PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_SeriesD2PreferredStockMember" xlink:to="lab_cv_SeriesD2PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_91c86037-4e0a-406f-853d-18d8fc13068c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8c5f45e1-40ae-4fa9-8423-e302d43b379b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_019b8f89-92ea-7075-880e-7a3ff967a4b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Positions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_26e99f3c-1e7c-46a0-9d8d-bba1eb0cb91d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_aab6f2da-7721-414a-994a-3ff485a4c6b4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b5d3b1eb-517b-40eb-bbfb-61d9825a0c08_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_eed2c9ba-52fb-495e-89b7-69d3f418cde2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_019c9608-cdf1-78b1-b61c-e113fe23381d_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_011f27ec-b82a-44a7-979d-10ca7757925c_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1372a968-1de7-4039-874d-9fb8192ca8d9_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceOperatingExpense_019cd444-3129-7c37-8417-f598e91f1d56_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received related to refundable payroll tax credits</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceOperatingExpense_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Operating Expense, Decrease (Increase)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceOperatingExpense" xlink:to="lab_us-gaap_GovernmentAssistanceOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_CustomerOneMember_d65dd788-92f0-4e93-9751-99beef955754_terseLabel_en-US" xlink:label="lab_cv_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_cv_CustomerOneMember_label_en-US" xlink:label="lab_cv_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_cv_CustomerOneMember_documentation_en-US" xlink:label="lab_cv_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_CustomerOneMember" xlink:href="cv-20251231.xsd#cv_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_CustomerOneMember" xlink:to="lab_cv_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_aa45fdbc-4b45-4a28-99b4-71f62e2e145c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50f3418d-477f-4332-a723-6a2e546f2fe3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9234a5e8-5aa5-4d00-8f04-e16dcfafd09e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_4407225b-c8cc-4774-a9f3-98ec22aca9e3_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized at point in time</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5e043d2a-a246-4eac-83f7-7257ddf148a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_19483c24-4304-4a4d-b24b-242cc0e65ea5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_56c851db-965d-47b0-8b7d-f6830b11c02d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9bb740f0-be12-4ffe-9ff8-11f0a5b5496b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, canceled, or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_RelatedPartyTransactionRatePerMonth_1de47c0f-c1c2-4750-9ec7-9726ed49ebbc_terseLabel_en-US" xlink:label="lab_cv_RelatedPartyTransactionRatePerMonth" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly interest rate</link:label>
    <link:label id="lab_cv_RelatedPartyTransactionRatePerMonth_label_en-US" xlink:label="lab_cv_RelatedPartyTransactionRatePerMonth" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Rate Per Month</link:label>
    <link:label id="lab_cv_RelatedPartyTransactionRatePerMonth_documentation_en-US" xlink:label="lab_cv_RelatedPartyTransactionRatePerMonth" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Rate Per Month</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_RelatedPartyTransactionRatePerMonth" xlink:href="cv-20251231.xsd#cv_RelatedPartyTransactionRatePerMonth"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_RelatedPartyTransactionRatePerMonth" xlink:to="lab_cv_RelatedPartyTransactionRatePerMonth" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_430ca905-a511-491f-9246-6e18369d442b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_019cd82b-c609-7a9e-aad2-108d08c18a43_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_019cdf31-62bc-75aa-9f1a-72e1f3578439_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ce9562a1-763c-4887-9fa7-93ac98055285_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_1fe1741c-8602-4e54-853d-74c8c828a372_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from promissory note issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2d138f85-279a-4b73-9ad7-be8b1d89cb2d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b8f6d-78c1-78a4-a767-d281d093f80b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_08ce3164-77ee-42c4-b157-48583f8a3136_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_SeriesF2PreferredStockMember_c39aab0b-45fb-4be7-b9de-8e0b840a448b_terseLabel_en-US" xlink:label="lab_cv_SeriesF2PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series F-2</link:label>
    <link:label id="lab_cv_SeriesF2PreferredStockMember_label_en-US" xlink:label="lab_cv_SeriesF2PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series F-2 Preferred Stock [Member]</link:label>
    <link:label id="lab_cv_SeriesF2PreferredStockMember_documentation_en-US" xlink:label="lab_cv_SeriesF2PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series F-2 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesF2PreferredStockMember" xlink:href="cv-20251231.xsd#cv_SeriesF2PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_SeriesF2PreferredStockMember" xlink:to="lab_cv_SeriesF2PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b2459201-0728-46ae-9bc7-bb21279bd769_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_19c1fd32-47f1-42e1-9d08-246b8fc437cb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_DeferredTaxAssetsOperatingLeaseLiabilities_019b8f6e-1e45-7ee7-896e-22be36f77148_terseLabel_en-US" xlink:label="lab_cv_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_cv_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_cv_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_cv_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_cv_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="cv-20251231.xsd#cv_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_cv_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d5747829-dbb4-4b6f-afe7-2ba678622ac5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0b933bce-f44f-492c-a0c3-d358d99b702e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f199ea22-c483-450c-b0d6-b2432a355fd8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net foreign exchange gains (losses)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_fa722e5d-48bd-4cad-b96b-2d3c33738776_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c98be244-e4c4-45eb-8664-8ecb49b60e02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_eaaf2a50-a3ee-4ac0-8b3e-93b29f577975_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_bb066ca3-df47-46db-9144-c24d8d65b53a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6315da6b-05c4-460e-b98c-19afe533b00e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7afb86be-a870-4921-b191-aaa36225a6b6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_d09a21ec-2b38-4a2a-aed7-9de82bb53d50_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_SeriesF1PreferredStockMember_db52d8a6-eef7-4eec-870a-016c05d1ada2_terseLabel_en-US" xlink:label="lab_cv_SeriesF1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series F-1</link:label>
    <link:label id="lab_cv_SeriesF1PreferredStockMember_label_en-US" xlink:label="lab_cv_SeriesF1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series F-1 Preferred Stock [Member]</link:label>
    <link:label id="lab_cv_SeriesF1PreferredStockMember_documentation_en-US" xlink:label="lab_cv_SeriesF1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series F-1 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesF1PreferredStockMember" xlink:href="cv-20251231.xsd#cv_SeriesF1PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_SeriesF1PreferredStockMember" xlink:to="lab_cv_SeriesF1PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_ad952ea3-76fc-4d31-b70e-83e323be6c50_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, liquidation preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_4c7ff04d-c444-420c-ad8b-2f0e1f738b0f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment for insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_547ff4ec-6eaa-4f00-916e-3248a37807e3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_974ed6ef-a837-4b0f-a434-1be6c146948a_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon promissory note repayment (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbb90bb0-974a-43a2-afee-d0a4eae30e19_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares sold in offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c9607-a8ac-7ed7-b87b-910cfe8ef8b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash paid for income taxes (net of refunds)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, State and Local, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:to="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5027bec8-f565-41ba-aac5-e437884436cd_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_64387f5b-0166-4a4d-9dff-ef5f26d352e1_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_9e8ae789-9de8-43bd-b214-778cc0864402_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_60308d16-0b10-457b-8caa-22bb0a24e171_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_019b8f80-96cd-7bcf-aa96-ac4a05be3c7c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D Tax Credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0be81bf5-9f54-4b56-a821-220205dbdc8c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_29727fb4-a4e0-467f-8fcf-30403422f5f1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_019b8f78-4157-7e28-8e97-89ad6e5681e6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TaxYearIndefiniteMember_019b8f7b-b5b5-711a-b896-aeefffb04664_terseLabel_en-US" xlink:label="lab_cv_TaxYearIndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_cv_TaxYearIndefiniteMember_label_en-US" xlink:label="lab_cv_TaxYearIndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year Indefinite [Member]</link:label>
    <link:label id="lab_cv_TaxYearIndefiniteMember_documentation_en-US" xlink:label="lab_cv_TaxYearIndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearIndefiniteMember" xlink:href="cv-20251231.xsd#cv_TaxYearIndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TaxYearIndefiniteMember" xlink:to="lab_cv_TaxYearIndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_019c92fd-596c-74d7-8812-9fde04671d49_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains/losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Unrealized Currency Transaction Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate_19b82dce-6165-4b98-a9ae-666fb24d3f00_terseLabel_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development agreement, origination date</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate_label_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Origination Date</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate_documentation_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Origination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate" xlink:to="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_5fdc524b-6c22-453a-a2ca-a7474976625e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred initial public offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16076504-0647-417c-9ac7-90d928b3e3f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_ab9627de-a888-4dab-a515-1343367c058b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_e675d10b-fbda-4dfc-a4fa-884ae2d0606a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_d0a62d8f-cebd-42c9-9110-46fde95d178a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7cb5-be98-8d77f9702be1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_86fdf24d-a3e2-495d-8849-97a3e830a7e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a7cc622d-4e89-4f7f-869a-347951d49aa7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityReverseStockSplit_a7c88960-1ea8-47b7-806b-f44489001aaf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityReverseStockSplit_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_d894a1ab-8d98-4ffb-a5a5-73c4fc4b584f_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c6b33bcc-4b89-423c-b6e6-611e8da5c98c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b38ffe0d-daa3-4aee-ac16-f04511a87a9d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_549d8db1-e34c-4fd7-bffc-54f214e9ec22_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_019b8f61-b344-751e-a35a-00c0606826ad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_cdf8bb3f-6370-4ca1-a661-9dec6ee4e64c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserved shares of common stock</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0c79324c-a1eb-426d-a072-f092e2ce4d1f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8c5ef6a9-9952-4b7c-b6ad-9a44809f6924_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_274c288c-09b4-4c30-956e-a327d1499ac4_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2581c965-e455-43b8-a1d7-1d357dd1ece4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_66ba8903-af57-494f-afb7-2ff8f2c86b08_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease_019c980f-afca-7961-8769-de3f73af2078_terseLabel_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development agreement, development fee increase</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease_label_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Fee Increase</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease_documentation_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Fee Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease" xlink:to="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_5f1bc966-9a6b-48b0-b1f8-9420254537f8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount of loan</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_019b8f5f-9f72-7b11-840f-3e55ec0875d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Federal Statutory Rate to Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c5a15a61-7fe1-4cf8-a5d0-63d4f87471f3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8cffcdf5-9854-4e2d-a20f-9aa66a2406d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_c4d5f651-b0c6-4c27-b6b7-551275a60904_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c9600-04d4-7eae-8aec-61a25ecd7bed_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e997a622-c421-4f1a-a88f-8117d8c8e7c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_32509255-4526-4653-9791-3e0a1319edeb_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_782427b5-c330-406d-b60d-510bec66e06c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_6210cd1e-5459-4c5c-b930-02753f880ae4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_55391651-83d6-4384-a178-90b48a145508_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_5e911871-6a77-46c1-9867-145a2df11646_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_dba29784-9416-4cbe-a85a-39849402d88c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_fb3a1cde-0d36-41fe-9044-ab8d43b8bda1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_cc43ae25-809f-45fe-a2b1-ab114e235e36_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2413481f-5b0a-477e-9c9c-a1baa222f205_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_da13f3a8-4c42-4166-9dec-e36a3f4e598d_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_bfb8430f-b691-4c0f-8e8c-98f152097a7a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c95fc-0d41-7310-b4a5-e656eaad8dcd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_70ececff-e110-4f5a-a4c9-97fce9e3669a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of Series H convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_118da79b-8d8d-4b1e-b74e-762bb4964577_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized over time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b8f5a-d08e-75fe-99f5-c3a41934e100_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherEquity_e65563d6-8910-4dd1-b0bc-f47a26e88890_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercises of options on common stock and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Other Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity" xlink:to="lab_us-gaap_ProceedsFromOtherEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_3f91da29-29b8-4f85-a862-575db5929a19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option award modification expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e9956618-a30a-40a6-bba4-520bc427ba15_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5dd1a125-153e-41b6-8c6d-75bee4d846c3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a171407f-fc42-47b4-b521-d2bee7f53cc0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f50be97d-92d3-4a7b-99c2-68f1bceb6104_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_SeriesC1PreferredStockMember_0e8e44b5-3ef4-4e9f-890c-498f8a802810_terseLabel_en-US" xlink:label="lab_cv_SeriesC1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-1</link:label>
    <link:label id="lab_cv_SeriesC1PreferredStockMember_label_en-US" xlink:label="lab_cv_SeriesC1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-1 Preferred Stock [Member]</link:label>
    <link:label id="lab_cv_SeriesC1PreferredStockMember_documentation_en-US" xlink:label="lab_cv_SeriesC1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-1 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesC1PreferredStockMember" xlink:href="cv-20251231.xsd#cv_SeriesC1PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_SeriesC1PreferredStockMember" xlink:to="lab_cv_SeriesC1PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_ece1c9db-6240-402b-8316-707260d1b976_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock (all series)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_09ad2f66-cc1d-4409-a904-5f8e4bf8c935_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b4ccd888-4d16-4174-8284-fdf5e38081d9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4a92ce29-5cb2-4474-ab8b-260a64417333_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_019b8f63-78ab-74b2-90a3-6e5160720dee_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_30ed18bc-c143-4dd8-a705-932c0705e620_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e83ecc2f-c5e2-404a-b1ac-b5d8f01525c8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ada4835-ce4b-4d9e-b27c-42712b50bc4d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019b8f5a-abf6-72ec-94f6-d8113084bd1d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nontaxable or nondeductible items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019ce262-b00c-719c-b2d9-f074fa4679a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2c15d381-e212-48ba-bcec-a32d43d79938_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Underwriters Warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_a38176b1-bf07-4561-a5c6-c1e6c6c44ed6_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c95ff-51c3-7be0-8a8f-36daf66a90ae_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of changes in tax laws or rates enacted in the current period</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_9c8648cb-20c0-478c-a6cd-ca01d6b51c3f_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bafa2bf2-5385-4e3e-86e0-107fb9ae30b5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_019b8f8c-a9bc-7898-87b5-b9cebbdde1d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_019b8f8c-d618-7c14-b545-8007c617ad1a_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b64b02cb-dd78-40ca-8d4d-eb058bba9467_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_019c9609-0916-7492-85b6-cd6bbde906a4_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_178b8245-bfc4-4772-b122-80ccecbd6f9e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_0643a105-15e3-4e5f-a2e8-e66048a74523_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019ca0c9-aaf1-7e8d-9407-08793963d31c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_00062a89-a46f-4c5d-afda-44057c33a103_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd7d6cc7-d06d-4d21-9b1b-60ca9459067a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TemporaryEquityDividendRatePercentage_f290bc87-8e53-4f14-98f5-6d61053e9f8d_terseLabel_en-US" xlink:label="lab_cv_TemporaryEquityDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_cv_TemporaryEquityDividendRatePercentage_label_en-US" xlink:label="lab_cv_TemporaryEquityDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Dividend Rate, Percentage</link:label>
    <link:label id="lab_cv_TemporaryEquityDividendRatePercentage_documentation_en-US" xlink:label="lab_cv_TemporaryEquityDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Dividend Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityDividendRatePercentage" xlink:href="cv-20251231.xsd#cv_TemporaryEquityDividendRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TemporaryEquityDividendRatePercentage" xlink:to="lab_cv_TemporaryEquityDividendRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_TaxYearDefiniteLivedMember_019b8f7c-5c9d-767c-8206-027503c186fb_terseLabel_en-US" xlink:label="lab_cv_TaxYearDefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definite lived</link:label>
    <link:label id="lab_cv_TaxYearDefiniteLivedMember_label_en-US" xlink:label="lab_cv_TaxYearDefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year Definite Lived [Member]</link:label>
    <link:label id="lab_cv_TaxYearDefiniteLivedMember_documentation_en-US" xlink:label="lab_cv_TaxYearDefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year Definite Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearDefiniteLivedMember" xlink:href="cv-20251231.xsd#cv_TaxYearDefiniteLivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_TaxYearDefiniteLivedMember" xlink:to="lab_cv_TaxYearDefiniteLivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_0482889d-8b03-4b55-9f09-19157e57c69a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f6fe726a-c579-4652-bc7a-20142773856e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b1f6333b-bbc6-44a5-a44c-a9cf81b12a4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f24c9013-c4be-4591-a180-ccbbaee68426_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd59a02d-9dab-45e0-959a-7e74409ed860_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_702bf983-e9b6-4322-9023-2fb3edbf07df_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1cdb9a30-5b73-435d-8b55-5ed64badaa73_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares of common stock outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d08b3353-3316-45cf-a551-6ff6453d1622_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3bd4a956-4488-4c91-b2b8-41b3eb661856_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_645aabf9-eb5d-4b83-8ee5-5466bf5655b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8c9940b0-149e-4ff1-895c-0fc3e7adefa7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NC_019c9609-2902-7f22-befe-15c987e87080_terseLabel_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">North Carolina</link:label>
    <link:label id="lab_stpr_NC_label_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NC" xlink:to="lab_stpr_NC" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate_3038d4ba-7242-43d2-bfd3-c770abdc6f04_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants maturity date</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ee2f3a49-3abd-4fa1-97ec-9359fb3f8660_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_dd76d347-8f53-4d44-88b8-fef9803e2878_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3982dcc7-503c-425d-829d-627048cbc353_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_389ad806-fc93-4d3e-80f5-a768270d8b71_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock in lieu of debt repayment</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Supplies_e0081071-995e-4253-929c-81b85c8c8314_terseLabel_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance payments for inventory purchases</link:label>
    <link:label id="lab_us-gaap_Supplies_label_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Supplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Supplies" xlink:to="lab_us-gaap_Supplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e18cafdd-21a3-452d-a0c3-98ca592c33e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6292e269-a3ad-4c5d-848e-e44b5907675b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4011a569-13f8-4bb8-ba05-d5afdec2fc4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a9c11354-f973-406d-ba2c-7e8398cd6945_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_76060d34-b999-4efd-8472-5738dbb5c18d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7a5baff0-94db-42e2-a191-2931c9e44f17_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5b27773d-2050-4a98-b6a1-8082c7b89f55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_56cbb810-3246-4a20-b1f8-8538c02b0cc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_0512e12b-e75c-427b-b2e0-3fa81a358044_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_d5af8344-cb60-48ae-b543-4e41b35c3c66_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesEPreferredStockMember_22ef6dc7-98b0-4782-8fba-03c53d0f28f1_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesEPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E</link:label>
    <link:label id="lab_us-gaap_SeriesEPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesEPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesEPreferredStockMember" xlink:to="lab_us-gaap_SeriesEPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_FutureGrantsMember_8cfd0704-bca0-4382-aa18-640bdd577017_terseLabel_en-US" xlink:label="lab_cv_FutureGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future grants</link:label>
    <link:label id="lab_cv_FutureGrantsMember_label_en-US" xlink:label="lab_cv_FutureGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Grants [Member]</link:label>
    <link:label id="lab_cv_FutureGrantsMember_documentation_en-US" xlink:label="lab_cv_FutureGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_FutureGrantsMember" xlink:href="cv-20251231.xsd#cv_FutureGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_FutureGrantsMember" xlink:to="lab_cv_FutureGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_e902c68f-c509-4b09-9810-ce387f57e33c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_98061f34-ab18-48be-a6b6-301f22288d7e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_935ba69b-eab8-4668-8fd3-1f8fad8917a8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory note and certain R&amp;D expenses</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding_266189a6-8ff3-435e-b9d3-117badfb8187_terseLabel_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding purchase commitment</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding_label_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Costs Outstanding</link:label>
    <link:label id="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding_documentation_en-US" xlink:label="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Costs Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding" xlink:to="lab_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c25689d7-8f6c-45c8-bc00-b46e7ac26318_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e18552cf-69b0-4b35-8914-b2ee71e9640c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c95fd-483d-72bc-bf86-2aaa47d115dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nontaxable or nondeductible items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cv_SeriesG1PreferredStockMember_b9a65823-fcf6-4887-874a-b7757382060c_terseLabel_en-US" xlink:label="lab_cv_SeriesG1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series G-1</link:label>
    <link:label id="lab_cv_SeriesG1PreferredStockMember_label_en-US" xlink:label="lab_cv_SeriesG1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series G-1 Preferred Stock [Member]</link:label>
    <link:label id="lab_cv_SeriesG1PreferredStockMember_documentation_en-US" xlink:label="lab_cv_SeriesG1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series G-1 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesG1PreferredStockMember" xlink:href="cv-20251231.xsd#cv_SeriesG1PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cv_SeriesG1PreferredStockMember" xlink:to="lab_cv_SeriesG1PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_6ca145f8-d954-4164-9988-957c941872ce_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_fb03b6ef-fe1f-449f-9c1e-ef8a01d5a32d_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series G</link:label>
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series G Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesGPreferredStockMember" xlink:to="lab_us-gaap_SeriesGPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_019b8f8a-c795-7346-80f4-b65695d7020d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for current tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_b8adfe8c-d592-4cc1-a4ed-b4ff3289a7bb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from IPO, net of commissions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_554af51e-af44-4607-949d-c84930ca9047_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_e11b7bff-c4fa-4178-9d66-8ac60fbab14b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_ca2194b0-4d35-4c9c-a91c-016d2450d1d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b5ebf9b6-0ecf-4bf1-a412-c28cd4bb2413_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in initial public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_468bb5d0-2f40-4b3e-8f4f-dbf8a18a299a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_20a478c5-aa4f-437b-ac22-095d2c3ce1da_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b8f74-1877-7aec-809f-c11de9519eec_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_bdbf3c21-1218-4bda-85b5-fb5413c786e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019bfc25-902f-7156-a9ba-e717e0a765a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019c0087-3da7-7de9-8474-76e842ec9239_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ddae13d6-8041-480f-9eac-58904dbd33aa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_0bf4fb5c-06b2-49c1-81e9-f111c73a525c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_df308395-0423-4cdb-b5d1-760765f018fd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>cv-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:f6bf459f-a2e0-444d-b980-8a4fe7868fb4,g:35023aa4-34fd-4178-a912-d615028dd0bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://capsovision.com/role/COVERPAGE" xlink:type="simple" xlink:href="cv-20251231.xsd#COVERPAGE"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/COVERPAGE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ea331d33-ec59-4a80-b1d7-26a680ef0ce1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_DocumentType_ea331d33-ec59-4a80-b1d7-26a680ef0ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_021bd7b7-a84c-451b-b916-a1027420e938" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_DocumentAnnualReport_021bd7b7-a84c-451b-b916-a1027420e938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e9f79db5-8b7a-487b-9149-c5532a863086" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_DocumentPeriodEndDate_e9f79db5-8b7a-487b-9149-c5532a863086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f515be8a-a8d5-4cb0-81f3-54284b09130a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_CurrentFiscalYearEndDate_f515be8a-a8d5-4cb0-81f3-54284b09130a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a2700a7a-a508-485f-bd85-e4555946d923" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_DocumentTransitionReport_a2700a7a-a508-485f-bd85-e4555946d923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_05ba0819-cced-4d6f-8f99-cd06d036f262" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityFileNumber_05ba0819-cced-4d6f-8f99-cd06d036f262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d3e2ed59-28e7-42f8-b51b-c60c3323c094" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityRegistrantName_d3e2ed59-28e7-42f8-b51b-c60c3323c094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_466d2793-16c1-4b67-aa14-2d9d0e37d226" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_466d2793-16c1-4b67-aa14-2d9d0e37d226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1463fb08-43c5-47fb-b891-11eb844e2529" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityTaxIdentificationNumber_1463fb08-43c5-47fb-b891-11eb844e2529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8bda0284-b054-41e0-8edf-dfe07f30a0f3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityAddressAddressLine1_8bda0284-b054-41e0-8edf-dfe07f30a0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_15cbaaf9-1e55-44a7-89a1-b2fe0a100154" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityAddressCityOrTown_15cbaaf9-1e55-44a7-89a1-b2fe0a100154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_30cbbe97-edb0-4d9f-8a39-2bcd61cd781f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityAddressStateOrProvince_30cbbe97-edb0-4d9f-8a39-2bcd61cd781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c3b53792-142c-4afe-82c9-9ba5b587b924" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityAddressPostalZipCode_c3b53792-142c-4afe-82c9-9ba5b587b924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_44f563ba-5911-437c-8496-b287563c9ccf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_CityAreaCode_44f563ba-5911-437c-8496-b287563c9ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3fe33696-a3bc-4a06-b8c2-8c63da298f6c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_LocalPhoneNumber_3fe33696-a3bc-4a06-b8c2-8c63da298f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37d7920d-2b4e-4737-b11a-74c1ba11ac37" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_Security12bTitle_37d7920d-2b4e-4737-b11a-74c1ba11ac37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d14361fd-ebbd-4a37-a869-e88a57441a88" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_TradingSymbol_d14361fd-ebbd-4a37-a869-e88a57441a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a7db46db-59d8-430f-bc12-6aaf7a1e8d33" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_SecurityExchangeName_a7db46db-59d8-430f-bc12-6aaf7a1e8d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5be3449f-8170-448f-8eca-6dfb54c5d6c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_5be3449f-8170-448f-8eca-6dfb54c5d6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_5fef544b-9045-41e1-ae1a-079511095df1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityVoluntaryFilers_5fef544b-9045-41e1-ae1a-079511095df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_167478a9-3a1f-444e-abea-3e4aea30c375" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityCurrentReportingStatus_167478a9-3a1f-444e-abea-3e4aea30c375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4491c340-6e84-4fcb-bc9b-f17d5c9b5966" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityInteractiveDataCurrent_4491c340-6e84-4fcb-bc9b-f17d5c9b5966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e4474c9c-39ba-4e79-b79c-bc83b6ed12e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityFilerCategory_e4474c9c-39ba-4e79-b79c-bc83b6ed12e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_81ff8c86-c5e5-4a77-9e96-46c764ffa6f2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntitySmallBusiness_81ff8c86-c5e5-4a77-9e96-46c764ffa6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0e3ebc48-43f1-4b9a-9c8c-2431045149ff" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityEmergingGrowthCompany_0e3ebc48-43f1-4b9a-9c8c-2431045149ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_de7de14b-b8dd-45ad-8eb6-90d062bcd248" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityExTransitionPeriod_de7de14b-b8dd-45ad-8eb6-90d062bcd248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_fc8ef329-57a4-4d61-abac-fff4876e91a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_fc8ef329-57a4-4d61-abac-fff4876e91a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_3789f471-dd72-4706-bf97-a1938d930672" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_3789f471-dd72-4706-bf97-a1938d930672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_752591e9-9716-4d35-a8c4-66cd58104841" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityShellCompany_752591e9-9716-4d35-a8c4-66cd58104841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e5be85c4-d30a-40f0-a207-307d5ad40b3e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityPublicFloat_e5be85c4-d30a-40f0-a207-307d5ad40b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5edaaf78-62af-49bb-9a67-e5c4ef0d47f2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5edaaf78-62af-49bb-9a67-e5c4ef0d47f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2781b44c-8d58-439d-b977-c93da3fc0028" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2781b44c-8d58-439d-b977-c93da3fc0028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d17fe8c8-00e4-4a7c-9ce3-55ae037fab01" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_EntityCentralIndexKey_d17fe8c8-00e4-4a7c-9ce3-55ae037fab01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b2002fce-016f-49a3-acb9-abcf675182de" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_DocumentFiscalYearFocus_b2002fce-016f-49a3-acb9-abcf675182de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ed7a7329-4c08-4a4d-a17a-48f083b25fcb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ed7a7329-4c08-4a4d-a17a-48f083b25fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_aefc7983-09ca-4cb3-8faa-de5c5e38f01b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0aebc0ea-ed82-49a8-bf7c-a15373493cf0" xlink:to="loc_dei_AmendmentFlag_aefc7983-09ca-4cb3-8faa-de5c5e38f01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/AUDITINFORMATION" xlink:type="simple" xlink:href="cv-20251231.xsd#AUDITINFORMATION"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/AUDITINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cv_AuditInformationAbstract_ef712bd3-ecc4-4aae-893c-4fc2aa99d025" xlink:href="cv-20251231.xsd#cv_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_68543afc-9149-4d41-8e89-65d847747f73" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cv_AuditInformationAbstract_ef712bd3-ecc4-4aae-893c-4fc2aa99d025" xlink:to="loc_dei_AuditorFirmId_68543afc-9149-4d41-8e89-65d847747f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_93763ea3-b004-42f7-b343-1f394584f015" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cv_AuditInformationAbstract_ef712bd3-ecc4-4aae-893c-4fc2aa99d025" xlink:to="loc_dei_AuditorName_93763ea3-b004-42f7-b343-1f394584f015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_2cda1d7a-dd9b-4f51-8172-7206e3acc5e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cv_AuditInformationAbstract_ef712bd3-ecc4-4aae-893c-4fc2aa99d025" xlink:to="loc_dei_AuditorLocation_2cda1d7a-dd9b-4f51-8172-7206e3acc5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorOpinionTextBlock_019cb673-f7aa-76ee-982f-8170a7578a3d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cv_AuditInformationAbstract_ef712bd3-ecc4-4aae-893c-4fc2aa99d025" xlink:to="loc_dei_AuditorOpinionTextBlock_019cb673-f7aa-76ee-982f-8170a7578a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="cv-20251231.xsd#CONDENSEDBALANCESHEETSUNAUDITED"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9e582ec3-4267-4b09-b3a6-ce35dc2e5424" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_10eb1eba-86d4-46f7-b292-1582a7f19586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e582ec3-4267-4b09-b3a6-ce35dc2e5424" xlink:to="loc_us-gaap_AssetsAbstract_10eb1eba-86d4-46f7-b292-1582a7f19586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_72597107-895c-4c7f-90ed-5b2d591d48e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10eb1eba-86d4-46f7-b292-1582a7f19586" xlink:to="loc_us-gaap_AssetsCurrentAbstract_72597107-895c-4c7f-90ed-5b2d591d48e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_9918159a-a190-4dcd-9b7b-cb51ae07679d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72597107-895c-4c7f-90ed-5b2d591d48e5" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_9918159a-a190-4dcd-9b7b-cb51ae07679d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_83efd831-5ef2-49fb-9424-93c97fa6cdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72597107-895c-4c7f-90ed-5b2d591d48e5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_83efd831-5ef2-49fb-9424-93c97fa6cdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a5dda505-a8f1-4a74-b764-4aa8ea77f540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72597107-895c-4c7f-90ed-5b2d591d48e5" xlink:to="loc_us-gaap_InventoryNet_a5dda505-a8f1-4a74-b764-4aa8ea77f540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dcfd330a-3722-4714-9106-4aec8268cd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72597107-895c-4c7f-90ed-5b2d591d48e5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dcfd330a-3722-4714-9106-4aec8268cd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7eba4905-c864-4b17-b038-9c75f503e685" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72597107-895c-4c7f-90ed-5b2d591d48e5" xlink:to="loc_us-gaap_AssetsCurrent_7eba4905-c864-4b17-b038-9c75f503e685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13504f34-e103-4a84-96bd-8ae92dee046c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10eb1eba-86d4-46f7-b292-1582a7f19586" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13504f34-e103-4a84-96bd-8ae92dee046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_002077ee-0edd-452e-99a5-509dcf35e3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10eb1eba-86d4-46f7-b292-1582a7f19586" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_002077ee-0edd-452e-99a5-509dcf35e3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7d961b79-831c-4ec1-87b2-808de025f25b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10eb1eba-86d4-46f7-b292-1582a7f19586" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7d961b79-831c-4ec1-87b2-808de025f25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_97b5d0bc-87e2-4e92-93f2-acd042e27616" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10eb1eba-86d4-46f7-b292-1582a7f19586" xlink:to="loc_us-gaap_Assets_97b5d0bc-87e2-4e92-93f2-acd042e27616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2854962-ca56-45a7-b482-ee0d4ca4763c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e582ec3-4267-4b09-b3a6-ce35dc2e5424" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2854962-ca56-45a7-b482-ee0d4ca4763c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_72540ea9-5e2a-4898-9b70-146fc1b013b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2854962-ca56-45a7-b482-ee0d4ca4763c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_72540ea9-5e2a-4898-9b70-146fc1b013b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7f95af70-58eb-4b10-a9eb-0a21c535576c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_72540ea9-5e2a-4898-9b70-146fc1b013b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7f95af70-58eb-4b10-a9eb-0a21c535576c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_00ae5bc9-1984-4f2d-9bb4-d99bd42baf31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_72540ea9-5e2a-4898-9b70-146fc1b013b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_00ae5bc9-1984-4f2d-9bb4-d99bd42baf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_303ed5ef-674f-4704-b58c-ffc955804ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_72540ea9-5e2a-4898-9b70-146fc1b013b4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_303ed5ef-674f-4704-b58c-ffc955804ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8a3077f8-8633-4d18-a2ee-2aa918aade81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_72540ea9-5e2a-4898-9b70-146fc1b013b4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8a3077f8-8633-4d18-a2ee-2aa918aade81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_05026168-4100-4ed0-bf4a-730573fa1ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_72540ea9-5e2a-4898-9b70-146fc1b013b4" xlink:to="loc_us-gaap_LiabilitiesCurrent_05026168-4100-4ed0-bf4a-730573fa1ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb9194ae-7a79-4647-831c-a00758b260e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2854962-ca56-45a7-b482-ee0d4ca4763c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb9194ae-7a79-4647-831c-a00758b260e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7070b47b-e83f-4b9d-9bd8-dbcf987c0ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2854962-ca56-45a7-b482-ee0d4ca4763c" xlink:to="loc_us-gaap_Liabilities_7070b47b-e83f-4b9d-9bd8-dbcf987c0ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f7b43748-b6f2-4370-b146-e6e4c7c4fa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2854962-ca56-45a7-b482-ee0d4ca4763c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f7b43748-b6f2-4370-b146-e6e4c7c4fa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_70604bf0-3a6b-4611-bf0c-5ba48f359657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2854962-ca56-45a7-b482-ee0d4ca4763c" xlink:to="loc_us-gaap_TemporaryEquityAbstract_70604bf0-3a6b-4611-bf0c-5ba48f359657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8b25fa50-ea14-4fa3-91a5-24b49ece176e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_70604bf0-3a6b-4611-bf0c-5ba48f359657" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8b25fa50-ea14-4fa3-91a5-24b49ece176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a38b2606-f7de-4662-a714-2cff01cb0d56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2854962-ca56-45a7-b482-ee0d4ca4763c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a38b2606-f7de-4662-a714-2cff01cb0d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_821fded0-f3fa-4821-8189-675feced6484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a38b2606-f7de-4662-a714-2cff01cb0d56" xlink:to="loc_us-gaap_CommonStockValue_821fded0-f3fa-4821-8189-675feced6484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4e211aa3-022a-45bc-8388-cbc791913003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a38b2606-f7de-4662-a714-2cff01cb0d56" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4e211aa3-022a-45bc-8388-cbc791913003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9fae8e25-a75d-4027-8d85-84f28c5a0a48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a38b2606-f7de-4662-a714-2cff01cb0d56" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9fae8e25-a75d-4027-8d85-84f28c5a0a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_69cc80c1-3812-4d2c-bd1f-4a9afb9d7c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a38b2606-f7de-4662-a714-2cff01cb0d56" xlink:to="loc_us-gaap_StockholdersEquity_69cc80c1-3812-4d2c-bd1f-4a9afb9d7c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3c336da6-feea-4693-800e-6a20ef04a945" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2854962-ca56-45a7-b482-ee0d4ca4763c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3c336da6-feea-4693-800e-6a20ef04a945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="simple" xlink:href="cv-20251231.xsd#CONDENSEDBALANCESHEETSUNAUDITEDParenthetical"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_55c7c836-ca70-4430-a513-3012a267f0af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_55c7c836-ca70-4430-a513-3012a267f0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_7cc263ce-3ca9-454f-85c7-f65c6c6a054c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_7cc263ce-3ca9-454f-85c7-f65c6c6a054c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_a5eb24c5-ad7f-47ae-9adf-bc153b3339fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_a5eb24c5-ad7f-47ae-9adf-bc153b3339fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7168f7ef-edfc-4f9b-a039-2d33ae15d0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7168f7ef-edfc-4f9b-a039-2d33ae15d0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_9cbf9672-a8d0-4193-a6df-5e13e0a7dda7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_9cbf9672-a8d0-4193-a6df-5e13e0a7dda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019d20e8-2bd2-7354-ae4a-026d3461051a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019d20e8-2bd2-7354-ae4a-026d3461051a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c43ab4e2-3577-40f9-a828-754a5cb7c804" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c43ab4e2-3577-40f9-a828-754a5cb7c804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3227fa19-2ffa-4793-b067-b4482f3de1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:to="loc_us-gaap_CommonStockSharesIssued_3227fa19-2ffa-4793-b067-b4482f3de1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f40c3587-b11e-422a-b153-4cde1d808ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72d4216e-0df2-4170-b800-909d51ddd2ab" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f40c3587-b11e-422a-b153-4cde1d808ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" xlink:type="simple" xlink:href="cv-20251231.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0319c2a4-ee9e-46b4-9ca5-7daa42995923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0319c2a4-ee9e-46b4-9ca5-7daa42995923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9928a44e-1cc7-4c5c-a84f-089f210a57cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9928a44e-1cc7-4c5c-a84f-089f210a57cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_baa183d9-b57c-4800-b812-c5bc4f7ad0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_GrossProfit_baa183d9-b57c-4800-b812-c5bc4f7ad0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_6d9f585b-adfa-4397-9e97-3901ca7d5936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_SellingAndMarketingExpense_6d9f585b-adfa-4397-9e97-3901ca7d5936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b06d4bd9-5f70-4304-af10-5087e89ab879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b06d4bd9-5f70-4304-af10-5087e89ab879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a0c54b6a-6d58-4f29-8410-77007ef52a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a0c54b6a-6d58-4f29-8410-77007ef52a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6152a10f-209a-48d1-8dca-c5bc154a8417" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_OperatingExpenses_6152a10f-209a-48d1-8dca-c5bc154a8417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c691d486-272f-4383-9c97-535229e034fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_OperatingIncomeLoss_c691d486-272f-4383-9c97-535229e034fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_035cb313-ed76-4fa1-a5d0-269d5386faec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_InvestmentIncomeNet_035cb313-ed76-4fa1-a5d0-269d5386faec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_af9a8e0f-7115-4536-980f-b69a95babdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_af9a8e0f-7115-4536-980f-b69a95babdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_82977111-9dc6-46fd-afc9-9b2471415b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_82977111-9dc6-46fd-afc9-9b2471415b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_31d87e07-2d70-4518-b1f4-750a8c1abe63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_31d87e07-2d70-4518-b1f4-750a8c1abe63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b567b3eb-f3a8-4722-9f51-4fa87740adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b567b3eb-f3a8-4722-9f51-4fa87740adb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2a00c596-30b7-40d6-9a3b-0dfc03f6baee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_NetIncomeLoss_2a00c596-30b7-40d6-9a3b-0dfc03f6baee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_09a9a5a6-3a82-42d2-a960-b2d26343d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_EarningsPerShareBasic_09a9a5a6-3a82-42d2-a960-b2d26343d30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3bed3d96-dc8a-4d43-b95d-74db081affa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3bed3d96-dc8a-4d43-b95d-74db081affa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bdfbace2-7e12-4dba-af72-40b5f1908ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bdfbace2-7e12-4dba-af72-40b5f1908ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d0d982e6-8681-4641-83bb-98dae2269f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0481ef36-879b-4816-81ed-15dbbfbc994e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d0d982e6-8681-4641-83bb-98dae2269f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED" xlink:type="simple" xlink:href="cv-20251231.xsd#CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_06d74e3e-7d2f-493a-9c28-b9d925da58b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2cd45fcb-6ad1-4958-8a0a-b97bcb575359" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_06d74e3e-7d2f-493a-9c28-b9d925da58b0" xlink:to="loc_us-gaap_StatementTable_2cd45fcb-6ad1-4958-8a0a-b97bcb575359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1222d2bf-64d5-41a2-9edb-c4b7b79ae879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2cd45fcb-6ad1-4958-8a0a-b97bcb575359" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1222d2bf-64d5-41a2-9edb-c4b7b79ae879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1222d2bf-64d5-41a2-9edb-c4b7b79ae879" xlink:to="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d1473c8a-41e3-40a4-bbf0-c7f40d589868" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:to="loc_us-gaap_PreferredStockMember_d1473c8a-41e3-40a4-bbf0-c7f40d589868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f7f3dcc0-7b49-4849-9c11-9d71b731bfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:to="loc_us-gaap_CommonStockMember_f7f3dcc0-7b49-4849-9c11-9d71b731bfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_69d0fadb-8037-4bda-96b5-23c7389121f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_69d0fadb-8037-4bda-96b5-23c7389121f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c373b5e2-72ba-4a78-9d50-6ec30053aed0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53254529-7c05-475b-8ea6-9df4cd666059" xlink:to="loc_us-gaap_RetainedEarningsMember_c373b5e2-72ba-4a78-9d50-6ec30053aed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_87cb4e74-aa36-4116-aa4a-e0f0a5447166" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2cd45fcb-6ad1-4958-8a0a-b97bcb575359" xlink:to="loc_us-gaap_StatementLineItems_87cb4e74-aa36-4116-aa4a-e0f0a5447166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87cb4e74-aa36-4116-aa4a-e0f0a5447166" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3053f03e-220d-4e53-8705-ab730ca5cb35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3053f03e-220d-4e53-8705-ab730ca5cb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_57dd155b-27be-4e6c-92ef-f75c6a108fad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_57dd155b-27be-4e6c-92ef-f75c6a108fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_9ea46aa3-824c-4714-b93e-f8cee77845b1" xlink:href="cv-20251231.xsd#cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_9ea46aa3-824c-4714-b93e-f8cee77845b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_29755a7f-9637-49a7-b938-76820e4b0cee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_29755a7f-9637-49a7-b938-76820e4b0cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1d18fedf-c17d-4238-ac83-7aaa45d98b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1d18fedf-c17d-4238-ac83-7aaa45d98b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_92d1ff46-f330-4414-975f-b90e5e1e921e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_92d1ff46-f330-4414-975f-b90e5e1e921e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_e5b11c25-0d08-4ef2-b7ee-7aa04d86c2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_e5b11c25-0d08-4ef2-b7ee-7aa04d86c2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a5019a67-8fa1-499c-b90f-191f72b654de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_12aa9ed9-64e7-4700-afed-88e31e95ee48" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a5019a67-8fa1-499c-b90f-191f72b654de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87cb4e74-aa36-4116-aa4a-e0f0a5447166" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bb196abd-7e2e-4782-9d48-258c0db2be3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bb196abd-7e2e-4782-9d48-258c0db2be3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_83627c5e-6aae-42b6-8ea9-66007b135a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockholdersEquity_83627c5e-6aae-42b6-8ea9-66007b135a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_393eb6c8-c485-409b-b767-5adfa1fd58bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_393eb6c8-c485-409b-b767-5adfa1fd58bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_b8e7e633-8c18-4776-9687-5e50e8d752e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_b8e7e633-8c18-4776-9687-5e50e8d752e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_203c72ce-6026-41c8-a82b-2dcbbb438a47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_203c72ce-6026-41c8-a82b-2dcbbb438a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e74be102-1658-4d90-913a-16edab498e44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e74be102-1658-4d90-913a-16edab498e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fb0c0d19-0a26-4295-867e-784c4fd8e01a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fb0c0d19-0a26-4295-867e-784c4fd8e01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cab448c8-7a82-43cc-a0c1-5046e8eee4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cab448c8-7a82-43cc-a0c1-5046e8eee4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_13d756a5-3c9a-4b0c-b3dd-a8a334dd87a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_13d756a5-3c9a-4b0c-b3dd-a8a334dd87a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_c5fb8a87-3240-4835-a73a-3f7ef14e11f9" xlink:href="cv-20251231.xsd#cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_c5fb8a87-3240-4835-a73a-3f7ef14e11f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_0dd83503-8d35-48a3-93f0-045c2a0a0bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_0dd83503-8d35-48a3-93f0-045c2a0a0bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6094bc66-09f4-4bf6-927b-1cd0b0f7d373" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6094bc66-09f4-4bf6-927b-1cd0b0f7d373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_6fc8beef-7d3b-429c-b205-ef7c54f77b34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_6fc8beef-7d3b-429c-b205-ef7c54f77b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a2fe3d64-3b57-4b58-a569-63ce2dff2335" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a2fe3d64-3b57-4b58-a569-63ce2dff2335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e079d350-edca-4c1e-865b-228cd271318f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e079d350-edca-4c1e-865b-228cd271318f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019bfcd2-1dfb-7118-a422-0610ee149f95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019bfcd2-1dfb-7118-a422-0610ee149f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3d0945a8-93d2-4e7f-9836-e37a0121049a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3d0945a8-93d2-4e7f-9836-e37a0121049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5183a246-baea-44c1-a03f-9b8275db68fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_NetIncomeLoss_5183a246-baea-44c1-a03f-9b8275db68fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9b76840f-8b9b-4453-905d-30d3305a3fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9b76840f-8b9b-4453-905d-30d3305a3fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bc5fd773-4849-4661-9ee7-2b1970d6bbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_489a4463-121d-485f-b5fd-cbe30b85f55a" xlink:to="loc_us-gaap_StockholdersEquity_bc5fd773-4849-4661-9ee7-2b1970d6bbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="cv-20251231.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2b1f3026-66cd-4abd-b843-e4924521480d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2b1f3026-66cd-4abd-b843-e4924521480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_678579ee-82aa-4fb4-ae5a-a26d23a23da0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2b1f3026-66cd-4abd-b843-e4924521480d" xlink:to="loc_us-gaap_NetIncomeLoss_678579ee-82aa-4fb4-ae5a-a26d23a23da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2b1f3026-66cd-4abd-b843-e4924521480d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_25889c12-06e8-4219-aafa-8dd9e6a057d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_25889c12-06e8-4219-aafa-8dd9e6a057d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_a92d2dcb-d8ef-48ab-8f3c-06368dc9a8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_a92d2dcb-d8ef-48ab-8f3c-06368dc9a8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_49f30993-7181-492a-840b-eefb9dcf4ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_49f30993-7181-492a-840b-eefb9dcf4ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_c9ccd8c3-c409-4545-ab3d-c5efe92088d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_c9ccd8c3-c409-4545-ab3d-c5efe92088d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9a8cba70-bd9e-4553-993b-716091770d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9a8cba70-bd9e-4553-993b-716091770d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_de43cb75-6e8e-496c-a509-58e2a817d8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:to="loc_us-gaap_ShareBasedCompensation_de43cb75-6e8e-496c-a509-58e2a817d8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1fc76b69-7fb0-4785-85b8-91791c5cba9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_1fc76b69-7fb0-4785-85b8-91791c5cba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2031331-bcd2-4c95-a436-833b0862deca" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cffc8226-290e-4416-9f8f-0e080682f731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cffc8226-290e-4416-9f8f-0e080682f731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c3b5fbcd-0997-439a-9719-7fad52591289" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c3b5fbcd-0997-439a-9719-7fad52591289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19febc43-b22c-480c-a31e-b4d3e2477f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19febc43-b22c-480c-a31e-b4d3e2477f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_21f2ccb0-7496-46f0-9963-3bd6a578d152" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_21f2ccb0-7496-46f0-9963-3bd6a578d152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2962ff98-20cc-48c2-ab3c-befa840bb33f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2962ff98-20cc-48c2-ab3c-befa840bb33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a4f01025-510e-4827-a770-166364a30d75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a4f01025-510e-4827-a770-166364a30d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b61094d2-e5f5-434e-9613-fccad99ffd54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b61094d2-e5f5-434e-9613-fccad99ffd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_86e3f086-d3cf-449c-86b1-88003f1ddcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_79305dee-1628-43b1-98e9-394f469a7401" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_86e3f086-d3cf-449c-86b1-88003f1ddcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38fc3540-84e8-4377-b782-23a2fe4d3f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2b1f3026-66cd-4abd-b843-e4924521480d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38fc3540-84e8-4377-b782-23a2fe4d3f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5080532-4ca7-4ac7-85d0-a5e78a40a2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5080532-4ca7-4ac7-85d0-a5e78a40a2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c1d4b608-3f02-4d9a-810e-e7fe632710c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5080532-4ca7-4ac7-85d0-a5e78a40a2d4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c1d4b608-3f02-4d9a-810e-e7fe632710c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4c0aacb3-40bf-43e9-93a4-05081ee265f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5080532-4ca7-4ac7-85d0-a5e78a40a2d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4c0aacb3-40bf-43e9-93a4-05081ee265f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9dbac96-776c-4b27-9cd0-292516600376" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9dbac96-776c-4b27-9cd0-292516600376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_5c1b52c4-b00b-4440-8c62-eec224fea670" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9dbac96-776c-4b27-9cd0-292516600376" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_5c1b52c4-b00b-4440-8c62-eec224fea670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_84c74568-c4df-4daf-94c4-c27176d5df01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9dbac96-776c-4b27-9cd0-292516600376" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_84c74568-c4df-4daf-94c4-c27176d5df01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_2064bdec-8873-495f-8414-a444445b44fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9dbac96-776c-4b27-9cd0-292516600376" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_2064bdec-8873-495f-8414-a444445b44fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_184fbfb3-b69c-46b1-a02e-5a85169d2f34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9dbac96-776c-4b27-9cd0-292516600376" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_184fbfb3-b69c-46b1-a02e-5a85169d2f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_43566602-8baf-4056-955b-1919eb0a7538" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9dbac96-776c-4b27-9cd0-292516600376" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_43566602-8baf-4056-955b-1919eb0a7538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_c6c62e38-fb92-47b7-9e7e-65fd6eeeadaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9dbac96-776c-4b27-9cd0-292516600376" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_c6c62e38-fb92-47b7-9e7e-65fd6eeeadaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b587dc15-248f-4768-afe4-b89583aab144" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9dbac96-776c-4b27-9cd0-292516600376" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b587dc15-248f-4768-afe4-b89583aab144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_451e5255-1f9b-41e5-89d3-f0f12c0407bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_451e5255-1f9b-41e5-89d3-f0f12c0407bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b7b60bda-0e26-4b2d-925f-88bd1e42b4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b7b60bda-0e26-4b2d-925f-88bd1e42b4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_161a2c9c-5251-429d-bb66-a3803260829a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_161a2c9c-5251-429d-bb66-a3803260829a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2d35084e-923f-435c-9abf-6a6777b23f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2d35084e-923f-435c-9abf-6a6777b23f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f0d0ed2d-d081-45fc-9224-27645c2b51ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f0d0ed2d-d081-45fc-9224-27645c2b51ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_240d865c-47e6-4f5c-86e1-0360295b8e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f0d0ed2d-d081-45fc-9224-27645c2b51ea" xlink:to="loc_us-gaap_IncomeTaxesPaid_240d865c-47e6-4f5c-86e1-0360295b8e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_be6f7088-ba74-4db5-8c32-4e0cddde53b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f0d0ed2d-d081-45fc-9224-27645c2b51ea" xlink:to="loc_us-gaap_InterestPaidNet_be6f7088-ba74-4db5-8c32-4e0cddde53b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e69645eb-cb0a-4713-af07-452e0376e54e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3167f4b-dd9e-450f-a6a8-0284e7e33899" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e69645eb-cb0a-4713-af07-452e0376e54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_db49c372-8651-4db6-8419-69571a39e58c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e69645eb-cb0a-4713-af07-452e0376e54e" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_db49c372-8651-4db6-8419-69571a39e58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5f72f2f2-7a4a-4517-9329-67b1390d4c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e69645eb-cb0a-4713-af07-452e0376e54e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5f72f2f2-7a4a-4517-9329-67b1390d4c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTURE" xlink:type="simple" xlink:href="cv-20251231.xsd#DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTURE"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTURE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aaf5463c-9530-4807-aea0-7bf81e8118c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_83474847-c2e4-46f8-8506-247a4e43420f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aaf5463c-9530-4807-aea0-7bf81e8118c5" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_83474847-c2e4-46f8-8506-247a4e43420f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/GOINGCONCERN" xlink:type="simple" xlink:href="cv-20251231.xsd#GOINGCONCERN"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/GOINGCONCERN" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8426f995-ee13-4b5f-8868-1b21e2451224" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_e8ecea34-f64b-4287-9856-75890b7ee4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8426f995-ee13-4b5f-8868-1b21e2451224" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_e8ecea34-f64b-4287-9856-75890b7ee4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cv-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_29ebb0bb-24ab-4b7b-96af-c2ef409aff44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8bdecb37-3255-4cda-9c46-e1fecf61711b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_29ebb0bb-24ab-4b7b-96af-c2ef409aff44" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8bdecb37-3255-4cda-9c46-e1fecf61711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cv-20251231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_783a1056-8adb-4f1d-84e6-0c012986a74e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_bf0f85a9-3986-4f92-a37e-03815319ac48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_783a1056-8adb-4f1d-84e6-0c012986a74e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_bf0f85a9-3986-4f92-a37e-03815319ac48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTS" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTS"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9109bf49-e082-42b9-b5e7-3c636d6b8fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6415f470-3958-48e8-8370-51619d8c0b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9109bf49-e082-42b9-b5e7-3c636d6b8fcd" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6415f470-3958-48e8-8370-51619d8c0b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUE" xlink:type="simple" xlink:href="cv-20251231.xsd#REVENUEANDDEFERREDREVENUE"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/REVENUEANDDEFERREDREVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e82c3ba1-43da-46ae-9f6f-03e59abbeff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_cde9b381-98cb-446c-93d4-d7e79ca770e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e82c3ba1-43da-46ae-9f6f-03e59abbeff5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_cde9b381-98cb-446c-93d4-d7e79ca770e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/NOTEPAYABLE" xlink:type="simple" xlink:href="cv-20251231.xsd#NOTEPAYABLE"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/NOTEPAYABLE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_77667c0c-7db7-44e5-8338-00dd00c5ab45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_69390a9c-6656-4126-94f9-68bc67c17ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_77667c0c-7db7-44e5-8338-00dd00c5ab45" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_69390a9c-6656-4126-94f9-68bc67c17ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASES" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d1bf3192-1832-4aba-917f-ad4da2c68d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_f51e5fac-bf1c-45e7-857f-657450096bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d1bf3192-1832-4aba-917f-ad4da2c68d7a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_f51e5fac-bf1c-45e7-857f-657450096bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f971d9e2-a0d9-42aa-afab-8dca1a41e9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bf595219-f9d6-4c12-be82-d73af08bc83c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f971d9e2-a0d9-42aa-afab-8dca1a41e9bb" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bf595219-f9d6-4c12-be82-d73af08bc83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/PREFERREDSTOCK" xlink:type="simple" xlink:href="cv-20251231.xsd#PREFERREDSTOCK"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/PREFERREDSTOCK" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4807d675-4c40-4d89-83c4-d960607467b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock_b18b3182-e42f-4c5f-bd6f-fb9514bfebf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4807d675-4c40-4d89-83c4-d960607467b9" xlink:to="loc_us-gaap_PreferredStockTextBlock_b18b3182-e42f-4c5f-bd6f-fb9514bfebf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMONSTOCK" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMONSTOCK"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/COMMONSTOCK" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_29d0490b-92e8-4f9a-b8c0-7f9b5f52759e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_231f5711-e08b-4e01-951c-17c9a5ce8b97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b10e58d9-d4b1-43ca-9d8d-dd1bf90940e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_231f5711-e08b-4e01-951c-17c9a5ce8b97" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b10e58d9-d4b1-43ca-9d8d-dd1bf90940e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/SEGMENTS" xlink:type="simple" xlink:href="cv-20251231.xsd#SEGMENTS"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/SEGMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3fe0c668-d30f-4a36-9b40-6859a6192c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_83a28d68-87e5-4514-8023-f250dff385f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3fe0c668-d30f-4a36-9b40-6859a6192c6c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_83a28d68-87e5-4514-8023-f250dff385f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXES" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0e641e19-066a-4ea0-984b-fab40180fed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b83846b0-c06e-4d86-9cab-52128c99d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0e641e19-066a-4ea0-984b-fab40180fed8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b83846b0-c06e-4d86-9cab-52128c99d9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="cv-20251231.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bea30228-86dd-4582-a728-988f62305410" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8acd1c54-00f1-48c8-b297-d3dea09e1305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bea30228-86dd-4582-a728-988f62305410" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8acd1c54-00f1-48c8-b297-d3dea09e1305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/RELATEDPARTIES" xlink:type="simple" xlink:href="cv-20251231.xsd#RELATEDPARTIES"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/RELATEDPARTIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ed5c39ed-dbc1-4eee-804d-96e1a321017f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_abbf651f-b82c-4e73-8bf4-5e01d95c4518" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ed5c39ed-dbc1-4eee-804d-96e1a321017f" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_abbf651f-b82c-4e73-8bf4-5e01d95c4518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="cv-20251231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c970465b-0da8-4231-87ed-b1d430faa8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_db1df9b6-6950-4d13-aafc-658e43ee109b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c970465b-0da8-4231-87ed-b1d430faa8bc" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_db1df9b6-6950-4d13-aafc-658e43ee109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="cv-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5f49f1d3-c928-49db-98b9-fc5fdfd13e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5f49f1d3-c928-49db-98b9-fc5fdfd13e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_7aa4ccfb-90ec-48d2-b3a3-c7519ebd618a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_7aa4ccfb-90ec-48d2-b3a3-c7519ebd618a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8db822a6-9543-4016-a23d-7714450f6f30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8db822a6-9543-4016-a23d-7714450f6f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e56e11b5-0057-4107-bdcc-59958c7cea51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_UseOfEstimates_e56e11b5-0057-4107-bdcc-59958c7cea51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d0b1a579-ff50-4151-b12e-a3969698c36f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d0b1a579-ff50-4151-b12e-a3969698c36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_25a52a97-5dc3-454e-80fe-9c7df4adb4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_25a52a97-5dc3-454e-80fe-9c7df4adb4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_fb0f7011-1aa1-444c-aa6a-115237612ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_fb0f7011-1aa1-444c-aa6a-115237612ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7fae9dfb-e943-46b3-b5d6-1565be0e80b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7fae9dfb-e943-46b3-b5d6-1565be0e80b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4d4352a2-ee2a-44ba-8280-702bada5d364" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4d4352a2-ee2a-44ba-8280-702bada5d364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_452bfcff-c5bc-4414-b248-03f1d851cc04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_452bfcff-c5bc-4414-b248-03f1d851cc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_cc4013b7-1ac3-4004-b77e-967703b494d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_cc4013b7-1ac3-4004-b77e-967703b494d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_1c079d0a-ab0d-467f-98c7-736308670e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_1c079d0a-ab0d-467f-98c7-736308670e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_26f77ea2-b007-4f35-b45d-a21574eee09f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_26f77ea2-b007-4f35-b45d-a21574eee09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_72d7a68e-0f93-46aa-88ff-86dd9b37288a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_72d7a68e-0f93-46aa-88ff-86dd9b37288a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a442060e-3a39-4ede-9019-bec6d5958832" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a442060e-3a39-4ede-9019-bec6d5958832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_0504fb9b-4b86-4639-932f-9fdd40e5d565" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_0504fb9b-4b86-4639-932f-9fdd40e5d565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2778cb7c-8929-4a75-97c0-4d862454b5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2778cb7c-8929-4a75-97c0-4d862454b5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_093c77c8-7e11-4cd2-ae51-d7ac9e404810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_093c77c8-7e11-4cd2-ae51-d7ac9e404810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_79052339-56b7-4c78-814c-076f4057c703" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_79052339-56b7-4c78-814c-076f4057c703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2f783286-f9b5-402b-863a-15c34c7a23d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2f783286-f9b5-402b-863a-15c34c7a23d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_5fa8281d-30c6-4e94-b1ac-56d746d7461b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_5fa8281d-30c6-4e94-b1ac-56d746d7461b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_422098c9-ea60-4df5-b92e-b837317c5104" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_422098c9-ea60-4df5-b92e-b837317c5104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7176084d-b93c-4604-b2c2-c0ad21d7ee40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af322380-4bcd-4910-b04f-ba242e131473" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7176084d-b93c-4604-b2c2-c0ad21d7ee40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="cv-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2e242aff-f5e2-4aad-9420-7ede9abcf4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_22376e7e-f36c-40a2-a226-a77affeda185" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e242aff-f5e2-4aad-9420-7ede9abcf4aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_22376e7e-f36c-40a2-a226-a77affeda185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSTables"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00f93456-17a5-4e03-8c79-52aed4fac63c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_cc1e412c-d9bb-4d7e-9c79-3fe2feb3abd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00f93456-17a5-4e03-8c79-52aed4fac63c" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_cc1e412c-d9bb-4d7e-9c79-3fe2feb3abd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_bdd7dd8a-7172-4828-8050-b6389730c453" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00f93456-17a5-4e03-8c79-52aed4fac63c" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_bdd7dd8a-7172-4828-8050-b6389730c453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_104760ad-fae4-4a59-b816-fed341ece21b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00f93456-17a5-4e03-8c79-52aed4fac63c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_104760ad-fae4-4a59-b816-fed341ece21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5931b235-7058-4d65-9c13-958ac52e5bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00f93456-17a5-4e03-8c79-52aed4fac63c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5931b235-7058-4d65-9c13-958ac52e5bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUETables" xlink:type="simple" xlink:href="cv-20251231.xsd#REVENUEANDDEFERREDREVENUETables"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/REVENUEANDDEFERREDREVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0d04dec-e53d-4aa1-bf6f-b5da2eeb1943" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e1bfb75f-80d1-4591-aa2e-a4906af5a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0d04dec-e53d-4aa1-bf6f-b5da2eeb1943" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e1bfb75f-80d1-4591-aa2e-a4906af5a65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESTables" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dd95f1f7-008d-457a-8c1e-9b3e024fc252" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_96153f9e-3f98-43bd-999a-79ddb0715b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd95f1f7-008d-457a-8c1e-9b3e024fc252" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_96153f9e-3f98-43bd-999a-79ddb0715b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_a11dd810-c208-4ad6-86e3-3e3e0eeebe1e" xlink:href="cv-20251231.xsd#cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd95f1f7-008d-457a-8c1e-9b3e024fc252" xlink:to="loc_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_a11dd810-c208-4ad6-86e3-3e3e0eeebe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_37903db2-6ed6-48bf-b9be-84221b38b4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd95f1f7-008d-457a-8c1e-9b3e024fc252" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_37903db2-6ed6-48bf-b9be-84221b38b4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/PREFERREDSTOCKTables" xlink:type="simple" xlink:href="cv-20251231.xsd#PREFERREDSTOCKTables"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/PREFERREDSTOCKTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_07eff839-e16d-48e3-a490-2a7a744fcd67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_0c179ce1-31ff-4b94-9605-2aaf354e7b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_07eff839-e16d-48e3-a490-2a7a744fcd67" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_0c179ce1-31ff-4b94-9605-2aaf354e7b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMONSTOCKTables" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMONSTOCKTables"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/COMMONSTOCKTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_76e7fddb-7e12-42e6-8eb0-fa213ad0a95d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d7cbcbaa-2e5e-45e1-9a05-a0ea2ea4ef9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76e7fddb-7e12-42e6-8eb0-fa213ad0a95d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d7cbcbaa-2e5e-45e1-9a05-a0ea2ea4ef9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_7bd8b945-380b-45c4-a671-5a9e8a89ea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76e7fddb-7e12-42e6-8eb0-fa213ad0a95d" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_7bd8b945-380b-45c4-a671-5a9e8a89ea8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07f96630-6c0c-4ef9-9c09-561126bd009b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_beb9030b-98d1-4194-957a-d3cb2cdc6e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07f96630-6c0c-4ef9-9c09-561126bd009b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_beb9030b-98d1-4194-957a-d3cb2cdc6e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3c1dd84e-5d8a-4bf0-a6e3-bb50e6bc46f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07f96630-6c0c-4ef9-9c09-561126bd009b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3c1dd84e-5d8a-4bf0-a6e3-bb50e6bc46f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b2d70ace-069b-4aa8-8d14-c10a27827208" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07f96630-6c0c-4ef9-9c09-561126bd009b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b2d70ace-069b-4aa8-8d14-c10a27827208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_c0fe2179-401a-4546-9e6a-21b28e601beb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07f96630-6c0c-4ef9-9c09-561126bd009b" xlink:to="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_c0fe2179-401a-4546-9e6a-21b28e601beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f57-5709-768d-88b7-f11031cd8354" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019b8f57-5709-7795-8cbb-d1f1ca6faec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f57-5709-768d-88b7-f11031cd8354" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019b8f57-5709-7795-8cbb-d1f1ca6faec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_019b8f5f-9f72-7a79-947c-d64e4b2e8d82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f57-5709-768d-88b7-f11031cd8354" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_019b8f5f-9f72-7a79-947c-d64e4b2e8d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019c9606-156e-7691-a51b-c672536fb46a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f57-5709-768d-88b7-f11031cd8354" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019c9606-156e-7691-a51b-c672536fb46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_019b8f65-fcd0-78b2-8dc4-7940ff5a5b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f57-5709-768d-88b7-f11031cd8354" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_019b8f65-fcd0-78b2-8dc4-7940ff5a5b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_019b8f74-a977-730d-a21a-229bf04c07f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f57-5709-768d-88b7-f11031cd8354" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_019b8f74-a977-730d-a21a-229bf04c07f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_019b8f85-8f13-7e0f-b0ec-0e3c9934c1af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f57-5709-768d-88b7-f11031cd8354" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_019b8f85-8f13-7e0f-b0ec-0e3c9934c1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_019b8f86-41ad-79e1-91c1-fe0a0ec1538f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f57-5709-768d-88b7-f11031cd8354" xlink:to="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_019b8f86-41ad-79e1-91c1-fe0a0ec1538f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_019b8f89-92ea-7979-801e-342be9598b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f57-5709-768d-88b7-f11031cd8354" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_019b8f89-92ea-7979-801e-342be9598b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="cv-20251231.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8f0e4279-e37e-4ed6-bd12-2a177078471d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a14e7cbe-af4f-4405-93c1-ee0fa5d9872c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8f0e4279-e37e-4ed6-bd12-2a177078471d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a14e7cbe-af4f-4405-93c1-ee0fa5d9872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6e6f99cd-8f4d-4a66-9f5c-628917cd164a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8f0e4279-e37e-4ed6-bd12-2a177078471d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6e6f99cd-8f4d-4a66-9f5c-628917cd164a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df0e7f65-5f30-419c-8f3a-85ebd49520f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1b8d84cd-e36f-4263-8fd9-19a064c48e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df0e7f65-5f30-419c-8f3a-85ebd49520f7" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1b8d84cd-e36f-4263-8fd9-19a064c48e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9a856304-b450-49d7-927f-62daf3cc3140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1b8d84cd-e36f-4263-8fd9-19a064c48e8c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9a856304-b450-49d7-927f-62daf3cc3140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cacce2a-4ba3-4f7f-a372-8267d63bf0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9a856304-b450-49d7-927f-62daf3cc3140" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cacce2a-4ba3-4f7f-a372-8267d63bf0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_8dce81e7-9739-4b44-b6fe-6d509e983c25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cacce2a-4ba3-4f7f-a372-8267d63bf0fa" xlink:to="loc_us-gaap_IPOMember_8dce81e7-9739-4b44-b6fe-6d509e983c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_9673da90-aef1-4a1b-818a-1ddc46289f76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0cacce2a-4ba3-4f7f-a372-8267d63bf0fa" xlink:to="loc_us-gaap_OverAllotmentOptionMember_9673da90-aef1-4a1b-818a-1ddc46289f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d864cc29-02f9-4dea-af41-3a9774af6572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1b8d84cd-e36f-4263-8fd9-19a064c48e8c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d864cc29-02f9-4dea-af41-3a9774af6572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_dcf859a3-cf9d-4be7-b69a-4f7803c2a49b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d864cc29-02f9-4dea-af41-3a9774af6572" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_dcf859a3-cf9d-4be7-b69a-4f7803c2a49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_4f115ef7-037c-4d81-b82f-5b1f68a390f4" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dcf859a3-cf9d-4be7-b69a-4f7803c2a49b" xlink:to="loc_cv_UnderwriterMember_4f115ef7-037c-4d81-b82f-5b1f68a390f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1b8d84cd-e36f-4263-8fd9-19a064c48e8c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_ab600f2f-82b5-40a5-a829-81c434cfa675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_ab600f2f-82b5-40a5-a829-81c434cfa675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9cd81cac-f817-4b96-b5d0-42e08c6b45c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9cd81cac-f817-4b96-b5d0-42e08c6b45c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_882b7ce0-b213-4c90-bca2-bcdd718a6b66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_882b7ce0-b213-4c90-bca2-bcdd718a6b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bae7d715-525b-4930-97ac-35e0b68963b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bae7d715-525b-4930-97ac-35e0b68963b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a758c78f-d819-4cdf-b48d-402fc0199c93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a758c78f-d819-4cdf-b48d-402fc0199c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_32ac01ea-7770-4b19-ad05-05ff28525cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_32ac01ea-7770-4b19-ad05-05ff28525cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a8d94601-9bda-48d9-a163-4a18af55d0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a8d94601-9bda-48d9-a163-4a18af55d0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionDate_9bda14b6-34e6-4f9b-970d-f1874e6508d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionDate_9bda14b6-34e6-4f9b-970d-f1874e6508d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockEffectivenessDate_83be258a-d8e0-49f1-ac3a-4d8a7774b9ec" xlink:href="cv-20251231.xsd#cv_SaleOfStockEffectivenessDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_836ef42b-129b-40c5-99f8-07a83c82f670" xlink:to="loc_cv_SaleOfStockEffectivenessDate_83be258a-d8e0-49f1-ac3a-4d8a7774b9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/GOINGCONCERNDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#GOINGCONCERNDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/GOINGCONCERNDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_246e708d-1a28-4ac7-96a3-1c6ce22d2bed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d845ce20-467e-4de5-b0c9-83797c451a45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_246e708d-1a28-4ac7-96a3-1c6ce22d2bed" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d845ce20-467e-4de5-b0c9-83797c451a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2db27a08-be0a-4b16-bc12-b02f236da98f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d845ce20-467e-4de5-b0c9-83797c451a45" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2db27a08-be0a-4b16-bc12-b02f236da98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06a531ce-6dbf-4bd1-bd44-aff30a0b2728" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2db27a08-be0a-4b16-bc12-b02f236da98f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06a531ce-6dbf-4bd1-bd44-aff30a0b2728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_cb7103d3-1655-4cec-9004-c7caf547e260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06a531ce-6dbf-4bd1-bd44-aff30a0b2728" xlink:to="loc_us-gaap_IPOMember_cb7103d3-1655-4cec-9004-c7caf547e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d845ce20-467e-4de5-b0c9-83797c451a45" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_d843ad61-ae74-45ce-87de-ab5f51b82c74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_d843ad61-ae74-45ce-87de-ab5f51b82c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_835c24a4-3df3-4548-b8b7-2c5a34cd67bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_OperatingIncomeLoss_835c24a4-3df3-4548-b8b7-2c5a34cd67bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e0abc12-2a4d-491c-ad54-36a6a573254a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_NetIncomeLoss_9e0abc12-2a4d-491c-ad54-36a6a573254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14fda9e8-d051-4c37-82fd-e5847fe8466d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14fda9e8-d051-4c37-82fd-e5847fe8466d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f076afb-a550-4c49-b97e-d2b517b7561e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2796f1c7-f981-4141-be6b-16123adeed0a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f076afb-a550-4c49-b97e-d2b517b7561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ff59a50a-b459-47ea-bd4e-c5e2c0f8f49d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ff59a50a-b459-47ea-bd4e-c5e2c0f8f49d" xlink:to="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a08878a9-9176-4ec8-b819-fbd34e94ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a08878a9-9176-4ec8-b819-fbd34e94ca9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a7c1f12-af8d-42b6-889a-5fd11e50ea10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a08878a9-9176-4ec8-b819-fbd34e94ca9c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a7c1f12-af8d-42b6-889a-5fd11e50ea10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f032ee5a-3e2b-4d14-a642-51c34fbf8bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a7c1f12-af8d-42b6-889a-5fd11e50ea10" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f032ee5a-3e2b-4d14-a642-51c34fbf8bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_cc9c269a-7936-40f3-a4ad-00be6b42b669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a7c1f12-af8d-42b6-889a-5fd11e50ea10" xlink:to="loc_us-gaap_AccountsReceivableMember_cc9c269a-7936-40f3-a4ad-00be6b42b669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_947751bc-13e7-4f29-90f8-60842e4a5657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_947751bc-13e7-4f29-90f8-60842e4a5657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3fda6b68-93eb-4d12-93f0-ea54fbc9e1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_947751bc-13e7-4f29-90f8-60842e4a5657" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3fda6b68-93eb-4d12-93f0-ea54fbc9e1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ba75a99a-bbb8-4e6f-8579-c9aa114fd75a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3fda6b68-93eb-4d12-93f0-ea54fbc9e1d8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ba75a99a-bbb8-4e6f-8579-c9aa114fd75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_be0b686b-978b-4043-9fb7-bacc07e6ae59" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_srt_MajorCustomersAxis_be0b686b-978b-4043-9fb7-bacc07e6ae59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d382680e-1474-476c-87d6-80b606c36022" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_be0b686b-978b-4043-9fb7-bacc07e6ae59" xlink:to="loc_srt_NameOfMajorCustomerDomain_d382680e-1474-476c-87d6-80b606c36022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_CustomerOneMember_f5607bf7-fc07-49b5-9a5b-9dfd98d33fd0" xlink:href="cv-20251231.xsd#cv_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d382680e-1474-476c-87d6-80b606c36022" xlink:to="loc_cv_CustomerOneMember_f5607bf7-fc07-49b5-9a5b-9dfd98d33fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a0edb9db-e203-489a-add7-bd4d567c3117" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_srt_ProductOrServiceAxis_a0edb9db-e203-489a-add7-bd4d567c3117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e821c148-923d-470a-bf0a-f12fc11633d0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a0edb9db-e203-489a-add7-bd4d567c3117" xlink:to="loc_srt_ProductsAndServicesDomain_e821c148-923d-470a-bf0a-f12fc11633d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_1f9e05d5-73bb-4f0e-ac60-a1fb77199db7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e821c148-923d-470a-bf0a-f12fc11633d0" xlink:to="loc_us-gaap_ShippingAndHandlingMember_1f9e05d5-73bb-4f0e-ac60-a1fb77199db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_HealthcareClinicalTrialActivitiesMember_2887bd0f-026c-4659-9cf0-b9ab2550c229" xlink:href="cv-20251231.xsd#cv_HealthcareClinicalTrialActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e821c148-923d-470a-bf0a-f12fc11633d0" xlink:to="loc_cv_HealthcareClinicalTrialActivitiesMember_2887bd0f-026c-4659-9cf0-b9ab2550c229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1b96c617-8444-4c51-8891-febf51c635f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1b96c617-8444-4c51-8891-febf51c635f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a83a6a-0d39-4b2d-a96d-a4cb7605d7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1b96c617-8444-4c51-8891-febf51c635f3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a83a6a-0d39-4b2d-a96d-a4cb7605d7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6db974ef-c577-49d2-b373-38ad04c82d13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a83a6a-0d39-4b2d-a96d-a4cb7605d7a0" xlink:to="loc_us-gaap_IPOMember_6db974ef-c577-49d2-b373-38ad04c82d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61717929-6237-4cb9-a39b-fefdacfdf4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61717929-6237-4cb9-a39b-fefdacfdf4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b6c2dcb5-b2a0-4faa-8e51-b348b6edac35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61717929-6237-4cb9-a39b-fefdacfdf4fd" xlink:to="loc_us-gaap_EquityComponentDomain_b6c2dcb5-b2a0-4faa-8e51-b348b6edac35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a1352f20-d2a4-4f9b-bf79-ccc03788fb27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b6c2dcb5-b2a0-4faa-8e51-b348b6edac35" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a1352f20-d2a4-4f9b-bf79-ccc03788fb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_107caac5-7902-4f5b-8457-c7aa738845e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b6c2dcb5-b2a0-4faa-8e51-b348b6edac35" xlink:to="loc_us-gaap_CommonStockMember_107caac5-7902-4f5b-8457-c7aa738845e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_59031d32-454d-4fc5-827f-98aec8b10931" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_59031d32-454d-4fc5-827f-98aec8b10931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_17dc5a10-e087-4aab-921d-81b9dcbf1d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_59031d32-454d-4fc5-827f-98aec8b10931" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_17dc5a10-e087-4aab-921d-81b9dcbf1d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_779dd589-dff2-4ae5-a488-5634f0b3d0e9" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_17dc5a10-e087-4aab-921d-81b9dcbf1d6e" xlink:to="loc_cv_UnderwriterMember_779dd589-dff2-4ae5-a488-5634f0b3d0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bc9936e4-d002-4a7e-9f93-b255af6ea731" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionDate_e83e6d01-f36a-4ada-846d-48fe316f7ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionDate_e83e6d01-f36a-4ada-846d-48fe316f7ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_e3ca90a1-f5d6-4c0a-a45f-505acda8a5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_e3ca90a1-f5d6-4c0a-a45f-505acda8a5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_1cb81b78-eb6e-42b9-8846-8ab164785953" xlink:href="cv-20251231.xsd#cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares_1cb81b78-eb6e-42b9-8846-8ab164785953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_0a287f15-eb35-4911-888d-c4bb97aef50f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_0a287f15-eb35-4911-888d-c4bb97aef50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1a5fb1de-02d6-4377-96c2-b9fb65b3c718" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1a5fb1de-02d6-4377-96c2-b9fb65b3c718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0ce54d7f-be0e-4aea-b857-5df1cd111dca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0ce54d7f-be0e-4aea-b857-5df1cd111dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_21c3bebc-cd19-48e9-8734-6e9b3a521775" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_NumberOfReportableSegments_21c3bebc-cd19-48e9-8734-6e9b3a521775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_331146d3-a12c-4ae8-92c6-9549b782102a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_331146d3-a12c-4ae8-92c6-9549b782102a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_aee79bb2-53fc-49b0-b881-5f5cf8bb00bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_aee79bb2-53fc-49b0-b881-5f5cf8bb00bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_856154df-fc71-426b-b28b-1415d34f17bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_856154df-fc71-426b-b28b-1415d34f17bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_81293aaa-4191-4aa0-b10f-3a7b797337e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_AdvertisingExpense_81293aaa-4191-4aa0-b10f-3a7b797337e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_609be6c5-c53a-43aa-b698-237bb08676d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_609be6c5-c53a-43aa-b698-237bb08676d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d0bcc340-d99a-4855-911b-456cd69855d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d0bcc340-d99a-4855-911b-456cd69855d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ae795d94-4220-4853-8c2e-f78cbdc97bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ffc6358f-3c80-4587-a40c-9c06450c9fa3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ae795d94-4220-4853-8c2e-f78cbdc97bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4254ea99-6c99-4b14-b6ac-e86155e58cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e19a21dc-a22a-467c-8fc0-b305e7041da6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4254ea99-6c99-4b14-b6ac-e86155e58cbd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e19a21dc-a22a-467c-8fc0-b305e7041da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aa828b0b-16e3-401a-8557-b4554b5cb0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e19a21dc-a22a-467c-8fc0-b305e7041da6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aa828b0b-16e3-401a-8557-b4554b5cb0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aa828b0b-16e3-401a-8557-b4554b5cb0e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_160a433e-26f3-43b2-9515-982bf24d471b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_160a433e-26f3-43b2-9515-982bf24d471b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_7e8b56c6-af01-40c1-9b7f-e3cd06340d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:to="loc_us-gaap_OfficeEquipmentMember_7e8b56c6-af01-40c1-9b7f-e3cd06340d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3957ce0e-5414-40d8-aecb-c11f0e9671a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a54ed008-54bf-4659-b693-478d0076a9ad" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3957ce0e-5414-40d8-aecb-c11f0e9671a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_250117d3-a8c8-4883-a201-0435713c6330" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e19a21dc-a22a-467c-8fc0-b305e7041da6" xlink:to="loc_srt_RangeAxis_250117d3-a8c8-4883-a201-0435713c6330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7ee4fdc-9a29-4d4a-9b9e-27e14bb5ca87" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_250117d3-a8c8-4883-a201-0435713c6330" xlink:to="loc_srt_RangeMember_c7ee4fdc-9a29-4d4a-9b9e-27e14bb5ca87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_68d7195f-68a7-4b0e-892a-2472307383bd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7ee4fdc-9a29-4d4a-9b9e-27e14bb5ca87" xlink:to="loc_srt_MinimumMember_68d7195f-68a7-4b0e-892a-2472307383bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6af0d5b8-c039-4e13-8796-2ebb794d99f1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7ee4fdc-9a29-4d4a-9b9e-27e14bb5ca87" xlink:to="loc_srt_MaximumMember_6af0d5b8-c039-4e13-8796-2ebb794d99f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a7eb38e-971e-426f-9c62-779320de90f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e19a21dc-a22a-467c-8fc0-b305e7041da6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a7eb38e-971e-426f-9c62-779320de90f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85ffe294-aca6-45fa-b7e8-fbdebd4151ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a7eb38e-971e-426f-9c62-779320de90f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85ffe294-aca6-45fa-b7e8-fbdebd4151ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_56719e70-2873-4b3a-a307-623f3f238052" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a7eb38e-971e-426f-9c62-779320de90f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_56719e70-2873-4b3a-a307-623f3f238052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSInventoryDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5dcda32-9d0a-4d41-93d9-32381729e186" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5c8348e8-3ec6-417f-a7b3-55dac648b497" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5dcda32-9d0a-4d41-93d9-32381729e186" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5c8348e8-3ec6-417f-a7b3-55dac648b497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_eaa171db-5dfb-479c-91fa-fb5e0711d940" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5dcda32-9d0a-4d41-93d9-32381729e186" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_eaa171db-5dfb-479c-91fa-fb5e0711d940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_35481b1c-e32c-4c34-9d9b-937d5022dda4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5dcda32-9d0a-4d41-93d9-32381729e186" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_35481b1c-e32c-4c34-9d9b-937d5022dda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_adeeee56-c4f7-4de4-8056-1c757003dab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5dcda32-9d0a-4d41-93d9-32381729e186" xlink:to="loc_us-gaap_InventoryNet_adeeee56-c4f7-4de4-8056-1c757003dab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a68ae58-2e5d-48b8-a948-621915a92b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_4402d8bf-1f33-4fdb-a439-25778de9fac6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a68ae58-2e5d-48b8-a948-621915a92b3f" xlink:to="loc_us-gaap_PrepaidInsurance_4402d8bf-1f33-4fdb-a439-25778de9fac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_ebe668b2-68da-45a5-8388-f5fd36fd81f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Supplies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a68ae58-2e5d-48b8-a948-621915a92b3f" xlink:to="loc_us-gaap_Supplies_ebe668b2-68da-45a5-8388-f5fd36fd81f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3216dd98-686b-488b-9689-5ab4f1e50787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a68ae58-2e5d-48b8-a948-621915a92b3f" xlink:to="loc_us-gaap_DeferredOfferingCosts_3216dd98-686b-488b-9689-5ab4f1e50787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_22e47b50-f318-488e-9d70-73cc319668d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a68ae58-2e5d-48b8-a948-621915a92b3f" xlink:to="loc_us-gaap_OtherAssetsCurrent_22e47b50-f318-488e-9d70-73cc319668d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8fc86a25-b9b5-45f3-ae28-eec447a3ba5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a68ae58-2e5d-48b8-a948-621915a92b3f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8fc86a25-b9b5-45f3-ae28-eec447a3ba5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60d77e6a-4069-4479-9c23-f60a38ced590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_1db8b2ce-c50a-414f-8966-7618666bd83a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60d77e6a-4069-4479-9c23-f60a38ced590" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_1db8b2ce-c50a-414f-8966-7618666bd83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_2b71e280-4be0-40e4-b244-7a7f962426b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60d77e6a-4069-4479-9c23-f60a38ced590" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_2b71e280-4be0-40e4-b244-7a7f962426b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_8f87563b-6c76-42d9-afbc-aa90486028df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60d77e6a-4069-4479-9c23-f60a38ced590" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_8f87563b-6c76-42d9-afbc-aa90486028df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7c51de9f-bd96-4adf-8453-c43e7c8066c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60d77e6a-4069-4479-9c23-f60a38ced590" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7c51de9f-bd96-4adf-8453-c43e7c8066c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2c38c075-4be7-4afa-862b-482a9aad500c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60d77e6a-4069-4479-9c23-f60a38ced590" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2c38c075-4be7-4afa-862b-482a9aad500c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94e94e7b-9020-43a9-b5a1-4189714d2a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_cb4b4c6d-6003-4570-bed4-ed1b26e106a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94e94e7b-9020-43a9-b5a1-4189714d2a1e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_cb4b4c6d-6003-4570-bed4-ed1b26e106a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_926f86e6-5d1c-4faa-9e2f-fd08831aa116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba062eb8-6930-47c9-b78b-078abe713278" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_926f86e6-5d1c-4faa-9e2f-fd08831aa116" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba062eb8-6930-47c9-b78b-078abe713278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_AccruedClinicalTrialExpenseCurrent_ceaa5025-0de0-4086-bf69-72cd90afa2dd" xlink:href="cv-20251231.xsd#cv_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_926f86e6-5d1c-4faa-9e2f-fd08831aa116" xlink:to="loc_cv_AccruedClinicalTrialExpenseCurrent_ceaa5025-0de0-4086-bf69-72cd90afa2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_AccruedResearchAndDevelopmentExpenseCurrent_52c03b72-8193-4c13-b2d8-079c96b9feec" xlink:href="cv-20251231.xsd#cv_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_926f86e6-5d1c-4faa-9e2f-fd08831aa116" xlink:to="loc_cv_AccruedResearchAndDevelopmentExpenseCurrent_52c03b72-8193-4c13-b2d8-079c96b9feec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_6d53c3b2-a949-465f-a162-5e425ba35692" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_926f86e6-5d1c-4faa-9e2f-fd08831aa116" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_6d53c3b2-a949-465f-a162-5e425ba35692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7f62fadb-c29b-41ab-866b-373a011a3f96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_926f86e6-5d1c-4faa-9e2f-fd08831aa116" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7f62fadb-c29b-41ab-866b-373a011a3f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e2f76d47-11b3-452d-891e-26f0bcdeab3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_926f86e6-5d1c-4faa-9e2f-fd08831aa116" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e2f76d47-11b3-452d-891e-26f0bcdeab3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_db088515-821c-4e7f-ba45-e45aa1947921" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4b8352a0-0406-4ff5-992a-68fd16c95808" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_db088515-821c-4e7f-ba45-e45aa1947921" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4b8352a0-0406-4ff5-992a-68fd16c95808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2540f084-7b93-4f5f-b444-eda653a5a1ac" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b8352a0-0406-4ff5-992a-68fd16c95808" xlink:to="loc_srt_ProductOrServiceAxis_2540f084-7b93-4f5f-b444-eda653a5a1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6edab9ee-5377-4214-bbe7-abd81780ef1c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2540f084-7b93-4f5f-b444-eda653a5a1ac" xlink:to="loc_srt_ProductsAndServicesDomain_6edab9ee-5377-4214-bbe7-abd81780ef1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_37bb8d29-d209-45bb-8875-85d8f0a30630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6edab9ee-5377-4214-bbe7-abd81780ef1c" xlink:to="loc_us-gaap_ProductMember_37bb8d29-d209-45bb-8875-85d8f0a30630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_b2e01a78-f2b3-42cf-9f08-d49f2e281355" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6edab9ee-5377-4214-bbe7-abd81780ef1c" xlink:to="loc_us-gaap_ServiceMember_b2e01a78-f2b3-42cf-9f08-d49f2e281355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_46d32425-72c3-49db-836f-50ea5f33a416" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b8352a0-0406-4ff5-992a-68fd16c95808" xlink:to="loc_srt_StatementGeographicalAxis_46d32425-72c3-49db-836f-50ea5f33a416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6ac1996d-407a-4779-b41f-518eea549057" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_46d32425-72c3-49db-836f-50ea5f33a416" xlink:to="loc_srt_SegmentGeographicalDomain_6ac1996d-407a-4779-b41f-518eea549057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1db4c4a1-6960-4971-9237-750186348d59" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6ac1996d-407a-4779-b41f-518eea549057" xlink:to="loc_country_US_1db4c4a1-6960-4971-9237-750186348d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_c8b5c4be-fca9-4914-ac87-ce8b19eae91c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6ac1996d-407a-4779-b41f-518eea549057" xlink:to="loc_us-gaap_NonUsMember_c8b5c4be-fca9-4914-ac87-ce8b19eae91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bee08f87-774b-48e4-9191-867306d50949" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b8352a0-0406-4ff5-992a-68fd16c95808" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bee08f87-774b-48e4-9191-867306d50949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52796414-41bf-493f-860b-907bdb6d2c31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bee08f87-774b-48e4-9191-867306d50949" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52796414-41bf-493f-860b-907bdb6d2c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_762779ff-7bdf-49b4-91c6-194c79fdb57a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_762779ff-7bdf-49b4-91c6-194c79fdb57a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60c6c3cb-5dd1-497d-99fe-c1fea03dbda9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:to="loc_srt_ProductOrServiceAxis_60c6c3cb-5dd1-497d-99fe-c1fea03dbda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_598e1158-3010-4e8e-b854-1be63950ebab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_60c6c3cb-5dd1-497d-99fe-c1fea03dbda9" xlink:to="loc_srt_ProductsAndServicesDomain_598e1158-3010-4e8e-b854-1be63950ebab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_6e2e9ff4-db0e-4790-a097-2128cdbbe9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_598e1158-3010-4e8e-b854-1be63950ebab" xlink:to="loc_us-gaap_ServiceMember_6e2e9ff4-db0e-4790-a097-2128cdbbe9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019cd849-44c9-7968-8e04-3bf7bb60cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_598e1158-3010-4e8e-b854-1be63950ebab" xlink:to="loc_us-gaap_ProductMember_019cd849-44c9-7968-8e04-3bf7bb60cc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b599ddc0-a482-482f-a4f6-047c65d6cb3a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:to="loc_srt_StatementGeographicalAxis_b599ddc0-a482-482f-a4f6-047c65d6cb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b599ddc0-a482-482f-a4f6-047c65d6cb3a" xlink:to="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b9eb13d3-21e4-4ae6-9065-c68a3c6474fc" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:to="loc_country_US_b9eb13d3-21e4-4ae6-9065-c68a3c6474fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_019cd82b-c609-7fdb-baa4-e25d6733d4d7" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:to="loc_country_FR_019cd82b-c609-7fdb-baa4-e25d6733d4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_019cd82c-13d2-75f1-b71e-e968e2e7e97f" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3ad90e74-e9c3-4c93-a5ca-2401077ec8e9" xlink:to="loc_country_DE_019cd82c-13d2-75f1-b71e-e968e2e7e97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_fff0a216-acf1-4260-83e4-94790bba31a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_fff0a216-acf1-4260-83e4-94790bba31a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_56fee1dc-c758-49d6-adc9-ac10cb6ea12e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_fff0a216-acf1-4260-83e4-94790bba31a2" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_56fee1dc-c758-49d6-adc9-ac10cb6ea12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_731df24e-8d07-4232-85f7-e744a2c5740d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_56fee1dc-c758-49d6-adc9-ac10cb6ea12e" xlink:to="loc_us-gaap_TransferredOverTimeMember_731df24e-8d07-4232-85f7-e744a2c5740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_d3b1434b-cd46-4590-8a90-1fd96a0df047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_56fee1dc-c758-49d6-adc9-ac10cb6ea12e" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_d3b1434b-cd46-4590-8a90-1fd96a0df047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90b7188b-91d4-4982-aa13-e6028865905e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fab4249b-e2ad-42a4-9d80-9de387db9e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fab4249b-e2ad-42a4-9d80-9de387db9e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f45f55f3-a504-4bc7-8cd9-bf90ddbdf5af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f45f55f3-a504-4bc7-8cd9-bf90ddbdf5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cdf24-098f-7461-b010-a3c351ffb2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cdf24-098f-7461-b010-a3c351ffb2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_GroupPurchasingOrganizationFeesContraRevenue_ab430aa1-e946-4f00-b99f-5d3342efa20c" xlink:href="cv-20251231.xsd#cv_GroupPurchasingOrganizationFeesContraRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_869f95a8-3db4-425a-97f9-5c9e3be644ba" xlink:to="loc_cv_GroupPurchasingOrganizationFeesContraRevenue_ab430aa1-e946-4f00-b99f-5d3342efa20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/NOTEPAYABLEDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#NOTEPAYABLEDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/NOTEPAYABLEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b648918d-b87d-4eca-b7e7-7a763b8f2dce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbd39281-fc9a-4371-9d62-f89282d48de4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b648918d-b87d-4eca-b7e7-7a763b8f2dce" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbd39281-fc9a-4371-9d62-f89282d48de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5f64301-25d4-4f21-9683-027688fc4284" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbd39281-fc9a-4371-9d62-f89282d48de4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5f64301-25d4-4f21-9683-027688fc4284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2d90fd27-a4e9-41a5-bf46-4cd08ffffcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5f64301-25d4-4f21-9683-027688fc4284" xlink:to="loc_us-gaap_RelatedPartyDomain_2d90fd27-a4e9-41a5-bf46-4cd08ffffcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_b0da6c98-6328-4214-9cfc-e5ffa6244cff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2d90fd27-a4e9-41a5-bf46-4cd08ffffcd1" xlink:to="loc_us-gaap_InvestorMember_b0da6c98-6328-4214-9cfc-e5ffa6244cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_73065c69-e6f1-4e02-8504-24bd8f7499f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbd39281-fc9a-4371-9d62-f89282d48de4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_73065c69-e6f1-4e02-8504-24bd8f7499f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_55fe6367-1e53-4f8d-9400-fee3e12fb4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_73065c69-e6f1-4e02-8504-24bd8f7499f6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_55fe6367-1e53-4f8d-9400-fee3e12fb4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_c52ef778-356a-4cf5-af33-a6e56a426804" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_55fe6367-1e53-4f8d-9400-fee3e12fb4e4" xlink:to="loc_us-gaap_IPOMember_c52ef778-356a-4cf5-af33-a6e56a426804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fbd39281-fc9a-4371-9d62-f89282d48de4" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ShortTermDebtOriginationDate_bb9c74d0-7be1-40ba-ba17-54d9bc843d46" xlink:href="cv-20251231.xsd#cv_ShortTermDebtOriginationDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_cv_ShortTermDebtOriginationDate_bb9c74d0-7be1-40ba-ba17-54d9bc843d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_a80cecc4-f702-4848-8373-0691c9d211f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_a80cecc4-f702-4848-8373-0691c9d211f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_RelatedPartyTransactionRatePerMonth_49638ac1-4c92-40c4-9a40-f22e44dcfb5d" xlink:href="cv-20251231.xsd#cv_RelatedPartyTransactionRatePerMonth"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_cv_RelatedPartyTransactionRatePerMonth_49638ac1-4c92-40c4-9a40-f22e44dcfb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_d3d046e3-236d-47a6-afd6-7bb064697dec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_d3d046e3-236d-47a6-afd6-7bb064697dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDate_f2072aea-c2c2-43ef-8e20-6430a648773e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_RelatedPartyTransactionDate_f2072aea-c2c2-43ef-8e20-6430a648773e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_abe2a876-9668-4e90-86cc-8b9939e5e1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_abe2a876-9668-4e90-86cc-8b9939e5e1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_eb74c61d-1242-4023-9b9b-dd83eaf9633a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_eb74c61d-1242-4023-9b9b-dd83eaf9633a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ShortTermNonBankLoansAndNotesPaymentDate_69e65679-ca74-4742-97c2-80372ddd4ad4" xlink:href="cv-20251231.xsd#cv_ShortTermNonBankLoansAndNotesPaymentDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_cv_ShortTermNonBankLoansAndNotesPaymentDate_69e65679-ca74-4742-97c2-80372ddd4ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2981fd64-496f-493d-a2be-84fa68547a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dbb5a1e5-2a47-4315-915c-82f64fdbc71a" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2981fd64-496f-493d-a2be-84fa68547a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/LEASESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4a0e02b3-75fe-4773-9727-8c9f2c6c1722" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f682c367-6d11-402d-a6a7-879e68b3cdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4a0e02b3-75fe-4773-9727-8c9f2c6c1722" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f682c367-6d11-402d-a6a7-879e68b3cdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbf78abb-4cc0-4a1a-a4a2-7b9e55318b60" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f682c367-6d11-402d-a6a7-879e68b3cdc7" xlink:to="loc_srt_RangeAxis_cbf78abb-4cc0-4a1a-a4a2-7b9e55318b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbd119e6-76a7-404b-9983-15cca78081b3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cbf78abb-4cc0-4a1a-a4a2-7b9e55318b60" xlink:to="loc_srt_RangeMember_cbd119e6-76a7-404b-9983-15cca78081b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d33ff6aa-c418-4f41-8b3f-661b66cc0238" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cbd119e6-76a7-404b-9983-15cca78081b3" xlink:to="loc_srt_MinimumMember_d33ff6aa-c418-4f41-8b3f-661b66cc0238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0954926b-66c2-4593-bc8d-e097a2d36543" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cbd119e6-76a7-404b-9983-15cca78081b3" xlink:to="loc_srt_MaximumMember_0954926b-66c2-4593-bc8d-e097a2d36543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd4fc071-ce4c-4507-a7e9-0270a92b1541" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f682c367-6d11-402d-a6a7-879e68b3cdc7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd4fc071-ce4c-4507-a7e9-0270a92b1541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_06c71e9d-4553-470c-bcde-7da5a98558f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd4fc071-ce4c-4507-a7e9-0270a92b1541" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_06c71e9d-4553-470c-bcde-7da5a98558f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5a5139ed-546b-4c08-8154-5e6a7a78d369" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd4fc071-ce4c-4507-a7e9-0270a92b1541" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5a5139ed-546b-4c08-8154-5e6a7a78d369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESTotalLeaseExpenseDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESTotalLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/LEASESTotalLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b79f9185-54a7-4953-a193-d4dd93d9991e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d582fb6f-c149-4bdc-b6a9-e948beb5ab7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b79f9185-54a7-4953-a193-d4dd93d9991e" xlink:to="loc_us-gaap_OperatingLeaseCost_d582fb6f-c149-4bdc-b6a9-e948beb5ab7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_08a0d9c5-496f-4892-9161-7c95baed07b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b79f9185-54a7-4953-a193-d4dd93d9991e" xlink:to="loc_us-gaap_ShortTermLeaseCost_08a0d9c5-496f-4892-9161-7c95baed07b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_eb324eab-cbbb-4635-9060-2c42d4865783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b79f9185-54a7-4953-a193-d4dd93d9991e" xlink:to="loc_us-gaap_LeaseCost_eb324eab-cbbb-4635-9060-2c42d4865783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b11a13c9-439f-4fc1-8bdc-8afa9a89ddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bedc6ebb-0b0e-4bba-be4b-3c3e91d77f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b11a13c9-439f-4fc1-8bdc-8afa9a89ddc8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bedc6ebb-0b0e-4bba-be4b-3c3e91d77f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f3c4e38-0a42-4c78-a625-e53405455827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b11a13c9-439f-4fc1-8bdc-8afa9a89ddc8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f3c4e38-0a42-4c78-a625-e53405455827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2cfbf4e1-e18f-44f9-8764-af93cc0c9930" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b11a13c9-439f-4fc1-8bdc-8afa9a89ddc8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2cfbf4e1-e18f-44f9-8764-af93cc0c9930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fbe8a90f-5e70-4edf-9646-8df172aedbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b11a13c9-439f-4fc1-8bdc-8afa9a89ddc8" xlink:to="loc_us-gaap_OperatingLeaseLiability_fbe8a90f-5e70-4edf-9646-8df172aedbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7fc0192b-5979-4b1b-a848-7983d23c5b64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b11a13c9-439f-4fc1-8bdc-8afa9a89ddc8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7fc0192b-5979-4b1b-a848-7983d23c5b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ffa1a1ec-6cb2-4fbe-a483-746e6ffb8604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b11a13c9-439f-4fc1-8bdc-8afa9a89ddc8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ffa1a1ec-6cb2-4fbe-a483-746e6ffb8604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESSupplementalCashFlowsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESSupplementalCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/LEASESSupplementalCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_821aab6f-6e7b-4b23-b79b-93b2be8aa0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeasePayment_489f6b68-3103-407d-88d8-fad63a1da8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeasePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_821aab6f-6e7b-4b23-b79b-93b2be8aa0f1" xlink:to="loc_us-gaap_VariableLeasePayment_489f6b68-3103-407d-88d8-fad63a1da8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9726f370-8ba6-4219-a55e-40b820bd431b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_821aab6f-6e7b-4b23-b79b-93b2be8aa0f1" xlink:to="loc_us-gaap_OperatingLeasePayments_9726f370-8ba6-4219-a55e-40b820bd431b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#LEASESFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1c297bf6-4a42-40ae-af3a-62e086bfd288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b677dd04-341d-4fc9-99c0-804dea712f01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c297bf6-4a42-40ae-af3a-62e086bfd288" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b677dd04-341d-4fc9-99c0-804dea712f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fb080796-52a4-4ab4-b3f6-b5427ae171f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c297bf6-4a42-40ae-af3a-62e086bfd288" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fb080796-52a4-4ab4-b3f6-b5427ae171f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_2037ef90-f55a-478d-af3a-d65e8c38205c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c297bf6-4a42-40ae-af3a-62e086bfd288" xlink:to="loc_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_2037ef90-f55a-478d-af3a-d65e8c38205c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f24e09b-bb2e-44c3-a42d-42e7329aabdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c297bf6-4a42-40ae-af3a-62e086bfd288" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f24e09b-bb2e-44c3-a42d-42e7329aabdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7abe441c-796f-4f6d-b371-d3adbff8ead9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_20d809b8-7d9c-432b-a81d-e136458a5195" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7abe441c-796f-4f6d-b371-d3adbff8ead9" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_20d809b8-7d9c-432b-a81d-e136458a5195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_8a206935-ef7c-4e68-be0c-bea22e61d936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_20d809b8-7d9c-432b-a81d-e136458a5195" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_8a206935-ef7c-4e68-be0c-bea22e61d936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3eca5133-edc2-4516-bd12-05adbd2283e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_8a206935-ef7c-4e68-be0c-bea22e61d936" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3eca5133-edc2-4516-bd12-05adbd2283e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseProvisionTermsMember_285ad862-59ba-40df-af13-7540c7c0aea6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseProvisionTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3eca5133-edc2-4516-bd12-05adbd2283e7" xlink:to="loc_us-gaap_PurchaseProvisionTermsMember_285ad862-59ba-40df-af13-7540c7c0aea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_20d809b8-7d9c-432b-a81d-e136458a5195" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate_586fe228-9d7b-453b-8629-098fff6b1931" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate_586fe228-9d7b-453b-8629-098fff6b1931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_0dc57da3-bdd5-48d1-9e7e-0c69baffedd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_0dc57da3-bdd5-48d1-9e7e-0c69baffedd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee_b7f378b3-72c5-4440-9669-6d57be23a22a" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee_b7f378b3-72c5-4440-9669-6d57be23a22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate_bfa5ffd5-d565-42ee-9b87-1c7bd5623336" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate_bfa5ffd5-d565-42ee-9b87-1c7bd5623336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet_4fefb520-5ce6-4f46-a1f5-3b0db321c6b5" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet_4fefb520-5ce6-4f46-a1f5-3b0db321c6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease_019c980f-afca-7d45-b339-d15ba0a484de" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease_019c980f-afca-7d45-b339-d15ba0a484de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9bccb7eb-2f94-48bd-ad61-0834855d7577" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9bccb7eb-2f94-48bd-ad61-0834855d7577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d3edce16-7fae-4160-887f-9734d884f8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d3edce16-7fae-4160-887f-9734d884f8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding_45377553-d62d-430a-9f19-5c477b6f6c9e" xlink:href="cv-20251231.xsd#cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding_45377553-d62d-430a-9f19-5c477b6f6c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceOperatingExpense_019cd444-3129-7d42-8cc6-791023fbbe98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceOperatingExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_GovernmentAssistanceOperatingExpense_019cd444-3129-7d42-8cc6-791023fbbe98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019cd518-c57d-7f29-b234-2a215b4d0051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_53dd6cae-4e9c-4d50-b6f5-ee3ba445b240" xlink:to="loc_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019cd518-c57d-7f29-b234-2a215b4d0051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#PREFERREDSTOCKAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_355cc345-9f91-480a-aefa-06136a6685d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_355cc345-9f91-480a-aefa-06136a6685d6" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f9a76184-0321-4108-9d20-5dce85eb5e59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f9a76184-0321-4108-9d20-5dce85eb5e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ba93a7b-bbc3-41ac-aae4-283b934713c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f9a76184-0321-4108-9d20-5dce85eb5e59" xlink:to="loc_us-gaap_ClassOfStockDomain_9ba93a7b-bbc3-41ac-aae4-283b934713c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_d8d9c7f2-1710-4fb0-b97f-5c68bd134f08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9ba93a7b-bbc3-41ac-aae4-283b934713c3" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_d8d9c7f2-1710-4fb0-b97f-5c68bd134f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c93f7e71-8bdd-491c-8b68-73976883941d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c93f7e71-8bdd-491c-8b68-73976883941d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c47a1246-1a24-4926-bc56-36f9da4df1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c93f7e71-8bdd-491c-8b68-73976883941d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c47a1246-1a24-4926-bc56-36f9da4df1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_e4418a9d-ea6f-4e0f-991d-5f098af36ec4" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c47a1246-1a24-4926-bc56-36f9da4df1b0" xlink:to="loc_cv_UnderwriterMember_e4418a9d-ea6f-4e0f-991d-5f098af36ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cc63bc9a-d655-4c85-b1bf-aeea295353d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cc63bc9a-d655-4c85-b1bf-aeea295353d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21f033c1-d0ba-4091-922d-e5cda6521588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cc63bc9a-d655-4c85-b1bf-aeea295353d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21f033c1-d0ba-4091-922d-e5cda6521588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_a231922c-a07d-4438-89cb-f0890439b24e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21f033c1-d0ba-4091-922d-e5cda6521588" xlink:to="loc_us-gaap_IPOMember_a231922c-a07d-4438-89cb-f0890439b24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_f822f7f4-c5ea-4eab-b35b-e7fd5bd3d33a" xlink:to="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_85eda10d-b570-4844-9f9b-7ee9b442610d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_85eda10d-b570-4844-9f9b-7ee9b442610d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_ecb60e60-b05d-46f0-9b9b-d68c403bcb99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_ecb60e60-b05d-46f0-9b9b-d68c403bcb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_63bbb9b5-3e30-481a-a55d-04bd0e8d7c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_63bbb9b5-3e30-481a-a55d-04bd0e8d7c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_bbd4223a-99dc-4d95-938c-d860ef008aac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_bbd4223a-99dc-4d95-938c-d860ef008aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ebd14175-e372-46e9-a069-26289c5a71c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ebd14175-e372-46e9-a069-26289c5a71c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_db10d6ed-7b51-4653-99d7-4c3de1c38a53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_db10d6ed-7b51-4653-99d7-4c3de1c38a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionDate_e235a0a9-24c5-40ef-af3b-c1fb7151b4be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionDate_e235a0a9-24c5-40ef-af3b-c1fb7151b4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_6b6afa5b-1e04-47eb-a5c1-1529cef32e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_6b6afa5b-1e04-47eb-a5c1-1529cef32e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityLegacyConversionRatio_de610a83-fa06-4781-be41-ab26e9ef1fd4" xlink:href="cv-20251231.xsd#cv_TemporaryEquityLegacyConversionRatio"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_TemporaryEquityLegacyConversionRatio_de610a83-fa06-4781-be41-ab26e9ef1fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityLegacyConversionPricePerShareMinimum_b2dc815a-5a50-4735-a754-cf1fceb48f70" xlink:href="cv-20251231.xsd#cv_TemporaryEquityLegacyConversionPricePerShareMinimum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_TemporaryEquityLegacyConversionPricePerShareMinimum_b2dc815a-5a50-4735-a754-cf1fceb48f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityLegacyConversionPricePerShareMaximum_090d1fb4-186f-446d-b9ed-189cbce9961e" xlink:href="cv-20251231.xsd#cv_TemporaryEquityLegacyConversionPricePerShareMaximum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_TemporaryEquityLegacyConversionPricePerShareMaximum_090d1fb4-186f-446d-b9ed-189cbce9961e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum_44b3b82a-a51c-4a39-980d-54e50ff1820b" xlink:href="cv-20251231.xsd#cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum_44b3b82a-a51c-4a39-980d-54e50ff1820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TemporaryEquityDividendRatePercentage_7414d27b-0540-4247-b770-5f97166a6f2c" xlink:href="cv-20251231.xsd#cv_TemporaryEquityDividendRatePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_TemporaryEquityDividendRatePercentage_7414d27b-0540-4247-b770-5f97166a6f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_NumberOfBoardMembers_a3e63e54-a1a4-4aab-911e-d1778af35a34" xlink:href="cv-20251231.xsd#cv_NumberOfBoardMembers"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_bfa0574e-6499-4384-b893-2b40e9ce1cef" xlink:to="loc_cv_NumberOfBoardMembers_a3e63e54-a1a4-4aab-911e-d1778af35a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#PREFERREDSTOCKPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ab658ceb-208d-41bf-8399-afbda845b6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_c0a2b389-fb80-4d9b-9878-3b3edd040f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab658ceb-208d-41bf-8399-afbda845b6e9" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_c0a2b389-fb80-4d9b-9878-3b3edd040f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_de07df3a-1243-4949-a450-b845fae4385e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_c0a2b389-fb80-4d9b-9878-3b3edd040f17" xlink:to="loc_us-gaap_StatementClassOfStockAxis_de07df3a-1243-4949-a450-b845fae4385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_de07df3a-1243-4949-a450-b845fae4385e" xlink:to="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f3b3b3bb-0740-40bc-8b8e-64cf32e00b36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f3b3b3bb-0740-40bc-8b8e-64cf32e00b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBMember_71fd40df-9c48-4b0a-b8d6-35d7f5e17f69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesBMember_71fd40df-9c48-4b0a-b8d6-35d7f5e17f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_71806dce-95a3-486e-b3fe-6e85685de970" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_71806dce-95a3-486e-b3fe-6e85685de970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesC1PreferredStockMember_dfe64b0d-14aa-4484-9127-3c5a22069cd8" xlink:href="cv-20251231.xsd#cv_SeriesC1PreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesC1PreferredStockMember_dfe64b0d-14aa-4484-9127-3c5a22069cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_323af2fb-c381-48ca-b8cd-31607fb8cfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_323af2fb-c381-48ca-b8cd-31607fb8cfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesD1PreferredStockMember_13098f14-123e-4551-9747-05539dae1e1e" xlink:href="cv-20251231.xsd#cv_SeriesD1PreferredStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesD1PreferredStockMember_13098f14-123e-4551-9747-05539dae1e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesD2PreferredStockMember_823d2a11-f3b0-4995-bc58-366544755d41" xlink:href="cv-20251231.xsd#cv_SeriesD2PreferredStockMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesD2PreferredStockMember_823d2a11-f3b0-4995-bc58-366544755d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_d74a5f96-0de0-4765-9cde-0f2ada27e645" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_d74a5f96-0de0-4765-9cde-0f2ada27e645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesF1PreferredStockMember_e56ab11a-f704-4427-b627-ed6359220ec8" xlink:href="cv-20251231.xsd#cv_SeriesF1PreferredStockMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesF1PreferredStockMember_e56ab11a-f704-4427-b627-ed6359220ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesF2PreferredStockMember_e5b41fdb-7fd2-485e-9dfe-0660bff73c15" xlink:href="cv-20251231.xsd#cv_SeriesF2PreferredStockMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesF2PreferredStockMember_e5b41fdb-7fd2-485e-9dfe-0660bff73c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_16acbce5-ca75-4959-afc1-f4478d24245e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_16acbce5-ca75-4959-afc1-f4478d24245e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SeriesG1PreferredStockMember_33c3888d-205d-47df-9129-2cbe023ddd48" xlink:href="cv-20251231.xsd#cv_SeriesG1PreferredStockMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_cv_SeriesG1PreferredStockMember_33c3888d-205d-47df-9129-2cbe023ddd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_f39afea5-2796-4c40-a1b4-6290df520b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9748e41f-b752-46c6-92a0-29d13f6fa350" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_f39afea5-2796-4c40-a1b4-6290df520b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_c0a2b389-fb80-4d9b-9878-3b3edd040f17" xlink:to="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_5c98fde2-71d4-4902-88b6-b894802ba4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_5c98fde2-71d4-4902-88b6-b894802ba4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_62b0ae32-bb87-44bd-9632-37d13cba6b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_62b0ae32-bb87-44bd-9632-37d13cba6b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_f929d9ec-e4fb-4ecd-be44-0dfcb6bb8628" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_f929d9ec-e4fb-4ecd-be44-0dfcb6bb8628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_447a9f12-61bd-476a-8bfb-c3c7ebb7a680" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_ffdb1011-bd82-46ab-9ce9-97c8ea34d1b6" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_447a9f12-61bd-476a-8bfb-c3c7ebb7a680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMONSTOCKAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_91f71bde-63f5-450f-8ac4-7abb9d3c78e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_91f71bde-63f5-450f-8ac4-7abb9d3c78e0" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06bf25c3-783d-4a42-bbe2-64448049cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06bf25c3-783d-4a42-bbe2-64448049cd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c40c9f85-ac86-433d-ac6a-9d54717ab314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06bf25c3-783d-4a42-bbe2-64448049cd20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c40c9f85-ac86-433d-ac6a-9d54717ab314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b112b3f0-e806-48b2-b1e7-09adb9acaa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c40c9f85-ac86-433d-ac6a-9d54717ab314" xlink:to="loc_us-gaap_IPOMember_b112b3f0-e806-48b2-b1e7-09adb9acaa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7202edd9-4c4f-4b0b-8d98-6fdb8784b840" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c40c9f85-ac86-433d-ac6a-9d54717ab314" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7202edd9-4c4f-4b0b-8d98-6fdb8784b840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c58d3186-8cb0-492a-863b-e52fe273be49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c58d3186-8cb0-492a-863b-e52fe273be49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5e39a25b-f0f7-47ad-a618-f104c6bfb903" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c58d3186-8cb0-492a-863b-e52fe273be49" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5e39a25b-f0f7-47ad-a618-f104c6bfb903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_d2ce998f-2e26-4420-936b-b0b31222e0c0" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e39a25b-f0f7-47ad-a618-f104c6bfb903" xlink:to="loc_cv_UnderwriterMember_d2ce998f-2e26-4420-936b-b0b31222e0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c0c67637-3599-414f-8e0e-776de7cec235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c0c67637-3599-414f-8e0e-776de7cec235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ee710bbb-b054-4efa-9ab1-ac761674394b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c0c67637-3599-414f-8e0e-776de7cec235" xlink:to="loc_us-gaap_EquityComponentDomain_ee710bbb-b054-4efa-9ab1-ac761674394b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d00648f2-8173-4efe-8944-c1394ee42320" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ee710bbb-b054-4efa-9ab1-ac761674394b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d00648f2-8173-4efe-8944-c1394ee42320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_30f5adce-50ed-48ed-bf60-0e0da0c468bd" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_772fe619-e96d-4bf7-b380-6f70097df446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_772fe619-e96d-4bf7-b380-6f70097df446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionDate_23dba560-e6fb-4582-817e-75a918ff115c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionDate_23dba560-e6fb-4582-817e-75a918ff115c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5491013b-703b-485a-91fa-68873aef8dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5491013b-703b-485a-91fa-68873aef8dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockEffectivenessDate_e1d98b37-740b-4783-894e-77695d3e19bc" xlink:href="cv-20251231.xsd#cv_SaleOfStockEffectivenessDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_cv_SaleOfStockEffectivenessDate_e1d98b37-740b-4783-894e-77695d3e19bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a96c4f0c-07ee-41a1-908c-e22ceda8a689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a96c4f0c-07ee-41a1-908c-e22ceda8a689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_138ef337-7275-4eb5-b991-6c1283c65337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_138ef337-7275-4eb5-b991-6c1283c65337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f31e06ba-f304-4ce5-a58e-58af445fe804" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f31e06ba-f304-4ce5-a58e-58af445fe804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_06ed92b3-89e1-42ea-8ced-01367dd2ae77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_06ed92b3-89e1-42ea-8ced-01367dd2ae77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights_b0bfad6d-e3b4-4c37-b04c-cc25104598e8" xlink:href="cv-20251231.xsd#cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights_b0bfad6d-e3b4-4c37-b04c-cc25104598e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_ca25abaa-ceb5-4006-8e6f-e1861addcd38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_ca25abaa-ceb5-4006-8e6f-e1861addcd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_348252c1-3c0a-4910-8a57-b5bc0d35eec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_348252c1-3c0a-4910-8a57-b5bc0d35eec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b0f1e815-190c-4df6-8ba4-6ffeb94709e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b0f1e815-190c-4df6-8ba4-6ffeb94709e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_02357c40-7f91-4a9f-b52a-e2a2ce854386" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_02357c40-7f91-4a9f-b52a-e2a2ce854386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_325bb7e4-c562-4328-90c1-a46f7f7a16b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_325bb7e4-c562-4328-90c1-a46f7f7a16b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_dbd67f6a-193c-481a-a547-d1aff7f282e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_cecb99b8-03d4-429b-8280-dbc21e60a146" xlink:to="loc_us-gaap_CommonStockSharesIssued_dbd67f6a-193c-481a-a547-d1aff7f282e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMONSTOCKBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a8b790b7-9080-466f-aa22-1b79fbea064f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c30b642c-fa44-4a4f-ad0c-9e84cdd21c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a8b790b7-9080-466f-aa22-1b79fbea064f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c30b642c-fa44-4a4f-ad0c-9e84cdd21c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0421083f-8e22-4000-aab9-0dc76c9ea664" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c30b642c-fa44-4a4f-ad0c-9e84cdd21c5d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0421083f-8e22-4000-aab9-0dc76c9ea664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_145f1d8f-2a80-4061-85e5-c17d77e99b12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0421083f-8e22-4000-aab9-0dc76c9ea664" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_145f1d8f-2a80-4061-85e5-c17d77e99b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_UnderwriterMember_b380ff80-2ff4-47cb-8e43-cc56e84a9045" xlink:href="cv-20251231.xsd#cv_UnderwriterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_145f1d8f-2a80-4061-85e5-c17d77e99b12" xlink:to="loc_cv_UnderwriterMember_b380ff80-2ff4-47cb-8e43-cc56e84a9045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2d23fd97-6566-4f30-8769-45debff2316b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c30b642c-fa44-4a4f-ad0c-9e84cdd21c5d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2d23fd97-6566-4f30-8769-45debff2316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85efdbc8-31bf-4d79-ad44-40058bed1836" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d23fd97-6566-4f30-8769-45debff2316b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85efdbc8-31bf-4d79-ad44-40058bed1836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9a17d1fe-7712-48d5-896c-60a1e2549a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85efdbc8-31bf-4d79-ad44-40058bed1836" xlink:to="loc_us-gaap_IPOMember_9a17d1fe-7712-48d5-896c-60a1e2549a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_4ca6ed77-2501-46bd-893f-8b15db1d190d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85efdbc8-31bf-4d79-ad44-40058bed1836" xlink:to="loc_us-gaap_OverAllotmentOptionMember_4ca6ed77-2501-46bd-893f-8b15db1d190d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c30b642c-fa44-4a4f-ad0c-9e84cdd21c5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b022a1ca-8ca1-4760-a8a9-f361dd56a743" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b022a1ca-8ca1-4760-a8a9-f361dd56a743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c0f15ff-89ba-4028-b8e2-5cac19d34567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c0f15ff-89ba-4028-b8e2-5cac19d34567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3535a0bb-c173-46aa-82fd-9dd6b4f603ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3535a0bb-c173-46aa-82fd-9dd6b4f603ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c8bbe947-875a-4f43-a614-f19866d83568" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d52f403d-0144-442c-adaf-2623cc40acb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c8bbe947-875a-4f43-a614-f19866d83568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#COMMONSTOCKCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ecf74282-e245-4a43-ba75-f0e0e329f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ecf74282-e245-4a43-ba75-f0e0e329f4e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8a7fc280-fa1f-4038-a016-7f291c4c201d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:to="loc_us-gaap_PlanNameAxis_8a7fc280-fa1f-4038-a016-7f291c4c201d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b685a016-de23-424d-9213-9ee8a3a7c967" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8a7fc280-fa1f-4038-a016-7f291c4c201d" xlink:to="loc_us-gaap_PlanNameDomain_b685a016-de23-424d-9213-9ee8a3a7c967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndFivePlanMember_67a62088-0489-4d5d-9b0b-72369f75b393" xlink:href="cv-20251231.xsd#cv_TwoThousandAndFivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b685a016-de23-424d-9213-9ee8a3a7c967" xlink:to="loc_cv_TwoThousandAndFivePlanMember_67a62088-0489-4d5d-9b0b-72369f75b393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndTwentyFivePlanMember_d9eda006-9d01-47ef-a972-56accd38f2dc" xlink:href="cv-20251231.xsd#cv_TwoThousandAndTwentyFivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b685a016-de23-424d-9213-9ee8a3a7c967" xlink:to="loc_cv_TwoThousandAndTwentyFivePlanMember_d9eda006-9d01-47ef-a972-56accd38f2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43af3204-3e7f-408c-974c-f9b72b9059b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43af3204-3e7f-408c-974c-f9b72b9059b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bfa3c8fc-4b0e-47a5-85be-cf0f9ea03f77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43af3204-3e7f-408c-974c-f9b72b9059b7" xlink:to="loc_us-gaap_ClassOfStockDomain_bfa3c8fc-4b0e-47a5-85be-cf0f9ea03f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_88bf57a9-1c29-43dc-982d-58e30bfb987b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bfa3c8fc-4b0e-47a5-85be-cf0f9ea03f77" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_88bf57a9-1c29-43dc-982d-58e30bfb987b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3109f6ec-1a55-4d2c-9000-c24d451bb1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:to="loc_us-gaap_AwardTypeAxis_3109f6ec-1a55-4d2c-9000-c24d451bb1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3109f6ec-1a55-4d2c-9000-c24d451bb1a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25c6f468-e40e-498b-a750-ee08b6575b00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25c6f468-e40e-498b-a750-ee08b6575b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4588f663-1b3c-4698-99c4-df1e65059157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4588f663-1b3c-4698-99c4-df1e65059157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_51c0f24b-1db4-4852-8e9f-a896fe2e82d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:to="loc_us-gaap_WarrantMember_51c0f24b-1db4-4852-8e9f-a896fe2e82d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_FutureGrantsMember_7f2975bc-f1ec-4f20-b428-624f993566ed" xlink:href="cv-20251231.xsd#cv_FutureGrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6e29482-4d0e-4515-b36c-b7e5a058c84b" xlink:to="loc_cv_FutureGrantsMember_7f2975bc-f1ec-4f20-b428-624f993566ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0f3e111-38e5-495c-9ae6-5fe593965b13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcfcd04d-d0fc-4ff4-ae4e-39f11df8ea75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0f3e111-38e5-495c-9ae6-5fe593965b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_412c15fe-2480-44f5-9f8d-82bb73a66e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0f3e111-38e5-495c-9ae6-5fe593965b13" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_412c15fe-2480-44f5-9f8d-82bb73a66e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATIONAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c40c607-ecfc-41e9-9e3b-f0894a59b03e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c40c607-ecfc-41e9-9e3b-f0894a59b03e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dac5e75a-4c96-4011-b30a-301ca8088b72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:to="loc_us-gaap_AwardTypeAxis_dac5e75a-4c96-4011-b30a-301ca8088b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dac5e75a-4c96-4011-b30a-301ca8088b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_FutureGrantsMember_2b9da768-d835-44e0-a8c6-40f567ca4e2d" xlink:href="cv-20251231.xsd#cv_FutureGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:to="loc_cv_FutureGrantsMember_2b9da768-d835-44e0-a8c6-40f567ca4e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1afb0b3d-ee9f-47ff-8d47-91ba06a11a80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1afb0b3d-ee9f-47ff-8d47-91ba06a11a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_89e92621-bb8c-4921-ad57-d12bf4589335" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f0e2b38-0ae8-4653-bd05-9826997d8209" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_89e92621-bb8c-4921-ad57-d12bf4589335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_287d7af4-fd7e-4c2d-8482-12f5fa9f628c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:to="loc_us-gaap_PlanNameAxis_287d7af4-fd7e-4c2d-8482-12f5fa9f628c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0cdabcc7-8b6c-4b93-a586-e0c85bfba2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_287d7af4-fd7e-4c2d-8482-12f5fa9f628c" xlink:to="loc_us-gaap_PlanNameDomain_0cdabcc7-8b6c-4b93-a586-e0c85bfba2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndTwentyFivePlanMember_2cb91c3f-709c-4288-b2b3-cb2cca6dfad7" xlink:href="cv-20251231.xsd#cv_TwoThousandAndTwentyFivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0cdabcc7-8b6c-4b93-a586-e0c85bfba2b5" xlink:to="loc_cv_TwoThousandAndTwentyFivePlanMember_2cb91c3f-709c-4288-b2b3-cb2cca6dfad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TwoThousandAndFivePlanMember_7ff6cf21-69d7-46e4-888b-ea49e39964ab" xlink:href="cv-20251231.xsd#cv_TwoThousandAndFivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0cdabcc7-8b6c-4b93-a586-e0c85bfba2b5" xlink:to="loc_cv_TwoThousandAndFivePlanMember_7ff6cf21-69d7-46e4-888b-ea49e39964ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_72ac904d-1ec0-47df-8485-f7d8c683203c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_72ac904d-1ec0-47df-8485-f7d8c683203c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe40e9ac-7921-49f7-9317-49191c228ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_72ac904d-1ec0-47df-8485-f7d8c683203c" xlink:to="loc_us-gaap_EquityComponentDomain_fe40e9ac-7921-49f7-9317-49191c228ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5575319e-ad9e-4ad5-aea6-192d4c42d345" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe40e9ac-7921-49f7-9317-49191c228ad6" xlink:to="loc_us-gaap_CommonStockMember_5575319e-ad9e-4ad5-aea6-192d4c42d345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_019bfcf4-e89e-7a8c-a52d-0fce123d95de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe40e9ac-7921-49f7-9317-49191c228ad6" xlink:to="loc_us-gaap_WarrantMember_019bfcf4-e89e-7a8c-a52d-0fce123d95de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_837a920e-ef6b-49a1-860a-facb29aa2bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_e5257182-7175-440b-b7a0-65cb3e832f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_e5257182-7175-440b-b7a0-65cb3e832f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9f96abfd-3740-4bc9-8f6c-65a92a8b12a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9f96abfd-3740-4bc9-8f6c-65a92a8b12a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_98d8c35f-5d61-4083-a4eb-11e800e8a919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_98d8c35f-5d61-4083-a4eb-11e800e8a919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b19ff116-1d42-4b7c-9091-09052ad87c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b19ff116-1d42-4b7c-9091-09052ad87c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_9e1715c1-b54a-4458-a6d7-6e5ae2ae37b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_9e1715c1-b54a-4458-a6d7-6e5ae2ae37b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_08e3d448-a03a-4dfc-8064-b0d095e303b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_08e3d448-a03a-4dfc-8064-b0d095e303b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cdf27-db53-7da1-bbd7-003cdc93b13b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cdf27-db53-7da1-bbd7-003cdc93b13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cdf28-b1c0-7f90-8a73-c8be458eebdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cdf28-b1c0-7f90-8a73-c8be458eebdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019ce262-b00c-7f2f-ac72-56b90964d14d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019ce262-b00c-7f2f-ac72-56b90964d14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019ce264-8d4a-7f6e-8d94-63a310cdcbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019ce264-8d4a-7f6e-8d94-63a310cdcbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_914dae40-9788-4b3c-9086-8e66e30da9df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_914dae40-9788-4b3c-9086-8e66e30da9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_cf166243-a708-41f7-ae64-8b93d6bda72d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_cf166243-a708-41f7-ae64-8b93d6bda72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f0251142-1cf6-491e-9827-ef67c8fee4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f0251142-1cf6-491e-9827-ef67c8fee4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60c77a07-3cbb-43d8-b6ab-6118f73c678f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60c77a07-3cbb-43d8-b6ab-6118f73c678f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019bfcad-9084-7be5-bbac-ed05b703a902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019bfcad-9084-7be5-bbac-ed05b703a902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019bfcb1-2e15-74ea-b205-d4b6b575a478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019bfcb1-2e15-74ea-b205-d4b6b575a478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_10b8d3b2-0112-4cfb-b03a-ced5e4e591a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_10b8d3b2-0112-4cfb-b03a-ced5e4e591a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019bfcf4-688f-7c7c-9863-2dff07d2d212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_96d9b271-062e-4e3d-963e-f4e8ab98ee1e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019bfcf4-688f-7c7c-9863-2dff07d2d212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834f1af4-0889-4509-9a54-7f1c448360d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_97248e4a-cd3d-4c12-99d6-956bd7e2adcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834f1af4-0889-4509-9a54-7f1c448360d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_97248e4a-cd3d-4c12-99d6-956bd7e2adcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_abe65d55-e27f-4185-8445-91ebfdf0f3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_97248e4a-cd3d-4c12-99d6-956bd7e2adcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_abe65d55-e27f-4185-8445-91ebfdf0f3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d292906f-5f89-445d-b0b4-6b2a06b1bab4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_97248e4a-cd3d-4c12-99d6-956bd7e2adcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d292906f-5f89-445d-b0b4-6b2a06b1bab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2682a47-7407-44e6-85bd-cca1b5ea898c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_97248e4a-cd3d-4c12-99d6-956bd7e2adcb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2682a47-7407-44e6-85bd-cca1b5ea898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ee7a7534-4173-42ab-be7c-61be2efd841c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_97248e4a-cd3d-4c12-99d6-956bd7e2adcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ee7a7534-4173-42ab-be7c-61be2efd841c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09b9db9a-80de-47b6-9656-e38281fbbd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_97248e4a-cd3d-4c12-99d6-956bd7e2adcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09b9db9a-80de-47b6-9656-e38281fbbd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b7f97b90-90e2-41a4-ac20-0ce213eac365" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834f1af4-0889-4509-9a54-7f1c448360d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b7f97b90-90e2-41a4-ac20-0ce213eac365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d6ed767-288b-4932-84f0-ebb1c0b8869b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834f1af4-0889-4509-9a54-7f1c448360d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d6ed767-288b-4932-84f0-ebb1c0b8869b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6bb9d457-df72-44e2-8639-717e90ae9bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d6ed767-288b-4932-84f0-ebb1c0b8869b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6bb9d457-df72-44e2-8639-717e90ae9bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b3df36c0-2339-4ac8-8821-c897bec56187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d6ed767-288b-4932-84f0-ebb1c0b8869b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b3df36c0-2339-4ac8-8821-c897bec56187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_24db2924-aed4-4b06-bce1-0f4f4e56423a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d6ed767-288b-4932-84f0-ebb1c0b8869b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_24db2924-aed4-4b06-bce1-0f4f4e56423a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2bdaf86b-25f6-4c52-a118-0383b0d61589" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d6ed767-288b-4932-84f0-ebb1c0b8869b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2bdaf86b-25f6-4c52-a118-0383b0d61589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_41b5c046-86bc-417f-85da-bf75d0bc3350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d6ed767-288b-4932-84f0-ebb1c0b8869b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_41b5c046-86bc-417f-85da-bf75d0bc3350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e5c9657e-e3a5-4f79-a56b-14045e7d760d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834f1af4-0889-4509-9a54-7f1c448360d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e5c9657e-e3a5-4f79-a56b-14045e7d760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c45ead8e-f91a-4df9-ab0c-1d93ecbfcec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834f1af4-0889-4509-9a54-7f1c448360d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c45ead8e-f91a-4df9-ab0c-1d93ecbfcec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bd81e154-3f46-4067-9edd-6940cd770898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c45ead8e-f91a-4df9-ab0c-1d93ecbfcec3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bd81e154-3f46-4067-9edd-6940cd770898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bc5b0faf-f1ac-4007-b656-37af4f34f26e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c45ead8e-f91a-4df9-ab0c-1d93ecbfcec3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bc5b0faf-f1ac-4007-b656-37af4f34f26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a03f8426-2b06-4f94-a812-1898e61eb5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834f1af4-0889-4509-9a54-7f1c448360d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a03f8426-2b06-4f94-a812-1898e61eb5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4bb93ebf-81b7-4858-8224-8969d55308de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a03f8426-2b06-4f94-a812-1898e61eb5cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4bb93ebf-81b7-4858-8224-8969d55308de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_41dca5c4-653d-4135-a604-af16d4ed4dca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a03f8426-2b06-4f94-a812-1898e61eb5cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_41dca5c4-653d-4135-a604-af16d4ed4dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2998683f-209b-4357-9e4a-a08b91caa0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a03f8426-2b06-4f94-a812-1898e61eb5cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2998683f-209b-4357-9e4a-a08b91caa0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4975919c-4de4-4a58-83e5-57d0e32c580d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834f1af4-0889-4509-9a54-7f1c448360d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4975919c-4de4-4a58-83e5-57d0e32c580d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3b51ffc-216b-4246-b755-aa347c60ba83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9bab3f07-2ec3-4963-8720-92e87fe3cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3b51ffc-216b-4246-b755-aa347c60ba83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9bab3f07-2ec3-4963-8720-92e87fe3cc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_069f67eb-1ad0-4697-b6ed-642938d14ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3b51ffc-216b-4246-b755-aa347c60ba83" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_069f67eb-1ad0-4697-b6ed-642938d14ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4e145341-db37-4605-965e-cfbcc9687aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3b51ffc-216b-4246-b755-aa347c60ba83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4e145341-db37-4605-965e-cfbcc9687aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9f26c486-c6c4-47aa-9740-7cbe81474cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3b51ffc-216b-4246-b755-aa347c60ba83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9f26c486-c6c4-47aa-9740-7cbe81474cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_683af00b-f019-4329-b019-4260a65f1bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a8330f7-47e2-44ef-b474-29afbfae8838" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_683af00b-f019-4329-b019-4260a65f1bd8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a8330f7-47e2-44ef-b474-29afbfae8838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76cb6401-3bbe-4d8a-a992-aceb3b6e21c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a8330f7-47e2-44ef-b474-29afbfae8838" xlink:to="loc_us-gaap_AwardTypeAxis_76cb6401-3bbe-4d8a-a992-aceb3b6e21c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c251e2d-f832-467e-a4fe-e36d84f1ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_76cb6401-3bbe-4d8a-a992-aceb3b6e21c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c251e2d-f832-467e-a4fe-e36d84f1ce7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7ea0a3e9-b429-4e7b-b848-6b625c1f2bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c251e2d-f832-467e-a4fe-e36d84f1ce7c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7ea0a3e9-b429-4e7b-b848-6b625c1f2bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb31385-c012-47b8-8791-b57af643953e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a8330f7-47e2-44ef-b474-29afbfae8838" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb31385-c012-47b8-8791-b57af643953e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb31385-c012-47b8-8791-b57af643953e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_814fa1ca-5dc4-49fd-8276-37e16eabc19e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_814fa1ca-5dc4-49fd-8276-37e16eabc19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e727565-644d-4d77-8830-80744fdd62f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e727565-644d-4d77-8830-80744fdd62f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019bfcfc-a136-7de2-bf00-2925b509523f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019bfcfc-a136-7de2-bf00-2925b509523f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21a1d4af-a890-4c42-b23f-ce6bde2a263e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e784e8b1-7843-4c85-9799-05efcf64f509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21a1d4af-a890-4c42-b23f-ce6bde2a263e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_cb6f9fee-f08e-447c-a450-207469b14988" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb31385-c012-47b8-8791-b57af643953e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_cb6f9fee-f08e-447c-a450-207469b14988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1136a36-33c2-4276-ae3a-9f56e6c92ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_cb6f9fee-f08e-447c-a450-207469b14988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1136a36-33c2-4276-ae3a-9f56e6c92ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2aaf19d2-bdc0-48f0-aefe-bee0b2c12ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0bd94ee-8293-4f7f-a728-56f74667c1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2aaf19d2-bdc0-48f0-aefe-bee0b2c12ba6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0bd94ee-8293-4f7f-a728-56f74667c1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c6c32171-e2b6-4202-899f-d158d56d0468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0bd94ee-8293-4f7f-a728-56f74667c1e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c6c32171-e2b6-4202-899f-d158d56d0468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c6c32171-e2b6-4202-899f-d158d56d0468" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f941ced6-9e5d-4f90-91dd-7d672a22fe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:to="loc_us-gaap_CostOfSalesMember_f941ced6-9e5d-4f90-91dd-7d672a22fe5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_80d24038-0869-4032-95bd-268ae88951ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_80d24038-0869-4032-95bd-268ae88951ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b9c02d7c-b7a1-423e-b6a9-80278f1a7775" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b9c02d7c-b7a1-423e-b6a9-80278f1a7775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a7164a91-0bcb-4f64-b0a0-fde5783fa635" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07a389c2-2746-46c8-ab7c-0ac78feb97b2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a7164a91-0bcb-4f64-b0a0-fde5783fa635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5645a3d6-80f2-475b-9803-8c20c2da413a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0bd94ee-8293-4f7f-a728-56f74667c1e0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5645a3d6-80f2-475b-9803-8c20c2da413a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_35c2f6e8-6d6f-448c-9b4a-6a042f9f8e79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5645a3d6-80f2-475b-9803-8c20c2da413a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_35c2f6e8-6d6f-448c-9b4a-6a042f9f8e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/SEGMENTSDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#SEGMENTSDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/SEGMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7bd71108-13ef-40bb-9047-b24b20c31ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2722c44c-5151-4a1b-bf08-a43687cdac21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7bd71108-13ef-40bb-9047-b24b20c31ba5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2722c44c-5151-4a1b-bf08-a43687cdac21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b3e85789-c63a-4ab3-9a03-2e84afc04ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7bd71108-13ef-40bb-9047-b24b20c31ba5" xlink:to="loc_us-gaap_NumberOfReportableSegments_b3e85789-c63a-4ab3-9a03-2e84afc04ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f53-3c12-72c0-be12-59f6f2408f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b8f53-3c12-7502-abf0-6ccc78e947f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f53-3c12-72c0-be12-59f6f2408f17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b8f53-3c12-7502-abf0-6ccc78e947f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b8f53-725f-7875-84d9-8d5fea1f447e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f53-3c12-72c0-be12-59f6f2408f17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b8f53-725f-7875-84d9-8d5fea1f447e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b8f53-b38e-797b-a3ef-862f9f81774e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f53-3c12-72c0-be12-59f6f2408f17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b8f53-b38e-797b-a3ef-862f9f81774e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESComponentsofIncomeTaxProvisionDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f60-d78f-79d2-99eb-dbc21430bb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f64-bf83-7bfd-9a5b-e4d0b9a9da11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f60-d78f-79d2-99eb-dbc21430bb5d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f64-bf83-7bfd-9a5b-e4d0b9a9da11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_019b8f60-d78f-78c6-9a5c-75b11c690ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f64-bf83-7bfd-9a5b-e4d0b9a9da11" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_019b8f60-d78f-78c6-9a5c-75b11c690ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_019b8f61-07f0-7f1e-bb32-ded1923b9864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f64-bf83-7bfd-9a5b-e4d0b9a9da11" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_019b8f61-07f0-7f1e-bb32-ded1923b9864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b8f61-2bfd-7287-b53f-d767de80e5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f64-bf83-7bfd-9a5b-e4d0b9a9da11" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b8f61-2bfd-7287-b53f-d767de80e5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_019b8f61-52e5-716f-930a-05ac437c51f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f64-bf83-7bfd-9a5b-e4d0b9a9da11" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_019b8f61-52e5-716f-930a-05ac437c51f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f65-4061-7915-a525-f4013b016e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f60-d78f-79d2-99eb-dbc21430bb5d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f65-4061-7915-a525-f4013b016e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_019b8f61-8554-79ac-b1cd-fb91010f1553" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f65-4061-7915-a525-f4013b016e5a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_019b8f61-8554-79ac-b1cd-fb91010f1553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_019b8f61-b344-7da2-aa07-4308520fb600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f65-4061-7915-a525-f4013b016e5a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_019b8f61-b344-7da2-aa07-4308520fb600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b8f61-db4b-7c21-8d37-14827558f655" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f65-4061-7915-a525-f4013b016e5a" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b8f61-db4b-7c21-8d37-14827558f655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b8f62-0537-72f8-9b6b-ecb2ff8213bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b8f65-4061-7915-a525-f4013b016e5a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b8f62-0537-72f8-9b6b-ecb2ff8213bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019b8f62-2913-7888-83c4-1de3529e73da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f60-d78f-79d2-99eb-dbc21430bb5d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019b8f62-2913-7888-83c4-1de3529e73da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f5a-7bfe-7d59-9c0f-f53112b60e13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f5a-7bfe-7d59-9c0f-f53112b60e13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c95fc-0d41-7971-a937-6de8e6861d60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c95fc-0d41-7971-a937-6de8e6861d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c95fc-5ac8-76b8-bb49-4f180d8abd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c95fc-5ac8-76b8-bb49-4f180d8abd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c95fc-9d94-7952-a15e-0e9724a9f4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c95fc-9d94-7952-a15e-0e9724a9f4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c95fc-cba7-7d0d-b949-19553b947eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c95fc-cba7-7d0d-b949-19553b947eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c95fc-f927-7fe7-855f-130d0dc1858a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c95fc-f927-7fe7-855f-130d0dc1858a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c95fd-2306-7f25-9521-61e3b49ac059" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c95fd-2306-7f25-9521-61e3b49ac059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c95fd-483d-7de8-975a-ea21f40e02d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c95fd-483d-7de8-975a-ea21f40e02d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c95fd-6a57-769f-aade-33eef04ca6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c95fd-6a57-769f-aade-33eef04ca6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fd-dcb2-7576-ba4c-6e536faabfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c9604-7fcb-7b63-8eba-8e000686b833" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019c95fd-dcb2-7576-ba4c-6e536faabfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f5a-7bfe-7d59-9c0f-f53112b60e13" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b8f5a-7bfe-7cf4-9df2-fe0aa1f83f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b8f5a-7bfe-7cf4-9df2-fe0aa1f83f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b8f5a-d08e-764c-80db-b077ea2a9047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019b8f5a-d08e-764c-80db-b077ea2a9047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c95ff-2931-7b78-9c4e-0cf92ef013bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c95ff-2931-7b78-9c4e-0cf92ef013bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c95ff-51c3-759c-ab73-bb508f80b166" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c95ff-51c3-759c-ab73-bb508f80b166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019b8f5a-f46c-7419-a01f-a9eaa3e0e7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019b8f5a-f46c-7419-a01f-a9eaa3e0e7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019b8f5b-19ef-7ea9-bc76-7e8a48a371e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019b8f5b-19ef-7ea9-bc76-7e8a48a371e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019b8f5a-abf6-7289-a16e-a9e26705e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019b8f5a-abf6-7289-a16e-a9e26705e07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c9600-04d4-7367-9c0b-6d0342cd6976" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c9600-04d4-7367-9c0b-6d0342cd6976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5b-6180-7a9d-82f4-16eda8fce58b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c9604-d4ff-7cfb-b14c-2201832103d3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b8f5b-6180-7a9d-82f4-16eda8fce58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESCashPaidforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019c9607-a8ac-7b7b-9d95-2b529208315e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c9607-a8ac-73fc-9fad-0265e4ed406e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019c9607-a8ac-7b7b-9d95-2b529208315e" xlink:to="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c9607-a8ac-73fc-9fad-0265e4ed406e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c9608-a486-7d26-a389-2a1277b1e18a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c9607-a8ac-73fc-9fad-0265e4ed406e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c9608-a486-7d26-a389-2a1277b1e18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c9608-a486-7b70-bafa-9c1b93ea20b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c9608-a486-7d26-a389-2a1277b1e18a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c9608-a486-7b70-bafa-9c1b93ea20b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9608-a486-7b70-bafa-9c1b93ea20b3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_019c9608-cdf1-7eed-a514-358f0065f2e1" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:to="loc_stpr_CA_019c9608-cdf1-7eed-a514-358f0065f2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_019c9609-0916-7992-b70f-aa9a18ce5ca2" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:to="loc_stpr_MA_019c9609-0916-7992-b70f-aa9a18ce5ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_019c9609-2902-72a8-bdc0-21e3091f4dfb" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NC"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:to="loc_stpr_NC_019c9609-2902-72a8-bdc0-21e3091f4dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_019c9609-4e3e-74d4-88b7-818c7f6e1de5" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c960a-0820-7a63-916a-120a62182af1" xlink:to="loc_stpr_NY_019c9609-4e3e-74d4-88b7-818c7f6e1de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c9607-a8ac-7477-9e91-eccc0610a4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c9607-a8ac-73fc-9fad-0265e4ed406e" xlink:to="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c9607-a8ac-7477-9e91-eccc0610a4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c9607-a8ac-7f32-b052-5b5dd0b15281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c9607-a8ac-7477-9e91-eccc0610a4f0" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c9607-a8ac-7f32-b052-5b5dd0b15281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f69-8240-7f04-9318-f51384d187dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f69-8240-7f04-9318-f51384d187dd" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b8f69-8240-74d2-a224-176473c7a3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b8f69-8240-74d2-a224-176473c7a3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_019b8f6d-2271-7869-a383-82f11a7aa9b1" xlink:href="cv-20251231.xsd#cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:to="loc_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_019b8f6d-2271-7869-a383-82f11a7aa9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b8f6d-78c1-712b-a8b2-a1905053554d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b8f6d-78c1-712b-a8b2-a1905053554d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_019b8f6d-a112-71d1-ab2c-ac304781840e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_019b8f6d-a112-71d1-ab2c-ac304781840e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_DeferredTaxAssetsOperatingLeaseLiabilities_019b8f6e-1e45-7047-8d28-9f1ee5cee6e7" xlink:href="cv-20251231.xsd#cv_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:to="loc_cv_DeferredTaxAssetsOperatingLeaseLiabilities_019b8f6e-1e45-7047-8d28-9f1ee5cee6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_019b8f6e-47d5-71fa-84d4-f090c9f77936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_019b8f6e-47d5-71fa-84d4-f090c9f77936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_019b8f6e-740a-7645-b5ae-81a38c97d456" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_019b8f6e-740a-7645-b5ae-81a38c97d456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b8f6e-9f37-728a-ad89-61e4725cc8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b8f6e-9f37-728a-ad89-61e4725cc8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_019b8f6f-b805-711b-9db2-8f5875c54fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b8f73-c03b-7e80-8b20-075158145a6d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_019b8f6f-b805-711b-9db2-8f5875c54fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b8f74-1877-778e-87ac-39cdbc273af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f69-8240-7f04-9318-f51384d187dd" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b8f74-1877-778e-87ac-39cdbc273af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b8f70-28a1-7f40-852f-8b575d0f6616" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b8f74-1877-778e-87ac-39cdbc273af1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b8f70-28a1-7f40-852f-8b575d0f6616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b8f70-4fac-7a4e-816b-62b068c1212f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b8f74-1877-778e-87ac-39cdbc273af1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b8f70-4fac-7a4e-816b-62b068c1212f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_019c8d61-9131-7bde-a4ee-72a6e179f492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b8f74-1877-778e-87ac-39cdbc273af1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_019c8d61-9131-7bde-a4ee-72a6e179f492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_019b8f70-8fe4-7614-b53b-82493e0f96ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b8f74-1877-778e-87ac-39cdbc273af1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_019b8f70-8fe4-7614-b53b-82493e0f96ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_019b8f70-dce2-7888-bf9c-977407a18e28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f69-8240-7f04-9318-f51384d187dd" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_019b8f70-dce2-7888-bf9c-977407a18e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ba70158d-a524-46a0-a67d-d0a87a513fce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_019ba458-32ec-7e5c-8580-5d92f1b62635" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba70158d-a524-46a0-a67d-d0a87a513fce" xlink:to="loc_us-gaap_ValuationAllowanceTable_019ba458-32ec-7e5c-8580-5d92f1b62635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019ba458-32ec-7d49-b612-1882f254b669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_019ba458-32ec-7e5c-8580-5d92f1b62635" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019ba458-32ec-7d49-b612-1882f254b669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019ba458-32ec-7d49-b612-1882f254b669" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019ba45a-412e-79cf-b771-646e527d4834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:to="loc_us-gaap_DomesticCountryMember_019ba45a-412e-79cf-b771-646e527d4834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019ba460-e3d3-7c42-b3bb-09dc0383d322" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019ba460-e3d3-7c42-b3bb-09dc0383d322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019ba458-32ec-754f-8c3f-8e761a09182d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019ba458-32ec-7718-b38e-5144d113ca5b" xlink:to="loc_us-gaap_ForeignCountryMember_019ba458-32ec-754f-8c3f-8e761a09182d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_019ba458-32ec-7e5c-8580-5d92f1b62635" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019b9f2a-2b3e-749a-8e39-554c40f85b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019b9f2a-2b3e-749a-8e39-554c40f85b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019ba45b-c3f1-7d44-8594-c459098692a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019ba45b-c3f1-7d44-8594-c459098692a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019ba460-02b1-7f1b-b23a-c5712e2d84af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019ba460-02b1-7f1b-b23a-c5712e2d84af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019ba458-32ec-7446-a305-980de0909f43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019ba458-32ec-7446-a305-980de0909f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_019c9852-bfa4-7b74-a9f4-53e09f3f4fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_019ba458-32ec-734d-9604-e674c9871a08" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_019c9852-bfa4-7b74-a9f4-53e09f3f4fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f76-8602-7709-94f9-7bb49613909c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-72a6-8625-fd2adfed1fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f76-8602-7709-94f9-7bb49613909c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-72a6-8625-fd2adfed1fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019b8f77-dad2-7977-a8a4-41bb066b814f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-72a6-8625-fd2adfed1fb9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019b8f77-dad2-7977-a8a4-41bb066b814f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7e18-9983-09a0349967da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019b8f77-dad2-7977-a8a4-41bb066b814f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7e18-9983-09a0349967da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019b8f78-4157-7006-9e83-8b4424080eca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7e18-9983-09a0349967da" xlink:to="loc_us-gaap_DomesticCountryMember_019b8f78-4157-7006-9e83-8b4424080eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019b8f79-7491-7cd8-a88a-0d1dda030a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019b8f77-dad2-7e18-9983-09a0349967da" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019b8f79-7491-7cd8-a88a-0d1dda030a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_019b8f7a-3ad1-799f-85b6-a27cbae47f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-72a6-8625-fd2adfed1fb9" xlink:to="loc_us-gaap_TaxPeriodAxis_019b8f7a-3ad1-799f-85b6-a27cbae47f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_019b8f7a-3ad1-799f-85b6-a27cbae47f2c" xlink:to="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearAfter2017Member_019b8f7a-a2f3-7a52-80d3-66e3998f5399" xlink:href="cv-20251231.xsd#cv_TaxYearAfter2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:to="loc_cv_TaxYearAfter2017Member_019b8f7a-a2f3-7a52-80d3-66e3998f5399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearBefore2018Member_019b8f7b-3fb8-700b-988f-702193b82212" xlink:href="cv-20251231.xsd#cv_TaxYearBefore2018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:to="loc_cv_TaxYearBefore2018Member_019b8f7b-3fb8-700b-988f-702193b82212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearIndefiniteMember_019b8f7b-b5b5-7b5b-a545-252bc0817e4c" xlink:href="cv-20251231.xsd#cv_TaxYearIndefiniteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:to="loc_cv_TaxYearIndefiniteMember_019b8f7b-b5b5-7b5b-a545-252bc0817e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxYearDefiniteLivedMember_019b8f7c-5c9d-7b82-a460-820303ceae2f" xlink:href="cv-20251231.xsd#cv_TaxYearDefiniteLivedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_019b8f7a-3ad1-76cf-b6fc-e7261f6ff934" xlink:to="loc_cv_TaxYearDefiniteLivedMember_019b8f7c-5c9d-7b82-a460-820303ceae2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_019b8f77-dad2-72a6-8625-fd2adfed1fb9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019b8f77-dad2-7617-9345-c0fdac9e0c89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019b8f77-dad2-7617-9345-c0fdac9e0c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_OperatingLossCarryforwardsExpirationTerm_019b8f82-503c-751f-bb20-033601858dee" xlink:href="cv-20251231.xsd#cv_OperatingLossCarryforwardsExpirationTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:to="loc_cv_OperatingLossCarryforwardsExpirationTerm_019b8f82-503c-751f-bb20-033601858dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_019b8f80-96cd-7b94-8549-bd3ad7544366" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_019b8f80-96cd-7b94-8549-bd3ad7544366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_TaxCreditCarryforwardExpirationTerm_019c437f-a973-7f83-9db5-fbd12ef97d9d" xlink:href="cv-20251231.xsd#cv_TaxCreditCarryforwardExpirationTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b8f77-dad2-7bc5-8e09-d4bed237089a" xlink:to="loc_cv_TaxCreditCarryforwardExpirationTerm_019c437f-a973-7f83-9db5-fbd12ef97d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/INCOMETAXESUnrecognizedTaxPositionsDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#INCOMETAXESUnrecognizedTaxPositionsDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/INCOMETAXESUnrecognizedTaxPositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f8a-4411-7100-a759-5ee0c4461d16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_019b8f8c-6542-743e-924f-8d295a363d94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b8f8a-4411-7100-a759-5ee0c4461d16" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_019b8f8c-6542-743e-924f-8d295a363d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_019b8f8a-4411-7081-9a6d-ad8b17d87683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_019b8f8c-6542-743e-924f-8d295a363d94" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_019b8f8a-4411-7081-9a6d-ad8b17d87683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_019b8f8a-c795-7ccf-b4b4-a330cd718a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_019b8f8c-6542-743e-924f-8d295a363d94" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_019b8f8a-c795-7ccf-b4b4-a330cd718a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_019b8f8b-2f6a-7b5d-bc1b-72f5004af6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_019b8f8c-6542-743e-924f-8d295a363d94" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_019b8f8b-2f6a-7b5d-bc1b-72f5004af6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_019b8f8c-d618-76d8-9542-4d9c0ffe7f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_019b8f8c-6542-743e-924f-8d295a363d94" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_019b8f8c-d618-76d8-9542-4d9c0ffe7f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/NETLOSSPERSHAREDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#NETLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/NETLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0d1eea51-bfbf-45f4-85dd-4e2b153472f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0d544a40-96cd-4678-a1de-c9f5f50ec172" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d1eea51-bfbf-45f4-85dd-4e2b153472f7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0d544a40-96cd-4678-a1de-c9f5f50ec172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ea87e2ec-7a2c-45ec-93be-60395309fcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d1eea51-bfbf-45f4-85dd-4e2b153472f7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ea87e2ec-7a2c-45ec-93be-60395309fcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_896ba82b-442d-48cb-8c9a-15e1b47483ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d1eea51-bfbf-45f4-85dd-4e2b153472f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_896ba82b-442d-48cb-8c9a-15e1b47483ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ceb3efed-8e74-4e61-9faa-ff3ff16c29b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d1eea51-bfbf-45f4-85dd-4e2b153472f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ceb3efed-8e74-4e61-9faa-ff3ff16c29b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_879c0cbb-28dd-4ae0-a29a-fc8a99358cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d1eea51-bfbf-45f4-85dd-4e2b153472f7" xlink:to="loc_us-gaap_EarningsPerShareBasic_879c0cbb-28dd-4ae0-a29a-fc8a99358cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a9815b6c-fe22-49ac-8d88-ccba4608ac21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d1eea51-bfbf-45f4-85dd-4e2b153472f7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a9815b6c-fe22-49ac-8d88-ccba4608ac21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#NETLOSSPERSHAREAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3b7c01e1-9623-469e-b6a7-986826ce4b02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_12242091-c88d-474f-ac44-5d9248cda661" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3b7c01e1-9623-469e-b6a7-986826ce4b02" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_12242091-c88d-474f-ac44-5d9248cda661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6506ad83-f216-4270-a600-526a052aef71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_12242091-c88d-474f-ac44-5d9248cda661" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6506ad83-f216-4270-a600-526a052aef71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6506ad83-f216-4270-a600-526a052aef71" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_93891124-8575-4d1b-8b2a-686e3dc007bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_93891124-8575-4d1b-8b2a-686e3dc007bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_290979fb-2fa5-43f5-92b9-8173188164eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:to="loc_us-gaap_WarrantMember_290979fb-2fa5-43f5-92b9-8173188164eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5023aef-2faa-4e3c-a4a8-ec7618ba073b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5023aef-2faa-4e3c-a4a8-ec7618ba073b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8d4276bf-ef99-4909-837c-4bef9611be1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7f0a6e13-427d-4a81-9674-f67c3b864991" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8d4276bf-ef99-4909-837c-4bef9611be1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_58b878ba-f6be-4f30-8879-2df1a7fedfed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_12242091-c88d-474f-ac44-5d9248cda661" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_58b878ba-f6be-4f30-8879-2df1a7fedfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f15e1cc7-b5c4-4700-b7b0-8f2a3cf86b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_58b878ba-f6be-4f30-8879-2df1a7fedfed" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f15e1cc7-b5c4-4700-b7b0-8f2a3cf86b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/RELATEDPARTIESDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#RELATEDPARTIESDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/RELATEDPARTIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e6c76cd3-6f6c-4fbf-9630-24a67a77ceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_b9cebb44-478c-478e-b5a2-553d3f2ca5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e6c76cd3-6f6c-4fbf-9630-24a67a77ceb8" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_b9cebb44-478c-478e-b5a2-553d3f2ca5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://capsovision.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="cv-20251231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://capsovision.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1b99cc51-967f-4976-a542-3f2d4514c212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1b99cc51-967f-4976-a542-3f2d4514c212" xlink:to="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_629e914d-623d-4153-9d5e-21f3e542c1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_629e914d-623d-4153-9d5e-21f3e542c1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ab01fb3b-d990-4981-ae7b-20ac1e6322a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_629e914d-623d-4153-9d5e-21f3e542c1e5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ab01fb3b-d990-4981-ae7b-20ac1e6322a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7148d1f6-0274-427b-947c-220e708f76fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ab01fb3b-d990-4981-ae7b-20ac1e6322a4" xlink:to="loc_us-gaap_SubsequentEventMember_7148d1f6-0274-427b-947c-220e708f76fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019ca0c8-00dd-7532-a353-be4f2c5d0b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:to="loc_us-gaap_AwardTypeAxis_019ca0c8-00dd-7532-a353-be4f2c5d0b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019ca0c8-00dd-7195-a48f-36a25577c7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019ca0c8-00dd-7532-a353-be4f2c5d0b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019ca0c8-00dd-7195-a48f-36a25577c7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019ca0c8-2d3f-7a04-b716-90ac41894e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019ca0c8-00dd-7195-a48f-36a25577c7f5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019ca0c8-2d3f-7a04-b716-90ac41894e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019cdf2f-e938-7143-96c2-0e0caa1dc4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019cdf2f-e938-7143-96c2-0e0caa1dc4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cdf2f-e938-71e2-a361-80bd75ef2937" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019cdf2f-e938-7143-96c2-0e0caa1dc4b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cdf2f-e938-71e2-a361-80bd75ef2937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019cdf31-62bc-7d60-a897-84e8bab0ffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019cdf2f-e938-71e2-a361-80bd75ef2937" xlink:to="loc_us-gaap_PrivatePlacementMember_019cdf31-62bc-7d60-a897-84e8bab0ffbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d821474f-4fc1-46ae-baa1-14c2407db4b7" xlink:to="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsDate_53cde999-31d9-408f-81c9-9fdccd582827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SubsequentEventsDate_53cde999-31d9-408f-81c9-9fdccd582827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_019ca0ca-4800-7f5c-a5e9-61cb0fb90352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_019ca0ca-4800-7f5c-a5e9-61cb0fb90352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019ca0c9-aaf1-7db0-b2a7-7338ade15eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019ca0c9-aaf1-7db0-b2a7-7338ade15eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019ca0db-e7d4-737b-8db7-b1135f20da01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019ca0db-e7d4-737b-8db7-b1135f20da01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments_019ca0df-2759-7960-aabd-7ed7a514d240" xlink:href="cv-20251231.xsd#cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments_019ca0df-2759-7960-aabd-7ed7a514d240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_019cdf2f-cf16-7fd6-98ca-b2c2b304a75a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_019cdf2f-cf16-7fd6-98ca-b2c2b304a75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cdf3a-8f1b-702b-8e0d-73d78d05303b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cdf3a-8f1b-702b-8e0d-73d78d05303b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cdf39-246d-7897-9ead-e0d1a5494609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cdf39-246d-7897-9ead-e0d1a5494609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cdf35-4c8b-79cc-8018-8e6202df1c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cdf35-4c8b-79cc-8018-8e6202df1c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019cdf38-501d-75da-bdd7-2968a795bc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019cdf38-501d-75da-bdd7-2968a795bc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockEffectivenessDate_019cdf32-8ff3-7863-b4de-2f1f624af4a6" xlink:href="cv-20251231.xsd#cv_SaleOfStockEffectivenessDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_cv_SaleOfStockEffectivenessDate_019cdf32-8ff3-7863-b4de-2f1f624af4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cv_SaleOfStockRegistrationRightsAgreementDate_019cdf37-4674-7344-af05-929a8d0167d0" xlink:href="cv-20251231.xsd#cv_SaleOfStockRegistrationRightsAgreementDate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0fddd8f5-9e9a-42ec-849b-9c9c8cc17c6d" xlink:to="loc_cv_SaleOfStockRegistrationRightsAgreementDate_019cdf37-4674-7344-af05-929a8d0167d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cv-20251231_g1.jpg
<TEXT>
begin 644 cv-20251231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[16(4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))301$       0     @   D    )      #A"24T$
M'@      !      X0DE-!!H      T$    &              $^   #J@
M  8 9P P #  ;@ Y #,    !                          $
M     ZH   $^                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   $^     %)G:'1L;VYG   #J@    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !/@    !2
M9VAT;&]N9P   ZH    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     4X0DE-! P     "S0    !    GP   #8   '@  !E0
M"Q@ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #8
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M[O\ @Y_[ZO/DE)A^<?-_U/YFOG_FY?S7_5?D_P )]8Q[/K$P#]$+1X/+0?\
MHN:M;!R[2TMZA@V-D_SE=E3@/[#WU/7B*2MY[]HWQ5I_.<'%_P WUM/X?P_>
MH5P<6O\ N3W.W]?]2^[6U=-(EMVV>Q:Z?G <@MJP]X'KMB#K#O _R5X>DJ#U
M(XN$_P YMUX'_]DX0DE-!"$      %<    ! 0    \ 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P "  ,@ P #( -0    $ .$))300B      $R34T *@    @ !P$2
M  ,    !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (
M  $Q  (    ?    <@$R  (    4    D8=I  0    !    J    -0   $L
M     0   2P    !061O8F4@4&AO=&]S:&]P(#(V+C(@*%=I;F1O=W,I #(P
M,C4Z,#$Z,S$@,3,Z-#@Z-#8       .@ 0 #     ?__  "@ @ $     0
M ZJ@ P $     0   3X         !@$#  ,    !  8   $:  4    !   !
M(@$;  4    !   !*@$H  ,    !  (   (!  0    !   !,@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0$Z17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;
M  4    !    :@$H  ,    !  (   $Q  (    ?    <@$R  (    4
MD8=I  0    !    J    -0   $L     0   2P    !061O8F4@4&AO=&]S
M:&]P(#(V+C(@*%=I;F1O=W,I #(P,C4Z,#$Z,S$@,3,Z-#@Z-#8       .@
M 0 #     ?__  "@ @ $     0   ZJ@ P $     0   3X         !@$#
M  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !  (
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M 0D# 2(  A$! Q$!_\0 '     <! 0                (#! 4&!P@!_\0
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MY@BD#G.=RV+<M;V:G8:3R*7KN"ZN@>\UM;0PPQ-)EE+G$1D/:S20&DG+G#!
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MZB;/AV+4^N64UX<"<I-SBIRJMY!*CI:,M)&%R-_--7C8:(-F,BX]Z D<$JZ
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MU9**[TM0S5&YKAW@HQ$4CV-&+LC/N<ZR"P/SW)!MT@JZ84U[M-/50@!N0W!
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?GH8HW5<(,;""\;$?%7KHH_Y;/D%9>LYY>>RZZ3__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cv-20251231_g10.jpg
<TEXT>
begin 644 cv-20251231_g10.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_[2KR4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0(+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      ! "6     $  @)8     0 ".$))300F
M       .             #^    X0DE-! T       0    >.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             &[@  !SP          0
M   !              <\   &[@                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   &[@    !29VAT;&]N9P  !SP    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P  !NX     4F=H=&QO;F<   <\     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    &.$))300,      \?     0   *    "9
M   !X  !'N    \# !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" "9 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M     P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0
M  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!
M8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&
M)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(!
M @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R
M@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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M+KK=&-Y*&;P.Z'??396ZJUH>QPAS2DAO4>O;0+_2<QI&Z'1NC^JIU7-!VN,
M\'P*JCK=K:O3K8T:1NY*I&_(>>(24[^H,)++QLG.8 W1[!PUW;^JX>Y:5;Q8
MV8VGNT]D%,DDD\)*4DDDDI__T>Z58 4WFK_!W395Y.^ED5?^[#/^O?Z-6$+)
MI=?26,<&VM(?2\\-L;_-N/\ (_,L_P"#22N7 !0%]1=M#QN\)U^Y IRJLBAM
MD;-TM?6>6/:=EM+OY5;U'H=>%TP7>M8'OLL<_P!2)<6DRQKOZB*&T7@(3K@.
MZK=0ZC59<XXS3L/<Z#PE4_7>[O\ (:I)=(Y 0W9('=4VMN?I'SU11B/>9?\
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MHK;G-V0@ITD*E*5%.DI>4I3))*5*4INZ79%2I23*22G_V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     23DU- "H    ( !$ "P "    )@   -H!   #     0R\   !
M 0 #     0PS   ! @ #     P   0 !!@ #     0 "   !#P "    !@
M 08!$  "    #0   0P!$@ #     0 !   !%0 #     0 #   !&@ %
M 0   1D!&P %     0   2$!*  #     0 "   !,0 "    '@   2D!,@ "
M    %    4<"$P #     0 !  #J'  '   (#    5N':0 $     0  "6@
M !'P5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X-   "  (
M  A#86YO;@!#86YO;B!%3U,@4C4    "6     $   )8     4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C4Z,#,Z,3,@,C$Z,#@Z-#4 '.H
M   (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                              B0   '    !# R
M,S&0 P "    %   "<Z1 0 '    ! $" P"@   '    !# Q,#"@ 0 #
M ?__  "@ @ $     0  !SR@ P $     0  !N[J'  '   (#   ">(
M,C R,SHP,SHQ-B Q,SHR.#HS,0 <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                  8! P #     0 &   !&@ %     0  $CX!&P %
M 0  $D8!*  #     0 "   " 0 $     0  $DX" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$25D5X:68
M $U- "H    ( !$ "P "    )@   -H!   #     0R\   ! 0 #     0PS
M   ! @ #     P   0 !!@ #     0 "   !#P "    !@   08!$  "
M#0   0P!$@ #     0 !   !%0 #     0 #   !&@ %     0   1D!&P %
M     0   2$!*  #     0 "   !,0 "    '@   2D!,@ "    %    4<"
M$P #     0 !  #J'  '   (#    5N':0 $     0  "6@  !'P5VEN9&]W
M<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X-   "  (  A#86YO;@!#
M86YO;B!%3U,@4C4    "6     $   )8     4%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,C4Z,#,Z,3,@,C$Z,#@Z-#4 '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                  B0   '    !# R,S&0 P "
M%   "<Z1 0 '    ! $" P"@   '    !# Q,#"@ 0 #     ?__  "@ @ $
M     0  !SR@ P $     0  !N[J'  '   (#   ">(     ,C R,SHP,SHQ
M-B Q,SHR.#HS,0 <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M      8! P #     0 &   !&@ %     0  $CX!&P %     0  $D8!*  #
M     0 "   " 0 $     0  $DX" @ $     0              2     $
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M!0         ! A$#!!(A,4%1!1-QP10S89&Q_]H # ,!  (1 Q$ /P#V8!$
MD!W16[(IALG"5DX:@5DX"0"*R!K)6[H@$]D  )P$03@(! T3@(@$^54!9. C
MRIPU!'9.&^2=SV,^9[0?5#S2?DC>[SV']T!AJ<-06E.Y8P>6I3<H'YW/=ZFP
M_LFD&7L;HYP!]437-.Q4;6-;\K0/0(DT#LE9#&ZQL=E-9 %DK(P$K( LE9&D
M @"R>R*R5D 63*2R;*@#HDI,J8-0  GL$8:GRH*T"Z(!(!%913)[) )P-$#
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M-"!T5NR !2MB 1'!%2 =%UPTES8"Y[+KBBN0 -5<4L#:9F9UC)^RHY:+"6-
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cv-20251231_g11.jpg
<TEXT>
begin 644 cv-20251231_g11.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2$@4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             E@   +Z          $                          0
M           "^@   E@                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   E@     4F=H=&QO;F<   +Z    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   )8
M     %)G:'1L;VYG   "^@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !SA"24T$#      6^0    $   "@    ?@   >
M .Q    6W0 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
M: !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5
M -L X #E .L \ #V /L! 0$' 0T!$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!
M8 %G 6X!=0%\ 8,!BP&2 9H!H0&I ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(,
M A0"'0(F B\". )! DL"5 )= F<"<0)Z H0"C@*8 J("K *V L$"RP+5 N "
MZP+U P #"P,6 R$#+0,X T,#3P-: V8#<@-^ XH#E@.B ZX#N@/' ],#X /L
M _D$!@03!" $+00[!$@$501C!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%
M*P4Z!4D%6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,
M!IT&KP; !M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,
M$@PJ#$,,7 QU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#
M$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
MCQ:R%M86^A<=%T$791>)%ZX7TA?W&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW
M&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=
M1QUP'9D=PQWL'A8>0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P
M(1PA2"%U(:$ASB'[(B<B52*"(J\BW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE
M"24X)6@EER7')?<F)R97)H<FMR;H)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX
M*6LIG2G0*@(J-2IH*ILJSRL"*S8K:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LM
MX2X6+DPN@BZW+NXO)"]:+Y$OQR_^,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;
M,M0S#3-&,W\SN#/Q-"LT932>--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPW
MUS@4.% XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B ^8#Z@/N _(3]A/Z(_XD C0&1 ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV %8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^ 7YB?L)_(W^$?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B 2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI &D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'# [,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X #D%D
M;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0
M% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,_\  $0@ ?@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$!
M 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%
M!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&A
ML4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*S
MA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7
MY_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2
MT? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-U
MX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P#
M 0 "$0,1 #\ ]2),E-N*BX^X_%-**&<E*2H2GE)3+<4MQ4)2E)3.3XI2?%0E
M*4E,Y/B@.>_>_P!Q^EIJB2@GZ3OBDE8OL_>/WI>I9^^[[RF3(*8OMMF ]VGF
M4&S(SG.=5B0^UH!<^U[FUMGZ+7>GNLLL=^XQ&+"3Q*R>KXW4;<+T<$P_[2\Y
M0DASF0=NQW[_ /-;44.A1DYP<*<W;7>02UU+W.K>!]+;ZH;978S\ZMZL>I9^
M^[[RL/ZN#J7['PQU%MC<AN0\5^L9M]$.=Z3K?^M;_P#K:VR$E*]2W]]WWE-Z
MMO[[OO*8A,DI3[;0QQWN!CQ*O4.)JK)))+6R?DL^W^;=\%>H/Z.H?R6_D24_
M_]#TUQ]Q^*C*9[O>[XE1W(K;9RGE#W);DE6DE*4/<EN25;.4I4-R6Y)5I)0C
MR[XE/N33S\4BD+))TD$LJR(CNAW5ESB^IWIV1!)&YICC>R6_1_D.3IY24AIH
MM#O5R;!==J&[&EC&@_N,<ZQ^]W[[WHAY3DIH24M"B5-1(14BN_FG?!7:3[:Q
MY-_(%2O_ )IWP5JD_P V/ZJ2'__1]&M=%K_ZQ4=RA<[]-9_6*AO3EB;<EN0M
MR;<DJTVY+<@[DMZ*DVY+<A D\ E2#+#^;]Z"F>Y2;J/FA^F_R"R>J?6*OIG4
M!@OV;W5BRL'<7.T+C]'^;^C[$"N#MIBH5VBREE[?H6-#VZ:PX;DMVX:()9RF
ME1U2!*2F4I*,E*4:4S42$@X)$A!2#(GTW'M!_$A6*7>^OXM5?(/Z)P1*7?I:
M_P"LU.6G=__2[R]T7V_UBHM+G':T$D\ (>2^,F[^NY2Q#NO'D)3^C'U3C'N/
M,#XG^Y3&+^\_[@B[CXI!Y[IME=08C'J',N^)4Q6P<- 3B3W4@$+74&*4*<@?
M%0+F@\I*:>5?U.MY;BX3;F=K#8 3_P!;]NU8^:SZT79U.31AL97LVY#"VESB
MX%P_1VW;K=CJMOYZZ/>SQ3&RL<N"=Q"@.$>?J6\)LGC/EZ:_Z+G57=?^B,&F
MJL:,:^P AOYK3Z;G-_S6K19ZA8WU0&V1[FM)<T'^2XAJ@<K&;S8/Q4#U#%'#
MB[X-/\4I&]HB/E:HQK>1E_>K_N4T);0JKNI,_,K)^)A"=GWGC:WX"?RH4NMO
M[? *+BQOTG!OQ*SG7W/^D]Q^:@E2+;[LG''?=\ A69C "6LT F2JR1U$'@Z'
MYHTJTAO9>SV]SJC4/F^O^NW\JJ,VUMVMT 1<9_ZS3_7;^5&EAE9?_]/L<M_Z
MW>/^$=^5&Z<9L>? !4\UT9N1_P 8[\JM=),^J?,!2'Y6(?,Z*9(IDQD7#BW@
MJ7K.C@*"22F1>XB.!Y**222F)0;44H5I24U+.4(\HEG*$>44,@I* 4@DIDDF
M224R23)2DI'OU1,5_P"M4?\ &-_*JKW0]P\RBX;OUS'_ .-9^5/Z,=ZO_]3I
MLYWZ]D_\:[\JO=&,UVG^4/R+-SW?K^3_ ,:_\JT>B:X]A_E_P"DE\K#'Y_M=
M$IDD'+R#C8SK@ XM+6C<=K!N<*_4M?\ FTU[M]KDQE3)+*_YR],87MM<X&EP
M9;96T/JW:^ZNS=O=5[+/TGI_X/W_ )BMU=2Q+GEE;G$B09:0=PU=7Z?T]S:S
MZO\ Q:2FTD@_;,4&#8&D\!T@ZZ]Q^[[_ .HF9ETVW.II=ZCF .L(F&AVK-3^
M^E^Q5C2^NR0H-A124&Q)35LY0G<HEG*$Y%#(%30P5,)*723)TDKI)DZ2FG<8
MM>/-3PG?KN-_QK/RH.48O=Y@'\$^"[]>QO\ CF?]4I.GT8/TOJ__U=[J)_RA
ME?\ '/\ RK4Z%_1'G_A'?D:LCJ)_RCE_\<_\JU^@_P!!<?\ A'?D:I9?*P0^
M<_5T2FG^Y.4RC9F!HQR\V.IK<]S0PN+&DEK3N:W4?FN3?9L;8*Q2QK&DN:UK
M0T!Q^DX>GM^E^<J?6\OK&'A^MTC!;U&X'])47[2UL?SE=8AV1_Q;'K!Z9]>\
MJ_(;B]2Z)F8]SG;2^BI[VCM[JK&MM:DIZC[+1! :0#$PX]N.?Y(VHC&MKK%;
M9VM$"=3XJ1$&/!,DI@4&Q&*#8BAJV<H+D6Q"<DI=JF$-I4PDIDDD$DE+RDF)
MT33*2FEGZ7 ^+?XJ. ?\H8O_ !S/^J"EU+2RL^+3^5#Z>?\ *&)_QU?_ %04
M@^7Z,,OG^K__UMGJ1_REE_\ '/\ RK4Z%EXK,8X]EK67&PD-<8D';&UQ]JH]
M0QJW=0RG'+I:3<\EI%LC7Z+MM+FJN[$QO3>+,VH-+3):VZ0/SH_0*:5<.K7C
M?'H]::WQ.TD>(U'X*"\L_9.*[(_R+UJ^NZ?T?H59\_\ LOAO70871_\ &2UH
M.-UUCVQJ,ZJV/_9O!8]1,[V:?U+(C<8\)*Q,<?7JIK6Y?['R".7,=D5D_P#;
M=+V_]%:F*<]X_7*\>D^--MM@_P VW%H_ZI)29,I[!_I&_<[_ ,BFV#_2-_Z7
M_D4E(G(-BL.K;_I&_<[_ ,BA65-_TK!\G_\ D$4-*SE!/*M/I9_IZ_N?_P"D
MT)U#)_I%7W6?^DTD(FH@3BAO;(J^ZS_TDFMJ>VLFFVFRP?1:\VL:3_*>VBUW
M_@:25]$UMM5%9MO>VFINILL<&-']I\+$S,3ZZY /V?-Z;AL':G[198?[=F*Y
M_P#VW6N)ZYTFTY0_:W6L<7]_M#,_Q_EX&Q!+V.9]>>@TV>CB.MZE?VKQ6RWY
MW6;&?YGJ(.%]:.KY.4[[3TX8&%$5N<[?;NGV[I+6[?ZM:Y3H_2<$95>SK>(7
M1IZ=>83'EOPZVKLL+"^K]3F_:.H-O?(C>RYK9_[9"*".B9UKK3O<\V3PXH_3
MO^4<3_CJ_P#J@C9>-AN<TTY5#6;=!MLC_H5.38&-4.H8KOM=+B+F$- MD^[Z
M(W4M:I+T^C 0>+ZO_]D .$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J    "  '
M 1(  P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $
M @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D    T
M 2P    !   !+     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#(U.C Q.C(T(#$R.C4V.C,W   #H $  P    '__P  H ( !     $   +Z
MH , !     $   )8          8! P #     0 &   !&@ %     0   1X!
M&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M-D5X:68  $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %
M     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"'
M:0 $     0   *0   #0   !+     $   $L     4%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,C4Z,#$Z,C0@,3(Z-38Z,S<   .@ 0 #
M ?__  "@ @ $     0   OJ@ P $     0   E@         !@$#  ,    !
M  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (   (!  0
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M1B;CJK'J'#>?REVG"O[OS_U,V6S&X5_=<'WMFQD\+=NFGS $ 0C90$ !1 0
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C-_E=G_I(]?WH_IX?XT_VTJ'R%/U5^ "KDL+DER0'.[,?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cv-20251231_g12.jpg
<TEXT>
begin 644 cv-20251231_g12.jpg
M_]C_X  02D9)1@ ! 0$!-P$W  #_[1#N4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $P< 5H  QLE1QP"   "   < E  "')R,3<W.#8U' (% "M-:6-R;W-O
M9G0@5V]R9" M(%!R;V1U8W0@9&5S8W)I<'1I;VYS,RYD;V-X.$))300E
M   0FJ;+)F2%&&@ZFEH+VEG$8CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!S=0(0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 3<    !  $!-P
M  $  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              /T   >K          $
M                 0             'JP   /T
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   /T     4F=H=&QO;F<   >K
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   #]     %)G:'1L;VYG   'JP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !3A"24T$#      &=
M  $   "@    %0   >   "=@   &6  8  '_V/_M  Q!9&]B95]#30 "_^X
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M!;C;F>\@[F\,_E#_ (1<.DB*_J_\]:>+7YO^8__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    D   "PAVD !     $   "\    Z    3<    !   !-P    %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#(U.C Q.C(T(#$S.C X.C(R
M ')R,3<W.#8U       #H $  P    '__P  H ( !     $   >KH , !
M  $   #]          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$!3D5X:68
M $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M"0   +"':0 $     0   +P   #H   !-P    $   $W     4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C4Z,#$Z,C0@,3,Z,#@Z,C( <G(Q
M-S<X-C4       .@ 0 #     ?__  "@ @ $     0  !ZN@ P $     0
M /T         !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !
M/@$H  ,    !  (   (!  0    !   !1@("  0    !              !(
M     0   $@    !_^% !VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M8W)S=(.$A:&CL<'3!S,T0U5E@I.4LB1$163#T?'_Q  9 0$! 0$! 0
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M#^Q;=OZ5<4:,->;?>8XBZAO-WU@9T_+YB'?E<5D3>;V'%IO-V#P<:373 _\
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M,D8<#JX 85H9>W+>/%5YB0#GBL8@;$ 0, J=L#'<0.7N4D0U.\^2LM AC!
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1/!@/B4DE8PBGZ)*<FO+/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>cv-20251231_g13.jpg
<TEXT>
begin 644 cv-20251231_g13.jpg
M_]C_X  02D9)1@ ! 0$!-@$V  #_[1& 4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $P< 5H  QLE1QP"   "   < E  "')R,3<W.#8U' (% "M-:6-R;W-O
M9G0@5V]R9" M(%!R;V1U8W0@9&5S8W)I<'1I;VYS,RYD;V-X.$))300E
M   0FJ;+)F2%&&@ZFEH+VEG$8CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!S61:
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 38    !  $!-@
M  $  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              00   >A          $
M                 0             'H0   00
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   00     4F=H=&QO;F<   >A
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $$     %)G:'1L;VYG   'H0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !3A"24T$#      '!@
M  $   "@    %0   >   "=@   &Z@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M7&<]U%):T0'&MAU_E.VK,L^L?3 :Q5AUQ$.<ZFL09'BSW*'6;[A@FM[I8^(
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M '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8
M   ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M    %    )P!.P "    "0   +"':0 $     0   +P   #H   !-@    $
M  $V     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C4Z,#$Z
M,C0@,3,Z,3 Z,3( <G(Q-S<X-C4       .@ 0 #     ?__  "@ @ $
M 0  !Z&@ P $     0   00         !@$#  ,    !  8   $:  4    !
M   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0
M   !              !(     0   $@    !.$))30/]       (
M  #_X0%.17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@   $V     0   38
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-3HP,3HR-" Q
M,SHQ,#HQ,@!R<C$W-S@V-0       Z !  ,    !__\  * "  0    !   '
MH: #  0    !   !!          & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@
M1@(. P$B  (1 0,1 ?_$ !L   $% 0$               4  @,$!@<!_\0
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M*(-CK$O5W>U?*HWN#$S*%+00H"\-SI"<K(VU DI4"+VUA%U;;FY*=C$SB>R
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'!G=-K&3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cv-20251231_g14.jpg
<TEXT>
begin 644 cv-20251231_g14.jpg
M_]C_X  02D9)1@ ! 0$!-@$V  #_[1$"4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $P< 5H  QLE1QP"   "   < E  "')R,3<W.#8U' (% "M-:6-R;W-O
M9G0@5V]R9" M(%!R;V1U8W0@9&5S8W)I<'1I;VYS,RYD;V-X.$))300E
M   0FJ;+)F2%&&@ZFEH+VEG$8CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!S8S^
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 38    !  $!-@
M  $  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              0,   >C          $
M                 0             'HP   0,
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   0,     4F=H=&QO;F<   >C
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $#     %)G:'1L;VYG   'HP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     CA"24T$#      &B
M  $   "@    %0   >   "=@   &;  8  '_V/_M  Q!9&]B95]#30 "_^X
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MH\W?2*(^K-MNL%CFU-WN]KC/YSM?:@78O5F^Z@"]C>U;H=_F.V_]4HN(MGA
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M7T9HZC[/5=+>WMC7S]Y5UOVLL_1?9@9_2>IN-L]]_P!%>6)(2KP^O$H7X_\
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M/_-?_]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   !-@    $   $V     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,C4Z,#$Z,C0@,3,Z,3$Z-#< <G(Q-S<X-C4       .@ 0 #     ?__
M  "@ @ $     0  !Z.@ P $     0   0,         !@$#  ,    !  8
M  $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !
M   !1@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0%.17AI9@  34T *@    @ " $2  ,    !  $   $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    )    L(=I  0    !    O    .@   $V
M     0   38    !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-3HP,3HR-" Q,SHQ,3HT-P!R<C$W-S@V-0       Z !  ,    !__\  * "
M  0    !   'HZ #  0    !   ! P         & 0,  P    $ !@   1H
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M7$*PL]JH3"OA<5 %ZA/I%T+![C&78ZU#QZ"BND3%NO[JJ\/?[GTQS]<3%_\
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M*R#BG;)1<$>L1K=I#C-R![L:\XGN[-],,>@6C%>)BVHJQ#7TJ2;$><'3;O\
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*)#UQ0/EF_&3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>cv-20251231_g15.jpg
<TEXT>
begin 644 cv-20251231_g15.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1;T4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M    3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT
M<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D
M;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!O
MX            $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L
M=                %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A
M=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N
M=$8C4FQT                5&]P(%5N=$8C4FQT                4V-L
M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             E    =0          $                          0
M           '4    E                       0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   E      4F=H=&QO;F<   =0    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   )0
M     %)G:'1L;VYG   '4     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      ,S@    $   "@    ,P   >
M %^@   ,L@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ ,P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M03]RAR9Y2-1/"$0P@#U"R\[^P^D3MVV$GMZUO_I1#MZ)TUC2[99 '#;K2?\
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M#;TRAPC5CB/:[N/W2YJS6/?2]I8]UC&G5DD@CET+:HM8\->WW-(DD<0G3$X
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MRWCU_'LL])6<7RC;Z-?)\W7ZO__9.$))300A      !5     0$    / $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J
M    "  ' 1(  P    $  0   1H !0    $   !B 1L !0    $   !J 2@
M P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D
M    T    2P    !   !+     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#(U.C Q.C(T(#$S.C4R.C,T   #H $  P    '__P  H ( !
M  $   =0H , !     $   )0          8! P #     0 &   !&@ %
M 0   1X!&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $
M     0              2     $   !(     3A"24T#_0      "
M    _^$!-D5X:68  $U- "H    (  <!$@ #     0 !   !&@ %     0
M &(!&P %     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "
M%    )"':0 $     0   *0   #0   !+     $   $L     4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C4Z,#$Z,C0@,3,Z-3(Z,S0   .@
M 0 #     ?__  "@ @ $     0  !U"@ P $     0   E          !@$#
M  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (
M  (!  0    !   !+@("  0    !              !(     0   $@    !
M_^%"1VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E
M9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z
M>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O
M8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T
M.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C R-2TP,2TR-%0Q,SHU,CHS-"LP-3HS
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(U+3 Q+3(T5#$S.C4P.C(R*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R-2TP,2TR-%0Q,SHU,CHS-"LP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R
M5&]O;#Y4;W5C:%5P(#<N,#PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E
M<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL
M;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.D8V-#DS031&,D-$045&,3%"-#$W1#=!.4%!0C V03)&/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.D9!-#DS031&,D-$045&,3%"-#$W1#=!.4%!0C V03)&/"]X;7!-33I);G-T
M86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z8F0V9CDU96,M93-B-2TT96,W+3@Y-&8M.#)F-6$X,3 S-S=B/"]X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I&-30Y,T$T1C)#
M1$%%1C$Q0C0Q-T0W03E!04(P-D$R1CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-2TP,2TR-%0Q,SHU,CHQ
M,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\
M+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC
M;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]P9&8@=&\@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@
M87!P;&EC871I;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T
M;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D8V-#DS031&,D-$045&,3%"-#$W1#=!.4%!0C V
M03)&/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(U+3 Q+3(T5#$S.C4R.C$Q*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M1CDT.3-!-$8R0T1!148Q,4(T,3=$-T$Y04%",#9!,D8\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M,#$M
M,C14,3,Z-3(Z,S0K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D9!-#DS031&,D-$045&,3%"-#$W1#=!.4%!0C V
M03)&/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(U+3 Q+3(T5#$S.C4R.C,T*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D8Y-#DS
M031&,D-$045&,3%"-#$W1#=!.4%!0C V03)&/"]S=%)E9CII;G-T86YC94E$
M/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D8V-#DS
M031&,D-$045&,3%"-#$W1#=!.4%!0C V03)&/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M8F0V9CDU96,M93-B-2TT96,W+3@Y-&8M.#)F-6$X,3 S-S=B/"]S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R
M;V1U8V5R/E1O=6-H57 @-RXP/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P
M.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB
M=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=
M)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:
M%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*/_  !$( *@"$P,!(@ "$0$#$0'_Q  <   !!0$! 0
M   $  (#!08' 0C_Q !/$  " 0," P4#! T)!@<! 0 ! @, !!$%(1(Q0083
M(E%A%''1,C6!L@<5%B-"4E15D9.4H=(D,T-R<W2BL<$E-&*"DK-$4V2#A.'P
M)C;_Q  : 0 " P$!               "!  ! P4&_\0 *1$  @(!! $$ 04!
M 0        $"$0,$$B$Q01,B,E$S!11"87&!(__:  P# 0 "$0,1 #\ ^==4
MO;K[97F+JX'W^3^E;\8^M"B\N\_[U<?K6^-.U/YSO?[>3ZQH85"!/MMU^57'
MZUOC2]MNORJX_6M\:@HC3[*XU"\BM;2)I9Y#A5%0@EO+HD#VJY.=L"5OC70.
MR/8/6-45+C4[N\M+9MUC[QN\8>XGP_36L[#=@K32 +F]"W.H ;$CPI[AY^M=
M#MXN% 0/%UKG9]97$!W%I?,P/1NS.GZ58B."#B'X32L78GU)JXATZR4JRVL+
M#U6E')][X"<$\J,M^$1DG)]*Y[S3;[&_22Z05;6.FMN;&VQ_9BB&TO32?]PM
M0WI&*K4N#%)F/EY'D:/2[22,<##UWY&J]67V5Z:^A[:5IK@_[/MOH2HUT72P
MH+6%O@_\-/2X"\7$WTU5W>KB&81.PX">8\J-99/R6L2^B673=+@< 6<&#U*U
M+#9Z: 3[':>_NQRJBU/4T8\2G<# WJG.O&2V(5_%G!J_5G]D]*/T;!K;31_X
M2TYY^0*&EM]-#9%I;G/0(*R<NJ$_)<C(P<FHSJN_"&.P\Z%Y9_8/HQ^@[M1V
M4TC78.'@>VF \,MM(49?T;'Z:XAVQ['ZWV>>26*[N;NP'],DC97^L,_OY5V1
M=49L%20/*O)[M9$"'!XAX@:8PZJ<.'RC')IT^CYL]MNORNX_6M\:7MMU^57'
MZUOC72.V?8J&X,MYHRB.899X/P7_ *OD:YBZLC,C@JRG!!&"#75QY(Y%:$9P
M<'3)O;;K\JN/UK?&E[;=?E5Q^M;XU!2HP35=ANT&J:3?W]U8ZC+;S^PRQB5I
M#X0Q13@GD<$X/2H=1UW4PJ+'K-ZQY^"\D/\ K53I7\UJ7]U/_<CH<\JA5A_V
M^UC\[ZE^UR?Q4OM[K'YWU+]KD_BJN S6B[/]GWO%%Q=ADMAR'(R>[T]:&4E!
M6P\>.626V(M)N=?U&0B+5=1$8^4YNI,#_%O6TT=KZS&?MGJ$CXW9[J0D_OVJ
M*WCCACX8U5%48"@8 HB)@J@D?32&34.?"Z.S@T<<?+Y98G6+X-P_;*[XCT]H
M?XU+]LM07'#?WI)Z>T/\:J+>Q$EP9')+'?G5@@&'4G' >?I6*D-;$&_;2]0
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M$9R,D[FJYHB)2A%;:6RX$WYCS%4EW:9GX^F-Z+%GM\E3Q4C/RX&0>E1"-VW
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M+SB. <@^E5X-+L;<W0CV Y],U"+AF'R.+U\J GN%7/GT)J>WDRF>( T+OLB
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M(S^5C^P&?MQ=8QGV1^?]9*WUNZD A0IY;U@>P'SO=;_^$?ZR5M(6"A@3G?\
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M+D#AC&3Q$@U>V$A1%!&0:'6V0GQ+R\JL;)5 P/D^M:%I46*!2JG'3I4I*M&
M.8\ZAB)R O(5)MGQ#%0EBD .%# &A&XQ(589\J)=AR"[5&7 .6&]$D"V!:D<
M6EQS&87^J:XWV5.-8@_J/]0UV2^8/;W6_P#028_Z37&.S4BQZO;%R #E<GS*
MD#]Y%.:?X2.1KOR0.T:0^-#5,8V&]6=BQ$.1U%46B72R6@A*D'&/=1]M.8'[
MMN72N;)#"+8.P&W*I(KGA.#RH(3[9&]->3[X#U(K/:'&1HK>ZP0%JVM[A<<3
MX)'*LA;2GB '.CHKG(PS9P:!Q#3-E87/%EB1GR%6,4R.<'Y7.L7IUUXRJM@
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M][ILTX5$BF1EZ]V=Z;%97:\(,,H8=2AI4J!Q1K'(Z'W4%PH21(9"X.#X#O\
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;0V/9WL]K2:1 K:1J*G+[&V<?A'TI4J50A__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>cv-20251231_g16.jpg
<TEXT>
begin 644 cv-20251231_g16.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1%^4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             /H   =@          $                          0
M           '8    /H                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   /H     4F=H=&QO;F<   =@    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #Z
M     %)G:'1L;VYG   '8     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !3A"24T$#      '5P    $   "@    %0   >
M "=@   '.P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ %0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M6?C76>E=C[&Y+6P]KB6^H&EWT]/Y[9_7>G0C*&DC:R<H&088S[FM;6Z^PO\
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MM:X/KQ?M0;_K_@]?GXV%Z_\ E#J&=ZGYN_!JC^QMZIL0V8_0H$9^5_[!5_\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J
M"  ' 1(  P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P
M  $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D
MT    2P    !   !+     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#(U.C Q.C(T(#$S.C4Q.C0U   #H $  P    '__P  H ( !     $
M  =@H , !     $   #Z          8! P #     0 &   !&@ %     0
M 1X!&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!-D5X:68  $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!
M&P %     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %
M )"':0 $     0   *0   #0   !+     $   $L     4%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,C4Z,#$Z,C0@,3,Z-3$Z-#4   .@ 0 #
M     ?__  "@ @ $     0  !V"@ P $     0   /H         !@$#  ,
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@ 1@(1 P$B  (1 0,1 ?_$ !P
M  $% 0$!              4  P0&!P(!"/_$ %40  $# P("!04("@\'!0
M  $  @,$!1$2(08Q!Q,B05$(%&%QTA8C,H&1DY2Q%1@V1F-SH:+!T1<D)C,T
M1%9B9'2#A+*SPB4G-4)%4E1#4X*2\?_$ !H!  (# 0$               (#
M  $$!0;_Q  J$0 " @$#! $$ @,!         0(#$1(A4003,4$B%%)QD3*!
M(S-A\/_:  P# 0 "$0,1 #\ O72SQW?;!QL:"VUY@I1312:.K8[M$NSN1GN"
M#6_I'XBJ)&-=='$DY/O+.7R(1Y0+C^R66C_PH?K>A/#5(YW:<[8=YYKC=5;*
M$WB1TJ(1<5E&ER\:7X1M<VX.Y;XB9^I#W\;<3:P1="UF>^*/V4QYF!IQG3C;
M)W70HVR-QH//O6:/52^Y_LT]J'""'NNXE+=;;HX-Q_[3#^A0*SC?B>%H+;L[
M/XJ/V4]#1Z(])! Y;*#6TFC+'M#LC*-=5/D'LPX!DW2'Q@QS@+S)MR]XB]E!
M[ATG\;PYT7Q[<?T>+V5(JJ8&32!D!5R[T@Y'=V$^%\\^0940QX"%CZ3^/JZO
M?$Z_RF-N"3YM#M^:KA2\<<7R,)=>G=_.&(?Z52N$+>V*FFF>/WU^WJ&RN$$$
M4C "S(QW[+0[GR+C3'@D^[;B\/(-X> .7O,6_P":N?=QQ=I.;Q)GQZB/V5!+
M&PR%H!(.XRI!C88^R-SNHKF4Z(\#,G'_ !CGL7F3'XB+V4Y3]('%KSI-Y?JQ
MOF&/V5"D@9J>9&@XWR%!ZML,N^^>]$K6RNS'@L9X[XL(VO#P?Q,?LII_'?%^
M>Q>9/F(O90;<9T#X7)2VQ QC5C?FK5K![27HDOX_XQT.+;R[(_ 1[_FH-<.D
M?CM@(@O<@.-L4\1/^%370-).G88P1XH;<*,$C2#CFB5F?9.W'@&NZ3.D;3MQ
M&\'^J0^PAAZ7ND=E6V%_$3SD[$4L._YB)OHF-:[+=RA=1:F.GBD#?@O!]2BL
MD7VHEAINDGI!>.W?G_1X?94B3I&X];LV_2$^/F\7LJ!!1ZG#;&?0BL5K:0#\
MJ!V->R^W'@&5'2/TA@99Q'*W^ZPG_0H4G2;TD-:2WB63/@:2'V%8WV@:3V<D
M*,;(TMU!@^1#WVO93IB_14)^F3I(@<6OX@D]!%)#C_ FV=-/2*7;\1/ \32P
M^PBMYX=#FGL#!50%J>RIDA>W)8?#N3%U&4#V$6NGZ7>D)_/B)Y]5+#["GQ=*
M'2%(-N(9!_=H?851@H3 YI(RP_D5AM]+K P,'QPDSZB2\,9&F/M#U5TJ=(U+
MVG7Z1[,]U-#R_P#HHO[,O'VH9X@>,_T:';\U3G6_+2"W(.Q]*JG$-F-,XS1#
ML:MP>Y57U+ELP94I>"\VSI6XVF(ZV^N=ZJ>+V5<[3Q[Q14!O671SL]_4Q^RL
M8L8^"0/4M!L#RUPSA8^IOL7B3&55PX--BXFOY+/]H.=GF#&S]2L5!?ZZ2+,M
M22>1[(V_(J?9<2EVL@D#&"B#BZF>X'!8>_P7+EU=WC6_VS2J:^$&ZKBBKA./
M./S0@E=QQ<(2=-81CNT-_4A=ZD;)3Y8X9QW?6LFXINDU&['6.))/R>"?19=8
M\:W^V+LKKBLX1;N*^E7B.FB=YC=3&[. >JC/UM5,?TQ\=ASL7]^/ZO#[*I-9
M<#-+F8.?\:&OD!<=.R[="G&.)-LP3TM[(T7]F3CPG'N@?GN_:T/LKIG3%QYG
M!O[S_=H?86=P]MP1*DI)922QCBT<SC]*:YM>64H)^B^Q=+O'!W-]D]7F\/LJ
M3%TN<;]H&\%WI\WBV_-5=M'#\DX:Y_89XDJQ1V>CCAP_42-NR%ALZU1>$Q\>
MFRLX'STH\=2,U"\N:T'!<*>+'RZ4<M?2'Q9YOUE5>Y97OW8WJ(@ /3V51ZV)
ML,F[GO8T[,=L/D"F4<P:>T<I4^HLE'9L.%,4]T:!#QOQ9+N;J\-'A#'[*D3<
M:\3A@;'<WY'-QBC]E5RVU;" "-L<D8B<Q^>R-EBEUMT7C+'+IX/T,U/&W&+-
M19>GX'X"/V4(FZ1N-H_^M./]A%[*)W"$.9V0,?6@-11ZB21S3J^LL?F3(^G@
MO0XWI-XV)Q]F7^CWB+V5"KNE3CF'5B]O;C^CQ>RFA1MC=J'=Z%,K[137BDUP
M#3)&W!P-RM<+Y2]B)PC'RCOB;I<XPMMZJZ2DK(G10N !?&2[!:#W'TH-#TW<
M<22 "H@TGOZH_K3G%-D:+S6U<CP(W.;J!.#\$#]""T%$VMERR'13MY?SDZG#
M@G+CEF2%<)13+Y:^DGC2HINOJ;C!&''L,$1W'CG*.4G'G$DQ:'5Q&1_VJH4U
M,W2QF@N:&Z 3W#U(Y0 0AC =VX&P[T;2'QZ>'!;8N)>(CI,E>\ [;)X<2WES
MCIN4I:TEI^)"8@\-)&SN8PNJ>-S6=MY<[Q*6_P#V[&1Z:M^BR17F[.CU.N,X
M.,XR/U+A]]N;(G/=<:D#NW'+QY(3&YQ;L<=Y3A()(=VSGO\ !(DWR_VQGTE7
M! XRXKXKMUJ=662M,_5;RLD;DZ?$8QR"HUAZ7^+[A7OIYJZ)K?-YI0Z./<%L
M;G [DCF!W*ZW<$TI'9TC9S<<^Y8G8XA3\6UL+1I#(*L > ZIZ.$FX2Y7_68K
MZ(P3P@[%TR\<D F^N=R_B\7LHC2=,/&3FYDO#C_81>RLIB+M#0/ ;*=22/9M
MAN#S[ULG*6/(<8K@V2@Z4^*)0#)=SO\ @8_95EM''U_J7$ON1<,X&8F#]"Q>
MTATKV@''J6C</4>&-UD[C( 7.MNG%_R9JA7!KPBUU7&G$+,Z+B\9Y>],_4G^
M&.+N(JKB"AIZRY%\,D[&N9U;!EI.XV"#^;8SEI)'@BG#M&/=#;9=&"VHC/Y5
M*NJEE)MARJAI>R-MPDDDN^<4^9^G>-KNDTD\_,H?K>H]D+(HV[[X77E!2:.D
M@XSGS.'ZWJK6NY.;@%QPN!UL&YLZM#^*-%;5ZFM&HX4R"H8X,:/A?6J5#<P[
M&^-T8M]8#IR1Z'+GM-&G465D<K&DZ@1RTX7,D)<PG;ENO:.H+F ..<C<KIU0
M&O&2"W.ZD9!1>2MW"@ZH:\'+M]E7:VC=("_?GZU?+AHEA(#L@\L(554[.IPT
M#NR? +17;R7)9 UIA$5OB8,Y)=R[MT4IW/:0QN02.>$[;8!YLQVD9!+=_64[
MU19(2P$Y[SW+3&>08Q(KX&ES T $;G?.5,@:,!N ,<DQ*>I:7$ZB#D-4V .E
MB#F-]&$6<%3CL0I])!#@-1VY=R#UK 6D8WSW(U<:<X+_  0">9K'CK.XIU;R
M+2P<Q.,;@'@D8VRB\48E8UQ/+TJ)#+#*S) .-\J4P ../B&4QL$Y?&&N&G<
M\@4Q.PG.L9VY+MV0X]LG?N3$KLG))(0Y*P00SK9< X^+9>5%, 6]D8)4R(L<
M_!):O:G VVP-QA7DF#VDBTN&!E'(6!D8<7=W/"'4H!8QQ!R[=%J:(3-(<<G"
MIE'#'L=(\-_Y>>Z]#<LT@@D\E)EHV#) .HJ#3$LJ6QNR,'&X_2DL.*&ZJC,C
M")!@XV57K+2!7/D:!VF#<#ORM%J(!U!+AG 0R2DU3LT@G(S^5)[F L(I_P!A
MP8'![004_::)H<6/#0YO-6Q] #,0_(&G( 0ZJBZBN88V@-D&"/2$,K,HO&!F
M.GC<_2WDH%YMC'T[VD;$8W1*=WFCP_;!V*595LEBY@@\PE*3R4S+X(?,ZM\9
M!&DX5NLE3H<#MZD O^([BV0<GC<CT+JFJ](V*;8M:R!%X-,M]PT2-<TC41OD
MHW'6!\693@D9YY65TUP/+)V[\HG'>G8TZR%SY].\[#U,,\0U)@RZ$]G')9'Q
M9<75,^EVQ!Y#N5KN]U+@\:B3S6>7&7KZE[CX\UT>AJP\LRW2VPB&W4_)QG/?
MX*2:![7C+FO! (+5Y!$0>_M(U04KY-FMRNA99I$1AD9H+;J([(^-7*S4A$0B
M#BYOAW*)06R5SF@G&>85VM%%'"P @<ERNIZG;9FZFE"HK:QL8,GAL%)FB8QC
ML@ <\Y3E1(Q@.G.P0"YW$XT G/(!<Z.J;-+22!U[#"3HWR@P$P ?"W4 =\$+
MJXWN.F#HV8?,=B__ +?0%"I1Y[32N-=2TG5L+PU^Q>1W# Y^M=.N#4=S%.:3
M+!:Z[3\/Q5AI;BTGLGN68171T9Q*22/^;O1>ANX.#JRALZ9O<*%JP:*ZH:8M
M1.=N2AS2-+3@\_%5Z"Z!P )RG7UK3R. L\:6ANK*)DQQ'V3WJ7P@)7W&9K3[
MWIR[Y4$Z[5G<*T\!&ECJYI)I"UY&".XK73!B+I)19"XUI7354;='8>[&4W:J
M".!K6-#=#3OZU9;_ &2JDI#6-&8'.U ]X/</5LA%N+6[2-S(3V@=CG"V4_P7
MX,E&'!8)T-M;I(()+>_Q4ID4#>VT-SRRTY7M/5,,1+3DYQMX<LIM\K&C0W '
MH1MX-,1^*;3OLUNK SS]2E0EG6%AU.<2"0.[P0B5A$CAJ&XSA3J9Q@@)D>>L
M &-(SD#Q*S3F/B3Z@.8QX8W4!X\BF7%P#G1N SN,GELF(9B_8R:G$\B,8"YF
MJ QI#N0.=(W^-*;&>$#KO4=7&X:@=0P[T%9'8I1/Q=6R- :UT%6<#D/>GK0>
M)[A'3T4TA)][8>S^A9KP<=5]D.,9I*G;^Q>GU_ZY,YW4OXL"4X:0T%V-@B+-
M&MH8-L*# .RT>@?$IU*UH.#G"TS9446OAV)@E:3L%H=NF;$QND[^A99;Z@Q2
M;' !V5HH+IAF"2=ER;XMLUUO!>XZH=;EQ)W^5'.')!->Z'1W5##GXUGD%PUO
MR'>I6[@ZJ+K];FMP,U#,X]:56FIQ_*"G+,6;NDO4EZPXA\L^442.DEV/_"A^
MMZSZDF+-LJ_>4:X#I)<._P RA^MZS6*0^.W@N5?',V=*EX@@]2U1#\'XE8[9
M4' SONJ1'+@M/@4>M]3V6X6&R V++W37,Q8"DMN4,K'%PR?!5)E2=. =BGZ=
MKBXEKMCXK-H0Y,,S5S0]C=PTD<CA>2U)#VG&1SWY*%+3DX:X#TJ--K: PYV"
M.*038<LE6'-GA+NVSMC/@2C]-$)&=8W)..16<TE6ZDO-/([.C][?Z6DK0*!T
MFHMCVP<')YIV. 5+ Q!1MJ)W.TX V \%/,(B8#W>CFIM.QC@"UVDYW.$JAH:
M7 8.-\E%EE2F!KA&YL8)( \%6*ZE8^;M-Y;@JT7*<&,M) ]"JU7.<.W"?6+U
M$%T75/[#CZLJ5#-AIWV]:%SU7/<97,4Y."=O I[8(8ZWWLD'\BC=>T'!)SX*
M"^I.DC.3ZU"Z]SZ@$8TJO1>0XQPUGO)W7KVN=G/,*)"XY#LX'I4B5^VSN?I0
MY+;"4$H+0"< <D:HYM,;'- /=@JJ03:7 YSX(I150);J;V0=]U&]@<EP@GBD
M)#=\<UVR .D!T@_$AE#5 9.Q#O%$HZN,-R"#G?/AZ$F1-6#JH=N&Z>["AEX9
M5- &Q;W#TJ8Z:/&IQP2@]+5LJ:QT@QIU$-QX<DB2V#C+(:PQT.HL((/RJG7^
MH-/+ ]N/A'(5MEK&-A!Y#!'QJD<12><2Q@'8$D@#Q0060F]R+<;EU\;L#&VW
MBA+JU^C!.R:K'Z,G4,8[T%K+@V*,]H)T:\[(5*6!GB"K!+-M\J#!5'.QW]:%
M5]::B8$'LI@3'DM:IV$J6Y98:_2X'FNI+CL=\#UJN=:[(!.%ZZ1Q&Q0]E!:V
M$:RL<\$-=S&Y4-D;9BW(W QD)F)I?C(1&AC <,C='M!; I:O)/MU PN!(RK/
M04T<>,-"%T@T[X4]M1U8RN?:Y29JK219*5D.,D@$)R>J#6D,*JYN6G.#LAUR
MOW5,=VO1A9H]/*3']Z,$6.Z7(Q-9E[':QD!K@3\?@J?=[V&AXC.7D8SGD@-9
M>))9'MR<N\"@\E0Y[SDY!73HZ)1W9ALZG/@(-G,TN_BK79>'I;G XQ55(PM;
MJ(EE#/BWYE4:)QW/<IL=:]L>D$CQW6BVIM8CL9T^29<8_-Y'-+AD'N4&2J'6
MZHM33WY*:EJ=>SMQS]*BRO:7' ('I.4R$,+#)DMEOGI_L4ZHFN+&U#<XA+3O
MCTKN@N7G$FEI]*IK7;C(.%.MTCXY 6#).R&="?@.-K1HM$1*\,U=H\E>.%Z4
M4U+4:G!]0YN6=GX."LOMLE9%U<[*<NCS@G&5LG#M533VDL<QK97'29&C!'Q(
M(5*&[ ML;1;XQ'=^%Y+;52&,-'9>P;M/,?E6<\11BA<)8Y'N?$-+SIW/I)5Y
MMU,>J>Y[]$;AG(//N4"IMU#-,_KHS(79#LGF@K?PC^$*Z>6F**?0W&*6,,:S
MLO P0,8\43I9FN9,7'0"._N[@4(J>$JBDJ*B>GE\VIVGWO7OJ!0JIDJJ9[8I
MGES,C=KL@JFF;XS7HN'5:]!+]6-\-YHI' QL+G!QP< ;<BJU:*ET[&@G<')V
M^16&FFZQA<TL+?$'9(E%C5,YJF9':&[=QZU7[I6FGA>Y^D:1G5R__4:KYNPX
M;:AV05G7&U1+);I&,[/5@NU XY*H0U/ ,Y[;%/XDO3[C(8FY9$PDEO/4?$KS
M@@_[;<<[BDJ<?,O0 OU.R3G*/<$_\:?_ %2I_P EZVSBHUM(PV/,6P3"XD G
MP"G0;\D,B/9;Z@IU._(5S0V(1B=A$Z:H(8-T&#\;A28I"=B<E99Q')ECM]47
M$9Y]ZO? E1GB6U#?+JF/?_Y++J.?1+MS*O7 %07<5V49V-9%_B"SZ/FOR6Y;
M,^J$DL)+T9R3Y0\I)V.DQW]1A^MZS%KB"<Y6D^4L?]Y[N?\  8/K>LN#L.QG
MY%S[5\F;JW\43HY,HM0S=D<_!5X/(Y*5256@@+/. U,M\$V -\^E%:*8.&QW
M*JE)4ZAS1:EGTXP[!*QR@QL9%NIGN<3X!>U(C>[EVL*%058,?=J[T]43#P'+
MQ6=)IC$R!5T@D!.X(Y^*M/#]VC,36//; P2JC45K1G6<'ZU =<!3NU1O /CE
M:J\@2>37!.S02UW9\4)KKCH<6@Y!W)5-I>)M+2"=L^/-,5-[:_.'9/><K1&*
M]BT%[O<B[5@=KNR56ZRX/QI<, IB>XA[B0?5Z$,GJ [5DY38HFHE/G&ZZ;5C
M&VZ$N?L<)AU1IV!PCTE9#,U8!R.^$[0O!;G(RJT*GK)-G9QW(A35!Q@*FL$3
M+*)\- R $U+5%K<9R4+CG+B<$IWM $NW:@9,DV.K.  B%#5R-U9'>@%GJF5A
M>-LM.QSS1V*'GN$+*U!-EU<R3&<;=RFLO+61Y?@_&JX^, ESGC2-SGD%6[UQ
M'14A,44HFD_F'("N,6_!3DD7JOXC?/D,)&V H]#<WPMT@;>*RSW4R-ES'$TC
MQ<=_R(I2\6MZLF6,9Y8"N73RX*5J-0DNLDT88-@$,KJ]D8.>TX!4FIXQ:R("
M(9U-V.0JU<>(*JL#P7!C#ML4$.EE+R4[4&^([^TS&*G(<1\(A5:6KDF<7/<2
MH9U/U$.&VZZ:.R-P<K?"I10AS<F2&/WYIYCM^[XDQ%'JSCZD[C?;O4:+B/AX
MSS3@))QG8IAHU'OV3K <Y(V]:6T,)D.WBIU,X-\% B!RI!<8\^@)$ED-;!B&
MITCFI,$WG$S(FN U''J58=4\^UA0YZ]S '1/+7C()W51Z?425N$&;O6.BJJB
M& ZVQ'<@_E5<JJI[W').#ONHYG<3G7N,[^":U$.R'!P&^XV*V0J43/*;EY$7
MEQ]*Z81E-XU.R,9.^!R7H^%C4 F8%DD-?U9>UF0O ]W,[%=LJW-I^JP'=WQ)
M@'&-\JL!)CK7-U9<"1X X36-EZ.:<9'J!QL?2J\!>3AHR44MC6YR[Q0QNY[]
MMD]'(8]P20>6%1,&N\'5#&P1B>HDD . P# &ZU2W6^W24.O!;-G4-\#XU\T\
M.WN:DFTMY9R-U>7\4UM12&&.JCIW%N!@9*"2R*<'G8U9UQ;3N$$D[69.PU=R
MAUEV;%O"=>^ZH]TCCCOM7-43%VIS3\+EV1LI,E7$^ .ADY>![O!9JH_XX_A%
M06(HN\M;%?(Q"&9(9I()V*"BTFGIJB*:1FD#(+FAP"KU+7BD(=$\#.Y[7-62
M"^TEQH71R2L$[>[/-'@<FT :5YI9'.<R2*F9V.M:,!N3M\>=D7%YBJ(2UATA
MK7$O'=Z0N:*A^RT%11/ ,4FY:YVV<\U0.*:*HL5<^$OQ 3ANEV<>@H)13-$9
MYV+;<;U'U;60ZM(: =\GTJB<45!GC."X-?@=H[G'Z%';<"69.#G^<H51*)W9
M>\>C=#&.EY"?@ 21EKLDY]".\$_\;=_4ZG_)>A]2U@SV@/C1+@LM^S;\$$^:
M5/\ DO3K)9K?X,UB^+ +-F-[M@I,<C2[L[!1FCLM]073!W(V@UL$6.R$[')C
M?)4.,G!R?E3C7[)+B&F$8)L/!_*KMT=R?NRL(S_'8?\ $%G392-]U<>C.JU<
M<</-S_'X1^>$O1\D6WLS[022279.<9;TC=#]%QKQ&;M4W>JI)#"R'JXHF.&&
MYWR?6JP/)RM@&!Q%</F(TDD#KB]V@E.2V3$?)SMI^^.X#^PC73/)UMK3]T5P
M^8C225=J'!?<ER2H.@*@A:0.(*XY_ ,4J/H-H6<K]6_,L220OIZWZ(K9\DN+
MH;I(\8O=6<>,+%Z[H<I'?];JP3X0L220_2U?:7W9\D>;H3I)>=^K!ZH&*$_H
M%I''[I*_'AU$:22)45KPBN[/D;CZ *-CLCB6X%I[C!&G#T!T.?NAK_F&))(N
MU#@G<ER(= = /O@KOF&)'H#MY!!O]=O^ 8DDIVH<$[DN3AWD_P!O(Q[H*_YB
M--/\GFVN^^&O!_$1I)*^W'@KN2Y(\'DX6Z)Y=[I;B[/C!&IT?D_VYKLF_P!<
M3^)8DDJ=47Y1:LDO9(CZ";>T[7VM^98O*CH)H987QMO]<S4,:A"S9))5V8<$
M[DG[(EM\GZBH"-'$E>\#N=3QHN.AFE VOM7G\0Q))6ZH/T5KER![IT Q7(D3
M<6W)L9_]-E/&&H3]K!:LD^Z>X_1XTDD2BEX16IB'DP6H'[I[C]'C70\F*U#[
MYKE]'C225X1,L7VL5J_E-<?#^#QI?:Q6K^4UQ^CQI)*:43+/6^3':1G]TMQ^
MCQKK[6:U#[Y;C]'C225:434SMODU6MHVXEN/T>-.-\FVU@8]T=P(_$1I)*:(
MEZY'3?)OM;<?NBN&?'J(UU'Y.5K:27<0U[LG.\$:22KMQX)KER.N\GFUGE?Z
MX>J"-<R>3M;9 <\15_A^\1I)*=N/!-<N2.[R;K8X;\27#Z/&F7>3+:B-^);C
M\Q&DDK44BM3.1Y,=I&_NEN/T>->_:R6D9QQ'< #_ $>-))7I1,L0\F2T@C]T
MEQV.?X/&E]K):M1/NEN._P#1XTDE-*)EB^UDM6/NEN/T>-(>3):A]\MQ^CQI
M)*:43+/1Y,UJ!^Z6X_1XUVWR:+4"<\27$Y_ 1I)*M*+UL1\FBU?RDN/S$:3?
M)HM33MQ)<,=X\WCW224T(FN1V/)MMC<Z.)+@W?(_:\9PG&>3K1-D+_=3<B3S
M_:\>Z22FB)-;+(WHGJ0W#N+K@[TFDAS]2?;T6RM9@<3UV?'S:']2225]-3]J
M TK@]/1;(?OFK?HL/ZEXSHLD!^Z>N/\ =8?U))*?2T_:B87!.INCGJ79=?*J
M3;DZ&,?4%[/T<1S.)-XJ!GN$$?Z0DDJ^EI^U$TK@&S]%#GG,7$]?$/ 4L)_T
MIK]B2;^5MP^B0>RDDI]+3]J+_HX=T0SGEQ=<!ZJ.#V4U+T.3R1/C=QC<M#VE
MC@*. 9!&",AN>222OZ:G[43^@']KA:\ >Z*OP-A^UXUV/)RM0SCB"O\ F(TD
MDSMQX"[DN3D^3C;/Y17#YB->CR<[8/OBK_F(TDE7:CP7W9<B^URMO?Q'<#_8
M1HGP[T$V^R7RW7**^ULKZ.H9.(W0L >6G.#CU))*=J/!.Y+DV7*2228 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>cv-20251231_g17.jpg
<TEXT>
begin 644 cv-20251231_g17.jpg
M_]C_X  02D9)1@ ! 0$!80%A  #_[20>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %P< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  AR<C$W
M-S@V-1P"!0 K36EC<F]S;V9T(%=O<F0@+2!0<F]D=6-T(&1E<V-R:7!T:6]N
M<S,N9&]C>#A"24T$)0      $ IYJ9ZF9DW7/V9HG'.*@IPX0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q =@S,T         IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ %A     0 ! 6$    !  $X0DE-!"8       X             /X
M #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      T$    &              2<   $
MF     8 9P S #( 80 P #$    !                          $
M        !)@   2<                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   2<     %)G:'1L;VYG   $F     9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $G
M  !29VAT;&]N9P  !)@    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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MJ]6OU'?RT18;?JEB1G"R^RS[?7D56 BN&C(%+'N96VL5[V-QJ_S/^,4?^9V
M;F6/L<Y@<]]M.VL,L=;:<J[UOT>Y]5GMH]%_L]"FC_1^]*=Z0F;8QY<&N!+#
MM>!V,!\'^P]KESX^I>)MV?:;=FUS (9(#Z68;[6/+-U>5LIJ_6&?X/?2RO\
M2VIW?4W"=4:_M%K06%I:P@,G9756[8=WLIV7NJJW[/US)K_F_H)3T*9W"H]*
MZ/C=*IM9C"77.#WN=R2UC*6-W?3]-C:_T>_U-BLFUX$65N'FWWC_ */O_P#
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MCMHW[H+F@@< _G+FZA]><3IK&OOIK%$M+7-K?L8P#T6RS^=W-]N_^<_TBZ;
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M$2[H'2+[6VW8X?8QNQKBYVC0QU&WZ7^B>Y.0Q?\ 6/HK75-&76XW/=6W:X$
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M!^;^"G!\$V@.B;*S!M$?DT4@F@^"6J*F:=)))"DDDDE/_]DX0DE-!"$
M %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( ,0    $
M.$))300B      %&34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    )    L8=I  0    !    O    .@   %A     0   6$
M   !061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C4Z,#$Z,S$@
M,38Z-#4Z-#8 <G(Q-S<X-C4      Z !  ,    !__\  * "  0    !   $
MF* #  0    !   $G          & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 4Y%>&EF  !-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L
M!0    $   !V 2@  P    $  @   3$  @   !\   !^ 3(  @   !0   "=
M 3L  @    D   "QAVD !     $   "\    Z    6$    !   !80    %!
M9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R-3HP,3HS,2 Q-CHT
M-3HT-@!R<C$W-S@V-0     #H $  P    '__P  H ( !     $   28H ,
M!     $   2<          8! P #     0 &   !&@ %     0   38!&P %
M     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M        2     $   !(     ?_A/Y1H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC,# R(#<Y+C$V
M-#0X."P@,C R,"\P-R\Q,"TR,CHP-CHU,R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @
M>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO
M<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V
M96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \
M>&UP.D-R96%T941A=&4^,C R-2TP,2TR-%0Q,CHT,#HT."LP-3HS,#PO>&UP
M.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @
M(" @/'AM<#I-;V1I9GE$871E/C(P,C4M,#$M,S%4,38Z-#4Z-#8K,#4Z,S \
M+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR
M,#(U+3 Q+3,Q5#$V.C0U.C0V*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@
M(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C N
M," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/&1C.G1I=&QE
M/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL
M:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(%!R;V1U
M8W0@9&5S8W)I<'1I;VYS,RYD;V-X/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F-R
M96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/G)R,3<W.#8U/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T
M/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/'!H;W1O<VAO<#I#
M;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @(" @/'!H
M;W1O<VAO<#I)0T-0<F]F:6QE/E4N4RX@5V5B($-O871E9" H4U=/4"D@=C(\
M+W!H;W1O<VAO<#I)0T-0<F]F:6QE/@H@(" @(" @(" \>&UP34TZ26YS=&%N
M8V5)1#YX;7 N:6ED.F0U-C!A8S(Y+61B-#DM834T92TY,6%D+6)D,&9D,#AC
M.&(Q93PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M
M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C-B,SAC,F0P+64R93DM-S<T
M-BTX.#=B+60W,F(W9C0Y,&0Y-CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C(P.3=F-F(V
M+61A-&,M-F(T-BTY.#@T+31A-6-A,F8Q.60Q9#PO>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,C Y-V8V8C8M9&$T8RTV8C0V+3DX
M.#0M-&$U8V$R9C$Y9#%D/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U+3 Q+3(T5#$S.C4P.C T*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C8N,B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C@Y,3%E,&0Y+3 Q,S8M-S8T,2UB,C@U+3=E-3@V,C4X
M9C=A.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R-2TP,2TS,50Q-CHT-3HT-BLP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E
M<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F0U-C!A8S(Y+61B
M-#DM834T92TY,6%D+6)D,&9D,#AC.&(Q93PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-2TP,2TS,50Q-CHT
M-3HT-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII
M;G-T86YC94E$/GAM<"YI:60Z.#DQ,64P9#DM,#$S-BTW-C0Q+6(R.#4M-V4U
M.#8R-3AF-V$Y/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12
M968Z9&]C=6UE;G1)1#YX;7 N9&ED.C(P.3=F-F(V+61A-&,M-F(T-BTY.#@T
M+31A-6-A,F8Q.60Q9#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C(P.3=F-F(V+61A
M-&,M-F(T-BTY.#@T+31A-6-A,F8Q.60Q9#PO<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N
M9#TB=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06
M%AH=)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*
M$R@:%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*/_  !$( /, \@,!(@ "$0$#$0'_Q  =  $  04! 0$
M        !@(#! 4' 0@)_\0 1A   @$# P(#!@,' @,##0   0(#  01!1(A
M!C$305$'%"(R87$CD:$50E)R@;'!"&(6,]$7)+(8)29#4V-D<W2"DJ+P_\0
M&0$!  ,! 0                $" P0%_\0 )!$! 0 " @(!!0$! 0
M  $"$0,A$C%!!!,B,E%AP?#_V@ , P$  A$#$0 _ /JFE1WJ74;V/5]'TG3I
MH+62_,S-<2Q^)M$:@[57(!8Y\SP%;BM!I77MU+%;)/IT<[ 1+<7,,P1"9+F2
MW1HT.25+1AN_ ;@G'(=!I7/-+ZZOIK:P>[L(_?KRUMWCM8IQX1DEED0?B$9
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M6$LIQ&/4@GD_:M1![.YI=4,!O8/=$7+S1(79F] H[?U/E76DC2%MR0Q*5P
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M"RS2!'@1<>62TX') [>6303"E0JPZ]M[K4HD%C>K93PP-'+X/*/)-+$!)@X
M+1J!C.=WIS4@Z5UG]OZ%:ZD+.XLQ.NX0SXW#GZ$C%!M:ID^0U55,GR&@UUP.
M:LPC\*7[BLJ5<YJS"/PI?O6DO2C FW'>%(#>1(SS7S_UQJ>H:KJDCRSVR&+\
M/;$OD,]\YKZ!;B0_>N#7MLEOK,RK"K,LKEAM[_$?^M:RZQ5LW7(.M'O4FBD6
M]A/P'C:.>:@,)>>^F=^7:.1F/KA376/:'J=EJD,5RT$,&IVI!0QJ0)XMVUE(
M]1D$>?>N3V>7E&,Y$,O;[,:PM\KM>348J;&(!C9CVX;'^*[STY;(W2-O;G5K
M<J)A-X:LN2P&T?H37!H%83+D$8.>:[1T7-!JO1W35K[O;VILGG6:? 4R_&&#
M,0,G@[?.N7ZGK#;;B_9<]HJLGM'Z@=;E%8WS+\PX!C'%9/LLUZ]Z>ZLTPV+P
M2->E;5VF7<%5B.0 1SVK)ZWN([OVAZ_:O;KM6]*A_KL'/IQD9^]:71[54ZUZ
M7$.2[7*H1COM(P?OC(KGSNLJMC'VE"'$2B9Q))YL%V@_TS2W^=_N*K-:'JZ]
MGTWI+7[ZSE\*YMK226.3 .U@I(//%>A/3!)H^QJJH+?];R)U EEI5O;WEH(4
ME><7" .&\0$H=WQ;#'R "3G''G@V_7NH+:VLM_:V$"R-:R2NDK.(XIH]PPIP
MSL&^$[<X!#8[X)=(I4 ZPZHO.GNKHIY)6?1(+(-<VZQ@DO)(R1N#C.=ZHF.W
MXF?*M1I?6VLZ=:FWU5K2ZOHI[AI3(?#,NVX$8@A"C!9<X&<_NY^8D!U:E<MM
M.O;N37?'G:U2QQ'$UN)CFV#79A+2Y'PL /MSCRR:5Z^OMSWEO$DR7GNT<"-(
M/!AR+DE\DKPWA*.2.2/L0ZI2L73+F2[TVTN)H?!EFB21XPX<(2 2-PX./4=Z
M4&56LUW1+36XDBOS<&$95HXKAXUE4]U<*0&4X['Z^IK9U!?:5-J?O>DVFDOJ
M0:=+G*6#JCEUC!C+%OW0Q'^<C-!(K3IS3+6[DN(H7+LTS;7E9E7QBID 4G #
M%0<=LY]36LM.A]!A4K:BZ22*1,2I>R^)'M0H$#;LA=C8V]L8^AJ/76G]5+')
M-=W&K3+-=2":.QG171!'^$8@< (9"2?/MGX016O5NJ]0+"VO95$5X\=U-91J
MY6X6"W X#+N0/XP()(SP1@# 3>]Z*T6]CGCGCN=DTDTCJEU(@_&'XJC#<(Q&
M2O;/-95STQID\"QB.6)DN)+E)89F21)),[R&!R =Q!':HA)IFLW5Q:S:@NN-
M<6NL+-,(KA5A:',JJ8@&SL"M'N!YQGN<U8L=/ZMNGABN9]7MTDF@]_<SH/CS
M)XI@(^6(C8.,?NXP=QH)M:]+:7;:NVI10R^\DNV&F=D!< .P0G;EMHR<<GGS
M-8/4/1.G:M9742 P37#EWD)9PVZ2)W!&1PQA0<$$>1%2E1@"E!'=(Z3M+.RB
MBNY)+R=!$#,[$'$4K2Q*!DX"%L#))P "36UT?3+;2+%;2R$BVZLS(KR,^W))
MP"3P!G@>59M*"W-+X6#X<C@]R@SC^G>K:W4,N521=_\ ">&_(\UD5;GC21,2
M(KCT89J4+##O5F-<1R"GNH3/@2R1#^$'<OY'./Z8JVIN$5\K'*/]IV'\CD?K
M5I_B&'*N)#7#^I1_Z1W*PG+&Y?D'Z]C^5=LFN$$C>*'B_G7 _/M7$_:;TO%H
ML\NN03!??;D\6\KJVXY.3SBM=7Q5^7)^OM(CT:W6:[^">Y/A6D)8;R-X+,<'
M&  !]S7-]&C?QWD"DXCF7C_Y;8KZ A]E.K=4Z;8:O8ZI D=Q%O433R%@"3P>
M",U"9.C;_1M7U..\U*SENK=)8C;W!:-W(C)!3</B4CL15)QY7O&%RF/[5S*V
MBENIV>8;52(J2W ^4XKH'LYN-NC6]O*?PS,X[^K 9_3]:B,-I-"]O%/"L2WJ
M>(FY^"F2O)[CL:ZSTEI6A7.F16UF9I;EYPL30;YADGMQ_FN/ZC#+/"R-N/*8
MY=LCK#3?"]HG4=PZ[E>\W;O)1M!/YX'/I6!HUQ;/[0>DO /AI[RI)W=@0 /S
M()^QKIW5_L;U"^US6=9_:MO%#-(UP4,D@PH3L<<#M4(]EG0S=4ZO!?V\L=O^
MSS',$GW,94)*DJ?IBLN3CRN6]+XY/J\^=6X0&:56 (/!!&<U<[51;_\ ,E^X
MKL^&2[%:VZA-L$0\/.S" ;<]\>E7&MX6*%HHR4(*Y4<$=B*JC\ZJH/"BDY*@
MGMR*I:&)F4M&A*MN4E1P?4?6JZ4%HV\)#@Q1D2?."H^+[^M>R0121LDD4;(P
MP5*@@_<5<I0    !@#RI2E IBE*!0  <"E*!2E*!2E*!2E*!7C?*:]KQ_E-!
MCFJ5[/1V"U:PLJ2(XRK#D5:1##F(60]_RKC_ +=DE:UTZ2VMF,"%S(RJ/FXQ
MG^GG71]=Z=TI+8S265ZP;C=;3R @_;=7-M2Z/O-1AGGZ9O->D"Y7P;@D D=U
M#'_/YUKC9ZVK9_B[[+]5NX/9P(X#BY1YTM@Z I\W!SGR)/K3KKJC0+WI.\&J
MFQDUZUMI C(A;PGVD,5?''&>/K7,.INB/:)*8EL=,U\1JI+)&ZA<Y] PKG^L
M=.]9:8[Q]2Z=KL%CX;N[2QL4&$;!SDCO]:MCR8X23Y5RPN79>R0Z[HFG0VT$
MSW2VKQ1(%R782=QCRY/Y5] _Z<];TC3>G&@U"6&VO08XD5UPV=OQ '^:OF_H
M^SZHU1%BZ9L]1O!"#O$%MO"<]LC^U=8T3IWKA;&%[O2]6\7Q-[*]D<]_O7';
MXSIMCCN]OH3VHZM[MT+U(;=9/%6T=,[<!0PVEL^@!-<R_P!/IG76(4BMY_=X
MM.>.5P,KDNK)R/7GBHA[1;/J].H]>F]UUH:2]RSY6)O"\/:,D^6W-2?V8=#Z
MA<VUEJ&L=175E;.N1;6DCI*Q(&,[?AQC[U3+/RRF,GI,QUV^A<Y'8_E5%J?Q
M)ON/[5%HNC]&("O/K,K']Z34+@9_)@*]U>,=-]#=0R:.\L$EM;2S1R/(TK*P
M3.<N2?SK7M7I-(_.JJYU>=1>\];K%8ZQ ]A[@DT*Q7L8667=.&PFTF4Y100&
M&,?6M+I/65_9:/%=VVK1:M =-MKF[EN61A:SL1O52NS<Q7<?"SN^'CN 9'7Z
M5;M91/;13*<K(@<'!'<9['D?UJY0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*I?Y
M355>/\IH,";O5,+99OY:]N>]6+/FX?\ EK2>E?E$NKNN(+'P+>W1)@6"LX<C
MPSVR1CM6NZ7]H^E6%F;:[5P_B.Y9<MQ^0!/TJYUMT='K$Z20WJ:?&JG>$@!+
MMGN3G]*@]W[/&M+:ZO!K N!#$\FR2UPIPI./FJMX-Y>4//4TZ3J?M=Z3L+<2
M&ZN97896-+9\G\QBH-UM[6]*O^EKU[&TN&N;JU<16[[=W;'Q@$X//8]Z^;NM
M-4U 268CD 4(=P"@[N?K6MT.]N+V\G5U2/8A<$+R/+'VK#DMD\OXOCWT[;_I
M?ZOL^F='U&QU*"Z64227 P@4,NU<XW$9/!X%=YT?VH])ZI9)<)J8M]Q(\.XC
M9'!^HQ7R=H5UI,?3%\-0O9UUI7W6T:P[D*@?*6S@9/J/*MGID'5LNDP76GV%
MY<VC*7DE6$LH \R1VQ@UCCGE+U\M+)\OI;JOVC:!8V]S9RR3R22M):J5CROB
M!<D$^0^I&*CND>T#1++3[>:9G54E6,LB@@D]B.<XX]*^?^OM7OQUSK:1-&$%
MY@':,D;!WJ/C5;J-['<L1>210'Y&/7SP<U7E\LLD861]OZ5UAH>L0 V%_"[N
M=HC8[6SG&,'SK86&"]R#_'C_ /45S3V;]%:'>].Z7K-Y;//?,/%):5MH8'C"
M_3 KH^EG<;H_^_(_05U<=N6,M4RDEZ;"."(;2(HQM^7"CC[57X,6S9X:;,YV
M[1C/VKV/SJJKH*4I0*4I0*4I0*4I0*4I0*5&+[K72[/5;G39G O(;JVM!"9$
M#R&?9M95)R0-_/'D:S;;JG1;FX,,&HPO)XJP@#/Q,Q8#:<88$HPR,C*D9H-U
M2M!)U9I30N]I=1W)5(Y#M)"A7<*N6(V@G<" 3D^E>IU?H3^\[-1B<V[;'558
MDMO,>% &6.\%<+GD8H-]2L;3+^VU.PM[VQE$UK.@DBD (#*>QYK)H%>/\IKV
MO'^4T&ON!S5JS4^.WVK(F%6[<8E/VJ\O2ORCW4);>P9"4SCBHE+;/(KI+)+)
M&P(9&X!!XQ70KP NU89 SV'Y5%SL6F.XY+JV@]/EHXING-/D11@;HP2?ZBN9
M=7]+R6VN/+T[HUO#:/$ 0OP?%CG'//-?1G4;+!:F2.*(R=@2@J,Q72Y#/96C
MD# S"IJN6^3'5DTIY8X9=OG:WZ?Z@5/$72X6 8@G>,_WS^E=&Z/?JW3M."BW
MU6*WY!BMVS&3C&",'C!KIMG>1.Q3]EZ?@GN(0#4XT&"TEM-QL(8]O!V@Y)S7
M+X>.7^NC'/'*=.2745K-U+KRZSH%D5$P]WE]Q9V<[1G)"U[:'I&$C=I5B)%P
M-KZ=D_JO%=.UB&%[Z</:H26[^M1JYTK3W)+:;$S;OF([U7/DN.S''%M- ZJT
MV)(K*TC9(N%2)(BJIS^Z,=JEVA'=%<'_ .)D_OBN?V5M!%J=MX4"1C>O;[U.
M-/NK?3],U&\O)5AMH)99)9'/"J.236W%G<IVKEK?3?1^=55@Z1J=GJEJ9["X
M2:(.8R1D%6'=2#@@_0BKL5_9RR)'%=0.[LZJJN"6*'#@#U4\'TK91DTJEG54
M9R?A7DXYJF"9)X8Y8R2DBAUR"#@C(X/(H+E* @@$'(-*!2E*!2E*!2E*"/7?
M26GW-_=WDF\SW%W;79;"Y5H-FT XR =@S]SVK71= VL20[-2O_$M3&+*0^&3
M;(CE@H&W##G!+9. /3-3*E!#(/9]8Q+;I[[>-'!;QVZCX SA'5P78*"YR@QG
MMN;&,UC=1= K=:?#'IMS*LT4N[\27P\J;@SL P4[6W8 .#QY>8GE*#7=.65Q
MIVA6%G>20R3P0K&S01[$X&/A7R&,>GV':L^12Z%0[(?5<9_6JJ4&,89Q\MR3
M_.@/]L5X1=@'+0./Y2O^3657C?*:G:---J=Q>6]E<316:SRQQLR)')DNP!P,
M8SR::'<7%W9Q3WEE)97#+\<#L&*G[BM@U41?.:ON>.M(UWMK-1?PW8XXK6/J
M%L"0TB@CZUM;]=TC8..:T,[6I4/,[$-G \(-V[GM5-2^UMV3IK>H;_3Y;;;+
M=QISD$M4>2XTCL-0A)([^(,5E]8=-Z3>6J-<RHBD@AEA'^*A;>S;IZ9MRZW/
M&W\O%6QQQU[<_);Y>G1=#T[2+A-WOZ.Q. 8YTQ6W2X2QD5;*Z:1$?8Q8J?/Z
M5QZ+V8Z1 A9.LIDRWR[2#73>D/9[I]JL$KZF;PJK8!4$-D$ D_3O_2N/DPW>
MJZN.SQ]*>H=<CMM5NU>0963;W'I48FZES,BI(,,?I6YZB]G]G<:U=79OT9Y9
M=Y25-P!QCUK76/3,.GL!%#I+$-\S6@8_J:SY<)-K87OMMM&>2[OK5P#L$BG)
M^]2R]TR76ND>H--MY$CFO!<0([YVJ6R 3CG'VK36MS_YPM8]D*X=1B-< ?:I
M?T__ ,BY_P#J9?\ Q5IP32MU\(/>=!ZU<6C1075C$)+Q[OXY'FD@8^%@K,ZE
MVSX;$_*?B #87!RFZ N%N1):IIELZW.H/'<1*1+&MSDK(/AXD0X&,X(&<CM7
M14\ZJKI5<ZT/H&>U>RDNS 6MUG.SQ3(HE>.)%D0!$"D>&Q/!.3G)))K'A]GU
M\+AVN[A;I39I;@K=M"01;+"R9$98J2"X.[ )R5)'/3:4&LZ8LKK3M"L[2_>W
M>YB3:YMXPB=SC   [8[  G)P.U;.E*!2E*!2E*!2E*!2E*!2E*!2E*!7C?*:
M]KQOE-!C-WJV.)QZ$5<>K9(5@35HAK;]6<RJ21GC([UH[C2T= BNRJ"2!W !
M\JDM]'N^)?/S%:6X:ZB),<6\>F0*BV_"9KY1WJZ,KIT:HA<*0.U1-%'G&P_^
MTU-]3O;T6[GW"5L>2[3G]:BNJ]12Z?$&N[*]B1S@$1Y!.,^1JOW/&:K//B\[
MN,>&PDN50I%(0'&3M/ ]:Z3TY):0+%&\JHX! !.*A?1_5*ZI=>%--?V]A$OB
M.T:,!GR#,#\(\Z\U;5;BXU&Y&FOJ-]:QR%$G4;@V.^&\^?.N?DW,MY?^^6O%
MCK'I*-4N;66YE='7!;UK66,ELTY#.O<\9[__ -BHN9+]N'M;\9_B _ZUD6<4
MJ2$O%('(P,_NY[G[XK#+*5I)6^LY$;5[81X),HQBIUH*[89\'@SR?^*M#TWH
MZV\2WDB$S8^!3WJ4:9;FVM$C8@R<LY]6)R:ZN*76ZSO3-3SJJJ4\ZJK9!2E*
M!2E*!2E*!2E*!2E*!2E*!2E*!2E*!7C_ "U[5+_+08TE6)1E2#YUDR#@UC..
M*MBK5<"CP-I.[ \ZUUTN">*RE)4Y!-4W 60<R$'[4L3*T\AQGBM4\O\ WD#P
M\@''?O6]GMB.5<MGZ5KI[+)R5.1YUCE;&DFU=S+_ -S<P6> 1ARJA<^@./\
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D*42]V+Z4V+Z4I0-B^E-H]*4H/0 .U*4H%*4H%*4H%*4H/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>cv-20251231_g18.jpg
<TEXT>
begin 644 cv-20251231_g18.jpg
M_]C_X  02D9)1@ ! 0$!8 %@  #_[1@X4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 6     !  $!8     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              0,   #L@    8 9P X
M #@ ;0 P #@    !                          $              [(
M  0,                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  0,     %)G:'1L;VYG   #L@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!0       0    #.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M   !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H # ,!  (1 Q$ /P#U5),DDI=),DDI=)),DI=5.H]1JP*0YPWVOD55
MSMF!N<][_=Z=-;?YVS_MMEM]E--MI<+]=/K W!ZH,=OVIN0P5.99BU-MV5_I
M'N]E_P"A>^V]U+_3_P"ZE%O^C24-6[FN^M^3<S[/G.PFW/#:V5TX^GL<_;8W
M,=D6M_FW_N/_ .!J1NG9OUAPZ&WY]WV^AS6F;&4UOU)_PF*YM5/TF;/5H]'_
M $V3C?SRX\?6_JCV-<;>K/?6=[7-PZ@-P!9/\T_\U[D]?URSX&.+NK-I:PL&
MW"HL.D-K'IV,8US-GT][T:\"GA/8OJ6-D5Y-+;ZB=C^Q!#@0=KV/8[W,LK>-
MEE;OYMZ*N9^I75ZNHTY#:V7UFD4^JS*866>H6NI?9PUKO7;CLN?M_P -9:NE
M00NDF224NDF2E)2Z229)2Z2222G_T/4MR6Y#W);D4)-R6Y#W);DJ2DW);D/<
MEN24DW+SKZXY55'UCN#L5F18^JDMLL)VM:&O&QH9?C>]S_SW;UZ#N7*=8K>W
MJ'6,RK(LHNIQ\45[-A:YSM[*_5;=5=^?9^8B+O310-&]?H>'\7 P&960WTL>
MII]I<[==M&ACOF^[]Y5FNLKR7UOJVV,EI]*WN/=O;9]JV^[Z"[2IUE[68S<C
M/=O+AZ<8@)#?I[7^DSZ+]J"S*R6DV?:\YK 7"TD8FA:XUV;/T&WVNV-1]6NN
MJ\9([^JCMZ_VH?J'8Q^3U1S*G4C] '![MQ<[]8._^<MV>TL9LW+K]RP>D5FK
MKW6 ZQ]SRW$+[+-NXG9</\"RFOVM_P"#6SN"&O5839TOZZI=P2D(6X)Y00DW
M!+<$/<EN24DW);D/<EN22DW)(>[\B22G_]'TC<EN4)2E.I"3<EN0Y2E*E)-R
M6Y#E*4J4DW+FNL%OVGK =8VMSZ,4U[B 7.J/K[6;B-[]JZ&5PWUU;CNZE=9;
M;0Q]%=3F,N=#G;FU#;2W:[<[1$:%(UT=_#R,1[ZWNR&/J87N>*SZ9]\[=MSL
MEVQWN_FD''RL=OZ#[56"76-VN $@N]7Z1R'5^GZ;=GJ>E^D>N/JNQJJ67&[#
M<7>X-;8'/_JOKK:Y];_^,0*K<-CG.-N(6L=L^E[G;@?>&.9OLK;M_G/\&EQ&
MY(]N.@TT?1NF65V=:ZM;4]MC'C%AS2'#1MX^DU+-P^LVY-C\7,;36ZVAS-S[
M!LJK'Z>D8S&>B]UEN^SU;'_IZ[OL]GI>A58L[ZI''!S68]M-[&-QV^IC'=62
M#E?1):S^VNAW($6IQ<3!^L[*JK+<UOJAH=91;:]XW;L>Q];K:Z?\/Z65ZC_T
M]>/7D?9\2O\ [4(_2NE]5PLEK\C-%U&VQUE;):'6V/?998]CZW;][GL?O]2G
MT?3]+^:L6GN2W)4FTFY+<A[DI20DW);D.4I14EW?D20I_(DE2G__TO0TI3PF
MA/0J4I2A*$E*E*4DR2%Y7,]9KK?UYOJ@%H:X0YY8-:<;\YG]5=*N3^MO3A^T
M*L[9]-FKFM:YQV 56U^__1L^SW[?Y>39^98C'<(D+B1W#IX6-TUK"1CM'FQU
MA_\ (H=.+TXY$_9V$^)=8T_D6%3CL]/^:M=II^AKU_Z"$ZEM;77.9:RMNKCZ
M%9 '^8G@_-INP^U+34Z>+U'0PUN7U!K8#0:PT!VX?SV?^>?I+7E8?U3PW485
MV0]C6/R7B8#03Z9M<=_I^U[J[<BS&W?]U_\ 1^FMM,.Y9P* '@O*:4DD$JE*
M4DR*EY32DF24RG_J4DO_ "*22'__T_1H30B0FA.0PA-"F0E"*F$)0I0E"2F$
M+/S[\&XVX-].3<6;'.-%%K]CB/4J?7?4QS?5:UW_ *+L_<6E"I5XF1=U;,]'
M,NQ1Z6.]S:FTN!<?7JG]9HO=]"FM E3SUG3LEKOU>SJ+6S]*NK(H=M[-=4[%
MS\7_ +8;B,_X%2QNG.WL=GGJ%K61[13DVO,&?Y]]&+73_P"@V'7D?Z+*J74_
MLW/_ /+;*_[;Q?\ WC2_9N?_ .6V5_VWB_\ O&EQ%+6Q<W&NL^RU56T.JK#A
M790^AHK!])GI^HUC-K?H^FU654JQ[J>LY NR;,HC$HVNM;6T@/MR=[?U:JC_
M $-?TE<1"%DR=))"R2=-"*5DH3I)*5_Y%)+_ ,BDDI__U/3(2VJ<)H10P+4V
MU$A-"*4<)H1830DI&&R0/$PL_IF!3U*IW5,KU-V:=U#6V65AN,TN;A,V4V,_
MG*S]KL_X;*L_P>Q:9;H?@>?@N>Z2:ATK"!ZAU)A&/3[&4$M'Z-GM8?L+O;_:
M0*G:_8G3_"W_ +?O_P#2R7[%Z?X6_P#;]_\ Z65#=3_Y9]4_[8/_ +P)MU/_
M )9]4_[8/_R/24DRL.KIN9C96/O]+)>W#RFO>^P0\N.#=-S[-GHY;O0]G^#S
M;?\ 1UJVPA[GM80YU9#7M;J6D@6-:_\ =W,<UZR,XL-=.W.S[B,K%(KNI+:S
M^LT?3?\ 8Z=O_;K%+J7U8Q\_*RL@Y#Z3E-:QX8RLF *JX]1P]1[/U>NREG_:
M?(_3UHA3ITVU9&[[.]MVP[7["';3^Z[;]%$+'-U+2!XPL:WZJXMK@XY5[?<]
MQ+=H>#9M]U-L;J+OT>Q]S?YW'?;C_P"$1>G?5[%Z?D,R:['.M:U[##6L9M?K
MZ-=;/YG&KL_24X[/96E:'230I0E"*F*2>$R2%?\ D4D__D4DE/\ _]7U*$T*
M<)0BIA":%.$H20CA*%.$H24CCYCP5+H-AKQ3TVP_I^FG[.X:2:@/U._^K?B^
MG_U[UZO\$M"%1S>FF^ZO,Q;?LN=2-K+PW<US"=SL?*IEGKX[G>[Z==M3_P"8
MNK]Z271U26.<_P"LK#M_9>/;$#U&Y>UIT^DUEF-O;_:3LS/K+<?3^P8V)/\
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #$    ! #A"24T$(@     !
M,DU- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    'P   '(!,@ "    %    )&':0 $
M 0   *@   #4   !8     $   %@     4%D;V)E(%!H;W1O<VAO<" R,BXP
M("A7:6YD;W=S*0 R,#(U.C Q.C,Q(#$V.C0V.C4U       #H $  P    '_
M_P  H ( !     $   .RH , !     $   0,          8! P #     0 &
M   !&@ %     0   2(!&P %     0   2H!*  #     0 "   " 0 $
M 0   3(" @ $     0              2     $   !(     3A"24T#_0
M    "           _^$!.D5X:68  $U- "H    (  <!$@ #     0 !   !
M&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "    'P
M '(!,@ "    %    )&':0 $     0   *@   #4   !8     $   %@
M 4%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*0 R,#(U.C Q.C,Q(#$V
M.C0V.C4U       #H $  P    '__P  H ( !     $   .RH , !     $
M  0,          8! P #     0 &   !&@ %     0   2(!&P %     0
M 2H!*  #     0 "   " 0 $     0   3(" @ $     0
M2     $   !(     ?_B__])0T-?4%)/1DE,10 !"0 (@'!!1$)% A   '!R
M=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,     $%$0D4
M           !  #VU@ !     -,M041"10
M                                    "F1E<V,   #\    =&-P<G0
M  %P    *W=T<'0   &<    %$$R0C    &P  "B!D$R0C(   &P  "B!D$R
M0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT  (XM$(R03( !;<H  (X
MM&=A;70 !^_<  "0D61E<V,         &E4N4RX@5V5B($-O871E9" H4U=/
M4"D@=C(
M                                                    =&5X=
M  !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US+"!);F,N  !865H@
M    M5H  +QG  "2,&UF=#(     ! ,)   !                     0
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MCJ%\HFJC5Z1%I3.F(*<.I_RHZJG7JL6KLZRAK8^N?:]KL%FQ1[(VLR2T$K4
MM>VVVK?(N+6YH[J0NWZ\:[U9OD>_-< BP1#!_L+LP]K$Q\6UQJ/'D<A^R6S*
M6<M$S"[-&,X!SNO/U="^T:?2D--YU&'52=8QUQC8 -CFV<W:LMN8W'W=8MY'
MWRS@$.#TX=CBN^.>Y'OE5^8SYP[GZ.C!Z9KJ<>M([!WL\.W#[I;O=O!5\3/R
M#_+J\\/TG/5S]DGW'O?S^,;YE?IA^RG[Z_RG_5S^"_ZT_UK__P   >@#IP4L
M!H0'OPCG"@0+%@P<#1X.' \9$!<1%!(0$PL4!!3\%?,6YA?8&,P9UAK>&^$<
MX1W?'ML?UB#1(<LBQ".^)+@ELR:N)ZHHIBFB*J KGBR=+9HNE2^1,(TQB3*&
M,X,T@35_-G\W?SB .8(Z?SM^/'P]?#Y\/WU ?T&"0H5#B42-19)&F$>:2)M)
MG4J?2Z-,IDVJ3J]/M%"Z4<!2QU/.5-55UU;95]M8WEG@6N-;YUSJ7>U>\5_U
M8/AA_&, 9 -E 67_9OQG^FCX:?5J\VOP;.YMZV[H;^5PX7'><MISUG3-=<-V
MN7>O>*5YFWJ0>X5\>GUO?F1_6(!-@4&"-8,IA!R%$(7^ANV'VXC*B;B*IHN5
MC(.-<8Y@CTZ0/9$LDAN3"I/ZE.F5V9;)E[J8IYF3FH";;9Q:G4B>-I\EH!2A
M!*'UHN:CV*3*I;VFL:>FJ)NID:J'JW^L=ZUOKF>O8+!:L52R3[-,M$FU1K9%
MMT2X1;E&NDB[2KQ.O5*^5[]=P&/!:L)RPWO$A,6*QI#'ELB=R:7*K<NVS+_-
MR,[2S]S0YM'QTOO4!M42UA[7*M@WV43:4=M>W&O=>=Z&WY3@G.&BXJCCK>2R
MY;;FNN>]Z,#IP^K4Z^7L]>X$[Q+P(/$L\CCS0_1.]5GV8_=J^&[Y;_IL^V3\
M5OU$_B__%___   "!0/8!6@&Q@@&"3(*4@ME#'(-> YZ#WH0>A%Y$G43<!1H
M%5X64A=%&#<9*1HT&ST<0!T_'CH?-" L(2,B&2,/) 0D^27N)N,GV"C,*<$J
MMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH .O8[[3SC/=L^TS_+
M0,1!O4*W0[)$K$6F1J%'G$B7291*D$N.3(M-BDZ)3XA0B%&)4HA3B%2(58A6
MB5>*6(M9C5J/6Y%<DUV67IA?FV"=89]BH&.A9*-EI&:F9Z=HJ&FI:JIKJFRK
M;:MNJV^K<*EQJ'*E<Z-TH'6==IEWE7B1>8QZAWN"?'Q]=GYO?VF 88%:@E&#
M2(0^A36&*X<AB!>)#(H"BO>+[8SBC=B.S8_#D+F1KY*EDYR4DI6)EH"7>)AP
MF6J:8YM>G%F=59Y2GU"@3Z%/HE"C4J15I5FF7Z=FJ&ZI>*J"JXZLG*VKKKNO
MS+#?L?.S";0@M3BV4;=LN(>YI+K"N^&] ;XAOT/ 9<&'PJK#SL3QQA7'.<A>
MR8+*ILO*S.W.$,\RT%31=-*4T[+4S]7KUP;8'MDVVDS;8=QTW8?>F-^GX+/A
MON+'X\WDT>72YM#GS.C$Z;KJK.N;[(?M;^Y8[USP6_%6\DSS/?0J]1+U]O;6
M][/XC?EB^B_Z]/NQ_&;]$?VS_DW^X?]Q__\   '9 XT%"094!W\(E@FA"J0+
MGPR3#8(.< ]?$$P1-Q(A$PD3\!36%;L6GQ>#&($9?1IT&V8<51U!'BP?%R
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M3>69YN?H-NF&ZMCL*^V [M?P,?&0\N_T3?6J]P3X6OFK^O;\.OU[_KO___\
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ME*)\"B?SD_-\_02JDW]_IKNSI.*#E*DJH5J"G)85G@J!T()@FOV!/FW;F#J
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MN;:!I(Y"M,* O7UBL 6 #6OSJXQ_GEFXIV1_<D9LHZY_@S%LH-Y_P1>PH3N
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M+3?/IIV%U2/RI%N&& L7I0>%40  A2F  (<^O J28'BEMQ:08FF$LD&.IEG
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MR1*!V6V7PYZ V%]'OCV #U!.N0M_H$!]M#I_;2]0L$=_=QM]KI)_JP27K$F
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M\P  AW*  *7UES:*0)7"E.J)'X3&DL>(#7+VD,V'#V ;CQ.&04PYC9:%E3;
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MK=Y[! "CI]-]+@  @ "  '*5P>V"VF6 O2:!^%?GN&J!0DFHL]* S#IFKZV
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M><1X(GA">EUXRF&O>O]Y>DG9>Z)Z&B[U?$EZD IK?;%ZJ,=E=BJ Y+2N=N:
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M@@<[=O:$Y+MN@I1JG*HQ@CAL>)?K@?EN*H1Y@=%OOV_\@;EQ35IP@;ARV4.
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MHF<BH)-XY5?OG=)Y/4>PFU1YH#8 F6=Y_B'KF,QZ%0B=F6=ZIP  @ "  ((
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MN3R*NUT>M1R)R5!$L0"(W$*>K0V($#/\J9&'DB.=ISJ'P _FIZN&N   F9"
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M.YE:='5R<(6V=79SF'$.=G-TO5MJ=W%UWT1V>%UVY"HX>05WD ;U>UMX%+O
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M=Q""9YQS=YB")8LW>!:!SWCZ>):!<F6N>2>!)E%:>;R Y3N/>CJ HR'F>F2
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M@0-XP%W @-YY54HX@-=YY#4%@/-Z3QLW@9IZ+   @ !^.I]F@!F )9 S?]V
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ME&=[,01TD<!\3   @ "  '@;G+^![VN(FG*!N5X>F#6!=D_(EA.!+4!HE#2
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M]R<VHA=J&Q(JI']IIP  F--N8@  @ "  &V#K!!I/V&ZJ1MJCU3]ID9KX4=
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MI*&=XU]6H:2<J%*9GIB:]T38FZ*95C8SF1>8SR7\EVJ6YQ*JEZF,G@ +CXJ
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MLO5\TE3IKZQ\OTB^K%U\K3NYJ31\G"V.II5\HAT9I8Y\F0GJI8A]&0  CL&
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MDD^+)V'UD-6*H554CT6)Y$>SC;^)%3D&C':(=BC/BYV(415UB^.(! $#A]^
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MG%Z/*U;,FDJ.FTK3F!R-OCW8E?V,VR^NE$2,=A^+DWZ,KPR)DR6(>@  A2&
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MIS22?DP,I'J2(D"GH;J1530NGR.0I"9GG2^0F18FG/:-Y 5JF'"#J0  @8"
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MB>)\\%GNB3!]2TX B&=]>T$)AY]]C3+>AP1]F2+9ALQ]HP\+AQ)]M0  @!N
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MDVN!$TZ6DCZ!.T-,D.J!(S;MCY> ["DNCJ6 SAD@CJF ZP=0C!R X   @ "
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M/   @ "  $['I MHIT2CHEEIWCFDH+9K 2VAGTEL !_ GK]LD0[&H#]L*
MF'=O*P  @ !]_P  @ "  $Y+H@MO<40KH&MP3CDSGL5Q$2TKG4QQI!^,G*5Q
M]@[ G=EQC@ UE@!U"0  @ "     @ "  $W7H&IV8$/*GM-V\#CDG2AW52SK
MFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "     @ "  $USGQ-]54-_G8-]
MHCBKF\]]L"RWFC=]GA\FF5U]C [1F>5]M0"PD@E^S@  @ "     @ "  $TD
MG@.$64-*G'.$<3B!FK:$,BR9F0B#WQ\*F!*#Y ZJF'>#>P"UD)F >P  @ "
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M<!:1AEJ^<2B0ZD[K<>"/VT(3<DN.LS0+<GZ. B0O<B&.-A$1<S^*\   @ "
M    @ "  &"FC&]1F%8'B^U4W$IWBZE7_3V<BY5:Y"\:B]==91X(C2E>^@F
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MB:MS@$:9B6=T7#O2B/UU#2_JB(QUCR)IB&AUUQ'BB1]UB )%AE5X2@  @ "
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M40  @ "  $:;G0U;G3TTG"U=K#+"FV]?CB;;FOEA)!C#F[UAZ@B7F\YB4
MC$-I40  @ !YJ0  @ "  $8'FCQB.CR$F6]CW#'VF+QE5B9 F$=FBQA'F.UG
M!@B F$QG7P  B=YN?   @ !]@   @ "  $5DE[AHZ#O=EPQJ*3%>EEAK0"6H
ME=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "     @ "  $3%E9-OOCM*E0IP
MIS#DE%MQ7R5,D[YQTQ>XE !QT B2DBER9   AA!Y9P  @ "     @ "  $0[
MD\)VG#K/DUIW.3""DJYWEB3XD@%WO!=HDAYWF0B"C])XFP  A+)]R@  @ "
M    @ "  $/)DD%]D#IMD?9][3 RD4]]^"3#D(A]VA="D'-]R A2C?!^>
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M8DJ#,E*D9&V#04=]9B&#!SM#9TR"LRVK9[."BAWL9NJ"MPN*;ER">P  @ "
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M:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%VQ00;J2%N 11>+6"ZP  @ "
M    @ "  $SOC:!*UT-@C6I.-CC5C8-1:2R]C?]41!Y5CU]65PR D=U6]@
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MO@  @ "  $>Z>^)M3#Y-?+!N<#/^?39O:"AQ?7UP(AK[?:9P; L3?H9PAP
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M#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!69A%NF*%7+P,)E159/P
M@:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>DCY: A\ZDM=;H!"@E,-<
M'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;_310CI]=]BH8CM5?J1YG
MCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6   @ "  #R:BQ1BFC-TBVED
M)BE$BZUE=!V9C")F2P^GC1!F9P*9B<5HAP  @ !T!   @ "     @ "  #O+
MA_)I73*FB(=J@2B0B.5K:QT&B4)K\0\_B:1KU@*FAP-N,   @ !Y.P  @ "
M    @ "  #L5A2EP*3'TA?YP[R?XAG=Q>1R-AK]QM [GAJYQA@*6A,5T4P
M@ !]F   @ "     @ "  #I\@KMW"C%=@\]W?"=VA&5WKAPNA)=WJ ZCA$EW
MD@)N@P)Z*P  @ "     @ "     @ "  #H-@*I^)S#G@?9^3R<+@JQ^,1OC
M@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "     @ "     __\  /__  #_
M_P  ;69T,@     $ PD   $                    !
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MZM3KY>SU[@3O$O @\2SR./-#]$[U6?9C]VKX;OEO^FS[9/Q6_43^+_\7__\
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MYGU5DE*%*GUU>P>$AGW&8\2#\7XU3(^#>'[I-9*#*(  [#V'?8C+UA2&<(=
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MNI6\842?I)*)4=6:?H]50OF5.(P4-.V/OXC!*&F)]X5NGRZSNJ>PC]:N>J-
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M,N"!6H!)WU&!08U!RL& V8MNM9: @HFXG\6 38@^B;* +H;P<Y2 *86^78^
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M>GYR>(6,HGYY936*V7ZE4A2)#W[G/SN'1W];+2N%=( ,P5F3HHA_KZ*1;X=
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M9Z^SPIF[6QRM-98.3K.FEY*!0K*?UX[Z-WR8RHMY+5B1D(@.)-J*583O@(?
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M9B>!.(;.4N*! X5>/]Z [H/8+9V ]H(>PPZ"I)A L4Z!]I6^GN"!99,VB]N
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M++.!V'N;O$F MG4;J\F AW8 FF. 7W;:B$N 1G>V=;* .WBB8NZ 1'FG4%N
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M%HIQ:JV">HC<6;^" X=522.!EH6\..:!2H0$*;F!%H(<JG:$G9?QFSF#P)7
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MSJ@_@R^37J2&=6>0T:!+9T:.19O+62J+X)=)2T2)H9+!/?N'8XXM,6.%0(F
M)C2#)83TB("F;&FG?%&B^&N!;Z.?I6U=8G:<26]'5068RG%01Y65*7.%.J&1
M9G7B+CN-?WB0(R&)@'N3B!*E5W%L>_RAZ')S;T>>@G.-8B.;%G3#5+R7E'8<
M1U^3^W>=.H200WD^+D^,;WL<(WF(A'TQAZ"D"GCR>VN@JGE%;LR=1'FK8:B9
MW7HR5%>69GK91Q>2WGNB.F"/.'R +ER+>GV'(\:'J'ZLAQ:BQ(!*>LV?;(
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M)H^ J8,,DT>%7YZ!AC*$>9OB>&B#@9C3:A^"DY5^6[F!U)(A36Z!1HZ\/[B
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M+&Y[6?^#NG"J2]&#6'+Z/@^# W5L,-""T7@@)-:"PWLAC>F#P'!1@:R#5G'
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M?H+\:KF/OH+/7^F-XX)[5,6+]H(029F*#H&J/J*(+X%5-"N&9($+*G6$KH#
M(C6#%(!W=)N0AHG*:D..U(D+7W>,_8@,5%F+%(;G23V)-H7#/F>'9X2J-"N%
MGX.;*HB$"8*!(F."DH%J=#R/T9!L:@B.*8\H7S^,2HUT5!Z*3XM]20F(;XF2
M/BV&MX>V- .%!H7I*I2#@80+(HB"*((U<_*/29;6:<&-GI4(7O6+N9*:4]F)
MN8_72-.'V(TB/@N&)8I_,_:$AH?L*IN#&852(J:!TX+;;4*B;UZP8WB?I&&
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M(DV!KGUJ> >!(GB=;8Z ^GED8IN QWH65T6 DWJ]2]F ;'MM0%6 ;'PO-7*
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M46[81A2(_7$?.WR'KW.,,8&&9W8;*$*%.WCB(&J$,7O&;CN+\&^"9).*YG$
M6HF)R7)_4#>(G70*1:6';W6I.SJ&2G=D,6^%+7DY*&*$*WLU(+Z#2'U ;86*
M+'9P8^B)/7=>6>:(-GA!3Y^''WD@14F&#7H2.OV%#WL9,5R$&'PP*'V#/7U?
M(06"@7Z1;.2(NGU-8UF'XGVO66B&Z7WO3RV%X7X>1.R$X7Y5.N:#\7ZB,5R#
M'W[\*)>";G]:(4"!VG^V;%J'A8/R8M2&PH/ 6.R%UX-93KV$VH+61)*#[()8
M.K.#$('F,6Z"1H&#*+*!O8$<(7&!48"P:^Z&F(IU8IJ%[(G$6+Z% 8BJ3I2#
M](=51'6#!H83.HJ"283G,4N!GH/2*,.!*H*K(9F X(&":YB%X9"_8DF%.8^*
M6&V$4XVZ3DV#2(N<1$&"6XF8.FV!IH>M,4:!#X77*-& N(/V(;B AX(M9=Z;
M,5FA7.>9"%SE4YF6YV!!2>V4GV._0!F2(F=H-F:/B6M,+5>,YV]?)0.*5W/'
M'@>'_'AB92*91V!]7&N7/V,I4RZ5&F7Q2:62S&C:/_606&OI-FJ-V6\K+82+
M5W*7)5N([G9*'HR&NWH=9)27)V<L6]25/VE,4K>3,VN 23V0^6W6/[2.H7!*
M-E:,1'+J+9^)Z76L):2'K'BF'P"%HWNP9 25&FVW6SB32V]04A:167#W2,V/
M/7*U/V2-"G2.-C**U7:'+:J(I'B:)=R&D7K8'V.$LGT;8W.35W0S6K"1HG5)
M49J/P'9@2%B-MG=Z/R2+H'BP-@^)D7H"+:R'AWMD)@>%G'SB'[>#Y'Y;8O"1
MZGJE6CV02WLZ43>.=7NX2 6,=WPK/N**<'RP-?^(<GU4+;"&BWX%)BB$R'Z_
M'_V#.']R8H*0P8#I6>*/-8$ 4.F-9X#?1[Z+;8"F/J&)=H!^-=B'C8!N+;N%
MLX!N)DB$%(!I(#>"J8!?8BJ/SX;P68Z.4X:$4)N,CH7!1WV*F(37/FZ(J(0
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M']^"/7R(9<> QW$L7/& XW*@4\* X'0-2E> RG5Z0-^ OG< -W. RWB>+KN
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M?GA.0(!4<#Q3UX!"8:A9IX T4OQ?R8 T1+=F-X \-Q5L^H!3*NASS8!YE^)
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MZ76/)0V ''B['QR!27OG7G!V3VP?5DYWF&X&3>-XP6_S149YW''J/*5[!G0
M-!=\3G8V+$)]HWB!)3!_$7KJ'VN ;GU'7:5SY'++59=U;'0A34=VSG5N1,)X
M(7;!/$%Y?G@H,_IZ]'FN+$5\@7M&)5-^*'SI'ZU_MWYZ7/1QR7E$5/)SCWH(
M3+=U*'JR1$YVJWM9.^IX-7P4,]!YV'SF+%U[A7W*)7E]7WZO'^-_'W^ 7&9P
M G^,5(AR!W_'3&=ST7_&1!EU<W^R.\=W''^[,Z9X['_=+$)ZP8 4)8]\O(!
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M'=""MGO'51%_*6H-3<%_JVPF1CE__FY,/I> ,7""-PJ 87+A+YN I'5?*.B
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M_P  __\  /__  !M9G0Q      ,$(0   0                    $
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M@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,7_J#0J_Z8^/_^Q-TKYOC!2Y\\O5='B+&C
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MY)EGA]R6<9+5DWN<SY"$I,N.C*O(BI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO
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M&+?V*2NI]S,\G?8\2Y'W1%B&]DUB??!6:G;K7G%NYV1V:N1K>F;B<GUDX'>
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M9W*PK6U^IZ=SB9ZA>I*6G8"9CYJ(GXF7D*2$E)BH?Y.BJGR2K:MZDKJL>Y'
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MJ9]S>Z&:>H2:EH&+E)*(D8Z/D):)C)F:A(JBG8&*K9]_BKN??HK(GG^)R9V
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M2CW_E4L\_YQ,//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3#S_GTRWO ,
MJ<L" )S; P"2_Q "B?\="(#_*A!U_S$8:_\X'V+_/B1;_T0I5/]*+%#_42],
M_U<R2?]<,T;_8#5$_V4V0O]I-T'_;C@__W,Y/?]W.CS_?#L[_X(\.?^'/3C_
MC#TW_Y,^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3ZJQ   G-(
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M7T/RNU]"\\Q@0?/G8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@0?/H8$'SZ&#>IP(
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MV[PY$<ZW12##LD\PN*Q7/J^G7TJFH655GIUL7I>9<V:0E7ILBI*!<H60B7>
MC9%\>XN;?W>*I8)TB;*#<HG"@W**VH-SB=Z!=(??@'6&X']UAN!_=8;@?W6&
MX']UAN!_=8;@?W6&X'__;QX#_X ; _^2(P3_H"L&^JDL!^VR+ ?BO#$'U< V
M$,F[0Q^^MDTNM+!6/*JK74FAIF14F:)J79&><66*FWAKA)A_<7^6AG9YDX]Z
M=9&8?G&0HX%ND*^";)"_@VN1U8)MC]Z!;XW?@'"+X']PB^!_<(O@?W"+X']P
MB^!_<(O@?W"+X'__<1P#_X,9 O^5(0/_HRD%]JTG!>BW)@3>PRH#T,,U#L2_
M01VYNDPMKK54.Z6P6T>;K&)2DZAI6XNE;V.%HG9J?I]\;WB<A'1SFHQY;YF6
M?&N7H7]HEZV 9I>\@668T8!FEM]_:)/@?FJ1X7YJD>%^:I'A?FJ1X7YJD>%^
M:I'A?FJ1X7[_=1H"_X<8 O^8( /_IB4#\K(@ ^2^'@+7R2("RL<S#;[#0!RS
MOTHKJ;I3.9^V6D66LF%0C:]G686L;6!^J71G>*9Z;7*D@G)MHHIV:*&4>62@
MGWQAGZM^7Z"Z?E^@SGY?G^%]8IOA?6.8XGQCF.)\8YCB?&.8XGQCF.)\8YCB
M?&.8XGS_>!@"_XL7 ?^='0+]JQX"[+@7 =[($0#/S1\"Q,PP"[C(/AFMQ4@H
MH\%1-IB]6$*/N5]-AK9E5G^S:UUXL7)D<J]Y:6RM@&YGK(ER8JJ2=5^IG7A<
MJ:IZ6JFY>EFJS'I8J>1Z6Z3D>EVAY'E=H>1Y7:'D>5VAY'E=H>1Y7:'D>5VA
MY'G_?14"_Y 4 ?^A& 'VL10 V<$+ -+/"P#(TAP!O-$N";'..Q>FRT8EG,A/
M,Y'$5C^(P5U)@+]C4GB\:EEQNG!?:[EW9&:W?VEAMH=M7;61<%FUG')6M*ET
M5+2X=%.URW13M>1T5+#G=5:LYW56K.=U5JSG=5:LYW56K.=U5JSG=5:LYW7_
M@Q(!_Y81 /^H$0#9N H SL0) ,?2"@"_V1D!M-@K!ZG6.12?TT0BE-!-+XK-
M5#N!REM$>,AB37'':5-KQ6]99<1V7F##?F)<PH=F6,&1:%7!G&M2P:AL4,&W
M;4_"RFU/PN1L3[WL;E"Y[&]0N>QO4+GL;U"Y[&]0N>QO4+GL;U"Y[&__B1 !
M_YT. -JO" #-NP@ Q,<' +S6"P"SWQH!JM\K!Z#>.1*6W4,>C-I+*H+84S5Y
MU5H_<=-A1FK2:$QET6]28-!V5EO0?EI7SX==4\^17U#/G&%.SZEC3,^X8TO0
MRV-,T.5B2L[R94O(\F9+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F;_D@T WJ8$
M ,ZT!@#"OP8 N<P( +#=# "GY1T#GN4M"Y3E.1:*Y$(@@>-**G?B4#-OX5@[
M:>!?06/@9D9>WVY*6M]U3E;??5%2WX933]^05DW?FU=+X*=82>"U64CAQEE(
MX=]91]_P64;<]5M&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5OMG 0 T:T$ ,*X
M!0"WPP4 K=$( *3M$ &;[2 %DNTN#HGL.AB [$,A=NQ**F[L4#%FZU8W8.M<
M/%OK9$!7ZVM#4^MR1E#K>DE-[(-+2NR,34CLEDY%[:%00^VN44+NO%%![\Q2
M0>_E4D#M\5% [?%10.WQ44#M\5% [?%10.WQ44#M\5'4I0  Q+(# +:\ P"K
MR04 H-@( )?T$P&/]20'A_4Q#W[V.QAT]D(@;/9()V7V3RU>]U4Q6?=;-57W
M8CA1]V@[3?AO/4KX=C]'^'Y!1/F'0T+YD45 ^IM&/OJF1SS[L4@[^[Y).OS/
M23G\XTDY_.-).?SC23G\XTDY_.-).?SC23G\XTG'K0  M[<" *K# @">T 0
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M0T'IND1 ZLU$0.KD1$#H]41 Y_A#0.?X0T#G^$- Y_A#0.?X0T#G^$/-HP
MO:X! +"X 0"DQ ( F= % (_A"@")\1H!@?$H!7CR,@QP\CL3:?)#&6+R2A]<
M\U C5O-7)U+S7BM/\V4M3/1L,$GT<S)&]'LT0_2$-D'UCC<^]9DY/?:D.COV
ML#LZ][\\.?C//#CWZ#PX]^P\./?L/#CW[#PX]^P\./?L/#CW[#R_J@  L;,
M *2_  "8R@$ C-@$ (3Z#@!\^QL"=/LF!6S\, IE_#@07OU %5C^1QE3_DT=
M3_]4($O_6B)(_V$E1?]G)D+_;2A _W4J/?]]*SK_ABTX_Y$N-O^;+S3_IC S
M_[(Q,O^^,C'_T#(Q_]8R,?_6,C'_UC(Q_]8R,?_6,C'_UC*RKP  I;H  )C&
M  "+T@  ?]\" 'G_$0%O_QD"9_\B!&#_+ =:_S0,5/\\#T__0Q-*_TD51_]/
M%T/_51E _UL;/O]A'#O_9AXY_VT?-O]T(#3_?2$Q_X8C+_^1)"W_FR4L_Z4F
M*_^O)BK_NR<I_[XG*?^^)RG_OB<I_[XG*?^^)RG_OB>FM@  F,(  (O.  !^
MVP  =?D' &O_#P%B_Q8"6_\> U3_)@5._RX&2?\U"$7_/ M!_T,-/O](#CO_
M3A X_U,1-?]8$C/_7A,Q_V04+O]J%2S_<A8J_WH7)_^#&"7_CADD_Y@:(_^@
M&B+_JALA_ZT;(?^M&R'_K1LA_ZT;(?^M&R'_K1N:O@  B\H  '[7  !PXP
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M5$RXOU1+N=A42[?M5$JV^55*L_Y62K/^5DJS_E9*L_Y62K/^5DJS_E;ZAP(
MUI@  ,FE P"]KP, L[@! *G"! "AS0@ FM 6 )+0* 2*SS8,@<Y!%7G,2AYR
MRU(F;,I:+6;)83)AR&@W7,=O/%C&=C]5QG]#4<6)14[%E$A+Q:!*2<6N2TC%
MOTM'QMA+1\7M2T;#^4U%PO].1<+_3D7"_TY%PO].1<+_3D7"_T[?D   S)\
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M+S?SYR\V\?,O-O'S+S;Q\R\V\?,O-O'S+S;Q\R^YIP  J[   )^[  "2Q@
MAM ! 'O=!0!T]Q$ ;?<< 6;X)@-?^"\&6ODX"E3Y0 Y0^D<13/I.%$C[519%
M^UL80OMB&D#\:!P]_' =.OUX'SC]@B V_8TB-/Z8(S+^I"0Q_[$E,/^_)B__
MSR8N_^,F+O_C)B[_XR8N_^,F+O_C)B[_XR:MK0  G[<  )+"  "&S0  >=H
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M5X)O_5>";_U7@F_]5X)O_5?_8!4!_VX1 ?][$P#_AA0 ]H\6 .>6& #;G!P
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M5UJ4O5A9E-17693L5UF3^59;D?Y56Y#^55N0_E5;D/Y56Y#^55N0_E7_<PD
M]80$ -B1 P#,G 4 PZ4% +NM! "SLPP J[4< :.T+ 6;LCD.DK!$%XJM32"#
MJU0I?:E<,'>G8C9QI6D\;*1O06BB=T5DH7])7Y^(3%R>DD]8GIY25IVK4U2=
MO%13G=%44YWK4U.<^%-4FO]35)G_4U29_U-4F?]35)G_4U29_U/_> 8 X8D
M -"6 @#&H0, O*D# +.P 0"KN @ I+H8 )RZ*0.4N38+C+=!%(2U2AU\LU(E
M=K%:+'"O8#)KKF<X9JUN/&*K=4!>JGU$6JF&2%:HD4I3J)U-4:>J3D^HND].
MJ,]/3J?I3TVF]T]-I?]/3J3_3TZD_T].I/]/3J3_3TZD_T_Z?P  V(X  ,F;
M 0"^I0( M*T! *NU  "AOP0 F\$4 )3!)0*,P#,(A+\^$7R]2!EUO% A;[I8
M)VJY7RUEN&4R8+=L-ERV=#I8M7P^5;2%05&TD$1.LYQ&3+.I2$JSN4A)M,Y(
M2;/I2$BQ]DE(L/]*2+#_2DBP_TI(L/]*2+#_2DBP_TKBA@  SI0  ,*A  "V
MJ0  J[$  *&Z 0"8PP4 D,D0 (K)( &#R2\%>\@[#73'111NQDX;:,56(6/$
M72=>PV0K6L)K+U;!<C-3P7LV3\"$.4S CSQ*P)L^1\"H/T; N$!%P,U 1<#H
M/T2^]D%#O?]"0[S_0T.\_T-#O/]#0[S_0T.\_T/6C0  QIL  +BE  "MK@
MHK8  )B_ @"-R 8 @]$+ '_2&@!YTBH#<M(W"&S10@]FT4L58=!3&ES/6Q]8
MSV(C5,YI)U'.<2I-SGHM2LZ#,$C.CC)%SIHT0\ZH-4+.N#9!S\TU0<[H-4#-
M]3<_R_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*E@  O*(  *^J  "CLP  F+P
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M&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  " R0  =-,  &?>  !>\@@
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M3VE[OE!H?-50:'SM3VE\^TYI?/]-:GO_3&I[_TQJ>_],:GO_3&I[_TS_9@H
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M2%&7]4A1E_]'49;_1U&6_T=1EO]'49;_1U&6_T?V=P  V(4  ,F1  "_FP$
MM*(  *NH  "AL   FK(1 )2S(@&-LC %A;$\#'ZO1A1XKDX;<JQ6(6VK7"=H
MJ6,L9*AJ,&"G<31<IGDX6*6".U6DC#Y1HYA 3Z.E0DVCM$-,H\A#3*/D0TNA
M]$-+H/]$2Z#_1$N@_T1+H/]$2Z#_1$N@_T3C?0  SXL  ,*6  "WGP  K:8
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M+CS%_RX\Q?\N/,7_+CS%_R[$DP  MI\  *FF  "=K@  DK<  (:_  ![QP,
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M"1S_W0F8L   BKH  'S$  !OS0  8M@  %7>  !)Y   1/L% #__#@ [_Q4
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M3"8"_T\O _]0.07_3D,'_TQ/"_]*6P__2&83_T5Q%OQ#?!GZ0H8;^$&.'/9
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M0WAJOT1V:M1%=FOM0W9K^T)V:_]!=FS_0'9L_T!V;/] =FS_0'9L_T#_70H
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M0V!]]D)@??]!87W_0&%]_T!A??] 87W_0&%]_T#_9P  XW0  -)_  #'B $
MOH\" +:5 0"NF 8 IIH5 )^:)@*8F3,&D9<_#(N52!2%DU :?Y%8('J/7R5V
MC64J<HML+FZ*<S)JB'LV9H>$.6.&CCQ@A9D_782F05N$M$):A,=#6H3C0EJ#
M]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@  WG@  ,V#  #"C   N9,
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M.4F;_SE)F_\Y29O_.4F;_SG;>@  R(<  +R2  "QF@  IJ   )RF  "1K
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M&C/._QJSF0  IJ$  )JI  ".L0  @;D  '7   !JQP  7LT# %34" !,W0T
M2MT8 $C>)@!&WC(!1-\\ D+?10,_WTT$/>!5!3O@708YX&8(-^!O"37A>@HS
MX88,,>&4#3#BHPXNXK,.+N/'#BWCXPXMX/(.+-_[#RS?_1 LW_T0+-_]$"S?
M_1"HH   G*<  (^P  "#N   =L$  &K)  !>SP  4]4! $G<!@!%Z0\ 0ND9
M $#J)  ]ZBX .NLV 3CL/@$V[$8",^U- S'M50,O[ET$+>YE!2ON< 4I[WL&
M*.^)!R;PEP<E\*<()/&X""/QS @B\N4((O#S""+O]0@B[_4((N_U""+O]0B>
MI@  D:\  (2X  !WP0  :LD  %W0  !1UP  1MT  #_J!0 \]@X .?87 #;W
M(  S]R@ ,?@P "[Y-@$K^3T!*?I$ 2?Z2@(E^U("(_M: B#\8P,>_&X#'/U[
M QO^B009_I@$&/^H!!?_MP06_\@$%O_@!!;_Y 06_^0$%O_D!!;_Y 23K@
MA;<  'C   !JR0  7=(  %#9  !$WP  .N0  #7W P R_PP +O\2 "O_&@ H
M_R$ )O\G "/_+0 @_S, 'O\Y 1S_/P$9_T4!%_]- 17_50$3_U\!$?]J A#_
M> (._X<"#O^6 @W_I (,_[ "#/^^ @S_P@(,_\("#/_" @S_P@*'M@  >;\
M &O)  !>TP  4-L  $/@   XY0  +_   "O_   G_P@ )/\. "'_$P >_QD
M&_\> !C_(P 5_R@ $_\M !'_,@ 0_S@ #O\_  S_1@$*_T\!!_]9 03_90$!
M_W(! /^! 0#_CP$ _YL! /^G 0#_J0$ _ZD! /^I 0#_J0'_+"\!_S L ?\R
M+ +_,S "_S$V _\P00/_+TT$_RU:!O\K9@?_*7,(_RA^"O\GB O_)Y$,_R>9
M#?\FGPW_)J4._R:K#O\FL0__)K@/_R; #_\FR0__)M</_R;F#_\F\ _^)OD/
M^R?_#_DG_P_Y)O\1^";_$?@F_Q+X)O\2^";_$O@F_Q+_+BP!_S,I ?\U*@+_
M-BT"_S8T O\U/P/_,TL$_S)7!O\P9 ?_+G )_RQ["O\LA0S_*XX-_RN6#O\J
MG0__*J,/_RJI$/\JKQ#_*;80_RF]$?\IQQ'_*=,1_BGC$?LJ[Q'X*O@0]BO_
M$/0J_Q+T*O\3\RK_%/,I_Q3S*?\4\RG_%/,I_Q3_,2D!_S8F ?\Y)@'_.BD"
M_SLR O\[/0/_.4@%_S=4!O\U8 ?_,VP)_S)W#/\P@@W_,(L._R^3#_\OFA#_
M+J 1_RZF$?\NK!+_+K,2_BZZ$OTNQ!+[+L\3^"[A$O4N[1+Q+_<2[R__$^XN
M_Q7M+O\6["[_%^PN_Q?L+O\7["[_%^PN_Q?_-"8!_SDC ?\](P'_/B8"_T$O
M O]!.0/_/T4$_SU0!O\[7 C_.6@*_S=S#?\V?@[_-8<0_32/$?PTEA+Z,YT3
M^3.C$_@SJ13W,[ 4]C.W%/0SP!3S,\P4\#/>%.TSZQ3I-/85YS/_%^8S_QCD
M,O\9Y#/_&N,R_QKC,O\:XS+_&N,R_QK_.",!_ST@ ?]!'P'_12,!_T<L O]'
M-@/_1D $_T1,!O]!6 C_/V0+^SYO#OD\>1#V.X,1]#J+$_,YDQ3Q.9D4\#B@
M%>XXIA;M.*T6[#BT%NHXO1;I.,D6YSC;%N,YZA;@./48W3C_&MLW_QS9-_\=
MUS?_'=8W_Q[6-_\>UC?_'M8W_Q[_.R !_T$< ?]%&@'_2R !_TTH ?].,@+_
M33P$_TI'!OI(4PCV1E\+\D1J#N]"=!'L07X3ZD"'%.@_CA7F/I86Y3Z<%^,]
MHQCB/:H8X#VR&-\]NQG=/<89VSW8&M8]Z1K2/?4=SCW^'\P\_R#+//\AR3S_
M(<D\_R')//\AR3S_(<D\_R'_/QP!_T47 ?]+%P'_4!T!_U,D ?]4+0+_4S<#
M]U%"!?%.30CL3%H+Z$IE#^5(;Q'B1WD4WT6"%MU$BA?:0Y$9V$*9&M5"GQO3
M0:8<T4&N'<]!MQ[.0<$>S$'0'\E"Y1_%0O,APD'^(\!!_R2^0?\DO4'_);U!
M_R6]0?\EO4'_);U!_R7_0A@!_TD3 /]0% #_5AD _UD@ ?]:* 'W6C("[U@]
M!.A520?C4U4*WE%@#ME.:A+43'06T$M\&,Y)A!O,2(P<RD>3'LA'FA_&1J$A
MQ$:I(L)%L2/!1;PCOT7))+U&WR6Y1N\FMD;[)[1&_RBS1O\HLD;_*+%&_RBQ
M1O\HL4;_*+%&_RC_1A4 _TT1 /]5$@#_6Q8 _UX; /E@(P'O8"P!YEXV ]]<
M1 7865 *T5=;#\Q4913(4FX8Q5!W&\-/?QW 3H8?ODV.(;Q,E2.Z2YPDN$JD
M)K9*K">T2K8HLTG#*;%)UBFN2NHJJTKX*ZE*_RNH2_\KITO_*Z=+_RNG2_\K
MITO_*Z=+_RO_21( _U . /]9$ #_7Q( _V,6 /)E'0#G924 WF0Q =1B/P7-
M8$L*QUU6#\):8!6^6&D9NU9Q'+A4>1^V4X$BLU*()+%0D":O4)<HK4^?*:M.
MJ"NI3K(LITZ^+:9.SBZC3N8NH4_U+I]/_RZ>3_\NG4__+IU0_RZ=4/\NG5#_
M+IU0_R[_3!  _U0- /]=#@#_8P\ ^6<1 .MI%0#?:AP TVHL <MH.P3%94<)
MOV)2#[I@7!6V7649LEMM':]9=2&L6'PCJE:#)J=5BRBE5),JHU.;+*%3HRZ?
M4JTOG5*Y,)M2R3&94N(QEU/R,993_S&55/\QE%3_,)14_S"45/\PE%3_,)14
M_S#_3PX _U@+ /]@"P#[9@P \&L- .1M#@#6;A8 S&\H <1M-P2]:T0)MVA/
M#[)E6!6N8F$:JF!I'J=><"&D77@EH5M_)Y]:ARJ<68XLFEB7+IA7H#"55JHR
MDU:U,Y%6Q3205MTTCE?P-(U7_3.,6/\SC%C_,HQ8_S&,6/\QC%C_,8Q8_S'_
M40P _UL) /]C" #K:@< W6X( -AQ"@#/<A, QG,E ;YR- .W<$$(L6U,#JQJ
M512G9UX9HV5E'J!C;2*<870EFF![*)=>@RN478LMDER3,(];G#*-6J8TBUJR
M-8E:P3:'6M8VAEOM-H5;^S6%7/\TA%S_,X1<_S.$7/\SA%S_,X1<_S/_4PH
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M.FUK]3AM:_\W;6O_-FUK_S9M:_\V;6O_-FUK_S;_6P  ZV<  -EQ  #,>0
MPWX" +N" P"TA D K848 *:%* &?A#4%F8) "I-_21"-?5(6B7M9&X1Y8!^
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M-5A^_S58?O\U6'[_-5A^_S7I:   U'0  ,9^  "[AP  LHT  *B1  ">E
MEI8. )&7' "+ERL"A98W!7^400IYDTD0=))1%7"06!ELCU\=:(YF(66,;25A
MBW0H7HI]+%N)AR]8B)(Q58>?,U.'K352A[XU48?6-5&&[C52A?LT4H7_-%*%
M_S-2A?\S4H7_,U*%_S/C;   SGD  ,&#  "VBP  K)$  **5  "7F0  CYL+
M (J=& "$G2<!?IPT!'F;/@ASFD<-;YE/$FJ85A=FEUT;8Y5C'E^4:B)<DW(E
M69)[*%61A2M2D9 N4)"=,$Z0JS%,D+PR3)#3,DR/[3),COHR3(W_,4R,_S%,
MC/\Q3(S_,4R,_S'<<0  R'X  +N(  "QD0  II8  )R:  "0GP  AZ(& (&C
M% !\I",!=Z0P W*C.P9MHD0+:*%,#V2@5!-@GUH779YA&UF=:!Y6G7 A4YQY
M)%";@R=-FHXI2IJ;+$B:J2U'F;HM1IK0+4:8ZRU&E_DN1I;_+D:6_RY&EO\N
M1I;_+D:6_R[1=P  P80  +:.  "JE0  H)L  )6?  "*I   ?:D  '>K$ !S
MJQX ;ZPL 6JK-P1EJT$'8:I)"UVI40]:J5@35ZA?%E.G9AE0IVX<3:9V'TJE
M@2%(I8PD1:69)D.DJ"="I+@H0:3.)T&CZB= HO@H0*'_*4"@_RE H/\I0*#_
M*4"@_RG)?@  NHL  *^4  "CF@  F*   (VE  ""J@  =;   &RS# !IM!@
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M#3++H@XQR[(/,,S'#S#+Y0XOR?4/+LC]$2['_Q(NQ_\2+L?_$B['_Q*NEP
MH9X  )6E  ")K0  ?+0  '"[  !DP0  6<8  $[+ P!%T @ /M4. #W5&@ \
MUB8 .]<Q #G8.P XV44!-ME- 3795@(SVEX",=IH S#;<P0NVW\%+-N-!2K<
MG08IW*T&*-W!!BC=W@8GV^\')MGY"";8_@DFV/X))MC^"2;8_@FDG0  F*4
M (NM  !^M   <;P  &7#  !9R0  3<T  $/3 0 ZV08 ->0- #/D%@ QY"
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M 07_H $$_ZX!!/^\ 0/_QP$#_\<! __' 0/_QP&#M   =;T  &?&  !:SP
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M(Z%)QB2?2MXDG4KP))M*_2692_\DF4O_))A+_R282_\DF$O_))A+_R3_2 P
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M+GI;]2UZ7/\L>5S_*WI<_RIZ7/\J>ES_*GI<_RK_40  \EL  -YD  #/:@
MQVX" ,!P! "Z< P LG$: *MQ*0&E<#<#GVY"!YIL2PR6:E01DFA<%8YF8QB+
M96D;B&-P'H5B>"&"87\D@&"()GU?D2E[7YPK>%ZG+79>M2YU7L8O=%[A+W1?
M\RYT7_\L=&#_*W1@_RMT8/\K=&#_*W1@_RO_4P  Z%X  -EG  #+;0  PW$!
M +MS @"U<PD K747 *=U)P&A=#0#FW(_!Y5P20N1;E(0C&Q9%(EJ8!B%:6<;
M@FAN'G]F=2%]97TD>F2%)G=DCREU8YHK<F*E+7!BLR]O8L0O;F+>+VYC\BYN
M8_XM;F/_+&YC_RMN8_\K;F/_*VYC_RO_50  Y6   --I  #(<   OW0  +=W
M 0"P=P< J'@5 *)Y) "<>#("EG8]!I%T1PN,<D\/B'!7$X1O7A> ;60:?6QK
M'7IK<R!W:GHC=&F#)G)HC2EO9Y<L;6>C+FMFL2]I9L$P:6;;,&EG\"]I9_TM
M:6?_+&IG_RMJ9_\K:F?_*VIG_RO^6   X6,  ,]L  #$<P  NW@  +-Z  "K
M>@0 I'L2 )Y\(@"8?"\"DGH[!8QX10J'=TT.@W55$G]S7!9[<F(:>'!I'75O
M<"!R;G@C;VV!)FULBREJ;)8K:&NA+F9KKR]D:K\P8VO8,&-K[R]D:_PM9&O_
M+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  # =@  MWL  *]^  "F?@$
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M*4^ _RG;:@  QW4  +I_  "PAP  IHP  )R/  "/D0  AI,% ("4$@![E2$
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M'$"?HAT^G[(>/9_&'CV?XQT]G?0>/9S_'SR;_Q\\F_\@/)O_(#R;_R#"?
MM8@  *F0  ">E@  DYL  (>?  ![I   ;Z@  &.L! !?K1$ 7*T? %JN*P!7
MKC8!5*Y  U&M2 5.K4\'2ZU7"4FM7@M&K&8-1*QN#T&L>!$_JX03/*N1%3JK
MH!8YJ[ 7.*O#%SBJX1<WJ?,8-Z?^&3:F_QHVIO\:-J;_&C:F_QJZA   KH\
M **6  "7FP  BZ$  '^F  !SJP  9Z\  %JT  !3M@P 4;<7 $^W) !-N#
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M B'5T@(@T^L"(-+V Q_1_P0?T?\$']'_!!_1_P2?FP  E*(  (>I  !YL0
M;;@  &"^  !4PP  2<<  #[+   UT $ +=4& "7;"P DWA( (]X< "+?)0 A
MX"X (. W !_A0  >X4H '>)3 !SC7@ ;XVH &N1X !CDB $7Y9H!%N:L 17F
MP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@  B:D  'NQ  !NN0  8<
M %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <[!  &^T7 !GM'P 7[B8
M%>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS>  ,](H "_6<  KUK@ )
M]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(  &^Z  !BP@  5<D  $?.
M   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T $OL2 !#\%P ._!T #?TC
M  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@  _W<  /^)  #_FP  _ZL
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M: 34.'$&T3AZ!\\W@0C--X@)RS:/"LHVE@K(-IT+QC6D#,4UK S#-;4-P37
M#< VSPZ]-N8.N3;T$+<V_Q&U-O\2M#;_$[,V_Q.S-O\3LS;_$[,V_Q/_.1
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M'HU*]AZ+2_\>BTO_'8I+_QV*2_\=BDO_'8I+_QW_10  _TT  .54  #960
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M(F];_R)O6_\A;UO_(6];_R'Z3P  X5H  ,]B  #$9P  NVL  +-L  "L:@0
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M(EQJ_R+C6P  SF8  ,!N  "V=   K'D  *-[  "8>0  D'H+ (I[%@"%?"0
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M'TU^HB!+?;$A2GW$(DI]X2%+?/0A2WO_($M[_R!+>_\@2WO_($M[_R#09P
MP'(  +1[  "J@@  H(8  )6(  "'B   ?(H  ':,#@!RC1H ;HXG &J.,@%F
MC3P#8XU$!6",3 A<BU,*6HM:#5>*81!4B6@248AQ%4^(>A=,AX4:2H:2'$B&
MH!U&AJ\>187"'D6%WQY%A/(>18/^'D6"_QY%@O\>18+_'D6"_Q[*;0  NG@
M *^!  "EAP  FHL  (^-  "!C@  =)$  &Z3"@!IE!4 9I4B &.5+@%@E3@"
M7)5!!%F42096E% (5)-7"E&37@Q.DF8/3))N$4F1>!1&D(,61)"0&$*/GAE
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M#S.EU \SI.X/,J+[$#*A_Q$RH?\1,J'_$3*A_Q&T@@  J(P  )V2  "2EP
MAIP  'FA  !MI0  8:D  %6L  !+KP4 1[ 0 $6P' !$L2< 0K$R $&R.P _
MLD,!/;)+ 3NR4P(YLEL#-[)D!#6R;@4SLGD&,;*'!R^QE@@NLJ8(+;*X"2RR
MT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP  H)(  )68  ")G0  ?:,
M '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P WO!X -;PI #2],@ SO3L
M,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_D0,FOZ(#)+^T R._RP,C
MON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@  (R>  " I0  <ZL  &>P
M  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!, )\D= ";))P ER3  ),HY
M "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;S9P &<ZN 1C.Q0 8S>0
M&,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F  !UK0  :+,  %RY  !0
MO0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0 !78&0 5V2( %-DK !/:
M-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$ #N"D  W@N  ,X-( "]_M
M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !JM0  7;P  %#!  !$Q0
M.,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G$@ -Z!D #.@A  OI*0 *
MZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4  #JIP  Z[P  .O2  #K
MZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@  4<4  $/)   WS0  +=$
M "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %]A(  _88  #U'@  ]24
M /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #VE0  ]Z<  />W  #XQP
M^-   /C0  #XT ![KP  ;;@  &#   !2R   1,T  #?1   KUP  (=P  !C@
M   1Y   #.<   ?O   $^@   ?\#  #_"   _PT  /X0  #^%   _QH  /\A
M  #_*0  _S,  /\^  #_2P  _UL  /]L  #_@   _Y(  /^A  #_K0  _[,
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M >,9U0'?&N@!W!OU M@;_P+5'/\#U!S_ ],<_P32'/\$TAS_!-(<_P3_*1<
M_RH3 /\I$@#_+!@ _RPA /\L*P#_*3< _2=# /<E3P'S(UH![R)D >PA;@'I
M(7<!YR%_ >4AA@'D(8T!XB"4 >$@F@'?(* !WB"G =PAKP':(;@"V"'# M4A
MTP+1(N<"S2+T \HC_P3((_\%QR/_!L8C_P;&(_\&QB/_!L8C_P;_+!( _RX/
M /\P$ #_,Q0 _S,; /\R)0#Z,#  \BX\ .PL20#G*E4!XRI? > I:0'=*7(!
MVBAZ =<H@@+5*(D"TRB0 M$HE@//*)P#SBBC \PHJP/**+,#R2B^!,<HS 3%
M*>($P2KQ!KXJ_@>\*O\(NBK_"+HJ_PBY*O\)N2K_";DJ_PG_, \ _S(+ /\V
M#0#_.!  _SD5 /DW'@#O-2@ YS,U . R0@#;,D\ U3%: = Q9 +-,&T"RS!U
M \DP? /'+X,$Q2^*!,0OD07"+Y<%P2^>!K\OI@:]+Z\&O"^Y![HOQP>X,-T'
MM3#N";(P^PJP,/\+KC#_"ZXP_PNM,/\+K3#_"ZTP_PO_,PP _S8& /\\"0#_
M/@P _3T0 .\\%0#D.1\ VSDM -(Z/ #-.DD!R#E4 <0Y7@+!.&<#OS=O!+TW
M=@6[-GT&N3:$![<VBP>V-9((M#6:";,UH0FQ-:H*KS6T"ZXUP0NL-=0+J3;J
M#*8V^ VE-O\.HS?_#J(W_PZB-_\.HC?_#J(W_P[_-P< _SL" /]  P#R0@4
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M%WU+_Q=]2_\6?4O_%GU+_Q;_0P  YDP  -93  #)6   P%D  +I8 0"T5@D
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M&65:_QGH3P  TUD  ,1A  "Y9@  L&@  *=I  ">90  EV8- )%G&0",:"<
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M&EEFHAM79K <5F;#'59FWQU69O,<5V;_&U=F_QI79O\:5V;_&E=F_QK;60
MQV(  +IJ  "O<   IG,  )IS  "/<   AW$% (%R$0!\<QX >',J '1S-0%P
M<S\#;7)'!6IQ3@=G<54)9'!<"V)O8PY?;VH076YR$EIM?!58;8875FR3&51L
MH!M2:Z\<46O!'%%KW!Q1:_$;4FO^&E)J_QI2:O\94FK_&5)J_QG47   PV8
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M%D" TA9!?^T607[[%D%]_Q9!??\607W_%D%]_Q;":@  M74  *I]  "?@@
MDH,  (6$  !YA0  :HD  &2* P!@C!  78T; %N.)P!8CC( 58X[ 5..0P)0
MCDH#3HU2!4R-609)C& (1XQH"D6+<@Q"BWT.0(J)#SZ*F!$\BJ<2.XJX$CJ*
MSQ([B.L2.X?Z$SN&_Q,[AO\3.X;_$SN&_Q.\<0  KWL  *6#  "9AP  C(@
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M!"6H_P4EI_\%):?_!26G_P6GB0  FX\  )&4  "$F0  >)X  &NB  !?I@
M4ZH  $BM   ]L   -+,# "^U#@ MM18 ++4@ "NV*0 JMC( *;<Z "BW0P G
MMTP )KA5 "2X7P CN&L (KAX 2"XB $?N)D!';FK 1RYP $<N-\!'+;R 1NU
M_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0  ;J8  &*K  !6L   2K,
M #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;PR8 &L,O !G$.  8Q$$
M%\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'N0 /Q]0 $,;N !#$^@ 0
MP_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\  %BT  !+N   0+L  #6^
M   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D #=$A  S1*@ ,T30 "](^
M  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #U<   =7<  '5[0 !U?8
M =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]   _P   -,,  "K'   A
MR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8  '>(   WB@  -\Q  #@
M/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X  .7!  #EU0  YN<  .;G
M  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   SR   *,P  !_0   7U
M$-D   O=   %X0   .0   #E!P  Y@T  .<1  #H%@  Z1T  .HE  #K+@
M[3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M  #TNP  ],@  /3(  #T
MR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0  '=8  !3<   .X   ".,
M  'F    Z@   .X   #N    [P0  / *  #Q#@  \Q(  /08  #V(   ^"H
M /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_I@  _[   /^P  #_L #_
M%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1 /\ 70#_ &@ _P!R /\
M>P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8 ^P"L /D LP#W +L ]0#%
M /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M /\ [0#_ .T _P#_&2
M_Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%60#_!&0 _P1N /\#=P#_
M X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J /,!L #Q ;@ [P'" .T!
MSP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\ Y@;_ .8&_P#_'!L _QL9
M /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_"V  _PMJ /T+<P#["WP
M^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)K@#K";8 Z G  .8)S0#D
M">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_ =L-_P'_'Q< _QX3 /\;
M$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L ]1!F /,0;P#P$'< [A!_
M .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A#[0 X ^^ -X/S #:$.$
MU1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3_P'_(A( _R(/ /\A#P#_
M(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@ .<6:@#D%G( XA9Z . 6
M@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$ T!>[ ,X7R0#,&-X R!GN
M <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_)@X _R4+ /\H# #_*1
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M"I(W_PJ2-_\*DC?_"I(W_PK_,P  ]CH  .0_  #80@  SD(! ,D^!@#$.P\
MNSX= +4_+ "Q/SH K3]% :D_3P&F/E@"HSU? Z$]9P2?/&T%G3QT!IP[>P::
M.X('F#N*")8[DPF5.IP*DSJF"Y$ZL@N0.\ ,CCO5#(P\[ V*//L-B3S_#8D\
M_PR(//\,B#S_#(@\_PS_-P  ZC\  -Q%  #.20  Q4D  +]& @"Z0PP LT09
M *U%)P"H1C4 I$5! :!%2P*=1%,"FD-; YA#8@660FD&E$%P!Y)!=@B00'X)
MCD"&"HU C@N+0)@,B4"B#8= K@Z%0+P/A$#/#X)!Z0^!0?D/@$'_#X!"_PZ
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M$'%+_Q#L0P  V4P  ,A3  "]5P  M%@  *Q7  "E4@$ GE,/ )A4' "35"D
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M$F-5H11B5:\5857!%F!5VQ9@5O$58%;^%&!6_Q-A5O\285;_$F%6_Q+@30
MRU8  +U=  "R80  J&,  )UA  "570  C5X) (=>$P"#7R  ?U\L 'M?-P%W
M7D "=%Y( W%=3P1O7%8%;%Q<!VI;8PEH6VL+9EIS#61:? ]B6H<18%F3$EY9
MH!1=6:X56UF_%EM9V!9;6>\56UG]%%Q9_Q-<6?\27%G_$EQ9_Q+<4   QUD
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M%$QGSQ1,9NL436;[$TUF_Q).9?\23F7_$DYE_Q+,6@  O&,  +!J  "E;P
MF&X  (QM  " ;   =VT  '%N"P!M;Q0 :7 A &9Q+ !D<38!87$^ 5YQ1@)<
M<$T#67!4!5=P6P95;V((4V]J"E!N<PQ.;GX.3&V*$$IMF!%);*<22&RX$T=L
MS1-';.H32&OZ$DAK_Q)(:O\12&K_$4AJ_Q''7@  N&<  *QN  "A<@  DW(
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M"S:!_PPV@/\,-H#_##: _PRV;P  JG@  )]_  "0?@  @W\  '>   !K@@
M7H<  %6*  !.C 8 2HX0 $B/&@!'CR4 19 O $20. !"D$  0)!' 3^03P$]
MD%8".Y!? CF0: ,WCW,$-8^ !3./C@8QCYX',(ZO!R^.PP<OCN$'+XST""^+
M_P@OBO\(+XK_"2^*_PFP=@  I7\  )B$  "*A   ?84  '"'  !EB@  6HX
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M 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0J   1:P  #NP   QL@
M)[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]+@ 0O3< $+Y!  Z^3  .
MOE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?  B^\  (O?H "+W\  B]
M_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP  /+8  #&X   GNP  '[X
M !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $RBP  \HV  +*0   RTP
M ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,X@  S.\  ,SQ  #,\0"*
MF@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X  ";!   =Q   %<@   _+
M   *S@  !-("  #3"@  TP\  -04  #5&@  UB(  -<J  #9-   VC\  -Q+
M  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R   WMX  -[B  #>X@!_H@
M<:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+   3SP  #=(   ?6
MVP   -X   #? P  X D  .$.  #B$@  XQ<  .4>  #F)P  Z#$  .H]  #L
M2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(  .[&  #NQ@!TJ@  9K(
M %BY  !+P   /<4  "_)   DS0  &=$  !'6   +VP   ]X   #A    Y0
M .@   #I    Z@   .L&  #M"P  [P\  / 3  #R&@  ]",  /<N  #Y.P
M^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO  #^KP#_$!\ _PX= /\*
M'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4 _P!N /\ =P#_ '\ _@"&
M /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S +4 \@"] /$ R0#O -P
M[@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H _P#_$QP _Q$9 /\-&0#_
M!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K /T <P#Z 'L ]P"# /4
MB0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +( Z@"Z .@ Q@#G -8 Y0#H
M .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_%1@ _Q,4 /\/% #_#1D
M_PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8 ;P#R '< [P!^ .T A0#K
M (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X -\ PP#= -$ VP#F -D
M\P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!, _Q40 /\2#P#_$A4 _Q$=
M /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I!7( Y@5Z .0%@0#B!8<
MX :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&P #0!\\ S@CE ,P)] #*
M"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD, /\8#0#_&!$ _Q<8 /\4
M(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T VPUU -@-? #5#8( TPV)
M -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&#L\ PQ#F , 1]0"]$O\
MO!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?" #_'PT _QT2 /@:&P#N
M%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O ,D4=P#'%7T QA6$ ,05
MB@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L MQCB +,9\@&Q&O\!KQO_
M :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\) < ]R$, .P=$@#A&AP
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M!X(W_P?T,@  XSL  -)!  #&1   O4,  +<_  "Q.PD JCL4 *4\(@"@/3
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M"G!$H@MO1*\,;D3 #&U%V0UL1>\,:T7]"VM&_PMK1O\*:T;_"FM&_PKE0
MSTD  ,%/  "U4@  JU(  *%/  ";2@  E$H, (]+%P"+3"0 ATPO (1,.@"!
M3$,!?DM+ 7M+4@)Y2E@#=TI?!'5)9@5S26T&<4EU!V])?@AM2(@):TB3"VI(
MGPQH2*T-9TF]#69)U YE2>T-94K\#&5*_PME2O\+94K_"V5*_PO@1   RTT
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M#U95S ]65>D.5E7Y#595_PU75/\,5U3_#%=4_PS130  P%8  +-<  "G7@
MFET  (]<  "&6   ?UD  'E:#0!T6Q< <5LC &Y;+@!K6S< :%M  65;1P%C
M6DX"85I5 U]:7 1=6F,%7%IK!EI9= A867\*5EF+"U19F U36*8.4EFV#E%9
MR@]16><.45CX#5)8_PU26/\,4EC_#%)8_PS-40  O%D  +!?  "C80  EF
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M#$-F_PM#9?\+0V7_"T-E_PN_7   L60  *9J  "6:0  B6D  'UI  !Q:0
M9VH  &)L 0!=;0T 66X6 %=O(0!5<"L 4W U %%P/0!0<$4!3G!, 4QP4P)*
M<%H#2'!B!$9O:P5$;W4&0F^"!T!NCPD_;IX*/6ZO"CUNP@H\;N */6WT"CUL
M_PH]:_\*/FO_"CYK_PJZ8   K6D  *!N  "1;0  A&T  'AM  !L;@  87
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M!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=@0  4H4  $F)  !!C
M.9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V300 LDTH *Y12 "J47  H
ME&< )Y1S 264@@$DE),!(I.D 2&3MP$@D\\!(9+L 2"0^@(@C_\"((__ B"/
M_P*D?   EX   (=_  ![@   ;H(  &*%  !7B0  38X  $*2   ZE@  ,ID
M "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR "*>.@ AGD( ()Y+ !^?50 >GV
M')]M !N??  :GXT &)^? !>?L@ 6G\D %I[H !:<]P 6F_\!%YO_ 1>;_P&=
M@P  CX8  (*&  !TAP  9XL  %N/  !0DP  1I@  #R<   SH   *Z,  ".F
M   <J L &JD1 !BI&  7J2$ %JHI !6J,0 4JCD $ZI# !.K30 2JU@ $:ME
M !"K=  .JX8 #JN9  VKK  ,J\$ #*K?  RI\@ -J/P #:C_  VH_P"6B@
MB8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G   KJ@  (ZX  !NP   4
MLP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y  >W0P &MT\ !+=;  .W
M:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$  +7W  "U]P"/D0  @90
M '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   CM0  &K@  !.[   .O0
M"< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##.0  Q$0  ,10  #$7@
MQ6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N  #$[@"&F   >9X  &NC
M  !=J0  4*X  $2S   WM@  ++D  "*\   9OP  $<(   S%   &R    ,L
M  #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0  TC@  -1$  #44@  U6$
M -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8W0![H   ;J8  &"M  !3
MLP  1;@  #B\   KOP  (<(  !?&   0R0  "LP   +0    U    -<   #8
M    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH  .4V  #G0P  YU,  .AD
M  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!PJ   8J\  %6V  !'O
M.<   "S$   @R   %LP   [0   'U    -D   #=    X0   .,   #D
MY@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G  #V,P  ]T,  /A4  #Y
M9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL _P<9 /\ &0#_ !P _P E
M /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#] 'L ^P"" /H B #X (T
M]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X PP#L -$ ZP#F .D \P#H
M /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5 /\!% #_ !@ _P B /\
M+@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '< \P!^ /( A #P (D [P"/
M .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C ,P X0#B -\ \ #> /L
MW@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&$ #_ A4 _P > /\ *0#_
M #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y .@ ?P#G (4 Y0"+ .0
MD #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@ T@#= -$ [0#0 /D SP#_
M ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_"Q( _P<9 /\") #_ #
M]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T >P#; ($ V0"& -8 C #4
M )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7 ,4 Z@## /< P@#_ ,$!
M_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X _PX4 /\*'@#U!BD ZP0V
M .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,!7P R@6" ,D%B #'!8X
MQ@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)Z0"W"_@ M0S_ +0,_P"T
M#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$. /(.%0#H#"$ W@HN -8+
M.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7< OPU] +T.@P"\#HH N@Z1
M +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K$OH J1+_ *@3_P"G$_\
MIQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40#@#9#A< SQ$F ,@2- #$
M$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X +$6?@"O%H4 KA:, *P6
ME "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O< G1O_ 9P;_P&<&_\!FQO_
M 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*%Q$ PAH@ +P<+0"W'3H
MLQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?>0"C'X  HA^' * @CP"?
M()@ G2"B )L@K &:(;D!F"'* 98BY &4(_4!DB/_ 9$C_P&0(_\!D"/_ 9 C
M_P'_(@  ZRD  -TN  #/+P  QRT  ,$G P"](@T MB,: + E* "L)C0 J"9
M *4G20"B)U( H"=: )XG80"<)V< FR=M )DG= "8)WL!EB>" 94GBP&3)Y0!
MD2B> 9 HJ0&.*+4"C2G& HLIWP*)*O("ARK_ H8J_P*&*O\"ABK_ H8J_P+T
M*   XS$  -$V  #%.   O#8  +8P  "R*PD JRP4 *8M(@"B+B\ GBXZ )LN
M1 "8+TT EB]5 )0N7 "2+F( D"YI 8\N;P&-+G8!C"Y^ 8HNA@*(+H\"ARZ:
M H4OI0.#+[(#@B_" X$PV@-_,.\#?3'^ WTQ_P-\,?\#?#'_ WPQ_P/M+P
MVS<  ,D]  "^/@  LSP  *PX  "G,P0 HC(1 )TT'0"9-2H E34U )(U0 "/
M-4D C350 (LU5P")-5X!AS5D 84T:P&$-'("@C1Y H T@@)^-(L#?326 WLU
MH01Y-:X$>#6^!7<VU 5V-NT%=#?\!70W_P1T-_\$=#?_!'0W_P3G-0  TCT
M ,-"  "X1   K$(  *0^  "?.0  FC@. )0Z&0"0.B8 C3LQ (H[.P"'.T0
MA#M, (([4P& .EH!?CI@ 7TZ9P)[.FX">3IU G<Z?@-V.H@$=#J3!'(ZG@5Q
M.JL%;SN[!FX[SP9M.^H&;3SZ!FP\_P5L//\%;#S_!6P\_P7B.0  S$(  +Y'
M  "Q2   I48  )U#  "7/P  DCX+ (T_%0")/R$ A4 M () -P!_0$  ?4!(
M 'M 3P%Y0%8!=S]= 74_8P)S/VH"<3]R W _>@-N/X0$;#^0!6L_G 9I/ZD&
M:#^X!V= S =F0.@'9D#Y!F5 _P9E0/\&94#_!65 _P7</@  QT8  +E+  "L
M3   H$H  )='  "10P  BT,( (9#$@""1!X ?D0I 'M%- !Y13T =D5% '1$
M3 %R1%,!<$19 6Y$8 )L0V<":T-O VE#=P1G0X$%9D.-!F1#F09B0Z<'842V
M"&!$R@A@1.8(7T7X!U]%_P=@1?\&8$3_!F!$_P;600  PTD  +9.  "G3P
MFTT  ))+  ",1P  A4<$ (!'$ !\2!H >$@F '5), !S23H <$E" &Y)20%L
M2% !:DA6 6A(70)F2&0"94AL V-(=01A1W\%8$>*!EY(EP==2*4(6TBT"%M(
MQPE:2.0(6DGV"%I)_P=:2/\&6DC_!EI(_P;110  OTP  +)2  "C40  EU
M (U.  "&2@  @$H! 'I+#@!V3!< <DPC &],+0!M338 :DP_ &A,1@!F3$T!
M9$Q3 6),6@)A3&$"7TQI UY,<@1<3'P%6DR(!EE,E0=73*,(5DRR"%5,Q@E5
M3.()54SU"%5,_P=53/\'5DS_!E9,_P;,2   O%   *]5  "@5   DU,  (E1
M  "!30  >DX  '5/# !P3Q4 ;5 @ &I0*@!G4#, 95 \ &-00P!A4$H!7U!1
M 5U06 )<4%\"6E!G UE0< 174'H%55"&!E10DP=24*$(45"Q"5!0Q E04.$)
M4%#T"%%0_P=13_\'44__!E%/_P;)2P  N5,  *M7  "<5@  CU4  (54  !\
M4   =5$  '!2"0!K4Q( :%0= &54)P!B5#$ 8%0Y %Y400!<5$@!6E1/ 5E4
M5@%75%T"5E1E U14;@125'@%452$!D]4D0=.5* (3%2O"$Q4P@E+5-\)3%3S
M"$Q3_P=,4_\'35/_!DU3_P;%3@  ME8  *=:  "860  BU@  (%7  !W5
M<%4  &I6!@!F5Q  8E<: &!8) !=6"X 6UDW %E9/P!7648 5EE- 5195 %3
M65L"45EC D]8; -.6'8$3%B"!4I8CP9)6)X'2%BN"$=8P A'6-T(1UCR"$=7
M_P=(5_\'2%?_!DA7_P;!40  LED  *-<  "46P  AUL  'U:  !R6   :UD
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M!3AF_P6T7@  IV4  )5E  "&9   >F4  &]E  !D9@  66@  %)J  !-; 0
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M ":"?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_]P$B?O\"(GW_ B)]_P*E<0
MDW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.    [@P  ,X8  "V)"@ J
MBA$ *8L9 ">+(@ FBRH )8PQ "2,.0 CC$( (HU* "&-5  @C5X 'XUK !V-
M>0 <C8H &XV< !F-K@ 8C,0 &(SC !F*]0 9B?\!&8C_ 1F(_P&==P  C'8
M 'UV  !R=P  97D  %I\  !0@   1H0  #R)   TC   +9   "63 @ ?E0P
M'982 !R6&@ ;ER( &I<J !F7,@ 8F#H %YA# !:830 5F%@ %)AD !.8<P 1
MF(0 $)B6 !"8J0 .F+\ #I?=  ^6\@ 0E?P $)3_ !"4_P"5?0  A7P  'A\
M  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP  )IH  !Z=   7H , $J(,
M !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +I%  "J1<  FD:@ 'I'L
M!J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A^P"-@P  ?X(  '&$  !D
MAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4  !>H   1JP  #*X'  >O
M#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<  +!3  "P80  L'$  +"#
M  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'B0  >(H  &J.  !=DP
M49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T   +M@  !;D#  "Z"@
MN@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(  "^5@  OF4  +YW  "^
MC   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@  <)4  &*:  !5GP  2:4
M #VK   RKP  *+0  !ZV   5N0  #KP   F_   "P@   ,0   #%!   Q@H
M ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.20  SUD  ,]J  #/?@
MSY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$  %NG  !.K@  0;0  #2W
M   HN@  ';T  !/    -Q   !L<   #*    S@   -    #1    T@(  -,(
M  #5#   UA   -D5  #;'   W20  . O  #B/   XTL  .1<  #D;P  Y8,
M .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R  !$N0  -;P  "C    <
MQ   $L@   S+   #SP   -,   #8    W    -\   #?    X0   .,   #D
M P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP  /1-  #U7P  ]G,  />'
M  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_ !@ _P C /\ +P#_ #P
M_P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@ @P#V (@ ]0". /0 DP#R
M )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A .< \0#F /T Y0#_ .0
M_P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4 _P ? /\ *P#_ #< _P!$
M /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M (0 ZP"* .H CP#H )0
MYP": .4 H #D *< X@"O .  N0#> ,8 W #: -H [ #8 /D U@#_ -8 _P#7
M /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P : /\ )@#\ #( ]P _ /0
M2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (  X "% -X BP#< )  VP"6
M -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#) /4 R #_ ,@ _P#( /\
MR #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P ( #Q "P [  Y .D 10#E
M $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "  ,X A@#, (P RP"2 ,D
MF #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /( NP#] +L _P"Z /\ N@#_
M +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F "4 X0 R -P /P#6 $D
MT0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$ @0#  (< O@". +P E "[
M )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[ *X"_P"M _\ K0/_ *T#
M_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT T@,K ,P#-P#(!$, Q 1-
M ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S!H, L@:) + &D0"O!YD
MK0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-_P"A#?\ H0W_ * -_P#_
M$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB , ,, "\#3P N U& +4-
M3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX IP^% *4/C0"D#Y8 HA"?
M * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5%/\ E13_ )04_P#_%0
M[1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03*0"P%#4 K!5  *D520"F
M%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>  )D7B "8%Y$ EAB; )08
MI@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\ B1S_ (D<_P#T'0  Y"4
M -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D'2\ H1XZ )X>1 ";'DP
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M G PR0)O,.4";C'W FTQ_P)M,?\";3'_ FTQ_P+?,@  R3D  +L^  "L/0
MH3H  )HW  "5,P  D#$* (PQ% "',B  A#,K ($S-0!_,SX ?3-& 'LS30!Y
M,U0 =S-: '8S80!T,V<!<C1O 7$T=P%O-($!;C2, FPTF )J-:4":36S V@U
MQ@-G-N(#9C;U V8V_P)F-O\"9C;_ F8V_P+8-P  Q#X  +5"  "F00  FS\
M ),\  "-.   B#8' (0W$0" -QP ?#@G 'HX,0!W.3H =3E" ',Y20!Q.5
M<#E7 &XY70!L.60!:SEK 6DY= %H.7X"9CF) F0YE0-C.J(#8CJQ V$ZPP-@
M.^ $7SOS U\[_P-?._\#7SO_ E\[_P+1.P  P$(  +!%  "A1   E4,  (U
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M!%1#_@-40_\#5$/_ U1#_P/(0@  N$D  *=+  "82@  C4D  (-'  !]0P
M=D,  '%$"@!M1!( :D4= &=%)P!D13  8D4X &!%/P!?14< 745- %M%5 !:
M1EL!649C 5=&; %61G8"5$:! U-&C@-21YP$4$>K!%!'O01/1]8%3T?O!$]'
M_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53   B4L  ']*  !X1@  <4<
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M T)1_P.Z3P  JE0  )A4  ")5   ?5,  '-3  !I40  8E(  %Q3  !85 H
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M 35C@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A^ (Q8?\",F#_ C)@_P*N7
MFUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB  !%90  068* #YG$0 \
M:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2 #-J6P Q:F4 ,&IP 2YJ
M?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"*V?_ BMG_P*I80  E6
M (1@  !W8   ;&$  &)A  !88P  3F8  $=H  ! :P  .FX% #9O#@ T<!4
M,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR5P J<F$ *7)M "=R>P F
M<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_ 2-N_P&A90  CF0  ']D
M  !R9   :&4  %YF  !4:0  26P  $)O   [<@  -'4  "YX"@ K>1$ *GD8
M "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A>UP ('MH !]\=@ =?(8
M''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW_P&9:0  B&D  'EI  !M
M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT  ">! P B@PT ((02 !^$
M&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8 %H9C !6&<0 4AH$ $H:3
M !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1;@  @6T  '1N  !I;@
M77   %-S  !)=P  0'P  #>    O@P  )X<  "&*   :C08 %8\- !.0$P 2
MD!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<  R1:@ +D7H "I&-  B0
MGP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P  >W,  &]S  !C=0  5W@
M $U]  !#@0  .88  #"*   HC@  (9$  !J5   3EP  #IH(  N<#@ )G!,
M")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=8@  G'(  )R$  "<EP
MFZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD  &AZ  !<?@  48(  $:'
M   \C   ,I$  "F5   AF0  &9T  !*@   .HP  ":8%  .G#   IQ   *<5
M  "H'   J",  *@K  "I-   J3\  *E+  "I60  J6@  *EZ  "IC@  J:$
M *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$  !5B0  28X  #Z4   T
MF0  *IX  "&B   9I@  $JD   VL   'KP   +(   "S!P  LPP  +,0  "T
M%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T  +AN  "X@@  N)<  +BJ
M  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.E@  0IP  #>B   LIP
M(JL  !FO   1LP  "[8   2Y    O    +X   "^    OP8  , +  #!#P
MPA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB  #)=0  R8H  ,F?  #*
ML0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I   .JL  "^P   DM0  &;@
M !"\   *OP   <$   #$    R    ,H   #*    S    ,T#  #."   T T
M -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?9P  X'P  ."1  #@I
MX+(  ."^  #@PP!FGP  6:8  $RM   _M   ,K@  "2\   8OP  $,,   C'
M    R@   ,T   #1    U0   -@   #9    VP   -T   #?    X00  .,*
M  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R6   \VL  /.   #TE   ]*,
M /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\ + #_ #D _P!% /\ 4 #_
M %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@") /$ C@#P ), [@"9 .T
MGP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L X@#_ .$ _P#A /\ X0#_
M .$ _P#_ !  _P . /\ #0#_ !( _P ; /\ * #_ #0 _@!! /L 3 #W %8
M] !? /$ 9@#O &T [ !T .H >@#I '\ YP"% .8 B@#E (\ XP"5 .$ FP#@
M *( W@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_ -$ _P#0 /\ T #_ -
M_P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W "\ ]  [ /  1P#M %$ Z0!:
M .4 8@#B &D X !O -X =0#< 'H V@"  -@ A0#5 (L TP"1 -$ EP#/ )X
MS0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,( _P#! /\ P@#_ ,( _P#_
M P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V ., 00#? $L VP!4 -4
M7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8 Q0", ,, DP#! )H OP"B
M +T JP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T /\ M #_ +0 _P#_!
M_P   /\   #_  8 [  - .4 %@#> "( UP O -$ .P#- $4 R@!. ,8 5P#$
M %X P0!D +\ :@"] '  O !U +H >P"Y ($ MP"' +4 C@"S )4 L@"> +
MIP"N +( K "_ *H T0"H .@ J #W *< _P"G /\ I@#_ *8 _P#_!@  _P4
M /$#  #H    X0 ' -4 $ #- !L QP G ,, ,P"_ #X O !( +D 40"V %@
MM !? +( 90"P &H KP!P *T =@"L 'P J@"" *D B0"G )$ I0": *, I "A
M *X H "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_ )D%_P#_"@  \0X  .00
M  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S!#< L 5" *T&2@"J!E( J =9
M *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";"8X F@F7 )@*H0"6"JP
ME0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_ (T._P#V$0  YA<  -8;  #'
M&0  OA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[ *(.1 "?#TP G0]3 )L/
M6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H CQ&4 (T1GP"+$:H BA*X
M (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M&@  W"$  ,HE  "[(@
ML1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86/@"4%D< DA9. ) 650".
M%UL C!=A (L79P")%VT B!=T (88? "%&(8 @QF0 ($9FP" &J< ?AJU 'T;
MQP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@  T"D  +\L  "P*@  IR<
M * C  "='P  FAH. )4<& "1'20 CAXO (P>.0")'D$ AQ]) (4?4 "#'U8
M@A]< ( ?8@!_'VD ?2!P 'P@> !Z(($ >2&, '<AEP!U(J0 ="*R ',CPP!R
M(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=*0  R#   +<R  "H,   GBX  )<J
M  "3)P  D",* (PC$P"()!\ A"4J ((E- " )CT ?29$ 'PF2P!Z)E( >"98
M '<F7@!U)F4 ="=L '(G= !Q)WT ;RB( &XHE !L**$ :RFO 6HIP %I*ML!
M9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P  PC8  *\V  "A-0  EC0  ) P  "*
M+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W+#@ =2Q  ',L1P!Q+$T <"Q4 &XL
M6@!M+&$ :RUH &HM< !H+7H 9RZ% &4ND0%D+IX!8B^L 6$OO0%A,-4!8##O
M 5\P_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";.@  D#@  (DU  "#,@
M?S ! 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ0P!J,4H :#)0 &<R5P!E
M,ET 9#)E &(R;0!A,W< 7S." 5XSC@%=-)P!6S2J 5HUNP%:-=(!637M 5DU
M_ %8-?\!6#7_ 5DU_P'(.   MSX  *0^  "6/0  BSP  (,Z  !]-P  >#0
M '0T"P!P-1, ;34= &HU)P!H-C  9C8X &0V/P!C-D8 839- & V4P!>-UH
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M/0X 83X7 %X^(0!</BD 6CXQ %@^.0!7/D  53]& %0_30!3/U4 4D!< %!
M90!/0&\!3D%Z 4U!AP%+098!2D&E DE"M0))0LL"24+H DE"^0))0?\"24'_
M 4E!_P&]0P  JD4  )A%  "*10  ?T4  '9#  !O0   :$   &-! 0!?00T
M7$$4 %E"'0!70B8 54(N %-"-@!10CT 3T)# $]#2P!.0U( 341: $Q$8P!*
M1&T!245X 4A%A0%'190!146C D5&M )$1LD"1$;G D1%^ )$1?\"147_ D5%
M_P&Z1@  ID@  )1(  "&2   >T<  ')&  !J0@  8T,  %Y$  !:10L 5D42
M %1&&P!11B, 3T8K $Y&,P!,1SH 2T=! $I'20!)2%  2$A8 $=(80!&26L
M1$EV 4-)@P%"29(!04FB D!)LP(_2L<"/TKE C])]P) 2?\"0$C_ D!(_P&V
M20  HDH  )%*  "#2@  =TH  &Y)  !E10  7D<  %E(  !520@ 44H0 $]*
M& !,2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$3$X 0TU6 $)-7P!!36@ 0$UT
M 3Y-@0$]39 !/$V@ 3M.L0(Z3L8".D[D CM-]@([3?\!.TS_ 3Q,_P&S30
MGDP  (U,  !_3   =$P  &I,  !@2@  64L  %1,  !0304 3$X. $E/%0!'
M3QX 14\F $10+@!"4#4 05 ] $!11  _44L /E%3 #U27  \4F8 .E)R #E2
M?P$X4HX!-U*> 392KP$U4L0!-5+B 392]0$V4?\!-E#_ 3=0_P&N3P  F4\
M (E/  ![3P  <$\  &9/  !<3@  5$\  $]1  !*4@$ 1E,, $-4$@!!5!L
M0%4C #Y5*P ]5C( /%8Z #M600 Z5DD .5=1 #A76@ V5V, -5=O #17? $S
M5XP!,5>< 3!7K0$P5\(!,%?@ 3!6] $Q5O\!,57_ 3%5_P&H4@  E5(  (12
M  !W4@  ;%(  &)2  !84P  3U0  $E6  !$5P  0%D( #U:$  [6A< .5L@
M #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=5P P76$ +UUL "Y=>@ L78D
M*UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:_P&C50  CU4  ']5  !R
M50  9U8  %Y6  !45P  3%D  $5;   _70  .E\$ #9@#0 T81, ,F(< #%B
M(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T *&1I "=D=@ F9(8 )627
M "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<6   B5@  'I9  !N60
M8UD  %I:  !07   2%X  $%@   Z8P  -&8  "]H"@ L:1  *FD7 "EJ'P H
M:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE !]L<@ >;(( '6R4 !QL
MI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57   @UP  '5<  !I70  7UT
M %9>  !,80  0V0  #QG   U:@  +VT  "AP!  C<@T (7(2 "!S&@ ?<R$
M'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U;@ 5=7X %'60 !-TH@ 2
M=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8   ?6   &]A  !E80  6V(  %%D
M  !(9P  /FL  #=N   P<0  *74  ")X   <>P< %WT. !9]$P 5?1L %'XB
M !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -?W@ #'^*  M^G0 *?K
M"7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE  !A9@  5F@  $QK  !"
M;P  .7,  #%W   J>@  (WX  !R!   5A   $(<(  V)#@ ,B10 #(D;  N)
M(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$  8F#  ")E@  B*D  (>^
M  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K  !;;   4'   $9T   \>
M,WT  "J!   CA0  '(@  !6,   0CP  #)(&  :3#  "DQ$  )06  "4'0
ME"0  )4L  "5-0  E4   )5,  "660  EFD  )5Z  "5C@  E*$  )2U  "3
MS   DN8  )+R  "2]P!X<   ;7   &!R  !4=0  27D  #]^   U@P  +(@
M ".-   ;D0  %)0   ^7   *F@  !)T#  ">"0  GPX  )\2  "@%P  H!T
M *$E  "B+0  HC<  *-#  "C4   HU\  *-Q  "CA   HID  **M  "AP@
MH=P  *'K  "@\@!S=@  9G<  %E[  !-@   0H4  #B+   ND   ))4  !N:
M   4G@  #J$   FD   "IP   *H   "K!   JPH  *P-  "M$0  K18  *X<
M  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R>0  LHX  +&C  "RMP  L<H
M +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9   FG@  '*,  !.G   -
MJP  !ZX   "R    M0   +<   "X    N0(  +D(  "Z#   NQ   +P4  "]
M&P  OR,  ,$M  #".@  PDD  ,-:  ##;   Q((  ,27  #$JP  Q+P  ,3+
M  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH   =K0  %+$   VV   &N0
M +P   "_    PP   ,0   #%    Q@   ,<   #)!   R@D  ,L-  #-$0
MSQ@  -(A  #5+0  UCP  -A-  #97P  VG,  -J*  #;G@  VZX  -NZ  #<
MPP!>E@  49P  $2C   XJ@  ++$  ""W   5NP  #;X   3"    Q0   ,D
M  #-    T    -(   #2    U0   -8   #9    VP   -X%  #@"@  X@\
M .46  #H(   ["T  .T^  #M40  [F4  .]Z  #OCP  \)\  /"K  #PLP#_
M !  _P . /\ #@#_ !( _P = /\ *0#_ #4 _P!! /\ 30#^ %8 ^P!? /@
M9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M (\ ZP"5 .H FP#H *( Y@"J
M .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#= /\ W@#_ -X _P#_  T
M_P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@ 2 #T %( \ !: .T 8@#K
M &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0 -P E@#: )T V "E -4
MKP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\ RP#_ ,L _P#_  @ _P #
M /\ !0#_  P _  4 /< 'P#R "L [P W .L 0@#G $P Y !5 .  70#= &0
MV@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L D@#) )D QP"A ,4 J@##
M +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_ +P _P#_    _P   /\
M  #Y  < \0 0 .H &@#D "4 WP Q -L / #7 $< T@!0 ,X 5P#+ %X R0!E
M ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z )0 N0"< +< I0"U +
MLP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T _P#_    _P   /T   #N
M  $ XP , -H % #1 !\ S  K ,@ -@#% $  P@!* +\ 4@"\ %D N@!? +@
M90"V &H M !O +, =0"Q 'H L "! *X B "M (\ JP"8 *D H0"G *L I0"X
M *, R "B .( H0#S *  _@"@ /\ H #_ *  _P#_    ]@   .H   #@
MTP & ,D #P#" !@ O0 D +D +P"V #H M !# +$ 3 "N %, K !9 *H 7P"I
M &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3 )P G0": *< F "T )8
MPP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0  Z@L  -P-  #+"@  P@4
M +P "@"V !$ L0 < *X * "J #, IP ] *0 10"B $T H !3 )X 60"< %\
MFP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !F0". J0 C *Q (L#P ")
M!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0  ,H5  "\$@  LQ   *X,
M  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7"4< E0E. ),)5 "1"EH D I?
M (X*90"-"FL BPIR (H+>0"("X( APN, (4,EP"##*( @0VP ( -P !_#=@
M?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=  "O'   IAD  *$5  ">
M$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!( (@03P"'$%4 A1!; (01
M80""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J  =Q.N '43O@!T%-4 <Q7N
M '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E(P  G"$  )8>  "2&0
MD10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X72@!\%U  >A=6 'D87 !W
M&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK &L<NP!J'-  :1WL &@>
M^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@  DR@  (TE  "((@  AAT&
M (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R'TL <1]1 &\?6 !N'UX
M;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(CN !A(\T 8"3I & D^@!?
M)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T  (4J  " *   ?20  'HB
M#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4< :"5- &8E5 !E)5H 9"9A
M &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:*LH 62KG %@J^ !8*O\
M6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O  !Y+0  =2H  '(H"@!O
M*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I* %\K4 !>*U< 7"M> %LL
M9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\< 4B_E %(O]P!2+_\ 4B__
M %(O_P#!-@  JC8  )DV  "+-@  @34  'DS  !S,0  ;R\  &LN!@!H+1
M9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O30!7,%, 5C!; %0Q8P!3
M,6P 4C)W %$RA !/,Y( 3C.A $TSL0!--,4!3#3C 4PT]@!,-/\ 3#3_ $PS
M_P"[.0  ICD  )4Y  "'.0  ?#D  '0W  !N-   :3,  &4R @!A,@T 7C(4
M %PS'@!:,R8 6#,N %8S-0!5-#P 4S1# %(T2@!1-%  4#58 $XU8 !--FH
M3#9U $LW@@!*-Y  23B? $@XL %'.,,!1SCA 4<X]0%'./\!1SC_ 4<X_P&W
M.P  HCP  )$\  "#/   >#P  ' Z  !J-P  9#8  & V  !<-@L 63<2 %8W
M&@!4-R, 4C<K % W,@!/.#D 33A  $PX1P!+.$X 2CE5 $DY7@!(.F@ 1SIS
M $8[@ !%.XX 1#R> $,\K@%"/,(!0CW? 4(\\P%"//\!0CS_ 4([_P&S/0
MGCX  (T^  !_/@  =3X  &P]  !F.@  8#D  %LZ  !7.@@ 4SL0 %$[& !.
M.R  3#LH $L[+P!)/#8 1SP] $<\1 !&/4L 13U3 $0^7 !#/F8 0C]Q $$_
M?@! /XT /T"< #Y K0$]0, !/4#= 3U \@$]0/\!/C__ 3X__P&N0   FD
M (E!  !\00  <4$  &A   !A/   6ST  %8^  !2/@4 3C\. $P_%0!)/QT
M1T E $9 + !$0#, 0T Z $)!0@!!04D 0$%1 #]"6@ ^0F, /4-O #Q#?  [
M0XL .D2; #E$JP$Y1+X!.$3; 3E$\0$Y0_X!.4/_ 3E#_P&J0@  ED,  (9#
M  !X0P  ;D,  &5#  !=0   5D   %%"  !-0@( 24,, $9#$@!$1!H 0D0B
M $%$*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y1V$ .$=L #='>@ V2(D
M-4B9 #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&_P"F1   DD4  ()&  !U
M1@  :D8  &%%  !91   440  $Q&  !(1P  1$<* $%($  _21@ /4D@ #Q)
M)P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\ ,TQJ #),=P Q3(8 ,$R7
M "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A1P  CD@  'Y(  !Q2
M9DD  %U(  !52   3$D  $=*  !"2P  /TP& #M-#@ Y3A4 -TX= #9/)  U
M3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G "Q1=0 K480 *E*5 "E2
MI@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@  B4H  'I+  !M2P  8TP
M %I,  !13   2$T  $-/   ]4   .5(" #53#  S5!( ,509 #!5(0 N52@
M+54O "Q6-P K5CX *E9& "E63P H5UD )U=D "97<@ E5X$ )%>2 "-7I  B
M5[< (E?/ ")7[  C5OH (U7_ "15_P"630  A$X  '5.  !I3@  7T\  %9/
M  !-4   15(  #]3   Y5@  ,U@  "]:"  K6P\ *EL5 "A<'0 G7"0 )EPK
M "5<,P D73H (UU# ")=3  A758 (%YA !]>;@ >7GX '5Z/ !Q>H0 ;7K0
M&EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1  !D4@  6U(  %)3  !*
M5   05<  #M9   U6P  +EX  "A@ P D8@P (F,1 "%C&  ?9"  'F0G !UD
M+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H %66+ !1EG@ 39;$ $F7(
M !)DYP 38_< %&+_ !1B_P")5   >%4  &M5  !@5@  5U8  $]7  !&60
M/5P  #9?   P8@  *60  "-G   =:@< &6P. !AL$P 6;1H %6TA !1M*0 4
M;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'  UNF@ ,;:T "VW"  ML
MX  ,:_, #6O]  UJ_P""60  <ED  &99  !<6@  5%H  $I<  !!7P  .6,
M #%F   J:0  )&P  !UO   7<@  $G4)  ]W#P .=Q0 #G<;  UW(P ,=RH
M"W<S  IW/  )=T< "'=2  =W7P %=V\ !'>   -WE  !=J<  ':[  %UU0 !
M=.L  G3V  )T_ ![70  ;5T  &)>  !97@  3F   $5C   \9P  ,VL  "MN
M   D<@  'G4  !=Y   2?   #7\&  F!#  %@1$  X$6  *!'0 !@20  ($M
M  ""-@  @D   (),  ""60  @F@  ()Y  ""C0  @:   ("T  " RP  ?^<
M '[R  !^^0!T8@  :&(  %YB  !39   26<  #]K   V<   +70  "5X   >
M?   %X   !&#   -A@  "(D$  *+"@  BPX  (L3  ",&   C!\  (TF  "-
M+P  CCD  (Y$  ".40  CF   (YQ  ".A0  CID  (VM  ",PP  C-\  (ON
M  "+]@!N:   9&<  %AI  !-;   0G$  #AV   O>P  )G\  !Z$   6B
M$(P   R/   &D@   )4   "6!P  EPP  )</  "8$P  F1@  )H?  ";)@
MFS   )P[  "<2   G%<  )QH  "<>P  G)   )NE  ";N@  FM   )KG  ":
M\0!J;0  7F\  %%R  !&=P  .WP  #&"   GAP  'HP  !:1   0E0  "ID
M  2<    H    *(   "C 0  HP8  *0+  "E#@  IA(  *<7  "H'@  JB8
M *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;  "KKP  J\,  *O9  "JZ !D
M=0  5WD  $M^   _A   -(H  "F0   ?E@  %IL  !"?   )HP   :<   "J
M    K@   +    "P    L0   +(#  "T"   M0T  +80  "W%0  N1T  +LF
M  "\,P  O4$  +U2  "]9   OGD  +Z0  "]I   O;<  +W&  "]UP!<?P
M4(4  $2+   XD@  +)D  "&?   7I   $*D   FN    L@   +8   "Y
MO0   +\   "_    P    ,$   ##    Q 4  ,8*  #'#@  R1,  ,L<  #.
M)@  T#4  -%%  #25P  TFL  -."  #3EP  TZD  -*X  #2Q !5C   29,
M #V:   PH@  ):@  !JN   1M   ";D   "]    P0   ,0   #(    RP
M ,T   #-    SP   -    #2    U    -@   #:!@  W0P  . 1  #C&@
MYB<  .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH  #LL@#_  T _P + /\
M"P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[ %( ^ !: /8 8@#S &D \0!O
M /  =0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D )T X@"E .$ KP#? +L
MW0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0 _P#_  @ _P $ /\ ! #_
M  T _P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5 .H 70#G &0 Y !J .(
M< #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D T0"@ ,\ J@#- +4 RP#$
M ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_    _P   /\   #_  H
M^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D 6 #5 %\ T@!E -  :@#.
M '  S !U ,H >@#) '\ QP"% ,4 C ## )0 P0"< +\ I0"] +  NP"] +H
MT "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_    _P   /T   #S  4 Z0 .
M .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$ %D P@!? ,  90"^ &H
MO !O +L = "Y 'H MP"  +8 AP"T (X L@"7 +  H "N *H K0"W *L R "I
M ., J #U *< _P"G /\ IP#_ *8 _P#_    _@   /$   #E    UP * ,T
M$0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %, L@!9 +$ 7P"O &0 K0!I
M *P ;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@ *4 G@"R )T P0"; -H
MF@#O )D _0"8 /\ F #_ )@ _P#]    \    .$   #1    Q@ $ +T #0"W
M !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4 *, 60"A %\ H !D )X
M:0"= &X FP!U )H >P"8 (, E@", )4 E@"3 *$ D0"M (\ NP"- ,\ C #I
M (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_!   MP   +$ " "K !
MIP 9 *0 ) "@ "X G@ W )P 0 ": $< F !. )8 5 "5 %D DP!> )( 9 "0
M &D CP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I (, N "! ,H @ #E (
M]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@  J T  *,(  "@ @P G  3
M )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"3@") E0 AP)9 (8"7P"$ V0
M@P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&M0!V!\@ =0CC '4)] !T
M"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,  )81  "4#00 DP@- (X'
M%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\ ?0Q4 'L,6@!Z#&  > QG
M '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L#LD :P_F &H0]P!I$/\
M:1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9  "(%0  AQ$' (4.$ "!
M#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0 '$15@!P$5P ;A)B &T2
M:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8 8A;C &$6]@!@%_\ 8!?_
M & 7_P#'(@  L",  )\D  "2(P  B2(  ((@  !^'0  ?!D  'H5#0!W%14
M=!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@840!F&%@ 91A> &,99@!B
M&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@ %@>] !8'O\ 6![_ %@>
M_P"_)P  J2@  )DH  "+*   @B<  'LE  !V(P  <R   '$<"0!N'!$ :QP:
M &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>'E0 7!]; %L?8@!9(&L
M6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D\@!1)/\ 423_ %$C_P"Y
M*P  HRP  ),L  "&+0  ?"P  '0J  !O*   :R4  &DB!0!F(0X 8R(6 &$B
M'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6)%  5217 %,E7P!2)6@ 429S
M $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!**?\ 2RG_ $LI_P"S+@
MGB\  (XP  "!,   =R\  &\N  !J*P  92H  &,G 0!?)PP 7"<3 %HG&P!8
M*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4 $TJ7 !,*F4 2BMP $DK
M? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX 12[_ $4M_P"N,0  FC(
M (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9+ D 5BP0 %0L& !2+"
M4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N60!&+V, 13!M $,P>@!"
M,8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_ $ R_P"J,P  EC4  (8U
M  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4, 8 43 . $XP%0!,,1T 2C$E
M $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P! ,V  /S1K #XU>  ]-8<
M/#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV_P"F-@  DC<  ((X  !U
M.   :S@  &,W  !=-@  5S,  %,T  !/- , 2S0, $DT$@!&-1H 134B $,U
M*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X .CAI #DY=@ X.84 -SJ5
M #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B.   CCD  'XZ  !R.P
M:#L  %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y$ !!.1< /SD? #XY)@ \
M.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG #0]=  S/8, ,SZ3 #(^
MI  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P  BSP  'L\  !N/0  9#T
M %P]  !5/   3CH  $D[  !%/   03T' #X]#@ \/14 .CX< #D^(P W/BH
M-C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!<@ N0H$ +4*1 "U"H@ L
M0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX  '<_  !K/P  84   %D_
M  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W0A( -4,9 #-#(0 R0R@ ,40O
M #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I1GX *$:/ "='H0 F1[,
M)D?) "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"  !G0@  7D(  %5"  !.
M0@  14(  #]$   [10  -T8  #1'"@ Q2!  +T@6 "Y)'@ L224 *TDL "I)
M,P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP (DN- "%,GP A3+$ ($S'
M "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D10  6D4  %)%  !*1@
M04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/&@ F3R$ )4\H "1/,  C
M4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D '%&* !M1G  :4:\ &5'% !E1
MY  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2   5D@  $Y(  !'20  /DL
M #E,   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?5AX 'E8D !U6+  <5C,
M&U<[ !I71  95TX &%=9 !=89@ 56'4 %%B' !18F@ 35ZP $E?" !)7X0 3
M5O0 %%7_ !15_P"$20  =$H  &9+  !<2P  4TL  $M,  !$30  /$\  #51
M   O5   *58  "19   >6P< &ET- !A=$@ 771D %EX@ !5>)P 47BX $UXW
M !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -7ZD #%Z^  Q>V@ -7?
M#5S\  Y<_P!^30  ;DX  &).  !83P  3T\  $A0  ! 4@  .%0  #!7   J
M6@  )%T  !]?   98@$ $V4) !%F#P 09A0 #V8;  YG(@ -9RD #6<R  QG
M.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,  F:W  -ESP $9>D !&3U
M  1D_ !W40  :5(  %U2  !44@  3%,  $-5   [6   ,UL  "M>   E80
M'V0  !EG   3:@  #VT&  MP#  (<!$ !W 6  5P'0 $<"0  W L  )P-0
M<#\  '!*  !P5P  <&4  '!V  !PB@  ;YX  &^R  !NR   ;>4  &WR  !M
M^0!P5@  8U8  %E6  !15P  1__B__])0T-?4%)/1DE,10 $"5@  #Y;   V
M7P  +F(  "9F   ?:@  &6T  !-P   .<P  "W8$  5X"P !> \  'D3  !Y
M&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\  'IP  !Z@P  >I@  'JL
M  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,7   0F   #EC   P:
M*&P  "!P   9=   $W<   Y[   )?@  !($"  """   @PT  (,0  "$%
MA1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H  "'>P  AY   (:E  "%
MN@  A=,  (3J  "$] !E8   7&   %%A  !&9   /&D  #)M   I<@  (7<
M !E[   2@   #8,   B'   "B@   (T   ".!   C@D  (\-  "0$   D10
M )(9  "3(   E"D  )4S  "50   EDX  )9?  "5<@  E8@  )6=  "4L@
ME,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70  "MY   A?P  &80  !&)
M   ,C0  !I$   "4    F    )H   ";    G (  )T'  ">"P  GPX  *$2
M  "B&   HR   *4I  "F-@  ID0  *95  "F:   IGT  *:4  "EJ0  I+T
M *31  "DY !;;   3W   $-U   X>P  +8$  ".'   9C0  $9(   N7   $
MG    *    "C    I@   *@   "I    J@   *P   "M!   K@D  + -  "Q
M$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$  +B(  "XG0  N+$  +?"
M  "WT !4=@  2'P  #R"   QB0  )I   !N7   2G0  #*(   .G    JP
M *X   "R    M@   +@   "X    N@   +L   "]    O@   , %  #!"P
MPQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ  #-D0  S:0  ,VT  #-
MP !-@P  08H  #61   IF0  'J   !.F   ,K    [$   "V    N@   +X
M  #"    Q@   ,@   #(    R@   ,L   #-    S@   -    #2 0  U0@
M -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F@@  YY8  .>E  #FL #_
M  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X /T 0P#Y $T ]0!5 /(
M70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4 Y "+ ., D0#A )D WP"A
M -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1 /\ SP#_ ,H _P#_  $
M_P   /\  0#_  P _P 2 /H '0#V "@ \P S /  /@#L $@ Z !0 .4 6 #B
M %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"% -  C #. ), S "< ,D
MI0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\ OP#_ +X _P#_    _P
M /\   #Z  < \0 / .L & #F ", X@ N .  . #; $( U0!+ -$ 4@#. %D
MRP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\ A@"] (X NP"6 +D H "W
M *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_ +  _P#_    _P   /<
M  #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P P@!% +\ 30"\ %, N@!9
M +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M (@ K "1 *H F@"H *4
MI@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$ _P#_    ]P   .@   #9
M    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _ *\ 1P"L $T JP!4 *D
M60"G %X I@!C *4 : "C &X H@!T *  >@"> (( G "+ )L E0"9 )\ F "L
M )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W    YP   -,   #&
MNP " +, # "M !( J@ < *< )@"D #  HP X *  0 "> $< G !. )H 4P"9
M %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"% (T CP"+ )H B@"G (@
MM0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L    TP   ,$!  "T    K
M *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1 $$ CP!( (T 30", %,
MBP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (  B@!^ )8 ?0"C 'L L !Z
M ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L  +(,  "F"P  G0@  )D$
M  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L @P!" (( 2 "  $X ?P!3
M 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S )( <0"? '  K0!N +X
M;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82  ":$0  D1   (L.  ")
M"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\ '<$0P!U!4@ = 5. ',%
M5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")  9PF= &4)K !D";P 8PK4
M &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0&   AQ8  ($4  !]$0
M? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,/@!L#$0 :PU* &D-3P!H
M#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^< %P0JP!;$+T 6A#6 %D1
M\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@  ?AT  '@;  !T&   <14
M '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C$3\ 8A%% & 22P!?$E$
M71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5J0!2%KH 41;2 %$7[0!1
M%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(  ' A  !L'@  :1L  &<8
M! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL 61=! %@81P!6&$T 51A4
M %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*'+@ 2AW/ $D=ZP!)'?L
M21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE  !F(P  8B$  & >  !>
M' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T] % =0P!/'4H 31Y1 $P>
M6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8 0R+, $,CZ0!#(_H 0R/_
M $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@)P  7"4  %DC  !7(0<
M52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB0 !((D8 1R-- $4C50!$
M)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?* #THZ  ]*/D /2?_ #XG
M_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P  6"@  %0F  !1)@0 3B4-
M $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!)T, 0"=+ #\H4P ^*5P
M/2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<LY@ X+/@ ."S_ #@L_P"=
M+   BBX  'LO  !O,   93   %TO  !8+@  4RL  % J  !,*@  22H+ $8J
M$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T  .RQ( #HL4  Y+5D ."YD
M #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S,/< ,S#_ #0O_P"9+P
MAS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM  !'+@  1"X( $$N#@ _
M+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #4Q3@ T,5< ,S)B #(R
M;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8 +S/_ "\S_P"5,0  @S,
M '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !",@  /S(% #PR#0 Y,Q(
M.#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U3  O-E4 +C9@ "TW;  L
M-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_ "HW_P"2-   ?S4  '$V
M  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@  .C8" #<W"P T-Q  ,C<6
M #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J.E, *3M> "@[:@ G.WD
M)CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[_P"--@  ?#@  &TY  !B
M.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L  #(["  O/ X +3T4 "P]
M&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U  (T!; ") :  A0'8 ($"'
M !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P").0  >#H  &D[  !>/
M53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!!0 J0@P )T(1 "9#&  D
M0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459 !Q%90 ;170 &D6% !E&
MEP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/   <ST  &8^  !;/P  4C\
M $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D1PH (4@/ "!)%  >21L
M'4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+8@ 52W$ %$N" !-+E  2
M2Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T   &%!  !70@  3D(  $="
M  !!0@  .D,  #)%   M1P  *$D  "-+   >308 &T\- !A0$0 74!< %E >
M !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /4FT #E)^  U1D0 -4:0
M#%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$  !310  2T4  $1%   ^
M1@  -D@  "]*   I3   )$\  !]1   :4P  %%8) !%7#@ 06!, $%@9  ]8
M(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@ !UAY  98C  %6)\ !%BS
M  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !02   2$@  $%)   Z2@
M,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@#  *8!  "6 5  A@'  '
M8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S  !@A@  7YH  %^N  !?
MQ   7N(  %[P  !>^ !L2@  7TL  %5+  !,3   14P  #U.   U4   +E,
M "=6   @60  &EP  !5?   08@  #64$  AG"P #9PX  &@3  !H&   :!\
M &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I@   :90  &BI  !HOP
M9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$  #A4   P5P  *%L  "%>
M   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T  '$0  !Q%   <AH  ',A
M  !S*   <S$  ',\  !T2   <U8  '-F  !S>0  <XX  '.C  !RN0  <=(
M ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<   J8   (F0  !MH   4
M;   #V\   MR   &=@   'D   !Z!@  >@H  'L.  !\$0  ?14  'X;  !_
M(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8  ("=  !_L@  ?LH  '[E
M  !]\0!<6   5%@  $E:   _70  -6$  "QE   C:@  &V\  !1S   .=P
M"7L   -_    @@   (0   "& 0  A@8  (@*  ")#0  BA   (L5  ",&P
MCB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5  ".JP  C<$  (W<  ",
MZP!970  3E\  $-B   X9@  +FP  "1Q   <=P  %'P   Z!   (A0   (D
M  "-    D    )(   "3    E    )8#  "7"   F P  )H/  ";$P  G1H
M )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?H@  G[<  )[+  ">X !3
M9   1V@  #QM   Q<P  )WD  !U_   4A0  #8L   :0    E    )@   "<
M    GP   *$   "B    I    *4   "G    J 0  *H)  "L#0  K1(  + 9
M  "R(P  LC$  +)"  "R5   LFD  +*   "RF   L:P  +*_  "QS@!,;@
M0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?    I    *@   "L
MKP   +$   "Q    LP   +4   "V    N    +H   "\!@  O@P  , 1  ##
M&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\  ,BO  #(O !&>@  .8$
M "Z)   BD   %Y@   ^?   'I0   *H   "O    LP   +<   "\    OP
M ,$   #"    Q    ,4   #'    R0   ,L   #-    SP,  -(*  #6$
MW!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B  #BK0#_  ( _P   /\
M P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@ \P!0 /  5P#M %X ZP!D
M .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #< ), V0"< -8 I@#3 +$
MT0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$ _P#_    _P   /\   #_
M  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+ .  4@#= %D V0!? -8
M9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X Q@"6 ,0 H #" *L P "Y
M +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_    _P   /X   #T  0
MZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H 30#' %, Q0!9 ,, 7P#!
M &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0 +( F@"Q *4 KP"R *T
MQ "L .$ JP#V *H _P"J /\ J@#_ *H _P#_    _0   .X   #B    U0 *
M ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U $X L@!3 +  60"O %X
MK0!C *P : "K &T J0!S *@ >@"F ($ I "* *, E "A )\ GP"L )X NP"<
M -( FP#N )H _P": /\ F0#_ )D _P#^    [@   -X   #+    P0 % +D
M#0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@ H@!- *$ 4P"? %@ G@!=
M )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2 )D D "F (X M "- ,@
MC #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<   "Z    L    *@ "@"D
M !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !( )( 30"1 %( CP!7 (X
M7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0 @@"@ (  KP!_ ,  ?@#=
M 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J    H@   )L !0"5  T
MD@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4 1P"# $T @@!2 ($ 5P!_
M %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"< '0 J@!R +H <0#1 '
M[ !P /L < #_ '  _P#-!   MP8  *<'  ";!@  DP0  (X   "*  @ A@ /
M (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W $< =@!, '4 4@!S %<
M<@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@ I@!G +8 9@#+ &4 YP!E
M /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T  ($+  !^!P$ ? $+ 'D
M$0!W !@ =0 A ', *0!Q #  ;P V &X / !L $( :P!' &H 30!I %( : !8
M &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!< [, 7 /' %L$Y !;!?0
M6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81  !S#@  <@P$ '$'#0!N
M!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=# &$'20!?!TX 7@A5 %T(
M7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[, 4@S' %(,Y !1#?4 40W_
M %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J%   9Q$  &<.!P!F# X
M8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-10!7#4L 5@Y1 %4.60!3
M#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'( $D1Y0!)$?< 21+_ $D1
M_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@  7Q<  %X4 0!>$0H 6Q 1
M %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/$D< 3A). $P250!+$UX
M21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7XP!"%_8 0A?_ $(7_P"?
M'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P  %<9  !5%@8 5!4. %$5
M% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T, 1A=* $484@!#&%H 0AED
M $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 ['?4 .QS_ #P<_P":(0
MAR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>  !/' ( 31L, $L:$0!(
M&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU' #X=3P ]'E@ /!YB #H?
M;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?, -B'_ #8A_P"6(P  @R8
M '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)(   1R ) $0?#P!"'Q4
M0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B3  W(E4 -B-? #0C:P S
M)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_ #$E_P"1)@  ?R@  '$J
M  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)   020% #\D#0 ])!( .R09
M #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q)U, ,"== "\H:0 N*7<
M+2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI_P"-*   ?"H  &TL  !B
M+0  62T  %$M  !,+   1RL  $,H   _*   /"@" #DH"P W*!  -2@6 #,H
M'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$ *RQ; "HL9P I+74 *"V%
M "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"**P  >"T  &HN  !?+P
M5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L"0 R+ X ,"T3 "XM&@ M
M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9 "4Q90 D,7, (S&# "(R
ME0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0  =2\  &<P  !<,0  4S$
M $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M,0T *S$1 "DR%P H,AX
M)S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U8P ?-7$ 'C:! !TVDP <
M-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(  &,S  !9-   4#0  $DT
M  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L )3<0 "0W%0 B-QL (3@B
M " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9.FX &#I_ !<[D0 7.Z0
M%CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U  !5-@  338  $8V  !
M-@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P. !X]$@ =/1@ '#T? !L^
M)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP $T!\ !) CP 10*( $4"V
M !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2.0  2CD  $,Y   ].0
M-SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#$  70Q4 %40; !1$(@ 3
M1"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y  U%C  -19\ #$6R  M%
MR0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P  1SP  $ \   Z/   -#P
M "X^   H0   (T(  !]$   :1@  %4@( !)*#0 12A( $$H8  ]+'@ .2R4
M#4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+AP %2YH !$NN  1*Q  %
M2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X  #T^   W/P  ,4   "I"
M   D10  'T<  !I)   53   $4X%  Y1"P +41  "E$4  E1&P (42( !U$I
M  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0  498  %&I  !1OP  4-P
M %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"   T0P  +44  "9(   @
M2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2  !9%P  61T  %DE  !9
M+0  638  %E!  !930  6EH  %II  !9?   69   %FE  !8N@  6-4  %?L
M  !7]@!C1   5D4  $U%  !%10  /T4  #='   O20  *$P  ")/   ;4@
M%E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A%   81D  &(@  !B)P
M8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@  !AM@  8<\  &#J  !@
M]0!=2   4DD  $I(  !#2   .DH  #)-   J4   (U,  !Q7   66@  $5T
M  U@   (8P   V8!  !G!@  : L  &D.  !J$0  :Q4  &P;  !M(@  ;2H
M &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !LL   :\@  &OF  !J\P!8
M30  3DT  $A,   ^3@  -5$  "Q4   D6   '5P  !9@   09   #&<   =K
M   !;@   '    !R P  <@<  ',+  !U#@  =A$  '<6  !X'   >2,  'HM
M  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@  >,$  '??  !W[P!440
M3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K   +;P  !7,   !W
M>@   'P   !^    ?P(  ( &  "!"@  @PT  (01  "&%0  B!P  (DE  "*
M,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D  (?1  "&Z !25@  1U<
M #Q:   R7P  *&0  !]I   6;P  $'0   IY   "?0   ($   "%    B
M (H   ",    C0   (\   "0!   D@@  ),,  "5$   EQ4  )D=  ";)P
MFS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'  "7W@!+7   0&   #5E
M   K:@  (7$  !=W   0?0  "8,   &(    C    )$   "5    F    )H
M  ";    G0   )\   "@    H@   *0%  "F"@  J X  *H4  "M'0  K2H
M *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "KRP!%9@  .6L  "YQ   C
M>   &7\  !"&   )C0   ),   "8    G0   *$   "E    J    *L   "K
M    K@   *\   "Q    LP   +4   "W 0  N0<  +P-  "_$P  PA\  ,(N
M  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^<@  ,G@  ">    <B
M$I    J7    G0   *,   "H    K0   +(   "V    N0   +L   "\
MO@   ,    #"    Q    ,8   #(    RP   ,X%  #1#0  UA0  -<C  #8
M-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_    _P   /\   #_  D _P 0
M /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J %D YP!? .0 9 #B &D
MX !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\ H0#, *P R@"[ ,@ T@#&
M .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P   /\   #^  4 ]P . /(
M%0#N !\ ZP J .D - #C #T W@!% -D 30#4 %, T0!9 ,X 7@#, &, R@!H
M ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[ *8 N0"T +< R "V .8
MM0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@   #M    Y0 + -T $0#7
M !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3 +P 60"Z %X N !C +8
M: "U &T LP!S +$ >0"O ($ K0"* *L E "I *  J "M *8 O@"E -L I #T
M *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7    RP & ,0 #@"^ !4
MNP ? +D * "W #$ M  Z +  00"M $@ JP!. *D 4P"G %@ I@!< *0 80"C
M &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F )8 M@"5 ,P E #K ),
M_0"3 /\ DP#_ ), _P#W    Y    -    #!    MP " *\ "P"K !$ IP 9
M *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7 %( E@!7 )4 6P"3 &$
MD@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (< KP"% ,( A0#B (0 ]P"$
M /\ A #_ (0 _P#E    S0   +P   "O    I@   )X !P":  X E@ 4 )0
M'0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P AP!1 (8 5@"$ %L @P!@
M ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W +H =@#3 '8 [P!V /X
M=0#_ '4 _P#0    NP   *L   "?    EP   )   @"+  L B  0 (8 %P"$
M "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+ '@ 4 !W %4 =@!; '0
M80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0 :@#) &D Z !I /D :0#_
M &D _P#     K    )P"  "0 @  B    (,   !_  8 >P - 'D $@!W !H
M=@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P 2P!K %  :@!6 &@ 7 !G
M &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@## %X X0!> /0 70#_ %T
M_P"T!P  H D  ) +  "$"P  ? H  '<'  !T!   <0 ) &\ #P!M !4 :P <
M &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@ $P 7P!2 %X 6 != %\
M6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0 V@!3 .\ 5 #[ %0 _P"I
M#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD# &8$"P!D !  8@ 7 &
M'@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4< 5@%. %4"5 !3 EP 4@-E
M %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*!^T 2@?Y $H'_P"A$
MCA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-!0!="0T 6@82 %@'&0!6
M!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E* $P)40!+"ED 2@IB $@+
M;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X 0@W[ $(-_P":%   AQ8
M '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4#@@ 4PT. %$-% !/#1L
M30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.3P!$#E< 0@]A $$0;  _
M$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+] #L1_P"3&   @1H  ',<
M  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P, 3!$+ $H0$ !($1< 1A$>
M $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \$U0 .Q-> #D4:0 X%'8
M-Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06_P".&P  ?!T  &X?  !C
M(   6B   %,@  !.'@  2AT  $@:  !&&   118' $,5#@!!%1, /Q4: #X5
M(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$ -!A; #,99@ R&7, ,!J#
M "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*'@  >"   &HB  !?(P
M5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:#  [&1$ .1D6 #<:'0 V
M&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9 "T=9  L'G$ *Q^! "H?
MD@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(   =",  &<D  !<)0  4R4
M $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U'@X ,QX3 #$>&@ P'B
M+QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B8@ F(F\ )2-_ "0CD  C
M(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24  &,F  !9)P  4"@  $DG
M  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T +B(1 "PB%P J(AT *2(C
M "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A)VT ("=] !\GCP >**$
M'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I  !6*0  32H  $8J  !!
M*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0 "<G%  E)QH )"<A ",H
M)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL &RM[ !HLC0 9+)\ &"RR
M !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3+   2BP  $,L   ^*P
M.2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L$@ @+!@ 'RP> !XM)0 =
M+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y !4PBP 4,)X %#"Q !,P
MQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@  2"X  $$N   [+@  -BT
M #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;,A4 &C(< !DR(@ 8,BD
M%S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$UB0 0-9P $#6P  XUQ@ /
M-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13   #XP   X,   ,S   "\P
M   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q, %#@9 !,X'P 2."8 $C@N
M !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,.ID "SFL  HYP0 *.=X
M"SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS   V,P  ,3(  "PS   G
M-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5  X^'  ./B, #3XJ  P^
M,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0 !#^H  ,^O  $/M< !3[L
M  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T-0  +C4  "DW   C.
M'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$&0 (1"  !T0G  9$+P %
M1#@  T5"  )%3@  15L  $5J  !%?   19   $2D  !$N0  1-$  $3J  !#
M]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.   *SD  "4[   @/0  &D
M !9"   21   #D<$  M)"0 '2@T !$L1  %+%@  2QP  $LC  !+*P  2S0
M $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+M0  2LX  $KI  !*]0!?
M.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX  ")!   <0P  %D8  !))
M   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@  %,?  !3)@  4R\  %,Y
M  !310  4U(  %-A  !3<@  4X<  %*<  !2L0  4<H  %'G  !1] !9/@
M3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'   72@  $DT   Y0   +
M4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:  !<(0  7"H  %PT  !<
M/P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4  %KD  !9\P!40@  2D(
M $)"   \0@  -$,  "Q&   E20  'DP  !=/   24P  #E8   I9   %6P
M %X   !@!   80@  &(,  !C#@  9!$  &46  !F'   9R,  &<M  !G.0
M9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>  !D\ !/1@  1T8  $!%
M   W1P  +TH  "9-   ?40  &%4  !)9   -7   "&    )C    9@   &@
M  !J    :P0  &P(  !M#   ;PX  ' 2  !R%P  <QT  '0F  !T,@  =#\
M '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P[ !,2@  14H  #M+   R
M3@  *5(  "!6   86P  $E\   UD   ':    &L   !O    <@   '4   !V
M    =P   'D"  !Z!@  ? H  'X.  " $0  @A8  (0>  "$*0  A#8  (1%
M  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*3@  /U   #53   K5P
M(EP  !EB   29P  #&P   5Q    =0   'D   !]    @0   (,   "%
MA@   (@   ")    BP0  (T(  "/#0  DA   )06  "6(   EBP  )8[  "6
M3   E6   )5V  "4D   DZ<  )*]  "2U0!$50  .5D  "]=   D8P  &FD
M !)O   ,=0  !'L   "     A0   (D   "-    D0   ),   "4    E@
M )@   ":    G    )X   "@!@  H@L  *40  "H%P  J2,  *DQ  "I0P
MJ58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,  "=J   =<   $W@   Q_
M   #A0   (L   "1    E@   )L   "?    H@   *0   "E    IP   *D
M  "K    K0   +    "R    M0(  +<)  "[$   OA@  +XF  "^.   ODL
M +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X   6@   #8@   6/
ME@   )P   "B    IP   *P   "P    LP   +8   "W    N0   +L   "]
M    OP   ,(   #%    R    ,H   #."   TA   -4;  #5+   U$   -17
M  #3;@  U(8  -2;  #3JP#_    _P   /\   #_  4 _P . /\ %0#\ "
M^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$ 7@#> &, W !H -D ;@#5
M ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W ,( S #  .P OP#_ +X
M_P"] /\ MP#_ +( _P#_    _P   /\   #Z  $ \P + .T $@#H !L Y0 E
M .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#& %X Q !C ,( 9P#  &T
MOP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +  P@"N ., K@#Z *P _P"M
M /\ J0#_ *8 _P#_    _P   /(   #F    W0 ' -( #@#- !8 R@ @ ,@
M*0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@ L0!= +  8@"N &< K !L
M *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0"> -( G0#R )P _P"= /\
MG #_ )D _P#\    [@   -T   #,    P0 " +H # "V !( L@ : +  (P"O
M "P K0 T *D / "F $( I !( *( 30"@ %( G@!7 )T 6P"< &  F@!F )D
M; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8 C #H (L _0", /\ C #_
M (P _P#M    V    ,4   "W    K    *8 " "A  X GP 5 )T '@"; "8
MF@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T 50"+ %H B@!@ (D 9@"'
M &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #< 'P ]0!\ /\ ? #_ 'P
M_P#9    P0   +$   "D    G    )0  P"0  P C0 1 (L & ") "  B0 H
M (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\ %0 >P!: 'D 8 !X &<
M=@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X [0!N /X ;@#_ &X _P#$
M    KP   *    "4    C    (8   "!  @ ?@ . 'P % ![ !L >0 B '@
M*0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\ ;0!4 &P 6P!K &( :0!J
M &@ = !F (  90". &, G0!B *T 80#" &$ Y !A /@ 80#_ &$ _P"T
MH    )$   "&    ?@   'D   !U  , <0 + &\ $ !M !8 ;  = &L ) !K
M "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/ &  5@!? %T 70!E %P
M;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$ 5@#_ %8 _P"H 0  E 4
M (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C !$ 80 8 &  'P!? "4
M7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8 40!5 %@ 4P!A %( :@!0
M '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z $P _P"="0  BPL  'P-
M  !P#0  : T  &(,  !?"@  708! %P!"0!:  X 6  3 %< &0!6 "  50 F
M %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+ %4 2@!= $D 9P!' ',
M1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $, _P"5#0  @P\  '00  !I
M$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0 $\!%0!. 1L 3 $A $L!
M)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$ 0@1: $ %9  _!7  /@9^
M #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".$   ?!(  &X4  !B%0
M6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D($0!'"!8 10@= $0((P!"
M""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8 #D+8P X#&\ -@Q^ #4,
MC@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P  =Q4  &D7  !>&   51@
M $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@! #1( /PT8 #T-'P \#20
M.PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/8@ Q$&X +Q!] "X0C@ M
M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD  &0:  !9&P  41L  $L;
M  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!  .! 5 #<0&P U$2$ -!$G
M #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J%&P *11[ "@4C  G%9X
M)A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =  !6'@  31X  $<>  !"
M'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02 # 4%P O%!T +10C "P5
M*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H (QEY "(9B@ A&9P (!FO
M !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3(   2B   $0@   ^'P
M.AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8%  I&!H )Q@@ "89)@ E
M&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW !T=B  <'IL &QZM !H>
MPP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@  2"(  $$B   [(@  -R$
M #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C'1< (1T= "$=)  @'BH
M'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@BAP 7(ID %B*L !4BP0 5
M(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124  #XD   Y)   -",  # B
M   L(@  *2$  "8A   D(08 (B$, " A$  >(14 '2(; !LB(0 ;(B@ &B,O
M !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2)I@ $2:K !$FP  0)MT
M$27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF   V)@  ,24  "TE   I
M)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8 !<G'P 6)R4 %2@M !0H
M-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8 #BJI  TJO0 -*M< #2KN
M  XI^P!L)   728  %$H  !(*   0"D  #DH   T*   +R@  "LG   G)P
M(B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L'  1+2, $"TJ ! M,@ /
M+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E  DNN0 (+M  "2[I  HN
M]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@  +2H  "DJ   D*@  ("L
M !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -,B  #3(G  PR+P +,S@
M"C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (SM@ ",\T  S/G  0R\P!D
M*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP  "8L   B+0  '2\  !DQ
M   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T !S@D  8X+  $.#0  S@^
M  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP  .,H  #CF   W\@!?+0
M4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P   ?,0  &C,  !4U   2
M-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA   ^*   /C$  #\[   _
M1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<  #WD   ]\@!:,   3C(
M $0R   \,@  -3(  # Q   K,0  )C(  " T   ;-@  %C@  !([   //0
M##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%)   12T  $8V  !&0@
M1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C  !#\@!5-   2C4  $$U
M   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/   $C\   ]!   ,1   "$8!
M  -(!@  20H  $H-  !+$   3!0  $T9  !.(   3B@  $XR  !-/0  3DH
M $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*\@!0.   1C@  #TX   W
M.   ,3<  "HY   D.P  'CT  !A    30P  #T8   M)   '2P   DX   !0
M!   40@  %(+  !3#@  5!$  %45  !6&P  5R,  %<L  !7.   5T0  %=2
M  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+/   0CP  #L[   U.P
M+3P  "8_   ?0@  &44  !-(   .2P  "T\   51    5    %<   !8 0
M6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F  !B,0  8CX  &%,  !A
M70  87   &"(  !@H   7[<  %[4  !=[@!'0   /S\  #H_   Q0   *4,
M "%&   :2@  $TX   Y1   *50  !%@   !;    7@   &$   !C    9 $
M &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O*@  ;S8  &Y%  !N50
M;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,  #5$   K1P  (TL  !M/
M   35   #E@   A<   "8    &0   !G    :P   &T   !O    <    '(
M  !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@  ?RX  '\]  !^30  ?6$
M 'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],   E4   '%4  !1;   .
M8   !V4   !J    ;@   '(   !V    >0   'P   !^    ?P   ($   "#
M    A0   (<#  "*"   C T  (\1  "2&0  DB4  )(S  "21   D5<  )!M
M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >7   %6(   YH   ';@
M '0   !Y    ?@   ((   "&    B0   (P   ".    D    )(   "4
ME@   )@   ";    G@8  *$,  "D$0  IAL  *8I  "F.@  I4T  *5B  "D
M>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0  #W    =W    ?@   (0
M  "*    CP   )0   "8    FP   )X   "?    H@   *0   "F    J
M *L   "M    L    +,$  "W#   NQ(  +L?  "[,   NT,  +I8  "Y<
MMXL  +>A  "WLP P8@  )6D  !IP   0>   "8    "(    CP   )8   ";
M    H0   *8   "J    K@   +    "Q    M    +8   "X    NP   +T
M  #     PP   ,<   #+ P  SPP  -,5  #2)0  TC@  -%.  #090  SWX
M ,V6  #,J0#_    _P   /\   #_  , _P + /P $0#Y !L ]P E /, +P#N
M #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C -, : #0 &T S@!S ,L
M>@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H N0#_ +@ _P"Q /\ J@#_
M *< _P#_    _P   /L   #V    [0 ' .< #P#B !8 WP @ -X *0#9 #,
MT0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P 8@"Z &< N0!M +< = "U
M 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y *4 _P"C /\ G0#_ )L
M_P#]    ]@   .L   #?    T0 # ,H # #% !( PP ; ,  ) "^ "P N0 U
M +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G &$ I@!G *0 ;0"B '0
MH !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0 _P"5 /\ D #_ (X _P#S
M    Y@   -$   #"    N    +$ " "M  \ J@ 6 *@ '@"H "< I@ O *(
M-@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H DP!@ )$ 9@"0 &X C@!V
M (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$ /\ @P#_ ($ _P#D
MRP   +H   "L    H@   )P ! "8  P E@ 1 )0 &0"3 "$ D@ H (\ , "-
M #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!: ($ 8 !_ &< ?@!O 'P
M>@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\ = #_ '0 _P#+    M@
M *8   ":    D@   (H   "&  @ @P . ($ % "! !L @  C '\ *@!] #
M>P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$ 6@!P &$ ;@!I &T <P!K
M '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_ &< _P"X    I    )4
M  "*    @0   'P   !V  0 =  , '( $ !Q !8 <  = '  ) !N "H ;0 P
M &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C %L 80!C &  ;0!> 'D
M70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H _P"H    E0   (<   ![
M    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8 &, 'P!B "4 80 J %\
M, !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8 5@!> %0 : !3 ', 40"!
M %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<    B0   'L#  !P P
M: ,  &(!  !?    70 $ %L "P!9  \ 6  4 %< &0!7 "  5@ E %4 *@!3
M #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!: $H 8P!) &\ 1P!\ $8
MC !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!   @ <  '$*  !F"@  7@H
M %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!- !L 3  @ $L )@!* "L
M20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$ 7P!  &L /@!X #T B  \
M )D / "K #P P0 [ .  .P#T #L _P")"@  > P  &H.  !?#@  5PX  %$.
M  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8 1  < $, (0!" "8 00 K
M #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X &@ -@!U #4 A0 T )8
M- "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00  !9$0  41$  $L1  !'
M$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8 #L"'0 Z R( .0,H #@#
M+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8 +P=S "X'@P M!Y4 + >G
M "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4%   3!0  $84  !"$P
M/A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(&0 T"1\ ,@DD #$)*0 P
M"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS "<,@P F#94 )0VG "0-
MNP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P  2!<  $(6   ]%@  .14
M #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M#1L + TA "L-)P J#2T
M*0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0A  ?$)8 'A"I !T0O0 <
M$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D  #\9   Z&   -1<  #(6
M   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@ )A > "40)  D$"H (Q$Q
M "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9%)4 &!2G !<4NP 7$]0
M%Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;   V&P  ,AH  "\9   L
M&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,: !\3(0 >%"< '10N !P5
M-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&), $QBF !(8N@ 2%]( $A?L
M !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T'0  +QP  "L;   H&@
M)AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6
M&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE  \<N0 .'-  #AOJ  \;
M^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P  +1X  "D=   E'0  (QP
M " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4'2( $QTI !(>,0 1'CH
M$1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@M0 +(,H "R#E  P?] !E
M'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B   "8?   C'P  (!X  !T>
M   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\ #R(F  XC+P .(S< #2-!
M  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &),< !B/C  <C\0!B'P
M5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A   A(0  'B$  !HA   6
M(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C  HG*P )*#0 ""@^  <H
M20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4  2CA  $G\ !>(@  420
M $8E   ])0  -24  "\E   J)   )B0  "(C   ?(P  &R0  !@E   4)@
M$2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L*  #+3   BTZ  $M10
M+5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@   L\ !:)   328  $,G
M   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@  &2<  !4I   1*P  #RP#
M  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0  ,BT  #(V   S0@  ,TX
M #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q\ !6)P  2BD  #\J   W
M*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP  !(N   /,   #3$"  HT
M!P %-0L  C8.   W$   .!0  #@:   X(@  ."H  #DS   Y/@  .4H  #E9
M   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1*P  1BP  #PL   T+
M+BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S   --0  "3<"  4Z!@ !
M.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O  ! .@  0$8  $!4  !
M90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@  0B\  #DO   R+P  +2X
M "@N   B+P  '3   !@R   3-0  $#<   PZ   )/   !3X   !!!   0@@
M $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(-0  2$$  $A/  !(8
M1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(  #8R   P,0  *S$  "4R
M   ?-   &38  !,Y   0/   ##\   A"   #1    $8   !( @  2@4  $L(
M  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,   4CP  %%*  !16@  46T
M %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U   O-   )S4  "$X   :
M.P  %#X  !!!   ,1   !T<   )*    30   $\   !1    4P(  %0%  !5
M"   5PL  %D.  !;$0  71<  %T?  !=*@  738  %Q$  !<5   6V<  %M^
M  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K.0  (SP  !P_   50P
M$$<   M*   %3@   %$   !4    5P   %H   !<    70   %\   !@!
M8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\  !J30  :5\  &AU  !G
MCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0   '40  !9)   030  "E$
M  15    6@   %T   !@    8P   &8   !H    :@   &L   !M    ;P(
M '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y10  >%D  'AM  !WA@
M=I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX  !!4   *60   EX   !C
M    9P   &L   !O    <@   '4   !W    >0   'L   !]    ?P   ((
M  "$ P  APD  (H.  ".$P  CQX  (XK  "..P  C4X  (MC  "*?   BI4
M (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA   !9P   &T   !R
M=P   'L   !_    @P   (8   "(    B@   (T   "/    D0   )0   "7
M    F@$  )T'  "A#0  I10  *0A  "D,0  HT0  *)9  "@<   GXL  )VB
M  "=MP P4   )54  !M;   28@  "VD   %P    =P   'T   "#    B
M (T   "1    E0   )@   ":    G    )\   "A    HP   *8   "I
MK    +    "T!P  N X  +H8  "Z)P  N3D  +A.  "W90  MGX  +66  "S
MJP I6P  'F(  !1I   ,<0   GD   "!    B0   (\   "6    FP   *
M  "D    J    *L   "L    KP   +(   "T    M@   +D   "\    P
M ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/6P  S7,  ,N-  #*H0#_
M    _P   /L   #Z    _  ( /@ #P#U !< ]  @ /$ *@#K #, Y@ [ .(
M0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@ R0!N ,8 =0## 'T P0"&
M +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E /\ G@#_ )L _P#]
M]P   /(   #P    YP # .$ # #< !( V  ; -8 ) #2 "T S  V ,8 /0#"
M $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G +$ ;@"O '8 K !_ *H
MB@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\ D@#_ (\ _P#S    [
M .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W "< LP O *\ -P"L #T
MJ@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X 9P"< &\ F@!X )< @P"5
M )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_ (( _P#G    W0   ,8
M  "X    K@   *@ ! "E  P H0 2 *$ &0"@ "( GP I )L , "8 #< E@ ]
M ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"( &@ AP!P (4 >P"# (@
M@0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8 _P#6    P    *\   "C
M    F0   ),   "/  D C0 . (L % "* !P B@ C (@ *@"% #  @P V ((
M.P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$ =@!I '4 <P!S (  <0".
M &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#     JP   )L   "/
MAP   (    !\  0 >@ , '@ $0!X !< >  > '< ) !U "H <P P '$ -0!P
M #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C &4 ;0!D '@ 8@"' &
MEP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L    F0   (H   !_    =P
M '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G "4 90 J &, +P!B #0
M80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@ 9P!7 '( 50"! %0 D0!3
M *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP   'P   !Q    :0   &0
M  !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\ 60 E %< *@!6 "\ 50 T
M %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+ &T 2@!Z $D BP!( )T
M1P"Q $< S !& /  1P#_ $< _P"0    ?@   '    !F    7@   %D   !6
M    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @ $T )0!, "H 2@ N $D
M,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@ 0 !U #\ A0 ^ )< /0"K
M #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=!P  508  % &  !,!
M2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $, ( !" "4 00 J $  +P _
M #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q #8 @0 U ), - "F #0
MNP T -T - #U #4 _P!^!@  ;0D  & +  !6#   3@P  $@+  !$"@  0@@
M $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z "$ .0 E #< *@ V #
M-0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X ?0 M (\ + "B "P M@ L
M -  + #N "P _ !W"@  9PP  %H.  !0#@  20X  $,.   ^#0  .PP  #D+
M   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T ,0 B #  )P O "P +@ R
M "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F 8P )0"? "4 L@ E ,H
M)0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1   Y$   -@\  #,.   Q
M#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,> "D#(P H!"D )P0O "8%
M-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL '@>= !X'L  =!L8 '0;C
M !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U$@  ,1$  "X0   L#P
M*@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)(  B"28 (0DL " *,P ?
M"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R> !<,L  6#,4 %@SA !8+
M\ !I$   6A(  $X4  !%%0  /14  #<5   Q%   +1,  "H2   H$0  )A !
M "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =#2, ' TJ !L-,@ :#CH
M& Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0LP 0#\D $ _D !$/\@!E
M$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4  "<4   D$P  (A,  " 2
M P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$ %A H !41,  4$3D $Q%#
M !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -$L4 #!+A  T2\0!B%
M5!8  $D8   _&0  -QD  #$9   L&   *!<  "06   A%@  'Q4  !P4 @ :
M$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F !$4+0 0%#8 #Q5!  X5
M3  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$ "!;=  D5[@!?%@  41@
M $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?&   '!<  !D6 0 7%@,
M%18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8*@ ,&3, #!D\  L:1P *
M&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:  09[ !<&   3AH  $,<
M   Z'   ,QP  "P<   G'   (QL  " :   =&0  &AD  !<8 0 5& ( $AD$
M ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P ('2\ !QXY  8>0P $'E
M Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =[ !8&@  2QP  $$>   X
M'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L  !8; 0 3&P( $1P$  X>
M!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP  2(U   B0   (TT  "-:
M   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5'0  2!\  #X@   U(
M+B   "@@   C'P  (!X  !T=   :'0  %AT  !,>   1'P( #B $  TB!P *
M) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R   G/0  )TD  "A7   H
M9P  )WL  ">0   GI0  )KL  ";6   E[0!1(   12$  #LB   R(@  +"(
M "8A   B(0  'B   !L?   8(   %"   !$B   /(P  #24#  HF!@ &* H
M RD-   K#P  +!(  "P7   L'@  +"8  "TO   M.0  +48  "U4   M9
M+7<  "R-   LI   *[H  "O6   J[@!-(@  020  #@D   P)   *20  "0C
M   A(@  '2(  !DB   5(P  $B0   \F   -*   "BH"  8L!0 "+@D  "\+
M   P#@  ,A   #,5   S&P  ,R(  #,K   S-@  ,T(  #-0   S8   ,W,
M #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G   M)P  *"8  ",E   ?
M)   &R4  !8F   2*   $"H   TL   *+@  !C !  (R!   - <  #4*   W
M#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX  #I,   Z7   .F\  #F&
M   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K*0  )B@  "(G   =*
M&"D  !,K   0+@  #3    DR   %-0   3<    Y @  .P4  #P(   ^"P
M/PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'  !"5P  0FH  $&!  !
MF@  /[(  #[/   ^[P _+   -BP  "\L   J*P  )2H  !\K   9+0  %"\
M ! R   --0  "#@   0Z    /    #\   !!    0P(  $4%  !&"   2 L
M $H.  !,$0  318  $T>  !-*   330  $Q"  !,40  2V0  $M[  !*E
M2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\  !LQ   5-   $#<   TZ
M   (/0   D    !#    1@   $@   !*    3    $X!  !/!   40<  %,+
M  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P  5EX  %9S  !5C0  5*<
M %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X   1/   #$    =$
M1P   $H   !-    4    %,   !5    5P   %D   !:    7 ,  %X'  !A
M"P  9 X  &83  !G'   9B<  &8T  !E1   9%<  &1K  !BA0  89\  &"Y
M  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,1@  !DH   !/    4P
M %8   !9    7    %\   !A    9    &4   !G    :0   &P!  !N!@
M<0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C  !S>P  <I4  '"O  !O
MR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@   %<   !<    8    &0
M  !H    :P   &X   !Q    <P   '4   !W    >@   'P   !_    @@0
M (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&<@  A8L  (.E  ""O  O
M0   )40  !Q)   33@  #50   1:    80   &8   !K    ;P   '0   !Y
M    ?0   (    "#    A0   (<   "*    C    (\   "2    E@   )D"
M  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P  FH$  )J9  "9KP I20
M'TX  !54   .6P  !6(   !I    <    '<   !]    @@   (8   "+
MCP   ),   "5    EP   )H   "=    H    *,   "F    J@   *X   "R
M    MPH  +L1  "Z'P  N3   +=%  "U7   M'0  +&.  "OI  B5   &%L
M !!B   ':@   ',   ![    @@   (D   "0    E0   )H   "?    HP
M *8   "H    JP   *X   "P    LP   +8   "Z    O0   ,(   #'
MS $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!  #*E@#\    ]@   /(
M  #Q    \P % /0 # #R !, \  < .T )0#H "X X@ V -X /@#9 $0 U !*
M -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^ '@ O "! +D C0"V )H
MLP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\ _P#T    [    .@   #G
M    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P ,  -P"\ #X N0!$ +<
M20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$ IP!Z *4 A0"B ), H "B
M )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H    WP   -D   #)
MOP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D ,0"F #@ I  ] *( 0P"@
M $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R )$ ?0"/ (L C0": (L
MK ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9    S0   +L   "N    I0
M )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1 #$ C@ W (P / "+ $$
MB0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X =0!\ (( >@"2 '@ HP!W
M +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0   *4   "9    CP   (D
M  "%  0 A  , (( $0"" !< @@ > (  )0!^ "L ?  Q 'H -@!Y #L =P!
M '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L 'H :@"* &@ FP!G *\
M9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )    "%    ?0   '<   !S
M    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J &D , !H #0 9P Y &8
M/@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ', 6P"" %D DP!8 *8 5P"_
M %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U    ;    &@   !D
M80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P *@!; "\ 60 S %@ . !7
M #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![ $T C !, )\ 2P"U $H
MW !* /H 2@#_ $H _P"2    @    '(   !G    7P   %H   !7    50 !
M %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !. "D 30 N $P ,P!+ #@
M2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $( A@!! )@ 0 "N $  RP _
M /( 0 #_ $  _P"%    =    &<   !=    50   $\   !,    2@   $@
M! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0 0P I $( +0!! #, /P X
M #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W ), -@"G #8 P  V .@
M-@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#  !# 0  00   #\  0 ^
M  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D #@ *0 W "X -@ S #4
M.@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X +0"B "T N  M -T +0#X
M "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [!P  . 4  #<#   V  0
M-0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #  )  O "D +@ O "T -@ L
M #T *P!% "H 3P I %H * !G "< =P F (D )@"= "4 LP E ,\ )0#P "8
M_P!M!@  7@D  %(+  !(#   0 P  #H+   V"P  ,@H  # (   N!@( +@,&
M "T "@ L  T +  0 "L $P J !< *0 < "@ (  G "4 )@ K "4 ,@ D #D
M(P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X K@ > ,< '@#I !\ ^@!H
M"0  60P  $T-  !##@  / X  #8.   Q#0  +0T  "H,   H"P  )PD$ "8&
M"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "( (  H !\ +@ > 38 '0$_
M !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8 ,$ & #A !@ ] !C#
M50X  $D/  ! $   .!   #(0   M#P  *0X  "8.   C#0  (@P# " +!@ @
M"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E !D%*P 8!3, %P8\ !8&
M1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P $@39 !(#[P!?#@  40\
M $80   \$0  -1$  "\1   J$0  )A   "(0   @#P  '0X" !P-!0 :#0<
M&@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0**0 3"C$ $@HZ !(+10 1
M"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2  T*Z@!<#P  3A$  $,2
M   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$   &A " !@/!  6#@< %0X)
M !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /#3  #@X[  T.1@ -#E$
M# ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.Z !8$0  2Q(  $ 3   W
M%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$" !41!0 3$ < $A ) !$/
M"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T "Q$V  H100 )$4T "!):
M  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5$@  210  #X5   U%@
M+18  "<6   B%0  'A0  !L4   8$P  %1(# !,2!0 2$0< $!$)  \1"@ -
M$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S  44/@ $%4H  Q58  (5
M9P !%7H  !6.   5HP  %+<  !3/   3Z0!2%   1A8  #L7   R%P  *Q<
M "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1$@@ #Q((  X3"0 ,% H
M"A4-  @6$  &%A, !189  07'P #%R<  A@P  $8.P  &4<  !E5   99
M&7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@  #D9   P&0  *1D  ",9
M   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8 #A4'  P6"  *%PH !QD,
M  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.   '40  !U2   =8@  '74
M !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;   M&P  )AL  "$:   =
M&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%  H:!P '' D  QT+   ?
M#0  (!   " 4   A&@  (2(  "$J   A-0  (D$  ")/   B7P  (G(  "&(
M   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K'0  )!T  " <   <&P
M&!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?!0 #(0@  "(*   D#
M)@X  "82   F&   )Q\  "<G   G,@  )SX  "=+   G7   )VX  ":%   F
MG0  );0  "31   C[@!$'0  .1\  # ?   H'P  (QX  !X=   ;'   &!L
M !0<   1'   #AT   T?   *(0  !B(!  ,D!   )@8  "@(   J"P  *PT
M "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M6   +6H  "V!   LF@
M*[(  "K0   I[P! (   -B$  "TA   F(0  (2   !T?   :'@  %AX  !(?
M   /(0  #2(   HD   &)@   B@    K @  +00  "\&   P"0  ,@P  #0.
M   U$@  -1@  #4@   U*@  -38  #5#   U4P  -&8  #1\   SE@  ,J\
M #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA   7(0  $R,  ! E   -
M)P  "2D   4K   !+@   #     R    - $  #8$   X!@  .@D  #P-   ^
M$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$  #QW   [D0  .JL  #G)
M   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4)@  $"@   TK   )+@
M!3     S    -0   #@    Z    /    #X!  !  P  0@<  $0*  !&#0
M21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q  !$BP  0Z4  $+#  !!
MZ  T*@  +"H  "<H   B)P  '"@  !8J   1+0  #3    DS   #-@   #D
M   \    /@   $$   !#    1@   $@   !*    3 ,  $X&  !0"@  4PX
M %03  !4'   4R<  %,T  !30P  4E4  %%J  !0@P  3YX  $VY  !,X  P
M+0  *RP  "8K   ?+   &"X  !(R   --0  "#D   (]    0    $,   !&
M    20   $P   !.    40   %,   !5    5P   %D!  !<!@  7PH  &(.
M  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P  7)8  %NP  !9SP O,
M*B\  "(P   :,P  $S<   X[   (/P   40   !(    3    $\   !2
M50   %@   !;    70   &    !B    9    &8   !I    ;04  ' +  !T
M$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L  &NF  !JP  N,P  )34
M !TX   4/   #D$   ='    3    %$   !5    60   %T   !A    90
M &@   !K    ;0   &\   !R    =    '<   !Z    ?@   (($  "&"P
MBA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;  !^L@ I.@  (#T  !9"
M   /2   "$X   !4    6@   &    !D    :0   &X   !R    =@   'H
M  !]    @    ((   "%    B    (L   ".    D@   )8   "; P  H P
M *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5IP C0P  &4@  !%.   )
M50   %P   !C    :@   '$   !V    >P   (    "&    B@   (X   "1
M    DP   )8   "9    G    *    "C    IP   *L   "P    M@0  +P-
M  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <3@  $U0   M<   !9
M &P   !T    ?    (,   ")    CP   )0   ":    GP   *(   "D
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M_/[______________________________________________________P
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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M@ZB)SH&GC,^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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M@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
ML8S"SLH(!L[1"AS&UPI!K^H.89WF''B0VC*(B]),E(G+7YR(QFZCB,-XJ(7
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M@Z.,U(&CD=2 I)G3@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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MEU]^W)-ND\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V
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MT8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[P7NDN\!ZI[O
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MK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MG%)4^YU58_&=6G/GFU^!WIEIC]:6<IK/DWRERI&%K<60C;3#BY*XP866N[^
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M/4-Z_TE+<_]246S^5U=E^UU;8?EC7E[W:&!;]6UB6/1R9%;S=V95\GMG4_&
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MKTU$[;%43>6S6U7<L&5ASJAL<<.?=("XEGR-KH^&F*6(D:&=@YVGEX"MJY.
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M@5RFWX%<IM^!7*;?@5RFWX%<IM^!_X / ?^.#@'_H@T V[4( ,[!" #&T D
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MAAD?_Y$:'O^<&Q[_I1P=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ =G,
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M4K22;UVLC'=GI(> ;YZ"BG>8?I1]DGN@@8UZK82*><"%B'K<A(=ZW8*&>M^
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M>&V,Y7AMC.5X;8SE>&V,Y7AMC.5X_VX3 ?][$0'_C1  _YT0 /JL$0#:NPL
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MMC<O_] X+O_O.2W__SDQ__\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SDS_/\YP:@
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M$!/_K1$3_[H1$__#$A/_PQ(3_\,2$__#$A/_PQ(3_\,2E[X  (;,  !WVP
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M:7A\\&EX?/!I>'SP:7A\\&EX?/!I_V 7 ?]N$@'_?A  _XP1 /^9$0#QI!,
MXZX6 -:V' '+M# (P; _%[>K2R6MIE0SI*%=0)R=94J4F&Q3C)5T6X:1?6)_
MCH=H>8R2;72*GG%PB*UT;8C!=&V)Y'-OA^IQ<(3L;W*#[6US@>YK=(#P:72
M\&ET@/!I=(#P:72 \&ET@/!I_V$7 ?]Q$ '_@@X _Y . /6=#0#CJ0P V;4,
M ,^Y&@#%N"X'N[0]%;&P22.GJU(QGJ=;/I:C8TB.GVI1AIMR67^8>F!XE81F
M<I./;&V1G&]ID*IR9I"^<V61X7)HCNMP:HKL;FR([6QMAN]K;H3P:6Z$\&EN
MA/!I;H3P:6Z$\&ENA/!I_V,5 ?]U#@'_A@T ^)0+ -RB" #4K0D S[@* ,F]
M%P"_O"L&M;D[$ZNV1R&AL5 OF*U9.X^J84:'IFA/?Z-P5WB@>%YRGH%D:YN,
M:6::F6UBF:AO7YF\<%Z9WV]@ENQN8Y'M;6:.[FMGB^]J:8GP:&F)\&AIB?!H
M:8GP:&F)\&AIB?!H_V<2 ?]Y# #_B@H WYH$ -.F!P#,L0@ Q[L( ,'"$P"X
MPB@$KK\X$*6\1!Z;N$XLD;57.(BQ7D* KF9+>*MM4W&I=EIKIW]@9:6*9&"C
MEVA;HZ9K6:.Z;%BCW&M9H.YK7)KO:E^6\&EADO%H8X_Q9F./\69CC_%F8X_Q
M9F./\69CC_%F_VL0 ?]^"0#QD 0 UIX# ,RJ!@#$M 8 OKX% +C($ "PR"0#
MI\8U#9W#0AN3P$PHBKU4,X&Z7#YYMV1&<;5K3FNS=%1DL7Y:7[")7UJOEF)6
MKJ5E4ZZY9E*OVV52J_)F5:3R9EB?\F9:F_-E7)?S9%R7\V1<E_-D7)?S9%R7
M\V1<E_-D_W - /^$! #=E@  SJ,# ,2N! "[MP0 M,(% *[-# "GSB "GLTQ
M"I7+/A:+R$DC@L92+GK#6CARP6) :\!J1V2^<TU>O7Q36;R(5U2[E5M0NZ5=
M3KNY7DV\VUU+N?=?3K'V8%&J]F!3I?9@5:'V8%6A]F!5H?9@5:'V8%6A]F!5
MH?9@_W<( .N,  #3FP  QJ@" +NQ @"RNP( JL<& *+3"@"=UAH!E=8L!HS4
M.A&#TD8=>M!/)W+.6#%JS6 X9,MH/U[*<D58RGQ)5,F(34_)E5%,R:532LFY
M5$G*W%-'R/=52,#\6$JX^UE,LOM:3JWZ6DZM^EI.K?I:3JWZ6DZM^EI.K?I:
M_W\  -R3  #*H@  O*P! +&U  "HP , G\L& );9"P"1X!L!BM\L!H+?.0YY
MWD,7<=U-(&K<5BACVU\O7=IG-5C9<3I3V7L^3]F(0DO9ED5(V:9'1MJZ2$7;
MVT=$V/1)0M/_343)_T]%PO]01[O_4D>[_U)'N_]21[O_4D>[_U)'N_]2YHH
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M*BS__RHL__\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RHO^?\JN:8  *JN  "<N0
MCL4  ('1  !UW@  ;?H) &7_$0%>_QH"5_\C U+_+ 5,_S0'2/\\"D/_1 P_
M_TP.//]3$#C_6Q(U_V,4,O]L%B__=Q<L_X09*?^3&B?_HAPE_[0=)/_,'B/_
M[1XB__T?(O__'R+__Q\B__\?(O__'R+__Q\B__\?K*L  )VV  "/P@  @,X
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M_W 7 ?]X'0'_?R0"_80N!?.&. KJAD(1XX1+&=M_5R/1>6(ORW1L.,5O=D#
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M68-O_%B#;_Q8@V_\6(-O_%B#;_Q8_U88 ?]D$0'_<@X _WX0 /^($0#UD10
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M/C[+_T! P_]"0;W_0T*Y_T1"N?]$0KG_1$*Y_T1"N?]$W8@  ,>8  "XHP
MJZL  *"T  "5O@  B\@# (#1!P!XX0T =.$= 6[A*P-HX#<(8>!"#ES@3117
MX%894^!?'4_@:2)+X',E1^!^*$3@BRM"X)HM/^&K+S[BP2\^XN4O/-_Z,3G>
M_S0YV?\V.M#_.#O,_SD[S/\Y.\S_.3O,_SD[S/\YS9(  +R@  "MJ   H;$
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M$Q[__Q,>__\3'O__$Q[__Q,>__\3IJD  )BS  "*OP  >\H  &[5  !@WP
M5.<  $[_! !)_PX 0_\4 #__'0$Z_R4"-O\L C+_,P,O_SH#*_]!!"C_2 0E
M_T\%(O]7!2#_8 8=_VP'&O]Y!QC_B@@6_YL(%?^M"13_PPD3_^,)$__X"1/_
M_PH3__\*$___"A/__PH3__\*FK$  (N]  !\R   ;=0  %_@  !1Y@  1_4
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M2)%@_T>18/]'D6#_1Y%@_T>18/]'_TX8 ?]:$0'_9 X _V\0 /]V$P#\?1<
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M24Z?_TE0F?])4I;_2%22_T=4DO]'5)+_1U22_T=4DO]'_VX  -Y_  #*C0
MOI@  +.@  "JIP  H:X  )>V  "1NA  C+HC 86Y,@9^N#X.=[9)%W&U4AYK
MLUHE9;)B*V"Q:C!;L',U5Z]].5.NB3U/K99 3*VE0DJMN4-)KMA"2*OU0T>J
M_T1)I?]$2Z#_1$V<_T1-G/]$39S_1$V<_T1-G/]$ZG4  -*&  ##DP  MYT
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M*S;*_RTVRO\M-LK_+3;*_RTVRO\MQ9   +:=  "HI0  G*T  (^V  "#O@
M=\<  &S/ @!BU@< 6N0. %CD' !4Y"D!4.0U TSE/P5(Y4D'1>53"D+F7 T_
MYF8//.9Q$CKG?A0WYXP6->><%S/HKADRZ<89,NCJ&3'E_ADOY/\<+N3_'BWB
M_R MXO\@+>+_("WB_R MXO\@NIH  *JC  "=JP  D+0  (.]  !WQ@  :\\
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M!0[__P4.__\%E:\  (:Z  !WQ0  :-   %K;  !,X0  0.<  #?S   R_P
M+O\' "K_#@ F_Q, (_\: !__(  ;_R8 &/\K 17_,@$2_S@!$/]  0[_2 $,
M_U(!"?]= @;_:P($_WT" O^0 @'_HP( _[8" /_- P#_[ , _^P# /_L P#_
M[ , _^P#B+D  'C$  !IT   6]T  $OC   ^Z0  ,NX  "O_   F_P  (?\
M !W_"  :_PT %O\1 !/_%@ 0_QH #O\?  O_)  )_RH !O\P  +_-P$ _T !
M /]* 0#_5@$ _V0! /]U 0#_B $ _YH! /^J 0#_NP$ _[L! /^[ 0#_NP$
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M^V8G ?)F,0/J93T&XV-*"]Q@5Q+576(9T%IM'\Q7=R/(58 GQ52)*\)2DB[
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M1E^!_T1@?_]"87W_06)[_S]C>O\_8WK_/V-Z_S]C>O\__UX  .EM  #6>0
MR(0  +Z,  "VDP  KI<  *:;! "@G1< FITI I.<-PB,FD,0AIA-&("651]Z
ME%TF=9)E+'"0;#%LCG4V9XU^.F.+B3Y?BI5!7(FC1%J)M$58B<M%6(CM1%B(
M_T-9AO]!6X/_0%V!_SY=@/\^78#_/EV _SY=@/\^_V(  .1Q  #/?@  PX@
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M-TB<_S=)FO\W29K_-TF:_S=)FO\WXG0  ,J#  "\CP  L)@  *6>  ";I
MD*L  (6Q  !ZN 0 =KD4 '*Y)0%MN3,$:+@_"&.X20Y>MU(36K9:&%:V8AQ2
MM6L@3K1U)$NT@"=(LXXJ1;.=+$*SKBU!L\4N0;/I+4"P_B\_K_\Q/JW_,D"H
M_S)!IO\R0:;_,D&F_S)!IO\RU7P  ,**  "UE@  J)T  )VC  "2J@  A[$
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M%BC:_Q8HVO\6LY@  *6@  "9IP  B[   'ZX  !QP   9<@  %G.  !.TP
M1-L$ #_I#0 ]Z1< .^HC #GJ+@ VZS@!-.M" 3'L2P(O[54#+>U? RKN:P0H
M[G@%)N^(!B7OF@<C\*X'(O'(!R+P[0<A[/\'(>O_""#K_PH?ZO\+'^K_"Q_J
M_PL?ZO\+J)\  )NF  "-KP  ?[@  ''!  !DR@  6-   $S6  !!W0  ..0
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M8@$ _W,! /^' 0#_G0$ _[(! /_* 0#_Z@$ __,! /_S 0#_\P$ __,!A+<
M '3!  !ES   5M@  $??   YY0  +>H  "/N   <_0  &/\  !7_   1_P0
M#_\+  W_#@ )_Q$ !O\5  /_&@  _R   /\F  #_+@  _S<  /]!  #_30
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M.VUL_CEM;/\W;FS_-6YK_S1N:O\R;FK_,FYJ_S)N:O\R_U,  /1?  #>:@
MS7,  ,-Z  "[?@  M8$  *Z#"0"HA1H HH4K IN$.@>5@D4.D']/%8I]6!N&
M>U\@@7EG)7UW;RIZ=G<N=G2 ,G-SBS5O<I8X;'&C.FEPLCQH<,8\9W#G.V=Q
M_#EH<?\W:'#_-6EO_S1I;O\S:6[_,VEN_S-I;O\S_U8  .MB  #8;@  R78
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M-%A__S-9??\R67W_,EE]_S)9??\R[V   -MN  #'>@  NX,  +*+  "HD
MGY,  )26  "-F0X B9H> (2:+@)^F3H'>9=%#7263A-OE588:I->'6:292%B
MD6TF7H]V*EN.@2U7C8TP5(R:,U&,JC5/C+TU3XS>-4^+]S1/BO\S4(G_,E&&
M_S%2A/\Q4H3_,5*$_S%2A/\QZF4  -)S  #"?P  MH@  *R0  "BE   F)@
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M)CND_R8[I/\FS'H  +N(  "ND@  HID  )>>  ",I   @*H  '6O  !IM
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MD (=Z:0"&^F\ AKJX@(:YOP"&>7_ QGD_P08X_\%&./_!1CC_P48X_\%HYT
M ):D  "(K   >K4  &R]  !?Q   4\H  $?.   \TP  ,MH  "K?   E[@D
M(_ 1 "'Q&0 ?\2( '?(K !OS-  9]#X %_1( !7U4@ 3]E\ $O9N 1'W@ $0
M^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT_P$-\_\!#?/_ 0WS_P$-\_\!F:,  (NL
M  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@  )N(  !_J   <^P8 &?\.
M !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )_TX !O]<  3_;  "_X
M ?^6  #_K0  _\H  /_P  #__P  __\  /__  #__P  __\ C:L  'VU  !N
MOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H  !7Y   2_P  $/\(  [_
M#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST  /])  #_5P  _VD  /]^
M  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@  __H @+4  '"_  !AR0
M4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_   +_P  "/\   3_!@
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M+7Q:^BQ[6O\J>UO_*'M;_R=[6O\F>EK_)7I:_R5Z6O\E_TD  /M2  #C7
MTF,  ,=H  # :P  NFL" +5K#0"N;1T J&XN :-M/ 6=:T@*F6I1#Y1H6A20
M9F(8C65J'(IC<B"'8GHCA&&#)H%@C"E^7Y<K>UZC+7E>L2]W7<0O=5[B+W5>
M^2UU7_\K=5__*75?_RAU7O\F=5[_)G5>_R9U7O\F_TL  /!5  #>7P  S6<
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M*V1K_REE:O\H96K_*&5J_RAE:O\H_5,  .-?  #.:0  P7$  +=W  "O>P
MIWT  )Y]  "8?A$ DX B (Z ,0*)?SX&A'U(#']\41%[>ED6=WE@&G-W:!YO
M=G A;'5X)6ET@BAF<XXK8W*:+F!QJ"]><;HP77'4,%UQ\BY><?\L7G#_*U]P
M_RE@;_\H8&[_*&!N_RA@;O\H\54  -YB  #*;0  O74  +-[  "K@   HH(
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M)DZ!_R9.@?\FX6,  ,EP  "[>P  L(0  *:*  ";C@  D9$  (23  !ZE0(
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MF@\SLZT0,K/%$#*RZ1 QL/X2,*[_%"^M_Q4OK/\6+ZS_%B^L_Q8OK/\6NX$
M *Z.  "AE0  EIH  (F@  !]I@  <:L  &6O  !9M   3K<  $.\!0! O1$
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M !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1V_\"GIH  )*A  "$J0
M=K$  &BX  !;OP  3L0  $+(   WS   +=   "35   <VP  %=\% !3I#@ 2
MZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B  GP=  (\8D !_*@  7R
MN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\ E:$  (:I  !XL@  :;H
M %O"  !-R   0,P  #31   JU@  (=L  !G@   2Y   #_ !  WY"@ +^@\
M"?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\80  _74  /R,  #\I
M_,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D  'FR  !JNP  7,0  $[,
M   _T0  ,M<  "?=   =X0  %>4   [H   *\0  "/T   7_ P !_PD  /\.
M  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30  _U\  /]U  #_C0  _Z8
M /_"  #_YP  __P  /__  #__P  __\ ?+,  &R\  !=Q@  3L\  #_6   Q
MW0  )>(  !KF   1Z@  #.X   7R    _P   /\   #_    _P   /\%  #_
M"@  _PX  /\2  #_&   _R$  /\K  #_.0  _TH  /]=  #_<P  _XP  /^D
M  #_N0  _]0  /_>  #_W@  _]X _Q@L /\9*0#_&2@ _Q4K /\0, #_"S@!
M_P-$ ?\ 40'_ %X!_P!L ?\ > '_ ((!_P", ?\ E '_ )P _P"B /\ J #_
M *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#] /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4 _QDG /\3+ #_#C0 _PM
M ?\(3@'_!5L!_P-H ?\"= '_ G\!_P*( ?\"D0'_ I@!_P*? ?\!I0#_ :P
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M&Y%'^1N/1_\:CD?_&8Y'_QB-1_\8C4?_%XU'_Q>-1_\7_SX" /]#  #K2P
MW5$  -%4  #*5 $ QE(% ,%1$0"Y4R( LU4S :Y400*J5$P%IE-6"*)17PR?
M4&</G4]O$9I.=Q283G\6EDV(&)-,D1F13)L;CTNF'8U+LQZ+2\4>B4OB'H=,
M]QZ&3/\=A4S_'(5-_QJ%3/\9A4S_&85,_QF%3/\9_T   /Q'  #E4   U58
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M('!:_QYP6O\=<%K_''!:_QQP6O\<_T@  .=2  #36P  Q6(  +MF  "S:
MK&@  *5F!0"?9Q0 FFDE )5I- *0:$ $C&=*"(AF4PR$95L0@61B$WYC:A9[
M8G(9>&%Z''9@A!YS7XXA<%Z:(VY>J"5L7;@E:E[.)FE>[B1I7O\B:E[_(&I>
M_Q]J7O\>:E[_'6I>_QUJ7O\=^4H  .-5  #/7P  P64  +=J  "O;   IVP
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M'EMJ_QY;:O\>ZU,  --@  #":0  MG$  *QV  "C>0  F7D  (UW  "'>0L
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MF1I#BJH;0HJ_&T&*X1M!B/D;08;_&T&%_QM"A?\:0H3_&D*$_QI"A/\:S6<
M +QT  "O?@  I88  )J*  ".C   @HT  '60  !GE   894( %Z7% !<ER,
M6I@O %>8.@%4F$0#4I=,!4^75 =,EUP)299E#$>6;PY$E7H1096($S^4EQ4]
ME*@6.Y2]%CN4WQ8ZDO@7.I#_%SJ/_Q<ZCO\7.H[_%SJ._Q<ZCO\7Q6X  +9[
M  "JA0  GHL  )2/  "(D@  >Y0  &Z7  !BFP  5YX  %*@#@!1H!L 3Z$H
M $VA- !+H3X!2:%' D>A4 -$H5@%0J%A!S^@:PD]H'<+.J"%#3B@E XVH*8/
M-:"[$#2@W0\TG?<0,YS_$C.:_Q(SF?\3,YG_$S.9_Q,SF?\3O7<  *^#  "C
MBP  F)$  (V5  "!F0  <YP  &>?  !;H@  3Z8  $>I" !$JA( 0ZH? $&K
M*P! JS< /ZQ! #VL2@$[K%,".:Q< S>L9P0UK',%,JR!!C"LD0<NK*,(+:RX
M"2RLV0@LJO4**ZC_"RJF_PPJI?\-*J7_#2JE_PTJI?\-M8   *B+  "<D0
MD98  (6<  !XH   :Z4  %^H  !3K   2*\  #VR   VM0L -+45 #.V(0 R
MMBP ,;<W #"W00 ON$L +KA5 "RX8 $JN&T!*;E[ B>YC0(EN9\#)+FT R.Y
MT@,CM_0$(K7_!2&T_P8AL_\'(;+_!R&R_P<ALO\'K8H  *"1  "5EP  B)T
M 'NC  !NJ   8:T  %6Q  !*M   /[<  #2[   KO@, ),(, "+"%  BPQ\
M(<,J "#$-  ?Q#\ 'L5* !W&5@ <QF, &\=S !K'A0 9QYD &,BN !?(RP 7
MQO$!%\3_ 1;#_P(6P?\#%L'_ Q;!_P,6P?\#HY$  )B8  "+G@  ?:4  '"K
M  !BL0  5K8  $JY   ^O0  -,   "K$   BR   &<P$ !/0"@ 1TA$ $-(:
M !#3)0 /TS  #M0\  [42  -U58 #=5E  S6>  ,UHT "]BD  K8O@ )V>8
M"M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?  " I@  <JT  &2T  !7
MN@  2;\  #W"   RQ@  *,D  !_-   7T0  $=8   S;!0 (W@L !M\1  7?
M&@ $X"0  N$N  'B.@  XT<  .16  #D9P  Y7L  .:2  #FJ@  Y\@  .?P
M  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !TKP  9;<  %>^  !)PP
M/,<  ##+   ESP  '-0  !39   .W0  ">$   +E    Z08  .D-  #I$0
MZA@  .LA  #M*P  [S<  /%%  #R5@  \V@  /-^  #TEP  ];   /;0  #W
M\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !FN   6,$  $K(   [S   +M$
M "/6   9W   $>    SC   $YP   .H   #U    ]    /4%  #U"P  ]@\
M /84  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_@0  _YH  /^R  #_SP
M_^T  /_Y  #_^0  __D >+   &BZ  !9PP  2\L  #O1   MV   (=T  !;B
M   .Y@  ".H   #M    \    /@   #_    _P   /\   #_    _P8  /\,
M  #_$   _Q@  /\B  #_,   _T   /]3  #_:0  _X$  /^9  #_KP  _\,
M /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&+0#_ #4 _P!! /\ 3P#_
M %P _P!I /\ = #_ 'X _P"( /\ D #_ )< _P"= /\ I #_ *H _P"P /\
MMP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_ #  _P ] /\ 2P#_ %@
M_P!D /\ < #_ 'H _P"$ /\ C #_ ), _P": /\ H #_ *8 _P"M /\ M #_
M +P _@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_ /@ _P#X /\ ^0#_ /D
M_P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP _P<Y /\#1@#_ %, _P!@
M /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_ *, _@"I /P L #Z +D
M]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\ _P#O /\ \ #_ /  _P#P
M /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT /\,00#_"DX _PA; /\'
M9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\ ]@:F /0&K0#R!K4 \ 7
M .T%S@#K!>0 Z0;S .8(_P#E"O\ Y O_ .0+_P'D"_\!Y O_ >0+_P'D"_\!
M_R$8 /\A$P#_(!$ _QL2 /\<&@#_&B0 _Q8O /\3/ #_$4D _Q!5 /P.80#Y
M#FL ]@YU /0.?@#R#H8 \ Z. .X.E0#M#IL ZPZB .H.J@#H#K, Y@^] .4/
MS #A#^, W1#S -D1_P'6$O\!U!/_ =,3_P+2$_\"TA/_ M(3_P+2$_\"_R43
M /\E$ #_) T _R,. /\C% #_(AX _Q\I /\<-0#Y&4, ]!A/ .\76P#L%V8
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M!JXN^P>K+O\(J2[_"*@N_PBH+?\(J"W_"*@M_PBH+?\(_R\( /\Q  #_-0
M]C<  .HV @#G,P@ Y"\/ -DN&P#/,2P R3,\ ,0T20# -54!O#5? KHU: *W
M-7 #M31X!+,T@ 6Q-(@&L#20!JXTF0>L-*((JS2L":DTN0FG-,H*I37E"J$U
M^ N?-?\,G37_#)TU_PN<-?\+G#7_"YPU_PN<-?\+_S," /\U  #V.@  Y3X
M -Q   #4/00 TC<) ,LX%0##.B8 O3TV +@^1 &T/E !L3U: ZX]8P2L/6L%
MJ3QS!J<\>PBF/(,)I#N+"J([E N@.YT,GCNH#9T[M Z;.\4.F3O@#I8[] ^4
M//\/DCS_#Y(\_PZ1//\-D3S_#9$\_PV1//\-_S4  /\Y  #J00  W48  -!'
M  #)1@  QD$% ,! $0"Y0B$ LT0R *]%0 &K14L"IT55 Z1$7@6A1&8'GT-N
M")U#=@J;0GX+F4*&#9=!CPZ509D/DT&D$9%!L!*00< 2CD'9$HM!\1*)0O\2
MB$+_$8A"_Q"'0O\0AT+_#X="_P^'0O\/_S@  /,]  #C1P  TDP  ,A.  #
M30  NTH" +9'#@"P21T JTLM *9,.P&B3$<"GDM1!)M+6@:92F((EDEJ"I1)
M<0R22'D.CTB"#XU'BQ&+1Y42B4:@%(=&K!6%1KL6A$;1%H)'[A: 1_\5?T?_
M%']'_Q)_1_\1?T?_$7]'_Q%_1_\1_SL  .Y#  #<3   S%$  ,%4  "Y5
MM%$  *Y-"P"H3QD HU$I )Y2-P&:4D,"EU%.!)115@:14%X)CD]F"XQ.;0V)
M3G4/ATU^$85-AQ."3)$5@$R<%GY+J1=\2[@8>TO-&'E,ZQAX3/X7=TS_%7=,
M_Q1W3/\3=TS_$G=,_Q)W3/\2_SX  .A'  #54   QE8  +Q8  "T60  K58
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M%&59_Q1E6?\4[T8  -I2  #&6P  NF$  +!E  "F9@  G6,  )5A  "/8@X
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MF1E1;:@:3VV[&TYMV1I.;/093VO_&$]K_Q=0:O\64&K_%5!J_Q50:O\5W54
M ,5A  "W:@  K'$  *)U  "4=   B70  'QS  !V=0  <7<0 &]X'0!L>2L
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M$SR$SQ,\@O 2/('_$CV _Q(]?_\2/7[_$3U^_Q$]?O\1Q68  +5Q  "J>P
MGX(  )*"  "%@@  >8,  &V&  !?B@  6(T! %2.#P!2CQL 4(\G $^0,P!-
MD#T!2Y!% DF03@-&D%8$1(]?!4*/: <_CW,)/8Z "SJ.CPPXCJ --XZS#C:.
MS XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'_P\VA_\/OFT  +!Y  "E@@  F8<
M (R(  !_B   <HH  &:-  !:D0  4)4  $F7"0!'F!, 19@@ $29*P!#F38
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M AJM_P(:K/\#&JO_ QJK_P,:J_\#J(@  )N/  "1E   A)H  ':?  !HH@
M6Z4  $^I  !$K0  .;   "^S   FM@  'KD% !B[#@ 7NQ8 %[P@ !:\*@ 5
MO34 %+U  !.^2P 2OE@ $KYG !&_>  0OXP $,"B  [ N@ .P.$ #[W[  ^\
M_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP  >:$  &NG  !>K   4K$
M $6T   ZM@  +[D  "6\   =OP  %<,   _&!0 +R@T "<H4  C*'0 'RB<
M!\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,JP  S<@  ,SM  #,_P
MR_\  <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH  &"P  !2M@  1;D  #F\
M   NOP  (\,  !O&   3R@  #<T   C1   !U D  -0.  #5%0  UAX  -@G
M  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP  W[0  -[9  #?]P  W_\
M -__  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z  !%OP  .,(  "S&   A
MR0  &,T  !#1   +U0  !-H   #>    X $  .$)  #B#@  Y!,  .4;  #G
M)   Z2\  .L\  #M2P  [ET  .YQ  #OB0  \*(  /"\  #PXP  [_D  /#_
M  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$   WR   *LP  !_0   5U0
M#MH   ?>    X@   .8   #I    Z@   .P   #N!0  [PP  /$0  #S%P
M]2   /@K  #[.0  _4H  /Y>  #_=   _XT  /^F  #_P   _^$  /_U  #_
M]0  __4 =*X  &6W  !6P   1\@  #C-   JT@  '=@  !/=   ,X@   ^8
M  #I    [    /    #S    ]    /8   #X    ^@   /T'  #_#0  _Q(
M /\;  #_*   _S<  /]*  #_7@  _W8  /^/  #_I@  _[H  /_1  #_T0
M_]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^ /\ 3 #_ %D _P!E /\
M< #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4 _P"K /\ L@#_ +H _P#%
M /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^ /\ _@#_ /X _P#^ /\
M_Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_
M '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G /X K@#] +8 _ #  /L
MS0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#U /\ _Q4=
M /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_ %  _P!< /\ 9P#_ '$
M_P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4 J@#T +( \@"[ /$ R #O
M -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_ .H _P#J /\ _Q@9 /\6
M%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L _P!7 /\ 8@#\ &P ^ !U
M /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I *X YP"W .8 PP#D -0
MX@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T _P#= /\ _QL3 /\:$ #_
M%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1 /<"7 #R F8 [@)P .H"
M> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L VP2T -@%P #6!=  TP;G
M - (^ #."O\ S O_ ,L,_P#+#/\ RPO_ ,L+_P#+"_\ _Q\0 /\>"P#_&@<
M_QD+ /\8$0#_%AD _Q(D /H0, #S#CX [@U* .D,5@#E#&$ X@QJ -X-<P#;
M#7L V0V# -8-B@#4#9$ T@V9 - .H #/#JD S0ZS ,L.OP#*#]  QA'I ,(2
M^0"_$_\ O1/_ ;P3_P&\$_\!O!/_ ;L3_P&[$_\!_R(, /\A! #_(   _R$%
M /\?# #_'!$ ]A@< .P5* #E$S8 WQ)# -D33P#3%%H T!5D ,T6;0#+%G4
MR1=] ,<7A0#%&(P Q!B4 ,(9G # &:4 OAFO +T:NP"[&LL N!OE ;0<]@&R
M'?\"L!W_ J\=_P*N'?\"KAW_ JX=_P*N'?\"_R8& /\E  #_)@  ^R<  /$E
M P#P(0L Z!P2 -X9'0#4&RT S1T\ ,@?20#%(%4 P2%? +\B: "\(G  NB-X
M +DC?P&W(X<!M2./ ;0DEP&R)* !L22J J\DM@*M)<8"JR7? J@F\P.E)O\#
MHR;_ Z(F_P2A)O\#H2;_ Z$F_P.A)O\#_RD  /\H  #V+0  YS   -\O  #9
M*P0 UB(* ,XC%@#&)B< P"@V +LJ1 "X*T\ M2Q9 +(L8@&P+&H!KBUR :PM
M>@*J+8$"J2V* J<MD@.E+9L#I"VE!*(ML02@+< $GRW8!)PN[P69+O\&ER__
M!I8O_P:5+O\%E2[_!94N_P65+O\%_RP  /\N  #J-0  W3D  -$Y  #*-@
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M"W%&_PMQ1O\+\SD  .!$  #,3   OE$  +13  "J4@  HDX  )U* 0"72Q$
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MF!)<6*<46UBX%%E9T!196/ 365C_$5I8_Q!:6/\.6E?_#5I7_PU:5_\-XT@
M ,M3  "[6P  L&$  *1B  "780  CE\  (5<  !_7@< >U\3 'AA(0!U8BX
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M$DEGR1))9^L226;_$$IF_P]*9?\.2V7_#4MD_PU+9/\-T50  +Y>  "Q9P
MIFT  )=L  "*:P  ?VL  '-K  !M;0  :&X, &5P%P!B<20 8'$P %YQ.@%<
M<4,"67%+ U=Q4P15<%H&4G!B!U!P:PE.;W4+2V^"#4ENCP]';I\016ZP$41N
MQQ%#;>H01&S_#T1K_PY%:_\-16K_#45J_PU%:O\-RU@  +IC  "M;   H7$
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M"#"#_P@P@O\(,('_"#"!_P@P@?\(MVL  *IV  "@?P  D'X  ()^  !V?P
M:H   %Z#  !3AP  2HL  $&. @ ]D X .Y 8 #J1(P YD2T .)(W #>20  V
MDDD -)-2 #.37 $QDV<!+Y-T BV2@P,KDI0#*I*G RB2O00HDN$#)Y#Z!">.
M_P4GC?\%)XS_!2>,_P4GC/\%L70  *5^  "9A0  BH0  'V$  !OA0  8X@
M %B+  !-CP  0Y,  #J7   RF@< +IL0 "V;&@ LG"0 *YPN "J=.  IG4$
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M  FR_P )LO\ FHT  )"3  "$F   =)P  &6@  !7I   2Z@  $"L   UL
M*K,  "&U   8N   $;L   R^ @ &P L  L 1  '!&0  P2(  ,(K  #"-@
MPT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:  #$]@  P_\  ,/_  ##
M_P  P_\ DY0  (>:  !XH   :J8  %RL  !/L0  0;4  #6W   IN@  '[T
M !;    0PP  "L8   /*    S 4  ,P,  #-$0  SA@  ,XA  #0*@  T34
M --#  #44@  U&,  -5X  #5CP  U:<  -;"  #6Z0  UOT  -;_  #6_P
MUO\ BIL  'NB  !LJ0  7K   %"V  !"N@  -+T  "C!   =Q   %,<   W+
M   &S@   -(   #7    V0   -H%  #<"P  W1   -\5  #A'0  XR<  .4S
M  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@  Z^\  .O^  #K_P  Z_\
M?:,  &ZK  !?L@  4;H  $+    TPP  )\<  !O+   2SP  "],   +8
MW0   .$   #D    Y0   .<   #I    ZP<  .T-  #O$0  \1D  /0D  #W
M,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(  /WM  #]]   _?0 <:P
M &&U  !2O0  1,0  #3)   FS0  &M(  !#8   (W0   .$   #E    Z
M .P   #O    \0   /,   #U    ]P   /D!  #["   _@X  /\5  #_(0
M_R\  /]!  #_5@  _VT  /^'  #_H   _[8  /_*  #_U   _]0 _PL@ /\'
M'@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8 _P!B /\ ;0#_ '8 _P!_
M /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_ +4 _P"^ /\ RP#_ .$
M_P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D _P#Y /\ _PT= /\+&@#_
M!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!> /\ : #_ '( _P!Z /\
M@@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[ +  ^0"Y /@ Q@#V -D ]0#K
M /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S /\ _Q 9 /\.%0#_"!0
M_P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\ 8P#^ &T _ !U /H ?0#Y
M (0 ]P"+ /8 D0#T )< \P"> /( I #P *P [@"T .T P #K ,\ Z0#F .@
M]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\ _Q(4 /\0$ #_# \ _P,0
M /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T &< \0!P .\ > #M '\
MZP"& .H C #H ), YP"9 .4 H #C *< X0"P -\ N@#= ,D VP#@ -@ \ #7
M /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40 /\2# #_#@D _PL, /\)
M$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H &$ Y0!J .( <@#@ 'H W@"
M -P AP#: (X V "5 -0 G #2 *, T "L ,X M@#, ,0 R@#9 ,@ [0#' /L
MQ0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5!0#_$   _Q & /\/#0#_
M#!0 _ <? /$#*P#G #D X@!& -X!40#: EL U0)D -(#; #/ W0 S01[ ,L$
M@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$ O0C5 +L)[ "X"_T M@S_
M +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_%P  _Q8  /L3!@#Z$ X
M[@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-9P#"#F\ P0YV +\.?@"]
M#X4 O ^- +H0E0"X$)T MQ"G +41L@"S$<  LA'5 *X3[@"K%/X J17_ *<5
M_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z'@  ZQX  .,<  #?%04 W@X-
M -,.& #+$2@ Q1,W , 41 "\%D\ N1=9 +<780"T&&D LQEQ +$9> "O&H
MKAJ( *P;D "K&YD J1NC *<<K@"F'+P I!W/ *$>Z@&>'OP!G!__ 9L?_P&:
M'_\!FA[_ 9D>_P&9'O\!_R(  /\A  #L)P  X"H  -0I  #-)   RAP( ,09
M$@"]'"( MQXQ +,@/@"O(4D K2)3 *HC7 "H)&0 IB1L *0D<P"C)'H H26"
M : EBP&>)90!G26> 9LFJ@&9)K<!F";) I4GY@*2)_D"D"C_ H\H_P*.)_\"
MCB?_ HXG_P*.)_\"_R8  /(I  #C,0  TC0  ,@T  # ,   NRD" +@C#@"Q
M)AP K"@K *@J. "D*T0 H2Q. )\M5P"=+5\ FRUG 9DM;@&8+G4!EBY] I0N
MA@*3+I "D2Z: X\NI@.-+K,#C"[% XHOX02'+_8$A2__!(0O_P.$+_\#@R__
M X,O_P.#+_\#^RD  .LQ  #9.   R3P  +\\  "V.0  L#(  *PM"P"G+Q<
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MF II1J8+9T:V"V9&S ME1NP+9$?_"61&_PAD1O\'9$;_!F1%_P9D1?\&Z#L
M -!&  "_30  LU$  *51  ":3@  DDL  (U'  "'2 L @TH6 ']+) !]3#$
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M#513Q0U34^8,4U/\"U-3_PE44O\(5%+_"%12_P=44O\'VD8  ,-0  "U6
MJ%L  )E:  "-6   A%<  'M4  !V5@$ <5</ &Y9&P!L6B@ :5HS &=;/0%E
M6T4!8UM- F%:50-?6EP$75ID!5M9; 98678(5EF""518CPM26)X,4%BN#4]8
MPPU.6.0,3EC["T]7_PE/5_\(3U;_"%!6_P=05O\'TTH  ,!4  "R7   HUX
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M1&'Y"D1@_PE$8/\(15__!T5?_P=%7_\'R%(  +A<  "K9   FV0  (QC  "
M8P  =F,  &IB  !C9   7V8& %MG$0!9:!T 5VDI %9J,P!4:CP 4FI% 5!J
M3 %.:E0"3&I< TIJ901(:6\%1FEZ!T1IB A":)@)0&BI"C]HO0H^:-X)/F?W
M"3YF_P@_9?\'/V7_!S]D_P<_9/\'PU<  +-A  "G:0  EF@  (=G  ![9P
M<6<  &5H  !<:@  6&P! %1N#@!2;Q@ 4&\D $YP+@!-<#@ 2W%! $IQ20%(
M<5$!1G%9 D1P8@-"<&P$0'!X!3YPA@8\;Y4'.F^F"#AONP@X;]L'.&[V!SAM
M_P<X;/\&.6O_!CEJ_P8Y:O\&O5P  *]F  "B;0  D6P  ()K  !W:P  ;&P
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M B&%_P(AA?\"JW(  *%\  "/>P  @'H  '-Z  !F?   6W\  %""  !&A@
M/(H  #2-   LD0  )I,, "24$P CE!P (I4F "&5+P @E3@ 'Y9" !Z63  =
MEE@ ')9D !J7=  9EX8 &)>9 !>7K@ 5E\D %I7N !:3_P$6DO\!%I'_ 1:0
M_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?A   5(@  $F+   _D   -90
M "V7   EF@  '9X! !:@#  4H1( %*$; !.A)0 2H2X $:(X !&B0P 0HD\
M#Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@_@ -G_\ #9[_  V=_P -
MG?\ GH0  )*)  "#B   <X@  &6+  !8C@  3)(  $&7   WFP  +IX  "2B
M   <I0  %:@   ^K!  *K@P !ZT2  :M&P %K20 !*XN  *N.0 !KD4  *Y2
M  "N80  KG,  *Z'  "NG0  KK0  *[5  "M]   K?\  *S_  "K_P  J_\
MEHL  (R0  ![D   :Y(  %V6  !0F@  1)\  #FC   OIP  ):L  !RN   4
ML0  #K0   FW   !N D  +@.  "Y%   N1P  +HE  "Z+P  NSH  +Q'  "\
M5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X  +O_  "[_P  N_\ D)(
M (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q   EM   &[<  !*Z   ,O0
M!;\   ##    Q (  ,4*  #%#@  QA0  ,<;  #()   RBX  ,PZ  #-20
MS5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_  #-_P  S?\ AID  '>@
M  !II@  6JP  $RR   ^M@  ,+D  "2\   9OP  $<(   K%   "R0   ,P
M  #0    T0   -(!  #3"   U0T  -<1  #:&   W"$  -\L  #A.@  XDH
M .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E_P  Y?\ >J$  &NI  !<
MKP  3;8  #^\   POP  (\,  !?'   /R@  !\X   #1    U@   -P   #?
M    X    .(   #D    Y@,  .@)  #I#@  [!4  .X>  #Q*P  ]#H  /5-
M  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P  ^?, ;:H  %ZR  !/N@
M0,$  #'%   BR0  %LX   W2   $V    -T   #A    Y    .@   #K
M[0   .\   #Q    \P   /8   #X P  ^@L  /T1  #_&P  _RD  /\[  #_
M3P  _V8  /]_  #_F0  _Z\  /_#  #_U@  _]8 _P0< /\ &0#_ !D _P <
M /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_ '( _P!Z /\ @@#_ (D
M_P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\ Q0#_ -D _@#L /T ^P#[
M /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8 /\!%0#_ !0 _P 6 /\
M&P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"*
M /T D #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T ,X \P#F /$ ]@#P /\
M[P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&$0#_ !  _P 0 /\ %@#_
M "( _P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P /< > #U '\ \P"% /(
MBP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,< Y0#> ., \ #B /X X #_
M .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_ 0P _P , /\ $@#_ !P
M_P H /P -@#Y $, ]@!. /( 60#O &( [ !K .H <@#H 'D Y@"  .0 A@#B
M (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3 -  Z@#. /H S0#_ ,T
M_P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P( _P ( /\ #@#_ !8 ]@ B
M /  +P#L #P Z0!( .4 4P#A %P W@!E -L ; #7 ', U !Z -( @ #0 (<
MS@". ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,  Y0"^ /4 O0#_ +P _P"\
M /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@! /\$"@#X !  Z0 : .,
M* #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X Q !T ,( >P#! (( OP")
M +T D "\ )@ N@"A +@ JP"V +< M #' +( X "Q ?( KP+_ *X#_P"M!/\
MK03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*  #I PD W0 2 -0 'P#-
M 2T R (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O +4&=@"T!WT L@>$ +$(
MC "O")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0 H@[_ * ._P"?#O\ GP[_
M )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2$ ( SPD+ ,@(%@#!"B0
MO PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1<0"H$7@ IA&  *41B "C
M$I$ H1*; * 3I@">$[, G!/# )L4W@"7%O0 E1;_ )07_P"3%_\ DA?_ )(6
M_P"2%O\ _QH  /0=  #E(P  U24  ,HD  #"'0  OA8$ +L0$ "T$QT KQ4K
M *L6. "G&$, I1E- *(95@"@&ET GAME )T;; ";'', FAQ[ )@<@P"7'8T
ME1V7 ),>H@"2'J\ D!Z_ (\?V ",(/$!B2#_ 8@@_P&'(/\!AR#_ 88@_P&&
M(/\!^AX  .LF  #:+0  RC   +XN  "U*   L"(  *X;# "H'1< HQ\F )\A
M,P"<(CX F2-( )<D40"5)%D DR5@ )(E9P"0)FX CB9V (TF?P"+)H@!BB>3
M 8@GG@&&)ZL!A">[ 8,HT0& *.X!?BG_ 7TI_P%\*/\!?"C_ 7PH_P%\*/\!
M]20  .,N  #/-0  P3@  +0V  "K,0  I2P  *(F!@">)A, F2@A )4J+@"2
M*SD CRQ$ (TM3 "++50 B2Y< (<N8P"&+FH!A"YR 8(N>@&!+X0!?R^/ GTO
MF@)[+Z<">B^W G@OS )V,.H"=3#^ G,P_P)S,/\"<R__ G,O_P)S+_\"\"H
M -PU  #'.P  NC\  *P\  "B.   G#,  )@O  "5+A  D# < (PR*0"),S4
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M!F!!P@9>0>(&7D'Y!5U!_P1=0/\#74#_ UU _P-=0/\#WSD  ,A#  "Y2@
MJ4L  )M)  "01P  B$0  (-!  !^008 >D(1 '9#'@!T12H <44U &]&/P!M
M1D< :T9/ 6I&5@%H1ET"9D9E F1&;0-B1G8$8$:"!%Y&C@5<19P&6T6L!EE&
MOP=81M\&6$;W!5=%_P171?\$5T3_ UA$_P-81/\#VCT  ,1'  "U3@  I$X
M )9,  "+2P  @TD  'U%  !X1@( =$<0 '!(&P!N22< :THR &I+/ !H2T0
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M!DA2_P5(4?\$25'_!$E0_P-)4/\#RD@  +E2  "J5P  F%8  (I5  !_5
M=E,  &Q1  !G4P  8E0( %]6$@!=5QX 6U<I %E8,P!86#P 5EE$ %593 %3
M65,!45E; D]89 )-6&T#2UAX!$E8A@5'5Y4&15>E!D17N 9#6-(&0U?R!D-6
M_P5#5?\$1%7_!$14_P-$5/\#QDP  +56  "E6@  E%D  (98  ![6   <5<
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M S)D_P,R9/\#MUL  *ED  "69   AF,  'AC  !M8P  9&0  %EE  !0:
M26L  $-M! ! ;@X /F\8 #UO(@ \<"L .G T #EQ/0 X<44 -W%. #9Q5P T
M<6$!,G%M 3%Q>@$O<8H"+7&< BMQKP(J<<@"*G#K BIO_P(J;?\"*FS_ BML
M_P(K;/\"L6$  *1I  "0:   @&<  '1G  !I9P  7V@  %5K  !+;@  0W$
M #QT   W=@H -'<2 #-X'  R>"4 ,7DN #!Y-P O>3\ +GE( "QZ4@ K>EP
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M:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\ $(K_ !")_P 0B?\ H7H
M (YY  !^=P  <G<  &1X  !8>P  37X  $*"   YA@  +XH  ">.   @D0
M&)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:.P )FD8 ")I3  :;80 %
MFG( !)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_  66_P %EO\ F8$  (=_
M  !Z?@  :WX  %V!  !0A0  18D  #N-   QD@  *)8  !^9   8G0  $:
M  RC @ &I0H  :40  "E%@  IA\  *8H  "F,@  IST  *=*  "G6   IV@
M *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D_P  I/\ D8<  (*&  !R
MA@  8X@  %6,  !)D0  /98  #*:   HG@  'Z(  !>F   0J0  "ZP   2O
M    L08  +$,  "R$0  LA<  +,?  "S*   M#(  +4_  "U30  M5T  +5P
M  "UA@  M9T  +6V  "UW   M/<  +3_  "T_P  M/\ BX\  'J.  !JD0
M6Y4  $V:  ! GP  -:0  "JH   @K   %K    ^T   )MP   ;D   "]
MO@   +X&  "_#   P!   ,$6  #"'0  PR<  ,4R  #&0   QE$  ,=C  #'
M>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\ @Y<  '&:  !AG@  4J,
M $6I   XK@  ++,  ""W   6N@  #KT   ;     PP   ,<   #)    R@
M ,P   #- P  S@D  - .  #2$P  U!L  -@E  #;,@  W4(  -U4  #>:0
MWH$  -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\  &BF  !9K0  2K,  #NX
M   MNP  '[\  !3"   ,Q@   \D   #,    T    -4   #9    V@   -P
M  #>    X    .(%  #D"P  YQ   .H8  #M)   \#(  /%$  #R6   \V\
M /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO  !,MP  /;T  "W!   ?
MQ@  $\H   O.    T@   -<   #<    X    .4   #G    Z0   .L   #M
M    [P   /$   #S    ]@<  /D.  #\%@  _R(  /\S  #_1P  _UT  /]V
M  #_D0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_ !4 _P 8 /\ '@#_ "<
M_P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"* /\ D #_
M )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G /H ^ #Y /\ ^0#_ /D
M_P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$ _P 2 /\ %P#_ ", _P Q
M /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #] 'X _ "% /H BP#Y )$
M^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X \@#L /\ [ #_ .P _P#K
M /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T _P - /\ $P#_ !X _P K /\
M. #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D [P!_ .X A@#L (P Z@"2
M .D F0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#< /L VP#_ -H _P#: /\
MV0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\ #P#_ !@ ^P E /@ ,@#U
M #\ \@!* .T 5 #J %T YP!E .0 ; #B ', X !Z -X @ #< (8 V@"- -<
ME #4 )L T@"D ,\ K0#- +D RP#) ,D Y #( /8 Q@#_ ,4 _P#& /\ QP#_
M ,< _P#' /\ _PH& /\!  #_    _P $ /\ "P#T !( [P ? .H + #E #@
MX@!# -T 3@#9 %< U !? -$ 9P#. &T S !T ,H >@#( (  Q@"' ,4 C@##
M )8 P0"> +\ J "] +, N@#" +D VP"W /  M0#_ +8 _P"U /\ M0#_ +4
M_P"U /\ _PP  /\$  #_    _@   /8  P#H  T X  7 -D ) #1 #$ S0 \
M ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y 'L MP"" +4 B0"S )$
ML@": +  I "N *\ K "] *H T "H .L IP#[ *8 _P"F /\ I0#_ *4 _P"E
M /\ _PT  /\'  #T"0  Z@D  .($  #:  < SP 1 ,@ ' #" "D O@ U +L
M0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K '4 J0!] *@ A "F (T I "6
M *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8"/\ EPC_ )<(_P"7"/\
M_Q   /<0  #H%   W!4  ,X1  #&#0  P@0+ +P % "W 2$ L@,N *X%.@"K
M!D0 J A- *8(50"D"5P H@IC * *:@"?"W$ G0MX )P+@ ":#(D F0R3 )<,
MG@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\ BQ#_ (L0_P"*$/\ ^Q,
M .T:  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K#1D IPXF *,/,P"?$#X
MG1%' )H14 "8$E< EA)> )4390"3$VP DA-S ) 4? "/%(4 C16/ (L5F@"*
M%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_ '\8_P!_&/\ ]1H  .0C
M  #/*0  P"H  +,F  "J(@  I1P  *05" "@%!, FQ8A )<8+0"4&3@ D1I"
M (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#'X  @A^+ ( ?EP!^(*,
M?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A_P!T(?\ [R$  -LK  #'
M,0  MC$  *DN  "@*@  FR8  )@A 0"5'A  D" ; (TA* ")(S, AR0] (4D
M1@"#)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP >"B' '8HDP!T** !<BBO
M 7$IP0%O*> !;2GW 6PI_P%K*?\!:RG_ 6LH_P%K*/\!Z"@  - R  # .
MKC<  *$U  "8,@  DBT  (XI  "+)PP AR@7 (,J(P" *R\ ?BPY 'PL0@!Z
M+4H >"Y1 '<N6 !U+F  <R]G '(O;P!P+WD!;R^# 6TOD %K+YT!:2^L 6@P
MO@%G,-L!93#U 60P_P%C,/\!8R__ 6,O_P%C+_\!XBX  ,HX  "Z/0  J#P
M )HZ  "1-P  BC,  (8P  "#+@D ?R\3 'LP'P!X,BL =C,U '0S/@!R-$8
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M0   ?CX  'D[  !T.@  <3H. &T\& !K/20 :3XO &<_. !E/T  9$!( &)
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M TA)LP-'2<H#1DGL T9(_P)&2/\"1T?_ D=&_P)'1O\"QD,  +9,  "B3
MD4P  (1+  !Y2@  <$D  &E&  !D1P  7TD& %Q*$ !:2QL 6$PE %9,+P!5
M33@ 4TU  %)-2 !13D\ 3TY7 $Y.7P%,3FD!2DYS DA-@ )&38\#14V? T--
ML0-"3<@#04WJ T%,_P)!3/\"0DO_ D)*_P)"2O\"PD<  +-/  ">3P  C4X
M (!.  !U30  ;$P  &-*  !>3   6DT" %9.#@!43Q@ 4E B %%1+ !/434
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M C%;_ (Q6O\",5G_ C)9_P$R6/\!ME0  *19  "06   @%@  '-7  !I5P
M8%@  %19  !.6P  2%T  $-?! ! 8 X /F$7 #UA(  [8BD .F(R #EB.@ X
M8T( -V-+ #9C5  T8UT ,V-H #%C=@$O8X4!+F.6 2QCJ0$K8[\!*F/C 2IB
M^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7   >UL  &];  !E6P  7%P
M %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S:20 ,FDM #%I-0 O:CT
M+FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1KIP C:[T (FK@ "-I^0$C
M9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\  &I?  !A8   5V   $UC
M  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X *'$F "=R+P F<C< )7)
M "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :<[D &7/< !IQ]P :</\
M&V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D  !=9   4F8  $AI   _
M;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L? !M[*  :>S  &7PY !A\
M0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4 #WW5 !![]0 1>?\ $7C_
M !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7:@  3&T  $-P   Y=
M,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"''P 0AR@ #H<Q  Z'.P -
MAT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)  :%[  'A/\ "(/_  F"
M_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@  1G4  #QY   R?0  *H$
M "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "DB   9(I  "2,P  DSX
M )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1Y0  D/H  (__  "/_P
MC_\ C7<  'UU  !P=   8G4  %5X  !)?   /X   #2$   KB0  (HT  !J1
M   3E   #I<   F;   !G0@  )T.  "=$P  GAH  )XB  "?*P  GS4  *!"
M  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@  G?8  )W_  "<_P  G/\
MAGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1   CE@  &IH  !*>   -
MH0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9  "M(@  KBL  *\W  "O
M10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\  *W_  "M_P  K?\ @80
M '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :I   $J@   RL   $KP
M +(   "V    MP   +<"  "X"   N0T  +H2  "[&   O2$  +XK  # .
MP$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y  # _P  P/\ >8T  &B0
M  !9E   2YH  #V@   QI0  ):L  !JO   1LP  "[@   *[    O@   ,$
M  #$    Q0   ,8   #'    R 4  ,H+  #,#P  SA4  - ?  #3*P  U3H
M -5,  #68   V'<  -B2  #8K   V<D  -GL  #9^P  V/\ <)D  &">  !1
MI   0ZH  #6P   HM@  '+H  !&^   )P0   ,4   #(    RP   ,\   #2
M    TP   -8   #8    VP   -T   #?!P  X@T  .43  #H'0  ["H  .T\
M  #M40  [F<  .^!  #OG   \+<  /#3  #P[   \/0 9Z8  %BM  !)M
M.KH  "J^   <P@  $,8   ?*    S@   -(   #6    W    .    #C
MY    .8   #H    ZP   .T   #O    \@(  /4*  #X$0  _!P  /\L  #_
M/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$ _P 4 /\ $@#_ !( _P 4
M /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_ &@ _P!P /\ > #_ '\
M_P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P N0#Z ,@ ^0#B /@ ] #W
M /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1 /\ #@#_  X _P / /\
M% #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &, _@!K /P <P#Z 'D ^0"
M /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M ,$ ZP#6 .H [@#I /X
MYP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\ "@#_  @ _P ) /\ $ #_
M !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F .X ;0#L '0 ZP!Z .D
M@ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D V@#* -< Y@#4 /@ T@#_
M -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_    _P # /\ #0#\ !8
M]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X 9P#; &T V0!T -4 >@#3
M (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#" ,, W #! /$ OP#_ +\
M_P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_    _P   /8 " #N !$ YP ;
M .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#& &< Q !M ,( <P#  'H
MOP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$ S@"P .H KP#\ *T _P"M
M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@   .@   #>  P TP 5 ,P
M(0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$ M !G +( ;0"P '0 KP!Z
M *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A ., GP#V )X _P"> /\
MG@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4   #+  8 PP / +T &0"X
M "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B *0 : "B &X H0!U )\
M? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P D@#R )$ _P"0 /\ D #_
M (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[!P  MP * +$ $@"L !X
MJ  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!8P"6 FD E )P ),#> "1
M X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP (0*_P"#"_\ @PO_ (,+
M_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@  J T  *8'#0"B!18 G0<B
M )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+#64 B0UL (@.= "&#GT
MA0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2_P!W$O\ =Q+_ '<2_P!W
M$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<  )D1! "8#A  DQ ; (\1
M)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6  ?A9H 'T6;P![%G@ >1>#
M '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M&_\ ;1K_ &T:_P!M&O\
MYR   - I  "\*P  JRH  )XH  "6)   D"   (T<  ",%PP B!@6 (0:(@"!
M&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C ',?:P!Q('0 <"!_ &XA
MBP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\ 9"+_ &0B_P!D(?\ X"8
M ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""( @ ?B 2 'LB'@!X(RD
M=20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG: !I*'$ 9RA[ &4HB !D
M*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_ %PI_P!<*/\ V"P  ,,U
M  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* , =B<0 '(I&@!P*B4 ;2LO
M &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A+VX 7R]X %XOA !<+Y(
M6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N_P!5+O\ T#$  +TZ  "H
M.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX- &LO%@!I,"$ 9C$K &0R
M- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L 635U %<U@@!5-9 !5#6?
M 5(UL %1-<8!4#7G 4\U_0%/-?\!3S3_ 4\T_P%/,_\!RS8  +@]  "C/
MDCP  (4[  ![.@  =#<  &\U  !L,P  :#0* &4U$P!B-AX 8#<H %XW,0!=
M.#H 6SA! %HY2 !9.5  5SE7 %8Z7P!4.F@ 4SIS %$Z?P%/.HT!3CJ= 4PZ
MK@%+.L,!2CKE 4DZ_ %).?\!23G_ 4DX_P%*./\!QSH  +-   ">/P  CC\
M ($^  !W/0  <#L  &HX  !F.   8CD' %\Z$0!<.QL 6CLE %D\+@!7/3<
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M 3I'^ $Z1O\!.D7_ 3M%_P$[1/\!NT4  *9(  "21P  @D<  '9'  !K1P
M8T8  %M#  !610  4D<  $Y("@!,21( 2DD< $A*)0!'2BX 1DLV $5+/@!#
M2T8 0DQ- $%,5@! 3%\ /DQJ #Q,=@ [3(4!.4R5 3=,IP$V3+P!-4S= 35+
M]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+  ".2@  ?DH  ')*  !H2@  7TD
M %5(  !02@  3$L  $E,!P!&31  1$X9 $)/(@!!3RL 0% S #]0.P ^4$,
M/%%* #M14P Z45P .%%G #=1<P U48( ,U&3 3)1I0$P4;H!+U': 2]0]@$O
M3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30  >DT  &Y-  !D30  6TT  %%-
M  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z52< .54O #A5-P W5C\ -E9'
M #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7HP J5[@ *5?6 "E6]0 I5?\
M*E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0  !@4   6%$  $Y2  !'
M4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK #%;,P O7#L +EQ# "U<
M3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4 (EW2 ")<\P B6_\ (UK_
M "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<5   5%4  $I6  !#6
M/%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB+@ G8S8 )F,^ "5C1P C
M8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63. !IC\0 ;8?\ &V#_ !Q@
M_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96   4%D  $=;   ^7@  -V
M #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =:S  '&LY !MK0@ :;$P
M&6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K[P 2:?\ $VC_ !-H_P 3
M9_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX  $)A   Y9   ,F<  "MJ
M   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D $74R !%U.P 0=48 #W52
M  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *<_T "W'_  QQ_P ,</\
MD6(  ']A  !P80  9&$  %IA  !/8@  164  #QH   S;   *V\  "1R   =
M=@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J  9_-  %?S\ !']+  )_
M6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<  'S_  ![_P  >_\ B6<
M 'AG  !K9@  868  %1G  !):0  /VT  #5Q   L=0  )'D  !U\   6@
M$(,   R& @ &B0H  8D/  ")%   BAL  (HC  "++   BS<  (M#  "+4
MBU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_  "'_P  A_\ @FT  '-L
M  !H;   6FT  $YO  !"<P  .'<  "Y[   E@   '80  !6(   0C   "X\
M  22    E 8  )4,  "5$   EA4  )<<  "8)   F"X  )DY  "91P  F58
M )EH  "9?0  F90  )BK  "7R   ENX  );_  "5_P  E?\ >W0  &]S  !A
M<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(   Z6   )F0   9P   "@
M    H0   *(&  "B#   I!   *44  "E'   IR0  *@O  "H/0  J4P  *E>
M  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P  I?\ =WL  &A[  !9?@
M2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D    J    *L   "N
MKP   +    "Q!   LPH  +0.  "U$P  MAL  +@D  "Z,0  ND   +I2  "[
M90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\ ;X,  %^&  !1BP  0Y
M #:7   JG0  'Z(  !6G   -K   !;    "T    MP   +L   "^    OP
M ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-)   SC,  ,]$  #06
MT&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\  %>4  !)F@  .Z$  "ZG
M   AK0  %K,   ZX   &O    ,    ##    Q@   ,L   #-    S@   -
M  #1    U    -8   #: @  W D  -\/  #C%P  YB0  .<V  #H20  Z5\
M .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D  !"JP  -+(  ":Y   9
MO@  #L(   3%    R@   ,T   #1    V    -L   #?    X    .(   #D
M    Y@   .D   #K    [@   /$%  #U#0  ^18  /PE  #].0  _D\  /]G
M  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_  \ _P 1 /\ %@#_ "(
M_P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\ <P#_ 'H _P"  /\ A@#_
M (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#: /4 \0#T /\ \P#_ /,
M_P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H _P + /\ $0#_ !T _P J
M /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W '0 ]0!Z /0 @ #R (8
M\ "- .\ E #M )L [ "D .H K@#I +H YP#- .4 Z0#D /L XP#_ .( _P#>
M /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $ /\ #@#_ !@ _P D /T
M, #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X Y@!T .0 >@#B (  X "'
M -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#. /0 S #_ ,L _P#+ /\
MQ0#_ +\ _P"\ /\ _P " /\   #_    _P   /T "P#W !, \0 > .T *@#J
M #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M ,X <P#, 'H R@"  ,@
MAP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T N0#^ +@ _P"X /\ MP#_
M +, _P"P /\ _P   /\   #_    ^0   .X !0#E  X W@ 8 -@ (P#2 "X
MSP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L ;0"Y ', MP!Z +4 @0"T
M (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X *8 _P"F /\ I0#_ *4
M_P"D /\ _P   /\   #U    Z@   -X   #0  H R  2 ,( '0"^ "@ NP S
M +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H &T IP!S *4 >@"D ((
MH@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8 _P"6 /\ EP#_ )< _P"7
M /\ _P   /4   #G 0  U    ,D   #   0 N  . +, %@"O "$ JP L *@
M-@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &< F !N )< =0"5 'T E "&
M )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"( /\ B #_ (@ _P"( /\
M^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8 $ "B !H G@ E )L , "8
M #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I (H < "( '@ AP"! (4
MC "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\ >P3_ 'L$_P![!/\ \0X
M -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7 !, DP > ) !*0"- C,
MB@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(; !]"'0 ? A^ 'H)B0!X
M"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_ &\-_P!O#?\ Z!8  - >
M  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X B0L7 (8,(P"##2T @ TV
M 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S$'$ <1%[ ' 1AP!N$90
M;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43_P!E$_\ WQX  ,8D  "P
M)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2 'P2'0!Y%"@ =A0Q '05
M.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T :!EW &89@P!D&9  8QJ?
M &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<&_\ U24  +TJ  "H*0
MF"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:& !O'", ;1TM &L=-0!I
M'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S %TA?P!<(8T 6B*< %DB
MK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\ S2L  +8N  "B+@  DBX
M (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G(Q\ 920I &,D,0!B)3D
M8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H? !4*(H 4RF9 %$IJ@!0
M*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#   + R  "<,@  C#(  ( Q
M  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P 7BHE %PK+@!;*S8 62P]
M %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.+H@ 3"^7 $LOJ !)+[L
M2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU  "7-0  AS4  'LU  !R
M-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B %8P*P!5,3, 4S$Z %(R
M0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4 1S25 $4TI@!#-+D 0C36
M $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3.   @S@  '<X  !M-P
M9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U* !/-C  3C8X $PW/P!+
M-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3 $ YI  ^.;@ /3G3 #PY
M\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P  ?SL  ',[  !J.@  8CD
M %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*.BT 2#LU $<[/ !&/$0
M13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]HP Y/;8 .#W1 #<]\@ W
M//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X  &\^  !F/0  7CT  %@[
M  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH 0S\R $) .@!!0$$ 0$!)
M #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T0K0 ,D+. #)!\  R0/\
M,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!  !B0   6T   %0_  !.
M/P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O #Q$-P [13X .D5& #E%
M3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K, +4;, "U&[P M1?\ +D3_
M "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?0P  5T,  %!#  !(0P
M1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)-  U2CL -$I# #-*3  R
M2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO* "=+[0 G2O\ *$G_ "A(
M_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@  5$8  $Q'  !$2   /TH
M #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O3S@ +D]  "Q02  K4%(
M*E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0ZP A3_\ (D[_ ")-_P C
M3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H  $E+  ! 3   .TX  #50
M   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53, )E4\ "5610 D5DX (E99
M "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :5?\ &U3_ !M3_P <4O\
MFTT  (9-  !U30  :$T  %U-  !430  34X  $5/   \40  -E,  #%5   K
M6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW !Q=0  ;74H &EU5 !A=
M80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X $UK_ !-:_P 46?\ E%$
M (!1  !P40  9%$  %E1  !140  25(  $%3   X5@  ,ED  "M;   E7@
M'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E.@ 2940 $650 !!E70 /
M96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_  UA_P -8?\ C54  'I5
M  !K50  7U4  %95  !.50  1%<  #Q9   T7   +%\  "9B   ?90  &6@
M !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *;CX "&Y*  =N5P &;F4
M!&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J_P #:O\ A5H  '1:  !F
M6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<  !]J   9;0  $W$   YT
M P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<  'A#  !X4   >%X  'AO
M  !XA   >)D  '>P  !VS0  =?   '7_  !T_P  =/\ ?E\  &Y?  !B7@
M65X  $U?  !"8@  .64  #!H   G;   'W   !AT   2=P  #7L   A^   "
M@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[  "$2   A%<  (1H  "$
M?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\ =V4  &ED  !?8P  4F0
M $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,@P  !H<   "*    C ,
M (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2/P  DDX  ))?  "2<P
MDHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L  &9J  !8:P  2VT  #]Q
M   T=@  *GL  ""    7A0  $(D   N-   $D0   )4   "8    F0   )H#
M  ";"   G T  )X1  "?%@  H!X  *(H  "B-0  HT0  *-5  "C:0  HH
M **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R  !1=0  1'D  #=^   L
MA   (8H  !>/   0E   "ID   &=    H    *0   "G    J    *D   "J
M    K 8  *T+  "O$   L!4  +(>  "T*0  M#D  +1*  "U70  M7,  +6.
M  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)@@  /(<  "^.   CE
M&)H  !"?   )I    *D   "M    L    +0   "W    N    +D   "[
MO    +X"  # "   P@X  ,04  #''@  R"P  ,D]  #*4   RF8  ,I_  #*
MFP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0  ,Y@  ">?   ;I0  $:L
M  FP    M0   +D   "]    P0   ,8   #(    R0   ,L   #,    S@
M -    #2    U 4  -D,  #=$@  X1X  .(N  #C0@  Y%<  .5O  #FC
MYJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D  !^P   3M@  "[P   #!
M    Q0   ,D   #-    T@   -8   #:    VP   -X   #@    X@   .0
M  #G    Z0   .T   #P"@  ]!$  /@?  #Y,@  ^D@  /M?  #\>@  _9<
M /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\ $P#_ !X _P J /\ -@#_
M $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z /\ @0#] (< _ "- /H
ME #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X [P#_ .\ _P#C /\ UP#_
M ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_ !D _P E /\ ,0#_ #T
M_P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$ >@#O ($ [@"' .P C@#J
M )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_ -T _P#4 /\ R0#_ ,(
M_P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0 _0 @ /H *P#W #8 \P!!
M .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #< 'H V@"! -@ B #4 )
MT@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0 _P#$ /\ NP#_ +8 _P"S
M /\ _P   /\   #_    _P   /< " #P !  ZP : .< )0#D #  X0 [ -P
M10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ', PP!Z ,$ @0"_ (D O0"2
M +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P /\ K@#_ *H _P"G /\
M_P   /\   #^    \0   .4  @#<  T TP 4 ,T 'P#* "H QP T ,0 /@#
M $< O !. +H 50"W %L M0!A +, 9P"R &T L !S *X >@"L (( J@"+ *@
ME0"G *  I0"M *, O@"A -L H #T )\ _P"> /\ GP#_ )T _P"; /\ _P
M /P   #N    X    -    #%  @ O@ 0 +D &0"U ", LP N +  -P"M $
MJ@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T <P"; 'L F@"$ )@ C@"6
M )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_ (X _P"/ /\ _    .\
M  #;    R0   +T   "U  ( K@ , *D $P"E !T H@ G *  ,0"= #H F@!"
M )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"- '4 BP!^ (D B0"( )4
MA@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (  _P"  /\ ] (  . )  #'
M"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A )( *@"/ #, C0 \ (L
M0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '  ?@!Y 'P A ![ )  >0"=
M '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S /\ Z0T  ,\0  "Y$
MJ1   )X.  "7"P  DP8  )  "P", !$ B0 : (8 ) "# "X @0 V '\ /@!]
M $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U '$!@ !O HT ;@*: &P#
MJ@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\ WQ0  ,,7  "N%P  GA8
M ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y!R@ =P@P '4(. !S"4
M<@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,?@!F#(L 9 V9 &(-J0!A
M#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P  +D=  "D'@  E1T  (D<
M  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B( ;@\K &P0,P!J$#L :1!"
M &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<$X@ 6Q.7 %D3IP!7%+H
M5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B  "=(P  C2,  ($B  !Y
M(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G &,6+P!A%S< 8!<^ %X8
M10!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4 4AN4 %$;I !/&[< 3AO0
M $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6)P  AR@  'LG  !R)@
M;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>*P!:'C, 6!\Z %<?00!6
M($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1 $DBH@!((K0 1R+- $8C
M[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P  @BP  '8K  !M*@  9BD
M &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3)#  4B4W % E/@!/)D4
M3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,HH !!*+( 0"C+ #\H[0 _
M*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\  '$O  !H+@  82T  %TK
M  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP 2RHT $HK.P!)*T( 2"Q)
M $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \+;  .BW( #HMZP Z+?\
M.BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR  !D,@  73$  %@O  !5
M+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q $4P. !#,#\ 0C%' $$Q
M3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\ -3+' #0RZ0 T,O\ -3'_
M #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@-0  630  %0S  !0,
M3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U-@ ^-3T /35$ #PV3  Z
M-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?% "\WZ  O-OX ,#7_ # U
M_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P  5C<  % V  !+-   1S4
M $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y.CH .#I" #8Z2@ U.E,
M-#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[Y@ J.OT *CK_ "LY_P L
M./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH  $TZ  !&.   0CH  #\[
M   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C< ,C\_ #$_1P P/U  +C]:
M "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D/_P )3[_ "8]_P F/?\
MGSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]  !"/0  /#X  #D_   V
M00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\ "M$1  J1$T *$18 "=%
M8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L 'T/_ "!"_P A0?\ FCX
M (4_  !T0   9T   %Q   !30   3$   $9    ^00  .$,  #1%   P1@,
M+4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)00 C2DH (DI5 "!*80 ?
M2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_ !I'_P :1_\ E4(  (!"
M  !P0P  8T,  %A#  !00P  24,  $)$   [10  -4<  #!)   K2P  )DT)
M "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <4$< &E!1 !E070 74&L
M%E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--_P 43?\ CT4  'M&  !K
M1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P  "M.   F4   (%,# !Q5
M#  :5A$ &588 !=6(  65B< %58P !16.0 35T( $E=- !%760 05V@ #U=Y
M  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .4_\ B$D  '9*  !G2@
M6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94   A5@  &UD  !5<!P 1
M7@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(  I>5  (7F( !UYS  5>
MA@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\ @4X  '!.  !B3@  5TX
M $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;70  %6   !!C P ,9@L
M"&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G3@  9UP  &=M  !G@
M9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(  &I3  !=4@  5%(  $M2
M  !"4P  .54  #!8   H6P  (5\  !IB   490  $&@   QK 0 &;@D  &\.
M  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2   <58  '%F  !Q>0  <8\
M '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57  !:5P  458  $97   \
M6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(   1V    > 4  '@+  !Y
M#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X  'U>  !]<@  ?8@  'RA
M  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !77   2UT  $!?   U8P
M*V<  "-K   :;P  $W,   YW   (>P   GX   ""    @P$  (0&  "%"P
MA@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6  "+:0  BX   (N9  "*
MLP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@  1&4  #AI   N;@  )',
M !IX   3?0  #8$   :%    B0   (T   "0    D@   )(   "4!0  E0H
M )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<7P  G'8  )N1  ";JP
MFLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$  #!V   E?   &X$  !*'
M   ,C   !)$   "5    F0   )T   "@    H0   *(   "D    I0$  *<'
M  "I#   JA$  *T8  "O(@  KS   *]!  "O5   KVL  *Z%  "NH0  KKX
M *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%   =C   $Y(   R8   #
MG0   *(   "F    J@   *X   "P    L0   +,   "T    M@   +@   "Z
M!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X  ,5W  #%DP  Q:\  ,71
M  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4G0  #:,   .I    K@
M +(   "W    NP   +\   #"    P@   ,4   #&    R    ,H   #-
MSP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H  #@A   X:$  .&]  #A
MX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP  !;4   "Z    OP   ,0
M  #(    S@   -$   #4    U0   -@   #:    W0   -\   #B    Y
M .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X<@  ^9   /FK  #XQ
M^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F /\ ,@#_ #X _P!( /\
M4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($ ^P"( /D CP#W )< ]0"@
M /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#= /\ S@#_ ,8 _P#" /\
M_P $ /\   #_    _P % /\ #0#_ !4 _P A /\ + #_ #@ _P!# /T 3 #Y
M %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@"" .@ B0#G )$ Y ": .(
MI #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\ P0#_ +L _P"W /\ _P
M /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T #( \  \ .P 1@#H $X
MY !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -  @@#- (H RP"3 ,@ G0#&
M *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_ *X _P"K /\ _P   /\
M  #_    ^@   /( !0#J  X Y0 6 .  (0#= "L VP V -, /P#. $@ R@!/
M ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X (( M@"+ +0 E@"R *$
ML "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$ _P"? /\ _P   /\   #W
M    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O +P . "X $$ M0!( +(
M3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L HP"$ *$ C@"? )H G0"G
M )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2 /\ _P   /8   #D
MT@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@ ,@"E #H H@!" *  20">
M $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!] )  AP". ), C "A (L
ML "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\ ^    .4   #-    O0
M +,   "J    HP * )\ $0"; !D F0 C )< + "5 #0 D@ \ )  0P". $D
MC !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($ @0!_ (T ?@"; 'P J@![
M +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0   -$"  "[ @  K $  *(
M  ";    E@ % )$ #0"- !0 BP = (@ )@"& "X A  V (( /0"  $, ?@!)
M 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R (@ <0"6 &\ I0!N +8
M;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,  "N#   G@P  ),+  ",
M!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P '8 . !T #X <P!$ '$
M2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0 90"2 &0 H0!C +( 80#)
M &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B$@  DQ(  (@1  " #P
M? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!,P!J CD :0-  &<#1@!F
M!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/ %H'GP!9![  5P?& %8)
MYP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&   BA@  '\7  !V%@  <1,
M &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B##4 8 P\ %\,0@!>#4@
M7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.GP!0#K$ 3@[( $T0Z@!-
M$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX  '<=  !O'   :1H  &87
M  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$ 6!(X %<2/@!6$D4 5!),
M %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'%:X 1A7% $45Z !%%OX
M11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B  !H(0  8A\  %\=  !<
M&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T $\8.P!.&4( 31E( $L:
M4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP /QO" #X<Y0 ]'/P /AS_
M #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C)0  720  %DB  !6'P
M5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?-P!''SX 1B!% $4@30!#
M(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+  #<BXP W(OL -R+_ #@A
M_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0  6"@  %0F  !1(P  3R(
M $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!)3L 0"5# #\E2@ ])E,
M/"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$GX0 Q)_D ,B;_ #(F_P S
M)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L  % J  !,*   2B8  $<G
M! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD .RI  #DJ2  X*U  -BM:
M #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L+/@ +"O_ "TJ_P M*O\
MH2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN  !(+   12L  $$K   _
M+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^ #0O10 S+TX ,3!8 # P
M8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/< )R__ "@O_P H+O\ G"X
M (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$,   0"\  #PP   Z,0D
M-S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T0P M-$P +#16 "HU80 I
M-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_ ",S_P C,O\ F#$  (,S
M  !R-   930  %HU  !1-0  2S0  $4T  ! -   .C,  #<T   T-08 ,C8.
M # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H.4D )CE3 "4Y7P C.6P
M(3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX_P >-_\ DS0  '\V  !N
M-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@  #(Y   O.@( +#L+ "H\
M$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8 (#Y0 !\^7  =/VD &S]Y
M !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8//\ CC<  'HX  !J.0
M7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^   I0   )D$( "1"#@ B
M0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1- !A$60 71&< %41W !-$
MB@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\ B3L  '8\  !F/0  6CT
M % ]  !(/0  0CT  #P]   V/@  +T   "I"   E1   (48# !U(#  ;21$
M&4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*5@ 02F0 #TIT  Y*AP -
M2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX  '$_  !B0   5D   $U
M  !%0   /T   #E!   R0@  *T4  "9'   A20  '$L  !9.!P 34 X $E 3
M !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *45\ "5%O  =0@0 %4)8
M U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#  !=1   4D0  $I$  !#
M0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$  !)4 P .5PH "U@0  I8
M%0 (6!P !U@D  98+  %6#8  UA   %83   6%H  %AI  !8?   6)$  %>G
M  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !92   3T<  $='  ! 1P
M.$@  #!*   I30  (E   !Q3   650  $5@   U; @ )7@D !%\.  !?$@
M7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C  !@=@  8(L  %^B  !?
MNP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53   3$L  $1+   [3   ,DX
M "M1   C5   '%<  !9;   17@  #6    AC   "9@<  &<,  !G#P  :!,
M &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J;P  :H4  &J=  !IM@
M:-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\  #]0   U4P  +58  "19
M   =70  %F   !!D   ,9P  !FH   !N    ;P,  ' (  !Q#0  <A   '04
M  !U&P  =B,  '<L  !W.   =D8  '96  !V:   =GX  ':7  !UL0  =-,
M '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8   O6P  )E\  !UC   5
M9P  $&P   IP   $<P   '8   !Z    ?    'P#  !^"   ?PP  ($0  ""
M%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74  (6/  "$J0  @\D  (+Q
M  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G9@  'FL  !5P   .=0
M"7D   %^    @0   (4   "(    B@   (L   "- 0  C@8  ) +  "1#P
MDQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&  "5H@  E,$  )/J  "2
M_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=   %7D   Y_   'A    (D
M  ".    D@   )8   "8    F@   )L   "=    GP   *$#  "C"   I0T
M *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "HF0  J+4  *?=  "G^
MIO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH   >0    E@   )H   "?
M    HP   *<   "J    JP   *T   "O    L0   +,   "U    N 4  +H,
M  "]$@  P!P  , M  # 0   OU4  +]N  "^BP  OJ@  +[)  "][P  O/X
M3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B    IP   *P   "P
MM0   +D   "\    O0   +\   #!    PP   ,8   #(    R@   ,T"  #0
M"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH  -NU  #;V0  V_( 1H(
M #B)   KD   '9@  !*@   *IP   *X   "T    N0   +X   #"    R
M ,L   #.    SP   -(   #4    U@   -H   #=    WP   .(   #F
MZ@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E  #UOP  ]=T _P & /\
M P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D _P!$ /\ 30#_ %4 _P!=
M /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U )( \P"; /  I@#N +,
MZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\ _P"[ /\ _P   /\   #_
M    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^ /P 1P#X $\ ] !7 /$
M70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L WP"5 -P GP#9 *L U0"[
M -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P /\ _P   /\   #_
M_P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .< 0 #B $D WP!0 -L 5P#7
M %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"- ,( F #  *0 O0"R +L
MQ@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\ _P   /\   #_    ]0
M .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#( $( Q !* ,  4 "] %8
MNP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T D "J )P J "J *8 NP"E
M -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P   /X   #O    WP   -
M  #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L K0!# *L 20"H $\ I@!5
M *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8 )0 E@"B )0 L@"2 ,D
MD0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P   #9    QP   +H   "Q
M  ( JP , *< $@"D !L H0 D *  + "> #4 FP \ )@ 0P"6 $D E !/ )(
M5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P A ": (( J@"! +X @ #@
M (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"    LP   *@   "@
MF0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (< /0"% $, A !) (( 3@"!
M %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4 '0 HP!R +4 <@#/ '$
M\0!P /\ < #_ '  _P!Q /\ X0   ,0   "P    H@   )<   "1    BP "
M (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X #T =@!# '0 20!S $X
M<@!4 '  6@!O &( ;0!J &L = !J (  : ". &< G0!E *\ 90#& &0 Z !D
M /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @  (D'  "" P  ?@   'L
M!@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@ :@ ^ &D 1 !G $D 9@!/
M &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!; *H 60"_ %D X0!8 /@
M6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.  !V#0  <0H  &\&  !M
M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y %\ /P!= $4 7 !+ %L
M4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *< 4 "[ $\!VP!. O0 3@/_
M $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L$@  9Q   &4.  !C"P,
M8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'.P!5!T( 5 =( %,(3P!1
M"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ $8*V !%"_, 10S_ $4,
M_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P  7Q8  %P3  !:$0  6@X&
M %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.#CX 30Y% $L.30!*#E4
M2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0W  ]$?8 /1'_ #T0_P ^
M$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L  %49  !3%@  4A,  %(1
M"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL 11-" $0320!#%%( 011;
M #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U%O4 -A;_ #86_P W%?\
MHQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >  !-&P  3!D  $L6!@!)
M%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_ #T91@ \&D\ .AI8 #D:
M8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/, +QO_ # ;_P P&_\ G1\
M (@B  !W(P  :20  %XD  !6)   4",  $LB  !((   1AT  $4< @!#' P
M01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?1  V'TP -"!6 #,@8  Q
M(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_ "H@_P K(/\ F2(  (0E
M  !S)@  92<  %LG  !3)P  3"8  $<E  !$)   0B$  #\A   ](0D .R$0
M #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P)$H +R53 "TE7@ K)6L
M*B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D_P E)/\ E"4  ( G  !O
M*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28  #HE   W)@8 -28. #0G
M%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4< *2E1 "@J7  F*FD )"IX
M ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A*/\ D"@  'PJ  !L*P
M7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J   R*P, ,"L, "XL$0 M
M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/ ",N6@ A+V< 'R]V !TO
MB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\ C"L  '@M  !H+@  6R\
M %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M+P  *S * "DQ$  G,14
M)C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS5P ;,V0 &C1T !@TA@ 6
M-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX  '0O  !E,0  6#$  $XR
M  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-   )34& ",V#0 A-A( (#<9
M !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5.6( %#EQ !(YA  1.9@
M$#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R  !A-   530  $LT  !$
M-   /30  #@T   S-   +34  "@W   D.0  (#H" !T["P ;/!  &3T5 !@]
M'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\ #SYO  X^@0 ,/I4 "SZI
M  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=-P  43<  $@W  !!-P
M.S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!!@ 40PT $D,2 !%#&  1
M0Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J  =$?  &1)  !$.E  )#
MO0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@  3CH  $4Z   ^.@  .#H
M #,Z   M.P  )ST  "%    <0@  %T0  !-& P /20H #4H/  Q*%  +2AL
M"4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*=P  2HL  $JA  !)N0
M2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX  $(]   \/0  -CT  "\^
M   I0   (T(  !U%   71P  $TH   ], @ +3PD !U -  -1$0  41<  %$>
M  !1)@  42\  %$Y  !11   4E$  %)@  !1<@  48<  %&=  !1M0  4-@
M %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!    Y0   ,D$  "I#   D
M1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,  !8$   6!,  %D9  !:
M(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$  %F9  !9L0  6-$  %CT
M  !7_P  5_\ 944  %A%  !-10  140  #Y$   U10  +4<  "5*   >30
M&%   !)3   .5@  "ED   1<    7@0  %\)  !@#0  81   &(5  !C&P
M9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3  !CK0  8LP  &'R  !A
M_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3   )T\  !]2   850  $ED
M  U=   (8    F,   !F    : $  &D%  !J"@  :PT  &T1  !N%@  <!T
M '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !OIP  ;L8  &WO  !L_P
M;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@  !A<   18   #&0   9H
M    :P   &\   !R    =    '4   !W!   > D  'H-  !\$   ?18  '\>
M  " *   @#4  (!%  !_5@  ?VL  '^$  !^H   ?;X  'SI  ![_P  >O\
M5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H   +;0   W(   !V
M>@   'T   "     @P   (0   "&    AP(  (D'  "+#   C1   ) 6  "2
M'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0  ([A  ",^P  C/\ 55D
M $A:   [70  +V$  "1F   9;   $7(   IW   "?0   ((   "&    BP
M (X   "1    DP   )4   "7    F0   )L   "=!   GPH  *(/  "D%@
MIB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0  "@]0  G_\ 3F$  $!D
M   S:0  )VX  !MU   1?   "X,   ")    C@   ),   "8    G0   *$
M  "D    I0   *<   "I    JP   *T   "P    L@   +4(  "X#@  O!8
M +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "WZ@  M_P 1FL  #EP   K
M=P  'W\  !.&   +C@   94   ";    H0   *8   "K    L    +,   "W
M    MP   +H   "\    OP   ,$   #$    QP   ,H   #-!0  T0X  -09
M  #4*P  U$   --8  #3=   TY(  -*P  #2TP  TO( /GD  #&    CB
M%Y$   V9   #H    *<   "N    LP   +@   "]    P@   ,8   #*
MR@   ,T   #/    T@   -4   #9    W0   -\   #C    YP4  .L/  #L
M'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@ _P   /\   #_  0 _P )
M /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_ %  _P!8 /\ 7@#_ &4
M_0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X H@#K *\ Z #  .8 X #C
M /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P   /\   #_    _P   /\
M"0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H \@!2 .X 6 #K %X Z0!D
M .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1 *< S@"V ,L S@#) /
MQP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\   #_    _P   /L  @#V
M  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+ -, 40#0 %@ S0!= ,L
M8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\ MP"M +4 P0"R .0 L0#]
M *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[    [@   .0   #<  @
MTP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H 2P"W %$ M0!6 +( 7 "P
M &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E )\ M@"= -$ G #S )L
M_P"< /\ E@#_ ), _P"0 /\ _P   /8   #G    TP   ,8   "]  , N  -
M +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A $H GP!/ )T 50"; %H
MF@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P K0"* ,, B0#H (@ _P")
M /\ AP#_ (4 _P"" /\ \P   .,   #,    O    +    "G    H0 ( )X
M#P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $, C !) (L 3@") %0 AP!9
M (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y +@ > #8 '< ]P!X /\
M> #_ '< _P!U /\ Y@   ,L   "W    J    )X   "6    CP $ (L # "(
M !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !# 'H 2 !Y $T =P!3 '8
M60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\ :0#( &@ [0!I /\ :0#_
M &D _P!I /\ T@   +@   "E    EP   (T   "&    @0   'P " !Y  X
M=P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P 0P!K $@ :@!. &@ 5 !G
M %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^ %P Y !< /L 7 #_ %P
M_P!< /\ P@   *H!  "8 P  B00  '\"  !X    =    '  ! !M  P :P 1
M &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!? $, 7@!) %P 3P!; %8
M6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$ U@!1 /4 40#_ %$ _P!2
M /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <  &4#  !C  < 80 - %\
M$P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\ 5 !% %, 2P!1 %( 4 !:
M $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !' .\ 1@#_ $< _P!' /\
MK P  )4.  "#$   =1   &L0  !C#P  7@X  %L,  !:"0( 600* %< #P!5
M !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %! $H"2 !) D\ 2 )7 $8#
M80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H /07\ #T&_P ^!O\ I!
M (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1#@  4 P% % )# !/!Q$
M30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*10!""DT 0 M5 #\+7P ]
M"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W] #4-_P V#/\ G1,  (<5
M  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P  21$  $D.!P!(#0X 1@T3
M $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [$$L .A!4 #@07@ V$&L
M-!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1_P O$/\ EQ8  ((9  !Q
M&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4  $(3 @!!$@L 0!$0 #X2
M%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@ ,Q11 #$47  P%6@ +A5W
M "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I%?\ D1H  'T<  !M'@
M8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8   [%P< .18. #@7%  V
M%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/ "L:60 J&F8 *!IT "8:
MA@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\ C1T  'D?  !I(0  7"(
M %(B  !*(@  1"$  #\A   \(   .1X  #@;   U' 0 -!P- #(<$@ P'1@
M+QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?5P D'V0 (A]R " ?A  ?
M'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2   '4B  !E(P  620  $\E
M  !')0  020  #PC   X(P  -2(  #,@   P( $ +B$* "PA$  K(14 *B(<
M "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?)&$ '21P !LD@@ 9))4
M%R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D  !B)@  5B<  $PG  !$
M)P  /B<  #DF   U)@  ,24  "XD   K)0  *24' "<F#@ E)A, )"<9 ",G
M(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\ &"EN !8I@  4*90 $BFH
M !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?*   4RD  $DJ  !"*0
M.RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K#  @*Q$ 'RP6 !TL'0 <
M+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL !$N?@ 0+I( #BZG  TM
MO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P  4"P  $8L   _+   .2P
M #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :,0X &3$3 !<Q&@ 6,B$
M%3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS>@ ,,XX "C.B  @RN0 (
M,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\  $,O   \+@  -BX  #$N
M   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P $C<1 !$W%@ 1-QT $#@D
M  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %.(H  SB?  $WM0 !-],
M C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q   Y,0  -#$  "\P   K
M,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.  P]$P +/1D "CTA  D]
M*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8  #V<   ]L@  /=   #SP
M   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W-   ,C,  "TS   G-
M(C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$$0 #1!8  D0=  !$)
M1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28  !#KP  0\T  $+P  !"
M_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@  ,#8  "DW   C.0  'CL
M !@]   30   $$(   U% 0 (1P<  TD,  !)#P  2A,  $L9  !+(   2R@
M $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*K   2LH  $GO  !)_P
M2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H  "4\   ?/P  &4$  !-$
M   01P  #$D   A,   "3P4  % *  !0#0  41   %(5  !4&P  5",  %0L
M  !4-P  5$0  %12  !48P  5'<  %2/  !3J   4L8  %+M  !1_P  4?\
M7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#   91@  $TD   ],   +
M3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1  !=%@  7AT  %\F  !?
M,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$  %OK  !:_P  6O\ 5D0
M $M#  !#0@  /$$  #)"   I10  (4@  !I+   33@  #E(   I5   #60
M %L   !>    8    &("  !C!@  90H  &8.  !H$0  :A<  &L?  !K*0
M:S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G  !F_P  9?\ 44@  $A(
M  !!1@  -T<  "Q*   C30  &U$  !-5   .60  "%T   %A    9    &<
M  !J    ;    &X   !P    <@4  ',)  !U#0  =Q$  'H8  ![(0  >RX
M 'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T_   <_\ 3DT  $=,   [
M30  ,$\  "93   <6   $UP   UA   &9@   &H   !O    <@   '8   !Y
M    ?    'T   !_    @0   (,"  "&!P  B P  (L1  ".&   CB0  (XS
M  "-1   C%@  (MO  "*C   B:H  (C/  "&]P  A?\ 35$  $%3   T50
M*5H  !Y?   490  #6H   5P    =@   'L   !_    @P   (<   "*
MC0   (X   "1    DP   )4   "8    F@4  )T,  "@$0  HQH  *,H  "B
M.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\ 1ED  #E<   M80  (6<
M !9N   .=0  !7L   "!    AP   (T   "2    E@   )H   "=    GP
M *$   "D    I@   *@   "K    K@   +$#  "T"P  N!$  +D>  "Y+P
MN$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0  #%I   E;P  &'<   ]_
M   &AP   (X   "4    F@   *    "E    J@   *X   "Q    L@   +4
M  "W    N@   +P   "_    PP   ,8   #)    S@H  -(3  #2(P  T3<
M -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX   =@   $8D   B1
MF@   *$   "G    K0   +,   "Y    O@   ,(   #%    Q@   ,D   #,
M    S@   -(   #5    V@   -X   #A    Y0   .H+  #K%P  ZBL  .I#
M  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_  $ _P ' /\ #0#_ !(
M_P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\ 6@#] &  ^P!F /H :P#X
M '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\ ., W #? /< W0#_ ,P
M_P"^ /\ M0#_ +  _P"M /\ _P   /\   #_    _P   /\ !@#_  T _P 4
M /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H %D Y0!? ., 90#@ &H
MW0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4 R0#" .T P #_ +L _P"P
M /\ J #_ *0 _P"A /\ _P   /\   #]    ^@   /@   #P  D [  1 .@
M&0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %( R !8 ,4 70## &, P !I
M +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L .$ J@#\ *@ _P"@ /\
MF0#_ )8 _P"4 /\ _P   /D   #R    YP   -L   #1  0 R@ - ,< % #$
M !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1 *P 5@"J %P J !A *8
M: "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P E0#Q )0 _P"1 /\ BP#_
M (@ _P"& /\ ]P   .P   #>    R0   +P   "T    KP * *L $ "I !<
MJ  @ *< * "B #  GP X )P /@": $0 F !* )8 3P"4 %4 DP!: )$ 80"/
M &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D (  _P"  /\ ? #_ 'L
M_P!Y /\ Z0   -<   #!    L0   *8   "=    EP % )0 #0"2 !( D  :
M (\ (@". "H BP Q (D . "' #X A0!# (, 2 "! $X ?P!4 'X 6@!\ &$
M>@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\ ]@!O /\ ;P#_ &T _P!L
M /\ V@   +\   "L    G@   ),   ",    A0   (( "0!_  \ ?@ 5 'T
M' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@ ;P!- &X 4P!L %H :P!B
M &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A /\ 80#_ &$ _P!@ /\
MQ0   *T   ";    C0   (,   !\    =P   '( !0!P  P ;@ 1 &P %P!L
M !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!( &  3@!? %4 70!= %P
M9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L 5 #_ %4 _P!5 /\ M@
M )\   "-    ?P   '4   !N    :0   &8  0!C  D 80 . &  $P!? !D
M7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4 20!3 %  4@!8 %$ 80!/
M &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_ $D _P!* /\ J@$  )0%
M  ""!P  = @  &H(  !C!@  7@0  %L   !9  4 5P , %8 $ !4 !4 4P ;
M %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!* $P 2 !4 $< 70!& &@
M1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $  _P!  /\ H @  (H+  !Y
M#0  ; T  &$-  !:#0  50L  %()  !0!@  3P(( $X #0!, !( 2P 7 $H
M'@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@ 0 !0 #X 6@ ] &0 / !R
M #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W /\ F T  (,.  !R$
M91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'"@!%! X 1 (3 $("&@!!
M B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05. #<%5P V!6( - 9P #(&
M@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\ D1   'T1  !L$P  7Q0
M %44  !.%   2!,  $02  !!$   0 X  $ -!@! "@P /@D0 #P)%@ ["AP
M.0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,5@ O#&$ +0QO "L,?P J
M#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(  '<4  !G%@  6Q<  %$8
M  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@ . X- #<.$@ U#A@ - X?
M #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H$&$ )A!O "00@  C$),
M(1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7  !C&0  5QH  $T;  !%
M&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+ #$2$  O$A4 +1(< "P3
M(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\ (!5M !\5?@ =%9$ &Q6E
M !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?'   4QT  $H=  !"'0
M/!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6#@ I%Q, *!<9 "<8(  E
M&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK !D:?  7&H\ %1JC !09
MN@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P  4"   $<@   _(   .1\
M #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D'!$ (AP6 "$<'0 @'2,
M'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?>@ 2'HT $1ZB ! >N  .
M'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(  $0B   \(@  -B(  #(A
M   N(0  *B   "<@   D'P  (B " " @"@ >(0\ '2$4 !PA&@ ;(B$ &2(G
M !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .(XL #2.?  PCM  +(]
M"R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D   Z)   -"0  "\C   K
M(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81 !8F%P 5)QX %"<E !,G
M+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(< "2B;  <GL0 %)\P !B?L
M  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W)@  ,28  "TF   I)0
M)24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L%  0+!L $"PB  XL*0 .
M+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8   LK@  +,D  "SK  $K
M_  "*_\ ;24  %TG  !/*   12D  #PI   U*0  +R@  "LH   G)P  (R<
M !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,,1< "S$>  HQ)@ (,BX
M!S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   QK   ,<<  ##J   P_
M,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L  "DJ   E*@  ("L  !PL
M   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0  S<;  (W(@  -RH  #@S
M   X/@  .$H  #A8   X:   .'P  #>2   WJ0  -L4  #;J   V_0  -?\
M8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M   B+0  '2\  !@Q   4
M,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7   ^'@  /B8  #XO   ^
M.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,  #SI   \_0  ._\ 7C
M % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >,@  &30  !0V   0.0
M#3L   H]   %0 4  $$*  !"#0  0Q   $04  !%&@  1B(  $8K  !&-0
M1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H  !#_@  0O\ 6#0  $LU
M  !!-0  .34  #(T   M,P  )C0  " U   :.   %#H  ! ]   -0   "4(
M  1%    1P,  $@'  !*"P  2PX  $P1  !.%0  3QP  $\E  !/+P  3SP
M $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+_@  2O\ 4SD  $<Y   ^
M.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(   Q%   '2    DH   !-
M    3P   %$$  !2!P  5 L  %4.  !7$0  61<  %H?  !9*0  638  %E$
M  !95   6&<  %A_  !7F@  5K<  %7C  !4_0  5/\ 3CT  $,]   \/
M-3L  "P\   D/@  '$$  !5$   02   "TL   5.    40   %0   !7
M60   %L   != @  7@8  & +  !B#@  9!(  &<8  !G(@  9BX  &8\  !F
M30  96   &5W  !DDP  8[$  &'=  !@_   7_\ 24(  $%!   Z/P  ,$
M "9#   >1@  %4H  !!.   *4@   U8   !:    70   &    !C    90
M &<   !I    :P$  &T%  !O"@  <@X  '42  !W&P  =B8  '8U  !U1@
M=%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8  $!%   U1@  *D@  "!,
M   740  $%8   E:   !7P   &,   !H    :P   &\   !R    =0   '<
M  !Y    >P   'T   "  P  @P@  (8-  ")$P  BAT  (HK  ")/   B$\
M (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,   N3P  (U,  !A8   0
M7@  "60   !I    ;P   '0   !X    ?    ($   "$    AP   (@   "+
M    C@   )    "3    E@   )D'  "=#0  H10  * A  "@,0  GD0  )U;
M  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F6@  &V   !%G   );0
M '0   ![    @0   (8   "+    D    )0   "7    F0   )P   "?
MH0   *0   "G    J@   *T   "Q!@  M0T  +@6  "W)@  MCD  +50  "T
M:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:   $W    MX    @    (<
M  ".    E0   )H   "?    I    *@   "L    K0   +    "S    M0
M +@   "[    OP   ,,   #'    RP4  -$.  #1&P  T"X  ,]%  #-7P
MRWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$   &+    DP   )L   "B
M    J    *X   "T    N    +T   #     P@   ,4   #(    RP   ,X
M  #1    U@   -L   #?    Y    .@&  #K$0  ZB,  .HZ  #I5   YW(
M .63  #CLP  X]0 _P   /\   #_    _P $ /\ "P#_ !  _P 7 /\ (0#_
M "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A /@ 9@#V &T ] !S /(
M>P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /< U@#_ ,  _P"R /\ J@#_
M *4 _P"B /\ _P   /\   #^    _    /P  P#^  L _P 1 /\ &@#] "0
M^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\ 7P#< &4 V !K -0 <@#0
M 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_ +  _P"D /\ G #_ )@
M_P"5 /\ _P   /H   #T    \0   /(   #J  4 YP . .( %0#A !X X0 H
M -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "] %X NP!D +D :P"V ',
MM !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\ _P"5 /\ CP#_ (L _P")
M /\ ^0   .\   #G    WP   ,\   #(    P0 * +\ $0"\ !@ NP A +D
M*@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8 H0!< )\ 8P"= &H FP!S
M )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"& /\ @ #_ 'T _P!\ /\
M[0   .    #1    OP   +,   "J    I@ % *( #0"A !, H  ; )\ (P";
M "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5 (H 6P"( &, A@!K (0
M=@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\ <@#_ '  _P!O /\ W0
M ,L   "V    IP   )T   "4    C@ ! (L "@") !  B  5 (< '0"' "4
MA  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8 5 !U %L <P!C '$ ;@!O
M 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_ &0 _P!C /\ R@   +0
M  "A    DP   (D   ""    >P   '@ !0!V  P =0 1 '0 & !S !\ <@ E
M '  + !N #( ;  W &H / !I $( : !( &8 3@!E %4 8P!= &( 9@!@ '(
M7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@ _P!8 /\ N0   *(   "0
M    @P   'D   !Q    ;0   &D  0!F  D 90 . &0 $P!C !D 8P @ &$
M)@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\ 5@!7 %0 8 !3 &P 40!Y
M %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!- /\ J@   )0   ""
M=0   &L   !D    8    %T   !:  4 6  , %< $ !6 !4 5@ ; %4 (0!3
M "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2 $D 6P!( &8 1@!S $4
MA !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\ G@   (D   !X P  :@0
M &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!, !$ 2P 7 $H ' !) "(
M2  G $< +0!% #( 1  X $, /@!" $4 00!- #\ 5@ ^ &$ /0!N #L ?@ Z
M )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,  ( '  !O"0  8@H  %@+
M  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \ 0@ 3 $$ & !! !X /P C
M #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V %T - !J #, >@ R (P
M,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,  !H#0  7 X  %(.  !+
M#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0 #H %0 Y !H .  @ #8
M)0 U "L -  P #, -P R #X ,0!& "\ 4  N %H +0!G "L =P J (D *0"=
M "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C$   5A$  $T1  !%$0
M0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%$@ R!!< ,04< # %(@ O
M!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E "0'=0 C!X< (@>; " &
ML  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@  4A,  $@3  !!$P  .Q,
M #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M"A0 + L9 "H+'P I"R4
M* PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-=0 <#8@ &@V< !D-L0 8
M#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8  $46   ]%@  .!4  #,5
M   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$ )@X6 "4/'0 D#R, (P\I
M "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5$(D %!"> !(0LP 1$,X
M$1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9   Z&0  -!@  # 7   L
M%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4 " 2&@ >$R  '1,G !P3
M+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(< $!2<  X4L0 -%,H #13K
M  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W&P  ,AH  "T:   I&0
M)A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7%P 9%QT &!@D !88*P 5
M&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8  H9K0 )&,8 "1CG  D8
M^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0  +QT  "H<   F&P  (QL
M "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4'!L $QPB !(=*0 1'3$
M$!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=J@ #'<(  QWF  0<^  %
M'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\  "@>   D'@  (1T  !X=
M   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@ #B$?  XB)@ -(BX #"(W
M  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ   (<   "'E   @^   (/\
M9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@   B(   'Q\  !P?   9
M(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<  DF(@ ()BH !B<S  0G
M/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\  "7D   E^0  )/\ 8R
M %0B  !'(P  /20  #0D   N(P  *",  "0B   A(@  'B$  !HB   7(P
M$R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K'P !+"<  "PP   L.@
M+$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD   J^@  *?\ 7R,  % E
M  !$)@  .B8  #(F   K)@  )B4  ",D   ?)   &R0  !<E   4)P  $2D
M  XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'   ,2,  #(L   R-@  ,D(
M #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O^P  +_\ 6B<  $PH  !
M*0  -RD  "\I   I*   )2<  "$F   <)P  &"@  !0J   1+   #BX   LP
M 0 ',@4  S0)   U#   -@\  #<2   X&   ."   #@H   X,@  .3T  #E+
M   Y6P  .&X  #B%   WGP  -[H  #;D   U_   -?\ 52H  $@L   ]+
M-"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O   -,0  "C0   <V   "
M. 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D  ! +@  0#D  $!'  !
M5@  0&D  $"    _FP  /K<  #WC   \_   //\ 4"\  $,O   Y+P  ,B\
M "PM   G+   ("T  !HO   5,0  $3,   TV   ).   !3L    ]    0 $
M $$$  !#!P  10L  $8.  !($0  2A8  $H>  !**   2C0  $E"  !)40
M260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,  #\S   V,P  ,#$  "HP
M   C,0  '#,  !8U   1.   #3L   @^   #00   $,   !&    2    $H
M  !,!   3@<  $\+  !1#@  5!(  %49  !5(@  5"X  %0\  !42P  4UX
M %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW   U-@  +S0  "8U   >
M-P  %SH  !$]   ,00  !T0   !(    2@   $T   !0    4P   %4   !7
M    6 (  %L&  !="P  7PX  &(3  !B&P  8B<  &(T  !A10  8%<  &!M
M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T.0  *CH  "$\   80
M$4,   Q'   &2P   $\   !3    5@   %D   !<    7P   &$   !C
M90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M  !Q/0  <$\  &]E  !N
M@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P  )$(  !I&   22@  #$\
M  14    6    %T   !A    90   &@   !K    ;@   '$   !S    =0
M '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%-   A$8  ()=  "!=@
M?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P  !-2   ,5P   UT   !C
M    :    &T   !Q    =@   'H   !^    @0   (,   "&    B0   (L
M  ".    D@   )4!  "9"0  GA   )X:  "=*0  G#P  )I2  "8;   EHL
M )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@   #9P   &X   !T
M>@   (    "$    B@   (X   "2    E0   )<   ":    G0   *    "C
M    IP   *L   "O    M D  +@0  "W'@  M3   +-&  "Q8   KWX  *R@
M  "KP0  J>X ,54  "1;   880  #FD   5Q    >0   ($   "(    CP
M )0   ":    GP   *0   "H    J0   *P   "O    LP   +4   "Y
MO0   ,$   #&    RP   -$*  #3%   T24  - [  #-5   RG$  ,B2  #%
MLP  P]X *6(  !QI   1<0  !WL   "$    C0   )4   "=    HP   *D
M  "O    M    +D   "\    O@   ,(   #%    R    ,P   #0    U
M -H   #?    Y    .H   #N#   [1H  .PO  #J20  Z&4  .:&  #DI0
MXL8 _P   /\   #_    _  ! /P " #^  X _P 4 /\ '0#_ "8 _P P /\
M.@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@ \@!O /  =@#M '\ Z@")
M .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H /\ GP#_ )H _P"6 /\
M_P   /L   #V    \P   /,   #V  D ^@ . /T %@#[ "  ]P J /( ,P#M
M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G ,\ ;@#, '8 R0"  ,8
MC #" )H OP"J +L P0"X .D M@#_ *< _P": /\ D@#_ (T _P"* /\ ^@
M /$   #J    YP   .<   #D  $ X  + -L $0#: !H VP C -$ + #* #0
MQ@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +, 9@"Q &X K@!W *P @P"I
M )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_ (  _P!^ /\ [P   .,
M  #:    TP   ,8   "_    N0 & +< #@"T !0 M  = +, )0"N "T JP T
M *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7 &4 E0!N ), >0"0 (<
MC@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ', _P!R /\ X    -    #&
M    M@   *D   "A    G0 ! )D "@"8 !  F  6 )< '@"4 "8 D0 M (\
M- ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X @ !F 'X <0!\ 'T >0"-
M '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E /\ S    +X   "K
MG0   ),   "*    A0   (( !0"   T ?P 1 '\ & "  "  ?0 F 'H +0!W
M #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !> &H : !H '4 9P"$ &4
ME@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\ O0   *D   "7    B0
M 'X   !X    <P   &\  0!M  D ;  . &L $P!K !D :@ @ &@ )@!F "P
M90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H 80!9 &T 5P![ %8 C@!5
M *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0   )@   "&    >    &X
M  !G    8P   &    !=  4 7  + %L $ !; !4 6P ; %H (0!8 "8 5@ L
M %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+ &8 2@!T $D A0!( )D
M1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D   !X    ;    &(   !;
M    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6 $T ' !, "$ 2@ F $D
M+ !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &  /P!N #X ?@ ] )( / "I
M #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N    80   %@   !1
M3    $D   !'    10 % $0 "P!#  X 0P 2 $, %P!" !T 0  B #\ )P ^
M "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H #0 >  S (P ,@"B #$
MO  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0  60<  % '  !)!@  0P4
M $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y !D -P > #8 (P U "@
M-  N #, -  R #L , !# "\ 3  N %< +0!D "P <P K (< *@"< "D M0 I
M -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL  $H+  !""P  /0H  #D)
M   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4 ,  : "\ 'P N "0 +  J
M "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C (( (@"7 "$ K@ A ,P
M(0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.   ]#@  . T  #,-   P
M#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7 "@!'  G "$ )@ G "4
M+0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\ &P"4 !H J@ : ,4 &@#K
M !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y$   ,Q   "\/   L#@
M*0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&&0 A!A\ ( <D !\'*P >
M!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1 !0'IP 3!K\ $@7D !(%
M^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@  ,!(  "L1   H$0  )1
M ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <#!P &PPB !H,*0 9##$
M& PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-IP -#+X #0S@  T,]0 -
M#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10  "@3   E$P  (A(  " 1
M   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH %@\A !40*  4$#  $A Y
M !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 ($+P !Q#?  <0]  '#_\
M:1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85   B%0  'Q0  !T3   :
M$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,> !$3)0 0$RX #A,W  T4
M0  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L  A/=  $2]  "$O\ 91,
M %46  !(%P  /1@  #08   M&   *!@  ",7   @%P  '18  !H5   8%0(
M%A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7(@ ,%RD "Q@R  D8/  '
M&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=   6]0  %O\ 818  %(8
M  !%&@  .QH  #(:   K&@  )1H  "$9   >&   &Q@  !@7   6%P( %!<#
M !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P ''"8 !1PO  0<.  "'$0
M !U1   =8   '7(  !R(   <H   &[D  !O>   :]@  &O\ 7A@  $\:  !"
M'   .!P  "\=   I'   (QP  !\;   <&@  &1D  !<9 0 4&0( $AH# ! ;
M!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,  "$K   A-0  (4   "%.
M   A70  (6\  "&&   @G@  (+@  !_>   >^   'O\ 6AL  $L=   _'@
M-1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;   2'   $!T"  X?!  ,
M(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H   F,@  )CT  "9*   F
M6@  )FP  ":#   EG   );<  "3?   C^0  (_\ 51X  $<@   \(0  ,B$
M "LA   E(   (!\  !T>   :'0  %AX  !,>   0(   #B$   PC @ ()04
M!2<)   H"P  *@X  "L1   L%@  +!T  "PE   L+@  +#H  "Q'   L5@
M+&D  "R    KF@  *K4  "G?   I^P  */\ 42(  $0C   X)   +R0  "@C
M   C(@  'R$  !P@   7(   $R$  ! C   .)   "R8   @H   $*@0  "P'
M   N"0  , P  #$/   S$P  ,QD  #,A   S*@  ,S4  #-#   S4@  ,V4
M #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F   U)P  +28  "<E   B
M)   'B,  !DC   4)   $28   XH   +*@  !RP   ,O    ,0(  #,$   U
M!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$  #L^   [3@  .V   #IW
M   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R*@  *RD  "4G   A)@
M&R<  !4H   1*@  #BP   HO   &,0   30    V    .    #L!   ]!
M/P<  $$*  !##@  11$  $48  !%(0  12P  $0Y  !$2   1%L  $-Q  !"
MC0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0  *2L  "0J   =*@  %RP
M !$N   -,0  "30   0W    .@   #P    _    00   $0   !&    2 ,
M $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/0P  3U4  $YJ  !-A@
M3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X  " N   9,0  $C,   XW
M   ).@   CT   !     1    $<   !)    3    $\   !1    4P   %4!
M  !8!@  6@L  %T.  !?%0  7B   %XL  !=/   7$X  %MC  !:?@  6)T
M %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV   3.0  #CT   A!
M10   $D   !,    4    %,   !6    60   %L   !=    8    &(   !E
M    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48  &M;  !J=0  :)0  &:V
M  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_   .1   !TD   !-    4@
M %8   !:    7@   &(   !E    :    &L   !M    <    ',   !V
M>0   'T$  "!"P  A1$  (0=  ""+   @#X  'Y4  !^:P  >XH  'JJ  !W
MU@  =?T .#T  "P^   B00  %T8   ]+   '40   %<   !<    8@   &8
M  !K    ;P   '0   !X    >P   'X   "     @P   (8   "*    C0
M )$   "6 P  FPP  )T3  ";(0  FC,  )=)  "48@  DW\  )"@  ".Q0
MC/, ,40  "5(   :30  $%,   A:    80   &@   !N    =    'D   !_
M    A    (D   "-    D0   ),   "6    F0   )T   "@    I    *@
M  "L    L@,  +<-  "W%P  M2@  +(^  "P5@  K',  *J4  "IM   I>4
M*D\  !Y4   26P  "F(   !J    <P   'L   ""    B0   (X   "4
MF@   )\   "D    I@   *D   "M    L    +,   "W    NP   ,    #%
M    RP   -$$  #5#@  TQT  - R  #-2P  RF8  ,:'  #"J0  P<L (EL
M !9B   ,:P   70   !]    AP   )    "7    G@   *0   "K    L0
M +8   "Z    O    ,    #$    R    ,L   #/    U    -H   #@
MY@   .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z  #DFP  X+L _P   /L
M  #V    \P   /0 !0#V  P ^@ 1 /\ &0#_ "( _P L /\ -0#_ #T _P!%
M /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L 'H Z0"% .4 D0#A *
MW0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )  _P", /\ ^@   /(   #L
M    Z0   .D   #L  4 \@ , /@ $@#W !L ]0 E /  +@#K #< Y@ ^ .(
M10#= $L V !0 -, 5@#0 %P S0!B ,H :@#( '( Q0!\ ,( B "^ )8 N@"H
M +< OP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"  /\ \    .4   #>
MV@   -L   #<    V  ' -$ #@#1 !4 T@ > ,L )P#% "\ P  W +T /0"Z
M $0 MP!) +4 3P"R %4 L !; *X 80"L &D J0!S *< ?P"D (T H0"> )X
ML@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\ X@   -,   #*    QP
M +P   "V    L  ! *\ "P"L !$ K0 8 *T ( "H "@ I  O *  -@"= #P
MFP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P =0"* (, B "4 (8 IP"#
M ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP   ,$   "Y    K0   *
M  "8    E    )$ !@"0  T D  2 (\ &0". "$ BP H (@ +P"& #4 A  Z
M (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T 'D <@") '$ G0!O +0
M;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@   +$   "@    D@   (D   ""
M    ?    'H  0!X  D =P . '@ % !W !H =  A '( )P!P "T ;@ S &P
M. !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '  7P!_ %X DP!= *D 7 #(
M %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-    ?P   '0   !N
M:@   &8   !E  0 8P + &, $ !C !4 8P ; &$ (0!? "< 70 L %P ,@!:
M #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W $\ B0!. )\ 30"Z $P
MZ0!+ /\ 20#_ $< _P!' /\ H@   (T   !\    ;@   &4   !>    60
M %<   !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1 "$ 3P F $X *P!, #$
M2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $( @0!! )< 0 "O #\ UP _
M /\ /@#_ #T _P ^ /\ E    '\   !O    8P   %D   !1    30   $H
M  !(    1P $ $< "@!&  X 1@ 1 $< %@!% !P 1  A $( )@!! "L 0  Q
M #X -P ] #X / !' #H 4  Y %L . !I #< >@ V (\ -0"G #4 Q@ T /4
M- #_ #0 _P U /\ B    '0   !E    6    $\   !(    0P   #\    ]
M    /  " #P !P [  P .P / #L $@ Z !< .0 < #< (0 V "8 -0 L #0
M,@ S #D ,0!! #  2P O %8 +@!C "T <P L (@ + "@ "L NP K .H *P#_
M "L _P L /\ ?P   &P   != 0  40(  $@#  !  P  .P(  #<    T
M,P   #( !0 R  D ,@ - #$ $  Q !, ,  8 "\ '0 M "( +  H "L +@ J
M #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9 ", LP B -X (@#_ ",
M_P D /\ =P   &4$  !6!@  2P<  $((   Z"   -0<  # &   M!0  + ,
M "L  P J  < *0 + "D #@ I !$ *  5 "< &0 F !X )0 D "0 *@ C #$
M(@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L K  ; ,T &P#V !L _P <
M /\ < 4  %\(  !1"@  1@L  #T+   U"P  , L  "L*   H"0  )0@  "0'
M @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L '@ @ !T )@ < "X &P V
M !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4 ,, % #N !0 _P 5 /\
M:P@  %L+  !-#   0@T  #D-   Q#0  + T  "<-   C#   (0P  !\+ 0 >
M"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@ &00> !@$(P 7!"L %@0S !4$
M/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P #P#E  \ _@ 0 /\ 9PL
M %<-  !)#@  /@\  #4/   N#P  * \  "0.   @#@  '0X  !L- 0 9#00
M& P' !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)(0 2"2@ $@DP !$).@ 0
M"44 #PE2  X)80 -"7, # B(  L(GP *![< "@;;  H%]@ *!/\ 8PT  %,.
M  !&$   .Q$  #(1   K$0  )1   "$0   =$   &@\  !@/ 0 6#@0 %0X'
M !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /#"< #@TO  T-.0 ,#44
M"PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,\0 ""_\ 7PX  % 0  !#
M$0  .!(  "\2   H$@  (Q(  !X1   ;$0  &!$  !40 @ 4$ 4 $A ' !$/
M"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0 "A L  D0-@ ($$$ !A!.
M  4070 #$&\  1"$   0G   #[0   [4   .\P  #O\ 7!   $T2  ! $P
M-A0  "T4   F%   (1,  !P3   9$@  %A(  !01 P 2$08 $1$( ! 0"@ .
M$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I  43,P #$SX  A-+   3
M6@  $VP  !."   2FP  $K0  !'7   1]0  $?\ 6!(  $D4   ]%0  ,Q8
M "L6   D%0  'Q4  !H4   7%   %!,! !,2!  1$@< $!()  X2"0 -$@D
M"Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G   7,   %SL  !=(   76
M%VH  !:    6F0  %;0  !79   4]P  $_\ 510  $86   Z%P  ,!@  "@8
M   B%P  '18  !D6   6%0  $Q0# !(3!@ 0$P< #Q,'  T4!P +%0@ "18)
M  88#  #&@X  1H1   :%@  &QP  !LD   ;+0  &S@  !M&   <50  &V<
M !M]   ;EP  &K,  !G;   8^0  %_\ 418  $,8   W&0  +AH  "8:   @
M&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$  L7!0 )&08 !AH(  (<
M"@  '@T  " 0   @$P  (!D  " A   A*@  (34  "%"   A4@  (&0  "!Z
M   ?E0  '[$  ![;   =^@  '/\ 31D  #\;   T'   *QP  "0<   >&P
M&AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @< P %'00  A\&   A"
M(PL  "4.   F$0  )A8  "8>   G)P  )S(  "<_   F3@  )F   "9W   E
MD@  )*\  "/:   B^P  (?\ 2!T  #P>   Q'P  *!X  "(>   ='   &1L
M !8:   2&@  $!L   T<   +'0  "!\   0A   !(P(  "4$   G!@  *0D
M "P,   N#P  +A,  "X:   N(P  +BX  "X[   N2@  +5P  "UR   LC@
M*ZP  "K4   I^P  */\ 1"   #@A   N(0  )B$  " @   <'@  &!T  !0=
M   0'@  #A\   LA   '(P   R4    G    *0   "P!   N P  , 8  #,*
M   U#0  -A$  #87   V'P  -BD  #8V   V10  -5<  #5M   TB0  ,J@
M #'/   P^@  +_\ /R0  #0D   K)   )",  !\A   ;(   %B   !$A   .
M(P  "B4   8H   "*@   "T    O    ,@   #0    W    .0,  #L&   ^
M"@  0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(  #YG   ]@@  /*(  #K'
M   Y^   ./\ .B@  # H   I)P  (R4  !\C   8)   $B4   XH   **@
M!2T    P    ,P   #8    X    .P   #X   !     0@   $4"  !'!@
M2@H  $T.  !-%0  3!\  $PK  !+.@  2DP  $EA  !(?   1YL  $6_  !#
M\P  0O\ -BP  "TK   G*0  (R<  !LH   4*@  #BT   HP   $,P   #<
M   Z    /0   $    !#    1@   $@   !+    30   %    !3 0  5@8
M %D+  !;$   6QD  %HE  !9-   6$8  %=:  !5=   5),  %*U  !0Z@
M3_\ ,S   "PN   G+   'BT  !8O   0,@  "C8   ,Z    /P   $(   !&
M    20   $P   !/    4@   %4   !8    6@   %T   !@    8P   &<&
M  !K#   ;!(  &L>  !K+   :3T  &=2  !F:@  9(D  &&K  !?W   7?\
M,3,  "PQ   B,@  &34  !$Y   */0   D(   !'    3    %    !4
M6    %L   !?    8@   &4   !H    :P   &X   !Q    =0   'D   !]
M!@  @@T  ((6  " )   ?C4  'Q)  ![80  >'\  ':?  !SQ@  </< ,38
M "8X   <.P  $D    M%   "2P   %$   !6    6P   &    !E    :0
M &X   !R    =@   'D   !\    ?@   ((   "%    B0   (X   "3
MF 8  )P.  ";&@  F"L  )9   "260  D7,  (V5  "+M0  B.@ *SX  "!!
M   51P  #4T   )4    6P   &$   !H    ;@   ',   !Y    ?@   (,
M  "(    C    (\   "2    E0   )D   "=    H0   *4   "J    L
M +<'  "X$0  M2$  +(U  "O30  JFD  *B(  "FJ   HM$ (T@  !A.   .
M5   !%P   !D    ;0   '4   !\    @P   (D   "/    E0   )L   "@
M    HP   *8   "I    K0   +$   "U    N0   +X   #$    R@   -(
M  #:"@  UA8  -(I  #.00  REP  ,5\  #"G0  P;T '%4  !%<   '90
M &X   !W    ?P   (@   "0    F    )\   "E    K0   +,   "X
MN@   +X   #"    Q@   ,H   #.    TP   -H   #@    YP   .T   #S
M    ] X  /(>  #O-@  [%$  .AN  #DD   W[$
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M[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
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M/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/KW%!0"PUP4
MH_\0 YG_(@F+_RD/?O\P%7/_.!II_T ?8O])(UO_4297_UHH5?]B*E+_:2M1
M_V\L4/]S+4__=RY._WHN3O]]+TW_@"],_X0P2_^(,$O_BS!+_XLP2_^+,$O_
MBS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,/^+' 3_B"@(_X0T
M#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F
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M+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+;'" 0"CT@
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M<<N;I'/0DZ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34CO^
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M4$__PU%/_\-13__#44__PU%/_\-13__#44__PU%/_\-13__#4=JO @#&O 4
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M6?%?Y5GQ7^59\5_E6?%?Y5GQ7_]P'@/_;"D&_VDS"?]R-PW_>3X2_WU'&?^
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MB(V1FH65EI:"GIJ2@*>=CW^SGHV PIZ+@,R:BX'2DHJ V(F)@-N&B8#;AHF
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M>$_6Y75/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW1/T^=T3]/G=/^/#P'_I X
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ML4,<Y;1+*=JO53K-J%Y*PJ!F6+F:;62QDW5NJHY\=J.*@WV>AHN"F8*3AY2
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M7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7/F9 P#4K ( Q;<$ +G#!0"PT@@
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M9U>O\6=7K_%G5Z_Q9U>O\6=7K_%G5Z_Q9_]_#@'_DPL X:4% -*S!P#)O@<
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M% &<Z2@&D^DT#HGH/1A_YT0B=^9.*F_F5S)IY5\X8^5G/5_D;T):Y'=%5N2
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M8&B2]U]HDO=?:)+W7VB2]U]HDO=?:)+W7_]O$0'_@0X _Y$. /*@# #:K0D
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M55"Z_E50NOY54+K^5?^% @#=F   S:8" ,&Q P"WN@, KL8& *?3"@"@W14
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M#AW_EPX<_Z$.&_^L#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/&_^N#Y>\  "(R0
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M5GF!_U%Y@?]1>8'_47F!_U%Y@?]1>8'_4?]E$P'_=0X _X,. /^0#@#UFPX
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M4F&8_U)AF/]289C_4O]R"P#_@P4 WY,! -&?! #)J@8 P;(% +N]! "TOQ@
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M3KG_2>^%  #4E0  QZ,  +JL 0"PM   I[\# )[)!@"5U L D-4= 8G4+@:
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M(C?YR"(V^>,B-OCS(C;W_"(V]_PB-O?\(C;W_"(V]_PB-O?\(K>F  "IK@
MG+D  )#$  "#SP  =]L  &_V"@!G_Q,!8/\= EK_)P-4_S %3_\X"$K_0 I&
M_T@,0_]/#D#_5@\]_UX0._]E$CC_;A,V_W<4-/^"%3+_CQ8P_YL7+_^I%R[_
MMQ@M_\@8+/_A&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8+/_O&*NK  ">M0  D,$
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M_QG_/?\9_SW_&?\]_QG_/?\9_SW_&?] *@+_02X#_T<N _]*,03_3#<&_TM
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M28ET_T2(=/]#B'3_0XAT_T.(=/]#B'3_0_]=$@'_:PX _W@. /^##P#]C!
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M1W*$_T=RA/]'<H3_1_]F#0#_=0< ]H,% -R/ P#2F 8 S*$' ,BH" "_J1H
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M/$/%WSQ$Q/,[1,/_.47"_S=%P?\W1<'_-T7!_S=%P?\W1<'_-]6+  #%F@
MMZ0  *NL  "@M   EKX  (O'! "!T @ >-D. '79( %OV"\$:=@\"6/61A!>
MUE 56=58&E748!]1U&@B3M1Q)DO3>RE(TX4K1=.2+D+4GR]!U*\P/]7",3_5
MX3 _T_(P/]+]+S_1_RX_T/\N/]#_+C_0_RX_T/\N/]#_+LJ4  "[H0  K:D
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M$2;_\A$F__81)O_V$2;_]A$F__81)O_V$:>I  "9LP  B[X  '[)  !PTP
M9-X  %CG  !2_PD 3?\1 $?_&0%#_R(!/O\J CK_,@,W_SD#,_\_!##_1@4M
M_TT%*_]4!BC_6P<F_V,'(_]M""'_>0D?_X<)'O^5"AW_HPH<_[$*&__ "QK_
MU@L:_]\+&O_?"QK_WPL:_]\+&O_?"YNQ  "-O   ?L<  '#2  !CW@  5>0
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M.9ME_S:;9?\SFV7_,YME_S.;9?\SFV7_,_]5$P'_8 X _VL. /]T$ #_>Q(
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M.H!U_SJ =?\Z@'7_.O]=#@#_:@8 _W8& .2  P#9B08 TH\( ,^4"@#%EAL
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M1U";T4=1F^Y$4YO\0%6;_SQ6F_\Z5IO_.E:;_SI6F_\Z5IO_.O%T  #9@P
MR)   +Z:  "SH0  JJ<  *&N  "7M08 DK88 (RU*@.%M#<)?K)"$7>P3!AQ
MKE0?;*U;)6>K8BIBJFDO7JEQ,UJH>C=6IX,Z4Z:./5"FFT!-I:E!2Z6Z0DNF
MT4)+I>T_3:7\/$ZD_SE/I/\W3Z3_-T^D_S=/I/\W3Z3_-^1Z  #/B0  PI4
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M)3O+_R4[RO\E.\K_)3O*_R4[RO\E.\K_)<.3  "UG@  J*8  )VN  "1M@
MA;\  'G'  !OS@0 9-8) %[>$0!;WB  5]XM E/?.@10WT0&3-]."4G?5PQ&
MWU\/0]]H$4'?<1,^WWP5/-^)%SK@EADXX*4:-^"W&C;AS1HVW^P:-=[Y&C3=
M_QLTW/\;--S_&S3<_QLTW/\;--S_&[F<  "JI   GJL  )*U  "%O@  ><<
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M!A/_Z083_^D&$__I!I>O  "(N@  >L4  &S/  !>V@  4.   $3F   \]0
M-_\$ #/_#0 O_Q, *_\: "C_(0 E_R<!(?\M 1[_,@$;_S@!&?\_ 1;_1@(4
M_TT"$?]6 A#_8 (._VP"#/][ PO_BP,*_YH#"O^H PG_M0,(_\(#"/_" PC_
MP@,(_\(#"/_" XJX  ![PP  ;,X  %[;  !/X@  0N<  #;L   Q_P  +/\
M "?_!P C_PX (/\2 !S_&  8_QT %?\A !+_)@ 0_RP!#O\Q 0W_-P$*_SX!
M"/]& 07_3P$!_UD! /]F 0#_= $ _X(" /^0 @#_G ( _Z8" /^F @#_I@(
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M0XP7]$*4&/-!G!GQ0:,;[T"J&^Y LASM/[L=ZS_&'ND_U1[E/^@?XD#T'M]
M_AW=0?\;VT+_&ME"_QC80O\7V$+_%]A"_Q?80O\7V$+_%_] 'P'_2!H!_TX8
M ?]2&P'_5B,"_U@L _]7-P3_54('_U)-"_E06@[U36<2\4QR%NY*?1CK2(8;
MZ4>/'>=&EQ_E19X@XT2F(N%$KB/@0[<DWD/")=Q#T";70^4FTT3S)-!%_B+-
M1O\@S$?_'LI'_QS)2/\;R4C_&\E(_QO)2/\;R4C_&_]$&P'_3!8!_U(4 ?]8
M& '_71\!_U\H O]>,@/]73T&]EI)"O!750_J56(3YE)M&.)0=QS?3H$?W$R*
M(ME+DB352IHFTTFA*-%)J2G/2+(JS4B\*\M(R2S(2-\LQ4CO*\)*_"C 2_\E
MOTS_(KY-_R"]3?\?O4W_'KU-_QZ]3?\>O4W_'O]'& '_3Q,!_U81 /]>%0#_
M8AP!_V4D ?YE+0+T9#@%[6%#">9?40[@7%T4VEAH&M16<A[05'LBS%*$)LI0
MC"C'3Y0JQ4Z;+,-.HR[!3:POOTRV,+U,PC&[3-,RN$SI,;9.^"VT4/\JLU'_
M)[-2_R2R4O\BLE+_(K)2_R*R4O\BLE+_(O]*%0'_4Q$ _UL/ /]B$@#_:!<
M_VH? ?9K* 'L:S(#Y&D^!]QF3 W38E@4S5]C&\A<;2#$6G8DP5A^*+Y6ABN[
M58XNN5.6,+92GC*T4J8SLE&P-;!1O#:N4,LWK%#C-ZI2]#.I5/\NJ%;_*ZA7
M_RBH5_\EJ%?_):A7_R6H5_\EJ%?_)?]-$P#_5@X _U\- /]G$ #_;!, ^W 9
M .]Q(@'D<2P"VW Z!=%L2 S):%04PV5?&[YB:"&Z7W$FMEUY*K-;@2VP6HDP
MKEB1,ZM7F36I5J$WIU:K.*55MCJC5<4[H57=.Y]6\#>?6/XRGUK_+IY;_RN>
M7/\HGES_*)Y<_RB>7/\HGES_*/]0$0#_60P _V,, /]K#0#_<!  ]703 .AV
M&@#==R4!T78V!,AR1 S!;E 4NVM;&[9G9"&Q96TGK6)U*ZI@?"^G7X0RI%V,
M-*)<E#>?6YTYG5JF.YI9L3V86;\^EUG3/I5:[#N57?LUEE[_,99?_RV68/\J
MEF#_*I9@_RJ68/\JEF#_*O]2#P#_7 H _V8) /]N"@#V= P [W@. .%[$@#4
M?"  RGLS!,%W00NZ=$T3M'!8&ZYL82&I:FDGIF=Q*Z)E>"^?9( SG&*(-IEA
MD#B67YD[E%ZB/9%>K3^/7;M C5W-08Q>Z#^-8?DXC6+_,XYD_S".9/\LCF7_
M+(YE_RR.9?\LCF7_+/]5#@#_7P8 _VD& /1R!@#B> 8 VWP) -E_# #-@1T
MQ'\P [M\/PJT>$L2K755&JAQ7B&C;F8FGVQN*YMJ=2^8:'TSE6>$-I)EC#F/
M9)4\C&.?/HEBJD"'8;="A6')0H1BY$&%9/<[AF;_-8=G_S&':/\NAVG_+8=I
M_RV':?\MAVG_+?]7# #_800 _FP# .1U 0#;>P4 TX ( -"#"@#'A1H OH0M
M [:!/ FO?4@2J'E2&:)V6R"=<V,FF7!K*Y5N<B^1;7DSCFN!-HMIB3J(:)(\
MA6></X)FIT& 9K1#?F;%1'QFX4-^:/4\?VK_-X!K_S.!;/\O@6S_+X%L_R^!
M;/\O@6S_+_]9"P#_8P$ ]&\  -]X  #4?P0 SH,& ,J'" #"B!@ N8<K K&%
M.@BJ@481HWY0&)UZ61^8=V$EDW5H*H]S;R^+<7<SB&]^-H5NACJ";(\]?VN9
M0'QJI4)Y:K%$=VK"1'9JW41X;/,^>6[_.'IO_S1[</\P?'#_,'QP_S!\</\P
M?'#_,/];" #_9@  YW(  -I[  #/@@, R8<% ,2*!@"\C!4 M(LH JR). >E
MA400GH).&)A_5QZ3?%\DCGEF*HIW;2Z&=70R@G1\-G]RA#E\<8T]>7"70'9O
MHD)S;J]$<6[ 17!NV45R</$_<W+_.75S_S5V=/\Q=G3_,79T_S%V=/\Q=G3_
M,?]=!@#_:0  XG0  -1]  #+A0( Q(H$ +^-!0"WCQ, L(\F :B--0>@BD(.
MFH9,%I.#51V.@5TDB7YD*85\:RV!>G(R?7AY-7IW@CEV=HL\<W650'!TH$)M
M<ZU$:W.]16ISU45L=.] ;G;^.F]W_S9Q>/\R<7C_,7%X_S%Q>/\Q<7C_,?]?
M @#W;   WG<  -"!  #'B $ P(T# +F1 P"RDQ$ JY,C :.1,P:<CD -E8M*
M%8^(4QR)AELBA(-B*("!:2U\?W Q>'YW-71\@#AQ>XD\;GJ3/VMYGD)H>*M$
M9GB[161XT45F>>Y :'O].FI[_S9K?/\R:WS_,FM\_S)K?/\R:WS_,O]A  #J
M;P  V7H  ,R$  ##BP  NY$! +25 0"LEPX I9<A 9Z6,067DSX,D)!(%(J.
M41N$BUDA?XE@)WN'9RMWA6XP<X1U-&^"?3=K@8<[:("1/F5_G$%B?JE#8'ZY
M1%]^ST1@?^Q 8H#\.F2 _S9E@?\S9H'_,F:!_S)F@?\R9H'_,O]D  #E<@
MTWX  ,>'  "^CP  MI4  *Z9  "FFPP H)P> )F;+@22F3L*BY9&$H643QE_
MD5<?>H]>)76.92IQC&PN;8IS,FF)>S9FB(0Y8H://5^%FC]<A:A!6H6W0EF%
MS$):A>H_7(;[.EZ&_S9?A_\R7X?_,E^'_S)?A_\R7X?_,OUH  #@=@  S8(
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M,DJ?_S!+G_\N2Y__+4N?_RU+G_\M2Y__+=UY  #)A@  O)(  +&:  "FH
MG*8  )&L  "&L@  ?;8- 'FV'0!UMBP";[4Y!FJT0PMELTP18+)4%ERQ6QI8
ML&,>5:]K(5&O<R5.KGTH2ZV(*DBME2U%K:,N1*VS+T.MR"]"K.<O0ZOY+42K
M_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&   #!C0  M9@  *F?  ">I0  DZP
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M$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  " N@  =,$  &C)  !<SP
M4M4# $C<" !%Y1( 0^4> $'F*@ ^YC4!.^<^ 3GG1P(WYU #-.A9!#+H8@4P
MZ&T&+NEY!RSIAP@KZI8)*>JG"BCJN@HGZ]8*)^GP"B?G_0DFYO\*)N;_"B;F
M_PHFYO\*)N;_"JB@  "<IP  C[   (*Y  !TP@  :,H  %O1  !/UP  1=T
M #[N"0 \\A$ .?,; #;S)0 T]"X ,?0W 2[U/P$L]4<!*?9/ B?V5P(E]V$#
M(_=L R'X>@0?^(D$'OF:!1SYJP4;^L %&OK>!1KY\@4:]_T%&?;_!1GV_P49
M]O\%&?;_!9ZF  "1KP  @[D  '7"  !GRP  6M,  $W:  !"WP  ..4  #7[
M!P Q_P\ +O\6 "O_'P I_R8 )?\M "/_-  @_SL!'O]# 1O_2P$9_U,!%O]=
M A3_:@(2_W@"$?^( A#_F@(0_ZL##O^^ P[_U0,._^T##O_P P[_\ ,.__ #
M#O_P Y.N  "$N   =L(  &?,  !:U0  3-P  #_A   UY@  +?0  "K_ @ F
M_PL (_\1 "#_%P =_QT &?\C !;_*0 4_R\ $O\U !#_/0 ._T4!#/]. 0K_
M6 $'_V4!!?]T 0/_A0$"_Y8! ?^F 0#_M0$ _\8! /_* 0#_R@$ _\H! /_*
M 8:W  !WP0  :,P  %K7  !+W@  /N0  #+I   G[0  (_\  !__   ;_P4
M%_\, !3_$  1_Q0 #_\8  W_'0 +_R( "/\H  7_+@ "_S4  /\]  #_1P
M_U(  /]>  #_;0  _WX! /^. 0#_FP$ _ZD! /^K 0#_JP$ _ZL! /^K ?\J
M+0'_+BL!_S K ?\P+@+_+C4"_RD] _\E203_(U<$_R%D!?\?<@;_'7\&_QV*
M!O\=E ;_'9P'_QRC!_\<J@?_'+$'_QRX!O\<OP;_',D&_QS6!O\=Y0;_'>\&
M_QWY!?\=_P7_'?\%_QW_!?\=_P7_'?\%_QW_!?\=_P7_'?\%_QW_!?\L*P'_
M,"@!_S,H ?\S*P+_,3$"_RTZ _\K1P3_*%0%_R9A!?\D;P;_(GP'_R*'!_\B
MD0?_(9D'_R&A"/\AIPC_(:X(_R&U"/\AO C_(<8'_R'1!_\AX@?_(NT'_R+W
M!_\B_P;](O\&_"+_!OPB_P;\(O\&^R+_!OLB_P;[(O\&^R+_!O\N* '_,R4!
M_S8E ?\W)P'_-2T"_S0X _\R1 3_+U$%_RQ>!O\J:P?_*7<'_RB#"/\GC0C_
M)Y8)_R>="?\GI G_)ZL)_R>R"?\GN0G_)\()_R?-"?\GW@G_)^L)_"?V"/DH
M_@CW*/\(]BC_"/4H_PCU*/\(]2C_"/4H_PCU*/\(]2C_"/\R)0'_-R(!_SHA
M ?\[(P'_.RD"_SLT O\Y0 3_-DT%_S1:!O\Q9@?_,',(_RY_"?\NB0K_+I(*
M_RV9"_\MH0O_+:<+_RVN"_\MM0S_+;X,_BW)#/LMV0SX+>@+]"[T"_$N_@OO
M+O\+[B[_"^TN_POL+O\*["[_"NPN_PKL+O\*["[_"O\U(@'_.QX!_S\= ?]
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M':)2_QVB4O\=HE+_'?]*#P#_4@H _UH) /]@"P#_90X ]6<1 .AH& #=9R0
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M.FUJSCIM:^LW;VW\,7!N_RUQ;O\J<6__*'%O_RAQ;_\H<6__*/]9  #K90
MVW   ,UX  #$?@  O((! +:$ 0"NA0X IX8@ *"%, .:@CT(DX!(#XY]416)
M>UD:A'E@'X!W9R-\=6XG>71U*G9S?2YS<H8Q<'&0-&UPG#=J;Z@Y:&^W.F=O
MRSIG<.DW:7'Z,FMR_RUL<_\J;'/_*&QS_RAL<_\H;'/_*/]<  #G:   U7,
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M,5F!_RU;@O\J6X+_*5N"_RE;@O\I6X+_*>QF  #8<P  QWX  +R'  "SC@
MJ9(  *"5  "6F $ D)D3 (J9) &%F#($?Y8^"7F42 YTDU 4;Y%7&6N07AUH
MCF4A9(UM)6",=2A=BWXK6HJ(+E>)E#%4B:$S4HBP-%&(PS50B.(T4HCV,%.(
M_RQ4B/\I58C_*%6(_RA5B/\H58C_*.9K  #0>   PH,  +>,  "MD@  HY8
M )J:  ".G@  AY\0 (.?( !^GR\">)T[!W.<10QNFTT1:9E5%F687!IAEV,>
M7I9J(5N5<B57E'PH5).&*U&2DBY.DJ P3)*O,4N2PC%*D> Q3)'U+4V1_RI.
MD/\H3I#_)DZ0_R9.D/\F3I#_)MYP  #)?0  O(D  +*2  "GEP  G9L  ).?
M  "&I   ?J8, 'JF&P!UIBH!<*8W!&RE00EGHTH-8Z)2$E^A619;H6$96*!H
M'52?<"!1GGHC3IV$)DN=D2E(G)XJ1IRN+$6<P2Q%G-\K19OT*4::_R='FO\E
M1YK_)$>:_R1'FO\D1YK_)-1W  #"A   MH\  *N6  "AG   EJ   (NE  !_
MJ@  =*X% &^O% !LKR0 :*\R F2N/05?K48)6ZQ/#5BL5A%4JUX44:IF%TZJ
M;AI+J7@=2*F#($6HCR)#J)TD0:BM)4"HP"4_J-\E/Z;T(T"E_R) I?\A0*3_
M($"D_R! I/\@0*3_(,I^  "[BP  KY4  *2;  "9H0  CJ8  (*L  !WL0
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M!:2>  "8I0  BZX  'VV  !PO@  8\8  %;+  !+T   0-4  #;<   OY0<
M+>T0 "ON&  I[B( )^\K "7O-  C\#P (?!% !_Q3@ =\E@!&_)D 1GS<0$8
M\X$!%_22 A7TI0(4];H"$_76 A/T[P(2\OP"$O#_ A+P_P(2\/\"$O#_ IJD
M  "-K0  ?[8  '&_  !CQP  5LX  $G3   ]V@  ,]\  "KC   F] 4 )/L-
M "'\$P >_1L '/TB !G^*0 7_C$ %?\Y !/_00 1_TH $/]5  [_80 ,_V\!
M#/^  0K_DP$)_Z8!"/^Z 0?_U $'_^L!!O_V 0;_]@$&__8!!O_V 8^L  "
MM@  <K\  &/)  !6T0  2-@  #O=   PX@  )N8  !_P   <_P  &?\) !;_
M#@ 4_Q, $?\9  __'@ -_R0 "_\K  G_,@ &_SL  _]$  #_3P  _UP  /]K
M  #_?0  _Y   /^C  #_M   _\8  /_6  #_U@  _]8  /_6 (*U  !SOP
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M+/\(W2S_"-TL_PC=+/\(W2S_"/\U&@#_.A8 _ST4 /\_%P#_01\ _T$I ?]
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M+7Q:SRY[6^PK?%S\)GQ=_R)]7O\??5[_'7U>_QU]7O\=?5[_'?]0  #U60
MX6,  -)J  #);@  PG ! +UP P"V<!  KG$B *AP,@*A;C\&G&Q*"Y=J4Q"2
M:%L4CF9B&(ME:1N(8W >A6)X(8)A@"2 8(DF?5^2*7M>G2MX7JDM=EZX+G5>
MS"]T7NDM=6#Z)W9A_R-W8O\@=V+_'G=B_QYW8O\>=V+_'O]2  #L7   W&8
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M*F9M_R9F;?\C9V[_(&=N_R!G;O\@9V[_(/99  #@90  SF\  ,)V  "Y?
ML7\  *F   "@@ < F8$7 )2!* &.@#4#B'Y!"(-\2@U^>E(1>GA9%79W8!ES
M=F<<<'1N'VUS=B-J<G\F9W&)*61QE2MB<*$M8'"P+UYPPB]=<-\O7W'U*F!Q
M_R9A<O\C8G+_(&)R_R!B<O\@8G+_(.]<  #<:0  RG(  +YZ  "U@   K80
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M'U"#_Q]0@_\?4(/_']YI  #)=0  O(   +*(  "HC0  G9$  ).3  "%E@
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M%+N%  "OD   HY<  )B=  ",HP  @*@  '2M  !HL@  7+8  %"Z 0!)O T
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M 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:_P(7VO\"%]K_ J"<  "4HP
MAZL  'FS  !LN@  7\$  %+&  !&R@  .\X  #'3   IV0  (=X% ![H#@ =
MZ!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ: !'M9P 0[G< $.Z*  [O
MG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\ #.O_ )>C  ")JP  >[0
M &V\  !?Q   4LH  $7.   YTP  +]@  "7=   =X0  &.P" !;W"P 4]Q$
M$?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\5P #_68  OYW  #]BP
M_9\  /RU  #\T0  _.T  /S\  #\_0  _/T  /S] (NK  !]M   ;KT  &#&
M  !2S0  1-(  #?8   LW0  (N$  !GE   3Z@  $/H   [_!@ -_PP "O\0
M  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_10  _U,  /]B  #_=0  _XH
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M'9)(V!V02>\;CTK^&(]+_Q:.2_\4CDS_$HY,_Q*.3/\2CDS_$O]%  #_2P
MZ5,  -Y8  #36P  S5L$ ,I8!P#"6!4 NEHG +-:-P&N6$0$J5=/!Z156 JA
M5& -GE-H$)M1;Q.84'85EE!^%Y1/AAF23HX:CTZ8'(U-HAV+3:X?BDV\((A-
MT""'3>L?AD_\&X90_QB&4/\6AE#_%(91_Q2&4?\4AE'_%/]'  #X3P  Y%<
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M('%<_QQQ7?\:<5W_&'%=_Q=Q7?\7<5W_%_U/  #E60  TV(  ,=H  "];
MMFT  *]L  "G:PL H&P9 )ML*@&5:S<"D&E#!8MH3 F'9E0,@V5;$(!C8A-]
M8FD5>F%P&'AA>!IU8($=<U^+'W!>EB)N7J(D;%ZP)6M>P29I7MXF:E_T(6M@
M_QUK8?\;;&'_&6QA_QAL8?\8;&'_&/51  #B7   SV4  ,-K  "Y;P  L7$
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M&EUM_QE=;?\976W_&>A:  #29@  PV\  +AV  "O>P  IGX  )U^  "1?
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M%\UM  "]>   L8(  *>*  "<C@  DI   (:3  !YE0  ;)<  &:7#@!CF!L
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M##&JL PPJL<,,*GG#"^G^@TOIO\-+Z7_#2^E_PTOI?\-+Z7_#;:$  "JC@
MGI0  )29  "'G@  >Z,  &^H  !CK   5Z\  $NR  !!M08 /K81 #VV'@ [
MMBD .K<T #FW/@ WMT< -K=0 32W6@$RMV0",+=O RZW? 0LMXL%*K><!2FW
MK@8HN,4%*+?F!2>U^0<FL_\')K+_"":R_P@FLO\()K+_"*^-  "BE   EYH
M (N@  !^I@  <:L  &6P  !9M   3;<  $*[   XO@$ +\() "W#$@ LPQX
M*\,I "K$,P IQ#T *,5' "?%40 FQ5P )<9H "/&=@$BQH8!(,:8 1_&JP$>
MQ\$!'L;D 1W$^ (<PO\#','_ QS!_P0<P?\$','_!*64  ":F@  CJ$  (&G
M  !SK@  9[0  %JY  !.O0  0L   #C#   OQP  )LL$ ![0"@ ;T1$ &M(:
M !G2)0 8TR\ &-,Z !?41  6U%  %=5= !35:P 3UGP $M>/ !'8I  0V;L
M$-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:  "1H0  @Z@  '6P  !H
MMP  6[T  $[!  !"Q0  -\@  "W,   DT   '-4  !7:!0 0X@L $.,1  [D
M&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (YVT !N:   7FE0 $YJL  N;$
M  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%J0  =[$  &FY  !;P
M3L8  $'*   US@  *M(  "'6   9VP  $M\   WC   +\0@ "?,.  ?S$P $
M\AH  O(B  #R*@  \C0  /(_  #R3   \EP  /)M  #R@@  \I@  /.M  #S
MQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !YL@  :KH  %S"  !.R0  0,X
M #/3   HV   'MT  !7A   /Y   "N@   7S   #_0$  /P(  #[#0  ^Q$
M /L6  #\'@  _"8  /PP  #]/   _DD  /Y:  #^;0  _X(  /^8  #_K
M_\   /_8  #_Y   _^0  /_D 'NR  !LNP  7<0  $_-  ! T@  ,MD  ";>
M   ;X@  $N8   SJ   %[0   /0   #_    _P   /\   #_!   _PD  /\.
M  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_6   _VL  /^   #_E0  _Z8
M /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD /\5)P#_$"T _PHV /\%0P#_
M 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )( _P": /\ H #_ *8 _P"L /\
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M ?\,8@'_"VX!_PMY ?\+@@'_"XL!_PN2 ?\*F0'_"I\ _PJE /\*JP#_"K(
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M";$RY0FM,_4)JS/_":HS_PBH,_\'J#/_!Z<S_P>G,_\'IS/_!_\W!P#_.@
M_SX  /I! 0#Q008 \3\- .8\$@#;.A\ T#LQ ,H\0 #$/$T!P#Q8 KP[80.Y
M.VH%MCIR!K0Z>@>R.8$(L#F(":\YD JM.)@*JSBA"ZDXJ@RH.+8-ICC%#:0X
MW@ZA.?$-GSK_#)XZ_PN=.O\*G#K_"9PZ_PF<.O\)G#K_"?\[ @#_/@  ]T0
M .9'  #?2 $ VD8& -E "P#-0AD Q40K +Y$.P"Y1$@!M4-3 [%"7 2N0F4&
MJT%L!ZE = FF0'L*I#^#"Z,_B@VA/I,.GSZ<#YT^I1";/K$1FCZ_$9@^U!*6
M/^T1E#_\#Y- _PZ20/\,DD'_"Y)!_PN20?\+DD'_"_\]  #_0P  Z4D  -Y.
M  #33P  S4X# ,I)" #"210 NTHF +5+-@"O2T,"JTI. Z=)5P6D2& 'H4=G
M"9Y&;PJ<1G8,FD5]#IA%A0^61(X0E$27$I)#H1.00ZP4CT.Z%8U#S16+1.@5
MBD7Z$HE&_Q")1O\.B$;_#8A&_PV(1O\-B$;_#?]   #R1P  XT\  -13  #+
M50  Q%0  ,!0! "Y3Q$ LE B *Q1,@"G43\"HE!* YY/4P6;3EP(F$UC"I5,
M:@R32W$-D4IY#XY*@!&,28D2BDF2%(A(G!6&2*@6A4BU%X-(QQB!2.08@4KW
M%8!*_Q* 2_\0@$O_#X!+_PZ 2_\.@$O_#O]#  #L2P  W5,  ,Y8  #$6@
MO5H  +A7 0"Q5 X JE8> *56+@"?5CL!FU5& Y=44 634U@(D%)?"HU19@R+
M4&T.B$]T$(9/?!*$3H43@DZ.%8!-F1=^3:08?$VR&7I-PQIY3=\:>$[T%WA/
M_Q1X3_\2>%#_$'A0_P]X4/\/>%#_#_U&  #G3P  UE<  ,A<  "_7P  MU\
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M$V=<_Q)G7/\29US_$NU.  #:60  R&$  +QG  "S:@  JVP  *)J  "99P(
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M$]Q<  #'9P  N6\  *]V  "E>P  G'P  )%\  "">   >GD' '5Y% !R>B,
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M%$""KA4_@\(5/H+B%3^!]Q,_@?\20(#_$4" _Q! @/\00(#_$,9K  "W=@
MK'\  **%  "7B0  C(L  (&-  !SC@  98\  %V/"0!:D!0 6) A %:1+0!3
MD#@!49!! DZ020-,D% $2H]8!4>/8 =%CFD)0HYS"T"-?PT^C8T//(V<$#J-
MK!$YC<$1.(WA$#B+]A XBO\/.8G_#SF)_PXYB?\..8G_#K]R  "R?0  IX8
M )R*  "1C@  AI$  'J3  !ME0  7Y<  %29 0!/F0\ 3IH: $R:)P!*FC(
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M B&O\P,@KO\#(*W_!!^L_P0?K/\$'ZS_!*J+  "=D0  DY<  (><  !ZH@
M;:<  &"K  !5KP  2;$  #ZT   SMP  *KH# "2\#0 BO14 (;T@ "&]*@ @
MO3, '[X] !Z^1P =OE( '+]> !J_;  9OWP &+^. !? H0 6P+8 %,#3 !6^
M\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F   BIX  'VD  !OJ@  8J\
M %:T  !*MP  /KH  #.]   JP   (<0  !G'!0 3RPL $<P2 !',&P 0S"4
M#\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.EP )SJP ",[&  C.Z  (
MS?L "<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4  '&L  !DLP  5[D  $J]
M   ^P   ,L,  "C&   ?R@  %\T  !'1   ,U@4 "-D,  ;9$@ %VAL !-HD
M  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>B   WYT  -^S  #?S@  X.X
M -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U  !8O0  2L(  #W%   Q
MR0  )LP  !W0   4U   #MD   G=   #X0   .,'  #C#0  Y!(  .49  #F
M(@  YRL  .DV  #K0P  [%(  .QB  #M=@  [HP  .ZA  #OMP  []$  ._K
M  #P]@  \/8  /#V (2G  !UKP  9[<  %F_  !+Q@  /,H  "_.   DT@
M&M@  !+<   ,X   !>,   #G    ZP   .L   #M!0  [@L  / 0  #Q%0
M\QX  /0G  #W,P  ^4   /I1  #[8P  _'<  /V-  #]HP  _K8  /[)  #_
MWP  _]\  /_? '>P  !HN0  6L$  $S*   \SP  +M0  "+:   7W@  $.(
M  GF    Z0   .P   #P    ]@   /8   #W    ^    /H'  #[#0  _1$
M /\9  #_(P  _R\  /\^  #_3P  _V(  /]W  #_C0  _Y\  /^N  #_N@
M_[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S /\ 00#_ $X _P!< /\
M: #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *( _P"H /\ K@#_ +4 _P"]
M /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[ /\ ^P#_ /L _P#[ /\
M^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\ /0#_ $L _P!8 /\ 9 #_
M '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D /\ J@#_ +$ _0"Y /L
MPP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S /\ \P#_ /, _P#S /\ \P#_
M /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_!48 _P)3 /\ 7P#_ &L
M_P!U /\ ?@#_ (8 _P". /\ E #^ )L _ "A /H IP#X *X ]0"U /, OP#Q
M ,L \ #? .X [@#L /D ZP#_ .H _P#J ?\ Z0'_ .D!_P#I ?\ Z0'_ /\@
M%P#_'Q0 _QP3 /\7%0#_%AT _Q,H /\0- #_#4$ _PQ. /\)6@#_"&8 _PAP
M /X'>0#\!X$ ^@>) /@'D #V!I8 \P:= /$&HP#O!JH [0:R .H&NP#H_^+_
M_TE#0U]04D]&24Q%  @)!L@ Y@;< .0&[ #B"/H X K_ -X+_P#="_\ W0S_
M -P,_P#<#/\ W S_ /\C$@#_(Q  _R$. /\>$ #_'A@ _QPC /\8+P#_%#L
M_Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.BP#I#I( YPZ9 .8.H #D
M#J< X@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_ ,T2_P',$O\!RQ/_ <H3
M_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1, _R,< /\@* #['#4 ]1I"
M .\83P#J%UH YA9E .,6;@#@%G< WA9_ -P6AP#9%HX UA:5 -06G #2%Z,
MT!>K ,X8M0#,&,$ RQC2 ,<:Z '#&_@!P!O_ ;X<_P&]'/\"O!S_ KP;_P*\
M&_\"O!O_ O\K# #_*P4 _RL# /\M"0#_+ X _RD5 /<F( #N(RT YR$Z .$?
M2 #;'U0 U2!? -$@: #.('$ S"%Y ,HA@0'((8@!QB&/ <0AE@'#(9X!P2*F
M ;\BKP&](KL"O"/* KDCXP*U)/0"LR3_ [$D_P.O)/\#KR3_ ZXD_P.N)/\#
MKB3_ _\O!@#_+P  _S(  /\S @#Y,@@ ]R\. .LK%@#A)R( V"<R - I00#+
M*DX QBI9 ,,J8@' *FL!O2IS ;LJ>@*Y*H("N"J) K8JD *T*I@#LRJA [$J
MJ@.O*[4$KBO$!*PKVP2H+.\$IBS^!:0L_P2C+?\$HBW_!*(L_P2B+/\$HBS_
M!/\R  #_,P  ^3@  .DY  #B.0  WC4' -XN#0#1+QL R3$L ,,S.P"],T@
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M#8@^Q Z&/^ .A#_T#8- _PN#0/\*@D#_"8)!_PB"0?\(@D'_"/\\  #K0P
MW$H  ,Q/  ##4   O$X  +=) 0"Q1@X JD@< *1)+ "@23H FTE% 9A(3@*4
M1U<#DD=>!8]&90:-1FP'BT5S"8E%>PJ'1(,+A42-#(-$EPZ!0Z(/?T.O$'Y#
MP!!\1-H1>T3Q#WI%_PUZ1O\+>D;_"GI&_PEZ1O\)>D;_"?4^  #F2   TT\
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M%&52^Q%F4_\/9E/_#693_PQF4_\,9E/_#.I)  #54P  Q5H  +I?  "P8@
MJ&(  )]?  "66@  CUH0 (I;'@"%6RP @5LX 7U;00)Z6DH#=UE1!'186 9Q
M6%\';U=F"6U7;0MK5G8-:59_#V=5BA%E59<38U6D%&%5M!5@5<@67U7G%6!6
M^A)@5O\/85?_#F%7_PUA5_\,85?_#.=,  #15@  P5X  +9C  "M9@  I&8
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M#E)B_PU28O\-4F+_#=E6  #$8   MV@  *QN  "C<0  FG,  (]Q  !_:P
M>&L% ')K$@!N;!\ :VPL &AL-P%F;$ "8VM( V!K3P1>:E8&7&I=!UEI90E7
M:6T+56EW#5-H@@]0:(\13F>=$TUGK!1+:, 42VC>%$MG]1),9_\/3&?_#DUG
M_PU-9_\-36?_#=):  # 9   LVP  *ER  "@=@  EG<  (IV  !Y<0  <7$
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M"\!I  "R=   IWP  )V!  "2A   AX8  'N'  !NAP  8(<  %6' 0!0B X
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M B:>H0(DGK4"(Y[. B.=[@,CF_X#(IK_!"*9_P0BF?\$(IG_!*R!  "@B
ME8X  (N2  !_E@  <IH  &6=  !9H   3J,  $*D   WI@  +J@% "FI#P H
MJ1@ )ZHB ":J+  EJC4 )*H_ ".J2  BJU, (:M> ""K:@ >JWD ':N+ !NK
MG0 :J[$ &:O* !FJ[ $9J/T!&*?_ ABF_P(8IO\"&*;_ J6)  "9CP  CY0
M (.9  !UG@  :*(  %RF  !0J0  1*P  #FN   OL   )K,  !ZU!@ 9MP\
M&+<7 !>W(0 6MRH %;<T !2X/@ 3N$D $KA4 !*Y8@ 1N7$ $+F#  ^YEP .
MN:P #;G$  VXYP .MOL #K7_  ZT_P .M/\ #K3_ )R0  "2E0  AIL  'F@
M  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@  ';T  !7    0PP8 "\8.
M  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #QF8  L9W  '&BP  QJ
M ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66  ")G   >Z,  &VI  !@
MKP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<   [*   (S@$  = *  #0
M$   T!8  -$>  #2)P  TS$  -0\  #520  UE@  -9I  #6?   UI(  -:G
M  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^I   ;ZL  &&R  !4N0
M1KT  #G!   MQ   (L<  !G+   1S@  #-(   75    VP   -P#  #="@
MW@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9  #H:P  Z8$  .F8  #I
MK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0  8[4  %6\  !'P@  .<8
M "S*   @S@  %M(   _6   (VP   -\   #C    Y0   .<   #H 0  Z@<
M .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X6@  ^6T  /J$  #ZFP
M^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX  $C&   YRP  *]   !_4
M   4V@  #=\   7C    Y@   .D   #M    [P   /$   #S    ]0   /8"
M  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P  _UH  /]N  #_A0  _YH
M /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$(0#_ "< _P P /\ /@#_
M $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D /\
MJ@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L ^P#_ /L _P#[ /\ ^@#_
M /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_ "$ _P M /\ .@#_ $@
M_P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E #_ )H _@"@ /T I@#\
M *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_ /( _P#Q /\ \ #_ /
M_P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T _P H /\ -@#_ $, _P!0
M /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W )8 ]0"< /0 H@#S *@
M\0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8 _P#E /\ Y0#_ .4 _P#E
M /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD /\%, #_ 3X _P!+ /\
M5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$ ZP"7 .D G@#G *0 Y@"L
M .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6 /\ U0'_ -4!_P#5 O\
MU0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.*@#_"S@ _0A% /@&40#T
M!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23 -T%F@#;!:  V 6H -4%
ML0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\ Q0S_ ,4,_P#%#/\ Q0S_
M /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V$3  [PX^ .H.2@#E#58
MX0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.E@#+#IT R@ZE ,@.K@#&
M#[D Q!#( ,(0WP"^$?( NQ+_ +D3_P"W$_\!MA/_ ;83_P&V$_\!MA/_ ?\E
M!@#_(P  _R,  /\D P#_(0H _1T1 /$:&P#H%B< X10U -H30P#3%$\ SA59
M ,L58P#(%FL Q19S ,,7>P#!%X( P!B) +X8D "\&)@ NQF@ +D9J0"W&;0
MM1K" +0:U@"P&^T!K1S\ :L=_P&I'?\!J1W_ :@=_P&H'?\!J!W_ ?\H  #_
M)P  _BH  .\J  #G)P$ YR() .0=$ #9&QT SQTM ,D>/ #$($D OR!3 +PA
M70"Y(64 MR)M +4B= "S(GP L2*# ; BB@&N(I(!K".; :LCI &I(Z\!IR.\
M :8DS@&C).@"H"7Y IXE_P*=)?\"G"7_ ILE_P*;)?\"FR7_ O\L  #_+0
M[3(  .(T  #:,P  TRX# -(E"@#))1< P2<G +LI-@"V*D, LBM. *\K5P"L
M*V  JBMG :@K;P&F*W8!I"M] :,KA *A*XT"GRN5 IXKGP*<*ZH#FBNV YDL
MQP.7+.(#E"WU!)(M_P.1+?\#D"[_ Y M_P.0+?\#D"W_ _\P  #R,P  Y#H
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M2P  M4D  *]#  "I/@L HC\7 )U )@"8030 E$$_ )%!20&.05$!BT!9 HE
M8 .'0&<#A3]M!(,_=06!/WT&?SZ'!WT^D0A[/IP)>CZI"7@^N IW/\T*=3_J
M"G1 _ AT0/\'=$#_!G- _P9S0/\&<T#_!O$[  #?10  S$P  +]/  "V4
MKD\  *=*  "@1 < FD44 )5&(@"01C  C$<\ (E&10&&1DX!@T95 H%%7 -^
M16,$?$1J!'I$<05Y1'D&=T2""'5#C0ES0YD*<4.F"W!#M0QN1,D,;43G#&U%
M^@IL1?\(;$7_!VQ%_P=L1?\';$7_!^P_  #820  QU   +M4  "Q50  J50
M *%0  "92@( DDD1 (U*'P")2RP A4PX ()+0@%_2TH!?$I2 GE*6 -W2E\$
M=4EF!7-);09Q278';TA_"&U(B@EL2)8+:DBC#&A(L@UG2,4-9DGD#69)^ MF
M2?\)9DK_"&9)_P=F2?\'9DG_!^A#  #230  PE,  +=8  "M60  I%@  )Q5
M  "33@  C$X. (=/&P""3RD ?U U 'M0/P%X3T<!=D]/ G-.50-Q3EP$;TUC
M!6U-:@9K37(':4U\"&=,APIE3),+8TR@#6),KPYA3<(.8$WA#F!-]@Q@3O\*
M8$[_"6!._PA@3O\(8$[_".-'  #-4   OE<  +-;  "J70  H5T  )A:  "-
M4P  AE(, (!3& !\4R4 >50Q '54/ !S4T0!<%-, FU24P)K4ED#:5)@!&=1
M: 9E47 '8U%Y"&%1A I@4)$,7E">#5Q0K0Y;4< .6E'>#UI1]0Q:4O\*6U+_
M"5M1_PA;4?\(6U'_"-]*  #)4P  NUH  +!?  "F80  G6$  )1>  "(5P
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M",I8  "Z8@  KFD  *-N  ":<0  D'(  (1Q  !T:P  :6D  &-I"P!?:14
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M!C=XH0<U>+,'-'C+!S1WZP<T=OT'-'7_!S5U_P8U=/\&-73_!KEH  "M<0
MHGD  )A^  "-@   @H$  ':"  !I@0  6X$  %&!  !(@ H 18$3 $.!'@!"
M@BD 08(R $"".P ^@D, /8)+ #N"4P$Y@EP!-X)F C6"<0,S@G\#,8&.!#"!
MGP0N@;$%+8'(!2V!Z00M?_P%+7[_!2U]_P4M??\%+7W_!;-N  "H>   G7\
M )*#  "(A@  ?8<  '"(  !CB0  58H  $N*  !!B@( .XL. #F+%P XC"(
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M !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5C   C)$  '^5  !QF@
M9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN   2L D $+$0 !"Q&  .
ML2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X  >QBP %L:  !+"U  2P
MT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP  @I@  '6=  !GH@  6J<
M $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -O , ![X,  .]$@ !O1D
M +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_@   OI4  +ZJ  "^P@
MO>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*   &JF  !<JP  3[   $*S
M   UM@  *K@  ""[   7O@  $,$   O$   $QP   ,D'  #)#0  R1(  ,H9
M  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@  SX<  ,^=  #/LP  S\X
M ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO  !0M0  0KD  #6\   I
MOP  'L(  !7&   .R0  ",P   #0    TP   -4   #6!@  V P  -D1  #;
M%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<  .2.  #DI   Y+H  .74
M  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#O@  -<(  "C&   <R0
M$\T   S1   $U0   -H   #>    X0   .(   #D    Y0,  .<)  #I#@
MZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\  #VDP  ]JD  />\  #W
MS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP  )\P  !O0   1U0  "ML
M  #?    X@   .4   #I    [    .T   #P    \0   /,   #U!   ]PH
M /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_@   _Y8  /^H  #_M@
M_[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N /\ / #_ $H _P!6 /\
M8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *P _P"T
M /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y /\ ^@#_ /H _P#Z /\
M^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\ -P#_ $4 _P!2 /\ 7@#_
M &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"< /P H0#[ *@ ^0"O /@
MN #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\ [P#_ .\ _P#N /\ [@#_
M /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_ $  _P!- /\ 60#_ &0
M_0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$ G0#P *, [@"J .P LP#J
M +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_ .$ _P#@ /\ X #_ /\4
M$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H _P!' /D 4P#U %X \@!H
M /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C )\ X0"F -\ K@#< +@
MV@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X _P#. /\ S@#_ /\7# #_
M% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !! .T 30#I %@ Y@!B .,
M:@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H SP"A ,T J@#+ +, R0"_
M ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_ _\ OP/_ /\;!@#_%P
M_Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #1@#< U$ U@1; -($9 #/
M!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:= +\&I@"]!K  NP>\ +D(
MS0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\ KP[_ /\>  #_&P  _QL
M /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+#4H QPU5 ,0.7@#!#F8
MOPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0HP"P$:T KQ&Z *T1R@"J
M$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_ /\B  #_(   \",  .8D
M  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0 N1=. +475P"S&&  L!AG
M *X8;@"L&74 JQE\ *D9A "H&HP IAJ4 *0:G@"C&Z@ H1NT )\<Q0">'-\
MFAWS 9@>_P&7'O\!EA__ 94?_P&5'_\!E1__ ?\F  #T)P  YBT  -HO  #/
M+0  RB<  ,<?" #!'!, NAXB +0?,0"O(#T JR%( *@B4@"F(EH HR-B *$C
M:0"@(V\ GB-W )PC?@";(X8 F22/ 9<DF0&6)*,!E"2P 9(EOP&1)=8!CB;O
M 8PG_P*+)_\"BB?_ HDG_P*))_\!B2?_ ?HI  #L,   W38  ,TX  #$-P
MOC(  +HK @"U)0X KB<= *@I*P"D*C@ H"I# )TK3 ":*U4 F"M< )8K8P"4
M*VH!DBMQ 9 L> &/+($!C2R* 8LLE **+)\"B"RK H8LN@*%+<X#@R[J X$N
M_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N  #D-P  TCT  ,4_  "[/P  M#P
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M!&9 _P1F/_\$9C__!.4]  #/1@  OTP  +1/  "J4   HD\  )E*  "11
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M!=!+  "_5   LEH  *=>  "=8   E&   (E=  !\5P  <E0  &Q3#@!H5!D
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M!D->H =!7K$'0%[(!T!>Z = 7?P&05W_!4%=_P5!7/\%05S_!<-6  "T7P
MJ&8  )YJ  "5;0  BFT  ']L  !O9P  9&0  %MB!0!68A  5&(; %)C)0!0
M8R\ 3F0X $UD0 !+9$@ 2F1/ 4AD5P%&9%\"161H D-D<P-!8W\$/V..!3UC
MG@8\8[ &.V3&!CMDY@8[8_H%.V+_!3MB_P4\8?\$/&'_!+Y;  "P8P  I6H
M )MO  "1<@  AG(  'MQ  !L;0  8&L  %5I  !/: T 36D7 $MI(0!):BL
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M B9[X0(F>O<")GC_ B9X_P(G=_\")W?_ JYL  "C=@  F7P  (Y_  "$@@
M>(,  &R$  !?A   480  $>$   \A   ,X0) #"$$0 OA!H +80D "R%+0 K
MA34 *H4^ "F%1P HAE  )X9: ":&9@ DAG, (X:# "&&E0 @AJ<!'H:\ 1Z&
MW@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0  DX(  (F%  !^B   <8H
M &6+  !8C   3(T  $".   VC@  +(\  "60#  CD!, (I < "&0)0 @D2X
M'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2D  5DJ0 %)&Y !.1V  3
MC_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@  (2,  !WCP  :9$  %V3
M  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P %9T3 !2=&P 3G20 $ITM
M !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +G9X "IVR  F=S  )G.P
M"IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2  !ME@  8)D  %2<  !(
MGP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-  BJ$P 'JAL !JHD  6J
M+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4  *FJ  "IP0  J.0  *CV
M  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !CG@  5J(  $JF   ]J
M,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V#P  MA4  +<=  "W)0
MMR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@  "WM@  M],  +;O  "V
M_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP  2ZP  #ZO   QL0  )K,
M !RV   3N   #;L   :^    P0   ,($  #""P  PQ   ,05  #$'   Q20
M ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(J@  R,,  ,CD  #(]
MR/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4  #&X   EN@  &KT  !'
M   +PP   \<   #*    S0   ,X   #/ P  T D  -$.  #3$@  U1D  -<B
M  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G   W[(  -[+  #>Y@  W_0
M -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!   9Q0  $,@   G,
MSP   -,   #9    W    -T   #?    X0   .(%  #D"P  YA   .@6  #J
M(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(  /.V  #SR0  \^$  //A
M &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .T   !M4   #:    W@
M .(   #F    Z0   .H   #L    [@   /    #R    ] 8  /8,  #Y$@
M_!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C  #_LP  _\$  /_! /\'
M&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $< _P!4 /\ 7P#_ &H _P!S
M /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_ *@ _P"O /\ N #_ ,0
M_@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8 _P#S /\ \0#_ /\+%0#_
M!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/ /\ 6P#_ &4 _P!N /\
M=@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *, ]P"K /8 LP#T +X \P#,
M /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L /\ ZP#_ /\-$0#_"1
M_P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\ 50#] &  ^@!I /@ <0#V
M 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F .D K@#G +@ Y0#% .,
MV@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\ W0#_ /\/#0#_# L _P,)
M /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R %H [@!C .P :P#I ',
MYP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D J0#5 +( T@"^ -  S@#.
M .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_ /\1" #_#0( _P<  /\%
M" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0 X != -T 90#9 &T U0!S
M -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$ *T P@"X ,  QP"] -\
MO #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4  #_#P  _PT  /\,  #_
M!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7 ,H 7P#' &8 Q0!M ,,
M= #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@ LP"S +$ P@"O -@ K@+M
M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_$@  ]Q(  .P1  #F#@
MY08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&6 "Y!F  MP=G +4';@"S
M!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP *4+OP"C#-0 H0WM )\.
M_@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0  ZAX  -\>  #5&@  T!,"
M ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L$%H JA!A *@1: "F$6\
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M 7@H_P%X*/\!>"C_ >\K  #=,P  RCD  +X[  "T.@  K38  *8O  "A* <
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M M8_  ##1P  M4P  *I0  "@4   ET\  (Y+  "$10  >D & '4_$0!Q0!P
M;4 H &M!,@!I03L 9T%" &5!20!C05  84%7 &!!7@%>068!74)O EM">@):
M0H8#6$*4 U="HP150[,$5$/)!%1#Z0130_T#4T/_ U1#_P-40_\"5$/_ M!"
M  "_2@  LE   *=3  "=5   E%,  (I0  !_2@  =44" &Y##@!K1!D 9T4D
M &5%+@!B13< 844_ %]%1@!=14T 6T54 %I&6P%91F,!5T9L E9&=P)41H,#
M4T:1 U%&H0101[$$3T?'!$Y'YP1.1_L$3D?_ TY'_P-/1_\#3T?_ \Q&  "[
M3@  KU0  *17  ":6   D5<  (94  ![3@  <$H  &E(#0!E2!8 8DDA %])
M*P!=230 6TD\ %E)0P!724H 5DE2 %5*60%42F$!4DIJ 5%*=0)/2H$#3DJ/
M TQ+GP1+2[ $2DO%!$E+Y@1)2_H$24O_ TI+_P-*2_\#2DO_ \A)  "X40
MK%<  *%;  "87   CEP  (-9  !V4P  :TX  &1-"@!?3!, 7$T> %I-* !8
M33$ 5DTZ %1-00!33D@ 4DY/ %!.5P%/3E\!34YH 4Q.<P)*3W\"24^- T=/
MG01&3ZX$14_#!$10Y 1$3_D$14__ T5/_P-%3O\#14[_ \1,  "U50  J5L
M )]>  "58   BV   (!>  !R5P  9U,  %Y1!P!941$ 5U$; %11)0!24B\
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M S1?W0,T7O4#-5W_ C5=_P(U7/\"-5S_ KA9  "J80  H&<  )9L  ",;@
M@6X  '9L  !G:0  7&8  %%D  !(8@D 1&(1 $)B&P!!8R0 /V,M #YC-0 ]
M9#T /&1% #MD30 Y9%4 .&1? #9D:0$U9'8!,V2% 3%EE0(P9:<"+V6[ BYE
MV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->  "G9@  G&T  )-Q  "(<P  ?7,
M ')R  !D<   6&X  $UL  !":@, /&D. #IJ%@ Y:B  .&HH #9K,0 U:SD
M-&M! #-L20 R;%( ,6Q< "]L9@ N;', +&R" 2ILDP$I;*4!*&RY 2=MU@$G
M:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;   F7,  (YV  "$>   >7D  &UX
M  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P<QH +W,C "YS*P M=#0 +'0\
M "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")UD  A=:( ('6W !]UT@ ?=/$
M'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\  " ?@  ='\  &=_  !:
M?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T< "-^)0 B?BT (7XV "%^
M/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\ %G^S !5_S@ 5?N\ %GS_
M !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![A   ;88  &"'  !4AP
M2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)'0 7BB8 %HHN !6*-P 4
MBD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO  R*R  ,B>H #8?\  Z'
M_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP  98T  %F/  !,D   09(
M #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,EQT #)<F  N7+P *ESD
M"9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5O@  E.   )3T  "3_P !
MDO\  9+_ )B"  ".B   A8P  '>/  !JD@  794  %"8  !$F@  .)L  "R<
M   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<  *,?  "C)P  HS$  *0\
M  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@  H=(  *'P  "@^P  H/\
M *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A   YHP  +:0  ".F   9
MJ   $:H   RL   %K@   *\'  "O#0  KQ$  + 8  "P(   L2@  +$R  "R
M/@  LDP  +);  "R;   LH$  +&7  "QK   L,8  +#H  "O]P  K_\  *__
M (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   MK   (JX  !BP   0LP
M"K4   *X    NP   +L   "\!P  O T  +T1  "^%@  OQX  , G  #!,@
MPD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7  #"[P  POH  ,'^ (&7
M  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@  %KD   Z[   'O@   ,$
M  #%    QP   ,@   #)    R@4  ,L+  #-#P  SA0  - <  #3)@  UC(
M -A!  #84P  V68  -E\  #9E   V:L  -G#  #9X0  V?   -GT ':?  !G
MI@  6:P  $NR   \MP  +KH  "&]   5P   #<0   7'    R@   ,X   #2
M    U0   -8   #9    VP   -T   #?!P  X0P  .,1  #F&0  Z20  .PR
M  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@  []T  ._D &JH  !;KP
M3+8  #Z\   OP   (,0  !3(   ,S    M    #4    V0   -X   #B
MY0   .8   #H    Z0   .P   #N    \ (  /()  #U#P  ^!<  /PC  #_
M,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\   /_& /\ %0#_ !0 _P 4
M /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_ &8 _P!O /\ =P#_ 'X
M_P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\ M #^ +\ _0#. /L Y@#Y
M /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_ /\#$@#_ !  _P 0 /\
M$0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$ _P!J /\ <@#_ 'D _0"
M /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R +D \ #& .X W@#M /
MZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'#@#_  T _P + /\ # #_
M !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E /4 ; #S '0 \0!Z .\
M@0#N (< [ "- .H DP#I )H YP"A .8 J0#C +, X0"_ -\ T #= .D V@#Y
M -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_ 04 _P # /\ "0#_ !
M_P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .< 9P#D &X X@!T .  >P#>
M ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X ,H QP#( .  Q@#S ,4
M_P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P  _P   /\  P#_  L \P 2
M .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1 &@ S@!N ,P = #* 'L
MR "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D P "W -0 M0#L +, ^P"S
M /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,  /<   #T  , YP - .
M& #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$ O@!H +P ;@"Z '0 N ![
M +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H ,L I@#F *4 ]P"D /\
MHP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-  #?"0  V@ & -  $0#)
M !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B *T : "K &X J0!U *@
M>P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8 F07B )@&] "6"/\ E0G_
M )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,%0  QQ   ,0'"@"] Q0
MMP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *8@">"VD G MO )L+=@"9
M#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B (L0]@")$/\ B!'_ (<1
M_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@  N1P  +04 0"Q#0X J@X9
M *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1$F, D!-I (X3< ",$W@
MBQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8] !]&?\ ?!G_ 'P9_P![
M&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<  *@@  "C%P@ GA83 )D7
M(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X A!QD ((<:P" '', ?QU\
M 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4 '0A\ !R(?\ <2+_ '$A_P!Q(?\
M<2'_ .@H  #2,   PC4  +<W  "M-0  I3$  )XK  "8(P( DAX0 (T@&P")
M(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![)%D >21? '<D9@!V)6X ="5W ',E
M@0!Q)HT ;R:9 &XFIP!M)[@ ;"?. 6HH[0%I*?\!:"G_ 6@I_P%H*/\!:"C_
M >$N  #+-@  O#L  +$]  "G/0  GSD  )<S  "/+0  B"<, (,G%@!_*"(
M?"DM 'DJ-P!W*C\ =2I' ',K3@!Q*U0 <"M; &XK8@!L*VH :RQR &DL?0!H
M+(D 9BV6 64MI %D+K0!8R[* 6$OZ0%@+_T!8"__ 6 O_P%@+_\!8"[_ =HT
M  #%/   MT$  *Q#  "B0P  F4   ) Z  "(-   @"X( 'HM$@!W+AX <R\I
M '$P,P!O,#L ;3!# &LQ2@!I,5$ 9S%7 &8Q7@!D,68 8S)O &$R>0!@,H4!
M7S*2 5TSH0%<,[$!6S3& 5HTY@%9-?L!637_ 5DT_P%9-/\!633_ =(X  #
M0   LT4  *A(  ">2   E48  (M   "".P  >34$ ',S$ !O-!H ;#0E &DU
M+P!G-3< 938_ &,V1@!B-DT 8#94 %\V6P!=-V, 7#=K %LW=@%9-X(!6#B/
M 58XG@%5.*\"5#G# E,YY )3.OD!4SG_ 5(Y_P%3.?\!4SG_ <T\  "\1
MKTD  *1,  ":3   D4L  (=&  !]0   <SL  &PX#0!H.1< 93DB &,Z*P!@
M.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7.V  5CMH %4\<P%3/'\!4CR- 5 ]
MG %//:P"3C[! DT^X0)-/O@"33[_ 4T^_P%-/?\!33W_ <E   "X2   K$T
M *%0  "740  CD\  (1+  !Y10  ;D   &8]"P!B/10 7ST> %P^* !:/C$
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M CY+V (^2O,"/DK_ CY)_P$_2?\!/TG_ ;U*  "O4@  HU@  )E;  "070
MAEP  'M9  !M4P  8D\  %=, 0!12@T 3DH5 $Q+'P!*2R@ 24LP $=+. !&
M3#\ 14Q& $1,3@!#358 0DU? $!-:@ _378!/4Z$ 3Q.E $[3J4!.4^Y CE/
MU (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.  "L5@  H5L  )=?  "-80  @V$
M 'A>  !I6   7U8  %12  !,3PL 24\2 $=0' !%4"4 0U M $)0-0!!43P
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M 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#;P  >6\  &YN  !@:P
M5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD*0 M9#$ +&0Y "ME0@ J
M94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q !]FR0 ?9NL (&7^ "!D
M_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0  =74  &ET  !<<@  3W$
M $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D;2P (VTT ")M/0 A;D8
M(&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9OQ@ 6;ND %VW\ !AL_P 8
M:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L  &1[  !7>@  2GD  #]X
M   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8 &7<N !AW-P 7>$  %7A*
M !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .=^8 #G;Z  ]U_P 0=?\
M$'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"  !0@@  1((  #B"   N
M@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G  Z#,  -@SD #8-$  R#
M4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L !('R  6 _P &?_\ !G__
M )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)BP  /8P  #&,   FC
M'8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/*0  CS(  ) ]  "020
MCU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN  ",^P  B_\  (O_ )2
M  "+A0  @HD  '2,  !FCP  69$  $R3  ! E0  -)8  "B6   >EP  %9@
M  ^:   *FP   IP)  "<#@  G!,  )P:  "<(@  G2L  )TU  "=0   G4X
M )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9^0  F?\  )C_ (Z(  "&
MC   >)   &J4  !<EP  3YH  $*=   VG@  *9\  !^A   5H@  #J0   BF
M    J    *D$  "I"@  J0X  *D3  "J&@  JB(  *LK  "L-@  K$0  *Q3
M  "L8P  K'<  *N.  "KI   J[P  *K>  "I]   J?T  *G_ (F.  ![DP
M;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K   -K@  !K    "R
MM0   +4   "U P  M@D  +<.  "X$@  N!D  +HA  "[*P  O#@  +U'  "]
M6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<  +O^ 'Z5  !PFP  8J
M %.E  !&J@  .*T  "JO   >L0  $[0   RW   #N0   +P   "_    P@
M ,(   ##    Q    ,8&  #'#   R!   ,H6  #,(   SRL  - Z  #12P
MT5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V '.=  !DHP  5JD  $>O
M   YLP  *K8  !VY   2O   "K\   ##    Q@   ,D   #-    SP   -
M  #2    U    -8   #9 @  VP@  -X.  #A$P  Y!T  .@J  #H/   Z4\
M .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F  !8K   2;,  #NY   K
MO   '<   !'$   )R    ,P   #/    TP   -D   #=    X    .$   #C
M    Y0   .<   #J    [    .X$  #Q"P  ]1(  /@<  #[*P  _3X  /Y3
M  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_ !  _P 1 /\ $P#_ !D
M_P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\ <P#_ 'H _P"! /\ AP#_
M (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#) /D X0#X /, ]P#_ /8
M_P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T _P - /\ #@#_ !0 _P A
M /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\ '4 ^P![ /D @@#X (@
M]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L U0#J .P Z #\ .< _P#E
M /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P & /\ "0#_ !  _P < /\
M*0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\ [0!V .P ? #J (( Z "(
M .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7 .0 U #V -$ _P#0 /\
MT #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\ ! #_  T ^@ 6 /8 (P#S
M #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O -H =@#8 'P U "" -(
MB #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@ P #O +\ _@"^ /\ O0#_
M +P _P"\ /\ O #_ /\"  #_    _P   /\   #T  < [0 1 .@ ' #C "D
MWP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8 ;P## '4 P0![ +\ @@"^
M (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G *X ^ "L /\ JP#_ *P
M_P"L /\ JP#_ /\$  #_    ]@   .X   #G    WP , -8 %0#/ "( R@ N
M ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S &\ L0!U *\ >P"M ((
MJP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X \@"= /\ G #_ )P _P";
M /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ % ,8 $ #  !H NP G +<
M,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@ H@!O *$ =0"? 'P G0"$
M )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/ /P C@#_ (T!_P"- ?\
MC0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H""@"T !( K@ > *H *@"F
M #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I ),#;P"1!'8 D 1_ (X%
MB ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P @0S_ ( ,_P" #/\ @ S_
M /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H"0T H@<6 )T)(P"9"BX
ME0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-:@"%#G$ @PYZ ((.A "
M#H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_ '03_P!T$_\ =!/_ .@>
M  #3)@  PRH  +@J  "N*   IR,  * <  ";$P, E@\0 ) 0&P",$2< B1(R
M (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y%6P =Q5T '86?@!T%HH
M<A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;_P!J&_\ :AO_ . F  #*
M+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<, (48%@"!&2( ?AHL 'L;
M-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6< ;1YP &L>>@!J'H4 :!^2
M &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A(O\ 82+_ -<L  ##-
MMC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@$@!W(1T ="(G '$B,0!O
M(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K &(E=0!A)8$ 7R:. %XF
MG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\ 62C_ ,\R  "^.0  L3T
M *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N)QD :R@C &DH+ !F*34
M92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK<@!9+'T 6"R+ %8MF@!5
M+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_ ,HV  "Z/0  K4(  *)$
M  "81   CT$  (4\  ![-P  <C$  &LL# !G+14 9"T? &$N* !?+C$ 72XY
M %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2,7H 43&( % REP!.,J@
M33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z  "V0@  J48  )Y)  "5
M20  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(< %HR)0!8,RT 5C,U %4S
M/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G< 2S:% $HWE0!(-Z8 1SBX
M 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R10  IDH  )Q-  "230
MB$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W(@!2-RH 4#<R $\X.0!-
M.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N# $0[DP!#/*0!0CRV 4$]
MT %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20  HTX  )E0  "/40  A5
M 'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-.R< 2SLO $D\-@!'/#T
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M #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(70  ?ET  '-:  !E50
M6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*+@ Y2C4 .$L] #=+1  V
M2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO "Q.QP L3ND +$W] "U-
M_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@  >V$  '!?  !B6P  6%@
M $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S4#( ,E Z #%00@ P44H
M+E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93Q0 F4^< )E/\ "=2_P G
M4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8  &UE  !@80  55X  $I;
M   _6   -58( #%5$  P5A< +E8? "U6)P L5B\ *U<V "I7/@ I5T< *%=0
M "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?6>4 'UCZ "!8_P @5_\
M(5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK  !=:   464  $9C   [
M8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR ")>.@ A7D, (%], !]?
M5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.( %U_Y !A>_P 97O\ &5W_
M *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8;@  3&P  $%K   V:0
M+6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG-0 89SX %V=( !9G4P 5
M:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W !!F_P 19?\ $67_ )]G
M  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@  1G0  #MS   Q<@  )W$
M !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0<3@ #G%"  YQ3@ -<5L
M#'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO_P );O\ "6[_ )MO  "1
M=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T  #5]   J?   (7P  !A\
M   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#( !'P]  -\2  !?%4  'QC
M  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@  >?\  'C_ )9W  ",?
M@X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'   CAP  &H<  !*'   -
MB $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV  ")0@  B$X  (A=  "(
M;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\  (3_ )!^  "'@P  ?H<
M '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :D@  $I,   V4   &E0
M )8&  "6#   E1   )85  "6'0  EB0  )8N  "6.0  ED8  )95  "690
MEG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_ (N&  "#B@  =8T  &>0
M  !9E   3)<  #^9   RF@  )IL  !N<   2G0  #)\   2@    H@   *,!
M  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P  ICP  *9+  "F6P  IFX
M *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-  !XD0  :I4  %R9  !.
MG0  0:   #.B   FHP  &Z4  !&G   *J0   :L   "M    KP   +    "P
M    L 4  +$+  "R#P  LQ0  +0;  "U)   MS   +<_  "W4   MV(  +=X
M  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !MF   7YT  %"B  !"I@
M-*D  ":K   :K0  $*\   FR    M    +<   "Z    O    +T   "^
MO@   , "  #!"   P@T  ,02  #&&0  R20  ,HR  #+0P  RU4  ,QJ  #,
M@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0  4J8  $2K   VL   )[(
M !JU   0N   ![L   "^    P0   ,0   #(    RP   ,L   #-    S@
M -    #2    U0,  -@*  #;$   WA@  .(D  #C-0  Y$@  .5<  #F<P
MYHT  .:E  #FO   YM,  .?G &.D  !5J@  1K   #BU   HN0  &KP   _
M   %Q    ,<   #+    SP   -0   #8    W    -T   #?    X0   .,
M  #E    Z    .H   #M!@  \0X  /46  #X)0  ^3@  /E-  #Z8P  ^WP
M /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\ $ #_ !8 _P C /\ , #_
M #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\ /\ @@#_ (D _P"/ /\
ME0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /  ] #_ /, _P#R /\ [ #_
M .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_ !( _P > /\ *P#_ #@
M_P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /< ?0#V (, ] ") /( CP#Q
M )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z ., _P#B /\ X #_ -4
M_P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X _P 9 /\ )0#] #( ^P ^
M /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F 'T Y "# .( B0#@ )
MW@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P _P#+ /\ R@#_ ,@ _P#"
M /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3 /$ ( #M "P Z@ X .<
M0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8 S@!\ ,P @P#* (D R "1
M ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W /\ MP#_ +8 _P"T /\
ML0#_ /\   #_    _P   /8   #N  4 YP / .$ &0#; "4 U0 Q -( / #.
M $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V +D ? "X (, M@"* +,
MDP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\ I0#_ *0 _P"D /\ I #_
M /\   #\    \0   .@   #@    U  + ,P $P#' !\ P@ J +\ -0"\ #\
MN !( +4 4 "S %< L !> *X 9 "L &D JP!O *D =0"G 'P I0"$ *, C "A
M )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_ )4 _P"5 /\ E0#_ /P!
M  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !< LP C *\ +@"K #@ J0!!
M *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8 '8 E@!] )0 A@"2 )
MD "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8 _P"& /\ A@#_ /0,  #D
M$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ; *$ )@"> #$ F@ Z )@
M0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '  B !W (8 @ "$ (L @@"6
M (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X!O\ > ;_ .H3  #6&@
MQAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4 'P"1 BD C0,S (L$/ "(
M!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR 'H(? !X"88 =@F2 '0*
MH !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\ ;0[_ .$<  #+(P  O"8
M +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$#"( @0TL 'X--0!\#CT
M>@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0=P!L$(( :Q"/ &D1G0!H
M$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_ -8D  ##*@  M2X  *HO
M  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP =A,G ',4, !Q%#@ ;Q4_
M &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B%WX 81B+ %\8F0!>&:D
M7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ  "],0  KS4  *0V  ";
M-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB &D;*P!G&S, 91P[ &0<
M00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD 6!^' %8@E@!5(*8 5"&X
M %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X-@  JSH  * \  "6.P
MC3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A)@!?(B\ 72(V %LB/0!:
M(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6# $\FDP!.)Z, 3">U $PH
MS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P  IS\  )Q!  "20   B3X
M '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7)RL 52@R %0H.0!2*$
M42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@KD !'+*$ 1BVS $4MRP!%
M+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,  )E%  "/10  A4,  'L^
M  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"< 3RPO $TM-@!,+3P 2BU#
M $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!,9X 0#*Q #\RR  _,^H
M/S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)  ",20  @T@  'A$  !M
M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K $<Q,@!&,3D 1#%  $,R
M1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP .S:O #HWQ@ Y-^@ .3?\
M #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*3@  @$P  '5(  !J0P
M8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U+P! -38 /S8] #XV10 ]
M-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM #4[Q  T.^8 -#O[ #4[
M_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@  ?E   '--  !G2   7$0
M %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [.C0 .CH[ #D[0@ X.TH
M-SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_P@ O/^0 +S_Z # __P P
M/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4  '%2  !D3   64D  $]%
M  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$ -3\X #0_0  S0$@ ,D!1
M #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I1.( *D/Y "I#_P K0O\
M*T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7  !A4@  5TX  $U+  !#
M1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V "]%/0 M148 +$5/ "M&
M60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.  )$CW "5'_P E1_\ )D?_
M *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?6   554  $M1  ! 30
M-4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*.P G2T, )DM, "5+5@ D
M3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV !Y,_P ?3/\ ($O_ *=3
M  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@  4EL  $=8   \50  ,E("
M "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A44  (%%) !Y24P =4E\
M'%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2_P 84?\ &5'_ *-9  "8
M8   CV4  (5H  ![:0  <6D  &9G  !99   36$  $)?   X7   +EH  "58
M"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P &%A% !994  565L %%EI
M !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 16/\ $5C_ )]?  "59@
MC&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF   S90  *6,  "!A 0 8
M8 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%   ]A2P .85@ #6%F  QB
M=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\ "U__ )MF  "2;0  B'$
M 'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M;@  )&P  !MK   3:P0
M#FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K1P %:U, !&MA  )K<0
M:H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_ )=M  "-<P  A'<  'MZ
M  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P  '78  !5V   /=@( "78*
M  1V#P  =A4  '8<  !V)   =2P  '4V  !U00  =4X  '5<  !U;   =7X
M '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U  ")>@  @'X  ':   !I
M@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$  !""   *@@   H,'  ""
M#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<  ()5  "!90  @7@  (&-
M  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$@0  >X0  &Z&  !@B
M4HH  $6+   YC   +(P  "&,   7C   $(T   F.   "CP   ) #  "/"0
MCPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-  "070  CW   (^%  ".
MG   CK,  (W0  ",\   B_X  (O_ (B$  " B   <HL  &2-  !6D   2),
M #N5   NE@  (I8  !>7   /F   ")D   ";    G0   )T   "= P  G0D
M )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@5   H&8  )][  ">DP
MGJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(  %F6  !+F0  /9P  #">
M   CGP  %Z    ZB   'I    *8   "H    J@   *H   "J    JP$  *L'
M  "L#   K1   *X6  "O'@  L2D  +$X  "Q2   L5H  +%O  "QB   L:
M +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?   _HP  ,:8  ".G   7
MJ0  #JL   6N    L    +(   "U    MP   +<   "X    N0   +H   "\
M P  O0D  +X.  # %   PQX  ,4K  #%/   QDX  ,9B  #&>@  QI0  ,:M
M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   RK   )*\  !:Q   -M
M [<   "Z    O0   ,    #$    Q@   ,8   #(    R0   ,L   #,
MS@   - &  #3#0  V!,  -P>  #>+0  WT   .!4  #A:P  X84  .&?  #A
MMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0  %[D   V\   !OP   ,,
M  #'    R@   ,\   #3    U@   -<   #:    W    -\   #A    XP
M .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W7   ^'0  /B/  #YI@
M^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ? /\ + #_ #D _P!% /\
M4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0 _@"* /T D #\ )< ^@">
M /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P /\ Y@#_ -P _P#2 /\
MS0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\ )P#_ #, _P _ /\ 2@#^
M %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$ .\ B@#M )$ [ "9 .H
MH0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\ V0#_ ,P _P#% /\ P0#_
M /\   #_    _P   /\  0#_  T _P 6 /P (@#Y "X ]@ Y /, 10#O $X
M[ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T A #; (L V "2 -4 FP#2
M *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_ +X _P"X /\ M0#_ /\
M  #_    _P   /X   #W  D \0 1 .L ' #G "@ Y  S .$ /@#= $@ V !1
M -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$ (0 P@", ,  E "^ )X
MNP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +  _P"L /\ J0#_ /\   #_
M    ^@   /$   #H  , X  - -@ %@#1 "( S0 M ,H -P#& $$ P@!* +\
M4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T KP"% *T C0"K )< J0"A
M *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P"> /\ G #_ /\   #W
MZP   .$   #6    RP ) ,4 $0"_ !L NP F +< ,0"T #H L0!# *X 2P"K
M %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^ )P A@": )  F "; )8
MIP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\ C0#_ /@   #I @  VP,
M ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D #0 H0 \ )X 1 "< $L
MF@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T @ "+ (H B0"5 (< H0"%
M *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_ .X*  #<#@  RA   +X.
M  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P DP U )  /@". $4 C !+
M (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!] (0 >P"/ 'D G !W *H
M=0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1  #-%P  OQD  +,9  "J
M%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O (, -P"  #X ?@!% 'T
M2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\ ;@*+ &P#F !K Z8 :02W
M &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$(   MB,  *LC  "A(
MF1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(, !T"#@ <@D_ ' )10!O
M"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR' &(,E0!@#:0 7PVV %X-
MS@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*   KRL  *0K  ":*0  DB0
M (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I#S( 9Q Y &400 !D$$8
M8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2D@!6$Z( 51.T %03RP!3
M%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(  )\R  "5,0  C"T  (,G
M  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T 714T %P5.P!;%D( 619(
M %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.&I\ 3!JP $L;QP!+&^D
M2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX  "0-P  AS0  'TO  !T
M*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP %0<-P!2'#T 41Q$ $\=
M2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P 12&N $0AQ !#(N8 0R+\
M $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-/0  @SH  'DU  !O,
M9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA,P!+(CH 22)  $@B1P!'
M(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K #TGP0 ])^, /2CZ #TH
M_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@  @#\  '8[  !L-@  8C
M %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$)C8 0R8] $(G1 !!)TL
M/RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<LOP W+.  -RSX #<L_P W
M+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40  '-   !H.P  7S8  %4Q
M  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S, /2LY #PK00 [+$@ .BQ1
M #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q,=X ,3'W #(Q_P R,/\
M,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%  !E0   6SL  %(V  !(
M,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -#%/ #,Q
M60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L +#7U "TU_P M-/\ +C3_
M *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B10  6$   $X\  !%-P
M/3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T/  P-40 +S5, "XV5@ M
M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT "@Y_P H./\ *3C_ *M%
M  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20  5D8  $Q"  !"/0  .#@(
M #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K.D$ *CI* "D[5  H.U\
M)SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]_P C/?\ (SS_ *A)  "=
M3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP  $I(  ! 1   -D % "\]
M#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\ )#]( "- 4@ B0%T (4%J
M "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =0?\ 'D'_ *5-  ":4P
MD%@  (9;  !]7   <EL  &=8  !;5   45(  $A.   ]2@  ,T<  "I#"P F
M0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5% !U%3P <1EH &T9H !E&
M>  81XH %T>> !9'LP 42,X %4?O !9'_P 71O\ %T;_ *)2  "76   C5T
M (1@  !Z80  <&   &5>  !96@  3U@  $14   Y40  +TX  "9+!@ @2@X
M'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,3  53%< %$QE !--=0 2
M38@ $4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_ )Y7  "470  BV(  (%E
M  !W9@  ;68  &-D  !680  2EX  #];   U6   *U8  ")4 0 :4@H %E(0
M !52%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /4U0 #E-B  U4<@ ,5(0
M"U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=  "19   B&@  'YK  !T
M;   :VP  %]J  !29P  160  #IB   P8   )EX  !U=   56P4 $%H,  Y:
M$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$ !EM>  1;;0 #6X   5N4
M  !;J   6\   %KB  !:]@ !6O\  EG_ )=D  ".:P  A&X  'MP  !R<@
M9W$  %EP  !,;@  0&P  #5K   J:0  (6<  !AF   19@$ #&4*  =E#P $
M910  V0;  )D(P  9"P  &0U  !D0   9$P  &1:  !D:0  9'L  &2/  !C
MI   8[L  &+=  !B]   8O\  &'_ )-L  ")<0  @'4  'AW  !M>   8'<
M %)V  !&=0  .70  "YT   C<@  &G$  !)Q   -<0  !G$(  !P#0  <!(
M ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O9   ;W4  &Z*  !MH
M;;8  &S6  !K\@  :_\  &O_ (YS  "%>   ?7L  '-]  !E?@  6'X  $M^
M   ^?@  ,GX  "9]   <?   $WP   U\   &?0   'T%  !\"P  ? \  'P3
M  !\&0  ?"$  'PI  !\-   >T   'M.  ![7@  >V\  'J$  !ZF@  >;$
M 'C.  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#  !=A0  3X8  $*'   U
MB   *8<  !V'   4AP  #8@   :)    B@   (H   ")!@  B0P  (D/  ")
M$P  B1H  (HB  "*+   BC@  (I&  ")5@  B6@  (E\  "(E   AZL  (;&
M  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3C0  18\  #B1   KD0
M'Y(  !22   -DP  !)0   "6    EP   )@   "7    EP4  )<+  "8#@
MF!,  )D:  "9(@  FBX  )H]  "930  F5X  )ES  "8BP  F*,  )>\  "6
MX@  EO<  )7_ (")  !RC   9(\  %:3  !(E@  .ID  "R:   ?FP  %)P
M  R>   #GP   *$   "C    I0   *4   "E    I0   *8"  "G"   IPT
M *@1  "I&0  JR,  *LQ  "K00  K%,  *QG  "K@   JIH  *JS  "JT
MJ>\  *G[ '6/  !GE   69@  $J<   \GP  +:(  ""C   3I0  "Z<   &I
M    JP   *X   "Q    L@   +(   "S    M    +4   "V    N 0  +D+
M  "[$   O1@  +\D  "_-0  P$<  ,!;  # <@  P(T  ,&F  # P0  O^,
M +[S &J7  !;G   3:$  #ZE   OJ0  (:L  !.M   +L    +,   "U
MN    +P   "_    P0   ,$   ##    Q    ,8   #'    R0   ,L   #.
M"   T0\  -48  #8)P  V3D  -I-  #;9   VWX  -R9  #<L   W,D  -SC
M %V?  !/I0  0*H  #*O   BL@  %+4   JX    NP   +\   ##    Q@
M ,L   #.    T0   -$   #4    U@   -D   #;    W@   .    #D
MYP8  .L.  #O&0  \"H  /(_  #S50  ]&T  /2(  #TH0  ]+8  /3' /\
M"0#_  8 _P ' /\ # #_ !$ _P < /\ * #_ #0 _P!! /\ 3 #_ %4 _P!=
M /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y )( ]P"9 /8 H@#T *P
M\P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -( _P#) /\ Q #_ /\  0#_
M    _P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [ /T 1@#Z %  ]P!8 /0
M7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P YP"3 .4 G #C *8 X0"Q
M -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"] /\ N0#_ /\   #_
M_P   /\   #_  L _  3 /< '@#T "H \@ U .X 0 #I $H Y@!2 ., 60#@
M &  W@!F -P ; #: '( UP!X -0 ?@#2 (4 T "- ,X E0#, )\ R0"J ,<
MN #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\ K0#_ /\   #_    _P
M /D   #R  8 ZP / .8 &0#A "0 W@ O -H .0#3 $, SP!, ,P 4P#) %H
MQP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D C@"W )@ M0"C +, L "Q
M ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_ /\   #_    ]0   .L
M  #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T NP!% +@ 30"V %0 LP!:
M +$ 7P"P &4 K@!J *P < "K '< J0!_ *< AP"E )$ HP"< *  J0"> +@
MG #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T   #Q    Y0   -D   #-
M    Q  & +T #P"W !@ LP B +  + "M #8 J0 ^ *< 1@"D $T H@!3 *
M60"? %X G0!D )L :@": '  F !W )8 @ "4 (H D0"5 (\ H@"- +  BP##
M (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C    T0   ,4   "]
MM@   *X "P"H !( I  < *  )@"< "\ F@ W )< /P"5 $8 D@!, )$ 4@"/
M %@ C0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/ '\ FP!^ *D ? "[ 'H
MU0!X /( > #_ '< _P!W /\ =P#_ .<'  #1#   PPT  +@,  "N"   J
M *( !0";  X E@ 5 )( 'P". "@ BP Q (@ .0"& $  A !& (( 3 "  %(
M?P!7 'T 70![ &, >@!K '@ <P!V 'T = "( '$ E0!P *0 ;@"T &P R@!K
M .H :@#\ &H _P!J /\ :@#_ -H0  #&%   N!8  *T5  "D$@  G X  )8'
M  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D =P!  '4 1@!S $P <@!1
M '  5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C )\ 8@"O &  Q !? .0
M7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?  ";'   DQ<  (L1  "$
M#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z &D"0 !G T8 9@-, &0$
M4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP 5PBM %8(P0!5">$ 5 OV
M %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4)0  BR$  (,;  ![%
M= X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+.@!="T  6PQ' %H,30!8
M#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL $P/P@!,$., 2Q#Y $L0
M_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0  ABD  'TD  !T'@  ;!<
M &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3$#L 4A%" % 12 !/$5
M3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I $04O@!#%=\ 0Q;X $,6_P!#
M%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$  '@K  !O)@  9B   %X9
M 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C< 218^ $@61 !'%TP 11=4
M $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [&]L .QSV #P<_P \'/\
M/!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R  !J+0  82<  %DA  !1
M&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ $$<00! '$@ /AQ0 #T=
M60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8 -2'T #4B_P U(?\ -B'_
M +(T  "D.@  F3X  (\_  "%/P  >SP  ' X  !G,@  72T  %0H  !,(@4
M1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA/0 Y(44 .")- #<B5P V
M(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R "\F_P P)O\ ,";_ *\X
M  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C.   6C,  %$N  !(* $ 0"0,
M #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S)D( ,B9* #$G5  P)U\
M+RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK_P J*O\ *RK_ *P\  "?
M0@  E$8  (I'  " 1P  =D4  &Q"  !A/0  5S@  $XS  !$+@  /"D) #<H
M$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M( "PK4@ K+%T *BQJ
M "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E+_\ )B[_ *D_  "=10
MDDD  (A+  !^3   =$H  &I'  !>0@  5#T  $LY  !!-   ."\& #(M#0 P
M+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]& "<P3P E,%L )#%H ",Q
M=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\ (3+_ *9#  ":20  D$T
M (9/  !\4   <T\  &A,  !<1@  4D,  $D_   _.P  -C8" "XR#  K,A$
M*3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U30 @-5@ 'S9E !XV=0 <
M-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_ *-'  "830  CE$  (13
M  ![5   <5,  &90  !:3   4$D  $=%   ]00  ,ST  "HY"0 E-PX (S<4
M "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :.E8 &3MC !@[<@ 6.X4
M%3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+  "540  BU4  ()8  !Y
M60  ;E@  &16  !840  3D\  $5+   Z1P  ,$,  "= !0 @/@T '3X1 !P^
M%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%, $T!@ !)!<  108( $$&7
M  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "35@  B5H  (!=  !V7@
M;%T  &);  !65P  3%4  $%1   V3@  +$L  "-(   ;10D %T0/ !5$%  4
M11L $T4B !)%*0 113$ $44[ !!&10 /1E  #D=>  U';0 ,1W\ "T>3  E'
MIP (1[X "$?@  E']@ *1O\ "T;_ )I5  "06P  AV   'UB  !S8P  :F(
M &!A  !37@  1UH  #Q7   R50  *%(  !]0   73@0 $4P,  ],$0 .3!<
M#DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.:0 $3GL  DZ/  %.I
M3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8  'IH  !Q:0  :&D  %QG
M  !/9   0F$  #=?   M7   (UH  !I8   25P$ #58)  E5#@ '51, !E4:
M  15(@ #52H  E4T  !5/@  54H  %97  !690  57<  %6+  !5H   5;8
M %34  !4\0  4_T  %/_ )-B  "*:   @&P  '=N  !O;P  8VX  %9L  !)
M:@  /6@  #)F   G90  '6,  !5B   .80  "6 (  -@#0  7Q$  %\7  !?
M'@  7R8  %\O  !?.@  7T4  %]3  !?80  7G(  %Z'  !=G   7;(  %S/
M  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J=0  770  $]S  !"<@
M-G   "MO   @;@  %VT  !!L   *;    FL&  !K"P  :@\  &H4  !J&@
M:B$  &DJ  !I-   :4   &E.  !I7   :6T  &B"  !HF   9ZX  &;*  !E
M[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B>P  57L  $AZ   [>@  +WH
M "-Y   9>   $7<   IW   #=P   '<"  !W"   =@T  '80  !V%0  =AL
M '8C  !V+@  =3H  '5'  !U5@  =6@  '1\  !TD@  <ZH  '+$  !QZ0
M</L  '#_ (9Y  !_?0  =G\  &B!  !:@@  3((  #^#   RA   )8,  !J#
M   1@P  "H,   *#    A    (4   "$ P  @P@  (,-  "#$   @Q4  (0<
M  "$)@  A#(  (0_  "#3P  @V   ()U  ""C   @:0  ("]  !_XP  ?OD
M '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-   GC0  &XT  !&.   *
MC@   (\   "1    D@   )(   "2    D@$  )('  "2#   DA   ),5  "3
M'0  E"@  )0V  "410  DU<  )-K  "3@@  DIP  )&V  "0V   C_,  (__
M 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6   <EP  $9@   F9    FP
M )P   ">    H    *    "@    H    *$   "A!   H@D  *,.  "D%
MI1T  *8J  "F.@  IDP  *5@  "E>   I9(  *2L  "DR0  H^L  *+Z '..
M  !DD0  5I4  $>9   YG   *IX  !V@   1H0  "*,   "E    IP   *D
M  "L    K@   *X   "N    KP   +    "Q    L@   +,&  "U#0  MQ,
M +D>  "Y+@  ND   +I4  "[:@  NH4  +FA  "YNP  NMX  +GR &>5  !8
MF0  2IX  #NB   LI@  ':@  !&J   'K    *\   "Q    M    +@   "[
M    O    +P   "^    OP   ,    #"    Q    ,8   #( P  RPL  ,\2
M  #1(   T3(  -)&  #370  U'8  -22  #5JP  U<0  -3B %N=  !,H@
M/:<  "^L   ?KP  $;$   >U    N    +L   "^    P@   ,<   #*
MS    ,P   #.    T    -(   #5    V    -L   #?    X@   .8+  #K
M$P  ["0  .TX  #N3@  [V<  /""  #PG   \+(  /'% /\  P#_  $ _P $
M /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_ %$ _P!9 /\ 8 #] &<
M_ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /( G0#P *< [@"S .P Q #K
M .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_ /\   #_    _P   /\
M  #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L \@!3 /  6P#N &$ [ !G
M .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#= *  VP"L -@ NP#4 -$
MTP#P -  _P#. /\ R #_ +T _P"V /\ L@#_ /\   #_    _P   /\   #]
M  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !- -P 50#9 %L U@!A -,
M9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #% )H PP"E ,  L@"^ ,4 O #E
M +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_    _@   /4   #L  ,
MY0 - -\ %0#: "  U  J -  -0#+ #X R !' ,4 3@#" %4 P !; +X 80"\
M &8 N@!L +@ <@"V '@ M0"  +, B "Q )( K@"> *P J@"I +L J #5 *8
M\P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[    \    .4   #8    S@ )
M ,< $0#" !H O@ D +L +@"W #@ M !  +$ 2 "N $X K !4 *H 6@"I %\
MIP!E *4 :P"D '$ H@!X *  @0"> (L G "6 )D HP"7 +( E@#' ), Z "2
M /X D0#_ )  _P"- /\ BP#_ /D   #K    W0   ,\   #&    O  $ +4
M#0"P !4 K  > *@ * "E #$ H@ Y )\ 00"= $@ FP!. )D 4P"7 %D E@!>
M )0 9 "2 &H D !Q (X >@", (, B@"/ (@ G "& *H A "\ (( W "! /8
M@ #_ '\ _P!_ /\ ?@#_ .P   #:    R0   +X   "V    K@   *< "0"A
M !  G  8 )@ (@"5 "H D@ R )  .@"- $$ BP!' (D 30"' %( A@!8 (0
M70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V *, =0"T ', S !Q .T < #_
M '  _P!P /\ < #_ -\%  #*"@  O L  +$)  "H!   H0   )L  P"4  P
MCP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L 1P!Y $P =P!2 '8 5P!T
M %T <@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N &4 PP!D .0 8P#Z &,
M_P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=$   E0L  (\#  ")  < @@ .
M 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L $8 :@!, &D 4@!G %@
M9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D O !8 -P 6 #T %@ _P!7
M /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0  C10  (4/  !^"0  =P$* '(
M$ !N !< :@ ? &@ )P!E "X 9  T &( .P!@ $  7P!& %T 3 !< %, 6@!:
M %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !. M( 303P $T%_P!-!?\
M307_ +\=  "P(@  HR4  )DE  "/(@  A1T  'T8  !U$@  ;@T" &<&# !C
M Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9! %,&1P!1!DX 4 =5 $X'
M7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]  1 SO $,-_P!##?\ 1 W_
M +DD  "J*0  GBP  )0L  "**@  @"8  '<A  !N&P  9A0  %\/!0!9"PT
M50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-0@!(#4D 1@U1 $4.6@!$
M#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q #L1_P [$?\ /!'_ +0I
M  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I(P  81T  %D6  !1$0@ 3 \0
M $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@! $44 /A)- #T25@ \$F$
M.A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06_P T%O\ -!;_ *\N  "B
M-   ES<  (PX  ""-@  >#0  &XN  !E*@  7"0  %0>  !,& 0 1A0- $(4
M$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D( -Q9* #874P U%UX ,QAJ
M #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N&_\ +AO_ *PR  "?.
ME#L  (H\  " /   =CD  &LT  !B+P  62H  % E  !''P  0!H* #P9$  Z
M&18 .!D= #8:(P U&BD -!HP #,:-P R&SX ,1M' "\<4  N'5L +1UG "P>
M=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\ *"#_ *DV  "=/   DC\
M (=!  !]0   =#X  &DZ  !?-0  5C   $TK  !$)0  .R ' #8>#@ S'A,
M,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA3@ I(5@ )R)E "8B=  E
M(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_ *8Z  ":/P  CT,  (5%
M  ![1   <D,  &<_  !=.@  4S8  $HQ  !!+   ."8# #$C#  N(A$ +"(6
M "HB'0 I(B, *",J "<C,0 F)#D )25! "0E2P C)E8 (B9C "$G<@ ?)X,
M'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^  "80P  C4<  (-)  !Z
M20  <$<  &9$  !:/P  43L  $<W   ^,@  -2T  "PH"0 H)P\ )R<4 "4G
M&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0 '2M@ !LK;P :+($ &2R5
M !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "51P  BTL  ()-  !X30
M;DP  &1)  !81   3T   $8]   ].   ,S0  "HO!@ D+ T (2P2 " L&  ?
M+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!> !8P;0 5,7\ $S&3 !(Q
MJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P  B4\  (!1  !V4@  ;5
M &).  !620  348  $1#   [/P  ,3H  "<V P ?,@L '#(0 !LR%0 9,AL
M&#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U:P 0-GT #S:1  XVI@ -
M-[P #3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,  'Y6  !U5@  :E4  &!3
M  !53P  3$P  $))   X10  +D$  "0]   <.@@ %C@. !4X$@ 4.!@ $SD?
M !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +.WH "CN-  D\H@ '/+@
M!SS5  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;  !R6P  :%H  %Y8  !3
M50  25(  #Y.   T2P  *D<  "%$   80@, $D + ! _$  ./Q4 #C\<  U
M(P ,0"L "T T  I /@ )04H !T%6  9!90 $078  T&*  %!GP  0;0  $'0
M  %![@ !0?P  D#_ )54  ",60  @UX  'E@  !P8   9F   %U>  !16P
M15<  #I4   O40  )4\  !Q,   42@  #D@(  M'#@ (1Q( !T<9  9'(  %
M2"@  T@Q  )(.P  2$<  $A3  !(8@  2',  $B&  !(FP  2+$  $?,  !'
M[0  1_L  $?_ )):  ")8   @&,  '=E  !N9@  968  %ED  !,8   0%T
M #5;   J60  (%<  !=5   04P  "U('  51#0 !4!$  % 6  !0'0  4"4
M % N  !0.   4$,  %!0  !07@  4&\  %"#  !/F   3ZX  $[)  !.ZP
M3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0  86L  %-I  !&9P  .F0  "]C
M   D80  &E\  !)>   ,7   !EP&  !;"P  6@\  %H3  !:&0  62$  %DI
M  !9,P  63\  %E,  !96@  66L  %A^  !8E   5ZL  %?%  !6Z0  5?L
M %7_ (QH  "";0  >G   ')R  !G<@  6G$  $QP   _;@  ,VT  "AK   =
M:@  %&@   UG   '9P   &8#  !F"0  90T  &41  !D%0  9!P  &0D  !D
M+@  9#H  &-'  !C50  8V8  &-Z  !BD   8:<  &#!  !?Y@  7_H  %[_
M (=O  !_=   >'<  &YX  !@>   4G<  $5W   X=@  *W8  "!T   6<P
M#G,   =R    <@   '(   !Q!0  <0H  '$.  !P$0  <!<  ' >  !P)P
M<#,  &]   !O4   ;V   &YT  !NBP  ;:(  &R\  !KX@  :O@  &G_ (-W
M  !\>P  <WT  &5^  !7?P  27\  #Q_   O@   (G\  !=^   /?@  !WX
M  !_    ?P   '\   !^    ?@4  'X*  !^#0  ?A$  'X7  !^(   ?BL
M 'TY  !]2   ?5D  'QM  !\A   >YP  'JV  !YV@  >/4  '?_ (!_  !W
M@@  :8,  %N%  !-A@  /X@  #*)   DB0  &(D   ^)   'B@   (L   ",
M    C0   (T   ",    C    (P#  ","   C0T  (T1  "-%P  CB(  (XO
M  "./P  C5   (UD  ",>P  C)4  (NN  "*S0  B>\  (G_ 'N%  !MB
M7HH  %"-  !"CP  -)$  ":2   9DP  #I0   :5    E@   )@   ":
MFP   )L   ";    FP   )L   "<    G04  )T+  ">$   GQ<  * D  "@
M-   H$8  *!9  "?<   GXH  )ZE  ">P@  G>@  )SY '",  !ACP  4Y(
M $26   VF0  )YL  !F<   /G0  !9\   "A    HP   *4   "H    J0
M *D   "I    J@   *L   "L    K0   *X!  "P"0  L@\  +,8  "T)P
MM#D  +5-  "T9   M'X  +.:  "SM   L]4  +/P &23  !5EP  1YL  #B?
M   IH@  &J0   ZF   $J    *L   "M    L    +0   "V    N    +@
M  "Y    N@   +P   "]    OP   ,    ##    Q0<  ,D/  #*&@  RRP
M ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB %B;  !)H   .J4  "RI   <
MJP  #ZX   2Q    M    +<   "Z    O@   ,,   #&    R    ,@   #*
M    RP   ,T   #/    T@   -4   #9    W0   .$%  #F#P  YQX  .@R
M  #I2   ZF   .M[  #KEP  [*X  .S" /\   #_    _P   /\ !@#_  T
M_P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L 6P#Z &( ^ !H /8 ;@#U
M '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M .< O0#E -@ Y #S .(
M_P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_    _P   /\   #_  D _P 1
M /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H %P Y@!B .0 : #C &X
MX0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\ M #, ,D R0#I ,@ _P#'
M /\ P0#_ +< _P"O /\ JP#_ /\   #_    _P   /\   #X  4 \@ . .X
M%P#J "( Y@ L .$ -P#= $  V !) -, 4 #0 %8 S@!< ,P 8@#* &< R !M
M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V +X M #= +, ]P"Q /\
ML #_ *@ _P"B /\ G@#_ /\   #_    ^0   .\   #F    WP + -8 $@#0
M !P S  F ,@ , #$ #H P !" +T 2@"[ %  N !6 +8 6P"U &$ LP!F +$
M; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C +0 H #+ )\ [@"= /\ G #_
M )D _P"4 /\ D0#_ /\   #V    Z@   -T   #/    QP & ,  #P"[ !<
MMP @ +, *@"P #, K0 [ *H 0P"G $D I0!/ *, 50"B %H H !? )X 90"=
M &L FP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_ (P X@"+ /H B0#_ (D
M_P"& /\ @P#_ /0   #D    U    ,@   "_    M0 ! *X "P"I !( I0 ;
M *$ (P"> "P FP T )@ / "6 $, E !) )( 3@"0 %, C@!9 (T 7@"+ &0
MB0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L SP!Y /$ > #_ '< _P!W
M /\ =0#_ .4   #1    PP   +@   "O    J    *  !@":  X E0 5 )$
M'@". "8 BP M (@ -0"& #P A !" (( 1P"  $T ?P!2 'T 6 ![ %X >0!E
M '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J .< :0#] &@ _P!H /\
M:0#_ -4#  ##!P  M@@  *L&  "B    FP   )0   "-  H B  0 (, & !_
M "  ?  G 'H +@!W #4 =0 [ '0 00!R $< < !, &\ 4@!M %@ :P!? &D
M9@!G '  90![ &, B !B )< 8 "G %X NP!= -P 7 #V %P _P!; /\ 6P#_
M ,D-  "Y$   K!$  *$0  "7#0  CP@  (@   ""  4 >P - '< $@!S !H
M;P A &P * !J "\ :  U &< .P!E $$ 8P!& &( 3 !@ %( 7P!9 %T 80!;
M &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O %  _P!0 /\ 4 #_ +\4
M  "P&   I!H  )D9  "/%@  AQ$  '\-  !W!@  <0 ( &L #@!G !0 9  ;
M &$ (@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5 $T 4P!4 %( 7 !0 &4
M3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8 ^P!& /\ 10#_ +@;  "J
M(   GB(  ),B  ")'P  @!H  '<5  !O$   : L  &$$"@!= !  60 6 %8
M'0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@ 20!/ $<!5P!& 6$ 1 )L
M $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \!_\ / ?_ +(B  "E)P
MF2D  (XI  "$)P  >R,  '$>  !I&   81(  %H- P!3" P 3P41 $P%%P!*
M!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+ #X)4P ]"5T .PIH #H*
M=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\ - W_ *TG  "@+   E2\
M (LO  " +@  =RH  &TE  !D(   7!H  %04  !,#P8 1@P- $,,$@!!#!@
M/PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.4  T#EH ,PYF #$/=  P
M#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_ *HL  "=,0  DC0  (<U
M  !]-   =#$  &HK  !@)P  6"$  $\;  !'%@  0!$) #L0#P Y$!0 -Q ;
M #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M$E< +!)C "H3<0 I$X(
M)Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q  ":-@  CSD  (4Z  ![
M.0  <38  &<Q  !=+0  5"@  $PB  !#'0  .Q<% #44#0 R$Q$ ,107 "\4
M'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0 )A=@ "08;P C&(  (1F3
M " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8.@  C3T  (,^  !Y/0
M;SL  &4W  !;,@  4BT  $DH  ! (P  .!X! # 9"@ L& \ *A@4 "D8&@ G
M&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q> !\=;  ='7X '!V1 !H>
MI0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0  BT$  (%"  !W0@  ;4
M &,\  !9-P  3S,  $8N   ]*0  -20  "T@!P G'0T )1T2 ",=%P A'1T
M(1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA:@ 8(GL %B*/ !4BHP 4
M([H $R/: !0C]0 5(_\ %B/_ )X\  "300  B40  ']&  !U1@  ;$0  &)!
M  !7/   33@  $0T   \,   ,RL  "HF P C(@L ("$0 !XA%0 <(AL &R(A
M !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3)GD $B:- !$GH@ 0)[@
M#B?6 ! H]  1)_\ $2?_ )Q   "110  AT@  'U*  !T2@  :DD  &!&  !5
M00  3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<. !DG$@ 8)Q@ %B<? !4H
M)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W< #BN+  TLGP ,++4 "RS/
M  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S3P  :4X  %Y+  !31P
M2D0  $)    Y/0  +S@  "4T   =, 4 %BT, !0L$  3+14 $BT< !$M(P 0
M+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(  @QG  &,;$ !C'+  8Q
MZP ',/P "##_ )=(  "-30  @U$  'I3  !Q5   9U(  %U0  !23   24H
M $!&   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .,Q, #3,9  TS(  ,-"@
M"S0Q  HU.P (-48 !S52  4V8  $-G$  C:$   VF0  -J\  #;(   VZ
M-OD  37_ )1-  "*4@  @58  'A8  !O60  95@  %M5  !14@  1T\  #Q,
M   Q2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$ "#L7  8['@ %.R8 !#LN
M  ([.  !/$,  #Q/   \7@  /&X  #R!   \EP  /*P  #O%   [YP  ._@
M #O_ )%2  "(6   ?UP  '9=  !M7@  8UT  %I<  !.6   0E0  #=1   M
M3@  (TL  !I)   21@  #40&  =##  #0Q   $,5  !#&P  0R,  $,K  !#
M-0  0T   $--  !#6P  0VL  $-^  !#E   0JH  $+#  !!Y@  0?D  $'_
M (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A  !)70  /5H  #)8   G50
M'E,  !51   .3P  "4T%  )-"P  3 X  $P3  !+&   2Q\  $LH  !+,@
M2ST  $M)  !+5P  2V<  $I[  !*D   2:<  $G   !(Y   2/@  $?_ (M?
M  "#9   >F<  '%I  !I:@  7FD  %!F  !#9   -V$  "Q?   A70  &%L
M !!9   *6    U<#  !7"0  5@T  %40  !5%0  5!L  %0C  !4+0  5#D
M %1%  !44P  5&0  %-W  !3C0  4J0  %&]  !0X@  4/@  $__ (AG  !_
M:P  =VX  &]P  !E<   5VX  $IL   ]:P  ,&D  "5H   :9@  $60   MC
M   $8@   &(!  !A!@  8 L  & .  !?$@  7Q<  %\>  !>*   7C,  %Y
M  !>3P  7E\  %UR  !=B   7*   %NY  !:WP  6?<  %C_ (1N  !\<@
M=74  &MV  !==0  3W0  $)S   U<P  *'(  !UP   3;P  #&X   1N
M;@   &X   !L @  ; <  &L+  !K#@  :Q(  &H9  !J(@  :BT  &HZ  !I
M20  :5H  &EL  !H@P  9YL  &:U  !EV   9/4  &3_ (!U  !Z>0  <'L
M &)[  !4?   1GP  #E\   L?   'WL  !1Z   ->@  !'H   !Z    >@
M 'H   !Y    >0$  '@&  !X"P  > X  '@3  !X&@  >"4  '@R  !W00
M=U(  '=E  !V?   =94  '2O  !SS@  <O$  ''_ 'Y]  !U@   9X$  %B"
M  !*@P  /(0  "Z%   AA0  %84   V%   #A0   (8   "'    B    (@
M  "'    AP   (<   "'!   APD  (<.  "($P  B!P  (@I  "(.   ATH
M (==  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$  !JA@  7(@  $V*   _
MC   ,8X  "./   6CP  #9    *1    D@   ),   "5    E@   )8   "6
M    E@   )8   "7    EP   )<'  "8#0  F1,  )H?  ":+0  FC\  )I2
M  "::   F8,  )F?  "8N@  E^(  );X &V*  !?C0  4)   $&3   SE@
M))<  !:8   -F0   9L   "=    GP   *$   "D    I0   *0   "E
MI0   *8   "G    J    *D   "J!   K P  *X3  "N(0  KC,  *Y'  "N
M70  KG8  *Z3  "NK@  K<T  *SO &&1  !3E0  1)@  #6<   FGP  %Z$
M  VC    I0   *<   "J    K    +    "R    M    +,   "T    M0
M +<   "X    N0   +L   "]    OP$  ,,+  #%%0  Q24  ,8Y  #'3P
MQV@  ,:%  #&H@  QKP  ,;> %69  !'G0  .*(  "FF   9J   #:L   "M
M    L0   +0   "W    N@   +\   #!    Q    ,,   #%    Q@   ,@
M  #*    S0   ,\   #2    U@   -L   #@#   X1@  .,K  #D00  Y5H
M .9T  #FD0  Y:P  .7$ /\   #_    _P   /\  0#_  H _P 2 /\ '0#_
M "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C /( :0#P &\ [P!T .T
M>P#K ($ Z0") .@ D@#F )P Y "H .( MP#? ,T W #N -D _P#9 /\ R@#_
M +X _P"U /\ L #_ /\   #_    _P   /\   #_  8 _P / /P & #X ",
M]  N /  . #K $( Z !* .4 40#B %@ X != -X 8P#< &@ V0!N -8 = #4
M 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C ,  ^P#  /\ NP#_ +
M_P"H /\ I #_ /\   #_    _P   /L   #S  $ [0 , .@ $P#C !X X  H
M -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#" &( P0!G +\ ;0"] '0
MNP![ +D A "W (X M "9 +( IP"O +< K0#0 *L \@"J /\ J0#_ *$ _P";
M /\ EP#_ /\   #_    ]    .D   #@    U0 ( ,X $ #) !@ Q0 B ,$
M*P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L K !A *H 9@"I &T I@!T
M *0 ? "B (8 H "2 )X GP"< *X F0## )< YP"6 /\ E0#_ )( _P"- /\
MB@#_ /P   #P    XP   -0   #(    OP # +D #0"S !, KP < *P )0"I
M "X I0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!: )< 7P"6 &8 E !L )(
M=0"0 'X C@"* (L EP") *8 AP"X (4 U@"$ /8 @@#_ ($ _P!^ /\ ? #_
M .T   #=    S    ,$   "X    K@   *< "0"B !  G@ 7 )H 'P"7 "<
ME  O )$ -P"/ #T C0!# (L 20") $X B !3 (8 60"$ %\ @@!E (  ;0!^
M '< ? "" 'H CP!X )X =0"O ', QP!R .P <0#_ '  _P!P /\ ;@#_ -T
M  #)    O    +$   "I    H0   )D  P"3  P C@ 2 (H &0"' "$ A  I
M ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T %@ <@!? '$ 9P!O '
M; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z &$ _P!A /\ 80#_ ,T!  "\
M!0  KP4  *4"  "<    E    (T   "&  @ @0 . 'P % !X !L =0 C '(
M*0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F %( 9 !9 &, 8 !A &D 7P!T
M %T @0!; )  60"A %< M !6 -  50#R %4 _P!4 /\ 50#_ ,$,  "R#@
MI@\  )L.  "2"P  B04  ((   ![  ( =0 + '  $ !L !8 :  = &8 (P!C
M "H 80 P &  -@!> #L 70!! %L 1@!: $P 6 !3 %8 6P!4 &0 4@!N %$
M>P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!) /\ 20#_ +D2  "J%@  GA<
M )06  "*$P  @1   'D+  !Q P  :P & &4 #0!A !$ 70 8 %H '@!8 "0
M5@ J %0 , !3 #8 40 [ %  00!. $< 30!. $L 5@!) %\ 1P!I $8 =@!$
M (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_ +(9  "D'@  F!\  (X?
M  "$'   >A@  '(2  !J#@  8@@  %P!" !7  X 4P 3 %  &0!. !\ 3  E
M $H *P!( #  1P V $8 / !$ $( 0P!) $$ 40 _ %H /@!E #P <@ Z ($
M.0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@  "?)   E"8  (DF  !_
M)   =2   &P;  !D%0  7!   %0, 0!.!@H 2@(/ $< % !$ !H 0@ @ $
M)0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V U8 -01A #,$;@ Q!7X , 60
M "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";*@  D"P  (8M  ![*P
M<B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'$  [!A4 .0<; #@'(0 V
M""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E, + I> "L+;  I"WP * R/ "8,
MH@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P  C3(  (,R  !Y,0  ;RX
M &4I  !<)   4Q\  $L9  !#$P  /! & #4-#  S#!$ ,0P6 "\,'  N#2(
M+0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/:@ B#WL (!". !\0H@ =
M$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8  ( W  !V-@  ;3,  &,O
M  !9*@  4"4  $@@   _&@  .!4  # 1"  L$ X *A 2 "@0&  G$!X )1 D
M "00*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;$W@ &A.+ !@4H  7%+4
M%A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[  !T.P  :S@  &$T  !7
M+P  3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0 "(3%0 @$QH 'Q,A !X4
M)P =%"\ '!4W !L500 :%DL &197 !<790 6%W8 %!B) !,8G@ 2&+, $1G.
M !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S/P  :3T  %\Y  !5-0
M3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7$@ :%Q< &1@> !D8)  8
M&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'  \=G  .';$ #1W+  T=
M[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P  :$(  %X^  !3.@  2C8
M $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5'!4 %!T; !0=(@ 3'2D
M$AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LBF0 *(JX "2+'  DBYP *
M(OL "R'_ )<^  ",0P  @T8  'E(  !P2   9T8  %Q$  !2/P  23L  $ X
M   X-   +S   "<L   >)P, %B,* !(A#@ 1(1, $"(9 ! B(  /(B< #B,O
M  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $)JP  R;$  0FY0 $)O<
M!B;_ )5"  "*1P  @4H  'A,  !O3   94L  %M(  !01   1T$  #\^   W
M.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6  PH'0 +*"4 "BDM  DI
M-P '*D( !BI.  0K7  #*VP  2M_   KE   *ZD  "O!   KXP  *_8  "K_
M ))&  "(2P  ?T\  '91  !M40  8U   %I-  !/2@  1T<  #Y$   S0
M*3P  " X   7-   $3$%  PO#  )+A  !RX5  8O&P %+R,  R\K  (P-0
M,#\  #!,   Q60  ,6D  #%\   QD0  ,:<  #"_   PX0  ,/4  "__ )!+
M  "&4   ?50  '56  !K5@  8E4  %A3  !.4   14T  #I)   O10  )4(
M !P^   4.P  #CD%  DW"P $-@\  383   V&0  -B   #8I   V,@  -ST
M #=)   W5P  -V<  #=Y   WCP  -J4  #:]   VX   -?4  #7_ (U0  "$
M5@  ?%H  ');  !I6P  8%L  %=9  !,5@  0%(  #5.   J2P  ($@  !=&
M   00P  "T$$  1 "@  /PX  #X1   ^%@  /AT  #XF   ^+P  /CH  #Y&
M   ^5   /F0  #YV   ]C   /:,  #R[   \W@  ._4  #O_ (I7  ""7
M>5\  '!A  !H80  7V$  %1>  !'6P  .E<  "]5   E4@  &U   !)-   ,
M2P  !DH#  !)"0  2 T  $<0  !'%   1AH  $8B  !&+   1C<  $9#  !&
M40  1F   $5S  !%B0  1*   $2X  !#W   0O4  $+_ (A=  !_8@  =V4
M &YG  !G:   6V8  $YC  !!80  -%X  "E<   ?6@  %5<   Y6   '5
M %,!  !2!@  40L  %$.  !0$0  3Q8  $\>  !/)P  3S(  $\_  !/30
M3ET  $YO  !.A0  39T  $RU  !+V   2O4  $K_ (5E  !\:0  =&P  &UN
M  !B;0  5&L  $=I   Z9P  +64  ")D   88@  $&    E?    7@   %X
M  != P  7 @  %L,  !:#P  6A,  %D9  !9(@  62T  %DZ  !92   6%@
M %AK  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L  !Y<   <W,  &AS  !:
M<@  3'$  #]P   R;P  )6X  !IL   1:P  "6H   !J    :0   &D   !H
M    9P,  &8(  !F#   9@\  &44  !E'   92<  &0T  !D0P  9%,  &1E
M  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W=P  ;GD  %]Y  !1>0
M0WD  #9X   I>   ''<  !%V   *=0   '4   !U    =@   '4   !T
M=    ',"  !S!P  <PP  '(0  !R%0  <B   '(L  !R.P  <4P  '%?  !Q
M=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@  9'X  %5_  !'@   .8$
M "N"   >@0  $H$   J!    @0   ((   "#    @P   (,   ""    @@
M ((   ""    @@4  ((*  ""#P  @A<  ((C  "",@  @D,  (%6  "!;
M@(8  '^A  !^O0  ?>8  'S\ ':"  !H@P  684  $N'   \B0  +HH  ""+
M   3BP  "HL   ",    C0   (\   "1    D@   )$   "1    D0   )$
M  "1    D@   )("  "3"0  E \  )09  "4)P  E#@  )1,  "38@  DWP
M ).8  "2LP  D=@  )#V &J(  !<B@  38T  #^0   PD@  (90  !25   *
ME@   )<   "9    FP   )T   "?    H    *    "@    H    *$   "B
M    HP   *0   "E    I@<  *@0  "H'   J"T  *E   "I5@  J6\  *F+
M  "HJ   I\<  *;L %^/  !0D@  098  #.9   CG   %)T   J?    H0
M *,   "F    J    *P   "N    KP   *\   "P    L    +(   "S
MM    +8   "W    N@   +T'  "_$   OQ\  , S  # 20  P&(  ,!^  #
MFP  P+<  +_8 %.7  !$FP  -9\  ":C   6I0  "Z<   "J    K0   +
M  "S    M@   +L   "]    P    +\   #!    P@   ,0   #&    R
M ,H   #,    SP   -,   #:!P  VQ,  -TE  #>.P  WU,  .!N  #?C
MW:D  -W" /\   #_    _P   /\   #_  < _P 0 /\ &0#_ "0 _P O /P
M.@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D Z0!O .< =0#F 'P Y "$
M .( C0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/ /\ Q #_ +@ _P"O /\
MJ0#_ /\   #_    _P   /\   #_  ( ^P - /< %0#S !\ [P I .H - #F
M #T X@!% -X 3 #; %, V !8 -0 7@#2 &, T !I ,X ;@#, '4 R@!] ,@
MA0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\ M #_ *D _P"B /\ G0#_
M /\   #_    _P   /8   #N    YP * .$ $0#< !H UP C -  +@#+ #<
MQP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@ : "V &X M !U +$ ?@"O
M (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_ )L _P"5 /\ D0#_ /\
M  #\    [@   .,   #8    S0 % ,8 #@#! !4 O0 > +D )P"U #  L@ X
M *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A &< GP!N )X =@"; (
MF0", )< F0"4 *@ D@"\ )  WP". /L C@#_ (L _P"& /\ @P#_ /@   #I
M    W    ,P   #!    N    +( "@"L !$ J  8 *4 (0"B "D G@ R )P
M.0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &  C0!G (L ;P") '@ A@"$
M (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W /\ =0#_ .8   #3
MQ@   +L   "Q    IP   *$ !0";  T EP 3 ), &P"0 ", C  K (H ,@"(
M #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@ 'D : !W '$ =0!\ ',
MB0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\ 9P#_ -,   ##    M0
M *L   "C    FP   )(   ",  H AP 0 (, %@!_ !T ?0 D 'H *P!X #(
M=@ X '0 /0!R $( <0!( &\ 30!M %, ; !9 &H 80!H &H 9@!T &0 @0!A
M )$ 7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_ ,4   "V @  J0(  )\
M  "6    C@   (<   "   4 >@ , '4 $0!Q !@ ;@ > &L )0!I "L 9P Q
M &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!: &0 6 !N %8 >P!4 (H
M4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*  "L#0  H T  )4,  ",
M"   @P(  'P   !U    ;@ ( &D #@!E !, 8@ 9 %\ 'P!= "4 6P K %D
M,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!. %X 3 !H $H =0!( (0 1P"5
M $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E%   F14  (X3  "$$0
M>PT  ',(  !L    90 # %\ "P!;  \ 5P 4 %0 &@!1 !\ 3P E $X *P!,
M #  2P V $D / !( $( 1@!( $4 4 !# %D 00!C #\ ;P ^ 'X / "0 #L
MHP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P  DQT  (D<  !_&0  =14
M &P0  !D#   708  %8 !@!1  P 30 0 $H %0!' !H 10 @ $0 )@!" "L
M00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8 :P T 'H ,@", #$ G@ P
M +, +P#. "\ [P N /\ +@#_ *<>  ":(@  CR0  (0D  !Z(0  <1T  &<8
M  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8 /  ; #H (0 Y "8 -P L
M #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K '8 *@"( "@ G  G +
M)@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J  !W*   ;24  &0@  !;
M&P  4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7 #$!'  P 2( +P(G "T"
M+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0 (@:& " &F@ ?!ZX '@?&
M !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T+@  :BL  &$F  !8(0
M3QP  $<7   _$@  . X$ #$+"@ N" X *P<2 "D'%P H"!T )P@C "4(*0 D
M"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R% !@,F0 7#*T %@S& !4-
MY@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R,P  :#$  %\L  !5)P  3",
M $0=   \&   -!,  "T0!@ F#0L ) P/ "(,$P A#!D 'PP? !X-)0 =#2P
M&PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0F  1$*X $!#& ! 0Z  0
M$/L $1#_ )DQ  ".-0  A#@  'HY  !P.   9S8  %TR  !3+0  2B@  $(D
M   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4 &! ; !<0(0 6$"D %1 Q
M !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -$ZL "Q/"  L4XP ,%/H
M#1/_ )<U  ",.0  @CP  '@]  !O/0  93H  %LW  !2,@  22X  $ J   W
M)0  +R$  "@<   @& , &10* !42#@ 4$A( $Q,8 !(3'P 1%"8 $10N ! 4
M.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@ !AB_  <8X  '&/4 "1C_
M )4X  "*/0  @$   '=!  !M00  9#\  %H\  !0.   1S,  #XP   V*P
M+B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8'  .&", #1DL  P:-0 +
M&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\  (<W0 "'/(  QS_ ),\
M  "(00  ?T0  '5%  !L10  8T0  %E!  !//0  1CD  #XV   U,@  +BX
M "4J   =)0  %"$$  \="P -'1  #!T4  L=&@ *'B( "!XJ  <?,P &(#X
M!"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z   AVP  (?(  "#^ )!   "&
M10  ?4@  '1*  !K2@  8DD  %A&  !.0@  13\  #T\   U.0  *S0  "(O
M   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"   B0H  $E,0  )3P  "5(
M   F50  )F4  "9W   FC   )J(  ":Y   FV0  )?(  "7^ (Y%  "$20
M>TT  '-/  !J3P  8$X  %=+  !-2   1$4  #Q"   Q/0  )SD  !XU   5
M,@  #RX#  HL"@ %*PX  2H1   J%@  *AX  "HF   K+P  *SD  "M%   L
M4P  +&(  "QU   LB@  *Z   "NW   KU@  *O(  "K_ (Q)  ""3@  >E(
M '%4  !H5   7U,  %91  !,3@  0TL  #='   M0P  (S\  !H\   2.
M##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q+   ,C<  #)#   R4
M,F   #)R   RAP  ,9X  #&U   PU   ,/(  "__ (E/  " 5   >%<  &]9
M  !F60  7ED  %57  !)4P  /D\  #),   H2   'D4  !5"   .0   "#T"
M  $\"   .PP  #H/   Y$@  .1@  #D@   Y*0  .30  #E    Y3@  .5T
M #EO   XA0  .)P  #>S   WT@  -O(  #7_ (=5  !_6@  =ET  &U?  !E
M7P  75\  %)<  !$6   .%4  "U2   B3P  &$P  !!*   *2    T8!  !%
M!@  1 H  $,-  !"$   014  $$=  !!)@  03$  $$]  !!2@  05H  $%L
M  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<  !\8   <V,  &QE  !D9@
M660  $MA   ^7@  ,EL  "99   <5@  $E0   Q2   $40   $\   !. P
M30@  $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY  !*1P  2E8  $EH  !)
M?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P  <FH  &ML  !@:P  4FD
M $1F   W9   *F(  !]@   57@  #5T   9;    6@   %D   !8    5P0
M %8(  !6#   51   %04  !4'0  5"<  %0T  !40@  4U(  %-D  !2>0
M4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$  &9Q  !8<   2F\  #QM
M   O;   (FH  !=I   .9P  !F8   !E    90   &4   !C    8@   &($
M  !A"   80T  & 0  !@%P  8"$  %\N  !?/   7TT  %Y>  !>=   78T
M %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV  !/=@  074  #-U   F
M=   &7,  !!R   '<0   '$   !Q    <0   '$   !O    ;P   &X   !N
M @  ;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8  &M8  !K;0  :H8  &FA
M  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$?0  -GX  "A^   ;?0
M$'T   =]    ?0   'T   !^    ?P   'X   !]    ?0   'P   !\
M?    'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/  ![90  >WX  'J:  !Y
MM@  >-\  '?Z '.   !E@0  5H,  $B$   YA@  *X<  !V'   1AP  !X@
M  "(    B0   (H   ",    C0   (T   ",    C    (P   ",    C
M (T   "-!   C@P  (X3  "/(0  CC(  (Y&  ".6P  C70  (V0  ",K0
MB\X  (KS &B&  !:B   2XL  #R-   MCP  'I   !&1   'D@   ),   "5
M    EP   )D   ";    G    )L   ";    G    )P   "=    G@   )X
M  "?    H0,  *(,  "B%@  HR8  *,Z  "C3P  HV@  **&  "BH@  HL
M *'H %R-  !-D   /Y,  #"6   AF0  $IH   >;    G0   *    "B
MI    *@   "J    JP   *H   "K    K    *T   "N    KP   +$   "R
M    M    +<!  "Y#0  N1H  +HM  "Z0P  NEL  +IW  "[E   N[$  +G2
M %"5  !!F   ,IP  ".@   3H@  "*0   "G    J@   *P   "O    L@
M +<   "Y    NP   +H   "\    O0   +\   #     P@   ,0   #&
MR0   ,T   #2 0  U \  -4?  #7-0  V$T  -AI  #7A@  UZ,  -:] /\
M  #_    _P   /\   #_  , _P - /\ %0#_ "  _  K /@ -0#T #\ \ !'
M .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #? '8 W0!^ -L AP#8 )$
MTP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$ _P"I /\ HP#_ /\   #_
M    _P   /\   #\    ]@ + /$ $0#M !L Z0 E .0 , #? #D V@!! -4
M2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\ PP!W ,  ?P"^ (H NP"5
M +@ HP"V +0 M #- +( \@"P /\ K #_ *, _P"< /\ EP#_ /\   #_
M^@   /$   #H    X  & -D #@#2 !8 S@ ? ,@ *0#$ #( P  Z +T 00"Z
M $@ N !- +8 4P"T %@ L@!= +  8@"N &D K !O *H > "H (( I@". *0
MFP"A *L GP#  )T Y@"; /\ F@#_ )0 _P". /\ B@#_ /\   #V    Z
M -P   #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N "L J@ T *@ .P"E $$
MHP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )< < "5 'H D@"& )  DP"-
M *( BP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_ /(   #C    T@   ,4
M  "Z    L0   *L !P"E  X H0 4 )X ' ": "4 EP M )0 - "2 #H D !
M (X 10"- $H BP!0 (D 50"( %L A@!A (0 :0"" '( ?P!] 'T BP![ )H
M> "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\   #,    OP   +0   "K
M    H0   )H  @"4  L D  0 (P %P"( !X A0 F (, +0"! #, ?P Y 'T
M/P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L ;@!U &P @P!J )( : "C
M &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\    KP   *4   "=
ME    (P   "&  < @0 - 'P $@!X !D =0 ? ', )@!Q "T ;P R &T . !K
M #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N %T >P!; (H 60"; %<
MKP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P    I    )D   "0    B
M ($   !Y  ( <P * &\ #P!K !0 9P : &4 ( !C "8 80 L %\ ,@!> #<
M7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %  = !. (, 3 "5 $H J !)
M ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP  ) *  "&!0  ?@   '8
M  !O    :  % &, # !? !  6P 5 %@ &@!6 "$ 5  F %, + !1 #$ 4  V
M $X / !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!" 'T 0 ". #\ H@ ] +@
M/0#= #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1  !_#P  =@P  &X%  !F
M    8  ! %D " !5  T 40 1 $X %@!+ !L 20 A $@ )@!& "L 10 Q $,
M-@!" #P 0 !# #X 2P ] %, .P!= #D :0 W '@ -@") #0 G  S +$ ,@#.
M #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z%@  <!(  &@.  !?"@
M6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ; #T (0 \ "8 .@ L #D ,0 W
M #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "% "L F  J *T *0#& "@
MZ@ H /X * #_ *$<  "5(   BB$  '\A  !U'P  ;!H  &,6  !:$0  4@T
M $L'  !$  8 0  + #P #P X !( -@ 7 #0 '  S "$ ,0 G #  +  N #,
M+0 Z "L 0@ J $L * !5 "8 80 E '  ) "! "( E0 A *D ( #! "  Y  ?
M /D 'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(  %\=  !7&   3A,  $8.
M   _"P  . 4' #0 #  Q !  +@ 3 "P &  J !T *0 B "< *  F "X )  V
M ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9 *< & "] !< WP 7 ?4
M%P+_ )HG  ".*P  A"T  'DM  !P*P  9B@  %TD  !4'P  2QH  $,4   [
M$   - T" "T)"0 I!0T )@,0 "0!$P B AD (0(> " ")  > RH '0,R !L$
M.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4 $0>[ ! 'VP 0"/( $ G_
M )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1)0  22   $ ;   X%@
M,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@((  7"2< %@DN !4*-P 3
M"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[  L-V0 +#?$ # W_ )4O
M  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0*P  1R8  #XA   V'0  +A@
M "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1#2, $ TK  \--  .#C\
M#0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40U  %$.\ !A#_ )(S  "(
M-P  ?CH  '0[  !K.@  83@  %@U  !.,   12P  #TG   U(P  +1\  "8:
M   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"  #! H  L1,@ *$3P "!)(
M  <250 &$V4 !!-V  ,3BP !%*   !.V   3T0  $^X  !/[ ) V  "&.P
M?#X  ',_  !J/P  8#T  %<Y  !--@  1#$  #PN   T*@  +"8  "4B   >
M'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F  85+P $%CH  Q9&  $7
M4P  %V(  !AT   8B0  &)\  !BU   7T   %^T  !?[ (XZ  "$/P  >T(
M ')#  !H0P  7T(  %8_  !,.P  0S<  #LT   S,   +"P  "0I   ;)
M$Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD   :+0  &S@  !M$   <40
M'&   !UR   =AP  ')T  !RS   <S@  &^T  !O\ (P^  ""0P  >48  '!(
M  !H2   7D8  %5$  !+0   0ST  #LZ   S-P  *C(  " M   7*0  $"4"
M  LB"0 %( T  1\0   ?%   'QL  " B   @*P  (38  "%!   A3P  (5X
M ")P   BA0  (9L  "&R   AS0  (.T  !_\ (I#  " 2   >$L  &],  !F
M30  74L  %1)  !*1@  0D,  #I    O.P  )3<  !PS   3+P  #2P"  <I
M"  !)PP  "8.   E$@  )AD  "8A   F*0  )C,  "<_   G30  )UP  "=M
M   G@@  )YD  ":P   ES   )>X  "3] (A(  !_3   =E   &Y1  !E4@
M7%$  %-/  !*3   04D  #5$   K0   (3P  !<Y   0-@  "C(!  ,P!P
M+PL  "X.   M$0  +18  "T>   M)P  +3$  "T]   M2@  +5D  "UK   M
M@   +)<  "RO   KRP  *NX  "K^ (5-  !]4@  =54  &Q7  !C5P  6U8
M %-5  !'40  .TT  #!)   E1@  '$,  !,_   -/0  !CH    X!0  -PD
M #8-   U#P  -!0  #0;   T)   -"X  #0Z   T1P  -%<  #1H   T?0
M,Y4  #*M   QR@  ,>X  ##_ (-3  ![6   <UL  &I=  !B70  6UT  $]:
M  !"5@  -E(  "I/   @3   %DD   Y'   (1    $(   !! P  /P<  #X+
M   ]#@  /1$  #P8   \(0  /"L  #PW   \1   /%,  #QE   [>@  .I(
M #JK   YR   ..T  #?_ (%:  !Y7@  <6$  &EC  !B9   5V(  $E>   \
M6P  +U@  "15   94P  $%$   I/   !30   $P   !*    200  $@(  !'
M#   1@\  $84  !%'   12<  $4S  !%0   15   $1A  !$=@  0X\  $*H
M  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=:0  3V8  $)D   T80
M*%\  !U=   26P  "UD   )8    5@   %8   !4    4P   %($  !1"0
M4 T  % 0  !/&   3R(  $\N  !//   3TL  $Y=  !.<@  38L  $RE  !+
MP@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0  1VP  #EJ   L:0  (&<
M !1E   -9    V(   !B    80   &    !?    7@   %T   !<!   7 D
M %L-  !;$@  6QP  %HH  !:-@  6D8  %E8  !9;0  6(4  %>@  !6O0
M5>@  %/^ 'EP  !S=   :74  %MT  !,<P  /G,  #!R   C<0  %F\   UN
M   $;0   &T   !M    ;0   &P   !K    :@   &D   !I    :0,  &@)
M  !H#@  :!4  &<A  !G+P  9S\  &92  !F9@  97\  &2:  !CMP  8N$
M &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[   8>@  #GD   1Y
M>0   'D   !Z    >@   'H   !X    >    '<   !W    =P   '<!  !W
M"   =PX  '<8  !W)@  =C8  '9)  !U7P  =7<  '23  !SKP  <M,  ''W
M '%^  !C?P  5(   $6"   V@P  *(0  !J$   .@P  !(0   "$    A0
M (8   "(    B0   (@   "'    AP   (<   "'    AP   (@   "(
MB <  (D0  ")'   B2P  (@_  "(50  B&T  (>)  "&IP  A<<  (3O &:$
M  !7A@  2(@  #F*   JC   &XT   ^-   $C@   )    "1    DP   )4
M  "7    F    )8   "7    EP   )<   "8    F    )D   ":    FP
M )T'  "=$0  G2$  )TS  "=20  G&(  )Q_  "<G   G+D  )OB %J+  !+
MC@  /)$  "V3   >E0  $)8   28    F@   )P   ">    H0   *0   "F
M    IP   *8   "G    IP   *@   "I    J@   *P   "M    KP   +$
M  "S"0  LQ4  +0G  "T/0  M54  +5P  "TC@  M*P  +3, $V2   _E@
M+YH  ""=   1GP  !:$   "C    I@   *D   "L    KP   +,   "U
MMP   +8   "W    N    +H   "[    O0   +\   #!    Q    ,<   #+
M    S0P  ,X:  #/+P  ST@  -!B  #0@   T)T  -"X
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MZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,!(0   0
M          $                    !     0(#! 4&!P@("0H+# T.#Q 1
M$A,4%187&!D:&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,3(S-#4V-S@Y.CL\
M/3X_0$%"0T1%1D=(24I+3$U.3U!14E-455976%E:6UQ=7E]@86)C9&5F9VAI
M:FML;6YO<'%R<W1U=G=X>7I[?'U^?X"!@H.$A8:'B(F*BXR-CH^0D9*3E)66
MEYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNL+&RL[2UMK>XN;J[O+V^O\#!PL/$
MQ<;'R,G*R\S-SL_0T=/4U=;7V-G:V]S=WM_@X>+CY.7FY^CIZNOL[>[O\?+S
M]/7V]_CY^OO\_?[_  $! @(# P0$!08&!P<(" D)"@L+# P-#0X/#Q 0$1$2
M$Q,4%!46%A<7&!D9&AH;'!P='AX?(" A(B(C)"0E)B8G*"DI*BLL+2TN+S Q
M,C(S-#4V-S@Y.CL\/3X_0$)#1$5&2$E*3$U/4%)355=86EQ>8&)D9FAJ;6]Q
M='9Y?'Z!@X:)BXZ0DI67F9N=GZ&CI:>HJJRMK["RL[6VM[FZN[R]O\#!PL/$
MQ<;'R,G*R\S-S<[/T-'2TM/4U=;6U]C9V=K;V]S=W=[?W^#AX>+CX^3EY>;F
MY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S\_3T]?;V]_?X^/GY^OO[_/S]_?[^_P !
M 0(" P,$! 4&!@<'" @)"0H+"PP,#0T.#P\0$!$1$A,3%!05%A87%Q@9&1H:
M&QP<'1X>'R @(2(B(R0D)28F)R@I*2HK+"TM+B\P,3(R,S0U-C<X.3H[/#T^
M/T!"0T1%1DA)2DQ-3U!24U576%I<7F!B9&9H:FUO<71V>7Q^@8.&B8N.D)*5
MEYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_ P<+#Q,7&Q\C)RLO,S<W.S]#1
MTM+3U-76UM?8V=G:V]O<W=W>W]_@X>'BX^/DY>7FYN?HZ.GIZNOK[.SM[N[O
M[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^_O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________XH$)24-#7U!23T9)3$4 "0G_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]/_________________________________________KT?______________
M___________________________WZ?[_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________AS=?_____________________________
M_________]VOEK?T_____________________________________\6,:*?G
M_____________________________________\R<B:3G________________
M______________________K.N\;U________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________<Q;WU
M_____________________________________[^3>H7%________________
M____________________VY!;/66H]O______________________________
M___^O'4T %2;Z__________________________________3E'Y)+$Z:[/__
M_____________________________]C4RK-^96VE^?__________________
M__________________3%KJ_)____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________PUL;L________________________________
M____YKN1=&.K]_________________________________;$FG-%)C1]S/__
M_____________________________[6 53 * !E@LO__________________
M____________SW0U"P    I2I_______________________________EC0
M      !/I______________________________V:1T   D,!@E2L?______
M_______________________+.PX3-4Q;34Q>P_______________________
M______^I8#9@AI^VK*FXV?_____________________________@EXV^Y?__
M____________________________________[?G_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^O9RKS'____
M_______________________________/FH%M6D:(ZO__________________
M_____________\1\/B80  !4L/______________________________X(,\
M       NA^W_____________________________K%,0       7;=;_____
M_______________________[@#$        )8<S_____________________
M_______26@(         7<S___________________________^H-0
M    7-/___________________________]]#0          5-;_________
M_________________^Y]10          1-3_________________________
M__RJ9"\"   $(C=)6,[____________________________II&M!*#]C?Y6G
MNMK______________________________]6RK++,Y/K_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^6[EW=BR/_________________________________;
MGF<V"@ "C/_______________________________\A_/P4     7L______
M________________________V8$Y        /*K_____________________
M________GDP         (Y#____________________________<;QH
M    $'WY__________________________^O2            &_N________
M__________________^$$P           &3F________________________
M_^Q1             %?>_________________________[@5
M $C6_________________________W04             #C/____________
M____________^:):$P           "/%_________________________]^;
M7"P           VZ___________________________OL7U5.2(1!P$"$2*R
M_______________________________?OZ69F)J@K+W:________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________COIV ?/O_____
M___________________________RMX17, X ':S_____________________
M_________]**3!4      '+S____________________________UG\V
M     $O)___________________________ZD3X          "^K________
M___________________ 6@           !J5________________________
M__^-)             B$_________________________^=>
M  !W_________________________[0E              !J____________
M_____________WT               !;]/_______________________2L
M              !,Z_______________________I0                 \
MX?______________________, P                MV?______________
M______^9BF$G               GU_______________________[;Z)52<
M           EW/_________________________^RIUV74H\,BTL,#E'WO__
M_____________________________>;=UM+0T]GD____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^_4N];_________________________________Y[B/
M:DLO%6_______________________________^2A9S0'     #S)________
M____________________UH([         !*7________________________
M___MA3$           !O__________________________^F0@
M  !0X?_______________________^QI               WR?__________
M_____________[,O               BMO_______________________WD
M               0I_______________________\C0
MF?______________________J0                  C/______________
M________1@                  ?______________________?
M            =/____________________^7                    :O__
M___________________.                    8___________________
M____*2(!                8?______________________N:. 5S<7
M        :/__________________________^M.NE(9\=7%P<G>!E/______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________;NIV":6G3________________________
M_______(DV4]&0   !V>____________________________VXY,$P
M  !N___________________________;?"P           !%U___________
M______________^+*@             BM/_______________________\)$
M               #E________________________WT!
M?_______________________YS8                 :O______________
M________G0                  6/______________________1@
M            1_C____________________I                    ->G_
M__________________^6                    )=O_________________
M__^\                    &,[____________________K
M        #\+_____________________                    "KG_____
M________________)P                  "K7_____________________
M<                   #;G_____________________X)R,<%5",R8;% \-
M#A(:)K_____________________________YY-C2SLS+S,_6X/S_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________K
MT[SC________________________________TJF%94@L$@&%____________
M________________\:MQ/ \       !/X/_________________________5
M?S4            ?LO_______________________^-U'0
MB?_______________________Y C                9_______________
M________U4,                 2/;_____________________B@
M            +MW_____________________.                   %\C_
M__________________^^                    !+;_________________
M__^<                     *7___________________^Z
M         )/____________________<                     (+_____
M________________                     '3_____________________
M$P                   &C_____________________0@
M     &#_____________________>@                   %W_________
M____________T0                   &'______________________R0
M                 &;______________________\FLF8E]=G%L:6=F9VMP
M>HS_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______BQ:J1>6%W_____________________________]VF=U L#      Q
MQ/_________________________@DDX3            C_______________
M_________])P'0              8/______________________[F\/
M            -^+_____________________EAP                 %,#_
M____________________0                    */_________________
M__^N                     (G___________________^>
M         '+___________________^\                     %______
M_______________:                     $W____________________Z
M                     #O_____________________#@
M     "KY____________________,P                   !OI________
M____________7@                    _;____________________CP
M                  ;0____________________T
M  #*_____________________RL                   #(____________
M_________X                    #+______________________<6 04%
M P$       $&#1C+_______________________\Z^'8S\S-S]#2U-?<XNK_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________\=K&________________
M_______________QQJ.$:$TR&  5J___________________________N7Q&
M&           <?_______________________]=\+P              .^/_
M____________________WV0)                #+7_________________
M____= ,                  (W____________________%%0
M         &K___________________^9                     $O_____
M______________^V                     ##]___________________7
M                     !GG___________________V
M      73____________________#@                    #!________
M____________+P                    "O____________________4@
M                  ">____________________>0
M  ".____________________I0                    " ____________
M________V                     !T_____________________S8
M              !M_____________________WP                   !I
M_____________________]<-                  !H________________
M______]P                  !A________________________4#Q&3E19
M76%D:&QP=GZ)________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________OU;NCBW-:E?__
M________________________^+^.9$$A!0      4OS_________________
M______>=5A@             %\'_____________________Y6P6
M         (W_____________________8P                   %[_____
M______________^=                     #7\__________________^A
M                     !'9___________________*
M      "[___________________N                      "A________
M____________#                     "*____________________+0
M                  !V____________________30
M  !D____________________;P                    !2____________
M________E                     ! ____________________O
M               P____________________Z@X                    B
M_____________________T0                    5________________
M_____X$                    +]?___________________\@+
M           "[/____________________]>                    Y?__
M___________________)'                   VO__________________
M____G0$             !PX7Q?_______________________]6YO,''SM7;
MX>;M]/O_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________C?S______________________________LQJ6(
M;50[(0< ,M[________________________7DEDI             *#_____
M_________________XDV                 &?_____________________
M9@                   #+V__________________^5
M      /(__________________^G                      "@________
M___________7                      !\____________________
M                  !>____________________)0
M  !#____________________2                      L____________
M________:@                     8____________________BP
M               %\___________________KP
MX?__________________U0                      S_______________
M_____R0                     OO___________________U0
M            KO___________________XL                     G___
M_________________\L.                    DO__________________
M__]7                    AO____________________^J"@
M        >?______________________;0                  9O______
M________________]U4                 1?______________________
M__]J(RLU/TI58&IU?H>1G/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Z,^VG8-I3KG_____________________
M____[+*#7#H= @       'O______________________\5M*0
M     $#_____________________@QL                   ?+________
M__________^2                      "8__________________^D
M                  !J___________________=
M  !!____________________#@                     =____________
M________.0                      Z/__________________8
M                SO__________________A0
MM___________________J                       H_______________
M____RP                      D/__________________[Q8
M            ??___________________SX                     ;/__
M_________________VD                     6O__________________
M_YD                     2?___________________](6
M        .?____________________]8                    *?______
M______________^B                    &?_____________________U
M5@                  !/______________________NR\
M     /C______________________ZLI                 ,__________
M_______________)1P     '$R N/E)HA.W_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___TU<G____________________________ZTK"2=UU"* P  $K_________
M_______________%?447             !'8____________________Q%
M                  "?__________________^B#
M  !H__________________^4                       V____________
M_______:                       '[/__________________%0
M                Q/__________________2
MHO__________________=0                      @_______________
M____G0                      :?__________________PP
M            4O__________________YP\                     /O__
M_________________S,                     *___________________
M_U@                     &/___________________X$
M        !?___________________ZP                      /______
M_____________]XB                     /+___________________]<
M                     -____________________^?
M     ,S____________________H2@                   +?_________
M____________H!8                  )S______________________WH"
M                 '?_______________________]Z"P
M!4S_________________________HE=H=("-G*N\T.?_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________[>/__________________________]*C>E@Z*2,<%@X&
M  "?_____________________ZQ2#@                !I____________
M_______D0P                     T__________________]Y
M                X__________________-
MLO__________________$P                      A?______________
M____3P                      7?__________________@P
M            .O__________________L@                      '/__
M________________VP,                      O__________________
M_RH                      /O__________________T\
M         .?__________________W0                      -3_____
M_____________YL                      ,#__________________\0'
M                     *W___________________ S
M     )K___________________]G                     (;_________
M__________^C                     '+____________________C1
M                 %S_____________________D08
M $'_____________________ZU\                  !W_____________
M_________\I+                  #________________________+5P
M#!@D,3].8'2+I\?__________________________]?G\O______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________^O4
MS<?"OKJWL["MJ:BE____________________W7Y3/S C&1$) @
MV_________________]V                        I_______________
M__^Z                        =?__________________!P
M            1O__________________3@                      &O__
M________________C                        /W_________________
MP0                       -O_________________\1D
M         +[__________________T0                      *3_____
M_____________VL                      (W__________________Y$
M                     'G__________________[<
M     &;__________________]XA                     %/_________
M__________]*                     #____________________]W
M                 "O___________________^L"@
M !;____________________G10                    #_____________
M________B@                    #_____________________UDT
M              #]_____________________Z<N                  #5
M______________________^8*@          !A@M16#@________________
M________J&-T@8^<J[O-XOK_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^?+MZF=E8Z)
MA(!\>'1P;&AED/________________^\:D@M&0H                 ,?__
M________________                         ___________________
M0@                       -S_________________C@
M         ++_________________S@                       (W_____
M_____________RD                      &O__________________UH
M                     $[__________________X8
M     #3__________________ZX                      ![_________
M_________]07                      K___________________H]
M                  #___________________]E
M  #___________________^.                      #_____________
M______^\&0                    #O___________________Q3@
M              #8____________________BP                    "_
M____________________S$,                   "A________________
M_____Y$9                  !Z______________________)T"@
M         !%?_______________________H=!,?+#A%4V)RA9NTTO7_____
M_____________________]?H]/__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________^_?S\>[LZ^OL\?__________________V;*9AWEM9%U644M&
M03PX,BTH(\3_________________2R4+                     )+_____
M____________B                        &;_________________UP
M                     #W__________________S,
M     !C__________________VP                       #_________
M_________YT                       #__________________\D,
M                  #V__________________$U
M  #?__________________];                      #+____________
M______^"                      "W__________________^I!@
M              "C___________________3+P                    "-
M____________________7@                    !W________________
M____DP<                   !>____________________S4,
M          ! _____________________X<0                   <____
M_________________]A>                    ____________________
M__^_3@      #APL/E)JAJ7(________________________PGR,FJ>VQ=;H
M_?__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M[N'7S\G#OKJVL:VIIZ:FIZ[_________________OH9M6TQ -R\H(AP6$ L$
M     !3_________________UP4                       #_________
M_________S0                       #V_________________W8
M                  #2_________________[
M  "R_________________^$D                      "6____________
M______]1                      !\__________________]Y
M              !F__________________^@                      !1
M___________________'(P                     \________________
M___N2P                     G____________________=
M           0____________________HQ8                     ____
M________________V$P                     ____________________
M_X@/                    _____________________\M3
M        ______________________^E.           "1TT3FN,________
M________________F3E#45]N?8Z@M<OE____________________________
M_^OY________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^O,N:RA
MF9&+AH%\>'1P:VAF9FCQ_________________V%%,B,8#@8
M  ">_________________WX                       !U____________
M_____\,                       !2__________________LW
M               R__________________]J                       6
M__________________^6                        ________________
M__^_&P                      ___________________F0@
M            ____________________:0                      ____
M________________D (                     ____________________
MN2P                     ]/__________________Z%P
M        V?___________________Y$8                    O/______
M_____________\I3                    G?____________________^8
M+@             0*49FQ/_____________________N?QT,&B@W1E=I?I6O
MS.[_________________________YZ"JN<C8Z?S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________]]?#KYN+?V]C4TM'0TM?@_________________\Z>BGQQ:6%;
M5E%,2$,^.C8R+RXQ_________________](E$0,
M__________________]"                        ________________
M__]]                        __________________^P"P
M            ]O_________________=.0                      W/__
M________________8@                      Q?__________________
MB0                      K___________________KR(
M        F?__________________UD@                     @O______
M_____________W(                     :?___________________Z$H
M                    3O___________________]-<
M    ,_____________________^6+@              %3)2=___________
M___________@<A,   $/'R]"6'"+J,CL________________________RF]N
M?HZ>L,/8[___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___YX-+(P+JUL*RHI:*?G9N;G*"G__________________^"9%9+0SPV,"LG
M(AT8$PX)!   U/________________^2                        K?__
M_______________,'@                      B__________________[
M4@                      ;?__________________@
M        4?__________________J1L                     .O______
M____________T$(                     (___________________]6@
M                    #/___________________X\4
M     /___________________[@^                     /__________
M_________^5M P                   /____________________^?-P
M            $"]0=/_____________________=<A0     !A<J05IUE+;:
M________________________O%A$5&1UAIJOR./_____________________
M_________]+-X?'_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________S[^OO]_______________________N
MN:B=EH^*AH)_>WAV=')S=7A_D/_________________K3SHP*"$;%1 +!P(
M        (___________________:0                       /______
M____________FPH                      /__________________R#D
M                     /__________________\&,
M     /___________________XH.                     /__________
M_________[ T                     /___________________]5;
M                 /____________________^%&@
M ^S___________________^Q20              &#E=@?______________
M_______E>QX       PA.%)OC[/9________________________NU@I.4E:
M;("7L,WM_____________________________[.>M,77Z_______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________KOY^'<V=;4TM#0T-'3V>#K]___________________N(I^
M=W%L:&1A7EM96%=765YE<?__________________OS$?%A *!0
M     /__________________[58                      .C_________
M_________X($                     ,S__________________ZLO
M                 +/__________________])7
M )O___________________=\$                    (7_____________
M______^B-P                 %*Y3____________________+80(
M       ,+%!VGM'____________________UC3        TC.U=VF;[E____
M____________________PV,8*CM,7W2-I\;G________________________
M_____ZA_EJB[T.?____________________________________]________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________]W.Q;^\N;:TL[&RLK6YP,G5X____________________Y=L9%Y9
M55%/3$I(1T9(2U!99J'__________________Z<F#@<"
M %;__________________\Y0                     #K_____________
M______1Y"P                   "'___________________^?,@
M              [____________________$6                 @Q6H3_
M___________________I?Q\           8G2W&:PNG_________________
M____ITD      A<O2FB*KM7\________________________TW4>)CA*7G6/
MJ\OO_____________________________ZYRA9BLPMOV________________
M___________________?[_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______^_LJJFHZ&@GY^AHZ:LM,#-W>S___________________^*6E-/2TA&
M1$-"04)#1TY9:7W___________________^>+@8                   #_
M___________________#5@                  %4'_________________
M___G>QH             "31@B[3_____________________GS\
M!"5*<9G"Z_______________________QF8/    $RI$8H.GS?7_________
M________________ZXXU*SY1:(&=O-[_____________________________
M_[YV?Y2IP=SY___________________________________2V//_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________;R\._O[_'S^/W_________________________
M___XL)^:EY:6EIB;GZ2LML+1X>[____________________^CE!*1T5$1$1%
M1D=+45IH@ZG_____________________ID$!           '-F./NN'_____
M________________QF4*       $)TQSG,3L________________________
MY8@O   3*D1B@J;,]/___________________________ZM0-DIA>Y:TUOK_
M_____________________________]*'?)BQR^G_____________________
M_______________4SNW_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^WEX^/DYNCM\?G_____________________________
M_;&4DI*5F9VCJ;*\T.W__________________________YU31TE-459@<XJO
MUOS__________________________[)6 !HU4&V+KM+W________________
M_____________\UO/E][F;?7^?_______________________________^Z?
M@Z;"X?_____________________________________CSNO_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________\
M
M
M                             /______________________________
M____________________________________________________________
M____________________________________________________________
M____________________     /_A0=]H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC,# R(#<Y+C$V
M-#0X."P@,C R,"\P-R\Q,"TR,CHP-CHU,R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @
M(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \
M>&UP.DUO9&EF>41A=&4^,C R-2TP,2TS,50Q-CHT-CHU-2LP-3HS,#PO>&UP
M.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(U+3 Q
M+3(T5#$S.C$U.C4Q*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C R-2TP,2TS,50Q-CHT-CHU-2LP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y4
M;W5C:%5P(#<N,#PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \9&,Z9F]R
M;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/'AM<$U-.D1O
M8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C<Y,6(R83AE+3@V,3$M
M.#$T8BUA-C%B+3-E-#0U-C,V,S@P93PO>&UP34TZ1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HP,F0Y-C5D-RUE-#=E
M+3,U-#$M.3-C.2UF-60S.#DW-#0S-C8\+WAM<$U-.DEN<W1A;F-E240^"B @
M(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HS9F)B8C@Y
M-"TX93%A+30X,3,M8CEC,RUD9C)F9F(S9C!F8S,\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C,Q,#!D930S+34V9# M9&4T-RUB
M,&1A+3DY9#)D-3(P.61F,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R-2TP,2TR-%0Q,SHQ-SHT,"LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(U+C(@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R
M=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO<&1F('1O(&%P<&QI8V%T:6]N
M+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI
M8V%T:6]N+W!D9B!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HU.3%C-68Q,BTU93ED+61F-#DM838Y-"UF9C(X.#DX9F4X
M9C$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C4M,#$M,C14,3,Z,3<Z-# K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<" R-2XR("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M,&9D934U-6,M,&$V9BUD-C0W+6(T8F8M83DR,C(R9#EB-V0W/"]S=$5V=#II
M;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U
M+3 Q+3,Q5#$V.C0V.C4U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @
M,C(N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A
M<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E
M<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@
M:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z,#)D.38U9#<M930W92TS-30Q+3DS8SDM
M9C5D,S@Y-S0T,S8V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(U+3 Q+3,Q5#$V.C0V.C4U*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP
M+FEI9#HP9F1E-34U8RTP839F+60V-#<M8C1B9BUA.3(R,C)D.6(W9#<\+W-T
M4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$
M/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HX.#$Y9&4V8RTX-65D+6,S-#0M861D
M,RTP-SDT-C<U.39A-3,\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HS9F)B8C@Y-"TX93%A
M+30X,3,M8CEC,RUD9C)F9F(S9C!F8S,\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @
M/'!D9CI0<F]D=6-E<CY4;W5C:%5P(#<N,#PO<&1F.E!R;V1U8V5R/@H@(" @
M(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-
M;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^52Y3+B!796(@
M0V]A=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@
M96YD/2)W(C\^_]L 0P &! 4&!00&!@4&!P<&" H0"@H)"0H4#@\,$!<4&!@7
M%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L 0P$'!P<*" H3
M"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H_\  $0@ ^0#D P$B  (1 0,1 ?_$ !P   (" P$!
M           " 0,%!@<$"/_$ $80  $# P("" $(" 0$!P    $  @,$!1$2
M(08Q!Q,4(D%187$R%4)5@9&5TM,6,U)35'*2H2,E8I,F=++!0V.$HK'"P__$
M !D! 0$! 0$!               ! @,%!/_$ "01 0 #  (#  $$ P
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M2$%1"4A782X15&%!"N+4A:J*B$N%;A*0B",;'W0F8-BA09="$+#00A" 0A"
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M1_3(#]171U@^,+$V_6DP,D$-9"\34L^,]5*,X)'B""01X@E'3BOZ7BS%4M2
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C0A (0A (0A *"%*$0AY)2$R"M0BLJ"$Q\5'@4"M"%*$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>cv-20251231_g2.jpg
<TEXT>
begin 644 cv-20251231_g2.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[28B4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M            !;0   63          $                          0
M           %DP  !;0                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P  !;0     4F=H=&QO;F<   63    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   6T
M     %)G:'1L;VYG   %DP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      ;^P    $   "<    H    =0
M 22    ;WP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ H "< P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M.RWTI ANL_E57JE@95BZF)<'>4?[T&SJ3Q19DM9OJI=Z<:07#W.^D6_HZ?\
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MV0/O8M?[!D_\V_1^S7S]OG;Z;Y_H_P!+Z.[:C16F0TUZO__9 #A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      $N34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -    $L     0   2P    !061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-3HP,3HR-" Q,SHQ-CHR.    Z !
M  ,    !__\  * "  0    !   %DZ #  0    !   %M          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
M @$ !     $   $N @( !     $              $@    !    2     $X
M0DE- _T       @          /_A 39%>&EF  !-30 J    "  ' 1(  P
M  $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$
M @   !X   !R 3(  @   !0   "0AVD !     $   "D    T    2P    !
M   !+     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#(U.C Q
M.C(T(#$S.C$V.C(X   #H $  P    '__P  H ( !     $   63H , !
M  $   6T          8! P #     0 &   !&@ %     0   1X!&P %
M 0   28!*  #     0 "   " 0 $     0   2X" @ $     0
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MH<'1%;&S%C,V='6RX20F-4-$8G*"E @E-$538V3P97/Q_\0 &@$  @,! 0
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M=1<&7%S+PAH4D]Q++*]C SR.Y+,QC7))[DUQY<2>RV>N*Z_X'_H7H']GV_\
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MN/RJ%?B%6;$D-Q:9VYHSXD?WCI1VD7]H&'BV\B<O63 8&IT_$[J,M"8W'FH
M--JRFBMN\A3Q#('C[.N]-R$3Q\LP\6/K@]1Z@T[?:;<6\CS:>2R]7C(V(]1^
M=#(ZNAEA#+R[21GJA_3UH7QV$K7*&WC$2,LF);=QC<9!]#ZU4M8T\65PK0DF
MWDW0GMY@U<UE0J<C,3_.'YU&W]L)HYK9AE2,HP['L:1DQ^C0T^;=P^RN1,%A
MZ4*=WKVK,$P1N*\*/:JHE1H-V&6VV]*=LL*]Q^RE#LP:3[:%=A^ Y=HOLJ-<
MY8T=*W+ :C@V7WKHG3?@/MCC VVHB4Y![4%&V"*(E;V>WV4+7(2? !<'V\BN
MS.!SG@OA\_\ X^W_ (:UQ?,3S'-=G<"G_,GA_P#L^W_AK5W3=LROJ#^*+Q2I
M4JOF,*E2I5QPJ5*E7'"I4J@^)=:&G1&&W(-TXR/)!YG\A0RDHJV%"#F]J&^)
M=<%DK6UJP-T1NW7PQ^M4"5O$D+2$MODD[Y/ZUZN+@LQ+$EFW9B<DD^M0/%MW
M/9Z*LEJW(TDHC+#J ?+UK/R9'-FQAPK$J1+I')+(4R%!Z G%07&"-+!;6<:Y
M4/XCMYGIBB^#[=7Y9&+%SC<G)^^I77K8/?IML#FEKD8Y4S[PSIF-/8!1@KC>
MFIM!7QF8)OYXJW:) BVBC':CO C"EWQCL/.K4,:HI3S-,S/4])6&$O*N5&X4
M_2/F?2J[%IMO%.U_K D9A[4, 7YWJQ/0>E:O?V1F<RM%XG=5.P]YJ#ON"=3U
M>19IFAB5NS,=A[J=#$D)R:J54C+=7U,WLP#311J=U5VV^\5]LKR*%Q%-'OC)
M9"&&*T&7X+[N R2Q+!/(1C).3]QK/];X=N=(DDC6.07'-LIP![L':G.&[LKP
MFKHEO!T^>-O 2,_6*C!SZU6=4TF>!VN-*E,<J[X['T(H:&6Z#%E0QRQG! /7
MW5;N&9XK]E%P"DX^;D8YO,?X4/1841GA&_.H0^%=P^!?J,,A^D/,5ZXCT,0Q
M/>V:X=1EU ZC]*E=9T(B/XY9 I/'[0Y>H]U!S:VUYI?AJO)<GV9-MAZCWU#.
MV^C/C,H'B("(V.ZGZ)\J>8%;0R)@JAP?/!KWJ]NL%Q\F/99?;]#YT*D_+:W$
M)).8OQS2VN&,@FIHK6HQB*]F"C ;VA]M"Q?.\L5(:Z,747K$,_>:CHSRFJ$N
MV:\.D&]83YT%&?;HM=T()H;E*MTH$-85,V8:BS(.?K1K$LF*C9TPW>B@@,C\
MARR94&B(I W6@[8\R8[U[BVDP3BH:)BSU=XYBRCM797 O]">'O[.M_X:UQM<
M(".N=J[)X%_H3P__ &?;_P -:LZ7MF?]1Z1>*5*E5\QA4J5*N.%2I5&:[JT>
MEVI;9IV'L)^9]*AM15L*,7)TAOB'6XM)M\;/<N/DX_S/I6=7-S)<O)),_/(Q
MRQ\S3=W=27,[SSN6>0[L>_Z"O+ PP22<F0HSN>IK/R97-_PV,&!88_T]119&
M6Z56^-YPT=M: '/B!C5DX82:[F:2=N8YV'8#T%1W&VFG]HPL!DC?-*[0U26Z
MF&\&P?)H<8Q4EQ!RI=<V=MJ^<,0^' !C<TQQ!*LUT2X^0B..OSSY>[SHX18J
M339*V%\L5J'D.(\;?[W^%%1W_BCQ92%3Z(/>J%<ZI++/$JQ\W-[2JVRA!U=O
M]T=AW]U5KB?C68MX5CS<O02\A)D(]W05>QQXLS\SITNS0.)]6,>5C::27.X5
ML!:K]CQOJ%C.429P!VDW'XUGFHZ_>I'RRJ#,XRK $8![D&@)+J2$MXS\TI&P
M7?)_.G(K[;-_TCX3(&(74(AR_7CVJ1XMO>']=T1^:>)I^4M&I/*^<=ZYODN[
MR"/Y:&2,'?!Z_=UJP<(7S:@WQ6Y4R6_T6^E&?3]*Z5/H*./R2%IISSH8Y(V:
M#)*-C#(?-3W'I7B97M95#(?8^F-JV_A.PM9]&^)W$2%@,K(!U'8CUJN<6\,I
M L@"YR,JWF*%CH9%=,K,7$40TL$GGN\<H7&,_P"]58NY%MH6D; 9M^G3UKTZ
M)9:D%?)B<8'H:$XC,<.F>+,?E7=2%ST6DM^"Y#&ER1?$C016!0,&E=AN#U)_
M+%19M/"MX%8YFDV.#]$=30TT<C7;RW&?B]NV(U^N>HHE)196TVH7S9/93W/9
M12\DZ5#\."WN?2*YK\@;57C4_P VH7[>OYT OS6(KPSM-.\LAR[L68^IKW)\
MTXJHW;+BC2"[5N8;"O$A]HTQ:R%33\@!&0>M!5,)<H\ [[4Q,F<T]DCKBFW;
MKM4H%]#<+<A/E1!7F7F[T*1WIV%ST.]$UY!B_ \"I!!.V*[*X&_H5P__ &?;
M_P -:XOD? (!WQY5V=P(3_(GA[^SK?\ AK3],N64?J#N,2\TJ5*KYC"I4J9O
M+F*SMGGG;EC09/KZ#UKNB4KX0QJVHQ:;:&67=CLB=V/E6;ZG=RWURSSN#(_7
MR \O=3VMZE)?W)FD..R)V1?UH:+PPH'+S,=L50RY-[KP:N##]J.Y]GB*/D8*
M0-^@'4T?J.G<NGDN3O@X%1VFYEU:1B<J&Y%]PJ\:A:Q_L1F+ -C:D8_G=>!F
M6>QK^E=X6M0H&!Z9I_7]/$\\9SG[.E.<.L%&WNJ6N$0R@$]-S5C'%,K9)-2L
MC[2Q\*VP-L]Q49?:6+AN:48MU^B-N?T]U6NW59@6<\L*['U]!7FZNK42@,55
M1T]FK48)+DIRS23X,<XOU&"RMKPMRB,KX2A1DN_U%'H.IZ#WUE4VK\[\@A9'
M[;'"_=77IL=)U"#EGM;6X7RDB4_E55UWX)N&M25WLX&TZ=OIP'*_:I_+%'&:
M?0O_ "<P1>)"'D#"8$^W@D_>#3:ZHJ7<DRL1*D3&+_B]/7&<5=/A#X$U;A-3
M+*@DL<^S=19Y?M^J??65WLPO;@0_S=P".61>C'U_6C[)3"]:XJ&HSVUM864=
MN$"KSQ@EY&^L3U)K2^"I@L4,TF%E8<L@\V!Z_;6>Z3I*6\J23PMXX/T#C)]W
MZ5=+6;XO", *3L$7? H:H?%VC<N'-:$/)[0Y>V]6K7^34-"DEC]HH.8>GG6*
M:->2^$A.<D;UJ?"MS+/9O R\PE3!SV/3]U18$HUR8]K\?-<%6&V:J*6]UJ&J
M2O>$I86YR?7'0"MUU3@_XS=/S>S''N3W-5C4.'BS>$@ @0Y/;)[DT$DDK+./
M,YO:NC.'A^,2275QB*UB!;?HH\_?5)US4FU2[Q&I2UBVB0_WCZFKOQD&NO\
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M\(,>-3M).S1$'[#_ (U5H#S&0%<@5;OA+D$1TG.WBRO""?,KS#^Z:JXC9D
M.#Y4K,JR,=IFI84,WD4-W;>'=Q!U796'5?MJ$,#Z5>QA27@D&5)ZU93&.0A?
MG?OJ.XIB#::"@S) P.W;SJKF2K=Y+>";3V>& :A T4HNH#[+;O[ZDQ(MY:(Z
MJ><"H_2KM;B)DFP?0T];.;&["2;QMT/I2>.T-DGT^T'6DKJ>N#W'E4[:7 E7
ME??UJMW*M$XE7=&W-2%C.,C# 8HH.G17R0W*R4=_#<JV>6O:VD,ZY)!!KY,H
MEA+*<G&]1T5TT)Y6R #3U*NROLW+@=N-#3F)B-!MI4B9#+M4LEZI ]H5]:\3
M."117$&I$(=/#;,N,#M7G]EQG.Q/F<5-B9#S$8-.(T;#IOZ&I5'7)$5;Z7'Y
M* -J>&FPL"K [>E'EH%.ZL ?MKZ'M!S>TQ-&D@6V#P:3IT14SC)ZX)VHM;FR
MM0/B<:!Q])1O]]#R&WD^9$6P-RQH:>0E2(@, =$V_&B3KH&K[89/>2N09Y.1
M!OCJ2*A-0U8>U&,I$.PW)]:;O+G,7*N7?L =AZ^M0=W&3[<Y)D._V4,IM%O!
MB5\C*R20WL=PO,_M9"=V'<>[%2-GI;3:@+5&^17VVE)^AU'WC% 6$4EW,4@7
M ^D_8"K1 $_92+$_L0GPI&SNPZC\Q2HI/EFA/,X*EV#<4WJ&!+6T0A.4*H'8
M"J-JLR3JH*$GF',2<8]*M.I2;/)SE4<D  >0JD7=P)'DB#,]PKB550?.'E2L
MN2V6=)CJ-(?N9K:TB19+@*.? 9CD*>O2J_,QNE$;,>9B0"#L1GK]U$:AI?\
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M&:K+'/T:/W<37,D '4"%YV)R*\-J@/<Y[4Q-I5S:7/Q:\+V[XR _0BG5TQ@
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:4LX59&0@J0@R"/.K>D3W.T9GU2<7"*3/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>cv-20251231_g3.jpg
<TEXT>
begin 644 cv-20251231_g3.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2#:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! !+     $  0$L     0 !.$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              5    ;-
M          $                          0             &S0   5
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   5
M    4F=H=&QO;F<   ;-    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
M CA"24T$#      6E@    $   "@    'P   >   #H@   6>@ 8  '_V/_B
M#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  (
M"0 & #$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !
M     -,M2% @(
M                $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H
M  )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I
M97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M#')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D
M97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@
M245#-C$Y-C8M,BXQ
M                      !865H@        \U$  0    $6S%A96B
M                6%E:(        &^B   X]0   Y!865H@        8ID
M +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT
M=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C
M+F-H
M     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:
M(       3 E6 %    !7'^=M96%S          $
M   "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D
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MK@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS
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M_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MN"YPI&W*H)C*QB=+:SHUF0YSO[*;P&]F3W\?"0#$:="'_]DX0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !+DU- "H    (  <!$@ #     0 !   !&@ %     0   &(!
M&P %     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %
M )"':0 $     0   *0   #0   !+     $   $L     4%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,C4Z,#$Z,C0@,3,Z,3@Z-#,   .@ 0 #
M     ?__  "@ @ $     0  !LV@ P $     0   5          !@$#  ,
M   !  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (   (!
M  0    !   !+@("  0    !              !(     0   $@    !.$))
M30/]       (          #_X0$V17AI9@  34T *@    @ !P$2  ,    !
M  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q  (
M   >    <@$R  (    4    D(=I  0    !    I    -    $L     0
M 2P    !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-3HP,3HR
M-" Q,SHQ.#HT,P   Z !  ,    !__\  * "  0    !   &S: #  0    !
M   !4          & 0,  P    $ !@   1H !0    $   $> 1L !0    $
M  $F 2@  P    $  @   @$ !     $   $N @( !     $
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M5G6!D9.AL=$(,S="4F*2L\'P%4-R<W2"HK+A)S5&8\+Q_\0 &@$  @,! 0
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M'8S_ /1KTS^!I^3FZ_&J_P!TW7H;9YI19YVX6*DD6A>]4KM\VY,]6PGR5#?
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M<=:,5=0I;<<OF4W5=U9:5R1);G,)) .5J-5?TI7M$.!_1S*^*0\#QX[!_/\
M.U2R_P!T1:8+DAY0\H4/,23O_P#I_P":H^[/.3ICLB2OB<4<DCEZ!X"DK5<?
MJ:+.V;_=EF]$=\3)M\>SN,E#K3:E)<3R*0<G/CO3EJ&-J"VE<AF:Y*A\_,2
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MK.1LU?.$^\*4#GJT\!(Y9[:]5?@:?DYNOQJO]TW7CO!\:]B?@:?DYNOQJO\
M=-UZ&G!0BHKH>?G)SDY/J6CJ*5IN+= +DQ&?GO-J;4GA25!' M659(&.%*AO
MW]U$GV,3)* 94)*S)ZUP(4D=:XTHJPL]O"O*N8W'I%*KKI.#<YC[[[TM(>/$
MXTAP!"E]66^+EG/ <<\;#:N#VB+0\L%Q+JAU:VE)44D*2I:U\R,@A3BB"D@[
MTY!AVYZ8ES2E7DDB1);25**!YS:\HR5' (/!CT"LO2=)S)*)+SML=?E L!:B
MDESD,?ZDC/<H=A%=I6DXDW@\OE3).&TM+ZQ:1U@25%/%PI&XXU#;'.N:-&6[
MW4NO2WG74=6XZMP<2AELC. !MU2!R[^TYH('=%H@(F)EMQ6D2$E2NL2,$E1)
M.<<\DD[]];S[;"N"0F;%9?Q[TK2"4^@\Q\E*Z* (=K"TNQ-.35P[E);90D*+
M,GW=  ([5>>/VJA<+4%WM\V#:)&GI%PA/E76R+?E?D^=@KA5C8[Y2"3@9'<;
M8OD(7&S3X1Y2&%M?.DBJ7TU<DW2UQWG2M,EA0:="5D%+B=B<^.,UCN5AIXR;
M[2.N#CG [7#1C>GK*](1+7UB'"0V1MP^%0.:4,7%N7#;$=(3QK<X?,20<GYR
M/KJV'KPQ<K4Y$F. /)RD%?;5=WFVN*24J;"TCD0JEG>86G ].SU2S)E<:GD/
MWJ<MY25J:2?,!V'I-1QV&KB'$!G/(58LV*IILCJ4H':<U&)RV(W%P>>X1SYX
MK%KRSL4XX6$1RY MHZE Y;GTUI)S&AM,\E'SE>DTL8:*W5/.##:-U$]]-$M\
MR9*E;@9VIEQ'7 L[HIO@1%EQ;C/;1%92D,M.D# )/%@_P\:<[_KN+ 3U%I:0
MX1L%J'"@>A(Y_5540%EM+JN\9'R&M9KQ,GM.U&I\D"HQ;U2+*E](BT6\=5"0
M)A3NM2LH![PGG\A-5?>KG*NDU<B<\MYU1]\H\O =PI9(.8@/>*:U-@JJ8MOF
M-*G&/U1S!(%'&>^A2=JT(RD[4Z0N6.MLGK;W0XM)':E1%;7"Z.O+ 6XXO'Z2
MB::HI(K#ZO=-J72LCJHU'(O:=*QDFE2' $&FU*^%L8%=4.$BH:+8U1]TDHG5
M=E_QS'[Q-%8TACV4V7_',?O$T5IM^3.;\C+,HGJJ[]#V@[Q=)=QN6G([\V4X
M7GG5.N@K6=R<!6*2>T9T;_!:+],[Z]%%;SS@>T9T;_!6+],[Z]'M&=&_P5B_
M3.^O110 >T9T;_!6+],[Z]'M&=&_P6B_3.^O110 >T9T;_!:+],[Z]2W2.D[
M'H^WNP=-V]N!$==+RVT*4H%9 &?.)/(#YJ** 'RBBB@ HHHH **** "HY%T1
MIV))D2(UL;;=D**W2%KPHYSG&<<R:**AQ3YC1G*/U>#:5HO3\I84_;4*4,;A
MQ8Y>@UL-&V$)X?Z/3C^\7]]%%)M0\5Z'WZGD_8G?T#IE].'K2VH>+B_OI"KH
MKT6HDFPL;_\ M<]:BBIVH>*#?J^3]LRYT6Z,<9#*K"QU8Y)#C@'^ZDR>A_0:
M3D:=CY_O7/6HHHVX=@WZOD_9O[4FAART\QRQ^-<Y?M5A?1%H5:N)6G8Y/?UK
MGK444;<.Q/Y%7R?MFQZ)=#E(3['V.$=G6N>M6GM0:$^#L?Z5SUJ**-N'8/R*
MOD_;,'H?T&?_ !R/]*YZU8]IW06,>QR/]*[ZU%%3HCV(WZGD_8#H=T$.6G(_
MTKOK5@]#F@2=]-Q_I7?6HHHT1[$;U3R?LS[3N@L8]CD?']Z[ZU9'0]H,<M.1
M_I7?6HHHT1[$[]3R?L[Q.BK14.2S(C6%AMYE:7&U!USS5 Y!]]WBBBBA12Y(
(656<OLVS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>cv-20251231_g4.jpg
<TEXT>
begin 644 cv-20251231_g4.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[18R4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $P< 5H  QLE1QP"   "   < E  "')R,3<W.#8U' (% "M-:6-R;W-O
M9G0@5V]R9" M(%!R;V1U8W0@9&5S8W)I<'1I;VYS,RYD;V-X.$))300E
M   0FJ;+)F2%&&@ZFEH+VEG$8CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !  $!+
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "RP  !V0    & &< ,0 S
M &$ ,  S     0                         !              =D   "
MRP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MRP    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   LL     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M3]GOC^8B=C_^^*6('''4;A:2>&6G0O\ _]DX0DE-!"$      %<    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( -0    $ .$))300B
M  %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (
M   )    L8=I  0    !    O    .@   $L     0   2P    !061O8F4@
M4&AO=&]S:&]P(#(V+C(@*%=I;F1O=W,I #(P,C4Z,#$Z,C0@,3,Z,S4Z,CD
M<G(Q-S<X-C4      Z !  ,    !__\  * "  0    !   '9* #  0    !
M   "RP         & 0,  P    $ !@   1H !0    $   $V 1L !0    $
M  $^ 2@  P    $  @   @$ !     $   %& @( !     $
M $@    !    2     $X0DE- _T       @          /_A 4Y%>&EF  !-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !\   !^ 3(  @   !0   "= 3L  @    D
M  "QAVD !     $   "\    Z    2P    !   !+     %!9&]B92!0:&]T
M;W-H;W @,C8N,B H5VEN9&]W<RD ,C R-3HP,3HR-" Q,SHS-3HR.0!R<C$W
M-S@V-0     #H $  P    '__P  H ( !     $   =DH , !     $   ++
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0              2
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P &! 4&!00&!@4&!P<&" H0"@H)"0H4#@\,$!<4&!@7%!86&ATE'QH;(QP6
M%B L(",F)RDJ*1D?+3 M*# E*"DH_]L 0P$'!P<*" H3"@H3*!H6&B@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M_\  $0@ R0(4 P$B  (1 0,1 ?_$ !P   (" P$!              0% P8
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MXRNN-]V(Z--<*(KN>9_;0N<\S'2!N?.X_90UWQ%X@  7/<Q!ZQ>_PK>, \L
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M/>G&'Q(\ME)X'/4F:[QZW6^[*PP5/SBBPW\RQ2 _SGF&P'_[EMS6K&88RXY
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MF.1V]J\V%Q23W'44PP.;/AB@?U6QP8WHSHKR#2KVT9Z?:Q(5I)A/??>B[%\
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M,%#^8TL3!/PHVT0!"DB>]!V5)42L]?:B$]$]/>*S,-SV_P"10ZO"^,/^W/\
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M .Q< MG2=,\_&LNX@Z06,D=:7WKK"XB&-MS7-RY ,F9_94W .<XQCM<!$[4
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M *ONJ+$WX2X/+DM(U="#[?52R[FJVF=05)(7;MM'W4MQWB)%LNIV*B%/M/\
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M*JI&IE"D]CWHDW1;M&XQ+DL -HB!VH8*SA1AP Y!TENIG[ZDU-<M72MLC2-
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M<N0K0-((D;0.]6GP=D2XBVF)<D%22)X'O75:ZA',P:1U8=A\L2UEB:)!T D
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@'?Y]<(2[;*&-*;P1Q65Z.:RO0A')%1Y&*<LTG+F?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>cv-20251231_g5.jpg
<TEXT>
begin 644 cv-20251231_g5.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1BV4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %0< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q-S<X-C4< @4
M*TUI8W)O<V]F="!7;W)D("T@4')O9'5C="!D97-C<FEP=&EO;G,S+F1O8W@X
M0DE-!"4      !!DCD>J&HG54),Y;Q;MQTD0.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+
M  $  0$L     0 !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    6CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             A,   87          $                          0
M           &%P   A,                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   A,     4F=H=&QO;F<   87    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (3
M     %)G:'1L;VYG   &%P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !SA"24T$#      .'0    $   "@    -@   >
M &5    . 0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ -@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
M 0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $#
M @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$
M!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,5
M8W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ XCJO
M5>JMZKG-;G9+6MR;@UHN>  +': ;E=Z3@_6/J+1<_J&3CXIU%CKK-SA_P3-_
MT/\ A7HG3NBLZE]8NI79+=V%BY-SK&_OO]1Y91_WZU;V?D%E0[-(DM&G]5K?
MZOT54YCF3&7MX_G_ $I?N_\ H3<Y;E1./N9/D_1'[S7#,?%@'(R<E[>7VY%A
M'_5[?^@F?U&00T6._P"N/C_JU3)%A#GP(; @1,:_VW_RT-]K6RT,,C0[G0J_
MJ)UE*1_O-JH#01B/HSR'^JT@9.9A./#Z[K7-']:MSW?]!8N;?UW#<"_J&194
M\Q7<R^PL=Y?3]C_Y#EI>H]PWL[<[23^!1:ZZ;Z]MK :,CV6M[;_S'C]U30S2
MAN3(=CJ6')@A/Y0(RZ$;?8\_^UNK_P#<_*_[>L_\FIT]1ZY?<RBG,R[+;#M8
MQMUA)/E[T'J&'9@9+J+> -S'?O,/T7?]]7;_ %:Z%7T[#%UP'V[):#:3RQA]
MS<9O]GW7_P O^HK&3,(PXAZN+Y6ICPRE,Q/IX?F1=)Z%G-#;.J=4RK+#_P!I
MJ<BP-'\E]V[=8[_B]G_&+H<7#PP!6QKOB^RQYG^M:][E6MQ+'MW5GS/P_JJ.
M/DO8\M?[7MT(*SYY\A-R)\AZ0WX\O #0#ZZI<_$I'L>'M'BVRQAC^M6]CESW
M4>D=1>'6],ZEE->/^T]M]A:?Y++MVYCO^-_[<74Y>52:-UA]P''DL1V5M=/9
M*&;(#<9$CL?4$3P0(HQ'TT>+MZCUNFU]-V9EUVUG:]CKK X'P<-ZA^UNK_\
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M_K5CQ;'I1_9;Z:S.HY0:'8M3MQ.ESAQ_Q3?_ $8J--UE%K+JC#V&6SQ_5/\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    D   "PAVD !     $   "\    Z    2P    !
M   !+     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#(U.C Q
M.C(T(#$S.C,Q.C(Q ')R,3<W.#8U       #H $  P    '__P  H ( !
M  $   87H , !     $   (3          8! P #     0 &   !&@ %
M 0   38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M     0              2     $   !(     3A"24T#_0      "
M    _^$!3D5X:68  $U- "H    (  @!$@ #     0 !   !&@ %     0
M &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M%    )P!.P "    "0   +"':0 $     0   +P   #H   !+     $   $L
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C4Z,#$Z,C0@
M,3,Z,S$Z,C$ <G(Q-S<X-C4       .@ 0 #     ?__  "@ @ $     0
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" "U A,# 2(  A$! Q$!_\0
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M8X0/TT(1BS<1 /AWD52N.:\##?(>DF!M9!XC]%4VYG;Y0_$.1VSX=U6:9QU
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MIY(]Q###)Q*S!@I0$G)R>=!+^-;65&A#A6_)X3A?KJU11-+'O@1D9!'.H5Q
M]UURHF+8+@ESV0?&C0;78.QX RW'&@)PU+KN';/"/*AC,;>>2)L\2G&",9'C
M7:S%D'.C; 7J<$UYR58+]OG4.:;A4MX]U,O,58@[5'D+YSG(J\8@Y3)*3]H9
M/#3HGPISW?IH7(_"<G;%,R7.#L<^5$5>07JX"ZW'""0=Z2SAMV)P-Z#"2:0$
MHA-.)!/( [L(T[]^5=]+';*>LPE+=+DX<8%5#I%J_P I)MK8D0J>T<^L?X5S
MK6HQ\;063%E&S2G\KW>5 Z>T^F4?<S.U.J<_8A4_I_\ 7[7\\G^H4Q3^G_U^
MU_/)_J%.")^@OH5_%AH/YI_VC4J7H5_%AH/YI_VC4JA#XX]/?XQM8_SUS^TK
M.JT;T]_C&UC_ #US^TK.:A!4J5*H0(:+J]WI%UUUG)PY]93NK#P(K4>C?2FQ
MUB,0,5@O#MU3G9O\)[_=6/5Z"1RS2NHTD+USP_L;TVLLT[XZ^C?FMDP0/TU
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M%K2HT<:_=+EF=;JI3XCPA4J5*G145*E2J$%2I4JA!4J5*H0)Z/K-QIIX5(>
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IY O,;_VZ5*H0VGH7H0Z,=&-/T9;EKH6B%.N9 I?))S@;#G2I4JA#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>cv-20251231_g6.jpg
<TEXT>
begin 644 cv-20251231_g6.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1Q:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $P< 5H  QLE1QP"   "   < E  "')R,3<W.#8U' (% "M-:6-R;W-O
M9G0@5V]R9" M(%!R;V1U8W0@9&5S8W)I<'1I;VYS,RYD;V-X.$))300E
M   0FJ;+)F2%&&@ZFEH+VEG$8CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !  $!+
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             ".    CL    & &< ,0 S
M &$ ,  R     0                         !              ([   "
M.                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M.     !29VAT;&]N9P   CL    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   C@     4F=H=&QO;F<
M  ([     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M=A^\YWYK4D@7H'1_YU?6C_RYSO\ V(?_ .21\;KOUSROZ/U3J#VCEYR'AO\
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MLC:6C0^:S;*W-<6S+W_0<=.0FG1!'5SK@U[@#);R8_@AFL N<2=![2=2K)V
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M_];B?K3_ .*GK/\ X>R/_/CEEK4^M7_BHZS_ .'LC_SXY9:2DV-DV8UF]@W
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M671:_I[0RNVMSCZ])@-<USO\(O<5\JI)*?_9.$))300A      !7     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #4    ! #A"24T$(@
M   !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )T!.P "
M    "0   +&':0 $     0   +P   #H   !+     $   $L     4%D;V)E
M(%!H;W1O<VAO<" R-BXR("A7:6YD;W=S*0 R,#(U.C Q.C(T(#$S.C,T.C$T
M ')R,3<W.#8U      .@ 0 #     ?__  "@ @ $     0   CN@ P $
M 0   C@         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%.17AI9@
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
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M 2@  P    $  @   @$ !     $   %& @( !     $              $@
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M-U9AL]((%"-U@92B%4)28I$DH:.QLM$F,U/"X52"@Y*3_\0 &@$  @,! 0
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M3#N<H)%QRHS1+'8#4TW(]T 4<C67D890%%SUJR9 C6Y%S34A(;O!YTJ1VS$
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M\,/\!*T/=S -M#:L407,BG._N45OGTF?75O#X8?X"5!X>X')LW$8LZ&5LB^
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M\W8^[,-\):*W&$\:?29]=6\/AA_@)7,48HP8&Q&H-=.^DSZZMX?##_ 2N84
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L ZT44 %AW46HHH +46HHH +46HHH +46HHH +46HHH +46HHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>cv-20251231_g7.jpg
<TEXT>
begin 644 cv-20251231_g7.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2.24&AO=&]S:&]P(#,N,  X0DE-! 0
M     $P< 5H  QLE1QP"   "   < E  "')R,3<W.#8U' (% "M-:6-R;W-O
M9G0@5V]R9" M(%!R;V1U8W0@9&5S8W)I<'1I;VYS,RYD;V-X.$))300E
M   0FJ;+)F2%&&@ZFEH+VEG$8CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !  $!+
M  $  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              [X   -P          $
M                 0             #<    [X
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   [X     4F=H=&QO;F<   -P
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   .^     %)G:'1L;VYG   #<     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !3A"24T$#      9&
M  $   "3    H    ;P  16    8_  8  '_V/_M  Q!9&]B95]#30 "_^X
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M>USOI^I_-[$)6>JV69 ;U1A]3!I]6EP9[O3V/]-^4YK?<]F^FRN__05_X/\
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M4X_H_0_PJO=/P\C*KKZ7?6*^G]-_19.T;1E6M,L9M_[B^F69&7_W)R+?L_\
M-U95=K?5S&R/M=IO;M_9_J8V@AI?8\9#G5_R&4?9]G_&+HDV(J[W)*Z1NJV
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M4%[;7_\ 7<M]_P#UJFE*NG*R<AF-B@![VN<ZUP!:QNC-[FG^<V[_ .9_PO\
MQ7J*75JW876BP_T;J#?5J_D7M(KO9_Q=[746?^&/4_TJA]H.(^O,!C[.X/?'
M>L^S(;_VR?4_KUHJ=;IN!1C5Y'3:9;]EN9967DN):178QYWS^>VVCV_Z/]'Z
M:UU1N 9U;&M;_AZK*GQP=NVZEQ_XO]-_V\KR"E+RSZ^66?67Z[8/U:H)]''+
M:[2V##K0+\VS_K&$QO\ ;7I?4<ZCIV!D9^08IQ:W6V'R8-T#^4[\U>=_XKL*
MW.ZEU+ZU9\!]CWUUN= 'JVG[1EN;^[Z3?1H;_P!<24^@X53&56XD 5U/-;6
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MYH8;,ASP) 94QWJ#^L_UMJAG=;IQGFFJMV1?)8UC2 '. #GM:X_Z%KMU]O\
M,4_X2WU?T:RL_,RL[T*[*30\.=N>TM>S9[=-X/TMS?6_ZTFRD!U71B2JIS[
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MUU5>F'._JO2ZI_B[Q<G+?D=.R?L++27/QS7ZE8<?I.HBREU+7?Z+^;_T?IK
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MYCJV,K=9ZGZOLMN]2NJSU?L_\VME)))"DDDDE/\ _]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
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M     0   [X         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0%.17AI
M9@  34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (
M   )    L(=I  0    !    O    .@   $L     0   2P    !061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-3HP,3HR-" Q,SHQ,SHU,0!R
M<C$W-S@V-0       Z !  ,    !__\  * "  0    !   #<* #  0    !
M   #O@         & 0,  P    $ !@   1H !0    $   $V 1L !0    $
M  $^ 2@  P    $  @   @$ !     $   %& @( !     $
M $@    !    2     '_X4 ':'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L
M(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(U+3 Q+3(T
M5#$R.C0P.C0X*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM
M<#I#<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-2TP
M,2TR-%0Q,SHQ,SHU,2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,C4M,#$M,C14,3,Z,3,Z-3$K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@
M(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C N
M," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D
M9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F
M875L="(^36EC<F]S;V9T(%=O<F0@+2!0<F]D=6-T(&1E<V-R:7!T:6]N<S,N
M9&]C>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @
M(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C$W-S@V-3PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z
M8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF
M;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D)!-D8R
M,C,P,C9$045&,3%!.#0T044X.#@P,S5#-D4X/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D(X-D8R,C,P
M,C9$045&,3%!.#0T044X.#@P,S5#-D4X/"]X;7!-33I$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z0C@V
M1C(R,S R-D1!148Q,4$X-#1!13@X.# S-4,V13@\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D(X-D8R,C,P,C9$045&,3%!.#0T
M044X.#@P,S5#-D4X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(U+3 Q+3(T5#$S.C$S.C0V*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z0CDV1C(R,S R-D1!148Q,4$X-#1!13@X.# S-4,V13@\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C4M,#$M,C14,3,Z,3,Z-3$K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC
M;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D)!-D8R,C,P,C9$045&,3%!.#0T
M044X.#@P,S5#-D4X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(U+3 Q+3(T5#$S.C$S.C4Q*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.D(Y-D8R,C,P,C9$045&,3%!.#0T044X.#@P,S5#-D4X/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.D(X-D8R,C,P,C9$045&,3%!.#0T044X.#@P,S5#-D4X/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z0C@V1C(R,S R-D1!148Q,4$X-#1!13@X.# S-4,V13@\
M+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$
M97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP
M+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P &! 4&!00&!@4&!P<&
M" H0"@H)"0H4#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M
M*# E*"DH_]L 0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@!(0$) P$B  (1
M 0,1 ?_$ !P  0 " P$! 0             &!P,$!0(( ?_$ $D0  $# P("
M!P4& P4&! <   $" P0 !1$&(1(Q!Q,405%A<2(R@9&A%4)28K'!"#-R(R1#
M@I(6-%.BLM$78\+A)39$5&7#\/_$ !H! 0$  P$!               ! @,$
M!0;_Q  J$0$  @$#! $$ @(#         0(1 R$Q!!)!\!-187&A(M$R@4*Q
MP?_:  P# 0 "$0,1 #\ ^J:4I0*4I0*4I0*4J.ZZO3MFLO\ <N'[0E."/&XA
MD!:L^T?)(!/PH,.I-90[1*,&,R[<;GCB,9C'L#Q6H[)'KO47>U1JN2>)'V3!
M3W("5O''F=AGTK0@1&X3!;;*EJ4HK<<4<J=6>:E'O)K8JX1N1M9:A@J!N$"'
M<6![QAJ+;H]$JV/IG-3G3]\@7^ )=M>ZQ /"M*APK;5WI4D[@U75:@EKT_<T
MWV)D)3A,YI/)YG.YQ^)/,'U%,*N*E>6G$.M(<;4%(6 I*AR(/(UZJ!2E*!2E
M*!2E*!7!U3J:-86VF^K<EW!_/41&O?<QS)/)*1WJ-=>X2VH$&1+D'#+#:G%G
MR R:J^UI>E./7>>,SYV%JSOU3?W&QY 8]36O4U.R&S2T^^6P]<-3W$\<FZLV
MU!W#$)H+*?5Q7/X"OQM[4457'&U"ZZ?P2V$+2?E@BMJE<?S7^KL^&GT=.PZS
M4N8U;]0QD09;IX67VU<3#Y\ H[I5Y&IG58SHC,Z([&DHXVG!@CO'@1X$<P:D
MW1[=)$VTNQ+@YUDZWN]F=</-P  H6?,I(SYYKIT=7OVGES:NEV;QPE%*4K>T
M%*4H%*4H%*4H%*4H%*4H%*4H%0#I#2I>H;(#NVVS(<Q^;V #\B?G4_J ]*I4
M&H:8JU(FK2M*2-LHRG(SW;\._AF@XU*PP^L[*UUW\SA'%@YW]:RUDC]%8I*$
MN17T+&4J;4DCRP:RBL<DXBOGP;6?^4T$RZ+)#DKH]L3KI*E=F",GO"24CZ 5
M*:CW1Y&3$T/8VD>Z(C:O]0R?UJ0UBI2E*!2E*!2E*"+])R^#1%S/%P@AM)/D
M7$@UP2 "0!@ X J1=([0>T1>$*Y!CB^(((_2HTPHK8;4>:D))^(KDZGPZ^F\
MO=*4KE=16WH5)1JB\X]U<=A1_JRL?H!7+N"2J"^D*2G*".)7(#O-;_10D,"Y
MQE)*G$%M1</(@C8#P&V0/.NCIX_DY^HG^.%@4I2NUQ%*4H%*4H%*4H%*4H%*
M4H%*4H%17I"M,JX6MEZW-J=DQ7./JDD!3K9!"D@GOP<CS%2JOQ:DH0I2U!*4
MC)). !05#;BLPFPXPY'4D<'5.XXTXV]K'?M6Q7DRF9LR?(BJXXSDE9:4.2AR
M)^>:]5E"%89J@F%)*C@!I?\ TFLM:-V:<G)CVJ.?[Q<71'&/NHYK5\$@T%EZ
M'24Z.L85D*$)G(/] KMUX8:0PRVTT EM"0E('<!L*]UBI2E*!2E*!2E*#@Z]
M;4[HR\I3S$9:O@!G]JB,-8<AQUI]U32%#XI%62^TA]EQIU(4VXDI4D]X.Q%5
M39FW(!E6>2HE^W.=4"?OM'=M7Q'Z5S=17:)=/33O,.G2E*XW8T[H7C%ZJ*VV
MZ^\H-(;<5PA95MC/=MWU,-$61^SVYXSBWVV2YUCJ6B2E  "4H!//"0!GOJ'7
M&2(2X,QQ"UM1I3;K@0,JX<D;#OYBK.BOMR8Z'F5!;:QQ)4.\5V=-$8F7'U$S
MG#+2E*Z7,4I2@4I2@4I2@4I2@4I2@4I6&7*8ALJ>E/-LM)W*UJ"0*#-7'NCH
MEW6-:A@H4@R'QXH!P$GR)^@-8#>Y4]7!8X*W$';M4D%MH>8'O*^  \ZTI6FI
MW:$W=FY+<OS22E"W!PL*1S+10.23X\P=Z")W6WO::EF/*23;GG5&-* ]D%1)
MZM?X3OL>1]:P2WUQD=8&5NMI]\-C*AY@=]6!9KG"U5:Y<67&"76R8\Z"_NII
M7@?$'F%#F-Z@%Q8-@U"BR%QV6VXWUL=Q*2M;:,X"'<<O!*N_'C5B1J+OMJ;A
MJE.7",AE(RHJ6 1_EYY\L5+^CRRNJ=<O]R:+;[Z.KB,KYLLG?)\%*V)\!@56
MNLUP7K _(9CL.N.*X5.]4 M*4'*SDC.1BK:M%_[#*BVR\'JTR$),"8K9$@8S
MP$\@X/#O&XI(E5*4J!2E*!2E*!2E*!4/US8GGEMWJU(2J?%04.M$X$AGF4Y_
M$.8/P[ZEZUI;0I:U!*$C)43@ >-0F9?3J%J8JVJ*-.Q6UJDSCL))2#EMOQ3X
MJ[^0J3$3&)6)F)S")QM4VR4RVJ*X\\ZL I82RKK/EC'UKIQ%R%-K>F)0RDC(
M;XL\ _,?&N-I.2Y&TS; XV\\I_@2RE RI76;I&_AO\*ZL>$N[:L19KW'?AP
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MD6+4K#4\\4>X'JA) PEQP>Z5#D%D;?FV\*"84I2@4I2@4I7EUQ#32W'5!*$
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M*].M]GE6T]T67!'7MG',$<JR]A'@/E4@<A84V>'[V.59.Q?E^E7O3XT;$$>
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M+Z1]3S+(Q)A6Z)#+LJ(&Y#H7U2T.JQP;]X[R-L<JV5ZKOS=[:C6Y49(<U"Y
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M\*_:&1C'Q%(_K]DQC*T%1 3R%?G8_*J[>Z1;M'BN]IMT-M4*XJA3Y@6MR,P
M 0O8<6#G&XV/.O+G29/XNU,VV,[;'I;T".$.DR%.MH)"BG&.$D>H&#5[]O??
M*=GOOX6-V08.PK][)MR%5WIF<8VC4:QN.I'I<MV,77&WGL14*4?<#:1D<)V\
M:P0^DF]36H\6-:8B;HN>]"6'UK;;' UU@5C!4,CN-6;3$S$^"*YC,+*[(/ 5
M^B(!W"H3H/7=QU!<X+%RMT:*U/@JFQU,O%:APKX%)7D>.XQW5";7<-3S/MB=
M&E74Q6'+@F6\^XGL_5I"@V&AS"P<;BI-YC]_K8BF?U^UW)C#B!P,I.16W51V
MSI"E6S32T.L-2'H-NM[H6\\0I]3^ 2?3ZU*=.ZN?FZENULN[4:W&,>)AIQ2@
MXZWG <R?9*2? Y!I/.".,IG2JXUIKRZ6.]7./!MT21$MD1F9(6Z\I*U(6OA*
M4@#&>_?:O$GI$EMW5Y3=OCFT,7)JV.%3I$@N. 'C2G&.$9&W,[FI&_O^O^UG
M;W_:RJ4I0*4I0*4I0<67I6QR[PBZR+9&7<4$$2.'"\CEDCGCSK&UH[3S2IJF
M[/#29J2B1AO^8DG)!\B=\"N]2@XLZR6)IF3(F0X:&SU;KSCB0!_9>XI1_+W>
M%<G1FAK)8XX?898ERW>L49BD J6EQ141X8P<>8J&=,LZZ*F72VKDW&-;W+4I
M41N''ZP2WR2%(60D\AC;;G6HB_WM&J[-;H*KC&C#J(;["D**5(4Q_,0.#"0%
M8]HJSGNJ1.5F,>_C^UFMZ,TXBWRH*+3%[')4%.L\.4J(.VV=L>59GM*V-Y@L
MNVN*ILR!*(*/\4# 7_5@<ZI%N]WJT:%A0X4Z^?:J%2E+=>2HI;<0HX:(#9*B
MH;@<CD[U8NHYM]F)T6U E2H2K@29JV602,-<6#D'ARK;XU?O^$\XG[I0WI*P
M-S)<M%IAB1+2I#RPWNL*]X'U[_&MU^SVZ1;F8#\-A<)G@+;*D^RG@W3@>6!B
MJ9M&H];.0;Y(#ZW+BU%=4Y 6TI2V7 Y@*;3P@8"<[9.>=9[G?YS;$40M0WU5
ML5#==1-[+Q.NS1CA94.#9/EC?EFIX]^ZXW6N]IRSNWA-U<@,&XI_Q\84=L;^
M.WC4?@Z(TXWJEV9;6XC1:C.19<)I(*5=:0K*QW;#EYU"W[OK94/4$YQ^:S(A
MQ8H3$;C@I2IQ(+SB=LJ4D9(2"<&N.W<;O 5J&99)-SD1)-PB(=N3[)0[U'5'
M*A['+.!Q!.WA3B<>[['CW\KC@Z+TY!;"(EFA-)"T. );^\C/"?49.*RRM)V*
M5;6+>_:XJH;"BIIKAP&R>93C<9R:@NB9>I;CJ>ULW*[O.0&K=VE:F&<-R5=8
M4I"E*2#GAQD#&<5:HK*81P9^CM/7!YEV=:(;[K3890IQO)"!R'F!YUW4I"4A
M*1@ 8 K]I4"E*4'"EZ0T_,NAN4FTQ')RO>>*-U;8W\=O&N/=NC>P2[>B'#A,
M0FNT,OO!IO/7);)(0K/=O\*FM1OI%F72!HZY2;$E:I[: 4%".-21D<2@GO(&
M3BIQ"QO+&WI?2K[:;8U;H"TP5]9V=/\ AJ5OE0SWX[ZZ#&F;*Q>%75FVQ47%
M6<OA XN6"?7'?5,0[G)@O:EE09=ZDM39,-IJY.M*:4$]6<J40C/"#MLG/=6>
MTW:]JN.GKS>9-Z+JK1*066&RD/O-K.$E)3LI21G?&<5??UE,+5&B--!^6\++
M""Y25)>PW@+!YY'+>L\#2=AM_5&':HC):<+J"E&X64\)5GQ*=LU >CN_WR=;
MM4]J?E/H8C)?A..H45H4ILDHXBA/$0H#;&QK@S[QK&):]/===YC?;H7:5RWF
MN$)DDC#2@E!(2!]T@9R=Z8\?CW]'*Y8-AM<!R,Y"@1V%QVBPRI",%#9/$4CP
M!.]9(]HM\>#(AL0V&XL@K4ZTE.$K*_>)'GWU5AOVH^T:C+\N:G4,9I7V?;&V
M#V9U 0#U@/#[9SDX*AX8KG"^:F?8<8LUVNLB"Y(A-=O>BCK6W'"0\@ I&4@8
M/+;QIC.WNYQO[LLRZZ7TKQPW;G;;<%-I1%CJ=2!@ ^P@>.XV%>W]$V%V3UX@
M-MNE]$AQ2.;BDG("O+.^/&JIU-*O$F_(AS95T?F0KTPF/"[/EE<=(]EY2PGF
M3S.?+%(6H]9.62_R53WDSVXQ*HI94IUA[K0 4)X,</#W95GG4K.8S[XE9C?'
MOF%SS;!:ISDMR9 CO+EM)8?4M&2X@'(2?$ UB5IBRJN[=T5;(IN"  E\H]H8
M& ?4#;/.MJQL/1K1%9E2G9;Z4#C?= "ED[DD#85O5<8E,Y@I2E I2E I2E I
M2E IW4I0*_/&E*@_>ZE*54!2E*BE*4JA2E*!2E*!2E*!3QI2@5^#F:4H'_>O
:WOI2I' #W:'N]:4IX(!2E*H4I2@4I2@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>cv-20251231_g8.jpg
<TEXT>
begin 644 cv-20251231_g8.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2#<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $P< 5H  QLE1QP"   "   < E  "')R,3<W.#8U' (% "M-:6-R;W-O
M9G0@5V]R9" M(%!R;V1U8W0@9&5S8W)I<'1I;VYS,RYD;V-X.$))300E
M   0FJ;+)F2%&&@ZFEH+VEG$8CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !  $!+
M  $  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8             !,H   5*          $
M                 0             %2@  !,H
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P  !,H     4F=H=&QO;F<   5*
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   3*     %)G:'1L;VYG   %2@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    "#A"24T$#      68@
M  $   "@    D0   >   0_@   61@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MH;!3:?I%S= #XJ?U;PKKJ*+&>UH<Z7>,.*O_ &89&>X,&Z7Z1X#251G,1G,
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M=2T-LN;E$<N<P,)^!J]O_@:LX?6<'+S+>GML#<['8RR[&)]S66?S=G\MCO\
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M_NV#Z3/_ "'[S4E,LEE]F/:S'L]&YS'"JTB=KB/:_:N2&!]>JWBECMU0?O\
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M/>ZEX-60S6RAWTA_+9_I:?\ A6(&19@,RJF7N%.5<#Z%I!871H:VWQZ3[/\
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MRJDDI^JDE\JI)*?_V3A"24T$(0      50    $!    #P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O
M ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @ " $2
M  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   $L     0   2P    !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C R-3HP,3HR-" Q,CHU-CHS. !R<C$W-S@V-0       Z !
M  ,    !__\  * "  0    !   %2J #  0    !   $R@         & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
M @$ !     $   %& @( !     $              $@    !    2     $X
M0DE- _T       @          /_A 4Y%>&EF  !-30 J    "  ( 1(  P
M  $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
M    Z    2P    !   !+     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#(U.C Q.C(T(#$R.C4V.C,X ')R,3<W.#8U       #H $  P
M  '__P  H ( !     $   5*H , !     $   3*          8! P #
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M*"@H*"@H*"@H*"C_P  1" #P 0D# 2(  A$! Q$!_\0 '0   00# 0$
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MI2?4Q=4RW0,'YPF>?X0D+=><(VAIP2WAWZS[%O3V=J(IY7NC&WM/3/HW^S_
MGJ6XJ7D#M6<%?U4K.%O#C8D=NZ::C4@D>X]1 <G.1QKR*]TP<721QN)[#&_[
M5UXT2:Q)'#>H47E?P6QHJ[T-!\&^1H:_)+=^WL\E85?60MAAFP#Q'(>1G&RY
MT9K5T4,#&45%*Z#(9*Z-X=PDYX3Z6#A.K^E*OEBX'04K&@  -A<0,?TUG"BQ
M/DZB[2IV<YS_ -%NW*4<$0C:YY>_<#D"3V>"US.8VU\<>7, P'9SAQ.3MYA4
M[_RFW6,GJ12X)SAT!_MK0WI"KW,+9>K /-K8,@__ #66IT,[<8,'VA7Y9_8E
M>J1%44DDP<1(P'B&-SXJN0\LJ"02-^Q+Z_6<]1%P,9"T8Q^  ^GC*8FU[2\O
MD#P?T6MQ[5Z-+II51<9'FU&JC:\QR3*AF=+&.%WICMQE;F5<YDD8 <CPYJ(Q
M7YT!S YP/Z;6D>U**?5E7%*9"6EV<Y$3.?K"K+2MOR"U:2\R6V626IJ'-D#A
M@@^2T]),L?W+;3PC9DC"3X[IA&M:R,N= 6L<<G/51_8G2T7-T]DJ[O>HX:UK
M:AL%'3RL;U;Y^'B<]X '$UC2/1S@EPSL#FL=))6J?&$6EJU*MPP\L@S'#B!X
MA@ ;Y7T[MO\ -]-^J;[ J'Z#V5-UZ/V5%\C;*Z:HE,7%$UH,6P&&@ <.>+&R
MM.EKJ^ <$50V1H'HMF;D>61@KH'@R2U"B8UB*0AMXMU33#'X6+X5GT;CYD]6
MR_6NYC_F-?3S'\T/P[YCNA(Y(0A "$(0 @\D(/) <"^Z5;P]-&I/&2(_ZEBK
MJ62*9S'/;)LQK"&N'Y( [O!6/[IG\=6H_E0_N6)HLUPTW#:*1E9553:@,'6M
M9%G#NW!Q]:AO!*AN9#\4OY,=4#XN;]B\8R('THIGC]%V/X584=WT<&.C%1<'
M<1 WAW^?L6T5.FV.!;'='$'\W;VJKL7H_P!BRI^Z_<KHM@<"&4]2#XOS_"AD
M;1\:EG?Y.(_A5CS5]@D((H[B2 ,  CL\^];672QAN#07,NYG./[2=Y]G^Q"I
MRNON5J8&N'P=).WS<7?PKUD) PZW2N\>)P4ZDO5@::CALESD$)'&X.]%@/YV
M^RTG4EB%/[X%AJS3\7!QEP XL9QG//"CO']+'<KZO=D,=2O=NRAD;X>D5FR!
M^,&UD^/$_P"U2N74MIB=%BP2M#CR>\.)\!X[A;X+_0U56:6DTNY]0T$EAE#3
M\Q4]X_I?M^2>YC]2]R%OHYR<LH2!W'/VK-M+.1@VU@\?2_M*:T=^I:BFF?'I
MZ-^#G.0>  [@X&_(K927VG?',^+3U.]L+>.1P>,-;D#/+O*;Y?2_;\CNH_4O
M?\$$%%4AV11,([G<O:MWO6H+2#;Z8'O _P!I31VIH ./[@4/ =AD_P!RP.K&
M!N([/0M\]_J4[I?3_'Y'=0^I>_X(4R@JFNR*: _*P?K6;J*I<W^34K?(-"F#
M-6.;N+7;\_)*].L:D\K?;P/U9^U-T_I_@=W7]7\D/AH*QO*&E/RFM/M"]DH*
MN3E%2M^2UH]@4O\ OSK0W$='0,\1&3]:Q&LKB-^HH<_J?[TS/T]QW=>>OL16
M.WU[&_%@QXL:?X4&U5\IR!%_19]C5*OOTNW9[T [NI_O6+M9W<C#7T[/DPCZ
MU.9^GN-E77/M_9'66ZYM;P\;/_3_ -E>?<*Z/=QGBSWB-WU!2/[\[UC'OB+_
M -%JUC5][#B16 ']4S[$\?I[_P!$;*EY^W]C1'9KP_T6R2?Z#OL7270/I2!O
M1N(KS2P5;IZV6?AGB#@,8:#AP_15#1ZJO,TH#[@]@QDEL;<_-A=3=$!G?T<V
M66JD,LTL;WN>?RLR.P?FPI6[S*N-:7A_C^R50Q,AB;'$QK&,&&M:, #N"V++
M&5YP]R%18(XZFG'&T' PX%1RLTE0U,YE+"QY.>)NQ3Q'(Z,Y:<9YCO7LD[WC
M&P'@@$M##-;(^KI+A5[?GOXVCU%.U+?JF(@5<3)F_G1>B[YCS3<M<H)C<&'A
M<00#W'O0$OMEQI+G3=?05$<\7$6$L<#AP."T]Q!V(2M<>] ^IKEH[I#J=/W$
MR-BJI'LEA>?BS-R0X?* (SVY!77'W0IO\JU"PJY+ R,_."@VI=604TS@Z0\#
M-N!IYE0ZMZ0IG\1:YL,+>P<UXY:R*>$>ZO0SDLO@K[ICZ%]4ZQZ4+S=[:;;!
M;:@Q=7-4U0:3B)K3Z(!/,%*M$]!<]EI;E37#5=#PU\/43LI:5TA:W?XKG.:,
M[]K2G6NUA55KSU;GF/P/-)9K]51-'".%WQME3XN?6*-7V="2Q-Y(]JOH"N%K
MMY=I*\BOI6O#I:.IC9#*\ _DO'HN)[ <>:B5XN=+8XIJ*\6*[T(#^)QGH0UP
M/=Q$XPKDT[KY]/51^_!(6M.<8!5AQZXHZRG(D%//3N'I,?L<>+3L5I#4I+QE
M+-#/_C63DAVOK,Z2"3WE4Y@&&%L3 #YCB6)Z0+2R6>2.AJ>*<<,F6QC;P&3A
M=$BUZ(OEZD%'I*U,<&E\DQI&#B.W9C 3FW2>G(A\'8;2WRHX_L7HA;&:S$\=
ME4JWMEU.,;AJ&8SW6.USOIK?<'-,D#BTDAHP,GY^7>FXW&K=:Q;C49H@_K.J
MVQQ=_>NXFV*T1_@[5;F^5+&/J68M]"P>A1TK?DPL'U*VXS.'9Z^NJW4SI9WR
M.I\=5AH]''D-SL-SW+.":YMKI*R(U/OJ0DND;&222<GL7<(AA;\6*,>3 $;#
MEMY)D'%EMEN]+"YE+1UOI@AQ;"[TLYS^3W%;F4=\DAZJ.S7!T>>+A%-)N>_X
MJ[.XC^<[YUYQG\YWSJ<@XX9:-4.C,<=ANIC._#[VDQ[%L9I?5DGQ--7+UT[A
M[5UG?+I2V>U5=QN$CF4M-&9)' $G'@.TDX"B6A-?T.L+Q<*:W0U/4P1,E:Y\
M/#P#D0\\1W+CL ,8'-3D% QZ)UH_XNF:[UQX]I6YG1_KE_+3M0/E%@]KEU>,
M=P7NV.01 Y69T::[DY60-^5-$/XEO9T5:\?_ /S:9GRJF/[5U$"%F'*4#F)G
M1!KEW."WL\ZIGU+?'T+ZU=\:6U,\ZC/L:NF6N67$IP#FN/H/U@[XUPM+/_%<
M?X$JCZ!]3O\ PE[M3/(2'^%=&!Q6;7*<('/+.@&^G\)J2@;Y0R%=$Z)M#K#I
M&T6E\K9GT=,R%TK6\(>1S./%&=D\QC$;1X!1)8(!>$AHR>2S6N09V5 8=<,[
M@K(8<,A1VZW2DMTK);M<Y:*)[RV)D; 1@'!<\EIVSY )]@)#W-<X.+3@D<CV
M@H0;.%8EIW6U>% 1VZZ<M-5<([M44$#[A2M+HJ@M]-I .-^WUJ1^]Y/\F[YD
MGJ&&1G5M_P 8YK//)Q]:G'5,_-"G(2.5[W6RR72J8WB=B5V0/E' 3=241ENO
MO6KD+ZESFMCA;N"YVP&.TY3]70QVZ:JG?A\IF>_?OXCA3CH4T=(^=VIKM'Z<
MA)I&/&_=UGU#UGN7'IAOEA'T%UO=PW,9X] W6+$=0(82W&QD&WGC*=J30U.V
M-QK*I[Y2,#JV@-;\^Y^A6I<[7[ZEZV*0,?C!!&Q2#[@3G.9XP/(E>Y:>*.6]
M78_/!5M5H)CG$P5,9;W/80?G";=06:33>GJNXL=3RRP-R&.!+?[_ ""N/[W)
M#GBJFCR9_>HUTC6)U'HN[5,=3(^:"GDFC#&X])K'.'?D;<D^'CZ%HZRWIDH'
M2W2O6NJHZ04D4?7S1MPV+&=SN7<6W/')7ZYW/L7)_1Y7U%9K.AI:F9\D$SG!
MW  W/HD@G;O 7;+=,4SF@F>;??L^Q:QCCA&$Y.7B9$7.6MQ4U&EZ+.\DY'RA
M]B]&F+>#OUQ\Y%;!GD@I*P/FI\--6P<XWGSD*S;IZU-&/>P/B7N^U,$9*]0I
M=JFW6^@L=1-34S&3 M:UP)R"2H#[YE(YE2#*^6RGO5GK;;6AQIZJ(Q/X=B >
MT>(.#ZE#>C[HRH]&766OI[E5U4KX3"6/:&,W.2<#GRV!Y*6FHF_.<L>OF_24
M@<L'Q7F#R *;VR3'L?\ 2MT)J&RL>V.0EK@[EW%2!:V"9Q]&*0GP:2MK*2K=
M\6FF(\(S]BM)DH<QKN\ KWK F05I';JXC(HYR/U96]MIN!_ZG/\ Z*L3K CC
M"G(( RRW$G'O20>>/M6UMAN1_P"KD>;V_:IWQA <$W,$);8+A@ET36XYY>%O
M:[ &5+*@Y@D /I%IQ\RB1C<S9P(]2AO)!EQ#O7K0"<+7Z)[4-P.65 &S4NGJ
M.]4;H*ZE=/$[/X-X8\ _& /YIP,A+J2%[&N=*P,<[&& YX6@8 RE39B!@C*Q
M<_B0&)7BR7B RHF=9<J)G^=XC_1!/V*8*,V)G'=@3RCB<?62!]14F0(@,^E=
M.SU773T#'2-?Q>F]Q!.<[C."/!/TEX%/$1&Z(\ P&  ;=RI*Y:Y?#4U#&2$\
M,CV[GQ(4>GU%<ZRI'5O>&>!7-C8U\J.NZ5+YWDZ:L%ZIKS3R/IW8DB=P2LSN
MTISX@J8Z%[GPWNX4LK\OJ86O;XN8=_H=]"MXO7NIDY0R^ISKX*$VH]!1QA0_
MI4:ZHT?40QOZMTCVL#@SCQG(/H_E;9V[4^7"Y4]!"9*J4,;W=I\@JYUMKBUU
M=LJ*(L$C7<B7#9PY*++8Q6&^2U-$['E+@YETM;NIU93]7+Q".88#>&-Y YY_
MN7=K9?0;OV!<QVVNTS'<J7-+&[X4/>1#P%@'9G?*Z!MEU@N=&RJI'\43OG![
MDKLC)X0MHG6LM<#T9O%8F<=Z;C+XK RK7)A@<34#O6)J$VF7Q6#9^-Y:,D#F
M>Q >:CJHO>'#,WC:7 X\E!ZBYTL9(%/]"EESC,\9!RHS4VX.<<M^A, ;G7N(
M'T:<?,L/N[W0-^9*'6MF=P/6L1;Z9OQI(AYO"E(&MM\E/Q80E]#7U<T@PP-&
M5JBAHHSZ51 ,?IA+Z.JML3@360>IV5*!-Z6I)IHRX[\(!\UM%05'H[M2.A+:
M:;K9#\5K&D[_ #)PBD<YH)&"5# Y"=9"=(8@]YPT$I7% &[O/$>[L4 WLD+A
MX=ZRXSC8K +T(0>K!S6O&' .'BLD8.>14@9:F)H<>*)T1)PT<\I.Z![1O\Q4
MBQV%:#2Q8]%H;Y* ,)!',+S)["G>:CV. "$WBF,SR( 3CF<808-()7N=E[)%
M+#L]I"U<80@>M,LS+5R_(8#Y D^U/J:M,L#;:7@8$DCG#RSCZDZH61P_JJGK
M[?=*EM91U4+342?".C/#CB.-QLE&F+O%4ME8Q[G&/;)_*\E=]7=+>^6=M4Z$
MCC<,$@]I4!O]!:9*YM5;H(F2YP7QCAXAV@CM7-4UT.NXL3:;N<MHOM)71DYA
ME#SXM[1ZQE7SJK5]'9Z;X*1LL[V@M&<AH(R"515=;^H8) -N::+O6R2U#0Y[
MG#A#3D^&REVR@L1\Q"B%CW2\A\U'JNJN,\KI:ASFN\>2A<TYED<]I<3WE*F0
MNE<0<DIPMUAFJ)/1CPP\\JD4C=M^70:J-TCG@B(9SSPKZZ((:IMBJ9)VEL3Y
M0(P>W W(^<?,F[1.@'5K&SU;.JI1CT\;R?)^U6S3VZ.G@CA@C#(HVAK6CD O
M116V][/%JKUM[M" @K M*=O>B/>87L.<,Y84CGMW62%[)9HG'F8W$94E]YCN
M7HHQW)@$,?IZ.0YEGJW^<SOM6/WL41!#F2.S^=(X_6IL*-O<LA2-[D!"&:5M
MS3GWJT^>2MT>FK>SXM%#_HJ9BE;W+T4S>X("*1V2E;\6FB'DT)1':H6\H&#^
MBI**=H[ O1"T(!BCH0WXK /(+>VEQN[9HYE/ B:M%P 90U!Q^0?8@$[&M:W#
M1@+)1NAN\D #)@9(QL#VA/\ 35$=3$)(G9;](0@VH0$'89/) 1CI%J;M2Z<D
MELG&)0\=:Z,9>R/!R6^O&3V!4K2:UN5H%3&*:2N$V'"1Q+SGM!.<A=(@]H37
M6:?L];(9*NUT4LAYN=",GUKUTWUQK=5D>'YKJ>&_362M5U<N4L8?0K7HNU3>
M:J\4]OJ7255-*TES7GC=!MG/%W=FZM\%):&@H[?&8Z&E@IV'F(HPW/GA*534
M6QMGNA'!KI*9TU[)RW,,H6*%YSTX!P#@0X CQ3/640EJA%3-)>1D@?D^:2Z@
MU$RBXX*,MDJ>1=S:S[2LNCF9\XN3YGE\CGL<2XY)V* E=#3MI*2*!IR&- SW
M^*WH0A)Q5#.^XWNM@=,-IY,;_IE29E)%1TQ!DXG;;I_U7;]-OKW55#10PUC)
MG%TD/H\7I'(<!L<IMNM*',;(P>@!GU+G93.MRAPKVQBU_#/ W]$'F[R"8I[,
MVH9Q,.'GDDNEJ5U6>*8O?,TX<2[)^E6)8;$^IJF0TT;I)7;XY!H[SW!5PVS3
M<H(CECL+W<+)8BZ;D&@9+O+O5MZ2T2R%C*BZQ@8W;3_6[[/G4DT]I^EL\0<T
M"2J(]*4C?R'<$\KU54)<R/!;J7+B)XUK6M#6@  8  Y+U"%Z3R A"$ (0A "
M$(0 A"$ (0A "2W7^;JGY!2I);H,VZI^04! BE%OK'T<W&W=IV<WO"3NYE>(
M41-*6HBJ(NLB<"WM[QYH>[B/AV*'PRR0OXHGEKN\):R[U+1APC=XD(6R22,[
M%9<U'(KU,QV7L8YO:!LG.FNM+-L7]6[N?M]* < =MT+ /:1D.:1X%(ZZZT="
MPNFG;GL8TY<?4@%KW!C2YY#6@9).P 4.U!J0R\5/;G%L?)THV+O+N'BF^]7V
M>Y$QMS%3#DP'=WB4T(0V8%37HT^-</Z'UJ&84UZ-1O7G&WH#VH0NI-T(0A<Y
M<GMC:26IJ)9A(U\S^7RBE-1)PV)@#?3>WA \.TIVNE TSU#6_%=(X@>LIAHF
M=37NX]X9/1\B%SCJCAIFV&2Y00T[>-U9AK.S#L\\]FWL5]Z;LD-FHA&")*AP
M'6S$;N/U!0/HDM$AJI*R5CA%2<<4;NQQ=]@]JM->FB'&YGCU%C;VH$(0O0>8
M$(0@!"$( 0A" $(0@!"$( 0A" $FN7\WU'R"E*:M1U+Z6W2R-8YX#3EK>9':
M@(>[XQ2&XS34S>OCCDEB8TET<;07./K\,\DKCECFC;+"\/C<,M<.1"]4E!'0
MW&EK6_ 2CB& 6.V<#Y?8E:3U-#!.\/?&!*.4C=G#U^I)WNKJ9K@QC*H?D9/"
M0?$]R+D9P+RL'<BO6%W5M,@ ?@<0!R 5B\[%02(YR<'=-TO-+Y^U(9!NA!BP
M++"&#99(#$A3?HW_  5P^4SV%0ASL*6=&\[Y!4NC:>H>X8?V.QW>'BA*)ZA"
M$+'+M;<*^KN51!)((V=:\ ,;P_E'F>:=XZ&2H9#!%$9)Y'!K6MYEW9ZUG/;V
M^^IIA_E'$'^D59?1WIQT1;=:YA:\CX"-PW /Y?K[%SX1<Y81T9S4(Y)3IBUB
MSV6FHR0Z1K<R.'Y3SN2G1"%[TL+!SV\\@A"%) (0A "$(0 A"$ (0A "$(0
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$$!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>cv-20251231_g9.jpg
<TEXT>
begin 644 cv-20251231_g9.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1_D4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             _4   1           $                          0
M           $0    _4                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   _4     4F=H=&QO;F<   1     !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   /U
M     %)G:'1L;VYG   $0     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !3A"24T$#      5O0    $   "@    E0   >
M 1=@   5H0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ E0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M:V14]H<^?\(W)I]-"ZA]7\'/]9SM]=EXESF.,!X;Z#<@5']']H;1^B;;M_\
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MJ=;9<XLK:7.VM+G0-3MKK#GO_L+)IP,FG)>ZI[/1>9 CW<?1<=GNVK6QQ8T
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
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M  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
M          !(     0   $@    !.$))30/]       (          #_X0$V
M17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;  4
M   !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4    D(=I
M  0    !    I    -    $L     0   2P    !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C R-3HP,3HR-" Q,SHP,3HQ.    Z !  ,    !
M__\  * "  0    !   $0* #  0    !   #]0         & 0,  P    $
M!@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$ !
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M\HW-/5>V1@]#FK#P_?<0VFJ6&GZK;&&&4MM$HW.RC/7=Z9]?*M-U"PENK)4
M42@ 'T[Y/7[*Y=1T_FZSIEP#@V\<@8 =\@#\ZQ+;>VNL3.A?U-OKG]*D:C]#
M_JL@'^\-?6NW<EAHFH7D(5I;>WDE4-V)521GX=*K+NI5+O>)+XW_  W;1/'
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M%*4H%*4H%*4H%*4H%*4H%*4H%*4H%9QQ7_\ <%[\T_PBM'K.>+!_M!>_\O\
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5:E*4"E*4"E*4"E*4"E*4"E*4'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER PAGE - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 25, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CAPSOVISION, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3369494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">18805 Cox Avenue, Suite 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Saratoga<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">95070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">624 1488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">common stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,838,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the Registrant's definitive Proxy Statement relating to the Registrant's 2025 Annual Stockholders' Meeting, to be filed within 120 days of the Registrant's fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001378325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AUDIT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Baker Tilly US, LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Santa Clara, California<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of CapsoVision, Inc. (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,112<span></span>
</td>
<td class="nump">$ 9,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,498<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,987<span></span>
</td>
<td class="nump">2,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">16,669<span></span>
</td>
<td class="nump">14,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">611<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">843<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">18,164<span></span>
</td>
<td class="nump">16,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,697<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,427<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8211; long-term</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,904<span></span>
</td>
<td class="nump">2,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies - Note 9</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible Preferred Stock (each Series: $0.001 par value)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">143,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 300,000,000 and 190,000,000 shares authorized; 46,865,051 and 2,090,945 issued and outstanding as of December&#160;31, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">168,878<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(155,665)<span></span>
</td>
<td class="num">(130,350)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">13,260<span></span>
</td>
<td class="num">(129,510)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">$ 18,164<span></span>
</td>
<td class="nump">$ 16,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">153,682,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
<td class="nump">35,559,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 152,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">46,865,051<span></span>
</td>
<td class="nump">2,090,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">46,865,051<span></span>
</td>
<td class="nump">2,090,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 13,554<span></span>
</td>
<td class="nump">$ 11,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">6,381<span></span>
</td>
<td class="nump">5,379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">7,173<span></span>
</td>
<td class="nump">6,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">7,530<span></span>
</td>
<td class="nump">6,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18,310<span></span>
</td>
<td class="nump">15,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,849<span></span>
</td>
<td class="nump">4,207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">32,689<span></span>
</td>
<td class="nump">26,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(25,516)<span></span>
</td>
<td class="num">(19,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income, net</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income (expense), net</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income, net</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(25,291)<span></span>
</td>
<td class="num">(19,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,315)<span></span>
</td>
<td class="num">$ (19,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (9.85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (9.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">24,555,381<span></span>
</td>
<td class="nump">2,020,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">24,555,381<span></span>
</td>
<td class="nump">2,020,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in-Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">35,559,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 128,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series H convertible preferred stock (in shares)</a></td>
<td class="nump">3,106,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series H convertible preferred stock</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of all convertible preferred stock to common stock - initial public offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">38,665,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 143,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,837,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="num">(109,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 607<span></span>
</td>
<td class="num">$ (110,452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of all convertible preferred stock to common stock - initial public offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercises of stock options (in shares)</a></td>
<td class="nump">253,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercises of stock options</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,898)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">2,090,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="num">$ (129,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="num">(130,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of all convertible preferred stock to common stock - initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of all convertible preferred stock to common stock - initial public offering</a></td>
<td class="nump">$ 143,625<span></span>
</td>
<td class="nump">$ 143,625<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">143,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of all convertible preferred stock to common stock - initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of all convertible preferred stock to common stock - initial public offering</a></td>
<td class="nump">143,625<span></span>
</td>
<td class="nump">$ 143,625<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">143,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,629,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in initial public offering, net of issuance costs</a></td>
<td class="nump">22,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">22,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Underwriters Warrants</a></td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of common stock upon promissory note repayment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Issuance of common stock upon promissory note repayment</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares', window );">Reverse stock split rounddown and cash in lieu payment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Reverse stock split rounddown and cash in lieu payment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock upon exercises of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock upon exercises of warrants</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercises of stock options (in shares)</a></td>
<td class="nump">438,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercises of stock options</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,315)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">46,865,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,865,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 13,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 168,878<span></span>
</td>
<td class="num">$ (155,665)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity shares for down round feature triggered for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 20A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-20A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,315)<span></span>
</td>
<td class="num">$ (19,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gains) losses</a></td>
<td class="num">(173)<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock in lieu of debt repayment</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(478)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(358)<span></span>
</td>
<td class="num">(434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,128<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,864)<span></span>
</td>
<td class="num">(20,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series H convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from IPO, net of commissions</a></td>
<td class="nump">26,557<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment of IPO offering costs</a></td>
<td class="num">(3,184)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from promissory note issuance</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of promissory note</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from exercises of options on common stock and warrants</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">23,604<span></span>
</td>
<td class="nump">15,074<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">650<span></span>
</td>
<td class="num">(5,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">143<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">9,319<span></span>
</td>
<td class="nump">14,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">10,112<span></span>
</td>
<td class="nump">9,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NON-CASH FINANCING AND INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Underwriters warrants issued in connection with the IPO</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of all convertible preferred stock to common stock - initial public offering</a></td>
<td class="nump">$ 143,625<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1. DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoVision, Inc. (&#8220;CapsoVision&#8221; or the &#8220;Company&#8221;), a commercial stage medical technology enterprise, that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (&#8220;GI&#8221;) system.  Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company is based in Saratoga, California.  Its customers include, in the U.S., gastrointestinal medical practices, clinics, and hospitals; outside of the U.S., the Company sells to distributor customers who resell products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s core technology platform is an orally ingestable capsule including multiple cameras facilitating 360 degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. This platform obviates the need for external data transmission or for a patient to remain in a medical facility throughout the digestive cycle. The Company&#8217;s products consist of (i) the on-market CapsoCam Plus&#174;, directed at the small intestines, and (ii) the in-development CapsoColon 3D&#174; directed at the large intestines (colon). Stored video imagery is downloaded from capsules with a data access device, CapsoAccess&#174; and enabling software, CapsoView&#174;. This video access solution permits on-site, on-demand video download and viewing by customers. The Company operates the CapsoCloud&#174; cloud-based software-as-a-service ecosystem as an off-premise video access and download solution. Using CapsoCloud&#174;, retrieved capsules are sent by customers to a centralized processing center for video downloading; patient video content is then made available via web portal or dedicated app access for customers to view, download, and generate patient reports. The Company&#8217;s services also include video reading; pursuant to this offering, physician customers may purchase a video reading and generation of patient report carried out by a second physician.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its 2005 formation, the Company&#8217;s organizational structure has comprised a single Delaware corporation with a branch office in Taiwan, Republic of China, the location of certain suppliers and Company personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CapsoCam Plus&#174; was cleared by the U.S. Food and Drug Administration ("FDA") in 2016 and has since been approved in various other countries.  CapsoColon 3D&#174; is completing the second arm of our pivotal clinical study with planned submission for regulatory clearance, starting with the FDA, and we anticipate filing with the FDA in the third quarter of 2026. The Company is subject to risks and uncertainties common to life sciences companies including, but not limited to, risks associated with the success of research and development, risks associated with contract manufacturing, competition from other companies, protection of intellectual property and the risk of litigation related thereto, compliance with government regulations, and the ability to secure additional capital to fund operations and research &amp; development. Current and future programs, including for products focused on other areas of the GI system, will require significant research and development efforts, extensive clinical testing, and submissions for regulatory approval prior to commercialization.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;3, 2025, the Company completed its initial public offering ("IPO") of 5,500,000 shares of its common stock, that was followed by the issuance of 129,978 shares of common stock on July 18, 2025 in connection with the partial exercise by the underwriters of their option to purchase up to an additional 825,000 shares (the &#8220;Over-allotment Exercise&#8221;) as further described in Note 11. COMMON STOCK), each at a price to the public of $5.00 per share. The Company received net proceeds of approximately $23.37 million after deducting underwriting </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discounts and commissions of approximately $1.59 million and offering expenses of approximately $3.18 million which were recognized in additional paid-in capital as a reduction of the proceeds generated from the offering.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross proceeds to the Company from the IPO was approximately $28.14 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection to the IPO, the Company amended and restated its certificate of incorporation (the &#8220;Restated Certificate&#8221;), under which authorized capital stock consists of 300,000,000 and 190,000,000 shares of common stock as of December 31, 2025 and December 31, 2024, respectively. Authorized common stock is reserved for future issuance, including pursuant to outstanding equity awards and future equity awards under the 2005 Plan and the 2025 Plan as further described in Note 11. COMMON STOCK.</span></div>On July 2, 2025, immediately prior to the completion of the Company&#8217;s IPO and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock, all shares of the Company&#8217;s convertible preferred stock converted into shares of the Company&#8217;s common stock<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2. GOING CONCERN</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations since its inception. Since the launch of CapsoCam Plus&#174; in 2016, the Company has been able to fund increasing portions of its operating expenses from sales. However, the Company has continued to incur operating losses, net losses, and negative operating cash flows. The Company expects to continue to experience similar circumstances until existing and future products&#8217; sales yield further growth in revenues, achievement of break-even, and realization of future operating income, net income, and positive operating cash flows. As of December&#160;31, 2025, the Company had cash and cash equivalents of $10,112. For the year then ended December 31, 2025, the Company had an operating loss of $25,516, a net loss and comprehensive loss of $25,315, and net cash used in operating activities of $22,864. The Company, having evaluated the extant facts and circumstances, concluded that the facts and circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date of issuance of these financial statements. While the Company completed the IPO in July 2025 and raised approximately $23.4&#160;million in net proceeds, as well as subsequent private placement further discussed in 17. SUBSEQUENT EVENTS, it is not probable that these funds are sufficient to fund expenditures necessary to achieve sales growth and innovation objectives. The Company intends to consummate additional capital raising activities, but there is no certainty as to such capital raising activities occurring at all, or occurring with sufficient timing or magnitude, sufficient to alleviate such substantial doubt.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). Any reference in these notes as it concerns U.S. GAAP is meant to refer to authoritative pronouncements as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reporting Entity</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s organizational structure reflects a single incorporated entity, CapsoVision, Inc..  This single entity has a foreign branch and physical presence in Taiwan, Republic of China, which is an extension of the U.S. corporation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2025, the Company amended and restated its amended and restated certificate of incorporation to effect a 1-for-3.33 reverse stock split of the Company's common stock, which automatically resulted in reciprocal adjustments (reductions) to the conversion ratios of each of the Company's series of convertible preferred stock (the "Reverse Stock Split"). The par values per share of the common and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All amounts for issued and outstanding common stock, convertible preferred stock, options to purchase common stock, warrants on common stock, and reserves related to common stock, as well as related per-share amounts, contained in the financial statements have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented. No fractional shares were issued as a result of the reverse stock split. In lieu of fractional shares, the Company rounded down to the next whole share and made a cash-in-lieu payment of $1 for 108 shares.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reporting currency for the financial statements of the Company is the United States Dollar. The functional currency of the U.S. corporation, and its foreign branch which is an extension of the U.S. corporation, is the U.S. Dollar. The assets, liabilities, and expenses of the Company&#8217;s foreign branch recorded in local currency are remeasured into the U.S. Dollar each period, with associated gains and losses included in operating expenses (as a component of general and administrative expenses). Monetary assets and liabilities denominated in currencies other than the functional currency are translated at exchange rates in effect at the balance sheet date with associated gains and losses included in operating expenses (as a component of general and administrative expenses). For the years ended December&#160;31, 2025 and 2024, the Company recorded $193 and $(93), respectively, of net foreign exchange gains (losses) as components of general and administrative expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the making and usage of  estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities, if any. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. The Company seeks to moderate the influence of subjectivity and estimation uncertainty through reliance on useful information from market participants and peers wherever possible. Estimates and assumptions affect various financial statement amounts and their related disclosures, including, but not limited to, the recognition of revenue, underwriters' warrants valuation, stock based compensation, research and development expenses, income tax-related amounts, lease-related amounts, and allowances for credit losses. Actual results could materially differ from estimates.&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Segments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized as, and managed as, one operating (and reportable) segment. Its chief operating decision maker is its Chief Executive Officer.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value Measurements&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where required, certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the three levels of the hierarchy:</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - defined as inputs other than quoted prices included in Level&#160;1 that are either directly or indirectly observable</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - defined as significant unobservable inputs for which little or no market data exists, therefore necessitating entity-specific assumptions&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. An asset or liability&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s financial assets (which include cash and accounts receivable) and liabilities (which include accounts payable) approximate fair value due to their insensitivity to interest rates and/or close proximity to maturity and qualify as Level&#160;1 measurements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentration Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of demand deposits at well-known financial institutions and accounts receivable.&#160; At times, the Company&#8217;s cash deposits may exceed U.S. Federal deposit insurance limits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sales to customers are typically originated with trade credit terms and receivables are uncollateralized, with limited exceptions for prepayments required for certain customers or credit card sales.  The Company historically has experienced insignificant levels of bad debt; allowances for credit losses on accounts receivable were insignificant for all periods presented.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s concentration risk related to revenues relates primarily to its product revenues being derived from a single product. With respect to customers, for the year ended December&#160;31, 2025, the same customer represented 9% of our revenue and 22% of our accounts receivable as of December&#160;31, 2025. For the year ended December&#160;31, 2024, that same customer represented 10% of our revenue and 21% of our accounts receivable as of December 31, 2024.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s supply concentration risk relates primarily to its materials procurement and contract manufacturing being substantially concentrated with vendors located in Asia.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) comprises net income (loss) and other comprehensive income (loss), which is defined as all changes in stockholders&#8217; equity (deficit) other than net income (loss) and those resulting from investments by and distributions to stockholders. Historically, and for all periods presented, there are no differences between net loss and comprehensive loss.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The core principle is that an entity should recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue using a five-step model resulting in revenue being recognized as performance obligations within a contract are satisfied. The steps within that model include: (i) identifying the existence of a contract with a customer; (ii) identifying the performance obligations within the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract; (iii) determining the contract&#8217;s transaction price; (iv) allocating the transaction price to the contract&#8217;s performance obligations; and (v) recognizing revenue as the contract&#8217;s performance obligations are satisfied.  Judgment is required to apply the model and make certain estimates and assumptions about the Company&#8217;s contracts with its customers, including, among others, the nature and extent of its performance obligations, its transaction price amounts and any allocations thereof (including estimates of standalone selling prices), the events which constitute satisfaction of its performance obligations, and when control of any promised goods or services is transferred to customers. The guidance also requires certain incremental costs incurred to obtain or fulfill a contract to be deferred and amortized on a systematic basis consistent with the transfer of goods or services to a customer.&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates (i) product revenue from the sale of capsule medical devices, (ii) service revenue from the provision of reading services for videos, and (iii) product or service revenue depending on which video delivery option is utilized by the customer to download and view capsule videos.  The customer&#8217;s delivery options include (1) a capsule data reading device shipped to the customer which works together with downloadable software installed locally on a customer&#8217;s computer (classified as product revenue), or (2) a software-as-a-service offering which involves the customer mailing capsule devices to an off-site Company-operated facility which processes uploads of video content to a cloud platform the customer can access via a web browser or a smart device application in order to view videos and generate reports (classified as service revenue).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts with customers contain fixed consideration reflecting prices negotiated with customers and immaterial variable consideration.  For contracts with variable consideration, the Company uses the most likely amount method to estimate the transaction price. Variable consideration is constrained to the extent that it is deemed probable that a significant reversal of the amount of revenue recognized will not occur. Where products or services are not sold separately or experience a range of selling prices, the Company estimates standalone selling prices using a cost-plus-expected margin approach and utilizes the resultant standalone selling prices to allocate transaction prices at transaction inception on a relative standalone selling price basis. The Company recognizes revenue for its product and reading service performance obligations at a point in time, that being when the performance obligations are satisfied and control is transferred to the customer (generally upon shipment for products, or conveyance of final deliverable for services).  For the software-as-a-service video delivery offering performance obligation, the associated revenue is recognized over time, typically less than one fiscal quarter, representing the estimate of the typical period of time in which customers derive utility from the cloud-based service.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any significant financing components as payment is received at or shortly after sale. Standard trade credit terms are typically 30 to 60 days from invoice date. Costs incurred to obtain or fulfill a contract are expensed as incurred when the amortization period is less than one year, which is the case for the Company. The Company considers all shipping and handling to be fulfillment activities and not a separate performance obligation. Shipping and handling costs are recorded as costs of revenue. The Company has elected an accounting policy to exclude sales taxes and other similar taxes from the measurement of the transaction price.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain U.S. customers characterized as group purchasing organizations that function as procurement agents for their underlying medical practice, clinic, or hospital members; these group purchasing organizations typically charge the Company percentage-based fees in exchange for the right to do business with the group purchasing organization.  Such fees, which do not provide a distinct separate benefit to the Company, are recorded as reductions to revenue in the same period as the recognition of the related revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s products are sold with the same limited quality assurance warranties offered to all customers; the Company typically does not allow returns of products, except for cases of damage or defect, whereby products would be replaced.  Actual product returns have historically been immaterial given the one-time-use nature of capsule devices; estimated product returns (periodically adjusted to reflect actual experience), if warranted, are accounted for as reductions to revenue with offsets to a product return liability included within accrued expenses and other current liabilities in the balance sheet.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities; Accounts Receivable and Related Allowance</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records contract assets when it has completed performance obligations prior to receiving consideration from the customer and where such amounts are unbilled; where billed, amounts are reflected as trade accounts receivable. The Company promptly invoices its accounts receivable; therefore, the Company&#8217;s contract assets were zero for all periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities, portrayed as deferred revenue, reflect (i) obligations to provide goods for which the Company has already received consideration (generally arising from up-front payments received) and (ii) performance obligations to provide services which are not yet satisfied in the context of a particular contract (principally consisting of video delivery obligations related to the Company&#8217;s off-premise cloud-based video delivery offering).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The Company grants trade credit to most of its customers in the normal course of business and generally does not require collateral. An allowance for credit losses arises subsequent to the origination of a sale for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts.  A provision (or a reversal of the allowance) is recorded as a component of general and administrative expenses.  In determining the amount of the allowance, the Company considers aging of accounts, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance when all attempts to collect have been exhausted. Allowances for credit losses were insignificant for all periods presented.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue include materials, direct labor, and manufacturing overhead costs related to sold products, as well as certain period costs such as non-allocated overhead, scrap, and outbound freight costs, fees paid to physicians for providing reading services, and the costs of operating the Company&#8217;s cloud-based software-as-a-service offering for video delivery such as shipping costs, processing costs, and data storage costs. Shipping and handling costs directly related to bringing products to their final point of sale are included in costs of revenue and were $117 and $51 for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses include costs directly attributable to actively marketing the Company&#8217;s products and services using both direct employees and outside contractors or vendors. These costs include, but are not limited to, salaries, bonuses, benefits, stock-based compensation, sales commissions, travel costs and expense reimbursements, and the costs of sponsoring programs, events, and conferences. Advertising costs were nil for all periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, bonuses, benefits, and stock-based compensation related to the Company&#8217;s executive, administrative, finance, human resources, and other supporting functions. Also included are professional fees for legal services, consulting services, tax matters and audits, information technology, office expenses, rent, insurance, and foreign exchange gains (losses).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expenses (including Clinical Trial Expenses)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development expenses include costs directly attributable to the conduct of research and development programs, including salaries, bonuses, benefits, and stock-based compensation for employees focused on research and development or clinical trials, costs of independent contractors and outside vendors, costs of supplies consumed in or product inventory utilized in clinical trials, and the costs of clinical trial activities as charged within the negotiated budgets by trial sites or vendors responsible for multiple trial sites.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes prepayments for goods or services, including trial device inventory, that will be used, consumed, or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed.  The Company also records expenses and accruals for estimated costs of research and development activities, including third party services for clinical trials.  The Company bases its estimates on information available at the time.  Costs for certain clinical trial activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the balance sheet as prepaid expenses or as accrued expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025 and 2024, the Company incurred $6,391 and $7,647, respectively, of expenses related to ongoing clinical trial activities which are included within research and development expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if options or warrants on common stock were exercised or convertible preferred stock shares were converted into common stock. Diluted net loss per share is the same as basic net loss per common share since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of incremental common shares issuable upon exercise of vested stock options, common stock warrants, and the Company&#8217;s various series of convertible preferred stock. Upon completion of the IPO in July 2025, all outstanding shares of preferred stock were converted into shares of Company's common stock (after giving effect to the 1-for-3.33 reverse stock split). Subsequent to the conversion, only common stock remains outstanding. Accordingly, the two-class method is no longer applicable for periods after the IPO.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents comprises demand deposits in the form of checking accounts and money market accounts (which may be deposited into and withdrawn at will with no restrictions as to investment or redemption) and includes cash balances denominated in the Euro and New Taiwan Dollar, for which fluctuations in exchange rates result in gains or losses reported within operating expenses as a component of general and administrative expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisting of materials, direct labor and manufacturing overhead, are subdivided into raw materials, work in process, and finished goods and are stated at the lower of cost (average cost) or net realizable value.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates inventories as to (i) net realizable value and (ii) circumstances or indicators of loss, damage, insufficient time to expiry (determined by battery life), excess quantities, or obsolescence and provisions accordingly via direct charges against the carrying value of inventory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at historical cost, less accumulated depreciation. The Company capitalizes major improvements and expenses repairs and maintenance as incurred. Depreciation is recorded using the straight-line method based on the estimated useful lives of the depreciable property or, for leasehold improvements, the remaining term of the lease, whichever is shorter.  Useful lives are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery &amp; equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 to 5 years</span></div></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-344">Shorter of remaining lease term or useful life</span></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal (retirement or sale) of property and equipment, as applicable, the cost and related accumulated depreciation are removed and any resulting gain or loss is reflected within operating expenses. Such amounts were insignificant for all periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are evaluated for impairment as warranted by triggering events related to changes in facts and circumstances. There have historically been no impairments and there were none for all periods presented.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and storage space in California and office space in Taiwan, Republic of China. The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (&#8220;ROU&#8221;) assets and the corresponding lease liabilities are depicted in operating lease liabilities, current and operating lease liabilities, non-current in the balance sheet. ROU assets represent the right to use an underlying asset, and lease liabilities represent the obligation for lease payments in exchange for the ability to use the asset for the duration of the lease term. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets and lease liabilities are recognized at commencement date and determined using the present value of the future minimum lease payments over the lease term. The Company utilizes an incremental borrowing rate when assessing lease classification and measuring lease liabilities. The estimated incremental borrowing rate considers credit rating practices applied by well known statistical rating organizations to borrowers, Company-specific factors, and the actual lease term at commencement date. The lease term may include options to extend when it is reasonably certain that the Company will exercise that option. The Company recognizes operating lease expense on a straight-line basis over a lease's term.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements which contain both lease and non-lease components, which it has elected to account for as a single lease component. Variable lease payments that are not dependent on an index or rate are not included in lease measurements and are accounted for as incurred. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary means of financing from start-up through development and into the commercial stage has historically been the issuance of convertible preferred stock in various series; these series share similar rights and obligations and contain similar qualifications as to the requirements an equity initial public offering would have to meet in order for the stock to convert to common stock. Convertible preferred stock is recorded at fair value on the date of issuance (historically, the same as the issue price), net of issuance costs. Application of the guidance contained in&#160;ASC&#160;480-10-S99-3A,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SEC Staff Announcement: Classification and Measurement of Redeemable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has led the Company to present each of the series of convertible preferred stock as mezzanine equity due to the similar features of the series concerning liquidation preferences and other rights and privileges inuring to the respective series&#8217; holders, one or more of which may result in a settlement in cash not entirely within the Company&#8217;s control.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2025, immediately prior to the completion of the Company&#8217;s IPO and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock, all shares of the Company&#8217;s convertible preferred stock converted into shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for employee and nonemployee equity compensation awards in accordance with ASC 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 718&#8221;).&#160; In accordance therewith,&#160;the Company accounts for </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock-based compensation for awards granted to nonemployees in a similar fashion to stock-based compensation awards to employees.&#160; ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation awards issued under the Company&#8217;s 2005 Stock Plan (the &#8220;2005 Plan&#8221;) and the Company&#8217;s 2025 Equity Incentive Plan (the &#8220;2025 Plan&#8221;) take the form of stock options (non-qualified or incentive stock options), restricted stock or restricted stock units (the "RSUs"). The 2025 Plan also provides for the grant of stock appreciation rights, stock bonuses, stock units and other forms of awards including cash awards to the Company&#8217;s officers, directors, employees, consultants and advisors. The Black-Scholes option-pricing model is used to determine the fair value of options; application of the model requires judgment to develop assumptions input into the model, some of which are more subjective, including: (i) the fair value of the underlying common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility of the underlying common stock; (iv) the risk-free interest rate; and (v) expected dividends. Income and market approaches to valuation are judgmentally weighted and combined to determine a composite value representing the fair value of the underlying common stock. In estimating the fair value of the underlying common stock prior to IPO, the Company utilized a third party professional valuation firm whose analyses supported management's concluded estimate. Post IPO the fair value of the underlying common stock is based on the Company&#8217;s closing stock price on the date of grant. An expected volatility assumption is based on stock price volatility of a peer group of comparable public companies over a similar expected term. The risk-free rate is based on U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term; no dividends are assumed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s employee and nonemployee stock-based compensation awards granted on or before December 31, 2025 contain only service conditions for vesting. The Company recognizes stock-based compensation cost as a component of the related functional expense (costs of revenue or category of operating expenses) on a straight-line basis over the requisite service period, which is explicitly stated in the case of awards issued to employees and implicitly understood to be the period over which services are provided for nonemployees. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with pre-vesting forfeitures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation awards in the form of the restricted stock units (the "RSUs") are issued to the Directors of CapsoVision, Inc, who are not employed by the Company ("Non-Employee Directors"). These RSUs are issued in lieu of annual cash compensation (annual base retainer). Each RSU granted to the Non-Employee Directors represents a right to receive one share of the Company common stock when the RSU vests. The Company estimates compensation cost based on the grant date fair value and recognizes the expense on a graded vesting basis over the vesting period of the award. Please, see Note 12. STOCK-BASED COMPENSATION for details.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, offering costs related to legal, accounting, and underwriting costs were net with the proceeds and recorded as a reduction in additional paid in capital, in the stockholders&#8217; equity section of the balance sheet. The Company also issued Underwriters Warrants (as defined in Note 11. COMMON STOCK) for services provided during the IPO to purchase 168,898 shares of common stock. The Underwriters Warrants are accounted for as equity instruments and are included in the Stockholders&#8217; Equity section of the balance sheet. The fair value of the Underwriters Warrants has been estimated using the Black-Scholes option pricing model.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC 740,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 740&#8221;), which requires that the asset and liability method be used. Deferred tax assets and liabilities are determined based on the differences between financial reporting (book basis) and the tax reporting (tax basis) amounts of assets and liabilities; these pre-tax differences are measured and reflected after-tax using the enacted tax rates and law that will be in effect when the differences are expected to reverse. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets at least annually and more frequently as warranted by changes in facts and circumstances and adjusts the amount of the valuation allowance accordingly. Factors considered include the presence of reversing taxable temporary differences as a source of taxable income, forecasts of future taxable income, and available tax planning strategies that could be implemented and are both prudent and feasible. The Company has recorded a full valuation allowance with respect to all of its deferred tax assets based upon the significant negative evidence presented by its accumulated deficit position, its operating losses and negative operating cash flows, and the uncertainty associated with the timing and amount of future profits and therefore taxable income that enable realization. In future periods, if the Company generates book income and taxable income, changes in judgment may reduce or eliminate the valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with a two-step model. Firstly, a recognition threshold must be met; a tax benefit from an uncertain tax position may only be recognized if the tax position would, more likely than not, be sustained by the taxing authority assuming an examination and the application of typical practices and precedents.  Secondly, a measurement rule is applied; the amount of tax benefit that can be recognized is the portion that is greater than 50% likely of being realized upon a settlement.  The determination as to whether a tax benefit will, more likely than not, be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances, without consideration of detection risk. As of December&#160;31, 2025 and 2024 the Company&#8217;s uncertain tax positions were principally related to the non-recognition of a portion of Federal and U.S. state research and development tax credits. The Company recognizes any interest and penalties associated with its income tax positions in the provision for income taxes.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Standards Issued and Recently Adopted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280):&#160;Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;("ASU 2023-07"). This guidance requires disclosure on an annual and interim basis of the following: (i) significant segment expenses regularly provided to the chief operating decision maker ("CODM") and a measure of segment profit or loss; (ii) an amount for other segment items by reportable segment and a description of its composition; (iii) all annual disclosures about a reportable segment's profit and loss and assets as currently required by ASC Topic 280; (iv) clarifying if the CODM uses more than one measure of a segment's profit or loss in assessing segment performance and deciding how to allocate resources; and (v) disclosing the title and position of the CODM and how the CODM uses the reported measures. Public entities with a single reportable segment are required to provide all the disclosures required by this amendment.  ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and for quarters in the years beginning after December 15, 2024; early adoption is permitted. The Company, a single reportable segment entity, early adopted ASU 2023-07 with effect from January 1, 2023; the related disclosures are included in Note 13. SEGMENTS.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the FASB issued ASU 2023-09,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) &#8212; Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;("ASU 2023-09"). The new guidance provides for disclosure on an annual basis of the following: (i) specific categories in the rate reconciliation, and (ii) additional information for reconciling items that meet a quantitative threshold of greater than 5% of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024; early adoption is permitted. The Company adopted this standard for the fiscal year 2025 annual financial statements and has applied this standard prospectively which had a disclosure only impact on its financial statements. See Note 14. INCOME TAXES.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2024-03").  The new guidance requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the statement of operations. ASU is effective for public business entities for annual periods beginning after December 15, 2026, and for quarters in the years beginning after </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 15, 2027; early adoption is permitted. The new guidance may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends certain aspects of the accounting for and disclosure of internal-use software costs. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted and the amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date, retrospectively to any or all prior periods presented in the financial statements, or through a modified prospective transition approach which is based on the status of the project and whether software costs were capitalized before the date of adoption. The Company is currently evaluating the impact ASU 2025-06 will have on its disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU 2025-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Reporting (Topic 270): Narrow-Scope Improvements, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides clarity about current interim disclosure requirements and adds a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, for public business entities and for interim reporting periods within annual reporting periods beginning after December 15, 2028, for entities other than public business entities. Early adoption is permitted for all entities. The amendments in this Update can be applied either (1) prospectively or (2) retrospectively to any or all prior periods presented in the financial statements. At the same time, the FASB issued  ASU 2025-12 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. If an entity adopts the amendments in this Update in an interim period, it must adopt them as of the beginning of the annual reporting period that includes that interim reporting period. An entity may elect to early adopt the amendments on an issue-by-issue basis. The Company is currently evaluating the impact ASU 2025-11 and ASU 2025-12 will have on its disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4. FAIR VALUE MEASUREMENTS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s demand deposit accounts include money market demand deposits which constitute cash, given the lack of investment restrictions or redemption conditions and the ability to immediately withdraw funds. The carrying amounts of the Company&#8217;s financial assets (which include cash and accounts receivable) and liabilities (which include accounts payable) approximate fair value due to their insensitivity to interest rates and/or close proximity to their maturities and qualify as Level&#160;1 measurements. There were no transfers between Level 1, 2 or 3 during any periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5. BALANCE SHEET COMPONENTS</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025 and December&#160;31, 2024, there were no provisions to write down inventories. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment for insurance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">324&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for inventory purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred initial public offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,072</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">898</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred initial public offering costs are specific incremental costs directly attributable to an initial public offering of equity securities that were reclassified from current assets to stockholders' equity and recorded as reductions to the gross proceeds from the offering.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">928&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">821&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment, office equipment, and purchased software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(575)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(359)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">611</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">720</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses of $216 and $206 for the years ended December&#160;31, 2025 and 2024, respectively, were recorded within costs of revenue and components of operating expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities comprised the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">568&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued sales taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE AND DEFERRED REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE AND DEFERRED REVENUE</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6. REVENUE AND DEFERRED REVENUE</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue disaggregated by geographic source, type of customer, and products or services was as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States (medical practice, clinic, and hospital customers):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products (capsules and capsule reading devices)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services (cloud-based video delivery and reading services)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside United States (distributor customers):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products (capsules and capsule reading devices)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,756</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025 and 2024, U.S. service revenues included (i) $621 and $548, respectively, from the Company&#8217;s cloud-based software-as-a-service video delivery offering (recognized over time commencing with the shipment of capsules) and (ii) $295 and $232, respectively, of revenue from the provision of video reading to customers (recognized at a point in time upon provision of deliverables).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues outside the United States are attributable to individual foreign countries based upon shipment destination. The Company&#8217;s distributor customers outside the United States typically serve the countries in which they are domiciled (and may distribute to adjacent countries or territories). Outside the United States, for the year ended December&#160;31, 2025, product revenues included $1,248 and $598 attributable to France and Germany, respectively, with the balance attributable to other countries; for the year ended December&#160;31, 2024 product revenues included $1,160 and $565 attributable to France and Germany, respectively, with the balance attributable to other countries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue (contract liabilities, all of which are current in nature) consists of upfront purchases by customers related to the cloud-based software-as-a-service video delivery offering and prepaid video reading services. Deferred revenue represents the excess of amounts invoiced over amounts recognized as revenues. For each component of deferred revenue, the recognition of deferrals as revenue occurred within three months.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred revenue balance was $177, $132 and $96 as of December&#160;31, 2025, December&#160;31, 2024 and December 31, 2023, respectively. During the year ended December&#160;31, 2025, the Company recognized $132 of revenue that was included in deferred revenue as of December&#160;31, 2024. During the year ended December&#160;31, 2024, the Company recognized $96 of revenue that was included in deferred revenue as of December 31, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fees paid to group purchasing organizations and recorded as reductions to revenue were $110 and $103 for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTE PAYABLE</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7. NOTE PAYABLE</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2025, the Company entered into a promissory note with Ching-Hang Shen, one of the beneficial owners of more than 5% of the Company's outstanding common stock, pursuant to which Mr. Shen provided to the Company a promissory note in a principal amount of $1,000 (such note, the &#8220;Investor Loan&#8221;) on May 28, 2025. The Investor Loan (i) had an interest rate equal to one percent (1%) per month, assuming a month of thirty (30) days and (ii) had maturity not later than ten (10) business days following the IPO, which was completed on July&#160;3, 2025. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2025, in connection with the repayment of the promissory note, the Company issued to Mr. Shen 7,508 shares of common stock at a fair value of $31 on the date of issuance pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 as a transaction not involving a public offering. The promissory note principal amount of </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1,000 and accrued interest were repaid in cash on July 11, 2025. After repayment, there were no outstanding liabilities or obligations in connection with the promissory note.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8. LEASES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and manufacturing space in California and office space in Taiwan, Republic of China, with remaining lease terms ranging from under one year to approximately two years as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not accounted for in the balance sheet; these are limited to minor leases in Taiwan, which are excluded from amounts presented in the following tables. The operating leases include certain variable payments related to operating expenses, which are billed by the landlord, as is customary with these types of charges for office space.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s existing leases contain escalation clauses and renewal options. The Company has evaluated several factors in assessing whether it is reasonably certain that the Company will exercise a contractual renewal option.  For leases with renewal options that are reasonably certain to be exercised, the Company includes the renewal term in the total lease term used in deriving the right-of-use asset and lease liability. The Company&#8217;s main office lease includes a renewal option of three years, which was excluded after evaluation of those factors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts comprising total lease expense, reflected in general and administrative expenses and costs of revenue (including amounts capitalized as overhead to inventory), were as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">474&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">476&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">511</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease-related amounts reflected in the balance sheet and data related thereto were as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">843</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities - current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities &#8211; long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">887</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease payments related to operating leases</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments related to operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases are as follows as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(104)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">887</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9. COMMITMENTS AND CONTINGENCIES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, post-acquisition of raw materials, relies significantly upon third-party contract manufacturers located in Taiwan. Management believes that supply risks related to dependence on fewer key suppliers or contract manufacturers, and political risk, can potentially be hedged with the use of more than one supplier and a readiness to quickly adjust the supply chain (and geographic sourcing within Asia).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;15, 2025, the Company entered into a development agreement with Canon Inc., a Japanese corporation, for the development of complementary metal-oxide-semiconductor (&#8220;CMOS&#8221;) image sensor samples to allow the Company to evaluate functionality and performance, conduct clinical evaluation of capsule endoscopies that incorporate Canon image sensors and obtain FDA 510(k) clearance thereof. Under the Agreement, the Company agreed to pay Canon a fee of approximately $4.1 million for Canon&#8217;s development efforts, which is comprised of (a) an initial fee of $1.0 million that was paid in cash on July&#160;31, 2025 upon the Agreement&#8217;s effectiveness, and (b) following delivery of a specified number of CMOS image sensors meeting agreed specifications within the required timeframe, a remaining development fee of approximately $3.1 million. Additionally, due to the changes in the development scope by the end of fiscal year 2025, Canon and the Company agreed to increase the development fee by $1.0 million and executed an amendment to the original development agreement in March 2026. For the year ended December 31, 2025 we recognized $2.4 million in R&amp;D expenses. The outstanding balance due to Canon was $1.4 million and included in Accrued Expenses and Other Current Liabilities in the balance sheet as of December 31, 2025. The outstanding purchase commitment for this agreement as of December 31, 2025 is $2.7 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Receipt of Federal Government Assistance</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, the Company received cash related to refundable payroll tax credits from the U.S. Federal government in the amount of $208 reflecting receipt of credit claims related to calendar 2020 and 2021 remitted to the U.S. Internal Revenue Service under the Employee Retention Credit program, a source of COVID-19 pandemic era Federal relief. This amount, due to the uncertainty of eventual receipt following claims made, was not recognized until receipt in the year ended December 31, 2025 and was reflected within <span style="-sec-ix-hidden:f-484">general and administrative expenses</span> given its relationship to payroll taxes reflected as operating expenses. There can be no assurance that the Company&#8217;s program benefit received may not be examined, and if examined, possibly challenged as to a portion or all of the benefit received which, if required to be returned, would have an adverse impact on the Company&#8217;s liquidity.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Litigation and Legal Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may be the subject of adverse litigation as a defendant, arbitration, claims, or proceedings related to things such as intellectual property infringement or disputes, commercial contract breaches or disputes, employment matters, or other matters in the ordinary course of business. Such matters are subject to many uncertainties and outcomes may be unpredictable. Such matters may be fully or partially mitigated by the effect of insurance coverage in place or counter-party indemnitors. The Company provides for liabilities via a charge to operating expenses when it is both probable that a liability has been incurred and the amount of the loss can be </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably estimated. The Company is not a party to any material litigation, arbitration, claims or proceedings and therefore did not have any contingency-related liabilities as of December&#160;31, 2025 and December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREFERRED STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">PREFERRED STOCK</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10. PREFERRED STOCK</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock &#8211; Financing History</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company has issued several Series of convertible preferred stock to investors (A, B, C, C-1, D, D-1, D-2, E, F-1, F-2, G, G-1, and H) as its primary financing vehicle to fund research and development and commercial stage maturity. For descriptions and discussion of Series preceding Series H, refer to the Capital Stock footnote in the Company's annual financial statements for the year ended December&#160;31, 2024 contained in the prospectus filed on July 3, 2025 with the Securities and Exchange Commission, as part of the Company's Registration Statement (File No. 333-287148).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had 14,461,804 shares of Series H Preferred Stock (&#8220;Series H&#8221;), par value $0.001 per share, for an original issue price of $4.83 per share. These shares were issued to various investors in the period of November 2019 to December 31, 2024 pursuant to the original financing round and subsequent extensions thereof, resulting in proceeds of $69,829 (net of issuance costs of zero) as of December 31, 2024. There were no issuances of Series H in the year ended December&#160;31, 2025.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Company&#8217;s IPO on July&#160;3, 2025 and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock on July&#160;2, 2025, all shares of the Company&#8217;s then-outstanding convertible preferred stock converted into shares of the Company&#8217;s common stock. Under the Company&#8217;s Amended and Restated Certificate of Incorporation, the Company is authorized to issue none and 153,682,280 shares of $0.001 par value convertible preferred stock as of December 31, 2025, and December 31, 2024, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock outstanding as of December 31, 2024 consisted of the following (in thousands, except share amounts.) </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Series </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preferred</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,962,675</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,394,197</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,801,802</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,747,127</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">880,187</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,876,405</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">848,599</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,222,222</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520,519</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,766,666</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166,833</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D-2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,083,333</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,920,649</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,151,977</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series F-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,043,479</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,201,203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series F-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,498,498</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series G</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,926,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,779,559</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series G-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,896,552</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,039,756</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series H</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,157,821</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,461,804</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">153,682,280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">38,665,583</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">152,378</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,625</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Liquidation preference includes two times the original issue price per share. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Series of preferred stock are collectively referred to as the &#8220;Preferred Stock&#8221;.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock - Conversion Rights</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock shares might be converted into shares of common stock at a ratio determined by dividing the original issuance price by the conversion price (the &#8220;Conversion Rate&#8221;). The conversion price was initially set at the original issuance price and might be adjusted downward, or upward, thereby reciprocally adjusting the Conversion Rate, for capital stock events such as stock splits, stock dividends, reorganizations, or other events where the consideration received relative to the number of shares issued would imperil or dilute holders of Preferred Stock.  Thus, the Conversion Rate was 1:1 at original issuance. As further described in Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, under the caption "Reverse Stock Split", the Company effectuated a reverse split of its issued and outstanding common stock which resulted in an automatic adjustment (reduction) to the Conversion Rates on all Series of Preferred Stock; there were no adjustments to Conversion Rates on any Series of Preferred Stock since original issuance and prior to the Reverse Stock Split.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock shares converted to shares of common stock (i) electively, upon the receipt by the Company of a written request consented to by holders of at least a majority of the Preferred Stock then outstanding at the effective date specified in the request (provided further that such conversion should not occur for either of Series G-1 and Series H unless a majority of holders within each of those series so consents), or (ii) automatically, upon the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, provided that the offering price per share of common stock is not less than $9.66 or $9.99, depending on the Series (as adjusted for recapitalizations) and the aggregate gross proceeds to the Company are $25&#160;million or greater. In connection with and prior to the amendment and restatement of the Company's amended and restated certificate of incorporation described in Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, under the caption "Reverse Stock Split", the holders of all Series of the Company's Preferred Stock elected, via written action, to convert all issued and outstanding Preferred Stock to common stock contingent upon the Company completing a planned initial public offering of its common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock - Liquidation Preferences</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidation, for purposes of liquidation preferences that favor holders of Preferred Stock, meant a liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary, an acquisition of the Company by another entity (other than a transaction which does not result in a change in the holders of at least 50% of voting stock outstanding before and after the transaction), or the sale, lease, exclusive license, or conveyance of all or substantially all of the Company&#8217;s assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liquidation preference for each series of Preferred Stock was the sum of (i) the original issuance price per share (as adjusted for recapitalizations) &#8211; that is, one times the original issue price, and (ii) all declared but unpaid dividends, with the exception of Series D-2, where the liquidation preference includes two times the original issue price per share.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidation preferences were rank-ordered by priority group - first: Series E, F-1, F-2, G, G-1 and H; second: Series D-2; third: Series D and D-1; fourth and last: Series A, B, C, and C-1.  Should distributable assets upon liquidation be insufficient to satisfy respective liquidation preferences within a priority group, the distributable assets were to be distributed to the stockholders within the priority group pro rata and in relationship to the proportion of available distributable assets to the full liquidation preferences that would otherwise be due. When distributable assets were sufficient for a priority group, the remaining distributable assets cascaded to the next priority group, and so on and so forth in descending order of priority group. Should remaining distributable assets exist, after satisfying the liquidation preferences of all Preferred Stock, such remainder were distributable to the holders of the Preferred Stock and common stock in proportion to the number of shares of common stock held by them on a combined basis, with the shares of Preferred Stock being treated as if converted.&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock &#8211; Dividends</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding shares of Preferred Stock were entitled to receive dividends, when, as and if declared by the Board of Directors at a dividend rate of 8.00% payable in preference and priority to any declaration or payment of any distribution related to common stock.  The dividends were not cumulative and Preferred Stockholders did not acquire rights to dividends because they were not declared or paid in any given year. The Company has never declared or paid any dividends.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock - Voting Rights</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Preferred Stock had the same voting rights as the holders of common stock, on an&#160;as-converted&#160;basis at the then-prevailing Conversion Rate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Board of Directors of the Company comprised eight members. Each holder of convertible preferred stock was entitled to the number of votes equal to the number of common stock shares into which the referred shares held by such holder converted. The holders of a majority of the voting shares were able to elect all of the directors.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock - Protective Provisions</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As long as any Preferred Stock was issued and outstanding, the Company should not, without first obtaining the approval (by vote or written consent) of the holders of a majority of outstanding shares of Preferred Stock, voting together as a single class:</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amend, alter or repeal any provision of the certificate of incorporation or bylaws (including pursuant to a merger) if such action would adversely affect the Preferred Stock;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increase or decrease the authorized number of shares of Preferred Stock (including any series thereof) or common stock;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Authorize or create any new class or series of shares having rights, preferences or privileges senior to or on parity with any series of Preferred Stock;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Voluntarily liquidate or dissolve, or enter into any transaction or series of related transactions deemed to be a liquidation, dissolution or any disposition of the Company&#8217;s property;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Effect a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enter into any transaction (other than customary service or employment agreements) with any officer or director of the Company, or any party related thereto or affiliated therewith, unless approved by a majority of the Board of Directors;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issue any indebtedness that is convertible into any equity security, or incur any other indebtedness other than loans, leases and similar transactions in the ordinary course of business; and</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Redeem, repurchase or otherwise acquire any shares of Preferred Stock or common stock, except for the repurchase of shares of common stock from employees, officers, directors, consultants or other persons performing services pursuant to agreements granting the Company option or repurchase rights upon the occurrence of certain events.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12. STOCK-BASED COMPENSATION</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Stock Plan</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Plan, which was adopted by the Company's Board of Directors in May 2025 and approved by the Company's stockholders in June 2025, became effective upon the consummation of the IPO. Upon the effectiveness of the 2025 Plan, the 2005 Plan was terminated and no further grants may be made under the 2005 Plan. The Company's 2025 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors of the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 4,204,204 shares of the Company&#8217;s common stock were initially authorized for issuance with respect to awards granted under the 2025 Plan. Shares subject to outstanding awards granted under the 2005 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated will be available for award grants under the 2025 Plan. In addition, the share limit will automatically increase on the first trading day in January of each year (commencing with 2026) by an amount equal to (1) 4% of the total number of shares of our common stock that are issued and outstanding on the last trading day in December in the prior year, or (2) lesser number as determined by the Company&#8217;s Board of Directors. Any shares subject to awards granted under the 2025 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, fail to vest, as well as shares used to pay the purchase or exercise price of awards or related tax withholding obligations, will become available for new award grants under the 2025 Plan. As of December 31, 2025, a total of 3,838,331 shares is available for award purposes under the 2025 Plan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amended and Restated 2005 Stock Plan</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2005 Plan, the Company granted equity-based incentive awards prior to the IPO to the Company&#8217;s employees, directors, and consultants.&#160; The 2005 Plan permitted the grant of stock options (either Incentive Stock Options (&#8220;ISO&#8221; &#8211; employees only) or&#160;Non-Qualified&#160;Stock Options (&#8220;NQSO&#8221;)) and restricted stock awards (&#8220;RSA&#8221;); only ISOs and NQSOs were outstanding during the periods presented. Under the 2005 Plan, 880,007 shares of common stock were reserved for issuance at December&#160;31, 2024. Upon the effectiveness of the 2025 Plan, the 2005 Plan was terminated and no new awards were granted under the 2005 Plan after the IPO, and there were no shares of common stock available for new award grants as of December&#160;31, 2025 under the 2005 Plan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and&#160;non-employees contain only service vesting conditions, with typical grants vesting over a four-years period (vesting 25% on the first anniversary of the award and 1/48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each month thereafter) but may be granted with different vesting profiles, including options that are vested-at-grant (immediate vesting) and that are subject to different vesting schedules. Options granted to employees and&#160;non-employees&#160;expire no more than 10 years from the date of grant.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, outside of the 2005 Plan, previously issued an insignificant number of warrants to purchase its common stock; of these, all have expired or been exercised with no shares remaining outstanding at December&#160;31, 2025 and 15,015 warranted common shares remaining outstanding at December&#160;31, 2024. Being </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside of the 2005 Plan, they are excluded from the stock option award activity and stock-based compensation presentations which follow. The Company previously recognized immaterial warrant-related expense.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Option Modification</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective August 27, 2025, the Company's Chief Financial Officer (the "Former Executive") stepped down from his position with the Company. As part of the termination of employment of the Former Executive, there were certain supplementary modifications to the Former Executive's non-vested stock option awards including acceleration of some non-vested shares and extension of their post-termination exercise period, and voluntary forfeiture of the remaining non-vested stock option awards. During the year ended December&#160;31, 2025, the Company recorded a one-time, noncash incremental stock-based compensation expense net of required reversal of previously recognized compensation in the amount of $159 related to these stock option award modifications which was included in General and administrative expenses in the condensed statement of operations. The Company accounted for the resulting net incremental stock option award modification compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Options&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the year ended December&#160;31, 2025 was as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options on Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding (vested and expected to vest) as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,298,905</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.47</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,961</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">534,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(438,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited, canceled, or expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(419,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding (vested and expected to vest) as of December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,975,648</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,869</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">880,289</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.7</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values are calculated as the differences between the exercise prices of the underlying options and the fair value of the Company&#8217;s common stock for options that were in the money. The Company had 1,095,359 unvested stock options outstanding as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, unrecognized compensation cost of $2,734 related to outstanding unvested stock options is expected to be recognized as expense over a weighted average period of 1.8 years.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the years ended December&#160;31, 2025 and 2024, was $3.70 and $1.83 per share, respectively. The total fair value of options vested were $798 and $72 during the years ended December&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2025 and 2024, 438,808 and 253,909 stock options were exercised and satisfied with newly-issued shares, resulting in cash proceeds of $158 and $75, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Black-Scholes option pricing model weighted-average assumptions.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.81 %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.30 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6 %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73.4 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; %</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating the fair value of the underlying common stock prior to IPO, the Company utilized a third party valuation firm whose analyses supported management's concluded estimate. Post IPO the fair value of the underlying common stock is based on the Company&#8217;s closing stock price on the date of grant.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2025 the Company granted a total of 17,322 restricted stock units (RSUs) to its six non-employee directors utilizing a fair market value (FMV) of $4.33 per share of the Company's common stock on the grant date. These RSUs vested on December&#160;31, 2025. </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.139%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value per Share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, the Company recorded $75 in stock-based compensation related to RSUs. The total fair value of RSUs vested during the year ended December&#160;31, 2025 was approximately $185.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation, measured at the grant date, is recognized ratably over the requisite service period, using the straight-line method of expense attribution. Forfeitures are accounted for as a reduction in expense in the period in which they occur; no compensation cost is recorded for awards that do not vest. The Company recognized total stock-based compensation expense for employees and non-employees as components of the statement of operations and comprehensive loss as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">826</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">156</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13. SEGMENTS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating (and reportable) segment known as the Capsule Endoscopy Segment; its chief operating decision maker is its Chief Executive Officer.  The composition of this segment reflects the Company&#8217;s focus on capsule endoscope medical devices addressing different areas within the GI tract. Refer to Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES and Note 6. REVENUE AND DEFERRED REVENUE for descriptions of products and services.  Segment accounting policies are the same as those described therein.  The chief operating decision maker assesses performance for the Capsule Endoscopy Segment and decides how to allocate resources based upon net income (loss) as reported in the statement of operations and comprehensive loss; also considered is operating income (loss), measured on the same basis as in the statement of operations and comprehensive loss. Net income (loss) and operating income (loss) are used in the process of evaluating expenses and determining where to prioritize resources.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment assets are identical to those reported in the balance sheet as total assets.  Segment revenue is identical to that reported in the statement of operations and comprehensive loss; significant segment expenses are identical to those identified in the statement of operations and comprehensive loss under the line items for selling and marketing expenses, research and development expenses, and general and administrative expenses.  Other segment items are represented by non-operating income (expense), net (which includes insignificant interest income) and the provision for income taxes as reported in the statement of operations and comprehensive loss.  Segment depreciation expense and capital expenditures are identical to amounts in the statement of cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14. INCOME TAXES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of loss before income taxes are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,424)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,220)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(25,291)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,887)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax provision are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current provision</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total income tax provision</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2025 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:58.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax, net of federal taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Taiwan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Local income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of changes in tax laws or rates enacted in the current period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nontaxable or nondeductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Adjustments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total effective tax rate</span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2024 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent book-tax differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and State research and development tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total effective tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of cash paid for income taxes by the Company are as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash paid for income taxes (net of refunds)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill was enacted (&#8220;OBBBA&#8221;), introducing significant and wide-ranging changes to the U.S. federal tax system. Significant components include restoration of 100% accelerated tax depreciation on qualifying property including expansion to cover qualified production property.&#160;&#160; Another major aspect includes the return to immediate expensing of domestic research and experimental expenditures (&#8220;R&amp;E&#8221;) which in some cases may include retroactive application back to 2021 for businesses with gross receipts of less than $31 million or accelerated tax deductions of R&amp;E that was previously capitalized for larger businesses.&#160; The </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legislation also reinstates EBITDA-based interest deductions for tax purposes and makes several business tax incentives permanent.&#160; Less favorable business provisions include limitations on tax deductions for charitable contributions. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are accounted for using the asset and liability method, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main components of deferred tax assets (liabilities) are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">39,670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33,830</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,295)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,384)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">375</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">446</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains/losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(375)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(446)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Valuation Allowance Considerations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance against a deferred tax asset must be established when it is &#8220;more likely than not&#8221; that all, or a portion of, deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. After consideration of all the information available, in particular the Company&#8217;s accumulated deficit and history of operating losses, it was concluded that uncertainty exists with respect to future realization of deferred tax assets. The valuation allowance increased during the years ended December 31, 2025 and December 31, 2024 in the amounts of $5,912 and $4,700, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Operating Losses and Tax Credit Carryforwards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has experienced and generated net operating losses (&#8220;NOLs&#8221;) for tax purposes since inception. As of December 31, 2025 (December 31, 2024), total available gross (pre-tax) Federal and U.S. state NOL carryforward amounts were $126,094 and $93,244 ($100,304 and $79,481), respectively. Under the Federal Tax Cuts and Jobs Act of 2017, NOLs incurred in tax years beginning on or after January 1, 2018, are carried forward&#160;indefinitely and subject to a usage limitation of 80% of taxable income; NOLs incurred in tax years prior to January 1, 2018, are subject to a twenty-year carryforward before expiring and not subject to a usage limitation of taxable income. As of December 31, 2025 (December 31, 2024), total Federal and U.S. state research and development tax credit carryforward amounts, net of unrecognized tax benefits, were 1,318 (1,318), respectively.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs and tax credit carryforward values are as follows as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Operating Losses (gross; pre-tax)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; Federal (arising after December 31, 2017)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expiry</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; Federal (arising before January 1, 2018)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; State - indefinite</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expiry</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; State &#8211; definite lived</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Tax Credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credits &#8211; Federal and State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 as amended (&#8220;Section 382&#8221;), or, for states, state laws, due to ownership changes that have occurred previously or that could occur in the future.  These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.  The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception.  If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382. Any limitation may result in expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 174 Capitalization</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBBBA made changes to Section 174 of the Internal Revenue Code of 1986 as amended for taxable years beginning December 31, 2024 with the Company being able to deduct domestic research and experimental (R&amp;E) expenditures in the year they are incurred when before these costs were capitalized and amortized over 5 years. The Company is still required to capitalize foreign R&amp;E costs and amortize them over 15 years. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the tax year ended December 31, 2025 the Company incurred $3,545 of foreign R&amp;D expenses which were capitalized and are being amortized over the respective period noted above. For the tax year ended December 31, 2024 the Company incurred $13,910 and $1,116 of domestic and foreign R&amp;D expenses, respectively, which were capitalized and are being amortized over the respective periods noted above. These amounts are reflected in gross deferred tax assets (together with previous periods&#8217; amounts, net of amounts amortized for tax purposes).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balance of total unrecognized tax benefits on a tax-effected basis for follows; these relate principally to research and development credit carryforwards.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized tax benefits, December 31, 2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,634</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for current tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes for previous tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized tax benefits, December 31, 2024</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,472</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for current tax positions</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes for previous tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized tax benefits, December 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,484</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet conducted a study of its research and development credit carryforwards. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, the tax assets associated with the research and development credit carryforwards have been fully offset with a reserve.  A full valuation allowance has been provided against the Company&#8217;s net deferred tax assets, and if an adjustment to the net unrecognized tax benefits were to occur, this adjustment would be offset by an equal adjustment to the valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recognized no interest and penalties associated with substantially all of its unrecognized tax benefits. There are no tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. Federal and State income tax returns in jurisdictions with varying statutes of limitations.  In the normal course of business, the Company is subject to examination by taxing authorities throughout the U.S.  These examinations could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with laws.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s remaining open tax years subject to examination by federal and state tax authorities include the years ended December&#160;31, 2019, through 2025 in the U.S and December 31, 2020 through 2025 in the Company&#8217;s foreign operations. However, for tax years from inception through the present, federal and state taxing authorities may examine and adjust loss carryforwards in the years in which those loss carryforwards are ultimately utilized.  There are currently no pending income tax examinations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15. NET LOSS PER SHARE</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss &#8211; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,315)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares of common stock outstanding &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,555,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,020,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share &#8211; basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.03)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9.85)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is the same as diluted net loss per share as the inclusion of potential common shares outstanding would have been anti-dilutive. The Company's convertible preferred stock Series constitute </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participating securities; however, as a result of the net loss position, they are excluded from the calculation of basic net loss per share.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the preceding calculations because they would be anti-dilutive were as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 10pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock (all series)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,279,825&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,665,583&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants on common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options on common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,027,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,298,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21,403,135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">40,979,545</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16. RELATED PARTIES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, the Company's material transactions with related parties were limited to a promissory note described in Note 7. NOTE PAYABLE and certain R&amp;D expenses ($1,207 and $320 for the years ended December&#160;31, 2025 and December&#160;31, 2024, respectively) for non-recurring engineering services with an R&amp;D and manufacturing services vendor that holds an insignificant percentage of the Company's capital stock. There were no other material transactions with related parties during the years ended December&#160;31, 2025 and December&#160;31, 2024 and no amounts due from or to related parties at December&#160;31, 2025 or December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">17. SUBSEQUENT EVENTS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2026 the Company signed a consulting agreement with Wen-Hung Tsai, one of the Company's shareholders and a former member of the Company's Board of Directors (till February 26, 2024). Per the consulting agreement Mr.Wen-Hung Tsai will provide strategic advice, help with industrial affiliation and partnerships, as well as work on the supply chain establishment for new products. As compensation for his services, the Company granted to Mr.Wen-Hung Tsai on February 12, 2026 an option to purchase 250,000 shares of the Company's Common Stock under the Company&#8217;s 2025 Equity Incentive Plan. Eighty percent (80%) of the option grant is scheduled to vest and become exercisable on February 12, 2027. The remaining portion of the option grant is scheduled to vest and become exercisable in three (3) equal monthly installments on the same day of each successful calendar month following February 12, 2027.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 16, 2026, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with selected accredited investors (the &#8220;Investors&#8221;), for the purposes of raising approximately $14 million in aggregate gross proceeds for the Company (the &#8220;Private Placement&#8221;). Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to the Investors in the Private Placement an aggregate of 2,867,089 shares (the &#8220;Shares&#8221;) of common stock of the Company, par value $0.001 per share (the &#8220;Common Stock&#8221;), at $4.883 per Share. The closing of the Private Placement occurred on March 16, 2026. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Private Placement, the Company entered into a registration rights agreement, dated March 16, 2026 (the &#8220;Registration Rights Agreement&#8221;), with the Investors, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the &#8220;SEC&#8221;) a registration statement to register for resale the Shares within 90 days after the closing of the Private Placement, and (ii) use commercially reasonable efforts to have such registration statement declared effective as soon as reasonably </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">practicable following the filing thereof with the SEC. The Registration Rights Agreement contains customary terms and conditions for a transaction of this type.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee oversight of cybersecurity risks, including responsibility for our controls and procedures for mitigating cybersecurity and other information technology risks, and our plans to respond to data breaches.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). Any reference in these notes as it concerns U.S. GAAP is meant to refer to authoritative pronouncements as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div>On July&#160;2, 2025, the Company amended and restated its amended and restated certificate of incorporation to effect a 1-for-3.33 reverse stock split of the Company's common stock, which automatically resulted in reciprocal adjustments (reductions) to the conversion ratios of each of the Company's series of convertible preferred stock (the "Reverse Stock Split"). The par values per share of the common and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All amounts for issued and outstanding common stock, convertible preferred stock, options to purchase common stock, warrants on common stock, and reserves related to common stock, as well as related per-share amounts, contained in the financial statements have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented. No fractional shares were issued as a result of the reverse stock split. In lieu of fractional shares, the Company rounded down to the next whole share and made a cash-in-lieu payment of $1 for 108 shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reporting currency for the financial statements of the Company is the United States Dollar. The functional currency of the U.S. corporation, and its foreign branch which is an extension of the U.S. corporation, is the U.S. Dollar. The assets, liabilities, and expenses of the Company&#8217;s foreign branch recorded in local currency are remeasured into the U.S. Dollar each period, with associated gains and losses included in operating expenses (as a component of general and administrative expenses). Monetary assets and liabilities denominated in currencies other than the functional currency are translated at exchange rates in effect at the balance sheet date with associated gains and losses included in operating expenses (as a component of general and administrative expenses). For the years ended December&#160;31, 2025 and 2024, the Company recorded $193 and $(93), respectively, of net foreign exchange gains (losses) as components of general and administrative expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates&#160;</span></div>The preparation of financial statements in conformity with U.S. GAAP requires the making and usage of  estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities, if any. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. The Company seeks to moderate the influence of subjectivity and estimation uncertainty through reliance on useful information from market participants and peers wherever possible. Estimates and assumptions affect various financial statement amounts and their related disclosures, including, but not limited to, the recognition of revenue, underwriters' warrants valuation, stock based compensation, research and development expenses, income tax-related amounts, lease-related amounts, and allowances for credit losses. Actual results could materially differ from estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Segments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized as, and managed as, one operating (and reportable) segment. Its chief operating decision maker is its Chief Executive Officer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value Measurements&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where required, certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the three levels of the hierarchy:</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - defined as inputs other than quoted prices included in Level&#160;1 that are either directly or indirectly observable</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - defined as significant unobservable inputs for which little or no market data exists, therefore necessitating entity-specific assumptions&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. An asset or liability&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s financial assets (which include cash and accounts receivable) and liabilities (which include accounts payable) approximate fair value due to their insensitivity to interest rates and/or close proximity to maturity and qualify as Level&#160;1 measurements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentration Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of demand deposits at well-known financial institutions and accounts receivable.&#160; At times, the Company&#8217;s cash deposits may exceed U.S. Federal deposit insurance limits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sales to customers are typically originated with trade credit terms and receivables are uncollateralized, with limited exceptions for prepayments required for certain customers or credit card sales.  The Company historically has experienced insignificant levels of bad debt; allowances for credit losses on accounts receivable were insignificant for all periods presented.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s concentration risk related to revenues relates primarily to its product revenues being derived from a single product. With respect to customers, for the year ended December&#160;31, 2025, the same customer represented 9% of our revenue and 22% of our accounts receivable as of December&#160;31, 2025. For the year ended December&#160;31, 2024, that same customer represented 10% of our revenue and 21% of our accounts receivable as of December 31, 2024.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s supply concentration risk relates primarily to its materials procurement and contract manufacturing being substantially concentrated with vendors located in Asia.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) comprises net income (loss) and other comprehensive income (loss), which is defined as all changes in stockholders&#8217; equity (deficit) other than net income (loss) and those resulting from investments by and distributions to stockholders. Historically, and for all periods presented, there are no differences between net loss and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The core principle is that an entity should recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue using a five-step model resulting in revenue being recognized as performance obligations within a contract are satisfied. The steps within that model include: (i) identifying the existence of a contract with a customer; (ii) identifying the performance obligations within the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract; (iii) determining the contract&#8217;s transaction price; (iv) allocating the transaction price to the contract&#8217;s performance obligations; and (v) recognizing revenue as the contract&#8217;s performance obligations are satisfied.  Judgment is required to apply the model and make certain estimates and assumptions about the Company&#8217;s contracts with its customers, including, among others, the nature and extent of its performance obligations, its transaction price amounts and any allocations thereof (including estimates of standalone selling prices), the events which constitute satisfaction of its performance obligations, and when control of any promised goods or services is transferred to customers. The guidance also requires certain incremental costs incurred to obtain or fulfill a contract to be deferred and amortized on a systematic basis consistent with the transfer of goods or services to a customer.&#160;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates (i) product revenue from the sale of capsule medical devices, (ii) service revenue from the provision of reading services for videos, and (iii) product or service revenue depending on which video delivery option is utilized by the customer to download and view capsule videos.  The customer&#8217;s delivery options include (1) a capsule data reading device shipped to the customer which works together with downloadable software installed locally on a customer&#8217;s computer (classified as product revenue), or (2) a software-as-a-service offering which involves the customer mailing capsule devices to an off-site Company-operated facility which processes uploads of video content to a cloud platform the customer can access via a web browser or a smart device application in order to view videos and generate reports (classified as service revenue).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts with customers contain fixed consideration reflecting prices negotiated with customers and immaterial variable consideration.  For contracts with variable consideration, the Company uses the most likely amount method to estimate the transaction price. Variable consideration is constrained to the extent that it is deemed probable that a significant reversal of the amount of revenue recognized will not occur. Where products or services are not sold separately or experience a range of selling prices, the Company estimates standalone selling prices using a cost-plus-expected margin approach and utilizes the resultant standalone selling prices to allocate transaction prices at transaction inception on a relative standalone selling price basis. The Company recognizes revenue for its product and reading service performance obligations at a point in time, that being when the performance obligations are satisfied and control is transferred to the customer (generally upon shipment for products, or conveyance of final deliverable for services).  For the software-as-a-service video delivery offering performance obligation, the associated revenue is recognized over time, typically less than one fiscal quarter, representing the estimate of the typical period of time in which customers derive utility from the cloud-based service.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any significant financing components as payment is received at or shortly after sale. Standard trade credit terms are typically 30 to 60 days from invoice date. Costs incurred to obtain or fulfill a contract are expensed as incurred when the amortization period is less than one year, which is the case for the Company. The Company considers all shipping and handling to be fulfillment activities and not a separate performance obligation. Shipping and handling costs are recorded as costs of revenue. The Company has elected an accounting policy to exclude sales taxes and other similar taxes from the measurement of the transaction price.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain U.S. customers characterized as group purchasing organizations that function as procurement agents for their underlying medical practice, clinic, or hospital members; these group purchasing organizations typically charge the Company percentage-based fees in exchange for the right to do business with the group purchasing organization.  Such fees, which do not provide a distinct separate benefit to the Company, are recorded as reductions to revenue in the same period as the recognition of the related revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s products are sold with the same limited quality assurance warranties offered to all customers; the Company typically does not allow returns of products, except for cases of damage or defect, whereby products would be replaced.  Actual product returns have historically been immaterial given the one-time-use nature of capsule devices; estimated product returns (periodically adjusted to reflect actual experience), if warranted, are accounted for as reductions to revenue with offsets to a product return liability included within accrued expenses and other current liabilities in the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Contract Assets and Contract Liabilities; Accounts Receivable and Related Allowance</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities; Accounts Receivable and Related Allowance</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records contract assets when it has completed performance obligations prior to receiving consideration from the customer and where such amounts are unbilled; where billed, amounts are reflected as trade accounts receivable. The Company promptly invoices its accounts receivable; therefore, the Company&#8217;s contract assets were zero for all periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities, portrayed as deferred revenue, reflect (i) obligations to provide goods for which the Company has already received consideration (generally arising from up-front payments received) and (ii) performance obligations to provide services which are not yet satisfied in the context of a particular contract (principally consisting of video delivery obligations related to the Company&#8217;s off-premise cloud-based video delivery offering).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The Company grants trade credit to most of its customers in the normal course of business and generally does not require collateral. An allowance for credit losses arises subsequent to the origination of a sale for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts.  A provision (or a reversal of the allowance) is recorded as a component of general and administrative expenses.  In determining the amount of the allowance, the Company considers aging of accounts, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance when all attempts to collect have been exhausted. Allowances for credit losses were insignificant for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Costs of Revenue</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue include materials, direct labor, and manufacturing overhead costs related to sold products, as well as certain period costs such as non-allocated overhead, scrap, and outbound freight costs, fees paid to physicians for providing reading services, and the costs of operating the Company&#8217;s cloud-based software-as-a-service offering for video delivery such as shipping costs, processing costs, and data storage costs. Shipping and handling costs directly related to bringing products to their final point of sale are included in costs of revenue and were $117 and $51 for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses include costs directly attributable to actively marketing the Company&#8217;s products and services using both direct employees and outside contractors or vendors. These costs include, but are not limited to, salaries, bonuses, benefits, stock-based compensation, sales commissions, travel costs and expense reimbursements, and the costs of sponsoring programs, events, and conferences. Advertising costs were nil for all periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, bonuses, benefits, and stock-based compensation related to the Company&#8217;s executive, administrative, finance, human resources, and other supporting functions. Also included are professional fees for legal services, consulting services, tax matters and audits, information technology, office expenses, rent, insurance, and foreign exchange gains (losses).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses (including Clinical Trial Expenses)</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expenses (including Clinical Trial Expenses)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development expenses include costs directly attributable to the conduct of research and development programs, including salaries, bonuses, benefits, and stock-based compensation for employees focused on research and development or clinical trials, costs of independent contractors and outside vendors, costs of supplies consumed in or product inventory utilized in clinical trials, and the costs of clinical trial activities as charged within the negotiated budgets by trial sites or vendors responsible for multiple trial sites.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes prepayments for goods or services, including trial device inventory, that will be used, consumed, or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed.  The Company also records expenses and accruals for estimated costs of research and development activities, including third party services for clinical trials.  The Company bases its estimates on information available at the time.  Costs for certain clinical trial activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the balance sheet as prepaid expenses or as accrued expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025 and 2024, the Company incurred $6,391 and $7,647, respectively, of expenses related to ongoing clinical trial activities which are included within research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if options or warrants on common stock were exercised or convertible preferred stock shares were converted into common stock. Diluted net loss per share is the same as basic net loss per common share since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of incremental common shares issuable upon exercise of vested stock options, common stock warrants, and the Company&#8217;s various series of convertible preferred stock. Upon completion of the IPO in July 2025, all outstanding shares of preferred stock were converted into shares of Company's common stock (after giving effect to the 1-for-3.33 reverse stock split). Subsequent to the conversion, only common stock remains outstanding. Accordingly, the two-class method is no longer applicable for periods after the IPO.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents comprises demand deposits in the form of checking accounts and money market accounts (which may be deposited into and withdrawn at will with no restrictions as to investment or redemption) and includes cash balances denominated in the Euro and New Taiwan Dollar, for which fluctuations in exchange rates result in gains or losses reported within operating expenses as a component of general and administrative expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisting of materials, direct labor and manufacturing overhead, are subdivided into raw materials, work in process, and finished goods and are stated at the lower of cost (average cost) or net realizable value.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates inventories as to (i) net realizable value and (ii) circumstances or indicators of loss, damage, insufficient time to expiry (determined by battery life), excess quantities, or obsolescence and provisions accordingly via direct charges against the carrying value of inventory.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at historical cost, less accumulated depreciation. The Company capitalizes major improvements and expenses repairs and maintenance as incurred. Depreciation is recorded using the straight-line method based on the estimated useful lives of the depreciable property or, for leasehold improvements, the remaining term of the lease, whichever is shorter.  Useful lives are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery &amp; equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 to 5 years</span></div></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-344">Shorter of remaining lease term or useful life</span></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal (retirement or sale) of property and equipment, as applicable, the cost and related accumulated depreciation are removed and any resulting gain or loss is reflected within operating expenses. Such amounts were insignificant for all periods presented.</span></div>Long-lived assets are evaluated for impairment as warranted by triggering events related to changes in facts and circumstances. There have historically been no impairments and there were none for all periods presented<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and storage space in California and office space in Taiwan, Republic of China. The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (&#8220;ROU&#8221;) assets and the corresponding lease liabilities are depicted in operating lease liabilities, current and operating lease liabilities, non-current in the balance sheet. ROU assets represent the right to use an underlying asset, and lease liabilities represent the obligation for lease payments in exchange for the ability to use the asset for the duration of the lease term. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets and lease liabilities are recognized at commencement date and determined using the present value of the future minimum lease payments over the lease term. The Company utilizes an incremental borrowing rate when assessing lease classification and measuring lease liabilities. The estimated incremental borrowing rate considers credit rating practices applied by well known statistical rating organizations to borrowers, Company-specific factors, and the actual lease term at commencement date. The lease term may include options to extend when it is reasonably certain that the Company will exercise that option. The Company recognizes operating lease expense on a straight-line basis over a lease's term.</span></div>The Company has lease agreements which contain both lease and non-lease components, which it has elected to account for as a single lease component. Variable lease payments that are not dependent on an index or rate are not included in lease measurements and are accounted for as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary means of financing from start-up through development and into the commercial stage has historically been the issuance of convertible preferred stock in various series; these series share similar rights and obligations and contain similar qualifications as to the requirements an equity initial public offering would have to meet in order for the stock to convert to common stock. Convertible preferred stock is recorded at fair value on the date of issuance (historically, the same as the issue price), net of issuance costs. Application of the guidance contained in&#160;ASC&#160;480-10-S99-3A,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SEC Staff Announcement: Classification and Measurement of Redeemable Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has led the Company to present each of the series of convertible preferred stock as mezzanine equity due to the similar features of the series concerning liquidation preferences and other rights and privileges inuring to the respective series&#8217; holders, one or more of which may result in a settlement in cash not entirely within the Company&#8217;s control.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2025, immediately prior to the completion of the Company&#8217;s IPO and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock, all shares of the Company&#8217;s convertible preferred stock converted into shares of the Company&#8217;s common stock.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for employee and nonemployee equity compensation awards in accordance with ASC 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 718&#8221;).&#160; In accordance therewith,&#160;the Company accounts for </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock-based compensation for awards granted to nonemployees in a similar fashion to stock-based compensation awards to employees.&#160; ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation awards issued under the Company&#8217;s 2005 Stock Plan (the &#8220;2005 Plan&#8221;) and the Company&#8217;s 2025 Equity Incentive Plan (the &#8220;2025 Plan&#8221;) take the form of stock options (non-qualified or incentive stock options), restricted stock or restricted stock units (the "RSUs"). The 2025 Plan also provides for the grant of stock appreciation rights, stock bonuses, stock units and other forms of awards including cash awards to the Company&#8217;s officers, directors, employees, consultants and advisors. The Black-Scholes option-pricing model is used to determine the fair value of options; application of the model requires judgment to develop assumptions input into the model, some of which are more subjective, including: (i) the fair value of the underlying common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility of the underlying common stock; (iv) the risk-free interest rate; and (v) expected dividends. Income and market approaches to valuation are judgmentally weighted and combined to determine a composite value representing the fair value of the underlying common stock. In estimating the fair value of the underlying common stock prior to IPO, the Company utilized a third party professional valuation firm whose analyses supported management's concluded estimate. Post IPO the fair value of the underlying common stock is based on the Company&#8217;s closing stock price on the date of grant. An expected volatility assumption is based on stock price volatility of a peer group of comparable public companies over a similar expected term. The risk-free rate is based on U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term; no dividends are assumed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s employee and nonemployee stock-based compensation awards granted on or before December 31, 2025 contain only service conditions for vesting. The Company recognizes stock-based compensation cost as a component of the related functional expense (costs of revenue or category of operating expenses) on a straight-line basis over the requisite service period, which is explicitly stated in the case of awards issued to employees and implicitly understood to be the period over which services are provided for nonemployees. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with pre-vesting forfeitures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation awards in the form of the restricted stock units (the "RSUs") are issued to the Directors of CapsoVision, Inc, who are not employed by the Company ("Non-Employee Directors"). These RSUs are issued in lieu of annual cash compensation (annual base retainer). Each RSU granted to the Non-Employee Directors represents a right to receive one share of the Company common stock when the RSU vests. The Company estimates compensation cost based on the grant date fair value and recognizes the expense on a graded vesting basis over the vesting period of the award. Please, see Note 12. STOCK-BASED COMPENSATION for details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, offering costs related to legal, accounting, and underwriting costs were net with the proceeds and recorded as a reduction in additional paid in capital, in the stockholders&#8217; equity section of the balance sheet. The Company also issued Underwriters Warrants (as defined in Note 11. COMMON STOCK) for services provided during the IPO to purchase 168,898 shares of common stock. The Underwriters Warrants are accounted for as equity instruments and are included in the Stockholders&#8217; Equity section of the balance sheet. The fair value of the Underwriters Warrants has been estimated using the Black-Scholes option pricing model.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC 740,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 740&#8221;), which requires that the asset and liability method be used. Deferred tax assets and liabilities are determined based on the differences between financial reporting (book basis) and the tax reporting (tax basis) amounts of assets and liabilities; these pre-tax differences are measured and reflected after-tax using the enacted tax rates and law that will be in effect when the differences are expected to reverse. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets at least annually and more frequently as warranted by changes in facts and circumstances and adjusts the amount of the valuation allowance accordingly. Factors considered include the presence of reversing taxable temporary differences as a source of taxable income, forecasts of future taxable income, and available tax planning strategies that could be implemented and are both prudent and feasible. The Company has recorded a full valuation allowance with respect to all of its deferred tax assets based upon the significant negative evidence presented by its accumulated deficit position, its operating losses and negative operating cash flows, and the uncertainty associated with the timing and amount of future profits and therefore taxable income that enable realization. In future periods, if the Company generates book income and taxable income, changes in judgment may reduce or eliminate the valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with a two-step model. Firstly, a recognition threshold must be met; a tax benefit from an uncertain tax position may only be recognized if the tax position would, more likely than not, be sustained by the taxing authority assuming an examination and the application of typical practices and precedents.  Secondly, a measurement rule is applied; the amount of tax benefit that can be recognized is the portion that is greater than 50% likely of being realized upon a settlement.  The determination as to whether a tax benefit will, more likely than not, be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances, without consideration of detection risk. As of December&#160;31, 2025 and 2024 the Company&#8217;s uncertain tax positions were principally related to the non-recognition of a portion of Federal and U.S. state research and development tax credits. The Company recognizes any interest and penalties associated with its income tax positions in the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Issued and Recently Adopted / Accounting Pronouncements Issued and Not Yet Adopted</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Standards Issued and Recently Adopted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280):&#160;Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;("ASU 2023-07"). This guidance requires disclosure on an annual and interim basis of the following: (i) significant segment expenses regularly provided to the chief operating decision maker ("CODM") and a measure of segment profit or loss; (ii) an amount for other segment items by reportable segment and a description of its composition; (iii) all annual disclosures about a reportable segment's profit and loss and assets as currently required by ASC Topic 280; (iv) clarifying if the CODM uses more than one measure of a segment's profit or loss in assessing segment performance and deciding how to allocate resources; and (v) disclosing the title and position of the CODM and how the CODM uses the reported measures. Public entities with a single reportable segment are required to provide all the disclosures required by this amendment.  ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and for quarters in the years beginning after December 15, 2024; early adoption is permitted. The Company, a single reportable segment entity, early adopted ASU 2023-07 with effect from January 1, 2023; the related disclosures are included in Note 13. SEGMENTS.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the FASB issued ASU 2023-09,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) &#8212; Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;("ASU 2023-09"). The new guidance provides for disclosure on an annual basis of the following: (i) specific categories in the rate reconciliation, and (ii) additional information for reconciling items that meet a quantitative threshold of greater than 5% of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024; early adoption is permitted. The Company adopted this standard for the fiscal year 2025 annual financial statements and has applied this standard prospectively which had a disclosure only impact on its financial statements. See Note 14. INCOME TAXES.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2024-03").  The new guidance requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the statement of operations. ASU is effective for public business entities for annual periods beginning after December 15, 2026, and for quarters in the years beginning after </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 15, 2027; early adoption is permitted. The new guidance may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends certain aspects of the accounting for and disclosure of internal-use software costs. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted and the amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date, retrospectively to any or all prior periods presented in the financial statements, or through a modified prospective transition approach which is based on the status of the project and whether software costs were capitalized before the date of adoption. The Company is currently evaluating the impact ASU 2025-06 will have on its disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU 2025-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Reporting (Topic 270): Narrow-Scope Improvements, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides clarity about current interim disclosure requirements and adds a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, for public business entities and for interim reporting periods within annual reporting periods beginning after December 15, 2028, for entities other than public business entities. Early adoption is permitted for all entities. The amendments in this Update can be applied either (1) prospectively or (2) retrospectively to any or all prior periods presented in the financial statements. At the same time, the FASB issued  ASU 2025-12 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. If an entity adopts the amendments in this Update in an interim period, it must adopt them as of the beginning of the annual reporting period that includes that interim reporting period. An entity may elect to early adopt the amendments on an issue-by-issue basis. The Company is currently evaluating the impact ASU 2025-11 and ASU 2025-12 will have on its disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481288/505-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Long-Lived Assets</a></td>
<td class="text">Useful lives are as follows.<div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery &amp; equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 to 5 years</span></div></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-344">Shorter of remaining lease term or useful life</span></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">928&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">821&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment, office equipment, and purchased software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(575)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(359)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">611</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">720</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment for insurance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">324&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for inventory purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred initial public offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,072</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">898</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">Useful lives are as follows.<div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery &amp; equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 to 5 years</span></div></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-344">Shorter of remaining lease term or useful life</span></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following amounts:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">928&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">821&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment, office equipment, and purchased software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(575)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(359)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">611</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">720</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expense and Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities comprised the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">568&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued sales taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE AND DEFERRED REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue disaggregated by geographic source, type of customer, and products or services was as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States (medical practice, clinic, and hospital customers):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products (capsules and capsule reading devices)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services (cloud-based video delivery and reading services)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside United States (distributor customers):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products (capsules and capsule reading devices)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,756</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Total Lease Expense and Supplemental Cash Flows</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts comprising total lease expense, reflected in general and administrative expenses and costs of revenue (including amounts capitalized as overhead to inventory), were as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">474&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">476&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">511</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease payments related to operating leases</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments related to operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock', window );">Lease-Related Amounts Reflected in the Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease-related amounts reflected in the balance sheet and data related thereto were as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">843</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities - current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities &#8211; long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">887</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments under Non-Cancellable Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases are as follows as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(104)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">887</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREFERRED STOCK (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Convertible Preferred Stock Outstanding</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock outstanding as of December 31, 2024 consisted of the following (in thousands, except share amounts.) </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Series </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preferred</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,962,675</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,394,197</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,850&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,801,802</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,747,127</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">880,187</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,876,405</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">848,599</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,222,222</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520,519</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,766,666</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166,833</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D-2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,083,333</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,920,649</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,151,977</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series F-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,043,479</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,201,203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series F-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,498,498</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series G</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,926,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,779,559</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series G-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,896,552</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,039,756</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series H</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,157,821</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,461,804</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">153,682,280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">38,665,583</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">152,378</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143,625</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>* Liquidation preference includes two times the original issue price per share.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes Option Pricing Model Weighted-Average Assumptions</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following assumptions:<div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Placement Underwriters' Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over-allotment exercise Underwriters' Warrants</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.96 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Black-Scholes option pricing model weighted-average assumptions.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.81 %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.30 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6 %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73.4 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; %</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,665,583&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercises of stock options under 2005 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,627,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,298,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercises of stock options under 2025 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserved for future grants under 2005 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">880,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserved for future grants under 2025 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,838,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total reserved shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,982,877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">41,859,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the year ended December&#160;31, 2025 was as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options on Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding (vested and expected to vest) as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,298,905</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.47</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,961</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">534,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(438,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited, canceled, or expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(419,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding (vested and expected to vest) as of December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,975,648</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,869</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">880,289</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.7</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes Option Pricing Model Weighted-Average Assumptions</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following assumptions:<div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Placement Underwriters' Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over-allotment exercise Underwriters' Warrants</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.96 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Black-Scholes option pricing model weighted-average assumptions.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.81 %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.30 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6 %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73.4 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; %</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based Compensation Expense for Employees and Non-employees</a></td>
<td class="text">The Company recognized total stock-based compensation expense for employees and non-employees as components of the statement of operations and comprehensive loss as follows.<div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">826</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">156</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.139%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value per Share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Domestic and Foreign Components of Loss Before Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of loss before income taxes are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,424)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,220)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(25,291)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,887)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Rate to Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2025 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:58.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax, net of federal taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Taiwan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Local income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of changes in tax laws or rates enacted in the current period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nontaxable or nondeductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Adjustments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total effective tax rate</span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2024 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent book-tax differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and State research and development tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total effective tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Amounts of Cash Paid for Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of cash paid for income taxes by the Company are as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash paid for income taxes (net of refunds)</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Provision</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax provision are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current provision</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total income tax provision</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets (Liabilities)</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main components of deferred tax assets (liabilities) are as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">39,670</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33,830</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,295)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,384)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">375</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">446</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains/losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(375)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(446)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Net Operating Loss Carryforwards and Tax Credit Carryforward Values</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs and tax credit carryforward values are as follows as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Operating Losses (gross; pre-tax)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; Federal (arising after December 31, 2017)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expiry</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; Federal (arising before January 1, 2018)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; State - indefinite</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expiry</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; State &#8211; definite lived</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Tax Credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credits &#8211; Federal and State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock', window );">Summary of Net Operating Loss Carryforwards and Tax Credit Carryforward Values</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs and tax credit carryforward values are as follows as of December&#160;31, 2025.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Operating Losses (gross; pre-tax)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; Federal (arising after December 31, 2017)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expiry</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; Federal (arising before January 1, 2018)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; State - indefinite</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expiry</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs &#8211; State &#8211; definite lived</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Tax Credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credits &#8211; Federal and State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Positions</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balance of total unrecognized tax benefits on a tax-effected basis for follows; these relate principally to research and development credit carryforwards.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized tax benefits, December 31, 2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,634</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for current tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes for previous tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized tax benefits, December 31, 2024</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,472</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for current tax positions</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes for previous tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized tax benefits, December 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,484</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss &#8211; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,315)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares of common stock outstanding &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,555,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,020,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share &#8211; basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1.03)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9.85)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the preceding calculations because they would be anti-dilutive were as follows.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 10pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock (all series)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,279,825&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,665,583&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants on common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options on common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,027,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,298,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21,403,135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">40,979,545</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 18, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 02, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,557<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Sale of stock, transaction date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  03,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionDate', window );">Preferred stock, conversion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">129,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionDate', window );">Preferred stock, conversion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_SaleOfStockEffectivenessDate', window );">Sale of stock, effectiveness date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_SaleOfStockEffectivenessDate', window );">Sale of stock, effectiveness date</a></td>
<td class="text">Jul. 18,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_SaleOfStockEffectivenessDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Effectiveness Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_SaleOfStockEffectivenessDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when preferred stock can be converted into common shares, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,112<span></span>
</td>
<td class="nump">$ 9,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,516<span></span>
</td>
<td class="nump">19,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,315<span></span>
</td>
<td class="nump">19,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,864<span></span>
</td>
<td class="nump">$ 20,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 23,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2025 </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 02, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Reverse stock split rounddown and cash in lieu payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,000<span></span>
</td>
<td class="num">$ (93,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,381,000<span></span>
</td>
<td class="nump">5,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,310,000<span></span>
</td>
<td class="nump">15,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in-Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Reverse stock split rounddown and cash in lieu payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares', window );">Reverse stock split rounddown and cash in lieu payment (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionDate', window );">Preferred stock, conversion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionDate', window );">Preferred stock, conversion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,000<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cv_HealthcareClinicalTrialActivitiesMember', window );">Healthcare clinical trial activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,391,000<span></span>
</td>
<td class="nump">$ 7,647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | Customer Concentration Risk | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity shares for down round feature triggered for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when preferred stock can be converted into common shares, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cv_HealthcareClinicalTrialActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cv_HealthcareClinicalTrialActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cv_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cv_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-Lived Assets (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Leasehold Improvements [Member]<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Computer equipment and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Computer equipment and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Purchased software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Purchased software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">994<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 2,987<span></span>
</td>
<td class="nump">$ 2,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepayment for insurance</a></td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Advance payments for inventory purchases</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred initial public offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">$ 898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">$ 928<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Computer equipment, office equipment, and purchased software</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(575)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 611<span></span>
</td>
<td class="nump">$ 720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 568<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued R&amp;D expenses</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Accrued sales taxes</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,697<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE AND DEFERRED REVENUE - Revenue Disaggregation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 13,554<span></span>
</td>
<td class="nump">$ 11,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">9,741<span></span>
</td>
<td class="nump">8,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | Outside United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE AND DEFERRED REVENUE - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 13,554<span></span>
</td>
<td class="nump">$ 11,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_GroupPurchasingOrganizationFeesContraRevenue', window );">Fees paid to group purchasing organizations</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | United States | Recognized over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | United States | Recognized at point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">9,741<span></span>
</td>
<td class="nump">8,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 598<span></span>
</td>
<td class="nump">$ 565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_GroupPurchasingOrganizationFeesContraRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Group Purchasing Organization Fees Contra Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_GroupPurchasingOrganizationFeesContraRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE PAYABLE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 07, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>May 27, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock in lieu of debt repayment</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Sale of stock, transaction date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  03,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ShortTermDebtOriginationDate', window );">Short term debt origination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 27,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Principal amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_RelatedPartyTransactionRatePerMonth', window );">Monthly interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Related party transaction, date</a></td>
<td class="text">Jul.  07,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">7,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermNonBankLoansAndNotesPayable', window );">Outstanding balance of promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ShortTermNonBankLoansAndNotesPaymentDate', window );">Payment date</a></td>
<td class="text">Jul. 11,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_RelatedPartyTransactionRatePerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Rate Per Month</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_RelatedPartyTransactionRatePerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ShortTermDebtOriginationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short Term Debt, Origination Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ShortTermDebtOriginationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ShortTermNonBankLoansAndNotesPaymentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short Term NonBank Loans And Notes Payment Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ShortTermNonBankLoansAndNotesPaymentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermNonBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermNonBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Total Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 511<span></span>
</td>
<td class="nump">$ 510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lease-Related Amounts Reflected in the Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">$ 1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8211; long-term</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 1,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Supplemental Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable lease payments related to operating leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments related to operating leases</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount', window );">Less: interest</a></td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized loan commitment, origination, and other costs (fees) and purchase premium (discount) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481598/310-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Jul. 15, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease', window );">Development agreement, development fee increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,310<span></span>
</td>
<td class="nump">$ 15,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,697<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceOperatingExpense', window );">Cash received related to refundable payroll tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Operating Expense, Decrease (Increase), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">General and administrative<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_PurchaseProvisionTermsMember', window );">Purchase Provision Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate', window );">Development agreement, origination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Development arrangement, fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee', window );">Development agreement, initial fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate', window );">Development agreement, initial fee payment date</a></td>
<td class="text">Jul. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet', window );">Development agreement, development fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding', window );">Outstanding purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Costs Incurred, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Costs Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Fee Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Initial Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Initial Fee Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Origination Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in expense from government assistance, classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes decrease (increase) in expense from government assistance, classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_PurchaseProvisionTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_PurchaseProvisionTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREFERRED STOCK - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">62 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 03, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>member </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 152,378,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">153,682,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_TemporaryEquityLegacyConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_TemporaryEquityDividendRatePercentage', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_NumberOfBoardMembers', window );">Number of board members | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 3,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Sale of stock, transaction date</a></td>
<td class="text">Jul.  03,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionDate', window );">Preferred stock, conversion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember', window );">Underwriter | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 1,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionDate', window );">Preferred stock, conversion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,461,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Convertible preferred stock, original issue price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,829,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,157,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_TemporaryEquityLegacyConversionPricePerShareMinimum', window );">Minimum legacy conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_TemporaryEquityLegacyConversionPricePerShareMaximum', window );">Maximum legacy conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum', window );">Minimum prospective proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_NumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Board Members</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_NumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prospective Proceeds From Issuance Initial Public Offering Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_TemporaryEquityDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Dividend Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_TemporaryEquityDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_TemporaryEquityLegacyConversionPricePerShareMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Legacy Conversion Price Per Share, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_TemporaryEquityLegacyConversionPricePerShareMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_TemporaryEquityLegacyConversionPricePerShareMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Legacy Conversion Price Per Share, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_TemporaryEquityLegacyConversionPricePerShareMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_TemporaryEquityLegacyConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Legacy Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_TemporaryEquityLegacyConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when preferred stock can be converted into common shares, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREFERRED STOCK - Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">153,682,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
<td class="nump">35,559,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 152,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 143,625<span></span>
</td>
<td class="nump">$ 128,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,962,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,394,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,801,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,747,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cv_SeriesC1PreferredStockMember', window );">Series C-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,876,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">848,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cv_SeriesD1PreferredStockMember', window );">Series D-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cv_SeriesD2PreferredStockMember', window );">Series D-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,083,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,920,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,151,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cv_SeriesF1PreferredStockMember', window );">Series F-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,043,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,201,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cv_SeriesF2PreferredStockMember', window );">Series F-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,498,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,926,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,779,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cv_SeriesG1PreferredStockMember', window );">Series G-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,896,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,039,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,157,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,461,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cv_SeriesC1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cv_SeriesC1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cv_SeriesD1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cv_SeriesD1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cv_SeriesD2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cv_SeriesD2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cv_SeriesF1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cv_SeriesF1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cv_SeriesF2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cv_SeriesF2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cv_SeriesG1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cv_SeriesG1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 18, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 02, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Underwriters Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,865,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,865,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in-Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Underwriters Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Sale of stock, transaction date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  03,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionDate', window );">Preferred stock, conversion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionDate', window );">Preferred stock, conversion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">129,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_SaleOfStockEffectivenessDate', window );">Sale of stock, effectiveness date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights', window );">Exercise date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">from the first day of the seventh month after July 3, 2025 (the &#8220;Original Closing Date&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_SaleOfStockEffectivenessDate', window );">Sale of stock, effectiveness date</a></td>
<td class="text">Jul. 18,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Date Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_SaleOfStockEffectivenessDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Effectiveness Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_SaleOfStockEffectivenessDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when preferred stock can be converted into common shares, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK - Black-Scholes Option-Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.81%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility of common stock</a></td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">73.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember', window );">Underwriter | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility of common stock</a></td>
<td class="nump">78.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember', window );">Underwriter | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility of common stock</a></td>
<td class="nump">78.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cv_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMON STOCK - Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">5,982,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,859,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock (all series)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cv_TwoThousandAndFivePlanMember', window );">2005 Plan | Exercises of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">1,627,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,298,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cv_TwoThousandAndFivePlanMember', window );">2005 Plan | Warrants on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">168,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cv_TwoThousandAndFivePlanMember', window );">2005 Plan | Future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cv_TwoThousandAndTwentyFivePlanMember', window );">2025 Plan | Exercises of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">348,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cv_TwoThousandAndTwentyFivePlanMember', window );">2025 Plan | Future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">3,838,331<span></span>
</td>
<td class="nump">4,204,204<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cv_TwoThousandAndFivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cv_TwoThousandAndFivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cv_FutureGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cv_FutureGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cv_TwoThousandAndTwentyFivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cv_TwoThousandAndTwentyFivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">5,982,877<span></span>
</td>
<td class="nump">41,859,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of award</a></td>
<td class="text">(vesting 25% on the first anniversary of the award and 1/48th each month thereafter) but may be granted with different vesting profiles, including options that are vested-at-grant (immediate vesting) and that are subject to different vesting schedules.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options (in shares)</a></td>
<td class="nump">1,095,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to outstanding unvested stock options</a></td>
<td class="nump">$ 2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="nump">$ 798<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">438,808<span></span>
</td>
<td class="nump">253,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of options on common stock and warrants</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">46,865,051<span></span>
</td>
<td class="nump">2,090,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">438,808<span></span>
</td>
<td class="nump">253,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock upon exercises of warrants (in shares)</a></td>
<td class="nump">15,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">46,865,051<span></span>
</td>
<td class="nump">2,090,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,837,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cv_FutureGrantsMember', window );">Future grants | 2025 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">3,838,331<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,204,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cv_FutureGrantsMember', window );">Future grants | 2005 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">880,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock option award modification expense</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options on common stock | 2025 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">348,551<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options on common stock | 2005 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved shares of common stock</a></td>
<td class="nump">1,627,097<span></span>
</td>
<td class="nump">2,298,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">17,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 4.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs vested</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cv_FutureGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cv_FutureGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cv_TwoThousandAndTwentyFivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cv_TwoThousandAndTwentyFivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cv_TwoThousandAndFivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cv_TwoThousandAndFivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options on Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,298,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">534,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(438,808)<span></span>
</td>
<td class="num">(253,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited, canceled, or expired (in shares)</a></td>
<td class="num">(419,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,975,648<span></span>
</td>
<td class="nump">2,298,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">880,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited, canceled, or expired (in dollars per share)</a></td>
<td class="nump">0.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">1.74<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 4,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">4,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">17,869<span></span>
</td>
<td class="nump">$ 4,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 9,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Black-Scholes Option Pricing Model Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.81%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility of common stock</a></td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">73.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Restricted Stock Units (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">17,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(17,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Costs of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 585<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Domestic and Foreign Components of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (24,424)<span></span>
</td>
<td class="num">$ (19,220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(867)<span></span>
</td>
<td class="num">(667)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (25,291)<span></span>
</td>
<td class="num">$ (19,887)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">U.S. State</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">U.S. State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Federal Statutory Rate to Effective Income Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory tax rate</a></td>
<td class="num">$ (5,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal taxes</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Local income taxes</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Effects of changes in tax laws or rates enacted in the current period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">5,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other Adjustments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal taxes</a></td>
<td class="num">(0.04%)<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Local income taxes</a></td>
<td class="num">(0.05%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effects of changes in tax laws or rates enacted in the current period</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">(20.60%)<span></span>
</td>
<td class="num">(23.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other Adjustments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total effective tax rate</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Cash Paid for Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">Total cash paid for income taxes (net of refunds)</a></td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">Total cash paid for income taxes (net of refunds)</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">Total cash paid for income taxes (net of refunds)</a></td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NC', window );">North Carolina</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">Total cash paid for income taxes (net of refunds)</a></td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NY', window );">New York State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">Total cash paid for income taxes (net of refunds)</a></td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_NC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 32,568<span></span>
</td>
<td class="nump">$ 26,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Capitalized R&amp;D expenses</a></td>
<td class="nump">5,087<span></span>
</td>
<td class="nump">5,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">39,670<span></span>
</td>
<td class="nump">33,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(39,295)<span></span>
</td>
<td class="num">(33,384)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets less valuation allowance</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains', window );">Unrealized gains/losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(446)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research And Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase</a></td>
<td class="nump">$ 5,912<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18,310<span></span>
</td>
<td class="nump">15,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">R&amp;D Tax Credits</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating operating losses</a></td>
<td class="nump">126,094<span></span>
</td>
<td class="nump">100,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating operating losses</a></td>
<td class="nump">93,244<span></span>
</td>
<td class="nump">79,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 3,545<span></span>
</td>
<td class="nump">$ 1,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - NOLs and Tax Credit Carryforward Values (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">R&amp;D Tax Credits</a></td>
<td class="nump">$ 1,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_TaxCreditCarryforwardExpirationTerm', window );">Expiration Term</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses (gross; pre-tax)</a></td>
<td class="nump">$ 126,094<span></span>
</td>
<td class="nump">$ 100,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Arising after December 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses (gross; pre-tax)</a></td>
<td class="nump">$ 77,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_OperatingLossCarryforwardsExpirationTerm', window );">Expiration Term</a></td>
<td class="text">No expiry<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Arising before January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses (gross; pre-tax)</a></td>
<td class="nump">$ 48,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_OperatingLossCarryforwardsExpirationTerm', window );">Expiration Term</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses (gross; pre-tax)</a></td>
<td class="nump">$ 93,244<span></span>
</td>
<td class="nump">$ 79,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Indefinite</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses (gross; pre-tax)</a></td>
<td class="nump">$ 3,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_OperatingLossCarryforwardsExpirationTerm', window );">Expiration Term</a></td>
<td class="text">No expiry<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Definite lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses (gross; pre-tax)</a></td>
<td class="nump">$ 89,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_OperatingLossCarryforwardsExpirationTerm', window );">Expiration Term</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_OperatingLossCarryforwardsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_OperatingLossCarryforwardsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_TaxCreditCarryforwardExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiration Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_TaxCreditCarryforwardExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=cv_TaxYearAfter2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=cv_TaxYearAfter2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=cv_TaxYearBefore2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=cv_TaxYearBefore2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=cv_TaxYearIndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=cv_TaxYearIndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=cv_TaxYearDefiniteLivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=cv_TaxYearDefiniteLivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Unrecognized Tax Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning balance</a></td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="nump">$ 1,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for current tax positions</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Changes for previous tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, ending balance</a></td>
<td class="nump">$ 1,484<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss - basic</a></td>
<td class="num">$ (25,315)<span></span>
</td>
<td class="num">$ (19,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss - diluted</a></td>
<td class="num">$ (25,315)<span></span>
</td>
<td class="num">$ (19,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares of common stock outstanding - basic (in shares)</a></td>
<td class="nump">24,555,381<span></span>
</td>
<td class="nump">2,020,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares of common stock outstanding - diluted (in shares)</a></td>
<td class="nump">24,555,381<span></span>
</td>
<td class="nump">2,020,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (9.85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (9.85)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">21,403,135<span></span>
</td>
<td class="nump">40,979,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock (all series)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">19,279,825<span></span>
</td>
<td class="nump">38,665,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">90,763<span></span>
</td>
<td class="nump">15,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">2,027,469<span></span>
</td>
<td class="nump">2,298,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">5,078<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Promissory note and certain R&amp;D expenses</a></td>
<td class="nump">$ 1,207<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 12, 2026 </div>
<div>monthly_installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(vesting 25% on the first anniversary of the award and 1/48th each month thereafter) but may be granted with different vesting profiles, including options that are vested-at-grant (immediate vesting) and that are subject to different vesting schedules.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsDate', window );">Subsequent event date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Sale of stock, transaction date</a></td>
<td class="text">Mar. 16,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares) | shares</a></td>
<td class="nump">2,867,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="nump">$ 4.883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_SaleOfStockEffectivenessDate', window );">Sale of stock, effectiveness date</a></td>
<td class="text">Mar. 16,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_SaleOfStockRegistrationRightsAgreementDate', window );">Sale of stock, registration rights agreement date</a></td>
<td class="text">Mar. 16,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Options on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Per the consulting agreement Mr.Wen-Hung Tsai will provide strategic advice, help with industrial affiliation and partnerships, as well as work on the supply chain establishment for new products. As compensation for his services, the Company granted to Mr.Wen-Hung Tsai on February 12, 2026 an option to purchase 250,000 shares of the Company's Common Stock under the Company&#8217;s 2025 Equity Incentive Plan. Eighty percent (80%) of the option grant is scheduled to vest and become exercisable on February 12, 2027. The remaining portion of the option grant is scheduled to vest and become exercisable in three (3) equal monthly installments on the same day of each successful calendar month following February 12, 2027.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage to occur on February 12, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments', window );">Number of monthly installments | monthly_installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_SaleOfStockEffectivenessDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Effectiveness Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_SaleOfStockEffectivenessDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_SaleOfStockRegistrationRightsAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Registration Rights Agreement Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_SaleOfStockRegistrationRightsAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the event occurred after the balance sheet date but before financial statements are issues or available to be issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 855<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>157</ContextCount>
  <ElementCount>379</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - COVER PAGE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/COVERPAGE</Role>
      <ShortName>COVER PAGE</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - AUDIT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/AUDITINFORMATION</Role>
      <ShortName>AUDIT INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED</Role>
      <ShortName>CONDENSED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED</Role>
      <ShortName>CONDENSED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTURE</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/GOINGCONCERN</Role>
      <ShortName>GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/BALANCESHEETCOMPONENTS</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - REVENUE AND DEFERRED REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/REVENUEANDDEFERREDREVENUE</Role>
      <ShortName>REVENUE AND DEFERRED REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - NOTE PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/NOTEPAYABLE</Role>
      <ShortName>NOTE PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - PREFERRED STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/PREFERREDSTOCK</Role>
      <ShortName>PREFERRED STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/SEGMENTS</Role>
      <ShortName>SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/RELATEDPARTIES</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/BALANCESHEETCOMPONENTSTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capsovision.com/role/BALANCESHEETCOMPONENTS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - REVENUE AND DEFERRED REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/REVENUEANDDEFERREDREVENUETables</Role>
      <ShortName>REVENUE AND DEFERRED REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capsovision.com/role/REVENUEANDDEFERREDREVENUE</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capsovision.com/role/LEASES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - PREFERRED STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/PREFERREDSTOCKTables</Role>
      <ShortName>PREFERRED STOCK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capsovision.com/role/PREFERREDSTOCK</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - COMMON STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/COMMONSTOCKTables</Role>
      <ShortName>COMMON STOCK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capsovision.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capsovision.com/role/INCOMETAXES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://capsovision.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTURE</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - GOING CONCERN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/GOINGCONCERNDetails</Role>
      <ShortName>GOING CONCERN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capsovision.com/role/GOINGCONCERN</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - BALANCE SHEET COMPONENTS - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - BALANCE SHEET COMPONENTS - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - BALANCE SHEET COMPONENTS - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/BALANCESHEETCOMPONENTSAdditionalInformationDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - BALANCE SHEET COMPONENTS - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - REVENUE AND DEFERRED REVENUE - Revenue Disaggregation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails</Role>
      <ShortName>REVENUE AND DEFERRED REVENUE - Revenue Disaggregation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - REVENUE AND DEFERRED REVENUE - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails</Role>
      <ShortName>REVENUE AND DEFERRED REVENUE - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - NOTE PAYABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/NOTEPAYABLEDetails</Role>
      <ShortName>NOTE PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capsovision.com/role/NOTEPAYABLE</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - LEASES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/LEASESAdditionalInformationDetails</Role>
      <ShortName>LEASES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - LEASES - Total Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/LEASESTotalLeaseExpenseDetails</Role>
      <ShortName>LEASES - Total Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - LEASES - Lease-Related Amounts Reflected in the Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails</Role>
      <ShortName>LEASES - Lease-Related Amounts Reflected in the Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - LEASES - Supplemental Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/LEASESSupplementalCashFlowsDetails</Role>
      <ShortName>LEASES - Supplemental Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - LEASES - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>LEASES - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capsovision.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - PREFERRED STOCK - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails</Role>
      <ShortName>PREFERRED STOCK - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - PREFERRED STOCK - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails</Role>
      <ShortName>PREFERRED STOCK - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - COMMON STOCK - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails</Role>
      <ShortName>COMMON STOCK - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - COMMON STOCK - Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails</Role>
      <ShortName>COMMON STOCK - Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - COMMON STOCK - Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>COMMON STOCK - Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - STOCK-BASED COMPENSATION - Black-Scholes Option Pricing Model Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Black-Scholes Option Pricing Model Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/SEGMENTSDetails</Role>
      <ShortName>SEGMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capsovision.com/role/SEGMENTS</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - INCOME TAXES - Domestic and Foreign Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Domestic and Foreign Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - INCOME TAXES - Components of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails</Role>
      <ShortName>INCOME TAXES - Components of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - INCOME TAXES - Reconciliation of Federal Statutory Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Federal Statutory Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - INCOME TAXES - Cash Paid for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Cash Paid for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - INCOME TAXES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - INCOME TAXES - NOLs and Tax Credit Carryforward Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails</Role>
      <ShortName>INCOME TAXES - NOLs and Tax Credit Carryforward Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - INCOME TAXES - Unrecognized Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/INCOMETAXESUnrecognizedTaxPositionsDetails</Role>
      <ShortName>INCOME TAXES - Unrecognized Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/NETLOSSPERSHAREDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capsovision.com/role/NETLOSSPERSHARETables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - RELATED PARTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/RELATEDPARTIESDetails</Role>
      <ShortName>RELATED PARTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capsovision.com/role/RELATEDPARTIES</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="cv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capsovision.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://capsovision.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cv-20251231.htm">cv-20251231.htm</File>
    <File>cv-20251231.xsd</File>
    <File>cv-20251231_cal.xml</File>
    <File>cv-20251231_def.xml</File>
    <File>cv-20251231_lab.xml</File>
    <File>cv-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cv-20251231_g1.jpg</File>
    <File>cv-20251231_g10.jpg</File>
    <File>cv-20251231_g11.jpg</File>
    <File>cv-20251231_g12.jpg</File>
    <File>cv-20251231_g13.jpg</File>
    <File>cv-20251231_g14.jpg</File>
    <File>cv-20251231_g15.jpg</File>
    <File>cv-20251231_g16.jpg</File>
    <File>cv-20251231_g17.jpg</File>
    <File>cv-20251231_g18.jpg</File>
    <File>cv-20251231_g2.jpg</File>
    <File>cv-20251231_g3.jpg</File>
    <File>cv-20251231_g4.jpg</File>
    <File>cv-20251231_g5.jpg</File>
    <File>cv-20251231_g6.jpg</File>
    <File>cv-20251231_g7.jpg</File>
    <File>cv-20251231_g8.jpg</File>
    <File>cv-20251231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="759">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>118
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cv-20251231.htm": {
   "nsprefix": "cv",
   "nsuri": "http://capsovision.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "cv-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "cv-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cv-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cv-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cv-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cv-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 350,
   "keyCustom": 29,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 49,
   "memberCustom": 16,
   "hidden": {
    "total": 6,
    "http://fasb.org/us-gaap/2025": 2,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 157,
   "entityCount": 1,
   "segmentCount": 70,
   "elementCount": 682,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 759,
    "http://xbrl.sec.gov/dei/2025": 40,
    "http://xbrl.sec.gov/ecd/2025": 5,
    "http://xbrl.sec.gov/cyd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://capsovision.com/role/COVERPAGE",
     "longName": "0000001 - Document - COVER PAGE",
     "shortName": "COVER PAGE",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://capsovision.com/role/AUDITINFORMATION",
     "longName": "0000002 - Document - AUDIT INFORMATION",
     "shortName": "AUDIT INFORMATION",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED",
     "longName": "9952151 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED)",
     "shortName": "CONDENSED BALANCE SHEETS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
     "longName": "9952152 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
     "longName": "9952153 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
     "longName": "9952154 - Statement - CONDENSED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "cv:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED",
     "longName": "9952155 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossOnDispositionOfAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTURE",
     "longName": "9952156 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE",
     "shortName": "DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://capsovision.com/role/GOINGCONCERN",
     "longName": "9952157 - Disclosure - GOING CONCERN",
     "shortName": "GOING CONCERN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://capsovision.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "9952159 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://capsovision.com/role/BALANCESHEETCOMPONENTS",
     "longName": "9952160 - Disclosure - BALANCE SHEET COMPONENTS",
     "shortName": "BALANCE SHEET COMPONENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://capsovision.com/role/REVENUEANDDEFERREDREVENUE",
     "longName": "9952161 - Disclosure - REVENUE AND DEFERRED REVENUE",
     "shortName": "REVENUE AND DEFERRED REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://capsovision.com/role/NOTEPAYABLE",
     "longName": "9952162 - Disclosure - NOTE PAYABLE",
     "shortName": "NOTE PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://capsovision.com/role/LEASES",
     "longName": "9952163 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://capsovision.com/role/PREFERREDSTOCK",
     "longName": "9952165 - Disclosure - PREFERRED STOCK",
     "shortName": "PREFERRED STOCK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://capsovision.com/role/STOCKBASEDCOMPENSATION",
     "longName": "9952167 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://capsovision.com/role/SEGMENTS",
     "longName": "9952168 - Disclosure - SEGMENTS",
     "shortName": "SEGMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://capsovision.com/role/INCOMETAXES",
     "longName": "9952169 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://capsovision.com/role/NETLOSSPERSHARE",
     "longName": "9952170 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://capsovision.com/role/RELATEDPARTIES",
     "longName": "9952171 - Disclosure - RELATED PARTIES",
     "shortName": "RELATED PARTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://capsovision.com/role/SUBSEQUENTEVENTS",
     "longName": "9952172 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesIntegratedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesIntegratedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://capsovision.com/role/BALANCESHEETCOMPONENTSTables",
     "longName": "9955513 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://capsovision.com/role/REVENUEANDDEFERREDREVENUETables",
     "longName": "9955514 - Disclosure - REVENUE AND DEFERRED REVENUE (Tables)",
     "shortName": "REVENUE AND DEFERRED REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://capsovision.com/role/LEASESTables",
     "longName": "9955515 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://capsovision.com/role/PREFERREDSTOCKTables",
     "longName": "9955516 - Disclosure - PREFERRED STOCK (Tables)",
     "shortName": "PREFERRED STOCK (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://capsovision.com/role/COMMONSTOCKTables",
     "longName": "9955517 - Disclosure - COMMON STOCK (Tables)",
     "shortName": "COMMON STOCK (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://capsovision.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9955518 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://capsovision.com/role/INCOMETAXESTables",
     "longName": "9955519 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://capsovision.com/role/NETLOSSPERSHARETables",
     "longName": "9955520 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
     "longName": "9955521 - Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE (Details)",
     "shortName": "DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://capsovision.com/role/GOINGCONCERNDetails",
     "longName": "9955522 - Disclosure - GOING CONCERN (Details)",
     "shortName": "GOING CONCERN (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "longName": "9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails",
     "longName": "9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-Lived Assets (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-Lived Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails",
     "longName": "9955525 - Disclosure - BALANCE SHEET COMPONENTS - Inventory (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9955526 - Disclosure - BALANCE SHEET COMPONENTS - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails",
     "longName": "9955527 - Disclosure - BALANCE SHEET COMPONENTS - Property and Equipment, Net (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://capsovision.com/role/BALANCESHEETCOMPONENTSAdditionalInformationDetails",
     "longName": "9955528 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9955529 - Disclosure - BALANCE SHEET COMPONENTS - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails",
     "longName": "9955530 - Disclosure - REVENUE AND DEFERRED REVENUE - Revenue Disaggregation (Details)",
     "shortName": "REVENUE AND DEFERRED REVENUE - Revenue Disaggregation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-53",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
     "longName": "9955531 - Disclosure - REVENUE AND DEFERRED REVENUE - Additional Information (Details)",
     "shortName": "REVENUE AND DEFERRED REVENUE - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://capsovision.com/role/NOTEPAYABLEDetails",
     "longName": "9955532 - Disclosure - NOTE PAYABLE (Details)",
     "shortName": "NOTE PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-65",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-65",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://capsovision.com/role/LEASESAdditionalInformationDetails",
     "longName": "9955533 - Disclosure - LEASES - Additional Information (Details)",
     "shortName": "LEASES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://capsovision.com/role/LEASESTotalLeaseExpenseDetails",
     "longName": "9955534 - Disclosure - LEASES - Total Lease Expense (Details)",
     "shortName": "LEASES - Total Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails",
     "longName": "9955535 - Disclosure - LEASES - Lease-Related Amounts Reflected in the Balance Sheet (Details)",
     "shortName": "LEASES - Lease-Related Amounts Reflected in the Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cv:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://capsovision.com/role/LEASESSupplementalCashFlowsDetails",
     "longName": "9955536 - Disclosure - LEASES - Supplemental Cash Flows (Details)",
     "shortName": "LEASES - Supplemental Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableLeasePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableLeasePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails",
     "longName": "9955537 - Disclosure - LEASES - Future Minimum Lease Payments (Details)",
     "shortName": "LEASES - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9955538 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cv:ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cv:ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
     "longName": "9955539 - Disclosure - PREFERRED STOCK - Additional Information (Details)",
     "shortName": "PREFERRED STOCK - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-90",
      "name": "cv:TemporaryEquityLegacyConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails",
     "longName": "9955540 - Disclosure - PREFERRED STOCK - Preferred Stock (Details)",
     "shortName": "PREFERRED STOCK - Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:TemporaryEquityTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
     "longName": "9955541 - Disclosure - COMMON STOCK - Additional Information (Details)",
     "shortName": "COMMON STOCK - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-95",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
     "longName": "9955542 - Disclosure - COMMON STOCK - Black-Scholes Option-Pricing Model (Details)",
     "shortName": "COMMON STOCK - Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
     "longName": "9955543 - Disclosure - COMMON STOCK - Common Stock Reserved for Future Issuance (Details)",
     "shortName": "COMMON STOCK - Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
     "longName": "9955544 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails",
     "longName": "9955545 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://capsovision.com/role/STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails",
     "longName": "9955546 - Disclosure - STOCK-BASED COMPENSATION - Black-Scholes Option Pricing Model Assumptions (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Black-Scholes Option Pricing Model Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails",
     "longName": "9955547 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
     "longName": "9955548 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://capsovision.com/role/SEGMENTSDetails",
     "longName": "9955549 - Disclosure - SEGMENTS (Details)",
     "shortName": "SEGMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails",
     "longName": "9955550 - Disclosure - INCOME TAXES - Domestic and Foreign Components of Loss Before Income Taxes (Details)",
     "shortName": "INCOME TAXES - Domestic and Foreign Components of Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails",
     "longName": "9955551 - Disclosure - INCOME TAXES - Components of Income Tax Provision (Details)",
     "shortName": "INCOME TAXES - Components of Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails",
     "longName": "9955552 - Disclosure - INCOME TAXES - Reconciliation of Federal Statutory Rate to Effective Income Tax Rate (Details)",
     "shortName": "INCOME TAXES - Reconciliation of Federal Statutory Rate to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails",
     "longName": "9955553 - Disclosure - INCOME TAXES - Cash Paid for Income Taxes (Details)",
     "shortName": "INCOME TAXES - Cash Paid for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails",
     "longName": "9955554 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)",
     "shortName": "INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails",
     "longName": "9955555 - Disclosure - INCOME TAXES - Additional Information (Details)",
     "shortName": "INCOME TAXES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails",
     "longName": "9955556 - Disclosure - INCOME TAXES - NOLs and Tax Credit Carryforward Values (Details)",
     "shortName": "INCOME TAXES - NOLs and Tax Credit Carryforward Values (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cv:TaxCreditCarryforwardExpirationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://capsovision.com/role/INCOMETAXESUnrecognizedTaxPositionsDetails",
     "longName": "9955557 - Disclosure - INCOME TAXES - Unrecognized Tax Positions (Details)",
     "shortName": "INCOME TAXES - Unrecognized Tax Positions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://capsovision.com/role/NETLOSSPERSHAREDetails",
     "longName": "9955558 - Disclosure - NET LOSS PER SHARE (Details)",
     "shortName": "NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails",
     "longName": "9955559 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details)",
     "shortName": "NET LOSS PER SHARE - Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://capsovision.com/role/RELATEDPARTIESDetails",
     "longName": "9955560 - Disclosure - RELATED PARTIES (Details)",
     "shortName": "RELATED PARTIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://capsovision.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9955561 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-153",
      "name": "us-gaap:SubsequentEventsDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cv-20251231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r813"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r1032"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "cv_AccruedClinicalTrialExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial expenses",
        "label": "Accrued Clinical Trial Expense, Current",
        "documentation": "Accrued Clinical Trial Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "cv_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued R&amp;D expenses",
        "label": "Accrued Research And Development Expense, Current",
        "documentation": "Accrued Research And Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r118",
      "r593"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r813",
      "r1176"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in-Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1118",
      "r1179"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon promissory note repayment",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Underwriters Warrants",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r27",
      "r82"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising costs",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r794"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r875",
      "r885",
      "r918"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r878",
      "r888",
      "r921"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r879",
      "r889",
      "r913",
      "r922",
      "r926",
      "r934"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r374",
      "r384"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r97",
      "r120",
      "r147",
      "r149",
      "r150",
      "r193",
      "r207",
      "r223",
      "r226",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r443",
      "r445",
      "r489",
      "r578",
      "r579",
      "r584",
      "r671",
      "r770",
      "r771",
      "r779",
      "r813",
      "r829",
      "r830",
      "r842",
      "r1058",
      "r1059",
      "r1134"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r127",
      "r147",
      "r149",
      "r150",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r443",
      "r445",
      "r489",
      "r813",
      "r1058",
      "r1059",
      "r1134"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cv_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://capsovision.com/role/AUDITINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r871"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://capsovision.com/role/AUDITINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r871"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://capsovision.com/role/AUDITINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r871"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://capsovision.com/role/AUDITINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Opinion",
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "CA",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment, office equipment, and purchased software",
        "label": "Capitalized Computer Software, Gross",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r742"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r71",
      "r146"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r71"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED",
      "http://capsovision.com/role/GOINGCONCERNDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r1144"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r121",
      "r122",
      "r123",
      "r147",
      "r150",
      "r177",
      "r178",
      "r185",
      "r187",
      "r195",
      "r196",
      "r236",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r284",
      "r285",
      "r287",
      "r288",
      "r290",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r489",
      "r624",
      "r625",
      "r626",
      "r627",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r659",
      "r680",
      "r703",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r959",
      "r1018",
      "r1019",
      "r1028"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "cv_ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise date of warrants",
        "label": "Class Of Warrant Or Right, Exercise Date Of Warrants Or Rights",
        "documentation": "Class Of Warrant Or Right, Exercise Date Of Warrants Or Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r153",
      "r300"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies - Note 9",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r90",
      "r586",
      "r658"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r253",
      "r254",
      "r730",
      "r1053",
      "r1055"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839",
      "r1024",
      "r1025",
      "r1027",
      "r1118",
      "r1175",
      "r1179"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r659"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r659",
      "r677",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value: 300,000,000 and 190,000,000 shares authorized; 46,865,051 and 2,090,945 issued and outstanding as of December\u00a031, 2025 and December\u00a031, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r285",
      "r292",
      "r587",
      "r813"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r234",
      "r618",
      "r619",
      "r729",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r234",
      "r618",
      "r619",
      "r729",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r234",
      "r618",
      "r619",
      "r729",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r729",
      "r761",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r234",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r729",
      "r761",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r234",
      "r618",
      "r619",
      "r729",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r305",
      "r307",
      "r326"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r307",
      "r326"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock (all series)",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of revenue",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r541",
      "r754",
      "r758",
      "r801",
      "r1006"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of Revenue",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1016",
      "r1021",
      "r1115"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1016",
      "r1021"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r1016",
      "r1021"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provision",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1016",
      "r1021",
      "r1115"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r1032"
     ]
    },
    "cv_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer One",
        "label": "Customer One [Member]",
        "documentation": "Customer One"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r945"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r945"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r947"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r947"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r949"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r947"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r940"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r941"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r941"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r939"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r939"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r939"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r942"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r944"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r944"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r945"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r948"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r946"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r943"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "DE",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Germany",
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOTE PAYABLE",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r147",
      "r148",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r259",
      "r260",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r457",
      "r506"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved shares of common stock",
        "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance",
        "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1021",
      "r1114",
      "r1115"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1021",
      "r1114"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred provision",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r104",
      "r1016",
      "r1021"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred provision",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r89",
      "r418"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred initial public offering costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1021",
      "r1114",
      "r1115"
     ]
    },
    "cv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D expenses",
        "label": "Deferred Tax Assets, Capitalized Research And Development Expenses",
        "documentation": "Deferred Tax Assets, Capitalized Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets less valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "cv_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized gains/losses",
        "label": "Deferred Tax Liabilities, Unrealized Currency Transaction Gains",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r140",
      "r193",
      "r210",
      "r226",
      "r753",
      "r770",
      "r771"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r156",
      "r172",
      "r447",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r459"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r337",
      "r368",
      "r369",
      "r372",
      "r791"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Reserved for Future Issuance",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r871"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r871",
      "r914"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/NETLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share - basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r134",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r174",
      "r177",
      "r185",
      "r186",
      "r187",
      "r192",
      "r283",
      "r373",
      "r439",
      "r442",
      "r471",
      "r472",
      "r577",
      "r598",
      "r760"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/NETLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share - diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r134",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r177",
      "r185",
      "r186",
      "r187",
      "r192",
      "r283",
      "r373",
      "r439",
      "r442",
      "r471",
      "r472",
      "r577",
      "r598",
      "r760"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r189"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r188",
      "r190",
      "r191"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r796"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r152",
      "r399",
      "r430",
      "r796"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r796",
      "r1016",
      "r1022",
      "r1103"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of changes in tax laws or rates enacted in the current period",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r796",
      "r1016",
      "r1022",
      "r1103"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r403",
      "r796",
      "r1016",
      "r1022",
      "r1103"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nontaxable or nondeductible items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r1016",
      "r1022",
      "r1103"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r1016",
      "r1022",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income tax, net of federal taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r796",
      "r1016",
      "r1022",
      "r1103"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r1016",
      "r1022",
      "r1103",
      "r1105"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to outstanding unvested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercises of stock options",
        "terseLabel": "Options on common stock",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r108",
      "r109",
      "r110",
      "r131",
      "r132",
      "r133",
      "r157",
      "r158",
      "r159",
      "r161",
      "r168",
      "r170",
      "r172",
      "r194",
      "r237",
      "r238",
      "r244",
      "r282",
      "r302",
      "r373",
      "r428",
      "r429",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r507",
      "r509",
      "r525",
      "r597",
      "r611",
      "r612",
      "r613",
      "r633",
      "r703"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r875",
      "r885",
      "r918"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r872",
      "r882",
      "r915"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "FR",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "France",
        "label": "FRANCE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://capsovision.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r476",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r576",
      "r804",
      "r808"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: interest",
        "label": "Financing Receivable, Unamortized Loan Cost (Fee) and Purchase Premium (Discount)",
        "documentation": "Amount of unamortized loan commitment, origination, and other costs (fees) and purchase premium (discount) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement."
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Jurisdiction",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign exchange gains (losses)",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r494",
      "r495",
      "r496",
      "r497",
      "r700"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized foreign exchange (gains) losses",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r678",
      "r840",
      "r1123",
      "r1124",
      "r1178"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r879",
      "r889",
      "r922"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r879",
      "r889",
      "r922"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r879",
      "r889",
      "r922"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r879",
      "r889",
      "r922"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r879",
      "r889",
      "r922"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "cv_FutureGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "FutureGrantsMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future grants",
        "label": "Future Grants [Member]",
        "documentation": "Future Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r682"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_GovernmentAssistanceOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceOperatingExpense",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received related to refundable payroll tax credits",
        "label": "Government Assistance, Operating Expense, Decrease (Increase)",
        "documentation": "Amount of decrease (increase) in expense from government assistance, classified as operating."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Operating Expense, Decrease (Increase), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Government Assistance, Operating Expense, Decrease (Increase), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes decrease (increase) in expense from government assistance, classified as operating."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r60",
      "r96",
      "r147",
      "r149",
      "r150",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r489",
      "r764",
      "r770",
      "r1030",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1058"
     ]
    },
    "cv_GroupPurchasingOrganizationFeesContraRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "GroupPurchasingOrganizationFeesContraRevenue",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees paid to group purchasing organizations",
        "label": "Group Purchasing Organization Fees Contra Revenue",
        "documentation": "Group Purchasing Organization Fees Contra Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "cv_HealthcareClinicalTrialActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "HealthcareClinicalTrialActivitiesMember",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Healthcare clinical trial activities",
        "label": "Healthcare Clinical Trial Activities [Member]",
        "documentation": "Healthcare Clinical Trial Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/GOINGCONCERNDetails",
      "http://capsovision.com/role/NOTEPAYABLEDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r871"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r25",
      "r78",
      "r137",
      "r754",
      "r805"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r151",
      "r398"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r92",
      "r96",
      "r578",
      "r580",
      "r595",
      "r755",
      "r757",
      "r758",
      "r764",
      "r770",
      "r1030",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r151",
      "r398"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r251",
      "r252",
      "r448",
      "r449",
      "r450",
      "r452",
      "r475",
      "r477",
      "r481",
      "r490",
      "r491",
      "r492",
      "r608",
      "r610",
      "r687",
      "r742",
      "r744",
      "r797",
      "r798",
      "r802",
      "r803",
      "r806",
      "r811",
      "r1116",
      "r1117",
      "r1146"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r448",
      "r449",
      "r450",
      "r452",
      "r475",
      "r477",
      "r481",
      "r490",
      "r491",
      "r492",
      "r608",
      "r610",
      "r687",
      "r742",
      "r744",
      "r797",
      "r798",
      "r802",
      "r803",
      "r806",
      "r811",
      "r1116",
      "r1117",
      "r1146"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails",
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r399",
      "r400",
      "r411",
      "r424",
      "r796",
      "r1111"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails",
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r399",
      "r400",
      "r411",
      "r424",
      "r796",
      "r1111"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r152",
      "r392",
      "r399",
      "r408",
      "r409",
      "r410",
      "r415",
      "r422",
      "r431",
      "r433",
      "r434",
      "r435",
      "r583",
      "r617",
      "r629",
      "r796"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/INCOMETAXESComponentsofIncomeTaxProvisionDetails",
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r105",
      "r147",
      "r171",
      "r172",
      "r193",
      "r211",
      "r226",
      "r397",
      "r399",
      "r432",
      "r599",
      "r755",
      "r757",
      "r758",
      "r796"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionLineItems",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Paid, by Individual Jurisdiction [Line Items]",
        "label": "Income Tax Paid, by Individual Jurisdiction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r424"
     ]
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionTable",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Paid, by Individual Jurisdiction [Table]",
        "label": "Income Tax Paid, by Individual Jurisdiction [Table]",
        "documentation": "Disclosure of information about income tax paid by jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r424"
     ]
    },
    "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash paid for income taxes (net of refunds)",
        "label": "Income Tax Paid, State and Local, after Refund Received",
        "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r423"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r395",
      "r396",
      "r415",
      "r416",
      "r421",
      "r426",
      "r623"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r796",
      "r1103"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of changes in tax laws or rates enacted in the current period",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r399",
      "r404",
      "r796"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r403",
      "r796",
      "r1103"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r796"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nontaxable or nondeductible items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r1103"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income tax, net of federal taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r796",
      "r1103"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESReconciliationofFederalStatutoryRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r1103",
      "r1105"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r73",
      "r1013",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r1011"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r1011"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r879",
      "r889",
      "r913",
      "r922",
      "r926",
      "r934"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r938"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r938"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r938"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r143",
      "r144"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r750"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails",
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r747",
      "r813"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r117",
      "r124",
      "r240",
      "r241",
      "r242",
      "r540",
      "r759"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r752"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r751"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r66"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestorMember",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock in lieu of debt repayment",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/LEASESTotalLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/LEASESTotalLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease expense",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r812"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Lease Expense and Supplemental Cash Flows",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://capsovision.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r524"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://capsovision.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r524"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Minimum Lease Payments under Non-Cancellable Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r1017",
      "r1023",
      "r1143"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r1017",
      "r1023",
      "r1143"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/LEASESFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r1017",
      "r1023",
      "r1143"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://capsovision.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r1126"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://capsovision.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://capsovision.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r43",
      "r147",
      "r149",
      "r150",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r444",
      "r445",
      "r446",
      "r489",
      "r657",
      "r763",
      "r779",
      "r842",
      "r1058",
      "r1134",
      "r1135"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r91",
      "r590",
      "r813",
      "r829",
      "r830",
      "r1016",
      "r1020",
      "r1047",
      "r1122"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r116",
      "r147",
      "r149",
      "r150",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r444",
      "r445",
      "r446",
      "r489",
      "r813",
      "r1058",
      "r1134",
      "r1135"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "MA",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Massachusetts",
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r781",
      "r785",
      "r823",
      "r827",
      "r1145",
      "r1147",
      "r1148",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://capsovision.com/role/LEASESAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r255",
      "r256",
      "r257",
      "r258",
      "r332",
      "r363",
      "r364",
      "r365",
      "r386",
      "r474",
      "r538",
      "r607",
      "r609",
      "r616",
      "r649",
      "r650",
      "r710",
      "r712",
      "r714",
      "r715",
      "r717",
      "r724",
      "r725",
      "r727",
      "r728",
      "r740",
      "r741",
      "r776",
      "r780",
      "r790",
      "r797",
      "r799",
      "r800",
      "r807",
      "r808",
      "r809",
      "r810",
      "r824",
      "r1060",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://capsovision.com/role/LEASESAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r255",
      "r256",
      "r257",
      "r258",
      "r332",
      "r363",
      "r364",
      "r365",
      "r386",
      "r474",
      "r538",
      "r607",
      "r609",
      "r616",
      "r649",
      "r650",
      "r710",
      "r712",
      "r714",
      "r715",
      "r717",
      "r724",
      "r725",
      "r727",
      "r728",
      "r740",
      "r741",
      "r776",
      "r780",
      "r790",
      "r797",
      "r799",
      "r800",
      "r807",
      "r808",
      "r809",
      "r824",
      "r1060",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "stpr_NC": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "NC",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "North Carolina",
        "label": "NORTH CAROLINA"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_NY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "NY",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York State",
        "label": "NEW YORK"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r781",
      "r785",
      "r823",
      "r827",
      "r1145",
      "r1147",
      "r1148",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://capsovision.com/role/GOINGCONCERNDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r74"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/GOINGCONCERNDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r74",
      "r93",
      "r110",
      "r114",
      "r128",
      "r129",
      "r133",
      "r147",
      "r149",
      "r150",
      "r155",
      "r160",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r183",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r283",
      "r286",
      "r289",
      "r294",
      "r373",
      "r439",
      "r442",
      "r472",
      "r489",
      "r596",
      "r679",
      "r701",
      "r702",
      "r755",
      "r757",
      "r758",
      "r840",
      "r1058"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss - basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r136",
      "r164",
      "r165",
      "r166",
      "r167",
      "r174",
      "r175",
      "r184",
      "r187",
      "r286",
      "r289",
      "r294",
      "r442"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss - diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r176",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r187"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Issued and Recently Adopted / Accounting Pronouncements Issued and Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r879",
      "r889",
      "r913",
      "r922"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonUsMember",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside United States",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1182",
      "r1183",
      "r1184"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CASH FINANCING AND INVESTING ACTIVITIES",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-operating income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "cv_NumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "NumberOfBoardMembers",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of board members",
        "label": "Number Of Board Members",
        "documentation": "Number Of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://capsovision.com/role/SEGMENTSDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1036"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://capsovision.com/role/SEGMENTSDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r775",
      "r1036"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/GOINGCONCERNDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "negatedLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r755",
      "r758",
      "r764",
      "r1030",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/LEASESTotalLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/LEASESTotalLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r812"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED",
      "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities - current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED",
      "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities \u2013 long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/LEASESSupplementalCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments related to operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r519"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED",
      "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r812"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://capsovision.com/role/LEASESLeaseRelatedAmountsReflectedintheBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r812"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating operating losses",
        "terseLabel": "Net Operating Losses (gross; pre-tax)",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "cv_OperatingLossCarryforwardsExpirationTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "OperatingLossCarryforwardsExpirationTerm",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Term",
        "label": "Operating Loss Carryforwards, Expiration Term",
        "documentation": "Operating Loss Carryforwards, Expiration Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTURE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r111",
      "r112",
      "r113",
      "r620",
      "r621"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r813"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r813"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-operating income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r801"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriters warrants issued in connection with the IPO",
        "label": "Other Significant Noncash Transaction, Value of Consideration Given",
        "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r877",
      "r887",
      "r920"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r880",
      "r890",
      "r923"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r880",
      "r890",
      "r923"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of IPO offering costs",
        "label": "Payments for Repurchase of Initial Public Offering",
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleConversionDate",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, conversion date",
        "label": "Preferred Stock, Convertible, Conversion Date",
        "documentation": "Date when preferred stock can be converted into common shares, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split rounddown and cash in lieu payment",
        "label": "Preferred Stock, Convertible, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for convertible preferred stock."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r301"
     ]
    },
    "cv_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split rounddown and cash in lieu payment (in shares)",
        "label": "Preferred Stock, Convertible, Down Round Feature, Increase (Decrease) in Equity, Shares",
        "documentation": "Amount of increase (decrease) in equity shares for down round feature triggered for convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r836",
      "r837",
      "r838",
      "r839",
      "r1175",
      "r1179"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCK"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREFERRED STOCK",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r287"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment for insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r777",
      "r1048"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from IPO, net of commissions",
        "terseLabel": "Proceeds from initial public offering",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Series H convertible preferred stock",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from promissory note issuance",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercises of options on common stock and warrants",
        "label": "Proceeds from Other Equity",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercises of options on common stock and warrants",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r758",
      "r781",
      "r783"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r541",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r745",
      "r754",
      "r757",
      "r758",
      "r781",
      "r783",
      "r822",
      "r824",
      "r825",
      "r828",
      "r831",
      "r960",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1056",
      "r1057",
      "r1145",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r541",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r745",
      "r754",
      "r757",
      "r758",
      "r781",
      "r783",
      "r822",
      "r824",
      "r825",
      "r828",
      "r831",
      "r960",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1056",
      "r1057",
      "r1145",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r523"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPropertyandEquipmentNetDetails",
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r523",
      "r582",
      "r594",
      "r813"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r102",
      "r103",
      "r592"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSTables",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-Lived Assets",
        "terseLabel": "Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r523"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "cv_ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum prospective proceeds from initial public offering",
        "label": "Prospective Proceeds From Issuance Initial Public Offering Minimum",
        "documentation": "Prospective Proceeds From Issuance Initial Public Offering Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r138",
      "r239"
     ]
    },
    "us-gaap_PurchaseProvisionTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseProvisionTermsMember",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Provision Terms",
        "label": "Purchase Provision Terms [Member]",
        "documentation": "Terms of the purchase provisions under research and development arrangements accounted for as a purchase contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r1102"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://capsovision.com/role/LEASESAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r255",
      "r256",
      "r257",
      "r258",
      "r329",
      "r332",
      "r363",
      "r364",
      "r365",
      "r372",
      "r386",
      "r474",
      "r536",
      "r537",
      "r538",
      "r607",
      "r609",
      "r616",
      "r649",
      "r650",
      "r710",
      "r712",
      "r714",
      "r715",
      "r717",
      "r724",
      "r725",
      "r727",
      "r728",
      "r740",
      "r741",
      "r776",
      "r780",
      "r790",
      "r797",
      "r799",
      "r800",
      "r807",
      "r808",
      "r809",
      "r810",
      "r824",
      "r834",
      "r1054",
      "r1060",
      "r1120",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://capsovision.com/role/LEASESAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r255",
      "r256",
      "r257",
      "r258",
      "r329",
      "r332",
      "r363",
      "r364",
      "r365",
      "r372",
      "r386",
      "r474",
      "r536",
      "r537",
      "r538",
      "r607",
      "r609",
      "r616",
      "r649",
      "r650",
      "r710",
      "r712",
      "r714",
      "r715",
      "r717",
      "r724",
      "r725",
      "r727",
      "r728",
      "r740",
      "r741",
      "r776",
      "r780",
      "r790",
      "r797",
      "r799",
      "r800",
      "r807",
      "r808",
      "r809",
      "r810",
      "r824",
      "r834",
      "r1054",
      "r1060",
      "r1120",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESUnrecognizedTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r872",
      "r882",
      "r915"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154",
      "r155",
      "r235",
      "r330",
      "r331",
      "r529",
      "r530",
      "r585",
      "r591",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r676",
      "r709",
      "r1177"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of loan",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_RelatedPartyTransactionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDate",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction, date",
        "label": "Related Party Transaction, Date",
        "documentation": "Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154",
      "r155",
      "r235",
      "r529",
      "r530",
      "r531",
      "r683",
      "r684",
      "r687"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/RELATEDPARTIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note and certain R&amp;D expenses",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "cv_RelatedPartyTransactionRatePerMonth": {
     "xbrltype": "percentItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "RelatedPartyTransactionRatePerMonth",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly interest rate",
        "label": "Related Party Transaction, Rate Per Month",
        "documentation": "Related Party Transaction, Rate Per Month"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154",
      "r155",
      "r235",
      "r330",
      "r331",
      "r529",
      "r530",
      "r585",
      "r591",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r676",
      "r709",
      "r1133",
      "r1177"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://capsovision.com/role/RELATEDPARTIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTIES",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r530",
      "r532",
      "r630",
      "r631",
      "r632",
      "r685",
      "r686",
      "r687",
      "r707",
      "r708"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of promissory note",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r1102"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development arrangement, fee",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development agreement, development fee",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Costs Incurred, Net",
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Costs Incurred, Net"
       }
      }
     },
     "auth_ref": []
    },
    "cv_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding purchase commitment",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Costs Outstanding",
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Costs Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cv_ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development agreement, development fee increase",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Fee Increase",
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Fee Increase"
       }
      }
     },
     "auth_ref": []
    },
    "cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development agreement, initial fee",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Initial Fee",
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Initial Fee"
       }
      }
     },
     "auth_ref": []
    },
    "cv_ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development agreement, initial fee payment date",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Initial Fee Date",
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Initial Fee Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r1102"
     ]
    },
    "cv_ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development agreement, origination date",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Origination Date",
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Origination Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r1102"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r742",
      "r755",
      "r756",
      "r770",
      "r1142"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses (including Clinical Trial Expenses)",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r873",
      "r883",
      "r916"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r874",
      "r884",
      "r917"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r881",
      "r891",
      "r924"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r82",
      "r589",
      "r614",
      "r615",
      "r628",
      "r660",
      "r813"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r157",
      "r158",
      "r159",
      "r161",
      "r168",
      "r170",
      "r172",
      "r237",
      "r238",
      "r244",
      "r282",
      "r373",
      "r428",
      "r429",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r460",
      "r462",
      "r463",
      "r465",
      "r470",
      "r507",
      "r509",
      "r611",
      "r613",
      "r633",
      "r1179"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r193",
      "r208",
      "r209",
      "r222",
      "r226",
      "r230",
      "r232",
      "r234",
      "r323",
      "r324",
      "r325",
      "r541",
      "r755",
      "r758"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r743"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE AND DEFERRED REVENUE",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r325",
      "r328"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/GOINGCONCERNDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "cv_SaleOfStockEffectivenessDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "SaleOfStockEffectivenessDate",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, effectiveness date",
        "label": "Sale Of Stock, Effectiveness Date",
        "documentation": "Sale Of Stock, Effectiveness Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/GOINGCONCERNDetails",
      "http://capsovision.com/role/NOTEPAYABLEDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/NOTEPAYABLEDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock upon promissory note repayment (in shares)",
        "terseLabel": "Shares sold in offering (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "cv_SaleOfStockRegistrationRightsAgreementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "SaleOfStockRegistrationRightsAgreementDate",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, registration rights agreement date",
        "label": "Sale Of Stock, Registration Rights Agreement Date",
        "documentation": "Sale Of Stock, Registration Rights Agreement Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockTransactionDate",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/NOTEPAYABLEDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, transaction date",
        "label": "Sale of Stock, Transaction Date",
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued sales taxes",
        "label": "Sales and Excise Tax Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expense and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amounts of Cash Paid for Income Taxes",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Provision",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Deferred Tax Assets (Liabilities)",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Federal Statutory Rate to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r796",
      "r1103"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Expense for Employees and Non-employees",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Domestic and Foreign Components of Loss Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1021"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r53",
      "r54",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r523"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154",
      "r155",
      "r529",
      "r530",
      "r531",
      "r683",
      "r684",
      "r687"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://capsovision.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development, Contract to Perform for Others [Table]",
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r1102"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r336",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r372"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r84"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKTables",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Black-Scholes Option Pricing Model Weighted-Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "cv_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease-Related Amounts Reflected in the Balance Sheet",
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Operating Leases [Table Text Block]",
        "documentation": "ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Positions",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r795"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r232",
      "r233",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r646",
      "r647",
      "r648",
      "r711",
      "r713",
      "r716",
      "r718",
      "r724",
      "r726",
      "r727",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r746",
      "r761",
      "r781",
      "r784",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r826",
      "r834",
      "r1145",
      "r1147",
      "r1148",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://capsovision.com/role/SEGMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENTS",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r193",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r212",
      "r213",
      "r214",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r234",
      "r765",
      "r768",
      "r769",
      "r770",
      "r772",
      "r774",
      "r775"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r229",
      "r232",
      "r766",
      "r767",
      "r773"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and marketing",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and marketing",
        "label": "Selling and Marketing Expense [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r1062",
      "r1066"
     ]
    },
    "us-gaap_SeriesBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesBMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B",
        "label": "Series B [Member]",
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series A."
       }
      }
     },
     "auth_ref": []
    },
    "cv_SeriesC1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "SeriesC1PreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-1",
        "label": "Series C-1 Preferred Stock [Member]",
        "documentation": "Series C-1 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r1062",
      "r1066"
     ]
    },
    "cv_SeriesD1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "SeriesD1PreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-1",
        "label": "Series D-1 Preferred Stock [Member]",
        "documentation": "Series D-1 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "cv_SeriesD2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "SeriesD2PreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-2",
        "label": "Series D-2 Preferred Stock [Member]",
        "documentation": "Series D-2 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D",
        "label": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r1062",
      "r1066"
     ]
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesEPreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E",
        "label": "Series E Preferred Stock [Member]",
        "documentation": "Series E preferred stock."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r1062",
      "r1066"
     ]
    },
    "cv_SeriesF1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "SeriesF1PreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series F-1",
        "label": "Series F-1 Preferred Stock [Member]",
        "documentation": "Series F-1 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "cv_SeriesF2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "SeriesF2PreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series F-2",
        "label": "Series F-2 Preferred Stock [Member]",
        "documentation": "Series F-2 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "cv_SeriesG1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "SeriesG1PreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series G-1",
        "label": "Series G-1 Preferred Stock [Member]",
        "documentation": "Series G-1 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesGPreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series G",
        "label": "Series G Preferred Stock [Member]",
        "documentation": "Series G preferred stock."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r1062",
      "r1066"
     ]
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesHPreferredStockMember",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series H",
        "label": "Series H Preferred Stock [Member]",
        "documentation": "Series H preferred stock."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r1062",
      "r1066"
     ]
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceMember",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r758",
      "r781",
      "r783"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "cv_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of monthly installments",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Number Of Monthly Installments",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Number Of Monthly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)",
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of RSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility of common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r336",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited, canceled, or expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited, canceled, or expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average fair value of options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options on Common Stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option award modification expense",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms of award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r341",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage to occur on February 12, 2027",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested stock options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShippingAndHandlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShippingAndHandlingMember",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and handling",
        "label": "Shipping and Handling [Member]",
        "documentation": "Packing and transport of product."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1069"
     ]
    },
    "cv_ShortTermDebtOriginationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ShortTermDebtOriginationDate",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term debt origination date",
        "label": "Short Term Debt, Origination Date",
        "documentation": "Short Term Debt, Origination Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/LEASESTotalLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/LEASESTotalLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease expense",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r812"
     ]
    },
    "us-gaap_ShortTermNonBankLoansAndNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermNonBankLoansAndNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding balance of promissory note",
        "label": "Short-Term Nonbank Loan and Note Payables",
        "documentation": "Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r655",
      "r656"
     ]
    },
    "cv_ShortTermNonBankLoansAndNotesPaymentDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "ShortTermNonBankLoansAndNotesPaymentDate",
     "presentation": [
      "http://capsovision.com/role/NOTEPAYABLEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment date",
        "label": "Short Term NonBank Loans And Notes Payment Date",
        "documentation": "Short Term NonBank Loans And Notes Payment Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://capsovision.com/role/INCOMETAXESCashPaidforIncomeTaxesDetails",
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r121",
      "r122",
      "r123",
      "r147",
      "r150",
      "r177",
      "r178",
      "r185",
      "r187",
      "r195",
      "r196",
      "r236",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r284",
      "r285",
      "r287",
      "r288",
      "r290",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r489",
      "r624",
      "r625",
      "r626",
      "r627",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r659",
      "r680",
      "r703",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r959",
      "r1018",
      "r1019",
      "r1028"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r50",
      "r51",
      "r108",
      "r109",
      "r110",
      "r131",
      "r132",
      "r133",
      "r157",
      "r158",
      "r159",
      "r161",
      "r168",
      "r170",
      "r172",
      "r194",
      "r237",
      "r238",
      "r244",
      "r282",
      "r302",
      "r373",
      "r428",
      "r429",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r507",
      "r509",
      "r525",
      "r597",
      "r611",
      "r612",
      "r613",
      "r633",
      "r703"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r232",
      "r233",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r646",
      "r647",
      "r648",
      "r711",
      "r713",
      "r716",
      "r718",
      "r724",
      "r726",
      "r727",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r746",
      "r761",
      "r781",
      "r784",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r826",
      "r834",
      "r1145",
      "r1147",
      "r1148",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r194",
      "r284",
      "r285",
      "r287",
      "r290",
      "r509",
      "r541",
      "r622",
      "r634",
      "r645",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r681",
      "r682",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r703",
      "r757",
      "r758",
      "r835",
      "r1177"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r194",
      "r235",
      "r284",
      "r285",
      "r287",
      "r290",
      "r509",
      "r541",
      "r622",
      "r634",
      "r645",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r681",
      "r682",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r703",
      "r757",
      "r758",
      "r835",
      "r1177"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r876",
      "r886",
      "r919"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of all convertible preferred stock to common stock - initial public offering (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r29",
      "r47",
      "r50",
      "r82",
      "r278"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercises of warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in initial public offering, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r47",
      "r82",
      "r624",
      "r703",
      "r720"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock upon exercises of stock options (in shares)",
        "terseLabel": "Options exercised (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r47",
      "r82",
      "r347"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of all convertible preferred stock to common stock - initial public offering",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r50",
      "r51",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercises of warrants",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in initial public offering, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r47",
      "r82",
      "r633",
      "r703",
      "r720",
      "r841"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercises of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r50",
      "r51",
      "r82"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r75",
      "r661",
      "r677",
      "r704",
      "r705",
      "r813",
      "r842",
      "r1016",
      "r1019",
      "r1020",
      "r1047",
      "r1122",
      "r1179"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r44",
      "r45",
      "r287"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r706"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r534"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r534"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r534"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r534"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r534"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsDate",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent event date",
        "label": "Subsequent Event, Date",
        "documentation": "Date the event occurred after the balance sheet date but before financial statements are issues or available to be issued, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://capsovision.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r535"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee [Line Items]",
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/GOINGCONCERNDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/GOINGCONCERNDetails",
      "http://capsovision.com/role/NOTEPAYABLEDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/SUBSEQUENTEVENTSDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/GOINGCONCERNDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://capsovision.com/role/GOINGCONCERN"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOING CONCERN",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Operating Loss Carryforwards and Tax Credit Carryforward Values",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfTaxCreditCarryforwardsTextBlock",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Operating Loss Carryforwards and Tax Credit Carryforward Values",
        "label": "Summary of Tax Credit Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BALANCE SHEET COMPONENTS",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Supplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Supplies",
     "crdr": "debit",
     "calculation": {
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/BALANCESHEETCOMPONENTSPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance payments for inventory purchases",
        "label": "Prepaid Supplies",
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r778",
      "r1048"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Tax Credits",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "cv_TaxCreditCarryforwardExpirationTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TaxCreditCarryforwardExpirationTerm",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Term",
        "label": "Tax Credit Carryforward, Expiration Term",
        "documentation": "Tax Credit Carryforward, Expiration Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "cv_TaxYearAfter2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TaxYearAfter2017Member",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arising after December 31, 2017",
        "label": "Tax Year After 2017 [Member]",
        "documentation": "Tax Year After 2017"
       }
      }
     },
     "auth_ref": []
    },
    "cv_TaxYearBefore2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TaxYearBefore2018Member",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arising before January 1, 2018",
        "label": "Tax Year Before 2018 [Member]",
        "documentation": "Tax Year Before 2018"
       }
      }
     },
     "auth_ref": []
    },
    "cv_TaxYearDefiniteLivedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TaxYearDefiniteLivedMember",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite lived",
        "label": "Tax Year Definite Lived [Member]",
        "documentation": "Tax Year Definite Lived"
       }
      }
     },
     "auth_ref": []
    },
    "cv_TaxYearIndefiniteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TaxYearIndefiniteMember",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESNOLsandTaxCreditCarryforwardValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite",
        "label": "Tax Year Indefinite [Member]",
        "documentation": "Tax Year Indefinite"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock (each Series: $0.001 par value)",
        "label": "Temporary Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity, by Class of Stock [Table]",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Disclosure of information about equity instrument classified as temporary equity. Includes, but not is limited to, description of share, value, share authorized, issued, and outstanding, redemption price per share, and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r285",
      "r287",
      "r288",
      "r293"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITED",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total convertible preferred stock",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r284",
      "r285",
      "r287",
      "r291",
      "r383",
      "r385",
      "r588"
     ]
    },
    "cv_TemporaryEquityDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TemporaryEquityDividendRatePercentage",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Temporary Equity, Dividend Rate, Percentage",
        "documentation": "Temporary Equity, Dividend Rate, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cv_TemporaryEquityLegacyConversionPricePerShareMaximum": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TemporaryEquityLegacyConversionPricePerShareMaximum",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum legacy conversion price per share (in dollars per share)",
        "label": "Temporary Equity, Legacy Conversion Price Per Share, Maximum",
        "documentation": "Temporary Equity, Legacy Conversion Price Per Share, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "cv_TemporaryEquityLegacyConversionPricePerShareMinimum": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TemporaryEquityLegacyConversionPricePerShareMinimum",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum legacy conversion price per share (in dollars per share)",
        "label": "Temporary Equity, Legacy Conversion Price Per Share, Minimum",
        "documentation": "Temporary Equity, Legacy Conversion Price Per Share, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "cv_TemporaryEquityLegacyConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TemporaryEquityLegacyConversionRatio",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "label": "Temporary Equity, Legacy Conversion Ratio",
        "documentation": "Temporary Equity, Legacy Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity [Line Items]",
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r287",
      "r288",
      "r290",
      "r293"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, liquidation preference",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, original issue price (in dollars per share)",
        "label": "Temporary Equity, Redemption Price Per Share",
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r287"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued (in shares)",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r287"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://capsovision.com/role/PREFERREDSTOCKPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r287"
     ]
    },
    "cv_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series H convertible preferred stock (in shares)",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series H convertible preferred stock",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://capsovision.com/role/PREFERREDSTOCKTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock Outstanding",
        "label": "Temporary Equity [Table Text Block]",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Axis]",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r781",
      "r788"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Domain]",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r781",
      "r788"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Assets and Contract Liabilities; Accounts Receivable and Related Allowance",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1042",
      "r1043",
      "r1046"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://capsovision.com/role/COVERPAGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransferredAtPointInTimeMember",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized at point in time",
        "label": "Transferred at Point in Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred at point in time."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r788"
     ]
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized over time",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r788"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "cv_TwoThousandAndFivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TwoThousandAndFivePlanMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2005 Plan",
        "label": "Two Thousand And Five Plan [Member]",
        "documentation": "Two Thousand And Five Plan"
       }
      }
     },
     "auth_ref": []
    },
    "cv_TwoThousandAndTwentyFivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "TwoThousandAndTwentyFivePlanMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Plan",
        "label": "Two Thousand And Twenty Five Plan [Member]",
        "documentation": "Two Thousand And Twenty Five Plan"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUEAdditionalInformationDetails",
      "http://capsovision.com/role/REVENUEANDDEFERREDREVENUERevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "cv_UnderwriterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://capsovision.com/20251231",
     "localname": "UnderwriterMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/COMMONSTOCKBlackScholesOptionPricingModelDetails",
      "http://capsovision.com/role/DESCRIPTIONOFBUSINESSANDORGANIZATIONALSTRUCTUREDetails",
      "http://capsovision.com/role/PREFERREDSTOCKAdditionalInformationDetails",
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter",
        "label": "Underwriter [Member]",
        "documentation": "Underwriter"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESUnrecognizedTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unrecognized tax benefits, beginning balance",
        "periodEndLabel": "Unrecognized tax benefits, ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r412",
      "r795"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESUnrecognizedTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Changes for previous tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r795"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESUnrecognizedTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for current tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r795"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://capsovision.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r197",
      "r200",
      "r201",
      "r202",
      "r578",
      "r580",
      "r762"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance increase",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceLineItems",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance [Line Items]",
        "label": "Valuation Allowance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceTable",
     "presentation": [
      "http://capsovision.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Asset, Valuation Allowance [Table]",
        "label": "Deferred Tax Asset, Valuation Allowance [Table]",
        "documentation": "Disclosure of information about valuation allowance representing portion of deferred tax asset for which it is more likely than not that tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r1108"
     ]
    },
    "us-gaap_VariableLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeasePayment",
     "crdr": "credit",
     "presentation": [
      "http://capsovision.com/role/LEASESSupplementalCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease payments related to operating leases",
        "label": "Variable Lease, Payment",
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKCommonStockReservedforFutureIssuanceDetails",
      "http://capsovision.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails",
      "http://capsovision.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants on common stock",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants maturity date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://capsovision.com/role/COMMONSTOCKAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/NETLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "terseLabel": "Weighted-average number of shares of common stock outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r187"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://capsovision.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
      "http://capsovision.com/role/NETLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "terseLabel": "Weighted-average number of shares of common stock outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r187"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481288/505-10-05-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "855",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "20A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-20A"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481598/310-20-45-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>119
<FILENAME>0001378325-26-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001378325-26-000010-xbrl.zip
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M Q/!^?_TJO>J-%<U>KC3\:(,U^(?;?J_PXGP/#!&#MI.!UZCO_&:YEY!*XL
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M=JY%D$F,23K)Z"XOZG/+BB5<?R4X6&Z8Q<=@V&]/M:R+%B9+N.J:ZT^54.%
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M#7OUYRV<M4I_9DGJ#Z9JG=[\V(]?ERE>IN_=R_[LWBT0)1-)YLO'*"TE!]W
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M8X8+:'Q><M*H\8F!RBF8^"$;%"S-@-CR6E!LCM0VDMC)S)YE(X-L%IO_Q;6
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M0'Q8U?% E\\<9T'J8SS"O.D:/8#J20U=6"():)G/LX%'5:L2<P_O8+4&*R'
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M1[IT+"'UR8O@!MEX0L:.# +E[^:>?<H]''#-'B5C7,Z ^( N'.M=+"FQG&E
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MI6NI3%./2WV!Q<L539U)%B<98WH>2JB2WTR7^E)SC4Q7^[^Y]E->$RHO'%^
MDG*M8W+5WOOQ!L):4R:MP3OK?LU_95SEG,OUD*6,%>>I_'$TT!8_+4_NFZ:B
M_MS*,I A\S;%M[@P&!7-RK'6("P8A<UDS-&VQ2IV>^VV96:G&.HDF"(0&G>O
M'4[SPT(Q>UPCM;58-F#WN3F[R_)QW[MPNL06K;]I;@='^5&(#A'G$T795&^&
M;7OXQ#U][#?*4Y5>^>,SZT*+F+MWK-[T5F?Z!4RJ)#/N\,-?6?'9888'4RJ5
MGZ90Q)O!*K12&#[61<3TY902^E0SF1S*HF+A("^0OH7&KF#'J@X(*(7T;-&
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MWZ6VZ9U3^N7Q\%X\8VGR8/]P?>E(1='A\!@,ZG7%+GSRJJCY=X'+.M7TS\&
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M4[*V^<!1KRGW,[BN$3\:K$"%S%WG+CS[[42:[5G@,'5GY*A/4LB$\:"VN(.
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MTWW@M?FQ.4[?IZ\+7GSX<&^X?_]#P8M'#_8>[E\/$_R,C]IZQ.&O>7FVFGT
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M_926^9M0Z)-KZU>)-=9DR.7B6(>?"_Q%GHG](*4K8=F8OP8'#'1&UJ2*:F[
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M5V$9!1>MJ8>]0MZ8]Y56"?1UB0E%JH5G#70#U;59/]T/_\9B2G*-LZ8IF,2
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MQ[MI^7+3 I:D3J1/+@MV@$17@MC)\YS=G2\Q:S%'!L"&4)[)B2L,AD["3.,
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MWRF-CTE1,*^!FV8@M8TN%R6:FR3D/ Q4LRODE"GUC<"*']T^0QA [#0W07Z
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M*M@SJ5,HF0*B1!8HH10R,7(!V6*[QL(NB_6;BG@75G&:<\A&A^:HEF+-/L2
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MX'7GRFZD/KYD\2R.CS+:WD6?5.P%61;<Y5Y*&=>;:-=P&+;P_?E\TO#4W%8
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M?I-'+?J^/_HV@X)?+";?[E&S>Q_U4!M=CIF6"_TAG!T/)$(4>GB![Q.>*Y7
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MN#>=-ARQM0-^/TYJUV8S.Y=XXZ;X1 1W;=;+"N[.$][![;IL9N<);SP"YVQ
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MU^]'H^EP,>_0=P/0=]M:FK04?7\(HMNF$S _RI72[*7Y\-N;R6@XGG;YR0T
MY!-F(6HZ(&\5^GZ$?*[-''E#"3=;=8SPVS+GDS_[E60?"P^^=J2\6_ZN5H5W
M!7-HO(?[PV]G;R:+Z6+TL.AD;>;9#HSM^^>3%GBX.T#=L#EJ=_:[+%))P:SX
MKU2A&%]+^T#ZQ"LIQ[YR>#_?)"$B\1OE<97@JPS_?AEEJWW4\+XF++Z'?M.I
M%]J!MQ?GPTD+\';;LDLN-U'2<)H(;O=Z*;''2XX]>C^"X'Z3>/]$5\AE"\@R
M_N_?AP/?GP_@C^EDU'_8-:[-;-L!J4?G0\KX:[A]U':W]<-E=&VFR 1T5TQ
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M[.%TPOYX4>[%Z8J075!XF$<Q\2[33][%C4KV<#:N0+HI;S@9P%_1V$FO@QY
MISB"=4BBP%M,!K-!G\ F8 VUVR"F2/8$2^#9S\:#^7-O.AR?^>/YG.X*G1[X
M^*U:YOAL>.WM[6T?\75Z$^&)Z:_PDJ:(2K< .7!T> A30,UP@"*[!1Z@DGUA
M3 2X:#T1VRA8$W5+L%4%N9RV=90$R2HBP\,\A"\P6C;;X"/\[2:(8F(XE^L#
M$D'E<#PM<,&AHXKM>6M .7B^5QO8<_CW"JZN,H#^2H$\@+LE;W_]"3Z67"M8
MW^TVRNEN/!-$?_7Z4F#Y<QAE3#*![M5^*1]%"VP3K39T10$@K=%DQL5#B2%?
M]V<O<[VN/5I5L!_ZU^D-*;$\Q17#)0ER4#5+D"$[]"^Q8O,(*7@*P5R6XJK'
M\ $>"\JL]1[V.Z=J@7P/PPC3U1XO=,X83D:!B\G;FBEJQ;021+FCG"6T'S9@
M[%]O<-^*#9P0_1PR1P HPKF+\&NP_#$80A\V!!_)!L5UA?? ^9$YXK=9[B(?
M<E3L\3B1X.6/PN,ODF1/(!^/#R_I!F9&WUJBJ0-2"86]N1X$>,W@46VG54_:
M)R1&U2<$RCFL%#Q0W8-8_\T2[,*<ZOI*L-(&]+S_9A$&2\\_R3UFO=YZ_N#L
MOVFK+UD='WU@?O9?#+O@X(5\B&F7TYQ,'_HLG'P,UIF##__8[;-\CR((/GS%
MAGGN^:-GP7/\G#]Y%CZ7(VKO^@5H3CS_1V+%7--#&?*E-Q5?HP>+;SB^N8?C
MISG*-?W ?S$>%'C&H406V4'8A.X@?4Q>V<,;_>E.H*V5R'D!=VC+'B.KX-U/
MT., =.$ 2[+C8 8DEQ$U)R&CJ 0DWDI9M%-Z*$]MMU\"3M<RQDA2]RT]^DN%
M4$>)?K0Y+'++2K)"6^%JH#C0VJ:G1P++IB4)3DH617X);UD% ):^1FK\NR_B
M!UH\N_!AE*_B-+>"G987?J^N4]05> T2%>>P$OLX=$0NF_E5F]GW+G+2,83-
M8>U@1W!O])[EO(7PD"AP#AG=X74:Q^DM_=Z\.49/8(A8X8;!:H%.S)M(W<I1
MN&\VI.OTH_C:N%^X)8=DX4X^=UX-!P<5S7TZ"6:;H#\U# J5ZW.,0R:(S>/!
MI%[S3/TJ/IJW>(= GYGK41H=_F;)0^3,@R\_^Q6',@K_]W>1\F=@M03!?#0*
MQHLY8,GE<C924Z7F(]]7L_\W&2]FD\G<GTP&B^^>GB9\ ^+)\R_ &$(GZH]L
M>3RM"TC/>8&>B6CU!5?R_TOW &KH>JU $:"K[\ZZW$A-D <7CSX>$7(^$RIE
M1^\2,8^*R5F/\!%/4\Z&Z)'P)@NU$E:)JYZ_(@).Y*\+RL7$K?9KOS5FHD&S
MK^ &[!DK4YPU">*[/"(H^*-!\Y=I(@$+YDC/]S&CQ7<[Q3UR<^WT=H9JK0&K
MM%@^D&9E=S?".O+_J("BMW #U2U,43UT*03$TW9IZ8?^ C'9'7N]YXQP969(
M&IW2_#.>)PLEWN*##35^"=I,P-/R,:."@Y7BKZ<K=EVL"(J@QT* # M4"JG@
M5WOD"5F[#JM3APO?*UYD>#%&6DA-(X5;9D9@'28PX$C=*-$+T5:O3:]BK<AC
M1LZ)KUBYGEXP,L_,P6"%G*4<BY&HTIW1!![C.)+,F1-VP4D<+(+YU?K0R61.
M'&]<%2SI>T_5=/A!%I46ZDT2@LS+[NHH/:NGIT."@0>7&69#)S]1!2"^G) <
M3AMQR"<\(+BC(,SVI<WG3VK1AM@G!PV)2)TWO(MC',<Q%ET<X[%KJ$\NG4>,
M=-M3Z^418\&5VK'L^P:GF%I*X>_N0!?F'G9R#4T,DM,?=""2:QNJ?C4F4%\U
M9+AV?QE.^B,/%BC6NOPO_J*_T#\A";[C^ S:A^4HZ,$(="04G@.Z;;MG=1ZJ
M=;2*"%O_!1!J?Z:?S2[,JH\"HHHI3)_#1F/'0_0 @(B'[4'3-,>6MCJ.P]!:
M_-PF7@YG9D,.REB1(8(62\+FT4=U9W41; *,!K%YHES0],)[%CT7Z Z[A8Y^
MFU1!(Z6\"7HM3 QSR]++8.N]CSDU17X2I_NPQ\Y2_.O9DM*1=S!,Q'<OX27P
MEH-GX:<3..;>+MHI/((F#T+I2L6>?>$EG/>$'@1/TF-UG^A./=JB3U 9]PN^
MZN(-0,^<[;5=4&PH&P*>H)N:%6D:"T9SLBX8U3V+;I[#4>7-0']*Y8+K;5G!
M9"@%Q3HI\@)6&^/B%SE?%;5"A^)!% 4^AF[":PK 7&< LDJ_Q<>!<8G.\QR&
M9'"O3DSY\=6%-_$'SSX^AR' /:+D0,U@:Q?Q><]8=GJ?[:5U5Y2B+7P>](QP
M'G=TTQ/M^*8'L7O;7GA[6''.YN?Q'8<\K0M#/.MZ0#P(]S90/*N'MP=L4!/4
MY%4UX]"0+XP(56L!1&_*HAMT\LNK8#3PI S7+>;W6K%UO!HB/BB;!8<2Y(QW
M$UC=,U :6RW[$-8EL'1XS3>$->$ K@$H+ &/%7 /,[AS:QIB6OV1GI>#G,?4
MG=*/67:L@RA&=%?8+[,'O^(;1LHR(+P5A O[ P*',G+": V+"W"5O!J$9M7Q
M2<,5AU,>Y9Q$(4<3-LW&L;7%P>_XNHAAM07"1[P"2C\Q/]97 D&2_W!943I4
MFH;KAZD_G9TSUAD%L/[K-"W0LO2R(,HYI++$1&$6F.E^63BA+7UFW--/UT:L
M9G&TI6A]):Z=JR^L!(P3Q>H(WUD2!#);3AM#"7I2I)'  V4&2N/);?=GXP=F
M9V@S[MWJ;[U3I2VR:8BXUHI7FXT/DM\.)L+1)NJ:S '0O'#-UV"-YR5?:Y1C
M4((-=XJ?9055".THB(4@"YZ\^LCFV_MW%%4E1SW\\!!#>264AOB)7HH&?RFC
M["\+B]-<[\Y?AH/^V  X.FCD#H%'C@3/3?J#Z@^,3\[J<"8F!5'\P?<CP<]-
MQ1_T_>JYC([GX@X1%K-N5^#+#B@ # 2U.9>J23 ?%D[[-^P:W6X4*7GTY. \
M]BLL;F8/9(3PBW'DET@3@E,J492BD.]1^T4$</2I9[>*:!N$&*C?*+HN08#R
M_$3*Y23VE$$C_[/'WUN)A]DX*0P=YH9?U3F\$@6PT 3&N)+9)-[;( .-ZD_I
M@$WY]7) _N*/G0-.0S;IOJL5G&$2.L[1_:U:2*-D@*^5$9ODJYUI6627P%LJ
MM-B,?B+3!+8,QU>2ZH>.KQBC"@?@D1(6<@Z[;W>Q#HKCUV7'- ;N<7Q$W,4Y
M]B7&/.PMF LW:6&PJ-:<\@'99NJJ4T*]QKC07E@]//L8F!M&0V'W,@6/6.&Y
M@P5V;(0]+0U^VSS\'S^]\?([L"JVY.U$YRWZ)_7.%!CPQ\PH_47K#>T!5 *<
M6U B(,XBVHIY(9&>DSO2]]X0ECS6MGN\6JX@R8.8Y!P?SEY)BH=J6?1L^AE_
MY QVZR,NBTDPZ0G^ _$(1A,<G5P\Z%YZ"XLMN;8<#0HC=!6%.ICEW!EZ'@X6
M7H.'WKDF>$-NTHS\ 0BJV1,,@!L,!NVB_3)P:16N=E^=\,SV'(W'=\P9JH;8
M.A>=%*D1,A;^VE1ZQT5[$'80EV^&BYM573A:F_V.'/SF'7P5>G)6X4#I#V^I
M<%<23$IQ?UHX=R'1'5Y:2"Y]N),]LDFB]^^L&.JN9M<XD.( =5)3/\&N28SH
MT4BK!T<,,X<B8^VB^MK"K-"ZSU81W> ]QTHW\%IU$\1[FZ/[Y5$$WCES-IQX
MPCLZH$>*R=%P)66T5:HXL.58/?(5XY<C8GIJ]^QI';&OM/TN0#+*)3+.&RQ(
MHG1)E&I+I1*=QWW@73ARTBQ!56@D$S($*+ODM \*Y;XU*_,MYJ4MTUL5OZP"
M-,;71!\\HP^>Z4=I1!5AY@3WU1"4[(IW%YZ1V(JVB#FTITL_3,5B!I67Y%#Y
M=V&-HW,T&71AC<>NX2]PLSSVVTF*G7OXRS?IGJM@C7C.Z\L5I9C"^665J .]
MH*/WB=;&<B'P;K PI4B#N2",^0P8<^!WJ- ?RM ](FPJ6<[WC?"K9*:4PYYA
M[>N+T53O4Y1@.<J+,W_^AX6%J[>) ,;TI9["G_7B\CJ L37!>?\=W;K!M<;O
M.Q T.MP@B<=@@8)(7D<LU<JGZ#"D<>>1V*'\;$D Y*/$9DY@J5WR=%W<2GIS
MN%]ATJ.-M=C0RS\C=?L<CX9[J+BH%1Z'-7-Y88I<*<%-FU48^'FK0LZ*[''&
M ,Z!/.59((^Z1EL(;71<!50B&5O9JQ1M%]+\%@U4%6"X!;: )@!T(9&-CJM(
M\.D?_:L^@;(HC *.DP< <Y,S^L4S)'R Z_'<F0B JM2[%>MP'65YP9!7>1=O
MSL*,D!ZH0,J\,_:;65,'=..4'?U8M6-LWG4WZAO=J!_W&:<OP:TIQ.-R@%(\
M+*I6A49$= ITI5N6!#::9/U%RSLZT2(AS3.1K[0D<Q-3HI2=>*Z IT(%VUQ"
MEY2>;40 9H=2'W89Y3.Z.X!FXQ L>ZYX%IN]%,O"\R952^1#R-)-8K+10H#N
M*-FU@-FENSWG4#YW,J4PQF>#>[ \QKU*;DX&?.B!4+?H)P/+@G.+CY]J8ZD%
M"1BV;;1C#2^A%CQ&8N"284:ZOB*ABK$2"Z.H-]%*,JZI'!C-132"0-7_B[TQ
M'&93!N2N4SP%GA0+&7\2287E<Z8&6-V95SW#F=W@&;SC=3V*%9.7< <"M.3_
MX-.$ T/S+E-DLJ48,HMPJ3#W&X86;)]+QA1.G425$TRUA3+&:02'#9\NGC#'
M_W0P'S=\S%Y /NY:CX=4V83IQBL,@ =ARJ7Q7[SA6$.OMAA$B#"53!^O(SC3
M0Q\ /U&.0LYX K_DDA"8+ W80L0T,K\H0Y^ MTFW2I++Y+5&!X(\59FDK7>B
M\AN)RC>F>$C[#3Z;QF"8'KB^Z!C8RD;KZGF\X@0<#Y(7M+>6R#.V6 1%[G.Z
M5 [<D3$YKPWR<LT3#>,X<81N54%I+$Y.K%PY*8IVZR_P(AP<_XDID"VPOL4H
M$OVPU_]P[ZY-#ZZXJ/PDD VK:$?3A)5;DFN]? 'EXF^C,&3'JI%:\++2/<6/
M@2C.CE[%U^=80FK90F8^W!)\R#^N]+/S#5S&F-X.D@--NR?F%KGW4KT.5AOK
MV7:,F[)3(=G#FJ3HQL#$7\X*0^F\P^)XU.ZW%8:5!KLN -; UV5X ?#[TB).
MK?9<B7E*KQ'6/U!(,@SX:'#'Q5 \-Z,T*26$';76(8=#0QG/*D3+SER_(9((
M,64W(=-+ID]2G(*D9MO50&>['I@?XAQ9A%'B<0[I_,H9HNCD31"S8RCZ V2+
M-F[J=#9_+*=;.R4)/4RM<JH5.!W=6OL42&.\Y;+G_&C9<]!-KNL1+%2UL0'V
ME"IVNFY@4,9X8X,IDIQHS77D<!5A4=@>_OBJ ,E#LMA[Y33VGIZ7S.(=Y4F9
MTXDOI+I!-$D_[;2S\:<W9P66&=YG$"_5'4IFUPS@66/X3I]'7?%,F,D=O;UQ
MY(M48<_-5RF'8[ X >-R"(4Q+7N%=;LJT02K=*D)"/&%PCVK3*QC_&^B=N@+
M,O?!P5.']RQ7\?I,,NW@JI74IVO2E.Y7.8I9L7PV&_-+G _.*C_ORTH]K4O[
ME7[V@X6*<HDK<*:H#7GP^72.IW'JX8X^Y*P>N.#(>GPIN7YEY@Z;:VC2$<K#
M/O8T8M)C? !"3L>\#Z$_KT4=I?*[KSK[A[ZTA_K1ON#4&'>QV:+/G07"EG(6
M/GL"#B(XK@,DS0[]'W(ZN&@;\9&55WH*CAT+WW=!ZA'[D#[_7WJL]'[@]]#Q
M)MCXR.F0X_:D7*I.3CZEK4J2[1DL",7#*=DB!\-8)3K/%S3<C8KBF(Z]ZQ$Q
MWL,<?I"S4\"%_HY:H&F9=9'<"KT(]SC*VQMI\KM(T[>H9?]:\>R:S?E7 G+.
MN.$WGCEO%*%GLNL-4X];(B$\C]K-%Z#WT ,\Q&@(OKF';909[,!$%@]0D#A^
MK'6D8G*&4?$[?8_?@'_!$G"P@C%8+.^J#&I1! 3SHP(PM)YMN<L4>PPINP7S
M-=/X;G?F>/215Y*L20ZM(4:-J+CFCH6$ZZO@]*W[=@!&<Q/E.-)_*2.@$@&%
M1+#)V)-&QH-A\8[&.Y,$K/:YJ <#+S4D1L<>12JL."+!?JC=T5,G>7'F@Z[D
M+KUQ+PMG'#<.B#_(G)/C5TZ@<T(ACK/$<;I0+*;"+W.?CX/G)$P(\MHC;VI^
M:$2[Q10I>FM7"DV=0^BMJV#U^-!VDNCJ,J ";IWTU/>NBF"-+E*Q](U"Y8FM
MT;IG<I10>S5IUW#%V?CG03(Q&8VSSTRHB-'(')2OY:+70:MN4SQE3."ZX<IL
MG@H7"8%=+BQ&UOZP4]/IB9(-2.X>*IL.2RZC!Y@'F7)JN-<2@^%:;EX4F&&%
M&=L(X^"'+,6"/>U>_XP<?I82J0INB@I9C"#J<VN\#/CC?&:/ZB K-IYM#(I/
M,4HLO]-$?S1<NR]BTSL,;AE9*?/1#SDQ+TG HJPK#; T1X\$JPA,T;[?.2D]
MNMZ-D]4+1GR'1PT-\\\*V)?N'==>JX?F#AV\P^QN11KXY_.*GAZ$H#.+J2#W
MG]K[C-23+L:O.>%<W27DE56G_$47[OE&X9Z#^WV?,##6VBE;7U*P/R]6T.C]
M1G898*&W6"J@41C'Z']Z8P\>:4NT5+?![ZGVJ#(]'XQ>#C!ZUM)0RC54*/2A
MZ7X7:S6M\%!+"0\\'LQ7I6MS$3NA#P>>$ET+?3M9B@Q7I7*W]#Y&LSHSG3V/
MNTQQ%HR01FF6);?8]M@C8XH*OA+Z4R&11G3XBH/G$ZW4%DFF\"WNC,7/SWS8
M5U9DT\>#6&_HB:_(Y7:2%"AK0/#X"5T%)Q>=SQ1_80]HN?0A0,<T#WLC))(X
M&S)!=@#D(Z%GQ'%0]#DC5AA#/<,_M0ZZQUZ%^Q$B4F21Y:-?7))WI?P-<0*Q
M?J$U/(7VM @U",]%O=HG+L%7XA--D[-2V7A5&-9XC.!&<)< <PT<$,]>$)K*
MRZ\A?NDD\WV2V3(BJ&2#9]M2.E61#=QC7YK;A4;I'V_M'HSD808N.F,%I>'X
M3/F==:C=ORH.68&U:/4M<3R4AW'TG#RR*ZQ#6G&I##DY':CK\B]4)!V)X>V\
MWPE/F9TP.2P.1L*M4;M"UXF27U1V\;F$D0]2X#\G-N\38;D;U$5^-;S *(P/
M,']PE$1VCZ;NE=0TH_\P"JY![6%U6\4H2)*R*[WB%.O(>XX%7E4ISB4@3Y0#
M7W%M2D'R:I?0E_MS*&/S/KE/Z]U)QV\D';_8IF3L:$ *YG9HS^*7V)AWE4(-
M=/CGC-6#\^':K%O4_0P:X7X)ARSAN2RPQ7H&+4;B$4)!%$>,9:J2-N4JN04Z
M)C I-*64CK'+,$PE$H4?*(I!2Y^35IPK,YSBK01O)'\=[Z6ML38@G,$+;P][
M&\]H TH(G"&-(R\*067(.QME6P/N[KPX6'TL 24)V9/VP&=)\(O[(Y&4.MJS
M:E-64%CN?A;=R8+U542#Q+T(]/2,O$7]E&D%IS- 19=BV6,I,5>/E"T%MX3N
M0-X>OF6EU:KNW<&?(G)"41V)8HLF*Z/)+O!T%'@:-B#P=*0H_M0EE)/\+.JK
M?D]##LKZ)7^.)#>3=%,!LXE)L81[_<DX(SB%-9G/^Z:GI/LAZC$24@H2^I;W
MB7-'MRF1#!?PW% 3*ITVL%&.G<.8<O1%:R$ XA?!;BF;>\7B_@3 ND<'/ MR
M-XO5\*B60B'/.1N1S"C=G&JWN<L)>W+ BH6>X8W.-;JP@U4V?82\K0 \L,LR
MMFE9*R;NQ$<@K#5I(<5MM-)H7#*\[+3ZWM]@O6Y4UG,2VIW%<XC$<U ?<9!Q
M\ 9>LJ? 7-FYTI.0(.Z:%V,.$I&[ .).+,:,<J/1M(DA&6A'$CI,A8\U0&!-
MI'@IK> ^(<*!("\=&OPX9QIPRJXJ-2BRPY!< E[^*,!CE&FW&*(&T!\Q2O1K
MHJFF] X1>SJ#EF B1XI*4!-V_O@ <C898V"ALF;/1D_L&X<7C8\[*!,D03XF
M("FQ:^V0E6-5U,GM_!6UBR0YO"7%5JIMJ,<%7 Y]T7W/R2/6I.M?EDOLA+[X
M>YA97.9;;G+\ZYLE:>;?.DNS9E=#4TD?ISZ7,BK+R9CET\[TFP<IH3 '^.<6
M8+:&M]8U+%UY@C#8">NG>& I3^.G-V:5M;HG1_P;5.E)(IXCVPS1[KQ^RA'C
M#7FC;7U&P$40<C=^0.2EE?(K3I!_1<HQT&I+=P!U<^HKPE/P?[^@6$;SA/F.
M)F@68"P=/2 LNZ7LX^<@V6--&A50((C/ .!1[8AXF$N$/*24J.")QJ$]7D$9
MR._0,\*^"!3JRP3SOF/AO,'O$;DJB/ S7I94*E?LO[C %!;[%8,<*FS#"V2&
M)14$1DNZD1&B@4V4:V.AJPOSMUG7N]D66.I*:G;'634<W[ED5DM)*V0F<<4[
M1T_XS&:5WF!KSBAM!!%1CZE+' U-KF<,&&GN&1['TGU/Z+R 8DNV0P52U9RQ
MMPZF@:+:X5&)[PA]E5R+K@\=A0L@?<954LIP3-R4']$V.0C*I54'>4]<6^23
ML%YV:3K*,R6^',SZ8&>?J0^2&#7NWE%Z865B1[4+] NVZ+GA[2G;^-:-G$BZ
MD3,=E\652%)AU@34&;Y^0L'+MU.Z&/'YT:+C"K 9;0 'QLI469:L=;F/8NK\
MH7)T-7 CH)RL9CSBV/L/XQ5$^X11_S3[R$^$1>&%D&:$^&]T;CAK)#\B!J+$
M?.$JA:>SKD^,V$K1!8NR@5+0GG/!&EVL+:F* ,MVY(Y%#C,^7TWR9.JL7'UK
M.3.*)IGC6MQ?.\;06"59BNTMRNUQ!];K<B]YF#-J.U0M#<HF0*:T1CB.M<E)
MV 0[VBYA$];L7-9 0CG[.=E );)P6_Y%IH((,IL^9<PNR?+ZG[W:\VU -6B"
M>2<C8.BBBA7G.MIN?/1KL5X3=9V"7+",<FLXMMC3_;G=1!B(+,J2I6 8&=%A
MJS-<,4=F:^Z:5:1_LW1'M'SWZ"N-7(A'B0P1.%Z1! "<H*KFW8GRDBB$&?0\
M!++(!!Q\=OG9!L<$./@:4O<>9,7IL&JP!\B5:>5FRKZ*5%>GLS_JL].K&1"C
M$IZRS]&8SJ:$^6BRLB0&G(CX<^D*CR'K4?S+)G5]!N%$N41 KO$MU-C^(&AT
MP 1NDO^E\$!1M],U]?G"JZ .NKD+:X<$P[! 0"?=ZL1?&V'4Z;V?#2*N%0EM
M*?S2Q'W6(2VKZP!/N;](5XWA=$U7;<RJ@/5R5:X!;)I8T9JQ4Q>:L92HZL7B
MT(^IC*KU$FDV<RH'P46^) WO*%W9\1A)QUK:7P'&7"Q_A(U5GNXVP;5".KYC
M\\9XSHU_H^) /:VK]K6$9LX.HV]?T;X(#/F2VBE=L(@9R73F=_M"7%EPL["(
M;D](#+2ZYD;GE MT6W$DELIJGM8J?K::Z<N6AJA#)/W_N)90I\-4U3<].UG6
MY-84,I>#+9/9@E!BFGYQ_)!S,Z$ND"AF\.CVW#X2Q"E973N)A+<8P0I,JK4
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MR71FC,;X!O,TB*4QGC$NT$ +R"BBSGR:VD2GBMS3/:*]H:5Q T)+G3CX"G&
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MX].YM-%N>"#K\!#5V--<-57-G3B61C23%M\PZ^'!:>P='D=]2B@F=XL#(A)
MJENDNA$>NBG'*E.#!W@G\(+1<TVA26D+R!Y(D.M HRI\./M6#7,B/18>@BKL
M\(R8)N=V8PB7E19=ZEE1K^CEY8H3.G5@WBN;)%=UF-3147+FP'C=G)V,7D%K
M"TM);R#Y(5FGE&$@W#TT ;,N\5TY=B@H%[^&T[!$<71,W(K/8Z!59A[A?34A
M(ZT!7/>C+GA%5P+;:&6RNSI)9-L/17.>RD5BK\\AN#7B]LO@;17G_:&:=!_
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MH5P>3;I)9"->Y";%\;#3UN.FW6SKW8X)>=B(KIN!\H LG[ND/+1L)"NEI=?
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MIKY2. \K5*Y8\T<^ 1F$49)B2U9T"3V]O//9J%6-.@_Q9D* #[>&S@/D9S)
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M\L0C22_:)L@Q@GGD1Y*9?&BY(<=KDLN\H <C(VC1+D(.:YB/QJ$0KD H+N*
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M0<:,8W)CU'Y #N[;N"M7%V+5&&IV/!66#-^-5B^:C6Y[65 L@BK7-3X,/*7
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ML2I\^;:T[P50'-ID/=;SKPD+1*6R2TEGR*=$M)0^\W3Q%M6VU&;CVQIDTF8
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M];@,NB5?>[@8HP*+2:"V3;=M.N"_\WS=38?<?'";^OX+_V/>/_?X'3_2KLV
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MMO::H/0O(#7L5#FOU ?BQT@>?.XOG6H^2HC#$71"1S1=Q.N"R=:QR1IZ;CU
MT0*IX">;;-5F#)KC-6<WWCPT; OM*!9I&G)G4J[8"XV[7#%7(2<I8T)QA'.>
M6<T+WRDN&HW/YH2WN?$)9R,D2;&./L\$1ZYK?Z:+Z]:CK*AGJJIR7@D=XVY
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M?-C=(=P5_@.E8U0+*4!Q25 _0#"_!@9/[,#AZ-(9QTBGH#&,;5.:D/IZH!<
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M9@_&]U48$Y%61)#.3]@5+Z9(ELA=* KW@8&'F<RV5G#@Z8M5[/'XGTJTP]I
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M 'D)&&Q7[D*;=#X7O)WWA>JE,WTS@5'HE^2%Q'JU &D2V,3,.= ZSN1UVTV
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M=/2 ,F[+GG'A#(C"VL )OKW9J*K/SK=W8_0%C2GW]S?]UX'[S<]A#(HLTZK
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M\[@"U5K6)D*H<(/\N(K)Q,?B.5%&7;>8Z3+LI-PN:_#[%$H1&RG*Z((X8/Y
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MST7%4EE-INW4JH01;A@F13"#<0M_.+I4@G*Y NCUKA:@'M.DG#NU#ZH\]SD
MH"HB&G#;>2%4F9D;<@H;<)R"H%3/G!R.7F&)92+7)<Q*,#1,M];H\2P*^1$S
M#($KJT@TCB5%=F=)7>G&=38+MNZBYHX!-(+>YC%@!,!+QGY=Q]5,QNTNS46S
M:Q@:J(:<[JHA3Q&VU*+7S5BOLO=&81^-Z=]E,U/VK>]"Y\T]CEF$%ZHG"L%'
M(89BY:\)DT@,B H >:!0>[& =.D",WC0^S=1\BJZ1Z@Z@VZCSVU"J]Y$I3+1
M2'EX8T;-O/0C$$-<KOMR*S,2UMT YJ6R%G&'ENN"XX,FQDB J8J?HN>+3B^&
M;-4L#"7*JD\4<96X.'S=OXAW?,C]9W0 063J&G)4!(P-''$*N+"_R?1?MJ9G
MFYPH4&*E-14XE<T\T858*8\F "U5C2A0@.J;V(H%O/7J7O"<4E2*J6CYK(91
M02JX55D?O$C:^U%"9)^XC<SM'=XO5+]T(5A-67TWTH7[X3?N?RT'"JYW+;NE
M3PK<[Q(O$(_^N-$ M]N;O3XX'*P_':2>>B4_AVH@%%Z06NB&;;][1DS<&&4X
MB8"1JLZ,_519#] 6;\T:!<,BL-8'X^<LDW9,^7G>U&SH:E!J6#JYE>G3GD'#
MAT04F!/:NB'/1EKK\:((P!G#Z\*-_ JSU=^G-+'"SP+VE828$8]I5ZB$4E;:
M49=-RA'R:<F!@NP50/.0N:D0G3[W*9">;:CQT&T:XJ<0KK4A'3>4D61<I1D+
M .2]>!LQ2GOQMLOVT/'9G_T/U"#T<M6 ')NM#*%=*45?WNM !1,MA?PLA4X4
MD[(#&)W;)BZ JDQI"O1*MFC3\2%-7!":<+LH5/A0&[$7M&LG&M^:E'_;.6+?
M=>3SEM)C98^PI"DGS*_ Y1NQK[?M^CDJ83F_ZBKM:JKVRCF1'R'7'-QO)?9?
MD/V%3U-862!2[@:YBN16RM+N -5M(6 ,=__*-[5C)NS=Y+W.J5SU1D!'JH-P
MZS\7X7%S-N$* 9?!T$Q5W)YY)A+S"58T)L&$Z4LAL-D'ABQANJ1'0-#-MAI.
M#J5*-FRSW_^.XG829$8CP"O5M%E&WG?9M&]Y6NXB=N::6ESBNI%;B=N0X@9S
M-7.WE[7H+QVBAI\/A1ZQ)ETD^B"W0W%7+4?SW$;M)H$@GJYX8S% T+/2_;$]
M*G\>NV,B^XG)&EQ:JKH;Y E#"[ ,:_YFVIZS:U+\S:D3Q\5&@5"HQ "U5D,T
M>0.O1J4<_91FTE+VJ(HG<ZHV3$1M=:D=$IAP6<<-ZJ/>>[<9F848C%(V,4O"
MP)_K%$"_P#$%AG&/;E]*%KYZ]X^WKP^.7^BW]R- U#37;@M^!M/2U(O"O:[[
MK^M%!;U;!?SM-"_+!!>I(OZ)N;.ZO!:3"?H%X*64M\C\#]8<'+XEX(KBIHDG
MD!EM($]+$(^)J0Q18G.6 K($LXS^+Q>%X,?=*7*W ]@N>"ZHZ;I_K)!I#-*C
M-'*XY*&>(T 3O__Q69Y>"6X&%[8R4J=*<\J[PP$HOX#.)#!B_CNN$CAY'$!C
MC,! [>(FJTK$"H%K2GG?V]A0KR+CA%L)MW/W_(+A1]Q)_/4SIO 4\_!SEB3N
M4GCC%MNM1AV[[8J%/QA_Z1[?^#DL/1T(@P606)9.R W"6;)ZQM4_X05CA5K<
M>2B>X;US>ZC6M @^WY%2<O@!!B*23IV=A>AM9;N7N2<)5_9?5&1)$M">'A17
M*F/?UJQB%63K 9.#_3P!U!+DBCUX13/;SM DC (TZ^Z>R\Y61(.2O-.D8D1E
M5DRKF H0O(TH#=0(;3'OT3I8TZR1FQL0<]#&THRX&5\8'+ 3)8)<$,.=(]Q[
ME.Q6 >;@MJ;N)9LF(]P2[GX4=?U$.;K6)8Y)M)XKGRYWB<9 C""/(8NB& ?L
MZ(%6%.[T@C\O"JYQ4QKSQDBJ!E0#B(@2G\!N#L7=]7@#,'X/[?1Y,NS^9_</
M?%J&N8B71$V)N$ P3*9P9/>9EI1B>FKGU^&@@^ZQA79FA6$-VY(D*<1/E"GA
MG]1^F7O-.X<9K48GE.TFH8"FO$IQDVI!27JT_2WH<U^23]L$2_7UEE2>[4HJ
M3Y"*"K'EOL4OL.&<'C4%#6_,R7!Q<S!PJ<?N^^55'(U>N1=S9K3(W'\7(!^*
M&I_V1$UCW/K8Q @9KG\[7R&$@,65.]M]9["5:.90.5>?A$,;\4.ND6('\[]H
M$:$A89$#=H4#[Z['[5,;B\1YLN K0JFV3E-.(I'KY$\]WK"8%R/7NE!P%]5V
M3-+8#@MOL#_:H'3M29;\KV^R]/ABDJ9Q_/ST-'[VXKG; ^/QQ6EZGJ;/3X^/
MTXO___C\_)O-0R&];=+9Z/A[H-.G=E5BFYA.H8:.8/$_'S_5?P)_*7O!76LN
MQL7I\XU=C5>'HU<0Z4E7Q,-?\MFS#7S)X-T(_O:S+R#!8?L(K=#I5<^+;^Q]
M\!N[I_\S^_*R*(M?%LC3@NZ4&]B'=.H&<'#\#9)2N/]<)B^#:8!9\)/PGO@5
MTOJMI#&3'_+XZIL10D0;M_9?FI?3[$N:'#B7/_T&]\/TX/3BF_],G.',G?$B
M3]BYICD^,4W^Y]^"D?TG- ($"X'(']M!5)7NIV=:,V=/6HOL$)%3_2+.N>@(
M@^5NDT1T$ )!(8U7ZJ6[*6:"TZ/7PI+V.ZQ@T?*/%M#A\&_IA%>%$"I.NEOI
M=3IOKIGW8P18Y@Q&AW@ )FK"#<'4&Y:IB0-]\*,3(/%\^_'=W]Z^>34Z<5OV
M^.7)T<D)OT0"'4*:F.<^H[):6GTFH8_YK[?O+R\C!-V%4WNUR!+R?G]\_?X#
M;?&X&D,FZ.#=ESQ=CMY^,CQ9J"53C_8^OOO?[A]^?+6/]SIUL\,=AYW[>;Q,
M57D0B,'@FH0] ]&:E)5\<=;?C-U5KS%C<V.H63VF?(N.X'^[>4QS7A&.@=;;
MXI112G>R"4_%^/F*HDB(J=&^7^+&A#E_.7J/R0!G&W$U8OT7;A1)8^I=BR<5
MP!3NLA@V?^M=\")M;LOJ,WWZ$2;Y$V1[WD.RYQVV&[FWOBR2MW2\..FJQGHM
M$^V\#IM"HLV8"#%.W;;2.Q+:I]/40_RFOV1?CG[%Z\7+V!$1O.]&'=7EM$&^
MF"EFM>/\@*@#Z5$$.#/M9=SI.(\;I!8)7!I@>;S)H#<5>E^IKR+C\+ LH 73
MC7BWVD^UVO_@")6\CW^X2RG!=7XY>JM4C9R"PS\04AQQ>GIYWIAG9*$@]TWP
M>&A[I2#17>'"XL-/C-AM4LYC#_E0[R">[\BFG_#J47:=RT6"U+4O1Q^H$<GP
M=-K%C^%SI U8U.0]IMYUCFVB/O0GU'^HE=2GN<O5#)A\P)&<NB>D>%OM-L%3
M;8*W!950W<*357XYNJ2;.<?V&"&PX\9+)HDT4IG8:<(G%4\Q0Y5G**2;0K.9
MT-+C:G(JG80H@SV2\5!VJ_MDJ_L:KM#WRG#V<O2FF%3+N9*GB<M(5RUB4AOV
M&ZFFG37FL"NG(Q?YC7/)Z57)%-+SJE3"8,"1[Q;UB1;5G51WFR)Y'\SZ!SY2
M+X&R^UZ%0INOF '7+98Q94^88CSZ7EF1S=S(J03'B(C=27VJ1?TH5O#5(H>\
MS$OPOQ.Z]T(SB;R,A!H$+ <62ACC8&C\Q)BJMVT1?518*++2DD'LUO+)UI(*
M+Z^P'B0+^W+TC[1((#IJ!?.P>$!))(ROS'S-%3$(?@&:NF'0R)6+\:C,KC3W
M7#(N\EWU0<41?T*@PJ>R_:D/JGHXE%F8QGGM4PLOOE% 1G+9T%^Y@6EJ&JJ"
M[--DSCQ2Y@\]%FJA#0\D!;E!U-/"& #:85[!<1OP>!BL@C]N^IL4&[H(GMY&
M3ZF%EW3P8'UN17O4%) BYDU[W]'SUD.,#PYBQ))VJE_IP22=%_G=7^-C2M<3
M'K%V@FB';NB@&\YVZ(:GL'5L2QC[F7A[0E1V(U(]C*0L\\Y"P%IP^AEJ+0(G
M6P=\9;UMA>0O.=MKD*LMZ"O2WQ%_\L1@%H+C?2B5(02D:2MZ4&_"XV3?M.=
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MTE&X"9U [%A$V 3*VQ!SG,_R@;^%FQ;WIS!]@!(!-V:.".7(<@F&1!X-)S&
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M1M*@,ISTL>.>A#L7*ERP%I=OE8UPFVHNOVD9;H$9?.S@/3I3;3PC4#4L/(4
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M]!+&E/1[7-GF?6BV$=_!X7V)10'V Q!PC&Q'23QG'MTX22K(2X%I^_&MIJ^
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M@NKOE3X22)N!N(N:55#%/:QVS+0'9IC4*H>'69+=BV"54\NG25DS8^Z& 36
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M%6@00]2GY#1P3V?8" 6O# /0(ZCWT)C&'8]8L#S\ B38/0Z*A27HO)&3#1A
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MU,38)HPX,]=H#<O3L%,H4SITQHLWG@ DB\&%M'( /KP7;+I5CZ 2 98KCH/
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MFI ."?G#T_4#)CWN1$2< .-<5STR?^7*%#L/"U#Y> D[.?[M42*;&')%VWR
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MR?T/O(&,T@Q6MB?@N<?4;H+2X?2(=.1R'5)-/F!J#"^>Y&UC^2*PX0'O:B)
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M^_7$]C=@ K:.OZ?!1Z=BE6,0;9/)ISSLO#L<]I2R]]6GO7*7@H6A)E<F!-=
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M=N/DO*4WRH6//-LXE1DR+@[E]>PZQ9$^>'*(FWQEU+NEBVKB/</;I89R@;E
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MZ^W6<G_-@DL47*+@$J\#CMW"'K4M'=@'X!=8?M=HZ,WF/F[L@G +PGVCA'M
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M8FQ=-E6IKRZ;>@6T>0?ZI"K"D%W&1H+-#)]I!)Y3=W(*5H1FT'D66N9N6N9
M@O0K0O067S*8?/<948<*_]XO[&V6TK&L6FF<G-=2ZJ8*C3.O.+.!H1X"9YJ
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M?<DF#"!KBD2;KF,.$-XK<UZK'=0 ]B&'0DO,#M;LS"N?B36U,@9<"[WQ& A
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M;O#)(E X(!V!YQJ/AF43!P$:TY[82)NY'HH@%Z43D@EAU6PF=SE)L%Y8&YZ
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M,@D=HMJ0ZCZT]$)1Z,Z%K<J8IH)B23)@';%C!UK&\Q'-+$\5P7#L@=**$[;
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M7R[Y&>X<%%/@SECI1'H>9O+-L> D5\"9 TQZZ\)5^>6&]6\D((FQ2E%L36<
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M:=5B PGKHHK>9$GE 3^@J'.41\OQ\ M'@#9S,O,O[!1RC#N#V3.%MY)+3,K
MS2C) RH]K""GP1$XQ408TZ52JLJ63>3 ^P='E+LI"$:D&MT!0$Q1X =MBI0A
MD3[,Q/@HM3QT_ ?U=GTQB\,Z!YP$FFM(\8SELF5)NA3/JJ4WQHCP.,J?SQ,O
M*'V4ORE"TIB?ZJ%F+!Y5X*3T^6P2K QR$43;2/3+*5RF6BLW>/'J%[Z+)JY'
MD!V9\N5@&)E:R^)**8,YR<B!898WNU(2\3 9%4#S%%$5\3070J@P\9 >H%Z
MCVI^#CK2,Z7SB'ZG!H4=2=XD*Z%0<V15LU(DQ1NLJ5)'U7TH*(QE^]C!01Z>
MQO(0SI32-WBQ4Q>3PHCG"R*<'Z>3Z#KNI[A>E4[P@V02ACZ%%^ M20M:"RU&
M<C#Q1L:D9E)(=0:0RNWOJ0( LT/PU![JIDC=/$SP#P=7N(ND:NYCA[K)H*O2
MZES0@O1R!^H292_-:D)[LJ&G'Q2"KE(HK4X3R;G?!)OJ,=1I-Q_)BRM73S=S
M$PBDSQTP).1?_E"SG_0:6-!+BG###(DAFL-(/Q()8&],A==1\ZA3\D3ID%#.
M& 6#4+6E@><Z)(S8C9$+Y]1[,D.(II?YI$&D0"_A)3CAPJ>S3V7+H>S4,(O:
M-,G9SI+CTJLFG-F,!;GMI8:14-:/1R.R&2Q!=_9/N5C.JZIIB?RYYAFS"EDQ
M8DX#[RD3T9A*Z=1RN[S$?KJSD1)%H/(>MX$?+U1[51[ZE P_D,DFU?)-6O )
M+N-6J&:OC(6FEC$SBI4J5VU!"!@<VCR!1;L3DO1W?LBCJN:$> D_RN#IJL5H
MQL1MW*8GJ"TT+D=*PJF0C>?2^26@/CPV=L3TJ(W$!U^Z!M Z-UA:A<]6' A/
MD6/&4.4 >S@T@A/87?/)&%3@U-5 ?3T*+\L+21-A _&GZA0(FR5%@JTLEU3K
M'K/7D^*F_23A)'ZGK$NR/]":U!=%YZ&0KP2?IW%H"D(L&Q9Q6V5$+SC2B$NX
MX6,:5:VI2RLAPJQB.]\X8)!U8J\PU):AK+;L)>G8<^KO%5 D:!+5N.O3^#'9
MAM'0@>;:8>Q1-BU*?&-^'6G %.B6F@L;7@MV$Y9#9# !!E9#'=L;R!BA$3>1
M#O%';7LXN;<=,F7)-YD]BZ5;A:H@3G7W.J(&8?*<$3-"F1&6T*I311E-TRW"
MO5 1!WG5Z06EFDW(NC>5BIU,@E@XZ39G$JY#O0>C5)&'Y)Y4P\F5A115<K1*
MCE;)T2HY^O+)T=X[3(YRHK,H_=G;="[*-W313CSG$N6[G& 77FOH-$/_$L3?
M:(>Q?0I:9ITDG1CT9U\2C?513>H+K6L#(P[?OI:VW8DJI=E/XTZ:O*'A%_.)
MD!?L1NR_Z('(91$IZI+!-@6>DASA9\1)D_B(BD7)I&(@A];J)"A55L'YSX3S
M47Z!_ZV6^HZTA&3++@H>%%7&I1Q8S%<N, (A P?<8J[@9Q^3TNZ26KKL:>$R
M-VGDW%O1KJ\(6TNT>B&B]/09BK[7_Q2!7S!LH-U<TDFP8%G=5UI6Z^ 8_[1&
M.\'R&K,]8C@M6E(=?3%[%-B/3,(Z7ZU[OBI;'[.R)J_A!!;IWW)>.NE8$&4"
M#_8,0]*/22 NS91&.-@.>$XU\6F\J,/_XMCOI&*1'W"DLK-'I:+ 6)Y.0<A!
M/C(1\2@B(WPM?0))AXR_Y%9U,8:*-*<=F@6T,F%/(8%I+KQLK,8HVBOB8\Q'
M D4ABB$5N2T)6.]7+J],*&9"'9$2ATX*B2)#*6.L5E-E]&EQ>LM-B-.16Y_3
M;!)2D@(M$V8&2696,%_52*VFW'Z)#+&26EON\J#4;D$!J\VU),;X>GG[JM!7
MAFALQC3@ Q)?G*MZ,76))V76_*::0B3EQ:@!PM",7<H'*)\9?7^M].1M8*3!
M@$0<4C8ZEP!4>SQ2F0\5F]I\M *\\-S+ <B2%&/J?>F4GQ&LOI4,I[91,UN-
MIRZAIO><M$$QNG37I"W (0+8&0Z\F%C"NW=!\.!AUJAD3;:.I1$#$SM4C:<Y
MP@"\+>XI%0'RP4=@T??2RT.2Q_[9D2 0 FP%9Q1$Z7W+%NF8)XAPTC"'0^0C
MC9E2XN>=32&91F+^%552;U0RO=7ZMS"ZG-Y@"+ZL'J>]V\TD9!I"EH/LD= ]
MS610-"Y(5U/69$\H:V:/_4"WHC;J*#&Q>0=Z6Z9C#!5&0=<D[FE,3%,I!AF3
MYE^JSF- .765,7?TXX'#)H&]J*FI<&.:D3X-:#O\A!H'[E5?6YZ%[-JZI0&J
M>49^IO%<-3WN0&>4DD;/A?:TF35=#C[24+%$/:M]ZD2:7+P$$1F?D&)#3!9*
M+8P/T^?+DV2Z:9=Q$6-<"D,&9#!9]Z#A7#EG]Q%,84N%:[8,R^;9V!E":;'9
M7+;A\K$U+ =^1R,1W/8;>3DW0$0%0U_:.)>L-2B94K/1LD;;7%;WX+A7,OA-
M5=.O/2C('%^S38%[PP"2WUD/PZ9.4EKX3"KA4F'<VV%A+/=6LWXWK(ST_BRU
MP3T2U');4OQBU['4 "O=Q"HM L NH*)>QG#YEAXLF3RB2+PEF3//2;PBQDG!
MF=PIE0 VQ\Q_%"J/$D=H>&D7R.?>,+* GFSQ4*U0KI<GBRA'RYPN G+(#LCM
M'/M>3!::S(2&<GA(O6AX".?Q<5"G&X:,!H>U8"<TB2!(1K@!=[GS,=KUY#,6
MZ( 03-;0#Z3<!/=ACLF[^^3;.,5'UC:#:>50$#D1WYM'658-13!>(4EXDR!&
M?\/82O-%5S/8<#4O>S;#S5;3?]'%C Z./7>V.MCTJX2C?E_M+YIMRV1;$#9F
MRH4(R;820;(J#B/4@(]:9D$UF:>"?[B+P4Q&%>['@;8Q):Z(744R#R4^!@4(
M5I9HL\MF?.Q4D!R#W9-IB_<Y$[>8!=.V*VY=%BHG'T;V3[3A(P58MF.'=FV.
MGJ(^T'!SMS0;#P>5&#.6 G)J=5LUW?1AV>B\[39NX#%08)U\2H9 26[*Y&XZ
MS7RWADYSQ[LU&%.NC UJV\0LH3HE^!-<^C?";JBO[%,_E>NRJ5X)LJ\0W5C2
M 6+0:=;254QOVP:B^#+?HO-#Z4%O:BO**#=7-$W+Q[(EIE%"L$\7O!3=U&;E
MU)_$,HI9^GYJD"KY(Y(A"VW"86-IK+QB2DOL4M->E0:J\2OJ/N5*K1+/9<=Z
M#3FG_CD>/.<QJ=5"+SF[BIQ!F?Y&"B ;2ERB8W9A,&I0QK%S*[A=#_\8RY),
M^YJ<152""NX^1YV ?3^,[Z\0T!5TJ8(N5="E"KKT\M"E_CN%+O4*H4O]\A$S
M9*;NN.V6*@6Q"7U/M65FCV#4.+FR<],D8"TD:U>U I6%9%0>.*8):TY-:UW"
M^P>HO57SX6E,\.126R!3<F+4P:F@CT:_LW_'2T;VE=%Y-#8RQ8@2.4!X:_,H
M9"< QB.E$,4$,\9.E.E<K1%&7[G^U-'=N8%#,N4Q78*>L3@RZRN9MFQZ@,9X
M9=GJRYT+> RGA5+MGLM-ER!5Z9E*.R_( Z7L=0I_,96SB8#L70>1X00$OU61
M.,9?8,MO<^ANYH&(LH+327P%.>0W!;8J0G!S*8J@+)&^-@:<9_'A^Q0E^?R4
M#(.9.-<^UT;9DVY[>?9DJ1^?CHIY\;SN^%%=/JX@N](!6=FO=48%"9:-TS[=
MSFLNO'UP/*CUN_E\53K+@X&8A"B-*)3OW?H462[EPP2TE*UZ6#E1>[O#(<[L
M !$;X94(;L"G$65II$YGA^,S%R GL&>M!;NP:!M[) I^LT.X)MUE=<'=:.=4
M04T$HKML4),1DL)DS*I?R,XC_!*,R& =]2TXI-0&F_M )L\+R97&REAJ&\*H
M %D0CME])$/L9Y1&\Z%.,(95..Z,1R:'8H*C35S,J7S"#^']J:WP'E(])/6#
MY&-\V4J1A[A3SP&L-U+-3Q" J&;2^Y[>"XVDIZ2-^"F"";4*4K7E 6-T0&](
MW"-_6^Z??B2_1UJ'<#C)4Y?N1);A4DV:3;BMI9<78H< K@:?8J68TJ8K#E/Z
M*)%;5W]L6%>98[L7Z5<AENT>)!F>DPJP4U#%;'9DTH$;AC&9$U2NKTZ1,(^"
M:L+XU.0]U#(G+Z\D"9QDP^[8/@.G#"-;<-G<DKMI6-\7?+D(!C?*',^O+M$N
M^&<,!\43"#!#8I*PHNII[KZ++CKY=H*R2VWLD"O(;QEH+F]-1M@V3-P;39G/
MJ!?T-8'P!/WA9C%SHT2\=L'1JH.:JG<:G4XVUB/1>T+1,?[TJ&'=Y$"(O-F0
MLJN^1UA68VM !Y0!,$ZO034( ?[C[)$MC.C!KU/3&=7 Q$60#] WF'R!:F2C
MXE8J5<6')B]LJW S.T2ECO]SEA!XJ9;:9;##J9I91<-R#';=(V55N@<KZ;.>
MG3ZDYJ%A#R64 G=B\H/0$0H]3# )WQ,*Z9#\Y3!Q+JCM&CU1L3+AFD!;.8']
MX%G*,:6L@X>^'O9(EP6I=L@#NU0G=?95'<$M_!AX+@TQ.<M(.B&X&X2/>K;A
MH)S% ;_]0CQ8WVSW 4[_$T8U@YJ!EY_.8BRD51V\DC0<]T/C9C3X!T[+8:Z0
MD9W<^BFQ"!-T6^*W/@FFNT6V/%<Q@5).[.\P)^K5[Q'GJ36[*HN<E"B4P#^7
MH#^YA#N,QV1-*H8"/C*?A=WBD#XETE$FE9&R[I)@C'3B*5;JJ, $3C64AB<8
M(8?*(,5_.Z*1EP*Q]QB8(D7"HPSWZ"[,P(W@:964JM,W) 4.5M<4[34I=)FX
MP22>HS:>B%#-<9W8#,>:DD2HR78#G-_'S+]+&A][!U%3E(4;T)0)AM^SES"F
MT,NC-7.G6+Z/30Q"G!*,-B5'K.!=/B9W@$FY1Y?G)$4#H<SCDEE #>XD87'>
M*TQ!W/5,1]X;V9R2O[8I<JX"%(31XQ4(Y@A, C0'R#,N%4&# J#!8*>!!E_
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MMCKM@NT7"2CCOW$_J =<T1J ;VC;PT['[HZ&PG;&XT%'](48=EHM,?C?[NA
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MUM7EE_/3\[.;&FP6CHTOQE[0]@^N!2Y72(:[P3L_4*='2M(2TRE8IR IX;W
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M818EY!P%FU0@BQ7(8@6R6($LY@&RV*Z7'60QT1)M)MK03;1/BVVDI-LEE%!
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M>FQWTW)?=0KE(MM&3DX-V[@P1E6:,.Z5,7(RR"URLC]8O.V<E^/#K>Y/RN^
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M\Z:E_%+M5:JI2C7MU03EVY<#S?>*9CQ4)NCA3-#<J*A?-"HZ!1-T5<Y*WSP
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MFOT7FDBDN MWSJ8UY3%T$YS8;&-A+B*'C4U/I_*CN<T3!2AY45#C:&=F8O8
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M,#D=S5F$6\ B3=F!6'087#K']0.5&:[?D8W+X)_ #9/7HV)IP)1I6"FA8^6
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MY!+M-E3SHQXW2C[<+I=M^!H!A4Q,CID"(I/W]2?AOYS/[6=N;)'DENZ ?(H
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MD.)J@(S/?E"9M"Z&B;P@[+0Y]DR_.GV4HC=KN=20#N$<I"9\]%_G1BR*P "
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MHD.4S4,='=U9G_A8($7/?;,JA%7(I2O^^/K%8!,X4+GQ=YMO_(6\QWJIQ2,
M8LN!YE!J":&51E9X _S0KQ![ ^L;HZ(,LR#LU; ]%Q.,.N:_B0F)USR'1 XN
MR7.)PAF0@IH'H?$0"+RA@/PC-MGP_7W P%!P9"Z8SH^VF!@#Q4W57+@9/)PB
M**@&5Q25,DN741XNEV -KTSL,UFY0\O"E.P#<7=-N3<9)G9<QOC>^*FDT&O$
M2A.23L'@[J=C4?B7WML_-0?H41>%*C.L3"B/!?)5ONH?D5>]E:\J#!$%=SED
M%//M!=E2(C%R#_3B2 %]>W^GHM0/P6(C-U#<<.P'0D&6R&)D+>H?!/SBR*U
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MC</<[6%..]#8(%WLN71=4?HB+\@2?ZY/\ )5"7=O\/R>\'9#:GG9A,,+0,<
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M(!V5P9?'PB!*HP9QOC&YL.%P \ZW"B>WP#$4@;$%7X86O!-62/MUQ$)LH>9
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MGOX44[$X_#,?^")%S7NG\6R;ZR[M[BGR0J>PO-"J^0?C>X8X:"="X^&IC*H
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MHLS , 2;\>W%=L.ER#RM@G:D:;]AD +6/_<P*(,G#=_:!EJW*5Q#%WW27D$
M_ (JQ=#H WH>MX>GE#M'F]9V,"JES!V/T46F]C;Q3$43==/N)6SJ1!,=;> Z
MP5/5A+MA5(M,7?BQJ<QD^;7KC?C"*2.)(&HOQE0^$^]B6.%56-J4J1A2&C/\
MR)V#4Z?B-1+H28.;C[69-B937D73&_<L\KTF@:9<[A# [8>6Y6EF F#C/_F[
M8*P%(\94#DYKH/<1N5Z7F^QP$5YKXQ]^D,A5>'#)$B4'<QGB"VU)R/>@MD#I
M?US;TZGA\F3M,WH=V+9 CH&KP<EE/8+0SM.%W*^8+_#M=+YV(#:,?/$?TAU
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MM>A)0J0+>I)\#%]_1L,Z&83A"BY9)=HWE%9(@T:6H:5UKEV+XU*T*N].=G
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M9VEO#9!6X+-RP(.MU:B@K*:^\;X=TB=F.#M,J_>(?CLJ]%F<Q0W3M;?B+Q'
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M)&YI Q<$/"0GP0:R+W7V+O+2_%IF$\0'3+\MJO(A$75'1)S,EJ?!>Y%Y*<I
MD;+&>M&"3?.JT%1BJ)$D)WCKQ6\CP"^/AATH\B$+3><.)-+.SY/0P#)S9$\6
M =$BUEG"5'8FB2!WZD!NPPL*FG$?C 6RGNNMLT]5/P6XY\6*:+3*'9L:JWI!
M+<Z@)L3^-+@DIHT>3AGE?%#*U-A'3LNGJYS5)4.**%FD7VF7[_P8ZE&(!W@2
MU4XE'9PNW+I?>;B.Q,B]"3&#14%^J74"?%8.A':)Y2@(8NN#A,?P[,-^U%"9
MBV^Z-M-$!RQY..H+)XVP22.0"TJ(:$&M!_JT&1O&;.12!Q&[,&;NH#AL1FPH
M]0YNNS:TWJ67&$URD$@0H)B/9)?0#JU#ICVZ9.WB/CMBV_87HD.+1DIPB9,9
M9ZTA_]N1N% S=-EJ@>UC9YOY"XW9=>LP@LED1:(YP$3=G8E/P8D((J<8HY(N
M*+M-%NW5J5''JU%;[6S90[\!2;9=1,X$<*-I9F7/P',9Z%?,(2KO4*DMSJR7
MS: -=-.!<WV4_^MJ-*[^P.C#8$'HR3_(L0O]\70H%R4RLL&X!Q8JXX77X(PE
M;]NII$IVR'AKIVIED(=-K&YU]I!D=N-5*ESB69D(Y.U5E2/],EE'I_!.^Q\(
MZRBD.HZ+1*Q7CM912PLI*)D2!)8X:*8,.D14H?EBM0*^PZ969YIZR"JWC:7K
MUAI\]D=_5(?R!B<^YE&='Q\G)R'U[S5A]W@P&H\NN"13TP0-,OD ];('HLR9
MMO4@I<K9V= Z'*6;D1PV4_= ^P\Y[3>(3;@;Z'W+XW@U^*-_/KCJY]<8QE=#
M?"CEVX?0%TF7Z +Y35(H1D*5&H(E@T(6BX4KY+S<2[Z8$ZW0",QA4G!'RIIS
MT+5Q<-[&XY@>]O,+1E-#:D;.>Z8Q*)HMX&5AP)1.(K# XOT8F<89'^MC/TR2
M[E3#<ZC:YE!VD4,^?9_D]1Z'7WN)9I9A7L5D##!?%"WDQ8 7-@)/F456;):V
M]:7@:@@/FW8=:FL.N;HZZ9WXZG/0EN0B8@'"%:L[14:"8!JPV*15L3;*;9ZG
M_*!6(UW-8=;&<8./3H3)'\^^5-V,3O[$8>J-R%L/HJ#,1H&,NN;X: =!&P]&
M)A2Y%"&;!\2OCO)%<JR5UN80K:NHP<FTF(\8F?6TES/ G,C721S!F1J6+5S*
MPG+)W9;NIQ:#?)$T:Z2S.2S;_,*ASH!?2"RYIKQA?Q2FVOCN3O_R[>8C[\*W
M^M91E=-4<*?]T7@XJ2DW.AM_PN&'3Z$_&^/?<32N)TQ3$5PP[F.A(0'/)8+E
MG*:3$@*8X0R1*U]\\T5P2V,[<$[O(T/F3(6M7)U,1AKO"^,<::BCWAAG5LIT
M0.>8!A^G3)@L !<RDU6L@R,_BT:IL :D.VD I0V,-,.4W\5-RR9C.FSJ[Q4C
MYE!^XXN<MS@F>0X^XYO!:'2AN9-!* ,Q(.U%M!E!8)(@12>LSM&XTIJ?=P <
M-IG6E_4<S6]\V?)HN)Z/UCC%"KCHR<=26H)G.H-D64JF@RRQP^H?S8.OYP2B
MQ41JLU9."W H8SAX1 LB<F]9-C%BZP('B\+__N7G>W1_0[^N683RU<G[X_/3
M=Q].S]Z>O?[E]_>G;T_>OS]Z^^KL_->CMZ?_WU']P]&;]Q_.?S_^\/OYR:M:
MF>!R=)=GR]297/,YFY>2;#' 5M4BK^*HEWMA^.W6)>N;FR!L:; H$6FIJ'.(
M)0W>%P?,!B>3$\78Y@Q[%-'&L^C[MY\-I_S]#<>?!K03?JUV'-YZ)EF$#SY\
M_;%I33T>778J9=KI3 $E:$EU)7O@/C"CDG+H4F?2V1S_UBI8MN/8 [-^5^K<
MFUJ8\V0[J>GF@]-&,@51D6.N?+;U\+J $3D4F9+D:BM3=Z<U,'=&CX4\W41-
M7205W JM"9_IY:U0FEG5H&40=E1*\VET.ZJKV4:=CX0Y-=3%;EC#4D@)18U6
M"62@%@(9I!7@A+'9R%A8<S=L5VQYJO3FKLBRB@HZ(,GIN[-9D3"7$SI.CHFW
MDOR4J&C$IB"8K)E'3[N\:'UJ^OWA.\AE;*R9^[F-:XFU@Q):9U]Q>'1Y.9@<
M+4T/0V? O+$R!\\@8.&@ H_@N O <T[*".>+;9TSLQ#,P>F_C=B[R&*]#*/1
M69G%>)\-SVO'G<DZEQW91TEX8*(043,&"$5QD,%;JT(QVK8NR+D0S(LW1=NH
MJ8.\QKG 9A-F&6@=V:"/P-J-\=E(@<O08@/I;VN!N8:8BM.>%M-4?*9EE7;%
M:&JL=+&.T488E&^=";UU8CQA9^Z %RL(O2$?TM>+W_OT%7\,>V,<SC8_53C7
M6"PP:1.-T7&(3A30D1?C@O2LW(M^FQ-@_N!KMV\]-)/WH)&P.K <;^UUMVVC
M,,:+$ UCA: X$6MV>M U<]63(9.45*D$8YL'6"Q$LP/;L<.CTC9"[Y8.3Z=W
M^41L)?,9BN,UH,T;B#J3]RR0N61BC?M^48EXVZ%,6\5T>R3U;CB-59A@O7!$
M:IN0012<?*U$_E%,0="/G"VY1R:V;WZV ,NADF-]@7=1'N4&U_& +"?ZUEDP
M2\+>5\QG=U@; UI"I4$+31+PDH&W1&*ID47C/#GC'2XG3P,\5,HT5DT'I75G
M08"C&>"["9G!:I>L*T!K'EG4*1>(RI%-1A9V8MS[Y%OG\3R&YZ!8TDSP'13!
M?3<<),0\>DT"N09V6F4=+M]=Q<M>.BL%AY."]2(0'O*TK+6T"49"&S+3P'0I
MPA&E4_/[CZ7!'19=.E%)!U5Q'@2''5V-/PV&O?^N:1HN>V48!U][YQ"A"1HW
MLA[BNE TV5&I\R)_-W .BA^MQ-Y!F9N%6; W5;XF_EE%QU4T(!4:\O9)!C6^
M#PIWEM[1S.76)NR2T Z**5VHHV'=FO3UM@%U0JL:V4E?L8^CT026DQ&%=@%J
MY1RREPJ'D&2HQSN!5CSRR/!>--J<$[#'GG 0RFXIQ87E8UI&P_YZ=OKVU^.S
MM\<GYV_7#G6=]R6;Q[$^"6T[0:K">E-XLE"\XZ"XXA#1$"L,C3]D,@Y8\U"3
MYQ.DFIW2"05QN=;64ADU1)8\.&F]34KSH)J?J!Y>D.HJ'.LT2'45=>Y_D*K(
M4=C ' F3U6@(;B F+FA(H@AI<O#MDWT/.DAU)7HL':2ZBIIV$VZX#,(?0:KK
MJ'/UN,-U=+&C(%43M.2U3FZ.I?:MI54]*P6A%%EK!PDK6J>(/;L@U8[)LHH*
M.@U23=%R)K.L)6\UJ(0)/&,*DDVA:&51F-;Y$GL>I+J*9A8&J:XBUBZ:PH?1
MI[I/?J7Q]L>CH_%U/YAIZC)MEV2]&?+Q:J>1NG6"LQDA1%TTCTXDV[IFTN.(
M]L['WL3P;2C\+N*7OTRNG_H?;R4T.ZF34$&!S$42)$7+GHL61-)!UA[9-K8.
M(YL#XZ!(L*F8.UCT[R:Q>]K7)CN:""J#\CQ!R)JPF4 KH*T]TP^L8$"'VEY?
MM!V$ A"8N@2]&PZ^]C+F7[[]/JI1*]\9>52/_F8]#54A2P8=9*9IS$E:<*)D
M0.V4+>B4,:TO8)9'=V@,Z4(I'40 K!:NX NS)I0(0==DKJ0\1$\^>!91<QNM
M-NT;2S[K2)*-CM0Z4\W"H(&69_KO?__MMZ/S_SQ[_?[TU[>GKT^/C]Y^.#H^
M/OO][8?3M[^^.WMS>GQZ\OZF5L]IOPR&GR<C7/L*H,$S-[\Q:#WP1A<,Q*%$
M%NJ,0[W1+9:6DHS4KH!,CKBCG86@&#DQB1FE6?*E>1O/Q6@V#T&X]\W30\.8
MO)<&%:VS3( *-#5\\1*BT#H4@\'*UF6RYR/9UF%_(WT_##786+S[<F3_8"B_
M?/L%^^G3YS"<'@L%YIQUP8/GUH#"5$UX[J'$+!5ZE8)O7?OD*4R[.L!OH?:G
MF+2)^#OI6'H?WS6ZV>'1,OBZ2MA[ MN.LO:::O1)NC10QRYH8X)-O)##&$H-
MZIRTUG0^@"Z9\]IQ,?#6A["[H<M3N7P[9<LJ6NB )>?X%?M76 ,Z"2KA3.-_
M],:?CJ]&X\'G[SELA4F!J -(%!%4Y@J"40(T3U*56%S,K8V6I8#M(&6PJ3X'
M72NC@Z/<HY1J.Y#1U/VKN^_U[4/R2=042>MK$W%6)%ES(0-CU=6LDC"^,4D6
M83DP7C01^5:VF&\?Z)].Z^TH:S6/";A$"ZH(6CY9<6"84P)5T$:W;EK[")S#
M-E?7$GH7524>C);^X74UK26@;<M(O8&U-_;I>BI\TB?>3/[;6#)N090EUX3%
M6ML:)QN;F/:7PJ!I7TL>>6Y?1'C+U%C=%NV<&:N(O0M&S*R;!Q!G>UP,5@=/
M>UR,T9'U;0HX;3TD'P*OMQ96M[XR? +2'E@7ZZKO/BT:RKZAJ3D:CB]^"_\U
M&%[C&TTF0)SDHIJ: >)J"H*2M&M&"S&DQ"R:@'HI Y.^_A8+Z+<;!LQ_\@%8
M#PU$VO#6KZ*9AD+=P31C]#*@5C$5GM#W0B#;-0Y::&C0E7@;KON/@\O2">,8
M E<U3LF:5..4R%<BS,PD:9A8JD; ?NE\P:Z_-96O(M6VQ:.N@9SUKWW6H@VS
ML5@H-!A0/FKP0=-@<\G>94G[V;UCQSFI<P^^=GM[<D-)#QJ)J?'6^VXXR%=I
M?';=0G%V"(HY^AP!!:M-,,@H"#G;&J::M;%)<KZ4/__$Q)SW[ /9?C<6:\,:
M"[?PC([Z^;I7YO<;C*=!-=R %P+9_@:\N8X>*KR1@!MOP8O!H1,\<44.A9"9
MEC!&YG^A'X6+DC@W4MY?H)^#UA_9@K>D]%7DVD6*SJ?>ER\UYJ^?_SWT,WWL
MXVRKX<4CTUF#E9'LC4*[5TB&0>!D=5CN20JMCVH7@MGN/MY(60_Z'[:0=,--
MG0R,?\=P.?Z4PA"/Z:^]%"X_#'OA\B8 =(90.&=C9@68(--%&>W!I\(@^E#W
M-Y:$\$]:9TL^[#GKNB.1=C'O%V:;\>A-,MR"4XILU:1YO9+B4# 6S6MH5FD=
M;K=W"<$=7-"T$7@'19&6R$-;!N&/U-YUU+EZMN8ZNMA10K@,3@83@.5)<PR1
M(7A#/U2*UM"&9T/S]E?/+;6W8[*LHH).4WL-6<U688&D;3VWR *BM!*D"YFI
MY$3FK3>5_4[M74DS"U-[5Q%K%V6CQV$\"7J>UL&HC8L'_4F>:>4VT9I;+SP8
M(0E<BAZ"])&X77)()1=56B=T/0KHD(R)9H+OH*;>/4S7D4Y+@.K(AI@+:$=F
M0SO%#;J2>@<;P7QPT2214]1$^<#([PT!'-(.&*5RT2 !E*WK8FV1"D_9!%MF
MPBK"[H !"[K>S_:QP*4613#((JAI/<=8:D1!2DQ:YTH4K<^:'@6T?9.A@=+N
MAX<VDW@714%N2L)>'X(QFT)(&JROVV'1D6QB;2'90#NAH]?-.ZD_ '$(:M],
MLEMM2J<]DSQ+4<M/9 )&$%UMONE=P.0B9[Y]TN.^-:7K(A2XB< ;ELU]%-B,
M\LM ^]%>;B4%KM!&;!WI;[F]'+<YZ< 9('-D$840P0N>P?'H::TL/)O6Q1V>
M3WNYKGBQBM"[;B]GK<]9.P^YE+HDHH:@G -MI"HLRLSPZ3NH/6\OMY*\'VLO
MMXJP.C#OEJWCCDZBR8Q#D280S$R&CC+$8%=0<E,LIN9-7/:UK'Y'%1&Z4,4V
M&?-J\$?_?'#5SZ\QC*^&>-I/0PPC?(73_Y[VIS;TT>>:#,<O4*;@6:!QZ&S(
M<V:!9*4+:*9#RL$%G5N[DJVP'S[GNE1FV_UGXR%,.YU<\!1I\;8.D!RWFN#I
M@3PN RY$;I1UVFOYY*[5",RSY]>.]-)%B[R*_M/@DKYM-,55L[R'(YQVR?ER
MV1M?L""<+5P31*EKZ;YZ-^@R)!6CMP&+9LTKLS\-Z]F3J"L5=%#^[O5@B+V/
M_>,K(GP_?;MUB_@K":[6=_P%"WWF0_CS@@==(L\(3-2E4EH+WB0!T9=H=)3)
M\M9IDBO .QC6=*62#CKE73>,_5[7\?VT,-7H@B4D/Y'\PX@,JW<0(#IM0>?"
M4^:<Y]2\WNHB, ?#C#;B[B# ZQK8.7X9#,?U>/$[,L&3C!@3$ Q/IC[2+FBE
M H,^RJ %M\U[?2]&<W!,V%#@'5S-/QCP.QS6-\)'Y!=2<DX>GX3 1:HTK:&O
MR8#7RI.E)#@3S5.J'\%S,'1H)O0NCN3G%!0Z&HUP_!;'%P'1^A@%:%E2339C
MM&XY#KKH5%R,C,76!NAC> Z)$&V$OK#[W2:$&(W/RJ^#0;X=$O^>S.0+IPVG
M?:Q (<.%7"83(0H7@2NNLU2%V]B^0^HB- =$AB8"?T@%OWG(QL2W'I$I<_+G
M%^R/\,)QX64( 13WO)Y/$SDYHW$'&ZVW4EILW:O](8J#4?V& IYSX+7Q,>PY
MCI"^\1-1\15YPY>#+Y,0I1DZPWQ$DS0D7?MQ$E"(QCL0TM+"Y(PU'13\>P30
MP3"AG=CGD&+S,.[/7T)O6!&=E3>#_L<WM;[[9,,:_3M>9G*)?R>4F<64I&*0
M:VD8Y;0&SWDD29B4"6[MY=PZQ'L98 =#DO9JF$.6S:N]S;O>O/:(WF.Z&DZR
MX([#Y65M/3'[W&CVP1'9/];K[!7M=[6'HM,27!((Q;H4<_)$^=8NZ8:0#X9@
MVU3='.K)775YN#>9.N[OL.!IV^KLL,Q@&_5T>#<<?"$#Y]N[2Z();6WUE'VR
ML=W0M4:V1>D0O.7U&L848JH18*V7@F7TK+3N_O8TJHTO=](GS%<U!6CALZ91
M?LA]$#PG"$*$VB\V@2N)3#[)-%JF> ZF\>B7Q;:M/A"-.?+@DJ<+5>Q+AXB%
M0[I5'C($1RXCJSU]4()B/ "9 !:BTEI%G2+#UB;[$K!VUNBY$SH\B'YHJY8.
M BT7C_ZF@N0R$#N*R%T"WFXB<YNK=EGJ;*B775%(*\R,.2!@95KC@AQ7 FT=
MO6U-\*'UB>'.J/-$[.Y>,&<%=73 F-]"^D2;^O#;;7C7.2J&!24E NWN!$A&
M 5YS<EV=B$6HK"QOW?7U$3C;]^B:JV_0C>P[B/P\*Z67\#XHBRYJDPR$PCC-
MA<3!1UL 9<K,2,6R:MW<:BZ0PZ/"YO+NHIS(H(S_"$.L5R"SE[<.0NL=R77=
M).FU336.0BNN"&AV$#!%2)P7AMY8'EJ?#RT-[O#(THU>&@94UAI>YZ'_<;J#
M"LTXM_4VW24'RCEZ)8C/3$EMN4Q&RA9%"K\_\"#]F/5%VH5>K\NE+0&C8?'1
M6X_>?KG1-85_7WT;2*YQ5=';<))%5(482<3T0-9%H(W&D_%AD:M(5FYP+2H&
M=Z[ 1RJ'MM7?*@)KK+??2%*?KSY?%QMRV7*O"Q@7+"CR1L!Y6E6$LD(R*YU<
M+O[CJ48+MQ^ZW6*0:XM]T$)FS5ME_'D;"-EU64<'B=5Z4\@E..L-"(S1>I6]
M+TN= S[9)>//9ZV\M66VS1.6WT=8KB[?] I>.%T*"J\@I&! Z1(@DBE?FU!B
MS(IKCJUC-I> M4=V<)MKA-:JZ"2!\DF(KW"4AKTO51-GY0,./Y_4>[Y1S9XZ
MZ5]]QNE]\H4F6]V3<0C"6?(2H@P0:*VJI8B*+$(ZIEL'>34#_Q*9UX%:%ZYF
M+2_GST_^?O+V]Y.CMZ]>G;P^.3\_>35[9];P]%5O%#Y^'.+'"?ZU;^77>\SF
MU_$-AM?H'O[NDVI>P@3 #4$C(G/%66*DBC4K08&O\8?.6,E,ULRKUCU:G\*T
MZ7*XX/NG7K&*3NI:6HDI1DMU*1I\M<J,*YF;Y+5CK7/E'L.SK;OVICRXOU U
M$_BN;]<7]GX06K'"G (;Z^E9(:L^UJJ]F(/1,NC PU)'TL^HUTT[I3[5\685
MX6ZMY\DRH%Y0QYN5=+14\Y-U!+PU[==">^0T(NB:N:L$5Q C6@@Q.VX=P\(;
MSO=][7C37NFKR+4;M[H"N[ZVL#&Z+#QDP<C'US&"<U:#T]D51@:R6>[&8#5G
MYP; OG0[64DI#WV4-27:14WRZ;BN6]4*9#Q8\L)%)/:*1*X7L1FR\D6@<%SJ
MYK>%MP$<@GK7EVCCI?I[R>1?<?!Q&+Y\JMUU)HM4S: 52FBP(LE:!Y\X)TVM
M$X1!%RF#XDL%TCZQ5"\$<%#V61LQ-[X+G&70WX8TH_8RH!H::0N!;-](:Z2H
M05=2;CW]%X(S(7%?NV<H9@,H:SW9*)S <8>UX;EGNL6=XI95_XBEMDW-KR+<
MEC78:@6XX;>+W]]?\!Q54H&#\8;1F"RO/=DL6,VX,U*Y_&B']Q&FOWX<?/UY
M]HU3#<]^N5'PS?.VNV<W$OQ@(ZEU8(>]'?1_OXX-2B[JI&A+*RGX6D:K7I(X
M"PE=Y!X#^N4\J16LL%N/?\[ZW%2:'?A/,QOC-8UZ7B&+DS_3Y56N?2Y'(Z3_
MS[42EA;6FTE<&*\A:%X6<(9%\,S&'$VFM:I]XOC*,+=_>=3IB6S7BEJX:&SE
MDNBFO<5IOPR&GSNZ)'KT,1U>$BT_O&U=$CGCB]?!@:2-A1P_'<#;XD$GCS*B
M42JV#C78Z2619]%RYXC[/--XO1,0 I> A@GGC*;ENG7!^6=Q2;0*#U:Z)%I%
MX'M[2618,DFF"#IG7JVN3$YW04B\8& DLAR6NDH]E$NBE93ZU"71*L+=WC7!
M$J!>T"712CI:[KY@#0%O3?O:.^1<TVK(.'E9Z+#6]E3 :264GKSN&)9*7-LO
MK:]Z2=1>Z:O(M8M\I#MGW@8%^E(4Y!K JZQG$)BW(+AP*<>(/K7V7_?R%F$E
MI3QZB["*1+L)EKQU8\6X3]DI\J55\D .D .'3(&,Q<9(W$[-PY_V\@YP$_6N
M+]&M71)%[7W.B=5..()\:5'H53' E$U&9Y.B7,J!.:A+HG7MLS9BWMHET3*@
M7MHET4J*6NJJ8!TI;^V22(;L&5H%M+=(H'5)0M"IIN+0:F<M)G>_?]AS4/U:
MET3M-;^*<+NY)(H>(Y=9D@F!JA;2-N"9T9","S(9955YS$9[KI=$*PG^X271
M*E)K:(==(WA]/C,51*1',C(52HX00Z#Q""*BE3*K1_MUK::WU^>'H+<5I=;!
M?'MU<HT@ =%'@-6%0ZSI+4C&'AGW%KU]K#C\:GI[=7((>EM1:AVTG?K0^]SK
M?SPKD[8UI9;UK(7'[_KRI106!#<04IE4'6?@9+UWJEY:C$'RT#K]:PE8!V,\
M=Z6*#MI//0%Q-B.6 =E1G;BE .ZF4EQS]:Y&GPUTT\%IVG)@M2F(M59)LMK5
MT"6"G9,G[)RE:#!PT?K";8<$>J)>W'[P9Q65=,&;&;@AYK.O."3,U^>'5O)<
MA$)PF=5X9BG Z6*!=F851-)6L=:5!1>"V7[82 ?*NT^/)I+OX.3V%K"C\;L!
M"?"T?PM=EI$KJ<@NSJHFX7N:$H%^\)*]"2P7<G&[X\4<1 =.CDUUL"?Q:25$
M)92/Y#^%3*0F3\IGQ^@'2F<S><FN]07/8<2G;1(,TK6B.EA]YN%\TPNQ=]D;
M?YOV!!U?%*6+UJ4ZAHQD$I,%E[*'6#S+.>:BPS;:IMW'=6#L::Z*#I:B1S'.
MI'&.:?"QW_MOS-/# =I;@7E7P"K#(=:;N""3U+R4*%)KSWLUA"^)0INII^'9
M3?IZ\>MP</7EW=4P?0JU6=C9\&,@2!.1O$8<3<<Q WQ!*Z1D(7! 7[??PAA$
M[POH+*42Y.L)=F\OF]-Q?I4G'@@KNI3SPL.9EJ'2;\\^G+P[^L^C7]Z<K!T'
M/><[-@]R?@I8HPCF<[P,8\SOPG!\NR_W#2MRC#IPU$!F [DNLM:XYCJ!$\6H
MDFEWX*TCF)_"U*[5S((GC7[Y=N<ODW/+$K/TPG$HJ?8(DS4U*!L!Q=&[(BN7
ML777G;6 ;BOFN2ES%K>@Z4I%NPZ&?D*,]\8W.;K*F@0G&0>AZ\EY$30\XR0P
M88US)2GA6C-P>72[K^K<&5,>N&"=:*P3K_X&S^P(8QE$'5T\/$2SFUN&KO3W
M"$TV$/YV:"&R9R6+VO<0/2@>-+E[U4)+F;E"_Y<Z:%*['3H\<6>P.S:L(O,.
M6'#:_XKDO@VO2Y2P'$SR#HP4;EKLQ*>2 '4IP0BE4FE] ',7P?8]HDUU<K_5
M[/H"[:*DSU4<]7(O#+^]#W5W?#\>I'].:%R38'4R'M#4&S!D]3*"*1 J9E>L
M(G^L>0/%16!>CM701A\=A+?<@O,V?,;9'<A4"K-9L0S"CHR&I]'MQHAHI,[[
M).E&%UWD^CR-5.N"1AH+Y /6(G@N@U>,04&4R$6)JKW#O".V/&%C[(PLJZB@
M"Q/CW=EU^0TML%CK0&I#*V<J&D*1$H)!>D,)XUAK+GQ_^/8-B]::N6]HK"76
MEI'(7R_>?QH,Q[5N^BN,X[-A[V.O/ZVV0%OF18P^6949V(BU+UH,$ .WH%7V
M,3DEL[IG8<PY37_L";NU%9N==K648P<FY((Q'WVNH;FC.ZR^"(XE3$E!L:QF
M1R@'3EKRC8SGR6?!>6E]#;<"O /A2]>*:1GT_G41RG-Z\QT.?QOTQY\NE#?2
MA<1K4+BH'13)20J*ED$A4*F<2M3YR95BB0<=" $ZD&JW'L7MC:^N:%EFIFJC
M7B%K32\;:N_,;&B!B\PHXVW&YDGA"]$<""D:B[V#F/@%PYY *X)9$3! $HFX
M*K& 0\&@GK0%HYRULG4 \R-P#HP2K03_D!.JI0-Y545$OWP*0QR=CD97F$_[
M=S:QB"(X:\ ;X\A-JM&1)I$,HO?2HT:>6Q<<7P7?@;&F,]4\I)'>F$;7]O/;
M0?^7T/_GFP%!.^KGMX,QCMZ%;].&KM&J9'@&+E3=#X6LG>TBY.PDAD*[Y7)%
M#%:ASQ*X#HTVK57QD"ZFA<>Z %Z]S)\LC,:CT<9Z2,$JVBP)I[>T1#HFK<@Y
MJY#5DS;ILD\[$ YT)=^'%+ ;'TK1(A;ZZ?LQ7#__(PQ)#N/1Z\%UO/_H;'A\
M&7HD#.$=)TNI)BJ:26W/#$%$!*=*,$Z3*<5:+QTK 3P0_G2OG(=,<NVC"=^<
M'+T_>=^VRNH2W[EYM.&JP!M%'[ZI.0KX!L/H=D/&6U3*JB1F.214"91F%H)%
M7V_<6? B<JU:AR4\ 6G3U6?^U\^N%XT3J9X)F\SK<9\@.IM@:_]<-"[*E%/K
M/*Q'X&PKCK E!^XO)ZVDO>M@P;L-TE,LUH480:7$0 4>(*@@:K,IU%IR%\U2
MWM RW>!W>4G?3'OWF\2O+,7&]9;N=-U> D;#(ENW'KW]LEIK"O^^^C:07*>*
M)"82^<!6'BJF(GCO))#I0X:N8XY'^1P4^$AQK-;Z6UY@C?7V&TGJIF5]EK(4
M$P(DQ1VHHCC0"E+ &!Z-H0$*N51GVR<T=^>AVRW-L[;8!RUDUO!J<@(D_'D+
M"/-:>6$B/;D>8VHO(2:7 9FW061IM&HQ[>X\]!DJ;VV9=1 6,MW7S[Y,FJSW
M/TXV^'.L<KC^K1XC7#!#GB+Z3 !KB(1EB5!F!)N##MYI[9K'*2Z';/L^=_<V
M<E-M=!"+,!]E'_\(EQ-X.F@N/6;0RM1=B3EP-&K02!.%9@:1NG4YXB<@O026
MK"?_A4M*RZ.8X[/??CO]\-O)VP_OC]Z^.CY[^^'T[:\G;X]/3]ZO?12SQ'=N
M?A2S*O!FB: C))5\.NKG5_@5+P=?JL-Z5 _?/DZ<V.O$[P^#=SBLIT.O!\.S
M\2<<CFX8IF7.)@6L]T#$L*P91%,T(,H8E-)1J-;W="UPMTPH71O-U*\5+#OF
MHZ-UM4I0B@C!<=J:N31*.YIEOGGOW6;HMY=ZNF6N/I:>ND6%[_H8JH'\?_GV
M@1XR\2%=$,QX21(OED:.QD'$:E9@$ (-SUZVMN^: -^'G)5MDNY!3,FVE=])
M"N3Z$J1'S(*XEQE$9\FT#0:PJ_S;K1.H'84WU/[>4EEBJA:\!,R3(P%N(&8N
M@.F08Q;"26Q]][3'%'XR9_@P&+R*TCM@[JQH$+X;SIR@ZDE>-^P5CD X(T#[
M&$"Q7" 4+L%JQ9)-+&!H;1T\AF<7<19;5_']]D2M]-,V]6@#P=Q/L-'.%"0A
M@,\VDG1D!!J2GQ0K*\5$[N^W6)Z;?M *S[,BV6:>U.[TV$FBU-HC.1Z,QJ/3
M?JJU%_.OP\%H=,%RTC8'21,U:U N<_!H$5@R--5*P9R7NH[:SE;\<  OB,6[
M)T#KE*VUQW%:E1PN7R->1%ND=9'V I$(OU*L!H=[,%G;B$*2>1.Z7%5OH+P@
M*NY$>VTK=C;!/TV<+4&70I,G:T-C$(C@H[/ DXWTEI#R_M%25PS\L:UO1XL-
ML]8V&\.=]?PMCB]4P1*U8* 3UI*GRD#@)$8968Y2\&2B[I*+]P']8.,V--DP
M8VZS4=!DHC$,ZWWMI!BS=ZQZ:BF S4I#E-)#YCH&%I13^8D;T&98?K"P8_UU
MD&LW?Q0G?W[!/H'S,:5H,8(H7I'5&C.$;#@P)Y73.EMMMW.". /T@AC67D$-
M4^^NP1VE-+S"?%TKOH>CZX8#66).R W84L?-:TLF9PMX*U5V3A576O<E6@CF
M!;*FC6(:9NHUV+;/KL:C<>C73B@72DMK:]!:-B)#S6X'7WBM:Z^L)2F9Y#O=
M]>X#>D$4VZ$F%^;[K;^"_3KXBL/^!/YHU*NHTDU$W/4J.VEX05XS2"Y\W:,%
MN)1H"GG.A"PQHF]]>K<,KA=$NL[4]9!2?AN4^MZ2_*R0)3CXC&?#X\'G+T/\
M5*\KO^+TS9,:!CCJQ4L\Z5]]GGS#H#\=GN8.ZHDB+>,TQBBD A$$V8PJ,Z9;
M)U!V/*0?1-XI2>:<-[/VP;OOSD]>GYR?G[QZ_^'L^'^WS:=>X;LW#^9==R"-
M@GH_X.<O@V$8?COY/U>]\;<;.L82F+8*P2CO:2=U"J+S$D14C B*/&'K:M^+
ML&S<W/+N]_[R[?@RC$;7A;"FR:).B&*+(H)CH!D8(OG-.@+:DG7,,K>O__(T
MJFT%RS;AP(-NEFV%OB^!K=]7T=O#F;8-]L$:3B)B4G!RA5B]:ZY'@>0@.8U1
MHVZ=7[(0S*X"4%LK_7Y0=1/A=]&1\!:>ZQ[A2R#J*/+S(9H=54!OHZ[[[07;
MR'H[+/ Q>!DL<3PF6;M%) @!R7!R,GJI+)=IJ=S3/=3^4Q7-MZ7\543<19E[
M'/9P]._O2'F3ULT3:-<IT"[[1-8R<,L9J!)K+T-;0"?C8N92%=;:TW\$SO;]
MHDVU=7_Y;R3J+CH83T<Z*T5U-CSO??PTGM9!\+)8M#7Y/6=0GM?"A\:!E;[V
M!))>\=9'UPO!'*A9T$;X'90YG@ML-A&6@=:M?3 /UFX,A48*7(86&TB_.XMA
M/D1E Q?*  ^BUJ\3!F+2!J0I/@>5"X^M,V6W3HPG;(@=\&(%H;<-K/R]3U_Q
MQ[ WQNOV8*@4=\%GP%!K%R(KX#W/H OS+A1I,#U=9?3!U^[,"MA<WH-&PMIJ
M+[64C(RU&5@V6H-*3D/DL4! #,)KJ65NGJZ];[W4NCX6:"+\#JK:+]'E9QF$
M/QJGK:/.U7MAK:.+W31.$[PP*1.'S":I59Z#%X(6/YUR,%IP[9H[EL^M<5K'
M9%E%!9TV3@NTV].3R8]FEDPA)1TXGR*0P^N9DCX*U;H]QGXW3EM),PL;IZTB
MU@X,BGM;YNWN"A=.8PZ<98C:LMJP28$O/H)%]%$I8>AOW5Y6W8:S?0YLX[YJ
M;8%WSX5W87@VG!ROYK^'RZO:U&F"]@)3- P-@\@T4=84-NN<8%Q2C!;#Z%O?
M0"T)[3 YTD01'>P-]V">8Z8WJKC?#7OI!B5MCY%0:9 H*ZMKA59->)F*F:'+
M-KG8+5T6(#M,MK100P=GE ^&3O_)80JSGK-C/]4VDUD)(0/YU+G&)GD-7KH$
MV1'/"V,NA-9-V9;!=9A$V5P%';BRL_8LUT[[=1>.20#N!<;,%;<:4%I!ZQUZ
MLIJ,!V$$V4PZ6)Y:NR./X3D06C03>;>]V1YT$HQD#1G,8*/FA$S+2EE+'IC,
M-%[I@FY]Y;U/#1P[H4(C<7>0\77W,O9XT/^*PW$-'YV^'%W#1"%U8($(JFK.
M."U9M0]UA,1+M%SSJ&)K+W5): ="D2X4T4&.UUPWZ^AJ_&DP[/TWN5HFFE""
MCL"1U=9?&,D:(E^>:T$"*%)@\_JP3T Z$'ZT%'S;3*[[P\6/(7V[8>UYM80N
M,I*3'9P$$H$A>(Y#1,4A1$%['Q9>EFBYM\R3GKFZNY!GPT2II^'=<8YF'24N
MHLC)<1U !TT^DI4:@M4*$N%,&)4KEFVJ_7D//G@R;"SMAAE/JZ*=-JRX8)YE
MVKL4<%=O?I7)$&N9>5Z/:Q-Z;_C3R9MK//B%<6,-:2_.!%J+'.^&@]$7),OW
M:ZTWF!#SZ#7)Z-HOFI6&>7<5+WOIK) QU.M_O*:T4E%&)^K1"B?O.4@/WK':
MBP U*X4[P>*3)-D P/,GR[:D/X<TFX35W!/#J][77L9^IDVP4CN1?QT^XH55
M7&5A(S"M:,43RD*TEH$NWG)C@BDBK;J&S'_4\R=">XG.4?DF1<*N.Y+_,@C#
M/+W-&UT$B48B;6*!!S)O0XC@.4?(W-H:'Z2#?-I^G/?-SU^A&\MKCOYDUQF?
M=]W=1JF>\[^T=8[G$M"[3NXLI1X;<;+YLZNGAU6[M'G7+ML.2;.9Q]:EDW>8
MW)E8$%$Z#R4Z5H_.:;3..I!18LY,L<);UQUZ!LF=JW!@C>3.582^_\F=&9G-
M10;@0DE07GD(JF;H.Z5+0%IK=>OCR^>8W+F2TI=.[EQ%^-M)ZUL&T8M-[EQ)
M74_G]ZTCZRTE=UKE4/%"EJVN*V@RX$5@('SFLI@2I.XH0V-_DSL;*W\5$7>6
MW'DT-^.PT*)&_R,/QU8/A\6:@N*J\9WJ:3ECL7ESJD?@[$=RYRK:FIO<N;FH
MNTCNF$#[90;&UJ/QVLS")^5 11:(W-F U-D6C=R6YGU$[P X$$VO(\[.9OCQ
M7-I9[IC)"<&3MPO*&80H"]$.G39.9_3W;QT::7HNG /1^^:B;EM2?H:*S\\J
M+VB(DAFX"@&4<@H\%Q9DTD'4WDSI?J.-.:=&CSWAV2JUI>2ZR+R:8'LU%YH4
M,A11(B3I.'$MU14G99#<,$N.2RJIFXU[+IQGRX#6HFY;#WV&:CXYN:QM?[@B
M(U5B;5?.@21@@6DM?0[(<8DKP\>>\&R5VE)R#:/-;F")N;"<D%D$SH$L13(0
MO=<UC=B!-$8K9;7.ZNDN78\]X0 4NKGD.@@'FV([F;^%6!5T\088.96@K-%D
M(V8$5D3(05C:8)IG3B^&\VP9T%K4;8._IJA>SU]M4)L0.0]0;(U)4V0_1$,_
M,!NI/9D1>#^N?.&TGO^$9ZO4EI)K&]XU@S5_M4$=:: Y@BV9ANHT&?QD*0(S
MAL52K$S\Z4XWCSWA !2ZN>0ZJ$(]Q?;K?)O A!KZHR$%JVD+T;YV'Z$=A?8/
MEX42JOW=R&(XSY8!K47=./IJ!FO^<B,E&?C.9=)437BT]3BG5DL7*2(C"R-G
MM>Q"/?\)SU:K+277,C3J+MOFU]0KTH>"08.P9!JHI!@$'A48X5DN6K!H6Q=%
MWOORA1M/[,U%W3)<:MGL )W([<LHP/)<ZS0Q <Y%4^.+E&,B!G6_1=T+2LMH
M&$FQD>"W58;B=L,5(R(+* 7$VG=1J9C!&_I56IH0*083;<=EXA]@.F1FK"OZ
M[JL,S,]:+IY61H\)4)4("E.N:2:*_,R2HB'@1K3.#'YFB>,-*;*Y"KJO+W <
MAL-OQ-ZCSX.K_OAH/![VXM6X!@]]&+P+DYYB9,L&7[@ PV,UB4P %R=GR,EB
MI(W0N(Y3 )\&>9@$:JR<A?<Z+<."C\]^^^WL;0==8);]XLW#@]<:0J,0X9OZ
M:6?#*0E^0S(^\FG_*X[&B#<\2UC+UD0'3%9+1/@(3C@&.2;!T;# 5?-KLV7!
M;>P%I4^8KR8Y]D\\<AKG*%G1H5Y7:X8T"QS]B,4P8,AR8$G5FN.M9;$:Q&V%
M%W?#GP>N4X?ZV9O@XX65#)F)1>@DP3I)HPFJFGSD$ABER =0/F71/ YEWTK(
M=LJ I>O)KJ*)W50&70;ACWJRZZAS]1*AZ^AB-ZQ)BB5?G(:0G $E"6Y(9-KY
MK)7E-D3)U8&P9>UZLAV39145=%I/-G(NHBP,T-7*$"[2.#E:8#[DZ$,*P;2V
M;?:[GNQ*FEE83W85L79PD'?V%8='EY>#\:0#Z*0,X77H):D#<_;UU+G4 %RR
MR[)W8,BO=-:IZ)I7W%D(YN#TWT;LV^H\,JV;K5V6G$;JTB0B2)"';V0$U**@
ML#*B:AW?OG<-B[9I;;;1Q+:[%RT![4?WHI44N$J7FC6DO^7N11JE#T+7>NG%
M@K*!%DW#'13.5")+*GK64>/#Y]"]J"->K"+TKKL795&K ;D" H6I$6@,O#01
M:*.37 B!+#U=LFO/NQ>M)._'NA>M(JPN$MRNTSEGUP"#SU\&_5IZ=LI6EHPU
MTH+4M:P()W/%(4.PUF2T"9.0S>-P'P/T$HR"=AKI(+GF'J;K36D)4!V9!',!
M[3@M?G/%#;J2>@>FP'QPB):S&.LZIA4H0@$^1$[NDS7<6"6]:MUA8(M46#9'
M?DM,6$78'3#@YN;R7>C12G@<OO3&X?)Z@V/,*%<$.&YE!8?@O%*0.,%"5$(V
MO\)X%-#V[8@&2AMT)?$N3(K%%<NM)2O7< _H#>V+D4RG*!T#4RQCWN:BVE\D
M[U&!^"W=F+:1?P?,6+90N9 Y!DWV$IH:MZ3=A,JT0NK@N2N%<]VZY\C>5HS?
M#F>ZT$S']UFSTH6WNW6=]F\1_D(KSQDGW]HR^J&<I@66TRIKG+,R8'&Y-(_4
M6 '?H5*I,QTU+OYP _.DE&EUVSZ.1M-."3Q[%\E$LXK%6B)=UAUT8J)YG25R
M'Y\N"OO8$PY-^2T%VFTWWKL=N((W2166@%E$LL4#!\]< A0B80XN&->\HL\"
M+(=&B::R[Z"/T=S3O>\K%J:K(8D?1\?A\A+S+]]FGQO-/CBZX-)AD972HB;D
M8=1 ,N)@$A=.)J/I;]LXYEX>\J$R;)N:[*"/TC6>HWZ> KJ5Z?$!AY\OBN3(
M3 Q09,WHKDF@03L$[0(9[+J@8ZU#=)["=*A4:JJ+#HIFS*7ZR9\X3+T13I;7
M[W_\SF]^P0QF+V+=<Y&31#" HR46R/(R-F<1T&YEJ7H*Z*&RJGNMM:W,\2C>
M:L\]A'L162PAFPPH8YT8M)Q&IA*D1%8Q4]H[?#H/?(T''QIGMB#^AE4_EEDW
M?POCN@-_FS@"*0@=8@B0ZC:K&#/@T!1 [@P/.:<L6V<%+HOMT)C4J6XZ*#1R
ME/_K:C2)EAM]&"PXX9Z-9=:<72HGM$@<9&(!ZE$"N*")^3HFEJ5&3+PQF58&
M>:BLZE9;+2N8?-^%!Y\_#_I31W11^_;("D?'-7#/:JOE0E,@!@6F%(Q>6>:Q
MN:7T-*Q#Y5!KC711)>46Q@<5&IB0VM:"';:0NZB"+T1F$0!%$ F=5M*UOLYZ
M!,X+8,E&&NBB>,H#;+>K-$BA8[2H(&DC0$GA@#C,(2A3;+&!F]@\$/(1/"^&
M'^OJ8'$SJX8$F6V&.69CBPFTK$E:UARO'?*4A<Q#(6#"">Q\Z3AL Z6%Y.<P
M0G5:Q^"7RT!PTR=Z>S3-&:G' ]50'V2\;%'08+DG-*ULL,:@6I4XJ(K_)8PP
MU^@;[(_"E-EDE7Z<!&C]\NWF(^_"M_K6T1]AF&\HF+4HBN@'C*M).<T$(8<"
MP@B9:.<)*8K6-T0;HVY8%.$I+*-%8&9MH22+I@JMA"J^H J)CPPYCTZEG 5/
MNL-R"9N!WUHAA>VR])$*"UM4]K[47EB<JL&4X,S)&ITI1#T.81!"],!RLB9Y
M#,:TOG;9YVRX;7)CZ3RY572TY32H9:#]R)-;28$KY$.M(_TM$X0K77BNF3^A
M=DQDAH/3M< OM]E:)+N7M[8LGD^>7%>\6$7H7>?)U=#;4@B&*(661)O(NT$E
M(9&O2JMB\.Q^EX/GER>WDKP?RY-;15A=!+4O+ XBLI E>PM&&P.J2 ;.&@]*
M9XRED*I,ZTR7?2[1M$,SH8V..DBG7Z+2Q#((?Q1O6D>=J]?C64<7NRG>1$MI
MR3$YD#P64-EZFBUUWC"F7<3,7?M&I,^M>%/'9%E%!9T6;_*!ME1>:DPUKVU"
ML@;G38)Z2HI"*Q]4ZY+]^UV\:27-+"S>M(I8MUJ\2:5@D&PH$)IQ4"9F E8-
MYLAUCCQSSUJ?K#VOXDV;Z+^-V+O8%-8]*WP=>L/)S?K1:'3U>3*BT7EO],_7
M0\33/MG9.!J?URB@R(0(/-5@P\!KF6?RO%SP4*3A.6L3K&I]:]GYH'; SQV?
MZ>X53;KPQRKZ^/0 XS(#//GS"Z8QYAKAS2]L8H7K0E/:QT"KA7 0'0K0*23N
MLU3:M(X!ZFXT+Y/YNR?&OB_]UR/[^^"2ON:R-_XVF=522QU8C/5\1M:. C2_
M1<G@<S91%<-D:-[0K?MAO<Q)L$=4Z>),I8LAONI][67LY\D DXL1O;+D+FJ:
M[D7)6N)+0>'>&9.=U*9UJ'KG@_HQ$W9*DVVW1;D5 W6.(QQ^Q5P&P]=7XZLA
MUG"HT$_8(JAHE><T#2U:>X#[$V"$K$CDG(-T.&GLF< '-* +:B^]T9'OC;_U
M9O\"C$HJ*3.5(;.2:/H5!0$5@O2%\UP<!MN\1.$+##!:A:7=!1BMHNQ]"3!Z
M=QGZ]8AJ<ACM@BVI1K"6P NY$-)!8-R +<+SI))@O/6AW>WG/__[P948<+_(
MT;J:Z,"9N\9R?5:Y!)J.KO_N(MG-5=_ZFEF@X@W$VKVRHW%Z B.C(,])$)N]
MX!(\H@LRV.2;'S!M0\E/W-!UI>-5I-DVHN?#'X,/GP97H]#/1_W\NO<5*[39
M/8&QP0CF'##E/*BL"5;M]&"%-+Y8':67C]O73SQA^Z[<)H(?M)=:PU/E![ ^
M_$';SK=[X++''&I6M,_UZL=B@>"M &U"JKG11>2GJX(]_9S#4.S&$NSB!/6Z
M+N_M]NZ3]4C)4*1@"B3:NAXY,F^M2E!\M")ZINF_K;V(16!>MI'61D?=]429
MX)E-E&40=1OB?0O-CHN>;Z:N^1&\F\JZNX#NV\AB"3*Y2O3(L+:"T. T3;E4
M6/$8F"Q=55?J7/O+UCGO6OFKB+@+I=_4P[U;*'>VK3D7B[;! T^"K!:9:;1.
M9- .):N]0)QM'0+\!*2=!8&OK;4'V;OM1-Y!^,%TLZ,/3]@N.?/%8 (>M":K
M51"8FK&0R'12FL?(0^LCW#L 7K;%L+XNNJ@TN[8@;H;1S_<,\F7&U%5P> ?C
MV8VEL@%-5KU3W):.=Q%DLL[8DD'AE1,TK+H1:*XA2I,@6B1'4[ODFC>#>3Z\
M?<+&VG/:KJ+:+IH/??YR.?B&.#$-[L3I"IU,4<8!J@K,NPBTAS! 9"X:;75D
MK=O.+ 2SAU$7G>OZ?N.B)HKJP)([Q]%XV*M1'1-HOY-F1N?O?[^.]M;.%6,D
M\%B+Q1COP/ND(!>.1I,;PW5KW^Y10#^8U%!A':Q'LQS8&1C-$RM"1>"Y%F5U
M6H!#7R X;PH*)(>E=8;W'0 _V+*!0MJV&YF&)/TZ*<1ZW0:\"$^K6P*B9O5Y
M!(.HA ,C5/%>:F/P7BS G.N$A]_[@I6^N9P[\ A?S4XO%LCF'[WQI]-^KA&%
M5^%R3CS;Z_OQ;!>*B\1U01"JYM2KHL$7E\&)&*T,-![6>EEI/H@]9&FW05"[
MI<%"PZEEX.FTV-O1^Y-7QV>_O3MY^_[HP^G9VYO:P*?],AA^GHQ\[:#3-9ZQ
M><#II@/;GV!3;[*/PG)@1M"JBC*#-Q*A*'0A>H?(]R:_X\W^!9LZ:8,7M!]A
M,9$6@,#!&1:@U!!T'X*(V#K'^B4&FZ["TNZ"35=1]KX$F]X]+<HA:9QD)21O
M0#':N:*D$4C&4W#,N6A;&PH'=B^Q$@<>O9=811?/Y5QWF3']N)=8Z5YB)9IL
MXX!W'1T_%_[*PE!$Z8 %=*",EA ST_4FV7AOLQ.L>??'9\/;E>XE]HZVJZBV
M;53PG!,($7T.UCBHV8#DJ6&ME9"JG(HV-@6%X@6?]*RDJD=/>E:1<P=7"8OO
M.'@HD44R8[&>-BI;:PAD9<'S&)@)G-,<^7$9U3EKVBJJ@UWN\;L-Y]$+(VAI
MC2Z1,4JO0M:U<X&(16GGI6R=ZO@2+J,V85([A740L7PGXT8XFVTH"DJVY%,G
MD<'5XW4NBB[!%R-<:DR>P\H\W,057%L3';+BNMCE$FA>2N;A2IIY/"MM';%V
MGWG(4@XQ)0LNFAJ6ZV7M7FP 67(ZED@D;KV#[(&KTI6.5Y%FEYF'<U.M1(J>
M)UG ,D_@A',0:S-A6JQ2"B:7D.V3/L<S2%9;20DK):NM(L$N<Q'OP2*;U*1"
MIH3QV9*Y@@H<^=> 07F4WAL5XHJ*/425;B"U+C,/I_W.J@4RZ%>;8[(F61&2
MK]'O'!,CKR.7NB9I*&1\)N.D8+*U;?8HH)=MK+7350?1)/<PS6;,,J Z,N+F
M MIQ+N+FBKM_8-!,ZEW$0,\%5VHXK0\);'4[E2\6O.2V]EVF74T(%W+KTO!;
MI,*RB8E;8L(JPNXD/_%[N-!UH*.V6G*/$#+]4"%K"!@,<"^R2DK48J7-,Q+O
M@=B^'=% .8N;B*XAV0[.F._&LS+N8TGDS* C,#:X1)82>32L)"1S+WN=6X?S
M[#C N+V*UY=H!S.Y?90@:J$M)P?7<EOO1%B$: ,#HU.42(M=T:U#EGX$BVX:
MQ+1;&G15KGT=>4Y^_!U'XU[_XSL<]@:97_CB38@E@[2*]N^8/+A26W)HLOF#
MBUR$K5_;KX#_Q;%Y9\K?IR+LM83\Z*Q,7E]X1Y:FU 5T-KR6QY 0%$;@'!UC
M)%':M_:%P;>!_Z!NY^KNJE3Z.BT13O[\TAM./CR=?1>1^U(X)VLW*T&3S];T
M8T^2]4R+D)U-GG?!VQ;@7R9WMZ[V7=346"3'R?GO(/=*+TW^R6D_#2?_8&(T
M??^FX\%H?.&16ZX3AZA5( -).P@F6S"H XJ TL:]69)7&-?+9/T^D>7AA% [
M6]"GL4ZCM[6XTFB,^>U5U>7LN'UTP1R)6JE:BU72L'))X)A1$%EF7J-D,K8.
M4^MH*"^3]CNFQ$.FZV8AE>36]A+.%_)W[),!C3X,YDS9MX/Q?^+X'-/@8[_W
MW[-PK=G8ZZ%/RD58R%%+L#G4B"V:SHS)E).7D<O6]6FV,K 7-POVCRX/YX39
MVSDQM?9>#X:SM^KG^/5H'42>&-CB&;A@)207D38^Q'B_ZO'^3HZY(_PQ2_:'
M0 ^GB]V9]S";[M,,@].9+_0/['W\5*7R%8?AXS3]X%48X_=V49/AHC""MDB6
M:D'[ B%-:EQ'<IJ,RERU;O&QY2&^N FSSQ1Z.&/<KMV+OT_6C>OA?A\6OQZ7
MJCD5@<9ED%YY!48&R1GMG3$V;U??T5A>YAS8-2D>DMUO'IE'EEV])L/\ZFKX
M_:)AZO[<-OM._L1AZM'@+CQ-OX"*@;?.@:J%QCQS!AP:0QY1#CZ7YN%ZJZ)\
M>03M5I%S[I(VOA5]-QPDQ#QZ3;*<CS 5;HRH+24M(X2\6 A8YTKT,IN8@[V?
M.;IYP/Y3H%X<L]JJ:0Z1=G<K.0VG.>V/QL.K25CMV?@3#C]\"OVYILM%J7'D
M7 G@J9@:7H,U3<[6,%N;7$%4S2L:;FML+X[6>TF:.;-C=ZVB5QSHTX:]8<G:
MP"Q(LFIJUP)RBDV(8#AWQ<IDK&MN.>S+X'_,KV=!NSD3<.,+W*/\7U>C\60H
M'P8W9?/>A1XY!,?A2V\<+N?[%^=(LACUQM=G5=,1WSI>^NXPQY)"KN:; AM1
M0XPA 6:FHV4R^.85,;L>TXN;+GM%DCFSH,VM;2?KP5W?>G)4>^<PB88=.0CD
M&JS" %$P#5E%$[7505GW;/:<QT;ZXF;,,R#4G'FT\9WPHX[^]/W7@^%L+1A=
M<!9=EE$ XUR 2B5"K'?9";-&A=KS]M'"*R%\>;SM3H%S^+;Q?>NM^/HIQ+.K
M\6@<^IF0W^2+&.<*V%1#XYR1('(IS&:1!6]M>3R&Y\5QJ9ERYC#';JM$]KPJ
M0HTK9#_VB*X*9"\]K/VICQUSE%PZ#8G5M<9&!\[Z&N=G0S%*>BU_U,=>G'8O
M@I.2%5M;.XM:@*] 5%:!\*'$$M YV=S6?('UL5=A:7?UL5=1]G[6Q[8F1:,8
M!QDC;3S9!0C>"P@)HXP&!4^M[Z,/K#[V2AQXM#[V*KIX+O6%EQG3C_K8*]7'
M7HDFVR@TO(Z.GPM_32*[$D6&XB3-;F,1@BH(*$UVJO"$MGE=HF?#VY7J8^\=
M;5=1[=8+W5H,+$CTM4^7)X?0DL?OE ,3C=")%Q&3:LR[EU#H=B6=KU3H=A6%
M[5-U@2</0K]'09\/+B]?#X:3=%ZT3J&+'.B_$E0B0]Q;[X%I+(GL[Z*WWS:@
MZ0CWD.\=.T7[2Z#G.5VF6607CJL2> J@<U*U+D_M3F<-2(O<8(B)^[TY3EEU
M<,]HDFR!I=N?4&M0;)_J@:P:1"71"JN-!J-4)@O26B#GFH%C5JF2LQ&ED](+
M/R+O#G4F;4"PKHJ4;.$R^_I2*$'@TH#-*" 6QD!XH2,I0@OY?&+P[H[MQT3:
MR43:@&#[5"UEY:U7\,"S"I/VZ0QJ\4N(-#9(:"*-.@BS/Y=EFUEW>ZF%)^,^
M;\^<%$WQ!1$*<PA*6:*GTD1*6MV-CUQY]WRBP-82P3-:')^-4]L9!9^QI?YT
M.';AM#$$VAND3*34ZJT$E %\T09-\@+S\YF+AYL%L _38&]3"E;A\,+)W'UD
MU>2P^H' 3OZL+[%QB-52S^HJUFKU@38*NEJJF,C1Y>2+Z-59N5\NI!82&=WL
M>-HH'60VY'>6NN/I"-XQ"2X)ED0.BLO6]:H;#Z%=.%8;8--(C<)B]HJ6'2<\
MN4[%DMENA0-M"JT[QB:.S6N[=3&0;85I[9+7BV.V=L6(?8G?.NW3.HC?VWN\
MF8US<L>>3)*"6PXHHJ$MB0EPWA?(7+NL36;*M#:K'H&S^]BNG7%ET(W..O )
M%D";W9<O ZZC\*U'@>TF#JN9&I>CQP8ZV#I1F W2>;*#!4T&4"8Y"+5(,@O)
MNH+1V]@Z"60'!'DBX&DW_%A%])UT7AJ-S\K[<(G7/>B+5SPA[?,>=::5TC/P
M/&>PV5@1A"BH6\?,/0"Q?2>[H9(>)/AL(N$NHB?PDO[T\:B??PO#?V+M33%S
MLZZ[?K,L%*O]Q)WQ0*\$>!TS".-J0+37')M'33Z!Z9 (T53^W80V(GWA)P+X
M"K_BY>!+%<!=B-$G)C(-.-K :3V46 LR>/(-!(V?!VMMZ_9L2\ Z)):TUD('
M-]Z_8A^'X9(0'N7/).K1N#9=^(IW00;+C0JUV4),D5:[2>WMP*!DU-;)$HQL
M396E@!T26=IKHH-[W9FGAGF^(S?#>B%U$L6@ Y-- :5< A]5 !.8$L47A[9U
M<.IRR';0*W"/CG ZT-Y"VZ;EL?KIV^.SWTX^'/W'R?OC,/I4J[&4P7 Z%3^$
M/W']/.6EOWGS(_/U!M'H@/S[8^IC?_EVT[?O_[D:]D:YEV;#F9&LED/UAED(
MKO:S5-:2G4N+#J:4F.$LJ-+ZG'8UA&U<Z2>>-CUUNB<+66@VE)"!"5,K/V3%
M3.L D^71;>L@ND/^S'>UFZMFOPZ/:7A'5^-/@V%O_&UR.#$;"MD+RM5X+6&@
MFA(@ A?61H[<M;YQFH]D5T?&7:E]$;O6%W]G)WNW45T;E$O@ZO3T]R&F71[\
M;J:W)ZFP@=!W2(IH&<10 OC$HY<8!(OR69-AJ4/>G7#A45EW$2]6'4UR":N?
M>6<EO.D47N$%8$XPL.3]@><F !<L&,&=".T3,AZ'M"N7?%/=/2@/UD[P#<]_
M1^,OPXOCHYNAI5PX6,0,07,%4KO"F-%%X&-Z'V'ZZ\?!UY_KUTUU7E_=Z'KV
MF!W$R;44^V!]F36<RI/'__;]\1X8(09;$^^)D05"\(&[A#J%Q^[GEE+9;X>D
MLA5EUO!P=/+XM\<WCQ>>"; B.(@Y,1 <)2$J*I?'6O(MI;*WQP>DLA5EUO"
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MW^O[_?^N]_^_G'J>YYS[/O?]N<]]SKF?<\YT/3'KF6V A*69A1D 8J5UH'4
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M[YIA3YU&6ZYXRJ&]%UU<[I"90&Y]MGFMN9)C\2[7$IWI5;1O)M[^I *(8>[
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M*8'8:W;04LY1'QL<#5HVE]\/6O6]#FMS"X)RMK@*K(L&@G'R['U R"D"9R?
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M/5511V,^_'?F/#DL1@]/H9%0# ,"">6*T\11Z?@-FC^H/T-86>EMHF \V+/
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M"'L9WYNED>(WB$A_",F7LHBP[9*4$W?7NK#4HO0J9&-><Q>VTKV_N$4G_7S
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MM(\)3"=S16=?A'1?$#7'G3BS73D!O,O(Q3S^QG/'H@:?#VUV^T?79!NWMG;
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MF8S(Z+<>$8FKWIG(O#4J\/F#T)TM[\,&O$9@V6[+NM\GK?MY@@)N5]W_I3_
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M3GB(&*0%@AA FC(^E[PH:GH%<*'N,LE&M.<'?BOP9T4+^#"#MRA^S2+8-7_
M387J=.]@\^"SV(LJF0C8)X0TYE7!3.X?5"Q0@"G&7"2:2"+0'BL/1IO2+Z:1
M\QB+(VWP1,PV/&V.70 ]@[FX!F<\F?8('$1M/GZ2M3C6A;YI@$+F0UT6VD[,
MX+L1B!.Q^3SD%&=Q+.VWDV@/KRX GF8MCEXW(RJ<15X<XKDPQ',>!$\BTV*U
MJ:$Z>SE;A#M7!Q&/1)-(U(*0:.$A%#K=+K,9<V#.B)#?GHFITI[+5"-C?">4
MS12?JPF-FA'=3N;FR\R/;&<3YR#FB_^-[,*+\J+\O] S<UE>E/\7>F8MS(L+
M_(6F.4OS[T3^0MOLQ?DW$G^A:_;R_!N)O] U8X%>C/T76F8OT;^1F*N+/@//
M#$YG4!:4G;5)FDF:+TTDX*CC<H;L)&&N)&WU<,7CJ&& &0)+_Y3<%&0^9W'L
M]$HZ8Y NQOX++0N,R]]++:YSHI86=NL7[T_XWSHT3V2.-MJO]<W8ODQEYTI1
MPP%S"C&8/OW1&W4-!H=&$"=!\[B+P9W<Y[#!X#]_]@JB H;\\3,>&C"8"ICZ
M\J_<\/F]:PMY/F>N^Y_F_4)3\1R1N9/L_[0B++@(S)%QGGNC[W]4"1:8F*=#
M$YB:Q@1FD9C$'>-#G#G/3>?GR2T4+OT^3/+PQY#14[.E*0GLXH\G3^!F<19"
MS9K:9U"X9E;-W!N#$U1G"RLC+@/UZ<^.SZO]_Y+$,,(PPC#",,(PPC#",,(P
MPC#",,(PPC#",,(PPC#",,(PPC#",,(PPC#",,(PPC#",,(PPC#",,(PPC#"
M,,(PPC#",,(PPC#",,(PPC#",,(PPC#",,(PPC#",/(/&^'Z]6ML:!S*4"9$
MQMAHO!TP!]A86-E86=C86-G8V=DXN 2XN#@YN9;R\?,(B"Y=MDQTJ8B(F*3\
M"C%Q60D1$; *6':E@M(JI>4K5"&JBA!Y125%FA(0.SL[%P>7$!>7D**8B)CB
MOYS&KP."', 8B),9) ,P"8*8!4'C-P$)  "Q@D S?H&."0 QL[*QL'-0N?H"
MU P3"PL+,QL;$]/D3]@QLPBR+I&&L@F9KI5!!.U9JA'++FOF[%,DK$D\7=T@
M%RX?9]XY1 6+@2;3+]T@*IB5C<I3$*22F4 L3%1;TSQ!9A:J7M.UK$)!U4LU
M$;%%XVT #S-53I!9$# &OFP6!(Y*-G@5*^V[>\/=06R/IPXG<.".V%VO2K!0
M*P"<9#'5X6#A%=H=S?+=#81Z*7OO)(PEV$'\]:E'2"._2RM<#1IWV3P?-(SZ
M:H+(JW%:[U*!9$_,UE9<<>I12-Z%L;M9R[>+9YX$#5L\T>IW#41Z?;S$;[)?
MB^^N)P^NJ*C5'@5"G3W$<G:WRK'8+":@>+M,L;N)R)JL8FPN<X;=FKP()X"S
M7W#?F7OAE[@S0&!!3TN-[7),!"V3ZS+4' LOZHOCA8]KE[]B:]UC>"*?4VCW
MZ1Z=G[%I'N+2EV,ZOEN_Y>HE][+EU-19?^"YDAR2UJB6(0C_2GBPO<I-.=A>
M^N*]]RF/^36)28I5W^,,GWM<&+MS*ZZRDE]\V:-CZ=M8/-9VVY\2EF_:P(8J
MC-;/)B^/]^/@)9OTU]T+X3ZJHX!-WD (-GW&Y+ZFEKT,8K&4%U5\AO,&B%H&
MNSML=_M/Z9B(V+!L<#E<S[%E1VZ<J2L301!(/Y>'EM?/VODP'989L@0+?%WK
M NSY9"T5$\I>YE8G)!];D;\I[R<//&#'^19[\?5UR^I?F.1*:Y[Z:/&J>Y!K
MT[;WSQ_S-ZK_R."484ZH^=31,RR> 6AYIO-;Q.=G,9FLK Q(UWIB3KX(WIY0
M&*'A&<ZILO>$8@?8J7*3EB35>^\<5X,7,&N7M-/%=<BGKR\)W>)9FW1?N?A2
MB,>.(6WE?96IB87^\DFVTKM\JWZ"JZI[E17.!/2A KPM/U["'LA7:+);-PXX
M;2],,0B.X3#1W<^<D7<[J+=OQ<O W?6*,?>VG18:_KXMTO<)[#T?HLKAIHKR
MAR7!+@U(H2;]ZBY,1^'37/@>O=R,6J4>Z>*2^O*OS3O=JFQ(N$8.?8&<&YPL
M<:[*6<?B<T4MXFR=XNQN*8-?<I5)1C[,/A#:YHW)QK[)_  J'RYY5%Q<3!&^
M*Y3R!=9/($F 6+#69H?4N. _A5TO*=@,)_+W7CTW#N09F^FKO33+!9\"A7)L
M3>]WLK$+.*W6 *(<6Z?Q6KZ/W8;=32A'LIXB>EI#3=-I*2[WDVL(R:!>;[-:
M08<+KB!E_05U8OBM8:DM[*Y;\\O<GCV5[C:LL1"QRJRSZ"O8Y':3^5X0\ZG*
M0"&CLU^=C$*JT,H8":N\M!5R2[I/+06M@'8TAR<_>OXNQGLCW+E%+_GDO>A,
M4EM-]AWN$[L_["#FESP-$^QLN+4VZ?C*R)<EU]+WM-@7)L4BOO96I==</O:
M?)WL4JQ,MO P-VFH5]9;N<S*ZYM^L#,LT5G+DZ74'G7<^M[.A&17($Y9/E"
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MDW+OL2:R+?/>L;>5\N05XZW_!U!+ P04    " "!A7I<%WX/I= N  !#=@
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MM&$$VP3"\1%83"0(MX.P3"@E# O"M%E6( R#!(<VW:,R9 PJ"(35:1$ANB/
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MZ84#3HY[CKH,"U^>\U65&N1I5DGY/"M-40E.GIA5YXD"!\^KQ:?BZ^B[,P^
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M^%S69M<#-4_*GYWN3ZV2V=WEE2$\LV7G(:.QOB&_EX<($,3,P,/6NG[YK.[
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MLC?LL_J0:>>)K[IZ@NF5'W:OL6020_=4^SJ_^L:CR-V^374XUA1:/MYJ&-V
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M]]2$DN<GA5R?&P6JQ66;BU2;#_77JUYHO'3 UHXK-%U&XQGK=NOD=5Z$=F-
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M&+T9W^Q9V\GO'Q:R)/N<IUII(\#C&U"4?+<_0X9YPW5)ZJO_#U!+ P04
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MIY]H%+Z5?V#82#\F!@ 5B"0'&!49UA,=B(+A_C(NH7BE=3/)P?Q3( %_B3C
MZ$=D4LRPWP@\BFET."0""L?M0^XA#QW0+SBTE#I29@NY(92"I<E/NNF]L>A
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MU$D=#Q_?,.'O+9#Z80+Q.<!"3<'D!/2!0N,Y:_BKWI18H2:3;P[*LVGNQ@W
ME0_,(LN8)[.TV5S7:42.$F2N+548(S$BAPOJ[7O+#7J\"Y;5>2)<&DN+TR%4
M9[7E;K?[&2(3=%5=Y#"GV!7#SR/TL9UOPLP>1U\5ZNYJL#EA.WM/7KE ^#A^
MPF'Z,-*G,W:J>=6W*R]O;UE3#^)CC*N6O-^QZ@KMR[;:%OI]=O5+G4H%8:XW
M/[.Z34:.AA],?3GJ;P*\KK@ZGN'Z**-]>DS*]LN]L(QGCLBEZZ-C;V OGL<5
M08+>K(YT.^]<:CWN@4>7,KU[U>#"V3HQU%MU)GR[M>?CM'XJ$ *1$([88A01
M\W8NS#QW:@SV[NK^0!,4G268U'A98?FA_6$I5?4#.C.1[ MA(Z9!(Y \F7E#
M^D.?1?5F=/3SH)ZPBFUEQ6[S?67=DDVO*_V7#AI_[!PO[:3MJ,B*CN^*;*QY
MH]O^>M78O.R49KH4]R1OI69?5^F1F$B]<Z?D/Z].#W:T%%0?EU![S\$>V;'5
M(3Z*;J[G0&;/E_.5R?4\Z3&Q#K(\494I' :<@SBO\*2<1;O%5H/@T?#1?/V9
M;0_\A"V@$BFZ(D?/=PR[[515BWRW?):J>S@LCPALC^<4+!#;WI5FUV<@,F^[
M PKIAX,3&$/$0K>I%"VDN<^[]&2YMF=\E<1&JSV]G?QZ*3Y<36+6Q%)7.Z?Q
MC:JZ^^+Q76G>WWJ9JWF"JEZDV;VALURL73KZ>>1:N9(,\O#)1P\9GJE)L.)E
M+S^>7G3KUT'X'9,LCVT#<UV#9=L?$OA<]B4E\1!;?JX$X[G)HVINN4\$97'/
M70:!Q>*,1P\>N\ZVWUL4W"GY3I$Q%NS#,1PN_J+;S<UJ4,#LCKY6?KF_/Y,"
ML;.NJO+Y:L*\]P 1R.>Q&HR^70+-.R#;3P3TBJPEW9T^$8&T 0V/HY.[=B%O
M?$3A_=J,B8#5#4T6[^?"Y=UXKNI*T:]?6^,MN=S>$0$MJF]')^\M^GF4F-?%
MM\&(P.O&FQIWKGS6.])V<'FNZFE2+.%H^]X'HE^+9OR:TA7PGU<8B,"+D_DQ
M!QU74KR?O:]X>R2."-@D/ECE0@W%._<,?UJ4UY(@ K>][NL??Y/.F![\EF69
MI^R"0=)2FJ@(^XI^WK2_\_X'[XR?9I0U1HL1B$ DRXKHUQLM2=9J*P>_MDX<
M[2,"J4O;CZ 71F8>#+]L( +FG\YP;;NX>NM-8= ;H3[HL@/V59(!I97Y!^._
M]>?X*=VS#2N2.CAG0#*MHN\%UU'SK+H;Y9/F*Q5+Y@KZEEP'1$_3?EG1/+#4
M5]*+ZF^*OF,^X?F@Q_C1[*<AYO+8U6X:VXIHG:&[+1*E<R2EK=.WNHE XXAW
M\+M3BUL/"]=>"1R>%LTA EM3>Y;8NT];0;_QBZ\NW85+"E6B\[Y]:CJS-/)E
M\,V*+:11+Y$5%N_@,P3]>*3_G2MMY>"E]^!9-,NJ'1$XX:YM<7KUUK>%O#,'
M+Z]"B0.4]6<;9<9U6ENA2.LM8 C 2,="3]*1$$PZ)/J0\GC2A:/DR ="KG_!
M 0:,20=*=6!]KTTC1IG2S:RM 1GR-@%@ &VA'+1 Y!4/)$ Y ).A42#!C7P0
M2/H[#VEK"%*B;!#).]9PD#(E3UY%TT ZE#QY;U\<C:"LJ639NZ2+M /^?G[X
M_J2LE^ ?;P6,'=3!TLX(% P=C-L!*"LJJVDK*FDKJX*55+05-;65E8'U=P)K
MR]55T)H]1")ID:9:QZ*_<95Z W=][TL'HOYN.]W/[0.I_V@?2._G]E&!UG6
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MFR";()L@FR";()L@FR";()L@FR";()L@_V40IA__U ]'P7:)!8OIZQ$' 6.
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M_<!Z[I!EO-@Y]F+G9'^9CWM+-'3X:KE3KFF]J)[N#"PNHI3#:8WVAS^Q7#W
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MG:003/,_:/NL5R3'^Z5K@-9M=9;FBYYSHQRZI-B3T2K?V+@\&I)$W45N3AE
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MWRA'I,/BN5B8JD+H/F[#<^F@5R4A NV+NB]G!(5<NOTM<R'K,[9M5R>Z<<F
M9L8LVWF?Y?<17RN[HI0K1O<ME@S7Q#^&?,L32WII90H2/0+$19T=%+Z"E*S2
MV<L]R\4O*R^I/:8C9B4NA.5K41XLCJ*6.-9TT&NM/L-4C2_*]:;4*XR-CXO
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M *OSG%0V_C@BCN"/"P(KRRL"ZGJFEC0T +E8; 6Y =1"XL9;J0" ]'<KE0W
M@,=#U-34H:I;J6@!64N4#QY'P/D2P<XX/ (L![;!XQ A/D0P DGPP:."B"@<
MEJ LC\#YA%/DBE/D<IPJN2>!B!?PAYUR8QYV;?6F],$H?5/D?M('1&DQ!^%1
M6*)U"#$HA$AJTI)I-@2BO3<.AZ:,,,42D4AL"&:]3O[51^/);78*KSTJG#Q"
M#T4D\_R0B<1;P3%(!T,7APVP-0:2!3A?>R0Q),C:.\"'1&8!;  \@"/]\07
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M^PN9,H.DUOC(Z:SS!OA!YZ1406LK#PT/I44.*!6ES4)Q\]'O#LLC?7A)U6<
M(+F71$<# @!H]?'J/,"BB\!Y(_?H6P)4JZ\!-DH+0!PD\ZV. '$ "P,# R,#
M"R,C"R<S$S,G+SL+"SNO #<W+S>W "<+I7S_^7,!L3(SL[*Q<K"Q<?"PL;'Q
MD+_8>-98./\= :LW 4X&DO)YU" 1@(H31,T)6GU",I1IM16D0]*2%D0IW]U(
M#8"H:&CIZ!D8F9A!?^T$ 534ZYT< (@&1$U%0T5+3\= 2\VB3.KDI*;9P06A
MU;6%<XL$'U*BXTG+OZ@G*L9K=\M;604?TZU/+YYN_V9\T8>@RE=0&RMAD.&
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MI=<^&SV; 5R_HZBB"$!"%'8D=@#@;)UT5],6 H? ;"'.='R<W !A614U5%3
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M+F2("N%Y0RX(%?G??&/80"&NSG]AH4.@=C9VOU9%!9US(XT+'H+&M7"%0Y1
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MS\E/JKH7XUX0?@H\ Y"XN3C5'/:;2$]$20R]W)S^Y*!86QK*;E9E4;Y8?NR
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MBI=<M*^WCV[[VGPF:_,>FUU>4%]_F(2[!%JRWNH"UVT+BE>'9^:IQC1YW8N
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MR)T+)A/>SIEE(\Y9%/E4*O\5',':AFTC"1=\C>/2UE3-/II&3C+")D25$V(
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MYZDCQ25>%TE]\SO.F9)"O+Z;'=+Y$'@QPU)=EE!JD%]E6#@:/'R!;Y>U42-
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M7OS)JG[))\*5*G1,7W,:]^9-4_9)/A2^YC7OS)JG[))\*5*H0V/9WL]K2:1
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M'N)7M&8VEN]N_FXU3J=]=A-(YB##D]TM8;S-,:=7]VZ#\>BUV.AWF\ EC9C
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MI*M#JQ6D$>2+]D7@H )!OCY(K$:0MA!)N0:A3B3+"@F0NN"\M86V_'?(PEI
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MY@E%>B#@.K+;@MN$OTR,[-;,_ _,& R%)+Z;^C=FC8 #)3PB$1BLCCL&Y2L
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MO6;B2 Y1&'T@574XPPE>K+CL_*25.RFO$<83D7/HQ-'1M>B0MY,EYXH_!-^
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M,QWD")1_:O^M^A'N>'!(<P+$<'VV X0!$>#GM/E+^H5VP'/ ^Z\-?J8_@P0
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MCB>X['L C_^ [@HP GC[[_87 0IE!Y@]V%95%\#?7P*H#DN PXT#OGTL\ =
M04I*>HR4XM@QBA/D9.0GZ*@I**CI&&EIZ6AI&4]0'*;OE]\G/$IR<DHJRN-4
M5,=/4E%1G3PX49W\QG+B/R-@_P5P@A2G?#(!'@> ?P*/X 3>_@BNHV3[K_&4
M<%H2X1VF[V8D /#P"8F(24B/D9'C_;T2#\ G^%%Y', CQ"/ )\0G(B$F)2*@
M$,-5GB @/$,C0J1\V8Z6P_.F*/')R)0"%4XN.L-Z>S%Q^*TN59*S44:?/JR
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M)E#%AFQE8B@NB*[6Y>"6J"UK)BW>J?SD]=J%CIYD[>#/J8-@M.Z%?6#(#RN
M,A4IW<K#39ORQZ'ANS#6PD']_NF/"B6C+2NM2VMC=/'N@KO$&PN[;!E&=<HX
MD;5U1D)?<0LJVQ/<_%G)GK]OPX3-1JL.TLOUT.*EC&8SZU>Q8&VV=X4TSFZ.
M;-4-%LSL*K8373/Y8-#6JCNH'+J^<";5EG4?F'IH@O;V8[//C])6F[7PCVW?
M>^.\@X$[&;RM'=^\;K7\IOM$C.W:Y<)GS[,B5NA*G:+P]H$L\XH1-'E&96DD
MZ&VNP-4<<>73NZ)CZ14NM,ML=$G>ZK-E-DV#QA49JDHU:Q6DD>C4604_U6/K
M,$G)?,(;TYY*0J[3OO$#._Y)B8X,[W#&I">NB6NUX@\-@]0(3?(K9O=NA?$,
MF6MA,)F3&.[@1S,C93MGP75JGGX:F'6I*8?: 5/WM<22\6?B-\@E%]:&&@M&
M/S:#LE@,>6 E2)O\O<PPT>1@SVQDR9/!Z@<;BA9\F"IOCG6WK0*1',]GPS<:
M[RR 2BL!EZXESID\OJVT];)YA?[!.QN;P2(S%7W]_:8 1U4NV_M-M)M]UUR=
M^5[A;G[W\'1PH^39_%.VW86/( *>BO%?=-P*5)P):#/W;#=;=U2'[5&CR;U;
M+FT25QHM:\N,9[B"DBH7-OA\0IKFOEP9E*@=\N_PSKX,[:_)R^M-:?/P*"TS
MW5I TWOW427>B5QW(IN?H_)[B\X)=Q84NEX%.0.SLP?9]3HWY)@8>'IU:O4-
M5<W&\YXYH:(*E]C"< U2H16?(_L-V@(,>]10DI%::ZWD$"DEYKZ\KD%$P5@L
M!#NW#R@XS<+WNNP'&E/*W_6!"MK1+B (9,$3\<896]G*LH3>!Z[-W.OI?!JE
M=59IOV?=F,)M0;YTN;&V*I&&_/1I]GAA.>S77#1;R9O6)*?>I3A)W\W*_GSZ
MH$A+"\F0A&RPG/D664'M&"Q-S38U=5FC>ZW;J+.V93[\<GWB78CW\;--,\7Z
MTS(R[' [1(F?R8N"O:+/21&[BY*R+7,\?EXUHQU=4IV0D7FCPKJ.786 G+U8
MY63C+74UUCPL2Y3UK/2H+C@W-\T#MR8S6_HQ;-5MK)\<VUG7XATM4B)+70&W
MN6 6,>\CTT8)YNWVC-Y-RHEZSONW\D-.7YFW>TT-DMPJA7R-W2I9OK*V>[D^
MCVDXP.:S0%&?(!%&2:UD.Z'?U]NRM'2YI28.;.[T!6S+/&<CPQ"RS8S(*1SH
MWQ#!^##(QIO/*=9#I[=\WN)6SY<;UF:S-1=CUF[<P<T7$@,-0NZ +M7&M(5W
ML:# NDY,R2VF?KT7S.FH(!-;-N7D-*V!PC.KYGM7;NX%K :L1:5S<*Z%[A5F
M].HDWHN:HF$=LIFBCQJ 0JRF%M'^X1597VDL/CQ/(C41(U S@PJ/:6W?6Y"L
MU+[N32JG:-WKB_XL_)GU-!OZ)D<T9%?G-$?3EMZ64!%LM[P\OEAWB7I4DB5W
M^D[/U_9-?_B2[/WS+2_7&U5/J5VL'AHH+@\'[0,J3'XZ[HB:8K>=]48R=[OF
M@K4(2>B[#\_RTL>F]NP)!PV0BIFU!?Z6"R!^B0ESQX'J7JO^N-ZMK+4$/XC;
M^MY]W!U984-)OZ?J5D@))KG(;CG/<[AKP^WRDIN__70E9Y"DNY?LV3X+G>MX
M[.+[0$*E_Y/S+"9?Z8=/8ST_30^/["VX>6V7H6MPH0J>%[$5OND>X;[NNP^L
M@,%Q2*L4T&/=4UY&EJ<_6S0"3;XF15]+I7I'UAB,=[*<"Y]9:'KIIB;<(&S=
M4%P$S>R%)3(([/';6FYQN]B1[*1XKMXZ51S;:WT[/,Y\GD27GMP5P;HU/!!4
MD5C6/24W8PYB[4@!PPQ!7_W[,I"@>085;+E3YP5(TIGW,SW%N,#'-AM0G_YP
MH!)*5]H3L4E^#BR$MFB2CHQT&LQ\QZ2P#Z3O(789II]+S0VH,>X#3E!YDV)3
M %U/05G[K""7>J2DQ-'!9!]@<%H_(3C#PK%MZ?[NPX9(%=/XM'-GT^6RV8!4
M='1$PSYP98O/VDC=&BJET%<&N0GDRRRCDBML^O<!Z;OM)3TL$0NP8I'2^Y27
M('>9A_M%MQ78QM:PT &<T_G&9DW,E:GB$\O<(E5*+[M<W&=IO:6/]IQ'/[Q7
MM<6VF[YF/+B.>"I2OY#^-E]B<9VH%,;1&&1>N6S4AZBIJM'=2Q/8Y5/2QCUV
M]*Z;M-GM7IQ=NUK$VJH;3VS:A)WM*WLG*6^F%FMNVEJ;]#@CLW9KMB5@7L(W
M.P.WGDPJ&3E3,8Q<0[V_H]<%4L>R0"#8Z'G?DD6!/>^]WJ+%OBV9\\:[6K.Q
MEI;#F^]:=,C/"^1(\B'<,.%8L]J\+I,MH:G= ".Q+9/1K!E#+6W<C:-AM-P?
M<X);O+QXSRJ(TNP>7]$)F#LN"$Z\.\Q*RGXGK$D_PV9LZ_;5*MN$]KD'FY(9
MHVV/GOD)\*Y9,>,')#;G#8\M9A!8)I><7'&;'6$6FP_2T*P[?5JJM"4[,TSN
M=HE$G,QH=H#V5%7/&V/_?#^CV2M)4D+9:_'"R.W[SHBR(6RV1V%E3IY[568S
M9AF4/"?7M5;W(=LB26=NNG_:PO>./@@.Q^0D?+9J\\UAWJV"9G:L/5K67QW@
M60]_NNN;1LO#EV>P#Q0MN*#:).2=-R1+K41&E_62%S*LG,=LX^V#9?UY:[/>
M.RC-$R6=#]?*]<Z<_6BC8'M5TL1V)K%LE<]_'PBH\6*SW,M;@R9V^0_.!/;>
M:VAPO!3!Y7MEJD-MV>\2]K[.;IY5G=I6P7K+^[;2M<I!W5"_&%L)T5=SE*<#
M+-P7QK:S;?.N^GE5=:<NV'N0# )<QI]:$ZTE%#84JUAB"QX2+\-O1%8PI/02
MO6?=]?(=R_SR0'J7+/[#P.S6Q\K5\BI4#@\3UJ\!ZZ=A5 =1N.]::[O"%GEU
MS2:ZSS/?/-S;J/)\7) ]J,O$G3;MU/Q$+<[_K*T+AZOQPIC!@R%%Y\2X!P;F
MWIU'>9U8>)E5$^*^F/(X(VUA'R!-8@D*%GRI$]4PKV1>(V\VJ+I0\FZQ<(LM
M',+HQL.SZ.:EF5[GN,WIVK@&68.S1<YMF?@5!0SQS7Y:\OL28PMB,5K$A*-@
MT 'QBI1VT#N=4IFZ\F!:KB@MWOV^=6/<TL2+RQ_Z#^XFQ!AW:&N[UG3Z@S[G
M4&.$YNT;S>Y8EQDL?F[SDAE2'^L/D)J50UG2[][2?VLR%UHQ9'HL>61E]5@O
M:6JHK[R-]X!^3A(G/;P^?30QR1+V9.E,E675K-AFG1]\UVB^S'B^1G*'HCIJ
MRTIJ=.Y=?Y4SPM8:;=%8UI,WXR>PC.MJ56Y>%]^<!'2.L1\<)]Q?7]%W8X"E
M?6-B5PC^L3*^=WNFIBGMJDRLXO."4L6F*A_DME\IVHA;?"VI]!+L.7)EKP(U
M&M0F;]5ZY7SVB5S*PF?5BF4:*<C.+;?<1K$U_3S<@OR2%Y6<][6C)(;<8FC$
M6DHFY'F]Y$!XM)4,=K1#=RE@NBZ@T[=]9LRLMO#J9+S);2,IX5N:D*>,WIWM
MV=V6I_S(Z=L287-^7'?B0!5Y*4NT=&(#D&Q'->.B'H17=POD,N5=[O@(7^*F
MO@X,+BQ5YNJN7S53-\O(GBM:4TYE'!DMI]A9779*K;INKY\IS%)Y&B^"JA]Z
M!^TM*/7$O'-+K72DYY-05JLZ]I%W4@_)R+PUQ#_:/PF2_\KK Z0\T3KEH_/K
M'92)=]99/S4I&BVN]2S<L!GM]Q\.H_C6\SD2HHEG$:*;9OF5DDW/.\S\Q\><
MTN9@FS#<L_.66K3U/F!U+O_.1-'9$$%!@;7&J42]L:+XCV:E';JC0T(;8DR5
M"]O6%;9/K&FT>*?];',%S[X,?GAU)+MT@5VBOR3DN0,4NIW09FN^O+N]#XPO
M[5JWSYUZ5V;=RR=Q10@!P?15/L\A=H?5?1W#/:%W!_0'/,IT?1KU0&')I2O,
M8^7$CM5):S3(M/JZQ?+V#/R\DT=4@E#;ZVU=G]IL=34,*K;70>:M'6M: O42
M5#_J@G^EMEBUOKR^C\EJ*]. #.ZA,%7_VL7^F">W7OA)N7\,)"<J_XJ!%<NS
M 8LF"R%N?(,HPXTX\:@IESW'IA*$X,P5:J*VN1J56QH "=X>ZAY>;=VMYB2-
M%=\VXJD/#8-G]AXP[47(399Y3<KOM#3D;I;C]S\&S4KD3DSE5RII2P[/C0P@
MEMVOJO([=O+H0Q(V_5TK^GV)%2KBL!NM%F>>&'K3%TN$@KQJXDSW@=2&8R36
MJMPQO$Y3A1MRD.$)A0Z/,[9S%37Z)'C]:RVW!ZK.E;R5J*TOZT8T%29[SPKF
M9BG-UZTW)(7>5Z<3&K0\YMGUWKQ*SZ\?ZSJ;'[Z*6[?;=T)UCH]U['T5]5S8
M>M7/XG(2^;F%&9(M5!*O!7%_Z93%U%)3)5*(\ X08NC-]KM4HEV7P^(Z1SF1
M?N7%B].NA)5--&Z[5F+=[NZ%=3J.JKNV3C,U"NM#E2?G3'+--.8&K_4K5N>H
MAI9F+8 :IR6PK:]JEG,QX1L2H^&KB:PEA@=WJP-_#0VXI64VZ:7VA45E4AF!
M 6]1)0ZQ& L\%Q>Q9IK@1]F8UY3HT\N7RI6[J<F)VF=#W/R*65_J*"TWH"2C
M>FB;$CIJ'Z%S(7"1N9H;VY8@U3^21X:[$[28S[UF&>H%V]O9[W4V7>]Q?YSH
MAIX_T^X\,#0@Y=3I/1WPX';D0)#JL(6YX'L2@LFOZ99MC5G9$/ZFK#S=1->U
M5(NQD0WT@VP&^4!J)0*2Y+CE+6W>B&,,7W.9Q9JV]0TH4A+5[R#N7-7?->WK
M&B?%=+Q76$(X)1659&Q;>I]74*P2>>7*#TIR%N09IBZ;%6G';]D',I=U^[;"
M_"G+0?21/M7O^)^2R+Y\W^GJ#H7-S&=[+=LLH^?WX)4"3IB"3Z&4!M8Q\=)C
M.2/J728E:UB7YW40+,*&U;(R*3='LF[:/8\[62W._W[_.J1RSO^M:U&W;)/!
MVU;^NI-F]R'DLQ6/G^+W@V36E?J?A6*3H_8!O;$N]&QMGNJ:3:HOR[<GALZ_
MA6?KEU'WR[4T'Q]_?RM$(RKPP76R,VH$]>Q13!J/J!M/*K9:8N52 Y ='TTE
MJU[L-K^B/F['@6=20DS+U7"G38NT#Y0O+BZ1&][>F?PFC)%D:H_,XSJM,]6]
MPB+B+K9H-?8$ZEL6J<]<NK6X#A#U]P</=V3.'.Y!F'W;LP$ :D 9< !@@#T
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M_@_1%V$@U$%4P]5]6S5P(XT3_Z=>8O9BTB!1!V$!L"A81D!*2EQ20%I:RE[
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M6HN-ZH"X6R')%@Y; [>";D;/.1];S^-[^8+*^7SSNGCSND1>1662Y?'7DOO
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MH4;I;O0F=XG'FF,D53'JW/C540/*U#-?;.A%0A;?B13)75])B#(,M*D4?)"
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MBY+T\0L2)T:NUG&;&5EY1O)$=)"W*UK6"J54\;$OEB]=JI6/!:F4X1[(Q16
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MU4)L'N65+MHV10+UT'*F3^8ZRO+)//VO*M\/5DM #?;J,*^24*\?MXOX8@&
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M4$[I)XEP%F/_M*;_Y==O"L:RI5<]3M@FV557Q3])8(8J@Q,?+8:UYK72C%>
MBB/V4DQSE<DID//#"G0N?-WJ1^8?>@:[T=D2EING@"FU]4VZKJ<[3=FC.%BO
MVQ)\::7RD>5\$!6"X-&K"3Q3N!,3;6[/M/E(D90<\"E [KI_7&R?V@UBQS')
MU$O*',BJ^8(8'XVE,E7H77G*$M;8CZ$^(2-">9#1]M4(W?Z1!&1WYBD@N']
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MA6=B^ZTAH4$ \/_B^7\:SX7G"PMV5E8^SJY.-G;'K0$Q64 &$VUQQ-)ZF0(
M1,>"8A?_P7#<UT]#^A8@#2RVOATP\O6/B[9P=CZ^6-UB6>#?253[]-"O-N_N
M^@_V_RDM#PB,6SQHFQ5=('^1$Z(J%R?:S@10]**<L?AV+ PM]45R-0#D28ED
MPW_(HHF6W[PH6QI:Z -BUA>!9:;U(MD $$>!_I(- <DFG44YV#<"!$A_? 0
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M/K=@(.J@@;P=D'%P%4T36AN?&^,/0R?D>Y+@3I#L WH( VCRNDSD9NB;EZM
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M%/A5_UK$RMQSNT,0UQ,_]40BK1LV;B>B$ '9';YH?P]L6QS:.GEG^U/48P#
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MA6_)E\# ! =*.717L)1:!M_O>IH6AKCT_QD 4U!+PI%!<GT6/@6BX(\@>,+
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M]2KD%7]@ Q.6P%^V0@1[PMOO] R&X1T8SN;*HB+-='YI29GJ.B&Z+%!95K8
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M]79'")N/.&9RF_,4,5GUP3!F[:#/A %P0?2\:A?P*7HC8B+?AGX#517OR_!
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MH DZ4'<SY25CI3;#_PDS3-+_OI+R^8S^]0G*_?'(@]\H[W8_&/Y,#=[\HLZ
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MIJG/]AKN43Z.R^A)E2<&>[5ND Q[V==M%SDLVR\7\ ^+7XS?[?*B$?>9M2U
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M=A'"U?R+]?R&(7RM;F7-(\Q'(*U<A&YEY)L I"UGIOXAXA!_4!,*GPJ^J)#
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M0VI/C"<N44;W^PB>E874[A(LIC(4#+R$UOA?8N?H;W/O8K[,Y'@;M)OU(H!
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M+$Y1@1:*+/(M?REMV7_R=9XYW'$<-,")[S["G50249//S2L]KYK//5[F!\\
MW*F-)1C03E^X_11O':,M<B/O!6NS[S+P$,?9X0G_"A#996;;L>Y7.[!;V67*
MR1QK]C=H!*>5 Q9KN4'<F=M'<[]S!R,&@-- F<]AWEF>O\,)_GC0IC.$R4$B
M*B^PIB%CY=6L>K@#/,\.@F.+<,Y(>$2R+><V-!@QBWL)8OJD %\A5X<.<#/_
M9L<HQBQQ=86<,2"2R7*8:<)D7AUK.CFG4,MZ)+B2E,*^CYO#4<XG;(O/6& -
M\ME!S]L%%[1]IWW5O+60]";U%&D.8XOB*]#%G"T[5K";^54BV];%'BW:%#Z*
MLXH<ZSW(->$2A_^<$KG0MIPVLV*QN9MVQE0@D=-YAD+N?4:0-CC_-W.5:O:V
M>:QXV;4P"ULC!KPA[@SBJ0,=.(B-;26HN8W6YO$TZUJC^#;MG\I6KCO=:,+S
M$QDZ_99$,?.D>E;8*O9<68=W!*=.--PA%\C&I[8N+GO?^<XDHW:T"L51M,T-
M-1PS?5HU/>\2XR^S7^(B9H3N\X:;K'8EXCV1$RD^XY "+,!?U8MQ(-M7S\=.
M[#A!2K&@?"=6/WJGD)L;BZ+%UQ+VH2LI":%ER%OJ[U5ER!G&1[M\Y#(GN:X3
M)8OC=%IT>LD;0H)T4FC,8TARV><=(/(WC4R8##]F>(2\@ \R?ZZR@@^PO]D5
MP,\ O]HN^  S6)L+E[+&"_BP%6LOXP#TG%V24PD-<5RV;(/:N2-#<J$6[A.O
MF]!9X-%_U&QP>(T)^ANRTFS@WX66X''\#F@D_1:?X#_(OL'G\$_''^<+^/M#
M1O,;^#N]&OCO^&UV!5 *OZJ:#QXBWZ@C0!WI@B6"5"*,=@;<+@C/^@YFX5'Q
MXT$5MC68!YY'$[U2^9Y(J%T!?PC^NTK'ZU'VJI)Y2H4;2N'190SJ1UZ^1)_E
MS0-%W9L9O%WD\>#9X%^"BUYVH!KK_H]:C6177@>NEV]25@"'#).0G4"CED'U
M ZI4W9E:X)#\7MPGW@3I\*"CO +11,_?X'C! [L"\#@JJ P'/&I.*,< UI5[
MD9G &//ZLAKN3X,D<R1@K3D11P4@Q?N@?."==)CG-9Z!O/P?58!Q*YYQ#[1.
M4BBYO8T>L(PKK;E8-H_+KEB4(>56&U/CY@"C-+*@10 AK_!LY 6*V/]12_%@
M@T7FEO5<W"SIV%'(NRW.S;M0XB,**+1+6RA<4*R,N4-\HRP)^"ZX2KV^L@P_
MR7AB\P>[PDG7/Y/D%[%%;\5+2^;QI@K?EW84\\E_RH)3.<0@]4U,HJ"3OB?
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MK/)LWB?)-G$-)LE+HT6Y6HH9^.P(F;<^J-HH^Z9]G7-1_D&S(EZOG*:N7GP
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M?RT4K4_)G,;5&E'6\+H3ZNZ$[]8GV*6(%/-(;%[ 4H,CRG'_\S]3WN?HBKU
M9C'<V[S,^W";F]>:#A5?;7AOI&<>K9NDOY=PS.JKJXZ89:K2O H(TZO55@\[
MS1W,VS$? Y#+]'>MR^LWXU8T.]6E%9]J*+-%96ZNQ9EO)QRQB(UM$5[&=7IA
M0*[NDY;J$:KAJLL=)9@KRB.L77.R>GX9N%*(NY8;UO^(.)1RH?<#Y7P,O7.
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M8&^#<W'KN)_AK+Q> 1\N39PBG@O30X;+1L.(1Z32!^YJS22?TX\P3::-U%%
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M21)/4&"=PWP.FBQ3\'-!A6EYT0N08/B1/@"*]"6Q!G"7=BAD$31+X^-= ZW
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M]H/T$J;*UE.KX7[6:?I!>#N.Q J#-Q<<XMR UR]=R-\.;X_\(CH)G_+GR1;
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M.A5MNH.E>8RS@'_E3-8YWHR:_9QS1 41Y)TIQE&E@BMIJ<S-HA_16W@>TMB
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MEI V)Q_?YD5:D3:VKHVT&GISQ5G2OJQEBUM)&0CB3^.D.G2?_U?X7Y(^<^_
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MY"VN;(\RJAK2ZJ2UR&:1F=C._W7_[V4;J?UT/7V0I&,.XW6<D7<-J-\8;&V
M;K\G,.\*>=:R/?;FT/;4F9DMB+ZIO9SJ 1^IIOU0N:0!4B>H137SS<0VZ_[?
MF6?=_5EO=O]R>A_)R.S'&W('WC6@V;(2**P&XVYW8-D:>+]G4\2YJ:V'1BYL
MP#0>V5>@Z_>32=ICRTL;,VJ+Z]"-1=6D5JZ9VIYKW?US3/0N6B6CFU3!["%4
ML-\YH-V\$JCW[@-5VUR>M:[WN3*VSO_P^=4)[>?6X\LG; NE_8$R?D>\H:@9
M9N;68RSY=:1&3@VUF55-:V68Z>W4JIP.<A6S@VAB=[YK0+=Q)3!LWP/JU]G?
M[O_%:>K,,I^NF[^D5)W90))9]_^2P6!)05>BAM.669[;C*EB-1)K& WD.FH]
MI9YLH340Z^B-^-J<)EPMJ_E= X;U*T'5NNV/.Y?OGIE>L*OWQI+ ZILKTQ5G
MMI"*C[KDYXV$"5C]R;*<[BPUK1.M)[?CC,0V0@6^E63"MI"KT,U4,ZJ)7HUL
M8KQSH'SMRM=-R]9?F)BW9N#J#S9U3Y8$JVZN32\^MQO//N[)HD]$%%)&4DJ)
M@YEEN'Z$#-V'5B![L4I$#UX%[R:JL[K(FLPNBA;62=.]:Z!FZ;*;@]\M&;GT
MK]4-CW]PT#Q?'L*_O26%?<D.13GM2R:<B&9B)E/R$!/0PJSQ+!YL#%$"'47Q
M(2.8TO01G"!MF"!,'2:)4H8H[]RCCF__<_C,/__=_.!?&_1@OJ/@Y>J#G/N[
MXRG773.PEX)0R+.'")FGDRB0D^GTU&E83O().#/I.(*5> S%3IC"Y,9/X3AQ
MDP1.["0Q[UV;F/C')VU7/_NI''R[20R6V.>#37[4)P<B</>\$[)OAJ9#KD5G
M)E^)STZXE(J,NPA!QUZ 80^=AV.CSR%PT>>0^*AS:'SD62PAXBR>^*X!Z8Y%
M0.2P%0B\78#8Y^ 3B5_B+6D@XH(DE#XMBN=-E$)DP\5H0V\1I;J[D%77F9?7
MV,[B-K?2>6TM9'Y',U'8U823=C=BU+T6E+&W]AUZ;WAO>&]X;_A?;Q"_,7BY
M@#+O@T^D/@FW9 &(B[)@VLFRF*()89ITF(_0]_*(YFY>3EU' :>QC9W?TL(H
M;&^FE'0U$H4]#3AI7SU&TV]&Z_M-[Q"0;E]L-6P#0D\7(/$\^%3NE7!;X9M]
M21E(G9%'%AXI2Y*,"#-U?7QL57<)K:ZCB-W8EL=I;69R.QMIO)YZDJ#?@I<.
MU6 TPT:,;E"/G7N_&NRW 9&'"Y!Z!#U5>,;?47G#+ZG]*:=4805'Y7'B$0E$
MVR]"F;H%I+H./K.QE<MN:\K-ZZYG%/;7D4N':PBR,2-6-:;&:8:5>.W07 .R
MWPQB=V<@<PMZIG*/NZ/QS+JL\R6?U@;G3ZJC16.*%/6 %%[14X:O[1#1&UM+
MF.V-^;F]=2SN4 U#,&JF*0^K"<K#4J)F1$+4#,^UMX8RJZ',S1G(70.?J=WB
M[NH\,J\8O$EG#(&<8_H(P;@V43FD@AE[%9CJ3BFEH57$:&\H9O?6%G"'*G/Y
M8WJF;$)*41P14M2C HIF9*[]C\'5&2A< I]K7&/O&MQ@5\L]"6<K_7)/5(3R
M)\KC9",&B*Y?CS1U:8B65AFEO5:8TUO!RQO6%O#&Y)RR"4&._$@Q737&HZM'
MYQJ0;;,:[+8!B8LS4#H'/-<ZQ]PSNF9<,[GCSU5[LZ:K@WE'JP^5C56GJ8:J
M$88N(\92KR*V59;1>K6E["$9CSLNY J/\#CRHP5LU7@!2STZUWXW2)V=@,HI
MX(7>*>9^A3/TNMD->[[.,V>F/I [U1@E.-*2*AVHSS*TFE!UU3I\FUY.Z96+
MF4-"0?X8KZ1T(I\G/YJ;KQIGYZO'YMK_95 [^K\P.!YZ8'*"W*AUP5QL]*"=
M;O//F^Z*Y$UTIXIZFF#ZAFI$744YMDVE(?6(Y8RA8@EG+$]4/,$2R8\P>,KQ
MG"+5V%P#<JM!8C7(G)R QL'_I=$^^J'9(>UFO1/J<IL;^5R?+W-F))HSVI\B
M;&^#ZFLLV;6Z*DRKQ$CL*='0!O.5[%&FG'>8)I=-4(2J<:I -3;7@'RKU7!@
M&Y [. *MG=^KB@-1CVKM4FXW.V1?ZW;%7QCSHYPX&LOH'TH6-'9"=!6-V36*
M&DR+H)+8Q;7NW2SKSDW1<,<(:M$X0:$:(\C4HW/M=X/"WA'H;7U?5]E$/*ZW
M2;K780>[/NR*/#L=@!F;#,]M'TX45G=E:#5-R.JR6GQ3216Y\\V[?[J!,4C4
MY8Y@M,6C:*U\!*U3SSF@^,V@.N  C/M]0,W>L&<M^^)N]Q](O3#EGCYYRH/8
M?>1@0>U G$37 35(K8;2.D)CD77W9E?2NFGEC#Z"@3V T7,'40;1(-(@F7-
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MUV5J-2:DN<R :^2I*>T<!:N;(>/V422" 8)$,T@4Z/M)?$/O7 +2WPPRNSU
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MH!>JP$,/E6&IMV6'LJ^6)1/.\[-R9K@X[A$V73!,RY/U$DHT'9@R8PM27=D
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MDCA7@146:Q"E$ET67Z^'E5H,F?QV?791APY1V*G]H]X:"K9\!R3;?P*:[4M
MY8X5S^IWK[[=:;OVTHC;FN/CGGL&!@*]FKO"(TW-,>DJ2Q)&:(;0N.7P/*8.
M4TQ2DT48)4L&EQ>J,F1B3;I4JTN5UEKKT$*$G9J,TC\.Y"[_!!1M_A;(MOX
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MVF?.NIIW=GOBF@]3J94'V/X%+;R@]+WBR(0Z:7Q4=51*:&5B9F!Y1JZ@M*C
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M$\I(]645).^A&I(&<Y7C8,W$,-"<*8*="SE@M)P&9FL]P6:#&SAM<0;7;0Y
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MEA!9%AD3T2B/BC@4'1EQ/B8B\D%T1,3#J(B(@<C(\,&(OP$NVB!;J@(IZR9
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M]"R"I%]#D.A!! F#&4H!,%^9#<M5J: QD0C;IKK"KIE.L&>.+5C,MP2[A::
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M$/72Y9?M*/:K_6?LF.-7E]>8;R[/G+]AG_X%N&NH %9+#8C:ZD WF X<L_G
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M"8RBD'1.7E"^?U9@A2!=U"1*$76*%:(+@4GBQ^)$\8@H(?!Y0'S@"R%*\"?
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M"[ ]80DVO58_;>Y9?;,9MOYB,VK]T>:;U7M;L'YA#S9/',#VH2/8_0E@-J@
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M?%1BM*<L_O^P;9=Q46;O_\"OF:&E%>GN[AAJ&(;N[NY&NCND14!21 1!0%3
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M.?*CEX\(>D1*H&NJ+#H5**%]C2K:MFD@LT<+&6MUD#&NB]:;]-!JFSY:[35
MRV/$.4.TN$4\,4*+M\2\$5JBX7?BJQ4:?6"@\?M?0)86#>WTV-"%\##B0&]S
M+O1UX$<?;Q'T#I= CV0Y=,U50J=*-;1OUD36*FVT'=1%YGH]M-FHCXPY V3L
M-D3KPT9H?9:X;HQ6CXC7QFC]Q?B;-1K/,]#H$P--WC#1]-4OH!U9@Z,.#=UU
M_O=;*GYT+@RTX\< 3Q'T"Y%$[P0Y],A61M<R=71JT$*'#AVT']!#NW4&R)HP
M1-LM1FB[PQB9!TR0><H$;?XR19L'IM]L7IE^L?ED^I&))A](#LDW>\9"^A.[
MGZ&])@V=R3J\M-C07Y<=@TVY,,R6'T/=13 H4!(#8N70)U,9/8LUT*U.&UU6
MZ*%3KP$Z#AFAPY@QVD^;H/U6LI>]9M_MCIM]M?N=_IEUE_[![@7]K=U'^FN2
M\=(.S9_:H\5]![2\]POH0-;PXWV0GSH;!FNQ8X0Q)T;;\&&TRQ*,\)/ D$AR
MU5)5T"]? [VK=-"C6?^[6Y?15]?5QO,N(Z9?G"?-/CG-T#\Z[3+_X'C8XKWC
M;Q9O'&]9O'!\9O'4Z8/%8T>T^L<1K>\X(>-O%[2Y\@OHJ$%F\.,=!.G?$1IL
M&&O(B0E6?)C@N!CCO"4P*E0.PQ)5O@5G:WX)*-/]Y+O<\(-WN_$[KU[3-QY#
M]-?N8Q8OW:8M7[AMLWKFNM_JJ>MIZ\>NUZT?N#VQNNOZGG'+]3OSN@O:7G9#
MUF_NR#KC\3-T42,S(%TWC'3-6#4V3-+CP#2+19AF)XPI'N+?$X)D/T?'*+^/
M2-=\$UJH]S*HVNA90+/I$[\N^B/? 8N'WB-6#[PGK>]YS3+N>.ZQN>UYPN:F
MYQ7F5<]'S,N>[U@7/+[;G_- AY->Z'#8&QT/_@*Z*U,QD/3,*-+]D\@L,G38
M,=N,![.9@M^6N8I^3/>3?I,4H?0\+EGC<72NWH.(<J.[H<O-;@>OL+@1V&-]
MS7_(YHK?F.T?OIM8O_OLL+O@<]C^G,\%AS,^#QQ.^KQQ.N;SS?FP#[KL]4.7
M'?[HLOT7T$N1BJ$R5(PCTLD\<C39L,"8ZWNA-?^' L<EKW*]))]DABC<3XU7
MOYV8J7LMMLCXSZAJ\]_#FZS/AW8PSP;WLTX'#=N?#)QP/!XPZWPT8*_+8?]3
MK@?\;[GN#7CAMBO@B_N. '2?#4+W3<'HOO$7T)=T_PBI__7_+ 4J%I*S*=7G
M_%1NONA5&4OH<;&;V-W\0-GKV=%JE]-3=<\GYYJ<B2^S.!%39W,TJI5U*&*5
MPX'PU4Y[0T===X=,N^T,WN&Q/?B(Y];@/SQG0IYX;0KYZ+4Q!+TVA*+7:!@1
MCIX+80#9?S3I>VFD=^:1]90JT[Y5Z;"_K37E?E++X+];Y21RK<Q7^F)!N.J9
M[$2]XQG+3 ^G%%KN3ZQD[HYOL-\1V^ZT-;K7=39RR'USQ ;/Z?!9[ZGP_3X3
MX>=\Q\(?^(Y&O/-=%X&^0Y'HLSH*?09^ 8/(_N-(UUPF3L$B:0I6*E(_U6O0
MGC<:<-QOLN"YWF O?+':2^IT68C*T<)8W?TY:::[,G.MMJ65VLZFU#IL2FQQ
MF8KO=-\0-^"Y/F;49R1ZD]]P]"[_H>B3 8/1=P(&8E[[]\5\\^^)1;]5<>C7
M%8>^"V$(V7\BZ=TY9!UEDJ1WRE'>-JE0'[7IL-UJ-^&\W,(4.K/<7?)H=:#*
MOK(HW1V%R2:SN5E6F[(*;2<S*AW'TAI<1E)6>*Q-ZO4>3%SKVY\PZ=\;ORUP
M5?S1H*[X:T$="2\#5R9\#5R1^#V@+?&[?VO2SS",=/YDTC?S2>^L%*=\:Y"F
MO&Q3H-SO5*?^W:7/<:Z=(7"\V55B?[V_\HZJ")V9L@23C449EN/Y>;8C.66.
M0\MJ75=GM'CTIG7YK$H=].M(&0]L3YX-;DT^&-*2_$=(4\JSX*:4+T&-J=\"
MEZ=^"UB>^OTG&$'VGT;Z7B'IG36B\+E9 IYV2%-N]RI2+O7JLI_NLN(_M,)9
M?%>3K])L?:CVQJHXX['R5,OAXFS;P8)BQ[Z\*M=5.8V>*[-6^K1E]OLW9XP&
M-:1O#JE/WQ=:FWXAM";C<4A-QJ?@ZLRO0=69WP)_!:/(.60(D=Z[F/2M)?!A
MQ5+XIUL,KJV6@O,#VFS'>BSX]G8ZBFUM\U:<;@K6&J^/-AJN3K987;&,V5-:
MX-!95.ZZHJ#>LSFOS:<AI\>_-GLXJ#IK8TA%UNZP\JRS8679_X2697\(*<W^
M&DP$EF9_^PG&D/UGD364"0$V",.;#F&XUR\,?PR)P^DUFFR'!NB\.WOL1;=T
M>"I,M 5IKFN*-%Q=GVC>4Y-ATU&99]]:7NK26%KK45?<XE-=N"J@O& HJ"1_
M,K0H;V=80=[IL(+\!V$%!>]#"O+G@POROP81@0MA'#F''-*[*XEF07BYBA]N
MK>&#"^M$X?BP.FW?&M-%6_M92S=VN\N-=@1H#+9%&/0TQ],[&M)L6NMR[!MJ
MBEUJ*ZL\*BN:?$K+.OT+2P>#\DHVA.84;P_+*CY!W W+*GD;DE4R'YQ=_#7H
M5S"1S""/].X:?GC7Q@?7^GC@\O B.#LJ H='56D[UYGP;%EC*S+>[R:[ML=/
MO:\S3+^S/=:LM36%T="495?34.A<7E_A7ES;X)U?O=(_IVH@*+-R+"2]8FM8
M:L6QL-3*6\2;D-3*^>"T\J]!Z;^ R:3[%Y+N7<<+=SM(]Q[@AG,CW'!B@S#L
MVZ!,W3IFQ#VUSF;QR)"+S," CVI7;XA>VZIHTX:.)*OJ]DQ6>5N^4U%+F5M>
M4YU75D.;7_KROL"4^M'@Q+J9T/BZP\1UXE5(0MU\<&+-UR B<"%,(_DEO/"F
MD1NNKN* \VNXX-08%QR:$H2=4PK4S9,&7&/CUL)K1IVDNH>]E5>L"=)I&(@T
MKNY+L"SK3F<6=N4ZY'24N&:VUWBFKFCQ26SK]H]K71<4W;(Y.++E8$ADRU7R
M]04Q'Q3=]"TPNO%GF,D+6,$-MUII\'LO!YQ>QP&')SA@]V9^F-TB1YG8I,LQ
MO-%2L'?"06+EN*=BXVB 5LVZ<,.RH3AZP6 J(WL@RRZCO\@IN;?*+;ZGR2MZ
M59=OQ*JU_J%=TX$A7?N"@KLN!P9W/0L,[OP<$+KRNW]H^\\PAQO>U[+!E94T
M.+N:G71/=M@S3?K_'"],;9.BC&S58A^8I?-W;+$3;9IVEZN9\E,OFPC3*QB/
M,<E:GVR9-IK)3%I78!\W7.$<.=3@%K:FPS-HS1J?@,$I7[_!O7Z^@Q>)I[Z^
MJS_Y^O6CKU_?S["0 ^XT ESHII+G@ 9[)TC_WT*!J9U<,+I;#%;O5J=U[3)9
MU+*#N:1VFXMTZ9R/<OY,B-:RS5$&J9L2S1*F,RQCIO)L(B;+[$(FZIT"-JQT
M\=TPZ.X]/NGAN6&WI\>&\YX>XX\]W<<^>KJO1T^/T9]]J0"XT@9P:H "^]=3
M8>LTR=\&,'R #08.+8&N0\K4EH.&7+4'K(5*]SF)Y^WUDL_<':2:LBM2.WYG
MO$'4CC23L.VYYD';2JW]M]8QO;>VVWG,K79PFYMP<IG;Y>2\]9R3\]QC)Z>9
M#\Y.6]#E5^[6 YSK CA,^O?V"=)_9TC^;@KT'F&']E."T'1*CE)S2I>]Y*0%
M7^X)^R49QSTDDXX%R,<>#5>-.!*G&7(X53?@4+:A[Z$2$\^#M72W@RLL70X.
M6#L>W,!P.+C3QO[@;\0CAMW^#TS6/K1E[4760G^V AP? -BY'F!Z$\"Z'S^#
M/T"%UI,<4'-Q$53\+@%%OVO0LG\WY4J[:"N0<-%5)/J"KT38^5#9H/,QBG[G
MDE6]SV5IN)\KUG8Y5Z/G=*[-P/Y<OQ'KW 9CVW,[39CG?S-FGGMD;//;>U/&
MF>]TZS/XD]/= 'O7 6R>!!B9(_FD?[8>IT'U>4XHO+H(<FZ*0<9-%6K234/V
MF)O6/.$WG02";WHM\;\9).I],TK2XV:BC.N-3#FGFX6*#C>KE%DW6U29-WO5
M&3?'-*QO;=.PNGU2P^K6/0W+&Z\U+:[/:YM?_Z:ST,$A@)EQ@-$M)'\WR3\"
M4/4;%?+_XH2,1P*0_$B2$OM(E1KQV( ]Z+$%E]]C.U[/)VX";D]\A9V?A(HX
M/(D1M7N:(LY\FBW)>%HB;?FT7L;\V4HYLV=KY$V?;U0P>;Y'T?C%>46C%P\5
MC9Z^)S[]9(Z<P=@T0-\.DG\(H/(,0-X?%$B^PP%Q;X4@XJT4)?B="M7OG1Z;
MYWLS#M?W-ER.'QQY[#YX\#(_^O,S/H8)6'Z,%3+_E++8]%/.$N-/94L-/S>(
MZG_N$M/],BRN\V6SA/;\?@FM^?.2FO/_$$]_LH&<0?]6DG^ Y)\"R+T$D'@3
M(.(-%P1_%P)?E*!XH"+5&35I]J3W,]&<W1J9'!;HR&F&'ES&Z,=MB"'<^AC-
MHXO)B[0PFU<#R_C4L(%?!5<)*..PH!)N$E+$W<(*>)JX\)/5LP!MY Y4G0#(
MN4CR;P $WP/P_<8![L@/3K@46"A#8: *U1RUJ:9H2#-$.DT/&6PZ:,>FB2[L
MZNC%KHH!'$H8SJ& \9QRF,$IC45<DEC')8$=W.*XAEL,-W"+XARQXR?MY Y4
M'R/[OT#RKP,$D7SW5P".2 5;Y 5+% (S%*,8H2Q%#Y4I6JA)54<]JC(:4Q71
MG"J'#)H,VM&DT)DFCIXT40Q@$\$(-F%,8A/";'8!+&?GQR:BBYT/UQ#K?H)T
M72I:ZM&0J4]#.R,VM#/G0#M[+K3WYD56N! RDY>B=;XX6E9)H7F+#-*[Y=!L
MC3R:KE=$TRE%-)E50I-=RFARD"SKM H:_T4\(%X2GU30!%6^$U__1_6+":HM
M]']KL-8E^83#C_<Q9ASHQ.)")T\^= P51KO$I6B;(X&,"FFT:I)%RTYYM!@@
M(UBGA/0)9:1O44&S[<1^530[05Q20[-[Q'.U[V8?U>;-OJM^IJ/J)S-4)S0^
M_ *:DS4PM4@^X:++AFZF[.C.Y$(W-SYT#1)&ISA1=%@FB:Q2&60N)Z-O5T3K
M7B6T6JN,5F,J:#FMBI9;U=!BCSI:'"7.JW^WN*TQ;_%4XY/%>_4/EM_5WUFB
MQEL+U'QC@5HO+5![(;34IJ*=.A5=U&GHH<6&WD;LZ&/-A3XN?.CE+XSNT:+H
MDBZ)3H6R:%^C@*Q6);1=I8+,056T&5%#FTGU[XP9C6^,G9I?&8<TOS#.:'YD
M7-=ZSWBL]9KQ3O,EXYO6<P9J/[-&W:?6J/</XV=HHT%%)Q4J>I#.[4/6$6#
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MWL78%#; G H=94V$3-N/A^QT6!]\PG$DY*;C<,A+QZ'0KXZ#H>@X$(8._;^
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M:%+?2FB2WQO9Q+_WLHGA!C91W,&V%$\2MXG[_]&Y":!N!T#AP?^?_SN UU4
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MLN^TF.G>?T2-]WP0-]Z-$D:[4/+?=I)G<+(78(CD=Y+\Y22_9 X@<Q= ['Z
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M<4G,%I/BF",CBF*NCRB,?43\95P8RQI]Q/ 3;P)I+L;0/$@A]Z?\ [GDO7G
MQAQR_UQR_SQ#+,ZS9'IR[;ASLMT$[5G^PI:,<'%3>IQB0UJ*<FU*MFIU2I%&
M57*55GE2@VYI8KM^46*/84'",N.\A$TC<A,.CLQ)N#(R.^'AB)S$MR8YB:PQ
M8?0YOX>0^],\.$_>>93R]Q20]Y)[K2E@L*Q0$7U%^N@I&LW,*9S$;<]W$;3D
M^0H;<T+DZ[*C%6JRDJ25&1DJY1D%ZB7IY5I%:76Z^:FS]'-3NXVR4P9,,E,V
MC$A/V3\R+>4R\=O(])0W)NFIK#%A]#D/PLG]DV@<J/X'*7\'^>\&VO:LH.N2
M$@EZ2W4PM\R":2^UX<PL<>+/*/*2K2T,$DW+CY14Y"4HE>:FJ13EY*GG9Y=J
MY69/U\G*:M'/R)QKF);9;YR2L6Y$4L:^D8D9%XG[(Y,R7ILD9;#&PR1GL$:?
MN$_KX2O:;IV@&NRCW*WD?FMH"SA UP458LRMU$1'E2E:*B=P9E0X\J:7>\A4
ME0:(RDO")<7%<4H%1:DJN84Y:MD%Q9H9!=4ZJ?E->LEY78:)N7W&\;EK1L3F
M[AD9DWN.^(7N7YG$YK#&<3FLT>?<B04NT=;S*-5@=QG-@VG 2G+@172=6RU"
M>XT:9DXWP8SIXYCI-?:\RFHW0>DT/[FBJE!Q7F6,8G9%LG)F>99:6EFA1G)I
ME79"R0S=N.+9!C'%BXRBBE:;1!3M&A%>=(:X2[PTB2ADC0FCR,_XD=;#N6P:
MAQ)@>Q5Y9RTP6 ]TUP'M]3)H;E!&PPQ#U,P8RU0V3.:6-+CP"^I]9'/K@D59
MM5&2M.F)2BDU&2J)U?GJ<=/*-:.KZG4BJ]KUPBH7&(94K#(*KMAA'%1QRB2H
MXHYQ4/D+X^!RUBBXC#7\G&]H'$[F WLKR#LI?ZB1O*\)Z"2:F[FHG:F(:2UZ
M*&\=Q12WVG#R6Z;RLF=ZRJ0W!\JE-$6($YOB%.(:4Z4Q,W)5(QM*-<+J:[6"
MZV?I!-;UZ/O7K3#PK=UFZ%-[PLBG]K:A[_0_#'UK6(-_\R6MQZ-4@YU4__64
MOZP%Z"4/;R6FMP,5LR4HZ=1"09<I<KK&,QF=#MS43C=^TFP_V;B.4+F8CAAQ
M9'NR8EA;EC1X5K%JX*QJ=;_6F5H^+=TZ7BW+=#U:MNBYS_R"^%'/O?F9GGO3
M>SWW1O9_.$<UV$]CL&4&U:"5:M !S.D$9I +E\TC]YHOA^P>563T&B&U=RR3
MU#N)$]?KS(ON\19$] 3)ALV/E N>GR ?T)VAX-==H.0]KTK%8VZ3FMO<N1HN
M<P8TG>9LTIHZYRAQ0VMJYU.MJ;/?:4_M8/^'+V@=[J*Q7T_Y@[/)/><"L^:3
M^Y$+YRT&TI?PD-2OB/BENH@=,$?4P$0F?,"1$[+4G1NTU)_OOS1,QK<_5NC5
MGRKRZ,\5NRXI5W!>TJ TI:]3V:%OB8I=WP;5R7V'B&]5)R]ZHC9YX5]JDQ:P
MZI-Z_\N!:JH!*= JRE]$_>ZD[!E]Y/]+@:QE0"QI4<20/$)7JR-XC3$"UUC"
M;\TDQF>-,^.UQIOCL2:(Y[HFBN^\)E$P=766K./J$CF[U;6B2:O;Q39#BR43
MA]8I3!@Z0%Q3F+#JL<+X%6\5QR]GE3YG^"QN+>4O[::U0"K6TD_^O9S\>XC\
MEUPT?"/@NX4/SZV*<-^J [=MIG#9-A[.V^TQ=;LKX[C=E['?'LJ9O#V6:[L]
MC6>]O8 _8?LTP;CMK3*6VQ;(CMV^6G;,]KW"T=N_E!V]]:%PU);7<J,VLR*+
M3?]E$XW_,LKO743^37VO74G^N19(VP1$DXO[[P1<]I(#[Y?#I /*L#VH!^N#
MYIAX:#PF'++'^$-N&'?8#Y:'PYFQAQ.8T8>S&(O#91SSPXT<TR/SN"./K.":
M'-G)-3YRGFM\^#[7^. KGM$!EO\YJRA_$>7/'@ :ACZ> 6VE,=@%!.X#W Z2
M Q\%K$[P8'%:!+,SRC ]JXN19TTQXJP53,Y-AO$Y%QB=]X7A^7 87$B$_H4\
MZ%ZLAL[%=FA?[(?FI<V,QJ63T+CX,S0N_,%HG/N+8#F?6#+\7:Q!H''UAS.@
MK!U '&4'':+\8\#D$Y1_!C"[P,#@2P$TKXN@]A]%J'ZC"=5OC:#R[2@H?S>1
M<(3T>R\HW0B%T@^)4/PA'XHWZR#Y<1XDMU9!?&LOY&]=A>C'1Y"_^0KR/[S]
MAV[*G[D&J-P,Y%#?XZG?093M=A*8=!88>Q$8<070NPZH?<= Z:8 BK^((?E%
M"O%]3<C?-X3H5W/(_38.PM_L(?/ '?P'P> ]2 #W00&8!PW ;ST$A3R@#W]P
ME?@5>/CD'UKI?TT;/H/: R0<!H(IVY6R;2E[#&4;?PUH?P\H_PA([@#RCSF0
M>RD'F9<2\%]*P7VI ;S0(T808PE;X*4+$4#0IN EO8A>TL/G)2VX5Q3VBH+^
M/$U\^0\U6SZ>0=&8AU#-W2C;EK)'_0<PO %HW *4?J;L7P 9:C;O#<"P7-H(
MRQ)BX+TBH4+W6H0A84Y,(*80O@2]%%G:%+%4#Y8F'TN+CJ5!9W?\ ZLSDC"A
MCR#7534%JS06K*(=6(DGPXI#&5:4R+!RN40Y44^T$EU$+[&$887+B"&PP@W$
M-F(O<0SOA1?PE_ F7@L?X(7P)9X+63R38_%4CF6>BOX75M\8K+XA6#U"D]JB
M/IK:8@M6V8W:$\2PBG$,*\DD2H@:HIGH(+J)1<128B7S7K*6^4NRF7DKV84W
MDL/X4W(6+R3?XYGD-SR6O,!#"<L\4&"9WX919)E?/X,UT@=K1,YO2.B3<^N;
M4UTF4EV<J#U^#*L:Q; JJ0RK7$!4,N^5&YB_E&<Q;Z1=S&MI+_.GM(]Y*5W&
MO)"N9OZ0;F2>2W<P3Z4'F=^EIYE'TF^87Y7O,_>47S _J[#,3RHLY[;J!VY]
M!CM"&^Q(\G\3-; CJ!TC:4Q,K*A-]M0>+["Z8<P[[43FM58V\TJKE/E#<SKS
M3+.9>:K9P3S1G,<\UES(/-1<RCS07,G\JKF>N:^YC?E%<S]S5_,D<T?S.O.C
MUGWFAO8+SC?:+.>Z#LN]1GREP_*N?@9K3OD6Y/_F4K"C-0@:D]&CZ&=;O#-U
MQ:L1@<QSXQCFB5$:\]"P@/G5L)+YQ;">N6O8POQLV,G\9-##W#;H8WXT6,;<
M-%C#W##<PGQGN)?SC>%QSG7#KSA7C'[A7#3Z@WO.F.6=,6;YIXU9P:E_P8ZF
M[+$*8*W(^R>H$%27\2/PQLH*S\8ZX.%H;_QB$<[<L4AD;IEG,S^8ES#?F54S
M_S%KY%PW:^-\93:7<\5L ?>R63_WDME*[@6S#=QS9CNX9\T.\TZ;7>"=-/^)
M=\SBJ>"PQ7N9@Q:L[/Z/[+-@A9]@K2A_O BLC1CL)&K'9%6\MM7#$VLS_#+!
M&K?&N^#[\8&X/BZ&^7)<&N>B53[GO%4Y]ZS5=.YIRR;>2<MVW@G+>?PO+!?R
MCUD."(Y8KA8<LMPB.&BY3V:_Y6F9O58_R.RR>BS<;O56;JL5*]K\D4V?P4Z0
MIWP!6 <A+6EYO'-4Q!,'5?P\61_?3QZ#JW8.N&CGS9R9',:<F)S .38IDWO$
MMI!WR+:"?\"F5K#/IEEFCTV'S&[K;MF=UGW"'=;+A=NLU\MML=XIVFQ]3+31
M^IIHG<UO\JMM_A0/V= *LF4E*_X%:RL#UIX#UHF+9RY\_.HBQ-VI$GPS10V7
MG$QQVMD&7SB[,8>< SG[G**YNZ<F\W9.R19L<RR6V>)8);O9H5ZXT:%%;KU]
MIVB=?:_\&ONEXB'[U>*5=ELE*^P/*BRSOZ@P8']/<8G#"Z4^!U9I,;'H7[!V
M#.4#3]S)^;S(_[WX^,I#B ON4ISP-,(AKW'8ZS65V>'IP]GJ$<;;Z![/7^^6
M)K/&-4]VR*54;J5+M6BY\PSY9<ZSQ -.<Q7ZG18I]CDM5UKDM%&ZT&FOM-?I
MC/)\I]O*\YR?J\QU9E7F$%TNK/+G#!\MOW8#?B;__H8>\9<".3CK+\!Q7P4<
M\-?%KH QV!)@QVSP]^"L\0ODK?*-$BSW29(=\,X4]GL5B/H\R\6+/*9+%G@T
M*?2X=RAUN_=(Y[HO5>YR7ZLRVWVG:H?[";5V]QMJLSQ^5VOQ>$>P:C,]6=7/
M8:?2JXOZ_P.Y[^50X!2YW]%0+@X$RV-'B"8VA9IC;:@-LS+$A3,8[,OK#PH3
M+ Z,DUT0D"K7XY\C/\^O6#+'MTJAT[=>J<.G5=KF,U>EU;M/=:;WD'J3]S:-
M1N^C&C-\OM:L]WFD4>?[%\&JUWY [1.L*W#/#_B:\L^2]QV-IGUV%(.=$4)L
MC%3#ZJ@16!XUGED:.86S*,*+UQL>+.@.BY*=$Y(H-SLD0[X].%\R*ZA,<69@
MC;0IL%EY1D"G:GW 0O7:@.4:-?Z;-:L##FE5!5S1J@QXH%49^$:S(I =1H-0
M_\2?'L!/0<"7D>2<<>3^">0:],K='"/ ZEAE+(LSPI(X2RR,M>=TQ[ASYT3[
M"SJBPF5G1<;)M42DRC>%YTAFA!4KUH552:>'-JA4A[2I587T:%2$#&J6A6S0
M*@G9KUT<<E&G*.2^=E'H:ZVB4'8834+C$T^\:1RH!N=CJ ;D?7M2:)^=3/O<
M! Z6)RIB29(>%B2-QKRD24QG@@NW+=Z7/S,N1*8Q-EJN(29)OC8Z4U(35:!8
M%54NK8BL52F+;%4KB9BG41C1KU40L4X[+V*O3F[$>=V<B'LZ.9&OM',B62U"
M,_<S'M X?!-![D_]/TCY.]+)_8F5=-^?(L&"5!W,2S/'[%1K9E;*5&YSLA>_
M(2E(IC8Q4EB=$"^JC$\3E\?E*I;&E4B+8FM4"F*;U?-BYFCDQ/1I9<6LT<F(
MV:V;'G.&^)EXJ9,>PVH36H3F)^[37/R*YL )ZOL^\N^M6>3^Y, #U(Z%&6+,
MR]3$["Q3M&:.9YHR'#GUZ1Z\FC1_055JF+ \)594DIPL+DK.5LA/*I+F)DY3
MR4YL5,M,Z-1,3UBDE9HPI).<L%,W*>$T<8=XH9.4P&H36LF?\7,(K0>:!T?3
MR/TI>R-M>582B^F^.T>$V3EJ:,TU06.N%5.78\>ISG;E563Y"DHS0V2+,J/E
M\C.2Q+GI&0I9:05*&6D5*FFI#6HIJ1T:22D+M1)25NG$I6S7C4TY2=PF_M")
M36&UXU)8K<^Y16OQ/,V#0^2^VRE[71$Y7R$Y']W/SI=%2X$R&@L-45LXAIE6
M.(E37N#,+<GWYA?D!<GDYD;*9><FR&?DI$O2LO.4DK/+E!.SZM3B,]LT8C-[
MM:(S5FA'9FS5B<@XKAN1\2/Q7"<R@Z4_8[4^YWL:A],T]OMS:"Y2_FKRSSYB
M#MVW%O,QHT0)TTOU4%5J@;)2:Z:H="HWO\23GU,<()-9'"Y,*XH3I12F2A(+
M<Q3C"TJD,?G35:/R6]0C\N9KAN4MTP[)W:(3G'N,N$$\I9_?:X7DL,-H?N(:
MC<-QF@>[:?N[L0Q843E\!D3.54[>6<&@NE(!%57:*)EFBL)IXYG<*@=.5I4;
M+[W23Y!2&2J;6!$C%U^>+!]3GJ4055:D%%XZ33FTM%DMN&2N1F#)@*9_\28M
MO^(CVK[%WVK[%?^NY5?T3LN_B-7T+_POEY* PU2#[26T'JO(.VN&SX" 9J*:
M[LNFRZ.P3AUY=2;(KK=D,NHG<U+J7;B)==[\^-H@F9C:2&'D] 11^/1T<4A-
M@4)0=:4TH+I1Q7=:EYKWM'YUKZH-&AY5AS0]JJYK>E0^T?"L^(M@-3S+6?5/
MG*7YOY_&?S/U?U4M>5\]T$'4$:6D!7E-0F0U*R-]I@%26D8CL<6&B6N9RHF>
MZ<&-G!G #YL9+A/2'"<,;$H5^3?EBGT;RQ2\&NN5/&;,5G:;T:?JTK!.S;EA
MOYI3PU4UY_I':LYU;]6<:]G_X0NJP2ZJ^_KA<RAR\.XF\JYF\IZ9Y%UMY+[M
M7"3-5D1\IS9BNTP1U34>X5WV3&B7*R>HRX<;T!G"]^N,%GC/3I+UG)TEY]Y1
M(N_242MQ:F]3F-*^2,FA?8W4OGVOU*[]LM1^U@.I?>L;9?L6]G\X6$QSD6H^
M1-F+6VDMS +J*;MT-I ^E]QS/A#9*X^P!6H(66"$H(5CX+_0!KX+IS+>"STY
MG@L#N.X+PGFN"^+YS@O2!5-Z"V4=>JN%=KVMHDF]O?(V/4-BZY[=DHD]%\03
MY_\JGMC]IV3B7%;A<W95?3B'&J#L^9U 2Q?5@++S*3MY(1"^A/Q_0 #O045X
M#FK#8]E(N"VS@NMR.S@O=V&F+O=F')<'<^R71W,F+T_FVB[+Y5DOJ^!/6-8D
M&+>L6\9JV0K9L<MV$&=EQP[^(CMFZ2OAF'Y6;LR2_[*%%&PE]7LA97=2;CUI
M8<DB(*.?_'\9^?\JP)TT<<HZ>3BL5X'=>GU,7F^.21O&PW:#/:PWN&+B1E^,
MWQC*C-L8QUANS.",V5C,&;6QGFNQL8MKMG& 9[IQ*V_DQI.\D1M^YHY8]X(W
M8BW+'['FOZRA_"5S@'FDQLV+@:H!\M\50.)J('0]X$5JZ+@5F+B#"\M=$HS9
MI8;1NPPP:K<Y+':/A_D>.YCM<87I'C^,W!L.D[V),-Z;"Z.]58S!WEF,_M[%
MC.Z^#8S.OJ.,SMX?&9W=SQCM77]QM'>R_S!(^3W4]UE4\QK2T0+*3MD 1%"N
M#RGIU-V ]3Y@-&F[R1$!]+\00_<+%>A\H0?MXR.A==P2FB<F0>.$,]1/^$#M
M9#A43R9#Y50AE$_50WIJ'I1.KX+BZ7U0.'T-BJ<>0_'$&R@>9_]AX0):BU3W
M.NI[\3I:!^3A43L!7W)QIP.4?Y@<_!A@?!+0/LM Y8( BE^*(+FB!/$53<(0
M\E<LB(D079T"N:O>$'X53J1 ]JL2"*XU@W]M$7C7-H![_2B8ZS>(1\3+?^A:
M"C2L^G &E+$-B*9LOT/4_Z-4_^. Q6G \!R@>0F07@7$7S,0?L^'X(88O!M*
MX/Z@ 1(LX*89\.,XX!9M4&][TL8H#+B3^N$?9?J9)OS/5.B[FPGJT-WKM'G[
MY1^:*+]\XX<SH!CJMS_]%:<3P(2_SW\ _2\!]6N XK> Z > ?QOT><1=&?I]
M,?"+$G!?#?A5%_AM!/!@+/!H\H>-^N^T.7I*+^2G]/!_U@X\IX(_IPGV!P7]
M<>8?*C=]. .*H[X'4K;36<J_")A> 72_!E1N ));@.P=@+E'V;\1CS_RA$<Y
M<I0AH<^6TN=I "^I)G]: &^L@7>T67T?\O&[(!4?OY/21]"D8[?^ ZMF#%:5
M/%>)$)N %9+O"FS!<MW (IB()[*($J*&:"+:B7G$ J*?6(YW6(VWV(C7V(%7
M.( 7.(GGN()G5+2G]-\3O*%FLW_SZ%^PF@9@-72I'82B/EB).5CYB6#EG,'*
M^(/E1X/EI1$%U*Y*HH%H)3KQCC,?;SF+\9HS@%><57C!68_GS%8\9?;B"?,%
M'C&7\8"Y@]^8)[C/>8M?>"SN\0G!_\+JD&=K:X)5U_C0#N415!,K:H\CM<>;
MVA,.5I1$Y."=J!1O1=/Q6JX)K^3:\4)N+OZ06X#G<DOP5&XYG@C7X)%P,QX(
M=^.^\"CN"2_B9^%/^$GN=_PH>HN;\BQNB#_PO9AE/L'JJX/54Z9V2*D]U!9M
M(ZK+\'G0I+_/@]Y+@_!:*18O%#/P7+$0ORM6XK%B/1XJMN WQ=GX5;$;]Q47
MX9[" .XJ#.&.PD;<5MB)6PJ'<5/A KY3O(WK2K_CJO0M+DM9YI(RRUS\R(6/
ML$:4;43^;T@8J7PX%S(P!:L['G]J3\$S35\\UHC ;^I)^$4M!S^KE> GM6K<
M4FO$3;59N*$V!]^K]>);M27X6FT%KJFMPU6U;?A2_0 NJ9_%!8V;.*/YF#FI
M]98YKL5RCFFSG*/_@ATI 3M"!-9,'JRY(EW5\'ZD ?XP&86'AI-PS\ -M_6#
M\(-^++[52\=UO7Q<U2_'E_JUN*3?A OZ[<QY_;G,6?V%S!G] >:4_A!STF 3
M<]Q@#W/,X 1SU/!KYJ#1;YQ]1G]R=QNQW%W&+'>G,<O;\1FL.>5;\,&.E05K
M2>T8HXCGH]1QW\P(MT9:XMN1CKAJZH.+IN$X9Y:(TV99S$FS0N:X:25SS+2.
M.6+:S!PV[> <-.WF'#!=S-EGNHRSQW0==[?9#NY.LR/<'6:7N5O-[_$VF;_D
M;;!@^>LL6,':?\&.H7RKX6--#EY.%.#)>#G<'ZN(&Z,U<&6L&<Y;VN*4E1N.
M607BL%4T<\ JA=EKE</9;5G,V659Q=EA6<_=9MG"W6K9R=T\MH>W:6P_;\/8
M5?QUEIOY:RWW\U=;GA.LLOI)L-SJN<R@%2L[,(Z574KT?\;?^?0X>3*)'J]V
MP/>3>?C:6HA+$Y5QRL8(1R:-P_Y)4[%[D@^S8U(8L]4VGK/)-HVSP2:/N\ZF
ME+?69AIOM74#?Y5U*W^E]1S!<NN%,H/6RV0&K-?+]EOOEEUB?5*XV/H'X0*;
M)W(]-N_DYMNR<MW_8OA8]R5E_SR5G,\%N.3"X.P4 4[8*^# %%WLFCH:VZ;:
M8=-4=V;=U$!F]90HSDK'1.YRQTS>H$,^?ZE#F:#?OD;09]\HL\B^77:!_7QA
MKUV_W'R[U:)Y=MM%<^V/RG?97Y>?[?!0W.[P5MSFP XC/^LS6%MZ_%+^#7J\
M7R+_/4D<\>!@OZL\=KAI8I.[*=9Z6&.5NS.SS-V7L]0ME-/G&LM=Y)K"7^"2
M+>AQ+I+I=JZ0G>M4)^QR:I'K=.H2=3@MDF]S6B%N==HLF>ET4*'9Z;)"H_.O
M"C.<7RLT.+,*#2ZLY'/>V-/KQXV<TY=<)X#V^>2?>\F#MWL+L<%;%4.^QECF
M.P[]OH[,(A]/3J]W(+?;.Y(WURN!W^69+NCPS)5I\R@1SO*8)M?BWBAJ=F\7
M-[KW2!K<!A7JW#8H3G??IU3C?EZIVOV>TC2/5TI5'JSB1Q0^\3O5X$?J^T7*
M/D:ON;WTRMU&KYD- 7RL"E#"0* !%@>-06_09*8[T)7I"O#C=OB'\MK\8_@M
M?LF"9M\LV4;? F&#3X6HSJ=.?KIWJZ3:>YY"E7>_8H7W6FF9]VYIJ?<9Y1*?
M.\K%/B^DQ3ZL4K'OWRA^XB&]VKZE?I^A_$.1P,XH\BVZ#H4P& A5P*(P'<P/
M,\><,&MTA#HQLT*].#-#@GB-P9'\^J $06U0FFQ-8*YP6F")J#*@1EP>T"PI
M]>]2+/9?K%3H/Z2<[[]#)<__I$INP&WB#^7< %;Z$:5/W/>@<0@B]X\@]X\A
M]R?W6TW70?IY4808W9&:Z(H:B;:H\6B)<F0:(]TY]1'^W.GA8?QI8;&"RK!D
MV?+0+&%I:)&H.*1*7!@R0R$_I$,Q-WBA-#MXI7)F\#:5C.#CJNDA-XEG*NDA
MK#(A_9SA\[CAL["CE+LK@6I [K>"KGWDPMTQ(G3&JF%6G#&:XRS1$&O'U,:Z
M<J;%^'(KHD-X95%1@N*H1)G"R QA?F2^*#>B7)P=4:>0&=&FE![>*TT-7ZZ2
M$KY%-3G\F%I2^/=J21%/59,BWJLD1;#*R1&L]!.W_,G]J<^'XFD>#I\!T79C
M*5U[Z>?.!"%:$Y31E&B ^L31J$FT92H3G#AE"5[<XOA 7F%<!#\O+DXF)S95
MF!6;*\J(*16GQ4Q72(EI54J*GB]-B%ZF$A^]634V^HA:;/0WQ!.Z?Z<2%\TJ
M$])/W*!Q.#U\%D?]WT+;KE7DGXOI.I=^GI4L0&.*$NI2=5&=:H&*U(E,:8HC
M4YCBP<E+]N?E)(?Q,Y-B9-*3DF53$[/EDA.+Y1,3JB7Q"3,58Q/F2:/C!U2B
MXC>J1L8?4HN(OTX\ION_5"+C665"^HGA,\'A\[@]U/^-6< RHC<3:*>?F](Y
MJ,U00%6&%LHR35&<.1X%F?9,;H8K)RO#EYN>'L)/38\6)*<ERB:D9<K%I1;*
MQZ162:)2FQ0C4N9(PU+ZE4-3UJN&I!Q0#4ZYJAJ<_$@U)/FM2D@RJQR:S$H_
M<27BPWG<C@Q@72[03\PE#YY)[:C-!BISQ"C-54=AK@GR\BR1G3>)R<AUYJ3F
M>G.3<X-X"3F1@KB<>)F8['1A5':^*#RK0AR:-4,A.+-3*3"S3QJ0N4[%/W.?
MBE_F916_C <J_AEOE?TS6&E ^G^Y0'/Q(/5Y*^4.%=):*!@^ Z+]?A[ET[6X
M0(3\0A5D%QDBHW@TTHIMF.3B*4Q"L0<GKLB?&UT4QH\LBA6$%Z;(AA;FR 45
ME,H'%-1)_/+;%7WR%REYYZV1>N7M5?;,NTC\INR5^T;JE<M*O7)8I4^<IC6P
ME_J\D;*7EY#WE@R? 0'51#'=YY;)(*-<":D5NDBJ-$-"Y03$5CDPT96NG(A*
M7VY890@OI"*:'U21)!-0GB7K6UXLYUTV7=ZS;);$O72!@FOID*)+Z6XEY]+S
M2BXE]XD_E5R*6477HO]R+/7#=[+6EI)WTO:[Z^\S('(.(IN</+6:@X3I$L35
M:B*ZS@21]98(KY_$A-8[,4'U7IR ND"N7UT$SZ<NGN]5FR[PJ"V0=9T^3<YY
M>HMH:DV/>$K-2HE#S0[BC,2A^I[$8=HKB4,5^S>.E1\X2'-P"_5WU31@036M
M!6(Z432=\NO).QJ!R&810F>J(+C% ($M%@AHG0B_5@?&I]6-\6KUY7BTAG+<
M6F*X+BTI/*>6/,&4F14R]C.;9"?/G"<WJ7F9R*9Y&W%*9-/TL\BF\:7(9@8K
M;]/P7W;3'%A?]>&[0'/K:"W0M;*!QH"R$UJ!<-*C@-D"^'0IPFN.%CSGC(#[
M7$NXS9T$E[E.<)KKR4R=&\@XSHW@V,]-Y$R>F\6UG5/*LY[3P)\PITLP;LZ
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MA_V(2(@/IT/^2!E$1UH@=W@Q9 ]OA,SA+X@?Z?YWR!YZ0_SU-_.IWZV+Z7E
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M.(Y=?3IG4GTAUZ9^.F]B?3MO?'T??US=>H%5W2'B.X%5[>\"JYIW!"NPJO[
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MAYCV4$'W+*>7$OGV;A+YW23.NYX2K_YF^-_DF4%*7K(02*<^1]%?]:/^.F\
M;$F+1Y.3&^\"M/8"R@< R2'\'UMG 1[5M7;_=68F+L1#$N(A[N[NF;B[NX=X
M()!  @$"P2VX2W$*%"E6*"TM]7MO>RN7"G6E+O-?DX1^?/?_/3P_9C*9V>O=
M[]YGGW=MSAF@<DT!XNL:+#JT"3W_#7K^&[;$C2?  . 6"X);\G\4X0GH.1YT
MSW%R/<?./7>(7.;K-/2W/B%?3S'*?/?)K\-AGXL/<PS8W^@SU'^:^A<!*W[$
MZ%E ^P:@_AR@^#S]/KN">TJ$<;S$.%XR8$%LRF+(AH4YB^37_($W&,<;+$3>
MY(+_)@_TMSC0;VTC]/S_8(/_?)F\.\7 KNGK<,KXJTQJQ["__M1UXMLLJ6MX
M&]"Z"ZC> T2O4/L-\@_R3_*V O".&HMR3> ]79H3(^ _EBR2Y6;%%WC( OFA
M_ O+N!!_Q@/^,P[ZYQSDS]G1SY\A-Z=H8WHJF/-L]CN.V@'7V/];@ 7[:T!=
M3>HJR77_1=Z=V0?Y<.9Z%/EU(0\%MLV<?*$.?*D%?*T/?,N<_& '_$33\C/C
M^(4GQE^Y&/[*@_\WSHW?F/C?F?3?3TXA4S.!3(F>'W+F$/G^@R<)(TDDEU1,
M[3_(,(_N?0"_8QB_81E^P3A^QEK\A,WX$=OQ"'OH\ _C.YS$-_3^7]/[?TGO
M_P6#_8R_^11_$=G_ATR3/EN5GE_0XT]\#BOB2H)(',FD;@DU:ZG72JT>MC:(
M[[$$WV*,6JNIM9Y:6ZFUDUK[V>XQJIYEJIYERNXQ=0_P/M_]'J-_CRV^.\._
M9Y!IZ4*F0<^OJ 69B+' C#@07Q))[13V+Y]]JZ!6([4Z\#GZJ+,0#S&"C[&"
M6A-4V4BM26KM8?N'\39.<<I<PIMX'J]-[81\A5?P*^ZSU9?)2T\@TY[%7-#S
MJQ,UG>EQ$=GP-^[,<3#[F4#-3.H54ZN&.LW4Z62K W@'0YPFHW@+*SE5UU)K
M,W5V4., >W\<+W \GL<MW.8D?HZMW&0F;[#EZX(,UT3_@TQ/C;E0)"I$D_%P
M3%3-\*.B [Z0^.)#<23>%Z?@'4DNWI*4X75)'5Z1M.)EA6[<4YB/%Q2&<5=A
M&>XHK,)MA?6XI; --Q3VXIKB45Q5/(<KBC=P2?D-/*/R&<ZK_8)SZC*<_2]D
MAA+&0?]O(.8CX]#6Q/>:^OA4W1+OJ;KB+;4@O*(>AWOJZ;BK7H#;&A6XI=&
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M>/I"Y?OYTU_6?I\#?9^=O,^.W;] GB?O3-$S"=3MYK%X$$AA?R.HZWV>^L\
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M:FOZH;IF',H3.Z$T<09*J^^23Z"TZA&4Q_\@K.>H-T!:227SG=L+)+//44-
MP"C]/W7M5U%_#?7ISW4WT8-O58;:I"94)G6A/&D,I4DK*$XZ0C+I!?%D"$3;
MN?ANYV*S7?XE5!S(R26$']QVA-"\;Z7?WOHE^9&%TB\8[N.YB=0QWT6TY^G#
M0"S['+R2_I^Z#M2UI$4UVDX/O(OZ>P&5 PH0'Z37/DAC<)!%\2%Z[4/6Q DX
MS*+L,$^XAWGB.<R#_# G]6$V?I@=.4R#?^@<H9$^^!'YAOR !<QU*_M<SE"S
MQS@&?&OH>LY!^34X.ZB_A_H'J$^[KD%_KG2"/IL>'6>4".,XPSC.,HZS+,C/
MT6L_S3C.LR \SY/_!2[V%WB@7^ @7V#G+C 7%YB+\U?):^03\CFZETU?AU,P
MP6-Q(X^#2?E]4(#S0<#J*/6IJ7UF>O]%<I':E\G5&9Y59 &DQF)T%G"#YN2F
M$8LR%N7/R8MTYD->&-SEHG^78W*7 WV7 WMW)_#"*7*=SU\E_T++.JZ)FSD/
MV>?8?5P'J.MV$K!ARHPN %K45.40"M=G]E^>G]D+D7./O"0&#1$+8QJU5YF3
MUPV M\R M^V!=QG'>RQ"WN?<>+^6)H:3_ ,.\ <4^H#)_( =^> F:AA6/G,M
M?0H(.\LY0%T;ZLZFKM9-0/GQ_LM+,WLO;\[LA?QKYMZ<=Q_OATB #U6!CVD<
M'S(GGW..?&4'?,MQ^8[%R/<\\?S Q>X'#OXC#O8C3JQ'Q\EINM[_:__!F020
M&)(V=3_,7_2ZOZ,1OZ(#/Z.7+GX0C["$3GJ,'GT5??(Z?(TM^ H[Z=</X'/Z
MW4]Q@=[Y.?KV=^BZO\(#MO!_WH<"+?+D_H/)S#TYWM2-X*>DU,RA7BFU:O -
MFJG128U^?#9S'<8G6$Z=U=39P#:WX0/LP7LX0N6S3-<U^O97\#HC>HTMO<J6
MY;SR!-/:*N3Q_H,!=:WX;C?J!K%_<>Q!.O4*J%/!?M13HY4:7?@WXW@;BS@T
M(QRB%=19P_8WX3YV<.@.X$6<P%T\@SO\^SE^\A:S=I,]F[H.@]R80296Y-\"
MD3^J,]?:[*\IOH #^^C+OD5PN)/8IRSJ%+$OE=1HH$8;-;K8^@"GZ2+<QBAU
M5E)C'=O?BF>9BRLXBDMX&A>I?I[1/LW>G,5O1/:_D'$JR? 81>99@_TU8#^M
M\ _FXE7FXB7.BQ>00IU<ME9"C2IJ-%"CC8=J%WLZ0)TAZBS%.<Z-,QR3T\S%
M21SDK#B-8WSW$;9TB.-QB!D^2"4Y!V:0\1"7*7#JBJ=O_?H/E-A?+>J:,(=V
M[)<76PBE5CQUTMF7/,9>RI:KJ=' ;+?A*7139SYUAG&8<_0@QV0_<[$7^[";
M4>QB-G8(+V&[Z!-,2AYAFT2&K0K3;%&0[XE-?]7.1_(M3BXU+W/)>5ZLQG'2
MQ661.<Z+G7%&XH>3"I%X2C$11Q0S<$@I'P>42K%?J1I[E1JQ1[D=NY1[L%-Y
M$-N51[!-916VJFS"9M7=V*AZ#!O4GL$ZM7M8J_XQ)C1^PFI-&5;-,$Y^T@8^
M,>2RPJ7V#I>YJUQV+S*>\ZH:.*5FB&,:-CBDZ8[]FD'8HQF-G;.DV#XK$]MF
M%6#KK#)LUJK!)JTF;-#JP#JM/JS5&L*$UG*LUEZ/<>V=6*%]!,MU+F"9SHL8
MU?T$(WH_8[&^;(KA&;XR!OYMR65H+KTWE_M3YO1]?.VPGB+VZVACEYX9)O4=
ML47?!QL-0K'>( YK#5(P89"-58:%6&E8CA6&M1@S;,8RPTZ,SIZ/D=FC6&PT
M@2&C;5AD?!"#QN>PP.0.YL]Y@'[3']%G*D/O$WQ,W5>XO#_K3-_KR-,8E[9=
M/ 5N9RQ;C36Q8<YLK#&UP2HS-ZPT"\"86026FB=@Q#P-B\US,&Q>A$7F%5AH
M7H\%%FV8;]&+?HLA]%FN1(_E)G19[4.GU6G,L[Z)#NOWT6;S UIM9%.TS/ N
M]9]W9^X]>4KEXPY78!-C6<=8)JQ5L=):%\MLS+%DKB.&YWICD6T(%MA&8[YM
M$OIM,]!KFX<>VQ)TV5:CTZX)'7:=:+=;@%;[96BQ7X\F^]UH=#@A-#A<$^H=
MWQ%J';\3:IUD0HT<QVG><.,ISQ<X079S:=_(T\P$8UGN0O_OJ(C%#EI8Z&B,
M^4YST>?DAAYG?W0YAV.><QS:G9/1YIR%%N<"-#N7H]&E#@TN;:ASZ4>MZPBJ
M7=<(5:X[A JW8T*YVQ6AW/U-H<S]&Z'4_4\B^YN7J'DYB.,?R!*'3/C3;S&6
MQ<S+0G<! VZ:Z'$W0*>[)=H]G-#JX8UFCV T>D2AP2,1=9YIJ/7,1;5G,:H\
MJU'AV8QRKQZ4>@T+)5ZKA&+O2:'0^XA0X'.)O";D^WQ%_A#R?&13Y)/GJ7D^
M=/H:F(TAP(I@ZC.6!7[TWHROTUL-;3ZZ:/8Q18./'>I\W5'CZX\JWS!4^L:B
MW#<99;Z9*/$K0+%?!8K\&E#@WRGD^R\4<OU7"CD!6X3L@$.BK("+HLS ^^0+
M\KN0&2@3,@.FN47-TQ&<ARQ[UI)1EF&#C*67<<QC?"T!RF@(T$9M@#&J FU0
M$>B,LD!OE 0&HS@H"H5!B2@(2D->4"YR@TJ1$UR+K.!V(3-XOI 1,B:DAVP2
M4D,.B%)"SY.7R&>BY-#?^"@34D*FN4;-XRPS)LDJ,LS2IY^QS&,<S8RO+D0!
M52&:* \U1$FH)8I"'5 0ZH&\T #DAH8C.RP666')R S+1D9X$=+"JY$:WBJD
M1/0+R1%+A:2(C4)BQ'Y10N0Y\B+YE/PJ2HB0R1'DR.\).Q)#WTV6DX4QT_LO
MK8RCCE1&""B-T$!1A![R(TV1&VF+[$A79$;Z(CTR!*F144B-2D)*5 :2HPL@
MC:Y$8G2SD!#3*\3'C AQ,>N%F)B]HIC8LZ+HV+ODH2@ZYA<B$\5,(SS#$N<
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M&K_#'2K<?H([_[7_(-^/^67J&HPY[)\=^^;)Z$.H%\<6TJB11XU2IKZ:0]"
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M+(7K2"F?Y_.U3,:1PG@2^9Y8?U5$!V@A(L 080'F" VP17" "X("O1$8&(2
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M2^E.<@H6TCNP2/H$EDD_PRI1-L5$%.<"=5I)58S\&B#F@"12,R*._:=5\DL
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M+4SIUT3*J,93IC26.JO1U/4:3MNIH;0#&K0<4K_E2^JS'%&O]6GP?? 1^ >
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MP[^ZB/][XF7K2Y6EWZ;4_@RE]&<KN=^OI/Z@$ONKE-#?K+B!7L4.3)C'K Y
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MGV8PF:8NIBG$-#^>HCVFE@-\8A*_7'@CWX?O+G@3?*0^]+0UFNN JM ;Y+4
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M$%M/(9%;3J%J-I_$HC:=(* WGJ!@ADHF>?>(0,?=HW3G[GZ2#QY^C0HF3L.
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M9G!'*,PB1X)4:L*'9]1[LK.@*EF+!:9IT<%U3:HJ0[V\VI245%OB(H0M,A2
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M(NS<OM*(<WN+(KL:"J(NU.5%7:S-C;I<G1/579D3=:5B,A!'.L22#@D[9J)
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MD"CZ-ETP$TO$$K!I;@2DE_E"<9T'U+8RH"OI !,9&U@K6,!!R00,%4.PU?3
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M0<^R :V("L=R1SC4TGY3]]%_V;6ZC-NVN_ZDG&3^I%Q@_;"YP?IFW<?^9#W
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M,_R_P)#,FCK;A&"Z10C66X5A)R$">WDQ.&G-@J/90E#M5X#"6@<KORTPCY*
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MFPES .Y64_>>#W"*NN<!ZG[;5U/^^NG^R8)EDU(P,*G+6K##FJ]MFYMXXY8
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MZ#,V:,&R1'N6*75^(_1C&V X1Q<3N+0PBTL=2[E5L9E'!1?S*N$XKR(>Y%7
M6WSR^($@G]S_PVHZ _UT!EL/_#?_"D#\;P!!-P#<[P(X?6+ '@7!&B7 '!7
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M47_^A$?M;^11>XR\JH^17^41"GQM'=T#R\8!>K8"-$[G'P/(. \00ST\X&<
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M'@4TKZ*@QA44^MH6NO]6T?E;3/-OH_QJFGW^ <JG'AYQFCKX!0"G*P!6/W'
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MKPOL5%H;L$AE+&"YZJC_N/I*_^T:(_Y'-9?Y7]-:ZO]<:S  -0?(X@#4Z ]
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M\9^BS9ZBFVOJ&'E,D/[[;W50?C7EY]*^)]"U!U&V,V6;_T*S_Q- Z29=^UT
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M?,U%X&O>^-\L!KYE!W_+1GW[(;__RJOX-QV[AG) .:=X#UP"_*\#,QBVB7>
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MHOI J/KA+P;Z(COQXCY"4WWQ"_X.??\%\6]64'?A>L: [<VA;AQU ]A6MT/
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M;[W!E-IZUI32^F=32LM7II1FBRFUR89&B^G>1N8%< !L E-@#/2#5E#?C.9
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MM?2&K?3,O7CBJ(Y,9T-NP:('=9"^N9_!>R&M;3QWZ'Q\:SP8R\EZ./63O#[
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MDJ+F*R%J4O%1FQ0;=4C145<I,NH>143]#GS">XNB(JVX!)[M<"XW]N#$(X-
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MHFQ"^\/7A)_+><WAIXDT7SAF^U)?-W@=ETGVJ\[+OVP%V\$N8.0F]H)]=M9
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M;#1(UT:/=&Q-2=O6FK1LG4C3MCMIV/4EH=T04K,;0P*[<%*U2R1ENZ6D9%=
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M'?F7CER(:"V*)/#D0: H/X%@(Q)ZQ C%S\V9"P>+AH!H_D D?&%.$NX!B8X
MDPA_@N\Q\H(\-]373K(/BZ_!44-]%;A<GO<9(9')UZ),_KLL$N=">&XB5A*(
M=^R3R8"/+((>2^ ;BTW$#XM;"-]< ,Z] %]* WN87TF4\@U1TA_DA?HZX6-+
MU%D/JJH'0CZW+\\S393(C*"_UJ%TK E)DP2BZ/)_YD(Z]LCP/1R;X",%Z+-\
MPS!_5LU6&'DS*K81!6[()%J+,7LU2/O*-^2*.EOS?5"HLQ!V5@R5!+>SZ*\\
M"*\;7WS=<49KAYP_UY[07WF0OZ_3J(,>3>BS39AL&M#)ZE#9&ABU"D:K1'M4
MU!.5_D0.\"M3F$@33:7,ZSQ'8E=>SRSZZUR2?^9!^,+\OS^WM^.<$+X6!.XF
MRDN(<B"RXF?$7$.;7(;370@4/ZOWU%*B-A30VDZ6D*T[C3^'"7V?UYFO[^'K
M4/@/OYQ\;9?(Y&20;PK@I+1C_PV7Q<\AZ5@+PA<-=.1 OB?QN:C/@-?H+Z_0
M)K^@KSZ'PSV%T,?S0? +<%_S_RO_\!NXQ%M2I8^B-1@&DLC72;(6Q%O$C#ZC
MDWR$L[X#&_D=COH&\?MK&/ 7,,_G8*-/P*M^0F/]@,:Y2W5@5A?I*DIM)?'>
ME^V2W$?'.9CB9Z"(]V \D> Y]/@5>KP'GWF':/AW1,RO$,$_0]S^"(SF ?2X
M"R9W$YWU&CK-93CO!3CO.>AQ!GJ<!.-N R-O@:1#<(XF.DKU]+/H&2S;)++Y
M_H]L20[B%8FW#]VCOQX_S)^)<I,4Z JXQ!7PB*O@,NV(W4^"31R#'D=@CT,8
ML)HP<#1@H*H#KZO!8+$7SEP%5E\!ARJ#$^^"\Q:CUMMQ1P'=@.M^%M6;GWV1
M)LE!\"<-\^-L>>Z#KT$X+6GF1I&;2=$^\+LJM$DU>'\U^'8YF,LNZ%&$"6,;
M!NT",#[.9#=C(,G#X+4! Y=X+\H<R$I"5\U&?3>BVY;A51MDOQ+E/WCN@^__
MX"?<S@*X&_%4WD&)B_/NM472#=:1/.PF #11K@&ZAP6M@![+H$<._&.Q:#6_
M+^SICZ$B$.6/@#>,Q_ Q#76,0AWGH65R*0X:QZ UHNF^:-\)SWOP',1D21ZB
M1>+N7/9Z^FL-!E^6-A^V2"4ET5F<J>"8*6!%B= C'NT2"TXU%^R/G\<9*3F/
M<Q:8> 0FD' ,JM/Q_S#<-05M,AD6FH06F@AOF0 /XT]^YGM >!Z"GT-10_^[
M!R11,C3-D0R/,T@6Y:D 0D ',$+9%BC;%N4ZH5PW2/1$[;U1=G]X:""\8R3^
M382,6?#:%'A,+@5#RE!X41"\/I#$^S\ZSJ HD<A/E\CF4P&?%OB4Q(?KT;#%
M*/CG2+3)2/C&*-)%V4;0WP)EVZ!L1Y3KBG(]805OE#T Y09A2A^#5V&B+)$?
M+<)4OQFMM@_3_K>B_1\^DI[._VZ4U)]/!=,ELOETP:<K_G,%_]EB(&PQ$)P[
M &T2 #T&0@]_,H8,"Y1O@_(=4;XKRO-$N3[PUH'PE&'4$Y;W0BMYHE5[P*.Z
MPS>[BTZ[^5UT"I&'9-19)K$_KS_/?X1(Y/*?:WBHPD.'/B0-*%!OC!F]21W0
MA P]R#!&^18HWP9E.8FR#^ZXZ@JM7&"9;K!%5]$)J@GX=!E0!&V;@:>B%7".
MDM&/VX#G@"8A!!DN+0Z)>.ZC-U[ST(F';ICQ4+H<H 0(($,(:$&./N280(8E
MRK)#F5W) =KPE2%VL)@M+&J#EK5&*W>!IUN)GCBT'W??$XV^_$2D+L1$2T%G
M8%H9@R$]$.&8GR)"-D5QJ.J":\X(29R@DR/)H'P%E*\"J $:D*,#.0:08PHY
M7?#/ >6ZHOR>L$Y_C"C!9 :/-45[F,#CC-$_C##B&&%4Y4_&XCLCC8%8R)BB
M*%X#$\#S+T!WP 5PQ#4[A.[6^+R+@C19R<J3E;0264JI0HXZY&A"CB[D&$&.
M.>38H,RN>-<#O;@OM!L"2XU%JT7@KE1HO ;8C5Y^'/A%E)7G)U5%HOP)D#=4
M5;Q<FX?HKH"3@.<]P#5PW0(P4Y$B4V4Y,E%4)!-Y%3*6$Y"QK)",9+7)0%8?
M,"5]62O2DW4D75EWTI'M0]JR TE+9A1IRDPG#9DD$DHO)Z%4B>A$:'7,$.KT
M1;1*<B;DCQ7P<T\09H.F= >Z G9 %UPS!TP (X$4&0AD25]5@?15E$A/2150
M(UTE3=)1TB5M)2/24H)EE.P %]) ,"Q4\B=UI1&DIA1& J4$4E5<1BJ*.TA9
MH8F4Y6^3LMQ;4I9E-!WR1T)& *<G?.V+AIBV\=R+!6 "&$(??74ITE63)1TU
M!=(6*)&60(6T5 6DJ2HD#55M$JH: &:DKFI+:H)N)!#T)%6!/ZD(AI.28"HI
M"N)(7I!#<H)M)*M:3S*J5TE:]35)JS#1SY'#(*<_Y'II@F< =H"5)L^[H/Z
M/J C!.\7RI&F4($TU)5(J*Y,0C554E-3(S5U31*HZY&JT 3H0LI")U(2]B!%
M83^2%P:3G' 2R0AC2$J(8% (SJN.&$X-P8X:(A8US!F0/Q3R?!'F])#D@&P
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MEAD<QK)"IK(EPR:SW.&3V8I_C?/M2M3R2%5J'S-5VL5<M/)8=^.EK$^7=#;
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MO3>I(JA@UXT%+*A84/&OV/7WCNZ]GG4^')'WRUG/66M_N#[/M3(S]_RN6??
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MPXZ9EJ RQQA4Y^F"Q@(MT%VH <:+U<%R\0E +SD.F*6JX+;T*."6'0'BLL-
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M'OCC7 =9!,?!<!_T8#3%>C")9C&8YV_VH)IN\N <W?CA(-WX]E.:\8UAZGB
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M$+8]8&_(*'L\Y%#P;LZYX%V<AYR=89_\=T8N> ]' VTP&MQW1(/+4L /SXW
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MMYHPUZ1$_+A)B^O99B.^/S?;BEUKI:P]6^^G=:PJQ/1 6:S=GJ)4\LZ\7-I
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M]U%5<-^OON!V3&/>[8+&#_)=S6_D%UI?R--:G\@_M3ZX@<8[=U![ZPZJ;SQ
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M2'$JK\IQ*ZHLIN955'EFE34QTTH[6<DE P$)Q?O8\27GV?&ES_R3RK]YI58
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M)3U[.RTE>YR1E#W%2,Q^1$_)_4I.RP?'C *PR2P$R\4@5 !!,A&]Q,UWMY*
MKM5SH?-M/.CT9AYTN&L%FNC2( UWF MN:W.6Z&RBK6ZM]U.IK^%H5U=%&594
M)IJ55&18YY?EVV>75#AG%->14PHW>206]-'B"G;38PI.,J(+[C/BBCZ[)9:
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M((^,0)V@!WH$;3 E:H -416<B,K@05( ;Y(<L$FK(8I+!M*XI*&$>R4T<*^
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M?Q+S+P"X_P)@>P/ Z"YF/P10_ - C@#($#Z0(L(@0<0Q3P9$B (($340(+K
M1TR 16R!3EP ;]01OAD2? &<^I\!$=QT9 7"C49PR.3G?ZG?-O4,$"!Q*A_/
M?=9U )O;  8/ %2? '"? TA^!1##8V 3&IXC'V8* 2]A P./A2(<_#D*2 WI
M(M._GX/,1L'PYV_0$'PA)OA&2/#B)ZO1Q+\0=5V*:&E31!MIZ5%$U80B"K8T
MPIU%(])!="(93R?BN70B5HE:4#<:1,O0*K2>3D2WHMWH"#J';J'?:$3L'?J&
MR/_;5+XN=FT]I#MU'(844;&B$247&I$/H!/9&#KA9-*)=!F#2#>B3M3'(%)#
M:!2M11-H!SI )U*GT'7T&/^;-^@K_8LTH7V6)O0IG_X71 >S#;!K&ZH@=>K/
MYS(ZYC2B.9-&U'SH1"6"3I12&42AD$'D:]%<U,,D\HO0"%J%UJ.M^,_WHN/H
M,N.;_$/&9_E7C/<*G^EO%0CC#7K]MU<_( :8;8)=VTR!(J9*^#T>DPFNAZ$]
MC>AYX#&&T(EF(H-HY#*)>@63J#6A3A91ZT-#: 5:R_JJ-L'ZHK:3]5GM,.NC
MVD^L=VKW6*_4_F#^KOZ)^5R=L'Y#3]&3_P4QP6P+[-I6,DB6(C8X$VM]BEC9
MT(BY&YV8!#"(40P>:P:3Z!>SONK5\GS2:^/YJ-O-\UYWD/>M[C#O&]TQWM>Z
MZWE?ZF[C_4-W/^_ONJ=Y?].]Q?M([W?>^WJ?>._J$;[;Z*8>X9URXP?$G O$
M!KNV'?9O!VD@,Q41[@M',XK8X7K8>-._6(4S/U@DL=Z8Y_&\-*O@?6':R/?<
MM(/O-Y,%_$],%O,_-EDN\-!DK<!]D\V"]TQV"]XQ.2%XR^17P6LFSX2NF'X0
MNFA*A,Z;$L%SZ*P9$3CS V*-^?9BF(O]WU4<B#O.Q%T-R"Q#ZIN++>V]TRSZ
M2X= YC/[6-;C&1F\#VR+^>[:U@C<MFD5O&'=)73=NE_XJM52D9^MQMB7K3:(
M7K3:+GK>ZK#8.:M+8J>L'HL=MWXO=L2:B!ZR(>R#-D3D@ T1WO\#8H>Y3MB]
MW83^>@[A@\?DJPA??;2I-UYFU#/WF;2'LWP8MUTC6-==DOE^=LH5O#BS3/@G
MQWKV6<>YHJ<<NL5/.@Q*'+=?)GG4?K748?L)Z8/V>Z0/V)_F[+6_R]EE_TIZ
MNP.1VN9()+8Z$O$M,XDH8D]''#'731#SL?_[XW%,?1XCD .O U7@28 ^=<?/
MEKKF.YM^T3N(YXQGK,")V>G"1]T+1 _-JA#?[]8@N=>U77JW:R]GI\LBF>W.
MR[G;G,=EMSI/RFUV/B*_R?FJPGKGY_+CKE^X:UP)9[4;D4*2JV81\>F(BS 0
M#UX@?M@[@_ X0H7@?9@H/ WEP*T0-;@<8DZ="7)A' OTXST8$"&XUR^)O=,G
M2WS2NUAJJU<59\*SB;O1HT-V_>R%\N.SAQ36N(\IK7+?I+S2?:_*J/M/*B/N
MCU66S?Z@,.Q)9)=Z$IDA+R*-I*8CL[#[>V/W#Z3!^W &_!;% X^B!.!.)!LN
M12G J2@CZG"D V-ON!?O]M 0P2W!L:(; ],DULW)DU[C7\I=Y5<K-^K;HK#<
M=[[2,I\!Y:7>(ZI+O,?5%GGO4!_T.J'1YW578Z'/6Y4%OD1Q@1^16^!/N(@S
M'9D]-0. SZ$ #Z(!;L33X><$'K@<QP^GXF7@4((>M3O>EKXUUIUW8]0<P;41
MD:)CX8F2*T(S.<M""F6'@BKD%P<V* T&MJOTS>E56Q PI-[COTJSRW^+5J?_
M8>T._QLZ\P)>:;0'$I7V(*+0'DSD$'<ZXL7 /0#P#-_F;F'?N9Q,P;E4)IQ.
MX85#*5*P*U6+VI)B15^?Y,JS.L%/<$5<F.AP3)SDXJA4SD!DKNS"\!*%WK :
MY:[0%M7.D/GJ\T(&-=N"5VBW!&_4:0K:K]L8?$6O(>2%=D/H-[6&,*+4&$X4
MD-QTQ(>"J>[] #O?+_@6=RX=^TXF'0YG,&%/IAALS5*']9GF]%7I3CPC*=Z"
M2Y*"10<2HB47Q"=QNF,S93MC"A7F15<HMT4UJ#5'SM-HC%BH51>^3*<F?)U>
M5?AN_<KPGPPJ(I[I5D9^T:B,(BI5T401R4\WM0YOL7O?P?Y_$?-/9N.]?BX%
M>W/I,)G+A@UY*K ZUX0VDNW 6I+I(="?/H?=DQHAT9D<SVE/2I-M3<A5:(HO
M5:Z/JU6KC6W3J(KIT:Z('M(MC5ZC7QR]PZ H^HQA8?03_:+83YK%<42U))XH
M(87IIGZK8VH=?IV:019V_WR O878N0HIV%0H#&N*%&%YH2%M2;X=LS]W%G]W
MMK](1V:81%MZK'136HIL?6JV0DURD7)54I5:>6*S9DE"EW91PF*]_/A5!KGQ
MDX8Y\2<-L^,?&N0D?M3*32)J><E$&2E.1P(!'N,Z_"<-X!1VK@-% #OQEF,S
M&B\5@M$R>5A:JD_UE]@P>XI<^>?E^PBWY@:+-^9$2]=F)7*K,C/DRS,*E$K2
M*U0+TQHT\E,[M'-2!O4RDU<:I"=O,4Q+/F:4FGS?,#WUO79&&E'/3",JF>E$
M:;JIO7 ?]^)%[/_'L/ONQ>QM%=@[*P%65O+#<!47!BMUJ-X**T9'F3-?:XF7
M<$-1H%A-081417Z\3&ENFGQ13JY2?G:I:DY6G49F9KMV>F:_7DK&"H.DC,V&
MB1E'C.(S[A@F9K[32<XB&D@U)9LH3?<.]\+M)%P'[/^'BG$&F#U1@]V[%KMW
M+0\,UDG#@CHMJK/6G-Y:/9.WH=)#J+H\0+2\-$RRN"16IJ X12ZW,%LQJZ!8
M-3V_1B,EKTT[,6^A;GSNB'YL[B;#Z-Q#AE&YMPQC\M[JQ.81C;A\HAJ?3Y2F
M>S&U%Z;6 ??!OG*< 6:OQ_XYVH3=NXD."YHDH+-9G6IK-*4W--CS5->Y"Y35
M^+&+JD,D\JJB.=D52;(9Y9D*J66%*DFE5>KQ)2U:,<6].I'%PWKA11L,PHH.
M&(06W3 (*WZM$U%,-")+B"I2FNYI+, 57(>C.(-=V#TG,']U*_8N[.$+\#:T
M8ZXHM+8K0\-<(UIUFRVSK,65O[#91SBW,4@LLR%2*JT^@9M<ERX?7YNO%%-3
MH1I9W:015M6M'5*Y5#>H<IW>G,I]^@&5U_3G5+[2#JHDZL&51"6DDBA-]R 1
MX"?<BP=Q!I,-. /,7C$/NV\GYF,7;^X2AKIN>:CJTJ-*YULQ"CJ=>+,[/ 73
MY\UAI\P-ETAHBY..;4V5C6K)50AO+E,.;FI0"VR:K^'?N$3+MW&MCG?C'O0?
M'>^&EYJ^#43-KX&H(,7I;N(ZG,1K80^NP68\_]4= $/=V#VQ!S?U 53W"T!9
MOPP4]6M1>?WF],P^!U;J0G?^Q 5^0G&](:)1/=&2X=W)G)"N;-G ^24*_IUU
M2CZ=':J>'8O49W>LT7#OV*TYJ^.RYJQY?ZBYSR,JL]N)DD<[49CN"KXF'<;K
M8#NN_SK,7]X#T(_9\[ 'URP!*%K*A-QA<<@:5H6T82,J::DM(VZI*T_4D#=_
M^)) H9#%D:*!BQ(D_!=E2/L,%LIX#M3(N0^T*[CV#RHY]Z]6=NK?I3*S_Y+*
MS+X72DX+ORDX+23RS@N(W'1GIF90A_L YS^&^8O[L?]C%6G"'ER&U2@=NWC2
M*F%(6"T'L:MUJ:C5%K2P58Z,X%6S67/&_/G\QL($O5?&"GNL3!.=-9HOX3):
M)>6THHWCL**?:[=BE>R,%3OE;%=<E+5=_D+6=MDWKNTPD9DQ3#C3'<%K<1+W
MP%K,'\;\A7CN;2/8?[&'YZW%_H5=.'R"%T(F)"!HLRK,V6Q$^6VVI7EO=J%[
M3G@SW2>">%PGHOB<)Y($'#?E"-EO*A>QW=0B:KVQ3]QRXYB$Q<8=$N:;+DB8
M;W@A8;;^FX39.B)A-OYONW$--F(=7('Y T.X!GCNM5C'"K$'IVX&B,0NZK>+
M@ME[A,!]CPRX[=4$U[VFX+S7CIJY=Q;EL->/9K<WE&ZS-XYIM3>#9;&WA-=L
M;R.?R=Y>?J.]HP*&>[<+&NP[+V"PYW=!_5W?A/1V$B&]'41XNBVX]\<P?S'F
MS\?\!CSWXDVX!MA#HW<!!.S##GJ( KOC++ ZR0;+D[)@<4H3S$^9@MEI.S ]
M/0N,3_M31J<C*(,S232],WDTG3,U=.TS70S-,R,,C;-;&>IGSS'43__.4#OY
MA:5Z@O"H'O^W-;C_EF)^#^8WC0.4XKEG[ "(P>R 0YB/-=GN%(#93PS0O<P'
M&E=%0/VJ#*A?4P>U:T:@>MT6N8+*KWZ@?","E&ZD@L+-8I"_V4+)W1JDN+?6
M43*WCE"<FX\HSJ\?*,YU0I.^]F_+</T78'[+^%_/H#+QW&,.8CYFNV&V[3D
M8^SCVE<!E&\R0>&Q,,@_E@39)PH@\T03.$^-0.JI-4C^Y@P2SWQ [%DXB#Y/
M ?;O)6@N"+]8"L)_; &A/\Z"X(MG(/C\"PC^1OZE'_/;QO]Z!I6U!_./8#YF
MNV*V-68;_@*@?@- _@X YQD-I-X+@,1[41#]( WL#PH@_%$=A#[J@\ G<^#[
M[  \GSV \24$Z%^3@?:M!.!K.\*+[ LN[I<+Z#GZ@K[^5SOF5TT] ]L+$(OG
M'G 6P.4B@"5FZV&V"F;+/  0?PK _@0@3%@@1 2!G["!AT@ @W"!(DH 1!,9
M(1OD"G_>(!)\0Y[Z'Q+]^>P!CX/@H,EQ].!?:C _%_/C\)?FG =P_AG  K-U
M[@(H/@2<,V;CH0MB/A\!8"$:8>!_RX>$$!M)("Y21MK(##DBG[\_"X)OB*0%
M+4*XZ<G.?R%*V"U5-/^BJ$,1&2.*B%E3A.U*$:$Y%!&,I0A_%HWPE:%&U$D1
MOCXTA%:@-6@317BWHWWH!/H9/40OT6? 5OL7/D+]KU2QZZMCOYRBBL<AKT<1
MCCE%))WP6/SP6*)H1#@=%:-:-!?UH$5H&1K#8UV/MJ#=Z"BZ@.ZA%]0WH4_4
M)R%"?13^QX<?$ U5(%I*?]%0 :*BA<MK0A$Y!YR)%T6DPVA$,HE&Q/-0)6I&
MG30BUH>&T JT!FU"V]%!=(;Z*G:+^BC^G'HK_H%Z+4ZH5^BE.*'](?$_$1WL
M^GIR"/NVKCPN)\YCZGF0NBVNCSNN3R"-R,?1B"RN![<$U2&<!1=GP1VD?>4.
MT[YPQVB?N>MH'[E;:1^X>VGON"=HK[G7:2^X3VG/9-_3GL@2VF-90G\D1^@/
MT8,ILO\@^IAM) W$6!*_8N<VQGD8Z0 QL*"(KC-%M'QI>/=#(VHIM"^J^?2/
MJI7T]RI-]+<J'?37*@OIKU06T_]064Y_H;*&_EQE@OY,92?]J<I1^F.5*_3[
MJD_HMU7?,6ZJ$L9U-<*XBGY!_T$_3T.,,==,#(@%]FU+<2#64\]DU/'OC2EB
M:D=]-?:@/A@$T][HQ]/_T,NB/]<MH3_5K64\UFEE/-3I8CS0Z6?<TUG*O*.S
MDGE;9SWSILXD\U>=0\QK.A=95W0?L<[KON4YJT=X3J.3Z 0ZKD=8TQ%SS+?&
M[FV#O=^>C9<4'I,#SL).!S[:6E*OK%RH9Q;^M$?FD?1[9BGTVZ;YC!NF%<QK
M)@VLGTW:69=->GDN&B_B/6\\PGO.> W?&>/-?*>-]_"?-#[%?\SDCL ADY<"
M^TV_">PU)?R[T2Y3PO<C8HVY=MB]'?F N.!QN.$\7&7@O8LJ_#[3$!XZS*!N
MVWM0U^Q":)=FQ#-^LLUDG;$IXCEI4\5WW+J)_ZCU/('#5@L$#UHM%CI@M4)H
MG]4ZX3U6DR*[K Z+[+3Z#WN;U3/V9NO/(IMLB/!&&R*TP88(KK<A M.1&9CK
MR,)<[+ZS\3@\A>"CAR@\G\V%>VX:<,W- BZXN5*G7?WIQUPBF8><DGGW.^7P
M[YE9(K#+L49HAT.S\*1#)WNK_4+1S?9#8IOLQ\0WVF^26&^_5V+<_JSD&ON'
MDF,.[\5''?$*<B3LY8Y$! DOG_D/XC!U_OARY0'PWH<&S_Q8\-17 .YYL>%G
M+P4XZVT$Q[P=J ->7HS=GB&L[;/C^+:ZIPE.S,H3WN!6QE[G5BNZUK55?+5+
ME\28RX#4J/.(]'+G<<XRY^TRP\['98:<;W,7N[R6'G0ED@-N1!R)(G;_-,2)
M^>='[-[[8O?&E_@;013\)X@%5P($X/0<&3@<J M[ FVIR0!WQH1_ ,]ZOTC^
M-3Z)0F/>F2*C7H6B(YX5XL,>]9)#'G.E%\_NY0S.7L+M=Q^37>B^66Z!^T'Y
M'O=?Y+MFOY"=[_&-,]^32'5Z$HE.+R(VW9]O+YX 3S#_9BC I0B LQ$,.!7*
M X=")6%7N"9L";>D-H2Z,-:$^/*,!H7RCP3&"BV=D\I>[)\C/N!7+-GG5RV]
MP+=9IL>GDSO?9T"NPWNY?+OW!L6YWGN46KW/*[5X_Z;8[/M%MMF/<) 4DFCV
M_\?4##[@#.YC[[P2!7 &.\_16!H<C&;"KBA1V!*C"NMB3*FQ:$?Z2*0GSU!X
M(/]@6*1P7VBB:&]PAGA74+Y49V YISVPGMLV9ZY<2\ "A:: I8H-_FN5Z_QW
MJ-3XGU:I#GBD7#WGHWQU(.%6!Q%I)(4DOYO:![]C_[^)Y_]3'/9>[#S[L7_N
M2J#!EG@16)>@!&,)1M2R>#OZXCAW5E^,/W]/=)C0_,@XT7D1J>)MX3E2S6'%
MG,;0:FY]2(M<34B78E7P8N6*X%4J9<';5$N"CZL5!]]7*PYYKU@22F1+PH@,
MDD92WQ$O7(=@@*O8_T]C]L%4S,?>LQ6_KD\1@K%4.5B6JD\M2K&A+TQR974E
M^/#/BP\1:HN+9C?')(DW1&=*U485<*HC*[@5D0WR91$=BL7A \J%X:.J^>&;
MU?+"CZCGA-]1SXUXIY072>3RH@@7<9#T=U^G]B)V[TMXNW$<<_=B]YS,PGMM
M_+HJ0P"69<K XDP=:F&&):TKS9G9GNK%UY(<*-B0%,&N38@7KXI/DRR/R^64
MQI5RBV+KY MBVA5SH_M4LJ.7JV5&;U+/B#ZHD19]4R,]YHUR1BR1SX@CLIEQ
M1 9QOGOK#W 7N_=/.(/#&=C]<[#OY&'?0,MS>&%QCC3TY6I"5XXYK3W;D=F<
M.9NW/CU L#HM3*0B-5:L)#E9HB@Y6SH_J9B;FU@MGY70JIB1T*N2%K],+3E^
M@WI2_'Z-Q/AK&HD)KU22$HE"<B*134DD,BE)A//='U/7X]0ZX SV8_YD < &
MO/T:0T,%3.@KD(#N0C5H+S"A->?;,^IR9_%6Y?@*E&6%"!=G1HL69"1*Y*9G
M2F>E%W STBKE4E.;%9-3NE424I:JQ26O4X]-WJL1D_(S>JD2FTH4XE*)7'PJ
MX2*9[Y[A]7!U:AUP!GOPEFL+WH:N+0,80?TE%'25BD)[J3(TEQI2=26VC,HB
M5Y[20F_^POP@X;R\2-'LW 2)C)QTJ=3L/)GD['*YA*Q&A=C,^<K1F4M4(S/6
MJH=G[-8(R[RD$9[Y0C4BDRA&9A&YJ"S"13+?/0X'N)B,ZX SV%&,^P#[[U@U
MS@!U8P^<6RD"354*4%>E3U566M-+RIU9!66>?+FE<P0S2\+9:<5QXLE%J5()
MA3F<N()2V>C\>H6(_ ZEL+Q%*B%YJ]6"\G:J!^:=1[^K!.=]4PC)(W*(&YI'
M9+Z[A[><9_$ZV(]KL+4<8+P&]T$]]KX&@';LPHUU0E!3SX6*>FVJN,Z"EE_G
MR,RNF<V;7NTGD%(5(IQ8&2T:5Y$L$5V>)1U17BP35E8K%US:KCBG=$#9OV1,
MQ:]DNZIOR3GT3-FOY*N"?PF1#2@A,M/=Q'4X@?U_-Z[!)LQ?U8@SP%O@'M2(
MJEKXH+15"@I;-2"WU826V6+'2&UV8R4U^?#%-04)1C=&BD0T)(B%U6=(!M<5
M2L^IK>;ZU;;)^=3T*7C5K%3RJ)E4GEUS1GEV]6^*'M5?Y#RK"1?)>%43SG=7
M4G =< :3./=UF+\<._@ UI*.#H!*5-3)@)SY8I#5I0QI7094TGQK6GRG$R.Z
MTY,GHB. /W1>F&!P>YS(G/94,;^Y>1+>;172'FTM,NZM"V7=6E?(N[1NE7=N
M/27OW/)4SJ7Y,]>EF7!<FXFT:],_SF;]]3QP N>_"JO(DDZ< ?;PYE[L?@NQ
M^V$?3NX7AH0!68@;T(;H 7,JO-^>'M(_BQG4Y\L3T!?,Y[LP6M!K0;*PQX(<
M]JS>,G&7WB9)IYY>:<>>Y1S[GBTR=CTG9>RZGW#LNCY)V\\G4DARNJ,X@^VX
M!NOP_$>P@_=A=COVX)I!@ +LHHE8CR*7\4'8,@D(&5&!H!%#"!BQIOQ&G&G>
MRSP9'LOF,-V7A?.X#B?P.0]G"C@N+1:V7]K MEW:+6H]M$S,:FBSN.72$^*6
M0X_%+!9_$K-81,0L!HFHY33[\#J8P'5?B?F+%P!T#> ^P.R29=B_1[%_KL+^
MA]7(>UP8/,>YX#&N">[CIN V;D>YC+M13N,^-,?Q8+K]> S3=CR59;VV@-=R
M;2V?V=KY B9KAP6-UVX2-%I[7-!HS2-!PU6?A S'B)#ARG^;Q#VP%N>_%/,7
MX+FW+,7^BSTX9S5 PCJ D(T GIL!9FYC@?VD*-A-*H#MI#;8;#<#Z^WV8+E]
M%EAL]Z/,MH=3)ML3:4;;<^@&VRL9>MO;F3K;ES"UMV]@:>TXRM3:_I"IN>TC
MC\86PJ.QF?!.MW'J.1CF]V,5;%\V]3D@@#SLP4F; ,*PBWIO!W#:#6"UCP+#
M0WR@?U@,] XK@.YA;= Y8@K:1^Q Z^@LT#SJ#QI'(T']6"JH'BNF5(XU4TK'
M!BC%8^.4PO&#E,*Q^Y3\D0\TN4.$+G?P3XSO5B[X^[-0(P!U./>"#0 IF!V.
M==0'N[#3 <P_#&"(G5CC- ,4SO.#[ 51X%[D@LQ%=>!<,D0V('W9!:0N^X$D
MWH1(7,D \9\K0>P_\T'TEU%@7]V-;@+[RFM@7R+ OD@H]H5_+,'\;LQOP-D7
MX;FGXGE'8+;/0<P_"F!Y D#_#( :=G*Y*P"2UYC OBL ['NB('R?BU1!Z($^
M"#ZP!(&'3L#_T!?X'D4![Z,L8#VL!>;#A<!X. ZTAT> >HA%_M%'A.7]X3]Z
M,;]IS5^?0TK#<X_ \_8YANM_"L#\'(#.10#EGP%DK@.(W0(0N@<@\)(7^%X+
M \]K<6"\X@+ME0K *QV$G?^5 \*;DE?X9OP*+_Q7>-&_PHW^>CW"'_SF 7J'
M/O]7"^:7X9Y+WX77X"',/PG@B-FFEP"T?@%0N('G?@= Y#X _V, YFL ^E<*
MX LOP&<A)(JD\.\5D 8R O@Z ^#;;(1O1M^F_AP*'@?!XR"XR0F>),$?3.[_
M5P7F9^*>BSH"X'L6\_&\3:[BVM\$D+V+YX[C$WR*V<\!CQF1Z;X_"Q%&8HCS
M]W.0J<^#6"(W%/KW9U)J$;[HD;&_G\?L_B\BJP%$#KLV%TEJ F'K ^&W ,)T
M!D+Y402B408J1G48/1?UH$5H&1I#Z]!FM!,=0F?1+?0,?4 $OOX_$$55I Q$
M <G@]^+:>%HF0 0=\12]*<(33A%&"D7H!:@*M:#Y0&A]: E:CE:CC7C,DV@?
M.HFNXT]_"E_@W9]'\9Z&Z 3>,?[&_ =1441R.$*D@-]SIN9AB*.=@3.9C<<3
M3!'!>(H(9*,R5(_:40]%^ ?1,,YM)1I'. O^W?"5_QA\YK\,[_D?P6O^-_ '
M/X$7 @1^%R3P7)!0/R+JV/4U.$#4I?$X\*O2U$QT<6TL =_5@$CX4T0,UT,T
M#14BG 6[F?K*[J2^L!=2G]B+J8_L$>H]>S7UCKV1>L/>#J_9A^ E^SP\9S^
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MR@>EG$*/98-3/G-"4HA42"J1"$TAXM_=P>OQ-.[!O7C.FS%_33' ,NS ?24
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MV%$C9-_1(3*C8PG;IF.=J'7'05&KCCMLJ_9W;*NY1,2Z[4_"W^W'?;BY"F>
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MHO@S<29$%1G^55K^_+,Y4Y])P>,@'7]_)@6'3G;]%Y%2Q:Z/_5(,"6/O9^D
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MH<QFBR2WV?R8(\S_#NIO8+M7K.7YN)'C8 O' <USMKHJ0],8L@?PI%-V.:#
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MJMSD9U0YR1\,RTG^Q3 G1=+/39'T<I,EW4=\R'Z_1:V+ZCH4O>>^8OHMLKX
M6,JXYF?H8W:F!69EVJ ERP4S,KU1GQDLU&1&BU4926)%1J:L+*- 7I)>KBA*
MK]<I2&_3S4OOUL])7VV8G;[-*#/]L"HC_<JP]/1WR4]&Z>F204:ZI*=%5\V[
M[(?KU#I/S:,E]/[E]/ZDMY1K_3RN=7.5:,TU15/N.#3D.:(V;SJJ<@.%\MQ(
MH30W02S.29<5YN3)\W-*%;DYM<KL[%;=S.SY^NG9*PW2LK<8I60?4B5G7U(E
M9;]%?C1*SI8,B#[1([IJ7D_F6& .GF+;#U7P7*BBY^-R>&4E,+>(?J-0AL9"
M8]066J&J:!(JBMQ06N0G%!>%"86%<6)>8:HLMS!'GEU8K,@LJ%:F%[3HIA;,
MTTO.7VZ0F+_9,#[_@%%<P=.JV(+7R0^&<06205R^I$_TB*Z:5W@.7&$.3K+M
M^VO8#UQ^KB?+ZH!V?M9(7UY=ID)YV4B4E$U 4?E4%)3[(*\\1,@ICQ&SRI+%
MC+(L65I9H3REK%*15-JDDU#:J1=7NE0_IK3?(*ITGV%DZ7FCB-)7R0/#B!))
M/[)$TM.BJ^8VSX&GV0?'V/;=7'9N:6(_- .+^#J3R_)J?EY:;8#":@ODU5@C
MI\896;73D5$;**371@JI-0EB<DVZ++$F7QY?4ZZ(J6Y01E5WZ$14]^B%56_0
M#ZW::Q!<?<XPJ/H5PZ"J[PV"JR3]X$I)C^B&:+G.<^ L^^ 0V[ZC!=@XB[ZS
MC6.1KS,82SECR9NA@ZP9)LB8,09I39.0TN2&I"8_)#:'"?%-L4)L4ZH8W90C
MBVPJD8?/J%.$SFA3!L]8I!,X8YVN?^-N/=\99_1]9[RL[]/XK9YOPT-=WP9)
MU[=>TGG$5>;@)-N[C_H#'?1]G?3>M$:=I'XV?1=]>4:;@*0V%1+:1R"NW0ZQ
M'2Z([O!$5$<0(CJBA+".1"&D(U,,[B@2 ]NK97[M,^4^[=T*K_8^I6?[3AV/
M]M,Z[NTOZKBW?:/C/NL?'?=62<>C55)ZS-1P07VGGOHN->IOFL<Y83[035LT
MJYO]P-=<DDRBYNLC?($90A>,14CW9 1WNR*HVQ<!W:'P[XZ%;W>JX-V=)WAV
M5X@>W4TRM^XNV;0%J^53%VR7NRPXJ7!><)-\+7?N^EOA/$]2.,]]S&F.@0-L
MZT 7<["0<T*/^NXD]L-2C@-Z\O3E0"P)7B["=X4*WBN&PVNE#3Q7.F'Z2@^X
MK_2'V\H(N*Y*Q+1569BRJD1P7MD@.*[L%!Q6KA GK=PF3EQY7)RP\H8X8<57
MXH3E?\DF+)4T+-%PE/V^FVWOIP5:1<WNE<S!:N: ?CR/5C5I'?W_>OI?>O-I
M&W7AW&\"I_Y1<.RW@T._,R;W3\>D38&PWQ2%B9M2,&%3'FPW5<%F4QO&;UJ"
M<9LV"V,V'1&L-ET3K/H_%ZPV_"F,7B\)H]=)XB/VL_W;V/8^6O0E:X#9:[4U
M&%K4=-K#:'IB_T' ;3O@L!.PWJV/<;M-,';W*(S98P>K/<X8O6<Z1NT)Q,@]
M,1BQ)QV6>XMAL7<&S/<N@-G>]3#=>P F>Z_">,\G,-GU.TQV2C#9(0F/V$']
M#6S[RCZ@B]I-M(-EU,RB7AS]>- ^P(.VW>$@/?@1>G#Z4],3>C ^:4Q&0'72
MACC"Z*0'"8+AR5@8G,R"_LE*Z)YLA\[)%5"<W 'YB3/D+GD Q?&'4!Z3_LTF
MYGT-\]W-=K>RS96[@!QJ)M"6!@_MBJ$'/LGV/P6,H#<VH54UNB2#SA5#R"Z;
M0K@\DI.<#:'7OD*/>X6+L*N\X%Y5;Q'E"7^5'7V%C;MRB-!O7_Z,_$JD?[.6
M?;V8;6_? =2PS7G43CP!A)RF/C4=S@/C+P+#Z<N-GP4,G@?D+]!KWZ+GOT7/
M?\L4N,TX7F0<+S*.ESV .XSC#B_&KW"R?X63S"L<Y*^P@:_PH*_<(=_PWW\G
M#X=8NE6S,Z?N %# -B>=H3[;ZD%;/ODJ,):A6]P 5+< W9>H?9>\1M2UD#>5
M7  9 F^; .]:<E$Z#OB 9N$C+M _81R?\&+T*2]^GW+2^XP)_XR=^]G37#R^
M3NZ3GX:8LQMH8)J*3G$>H'8HV^OQG&97C!5US5X&#%]EV]6:[Y /B'IWRB?D
M,W4]1$93H@=\K>+BF#GY;A2-BAT7Z]. GQG'SUP8_,*)^!=.>K^RTW_EP/J-
M#?R-^?CMPR%F<)P5LZ]3F>_P:\!TYMF>[1W-]II05_]1_>43;?WET0Z1[[2[
M1/Y="Y'S>/K G\; WY;:NV1<M$\*43^QI$I[A\Q&[9-2V='2U2$D(ROZ[-'@
MF4I'/);0<\.%^)$8DD%*23UI^Y_UA_^\2^8I[>Z06_3J[]-M?X>_Z=@?U3[^
M^%\U$&-Z?:/AD)26_&F$-@[U#A5/$DY22 &I)LVDDW239:27.ANILVUH9\9?
M.$"-X_@=Y_$KKN%GW&.*OJ3S_W6HUO% 6_-XH.5[+9*I.:1AIO3Y!&I&D0G0
M[)()(O':>E 9M>JI,XLZ<_$;%N$7K*!.'W7ZV24#//YN'O,0N^HT[C,77^%%
M1O QN_ '?,IO?SI4'9+XB8:/M S5/DQ4S(41))UA[!,+?CK^B7I0)#53J5?
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M,P:_X;21A)/DA!J5A.-:AAX^/%K#GSRU?[%4X%?&\8W* I\8V. M@VFX:QB
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M/&8O/?A^P/B@ @:'C:![R PZAT9#><@.BD,ND!_R@G@H#(+ZXGN($\NA!K*
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ME+1<$Y(WJR'YH.I3;E9=ZGVJ37U.M6D?J";-;$%MJA6/4>:?H/^\L0X&#GX
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M@6O?2[U<QH[+) :7&70NTZ@O$]B7*>QE!/Z$^KB7^KCWG^ [ZQP,NJ>>HB]
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MK%!%X%:5!QU1:=!%E00_HN+@/ZHXY'.5A)B_QQ52T-OAU3<QO-Y *KJSB!B
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M?YQR?=R4Y>VI3!]_I?N$*LTG1BD^24KVS522;X$2_2J4X->H>/\NQ?E/5TS
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M2:!N(A*=%!SOKL!X+P7$!\@O/ER^";'RX4/OA#QY)5: )GDF]<B4-%?NR:O
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M228O)9@"%&\*4ZPI1C&F)$5[9BG*LTB1GM6*\&I5F-<4A7K/5[#W:@5Y[U6
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M.+_<M/D>U '@)UT3/@WD$L^XBNBO4#$IT)4'/2704@<M';3)"+3,0<L&M)Q
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M<: _ K0'1F)<0FP\A*=]\+,GV.^&S_W!BRMD8@T^C! N:4!/.&BBC),($7.
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MM%[P\N#ET9U:=%9YCJ#R%Q6./[1:((T5 3_'121[9#4^SVPS<-P%,/&+?1N
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M[LK:B)W K_9V-VF !S] @UZLV4L-/7':1UE( <AR"K"3!LR@ #=HP&B:21K
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MM;O/_>73S\+T([T0N,O:4#LDP:NCB:ZZ@@3;(6VLB^:?OJEQ<Y]__Q/)A1_
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M6Q</1V?;9,\49]O4-*>TM&3G-(>T%.?6^@74P:+3-;,((B_UY=/<)IO2DS>
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M6A\@/_QNL!C$D8#(]@)(] \1] G@,H $'X2O C@2)F CT'TI10 9O@;@G94
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MM,5-8_IE6R\GE]Z3;2 =5N>HH4C)/1E93V($>HQV;0[F?9:J96N9W64W]>'
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MH847X^$]*(0Y#.N*/+C?9]G=4D5A:%[ XC[,VU?_ 29?>?""1=LJUJ:<GD,
MW&0_8(S1E7:P=@0'#FUD0#J%#037:@:X.:1GJ)P*O(0E30]?2U*&1Z\73-/U
M.DV*8,R5'K+<3GM/LZO>8HV5*GF3]>M-%)LXN0:I&9\]AJO["2?RY+CV&(_K
M6'%K=[BI]XOBC\.TLYQ>NK/B*Y\&A^.,AI/F9/0%>G,X .]&N(O:03C4;K%'
M-YXV?]]@?28?^2:IZN7(B^BS&!I+UWQBW.[H>$7[LF(@//B)\S&:S]X#,%J[
MG3E*:<,A$[NK1W5=!:A=M./$:2-GQI@WS#"DDV)7X/4&DGI,:]8.M;'3Q8N
ML]!>8<M'*Z;Z AXV;_?F8B=AUJWD"[:%^^H&&0] 6A6O(S!<90\[K9>4B+5#
M^L%O(]SLDR_A0VN"P0N+<  ;#ER(#WR>.-D@3%#X>;]"8UK=&"7NIFVTSL+
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M(?+#7<?.F;L' L7KAGAV!^!)/J\P!SC O&_.-RO2HK< >)(>ZA1 N2;L:.
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M.DTN#M@P[J[  ?PMT46Q\80/:-5"M7<PT/O[?<(CG3K-O,9J91?@ ._I6MF
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M.-P5;\7]Q+LJC^,]?4PD%G?YDI7X-4W^(SZ.!UK&QZ+2I#*Z*1I[XW9=(SH
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M@C&0?LK2=%@ACT>P2.,*BP1A5'8<HVJSI^V4M;.XHKOP@QXU.TD[-$0?L/\
MC56@/,9 5R!5N^$N01'2<[>+*\()\RO,/[IJKB-F0  X/E2LRK(QVF:EA0S>
M10W=MX=W$'5=E8=5^VH0P/I5[&%)>"094GK5E,8Y"%^=^^H[BF(-IH*#,D#
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M5FF[R6K\H\R!D?B*Q?X--8:?05M2.9[5N3K]$[C\_NKM0JDF'HFWC<47?PP
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M#^H6_P##6K6B7+,CZJ_A$NM8C_VBK BZTB_ V='@8^X\P_>:VZL_^''3OCO
MD\P'MV<J3CW9Y3^#5?RJX,Q=/+;D1SGH>J2:1J<=RGM*/9D7ZR]ZVJTN8[NS
MBGMWYXY%#*1Y5@LJ^V15MX$U][.9=/G;Y"1LQDGYI\O<:SVC;-+251( V"<_
M-HJ6:*XA>VFCS#(,-Z>HH-70R\R*"5[^M/1*9&S\T=34+T1)+ME,U>!K6:>R
MG'.H.5?S'8U!1SR6DWRA8+G((J^<2Z3^T8$-K_XJ($8/TU\O?5%ETV_:98TL
M;EF!Q@QG%4LN-I\&E@R1E'EDS:WOB MSAL?C4E%<JR[[-YU6X.'N(+<F86,@
M3)/49/V5Z2]:)C%<*Z2@^V&&,&@VRCVCFHR_%V6SQBR $Y!/0TW(%8$5#0WF
M>4ELBB5O#L0?M/>IL5L:Z'S"%!Y6^PU["L&Y@H88W%"?'<D;[4A=X7?;-2CJ
M9("X*@ VZ$#/GDTX+I2J9M4'+L?:.]1IO57O7D7JGOM1*5$?;OP27Q_PE90@
MSGV3C8^^AWU%\<I8D#I0,EX#GF  % SWBC.]=N.6(-GO 0349<7A).#MZ4'<
MW?L9'0U%W-X=QD' SM7)L8L:1-66KI933O+&90\#Q<H8KNPQU&X^RO.H\97C
MV\T+00Q&<,Q<<RD\P(R-_)NO? J#TO58K:]#W5N;FW92CQ[ L#TP>QR!^-34
M&OP3PJ#IL7C<R&5C&I$@'+S8W]GH<;'YU.B^*L5."3O;8P.+=1NGEDBMXA(5
MY7D4OLI+8[X!RY]KJ:+BXLGLK:WBAAMT,/+R!2P^:0?/N1^)KVW$FG6LGR&F
M(J\F, +\X'"G<=E"^\Y/>A;K6[*ZT.]YU2*[DB\,(%4F64\GRAVVQRMT/>B4
MJ3^0&Q-KX\ QX@OKVRFM19BY@Y%63D+AM@H!+ _^WGR.]16G<3'2YI'L[2W,
M7CB>-9&),9 P,'W?O-2_\J["&WABM[";*1A&)9<L!G8GN-SOZTP>)[ -DZ2)
MD )42+&.3)V08&ZJI<#.^2#VHE[W<AI<5LX !QE?",QQ0Q*?8/,CL,E1C?T*
MX!'ZTH>*KGXC/:BWMQXS2/)(>;F9GY\D[]?E",^@H;7=5MM2M[>.&U,#Q2R,
MN H C/S5V^<PP/:.*AXXVF?E52?,^E#*;ZL9''%\T/P\SO\ -P*4YYI.7? Z
M41RK:P\JG)/>FK6+Q&YCO2D_)9BJ5GQ$Y(RWV4-&X:\0$=\43?R #E7[:"LU
M/QJ/S'4U,>K9$F'7I'*PSMC%=9<$?T,T#^S[?^&M<DW3'#CEY@.M=:\$G_,S
M0-O_ "^W_AK5O1=LQ_JOXQ+M0'$&GKJNB7]@X!%Q \>_F1M^-'TJTC!3KDXJ
MO(7@N'BE&'0E6'J#@TT1C#*2"-P15V^&#2!I/&]^L8Q#<$7"?\VY_'-4KH*S
M9*G1O8Y*44S4.!]:75+$PR,!=PCVQ]8?6%6H(Q0 ;+W\S6$V=[<:9>17MD_+
M+&>G9AW!]#6Q\/:O;ZUIT=Y:N0W22,G>-O(T'04D3<<@1=@,CN>M.174ASSR
M-OZT-R\S9.YI\!1'FBW,4X(8NCDDAF-5+C:V2[MK=6&+C!*MWV\_2K:=SCM4
M+Q%H]W?R1O:"-XU3&\@!!SY&ESN46AV"HS3;HS*&ZE@E9)%Y778@=,T6FIL#
MAV&W0BIV]X-U.Y((MU1AL&:1=_?0LO >LIOX-NXQT689JLL<_1H_=Q-<R0 =
M0(7G8G(KPVJ ]SGM3$VE7-I<_%KPO;OC(#]"*=73& !4)+[STJ$D<^.3T=0Y
MEV#$D4S^TA'GF&1GKFC5TUIW7GLSA5P CX'VTT^A%G4K9J@!W'.3FBV+V!]S
MP OK&",'/>AC?RW+E(%>1\9(49J;.D"+/A6<2G&Q;VL??7VUM[JVC\."3P01
M@E-B1Y9J5%+L'[GHKV9F_G495Z^UUQ[J96TDE;8G'J*LZP01@LY+R>9H>6=1
MD(H /E7<$J39YX>%OI=S//<*N3;R(F020S# QY'KO4O-J&B6=G=PV,@/BK(%
MY8VVR) @W'4!E!J+TA(+FZG2[4,AMY"B^(J$OCV0&;8'RS1DNFZ%8I)*]\UV
MH2;8,@&0KX7/9@0N#N#FF1;K@5.,6_E8#:76A16D7CQDSR1 3JQ<*"KJ,9&=
MF 9B<;=*;SPUXA;XP".; !ADWP[DDCH%*\@[D;[5[NM*T3D"_M+VF8HC+(FV
M?$(9_/'*HVQUKY^S]'LKW2@0EQ"#<M*S3H?&"H#&3CHI/13OVHTGVZ)N/AL<
MEO\ AJ1X(@Z&U@9BL<T<F'7,A5<J,@Y9=^PS34,G#<,$:*8?C'*ADD:&3;$B
M,>4=FY><=\@#/6B+3AK275_%O53QN0+(SH=BR'G0#YN<LN&Z8S7W6=)TNTL_
M'M&59T6%'C>9'R2OM;K\YL]>@&U<Y.*O@!;9.DV..>'F8RV]JFR_)!TD!;IG
MQ.F^>;'+VZU!:A'96UQ<+9_^'\1O"9NO)DX_"AIKEC&H&WNJ-ED,C$=<=Z1*
M3F6\6+9S9];,SX!RN=J,Y? @V[U]LK;ECYCU&]!W]P1S!3C.QH>W2&=@KGQ)
M<DX'0XIV!2&/*/9_&O%I$>4E@<GI3Q#*7;)  Q1/T0QJ7#JQ+')[#O76_!/]
M#=!_J%O_  UKD.1BWL@Y+;8%=?\ !:XX/T(>5A!_#6KNC[9D_55\8ERI4J5:
M)Y\QW_M#Z/XMGINJHO\ -L;>0X['=?Q!^^L)<>Q@]177W&>C)KW#.H:>PRTL
M9,?HXW4_>*Y=EX4X@W_[CU/(V/\ DK_I5/-#Y6C4T>5;-K?1 Q[Y!Z&B=!UB
MYX>U,7-OEHC[,T6=I%_7R-2"<*\0!O\ 06J?]*_Z4IN$N(&&1H>I_P#2O^E(
MVOT75.-=FO:-?6VJ6$=Y9R<\+C(\P>X([$4](Q9&\JRWA.SXKX>ORT>A:K):
M2?ST7Q5\-ZC;8BM<M["[FA$BV=T PY@&A92/>"-C4;7Z%R<?8##RXP"31447
M,=]A3J:7>$@BSN!CSC-/BSO!_L=R?+Y(UVU^B7./L:5!G<[#SINXY'50BD'/
M7SHK]G7[KO:3@>7(:=CTR[+Y:VGPO0<AHDI>A>Z/=E,X\TY;G1F9AF6$\T38
MW]1]M9O%J!A!CE4JR=4Z&M/XE@UB[G,=OI=Z(8VV^0<\Q^ZJIK7"^K:DPE;2
M+Y;CNXMG&3YG:JV6#E*TC1TV2,(;9M5_DB;3640L0VPZ#SH@ZV&ZMBH>?A/B
M:*0_]QZF23C*6SD?NIG^37$F?]!:MM_\23]*!0GZ+#^R^;7^RQC5%D ',*!G
MO 3L^P.*CXN'>)UV;0M5QY_%'V_"E)H/$:,1_)_5V7TM'W_"H<9^@4L2_9#L
MERI0AB/.@I9U SG?K7I^'N)7RJ\/:OUV)M)/TKY%PEQ),_*^BZLB^9M'_2N^
MW-]H+?BC^R/.E6TNLZ@ME"W)S LSE<A1TR?3)%%?R/NI"[&ZC)B4-.JQ,3&"
M"1CZQV/3I3MIPCQ!"<QZ/JROTYQ!(I'W"BX.%>(("&&EZOS#<<L,F1]M-C#:
MN4(EFM_&2(]^$&DU*\AAF\.".^^)1<T98EO-B/FC'<]:+M>#GCBM^9T%S<X$
M,+(P+-REN7T.V/>:?30.((_$?]D:P0WSHUMY!SGUVWH*YT'BF>3Q9='UEFYN
M8$P2$@_=75_"-[E^Z"GX;D\6!5O[5FFR8XU!)DQS8QYY*D;XZBJM<7+2,2R*
M".P&,>E37\GN*E 6/2-;5!G"K!* ,]>W>F8^$.(F/M:%J@'K:O\ I0.+?2&P
MG%?E)$#AG.U&V5N1NU3D/"&NK_Y'J?\ TK_I13<,:\B871=2./*U?]*%QD_
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M&X- 47>R4!3FKP;Q/U3[4UG.:TKAS5X"^/R4 *XV/@#R_A% Q\L*0'PN4EI
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MU>6JS,V9J5D,66%9;[+=LYMS='(*<H5RXW,7\S!YP_G.^4T%V@4%A<*%)XK
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M:E94\QF!KX$$1$UKN8@2&6"ME_;V@,YZE;T+'G!W865Z?N=M'6HIL?'K3C*
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M\W]U=O[7(Z:I\C\\8FMW9^LC]G>OI[]90JBKS-H-XO]_2^G_Y9W^[^?D/]U
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MZ]ZHR"ZTP>T'*3Y6/(T*B[C.\S?$%1PX/3**^_+) ,3QP=V^EVY+8[73VC;
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MMQY7T4$6J@1%2IL(DV?E)54VLNI!F$07%ZQ/,+YC,G40>D=1.:T[>,@BQMQ
M (PRU<B D%KX?&!( 5?>GN^&;_F08Z>JX4KM\[S/-^A;B'F+N%##2"G1YP1[
MA3:;&=UM@X7E%W6T4!VSHT,3LELA51+KN74"=%YAX"G7=LP?$TO/(M1RPYKK
MW1,4#*QIK[.OY%Z$T7!")O#,]RYHO.(\FI5Y4&YQ_;$L>O>!2BHBG8\C'VI'
M1BR36R':HCPS,UTX'B%'RMB,^\K,85S"PU$\<$NA0E(H"X?P$N&2<?>>'.K3
MW?ZU &*'M/WIGGJ+$R!E1<]Z]FL8+79W\0E@:\OZ/.T$L&QC@BS%))JJ9'VC
M/.E#2Z$!3_B\7!O?<*TPX)_@BMH/3%MY?_0PS1_LO>OM#SMV/G#?)]Y.WO;P
M@^\\E(P9*5L[2A<_ 2:\4H4>*DR([W!'I1#GJLB,B?%=DC?/N:_8X09J*!6:
M.E"V:1A]7W@"/#D(6:_N2!V=D0YUJ_)AW+;W$^#.2]7)X":<^TB4H_S4L_#"
M4?B2_V3TR)#T.^+#+!N_IMV.\;D30.X$(.-H8S@0:XM%$7]@6)F>_E;\@8=?
M2^I!;_0)\+Y/IK1*6'JJNL(WF412QZ8<,X1$-?R+KD^067K0;,G<<=O4^H'Y
MY-3[8PLES:EO]00?=CLWMTD=;@[:/$_OK3LRJJRI?E%])6A\^NOA^G)Q[SM=
M3^I(L=PH?Z=C_\V4&CS_6[[IJ39'F<NP(XJIYUM'E1.(F@-JCZ/"SR= \+9'
MJUV#S:;THR-GSB :!WK<+I$TU_UGU^QLBE7'/L?-X]/-EF,:/$P8VE14=;WY
M:>.FP93-B!2\ AK:O>\J\Z4A>>EX:4$\=(7JB&><5:/>EZ:_X*XRX$ /[G>_
M!3$3T=*I',DHI*FKFZY0SIS^9"Q<+>$>XG-H<!L^JI.[>D'KFX7-(<A,IJR*
M)A6:./PM169)7R=:RI-).J#DN1F]ZVSY3&96E-!:X>1\5>\D8GI#FGU9QMK;
MV[=<Q,>F=T;78P6NT[^[KF=R',.N&C;5+4-&XD/FB$B::R-/</2,$L'J7-^F
MS9@:Z;59[9?9L_C**+*KN>NO-;H>,\_@+G/\-3OLLO, C.*^)R17_@0X&3W;
M@U\YVW4:?=^E(]\Y #G "H #E@ $H >T 5MD'H&\7,]RIT=J9/\/->@!?N1+
M,_^/HX,S#(:SC:VRA@; ?OJR!&"CD)P=5J&<[OM1+IT=(IZ"PU"H?^7=4=A^
MU$&^(*/PG;TFTR$O/Q3^L_SINT0RBL19_O0DI"S4[NS-XE3V!?+ZC,Q^/X/Y
M\3Q[:Z#_XV257YB;GY[-R YF!?=PO0KP\_(+B?/RB?,+TO,)B L(B?.+ 3\/
M5L\V[6DHW^TY/:5)0_V)A665AO8S_^L$ !,%[8?MF+_[AR+\AW\HTK_[AXKR
M4P>*,NHOW;^2ZH_RV?/L!.;HC([]L\+)#(JFDJ>=-?(M]CS&_PLQ/IF18[-%
M()S$>7A@KMR@4Z^XP7!''D^0$P\?-R\/("GCZ00".T 0])80&SN8%,-Z?0,#
MO9V5%(.1D :OAI,"Q-9.U=L%HN>MJ0_V=@"+63'(2.-*>HI[.CHY0A @>D]'
M*,Q5W%.*X4RY.#)_2N9AH#^K@G"08O@>2V,-;7H%N N$7HR;CPO,R\M/+R+&
M#>(#6_'Q6W/2(P,JR,/'A_SGXA,3YQ45%Q2F_Y$8I'&1=TD7*VMQ747E'WC(
MDA3##\<\/#RX/02XX2XV/'QB8F(\O/P\_/Q<R!I<KEXP!,B3"^;*^%W)3SV*
M?_R"0']:!EG"W1!2# RX]+^E'XXY.OT"^L<(_I.0TV_6_4D(R4 *"?RCD!7X
MEXR3FPOTS!\K, \$"G&$P!"N2#F^?P;[V4G_!?(G^U^M1;JHH?&?G71T_$=)
M5X22.^(_2[J>'M[PZ$)<X6XN8(B2.](5QG]6I0OYEZ#]LRID]7]4A+"S_A<]
MIYQ_#0($.>G\L]@IY[N8]!]RDLB@B2NX0$ (B"+RDCZ=$+AX^;CX!?7Y^,4%
M><4%13EXA<0%>"5Y_E+SGW3 7?3A<*BTMMY9KQ3BMH)"Z0TA+JZG_5.(FY^;
M_S<M/^K^18T&W,K.VNMOIOR8FWXWY;>:?]6!'+=6( 3HOZ3E][J_Z4%V</'O
MO]-!7*3EP"YP2Q""7M'.%6$'A4)<Z/EXN9%_?TRDDCQ_$OA-D148V9((Z._*
MZ7^,7CDHXL_4GPRHW6ECBD-!,!LI!D^N'R>,#-+_C5\2)7F^*_H++,_?<25Y
M_L'$4[/!WUOI'PS7@SC_F^'2/U>/_V3 G^7/#/@[V*D)UG 71Q!"VLX19 /A
M@3BY6I_5_4']O;5^S@WB9^>LR*X!D1:4Y/DG\I_[BH:&N!K,%0&"G1ZQ2R,)
MW'9V5N+68#Y^*V$K7BXQ*WY++K" ("\72  BQ&5M)<9G)0BR! N*@<^ZSY_%
M_Z9:$0YV.YWSD+SOBPJR99#J_S!+3!3,9RG*+\K%#Q*$<%F"!/FY1 7$K+B$
M^4"B8$$A")@/)/83Z#=E?P/Z?M(/@OY6Y]07*R28I9  6(S?&ND!+[\P%X3_
M%$)83 AY PE;@<1X^:PLA7Y"_(.:OT&I(L< W,7KO]<KSA8G)Y"+Z]G/#%(,
M/^<^AK\)G,J<S<;B(/!I=Y9V!;E#K"1Y_D3[=R&[OS?F?RT ?Q/_=PP/6PCL
M+],*<@<E)/!S6OFMUK\K.1W%'B 7B)P-,L[2_WF7]E/EGV7^73?8%CEQ0*RD
M>7X*_B3\K77^<8S^?Z/9^$0$!?AY>:VYA(5X(5R"HLAFL^07 G.)"/*+( >G
M)3\$ OZ?-MN?5H/S9D,V$1@.._W-Z[_1=$@<$'*CC%SDI:U=X([T("<GJ!T8
M="K%XPZS^K'_^#7ET2/@]+]/YW]3\G_162N(B]U_IY?^9N6O.-'__\WI__'
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M^8NUH<JZ1T+D R9:J/E)(>0IVRP;_=G>PE?0Z@I)/J.P&O9I&/%]\V%\OJ_
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MQOUL/9%/^A9'M[S7N-O#REXU,:,HWY"V(!0M:Z7-2L]->\CO/IOY\L$RHX:
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M)DQ\R)]OO.XJ55G!(FM)<S'MY;=37571O49]1G412O?*OG521V.XV0\GZ+0
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M.,.ND5N/A!9Q<_OZ![8++,(W(HB+F;P"W!8>+]F],634R8HX%I!HO<5G2)#
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M<61QT'R>@,N<B:")5RP=-N.&4L;WU@"\WGS:],P#74)3%%^Y6M""-P+B^@G
M,5^7GYCS?5&F]5?>N)WR%6E"@9&34E@ <+"$U55)))]@3CBH%'EOBLPC6*BU
MJW%C.+#)N,6SOK]_?LB?YM;&5&#Q!,^6%@7AW/P0^&!'L3XA30<5/)8NYC\_
M9FCP,L^1;/)K9KG^,F2/?.X=VJQ^7N7L ->@4Q7KP8YYZ^RQ%I_(A[4+ER@E
M4M\C>V%$H0?_( ??._O@4FD=%IM*28<FWS*+@^.PQ;?K\5R)$M)HK675=Y_/
MV;B3X@6W:.T54+ZYC7'[!>C0Y=K:F%.-XROI@A)3RM)AJIPL>IJF(#*_FX\G
MFOY/ #TDPMMYXLR3? 4L>1_F:+Q4ENBO?Y.\%M?<PQLC^3XPPM^.5!Z_-L+!
M_M5NQE7R?I<U)_IV2L@_H^%Z_P#>I2S-;FTX,KRI_A7>J %$!1()%';9\E[_
M "*L,N;++A</X+PEA+J#QUY5PD*38PV\<_K4:F9^#;-L(R^-RI,[X?#?CJF&
MZ4M*B&4+:A/2N+5^UYZG%2UN(.GKS0VF3X5[_(W@M<3+K^5O JLK&QXS[#]'
MP_XZX;./ A0AK/C..)^;8?\ '5$\T%3O4=R7GWHJO_E'>&^IEUN9I\GSMNGC
M.09,8;#_ (J'Q%_Y/,226'C;ZL-A_P 55%+,,I8U.MG5L203S H[2EPH[PF]
M\F/?*^3K<3XX]_T;#?BJ+YI\G ;Z7CF3_LV&_%29T"R!N1[5R@'GH3;#*-X/
M6BL6^E"/#_Z9]1_(%;R6WX%N+X;.9'!?/+L_E%$2Z'],[(2(XBLH7^3EH/@3
M%&T24.8WB)^"5E>G3EF@F>=-6DT>'?*3AVL?*-XF%PK+8YK@ WD%1%(K<^@1
M[FK3\J?K^4?Q$9W&( X[**KMNR6G4Q$@00*\7$O^61ZV&7\:(+EO7RL=5/:H
M/++(9Y4\TT-O2J[D[;5#Y,#U;>PK.I%\H"MHG;:#!GWJ=;4STC<S4QM*"W;J
M*T8X'/WTV8G8Y1@BG[*D4ZB2%(+>]1V[;2!('![S1EJW;M(URXPU S':E;L%
M!>'MPA8W!';J*W<NW+S(B?1.X/PH$XBYB"%M+"D_53'+;(M*-]1//[ZC)6U9
M6(URRV%"W'$Z=]A1MW$FR=88 $P#$S2BYB[=BV\ @"3SO2+,,V+W&6V2%B0T
M\5"-%U'<YNP]Q^<($(!!,SIU?557QF:W;SF6<H/U1P#0%W$7'/: =Q6-:N-;
M5M!*L=,\!B*VTZ$:9%R;!O,N$:6XDD5&5(V;<5+Y9F9)/05TMO>+A/<;UIND
M):YS;2&D"3%$VTF>8[5W8LZAOU&]&6[.EHCFIRD.D"+;) ,#C[*WAPJ7";H:
M O(I@UH1( [;4)?MLJD<&*52N&Q%;3J >_M4RCTR ((Z&N;:NFP$@;\\UV&D
MG2)/L*Y@.2($3L=_C7:H#R#]M=V4:Y<9$0,8: =N-S6TMDVE@R3M0N,M2+0!
MJE WU[Q4-Q1ZI )[D4;<M.L,P@0()ZBH6MZ@>HBN3"T >G<;]^.*CN ;F*,N
MH- (D'M'-<:0QCVGBJ*0+$N#Q;6"H?5 (WYB.E6G+,\_JW1<N,?I<$=Q':JH
MEC\RMPW$W)703N/?X5JU<>U<#H0".2.M2G3C,:,K'LV5XZWC %M!M3_2)/04
MX?!(RMZ0"\"O+L%FMG!X7"W+6.:\[6R[V2NGRCV]YKU;P_B;.9X-88#$6D!@
MF-/&YKRZT73#_:*?GF2, 558;DM[55+EAK5QD;IL8ZU['F>!+8=3ITLRG4>2
M:H6>Y6RMJ4>@CJ*>G5'CJBJAO4.A[FNIU""P@]JW?M,I;4I!',BHE-L)#*1'
M6M&\YH+L-ZQ+"!T%3,H (U$?PI?8)Z#];FNKMRZ(TKJ'!^$TKCJ<@]D(!Y)(
MTA?ZQ-9APOFJP^BWIU,8!(YFA%NZKC:Y)F%^!KM+H+2X8@-L">30RL8+MOH
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M7&MI<M!FTFX5YY/%*[V MW+8+*.C;CK'-"G7E#>/:YY("]LMK![U);OKL'V
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M4Q3"W,1:1D1F E=N >M*;UEUQ!#J8F6D\4T6I/4YFQB=2;F !MW%;LW0RKJ
MN*>5^\T'? 0:PI#'Z,[ZA4EBXVF];+);MFV?K,\"J9=!4=G$O;Q4GTD$$P_Z
MO:.]-DQ0:R"S'5QOO5>M*EL JA\H ,21UWBC</=#VI+"2-3#DBA4@F-<.Q%U
MRL(! W,]1[=JA6XMJ[ZA-LK)G]7_  K8N@VX)8 F=J%Q#+</YUSH[<2>T=:6
M,?(-R>[?M$,UME(^B-_I?"HPP<'@;['K48!+!F$L1SU K=A0N)@B.A ,CXC]
M]-9(X'Q( *@:0N^YJ'R9#!1MV]Z+N7%N73<4$H/2IC<@=:@N0=4&9$STFJ1;
ML3D!/94G>>\5"]GRU4N!#<'K1EQ"%DP6/>H25W4@2PB8XJJ8IT+3"[ZT93&P
M;M1 TBVVU0HSW%6X6&D"!O.]3+Z"3)[P.E*PI$=T[&%;4#N>WPKAXG8J9W%3
M/>&AU)0B9F3-#N9LZ8('O-<@M'T)_)ZD^!\3//S^[_=2LKG^3M_^1,1[X^[_
M '4K*^EH?BCZ(\"M^27J>1_*2CO\H/B6X%A4Q*@D\_1%) J/Z4!))!GL1S3[
MY1P?_P 1/$+:9_2!U_Z@I5AUN6FUVSH;I(F*\#&.U:1[&%_%$7WT=8)$L> :
MB5"2QCD;BF-[#S&I@0/>H&0+N#&V\=:@I:&@"\MND+-<+9>ZY@G3,$BC[.&>
MXS*?HC];M1-P6\&JCTS'2F<[:(F1V[-O"V@VQ'6:2YMF:RP3:1Q]=<9MF37%
M-M")GIVI,+3,3J^,U:E2XI$Y2\D;N7VQ%X%HC80.G^-$6;9;J8X.];LX=!I(
M^E[T;:4=-XJLI+<A8HBMVH6?VBN[>P(,@S1 $H2%V.^YJ-EC<5*]QCBV-,RH
M.^\=:DF-^1\>E1HH"@$F">L[FL*SN8)G:N.)Q< Y$"MACO'UB*&DHQ68)W'N
M*GMW%TD?JUUCB2Q*D@$R>A[T8JZE;3$B/\:7V[I!&B._-3A]6P,GG8TC11';
M1J(EJA<>OB11+*0!/TN!!J&XD26.]!,#1"\JQ+& .HZ5U9N,44F-SUK@N"[3
MZH',5S:="T7 0H)'/V4]M! Q79GA!N>U;6YZD,F9CC_.]!"X>\F))!^RMB]$
MD D^YB.]#*<F'K<W)4]-IKGS-CN6H9;J@['8<"I4:&5M(,;'L:7*.I'0"1OR
M?\_74*D6GCC]U;OF+A@'3T]J@<EBI!,\DQM3)"MDCZKA,$D#8 ;37!L%1.L&
M.LUU;8CK(GJ*[&\3ZN0!1W'7!S:(#2Q-$X528^,5@]6K<Q7=LD,2-A0;.09@
MG-N\K!%)&^XWKTSPYF.(NY2EN\P?U%@)B#[UYIAMFV.X&U7WPP'^;67N>6J3
M&IV^E]59ZD,R#FL7&TJ%%&H$M&X.PGI73X6$"%=*<EN8%=X7#CRK8156V26)
M)@MU@"H\0U^]@Q:?2ANR @/K"@\GXUDE1*1GH -:!6Z]N&4@B-.S4OQF!#+&
MG@[^]/Q;6RO!6T@@+&KZJ"OS<8VQ*N>/3QUW-0E!H"F4_'99ARSW+]OG91_G
MVJK8G+KMN\&N(K+!* 'C>O3;^#6Y=/FML$VXW-(L7EOF.YNLJVR!+%?MJM*L
MX[Q[IE7P=T)I=U:X6/TEZ^T?53; NMUW4+H8DE9.P6.!2S,L$N%N(R%B+9]>
MD?2^'[*VN)!-@$:64A@I&P!YU5>45-70R+*]CS5U,"P&D #MT- W,.2";<A6
M/4;R*XP6,T6P6OJML&5*C?<U/;S##W+A5KQ5Y(E4V(YV]ZRJ,HC XRL;OIW(
MV F ?\]:BO82XML+<)T,T :?NI]A[)NEKEL,UN8U$<Q4&)$%D(WY6.@KE5=[
M T$ 0Z@I'7ZVHBW;+E;-M=3D01OU.X]S1N(P[7+D*T#2")&T#O5I\'9$N(MI
MB7)!4DB>![UU6NH1S,&D=6'8?+$M98FB0= )  BJ)G]A5QSDHD-[5ZQF%KR\
M"1;N#43IU=#UKS+/0_STZ&4GMTK%@JC<FVP*:FKHKEO#B";0ESR 8 %17<.C
MN)'/!CD#_G3&]:;RR&!!F#"[&H;B$B%6 HA8'O7KQF&V@ON6UMII$N3Z=(ZG
MI7 5QNS>DG<,.".A([U/;+F-2M(W56$:A_&B/FNA ')T@==@3VI\UM&"P+:+
M1,_1G5.^];OEP@\MC'6%D@]:ELJ6L'8J>".U%OAF;"*00=2R2-H/%!R28!:M
MPF-056)U1/&VU26%#6-X+CT[&!J/7X5U>RZY:#E(*$#U=_C7>"1BX $!3',1
MOQ]=%M6N@JXNQ2GSA;(.D&!!V^/M42N$0A^-HC@>U-,3;7S6M0-2<F=M^E+\
M-AS?Q"*+JVPQC6P]*^\=J>#NA9 Q;5&VTQ_A0]YO-?H!I'%3^63)=@?AUYW%
M<K9.P ,=)%55D)<DM6W-LW8 4,!,]:*TI<!%M22#J!_STJ&VI4[KW&Q]Z/L+
M<M M;;22"!(X'6DDQT+;R,I!B6/ -1Z-F@;'<^U,+V']0U,"![\5"]L*>2)'
M3K7*1Q[W_)[!'@?$@B/T^[_=2LKO^3^"/!>*!Y&/N_W4K*^EP_XH^B/ K?DE
MZGE'CTHWCWQ*#,_.P/[ I0MR VD2>L]*:>.;Z7O'WB7RB#IQF@DCJ$$BE0](
MG]?VKY[&?FEZGLX7\43G2&)V# 5/9PJL1J$ "1.\^U<(0NLL/K&]9>OW-"E0
M @V&_-9-7N-!O&8BWA[3!>NW$U6L=>N8AMN!MMS3.ZNQU$@3O!V!H:_Y4:M(
M)F 08J])*).6HD?#$-$]>]3(H-LA@1I&P! CM13+IEU!99^NA@5$I!^R*TW;
M);CE"3,C?M72/ZCT@;P.1-=HIC8P>:Q!IU"6WH'$JD%2%63'6L8$(&@1,?LJ
M!# ;Z1,UTKB95?;?J*ZQUSNWIY;<P8!-9;GC;[.:T+FY4=QP*[PX-_%V[*MI
M#-$FN!<AOJL$1,GGL:W:&Y T['@U;7R["MA_*>V%4#3,>KOS5=S7"+@\9Y=I
MRZ,H(+#?X5.%53T.31':16 (,=1&U=!?5,#<< U#;9H,G?D5*DEE.J #)VIF
M53N=-<!,'IML.*Y)D1OOM6[C+)4&3\:B(9]7UUR.;(FCJW&VU1B0VI?H@P37
M0M2QEMA7?E)$$2!Q%.M"9 A+0206;L:G@[@ &=N*X>U$:03&T>QYJ:VBLRCO
MM\*YL".;:MTBI;:P3 DU);M*1OU!_P"5;==(VC]U+<9'3IJ$1!&WQH9T>WM)
M&K8CVHBVP$DP2-_A6G'FC<ZN"3-!:',@1#(,F.HJ>W;;;L*Z%O< "/WUM5V!
M4;3]M=<ZQI+9@S%2"W(.WI^%9;C49D;5W([1MWVFD; C+?IW*^\S5E\,9E84
M6;?EEKFN%!,R?W"JHSP&D,?A4&%Q=S"7PUN"=5/%7!)7/>L%>N)=#LTXD[2W
MT44=J(?'6\4;CI>5+GIMW'(DD=EJD^'<Y5@+3,&NW!N9X JW6%\ZVZ6WAF$@
M@#T@=:$Z9-3MO#I2UAW>[;M6[0^EJ,LX'M4%^T_S@W;8BPU@&#^L9F3VJ2RJ
MOB$9F)%I= \_8L_0Q\*XQ*G'6KZHI6Z0MJ\$:0HGD>\5FE3.4@8^7=L ,EOT
MVPR>7)8 \@].:AQN' MHR6CY>Y.KGCM3)EN"^MC!I;2U;V9FWZ<1^^AU:XZW
MK]RXI\MO+MD<3.YK+.GR'4K,JN.RYD"B 5 +$QO':JQC<";3/=34K,9/\:]-
MQ.#5C;1=]4AKAX/PI)F6&+8=,.+!+VV*^;U^!%)";@6C.YY_;N^4JI<UPHV,
M;*?>I,-BVM@JS$ES+,!UGB*/S3 W$+L24),1S,4E1[INP2@U?K-L)]JV1M-7
M*;BV83,TMJ[O?>6((0[ B(CVK9Q#VG,V1Y9<%79YU(!P*0V]7E+LK,8);L9J
M#61<+.I(3Z2LVQ!["HJBKZ'7++8MO<Q5SRET>8R"#<$#I$GI5U\,9B,,GE7#
M!D"0\KVC;WKSC#M:>PZ:=7F2VYXC@&F6&O6X54M:;0 )&KCX5EQ%'Q%9G;]&
M>I8_$K<AE=B"A7]8 =YKS[&HOG,Q ;O^ZMV\UQS)Y?G:;)X]1D]IJ+$.WF%;
MEP:B)!&\^U9J-%TWJ-"*BK 6*5BL 3J69!X]J47<,2C;>G8>X[[TW/#(I)<&
M/KH>]J,#:!'&];J<K!8'8PQ5@ !/$@;@<T0J\APVH<,3(WJ>RPV*B.D??7%Y
M_+M.7<<'[IHYFV! MFR$PZC3 Z#FI+8*H"5@$BNL.P5 "P@ $@^XKNZFFT3.
MG?T@_LHMZV9VXYOW-0"[ $"%_?0+""]P#8- D['WK0=W=[9]3"5UZ8B>*((5
M;<:C V&U.EE.N 7[TX@J6#,#I+=3[U&+&M7EB%)/(!^JNK]GS+JLS<$@'C3U
MK:NHV9MV$U9;M!2.X@-M[:L8Y*[0T=#4)5%V@1SOWJ3S!YLL" 0((_?6W$D$
M+&_7>F0IJUY?EP-]_A1"O"L% ,\STJ :N(4'X5*#I&H?2)WBE88FM(8F0& ,
M2#4]K"J3+[%1M/6HTA4?4.O(%9?O78!"@)]$">:75Z(<]U^0[3_HGB]''SZY
M_=2LJ#Y Q'@S%?[_ '?[J5E?5X96HQ7](^=K_DEZGC/B=@GCSQ:3N3F=V!_W
M5H#S##$[#8BB?%SE/'OBOTR/RG<_NK2X//T9D#>#MS7A8N/\TCU\,[4HAH*%
M)D[C>H6W0@"1S,\5W;8,0"_)XCMS7.-LLEI;X&FW>8A%/TH YBLB6I=RL",T
MCTDP12^\"+I! U#]M%7'"C<G;8T)=O+K<*)!X?J*T00C9K%+! TZ01S0RM-S
MV'%:%P:YN7"XB &Z 4.[^HD"/:JI$[AA?3/.^VWM7"N"(ZFH#<D03/MVJ*3)
M!)&U%1!<G+D;SO66Y*=8&\=:X3D$[@;5+:4$&#!KCCB2HY-=V':UB%N*T,AD
M&N;H8G2!-2V['IW.GOUKO(XM67YH,78TM(=1Z@=]^]<8VPMW2S06!T_52"S=
M.&BY;;?K[TPMYG;N!@84GC>LSIY7>(MK URV+-QPNP'>A[CE]I$#J*YQ+M=Q
M#;RHV%=VK8D#?856UMY2+-*A]3&0H$B3S4K"0L;"M/ 3=0I[5Q#-/41L*[>%
MG** Q YZUU!TS[5J2HXBL+@R-Z("-O03SOQ68<A6@<#J*V"H8+P)WJ$/ZR$4
MA1RW];ZOA12 -D\L@"1MWKF[(!"S!@=Z'L,"!I.G;M-=8B[H"GJ=Q]E);4+9
MT%&GU$'NPYK6QG>!\.E0"ZK*0!!B"#6_)8_1(WZTUN8N8+ML-.Y([_?4@V"C
M;;[:'LV[@X,'BIK5NYJ B"W/:D8R9J8U1$D5L&00X'O%;*$$B*BNHX!8CC:!
MUKD"Y$]S2#/'%"W6CM$3M7;"X5@J"3"G?@T.RN.0>\#I5(HZX7@,S?!;JY]1
M!D\Q7I'AOQ;;QKJJ70MPD(#' KR"^22T;1VWGVK>!S-\#?0?^BU:VT\DQQ5X
MQS(C-7/H<8JS=8.\W)<BUSZF-&38R]A86R;SL-=QEVB!7G_A7Q [VUN78 "
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MX:^T:RCL*YG;9+D?&=O(\T@:,KS!2-S.$N?#^K4#Y)FQYRK'C8R?FETD[_\
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MKT(1R14>1BG+-)RYG__94$L#!!0    ( (&%>ES)*;&G1%\  (FN   2
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MOJVKJ_,YARH4#H% /5U^U,^N\LZPLS;!N:R^H\\9AYPC_$SF=YT0F):-"\1
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MVAG?&?\_,OPLOR\7 -33^2SMD,_D;5T]H6"//\U6$)SOAYEG*?Y+>@%_RD-
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MWCH+*,9Y&_?<I;2_.>P9XB.,J$X! .0:@HX$4 !(I\.GZP"N+-C5%G)=7A-
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M;'9M>"T*4:W]1)*$3!'*?<KAU;E[M2X!(G:0(1=[I^'50GR,MXU^]]:A):>
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M\2$)_SX^).E?QX>,]$,'DA+R3]T_B\IO[?/K^>G?\3D=\P?#Z322EJ*/HQT
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MB$"NT+,'Q/^-T"%P;!"_V"$P#VD[F*L+@XV;F[,CR.9,BL<+"OYM1?ZYY#'
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MM!2U@%/>VC.*__QC?@3>:,.7'A>?/>&M%E7&:*)6MYV<W:_&U1&II"PQ=:<
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M(SN&%?XSI]L.F'RMT3E% (B/^@KB:0+0I)<+PFM7!Y]Z8Z:&TXF4X VCH7>
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M'YHSN*TIM14?0QD5&$&$W+G!L+,G#^7M3%30#[47K!KN ,/AA8?)\)VRD#N
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MV"F]G&!&4M<_G5W^;NI_ %!+ P04    " "!A7I<5.4$:24Z  !P?P  $@
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M^6P F^D7@.ND/8'"UXZO:T<#.>4J&\\,CEG=JUB:OAXQ/LX;XBR#XI<K>2T
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M)ZZ*^%]<W'8;\BU+?W'<"N;]+\=5=ZX>_Y4#O^KC'?@3;-L%9R3* XQ1A7N
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MTS]]JK49X ( $!$AZ.<//6Q_AA6T_1U6'%N/#B  $1 2$Y*1XKJ _VP$ 2%
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M>_%52AP6CA5EY,=7AR%/PC^^LM5AK[! VO:P;D9)M58EBE>8-=U=/2J"U'E
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M[)9)R]NA>/_.V1/Z,DV=##.4SPME^55?WKONTJZ;Y$YB:R/'8H\(J+F=M#[
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M[.@7#( 0HPY+VB5X/;DEZ)6GE-CO.SMZPU7?@MQ!*8FEX9F;8-_X/DBFN'1
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M %3I;^?W/-J?=OJ6ICR-H0G\U/XLH-4C3]>?IOMK^(5V6NZT_#\6^!E^'Q@
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MK0.?MPWL/$/B,BO:!N=VA)0,[;U"X[,JVX?F=XD 5%2DMNAG.F%A8@B<J<#
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MP/9Y+T6V*Q?6CEI%"';QY<K1O6ET9&YRI-"D/L1*"-J_##ZYNB19J=7+D6+
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M9_'3_>>7H>"S?9]3WE?(\PLR^FV/^_O];$^'_O<W5^1T!>G9#,$NME O#W:
M[QJ?@.@U7E$^?GK>ZZ+(0X 7^/'>RK<ME124;_H@$ "0@OH#"\TU!>UG_,?^
M+"8*VG?=,7^M'XK@[_5#D?RU?J@H/V2@**+^E/TS*']/G]W/]KV/S^C8/PH@
MIE T%+S!=@!P;N/_A(T14])8#C"8JR@/CXL'M]5IK;AMH! >;RM7'E[N:SR
MN)2WJY6-$PA&;PVR![M(,*[5-C#2@VTE& T%U*^IN\J!',#*ONX@75\-/1M?
M)QL16T8I25QQ;U%OB"L$!+.B]X8XNWB(>DLPG@D71<9/R3R,]&=%8$X2C-]L
M::2N12\'=0?1"W!?Y[*YQLM++RC(S<LO("C(>Y6>[QHO'\\UY"'(Q<LO*B H
MRB=$_STP2N(BK^+NMG:B.O**W^&0*0G&[_7R\O+B]KK.#76WY^$5$1$Y%</'
MQX4LP>7AXP*S\N9R\6#Z)N2''/G?7]"B/TU;64/A, E&1ESZ7\+W>D%<?P+]
MK0%_2CX5CBPM*N<.LH*!Y)&GY*F;<%WCY>+CU^/E$^6_)LHOS'E-0/3Z-7&>
M/Y7\.QE0=STHU%E22_=,5P%N6V=G>@.0N\>IU@+<?-Q\OTCY7O9/8M2AMF [
MG[^H\MUC?U7EEY)_EH%L3%LKF-5_2\JO97\8G.=/%O^?MH3K+TW^AY9 9B!;
MXOH?6P))%/WV/A[(75+&QAUJ;06CEP=[P,#.SB!W>MYKW,B_WWNT.,\?&/[3
MNMO:_%3=%>[N?.:KMC8\(&<0!.0"\T"JS_M']6UM1&%@F/.OK?$#5L89]D?J
MCPQG\"F:J+.5B[T$HS?7][<?&"7_C?<4OU78&?PG6)Z_XHKS_(V*IVK;?'/'
MOU%<%^3V3XI+_A@\_Y4"?^0_4^"O8*<JV$'=(58P23#$RA[$ W+UL#LK^YWZ
MGVY:I-^KJ__K(0("X?D[3@^8@B?L7W-ZG+Z7PJ,#\H#"W6U "IY(9V'Z>U$Z
MH'_H'7\O"EF<Z<\CE[JZJ(J+!\S*Y?2E)DDD@1L,MA65E1%4Y..[?HU/4%Y&
M09&75T:8GU]&05A8^-IU 3E!!>&SGO]'UK^(E8?:P$\=_;M8VU.QPO\]L;^P
M_D7LM[>HK)S_%^+_1L1?8)21HP;4W>??\^@SMW&U<O<X>WU+@O&'X1G_PG#*
M<^8*HE8V9X[H8>4)LA7G^0/MGYG ?]-D_V7E_\+ZS_*]'$ N?QWW^05_C/N_
ME/IG(:>CCY>5.TC&'FECR7^YMOHA\8\L_RS:Q@$YWH%L)7E^,/X@_*5A_G9H
M^;^DQ43^?V^QWV?J\Q9SD;2!NIR^0?AOM!H2QPJYL$6NOR3MW*$0>BM75V>P
MC=4I%X^GB^WW$=?UIXE@4/I?)Z"_"/D_6%E;D#OXWW'07[3\:2?Z_]<J_;_O
MD__EQ'?>)_](_?,"[9^FSQ^K@F]NJ7CJ6/^]=A8_6^?\3P?0/['^G63;_\E*
MXB^L?R<9^K]9J_RCB+]:^Q>C_N>?P'[XVC\\A_W(_NMS\<\LT;.WK9%/FR!)
M?G&>OR/_2Z6_477D%25QD17^\1/$W_GU?SZ<@YR#G(.<@YR#G(.<@YR#G(.<
M@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#
MG(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@_R'07!__Z=^D(NM!*,7HY0D
M8A20 S#1,3 QT#$QS[Y/C8U[$1<7!P>7E( 0[^)E4G+RRZ27+E'2L-!14C%1
M7[I$?Y6>Z0HK.P<[!1W7-2ZV:RQL[&RG0E"PL+!PL7%)<'%)V"@O4;+]V^'L
M ^ H#"@XOWP _#5 ??8U[]^_[7WZ800L-'0,5.S37)6+  H:&BHJ%@8F&@8F
M.A8 H*"BH0,81)@,Q+Q8)*1G']CF"XI,)9/5L2YNPK[NSL0L%QQUB5_W14G/
M99OF*19!>3U0RSI2%.4I!MJO.&>R,#"1>1Q$2"50T-!1T%%1T7[DG7["&YU8
M9IT$B9'*V,,7)%O<],=/;1]DQF2@?C^R5VOJQ.Q*$(#[U*&L;K"X"\/C2_F'
M2F_I2=936G($8L3DTS"O<X^Y>$_S)K2_%#=(*U$JW+[LI^=8S7J?SK9)TQW5
M8*/]R4?[WC)Z>1<2C(IW<1EL!>VD[ED&/CE*KQ(_YMUU41PT"<$-JI(.=;OI
MUT;YP"5"/L]FX5G_O.8$O>4DCN=0S6NTYK)LUX)RKPP5L3OZ XXX3GV[_!/6
MMBS"-^:BW\YY5+=/:U[S5[B6%Q;[.>OBDK);.0;#378.ZM_$'_EFDV:P?3O(
MF@9$$P7N53Q='(MW#9205ZS;Y>V,?LM.LR@P5*7FB$Y!/$O-U^+H9O\&+S%O
M!>RK&V$^__!#TKT\L6WUX[;VQ^3; D6ZNB54_&6'GU]NM^B.:5(_S1/LIVFY
MF'B!?=O-[ 2U@<I/6\&0&B*[E+6N9G5!9?]FV$B&V]'00:TDI3^-&$&ISIP
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MMUYR4#^1 INSCDO.+"T.?SAB=I:TY]@;='-UJ[O4Q^G]I))U@E#BS3I&-E>
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MPN[;9SS'([5,[9]^JXG.%N4) !)Y"JI;Z1;\Q.6W<+3;DL1Y,5J0IJ0HJX9
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M3QI2@5^#F:4H'_>OWOI2I' #W:'N]:4IX(!2E*H4I2@4I2@__]E02P,$%
M  @ @85Z7"T:]"TH2@  A8T  !(   !C=BTR,#(U,3(S,5]G."YJ<&?LO <\
ME>__/WYS[(P0V2,D6=F;D)V1/1/'L3DXQYX1E8P0V9*]LU=$-LF6F1G9E)5U
M_H?&N_?X?.?G_WO\?H^'2_>YK^NUGJ_K=;VNZY[=B!'$-'!1459!%D!!%C84
M-@! K-%-J%E"X5"8)=2!CH?C!B HI:",A@:<EMM4*/H B)))C@H5 )#_J%#5
M "PG)RX! 4%^/BI4=(!5V0KL!(5!S>%T.E G,SIV.C4GJ)DS&$YG!H&!G:P<
MX%90>Q@/AQD4['9FE^G,[L7XS*ZK9H%DEL+Q^A?&])I-SWC"9[Q/IWSDAG+6
MNN#@9&4/5W6&.SC#D4WT4YH:#*YA"H7:GDDHV,,A$'MGNY_UT[VTK=-IF^!,
M5\/*[51"R@I^JO.'38B3BHD=1%-&5_,7V'<%9 ^@YAH0N+.#JJDU&$G&!=0
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M:B>+$4"GP9-0!'#IK7C6T&*$[['^ZE/U2 7&9P@ T;NC-2LQYXH 2#$1 ,[
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MPTGD$\<"(A#'Z C?&FTCM]=S0LR0X#=]ZUWX;JW'P-1.BEPE*\DW_JKQF_B
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MY9NWOI\SEC)'T"(!BD@X:+;*N&AP>L<5K#V12V:=U.-3>V^=Z^J;K*.'""!
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MEO]]G^B>@B3BP]#2Y-7QDDD5P1/X<Z$M^E#&DXBNVI;6+&*:UQZR8RL7^Q"
MCT2GDP?7YS:++!F[@E)&7MFLZENW'PAZ?7CO=1<9EZCA7P$ZO?5P>HG(QU-C
M?A4&5$<NQ(%;PZR.ES].>5(?:SV)&X YCBROY3NS26\'Q ]8@O;R7#\[52"
MX4($$&)TW13E$Y-HB\Z IU*N@X-Y.,5#WI.UZ!I:X]W^5Y85/#4<5PT"7UG7
MU? ?O/\0OE:Y)/"-8)<MK\9")TLV^,OHZ,"2Q*':.(OKKC=CA#)SJ*:>T;?+
MN+;F#PW7%"1D0A&  O1X*V6&)/= 5:?=P2;/G-7S=>V0PTD:Q3#/T5[!>M*
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M7\MH71]-BU-%O5IP&2"75G/\ACGBI]):7M DB]HA^]G^RTW050SYUH;=!PA
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M9]D+7"NOEB&W=P"M%DCAV%G,>YP6((BFFJ: 5%T3H?M[]!]02P,$%     @
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M#=@Q>W>)W'U*? ]R?;YZ)AU&YQ3--F EO#X*T$=B;:S19-,9+V.AXV.%\5!
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M$QLC],[5>:%7IL@X$Q5B&4>IJ6X5>'B_;W9O2D/0]=*XAP UI+@KY*A?,VN
M?RJG0EA,+KLLR38 4[*Z!/9%1^PE_$C$1&ZMJ&5X1A"SBF;F2MSRH&34=E;N
MJWKUT@F3""MB6L-]M+JVHZWM_%=;T?Q3V6YCJ!D,+VXI!)'T.N?8_MU^R=N>
MW&MERYS6-R.$&*! GV6]-?5JHC3^]'V%QNBNFX^?<:\J;5R7SL8X;IM8T$TW
M=<=^OIJ@L^OFTTNU*;W-K5<L$!-@S4DW0B5<]6HII-J^[GK=GMDX)*N,=>OQ
M/<TCM<@#VU>?/R A)7SUJT2V"-$ZA;6)+;.IR3OLK?3&52K9 ^AKC^MTZ-5'
M'W"7U=35+/<%A<-]ZO>1WI';+Q>\(*])KZTZ*9<#G2;DFAYP05JVHX6OS)=6
MW.C.9SD!+,78%#K0T##VW)KM-VR>" GK.1P^ 3PJ/QXO5)X%DE;TO[OG$K J
MO9')WE*WXJJ1;Y&;[ZDVRNV$Z9"[77<M[IM/YDIOCU9L7?P)0&W)<%_0WKOH
MXT@_K1^V3Y9]9N>%@[(U2)1A:=VKW$K"+>G/YO.1F[[WA9N%Y*R_3 $1V]*)
M8^G?8)_KEB['^/N;]6@$CBSYB)2&4%LY[-S<\93,9#_I/XLS0;$PA7?+>@/0
MVTY( CC8CZ1RRXJ"0$3H8)-CM_R81(M>1\S U@Z91U(ZW11*9&LSL@0)1AI+
MRVC7)$[U^H@^6QDNOZ2B0:@Y0$/-YFE?5.\9WT*=XP0/;0#&#PU/:6ST'KV:
M6-^6CC_BF><R<=!4P@I6W_]@S#EE0.97^#)B-&8U-]9':(OL>806D>STEC/]
M9T<+^FT"9SHYL>0LOMR4,:[!03'A=;K\KRY>/)HNJ-NH?)C_<* ;S7I=GX=I
M5S:SB7DY@K^2V)5H@6YYQ>0$H.5R#:HP(F2N)^[@&<]94NV6E+(@'+BVKW&L
M-;[B/F!9]-C8.-_.W3U%J/M"CH\/*/($D!BXD3M\')1SHP=8%DV;9VN5]&JB
MD6_,IR".Z>J7EJ"5=V_TM36I^Q-"Q>0^*U3L&L9Y.N0U>R0."9CFVKQ:0*UA
M,VBQL@L\YJ\AAO#A8"&'RD9_8A%A=J#/4EY0WI&]M;GNXH3IBVU]<\T"J2')
MR04*$>L/T)[YL<K)Q.U"I6_-64,!S5>C#,OB" Z,/L[NBT"N^^P<B;QF5U.E
M^,8 2,J6+-L:OS=D;"IOI-8&'!;RC", [DK>G=Y^0^@;"=QH$3&&!U'#(4 Y
M XU=OE+3I>KQS76/-7ZQ(/HG<)/!*-ZG,@Q55Q:$/E2/9M6M>(7P0&Y0?!HQ
ML$-_79FF?.P*=D":];A^T(A/E>O[MIHU4/Z^ZIE8:&?@8M5CZ./]KI"WI2U(
M*R_AW+D>+Q-(<'-JF5"G;=643!1!/D2^9H!OE65,N*,FJ:)4S$^ X 6LB1 .
M?E-]-<3187 Y/]UT<J@T>DRA6OICW^T)%>?A"9$5%H<FJ=3<VGC[V -:6,:4
M;I+]@86W9+1H)7?'MI,7JR%0RC]S/REU,2^,:(WU4E(I8#PA9-M/XR,]?8K_
MXZ'JB1, 5L0SU 3&?C+P?9I$Y7^N'S>IRLTZ)G1APU-.O&C,T<-]6W5960/;
M-FFF!I,KK8[]V+XG@%<#.8-AI54^45(K$*,;=QU@]3=TV5M]^KU]D;?R1M<]
MC9.Q%@BDBZZ$A6U3+T^X\*TU><\3&ZD/ND@/&:]AV"KFB1 ]47S?-L&:'F\#
MC+5.IU##2]AKK!Q=G]@*?*DIOU3A$CVC9>L95U 9=B^J^ZCJS;&C,70?-]N_
M6@=-]0IUV7YS^M1XA)LD:CD#)UI1/RXX#%) 3V6.4/YC]A_\AV9)*J2O0<,F
M2[P&*\T;L/MLWG),W'D9$T9;HZ8T.8]ZU/96>M>6#53\B(=@2"=XOBB4-RK%
M-E#B3^#YD&,5?!_-(*<,1":B^5[7K(^]J"J/FV_$>N;N)2-F\+S:[<WBPJ^4
M#LD=:*-N"[M>J5WJN(:Q(**5\N-4I15R$9VVQLP$OG70JUXS@Z^&H_:5P<S^
M Y4YK5[DWCZ'BDI?R56JYIX<[1P3['()!L83U!FMML,GI]71IT"ZL0E"04XF
M&W=V=&O&-H_'VW<\]!R.X5LG@)0[9$<P)(%7:,HGH5PX."%X6]I@6R0VH6IT
M9+_\):I_3P!] \MYCY@O+R#JQA@[L.]P>7DG*);?'TSXO&$8FE=N7/U59&S9
M85LZ)KWOB"66_72Q-O1WK\T@.\5,/B\4&;O[DZ1(OA[UB3C*CJV^LL]CF[E^
MW3'))878Q^-*]5AFWO*$KA^<AN&1;[^808Z?[92!5 ?SU[%[WAY7N1PXBF@P
M)_;(P]+L,@='X$&<=O"RDLKW0N+@'-&-XW=MZ1C7XJ.KTHL_N#]EFFCYX#2R
M/EI:V!0"B&JC(TZPN+A<G&ZN32/)"+GK2/[8_^ET9?6([=26CJ38)NH)U.#Q
M4S6YNX*DAU%L5L9P/V-,$43537[L^1. G? UDC:6N=I(G]HV"^G^K9WR V6[
MN6_9>E.:&=%QTO4%$)N6K_'Y6;-THV_)3.2,D\&C-$QS2ZA >,!AJH-\/!%@
M#=A6N_!@.:SHU<S@ODO-Y&N''8@G.'VKU'#Y^-F'HBK8S;W, 15X3_D*/ A*
MN3VX$TVDD)J:!_ .*8-6CDFJF73M%&]%ZIL&3JE).E@/PZEO1!.L<8_2M92]
M$19Z4&;J:="1<P"ND?[LHGVXL/1>.P?E\/23]]LZT>V9S.G+*?]T2:6 C+HV
M#^]JDLS7ZJNP2*O.'7=-"J\G?6,+V_?9;5)OP'/M+9\?]/DTU-W&'+UT'39B
MEC%1424XA5:W)5FWD.M$S!3ZOE9/A5E:E[E6%Z7@]\O)R/<WNU?/WEWJ?G_7
M"P 0 60 5@ 8P!(  C  ;@-L47D$ZH2?Y4ZW5DG_DQH, #F -D 8\&/7"I/Q
M[.4HM[HZ@./TA3L &^W2V98EVNF[8[0K9UO)I]"6:-0_\_9H;'_404?]\)UM
MM9SN_3BC\9_E3]]'/_6W.WLC?5H_!76^1V6_[[[]<3U[V\SPY[ZXG+8P YN^
M'=0*Y@IG!_#S\@N)\?*)\0LR\ F<9OAN   8R6C?<4]. (!D]!_Z,6\F8_S(
M_]PMPD+#^,-&K%_;@4;W9SO0KOW:#G2T'SK0N-%_ZOZ9E/\HGUW/=N&.SN@X
M/RJ<3*,)*[C960, Y[[\[_CR9%H.WQ:!<!3CX8'"N2U.6\(-A$%XW"P<>?BX
M>7D $M)NCA9 , C!8 FRL8-*,FY4US$RV%E),NH+J?.J.\J!;.V4/9Q!VAX:
M.D /,%#4BE%:"E?"3<P-X@@!(2P8W" .4+B8FR3CF7(Q5/Z4S,/(<%8% 99D
M_.X_ _7;#'(P9Q"#$+< %Y"7CX]!6)B;3U!(6)CO.@,_+Q\_#R_J$.;B$Q03
M$A;C%V'X(S%*X:)^)9RMK,6TY!7_@$.5)!G_:)>KJRNWJP WS-F&AT]45/14
M#3\_%ZH&%]P=BK!PXX+"F;XK^:%''@0'.MN=_5L#PVG9PA*&1$@R,N(R_)+^
M:!?$\2?0/SKPI^93Y:C:8NHP*SMK=WD+!$CJ-#2X>/FX^ 5U?H0&)Z^0F "O
M!,]?:OY%AYPS"$7]FPY^,2%1,3[17W7\4O.O=J!ZP<H"8?%?LN37NO]D"\Q9
M!P9SD-*!(8&VNHX,(MR_PO_!_.%AGK^X^'_5]5; GYYW1#H[G'6P%9 'Y ""
M@* (.,K[?+][WPHH9@USAE@@I.P@%C8@'I CW%J"YT_J_[2!* >HJ__'T0&!
M\/R3)!RAX(+XCR7AIQNA/%H@. SI# 0IN*":S/3/JK1 UO\=5:CJ3'\-6G5U
M,7D8$'GJ5Q5Y*12!V\K.2DQ$1%%$7DA>A%]07D9!D8]/5I!/1%Y$1E1&1I97
M6(9?\2P$?A?]FUH5*!QA 3W=G#]3:W>J5OZ_IO87T;^I_;YM;^'P"S02B=(M
M)&)I82T@ .(""5H(<PG>L!3BNF$M(LPE(B0@!!3E$Q*R$!+^H?\?=/P-1]D.
MC@IO=ZG?''\6)]H@I]^I/Q@.=F=QXVCA##_[AP%)QA^>9_R;P*G,62R(60#/
M(A%NX0*RDN#YC?;O0G;_X%SA_\RY?Q/]=_VNMB#HWR<@0>$?4\<OM?Y="1QF
MC7"U< ;)V*!\+/4?WDM_:/Q=Y-]5 VTMH#8@*RF>'X(_"'_K&)[O/?-_H,>
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M0=FCK4,:FYR732ZY1%SPLCOLJC? >'84C\Q;4]*IWGU<[C8YGD3!=E4CT93
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MCRRC(0KS+[6B*,RO5N&>YZ&Z113#6&IN,9J6IG#H^7HEO7L3/:%P."DFN^6
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MLS&92<S%L-\GK1"UIU+)L>L!,BD9]@;OW*R9I:ZF)KC"27GI> 8B/?G)Q2D
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MX<,>$9)/8O@UKDO^]O6+BCJ<*7="F<OF_,RE&OU9&(UF^?\W 5!+ P04
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MIG <XNFU,70?N(9@TR/< W,RRLT7ZC*C<WUWUZ!.1GUZC$U]+?(*+V?X6FS
M]%!>BC]\Y#^U8,1" \JTAM.J[AZJ[%O%,LH:;;FU-$CI7W[@/RU6)7S$^'EQ
MPX^YXCY]S-(D)3BKKO.,X/++0X&S$A.ARW_#RQ6[22[RK$PI*VK]_DOZPC)[
M@6P26PZET",V/[]<%L.(\+,N<EP2N0GVHR!85.OO_X)E\-?[#M4:'W/(_*#
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M6N7>)%<9R9_837&1/ST7[ O_E%]OFC]>"B]/*:3F,EL]M;<?<>$@U+-#2+R
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M=^K\C08D.!<MQQX[%VG\RB6 IB\I7<EF(AZE?5CZ39"M>%,;I[A-[C"5T3%
MGEXRQZ$%Y\OC&"!G*X5CZ#F]0_T2%QE?LN27A?JF\ Z7*;^EN&$2LY! XKL!
M1![Q88S<!,9^XGLNL_R8VHL75L2Y[-E]$([*-[(/32%L48%E7G+CG16-EP5
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M["$K#.Q8MN>,),B)A7F#!2 M&OP&RO$ >(V(=/L362X."_DTO%$3^!Y;.@Q
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M/1'&!"_@[<PGE^WJ]6Z5[7"YI]^)_N   ="E,[+D(25W>7[] B ET9)((B&
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ME 6_^O0V'$@ HE]^:Q3V%V_+A]<R\C;E+25<.;8&]>@3GG9P#U@A!X-\X"O
M;^7.GYY6%]\73W>+>O%W,K]>2,C8ZDUVY=6KQ4,AA[Z?O\R+^3^J=I/5O+@#
M+^PX"A'\5"I=Z5TTU_G"R=R)Y^7>V_2 +4MA.2+F6S=-(&V%GQJ@?#Z?>W?"
MX<NT_IU8MFX#[,97;2"4WP&%J=9%_5M$^'<8OVAT^@E@?NM#M&\QECI)G49W
MHW!JDUV?&BNB>\-JO@@8*,P8U$S]\O?&VS;C4S;#U;Z*O?3[_.UZ48M09]X,
MYY.7.\1G)0K3.$<IS1@J\B)&.0^C."@(]DNFB2(V#<>./>YN).!S0UM8ZXZX
M-HC51%]OV)W^E-\$YH(M0%J>-^,3VC"SD>7,:[_S;>FU\GC7/_%WUD8R^_F^
MMQG,V<_VW2$X:--^@UZ0M(G8F I!;5JM=N#5)B9L6JW5%"7<D1D31[!'GI H
MB<)2[.BX0!BG.2(^+E% J?A]Q'S.00G9O?4=;\(J8:!FE,E(VJS@8E\C>NF2
M$^2$;6P;0IZDU*W<OB O,_%3H2H?-@^==:;<;/(D-@NTCLILK2[K_>H3EV,=
M%>VP"NOX8Z9@]N*8)^<4WBP7G\CBG[+>0,XRO%FN>"T<A,+>XF49)TGAH]3/
MA8'F/D&DI!DJDS@O_8+Q)-1"[X40=5T6L(-1]@HR5S,71!S](K[*K*Z7XK2[
M6.KBP()TJ6?:MC4$#60%=23)2\R.0M!OZIH:$(\5]UH.+(X=APAL#?-<@^3$
M*.7Z2CC$%0>\:UZW\'E64S+_!R?59_$WXDA>A$D9"=>09#Q%N$PQRHK(1T&<
M^@DI(I*R$EJZL$=CJNJ%AJPGZ7J*,+R"85\[P\9N26:8;1N(:U3+T"/02>4,
M^VM.7M'0(]2QHH:^1\VV:1&OS^K;\IRJ,C^Q:1T'AF-QFE$<1RB,1/R,_;1
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MKSOV_\DP%4KFLAM;)F<NEHMZQE29]7)QSRF7-7*WBX>*+&I"54J@+'$99[A
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M@Z[& <%.Z&T\MNK$'8X#@AWV.0X]##-+^CJ,\B?#_D.0O\<T#'F):8"2()0
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MNA<L.H^;[<=?>%USWM.6NQGO=+GF$J'TX<_E8YZ$11EG$8JQ+PYX-$E1EI-
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M][R?TE+3KC1U(\U[ 8ZTS^P]8+;Y-7;V;25V$9DWDSVL"C7NQZQ^C%*?^T%
M4<"QO&?(*<HBL15&,>8AHSF-0A#F_0 MYU<$+<UF$KIJ%MV0/]LB?OTA.0$B
M-0[I3V_GLZ058+K*AD+ NZ"&J)8VP2%*D^Z!&B+O;X$ZKYQB[%]$9/-9,'IL
M9,\G7HH >[OY\KJ-M]LX.(Y0&L8E2F/L(T)YC$@0^QG)DB*+2[@O,&%EFK.L
MB1<P4BS$2;A6%\R'M&[C%\G57SSYH]\S%*Q0K'6:]'F];=VW[5Q.49%5WV/$
MR >XIE,4=MQSG;2B6>NO'')\SOZK_O9*+^I5FSH"M/L>>]]U++]M8-V,QN[<
M7GKM-:2Z((=U]AY5Q;"3L:4%8/"OK0"+>34=48T;=8\N.FES[I!8^PVY@\^:
M(KY7,XF:J0 TV^J/1U(DOL]9B7CA^^*PG0>(9#A .2-1&J=IF(>@Z[!C1!S;
MZH:D-U>5*R\-T=JK6D#@U=);;@&!Y\/HLOJ*TXL,3E4'S&BWFE#DSC8E/C81
MW?O%L0;G?H3$Q%CN_4(> KD//&M\#% E6)>\^>_UXGKQ*I9=5JI9PP_+"%.,
MDB00]NI'*2I(F(A3?^ACG 6\R,@VXPT*^/N)FJ2\#7HU6X)OX.!^0%W:\?N)
MTIN&Z$VQW2\;PG^1T'T=VE;C[W$1[878 [2FCJ+'Q3X2*&N\9&K=[4_Y#5\]
M8I(&Q(]"5!0L0YCX(<J"-$!^'#-ASVD6^" 8ON[BCC==8VOMBE_$:2"!.S*?
M2O&9B#TD_E;,A"\+:1K$)'E<Z5_;&8L/OY^S(;ZN;S(3"NJ*6BIGWLW ( L#
MMW/(O34OTUEZ8J=R*-2A#SGRC)4)VWNS)!+"(I[26#@-0A$N&4=9&*:(E&'!
M>2J,J "U&PQ2<^Q4NLU^^ZCNM^M5O2(+!BY8'5:?GA%:4PK,*O<G:4/FF)PZ
M07MH[(7MX=D?,>X")/;(R&PKPRCJ:O7X=;:8/:^?-[5G2<D2$1H@GO@,85H6
MJ,!AB&@4QSQ)<TRY5NW9P<J.S;BEI6>FAV(/F^1)PL#,KR5C,<'5R_R078F7
M.C8E_K2SI\/U)K&=7C$V=M+_@&%W;C.1_G>%>+:ZK>YG3]]7-VNY\FVYZP&^
M(/.Y!%AHGZO;!^O',,<EB0..TA*+31+[%&4RU14&A5_0B/MI 6K@.)$?Q_:W
M(>?-FC[[7\2ALI:--?5?@!V^)ZI=;W.=4)DP^U>,R2OXEJ3XD?4431$D*_;D
MO^T8]!H.)13+]@MLWK!XDK>D+EO=QB=R,VT[LAW5'?0K6UK6L&^-S'E]OF!7
M/^BLEM=V=^1-QB,7$B%NL7I,<$JSF!8H*;),-KPPE/&X1 P'480Y24@(:UX;
MIN?Z8H[22OJT6G)A@N,_IBX]GV51"3"?I BK/K:&M*J-;8F?>2UYBQUM>G+:
M:FL;H39M;YN>Z <-;IJO&:(74+I^7JM[K4O^4G':H.6+W\^Y*D-:L//GI3A"
M_UO]_5TE;[Y6;W?B9V@EF1+'%04U^5AFC+(@+5"481]A7O@2-HXCGV6)\!9!
M1A)J<(]@B[]IKAPZW'JLPZZR+]+A$PA68.LCZ?FB275N5DS0T7.7Q3-ORZ12
M>9?-,V_#J/B=9/6L\7H;;BV"$5C6GRW0 5ML30LN8%F9!R "MM<WG,)$JL5L
M\53?\4I!%MPMYS/ZMDLK!B*P"O,RD[D:X5XIIRB/(W'JC+,X+G)2$-C-S@@]
MQT'7#5]YLFY,0K4U&"+ V4DCVM+S<Q9U '-?&\([\85+4L2]/]K_.LG(:@IL
M:T;1"+5IQP_IB7XP64CS-=,I!IO:HMOR9KGB=1O:/>9)4!8Y3U'DYR'"<9JB
M/,]3%'*_*%D<9EGF&P13??2F"8ZVU&66XT5\H5E=+ZLW;[&$P@GTZDW/[D]2
M@R'^_[:(3,BN:&[.6#;Q^X?%L@;%WT-F8E3]86$/ ?)'GH=9,'U]%">Q?W!2
MG9=B_PO](.WT]V=E2A )RPBE&>$HR],,)>)(1!A),I)J94=Z*;C.AU2S6B';
M2*HBG*:*J!<%9Y[D0<]0^]4S;*%6A 9>B9(?GB3H*8I*QO'[&4UA60O7K")'
MMT*_(W6*\*?[HU%Y&D=$7Y5O"<(H4/ZE_[5)',LHUQN/,OX@O*GA8OF-SSD5
M^^I73N187<@<Y*,O.R^L>'XABS=O0]EK20]/ -:4>]A'6!$9>&]C)"VH2V%0
M(J,6A>,K3M:?,"A0MSEA^$'#Z]UEO;HM5>9T_VB8!C%.<5P@FI0IPCD/4(X3
MC##)LR2.PIQD6D,YQTDY-\&Z"2?O^2M?#* +0S6D%T3;D1MJA[4Z//RZ7++F
MSF+3-^3TV#PNJJV[SWY"TUYKC@I\<&,Y_H8I6D^QVDV;W_V0QB4)*8L)PC0/
MQ"^,(Y)S@N*<^UGB\S),06;<0\=U'NSVX<J[.__'^:<O5U ,GN-ZT3->"]+"
M+%<2]'84+0^4T13+&N+.<2H3@^T,BGJ(LS/\.#QD?:C8>57MBA'.GY[.7\EL
M?OZ\T@U<!Y9P?<C=-J,J@H-Y&)#DXZ&K):&!A]R*R#KG]]#<G4*C(_J0=V=K
M&[=BFD(;Q;A#ZTX6Z6H(UXUW=1XW+-Q9%S7_UUI\W"O9*U K2-60L+((Y=A%
M/Q'Q+B<Q*DI6HD#LD660L@)'%%2M<X2(8VO=D?1DJ+LR * ]JAJ]O?)4@6&6
MVI%5D3NSC"$[)(VMHIMC)*:MM!D0\J"\9NA9XYH:Z3KKO4*P/ G\)/=CQ'@@
M+3&*$4D+'X4LQ"&E),Q#T%BTXV1<[YPM4=D5K[]MCFA&SQ!/EQ=FBEM1W57#
M#8MDK^[C&)&IJS@&!#U2DS'TM)E5WFX@&[JM]?5CC),X3_,2<9Z*TZ0?^XCX
M"4<QPV5!HR)*<Q >\W$RKG-!<OB4?9R*'I7IF>OIBH"9ZY;>'EB%Q4KY89$L
MF6L/D4G-=5C0?7,=>?J$$:3G+[N*K*:V_=OY_3=]P"?MQ5Q'L*KCM,M V\7A
M_2)X@';1C*M&,[*UJ15@F#NB$ ?8ZMK2VAR^.4AO^@&;.N(?':*I]:*9H=_P
MU0Y(;IM^>%A>J$&YBOKWY5RL5U_.YFNQKSVR@+(@CR/$"WFDS?(4%>(8B\(H
M9+)!/20)"&(*S('KK#!?>7-9'8D\UA"$^0>X1O7\A5,]P?R'5-%[0,I=XDJ$
M/0U'7I<E<9 >T278HQCKPY*'@=.?U.,8JV?? YDO9  O.9]?_>!TO9J]\@L1
M13\IC!X@Q.3 &JZ/Y_.YMZ7M[8@#0"6'%#">WK8E._"HWB.V;2A)#>',X"2'
M%IX.4E)#O'>PDCK/&T;_]#MGZSF_+3<3(A[(C_.ZYBO9"M<9$K&'OM)67V)$
M9,UE*E/>14:H^!W#4<Q\%E+06&U#/EP?)UJNFGGVSR_+Q::T^-V$DX9/L4'N
MV(2>- P_@^;YP[UR@:>2CEZ/:5)6G'38<HJ><Z)R;!UB#+F8]FASFJH.#CPG
M+G<BCM_GV6)6"PY4D9,(?6[+>U[SZI77CZ1@XGC#4D1YB1'F28QR/\I1S%->
MTH@Q'(-RE1HT'7NR#6'O25(VQ+X;T)B>([*L!YC3Z2#E;;6AZ"ODO*; K^'!
M 8K>N,"VP?4&*'X,YMZX"GJA^#1>-:U?W9YLFFGR&>-97# ?X905XI>$H:S(
M9&M)D@9E%ODX!=WB[Q-P?3_1G,?;4;+_T_^K[P?>"ZF\5TG\/[W(]\_\YG]J
MDPWRW9\;H"&/K%??17SY;\[^YN'D+$OB,S\.U-/AF2^>SW&\P2>2?[G<P?MY
MI(V-FEZ6__@?0>+_K6EH"6/U\-%_PF>>(/S"J8QOYT!@SH,OJ.>)3ODN,+?3
M39&<>8K8F7>M]&>S<O:X.-;J9?>6G[A*]KAPA[6Q/<\9HG>2'\VX>C5T:MMN
M%DFTV[3( D2"A",_2-,LX&F<4M"@GG>K._8*"FE&$3.:Q?5>$7KV92P>S+CT
M)8.C:AZ3P!:*YKNUIT7-/";6 4KFT8<,M]BFJ* =2"-6;J?&?^(+7LY6K6$E
M 0J+DJ&4R8Y.5B2(IHE/BI#2A*2@'7>8GNLXVV3,U9B*-+<T>X(#=[B&\&;T
ME#K(M[2]7UKJ_?D0^%ZG)Z>MK6^$VK0[H9[H!QNCYFOF,?2L&2\DCNW-=*HG
MOJ#BX'ZL<2(KHS +@@1%&:.RJX2AG/(,)45.$K^@>8I!F4,8>=?Q]^W7K]</
M7Z]N'KYYYS>7WL7MS</US:]7-Q?75]_@@2U K?IAKQMEP8/BE@]U+GC'B?O^
M%3,U6 RF <0G#[7ABCD6B!NL8N9^?N>R3(*S\U=>D2>^0>]L;R@5F$S=@:!_
MC'"8)CSSQ9%>]J4&/D>YGX2H)(RQ.,TI)MFC6*M8ZGH@( <0J^KRH6U<&WX0
M:1CR:)L5: [XW0/[MO#!'&H8JO\8!WF8R5["/$\03F1U=I04* HXC=*R"-,8
MU%#H4/LF",[[NE]L\88WZB^WWT/59GWPY]#;-QPJ&;9Q;!CQ6DZZ>,Z-?CML
M."A%,52$I:T#2GW2O<-0-?N;A^DR8%RA;US>HE\&VWDE*G/4%F#DU(^3D*4H
MXP%!."LRE(<%1WXH-@N2EQ'S(TUTH2$ZKN^O%6GO$@7:"#N#6AEV%A9EA3F%
MG9@'PV? "$.#\FOC#-G2@QG:4+\^K( .Z0C7"STT^/)4 $0Z$G1@B+0>-ZR_
MX4_R^][S%PE]NGAJ0!WVD4**.,_]"&-49$4DO%%)4.;S$*5ERL,BR>. @4!)
MM:@Z]TU/PUTC)^A++ZBQK@6HUU+DO2W]:;!)05+;JF[1HCEM+0M$#0>5*Z"7
MK:?5'G%._+C$XN1*I#_(288*FN<HQ@DK<,SC/ 3Y@P%:$UQ8=Q-!]%TB""D(
M3R^WECD[/4WV03FQ27)?TR6Z?IJLED$*Z]0=7YY@"E)S)BM*^:)6L5T',.33
MV^Z1ML?O_$]2L=L7^6#]=UZ+<]#UHKF@^TQFE;KL#N1%&N5A@E'&,$%I*CQ#
MGH0%(KPD02QB!#\N0$&"(T9=W\ )0DVYBTP*+!M>O%?%###6</6E-,.3GT#_
MP(A&LH,^27Z\+L]=.!PY9*O[7,NXIS@_\UK>S[R&>SE5N^'_S%,?5HE@,1AR
MK&-;\9,K-J<-N1PK^R!*<TT/WO5TLUS\*EAK 3@O>4VKF2*V.[MH]CZ-K^38
MSPH&T*_GYW=;C-8.#_I=4!H*&?:6]G4!\WE#:K!\>PD3U:@_2F/YR;JD]$7M
M]DH!WH)GC(EL5E#)GWO^-*M75:=/^_RIXLJK*,@K&8RQ,DH13E*,TC@N4);&
M :*$90DF&!>A%NXTB*KKC UI.G;:ZN*JPXQ7-: "9,,. #H,IMCQ%+03=0$#
M(:FIVW)3]-OE8P._L.5D&'?L!$WI)ZN=:,PP=6U-<Z",-E@#_?EM_:4FRW:#
MI>OFON$OP_PJX[/'*W&\7KU]>R;S^:=U/5OPNGX,.$VR,A=^4R@8X3)($0G$
M'S&)_#Q@088CK1ZLGO4=^\J&HJ=(>AN:>E;>IY!ASV=!3)B/@TFH;8TC<@Q$
M->+-)JH1O]E%-7WK36)\(\)LS&SL,=.KI;GXUZ?S!?M*JG]RF<!JZS[;VTR>
M!$&6\  5+,X0+K("%25-4!G$A9_3+$E]'W:K-$S0^862(J]RI\\;!J"W2R,J
MT[U8LJ<(Z)W23@=;VMMB; =83YJ26KM'&B$W\162GO"'MT>:[QE>')&7V8K,
M90>?S'NLA2E]6Y:K/TG%?ZV68B/AI,C\@ 0H$PY [*QAA@I.*$I"+CQ!&H8T
M!74WCQ%T?X6D:'I\,R+T3)Q22CFMHO,WTB)>Q K?5=:Q;OD#7BR-:5;S=LFB
MOH!73#O*WE9M&]IGGJ)N\:9)4TY;UTUCY*:]<](4_N#B2?<],^=PMQW.IT)Z
MV8=*A#QJQLVCG\0I26**:,)]A#$6P;=?<!3SJ/!#2AGEH%:L(6*N@P%5_35K
M*7I4DH09^Z"F] S=EOPP([_K3,!LU+ A[%T,J@%LX#KR63+N05*3&K:.T/M&
MK?6.*9R)!&Q[(#]VG17GA3RE4]V^P8$5W/V0MIB"LE6PV^VS(6PQ1-40SQKT
M1C^EB2$W1D4^A-H8?^6D_M]O*[+B$M9'?+#Y0!>PGY8^2BDO41'P''&:E3Q.
M@ZS(06=1+:J.]Z#?_OKMKY[BP*@=>$1CFK&F;3T  \ZV-5C1;V"]) <3M0CK
M26VW47B$YD>T"^NIH:=I6/-E>,[WLKT?>*C(HIZIG+(JIWP,<)B0LH@0"2*,
M,,.AK&B*4)%CCO.@"/Q"._';1\2QY6_(>CNZ;9FO?@JX5S_C>6 ;4L/LW$!@
M4$9X3"*CM'#OHI/EAL?$ZB:(1Y\UVYYE24M3%S.?+_^44>F7V8)?K_AS@WE#
M<)RA*.04I7&2H2()*8K$<;#(\BA*&*A5?X"68X/<4O:VI+T_)'%/40<"X@SI
M3&];MJ0)F)$:*P&\_VJ(9VG7':(TZ5ZK(?+^#JOSB@&PMJQ@^VW!JOG;4V?X
MG?ZTR-X%7(?+"R'@_$U>6.S( O"T>^4>-DEK(L.,49'TCLIL=2+DJ&AF.-J]
MJTX'HCTFV#L$[=&'39MT!)^+;4U$_<_=1A#X91+%-$0^8:7L(/914:04^:4?
M$QKE:1  <6[Z2#F_7^D0]B3E$[;. 85I'FBMJ %XBC74@$%OSIAPUEIS>@E-
MW)DS)O!A8\[H&V:F?(!!W0&@ON&;#%4J[3F(4>KC&.54G$W+E% _B<,BC>GC
M:KDB<SU['J$',NHM5>T?:8EXS#:MX2ORPR.*!^AL]&&5Z5FT144 #ZV'R/,*
M"MKFG'0MT:S-2Q^F-O'<="W1#^>GZ[UF6!*U?GXFU=MM*9:_$%1FJPM256_E
MLI+Q0;T_WB)+$ X($\:>"6./"4<T3K.BI)G8OK7*MZ&$7=^*-FS(FT'I #J3
M'.44K'<LJ62M-(R&W7?_V'1A03OW=76OYS5<:!3F/CK*[-&3X\$50 U8FSJM
M27;B2=0P91Q.IP:^;^: KOZUGJW>MJ-D+I?/9+801X6B$$&$;-KU(X1Y4**\
MC%-$LX!'?A'ST <-K#Y*Q;%K:6CNIN1X?S1D@>>#XPK2<PDGBPVS?[C$8!,?
ME,B2/1^G,:GQ#HJY;ZG##YO?0S5=GE<+UO1O^2&)"F&(V(]"A,N<H8S@$I$P
MSWC!&2]\+;CW7@I3W4"UZ.A7<OB"]DUTOU[T+Y^,I36\>=(5U.C>Z:@P)UTZ
MO5]Q\ANGHP(=NVXZ_B \+7W'E^=TM2;S^=L=F:G:1D!.^OC;CFWH[NK6VU#U
M)-D]4(/A+*VN!L:STZ<+#S.IT^0&9:>'13-*3?<L.5E>>EBD;E)ZY,D3X&4^
MC8,>?.H!/?B\K$H^6ZW%S\?Y@EW]>)DUJ;9Z@X/P2%@>!93G*"FC F$F03)C
M$J DXAB'!?6CDCXN^)/P%^P!"#?CDG$M@\D;@SE@7]MX6C8X._.HO-*;R]\M
M*X]+ADX!]G7_834/WC_%=_IP?)J.&"I5TA%D!UIC&:AF"JW;1*QQRN_TT#53
MJ/\HALTDA*V5G^\R>9@P[F.&44;3&.&0IXCX-$2)7P8D*7(>$. 8S7YBCF/!
MZYN+VZ]7WL/Y_P^=XS&H(3V7:TMNF+?L*=%WDLO4D=!=E?X'Y2QUA-:HT[>5
MF_RV?GF9*Y]"YI_(7 8OW[YSOMI1ZB3I);A-%#"&&,;"M$F 44X8133F-(AP
MF,2<P2Y(](D[-O5/YU_.;RZNO&__Z^KJP1-F?W=[(P?Z0*\[ -K4O?)PHR/H
MM<>."Z]EPU-\=-Q$[<A/F*C VKT'@/3$=Q]PI1S>?QBL8>9GY.A>\=)W$8]<
M\E<^7ZH.[4Y((]%69>/1PU*$*.6R>A9!S.WJN[#D+]MBH0*'?N#G#/&,^L+_
M\ 01'F(D HLLC(HX8!GHRL0&4X[]TH;%=I#NELGNZ>7,V_#IK99>RZDG?O$:
M7D^HW++RV?0<W=0? ^8 I_L.8/=H4W&6W*85EB9UIS:5N.]FK:YM6!M>7PB'
MSA^67Q<O,^G>58D"&']48RG'_K#AP%,LR)3+PTR<5H2U?;VYN^Z&(F>>8@M8
M23ZBI?&LO64%P7R4KFZ<%*@ I3<O0!]9?]I2=#UA#XK2-5\SG6X5'IUCE/I)
M$H:Q[.E**<)I4J(L2B.4Y@$I A_G60"<;G64CNMJMLV8HQ ZW>FX5H9MVJ*L
MP /75DQKTZV.RP^=;G6R'DZ<;G6@#YO3K0:%&YMN=?SEB:=;#4IP.-UJ^''3
MH]XK7ZSY9\'=)K#Y?;;Z?K&N5\MG7@&!2C17<QGY*P8\J>U=@/^GX,';,.$$
MP@0HN+7(78_JQ,$Y2!6'\3?L==,[^&6U>N#5\Q=.:H7R\Y@'-$M\B0?.?8*P
M+W?<.&(HR%A6TB#RDXS"AK/LDW"]V4J"2+SX[,TE27FA+8$@H)?8!YK1O74^
M15[H-;$451+S%+4SA9ME\RZW3Q9KEZ\'!":^+>T3\/!ZL_?)CYFN=/6#5W16
MRR!\;Q#M/9>%IK/%T\9QK,E<<A[\W^[>O3=N'=L7_/]^"@$#G-D-F&?TH"3J
M'N "WHZ3]IWLV.,XW>C)'P6^E%1WN<HME;WC\^F'U*-*=I4D+A8E)P-T)]Z.
MQ/6@UN(BN=9O+0B/<QS+0)DUE0CG-$,$AQ&2D1\*'+$HS69MO&0AP\3.H\/1
MO"V8;*;3U"']U),$]7CN$F,Z@IUY!^VZ=\)Y'>D\+=[/T]3IA*GY2?H]V4CP
M2[6".F&*7'>).H45RS6.?Y?B4;=E^+(N)-]\6VNTV#OZHP'E*F\WJ]7[NG+I
MU;%E4]>8H2R4%*5^&B-"?(E2&N5YEJ04,PQ:JJQ9F3I<;1C3U7E=UJITEIM-
M#: $K6"TU[OAFC*+-H%+PY B6[X\S9C7<#9MT>/)*G+EHNT9F=?3GJRP X=Y
M^HC6N8:%WB:\D_7?5^M= 7.U?6A+Q9\782*S+(\X"J0^WTZHCS)!!&*,!I+Y
MG&4!*#O)F/+$7FU?L%WOP5?[XGAP4J*A*LT\UR0*@CFJE@7OMY:)O^B;KTZ-
M>_6O.TZ<)B_"A'>7R6A(=^ZT1I@ZCN0X @<X 7U4O;J@E"5Y*'3]=:AV\0&F
M*,O4'RHFPB2FF"=F4='K@2?V!GO03?6D!;"H%GW8O$\1"&:]9K+8889V&#\-
M)U0/-#\V:(?]HWB@W7^W1"6@A=ZFE#>RJ+8Z^[B5Q2)B:LE$<9 RA'WU$V,Y
M0TD@,A+&U.<^",2LE]+$IO+I\L[[>/WYLW=S>>M]_NOY[240EJ!70V;KHQ.Y
M81;5DM399_7!S40YN:.RN0(JZ*4S+UC!F+@'@ 6C+\ 3N:X?M^66KH4:]U:%
MX$^R>+Y:BT_TW@B5:'B$J4U1D3#/Q1H0=-CRW,D(,[L.3:\E>N8ILLNGI=!G
MG8/R@W*LQL6S2JT:&':VC*IQT;J)5 9/VRV,YT)4!T5TI0NTK]9-<Z:%E"+D
M&:,H#M5BB+-8(I*Q%"69B'(<$"YD"%D6>^A,;(E[JMZ#(HO4;HG7A&&+8Y^6
MS)9&![+#++0C=@5NH,2^&!$;O":.".5H1>RC,NMZ."+JZ]5P['&8H9;;AV)Q
M<5ZU6\\2GR N\@"EA 6()0%',@BB7(911,P.?)KQ)C:\"[I:YAL5%5 S0VNE
M'#8H"]YAAG-Q_O'J_?7MIZOSTPWE%;,#"Y5^LC8&_=/>"-H19OG87[';?M2O
M?VVWREQ7S2HOVUZ533:F'P1YF$J.& DIPIBF*$LS@0*?TS2-TRR,01E#1ZE,
M_:$?M.:LBF9>=^>$+3?'U66VV)RL!& P6 NZHS=!!]Y!B1RM,\=IS+K*#(KY
M>HT9?ABXPA3;Q4VQ$8]\>UU\EL63&OG\Q[)<!%$:TBPA*! RU3!Q&2(I%BC+
M&0FRD%,B,J,EIX? Q*;9D*SLL:'J?=5T#9/)>_4RLD@YD!9F@Q:"FJ]B(](,
MV9]ZMV-[ZK\Z2UO?L/.L=2-"[1:_L>?L5L,/>O^VKK(LRG*I]W5<[L[_F^YC
M5;PG,,8H"L(,I3Q*$<%!BO(X(S(+\D#$"61Q-"$Z>5!8?O<*R>7R20KUPTH#
M4.F:+?4-/:Y%=:7^0)\+?=.N =MYA5(+O/<S4J[94NI:93"KWE/W]N3/.K=]
M#0=G7GN+Y/W6WBLY;#0(48*CQ=B(Y*QK,T0)KY=JT+O@(K@VK_]Z+=L:IR06
M(B4$96'N(RRS2$75<8"RC$F99W&<QD97?<<&G]I!M"4FBJ!QP=>A!H:M^U2Y
M@#O*CDCP8K8CLVM:P7:2C'9E:T;3!RE4ZY6AMSKM\(VY2M)Z>>W4H?4_,TGQ
M6?/)4(KC7#".,*N C$*B?0%&:9 GH0QE@&';;".J$WN*A@<HOH>)NLQB ^=*
M@+D5DSJ]W^6:?[^GA4$1K>MZO4GVZ&8T?Z9:O>$]/.SE23S$Y0^^>M272KH3
MC?J?SG%<Q'X>X8 (A-,T1SB*0D33,$()#66,DSS,I5'I_ D\3'U!*[=JS^'>
M@QQ5IQ-_<JJ2G'L77073L.2U/.F$Z=E<S)!&YG$X1SGXF=S/D(J SFAP* N4
MGM5JGR]0-@NO*2S/D7>GOD9>K3KY#9".K<?D''8(+D2$6?LKZ1Q&"V.RV.'B
M'!MP/B"< 7%>(-\,/6>WEK^GRZ)J2]9!-P+B2PP-,=T'IJG6#=5> C--@"-A
M(J"CU6&0U*S+@(G0K_V]T3MVWVE305C>;<[YOQ^7A;PI-@^RV#[?J*]BJS&Z
MVVNK119&F,:2H)A2M345OH]([F,D@T3PG.;"SZ1%HP5S#HP^^I,[)MRHWW^G
M:N'4)68/#2_5=8WE!3% Q6:.P;'&[*ZQ&A[TC4##A=>R<>95C)S5C0A&E0;V
M&W#Y'7D1 .%9?0I<(:\]C,4(=O[FKJ#KLL9U.M_>;);K[=5:HP$VX1;&?AJ&
M,4.<<(T$EV)$LSQ"&9$\#"FG&6P[.TQN\G.O774JW7H/FKK.[MLN33..#95F
MYC7<J0+F*3ITM1IN6C54&)#N#[O,Q'3D$$:(S>H$S 1_;?B&;\%WC>^5')NU
MM"P'./[VU"=-H%* '@''-XRGRP:,Z&MZ4Z?_#XMEM7OL&7*V_>.P2-T=Y,B3
M,X-'[?OJ-*VT8NGC2(04T1 G"$O*$8GR%*5AG J1!YA04'Z*,\XFMN@].>]A
MN /6Q!-@MD2_B5IASL0!-%-G4B9I2^92@6\-H'3 UZ\!B]2G3F=@1[T$+ NK
MRE)NRXM'%0:I77B081+Q$",<^>H/B@5B(68HQ"'GODQB2>/%=K.E*S-O^6)T
MD,?;T3"/MO4K'J]I>;2B#"R?>J$+,\=E+2'P\+LB<^8UA!S61QWCWU55U(NQ
MYZV%.B;60074T8?@6>FWVF:KE.LXX20.!$-9$NN+:>8CPE*!\H1$/@L"[H=F
MU4_=42>.%#[K]*ERN^3*>OZ05!^QUA42P!STO1:&+<=:-N!R;2<6*./\0(P3
MTLSW8\V66W[ ?C>A_/ ?X3OAB^_K;U?K]_H$_SK7M<%B_>U\+;ZLG\JMN/SW
M]OG\ST*4'XKU5ERM;XKB'P7PDM6:P,0V]0])"Z3W0TC_Y%U\U\K41S^=.Z9-
M7IT0;Y^]ID?(![7VZTQSW;16K>R%I]\MO;OO5"UGA?2Z!>WZ?%E)*4OU@OG&
MW7X^QO?VLTP%S 7,.@N.[Z-/5J?5L8,]U=E.)DY63/?PXO3!3CC?F+*9\"L
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MX'4@<&H>KJV_^8^]X7>&FF<C<L#Z;K-Q^"^6]5'%\DEO3U:4RQ=HF.HSSZ,
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MY7&:9FF\>)(%VQB?<1VG!+&6+CW0)JD"4]DU%/&0)VKB3AJ.]*G0\&CI=+7
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M#ZI"H8\;#0NJ<^]N52BT%G6.EQ15W_0L\5,5?E".4GUIS$BJ<RY]GDLB<\)
M-=T@ZE.G:51P59R6W[WJQ*,^U:D:GF[I#^79?UO+K7;T1<45=$&$*=K,$TRF
M/IA[:-K":L0ZS<B95[%2;= J9MH\SIH?KV7(:6$F7 _N*C0!M.<NU82KY4C-
MIL4@ENVH-^L=7%Q-M\%-6<1^F#+)"<KC)$8X8!11RF,D<902@G&4< '!PNNE
M!'(RMIAXZ\T:[7'Q:B=CD>O=KRXS]^%$"3!7T26Y:R?=4.UWJ/!.T6.2N>H)
MW4MGWN[/8^(>]'D>?0&>LGG^*)9J5CXV2#2+!$<DS6.F,U 2A"D6*!-YCF0>
MYV$BHCB4@6G&YJNQ)XX$&FI>2\X\4_.U#H;M\$3)8)9G+!0H0;.'?:O\S-=C
MS9:>V2-$-SNS[Q&[=>Y#L2G+FV*3+[>+3!(J4Y)5V9<(1TP@%@:Z9QKAW"<)
MQAIZP'QEZXP]\5I64=*'<HH4;.'JRF^V5%E*!3.16J";88' :]$1UAVM/MV1
M9UUOCHCT>H4Y]LBIB![GZ^VRJB!7H6:3+KV4Y>4/OGH44NCVYKKV\'';(*&]
MWC'ONW0G?N03$23(9X&/<*QVL(13JE'HF4]#+(/4:&F:CL6ICWL;AO5VMLNR
MM^?9%@W$V209'@J_J>J!1\?C6O=:?CUM=5Z'8_W2L7.X*J?8<]K"?7K=.D<J
M<<;@&\&8N%9P/\:)<TJ6::3'VMK66*A-DQ#BHTSMZE'*>*XV^UF"*,?4CYF,
M>,I!V:/]M";VL[?_0>\?_NM=IT<ST*\.J<G,03H2'N;I>GI2MVBW#C,_QZ5S
ME? Y0&G>/,]QD0_2.PU><871V'8S_OMR^_WBL=QN[F71PKL]+WPF2<#R&&5Y
MK'M:Q,JJ21BHR,L/_5@PP0G(M('T)S;W7?.60C[)]2,P%Q2J2^,[@JDT!+XE
M.(;8V'+C_:G8\5I^SG8(C@XJ24]4Q610CL/4WQC5T4@UXP"/9L/8XD3</Q3R
MN\[(>I+U,>;-9K7DS_6?^ZU$F*5AFC.,*)9JOY>D.2*YBBHB'_L1#L,\SD'[
M/5/"$[N;%VSL3M,KO&4H6H2A(LU<SA3J@?F:8YHY\VKRWM?F[TGV3%#9G0%*
M&)*=&5@"IHQ#@ G@^W9^Y)T:M]PN^84.B(KGIG2RWH6D!.$@3E$J0X*(S'2_
M0BH2&2<DD"!DZ:-4)O80[Z72 EW!O,%Q=9B9_LE"PNR\)5=ML/ZWVLN68MD@
MLXZ5T8(M>U T1V9\G,:L-CLHYFL#'7X87."N9O$?DA97:R'SY7JYE2]-D2$6
MLQBE04 1(_I 0,H\SYF/DP0;UK;WD)C8#O?DC,NZ^W0Q;(=N)(1O]C5%;T\2
M7L7>)ZYQ ;L#L>UJUX^([Z1H?42@WGKUOO?F*E4?X;M3I3[VI.5JON_8V8&5
M_[)6&Y*JY5)/YXJR3FX,<X'B+.$HQ4*M]20(498+J5Q,&@B<+=;RFP:"O@.L
M^Y;\&'VY6?WE'G!E_/7N^:@[V/Q?=0,;8,1@JW+#H&)*#9[>WKC#TYG7T>>Q
M3C=>Q9C#H.1$U;B*6VS9F#>T.5%9!]'/J>.! Z1;62J'R;^?K\4[^217FZI@
MK=-IKCUNN=O<R"+?%/?O-\6U;AU37A?+;[IIIF+BG?(5"QU2A8)+E 0ZHY)E
M!-&,JO],DIR%6$2Y;P31X92KR<]G=]QY]%LAF^9\FST3GJ" &,WA=(R&=6^C
M9)A;;'GT%)->5]DO>B'N3GSO-E[#JNX.YM7,GGD==KUW;S0=QF'GVTR+7:0Z
M\_1 @EWW:NR-CQV2FBND=J^=3A0^P>"G!>[73?%IU;ER$>>"QR%F*.%AB' <
M441#KOY(<8JS-$G"&(3U?)3*7/>">I>SI"OOX9&MEGQ?9LLU$W8Q]TMMP0)J
M:QU81LLM/>]B4%[K*/BH/(Y#W)<TWB1^/2IF7W!Z_&'+5,SCW6?WKJ+\_7G_
M3-,(N6JZ<5V!*)27/V3!EVI_>;6NN]/^72Z_?5<[U_,G6=!OLOWWFV+)58B:
M^&D2^QCYB6[N$*0<992G*/-%%NJV2!'LVFY>]B?V*2TM-\V49IY9,S?U\\X7
MS/]UNX._:#W3%<5CS][1-N)UXE0CD>XDWLBDDR=JJ<Z\5BZO$6SWE%>)YC E
M]$VFQ%6ZZ+S,SYM*^B83<Y!F^C9<V.:N/<E2?>[-30-E61*F0G<8( 1A01FB
M<1"C(,)1E*3<CPF#I:9UAY_\@JDF!LTX>Z$!,Z]L+Q?,:[9T)KC*/2Z"LSRO
M%X//G,9U3+##+*VC3SG! ^YBIBQDDL8B\!G*F:#*I'*.*,XI(@13&0H_\1-0
M=ZX!6I.G6@V@_]8 2=ZR1OZQADP:TJ29:3K2#_#Z]P#N]P42TF0HO\>DFP;<
M]P6EM\3T/2;R")3OT5<L=W_Z:_^^6:DWRGKP3YNMO)5"RGM=A/02;+PB6>=I
M+81/DU"0''')!,(ASU 6Z,J[)!<R4RXB)2 _8,W)C%["%,?>L:H-=U9S*!"X
M2>JP]'\VKL337)UY>[Y>:_6L=C+SI':>K#17VQAK/N;=D9RJKH/-Q<D#PIO\
M5GN3N_MO[Y8E_[A<RZNMO!\[9>U];SKCJ<AY=\M[?;BJ::XVY:->@[]JXEY%
MW5%CVT')K#K;'A]QMM:V@P)U>]L./VBWIEZW*"PZ:[];G57NO[8F^S%%@HH0
MI9S%B,F,("+2-,]2/V1F0"H FA.ODSL.JBZN+TH$#3]9:V6:K8^.500SYM.U
M U[: /(Z6L1,*,ZZ7 %4\'IA@KQZ*@:&WKNOU60^-ZUVJ_+_?8$.41%U'F*!
M:"1#A%5LK3?;*MQ.U2](Y-,4YBM,"4_L,+K("3M&;!$J1E1H&$%/H!A@P'Q,
M)[N.V#,!0Y@)[QSN883L&X$XF"FC'YK!\/TWNKO]H)[<FEWOT93S) S55E^2
M#.%<UULF&4413K-8IU%3FLYZ<6O.^\2.K&+D9[FS!<SH3!>VT\S3&][6U@+]
MFE>U\,GX6>YI 9S_6I>T\"EQ?D-KP8*KX^9;^:0];O4/GQ]6RZU>: C)$A\%
MDA*$4Y8BXB<,Y1ACDOE^0"FHAYP!S8D7B(9>T_:DU!1//3H^5)OM(?%)RCC]
M.%B?!-?:J5OE?A[4CH/SW5YY)SO)/:3XQF>VO2H8/YWM?Q4.+GRYWJH1_RY7
MJ_][O?ES_5G2<K.6HCKD+1:"9)@&E"$B,N4&\ERG;M 8I1''.<<L)MC(#8Q2
MFCJGKZ+M:>+H7YJZUY*O[SD,TSO&%3;L )RJ 6;V]AH P18;26<%8CP\\FR0
MQD8"=@&.S5ZP['=S_[#:/$MY*U>Z2K53*]=L=!<\85'$.$>8Z0UC&''$$IF@
M) @D$33F&0P6;)3BQ(9\SGFA<T%X)\:"+>/C.C-;Q)UJ FC+#6E4U+1?%LHV
MY!UV#S*5U%4;H5%Z\_83,A7_H+&0\8MVUO]1EJ64^S-RC0NV0P!K-ACENT>Y
M8!')<^D+)"B-$*;JRZ$\2%#NXS@(*$EI!NKQ84H8Y ML6W[<+]?+^\=[;U5!
MX#5]"X$E/\::-',-4^@'YB%J#O1QR>[&2S/1 ?\[\[8;C\FJKY [5P&5W)''
M,"8[J^. *N.U_P"_[\Z-W,JU_).N=&?618PS000+D(RPBB-RW9HLSSF*<1X&
M6&:2AR$DA!BA-_DQ0$7)4Z_>G^XDNGJR]PV6TCMR":U&[H8TXL03')%S0@?0
MI?;F=G]$=!-S/_;::37 +QJ-[5J0-4V*?E?D=.N0.C$F"1"+,$9I'*B (8HI
M\GVN4\M)F%!A4QIL0GQB^__RGY__LVZC9U<5;*0_,U<PE59@?N'=/N_S16_!
M%O94 _$TO'B_-=PX;"AFHP3'A<=&I-^D'AFBE+XR9= 8I_F6GHL/C5!\M1;+
MIZ5XI*N+JOMX=7:I 1**)RG>;XKWC]O'0K9=RA=<Y(2Q*$=)E/H(<QH@FBA_
ME G)$RFQ3##HV,(YAY-'*37=M@+F5==V.]?E;GI@_NU-E&[I!/ONI6L0]3V[
M&LVEFH_ZPF0W7[JW;<VTUW+MWE<Z5ZACA^J.OS?QNL[5V^>:W1.R[ XKM_7"
MH-,L%SY/LRA46ST:2(9PF A$_31$N9^%,N02BR '=83MCC[QD9"BY6F<16"[
MUQ?R$Q[+/*$9RK(X1)BE^LB<"I11C(F?Y4D6&F'BGBX_?-UP(7^88AX2PI&?
M,:S6WLA'69SH'4"8B@!G&>6X1>N<2@,OT3?GUX'9 F<]L[#%20OTH@>!=[[=
M%DOVN*T24;<;[X:Z/?$_*IBKSKXOQIZWF^\QL0XZ^!Y]R#+3YI&5\M^/:FXN
MG]JTTT48DX!GB6ZQ'<>Z+RE1GE:D*!!1G H12.5B0:DU1XA,[&;V)+V*9I,3
M#:PJ.:H=,\L[56:8 8+%A6?(#,CC*B7F&(EY<V &A#Q(>AEZUMX8EV))B^?K
MHLZC^4-NOV]$#=H@Y<==*5.2,$HR/T(TCU.$,YRKGUB*PCPG><A)PGP"M5 C
MRC.8;<V'4EQ;"5RSXK6\G% E9JY@<R-WKC:XY;O1F)5+ $GOT$^8T9W=>8#4
M<<RCP : %S7?%4+MXRY_/"R+/>*M@:/H>W?JK+@=,0 <<*^<PT;M0D28[=X5
M5.AKKNXICJG$H,+M(;&LZK:/#CA;V?:0.-VJ[<'GY@1@?R]EVQZO;C5!?+U@
M<XK2+ D029,,"1GE:43ST$^-EFYG'$ULPCW ZZ+SZUPM4<N&FSD0O[O3,>P3
MWD3),"?B!ME;L>I=O=$4S &X;CD5;PFV;C0E,P&M'U'?%"#K73*_ ,#Z$:VX
M 5<_-K#=EK+)[+RAQ;;;BZ1N %U>YYW?+>(\8#Q+$I31A"%,F(]8D!.483W%
M.([2'+2I!-">> VZ*=3RLGR@*X]6Q/5MY6I#@7G9$%V:[1\GTA!T :E3M"LN
MN@V+VI;MU>5NY_?N=I 6\CO:0T(HS[J+M%#)ZWVDS1"G8I-<YKE4([:M6N_H
MCUNJ ;JTU,O5LEH_7X%MU"E<<8ZR/ U1R@(5"&,5%T<RCB7W21J+S ZO!,[,
MY,D27=+:G)KNK%5*TZ/&?? TB_JF9,=\-[WI%IP-=M+4&)Y^S:1PX(%8!QNE
M5Y?>JQF9!S'%7DW.450L6'DC9!5[I?6CK9PPIJN"=D5Y]:A/?VXV1>6=.Q>F
M=YM/BA$='6Y6:M!O5VOE<V2Y/6=E%3 N>$R#F"8!2G,9(,Q5D$9CX:,D$C@G
M*4Z#/#JM]OT4]J:^(^@P^Q__!PF#]+^:<^]3J^5/FA-#G_EFFH9YT;;J?L>=
MU[!W<+/_DD.O9='[VC(Y*0RK"^U-5M%_$G-O7/SO0K'C. %.J$P$BM4'AE+]
M\3?=^URQ72&A! O"\YR+/$89B3'",A2(ABJ6S2A-$AIB/Q$PA^R0N8G=<4-,
M0UDI:HYAK"!S8.B WTBSP"#6 (AJ!(>JQ@5N9^=F>';<(TQ9J'$N""D(:S\7
M1I2%4L$@4#8T+-N'5)C5S7E$+HOK_,-F(ZZ+S[)X6G)Y_F-9+C@6<9[$ 6(^
M3U2D&Z:()2Q%<1R$J0J!_<P'I:(9T)S87S9(W>V1FN)!_ZRYT D<#1\J>E*<
M +-;3/1IYB0=:PEX*^Y"0? .(^8BN^HT8D!QWHXCYBHXZ#P">-422,9@RUY=
MGIR+?SZ6VZKRO+YK3WP?^5A@E$HJ$:&2HR2@82RY2)D$58G:,#&Q.ZG(>1UZ
M0*P9&[6:.9&IE07<T!H>!9YY!QH]T]$3=PM8<X)N7&'8V+ P+ZS-"4HZ0+HY
M92P[CW53;-2>:/M\H[[#[?E:Z!UO=07\26X7,LM2FH0AXC@,$,X#JGL/YH@$
M02H()S+E(+#V(6*37Z[6I*O";-G2/?/6$@A?.:BP*(S]+-3E"'&H L$DCE"6
M9@&*I$^#*,BDD Q2\^5,8? 2L'D49N:D7:D!YHQ;JLJS:KJ5(B[WBO@TH BP
MJS61T)%+'20UJ^LT$?JUBS1ZQS;C^%QL'NSRC;MO3NS)6E)6N<8O)!PVOM.%
M ^ZHCN09F\EJD65\3*03<HQ?##=SAO$Q40[SBX\^!;<3?1QSSK>/=+5ZUI!G
M?RMW=7[[BWE#RS$9:V);>GEJV?!28;EY3^5_>ON*47,[,]+0N.6Y5@[,%HWU
MXGUUFHT E=S*9(T(S&;$$'&[9@UZS[;_>)W=^4[6?U^MSSFOTK/4ED0NGZI"
MTY2$.$Q9C'@4^4C?(2&6^ +%@<\D3Q+I)[PM<[^#-"<?IVWT_;\L@;^S6&\;
MNEZQ(PQM8FZ@1K- V)E6+!N>UU2]WUKZ?]&-0W8*NAU7D$4G='.)G?5'-R Y
M<]=T<R4<]E('O&OG)]H4<0VX<O%8;I4+*L[+4E8[O"0,?"X"B6(<9PCSF".6
M*4_AAVD<Y83X%%:F/T1L\FBAJ86@FA[P#'-026;6[TIT:"S02%U!-[5TS[R*
M\IE'\ZT^B%RM-G]J")T*N>FBD&*YK;I#NO,$)M([\@"#I&:U?!.A7UN\T3NV
M$4'3 *[N6[P/:.,XR@)] THBD2 <$8QHD!*4^0P3&N XAI7Z]Q&:V,(M6S?V
MJL5T53]=6.A*OFO'.$=C\C$!G2W</61F7JR'A3U<H$>>M\P<D\52EN<O>X[_
M(>^9+!:QS(* I %*:)HBG/  921)D;)3&HH\"!*<@!+!^FE-;+ U9>\<F-$U
MH!LSDW4D,<QJ6V&]'=D&-O%K3=EE#NNX?*X2H08HS9O7-"[R09J2P2NVK:2:
MWA:W\D$GG:Z_534XY4(P&F:I6EXS'.A4(R81)3%%449PAOU0$+-&-&.$)K;;
MFO2N%_".>%UJ9!A:CRIKV)9=J@!FR+;26[20&A;MA Y2/0//W$!J6+S#_E$C
MS\.,M2RVBS_H/S=%&V675?9:SB(:<"&1+R)EHD$N51B,54#,B- P=4Q0HUOS
MX\-/O<=M:(%R^WH4,6Q^IXL'W,<:2F9L9,,"#"V/ZLW.TJC^:V]@/8/.8E;#
M K7&-/*4;;1:54]\D&M=<'J^%N="-R32-10Z'Z:!62]?[Z\XQQ&588PTH"S"
ML3(U&K) F5H08!E&L8R @:P-&Y/'N!539U[#5I6(\)*QMK, \$S*4NNF(?+4
MNH1&S^9JG&=;?)J&G,7?5DS,')J?HJC#J/VDT>"7YE510GFQVI3R;O/'^F'Y
M;EGR&J;5\*J\?X2IDTTJPEY%6=_UW"WOJWK*/S[=7'F:"?4/CX6IWQE1QK!?
M<:<'F-\P58$[-%LS2:WNO@>&G>W&>URT[CVWP=-V(<>N0U07LQT'$29!CF+F
M4X335(7N/-,0_HS2, SST(\A^9M':( ,%IZVN6]+!L=N/Z81M5>)\DCWKN<X
M5)L9#;PD)$<JL*)1CF6<$0%#L;?5R2E8]JZU8A8!G3C[,#>U%_$%QKV[:&5
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MVZ4I7,&XCLRV"4XDA]E@AV0M=965X;X.8E0T5S"+O73F!5<<$_< 4G'TA>F
M%*NMAEIK/ZI97.V>DV7;LX4BX1-ESSHK-,MRC5! <9!%6 :^[QI0L8^9B8V_
M(EO%E?I;7ND&A?HT?4M_5$A=.E[-FR/WK6;'/>YB[RR8^8ZY=#O-E<:9MY^
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MQ\_.88[O B9QJ?;Z<N0P+1B8U1W:*^BULSMAI.E +3]MUHJ71UYEB;77(SM
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M?&B'UW!BB49MIE4S1^9<5S"?Y4A-\/:F$+%=M3HUHCEOVU.(&@Y:H()>MJQ
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M<XJ(P ))YL>$,9KA) 5=4+K@:N+(M<NC5^Z8K!+WJF0]*.:MFZDPO,J<6\'
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M'LF4"IE3$*Z^<PXG]HX=>O:G:NZGQ= [OJ6R[?>6EGAH#=-Z&[ICNT5)^PD
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MFOB)+R*,6)9E",M<'P>F(8K3B C&8AX04*S50V=6K]"@@B\KRO8017TJ [L
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M)S&1JF#^XC+/):^<1<U.U=5$-PKS7G*E',@+#3:,N0,U/$$KKKH: "C/V],
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MO]Z\_'P*,T3,@MDO^(W5$\J[-B($?LQAG&#)W]5+1I-XYT.C(MW)].HW1S[
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M2VT"U'KFZKG*D(VP\Q@A+3@X=3"SM9@;P,J2_H$S024:(M(*Z(&A:<2(#P-
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MTI4(0@B7.S['N$U.WV%H'[C:0!&M8NKVL!##M,T&,H&42V] %XBGPA&>A/#
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M_@0I_5J0+?3]L(7:]J)NU!84G^'P8$-#</N7:SDPCQ+3C0G@+E'I:"".E_E
MV7D2;*3$9!=45MPH5_N@^S$34+F8JTCO \:.'\L9W][!R:(8?X/BK<>?4Z58
M:PT2:Z6]KG?P<L7DK,Q.7M![#*/2]')W,IO/3KZC/0D8NJ2KKL(W"!$L*\-8
M.?D)Y9HI([BR(V$F.J\BV.!JYZ*WHWCK--JZ;_]P^^VW+2(%9=$'2S*4!'3$
M:#+91%(),QUUDD+M6'M+DGM.R[T=/A^D[]Y0U8UN?B=[GS<L KO^S2KV\%$R
M*EG $_A6%'<,YY/IXIK?%79$!AJUMB0)BLZ+%YJX@*Z1MLIYS1R/NG8 ^A0M
M6Q=,W'ONXW=1/+<)V;4&5+E**(FE7)#,%4TY"ZMR[2'R:Y#5<]N/&MAX4/%0
M61F-VH[] W1>]DYW_F.33.#M7ZYA09XDII(1N>[=\DCNA8*6#)@C5&N/>Y"G
MQ%D92/:(&&9IAE1[RW^&G&J=@1[-_5AAI0Z41*JAQ)"X+*(/1''&;70NN5R[
M6>AS]/1K/&IAXLD^0=MJH%'#<;!W^N7PY.1H[_CD;SN;7/B^_X JY0?/$54K
M^O;3,>X'I:WQPJ^\Z3 .7E#.<3?0*>%N8#GQ!O_IK,V:"ZHDJSV!["E:MNYH
M?.^YM[8\'Q.+2A)*,[K+-EH2N#.XPR9<'@X8\MDQDXT8CBHX>-#[MXK@&S49
MQWM?=D[W/A[M')]N=/!X[_?KE$\^35*UFLE%('KDI_.?M[K=W.I+DE04#C#D
M#!$U"P#H1<I$G ;F!6>4F=JESR_1M'V5Y.//?VPO]"%DK5@FP?*([!M!;,B2
M** L.171K:X_KF=M\OJNE:R(G8=%DMTHJ5'K<_+UP\G>__ZZ=W!:"J0WRI;<
M?T*=*[_/D54K>W(19O#?%TC@WN6=S%MTADJM J')6R*1TQ++)A)8DA@S>V]#
M]>S)$[34:%IP^[DWX$W(379!EW9AY<RL-'[R.1*M+$@!4.Y%=,QD(_:D"@X>
MZS*PO>";M1KKW,B_NFB\B4UYU?/?KLG XRQUWVS 9\&YL B7$-%[=HR20"5N
M/)Y+CEXNDZ9VI7/GS0;NO>#G\L^;=:*RQ( _"1(=Q@G2I8#!0G D1Y53QF4#
MO'81QWJ4-=M X#4H>:*!0$VEM-)S\OMDA"J9+8_G[S-DO)<Q9F2# OIP-G$2
MA$?^C"IS&)-FMGK7^9>(ZK=W9$< JZN*!K#U:3*%X;?Q[@6^>QSO1B+CM/CG
M:#FUX3ZC-F' P'T9^"D%D91IXKE(Q!@F2Z-CG47MG-C&Q/8[>;HC++Z-ZAK
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M^C29?D6F$@TQ"DE)*IU,I%6*.,8""D['A-R5J<>U+R2L0]AZ 'LO^?3N=-(
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MQO/DL^"\M$[7;4#>N+;X(%@;6DGC7DU/</6)?O@1YW_.IN??3I4WTH7$:V<
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MG87<W=NU8F)QZJTP19+EYV(P=0:?AZ UUBDA3K"8E>1QT!?JBI*N//Y=P-)
MT%V_-N\NSB_FN"J1O,/CCD_.RQ_<[MW9D(EA'A^>A+>Q$!J6P1\6L(X)"V $
M,F=BR<+U'9E^K#SDVK.\%N@%?B#Y??D7GOW$Y8"/Q6DTUN;,%$C%<[7S/'B?
MZ&PPE3%8+@H;IA1Q<UJ[>L0V0<PZM3S-E=7!0[<NG_^)8?[E7[/3$IECUAO0
M=6N2"E%!E"3BJ)6P ;EM/T)J0Q*[>AKW <%M5-,!\MY-IF&:B+%/F'#RLUJ,
M?TW#]]G\O.ZKJ4W2;V;?OT_.*YNW9K2]0SR:YH]S_#ZY^'[EJ)X*)BT6SZ!H
M'4!9ER_EG(U&ER39#+KUZ*"6]'<5<]\%LZ,I=7- ^TM 3^LN'<Q?]GZCGHJZ
MTY61G1RC(,M6)0DD\+J/#JT4GDSJW!JSZ]+651Q_'W?H1LKHM(;FS<F??[[_
M\N?QAR^?CSZ\?7/RX<O[#[\??WCS_OCSUK[&&I_9PLW8E/1&'L;-753G<=0E
M5X01I/L+%X^LM['T 4KQ!'99;E=,IO?5<L@RY%B*PY!;QXDV(K#EQJ0%V13I
M&WWG6_R)9[,?E82C.C/BZS+\>+5[[LOL(\[K@()WL_G)^3>Z0R\;@@3+C@Z3
M YM] B5%S520.8Q<&J5=T-SKQJ)J1_VX/LQPF'QNY=(>]=V!Z;D#O[_]^D)?
MLFR3=D$PXZ4&+):81N,@8FT7PB $&IZ];-W#U83P?K8W[1-U#X86[AL"AXW[
MRO)JZK_$5!N9)&!>-OIR<C$S%\ TW3E9"">Q=?E;$\+'GF6^=\"U@_R6VN\
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M[$$+/-E(/Q)2WH_Q#87>'G;2'#B"-];HP:+XSKOS <]/5<$2M6"@$YHZE=%
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M!.Z/#-M6'QUA:95HB,;I);D9!=G9@@3B!9?@$5V0P2;?/*QQEX)Q\;2])I^
MQ!9B';<NZ<N_9E^^S2X689J/IOG=Y"=65E8)(V.#$<PY8,IY4%D3&W6MAQ72
M^&)UE%X^;UB]\ U]:'\;I<W:2[ G('SY%\GOUSUFLL<<:NNTSS5_:+% \%:
M-B'5!NHB\LOSVE[^GG&CDT. 8F=I=O!P7(]%7]7XW53'*!F*%$R!1%OO39?
M6Y6@^&A%]$S3/UL;QT\1\UK*V'8Q3]IHJ@/(W:;_ZCB6().K(HD,ZU80#4Y'
MA%18\1B8+$/-'+I%12?["793[^-5UMO*N@>TW(SNO3O3=W7?.A>+ML$#3X*>
M8IE).DYDT XEJ_MDG&U=;?L"25W4:F^M\0=MENW$WP&:+N]B^LO+DR4Y\\5@
M AZT)C-.$/&UB2&1/: TCY&'UJ43=PAX+25!NSQKVVND SAM+[@;MJ?YGFV:
M# JOG"#VZW'57$.4)D&T2#:K=LDUW]<S!!_C7H,[P&K3C,[0.NX Y\???YS-
M?B$N;_X[Q:=")U.4<8"J,N)=!#KL#!"9BT:3*\Q:;P9ZDIC.J\8&Q\G]O51-
ME+8U^LALB+-&^/N$B_/YI*9"E\S\-9V<+SY]_NNJ %H[5XR1P&,=^6"\ ^^3
M@EPX&DWV,=>MO8=G">J\#FO?.&RGO YNPE4/Y(IXS1,K0D7@N0[ =%J 0U\@
M.&\*"B1+N'4A^AT".B]8VC?2ME?.N$':RUJ WY<S+Z^V;A?AZ1XF+Y]C-:D%
M@ZB$ R-4\5YJ8_!>/O"1H.S#S^V\-F=?@-E=YAU<10TJG9 5B9QSD [)+O::
M[.* !G1![:4W.O)N>@?^Z&XSWYC!X/WJO@.TOUU][1/\_L?D_-O[::Z%<A?A
M[)&2JW?W2ZY.%1>)$[<@5)U<H(H&7UP&)V*T,M!I9ZT?[^9,=.[R-$;AK"=(
M=%I;>3E?[>CS\=LW)W]^//[P^>C+^Y,/-Q.+WT_+;/Y]^2U;UU5N\1TM:BIW
M9:U1/>7;R2*=S1:$FY-R&WJ?\*S.Y'TS6YPO'K2:+*YKY5Q2+!EF 5.]]CEZ
M\"@C%.:\"MI')ENW3NQ&<3_UFD[:X 59>5A,I,LB<'"&!2BU(MN'("*V'DSP
M2NHU]XC9X>H[-U%_!Q;+W1!T#DGCLF(_>0.*T9,7)1$O&4_!,>>B;6UM;)YK
M.H *SXU \&RN:1.-= "G09QG61B**!VP@ Z4T1)B9KKF<(WW-CO!FJ]A?.6Y
MIHU@M8]<TR8Z[BX.)J+/P1H'M;&)+'*LK>JIRK5H8U-0* :+@QU6JF@C-3\;
M!]M$YAU<C$_GN7@HD469 6O<5]G:PIV5!<]C8"9P3N>QJ^3D826%MD%<6Z5U
M@+[GLUO.HQ=&T!,0'1G.GGX7LJ[3Z$4L2CLO9>L.L]U3DX>5,-H%A>V4UP$2
M[W2]"&>S#45!R1;)%!$97$V2<%%T";X8X5)CX&W<3W8 !=N[>!M;ZZ,C+*W.
M&$LYQ)0LN&AJ&:F7=?&M 63)Z5@BR:'U-=:3@;^])I_O)]M$K-VW$8D4/4^R
M@&6>F!'.0:Q+:.F@I!1,+B';%RWU1FU$^^HMVTB!&[41;2+-GJ!QCPVRWDPJ
M]' :GRT]SJC D0<,&)1'Z;U1(6X(BHZ[RIK 80<)=O!P7+>Q7$X(J*_N;+J,
M)=>[TXJ0?$UY<TR,;/M<ZMVIH9"9EHR3@LG65LFS!+V6 OQ=S)1V&NL ?O=X
M6)W+4NM<?4A@JPVO?"%O4G);E[+2)2N$"[GU5/1'">FDPVQW1=]WYG>6>@?0
MN54@<%5 J*V6W"-Y??2+(M\/ @8#W(NLDA)U\E]CV#P@HH<Q+SLI]NFU?5M(
MN0.8W*TQ9=S'DL@90$?$V^ 2O?CD$;"2D$R8['5NG<S?O !X,/.G/3RVEVX'
MT&A0#N5-]E%8#LP(.@PH,W@C$8I"%Z)WB+R;N9I_O+:"S)VLJ/WJO@.TMZ^^
M0RVTY4Z Y;;FG5B$: ,#HU.42"9(T:W+>_ZG(',G% Y>D+D))#HX$UO+?_G+
M/W!Q/IE^_8CSR2SS4U^\";%DD%:111Z3!U?JCAA-MU1PD8NP]]J,#>CO/.$Y
M[$D8#0B'? CJM/7%25G^_M0[\CNE+J"SX77JB82@, +GZ!@C#9 UV0OZ;Q/>
M>8:U4]AOK?I>\+[-YH'COW],YLN_?'G23R/WI7!.OF]6@@ZZK6,*/&G",RU"
M=C9Y/@3F6Q#?>6?A'G"_=PCT@OUMY+[,<,SRI$S2\G_R?IKFR__!TC"\_J1:
MF'[JD5NN$X>H52 C4#L()ELPJ .*@-+&;IZ"#?A:Z\3HUWQB>@).+X=IFUOD
MLGYN\:'.ZEJ<8_YP4<-GJX#(XI0Y4HU2=>ZM)#'DDL QHR"RS+Q&R61L708Y
M$"MK'1GSFH_,R/#HX)1<5X[B_.<DX>-*N>9U*8#%E]DCU\.'V?E_XODG3+.O
MT\E_KTH 5[*JH>>4B["0HY9@<ZA5@'1U$$,I)R\CEZV'<.V%L;5.D'VE)Z@_
MZ+SF\W1IT;Z;S5<_JG^/7TG'0>2)@2V>@0M60G(1Z8%&C/>G3?=[L![E<*T3
MYO[GA.T;3!T<M:V5L[I:+KMTWJ]\Q?_ R==O58H_<1Z^7K;PO WG>+U):BD>
M%$;04\Y277A0(*3E+/)(3J51F:O62T7VS.):A\V_TL/6,YQZ.6T[V,O_6-Y1
M5^*Y%@._DH.J?4F!Y&"0?N<5&!DD9_3&Q]BZG&PH7M9+5[+7?(#&1D@/)Z6:
MKS7GBOGMQ?PZ\W3I']ZV;8__QGF:D#!./9WU@(J!M\Z!JK,;/7,&'!I#+F,.
M/I?FE;R;4KD>NE]K-GY@K7: VX_S64+,BW<D^L<92H4;(^J*3,N((5XL!*SG
M,GJ93<S!WF\?W[UQZ26BUD/E:\V,M]59!R#<6IZ7U9/OIXOS^<6R.NWD_!O.
MOWP+TT?ML]-2VV*X$L!3,;6:$FN/JZW5:C:Y@JB:#YO=%V_K'8G_R9KO$4'_
M1B?K9<_'L&1M8!8D66YURXF#:$($P[DK5B9C77-KIQ?FUSN;KSJSWX,:-L)@
M!X?W*/_7Q>)\R?F7V<V,QH]A0@[3F_!C<A[.'O>_/B&);C$YOPHB7@KH5MSO
M.AH12PJY6J@*;$0-,88$F)F.ELG@FX]O'9JG]8[::RT)Z HQ'9R@X:Z>NW&+
M9?S]3I2/I!0Y".0:K,( 43 -6443M=5!67<P;]USG*YWVEYU-4'?Z.KA##X7
M0[G\^;O9?'7M+$XYBR[+*(!Q+D"E$B'6HHJ$6:-"[7G[DOV-*%P/\Z\U_S^@
M-CO ZJV&FDN.3B[.%^=AFHG1FU9*XUP!FVI=J3,21"Z%V2RRX*VMI>?H60^'
MKS5+WDQ3!S6#_E:T[RB=3W[2*])X OTSWS#<_/EUV>ID^KQ4A=?I5<S5S?6:
M>?!!DS5<>%+*2<-RZXTO(T^?WS%)?NMH?IJ=G='[<-FC8H5RJ.@QR'3R5:('
MPOMLP&L3LT41<MK[DLZM.#GLN?0;H+EU]40#8'1@-#24PF59\2E]A]%9:T!1
MUY5SI\$II<%SC"67Y;Z7?D_&)1,'VL7=$)G#'98M8++U.?EQ:=^?A_EY%Z?E
M;LSW]_ELL3C-P@O/3 %=ZAVF="8O(Y+Y%T5@)O(8HNKLO#S"QH%V>_=[8G:%
M2@]OR^8%*%D8)X*R8!6S=?2\ :=CAI0"CQJ#\\W'%@]45M1?LGI K ^KZ,VA
M["^A/,6OU8K\THVU1,(N.*D33A9'TUO-OS<I>D0;K):*7D0K08D0(:)-8'A$
M@24[Q9L?@*&9.M#6\'[?AK8P>CW'ZZ&5R7ST.?H CF4$92,IR&@#*)UPO,1(
MRNOL.&WGC/27%.[W^.P&DQV=D>-I[N*LK)[B.OAN)81HB[?1,_ ,!5T<04%(
M@@%+*+C$D*1I/>ZT.1/CNB$'',W:#0X].!OM+H5[M5A71NO'^21AO</*U1V6
M#69K+(@ZD%UY*<"IP@!C;4>,SAG?<0QX32['=78.^$0-#*A_GR-W:B*]SJHN
M7BI65%^1Q&*DKS,AT;. /J9!YI<,S]JKB3,/@O!Q#N1&<#N<R/23LX_7*4>^
M*Z H<Y$F,1"2Q*)"<N"<X) <&0R8M.'.[OL\MF/OU42RNSB3(\'N$%['ET1S
MQ?UZTA$J1^$%&>F8%:C(#,2$'%A11:$V2LC6P[/WR^&KB;H?Q+D<#GR'<#1W
MC;\^+ZR80W$F@M"U"R]I 8%S!TPZ&5DV7+MNQEFV8/C5A/^[.+C=0/,5G.-U
M/0+%HTY,&?(#8JHIE0).YP"Q6)U93%+JU^R 'D)NX1#.YA!P>WW9B&=%@SIY
MHRT"RJ!!%>LA:+JON&)*HR7-LM[R>6NR-NXK><!QUB&@\PK>MIL&VAO=WB@L
M$<LA.X3B^7+F+PDCL@0\>XDIEH2I=1O H R-^XX=\.EI!Y->SLR#[O#UY[D]
M_4!_PKK:D'[^9C9=BN8BG-6=)>(T9L>1D[9DH1=;,3(M/.8,QBN6LK7,^4':
MI??+YF$G*AJ"O/$$P:$1]PH.Y=/O^U,BXJ<QZ<A**$#W*EG0C%F(M9Y'6KIF
M"UVWP@RR1G._;!YVIJ+?0SDTXGHYE#LH[W+&PV6$"5,M IW5'UVK+S!9G!(&
M1(T%J^(5!,<%<+J;T' D![>;@5GKL33NZI$#MC!;0N45G)Q;+_Y[ND,FT\4D
M78Y&43'2W18+.!XM**<=."$4.&]\UEHRUWR7^&#,'+:]V!2RPP41=\#/X=2M
M;)JG7,X;NB\9GE/028'1M=B<2PW!,%):X28KS(K^N+.3M0Y?AVW_]7S(FJ/J
M53]<PGMGG"QT"GR=3*FK0ZH"!.:BYRD$UGRES[@/5[=5)CV?J3;XZ2G?U<;%
MO"L,?JJ\U9Y[<B(S*E"A/N,2-6B;&4J1M!LFQ34(-^.NFQO;:QH?( <U(.RW
MLY#^^3E]H[^QN!1#S=S1??'G+./9T6)Q\?U2.(W'AFW\O<,-$]M-!'V,& LR
M:EY* L$-7>="&8A6DW$4I++)L!C<_XP86Y[UZ[&HMQ3[:;+XY[LYUE./A*WS
M3\3 J8\ARL(L"$P2E#<2G!4,O$!G"\J41#<SE=9EZJ 'CVV"\6:&U"!PZ<4S
MV>:M?$P@UY;O,BS/C"_&8@0>,@-E? W+8P:CA)<N<Q5PD%K;0;@YZ.;FG4_,
M^ #IY:BTNCNN)/&/&6EP<C8Y_[6\/11RI:7BD*.T)!*FZS $A%1B2MXX&V(W
MT;+UV3KH/N9NGIL&D'FMI^CMY.<DD_E]^0(789)R!A+] Y0- ;Q5#&R*Z+BR
M*I5N<CGK,G70%:K=G:"MX7)0+OTG,DG)@25^EV/@_II.SEM[[\]]Q7".^MJ,
M]>&3&R=#82Q"8=R#DL)#7/Y.&!:,+CSFUE6*(_ODZ1OFBS/Z[NU;(;_4Z-NI
MH)M!LD+/FL7E.( "D4XD"!]*+ &=D\T+/%L1?] ^]B:8?7!ECZ+^#DR;2\KI
M+Q_]/5F<6I.B48R#C!%!91<@>"\@)(R2_!S!4^M-Y7<(&+D,9!P0W%]KMK5&
M.H#3]H*[87N:/YZ%Z8?P'=_.:OGDJ4GTJ*/(4)PD:9+[#4&5VIACLE.%)[1[
MSQ=OP<>XX-X!5LUF!332<0<X?\R<^_3YKS]Q.0K/8F!!(KT_BAXAA39"=,J!
MB4;HQ(N(J?6(]F<)ZKRZ;G"\S(927@=(W-K9_.-Z-57,47+I-"16]Y;9Z,!9
MSR%J&XI1TFO93?#AFNJ1B]FZ,!7VK/M#1ON+6R@_S*8_E]50MZ<.HW4*7>1
M_Y2@$LG)6^^!:2R)Q%,TZV;TRE8<=OXR-,;OWE::[@RF?X^CMIH<[+@J@:<
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M;/:C"NPN2]$G)C()*-K Z=Z69,":X,$Q0?+BP5JK&\-K#;+&S<\.A[#6&ND
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M?UM)<LQTZP5) ]JM;R[F]8Q??\,J'OD;3K%,SA\[=/<%H2 61V]*++GN)XJ
M*K/H@\^!MP[\;$]M[U;K>GAZ4#2S'^UU8 RL.'V'N69#'[!Z7XHNF<I.(FL\
M<IZ,9Z6T+J1^@:1Q$;<O9#P.R"9JZ@=UR[S^T337M/[33'%@EKP^6SA"C%(
MO4/<"QF],ZWG,ZY%V+@.T+@(;*BR?G"X<N2>84=465GA+$0M"YTR8S,ZACJT
M=F=>(&E<EV3DVZ^%FOI!W1-2O.%&"]1@N2G@)0O =$A*VJ1Y:=W9\3Q%XY:
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M9@WR1MZ!V!X<3TPI;ZVI$4&8?C[DZDWX,3D/9Y/_QGQ5^TOVQ%O\B6>S'[7
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M&Y3ELJIO+65E]HW(Q?NP7JTV>:NRRA[C]#HO+I[3./U>0& V^&LZ3VIMB.4
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M7S$D_3\1YP[]S>_1MW^A?L2DY/_]'_\/4$L#!!0    ( (&%>ESBX^WF'TP
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MX6CM!_<(M =7XDON)?4@6![;),U\)D7<ON>#^PPI6[A* RNJ,UW0HG#A"D'
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MP*CK$G05Z?'*D1LCQ5;*XU$U#VBZ68/1U+(=IU[JNZNV:BGPO/H![U@*E79
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MAJ0%N X$0='<J<U ?ZEEWDRW]8X-?88;>H1,;J>KC*'M%:@J(> 2^$UNQK.
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M"YXIY45>>@/]M2N4C;F^1-]U#N_D?^-ETU1PF7 S17A_F6Y P!-NSQD_MK_
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M[.B?&UJZ?O MW9<TR9@8^2Z;PLVP,]IT*70NI"6PESR\]&0T;8[<8Q?57:$
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M-R*_,Z4<T9B995X(./6E )5FG&:0C=@X3MH47&!FL*J-J4$=M*G <I'I.IP
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MW61QL5 #! )&;^!V%CZ3JSG!1E)+.[BD6-.U4.)DJUQ679%3.>%B@6G1/*$
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MIR](M#=JT$0Z]:Q-O&^#33V%Q$ @P2">N1*I5T%<NL22=#;U\M!^OFF0E[-
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M,VR-H$B98#:4(C?"30]'AD)%&/-G'E5$'<'!OJ;M0T5YI7<5UOO!;<CHFDP
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M< !^<=\FH.)2O<",UJ.A]^']T?MP(S/'"OT/8.=>A!YG# H5R Q.J,ABU*Y
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M0-$617#8[0&\CP/,TYEI5J:1A$38"9"18DX3@=%23%9Z6)U+88)S@3@5AGP
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M6O2CXTFTUB5M[C(S*' <UW3@=RIVP7OL+FH"YFAN;*9%IXQ.B[:$L5!(Q*@
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M;[T-S S+54B=&)U*8OQ<!G$%Q&"[+=G8CE:F3]CE >7ARC+@-RZ5^03&O1_
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M%$I-[ACSZO%U2Z5+DZYW7$3;MFIP;Z\XR^TU#_G"4%BO:@Q")*#M-\ZU<(]
MLL%8;/DT,!!REZ(,YAS>QP7,:BYY5A0G6V#V/K$^!U@1S4 UDVI2IN'D>W;3
M<_RO\6BQCI;H6"32P0-M+H<Q#;QI?-:U*D@-WMJ/?O;Q2;.0%-6N9Y0H,'^+
M-8S("XZ*E:8Y>&67"-=% ]SX!5+ *!P+#H0\(!A4Q4LX:QQZUTC_U"63<R6
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M41(2(Q&^YGI^R"B(9<VR6.([ZZ;_EI&RS2DOMYD!N]:PPQP>VY*PHG"8D;E
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M$G8(1A$\TZL>SX!RQ%49A.4'0?4*">>#Z%4$ 5];"PT+=.@6%&M@#6%2S!J
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M<G$'"1)?XM)NIQ&:A\2Z#/2AL51ILIZ'<U!I4=A5)%ZW'T2A44(L"(<T)C!
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M)MC9]@;NZ/%XS2&20M?MS$@P*0<4D52%5,R@%!!6H'C"%1=1[;(1"[Y&;=J
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MZS9ALH#)\?Q\.3O^C-SN=]F72JY.:>CV8'X"RY]GL)A<_#@YFRV<^>^_SOZ
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M>KGCX%:IRF3/F5*!<XSB3. \X2O=B%66/%*3RQ>\$05(^QQ'GXIB(<F/=X_
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M<D+RAUPJ+PWUG![1TX%*Q?X5G'2N,S@+)5"X<Z)\XJ1CS:7[YN'3YQ=,JGI
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M,#(U,3(S,2YH=&U02P$"% ,4    " "!A7I<%[+^J0(1  "EN   #P
M        @ 'RH@, 8W8M,C R-3$R,S$N>'-D4$L! A0#%     @ @85Z7+BG
M:8$.(   .D4! !,              ( !(;0# &-V+3(P,C4Q,C,Q7V-A;"YX
M;6Q02P$"% ,4    " "!A7I<0[E+/,Q8  "] 00 $P              @ %@
MU , 8W8M,C R-3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( (&%>EP<??Q$ 2@
M ,ES   2              "  5TM! !C=BTR,#(U,3(S,5]G,2YJ<&=02P$"
M% ,4    " "!A7I<6C]1J^D]   JQP  $P              @ &.500 8W8M
M,C R-3$R,S%?9S$P+FIP9U!+ 0(4 Q0    ( (&%>EP7?@^ET"X  $-V   3
M              "  :B3! !C=BTR,#(U,3(S,5]G,3$N:G!G4$L! A0#%
M  @ @85Z7#>4>YD?*P  2&X  !,              ( !J<($ &-V+3(P,C4Q
M,C,Q7V<Q,BYJ<&=02P$"% ,4    " "!A7I<:2]>A&8P  "$<P  $P
M        @ 'Y[00 8W8M,C R-3$R,S%?9S$S+FIP9U!+ 0(4 Q0    ( (&%
M>ER@7%&1!BP  $]O   3              "  9 >!0!C=BTR,#(U,3(S,5]G
M,30N:G!G4$L! A0#%     @ @85Z7+6 @DF%4P  KY@  !,
M ( !QTH% &-V+3(P,C4Q,C,Q7V<Q-2YJ<&=02P$"% ,4    " "!A7I<C[V.
M&),M  !]<P  $P              @ %]G@4 8W8M,C R-3$R,S%?9S$V+FIP
M9U!+ 0(4 Q0    ( (&%>ESY0D5?O4P   V/   3              "  4',
M!0!C=BTR,#(U,3(S,5]G,3<N:G!G4$L! A0#%     @ @85Z7+MQ>(:W"@8
M1?,( !,              ( !+QD& &-V+3(P,C4Q,C,Q7V<Q."YJ<&=02P$"
M% ,4    " "!A7I<37&P9]Q>  #/I   $@              @ $7) P 8W8M
M,C R-3$R,S%?9S(N:G!G4$L! A0#%     @ @85Z7.SMG-A7+@  578  !(
M             ( !(X,, &-V+3(P,C4Q,C,Q7V<S+FIP9U!+ 0(4 Q0    (
M (&%>EPDU?,N2F@  %:K   2              "  :JQ# !C=BTR,#(U,3(S
M,5]G-"YJ<&=02P$"% ,4    " "!A7I<R2FQIT1?  ")K@  $@
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M,C4Q,C,Q7V<Y+FIP9U!+ 0(4 Q0    ( (&%>ER.F#/#:AP! #$M"P 3
M          "  ?N3#@!C=BTR,#(U,3(S,5]L86(N>&UL4$L! A0#%     @
M@85Z7"#$G'!AM@  1*4( !,              ( !EK / &-V+3(P,C4Q,C,Q
M7W!R92YX;6Q02P$"% ,4    " "!A7I<XN/MYA],   H.@( %0
M    @ $H9Q  8W8M,C R-C S,C9X97@Q,#<N:'1M4$L! A0#%     @ @85Z
M7/Q>G:X8)P  2;H  !4              ( !>K,0 &-V+3(P,C8P,S(V>&5X
M,30Q+FAT;5!+ 0(4 Q0    ( (&%>EP2?W:&>R<  -K4   5
M  "  <7:$ !C=BTR,#(V,#,R-GAE>#$Y,2YH=&U02P$"% ,4    " "!A7I<
M4B +V!P#  #4"0  %0              @ %S A$ 8W8M,C R-C S,C9X97@R
M,S$N:'1M4$L! A0#%     @ @85Z7*O6NY-Z!P  .",  !4
M ( !P@41 &-V+3(P,C8P,S(V>&5X,S$Q+FAT;5!+ 0(4 Q0    ( (&%>ER@
MV1$<= <  !TC   5              "  6\-$0!C=BTR,#(V,#,R-GAE>#,Q
M,BYH=&U02P$"% ,4    " "!A7I<'@5Y#"\%  "G$P  %0
M@ $6%1$ 8W8M,C R-C S,C9X97@S,C$N:'1M4$L! A0#%     @ @85Z7'$K
MWWDH!0  GQ,  !4              ( !>!H1 &-V+3(P,C8P,S(V>&5X,S(R
M+FAT;5!+ 0(4 Q0    ( (&%>EQV)G1Y; P  +PW   5              "
M =,?$0!C=BTR,#(V,#,R-GAE>#DW,2YH=&U02P4&     "$ (0!B"   <BP1
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>cv-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cv="http://capsovision.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cv-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <instant>2026-03-25</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-02</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-02</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cv:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cv:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cv:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cv:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cv:HealthcareClinicalTrialActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cv:HealthcareClinicalTrialActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-27</startDate>
            <endDate>2025-05-27</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-07</startDate>
            <endDate>2025-07-07</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <startDate>2025-07-07</startDate>
            <endDate>2025-07-07</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-11</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-15</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesC1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesD1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesD2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesF1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesF2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cv:SeriesG1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-07-02</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-02</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-07-02</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cv:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-01</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cv:FutureGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cv:TwoThousandAndTwentyFivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearAfter2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearAfter2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearBefore2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearBefore2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearIndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearIndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">cv:TaxYearDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-12</startDate>
            <endDate>2026-02-12</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-12</startDate>
            <endDate>2026-02-12</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-12</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-16</startDate>
            <endDate>2026-03-16</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001378325</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-16</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cv:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="member">
        <measure>cv:member</measure>
    </unit>
    <unit id="monthly_installment">
        <measure>cv:monthly_installment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0001378325</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-36">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration contextRef="c-4" id="f-344">http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-74" id="f-484">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</us-gaap:GovernmentAssistanceOperatingExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-42705</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">CAPSOVISION, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">20-3369494</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">18805 Cox Avenue, Suite 250</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">95070</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Saratoga</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="c-1" id="f-14">408</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">624 1488</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">CV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-26">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="INF" id="f-30" unitRef="usd">0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">49838211</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of the Registrant's definitive Proxy Statement relating to the Registrant's 2025 Annual Stockholders' Meeting, to be filed within 120 days of the Registrant's fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-37">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-39">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-40">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee oversight of cybersecurity risks, including responsibility for our controls and procedures for mitigating cybersecurity and other information technology risks, and our plans to respond to data breaches.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-42">23</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="c-1" id="f-43">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have audited the accompanying balance sheets of CapsoVision, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/div&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c-1" id="f-44">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-45">Santa Clara, California</dei:AuditorLocation>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">10112000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">9319000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">2498000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">2001000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">2987000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">2629000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">1072000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">898000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">16669000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">14847000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">611000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">720000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">843000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">1195000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">41000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">41000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">18164000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">16803000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">1143000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">749000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">2697000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">569000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">177000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">132000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">410000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">351000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">4427000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">1801000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">477000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">887000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">4904000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">2688000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-78" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-79" unitRef="usd" xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-4" decimals="INF" id="f-82" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-5" decimals="INF" id="f-83" unitRef="shares">153682280</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-4" decimals="INF" id="f-84" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-4" decimals="INF" id="f-85" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-5" decimals="INF" id="f-86" unitRef="shares">38665583</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-5" decimals="INF" id="f-87" unitRef="shares">38665583</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">152378000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">143625000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-92"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-93"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">143625000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-96"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-97"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-98" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-99" unitRef="shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-100" unitRef="shares">46865051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-101" unitRef="shares">46865051</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-102" unitRef="shares">2090945</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-103" unitRef="shares">2090945</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-104" unitRef="usd">47000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-106" unitRef="usd">168878000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">838000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-108" unitRef="usd">-155665000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">-130350000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-110" unitRef="usd">13260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">-129510000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">18164000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">16803000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">13554000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">11756000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">6381000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">5379000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">7173000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">6377000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">7530000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">6967000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">18310000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">15120000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">6849000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">4207000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">32689000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">26294000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">-25516000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">-19917000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">269000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">26000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">-44000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">4000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">225000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">30000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-25291000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">-19887000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">11000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-25315000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">-19898000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-1.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">-1.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-144"
      unitRef="usdPerShare">-9.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-145"
      unitRef="usdPerShare">-9.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-146" unitRef="shares">24555381</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-147" unitRef="shares">24555381</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-148" unitRef="shares">2020077</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-149" unitRef="shares">2020077</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-7" decimals="INF" id="f-150" unitRef="shares">35559025</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-7" decimals="-3" id="f-151" unitRef="usd">128625000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-152" unitRef="shares">1837036</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-153" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-154" unitRef="usd">607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-155" unitRef="usd">-110452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-156" unitRef="usd">-109843000</us-gaap:StockholdersEquity>
    <cv:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="c-6" decimals="INF" id="f-157" unitRef="shares">3106558</cv:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-6" decimals="-3" id="f-158" unitRef="usd">15000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-11"
      decimals="INF"
      id="f-159"
      unitRef="shares">253909</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-12" decimals="-3" id="f-160" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-161" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-162" unitRef="usd">156000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-163" unitRef="usd">156000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-164" unitRef="usd">-19898000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-165" unitRef="usd">-19898000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-5" decimals="INF" id="f-166" unitRef="shares">38665583</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-5" decimals="-3" id="f-167" unitRef="usd">143625000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-168"
      unitRef="shares">2090945</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-169" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-170" unitRef="usd">838000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-171" unitRef="usd">-130350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-172" unitRef="usd">-129510000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-17"
      decimals="INF"
      id="f-173"
      unitRef="shares">38665583</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-17" decimals="-3" id="f-174" unitRef="usd">143625000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-18"
      decimals="INF"
      id="f-175"
      unitRef="shares">38665583</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-18" decimals="-3" id="f-176" unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-19" decimals="-3" id="f-177" unitRef="usd">143586000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">143625000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-18"
      decimals="INF"
      id="f-179"
      unitRef="shares">5629978</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-18" decimals="-3" id="f-180" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="-3" id="f-181" unitRef="usd">22848000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">22854000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-19" decimals="-3" id="f-183" unitRef="usd">519000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">519000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-18"
      decimals="INF"
      id="f-185"
      unitRef="shares">7508</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts contextRef="c-19" decimals="-3" id="f-186" unitRef="usd">31000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">31000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <cv:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares
      contextRef="c-18"
      decimals="INF"
      id="f-188"
      unitRef="shares">-108</cv:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1 contextRef="c-19" decimals="-3" id="f-189" unitRef="usd">-1000</us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1 contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">-1000</us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-18"
      decimals="INF"
      id="f-191"
      unitRef="shares">438808</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-19" decimals="-3" id="f-192" unitRef="usd">158000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">158000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-18"
      decimals="INF"
      id="f-194"
      unitRef="shares">15015</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-19" decimals="-3" id="f-195" unitRef="usd">73000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">73000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-18"
      decimals="INF"
      id="f-197"
      unitRef="shares">17322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-3" id="f-198" unitRef="usd">826000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">826000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-200" unitRef="usd">-25315000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">-25315000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-4" decimals="INF" id="f-202" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-4" decimals="-3" id="f-203" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-204"
      unitRef="shares">46865051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-205" unitRef="usd">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-206" unitRef="usd">168878000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-207" unitRef="usd">-155665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-208" unitRef="usd">13260000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">-25315000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-210" unitRef="usd">-19898000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">216000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-212" unitRef="usd">206000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-1000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-6" decimals="-3" id="f-214" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">351000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-6" decimals="-3" id="f-216" unitRef="usd">315000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">173000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-6" decimals="-3" id="f-218" unitRef="usd">-103000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">31000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-6" decimals="-3" id="f-220" unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">826000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-3" id="f-222" unitRef="usd">156000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">11000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-6" decimals="-3" id="f-224" unitRef="usd">8000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">478000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-6" decimals="-3" id="f-226" unitRef="usd">176000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">358000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-6" decimals="-3" id="f-228" unitRef="usd">434000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">174000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-6" decimals="-3" id="f-230" unitRef="usd">316000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-6" decimals="-3" id="f-232" unitRef="usd">-1000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">376000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-6" decimals="-3" id="f-234" unitRef="usd">388000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">2128000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-6" decimals="-3" id="f-236" unitRef="usd">-204000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">45000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-6" decimals="-3" id="f-238" unitRef="usd">36000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">-351000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-240" unitRef="usd">-276000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">-22864000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-242" unitRef="usd">-20091000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">90000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-244" unitRef="usd">153000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">-90000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-246" unitRef="usd">-153000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c-6" decimals="-3" id="f-248" unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">26557000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-6" decimals="-3" id="f-250" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">3184000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c-6" decimals="-3" id="f-252" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">1000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-6" decimals="-3" id="f-254" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">1000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-6" decimals="-3" id="f-256" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromOtherEquity contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">231000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity contextRef="c-6" decimals="-3" id="f-258" unitRef="usd">74000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">23604000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-260" unitRef="usd">15074000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">650000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-6" decimals="-3" id="f-262" unitRef="usd">-5170000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">143000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-6" decimals="-3" id="f-264" unitRef="usd">-70000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-265" unitRef="usd">9319000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">14559000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-267" unitRef="usd">10112000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-268" unitRef="usd">9319000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">9000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-6" decimals="-3" id="f-270" unitRef="usd">6000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">15000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-6" decimals="-3" id="f-272" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">519000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 contextRef="c-6" decimals="-3" id="f-274" unitRef="usd">0</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">143625000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-6" decimals="-3" id="f-276" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-277">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;1. DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CapsoVision, Inc. (&#x201c;CapsoVision&#x201d; or the &#x201c;Company&#x201d;), a commercial stage medical technology enterprise, that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (&#x201c;GI&#x201d;) system.  Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company is based in Saratoga, California.  Its customers include, in the U.S., gastrointestinal medical practices, clinics, and hospitals; outside of the U.S., the Company sells to distributor customers who resell products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s core technology platform is an orally ingestable capsule including multiple cameras facilitating 360 degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. This platform obviates the need for external data transmission or for a patient to remain in a medical facility throughout the digestive cycle. The Company&#x2019;s products consist of (i) the on-market CapsoCam Plus&#xae;, directed at the small intestines, and (ii) the in-development CapsoColon 3D&#xae; directed at the large intestines (colon). Stored video imagery is downloaded from capsules with a data access device, CapsoAccess&#xae; and enabling software, CapsoView&#xae;. This video access solution permits on-site, on-demand video download and viewing by customers. The Company operates the CapsoCloud&#xae; cloud-based software-as-a-service ecosystem as an off-premise video access and download solution. Using CapsoCloud&#xae;, retrieved capsules are sent by customers to a centralized processing center for video downloading; patient video content is then made available via web portal or dedicated app access for customers to view, download, and generate patient reports. The Company&#x2019;s services also include video reading; pursuant to this offering, physician customers may purchase a video reading and generation of patient report carried out by a second physician.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its 2005 formation, the Company&#x2019;s organizational structure has comprised a single Delaware corporation with a branch office in Taiwan, Republic of China, the location of certain suppliers and Company personnel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CapsoCam Plus&#xae; was cleared by the U.S. Food and Drug Administration ("FDA") in 2016 and has since been approved in various other countries.  CapsoColon 3D&#xae; is completing the second arm of our pivotal clinical study with planned submission for regulatory clearance, starting with the FDA, and we anticipate filing with the FDA in the third quarter of 2026. The Company is subject to risks and uncertainties common to life sciences companies including, but not limited to, risks associated with the success of research and development, risks associated with contract manufacturing, competition from other companies, protection of intellectual property and the risk of litigation related thereto, compliance with government regulations, and the ability to secure additional capital to fund operations and research &amp;amp; development. Current and future programs, including for products focused on other areas of the GI system, will require significant research and development efforts, extensive clinical testing, and submissions for regulatory approval prior to commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;3, 2025, the Company completed its initial public offering ("IPO") of 5,500,000 shares of its common stock, that was followed by the issuance of 129,978 shares of common stock on July 18, 2025 in connection with the partial exercise by the underwriters of their option to purchase up to an additional 825,000 shares (the &#x201c;Over-allotment Exercise&#x201d;) as further described in Note 11. COMMON STOCK), each at a price to the public of $5.00 per share. The Company received net proceeds of approximately $23.37 million after deducting underwriting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discounts and commissions of approximately $1.59 million and offering expenses of approximately $3.18 million which were recognized in additional paid-in capital as a reduction of the proceeds generated from the offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross proceeds to the Company from the IPO was approximately $28.14 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection to the IPO, the Company amended and restated its certificate of incorporation (the &#x201c;Restated Certificate&#x201d;), under which authorized capital stock consists of 300,000,000 and 190,000,000 shares of common stock as of December 31, 2025 and December 31, 2024, respectively. Authorized common stock is reserved for future issuance, including pursuant to outstanding equity awards and future equity awards under the 2005 Plan and the 2025 Plan as further described in Note 11. COMMON STOCK.&lt;/span&gt;&lt;/div&gt;On July 2, 2025, immediately prior to the completion of the Company&#x2019;s IPO and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock, all shares of the Company&#x2019;s convertible preferred stock converted into shares of the Company&#x2019;s common stock</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockTransactionDate contextRef="c-24" id="f-278">2025-07-03</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-24"
      decimals="INF"
      id="f-279"
      unitRef="shares">5500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-25"
      decimals="INF"
      id="f-280"
      unitRef="shares">129978</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <cv:SaleOfStockEffectivenessDate contextRef="c-26" id="f-281">2025-07-18</cv:SaleOfStockEffectivenessDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-27"
      decimals="INF"
      id="f-282"
      unitRef="shares">825000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-28"
      decimals="2"
      id="f-283"
      unitRef="usdPerShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-24" decimals="-4" id="f-284" unitRef="usd">23370000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-29" decimals="-4" id="f-285" unitRef="usd">1590000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-24" decimals="-4" id="f-286" unitRef="usd">3180000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-24" decimals="-4" id="f-287" unitRef="usd">28140000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-288" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-289" unitRef="shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockConvertibleConversionDate contextRef="c-30" id="f-290">2025-07-02</us-gaap:PreferredStockConvertibleConversionDate>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c-1" id="f-291">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2. GOING CONCERN&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred operating losses and negative cash flows from operations since its inception. Since the launch of CapsoCam Plus&#xae; in 2016, the Company has been able to fund increasing portions of its operating expenses from sales. However, the Company has continued to incur operating losses, net losses, and negative operating cash flows. The Company expects to continue to experience similar circumstances until existing and future products&#x2019; sales yield further growth in revenues, achievement of break-even, and realization of future operating income, net income, and positive operating cash flows. As of December&#160;31, 2025, the Company had cash and cash equivalents of $10,112. For the year then ended December 31, 2025, the Company had an operating loss of $25,516, a net loss and comprehensive loss of $25,315, and net cash used in operating activities of $22,864. The Company, having evaluated the extant facts and circumstances, concluded that the facts and circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date of issuance of these financial statements. While the Company completed the IPO in July 2025 and raised approximately $23.4&#160;million in net proceeds, as well as subsequent private placement further discussed in 17. SUBSEQUENT EVENTS, it is not probable that these funds are sufficient to fund expenditures necessary to achieve sales growth and innovation objectives. The Company intends to consummate additional capital raising activities, but there is no certainty as to such capital raising activities occurring at all, or occurring with sufficient timing or magnitude, sufficient to alleviate such substantial doubt.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-292" unitRef="usd">10112000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">-25516000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">-25315000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">-22864000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-24" decimals="-5" id="f-296" unitRef="usd">23400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-297">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). Any reference in these notes as it concerns U.S. GAAP is meant to refer to authoritative pronouncements as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reporting Entity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s organizational structure reflects a single incorporated entity, CapsoVision, Inc..  This single entity has a foreign branch and physical presence in Taiwan, Republic of China, which is an extension of the U.S. corporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;2, 2025, the Company amended and restated its amended and restated certificate of incorporation to effect a 1-for-3.33 reverse stock split of the Company's common stock, which automatically resulted in reciprocal adjustments (reductions) to the conversion ratios of each of the Company's series of convertible preferred stock (the "Reverse Stock Split"). The par values per share of the common and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All amounts for issued and outstanding common stock, convertible preferred stock, options to purchase common stock, warrants on common stock, and reserves related to common stock, as well as related per-share amounts, contained in the financial statements have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented. No fractional shares were issued as a result of the reverse stock split. In lieu of fractional shares, the Company rounded down to the next whole share and made a cash-in-lieu payment of $1 for 108 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reporting currency for the financial statements of the Company is the United States Dollar. The functional currency of the U.S. corporation, and its foreign branch which is an extension of the U.S. corporation, is the U.S. Dollar. The assets, liabilities, and expenses of the Company&#x2019;s foreign branch recorded in local currency are remeasured into the U.S. Dollar each period, with associated gains and losses included in operating expenses (as a component of general and administrative expenses). Monetary assets and liabilities denominated in currencies other than the functional currency are translated at exchange rates in effect at the balance sheet date with associated gains and losses included in operating expenses (as a component of general and administrative expenses). For the years ended December&#160;31, 2025 and 2024, the Company recorded $193 and $(93), respectively, of net foreign exchange gains (losses) as components of general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the making and usage of  estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities, if any. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. The Company seeks to moderate the influence of subjectivity and estimation uncertainty through reliance on useful information from market participants and peers wherever possible. Estimates and assumptions affect various financial statement amounts and their related disclosures, including, but not limited to, the recognition of revenue, underwriters' warrants valuation, stock based compensation, research and development expenses, income tax-related amounts, lease-related amounts, and allowances for credit losses. Actual results could materially differ from estimates.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is organized as, and managed as, one operating (and reportable) segment. Its chief operating decision maker is its Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where required, certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the three levels of the hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - defined as inputs other than quoted prices included in Level&#160;1 that are either directly or indirectly observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - defined as significant unobservable inputs for which little or no market data exists, therefore necessitating entity-specific assumptions&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. An asset or liability&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company&#x2019;s financial assets (which include cash and accounts receivable) and liabilities (which include accounts payable) approximate fair value due to their insensitivity to interest rates and/or close proximity to maturity and qualify as Level&#160;1 measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of demand deposits at well-known financial institutions and accounts receivable.&#160; At times, the Company&#x2019;s cash deposits may exceed U.S. Federal deposit insurance limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's sales to customers are typically originated with trade credit terms and receivables are uncollateralized, with limited exceptions for prepayments required for certain customers or credit card sales.  The Company historically has experienced insignificant levels of bad debt; allowances for credit losses on accounts receivable were insignificant for all periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s concentration risk related to revenues relates primarily to its product revenues being derived from a single product. With respect to customers, for the year ended December&#160;31, 2025, the same customer represented 9% of our revenue and 22% of our accounts receivable as of December&#160;31, 2025. For the year ended December&#160;31, 2024, that same customer represented 10% of our revenue and 21% of our accounts receivable as of December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s supply concentration risk relates primarily to its materials procurement and contract manufacturing being substantially concentrated with vendors located in Asia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) comprises net income (loss) and other comprehensive income (loss), which is defined as all changes in stockholders&#x2019; equity (deficit) other than net income (loss) and those resulting from investments by and distributions to stockholders. Historically, and for all periods presented, there are no differences between net loss and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The core principle is that an entity should recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue using a five-step model resulting in revenue being recognized as performance obligations within a contract are satisfied. The steps within that model include: (i) identifying the existence of a contract with a customer; (ii) identifying the performance obligations within the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contract; (iii) determining the contract&#x2019;s transaction price; (iv) allocating the transaction price to the contract&#x2019;s performance obligations; and (v) recognizing revenue as the contract&#x2019;s performance obligations are satisfied.  Judgment is required to apply the model and make certain estimates and assumptions about the Company&#x2019;s contracts with its customers, including, among others, the nature and extent of its performance obligations, its transaction price amounts and any allocations thereof (including estimates of standalone selling prices), the events which constitute satisfaction of its performance obligations, and when control of any promised goods or services is transferred to customers. The guidance also requires certain incremental costs incurred to obtain or fulfill a contract to be deferred and amortized on a systematic basis consistent with the transfer of goods or services to a customer.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates (i) product revenue from the sale of capsule medical devices, (ii) service revenue from the provision of reading services for videos, and (iii) product or service revenue depending on which video delivery option is utilized by the customer to download and view capsule videos.  The customer&#x2019;s delivery options include (1) a capsule data reading device shipped to the customer which works together with downloadable software installed locally on a customer&#x2019;s computer (classified as product revenue), or (2) a software-as-a-service offering which involves the customer mailing capsule devices to an off-site Company-operated facility which processes uploads of video content to a cloud platform the customer can access via a web browser or a smart device application in order to view videos and generate reports (classified as service revenue).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts with customers contain fixed consideration reflecting prices negotiated with customers and immaterial variable consideration.  For contracts with variable consideration, the Company uses the most likely amount method to estimate the transaction price. Variable consideration is constrained to the extent that it is deemed probable that a significant reversal of the amount of revenue recognized will not occur. Where products or services are not sold separately or experience a range of selling prices, the Company estimates standalone selling prices using a cost-plus-expected margin approach and utilizes the resultant standalone selling prices to allocate transaction prices at transaction inception on a relative standalone selling price basis. The Company recognizes revenue for its product and reading service performance obligations at a point in time, that being when the performance obligations are satisfied and control is transferred to the customer (generally upon shipment for products, or conveyance of final deliverable for services).  For the software-as-a-service video delivery offering performance obligation, the associated revenue is recognized over time, typically less than one fiscal quarter, representing the estimate of the typical period of time in which customers derive utility from the cloud-based service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any significant financing components as payment is received at or shortly after sale. Standard trade credit terms are typically 30 to 60 days from invoice date. Costs incurred to obtain or fulfill a contract are expensed as incurred when the amortization period is less than one year, which is the case for the Company. The Company considers all shipping and handling to be fulfillment activities and not a separate performance obligation. Shipping and handling costs are recorded as costs of revenue. The Company has elected an accounting policy to exclude sales taxes and other similar taxes from the measurement of the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has certain U.S. customers characterized as group purchasing organizations that function as procurement agents for their underlying medical practice, clinic, or hospital members; these group purchasing organizations typically charge the Company percentage-based fees in exchange for the right to do business with the group purchasing organization.  Such fees, which do not provide a distinct separate benefit to the Company, are recorded as reductions to revenue in the same period as the recognition of the related revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s products are sold with the same limited quality assurance warranties offered to all customers; the Company typically does not allow returns of products, except for cases of damage or defect, whereby products would be replaced.  Actual product returns have historically been immaterial given the one-time-use nature of capsule devices; estimated product returns (periodically adjusted to reflect actual experience), if warranted, are accounted for as reductions to revenue with offsets to a product return liability included within accrued expenses and other current liabilities in the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities; Accounts Receivable and Related Allowance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records contract assets when it has completed performance obligations prior to receiving consideration from the customer and where such amounts are unbilled; where billed, amounts are reflected as trade accounts receivable. The Company promptly invoices its accounts receivable; therefore, the Company&#x2019;s contract assets were zero for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities, portrayed as deferred revenue, reflect (i) obligations to provide goods for which the Company has already received consideration (generally arising from up-front payments received) and (ii) performance obligations to provide services which are not yet satisfied in the context of a particular contract (principally consisting of video delivery obligations related to the Company&#x2019;s off-premise cloud-based video delivery offering).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The Company grants trade credit to most of its customers in the normal course of business and generally does not require collateral. An allowance for credit losses arises subsequent to the origination of a sale for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts.  A provision (or a reversal of the allowance) is recorded as a component of general and administrative expenses.  In determining the amount of the allowance, the Company considers aging of accounts, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance when all attempts to collect have been exhausted. Allowances for credit losses were insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Costs of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs of revenue include materials, direct labor, and manufacturing overhead costs related to sold products, as well as certain period costs such as non-allocated overhead, scrap, and outbound freight costs, fees paid to physicians for providing reading services, and the costs of operating the Company&#x2019;s cloud-based software-as-a-service offering for video delivery such as shipping costs, processing costs, and data storage costs. Shipping and handling costs directly related to bringing products to their final point of sale are included in costs of revenue and were $117 and $51 for the years ended December&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expenses include costs directly attributable to actively marketing the Company&#x2019;s products and services using both direct employees and outside contractors or vendors. These costs include, but are not limited to, salaries, bonuses, benefits, stock-based compensation, sales commissions, travel costs and expense reimbursements, and the costs of sponsoring programs, events, and conferences. Advertising costs were nil for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries, bonuses, benefits, and stock-based compensation related to the Company&#x2019;s executive, administrative, finance, human resources, and other supporting functions. Also included are professional fees for legal services, consulting services, tax matters and audits, information technology, office expenses, rent, insurance, and foreign exchange gains (losses).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses (including Clinical Trial Expenses)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in accordance with ASC 730,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Research and development expenses include costs directly attributable to the conduct of research and development programs, including salaries, bonuses, benefits, and stock-based compensation for employees focused on research and development or clinical trials, costs of independent contractors and outside vendors, costs of supplies consumed in or product inventory utilized in clinical trials, and the costs of clinical trial activities as charged within the negotiated budgets by trial sites or vendors responsible for multiple trial sites.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes prepayments for goods or services, including trial device inventory, that will be used, consumed, or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed.  The Company also records expenses and accruals for estimated costs of research and development activities, including third party services for clinical trials.  The Company bases its estimates on information available at the time.  Costs for certain clinical trial activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the balance sheet as prepaid expenses or as accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025 and 2024, the Company incurred $6,391 and $7,647, respectively, of expenses related to ongoing clinical trial activities which are included within research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if options or warrants on common stock were exercised or convertible preferred stock shares were converted into common stock. Diluted net loss per share is the same as basic net loss per common share since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of incremental common shares issuable upon exercise of vested stock options, common stock warrants, and the Company&#x2019;s various series of convertible preferred stock. Upon completion of the IPO in July 2025, all outstanding shares of preferred stock were converted into shares of Company's common stock (after giving effect to the 1-for-3.33 reverse stock split). Subsequent to the conversion, only common stock remains outstanding. Accordingly, the two-class method is no longer applicable for periods after the IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents comprises demand deposits in the form of checking accounts and money market accounts (which may be deposited into and withdrawn at will with no restrictions as to investment or redemption) and includes cash balances denominated in the Euro and New Taiwan Dollar, for which fluctuations in exchange rates result in gains or losses reported within operating expenses as a component of general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, consisting of materials, direct labor and manufacturing overhead, are subdivided into raw materials, work in process, and finished goods and are stated at the lower of cost (average cost) or net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates inventories as to (i) net realizable value and (ii) circumstances or indicators of loss, damage, insufficient time to expiry (determined by battery life), excess quantities, or obsolescence and provisions accordingly via direct charges against the carrying value of inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at historical cost, less accumulated depreciation. The Company capitalizes major improvements and expenses repairs and maintenance as incurred. Depreciation is recorded using the straight-line method based on the estimated useful lives of the depreciable property or, for leasehold improvements, the remaining term of the lease, whichever is shorter.  Useful lives are as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery &amp;amp; equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-344"&gt;Shorter of remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon disposal (retirement or sale) of property and equipment, as applicable, the cost and related accumulated depreciation are removed and any resulting gain or loss is reflected within operating expenses. Such amounts were insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are evaluated for impairment as warranted by triggering events related to changes in facts and circumstances. There have historically been no impairments and there were none for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for office and storage space in California and office space in Taiwan, Republic of China. The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (&#x201c;ROU&#x201d;) assets and the corresponding lease liabilities are depicted in operating lease liabilities, current and operating lease liabilities, non-current in the balance sheet. ROU assets represent the right to use an underlying asset, and lease liabilities represent the obligation for lease payments in exchange for the ability to use the asset for the duration of the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets and lease liabilities are recognized at commencement date and determined using the present value of the future minimum lease payments over the lease term. The Company utilizes an incremental borrowing rate when assessing lease classification and measuring lease liabilities. The estimated incremental borrowing rate considers credit rating practices applied by well known statistical rating organizations to borrowers, Company-specific factors, and the actual lease term at commencement date. The lease term may include options to extend when it is reasonably certain that the Company will exercise that option. The Company recognizes operating lease expense on a straight-line basis over a lease's term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements which contain both lease and non-lease components, which it has elected to account for as a single lease component. Variable lease payments that are not dependent on an index or rate are not included in lease measurements and are accounted for as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary means of financing from start-up through development and into the commercial stage has historically been the issuance of convertible preferred stock in various series; these series share similar rights and obligations and contain similar qualifications as to the requirements an equity initial public offering would have to meet in order for the stock to convert to common stock. Convertible preferred stock is recorded at fair value on the date of issuance (historically, the same as the issue price), net of issuance costs. Application of the guidance contained in&#160;ASC&#160;480-10-S99-3A,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;has led the Company to present each of the series of convertible preferred stock as mezzanine equity due to the similar features of the series concerning liquidation preferences and other rights and privileges inuring to the respective series&#x2019; holders, one or more of which may result in a settlement in cash not entirely within the Company&#x2019;s control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;2, 2025, immediately prior to the completion of the Company&#x2019;s IPO and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock, all shares of the Company&#x2019;s convertible preferred stock converted into shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for employee and nonemployee equity compensation awards in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 718&#x201d;).&#160; In accordance therewith,&#160;the Company accounts for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock-based compensation for awards granted to nonemployees in a similar fashion to stock-based compensation awards to employees.&#160; ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation awards issued under the Company&#x2019;s 2005 Stock Plan (the &#x201c;2005 Plan&#x201d;) and the Company&#x2019;s 2025 Equity Incentive Plan (the &#x201c;2025 Plan&#x201d;) take the form of stock options (non-qualified or incentive stock options), restricted stock or restricted stock units (the "RSUs"). The 2025 Plan also provides for the grant of stock appreciation rights, stock bonuses, stock units and other forms of awards including cash awards to the Company&#x2019;s officers, directors, employees, consultants and advisors. The Black-Scholes option-pricing model is used to determine the fair value of options; application of the model requires judgment to develop assumptions input into the model, some of which are more subjective, including: (i) the fair value of the underlying common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility of the underlying common stock; (iv) the risk-free interest rate; and (v) expected dividends. Income and market approaches to valuation are judgmentally weighted and combined to determine a composite value representing the fair value of the underlying common stock. In estimating the fair value of the underlying common stock prior to IPO, the Company utilized a third party professional valuation firm whose analyses supported management's concluded estimate. Post IPO the fair value of the underlying common stock is based on the Company&#x2019;s closing stock price on the date of grant. An expected volatility assumption is based on stock price volatility of a peer group of comparable public companies over a similar expected term. The risk-free rate is based on U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term; no dividends are assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s employee and nonemployee stock-based compensation awards granted on or before December 31, 2025 contain only service conditions for vesting. The Company recognizes stock-based compensation cost as a component of the related functional expense (costs of revenue or category of operating expenses) on a straight-line basis over the requisite service period, which is explicitly stated in the case of awards issued to employees and implicitly understood to be the period over which services are provided for nonemployees. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with pre-vesting forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation awards in the form of the restricted stock units (the "RSUs") are issued to the Directors of CapsoVision, Inc, who are not employed by the Company ("Non-Employee Directors"). These RSUs are issued in lieu of annual cash compensation (annual base retainer). Each RSU granted to the Non-Employee Directors represents a right to receive one share of the Company common stock when the RSU vests. The Company estimates compensation cost based on the grant date fair value and recognizes the expense on a graded vesting basis over the vesting period of the award. Please, see Note 12. STOCK-BASED COMPENSATION for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO, offering costs related to legal, accounting, and underwriting costs were net with the proceeds and recorded as a reduction in additional paid in capital, in the stockholders&#x2019; equity section of the balance sheet. The Company also issued Underwriters Warrants (as defined in Note 11. COMMON STOCK) for services provided during the IPO to purchase 168,898 shares of common stock. The Underwriters Warrants are accounted for as equity instruments and are included in the Stockholders&#x2019; Equity section of the balance sheet. The fair value of the Underwriters Warrants has been estimated using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC 740,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 740&#x201d;), which requires that the asset and liability method be used. Deferred tax assets and liabilities are determined based on the differences between financial reporting (book basis) and the tax reporting (tax basis) amounts of assets and liabilities; these pre-tax differences are measured and reflected after-tax using the enacted tax rates and law that will be in effect when the differences are expected to reverse. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets at least annually and more frequently as warranted by changes in facts and circumstances and adjusts the amount of the valuation allowance accordingly. Factors considered include the presence of reversing taxable temporary differences as a source of taxable income, forecasts of future taxable income, and available tax planning strategies that could be implemented and are both prudent and feasible. The Company has recorded a full valuation allowance with respect to all of its deferred tax assets based upon the significant negative evidence presented by its accumulated deficit position, its operating losses and negative operating cash flows, and the uncertainty associated with the timing and amount of future profits and therefore taxable income that enable realization. In future periods, if the Company generates book income and taxable income, changes in judgment may reduce or eliminate the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with a two-step model. Firstly, a recognition threshold must be met; a tax benefit from an uncertain tax position may only be recognized if the tax position would, more likely than not, be sustained by the taxing authority assuming an examination and the application of typical practices and precedents.  Secondly, a measurement rule is applied; the amount of tax benefit that can be recognized is the portion that is greater than 50% likely of being realized upon a settlement.  The determination as to whether a tax benefit will, more likely than not, be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances, without consideration of detection risk. As of December&#160;31, 2025 and 2024 the Company&#x2019;s uncertain tax positions were principally related to the non-recognition of a portion of Federal and U.S. state research and development tax credits. The Company recognizes any interest and penalties associated with its income tax positions in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accounting Standards Issued and Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280):&#160;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;("ASU 2023-07"). This guidance requires disclosure on an annual and interim basis of the following: (i) significant segment expenses regularly provided to the chief operating decision maker ("CODM") and a measure of segment profit or loss; (ii) an amount for other segment items by reportable segment and a description of its composition; (iii) all annual disclosures about a reportable segment's profit and loss and assets as currently required by ASC Topic 280; (iv) clarifying if the CODM uses more than one measure of a segment's profit or loss in assessing segment performance and deciding how to allocate resources; and (v) disclosing the title and position of the CODM and how the CODM uses the reported measures. Public entities with a single reportable segment are required to provide all the disclosures required by this amendment.  ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and for quarters in the years beginning after December 15, 2024; early adoption is permitted. The Company, a single reportable segment entity, early adopted ASU 2023-07 with effect from January 1, 2023; the related disclosures are included in Note 13. SEGMENTS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, the FASB issued ASU 2023-09,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) &#x2014; Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;("ASU 2023-09"). The new guidance provides for disclosure on an annual basis of the following: (i) specific categories in the rate reconciliation, and (ii) additional information for reconciling items that meet a quantitative threshold of greater than 5% of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024; early adoption is permitted. The Company adopted this standard for the fiscal year 2025 annual financial statements and has applied this standard prospectively which had a disclosure only impact on its financial statements. See Note 14. INCOME TAXES.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2024-03").  The new guidance requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the statement of operations. ASU is effective for public business entities for annual periods beginning after December 15, 2026, and for quarters in the years beginning after &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 15, 2027; early adoption is permitted. The new guidance may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends certain aspects of the accounting for and disclosure of internal-use software costs. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted and the amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date, retrospectively to any or all prior periods presented in the financial statements, or through a modified prospective transition approach which is based on the status of the project and whether software costs were capitalized before the date of adoption. The Company is currently evaluating the impact ASU 2025-06 will have on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU 2025-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which provides clarity about current interim disclosure requirements and adds a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, for public business entities and for interim reporting periods within annual reporting periods beginning after December 15, 2028, for entities other than public business entities. Early adoption is permitted for all entities. The amendments in this Update can be applied either (1) prospectively or (2) retrospectively to any or all prior periods presented in the financial statements. At the same time, the FASB issued  ASU 2025-12 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. If an entity adopts the amendments in this Update in an interim period, it must adopt them as of the beginning of the annual reporting period that includes that interim reporting period. An entity may elect to early adopt the amendments on an issue-by-issue basis. The Company is currently evaluating the impact ASU 2025-11 and ASU 2025-12 will have on its disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-298">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). Any reference in these notes as it concerns U.S. GAAP is meant to refer to authoritative pronouncements as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-299">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;On July&#160;2, 2025, the Company amended and restated its amended and restated certificate of incorporation to effect a 1-for-3.33 reverse stock split of the Company's common stock, which automatically resulted in reciprocal adjustments (reductions) to the conversion ratios of each of the Company's series of convertible preferred stock (the "Reverse Stock Split"). The par values per share of the common and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All amounts for issued and outstanding common stock, convertible preferred stock, options to purchase common stock, warrants on common stock, and reserves related to common stock, as well as related per-share amounts, contained in the financial statements have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented. No fractional shares were issued as a result of the reverse stock split. In lieu of fractional shares, the Company rounded down to the next whole share and made a cash-in-lieu payment of $1 for 108 shares</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:PreferredStockConvertibleConversionDate contextRef="c-31" id="f-300">2025-07-02</us-gaap:PreferredStockConvertibleConversionDate>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c-1" id="f-301">1-for-3.33</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1 contextRef="c-32" decimals="-3" id="f-302" unitRef="usd">-1000</us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <cv:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares
      contextRef="c-33"
      decimals="INF"
      id="f-303"
      unitRef="shares">-108</cv:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityShares>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-304">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reporting currency for the financial statements of the Company is the United States Dollar. The functional currency of the U.S. corporation, and its foreign branch which is an extension of the U.S. corporation, is the U.S. Dollar. The assets, liabilities, and expenses of the Company&#x2019;s foreign branch recorded in local currency are remeasured into the U.S. Dollar each period, with associated gains and losses included in operating expenses (as a component of general and administrative expenses). Monetary assets and liabilities denominated in currencies other than the functional currency are translated at exchange rates in effect at the balance sheet date with associated gains and losses included in operating expenses (as a component of general and administrative expenses). For the years ended December&#160;31, 2025 and 2024, the Company recorded $193 and $(93), respectively, of net foreign exchange gains (losses) as components of general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">193000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-6" decimals="-3" id="f-306" unitRef="usd">-93000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-307">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&#160;&lt;/span&gt;&lt;/div&gt;The preparation of financial statements in conformity with U.S. GAAP requires the making and usage of  estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities, if any. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. The Company seeks to moderate the influence of subjectivity and estimation uncertainty through reliance on useful information from market participants and peers wherever possible. Estimates and assumptions affect various financial statement amounts and their related disclosures, including, but not limited to, the recognition of revenue, underwriters' warrants valuation, stock based compensation, research and development expenses, income tax-related amounts, lease-related amounts, and allowances for credit losses. Actual results could materially differ from estimates.</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-308">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is organized as, and managed as, one operating (and reportable) segment. Its chief operating decision maker is its Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-309"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-310"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-311">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where required, certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A framework is used for measuring fair value utilizing a three-tier &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the three levels of the hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - defined as observable inputs, such as quoted prices unadjusted in active markets for identical assets or liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - defined as inputs other than quoted prices included in Level&#160;1 that are either directly or indirectly observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - defined as significant unobservable inputs for which little or no market data exists, therefore necessitating entity-specific assumptions&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. An asset or liability&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company&#x2019;s financial assets (which include cash and accounts receivable) and liabilities (which include accounts payable) approximate fair value due to their insensitivity to interest rates and/or close proximity to maturity and qualify as Level&#160;1 measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-312">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of demand deposits at well-known financial institutions and accounts receivable.&#160; At times, the Company&#x2019;s cash deposits may exceed U.S. Federal deposit insurance limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's sales to customers are typically originated with trade credit terms and receivables are uncollateralized, with limited exceptions for prepayments required for certain customers or credit card sales.  The Company historically has experienced insignificant levels of bad debt; allowances for credit losses on accounts receivable were insignificant for all periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s concentration risk related to revenues relates primarily to its product revenues being derived from a single product. With respect to customers, for the year ended December&#160;31, 2025, the same customer represented 9% of our revenue and 22% of our accounts receivable as of December&#160;31, 2025. For the year ended December&#160;31, 2024, that same customer represented 10% of our revenue and 21% of our accounts receivable as of December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s supply concentration risk relates primarily to its materials procurement and contract manufacturing being substantially concentrated with vendors located in Asia.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-34" decimals="2" id="f-313" unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-35" decimals="2" id="f-314" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-36" decimals="2" id="f-315" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-37" decimals="2" id="f-316" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-317">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) comprises net income (loss) and other comprehensive income (loss), which is defined as all changes in stockholders&#x2019; equity (deficit) other than net income (loss) and those resulting from investments by and distributions to stockholders. Historically, and for all periods presented, there are no differences between net loss and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-318">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The core principle is that an entity should recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue using a five-step model resulting in revenue being recognized as performance obligations within a contract are satisfied. The steps within that model include: (i) identifying the existence of a contract with a customer; (ii) identifying the performance obligations within the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contract; (iii) determining the contract&#x2019;s transaction price; (iv) allocating the transaction price to the contract&#x2019;s performance obligations; and (v) recognizing revenue as the contract&#x2019;s performance obligations are satisfied.  Judgment is required to apply the model and make certain estimates and assumptions about the Company&#x2019;s contracts with its customers, including, among others, the nature and extent of its performance obligations, its transaction price amounts and any allocations thereof (including estimates of standalone selling prices), the events which constitute satisfaction of its performance obligations, and when control of any promised goods or services is transferred to customers. The guidance also requires certain incremental costs incurred to obtain or fulfill a contract to be deferred and amortized on a systematic basis consistent with the transfer of goods or services to a customer.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates (i) product revenue from the sale of capsule medical devices, (ii) service revenue from the provision of reading services for videos, and (iii) product or service revenue depending on which video delivery option is utilized by the customer to download and view capsule videos.  The customer&#x2019;s delivery options include (1) a capsule data reading device shipped to the customer which works together with downloadable software installed locally on a customer&#x2019;s computer (classified as product revenue), or (2) a software-as-a-service offering which involves the customer mailing capsule devices to an off-site Company-operated facility which processes uploads of video content to a cloud platform the customer can access via a web browser or a smart device application in order to view videos and generate reports (classified as service revenue).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts with customers contain fixed consideration reflecting prices negotiated with customers and immaterial variable consideration.  For contracts with variable consideration, the Company uses the most likely amount method to estimate the transaction price. Variable consideration is constrained to the extent that it is deemed probable that a significant reversal of the amount of revenue recognized will not occur. Where products or services are not sold separately or experience a range of selling prices, the Company estimates standalone selling prices using a cost-plus-expected margin approach and utilizes the resultant standalone selling prices to allocate transaction prices at transaction inception on a relative standalone selling price basis. The Company recognizes revenue for its product and reading service performance obligations at a point in time, that being when the performance obligations are satisfied and control is transferred to the customer (generally upon shipment for products, or conveyance of final deliverable for services).  For the software-as-a-service video delivery offering performance obligation, the associated revenue is recognized over time, typically less than one fiscal quarter, representing the estimate of the typical period of time in which customers derive utility from the cloud-based service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any significant financing components as payment is received at or shortly after sale. Standard trade credit terms are typically 30 to 60 days from invoice date. Costs incurred to obtain or fulfill a contract are expensed as incurred when the amortization period is less than one year, which is the case for the Company. The Company considers all shipping and handling to be fulfillment activities and not a separate performance obligation. Shipping and handling costs are recorded as costs of revenue. The Company has elected an accounting policy to exclude sales taxes and other similar taxes from the measurement of the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has certain U.S. customers characterized as group purchasing organizations that function as procurement agents for their underlying medical practice, clinic, or hospital members; these group purchasing organizations typically charge the Company percentage-based fees in exchange for the right to do business with the group purchasing organization.  Such fees, which do not provide a distinct separate benefit to the Company, are recorded as reductions to revenue in the same period as the recognition of the related revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s products are sold with the same limited quality assurance warranties offered to all customers; the Company typically does not allow returns of products, except for cases of damage or defect, whereby products would be replaced.  Actual product returns have historically been immaterial given the one-time-use nature of capsule devices; estimated product returns (periodically adjusted to reflect actual experience), if warranted, are accounted for as reductions to revenue with offsets to a product return liability included within accrued expenses and other current liabilities in the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-319">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities; Accounts Receivable and Related Allowance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records contract assets when it has completed performance obligations prior to receiving consideration from the customer and where such amounts are unbilled; where billed, amounts are reflected as trade accounts receivable. The Company promptly invoices its accounts receivable; therefore, the Company&#x2019;s contract assets were zero for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities, portrayed as deferred revenue, reflect (i) obligations to provide goods for which the Company has already received consideration (generally arising from up-front payments received) and (ii) performance obligations to provide services which are not yet satisfied in the context of a particular contract (principally consisting of video delivery obligations related to the Company&#x2019;s off-premise cloud-based video delivery offering).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The Company grants trade credit to most of its customers in the normal course of business and generally does not require collateral. An allowance for credit losses arises subsequent to the origination of a sale for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts.  A provision (or a reversal of the allowance) is recorded as a component of general and administrative expenses.  In determining the amount of the allowance, the Company considers aging of accounts, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance when all attempts to collect have been exhausted. Allowances for credit losses were insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-5" decimals="INF" id="f-320" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-4" decimals="INF" id="f-321" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-322">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Costs of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs of revenue include materials, direct labor, and manufacturing overhead costs related to sold products, as well as certain period costs such as non-allocated overhead, scrap, and outbound freight costs, fees paid to physicians for providing reading services, and the costs of operating the Company&#x2019;s cloud-based software-as-a-service offering for video delivery such as shipping costs, processing costs, and data storage costs. Shipping and handling costs directly related to bringing products to their final point of sale are included in costs of revenue and were $117 and $51 for the years ended December&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-38" decimals="-3" id="f-323" unitRef="usd">117000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-39" decimals="-3" id="f-324" unitRef="usd">51000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-325">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expenses include costs directly attributable to actively marketing the Company&#x2019;s products and services using both direct employees and outside contractors or vendors. These costs include, but are not limited to, salaries, bonuses, benefits, stock-based compensation, sales commissions, travel costs and expense reimbursements, and the costs of sponsoring programs, events, and conferences. Advertising costs were nil for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries, bonuses, benefits, and stock-based compensation related to the Company&#x2019;s executive, administrative, finance, human resources, and other supporting functions. Also included are professional fees for legal services, consulting services, tax matters and audits, information technology, office expenses, rent, insurance, and foreign exchange gains (losses).&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="INF" id="f-326" unitRef="usd">0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-40" decimals="INF" id="f-327" unitRef="usd">0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-41" decimals="INF" id="f-328" unitRef="usd">0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-6" decimals="INF" id="f-329" unitRef="usd">0</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-330">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses (including Clinical Trial Expenses)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in accordance with ASC 730,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Research and development expenses include costs directly attributable to the conduct of research and development programs, including salaries, bonuses, benefits, and stock-based compensation for employees focused on research and development or clinical trials, costs of independent contractors and outside vendors, costs of supplies consumed in or product inventory utilized in clinical trials, and the costs of clinical trial activities as charged within the negotiated budgets by trial sites or vendors responsible for multiple trial sites.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes prepayments for goods or services, including trial device inventory, that will be used, consumed, or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed.  The Company also records expenses and accruals for estimated costs of research and development activities, including third party services for clinical trials.  The Company bases its estimates on information available at the time.  Costs for certain clinical trial activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the balance sheet as prepaid expenses or as accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025 and 2024, the Company incurred $6,391 and $7,647, respectively, of expenses related to ongoing clinical trial activities which are included within research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-42" decimals="-3" id="f-331" unitRef="usd">6391000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-43" decimals="-3" id="f-332" unitRef="usd">7647000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if options or warrants on common stock were exercised or convertible preferred stock shares were converted into common stock. Diluted net loss per share is the same as basic net loss per common share since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of incremental common shares issuable upon exercise of vested stock options, common stock warrants, and the Company&#x2019;s various series of convertible preferred stock. Upon completion of the IPO in July 2025, all outstanding shares of preferred stock were converted into shares of Company's common stock (after giving effect to the 1-for-3.33 reverse stock split). Subsequent to the conversion, only common stock remains outstanding. Accordingly, the two-class method is no longer applicable for periods after the IPO.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c-1" id="f-334">1-for-3.33</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-335">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents comprises demand deposits in the form of checking accounts and money market accounts (which may be deposited into and withdrawn at will with no restrictions as to investment or redemption) and includes cash balances denominated in the Euro and New Taiwan Dollar, for which fluctuations in exchange rates result in gains or losses reported within operating expenses as a component of general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, consisting of materials, direct labor and manufacturing overhead, are subdivided into raw materials, work in process, and finished goods and are stated at the lower of cost (average cost) or net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates inventories as to (i) net realizable value and (ii) circumstances or indicators of loss, damage, insufficient time to expiry (determined by battery life), excess quantities, or obsolescence and provisions accordingly via direct charges against the carrying value of inventory.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-337">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at historical cost, less accumulated depreciation. The Company capitalizes major improvements and expenses repairs and maintenance as incurred. Depreciation is recorded using the straight-line method based on the estimated useful lives of the depreciable property or, for leasehold improvements, the remaining term of the lease, whichever is shorter.  Useful lives are as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery &amp;amp; equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-344"&gt;Shorter of remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon disposal (retirement or sale) of property and equipment, as applicable, the cost and related accumulated depreciation are removed and any resulting gain or loss is reflected within operating expenses. Such amounts were insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;Long-lived assets are evaluated for impairment as warranted by triggering events related to changes in facts and circumstances. There have historically been no impairments and there were none for all periods presented</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-338">Useful lives are as follows.&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery &amp;amp; equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-344"&gt;Shorter of remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment comprised the following amounts:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment, office equipment, and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;720&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-44" id="f-339">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-45" id="f-340">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-46" id="f-341">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-47" id="f-342">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-48" id="f-343">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-345" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-6" decimals="INF" id="f-346" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-41" decimals="INF" id="f-347" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-40" decimals="INF" id="f-348" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-349">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for office and storage space in California and office space in Taiwan, Republic of China. The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (&#x201c;ROU&#x201d;) assets and the corresponding lease liabilities are depicted in operating lease liabilities, current and operating lease liabilities, non-current in the balance sheet. ROU assets represent the right to use an underlying asset, and lease liabilities represent the obligation for lease payments in exchange for the ability to use the asset for the duration of the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets and lease liabilities are recognized at commencement date and determined using the present value of the future minimum lease payments over the lease term. The Company utilizes an incremental borrowing rate when assessing lease classification and measuring lease liabilities. The estimated incremental borrowing rate considers credit rating practices applied by well known statistical rating organizations to borrowers, Company-specific factors, and the actual lease term at commencement date. The lease term may include options to extend when it is reasonably certain that the Company will exercise that option. The Company recognizes operating lease expense on a straight-line basis over a lease's term.&lt;/span&gt;&lt;/div&gt;The Company has lease agreements which contain both lease and non-lease components, which it has elected to account for as a single lease component. Variable lease payments that are not dependent on an index or rate are not included in lease measurements and are accounted for as incurred.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="c-1" id="f-350">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary means of financing from start-up through development and into the commercial stage has historically been the issuance of convertible preferred stock in various series; these series share similar rights and obligations and contain similar qualifications as to the requirements an equity initial public offering would have to meet in order for the stock to convert to common stock. Convertible preferred stock is recorded at fair value on the date of issuance (historically, the same as the issue price), net of issuance costs. Application of the guidance contained in&#160;ASC&#160;480-10-S99-3A,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;has led the Company to present each of the series of convertible preferred stock as mezzanine equity due to the similar features of the series concerning liquidation preferences and other rights and privileges inuring to the respective series&#x2019; holders, one or more of which may result in a settlement in cash not entirely within the Company&#x2019;s control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;2, 2025, immediately prior to the completion of the Company&#x2019;s IPO and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock, all shares of the Company&#x2019;s convertible preferred stock converted into shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:PreferredStockConvertibleConversionDate contextRef="c-30" id="f-351">2025-07-02</us-gaap:PreferredStockConvertibleConversionDate>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-352">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for employee and nonemployee equity compensation awards in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 718&#x201d;).&#160; In accordance therewith,&#160;the Company accounts for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock-based compensation for awards granted to nonemployees in a similar fashion to stock-based compensation awards to employees.&#160; ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation awards issued under the Company&#x2019;s 2005 Stock Plan (the &#x201c;2005 Plan&#x201d;) and the Company&#x2019;s 2025 Equity Incentive Plan (the &#x201c;2025 Plan&#x201d;) take the form of stock options (non-qualified or incentive stock options), restricted stock or restricted stock units (the "RSUs"). The 2025 Plan also provides for the grant of stock appreciation rights, stock bonuses, stock units and other forms of awards including cash awards to the Company&#x2019;s officers, directors, employees, consultants and advisors. The Black-Scholes option-pricing model is used to determine the fair value of options; application of the model requires judgment to develop assumptions input into the model, some of which are more subjective, including: (i) the fair value of the underlying common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility of the underlying common stock; (iv) the risk-free interest rate; and (v) expected dividends. Income and market approaches to valuation are judgmentally weighted and combined to determine a composite value representing the fair value of the underlying common stock. In estimating the fair value of the underlying common stock prior to IPO, the Company utilized a third party professional valuation firm whose analyses supported management's concluded estimate. Post IPO the fair value of the underlying common stock is based on the Company&#x2019;s closing stock price on the date of grant. An expected volatility assumption is based on stock price volatility of a peer group of comparable public companies over a similar expected term. The risk-free rate is based on U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term; no dividends are assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s employee and nonemployee stock-based compensation awards granted on or before December 31, 2025 contain only service conditions for vesting. The Company recognizes stock-based compensation cost as a component of the related functional expense (costs of revenue or category of operating expenses) on a straight-line basis over the requisite service period, which is explicitly stated in the case of awards issued to employees and implicitly understood to be the period over which services are provided for nonemployees. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with pre-vesting forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation awards in the form of the restricted stock units (the "RSUs") are issued to the Directors of CapsoVision, Inc, who are not employed by the Company ("Non-Employee Directors"). These RSUs are issued in lieu of annual cash compensation (annual base retainer). Each RSU granted to the Non-Employee Directors represents a right to receive one share of the Company common stock when the RSU vests. The Company estimates compensation cost based on the grant date fair value and recognizes the expense on a graded vesting basis over the vesting period of the award. Please, see Note 12. STOCK-BASED COMPENSATION for details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO, offering costs related to legal, accounting, and underwriting costs were net with the proceeds and recorded as a reduction in additional paid in capital, in the stockholders&#x2019; equity section of the balance sheet. The Company also issued Underwriters Warrants (as defined in Note 11. COMMON STOCK) for services provided during the IPO to purchase 168,898 shares of common stock. The Underwriters Warrants are accounted for as equity instruments and are included in the Stockholders&#x2019; Equity section of the balance sheet. The fair value of the Underwriters Warrants has been estimated using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-28"
      decimals="INF"
      id="f-354"
      unitRef="shares">168898</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-355">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC 740,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 740&#x201d;), which requires that the asset and liability method be used. Deferred tax assets and liabilities are determined based on the differences between financial reporting (book basis) and the tax reporting (tax basis) amounts of assets and liabilities; these pre-tax differences are measured and reflected after-tax using the enacted tax rates and law that will be in effect when the differences are expected to reverse. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets at least annually and more frequently as warranted by changes in facts and circumstances and adjusts the amount of the valuation allowance accordingly. Factors considered include the presence of reversing taxable temporary differences as a source of taxable income, forecasts of future taxable income, and available tax planning strategies that could be implemented and are both prudent and feasible. The Company has recorded a full valuation allowance with respect to all of its deferred tax assets based upon the significant negative evidence presented by its accumulated deficit position, its operating losses and negative operating cash flows, and the uncertainty associated with the timing and amount of future profits and therefore taxable income that enable realization. In future periods, if the Company generates book income and taxable income, changes in judgment may reduce or eliminate the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with a two-step model. Firstly, a recognition threshold must be met; a tax benefit from an uncertain tax position may only be recognized if the tax position would, more likely than not, be sustained by the taxing authority assuming an examination and the application of typical practices and precedents.  Secondly, a measurement rule is applied; the amount of tax benefit that can be recognized is the portion that is greater than 50% likely of being realized upon a settlement.  The determination as to whether a tax benefit will, more likely than not, be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances, without consideration of detection risk. As of December&#160;31, 2025 and 2024 the Company&#x2019;s uncertain tax positions were principally related to the non-recognition of a portion of Federal and U.S. state research and development tax credits. The Company recognizes any interest and penalties associated with its income tax positions in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-356">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accounting Standards Issued and Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280):&#160;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;("ASU 2023-07"). This guidance requires disclosure on an annual and interim basis of the following: (i) significant segment expenses regularly provided to the chief operating decision maker ("CODM") and a measure of segment profit or loss; (ii) an amount for other segment items by reportable segment and a description of its composition; (iii) all annual disclosures about a reportable segment's profit and loss and assets as currently required by ASC Topic 280; (iv) clarifying if the CODM uses more than one measure of a segment's profit or loss in assessing segment performance and deciding how to allocate resources; and (v) disclosing the title and position of the CODM and how the CODM uses the reported measures. Public entities with a single reportable segment are required to provide all the disclosures required by this amendment.  ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and for quarters in the years beginning after December 15, 2024; early adoption is permitted. The Company, a single reportable segment entity, early adopted ASU 2023-07 with effect from January 1, 2023; the related disclosures are included in Note 13. SEGMENTS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, the FASB issued ASU 2023-09,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) &#x2014; Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;("ASU 2023-09"). The new guidance provides for disclosure on an annual basis of the following: (i) specific categories in the rate reconciliation, and (ii) additional information for reconciling items that meet a quantitative threshold of greater than 5% of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024; early adoption is permitted. The Company adopted this standard for the fiscal year 2025 annual financial statements and has applied this standard prospectively which had a disclosure only impact on its financial statements. See Note 14. INCOME TAXES.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2024-03").  The new guidance requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the statement of operations. ASU is effective for public business entities for annual periods beginning after December 15, 2026, and for quarters in the years beginning after &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 15, 2027; early adoption is permitted. The new guidance may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends certain aspects of the accounting for and disclosure of internal-use software costs. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted and the amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date, retrospectively to any or all prior periods presented in the financial statements, or through a modified prospective transition approach which is based on the status of the project and whether software costs were capitalized before the date of adoption. The Company is currently evaluating the impact ASU 2025-06 will have on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU 2025-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which provides clarity about current interim disclosure requirements and adds a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, for public business entities and for interim reporting periods within annual reporting periods beginning after December 15, 2028, for entities other than public business entities. Early adoption is permitted for all entities. The amendments in this Update can be applied either (1) prospectively or (2) retrospectively to any or all prior periods presented in the financial statements. At the same time, the FASB issued  ASU 2025-12 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. If an entity adopts the amendments in this Update in an interim period, it must adopt them as of the beginning of the annual reporting period that includes that interim reporting period. An entity may elect to early adopt the amendments on an issue-by-issue basis. The Company is currently evaluating the impact ASU 2025-11 and ASU 2025-12 will have on its disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-357">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;4. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s demand deposit accounts include money market demand deposits which constitute cash, given the lack of investment restrictions or redemption conditions and the ability to immediately withdraw funds. The carrying amounts of the Company&#x2019;s financial assets (which include cash and accounts receivable) and liabilities (which include accounts payable) approximate fair value due to their insensitivity to interest rates and/or close proximity to their maturities and qualify as Level&#160;1 measurements. There were no transfers between Level 1, 2 or 3 during any periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-358">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;5. BALANCE SHEET COMPONENTS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory comprised the following amounts:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,987&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025 and December&#160;31, 2024, there were no provisions to write down inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets comprised the following amounts:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayment for insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advance payments for inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred initial public offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred initial public offering costs are specific incremental costs directly attributable to an initial public offering of equity securities that were reclassified from current assets to stockholders' equity and recorded as reductions to the gross proceeds from the offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment comprised the following amounts:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment, office equipment, and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;720&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expenses of $216 and $206 for the years ended December&#160;31, 2025 and 2024, respectively, were recorded within costs of revenue and components of operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued sales taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,697&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-359">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory comprised the following amounts:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,987&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">107000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-5" decimals="-3" id="f-361" unitRef="usd">176000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-3" id="f-362" unitRef="usd">994000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-5" decimals="-3" id="f-363" unitRef="usd">897000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-3" id="f-364" unitRef="usd">1886000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-5" decimals="-3" id="f-365" unitRef="usd">1556000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-366" unitRef="usd">2987000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-367" unitRef="usd">2629000</us-gaap:InventoryNet>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-368">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets comprised the following amounts:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayment for insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advance payments for inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred initial public offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance contextRef="c-4" decimals="-3" id="f-369" unitRef="usd">324000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-5" decimals="-3" id="f-370" unitRef="usd">64000</us-gaap:PrepaidInsurance>
    <us-gaap:Supplies contextRef="c-4" decimals="-3" id="f-371" unitRef="usd">300000</us-gaap:Supplies>
    <us-gaap:Supplies contextRef="c-5" decimals="-3" id="f-372" unitRef="usd">349000</us-gaap:Supplies>
    <us-gaap:DeferredOfferingCosts contextRef="c-4" decimals="-3" id="f-373" unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c-5" decimals="-3" id="f-374" unitRef="usd">225000</us-gaap:DeferredOfferingCosts>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-375" unitRef="usd">448000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-376" unitRef="usd">260000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-377" unitRef="usd">1072000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-378" unitRef="usd">898000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:MachineryAndEquipmentGross contextRef="c-4" decimals="-3" id="f-379" unitRef="usd">928000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="c-5" decimals="-3" id="f-380" unitRef="usd">821000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="c-4" decimals="-3" id="f-381" unitRef="usd">101000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="c-5" decimals="-3" id="f-382" unitRef="usd">101000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">157000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-5" decimals="-3" id="f-384" unitRef="usd">157000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-385" unitRef="usd">575000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-386" unitRef="usd">359000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-387" unitRef="usd">611000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-388" unitRef="usd">720000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">216000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-390" unitRef="usd">206000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-391">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued sales taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,697&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-392" unitRef="usd">568000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-393" unitRef="usd">349000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cv:AccruedClinicalTrialExpenseCurrent contextRef="c-4" decimals="-3" id="f-394" unitRef="usd">83000</cv:AccruedClinicalTrialExpenseCurrent>
    <cv:AccruedClinicalTrialExpenseCurrent contextRef="c-5" decimals="-3" id="f-395" unitRef="usd">13000</cv:AccruedClinicalTrialExpenseCurrent>
    <cv:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-4" decimals="-3" id="f-396" unitRef="usd">1448000</cv:AccruedResearchAndDevelopmentExpenseCurrent>
    <cv:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-5" decimals="-3" id="f-397" unitRef="usd">0</cv:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-4" decimals="-3" id="f-398" unitRef="usd">79000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-5" decimals="-3" id="f-399" unitRef="usd">67000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-400" unitRef="usd">519000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-401" unitRef="usd">140000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-402" unitRef="usd">2697000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-403" unitRef="usd">569000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;6. REVENUE AND DEFERRED REVENUE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue disaggregated by geographic source, type of customer, and products or services was as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States (medical practice, clinic, and hospital customers):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products (capsules and capsule reading devices)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services (cloud-based video delivery and reading services)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside United States (distributor customers):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products (capsules and capsule reading devices)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;13,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;11,756&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025 and 2024, U.S. service revenues included (i) $621 and $548, respectively, from the Company&#x2019;s cloud-based software-as-a-service video delivery offering (recognized over time commencing with the shipment of capsules) and (ii) $295 and $232, respectively, of revenue from the provision of video reading to customers (recognized at a point in time upon provision of deliverables).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues outside the United States are attributable to individual foreign countries based upon shipment destination. The Company&#x2019;s distributor customers outside the United States typically serve the countries in which they are domiciled (and may distribute to adjacent countries or territories). Outside the United States, for the year ended December&#160;31, 2025, product revenues included $1,248 and $598 attributable to France and Germany, respectively, with the balance attributable to other countries; for the year ended December&#160;31, 2024 product revenues included $1,160 and $565 attributable to France and Germany, respectively, with the balance attributable to other countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue (contract liabilities, all of which are current in nature) consists of upfront purchases by customers related to the cloud-based software-as-a-service video delivery offering and prepaid video reading services. Deferred revenue represents the excess of amounts invoiced over amounts recognized as revenues. For each component of deferred revenue, the recognition of deferrals as revenue occurred within three months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's deferred revenue balance was $177, $132 and $96 as of December&#160;31, 2025, December&#160;31, 2024 and December 31, 2023, respectively. During the year ended December&#160;31, 2025, the Company recognized $132 of revenue that was included in deferred revenue as of December&#160;31, 2024. During the year ended December&#160;31, 2024, the Company recognized $96 of revenue that was included in deferred revenue as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fees paid to group purchasing organizations and recorded as reductions to revenue were $110 and $103 for the years ended December&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-405">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue disaggregated by geographic source, type of customer, and products or services was as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States (medical practice, clinic, and hospital customers):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products (capsules and capsule reading devices)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services (cloud-based video delivery and reading services)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside United States (distributor customers):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.24pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products (capsules and capsule reading devices)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;13,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;11,756&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-49" decimals="-3" id="f-406" unitRef="usd">9741000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-50" decimals="-3" id="f-407" unitRef="usd">8302000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-51" decimals="-3" id="f-408" unitRef="usd">916000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-52" decimals="-3" id="f-409" unitRef="usd">780000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-53" decimals="-3" id="f-410" unitRef="usd">2897000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-54" decimals="-3" id="f-411" unitRef="usd">2674000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-412" unitRef="usd">13554000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-413" unitRef="usd">11756000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-55" decimals="-3" id="f-414" unitRef="usd">621000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-56" decimals="-3" id="f-415" unitRef="usd">548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-57" decimals="-3" id="f-416" unitRef="usd">295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-58" decimals="-3" id="f-417" unitRef="usd">232000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-59" decimals="-3" id="f-418" unitRef="usd">1248000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-60" decimals="-3" id="f-419" unitRef="usd">598000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-61" decimals="-3" id="f-420" unitRef="usd">1160000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-62" decimals="-3" id="f-421" unitRef="usd">565000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-422" unitRef="usd">177000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-423" unitRef="usd">132000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-7" decimals="-3" id="f-424" unitRef="usd">96000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-3" id="f-425" unitRef="usd">132000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-7" decimals="-3" id="f-426" unitRef="usd">96000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <cv:GroupPurchasingOrganizationFeesContraRevenue contextRef="c-1" decimals="-3" id="f-427" unitRef="usd">110000</cv:GroupPurchasingOrganizationFeesContraRevenue>
    <cv:GroupPurchasingOrganizationFeesContraRevenue contextRef="c-6" decimals="-3" id="f-428" unitRef="usd">103000</cv:GroupPurchasingOrganizationFeesContraRevenue>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-429">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;7. NOTE PAYABLE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2025, the Company entered into a promissory note with Ching-Hang Shen, one of the beneficial owners of more than 5% of the Company's outstanding common stock, pursuant to which Mr. Shen provided to the Company a promissory note in a principal amount of $1,000 (such note, the &#x201c;Investor Loan&#x201d;) on May 28, 2025. The Investor Loan (i) had an interest rate equal to one percent (1%) per month, assuming a month of thirty (30) days and (ii) had maturity not later than ten (10) business days following the IPO, which was completed on July&#160;3, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2025, in connection with the repayment of the promissory note, the Company issued to Mr. Shen 7,508 shares of common stock at a fair value of $31 on the date of issuance pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 as a transaction not involving a public offering. The promissory note principal amount of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1,000 and accrued interest were repaid in cash on July 11, 2025. After repayment, there were no outstanding liabilities or obligations in connection with the promissory note.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <cv:ShortTermDebtOriginationDate contextRef="c-63" id="f-430">2025-05-27</cv:ShortTermDebtOriginationDate>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-63" decimals="INF" id="f-431" unitRef="usd">1000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <cv:RelatedPartyTransactionRatePerMonth
      contextRef="c-63"
      decimals="INF"
      id="f-432"
      unitRef="number">0.01</cv:RelatedPartyTransactionRatePerMonth>
    <us-gaap:SaleOfStockTransactionDate contextRef="c-24" id="f-433">2025-07-03</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:RelatedPartyTransactionDate contextRef="c-64" id="f-434">2025-07-07</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-64"
      decimals="INF"
      id="f-435"
      unitRef="shares">7508</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-65" decimals="-3" id="f-436" unitRef="usd">31000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShortTermNonBankLoansAndNotesPayable contextRef="c-66" decimals="-3" id="f-437" unitRef="usd">1000000</us-gaap:ShortTermNonBankLoansAndNotesPayable>
    <cv:ShortTermNonBankLoansAndNotesPaymentDate contextRef="c-64" id="f-438">2025-07-11</cv:ShortTermNonBankLoansAndNotesPaymentDate>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-439">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;8. LEASES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for office and manufacturing space in California and office space in Taiwan, Republic of China, with remaining lease terms ranging from under one year to approximately two years as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of twelve months or less are not accounted for in the balance sheet; these are limited to minor leases in Taiwan, which are excluded from amounts presented in the following tables. The operating leases include certain variable payments related to operating expenses, which are billed by the landlord, as is customary with these types of charges for office space.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s existing leases contain escalation clauses and renewal options. The Company has evaluated several factors in assessing whether it is reasonably certain that the Company will exercise a contractual renewal option.  For leases with renewal options that are reasonably certain to be exercised, the Company includes the renewal term in the total lease term used in deriving the right-of-use asset and lease liability. The Company&#x2019;s main office lease includes a renewal option of three years, which was excluded after evaluation of those factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts comprising total lease expense, reflected in general and administrative expenses and costs of revenue (including amounts capitalized as overhead to inventory), were as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease-related amounts reflected in the balance sheet and data related thereto were as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.126%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;843&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease payments related to operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments related to operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases are as follows as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-67" id="f-440">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-68" id="f-441">P2Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-4" id="f-442">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-443">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts comprising total lease expense, reflected in general and administrative expenses and costs of revenue (including amounts capitalized as overhead to inventory), were as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease payments related to operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments related to operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-444" unitRef="usd">474000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-3" id="f-445" unitRef="usd">476000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-446" unitRef="usd">37000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-6" decimals="-3" id="f-447" unitRef="usd">34000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-448" unitRef="usd">511000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-6" decimals="-3" id="f-449" unitRef="usd">510000</us-gaap:LeaseCost>
    <cv:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease-related amounts reflected in the balance sheet and data related thereto were as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.126%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;843&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.88pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cv:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-451" unitRef="usd">843000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-452" unitRef="usd">1195000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-453" unitRef="usd">410000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-454" unitRef="usd">351000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-455" unitRef="usd">477000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-456" unitRef="usd">887000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-457" unitRef="usd">887000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-458" unitRef="usd">1238000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-459">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-460">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-461" unitRef="number">0.118</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-462" unitRef="number">0.118</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:VariableLeasePayment contextRef="c-1" decimals="-3" id="f-463" unitRef="usd">0</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment contextRef="c-6" decimals="-3" id="f-464" unitRef="usd">39000</us-gaap:VariableLeasePayment>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-465" unitRef="usd">474000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-3" id="f-466" unitRef="usd">437000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-467">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases are as follows as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-468" unitRef="usd">488000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-469" unitRef="usd">503000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount contextRef="c-4" decimals="-3" id="f-470" unitRef="usd">104000</us-gaap:FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-471" unitRef="usd">887000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-472">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;9. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company, post-acquisition of raw materials, relies significantly upon third-party contract manufacturers located in Taiwan. Management believes that supply risks related to dependence on fewer key suppliers or contract manufacturers, and political risk, can potentially be hedged with the use of more than one supplier and a readiness to quickly adjust the supply chain (and geographic sourcing within Asia).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;15, 2025, the Company entered into a development agreement with Canon Inc., a Japanese corporation, for the development of complementary metal-oxide-semiconductor (&#x201c;CMOS&#x201d;) image sensor samples to allow the Company to evaluate functionality and performance, conduct clinical evaluation of capsule endoscopies that incorporate Canon image sensors and obtain FDA 510(k) clearance thereof. Under the Agreement, the Company agreed to pay Canon a fee of approximately $4.1 million for Canon&#x2019;s development efforts, which is comprised of (a) an initial fee of $1.0 million that was paid in cash on July&#160;31, 2025 upon the Agreement&#x2019;s effectiveness, and (b) following delivery of a specified number of CMOS image sensors meeting agreed specifications within the required timeframe, a remaining development fee of approximately $3.1 million. Additionally, due to the changes in the development scope by the end of fiscal year 2025, Canon and the Company agreed to increase the development fee by $1.0 million and executed an amendment to the original development agreement in March 2026. For the year ended December 31, 2025 we recognized $2.4 million in R&amp;amp;D expenses. The outstanding balance due to Canon was $1.4 million and included in Accrued Expenses and Other Current Liabilities in the balance sheet as of December 31, 2025. The outstanding purchase commitment for this agreement as of December 31, 2025 is $2.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Receipt of Federal Government Assistance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2025, the Company received cash related to refundable payroll tax credits from the U.S. Federal government in the amount of $208 reflecting receipt of credit claims related to calendar 2020 and 2021 remitted to the U.S. Internal Revenue Service under the Employee Retention Credit program, a source of COVID-19 pandemic era Federal relief. This amount, due to the uncertainty of eventual receipt following claims made, was not recognized until receipt in the year ended December 31, 2025 and was reflected within &lt;span style="-sec-ix-hidden:f-484"&gt;general and administrative expenses&lt;/span&gt; given its relationship to payroll taxes reflected as operating expenses. There can be no assurance that the Company&#x2019;s program benefit received may not be examined, and if examined, possibly challenged as to a portion or all of the benefit received which, if required to be returned, would have an adverse impact on the Company&#x2019;s liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Litigation and Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may be the subject of adverse litigation as a defendant, arbitration, claims, or proceedings related to things such as intellectual property infringement or disputes, commercial contract breaches or disputes, employment matters, or other matters in the ordinary course of business. Such matters are subject to many uncertainties and outcomes may be unpredictable. Such matters may be fully or partially mitigated by the effect of insurance coverage in place or counter-party indemnitors. The Company provides for liabilities via a charge to operating expenses when it is both probable that a liability has been incurred and the amount of the loss can be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reasonably estimated. The Company is not a party to any material litigation, arbitration, claims or proceedings and therefore did not have any contingency-related liabilities as of December&#160;31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cv:ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate contextRef="c-69" id="f-473">2025-07-15</cv:ResearchAndDevelopmentArrangementContractToPerformForOthersOriginationDate>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="c-69" decimals="-5" id="f-474" unitRef="usd">4100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <cv:ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee contextRef="c-69" decimals="-5" id="f-475" unitRef="usd">1000000.0</cv:ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFee>
    <cv:ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate contextRef="c-70" id="f-476">2025-07-31</cv:ResearchAndDevelopmentArrangementContractToPerformForOthersInitialFeeDate>
    <cv:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet contextRef="c-69" decimals="-3" id="f-477" unitRef="usd">3100000</cv:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredNet>
    <cv:ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease contextRef="c-1" decimals="-3" id="f-478" unitRef="usd">1000000.0</cv:ResearchAndDevelopmentArrangementContractToPerformForOthersFeeIncrease>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-71" decimals="-5" id="f-479" unitRef="usd">2400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-72" decimals="-5" id="f-480" unitRef="usd">2400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-73" decimals="-5" id="f-481" unitRef="usd">1400000</us-gaap:AccruedLiabilitiesCurrent>
    <cv:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding contextRef="c-73" decimals="-5" id="f-482" unitRef="usd">2700000</cv:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsOutstanding>
    <us-gaap:GovernmentAssistanceOperatingExpense contextRef="c-74" decimals="-3" id="f-483" unitRef="usd">208000</us-gaap:GovernmentAssistanceOperatingExpense>
    <us-gaap:PreferredStockTextBlock contextRef="c-1" id="f-485">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;10. PREFERRED STOCK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock &#x2013; Financing History&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, the Company has issued several Series of convertible preferred stock to investors (A, B, C, C-1, D, D-1, D-2, E, F-1, F-2, G, G-1, and H) as its primary financing vehicle to fund research and development and commercial stage maturity. For descriptions and discussion of Series preceding Series H, refer to the Capital Stock footnote in the Company's annual financial statements for the year ended December&#160;31, 2024 contained in the prospectus filed on July 3, 2025 with the Securities and Exchange Commission, as part of the Company's Registration Statement (File No. 333-287148).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Company had 14,461,804 shares of Series H Preferred Stock (&#x201c;Series H&#x201d;), par value $0.001 per share, for an original issue price of $4.83 per share. These shares were issued to various investors in the period of November 2019 to December 31, 2024 pursuant to the original financing round and subsequent extensions thereof, resulting in proceeds of $69,829 (net of issuance costs of zero) as of December 31, 2024. There were no issuances of Series H in the year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the closing of the Company&#x2019;s IPO on July&#160;3, 2025 and upon the receipt by the Company of a written request consented to by holders of a majority of the Preferred Stock on July&#160;2, 2025, all shares of the Company&#x2019;s then-outstanding convertible preferred stock converted into shares of the Company&#x2019;s common stock. Under the Company&#x2019;s Amended and Restated Certificate of Incorporation, the Company is authorized to issue none and 153,682,280 shares of $0.001 par value convertible preferred stock as of December 31, 2025, and December 31, 2024, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible preferred stock outstanding as of December 31, 2024 consisted of the following (in thousands, except share amounts.) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Series &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,962,675&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,394,197&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,801,802&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,747,127&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;880,187&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,876,405&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;848,599&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,222,222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;520,519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,766,666&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;166,833&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D-2*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,083,333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,920,649&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,151,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series F-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,043,479&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,201,203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series F-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,498,498&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,926,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,779,559&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series G-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,896,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,039,756&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series H&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,157,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,461,804&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;153,682,280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;38,665,583&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;152,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;143,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Liquidation preference includes two times the original issue price per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Series of preferred stock are collectively referred to as the &#x201c;Preferred Stock&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock - Conversion Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Preferred Stock shares might be converted into shares of common stock at a ratio determined by dividing the original issuance price by the conversion price (the &#x201c;Conversion Rate&#x201d;). The conversion price was initially set at the original issuance price and might be adjusted downward, or upward, thereby reciprocally adjusting the Conversion Rate, for capital stock events such as stock splits, stock dividends, reorganizations, or other events where the consideration received relative to the number of shares issued would imperil or dilute holders of Preferred Stock.  Thus, the Conversion Rate was 1:1 at original issuance. As further described in Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, under the caption "Reverse Stock Split", the Company effectuated a reverse split of its issued and outstanding common stock which resulted in an automatic adjustment (reduction) to the Conversion Rates on all Series of Preferred Stock; there were no adjustments to Conversion Rates on any Series of Preferred Stock since original issuance and prior to the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Preferred Stock shares converted to shares of common stock (i) electively, upon the receipt by the Company of a written request consented to by holders of at least a majority of the Preferred Stock then outstanding at the effective date specified in the request (provided further that such conversion should not occur for either of Series G-1 and Series H unless a majority of holders within each of those series so consents), or (ii) automatically, upon the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, provided that the offering price per share of common stock is not less than $9.66 or $9.99, depending on the Series (as adjusted for recapitalizations) and the aggregate gross proceeds to the Company are $25&#160;million or greater. In connection with and prior to the amendment and restatement of the Company's amended and restated certificate of incorporation described in Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, under the caption "Reverse Stock Split", the holders of all Series of the Company's Preferred Stock elected, via written action, to convert all issued and outstanding Preferred Stock to common stock contingent upon the Company completing a planned initial public offering of its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock - Liquidation Preferences&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidation, for purposes of liquidation preferences that favor holders of Preferred Stock, meant a liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary, an acquisition of the Company by another entity (other than a transaction which does not result in a change in the holders of at least 50% of voting stock outstanding before and after the transaction), or the sale, lease, exclusive license, or conveyance of all or substantially all of the Company&#x2019;s assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The liquidation preference for each series of Preferred Stock was the sum of (i) the original issuance price per share (as adjusted for recapitalizations) &#x2013; that is, one times the original issue price, and (ii) all declared but unpaid dividends, with the exception of Series D-2, where the liquidation preference includes two times the original issue price per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidation preferences were rank-ordered by priority group - first: Series E, F-1, F-2, G, G-1 and H; second: Series D-2; third: Series D and D-1; fourth and last: Series A, B, C, and C-1.  Should distributable assets upon liquidation be insufficient to satisfy respective liquidation preferences within a priority group, the distributable assets were to be distributed to the stockholders within the priority group pro rata and in relationship to the proportion of available distributable assets to the full liquidation preferences that would otherwise be due. When distributable assets were sufficient for a priority group, the remaining distributable assets cascaded to the next priority group, and so on and so forth in descending order of priority group. Should remaining distributable assets exist, after satisfying the liquidation preferences of all Preferred Stock, such remainder were distributable to the holders of the Preferred Stock and common stock in proportion to the number of shares of common stock held by them on a combined basis, with the shares of Preferred Stock being treated as if converted.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock &#x2013; Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding shares of Preferred Stock were entitled to receive dividends, when, as and if declared by the Board of Directors at a dividend rate of 8.00% payable in preference and priority to any declaration or payment of any distribution related to common stock.  The dividends were not cumulative and Preferred Stockholders did not acquire rights to dividends because they were not declared or paid in any given year. The Company has never declared or paid any dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock - Voting Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of Preferred Stock had the same voting rights as the holders of common stock, on an&#160;as-converted&#160;basis at the then-prevailing Conversion Rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Board of Directors of the Company comprised eight members. Each holder of convertible preferred stock was entitled to the number of votes equal to the number of common stock shares into which the referred shares held by such holder converted. The holders of a majority of the voting shares were able to elect all of the directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock - Protective Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As long as any Preferred Stock was issued and outstanding, the Company should not, without first obtaining the approval (by vote or written consent) of the holders of a majority of outstanding shares of Preferred Stock, voting together as a single class:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Amend, alter or repeal any provision of the certificate of incorporation or bylaws (including pursuant to a merger) if such action would adversely affect the Preferred Stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Increase or decrease the authorized number of shares of Preferred Stock (including any series thereof) or common stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Authorize or create any new class or series of shares having rights, preferences or privileges senior to or on parity with any series of Preferred Stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Voluntarily liquidate or dissolve, or enter into any transaction or series of related transactions deemed to be a liquidation, dissolution or any disposition of the Company&#x2019;s property;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Effect a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Enter into any transaction (other than customary service or employment agreements) with any officer or director of the Company, or any party related thereto or affiliated therewith, unless approved by a majority of the Board of Directors;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Issue any indebtedness that is convertible into any equity security, or incur any other indebtedness other than loans, leases and similar transactions in the ordinary course of business; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Redeem, repurchase or otherwise acquire any shares of Preferred Stock or common stock, except for the repurchase of shares of common stock from employees, officers, directors, consultants or other persons performing services pursuant to agreements granting the Company option or repurchase rights upon the occurrence of certain events.&lt;/span&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c-75"
      decimals="INF"
      id="f-486"
      unitRef="shares">14461804</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-75"
      decimals="INF"
      id="f-487"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="c-75"
      decimals="2"
      id="f-488"
      unitRef="usdPerShare">4.83</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-75" decimals="-3" id="f-489" unitRef="usd">69829000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-76" decimals="INF" id="f-490" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c-77"
      decimals="INF"
      id="f-491"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SaleOfStockTransactionDate contextRef="c-24" id="f-492">2025-07-03</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:PreferredStockConvertibleConversionDate contextRef="c-31" id="f-493">2025-07-02</us-gaap:PreferredStockConvertibleConversionDate>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-4" decimals="INF" id="f-494" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-5" decimals="INF" id="f-495" unitRef="shares">153682280</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-496"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-497"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="c-1" id="f-498">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible preferred stock outstanding as of December 31, 2024 consisted of the following (in thousands, except share amounts.) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Series &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,962,675&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,394,197&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,801,802&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,747,127&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;880,187&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,876,405&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;848,599&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,222,222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;520,519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,766,666&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;166,833&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D-2*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,083,333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,920,649&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,151,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series F-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,043,479&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,201,203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series F-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,498,498&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,926,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,779,559&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series G-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,896,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,039,756&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series H&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,157,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,461,804&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;153,682,280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;38,665,583&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;152,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;143,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;* Liquidation preference includes two times the original issue price per share.</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-78"
      decimals="INF"
      id="f-499"
      unitRef="shares">17962675</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-78"
      decimals="INF"
      id="f-500"
      unitRef="shares">5394197</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-78" decimals="-3" id="f-501" unitRef="usd">4850000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-78" decimals="-3" id="f-502" unitRef="usd">4850000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-79"
      decimals="INF"
      id="f-503"
      unitRef="shares">6000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-79"
      decimals="INF"
      id="f-504"
      unitRef="shares">1801802</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-79" decimals="-3" id="f-505" unitRef="usd">4319000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-79" decimals="-3" id="f-506" unitRef="usd">4319000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-80"
      decimals="INF"
      id="f-507"
      unitRef="shares">5747127</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-80"
      decimals="INF"
      id="f-508"
      unitRef="shares">880187</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-80" decimals="-3" id="f-509" unitRef="usd">2550000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-80" decimals="-3" id="f-510" unitRef="usd">2550000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-81"
      decimals="INF"
      id="f-511"
      unitRef="shares">3876405</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-81"
      decimals="INF"
      id="f-512"
      unitRef="shares">848599</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-81" decimals="-3" id="f-513" unitRef="usd">2515000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-81" decimals="-3" id="f-514" unitRef="usd">2515000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-82"
      decimals="INF"
      id="f-515"
      unitRef="shares">2222222</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-82"
      decimals="INF"
      id="f-516"
      unitRef="shares">520519</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-82" decimals="-3" id="f-517" unitRef="usd">1560000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-82" decimals="-3" id="f-518" unitRef="usd">1560000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-83"
      decimals="INF"
      id="f-519"
      unitRef="shares">6766666</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-83"
      decimals="INF"
      id="f-520"
      unitRef="shares">166833</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-83" decimals="-3" id="f-521" unitRef="usd">500000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-83" decimals="-3" id="f-522" unitRef="usd">500000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-84"
      decimals="INF"
      id="f-523"
      unitRef="shares">11083333</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-84"
      decimals="INF"
      id="f-524"
      unitRef="shares">2920649</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-84" decimals="-3" id="f-525" unitRef="usd">17506000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-84" decimals="-3" id="f-526" unitRef="usd">8753000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-85"
      decimals="INF"
      id="f-527"
      unitRef="shares">14000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-85"
      decimals="INF"
      id="f-528"
      unitRef="shares">4151977</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-85" decimals="-3" id="f-529" unitRef="usd">15900000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-85" decimals="-3" id="f-530" unitRef="usd">15900000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-86"
      decimals="INF"
      id="f-531"
      unitRef="shares">13043479</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-86"
      decimals="INF"
      id="f-532"
      unitRef="shares">1201203</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-86" decimals="-3" id="f-533" unitRef="usd">4600000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-86" decimals="-3" id="f-534" unitRef="usd">4600000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-87"
      decimals="INF"
      id="f-535"
      unitRef="shares">12000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-87"
      decimals="INF"
      id="f-536"
      unitRef="shares">2498498</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-87" decimals="-3" id="f-537" unitRef="usd">10400000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-87" decimals="-3" id="f-538" unitRef="usd">10400000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-88"
      decimals="INF"
      id="f-539"
      unitRef="shares">5926000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-88"
      decimals="INF"
      id="f-540"
      unitRef="shares">1779559</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-88" decimals="-3" id="f-541" unitRef="usd">8000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-88" decimals="-3" id="f-542" unitRef="usd">8000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-89"
      decimals="INF"
      id="f-543"
      unitRef="shares">6896552</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-89"
      decimals="INF"
      id="f-544"
      unitRef="shares">2039756</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-89" decimals="-3" id="f-545" unitRef="usd">9849000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-89" decimals="-3" id="f-546" unitRef="usd">9849000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c-75"
      decimals="INF"
      id="f-547"
      unitRef="shares">48157821</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-75"
      decimals="INF"
      id="f-548"
      unitRef="shares">14461804</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-75" decimals="-3" id="f-549" unitRef="usd">69829000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-75" decimals="-3" id="f-550" unitRef="usd">69829000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-5" decimals="INF" id="f-551" unitRef="shares">153682280</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-5" decimals="INF" id="f-552" unitRef="shares">38665583</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c-5" decimals="-3" id="f-553" unitRef="usd">152378000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-5" decimals="-3" id="f-554" unitRef="usd">143625000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <cv:TemporaryEquityLegacyConversionRatio
      contextRef="c-90"
      decimals="INF"
      id="f-555"
      unitRef="number">1</cv:TemporaryEquityLegacyConversionRatio>
    <cv:TemporaryEquityLegacyConversionPricePerShareMinimum
      contextRef="c-91"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">9.66</cv:TemporaryEquityLegacyConversionPricePerShareMinimum>
    <cv:TemporaryEquityLegacyConversionPricePerShareMaximum
      contextRef="c-91"
      decimals="2"
      id="f-557"
      unitRef="usdPerShare">9.99</cv:TemporaryEquityLegacyConversionPricePerShareMaximum>
    <cv:ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum contextRef="c-92" decimals="INF" id="f-558" unitRef="usd">25000000</cv:ProspectiveProceedsFromIssuanceInitialPublicOfferingMinimum>
    <cv:TemporaryEquityDividendRatePercentage contextRef="c-1" decimals="INF" id="f-559" unitRef="number">0.0800</cv:TemporaryEquityDividendRatePercentage>
    <cv:NumberOfBoardMembers contextRef="c-5" decimals="INF" id="f-560" unitRef="member">8</cv:NumberOfBoardMembers>
    <us-gaap:SaleOfStockTransactionDate contextRef="c-24" id="f-561">2025-07-03</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:PreferredStockConvertibleConversionDate contextRef="c-31" id="f-562">2025-07-02</us-gaap:PreferredStockConvertibleConversionDate>
    <us-gaap:SaleOfStockTransactionDate contextRef="c-24" id="f-563">2025-07-03</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-24"
      decimals="INF"
      id="f-564"
      unitRef="shares">5500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-28"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-93"
      decimals="INF"
      id="f-566"
      unitRef="shares">825000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <cv:SaleOfStockEffectivenessDate contextRef="c-26" id="f-567">2025-07-18</cv:SaleOfStockEffectivenessDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-25"
      decimals="INF"
      id="f-568"
      unitRef="shares">129978</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-94"
      decimals="2"
      id="f-569"
      unitRef="usdPerShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-28"
      decimals="INF"
      id="f-570"
      unitRef="shares">168898</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-95"
      decimals="INF"
      id="f-571"
      unitRef="shares">3898</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-95"
      decimals="2"
      id="f-572"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-95" id="f-573">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <cv:ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights contextRef="c-29" id="f-574">from the first day of the seventh month after July 3, 2025 (the &#x201c;Original Closing Date&#x201d;)</cv:ClassOfWarrantOrRightExerciseDateOfWarrantsOrRights>
    <us-gaap:SaleOfStockTransactionDate contextRef="c-24" id="f-575">2025-07-03</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="c-95" id="f-576">2030-07-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-19" decimals="-3" id="f-577" unitRef="usd">519000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-578">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following assumptions:&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Initial Placement Underwriters' Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over-allotment exercise Underwriters' Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.96 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes Black-Scholes option pricing model weighted-average assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.81 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.30 %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.6 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73.4 %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-96" decimals="4" id="f-579" unitRef="number">0.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-97" decimals="4" id="f-580" unitRef="number">0.0396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-96" id="f-581">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-97" id="f-582">P4Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-96" decimals="4" id="f-583" unitRef="number">0.7883</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-97" decimals="4" id="f-584" unitRef="number">0.7894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-96" decimals="3" id="f-585" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-97" decimals="3" id="f-586" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-28"
      decimals="2"
      id="f-587"
      unitRef="usdPerShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <cv:SaleOfStockEffectivenessDate contextRef="c-98" id="f-588">2025-07-01</cv:SaleOfStockEffectivenessDate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-589"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-590"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-591" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-592" unitRef="shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-593" unitRef="shares">46865051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-594" unitRef="shares">46865051</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-595" unitRef="shares">2090945</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-596" unitRef="shares">2090945</us-gaap:CommonStockSharesIssued>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-597">&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Conversion of preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,665,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercises of stock options under 2005 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,627,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,298,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercises of stock options under 2025 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercises of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserved for future grants under 2005 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;880,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserved for future grants under 2025 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,838,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total reserved shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,982,877&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;41,859,552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-99"
      decimals="INF"
      id="f-598"
      unitRef="shares">0</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-100"
      decimals="INF"
      id="f-599"
      unitRef="shares">38665583</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-101"
      decimals="INF"
      id="f-600"
      unitRef="shares">1627097</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-102"
      decimals="INF"
      id="f-601"
      unitRef="shares">2298947</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-103"
      decimals="INF"
      id="f-602"
      unitRef="shares">348551</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-104"
      decimals="INF"
      id="f-603"
      unitRef="shares">0</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-105"
      decimals="INF"
      id="f-604"
      unitRef="shares">168898</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-106"
      decimals="INF"
      id="f-605"
      unitRef="shares">15015</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-107"
      decimals="INF"
      id="f-606"
      unitRef="shares">0</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-108"
      decimals="INF"
      id="f-607"
      unitRef="shares">880007</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-109"
      decimals="INF"
      id="f-608"
      unitRef="shares">3838331</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-110"
      decimals="INF"
      id="f-609"
      unitRef="shares">0</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance contextRef="c-4" decimals="INF" id="f-610" unitRef="shares">5982877</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance contextRef="c-5" decimals="INF" id="f-611" unitRef="shares">41859552</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-612">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;12. STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2025 Stock Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Plan, which was adopted by the Company's Board of Directors in May 2025 and approved by the Company's stockholders in June 2025, became effective upon the consummation of the IPO. Upon the effectiveness of the 2025 Plan, the 2005 Plan was terminated and no further grants may be made under the 2005 Plan. The Company's 2025 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A total of 4,204,204 shares of the Company&#x2019;s common stock were initially authorized for issuance with respect to awards granted under the 2025 Plan. Shares subject to outstanding awards granted under the 2005 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated will be available for award grants under the 2025 Plan. In addition, the share limit will automatically increase on the first trading day in January of each year (commencing with 2026) by an amount equal to (1) 4% of the total number of shares of our common stock that are issued and outstanding on the last trading day in December in the prior year, or (2) lesser number as determined by the Company&#x2019;s Board of Directors. Any shares subject to awards granted under the 2025 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, fail to vest, as well as shares used to pay the purchase or exercise price of awards or related tax withholding obligations, will become available for new award grants under the 2025 Plan. As of December 31, 2025, a total of 3,838,331 shares is available for award purposes under the 2025 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Amended and Restated 2005 Stock Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the 2005 Plan, the Company granted equity-based incentive awards prior to the IPO to the Company&#x2019;s employees, directors, and consultants.&#160; The 2005 Plan permitted the grant of stock options (either Incentive Stock Options (&#x201c;ISO&#x201d; &#x2013; employees only) or&#160;Non-Qualified&#160;Stock Options (&#x201c;NQSO&#x201d;)) and restricted stock awards (&#x201c;RSA&#x201d;); only ISOs and NQSOs were outstanding during the periods presented. Under the 2005 Plan, 880,007 shares of common stock were reserved for issuance at December&#160;31, 2024. Upon the effectiveness of the 2025 Plan, the 2005 Plan was terminated and no new awards were granted under the 2005 Plan after the IPO, and there were no shares of common stock available for new award grants as of December&#160;31, 2025 under the 2005 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted to employees and&#160;non-employees contain only service vesting conditions, with typical grants vesting over a four-years period (vesting 25% on the first anniversary of the award and 1/48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; each month thereafter) but may be granted with different vesting profiles, including options that are vested-at-grant (immediate vesting) and that are subject to different vesting schedules. Options granted to employees and&#160;non-employees&#160;expire no more than 10 years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company, outside of the 2005 Plan, previously issued an insignificant number of warrants to purchase its common stock; of these, all have expired or been exercised with no shares remaining outstanding at December&#160;31, 2025 and 15,015 warranted common shares remaining outstanding at December&#160;31, 2024. Being &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outside of the 2005 Plan, they are excluded from the stock option award activity and stock-based compensation presentations which follow. The Company previously recognized immaterial warrant-related expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Stock Option Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective August 27, 2025, the Company's Chief Financial Officer (the "Former Executive") stepped down from his position with the Company. As part of the termination of employment of the Former Executive, there were certain supplementary modifications to the Former Executive's non-vested stock option awards including acceleration of some non-vested shares and extension of their post-termination exercise period, and voluntary forfeiture of the remaining non-vested stock option awards. During the year ended December&#160;31, 2025, the Company recorded a one-time, noncash incremental stock-based compensation expense net of required reversal of previously recognized compensation in the amount of $159 related to these stock option award modifications which was included in General and administrative expenses in the condensed statement of operations. The Company accounted for the resulting net incremental stock option award modification compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Stock Options&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the year ended December&#160;31, 2025 was as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Options on Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding (vested and expected to vest) as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,298,905&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,961&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;534,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(438,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited, canceled, or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(419,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding (vested and expected to vest) as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,975,648&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1.74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;880,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values are calculated as the differences between the exercise prices of the underlying options and the fair value of the Company&#x2019;s common stock for options that were in the money. The Company had 1,095,359 unvested stock options outstanding as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, unrecognized compensation cost of $2,734 related to outstanding unvested stock options is expected to be recognized as expense over a weighted average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair value of options granted during the years ended December&#160;31, 2025 and 2024, was $3.70 and $1.83 per share, respectively. The total fair value of options vested were $798 and $72 during the years ended December&#160;31, 2025 and 2024, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2025 and 2024, 438,808 and 253,909 stock options were exercised and satisfied with newly-issued shares, resulting in cash proceeds of $158 and $75, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes Black-Scholes option pricing model weighted-average assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.81 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.30 %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.6 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73.4 %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014; %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In estimating the fair value of the underlying common stock prior to IPO, the Company utilized a third party valuation firm whose analyses supported management's concluded estimate. Post IPO the fair value of the underlying common stock is based on the Company&#x2019;s closing stock price on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2025 the Company granted a total of 17,322 restricted stock units (RSUs) to its six non-employee directors utilizing a fair market value (FMV) of $4.33 per share of the Company's common stock on the grant date. These RSUs vested on December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2025, the Company recorded $75 in stock-based compensation related to RSUs. The total fair value of RSUs vested during the year ended December&#160;31, 2025 was approximately $185.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation, measured at the grant date, is recognized ratably over the requisite service period, using the straight-line method of expense attribution. Forfeitures are accounted for as a reduction in expense in the period in which they occur; no compensation cost is recorded for awards that do not vest. The Company recognized total stock-based compensation expense for employees and non-employees as components of the statement of operations and comprehensive loss as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;826&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-111"
      decimals="INF"
      id="f-613"
      unitRef="shares">4204204</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-109"
      decimals="INF"
      id="f-614"
      unitRef="shares">3838331</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-108"
      decimals="INF"
      id="f-615"
      unitRef="shares">880007</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="c-107"
      decimals="INF"
      id="f-616"
      unitRef="shares">0</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-112" id="f-617">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="c-1" id="f-618">(vesting 25% on the first anniversary of the award and 1/48th each month thereafter) but may be granted with different vesting profiles, including options that are vested-at-grant (immediate vesting) and that are subject to different vesting schedules.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-112" id="f-619">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-113"
      decimals="INF"
      id="f-620"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-114"
      decimals="INF"
      id="f-621"
      unitRef="shares">15015</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-112" decimals="-3" id="f-622" unitRef="usd">159000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-623">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the year ended December&#160;31, 2025 was as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Options on Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding (vested and expected to vest) as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,298,905&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,961&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;534,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(438,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited, canceled, or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(419,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding (vested and expected to vest) as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,975,648&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1.74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;880,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-624" unitRef="shares">2298905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-625"
      unitRef="usdPerShare">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-6" id="f-626">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-627" unitRef="usd">4961000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-628" unitRef="shares">534722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-629"
      unitRef="usdPerShare">5.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-630" unitRef="shares">438808</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-631"
      unitRef="usdPerShare">0.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-632" unitRef="usd">4532000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-633" unitRef="shares">419171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-634"
      unitRef="usdPerShare">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-635" unitRef="shares">1975648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-636"
      unitRef="usdPerShare">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-637">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-638" unitRef="usd">17869000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="INF" id="f-639" unitRef="shares">880289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-640"
      unitRef="usdPerShare">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-641">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-642" unitRef="usd">9005000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c-4" decimals="INF" id="f-643" unitRef="shares">1095359</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-4" decimals="-3" id="f-644" unitRef="usd">2734000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-645">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-646"
      unitRef="usdPerShare">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-6"
      decimals="2"
      id="f-647"
      unitRef="usdPerShare">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-1" decimals="-3" id="f-648" unitRef="usd">798000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-6" decimals="-3" id="f-649" unitRef="usd">72000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-650" unitRef="shares">438808</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-6" decimals="INF" id="f-651" unitRef="shares">253909</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-652" unitRef="usd">158000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-6" decimals="-3" id="f-653" unitRef="usd">75000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-654" unitRef="number">0.0381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-6" decimals="4" id="f-655" unitRef="number">0.0430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-656">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-6" id="f-657">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="3" id="f-658" unitRef="number">0.796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-6" decimals="3" id="f-659" unitRef="number">0.734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-660" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-6" decimals="INF" id="f-661" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-115"
      decimals="INF"
      id="f-662"
      unitRef="shares">17322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-663"
      unitRef="usdPerShare">4.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="c-1" id="f-664">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-116"
      decimals="INF"
      id="f-665"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-115"
      decimals="INF"
      id="f-666"
      unitRef="shares">17322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-667"
      unitRef="usdPerShare">4.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-115"
      decimals="INF"
      id="f-668"
      unitRef="shares">17322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-117"
      decimals="INF"
      id="f-669"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-115" decimals="-3" id="f-670" unitRef="usd">75000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-115" decimals="-3" id="f-671" unitRef="usd">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-672">The Company recognized total stock-based compensation expense for employees and non-employees as components of the statement of operations and comprehensive loss as follows.&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;826&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-3" id="f-673" unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-3" id="f-674" unitRef="usd">2000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-3" id="f-675" unitRef="usd">20000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="-3" id="f-676" unitRef="usd">17000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-122" decimals="-3" id="f-677" unitRef="usd">212000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-3" id="f-678" unitRef="usd">53000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="-3" id="f-679" unitRef="usd">585000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="-3" id="f-680" unitRef="usd">84000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-681" unitRef="usd">826000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-682" unitRef="usd">156000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-683">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;13. SEGMENTS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating (and reportable) segment known as the Capsule Endoscopy Segment; its chief operating decision maker is its Chief Executive Officer.  The composition of this segment reflects the Company&#x2019;s focus on capsule endoscope medical devices addressing different areas within the GI tract. Refer to Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES and Note 6. REVENUE AND DEFERRED REVENUE for descriptions of products and services.  Segment accounting policies are the same as those described therein.  The chief operating decision maker assesses performance for the Capsule Endoscopy Segment and decides how to allocate resources based upon net income (loss) as reported in the statement of operations and comprehensive loss; also considered is operating income (loss), measured on the same basis as in the statement of operations and comprehensive loss. Net income (loss) and operating income (loss) are used in the process of evaluating expenses and determining where to prioritize resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment assets are identical to those reported in the balance sheet as total assets.  Segment revenue is identical to that reported in the statement of operations and comprehensive loss; significant segment expenses are identical to those identified in the statement of operations and comprehensive loss under the line items for selling and marketing expenses, research and development expenses, and general and administrative expenses.  Other segment items are represented by non-operating income (expense), net (which includes insignificant interest income) and the provision for income taxes as reported in the statement of operations and comprehensive loss.  Segment depreciation expense and capital expenditures are identical to amounts in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-684"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-685"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-686">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;14. INCOME TAXES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of loss before income taxes are as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(25,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax provision are as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.750%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income tax, net of federal taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Taiwan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Local income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of changes in tax laws or rates enacted in the current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent book-tax differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and State research and development tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts of cash paid for income taxes by the Company are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Massachusetts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;North Carolina&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New York State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash paid for income taxes (net of refunds)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill was enacted (&#x201c;OBBBA&#x201d;), introducing significant and wide-ranging changes to the U.S. federal tax system. Significant components include restoration of 100% accelerated tax depreciation on qualifying property including expansion to cover qualified production property.&#160;&#160; Another major aspect includes the return to immediate expensing of domestic research and experimental expenditures (&#x201c;R&amp;amp;E&#x201d;) which in some cases may include retroactive application back to 2021 for businesses with gross receipts of less than $31 million or accelerated tax deductions of R&amp;amp;E that was previously capitalized for larger businesses.&#160; The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;legislation also reinstates EBITDA-based interest deductions for tax purposes and makes several business tax incentives permanent.&#160; Less favorable business provisions include limitations on tax deductions for charitable contributions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes are accounted for using the asset and liability method, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The main components of deferred tax assets (liabilities) are as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;39,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;33,830&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(33,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Valuation Allowance Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance against a deferred tax asset must be established when it is &#x201c;more likely than not&#x201d; that all, or a portion of, deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. After consideration of all the information available, in particular the Company&#x2019;s accumulated deficit and history of operating losses, it was concluded that uncertainty exists with respect to future realization of deferred tax assets. The valuation allowance increased during the years ended December 31, 2025 and December 31, 2024 in the amounts of $5,912 and $4,700, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Net Operating Losses and Tax Credit Carryforwards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has experienced and generated net operating losses (&#x201c;NOLs&#x201d;) for tax purposes since inception. As of December 31, 2025 (December 31, 2024), total available gross (pre-tax) Federal and U.S. state NOL carryforward amounts were $126,094 and $93,244 ($100,304 and $79,481), respectively. Under the Federal Tax Cuts and Jobs Act of 2017, NOLs incurred in tax years beginning on or after January 1, 2018, are carried forward&#160;indefinitely and subject to a usage limitation of 80% of taxable income; NOLs incurred in tax years prior to January 1, 2018, are subject to a twenty-year carryforward before expiring and not subject to a usage limitation of taxable income. As of December 31, 2025 (December 31, 2024), total Federal and U.S. state research and development tax credit carryforward amounts, net of unrecognized tax benefits, were 1,318 (1,318), respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs and tax credit carryforward values are as follows as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expiration Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Operating Losses (gross; pre-tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; Federal (arising after December 31, 2017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; Federal (arising before January 1, 2018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; State - indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; State &#x2013; definite lived&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D Tax Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D tax credits &#x2013; Federal and State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 as amended (&#x201c;Section 382&#x201d;), or, for states, state laws, due to ownership changes that have occurred previously or that could occur in the future.  These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.  The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception.  If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382. Any limitation may result in expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Section 174 Capitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OBBBA made changes to Section 174 of the Internal Revenue Code of 1986 as amended for taxable years beginning December 31, 2024 with the Company being able to deduct domestic research and experimental (R&amp;amp;E) expenditures in the year they are incurred when before these costs were capitalized and amortized over 5 years. The Company is still required to capitalize foreign R&amp;amp;E costs and amortize them over 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the tax year ended December 31, 2025 the Company incurred $3,545 of foreign R&amp;amp;D expenses which were capitalized and are being amortized over the respective period noted above. For the tax year ended December 31, 2024 the Company incurred $13,910 and $1,116 of domestic and foreign R&amp;amp;D expenses, respectively, which were capitalized and are being amortized over the respective periods noted above. These amounts are reflected in gross deferred tax assets (together with previous periods&#x2019; amounts, net of amounts amortized for tax purposes).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balance of total unrecognized tax benefits on a tax-effected basis for follows; these relate principally to research and development credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized tax benefits, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,634&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for current tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes for previous tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized tax benefits, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for current tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes for previous tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized tax benefits, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not yet conducted a study of its research and development credit carryforwards. This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, the tax assets associated with the research and development credit carryforwards have been fully offset with a reserve.  A full valuation allowance has been provided against the Company&#x2019;s net deferred tax assets, and if an adjustment to the net unrecognized tax benefits were to occur, this adjustment would be offset by an equal adjustment to the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recognized no interest and penalties associated with substantially all of its unrecognized tax benefits. There are no tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files U.S. Federal and State income tax returns in jurisdictions with varying statutes of limitations.  In the normal course of business, the Company is subject to examination by taxing authorities throughout the U.S.  These examinations could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with laws.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s remaining open tax years subject to examination by federal and state tax authorities include the years ended December&#160;31, 2019, through 2025 in the U.S and December 31, 2020 through 2025 in the Company&#x2019;s foreign operations. However, for tax years from inception through the present, federal and state taxing authorities may examine and adjust loss carryforwards in the years in which those loss carryforwards are ultimately utilized.  There are currently no pending income tax examinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-687">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of loss before income taxes are as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(25,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-688" unitRef="usd">-24424000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-6" decimals="-3" id="f-689" unitRef="usd">-19220000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-690" unitRef="usd">-867000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-6" decimals="-3" id="f-691" unitRef="usd">-667000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-692" unitRef="usd">-25291000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-693" unitRef="usd">-19887000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-694">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax provision are as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-695" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-696" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-697" unitRef="usd">11000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-698" unitRef="usd">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-699" unitRef="usd">13000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-700" unitRef="usd">7000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-701" unitRef="usd">24000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-702" unitRef="usd">11000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-703" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-704" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-705" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-706" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-707" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-708" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-709" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-710" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-711" unitRef="usd">24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-712" unitRef="usd">11000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-713">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.750%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income tax, net of federal taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Taiwan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Local income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of changes in tax laws or rates enacted in the current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company's effective tax rate and the statutory tax rate for the year ended December 31, 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent book-tax differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and State research and development tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-714" unitRef="usd">-5311000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-715" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-716" unitRef="usd">11000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="4" id="f-717" unitRef="number">-0.0004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-718" unitRef="usd">13000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="4" id="f-719" unitRef="number">-0.0005</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-3" id="f-720" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="3" id="f-721" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-722" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-723" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-724" unitRef="usd">5213000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-725" unitRef="number">-0.206</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-1" decimals="-3" id="f-726" unitRef="usd">100000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-727" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-728" unitRef="usd">-1000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-729" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-730" unitRef="usd">24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-731" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="3" id="f-732" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-6" decimals="3" id="f-733" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-6" decimals="3" id="f-734" unitRef="number">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-6" decimals="3" id="f-735" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="3" id="f-736" unitRef="number">-0.236</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-6" decimals="3" id="f-737" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-6" decimals="3" id="f-738" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c-1" id="f-739">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts of cash paid for income taxes by the Company are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Massachusetts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;North Carolina&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New York State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash paid for income taxes (net of refunds)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-126" decimals="-3" id="f-740" unitRef="usd">1000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-127" decimals="-2" id="f-741" unitRef="usd">500</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-128" decimals="-2" id="f-742" unitRef="usd">1000.0</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-129" decimals="-2" id="f-743" unitRef="usd">5600</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-1" decimals="-3" id="f-744" unitRef="usd">8000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-745">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The main components of deferred tax assets (liabilities) are as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;39,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;33,830&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(33,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-746" unitRef="usd">32568000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-747" unitRef="usd">26441000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <cv:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses contextRef="c-4" decimals="-3" id="f-748" unitRef="usd">5087000</cv:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <cv:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses contextRef="c-5" decimals="-3" id="f-749" unitRef="usd">5657000</cv:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-3" id="f-750" unitRef="usd">1318000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-751" unitRef="usd">1318000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-4" decimals="-3" id="f-752" unitRef="usd">443000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-5" decimals="-3" id="f-753" unitRef="usd">95000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <cv:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-4" decimals="-3" id="f-754" unitRef="usd">212000</cv:DeferredTaxAssetsOperatingLeaseLiabilities>
    <cv:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-5" decimals="-3" id="f-755" unitRef="usd">306000</cv:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-756" unitRef="usd">42000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-757" unitRef="usd">13000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-758" unitRef="usd">39670000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-759" unitRef="usd">33830000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-760" unitRef="usd">39295000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-761" unitRef="usd">33384000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-762" unitRef="usd">375000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-763" unitRef="usd">446000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-764" unitRef="usd">132000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-765" unitRef="usd">151000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-766" unitRef="usd">202000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-767" unitRef="usd">295000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains contextRef="c-4" decimals="-3" id="f-768" unitRef="usd">41000</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains contextRef="c-5" decimals="-3" id="f-769" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-770" unitRef="usd">375000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-771" unitRef="usd">446000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-772" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-773" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-3" id="f-774" unitRef="usd">5912000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-6" decimals="-3" id="f-775" unitRef="usd">4700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-130" decimals="-3" id="f-776" unitRef="usd">126094000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-131" decimals="-3" id="f-777" unitRef="usd">93244000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-132" decimals="-3" id="f-778" unitRef="usd">100304000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-133" decimals="-3" id="f-779" unitRef="usd">79481000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-3" id="f-780" unitRef="usd">1318000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-781" unitRef="usd">1318000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock contextRef="c-1" id="f-783">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs and tax credit carryforward values are as follows as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expiration Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Operating Losses (gross; pre-tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; Federal (arising after December 31, 2017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; Federal (arising before January 1, 2018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; State - indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; State &#x2013; definite lived&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D Tax Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D tax credits &#x2013; Federal and State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="c-1" id="f-782">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs and tax credit carryforward values are as follows as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expiration Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Operating Losses (gross; pre-tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; Federal (arising after December 31, 2017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; Federal (arising before January 1, 2018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; State - indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs &#x2013; State &#x2013; definite lived&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D Tax Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D tax credits &#x2013; Federal and State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c-134" decimals="-3" id="f-784" unitRef="usd">77974000</us-gaap:OperatingLossCarryforwards>
    <cv:OperatingLossCarryforwardsExpirationTerm contextRef="c-135" id="f-785">No expiry</cv:OperatingLossCarryforwardsExpirationTerm>
    <us-gaap:OperatingLossCarryforwards contextRef="c-136" decimals="-3" id="f-786" unitRef="usd">48120000</us-gaap:OperatingLossCarryforwards>
    <cv:OperatingLossCarryforwardsExpirationTerm contextRef="c-137" id="f-787">2027</cv:OperatingLossCarryforwardsExpirationTerm>
    <us-gaap:OperatingLossCarryforwards contextRef="c-138" decimals="-3" id="f-788" unitRef="usd">3327000</us-gaap:OperatingLossCarryforwards>
    <cv:OperatingLossCarryforwardsExpirationTerm contextRef="c-139" id="f-789">No expiry</cv:OperatingLossCarryforwardsExpirationTerm>
    <us-gaap:OperatingLossCarryforwards contextRef="c-140" decimals="-3" id="f-790" unitRef="usd">89917000</us-gaap:OperatingLossCarryforwards>
    <cv:OperatingLossCarryforwardsExpirationTerm contextRef="c-141" id="f-791">2028</cv:OperatingLossCarryforwardsExpirationTerm>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-4" decimals="-3" id="f-792" unitRef="usd">1318000</us-gaap:TaxCreditCarryforwardAmount>
    <cv:TaxCreditCarryforwardExpirationTerm contextRef="c-1" id="f-793">2033</cv:TaxCreditCarryforwardExpirationTerm>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-142" decimals="-3" id="f-794" unitRef="usd">3545000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-143" decimals="-3" id="f-795" unitRef="usd">13910000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-144" decimals="-3" id="f-796" unitRef="usd">1116000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-797">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balance of total unrecognized tax benefits on a tax-effected basis for follows; these relate principally to research and development credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized tax benefits, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,634&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for current tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes for previous tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized tax benefits, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for current tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes for previous tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized tax benefits, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-798" unitRef="usd">1634000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-799" unitRef="usd">3000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-800" unitRef="usd">165000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-801" unitRef="usd">1472000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-802" unitRef="usd">12000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-803" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-804" unitRef="usd">1484000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-805">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;15. NET LOSS PER SHARE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares of common stock outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,555,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,020,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss per share &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9.85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is the same as diluted net loss per share as the inclusion of potential common shares outstanding would have been anti-dilutive. The Company's convertible preferred stock Series constitute &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;participating securities; however, as a result of the net loss position, they are excluded from the calculation of basic net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities that were not included in the preceding calculations because they would be anti-dilutive were as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 10pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible preferred stock (all series)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,279,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,665,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants on common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options on common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,027,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,298,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;21,403,135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;40,979,545&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-806">&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares of common stock outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,555,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,020,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss per share &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9.85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-807" unitRef="usd">-25315000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-808" unitRef="usd">-25315000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-6" decimals="-3" id="f-809" unitRef="usd">-19898000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-6" decimals="-3" id="f-810" unitRef="usd">-19898000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-811" unitRef="shares">24555381</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-812" unitRef="shares">24555381</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-813" unitRef="shares">2020077</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-814" unitRef="shares">2020077</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-815"
      unitRef="usdPerShare">-1.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-816"
      unitRef="usdPerShare">-1.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-817"
      unitRef="usdPerShare">-9.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-818"
      unitRef="usdPerShare">-9.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-819">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities that were not included in the preceding calculations because they would be anti-dilutive were as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 10pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible preferred stock (all series)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,279,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,665,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants on common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options on common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,027,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,298,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;21,403,135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;40,979,545&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-145" decimals="0" id="f-820" unitRef="shares">19279825</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-146" decimals="0" id="f-821" unitRef="shares">38665583</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-147" decimals="0" id="f-822" unitRef="shares">90763</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-148" decimals="0" id="f-823" unitRef="shares">15015</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-149" decimals="0" id="f-824" unitRef="shares">2027469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-150" decimals="0" id="f-825" unitRef="shares">2298947</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-151" decimals="0" id="f-826" unitRef="shares">5078</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-152" decimals="0" id="f-827" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-828" unitRef="shares">21403135</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="0" id="f-829" unitRef="shares">40979545</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-830">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;16. RELATED PARTIES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2025, the Company's material transactions with related parties were limited to a promissory note described in Note 7. NOTE PAYABLE and certain R&amp;amp;D expenses ($1,207 and $320 for the years ended December&#160;31, 2025 and December&#160;31, 2024, respectively) for non-recurring engineering services with an R&amp;amp;D and manufacturing services vendor that holds an insignificant percentage of the Company's capital stock. There were no other material transactions with related parties during the years ended December&#160;31, 2025 and December&#160;31, 2024 and no amounts due from or to related parties at December&#160;31, 2025 or December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-1" decimals="-3" id="f-831" unitRef="usd">1207000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-6" decimals="-3" id="f-832" unitRef="usd">320000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-833">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;17. SUBSEQUENT EVENTS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2026 the Company signed a consulting agreement with Wen-Hung Tsai, one of the Company's shareholders and a former member of the Company's Board of Directors (till February 26, 2024). Per the consulting agreement Mr.Wen-Hung Tsai will provide strategic advice, help with industrial affiliation and partnerships, as well as work on the supply chain establishment for new products. As compensation for his services, the Company granted to Mr.Wen-Hung Tsai on February 12, 2026 an option to purchase 250,000 shares of the Company's Common Stock under the Company&#x2019;s 2025 Equity Incentive Plan. Eighty percent (80%) of the option grant is scheduled to vest and become exercisable on February 12, 2027. The remaining portion of the option grant is scheduled to vest and become exercisable in three (3) equal monthly installments on the same day of each successful calendar month following February 12, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 16, 2026, the Company entered into a Securities Purchase Agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with selected accredited investors (the &#x201c;Investors&#x201d;), for the purposes of raising approximately $14 million in aggregate gross proceeds for the Company (the &#x201c;Private Placement&#x201d;). Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to the Investors in the Private Placement an aggregate of 2,867,089 shares (the &#x201c;Shares&#x201d;) of common stock of the Company, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), at $4.883 per Share. The closing of the Private Placement occurred on March 16, 2026. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Private Placement, the Company entered into a registration rights agreement, dated March 16, 2026 (the &#x201c;Registration Rights Agreement&#x201d;), with the Investors, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) a registration statement to register for resale the Shares within 90 days after the closing of the Private Placement, and (ii) use commercially reasonable efforts to have such registration statement declared effective as soon as reasonably &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;practicable following the filing thereof with the SEC. The Registration Rights Agreement contains customary terms and conditions for a transaction of this type.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventsDate contextRef="c-153" id="f-834">2026-02-12</us-gaap:SubsequentEventsDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="c-154" id="f-835">Per the consulting agreement Mr.Wen-Hung Tsai will provide strategic advice, help with industrial affiliation and partnerships, as well as work on the supply chain establishment for new products. As compensation for his services, the Company granted to Mr.Wen-Hung Tsai on February 12, 2026 an option to purchase 250,000 shares of the Company's Common Stock under the Company&#x2019;s 2025 Equity Incentive Plan. Eighty percent (80%) of the option grant is scheduled to vest and become exercisable on February 12, 2027. The remaining portion of the option grant is scheduled to vest and become exercisable in three (3) equal monthly installments on the same day of each successful calendar month following February 12, 2027.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-155"
      decimals="INF"
      id="f-836"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-154" decimals="2" id="f-837" unitRef="number">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <cv:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments
      contextRef="c-154"
      decimals="INF"
      id="f-838"
      unitRef="monthly_installment">3</cv:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMonthlyInstallments>
    <us-gaap:SaleOfStockTransactionDate contextRef="c-156" id="f-839">2026-03-16</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-156" decimals="-6" id="f-840" unitRef="usd">14000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-156"
      decimals="INF"
      id="f-841"
      unitRef="shares">2867089</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-157"
      decimals="INF"
      id="f-842"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-157"
      decimals="3"
      id="f-843"
      unitRef="usdPerShare">4.883</us-gaap:SaleOfStockPricePerShare>
    <cv:SaleOfStockEffectivenessDate contextRef="c-156" id="f-844">2026-03-16</cv:SaleOfStockEffectivenessDate>
    <cv:SaleOfStockRegistrationRightsAgreementDate contextRef="c-156" id="f-845">2026-03-16</cv:SaleOfStockRegistrationRightsAgreementDate>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-41" id="f-846">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-41" id="f-847">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-41" id="f-848">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-41" id="f-849">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-850">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
